<SEC-DOCUMENT>0001564590-23-005432.txt : 20230404
<SEC-HEADER>0001564590-23-005432.hdr.sgml : 20230404
<ACCEPTANCE-DATETIME>20230404172351
ACCESSION NUMBER:		0001564590-23-005432
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		85
FILED AS OF DATE:		20230404
DATE AS OF CHANGE:		20230404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAIA Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001878313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269606
		FILM NUMBER:		23799539

	BUSINESS ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
		BUSINESS PHONE:		312-416-8592

	MAIL ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>maia-s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4017515+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:maia="http://maiabiotech.com/20230330" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
maia-s1a.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001878313_20220101_20221231">S-1/A</ix:nonNumeric>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001878313_20220101_20221231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityCentralIndexKey" contextRef="C_0001878313_20220101_20221231">0001878313</ix:nonNumeric>
			<ix:nonNumeric id="F_000378" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001878313_20221231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000677" name="maia:ClaimExpirationTerm" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000377" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0001878313_20220101_20221231">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001878313_20221231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001878313_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:PreferredStockValue" contextRef="C_0001878313_20221231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:PreferredStockValue" contextRef="C_0001878313_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000586" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231" decimals="3">0.028</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000587" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231" decimals="3">0.006</ix:nonFraction>
			<ix:nonNumeric id="F_000590" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">P4Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000591" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000594" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231" decimals="2">0.78</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000595" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231" decimals="2">0.81</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000588" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231" decimals="3">0.041</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000589" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231" decimals="3">0.013</ix:nonFraction>
			<ix:nonNumeric id="F_000592" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000593" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">P7Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000596" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231" decimals="2">0.92</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231" decimals="2">1.06</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="4">0.0214</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="4">0.0036</ix:nonFraction>
			<ix:nonNumeric id="F_000634" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000635" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000638" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="3">0.719</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000639" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="3">0.714</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="4">0.0445</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000633" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="4">0.0127</ix:nonFraction>
			<ix:nonNumeric id="F_000636" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000637" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">P6Y6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000640" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="3">0.879</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="3">0.815</ix:nonFraction>
			<ix:nonNumeric id="F_000584" name="maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm" contextRef="C_0001878313_20210101_20211231">P7Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000585" name="maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm" contextRef="C_0001878313_20220101_20221231">P5Y1M28D</ix:nonNumeric>
			<ix:nonNumeric id="F_000620" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001878313_20210101_20211231">P8Y7M2D</ix:nonNumeric>
			<ix:nonNumeric id="F_000621" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001878313_20220101_20221231">P7Y10M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000622" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001878313_20220101_20221231">P7Y7M2D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="maia-20230330.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001878313_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001878313_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001878313_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-08-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaMAIADrugDevelopmentCorporationMember_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220101_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220501_20220531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-05-01</xbrli:startDate>
					<xbrli:endDate>2022-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-31</xbrli:startDate>
					<xbrli:endDate>2022-08-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-03</xbrli:startDate>
					<xbrli:endDate>2022-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:OfferingAndOverallotmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-03</xbrli:startDate>
					<xbrli:endDate>2022-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_maiaUnvestedRestrictedStockAwardsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:LeighAnnDurantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210401_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210929_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-29</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210929_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-29</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20221001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-10-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20210416_20210416">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-16</xbrli:startDate>
					<xbrli:endDate>2021-04-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190101_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRelatedPartyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RelatedPartyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyOneWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapShortTermDebtTypeAxis_maiaConvertibleNotesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">maia:ConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-05-01</xbrli:startDate>
					<xbrli:endDate>2022-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220803_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-03</xbrli:startDate>
					<xbrli:endDate>2022-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210813_20210813">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-08-13</xbrli:startDate>
					<xbrli:endDate>2021-08-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_20210813_20210813">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-08-13</xbrli:startDate>
					<xbrli:endDate>2021-08-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_20220731_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-31</xbrli:startDate>
					<xbrli:endDate>2022-08-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-03</xbrli:startDate>
					<xbrli:endDate>2022-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-03</xbrli:startDate>
					<xbrli:endDate>2022-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandEighteenStockOptionPlanMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20220801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardDateAxis_maiaJuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardDateAxis_maiaMarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-11-01</xbrli:startDate>
					<xbrli:endDate>2018-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-11-01</xbrli:startDate>
					<xbrli:endDate>2018-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaUniversityOfTexasSouthwesternMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaRegeneronPharmaceuticalsIncMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapAustralianTaxationOfficeMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20220101_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230116_20230116">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-01-16</xbrli:startDate>
					<xbrli:endDate>2023-01-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230416_20230416">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-04-16</xbrli:startDate>
					<xbrli:endDate>2023-04-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-03-08</xbrli:startDate>
					<xbrli:endDate>2023-03-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230306_20230605">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-03-06</xbrli:startDate>
					<xbrli:endDate>2023-06-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-03-08</xbrli:startDate>
					<xbrli:endDate>2023-03-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-12-21</xbrli:startDate>
					<xbrli:endDate>2023-03-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As filed with the U.S. Securities and Exchange Commission on April 4, 2023. </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration No. 333-269606</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Double 3pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br />Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM S-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amendment No. 1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000004" name="dei:EntityRegistrantName" contextRef="C_0001878313_20220101_20221231">MAIA Biotechnology, Inc.</ix:nonNumeric><span style="font-weight:normal;"><br /></span><span style="font-size:8pt;font-weight:normal;">(Exact name of registrant as specified in its charter)</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:32.05%;"></td>
<td style="width:2.03%;"></td>
<td style="width:32.05%;"></td>
<td style="width:1.92%;"></td>
<td style="width:31.94%;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityPrimarySicNumber" contextRef="C_0001878313_20220101_20221231">2834</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001878313_20220101_20221231">83-1495913</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Primary Standard Industrial<br />Classification Code Number)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressAddressLine1" contextRef="C_0001878313_20220101_20221231">444 West Lake Street</ix:nonNumeric>, <ix:nonNumeric id="F_000013" name="dei:EntityAddressAddressLine2" contextRef="C_0001878313_20220101_20221231">Suite 1700</ix:nonNumeric><br /><ix:nonNumeric id="F_000014" name="dei:EntityAddressCityOrTown" contextRef="C_0001878313_20220101_20221231">Chicago</ix:nonNumeric>, <ix:nonNumeric id="F_000015" name="dei:EntityAddressStateOrProvince" contextRef="C_0001878313_20220101_20221231">IL</ix:nonNumeric> <ix:nonNumeric id="F_000016" name="dei:EntityAddressPostalZipCode" contextRef="C_0001878313_20220101_20221231">60606</ix:nonNumeric><br />(<ix:nonNumeric id="F_000017" name="dei:CityAreaCode" contextRef="C_0001878313_20220101_20221231">312</ix:nonNumeric>) <ix:nonNumeric id="F_000018" name="dei:LocalPhoneNumber" contextRef="C_0001878313_20220101_20221231">416-8592</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:ContactPersonnelName" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">Vlad Vitoc</ix:nonNumeric><br />Chief Executive Officer<br />c/o MAIA Biotechnology, Inc.<br /><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine1" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">444 West Lake Street</ix:nonNumeric>, <ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine2" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">Suite 1700</ix:nonNumeric><br /><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">Chicago</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">IL</ix:nonNumeric> <ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">60606</ix:nonNumeric><br />(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">312</ix:nonNumeric>) <ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">416-8592</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Copies to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:51.07%;"></td>
<td style="width:0.96%;"></td>
<td style="width:47.97%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mitchell S. Nussbaum, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Janeane R. Ferrari, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loeb &#38; Loeb LLP</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">345 Park Avenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10154</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phone: (212) 407-4000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax: (212) 407-4990</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">William N. Haddad, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arif Soto, Esq.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Venable LLP</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">151 W. <span style="font-family:Times New Roman Bold;">42<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup></span> Street, 49<span style="font-family:Times New Roman Bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></span> Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10036</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phone: (212) 307-5500 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax: (212) 307-5598</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approximate date of commencement of proposed sale to public: <span style="font-weight:normal;">As soon as practicable after the effective date hereof.</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:30.45%;"></td>
<td style="width:2.92%;"></td>
<td style="width:0.13%;"></td>
<td style="width:0.13%;"></td>
<td style="width:26.28%;"></td>
<td style="width:0.13%;"></td>
<td style="width:37.05%;"></td>
<td style="width:2.92%;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityFilerCategory" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntitySmallBusiness" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000011" name="dei:EntityExTransitionPeriod" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000002" name="dei:AmendmentDescription" contextRef="C_0001878313_20220101_20221231">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Double 3pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.97%;"></td>
<td style="width:1.1%;"></td>
<td style="width:31.97%;"></td>
<td style="width:1.05%;"></td>
<td style="width:31.91%;"></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRELIMINARY PROSPECTUS</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBJECT TO COMPLETION</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#C00000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DATED APRIL 4, 2023</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3,360,000 Shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:24pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000001.jpg" title="" alt="" style="width:290px;height:110px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are offering 3,360,000 shares of our common stock at an assumed public offering price of $3.57 per share, the last reported sale price of our common stock as reported on NYSE American, or the &#8220;NYSE American,&#8221; on April 3, 2023.&#160;&#160;The actual public offering price per share of common stock will be determined between us and the underwriters at the time of pricing and may be at a discount to this assumed offering price.&#160;&#160;Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on NYSE American under the symbol &#8220;MAIA.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;) and, as such, have elected to comply with certain reduced public company reporting requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. See &#8220;<a href="#RISK_FACTORS"><span style="font-style:italic;text-decoration:underline;">Risk Factors</span></a><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221; beginning on page 13. Neither the Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price to the public</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underwriting discounts and commissions<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds to us, before expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the offering price payable to the underwriters. We refer you to &#8220;<span style="font-style:italic;">Underwriting</span>&#8221; beginning on page 151 for additional information regarding underwriters&#8217; compensation.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted a 45-day option to the representative of the underwriters to purchase up to 504,000 additional shares of common stock solely to cover over-allotments, if any.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters expect to deliver the shares to purchasers on or about &#160;&#160; &#160;&#160;, 2023.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;, 2023</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:92.3%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:7.7%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUMMARY"><span style="text-decoration:underline;">PROSPECTUS SUMMARY</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%; border-top:solid 1.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><span style="text-decoration:underline;">RISK FACTORS</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"><span style="text-decoration:underline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><span style="text-decoration:underline;">USE OF PROCEEDS</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DIVIDEND_POLICY"><span style="text-decoration:underline;">DIVIDEND POLICY</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAPITALIZATION"><span style="text-decoration:underline;">CAPITALIZATION</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DILUTION"><span style="text-decoration:underline;">DILUTION</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MANAGEMENTS_DISCUSSION_ANALYSIS_FINANCIA"><span style="text-decoration:underline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td>
<td valign="bottom" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BUSINESS"><span style="text-decoration:underline;">BUSINESS</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MANAGEMENT"><span style="text-decoration:underline;">MANAGEMENT</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXECUTIVE_DIRECTOR_COMPENSATION"><span style="text-decoration:underline;">EXECUTIVE AND DIRECTOR COMPENSATION</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PRINCIPAL_STOCKHOLDERS"><span style="text-decoration:underline;">PRINCIPAL STOCKHOLDERS</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRAN"><span style="text-decoration:underline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><span style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MATERIAL_US_FEDERAL_INCOME_TAX_CONSEQUEN"><span style="text-decoration:underline;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#UNDERWRITING"><span style="text-decoration:underline;">UNDERWRITING</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><span style="text-decoration:underline;">EXPERTS</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><span style="text-decoration:underline;">LEGAL MATTERS</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION"><span style="text-decoration:underline;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p></td>
<td valign="top" style="background-color:#CFF0FC;width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
</tr>
<tr>
<td valign="top" style="width:92.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">INDEX TO FINANCIAL STATEMENTS</span></a></p></td>
<td valign="top" style="width:7.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this prospectus, unless the context indicates or otherwise requires, &#8220;the Company,&#8221; &#8220;our Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to MAIA Biotechnology, Inc., a Delaware corporation, and its consolidated subsidiaries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PROSPECTUS_SUMMARY">PROSPECTUS SUMMARY</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This summary highlights certain information appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including &#8220;Risk Factors&#8221; beginning on page 14 and the financial statements and related notes included in this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This prospectus includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus are the property of their respective owners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia.&#160;&#160;In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating THIO in patients with NSCLC. Patients with advanced Non-Small Cell Lung Cancer (NSCLC) will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo&#174; (cemiplimab) manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. Cemiplimab has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study. In return, we have granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. Based on the clinical data generated by our THIO-101 trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC, but even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. In addition, in the Fourth Quarter of 2023, we plan to initiate a Phase 2 clinical trial in multiple solid tumor indications of THIO administered in sequence with Anti-PD-1 or Anti-PD-L1. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Product Candidate </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-dG or 6-thio-2&#8217;-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, our research team discovered that THIO produced telomere modifications and disruption, which ultimately induced cancer-specific innate and adaptive immune responses against immunologically &#8220;cold&#8221; or tumor types that were unresponsive to immune checkpoint inhibitors. This hypothesis was tested and demonstrated in syngeneic and humanized mouse models. THIO administered to mice in low doses and followed by an immune-checkpoint inhibiting agent, such as an anti-PD-1 or anti-PD-L1 compound, induced complete tumor regression with no tumor recurrence during the 14 weeks of observation. Further, no toxicities were reported in the tumor-free mice. These new findings were published in the peer-reviewed research scientific journal, <span style="text-decoration:underline;">Cancer Cell </span>in July 2020. Based on these recent discoveries, a new therapeutic approach has been designed to advance THIO into a Phase 2 clinical trial (THIO-101) in patients with advanced NSCLC.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, and do not plan to rely on clinical data generated by unaffiliated third parties, we take added confidence in the potential tolerability of THIO in light of the fact that the THIO doses we plan to test represent a range 4 to 40 times lower than the maximum tolerated dose tested in the earlier clinical trials sponsored by the National Cancer Institute in the 1970s. A<span style="color:#000000;">s part of the existing data base of clinical experience with the drug, we expect to reference the older NCI studies in the public domain as well as reference NCI&#8217;s original IND filing in support of an IND filing, pursuant to FDA </span></p></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">regulations, and we are currently working with experts to evaluate the extent and quality of the existing data supporting THIO. </span><span style="letter-spacing:0.2pt;">The planned THIO-101 phase 2 trial is intended to be a proof-of-concept study that may be modified depending on interim results to include both primary and secondary endpoints and be consistent with previously approved cancer treatments. </span><span style="letter-spacing:0.2pt;">In September 2022, we submitted a pre-IND meeting request to FDA to discuss, among other elements, the existing non-clinical and clinical data to support the conduct of our planned THIO-101 phase 2 trial under an IND to include patients from the United States. MAIA received feedback in-line with the proposed plans from the FDA regarding its manufacturing, preclinical and clinical development plan. MAIA also obtained guidance from the FDA on the assessment of its safety and efficacy in the THIO-101 Phase 2 trial that will be incorporated in the U.S. IND application. MAIA plans to file its U.S. IND in the first half of 2023 and commence enrolling patients in the U.S. in the second half of 2023.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the clinical data we aim to generate in the THIO-101 study and assuming THIO achieves its intended clinical effect with a manageable safety profile at one of the doses tested in the study, we expect to seek early FDA guidance on the possibility of utilizing one or more of FDA&#8217;s expedited programs for serious conditions, such as fast track designation, breakthrough therapy designation, priority review and/or accelerated approval designation. <span style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span> The THIO-101 study protocol may need to be amended to increase the number of patients enrolled, undergo modification of the statistical analysis, or change in the trial design and/or primary endpoints. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Science--Driven Telomere Targeting Approach</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive DNA nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes in cells. THIO&#8217;s mechanism of action comprises telomere targeting and induction of anti-cancer immunogenicity. The enzyme telomerase recognizes THIO&#8217;s metabolite formed <span style="font-style:italic;">in situ</span> and incorporates it into the structure of the cancer cell&#8217;s telomeres, creating a faulty structure, which breaks apart the telomere spatial structure. As a result, the THIO-modified telomeric structure unwinds, recognized as DNA damage, and the cancer cells die. We believe THIO transforms &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours. We also believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomere maintenance is a fundamental biologic process for cell proliferation and resilience in cancer cells, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in most human cancer cells (over 85% in the aggregate), across various tumor types. In contrast, its activity is detected in less than 1% of normal cells. THIO has only been shown to be active in cancer cells that are telomerase positive (TERT+) and actively dividing. Cancer cells are constantly telomerase positive due to an uncontrolled division process, while a relatively small number of normal cells are telomerase positive only transiently. Therefore, THIO activity is expected to be highly specific to cancer cells versus normal cells. Cancer-specific disturbance of telomeric structure, mediated by telomerase, is likely to lead to disruption in the cell cycle, followed by a very rapid and telomere-length independent cell death. THIO was observed to induce cancer-specific telomere disruption, by using the enzyme telomerase, which differentiates THIO from all other available cancer therapies currently in clinical use. We are also currently developing potential next generation small molecule telomere modifying agents with the goal of identifying additional proprietary drug candidates, across multiple cancer types. We have generated 82 new telomere-targeting compounds of which 60 compounds have been evaluated in vitro. Currently, seven molecules have been selected for further evaluation in additional in vitro and in vivo models.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials prior to approval are typically conducted in three sequential Phases that may overlap or be combined. In Phase 1, the drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In Phase 2, the drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. In Phase 3, larger-scale clinical trials are undertaken to evaluate clinical efficacy and safety and the overall risk/benefit ratio of the product. Post-approval studies, or Phase 4 clinical trials, may be conducted voluntarily, or as a condition of FDA&#8217;s approval of a drug. These studies may be used to confirm preliminary efficacy results, gain additional experience from the treatment of certain patient populations, or to support additional indications or labeling changes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia was approved on March 1, 2022, by the Australian Regulatory </p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency - </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bellberry</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Human Research Ethics Committee</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating THIO in patients with NSCLC.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma and in May 2022, the FDA granted the second ODD to THIO for the treatment of small cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;" id="BigHand_Transcription">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="gjyjiv3jrhol000002.jpg" title="" alt="" style="width:594px;height:314px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Second-Generation Molecule Candidates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. This program may also allow us to strengthen our patent portfolio. Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create a second generation of THIO-like compounds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current 2nd-generation pipeline of potential telomere-targeting agents includes seven compounds that have successfully undergone <span style="font-style:italic;">in vitro</span> inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO. Based on those data, we have progressed those seven compounds to <span style="font-style:italic;">in vivo</span> testing. In January 2023, we nominated one lead new molecular entity candidate (designated as MAIA-2021-20) and one back-up new molecular entity candidate (MAIA-2022-12) for further advancement into preclinical GLP-toxicity and other studies and may advance one of these candidates into human clinical trials upon completion of the required preclinical evaluations. We also filed a broad provisional patent application covering the composition of matter for the new telomere-targeting molecules in the fourth quarter of 2022.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OUR PIPELINE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our robust pipeline includes several targeted immuno-oncology candidates for relapsed and refractory <span style="color:#3E677D;">cancers</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000003.jpg" title="" alt="" style="width:601px;height:338px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules. Our initial focus is to efficiently advance our Phase 2 clinical program using THIO in sequential combination with cemiplimab. Ultimately, we envision positioning THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer. To date, THIO has never been tested in clinical trials in combination with any check-point inhibitor. The key elements of our strategy are to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Advance our existing clinical programs, including seeking accelerated approval for THIO in NSCLC as a tumor mass-reducing and simultaneously immune system priming agent administered in advance of the immune-activating agent, cemiplimab for treatment of advanced NSCLC, and ultimately, as a cancer treatment foundation in multiple indications and geographies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Broaden the clinical development of THIO by exploring synergistic administration prior to other standard-of care immune-therapies including cell therapy. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Develop a franchise of telomere-targeting cancer treatments not inclusive of checkpoint inhibitors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Leverage our regulatory strategy to acquire additional human data faster outside U.S. for other cancer indications.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Selectively enter into strategic collaborations with pharmaceutical and biotechnology companies that have immune activating therapies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expand our existing intellectual property portfolio.</span></p></td></tr></table></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face certain challenges in implementing our business strategy including, among others, the fact that earlier development of THIO was not commercially pursued. Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities. The FDA&#8217;s accelerated approval pathway, even if initially granted, does not guarantee an accelerated review or marketing approval by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our global patent and patent-pending estate covers several areas. Telomerase mediated telomere altering compounds and treatment of therapy-resistant cancers are part of our portfolio. Further, THIO&#8217;s immunogenic treatment strategy, which focuses on sequential combination with checkpoint inhibitors has been filed. We maintain four issued patents and have 16 pending applications.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Leadership Team </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled an experienced management team with deep research, development, and commercialization experience in the areas of cancer treatment, telomere-related science, immunotherapy, and spreading across a vast array of oncology indications. Members of our team bring experiences from multiple biotech and pharmaceutical companies including Pfizer Inc., Bayer Oncology, Novartis Oncology, Astellas Pharma Inc., Janssen - a Johnson &#38; Johnson pharmaceutical company, Incyte Corporation, Pharmacyclics Inc., Juno Therapeutics Inc., Celgene, Cephalon Inc., Geron Corporation, and AbbVie Bio Corp., among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in August 2018, and we have operations in Chicago, Illinois, with some of our team members setup virtually and working remotely in California, Nevada and Florida, among others. Our principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL 60606, and our phone number is (312) 416-8592. In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various preclinical and clinical activities for the development of our product candidates. In April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Our website address is <span style="font-style:italic;text-decoration:underline;color:#0000FF;">www.MAIABiotech.com</span>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and registration statements&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If some investors find our common stock less attractive as a result of these exemptions, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being a Smaller Reporting Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by non-affiliates equals or exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates equals or exceeds $700 million as of the end of that year&#8217;s second fiscal quarter.</p></div></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="FERING">THE OFFERING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuer</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock offered</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,360,000 shares of common stock.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock to </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be outstanding </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after this offering</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,356,404 shares (or 14,860,404&#8236;&#8236; shares if the underwriters&#8217; option to purchase additional shares is exercised in full) of common stock.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering price</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumed offering price is $3.57 per share, the last reported sale price of our common stock as reported on NYSE American on April 3, 2023.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-allotment option</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted the underwriters a 45-day option to purchase up to an additional 504,000 shares of our common stock at the offering price, less the underwriting discount, to cover over-allotments, if any.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of proceeds</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that we will receive net proceeds of approximately $9.90 million from our sale of common stock in this offering, or approximately $11.57 million if the underwriters exercise their over-allotment option in full. We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, to fund the ongoing clinical trials of THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes. See &#8220;<span style="font-style:italic;">Use of Proceeds</span>&#8221; in this prospectus for a more complete description of the intended use of proceeds from this offering.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of ownership</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of this offering, our executive officers and directors will beneficially own, in the aggregate, approximately 44.69 % of the outstanding shares of our common stock.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading market and symbol</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on NYSE American, or the &#8220;NYSE American,&#8221; under the symbol &#8220;MAIA.&#8221; </p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk factors</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. See &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; beginning on page 14 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors and officers have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of six (6) months from the date of this Offering.</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-top:2pt;margin-bottom:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of our common stock to be outstanding after this offering is based on 10,996,404 shares of our common stock outstanding as of April 3, 2023, and excludes the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">7,217,915 shares of common stock issuable upon exercise of options to purchase shares of common stock outstanding as of April 3, 2023, with a weighted-average exercise price of $2.69 per share&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">599,126 shares of common stock reserved for issuance under our 2021 Equity Incentive Plan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warrants to purchase 796,985 shares of common stock, with a weighted average exercise price of $6.04 per share.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we indicate otherwise or unless the context otherwise requires, all information in this prospectus assumes the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">no exercise of outstanding options or warrants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">no exercise by the underwriters of their option to purchase up to 504,000 additional shares of our common stock from us to cover over-allotments, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">no exercise of the representative&#8217;s warrants to be issued upon consummation of this offering at an exercise price equal to 125% of the offering price of the common stock&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an assumed offering price of $3.57 per share, the last reported sale price of our common stock as reported on NYSE American, 2023. </span></p></td></tr></table></div></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SUMMARY_RISK_FACTORS">SUMMARY OF RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to a number of risks of which you should be aware of before making an investment decision. These risks are discussed more fully in the &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; section of this prospectus immediately following this prospectus summary. Some of these risks include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have incurred losses since our inception and anticipate that we will continue to incur increasing losses for the foreseeable future.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Even if this offering is successful, we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we are unable to obtain FDA approval for our IND application for the planned THIO phase 2 trial, our&#160;&#160;clinical development of THIO may be significantly delayed and our business may be substantially harmed.</span></p></td></tr></table></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">A variety of risks associated with operating internationally could materially adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#8220;CROs&#8221;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Intellectual property rights do not address all potential threats to our competitive advantage.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The price of our common stock may be volatile and you could lose all or part of your investment. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</span></p></td></tr></table></div></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:6.7%;padding-Right:6.7%;padding-Top:5.18%;padding-Bottom:5.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We may, in the future, issue additional capital stock, which would reduce investors&#8217; percent of ownership and may dilute our share value.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our shares of common stock are currently listed on NYSE American. If we are unable to maintain listing of our securities on NYSE American or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:11pt;">&#160;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SUMMARY_FINANCIAL_INFORMATION">SUMMARY FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present our summary consolidated financial and other data as of and for the periods indicated. The summary consolidated statements of operations data for the fiscal years ended December 31, 2022 and December 31, 2021 and the consolidated balance sheet data as of December 31, 2022 and 2021 are derived from our audited financial statements included elsewhere in this prospectus. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summarized financial information presented below is derived from and should be read in conjunction with our consolidated financial statements including the notes to those financial statements, which are included elsewhere in this prospectus along with the sections entitled &#8220;<span style="font-style:italic;">Selected Financial Data</span>,&#8221; &#8220;<span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; and &#8220;<span style="font-style:italic;">Capitalization</span>.&#8221; Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any future period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,933,314</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,143,527</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ratchet share expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,360</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,176,201</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,176,201</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,967</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,625</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,394</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes and convertible notes,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,922</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,769,279</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on warrant modification</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,219,857</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic and diluted(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding - basic and diluted(1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,276,761</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,435</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> See Note 1 to our audited financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:69.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:14.04%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:13.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="width:69.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:14.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="width:12.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,950,927</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="middle" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,539,131</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:12.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,022,040</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="middle" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,268,906</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,996</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:69.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity </p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:12.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="middle" style="width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="middle" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> We define working capital as current assets less current liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="RISK_FACTORS">RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Any investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision to invest in our common stock. Please note that the risks highlighted here are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our common stock could decline and you could lose all or part of your investment.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $15,769,279 and $12,578,211 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $44,207,272. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant additional operating losses for the next several years, at least, as we advance THIO and any other candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other candidates, if approved. The costs of advancing candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>enroll our Phase 2 trial, or conduct clinical trials for any other indications or other candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish sales, marketing, distribution, and compliance infrastructures to commercialize our drug, if approved, and for any other candidates for which we may obtain marketing approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintain, expand and protect our intellectual property portfolio&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>hire additional clinical, scientific and commercial personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>add operational, financial and management information systems and personnel, including personnel to support our development and planned future commercialization efforts, as well as to support our transition to a public reporting company&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acquire or in-license or invent other candidates or technologies.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<span style="letter-spacing:0.2pt;">Furthermore, our ability to successfully develop, commercialize and license any candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212; Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212; Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely affected.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if this offering is successful, we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of THIO and launch and commercialize THIO, if we receive regulatory approval. We will require additional capital for the further development and potential commercialization of THIO and may also need to raise additional funds sooner to pursue a more accelerated development of THIO. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our cash reserves as December 31, 2022 of $10.95 million and current financial condition as of the date of this prospectus, there is substantial doubt about our ability to continue as a going concern. (See <span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Capital Resources &#8212; Our Ability to Continue as a Going Concern</span>&#8221; for further information.) Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for THIO or any other future candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>clinical development plans we establish for THIO and any other future candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>number and characteristics of candidates that we discover or in-license and develop&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>effects of competing technological and market developments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs and timing of the implementation of commercial-scale manufacturing activities&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, to fund our current or future operating plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate candidate development or future commercialization efforts.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware and began our operations in August 2018. Our operations to date have been limited to financing and staffing our company, licensing candidates, conducting preclinical studies, manufacturing clinical supply, and preparing for clinical studies of THIO. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage candidate is THIO. As a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize THIO in a timely manner. We cannot commercialize THIO in the United States without first obtaining regulatory approval from the FDA&#59; similarly, we cannot commercialize THIO outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of THIO for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that THIO is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. Even if we were to successfully obtain approval of THIO from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for THIO in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for THIO, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize THIO, we may not be able to earn sufficient revenue to continue our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may face future business disruption and related risks resulting from the outbreak of the coronavirus (COVID-19) or from another pandemic, epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease like the outbreak of COVID-19. For example, as a result of measures imposed by the governments in regions affected by COVID-19 businesses and schools have been suspended due to quarantines or &#8220;stay at home&#8221; orders intended to contain this outbreak. The spread of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 from China to other countries has resulted in the Director General of the World Health Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC), based on the advice of the Emergency Committee under the International Health Regulations (2005). In March 2020, and subsequently, various international travel restrictions were imposed and modified between the US and foreign countries and such restrictions may continue, be reimposed, or be expanded or otherwise further modified for the foreseeable future. COVID-19 continues to spread globally, including with the advent of the new &#8220;Delta&#8221; variant throughout 2021. The COVID-19 outbreak has impacted international stock markets, which continue to reflect the uncertainty associated with the slow-down in global economies and the reduced levels of international travel experienced since the beginning of January 2020. We continue to assess our business plans and the impact COVID-19 may have on our ability to advance the development of our drug candidates, including delays in starting or completing clinical trials, or to raise financing to support the development of our drug candidates, but no assurances can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular. One of our initial clinical studies is taking place in Australia, which previously imposed one of the strictest COVID-19-related measures, including </span><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lock-downs</span><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and may do so again in the future. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and out-license partners&#8217; ability to perform preclinical studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent to which the coronavirus impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, THIO and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">obtaining regulatory approval to commence and continue to conduct a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">obtaining Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">having patients complete a trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">imposition of a clinical hold by regulatory authorities, or IRBs, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">clinical sites deviating from trial protocol, failing to adequately enroll study subjects, committing fraud or other violations of regulatory requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">addressing patient safety concerns that arise during the course of a </span><span style="letter-spacing:0.2pt;">trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>manufacturing sufficient quantities of THIO for use in clinical trials.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<span style="letter-spacing:0.2pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;&#8212; Risks Related to Our Dependence on Third Parties.&#8221;</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. Because all our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates will experience similar failures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#8217; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical testing and receive approval of a biologics license application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we develop our product candidates and initiate clinical trials of our additional product candidates, serious adverse events, or SAEs, undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe SAEs in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADA caused by such products, several potentially significant negative consequences could result, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to change the way a product is administered or conduct additional clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the product may become less competitive, and our reputation may suffer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may decide to remove the product from the marketplace&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the global COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for several reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to design such product candidates with the properties that we desire&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for THIO or any other candidates. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of a NDA from the FDA. Our ability to obtain approval by the FDA or other regulatory authorities can be adversely impacted for various reasons including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe and effective for its proposed indication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our candidates, or other products containing the active ingredient in our candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may be unable to demonstrate that a candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical </span><span style="letter-spacing:0.2pt;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct our clinical studies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<span style="letter-spacing:0.2pt;">Prior to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The planned THIO-101 phase 2 trial is intended to be a proof-of-concept trial that may be expanded depending on interim results and includes both primary and secondary endpoints consistent with previously approved medicines. If THIO achieves its intended effects and does not exhibit unacceptable safety risks, we plan to seek accelerated approval of THIO based on positive results of the expanded phase 2 THIO-101 trial, followed by full approval based on the results of a single phase 3 clinical study, as opposed to the traditional approach of conducting two or more phase 3 studies. </span><span style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span><span style="letter-spacing:0.2pt;"> A single-study approach is permissible in certain circumstances, particularly in oncology, but such circumstances are exceptional and FDA may not agree with that proposed approach, and thus we may be required to conduct two phase 3 trials.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">if our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">if the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">if the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">if the FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>if based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">if the FDA determines that our labeling is false or misleading in any particular way.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs that enter clinical development, only a small percentage successfully complete the regulatory approval processes and are approved and commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market THIO or any other candidates, which would significantly harm our business, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or an applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, the FDA or foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions, that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll enough patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the patient eligibility criteria defined in the protocol&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the nature of the trial protocol&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the proximity of patients to clinical sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">competing clinical trials being conducted by other companies or institutions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">our ability to maintain patient consents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the risk that patients enrolled in clinical trials will drop out of the trials before completion&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays or difficulties in enrollment and completion of studies due to the COVID 19 pandemic.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for THIO are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious adverse events or undesirable side effects caused by THIO or any other candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. <span style="color:#000000;">THIO has been previously evaluated in at least 19 clinical studies both as monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies. A classic treatment strategy was used where patients were treated to maximum tolerated dose (MTD).</span> <span style="color:#000000;">Dose-limiting reversible toxicities </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">were mainly hematologic (leukopenia, thrombocytopenia), gastrointestinal (nausea, vomiting) and generalized skin rashes&#59; increases in blood urea nitrogen, creatinine, aspartate aminotransferase, alanine transaminase, and bilirubin were also recorded (Douglass, 1979&#59; Gagliano, 1981&#59; Higgins, 1985)</span><span style="color:#0000FF;">.</span><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">The available data provides substantial information on the safety profile of THIO in over 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">regulatory authorities may withdraw approvals of such product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the product may become less competitive&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our reputation may suffer.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to initially seek approval for THIO for use as a priming treatment in combination with the immune check point inhibitor cemiplimab in non-small cell lung cancer (&#8220;NSCLC&#8221;) in the United States. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and primary and secondary market research, and may prove to be incorrect. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a development candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our development candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO is active in cells that are telomerase positive (TERT+). The status of a tumor as being TERT+ can only be established by use of an in vitro test of the tumor cells. While experimental versions of such tests currently exist, none to date have received FDA approval. Under current FDA Guidances, for drugs and therapeutic biologics where the use of a specific diagnostic test is essential for the safe and effective use of the therapeutic product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test, the FDA generally will not approve the therapeutic product if a relevant &#8220;companion diagnostic&#8221; test is not also approved or cleared for the appropriate indication. As stated in its Guidances, the FDA may decide that it is appropriate to approve such a therapeutic product without an approved or cleared <span style="font-style:italic;">in vitro </span>companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared <span style="font-style:italic;">in vitro </span>companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared <span style="font-style:italic;">in vitro </span>companion diagnostic device. Although the vast majority of cancers are TERT+, the FDA may determine that THIO can only be approved (if at all) for patients whose cancer has been confirmed to be TERT+ through use of an FDA-approved companion diagnostic. If the FDA were to take such a position, the development and potential approval and commercialization of THIO would take longer, be more expensive, and could become impractical. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for THIO or any development candidate, we will still face extensive and ongoing regulatory requirements and obligations and any development candidates, if approved, may face future development and regulatory difficulties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">restrictions on manufacturing such products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">restrictions on the labeling or marketing of products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">restrictions on product distribution or use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">requirements to conduct post-marketing studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">warning letters or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">withdrawal of the products from the market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">refusal to approve pending applications or supplements to approved applications that we submit&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">recall of products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">fines, restitution or disgorgement of profits or revenues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">suspension or withdrawal of marketing approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">refusal to permit the import or export of our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">product seizure&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>injunctions or the imposition of civil or criminal penalties.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for THIO from the FDA. However, we might not seek such designation or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development or regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for THIO or one or more of our other candidates. Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). For purposes of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer to findings that suggest an effect on IMM or serious symptoms. For drugs that have been designated as breakthrough therapies, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for </span><span style="color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fast track</span><span style="color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> designation (under a separate request), priority review, or accelerated approval, if supported by clinical data at the time the NDA is submitted to the FDA. FDA encourages a Breakthrough Therapy designation request to be submitted, and received by FDA, no later than the end-of-phase-2 meetings. </span><span style="color:#000000;">Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a Breakthrough Therapy is within the discretion of the FDA both at the time of the submission of such a request, and during FDA&#8217;s review of the drug and supporting data. Even if we believe that one of our candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation or may grant such a designation and subsequently rescind the designation prior to approval. Even if we receive and maintain Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of THIO or any other candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>impairment of our business reputation and significant negative media attention&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>withdrawal of participants from our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>significant costs to defend the litigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>distraction of management&#8217;s attention from our primary business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>substantial monetary awards to patients or other claimants&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>inability to commercialize THIO or any other product candidate&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>product recalls, withdrawals or labeling, marketing or promotional restrictions&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>decreased market demand for any product&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>loss of revenue.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product liability insurance coverage we plan to acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We intend to acquire insurance coverage to include larger clinical studies, different countries and the potential sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If THIO is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research&#59; seek patent protection&#59; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtain quicker regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>implement more effective approaches to sales and marketing&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>form more advantageous strategic alliances.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel&#59; establishing clinical trial sites and patient registration&#59; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than THIO. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for THIO, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may face early generic competition for THIO or our other products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies developing novel products face intense competition from generic drug manufacturers who aggressively seek to challenge patents and non-patent exclusivities for branded products, and who are able to use much less-onerous product development and FDA approval pathways for their generic products. The active ingredient of THIO was extensively tested as early as the 1970s and we intend to rely in part on the clinical data previously developed for the drug in support of an NDA for THIO. Generic drug applicants and other competitors may be able to similarly rely upon the prior clinical data in support of efforts to gain approval of competing products using the same active ingredient as THIO. If one or more such competitors complete development and seek and obtain regulatory approval before we do, our ability to obtain approval of and market THIO may be delayed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDA&#8217;s generic drug approval processes, described in more detail in the section titled &#8220;Hatch-Waxman and Generic Competition,&#8221; we believe that THIO, if approved before any other application for a drug containing the same active ingredient, may be eligible for a five-year regulatory exclusivity period known as new chemical entity, or NCE Exclusivity, which would delay FDA review and approval of a competing product application that relies in whole or in part upon the FDA&#8217;s approval of THIO, but such exclusivity is only determined by the FDA after a drug is approved and the FDA may determine that THIO is not eligible for NCE Exclusivity, or that approval of THIO must be delayed due to another applicant&#8217;s relevant exclusivity. A new drug may, upon approval of its initial NDA or approval of supplemental NDAs, qualify for a three-year exclusivity period during which no generic version could be approved for the specific conditions of use </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covered by such exclusivity. Three-year exclusivity does not prevent FDA approval of another drug with the same active ingredient for a different indication or other conditions of use not protected by the exclusivity. Even if a competing version of THIO was approved with a different indication or condition of use, physicians would be free to prescribe such drug for uses that are covered by our regulatory exclusivity, if any. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as THIO, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will influence our ability to successfully commercialize our drug and any other product candidates we develop. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No<span style="letter-spacing:0.2pt;"> uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when a comparable alternative drug, an equivalent generic drug, a biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as alternatives to less expensive drugs and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If THIO or any candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the efficacy and potential advantages compared to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">effectiveness of sales and marketing efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the cost of treatment in relation to alternative treatments, including any similar generic treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">our ability to offer our products for sale at competitive prices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the convenience and ease of administration compared to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the strength of marketing and distribution support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the availability of third-party coverage and adequate reimbursement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the prevalence and severity of any side effects&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>any restrictions on the use of our product together with other medications.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any infrastructure for the sales, marketing or distribution of THIO, or compliance functions related to such activities, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. To market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial, compliance, and other non-technical capabilities or make arrangements with third parties to perform these services. We expect to build a focused sales, distribution and marketing infrastructure to market THIO, if approved, in the United States, with expected licenses in other countries and regions, including large markets such as Japan and Europe. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, oversee the compliance of sales and marketing functions, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, distribution and compliance capabilities could delay any product launch, which would adversely impact the commercialization of that product. For example, if the commercial launch of THIO for which we recruit a sales force and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our product candidates on our own include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe our products&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of THIO, if approved, for certain markets overseas&#59; however, we cannot assure you that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of THIO, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for THIO we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for THIO at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A variety of risks associated with operating internationally could materially adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of our product candidates and in April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Additionally, our business strategy includes potentially expanding further internationally if any of our product candidates receive regulatory approval. Doing business internationally involves several risks, including but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to obtain and maintain regulatory approvals for the use of our products in various countries&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>additional potentially relevant third-party patent rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>complexities and difficulties in obtaining protection and enforcing our intellectual property&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulties in staffing and managing foreign operations&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>limits in our ability to penetrate international markets&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the expansion of the Russian military invasion of Ukraine&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>certain expenses including, among others, expenses for travel, translation and insurance&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#8220;CROs&#8221;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities&#59; manufacturing standards&#59; data privacy, security, fraud and abuse and other healthcare laws and regulations&#59; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained during clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently rely on third-party contract manufacturing organizations, or CMOs, </span><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">for the production of</span><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of THIO and any candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of THIO drug substance to enable us to complete our clinical trials, and we have also engaged a CMO to provide clinical and commercial supply of the drug product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently do not have any agreements to produce these raw materials. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to continue to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2 trials of THIO. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with the good laboratory practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<span style="letter-spacing:0.2pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates, if approved, and may affect the prices we may set.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, has substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>expansion of eligibility criteria for Medicaid programs thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such </span><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establishment of a Center for Medicare Innovation at the Centers for Medicare &#38; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>expansion of the entities eligible for discounts under the Public Health Service program&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a licensure framework for follow on biologic products.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8203;<span style="letter-spacing:0.2pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or</span> <span style="letter-spacing:0.2pt;">under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical </span><span style="letter-spacing:0.2pt;">devices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities&#59; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we conduct clinical trial programs or enter into research collaborations in the European Economic Area, or EEA, we may be subject to the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the EEA/European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The United Kingdom has implemented its own version of the GDPR, which contains similar requirements. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent legislation may materially adversely affect our financial condition, results of operations and cash flows.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and Internal Revenue Service, or the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reduction of the corporate tax rate under the legislation may cause a reduction in the economic benefit of deferred tax assets available to us. Furthermore, under the legislation, although the treatment of tax losses generated before December 31, 2017, has generally not changed, tax losses generated in calendar year 2018 and beyond will only be able to offset 80% of taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going-forward basis. We intend to work with our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license agreements with UTSW under which we were granted rights to patents and patent applications, as well as proprietary technologies, that are important and necessary to our business. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents, as well as the exploitation of proprietary technology, are subject to the continuation of, and our compliance with, the terms of our license agreements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreements impose upon us various diligence, payment and other obligations, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our obligation to pay UTSW various milestone payments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our obligation to pay UTSW royalties based on net sales&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our obligation to pay UTSW fees associated with the prosecution, maintenance, or filing of the patents and patent applications we have licensed.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with any of our obligations under the license agreements, or we are subject to a bankruptcy or dissolution, UTSW may have the right to terminate their respective license agreements, in which event we would not be able to market any product candidates covered by the licenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently own any patents, and we are heavily reliant upon licenses from UTSW to certain patent rights that are important or necessary to the development of our technology and product candidates. As a result, we may be limited in our ability to prevent competitors from developing and commercializing competitive products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the license agreements. Thus, these patents and patent applications were not drafted by us or our attorneys, and we do not directly control the prosecution of these patents and patent applications. We cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents. UTSW directly controls the preparation, filing and prosecution of patent applications, and is responsible for maintaining the patents, covering technology that we license.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with the obligations under our license agreement, including as a result of COVID-19 impacting our operations or due to lack of funds, or if we use the licensed intellectual property in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates covered by our agreement. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise regarding intellectual property subject to, and any of our rights and obligations under, any license or other strategic agreement, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which our technology and processes infringe, misappropriate or violate the intellectual property of the licensor that is not subject to the license agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the sublicensing of patent and other rights to third parties under any such agreement or collaborative relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the priority of invention of patented technology.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to seek alternative options, such as developing new product candidates with design-around technologies, which may require more time and investment, or abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted licenses of use to patent applications in many countries worldwide. These applications cover a range of treatment methods. Unless and until the pending patent applications are issued, their protective scope is impossible to determine. It is also impossible to predict whether or how many of the patent applications will result in issued patents. Even if pending applications are issued, they may be issued with coverage significantly narrower than what is currently sought.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our proprietary position for our product candidates currently depends in part upon licenses to patents protecting methods of use, which may not prevent a competitor or other third party from using the same product candidate for another use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition of matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to be the favored form of intellectual property protection for pharmaceutical products, as such patents generally provide protection without regard to any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use of a product for the specified method. These types of patent claims do not prevent a competitor or other third party from making and marketing an identical API for an indication that is outside the scope of the method claims. Moreover, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents further cover THIO or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to any patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of Supreme Court Cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Further, publications of discoveries in scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. While various extensions may be available, the life of a patent is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly and/or time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, <span style="font-style:italic;">inter partes</span> review, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to third-party claims including infringement, interference, or derivation proceedings before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement claims are without merit, a court of competent jurisdiction could hold that the third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending such claims would cause us to incur substantial expenses and, if unsuccessful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (AIA) which was passed in September 2011, resulted in significant changes to the U.S. patent system.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries having similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a non-expired patent which claims a human drug product, a method of using the product, or a method of manufacturing the product, as compensation for effective patent term lost during product development and the FDA regulatory review process. Moreover, only one patent may be extended covering the drug product and the total patent term including the extension cannot exceed 14 years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO (referred to as Patent Term Adjustment, or PTA). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may develop, acquire, or license intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention&#59; (2) government action is necessary to meet public health or safety needs&#59; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as march-in rights). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. </span></p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, some of our intellectual property, including the intellectual property licensed from the University of Texas Southwestern Medical Center was funded in whole or in part by the United States government, the United States government has certain rights to such patent rights and technology, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes and march-in rights, and impose certain reporting and domestic manufacturing requirements. These rights may permit the United States government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to United States industry. In addition, our rights in such inventions are and may be subject to certain requirements to manufacture products embodying such inventions in the United States. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not address all potential threats to our competitive advantage.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>others may be able to make products that are similar to THIO or our future product candidates but that are not covered by the claims of the patents that we own or license from others&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>it is possible that our pending patent applications will not lead to issued patents&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.2pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0.2pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>ownership of our patents or patent applications may be challenged by third parties&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.2pt;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture THIO and any future product candidates, and we expect to collaborate with third parties on the development of THIO and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for any other of our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any proprietary name we propose to use with our clinical-stage product candidates or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. The EMA may also object to our proposed proprietary product name that infringes the existing rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of THIO or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize THIO or our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. At this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize THIO.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our proprietary information may be lost, or we may suffer security breaches.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, damage to our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Vlad Vitoc and Mihail Obrocea, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize product candidates will be limited.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;letter-spacing:0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of THIO or any other product candidate could be delayed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Offering and Ownership of Our Common Stock </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active, liquid trading market for our common stock may not develop. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock was listed and began trading on the NYSE American on July 28, 2022 under the symbol &#8220;MAIA.&#8221; Prior to the listing, there was no public market for our common stock.&#160;&#160;An active trading market for shares of our common stock may never develop or be sustained. If an active trading market does not develop, you may have difficulty selling any of our shares that you purchase. The offering price of our common stock will be determined by negotiation between us and the underwriters, and may not be indicative of prices that will prevail after the completion of this offering. The market price of our common stock may decline below the offering price, and you may not be able to resell your shares at, or above, the offering price. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our common stock may be volatile and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities markets worldwide have experienced in the past, and are likely to experience in the future, significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions could reduce the market price of our common stock regardless of our results of operations. The trading price of our common stock has been and is likely to continue to be volatile and could be subject to wide price fluctuations in response to various factors including, among other things, the risk factors described herein and other factors beyond our control. Factors affecting the trading price of our common stock could include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the broader stock market&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated variations in our quarterly results of operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments in our industry in general&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse results or delays in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated serious safety concerns related to the use of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory or legal developments in the United States and other countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of expenses related to future product candidates or clinical development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to achieve product development goals in the timeframe we announce&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issuance of new, negative or changed securities analysts' reports or recommendations or estimates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales, or anticipated sales, of our stock, including sales by our officers, directors and significant stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory or political developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the public's response to press releases or other public announcements by us or third parties, including our filings with the SEC&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements, media reports or other public forum comments related to litigation, claims or reputational charges against us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">guidance, if any, that we provide to the public, any changes in this guidance, or our failure to meet this guidance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the development and sustainability of an active trading market for our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">investor perceptions of the investment opportunity associated with our common stock relative to other investment alternatives&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other events or factors, including those resulting from system failures and disruptions, earthquakes, hurricanes, war, acts of terrorism, global outbreaks or pandemic, other natural disasters or responses to these events&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">changes in accounting </span><span style="color:#000000;">principles&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">litigation and governmental investigations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changing economic conditions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors may cause the market price and demand for shares of our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action litigation against the company that issued the stock following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. Securities litigation against us, regardless of the merits or outcome, could result in substantial costs and divert the time and attention of our management from our business, which could have a material adverse effect on our business, financial condition, and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales of our common stock, or the perception in the public markets that these sales may occur, could cause the market price for our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shares of common stock sold in this offering will be freely transferable without restriction or further registration under the Securities Act. At the time of this offering, 594,397 shares of common stock are reserved for issuance under our 2021 Equity Incentive Plan. We cannot predict the effect, if any, that market sales of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Sales of substantial amounts of shares of our common stock in the public market, or the perception that those sales will occur, could cause the market price of our common stock to decline. Of the shares of common stock outstanding, 8,635,904 are restricted securities within the meaning of Rule 144 under the Securities Act and subject to certain restrictions on resale. Restricted securities may be sold in the public market only if they are registered under the Securities Act, or are sold pursuant to an exemption from registration such as Rule 144 or Rule 701. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, each of our officers, directors, and certain of our stockholders agreed in connection with our initial public offering, which was consummated on August 1, 2022, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of our IPO prospectus, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of our IPO prospectus, without the prior written consent of the representative. In connection with this Offering, our directors and officers have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of six (6) months from the date of this Offering. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. See the section of this prospectus entitled &#8220;<span style="font-style:italic;">Underwriting</span>&#8221; for additional information. See &#8220;<span style="font-style:italic;">Underwriting</span>&#8221; for additional information. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts publish unfavorable research about our business, or if our competitors' stock performance decline, the price of our common stock and our trading volume could decline. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts may publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our common stock or publish unfavorable research about our business, the price of our common stock likely would decline. Additionally, if one of our competitor's stock performance declines, the price of our common stock and our trading volume could decline as well. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, or if one of our competitor's stock performance declines, demand for our common stock could decrease, which might cause the price of our common stock and trading volume to decline. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. As a result of our current dividend policy, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it. Any future determination to declare and pay cash dividends will be at the discretion of our board of directors and will depend on, among other things, our financial condition, results of operations, cash requirements, contractual restrictions and such other factors as our board of directors deems relevant. Our ability to declare and pay dividends to our stockholders is subject to certain laws, regulations, and policies, including minimum capital requirements and, as a Delaware corporation, we are subject to certain restrictions on dividends under the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Under the DGCL, our board of directors may not authorize payment of a dividend unless it is either paid out of our surplus, as calculated in accordance with the DGCL, or if we do not have a surplus, it is paid out of our net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Our ability to pay dividends depends on our receipt of cash dividends from our operating subsidiaries, which may further restrict our ability to pay dividends as a result of the laws of their jurisdiction of organization or agreements of our subsidiaries, including agreements governing our indebtedness. For more information, see &#8220;Dividend Policy.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will have broad discretion in the application of the net proceeds from this offering and our shareholders will not have the opportunity as part of their investment decision to assess whether the net proceeds are being used appropriately. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our failure to apply the net proceeds of this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. See &#8220;<span style="font-style:italic;">Use of Proceeds</span>&#8221; for a description of how we intend to use the proceeds of the offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If you purchase shares of our common stock in this offering, you will incur immediate dilution in the book value of your shares.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The offering price of our common stock will be substantially higher than the as adjusted net tangible book value per share of our common stock. Therefore, if you purchase our common stock in this offering, you will pay a price per share of our common stock that substantially exceeds the book value of our tangible assets after subtracting our liabilities. Based on the assumed offering price of $3.57 per share, you will experience immediate dilution of $0.50 per share, representing the difference between our net tangible book value per share, after giving effect to this offering, and the offering price. Further, the future exercise of outstanding options and/or warrants to purchase shares of our common stock will cause you to experience additional dilution. See &#8220;<span style="font-style:italic;">Dilution</span>.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Pursuant to our amended and restated bylaws and the DGCL, our directors will not be liable to the Company or any stockholders for damages for any breach of fiduciary duty, except (i) acts that breach his or her duty of loyalty to the Company or its stockholders&#59; (ii) acts or omissions without good faith or involving intentional misconduct or knowing violation of the law&#59; (iii) pursuant to Section 174 of the DGCL regarding director liability for unlawful payment of a dividend or unlawful stock purchase or redemption&#59; or (iv) for any transaction from which the director derived an improper personal benefit. In addition, we have entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the DGCL. The bylaws also require us, if so requested, to advance expenses that such director or officer incurred in defending or investigating a threatened or pending action, suit or proceeding, provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may, in the future, issue additional capital stock, which would reduce investors&#8217; percent of ownership and may dilute our share value.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the right to raise additional capital or incur borrowings from third parties to finance our business. We may also implement public or private mergers, business combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional capital stock to outside parties, causing substantial dilution in the ownership of the Company by our existing stockholders. Our Board of Directors has the authority, without the consent of any of the stockholders, to cause us to issue more shares of common stock and/or preferred stock at such price and on such terms and conditions as are determined by the Board of Directors in its sole discretion. The issuance of additional shares of capital stock by us will dilute your ownership percentage in the Company and could impair our ability to raise capital in the future through the sale of equity securities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain stockholders who are also officers and directors of the Company may have significant control over our management.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors and executive officers own as of April 3, 2023, an aggregate of 3,210,746 shares of our common stock, which constitutes 29.20% of our issued and outstanding common stock and, upon closing of this offering, will own an aggregate of 3,210,746 shares of our common stock, which will constitute 22.36% of our issued and outstanding common stock. As a result, our directors and executive officers may have a significant influence on our affairs and management, as well as on all matters requiring stockholder approval, including electing and removing members of our Board of Directors, causing us to engage in transactions with affiliated entities, causing or restricting our sale or merger, and certain other matters. Such concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even when such a change of control would be in the best interests of our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover protections in our amended and restated certificate of incorporation and our amended and restated bylaws, or our contractual obligations may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions contained in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of the DGCL, could delay or make it more difficult to remove incumbent directors or could impede a merger, takeover or other business combination involving us or the replacement of our management, or discourage a potential investor from making a tender offer for our common stock, which, under certain circumstances, could reduce the market value of our common stock, even if it would benefit our stockholders. Among other things, these provisions: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">do not permit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">delegate the sole power of a majority of the board of directors to fix the number of </span><span style="color:#000000;">directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide the power to our board of directors to fill any vacancy on our board of directors, whether such vacancy occurs as a result of an increase in the number of directors or otherwise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">generally limit stockholders ability to call special meetings of stockholders and generally prohibit stockholder action to be taken by written consent&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, agents or other stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on our behalf, (ii) action asserting a claim of breach of a fiduciary duty or other wrongdoing by any current or former director, officer, employee, agent or stockholder to us or our stockholders, (iii) <span style="color:#000000;">any action or proceeding asserting a claim against us or any current or former director, officer or other employee of the company, arising out of or pursuant to </span>arising under any provision of the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware, except for, as to each of (i) through (iv) above, any action as to which the Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the personal jurisdiction of the Court of Chancery of the State of Delaware (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery of the State of Delaware within ten (10) days following such determination), in which case the United States District Court for the District of Delaware or other state courts of the State of Delaware, as applicable, shall, to the fullest extent permitted by law, be the sole and exclusive forum for any such claims. However, the exclusive forum provisions shall not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, for which the federal district courts of the District of Delaware shall be the sole and exclusive forum unless the Company consents in writing to the selection of an alternative forum. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in any shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our amended and restated bylaws. This choice of forum provision may limit a stockholder's ability to bring a claim in a different judicial forum, including one that it may find favorable or convenient for a specified class of disputes with us or our directors, officers, other stockholders, or employees, which may discourage such lawsuits, make them more difficult or expensive to pursue, and result in outcomes that are less favorable to such stockholders than outcomes that may have been attainable in other jurisdictions. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies' certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are considered a &#8220;smaller reporting company&#8221; and are exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rule 12b-2 of the Exchange Act defines a &#8220;smaller reporting company&#8221; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated offering price of the shares&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a &#8220;smaller reporting company&#8221; we are not required and may not include a Compensation Discussion and Analysis section in our proxy statements&#59; we provide only 3 years of business development information&#59; provide fewer years of selected data&#59; and have other &#8220;scaled&#8221; disclosure requirements that are less comprehensive than issuers that are not &#8220;smaller reporting companies&#8221; which could make our stock less attractive to potential investors, which could make it more difficult for you to sell your shares.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are considered an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially impact reporting of our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant volatility to our reported or expected financial performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Under standards established by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) and the Exchange Act, a deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB and Rule 12b-2 of the Exchange Act define a material weakness as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely basis.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the first fiscal year beginning after the effective date of our IPO and in each year thereafter. Our auditors will also need to attest to the effectiveness of our internal control over financial reporting upon losing our Emerging Growth Company status and becoming an accelerated filer or a large accelerated filer. If we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material adverse effect on our business, financial condition, and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire investment in our Company.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon becoming a public company, we are required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our controls over financial reporting. Although we are required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal controls over financial reporting pursuant to Section 404 until the year following our first annual report required to be filed with the SEC. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting, as well as a statement that our independent registered public accounting firm has issued an opinion on the effectiveness of our internal control over financial reporting, provided that our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the Securities and Exchange Commission, or SEC, following the later of the date we are deemed to be an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer,&#8221; each as defined in the Exchange Act, or the date we are no longer an emerging growth company, as defined in the JOBS Act. We could be an emerging growth company for up to five years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified deficiencies in our internal control that we consider to be material weaknesses in our internal control over financial reporting which existed as of December 31, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not maintain an effective control environment <span style="color:#000000;">as there was an insufficient complement of personnel within the finance and accounting function with appropriate degree of knowledge, experience and training in the application of U.S. generally accepted accounting principles (&#8220;U.S. GAAP).&#160;&#160;</span>These factors contributed to the following additional material weaknesses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We failed to design, implement and maintain effective controls regarding:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risks associated with segregation of duties&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>risks associated with accounting for non-recurring complex transactions.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As we work towards remediating these&#160;material weaknesses, we will design and implement controls to properly account for non-recurring complex transactions in accordance with U.S. generally accepted accounting principles. In addition, we will design, document, and consistently perform control activities in the identified areas which are currently lacking. To assist us in the remediation and performance of remediated controls we hired a Corporate Controller, and we will continue to utilize an accounting and financial reporting advisory firm with significant experience with publicly held companies to assist our management in the accounting treatment for complex transactions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely affect our reputation, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unanticipated changes in the insurance market or factors affecting self-insurance reserve estimates could have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a combination of insurance and self-insurance coverage to provide for potential liabilities for workers' compensation, general liability, property losses, auto liability, directors and officers liability, pharmacy liability and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee health care benefits. However, there are types of losses we may incur but against which we cannot be insured or which we believe are not economically reasonable to insure, such as losses due to acts of war, employee and certain other crime, certain wage and hour and other employment-related claims, including class actions, actions based on certain customer protection laws, certain cyber events and some natural and other disasters or similar events. If we incur these losses and they are material, our business could suffer. Liabilities associated with the risks that are retained by us are determined, based in part, by considering historical claims experience, severity factors, inflation, and other actuarial assumptions. Our determination of the risk we retain is subject to a high degree of variability related to, among other things, future interest and inflation rates, future economic conditions, litigation trends and benefit-level changes. Any deviation of actual claims and other expenses related to these and other risks in excess of our assumptions, estimates, and historical trends, may have a material adverse effect on our business, financial condition and results of operations.</span></p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets. Additionally, Russia&#8217;s prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this registration statement on Form S-1.</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past led and may in the future lead to market-wide liquidity problems. On March 10 and March 12, 2023, the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) took control and was appointed receiver of Silicon Valley Bank (&#8220;SVB&#8221;) and Signature Bank, respectively, after each bank was unable to continue its operations. We are unable to predict the extent or nature of the impacts of the failures of SVB and Signature Bank and related circumstances at this time. Similarly, we cannot predict the impact that the high market volatility and instability of the banking sector more broadly could have on economic activity and our business in particular. The failure of other banks and financial institutions and measures taken, or not taken, by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not hold any of our funds at SVB or Signature Bank, if the financial institutions with which we do <span style="color:#000000;">business enter receivership or become insolvent in the future, there is no guarantee that the Department of the Treasury, the Federal Reserve and the FDIC will intercede to provide us and other depositors with access to balances in excess of the $250,000 FDIC insurance limit, that we would be able to access our existing cash, cash equivalents and investments, that we would be able to maintain any required letters of credit or other credit support arrangements, or that we would be able to adequately fund our business for a prolonged period of time or at all, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, if any parties with which we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to continue to fund their business and perform their obligations to us could be adversely affected, which, in turn, could have a material adverse effect on our business, financial condition and results of operations.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain statements contained in this prospectus, which reflect our current views with respect to future events and financial performance, and any other statements of a future or forward-looking nature constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. We intend the forward-looking statements to be covered by the applicable safe harbor under the federal securities laws. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; or the negative of these terms or other similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on the information we have when the statements are made or management&#8217;s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth above under &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; and elsewhere in this prospectus. The factors set forth above under &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; and other cautionary statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance on such statements. We operate in an evolving environment where new risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDUSTRY AND OTHER DATA</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Information that is based on estimates, forecasts, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information based on various factors, including those discussed in &#8220;<span style="font-style:italic;">Risk Factors.</span>&#8221;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business in the United States and/or in certain foreign jurisdictions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &#174; and &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="USE_PROCEEDS">USE OF PROCEEDS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the net proceeds from the sale of the 3,360,000 shares of common stock we are offering will be approximately $9.90 million. If the underwriters fully exercise the over-allotment option, the net proceeds of the common stock we sell will be approximately $11.57 million.&#160;&#160;&#8220;Net proceeds&#8221; is what we expect to receive after deducting the underwriting discount and commission and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approximately $8-$10 million to fund the ongoing Phase 2 trial of THIO for NSCLC indication (THIO-101)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approximately $1-$2 million to fund the planned Phase 2 trial of THIO for CCRC indication 9THIO-102)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approximately $1-$2 million to fund pre-clinical to IND development for two second-generation telomere targeting compounds</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the remaining proceeds to fund our other research and development activities, as well as for working capital and other general corporate purposes.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net proceeds from this offering, together with our cash, will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the clinical trials we may commence in the future, as well as any collaborations that we may enter with third parties for our product candidates and any unforeseen cash needs. As a result, our management will have significant discretion in the use of any net proceeds and Investors will be relying on the judgment of our management regarding the application of the proceeds. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our planned use of the net proceeds from this offering and our existing cash, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 15 months. In particular, we expect that these capital resources will allow us to fund:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our planned advancement of two clinical trials&#59; THIO 101 in NSCLC and THIO 102 in NSCLC and CCRC&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our planned pre-clinical to IND development for two second-generation telomere targeting compounds</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. Our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds from this offering, may or may not be sufficient to fund development of our product candidates through regulatory approval and commercialization. To obtain the capital necessary to fund our product candidates through regulatory approval and commercialization, we expect to finance our cash needs through public or private equity offerings, debt financings and/or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="DIVIDEND_POLICY">DIVIDEND POLICY</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future. Investors should not purchase our common stock with the expectation of receiving cash dividends. The payment of dividends, if any, in the future is within the discretion of our Board of Directors and will depend on our earnings, capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance the development and growth of our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CAPITALIZATION">CAPITALIZATION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our cash and capitalization as of December 31, 2022:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">on an actual basis&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">on a proforma basis after giving effect to the issuance of 18,000 shares of commons stock in January 2023 and from the issuance of 22,500 shares of common stock in March 2023 for investor relation services.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">pro forma as adjusted basis to give effect to the sale of common stock in this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares, at an assumed offering price of $3.57 per share based on the closing price of our common stock on NYSE American on April 3, 2023, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and the application of the proceeds therefrom as described in &#8220;<span style="font-style:italic;">Use of Proceeds</span>.&#8221;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual offering price and other terms of this offering determined at pricing. You should read the information in this table together with our financial statements and accompanying notes appearing at the end of this prospectus and the &#8220;<span style="font-style:italic;">Selected Financial Data</span>,&#8221; &#8220;<span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; and &#8220;<span style="font-style:italic;">Description of Capital Stock</span>&#8221; sections of this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.08%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="9" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Actual</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pro Forma</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:15.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pro Forma</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted</p></td>
<td valign="top" style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:15.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,950,927</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,950,927</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;width:14.22%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,850,164</p></td>
<td valign="top" style="background-color:#CFF0FC;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1.28%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:14.22%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="top" style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; Equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:14.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value, 30,000,000 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares authorized, 0 shares Issued and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding, actual&#59; 0 shares issued and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding, pro forma&#59; and 0 shares issued and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding, pro forma as adjusted</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:14.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value, 70,000,000 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares authorized, 10,955,904 shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding, actual&#59; 10,996,404 shares issued </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding, pro forma&#59; and 14,356,404</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued and outstanding, pro forma as</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; adjusted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,100</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:14.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436</p></td>
<td valign="top" style="background-color:#CFF0FC;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,729,942</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,729,938</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:14.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,628,839</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,207,272</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,207,272 </p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:14.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,207,272 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,973</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,973 </p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:14.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,973</p></td>
<td valign="bottom" style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:14.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,407,030</p></td>
<td valign="top" style="background-color:#CFF0FC;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total capitalization:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="top" style="width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="top" style="width:1.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:14.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,407,030</p></td>
<td valign="top" style="width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock issued and outstanding actual and pro forma in the table above is based on <span style="color:#000000;">10,955,904</span> shares of our common stock outstanding as of December 31, 2022, and excludes the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">6,545,628 shares of common stock issuable upon exercise of options to purchase shares of common stock outstanding as of December 31, 2022, with a weighted-average exercise price of $2.55 per share&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">1,271,413 shares of common stock reserved for future issuance as of December 31, 2022, under our 2021 Equity Incentive Plan&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">796,985 shares of common stock issuable upon exercise of warrants to purchase shares of common stock outstanding as of December 31, 2022 with a weighted-average exercise price of $6.04 per share.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="DILUTION">DILUTION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you purchase common stock in this offering, your interest will be diluted immediately to the extent of the difference between the assumed offering price of $3.57 per share and the net tangible book value per share of our common stock immediately upon the consummation of this offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net tangible book value as of December  31, 2022 was $8.51 million, or $0.78 per share. Net tangible book value per share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of shares of common stock outstanding as of that date.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value dilution per share to new investors represents the difference between the amount per share paid by purchasers in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to our sale of 3,360,000 shares of common stock in this offering at an assumed offering price of $3.57 per share, and after deducting underwriters&#8217; commissions and estimated offering expenses, our as adjusted net tangible book value as December 31, 2022, would have been $18.41 million, or $1.28 per share. This represents an immediate increase in net tangible book value of $0.50 per share to existing stockholders and an immediate dilution in net tangible book value of $2.29 per share to purchasers of securities in this offering, as illustrated in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering price per share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.57</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value per share as of December 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in net tangible book value per share attributable to new investors</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.50</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As adjusted net tangible book value per share as of December 31, 2022, after giving effect to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; the offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilution per share to new investors in the offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the underwriters exercise their option in full to purchase 504,000 additional shares of common stock in this offering at an assumed offering price of $3.57 per share, the net tangible book value per share after this offering would be $1.35 per share, the increase in the net tangible book value per share to existing stockholders would be $0.57 per share and the dilution to new investors purchasing common stock in this offering would be $2.22 per share.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that outstanding exercisable options or warrants are exercised, you may experience further dilution.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may choose to raise additional capital due to market conditions or strategic considerations, to fund our current or future operating plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be further diluted.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SELECTED_FINANCIAL_DATA">SELECTED FINANCIAL DATA</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read the following selected financial data together with our financial statements and the related notes appearing at the end of this prospectus and the &#8220;<span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; section of this prospectus. We have derived the statement of operations data and balance sheet data for the years ended December 31, 2022 and 2021 from our audited financial statements appearing at the end of this prospectus. The audited financial statements reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for a fair presentation of the audited financial statements. Our historical results are not necessarily indicative of results that should be expected in any future period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,950,927</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,292</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,539,131</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,022,040</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simple agreement for future equity payable</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>We define working capital as current assets less current liabilities</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,933,314</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,143,527</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ratchet share expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,360</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,176,201</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,176,201</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,967</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,625 </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666 </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,394</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes and convertible notes, related parties</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,922</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,769,279</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,331</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on warrant modification</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,578</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc.</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,219,857</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,503,880</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share &#8211; basic and diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.75</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding &#8211; basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,276,761</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,435</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup> See Note 1 to our audited financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="MANAGEMENTS_DISCUSSION_ANALYSIS_FINANCIA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion together with our financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting cancer. Our initial disease target is lung cancer, a serious medical condition with an incidence of over 236,000 new cases in the US in 2022, representing 12.3% of all cancers, and over 130,000 deaths, or 21.4% of all cancers. Worldwide, lung cancer incidence is over 2,200,000 per year (ranking second only after breast cancer), and mortality over 1,800,000 (ranking first). Specifically, we are targeting Non-Small Cell Lung Cancer (NSCLC), which represents 85% of all lung cancers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accomplished the following key milestones:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In November 2018, we in-licensed THIO from University of Texas Southwestern, in Dallas. The patent license is global and exclusive for the duration of the patients&#8217; lives.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In 2019, we completed a common stock seed round in the amount of $2 million.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In 2019, we generated the first data for THIO demonstrating complete regression with no recurrence when administered in advance of atezolizumab (TecentriQ&#174;&#59; Genentech), in colorectal and lung cancer preclinical models.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the First Quarter 2020, we filed a provisional patent application for THIO in sequential combination with checkpoint inhibitors, covering all tumor types. The patent was allowed in the US in the First Quarter 2021 and expires in 2041.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the First Quarter 2021, we entered into a Drug Supply Agreement with Regeneron Pharmaceuticals, Inc. Under this agreement, Regeneron will provide cemiplimab (LIBTAYO&#59; anti-PD-1 checkpoint inhibitor) at no charge for the THIO-101 trials, testing THIO administration for immune activation followed by cemiplimab in NSCLC. This drug supply agreement replaces direct drug purchase expense that we would be otherwise required to incur. In exchange, Regeneron received development exclusivity in NSCLC for the duration of the trial which is expected to be two years, meaning we cannot conduct trials in NSCLC with another checkpoint inhibitor during the time of the trial. All other areas of study and development in any other tumor types remain open.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the First Quarter 2021, we initiated our clinical supply manufacturing (CMC) under Good Manufacturing Practices (GMP) conditions to provide clinical supply for THIO-101 and other development needs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the Second Quarter 2021, we completed a convertible note funding round in the amount of approximately $8 million.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the Third Quarter 2021 and Fourth Quarter 2021, we sold common shares of MAIA for total proceeds of approximately $6.2 million. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the First Quarter 2022, we completed the Crossover Round for total proceeds of approximately $2.4 million. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the First Quarter 2022, THIO received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the THIO-101 Phase 2 clinical study.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small-cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">In May 2022, we completed the Additional Round for total proceeds of approximately $99,999. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In May 2022, we entered into a research and collaboration agreement with the Nationwide Children&#8217;s Hospital to evaluate the potential of THIO in combination with current standard-of-care therapies for brain cancer. The organizations is conducting preclinical studies to assess the efficacy and safety of THIO in combination with radiotherapy and immune checkpoint inhibitors in vitro and in vivo models.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In July 2022, we completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia. We have also submitted a similar application to conduct the same Phase 2 study in Europe.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On July 28, 2022, the Company&#8217;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5.00 per share for net proceeds of $10,000,000 in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5.00 per share when the underwriter exercised the overallotment for net proceeds of $1,500,000 prior to deducting underwriting discounts, commissions, and other offering expenses. We believe we have raised sufficient capital to fund the THIO-101 lead-in and preliminary efficacy of the phase 2 THIO-101 trial. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, MAIA&#8217;s Phase 2 clinical trial. THIO-101 is a critical component of THIO&#8217;s clinical development process and it is of the utmost importance that we collaborate with leading cancer institutes in Australia and now in Europe, for a target total of 30 clinical trial sites in six countries.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In November<span style="text-decoration:line-through;"> </span>2022, we completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC).</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In the first week of March 2023, the first two patients were dosed in Europe in MAIA&#8217;s Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Following regulatory clearances in Hungary, Poland, and Bulgaria, nine clinical sites have been activated in these three European countries.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on Our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our initial clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the War in Ukraine on Our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The short and long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time. The imposition of sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. Because of the highly uncertain and dynamic nature of these events, the Company terminated any planned research activities in Russia. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview and Analysis </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> the Years Ended December 31, 2022 and 2021</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td rowspan="2" colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:31.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollars</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,933,314</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496,796</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436,518</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,143,527</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,289,831</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,853,696</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ratchet share expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,360</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,360</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,176,201</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786,627</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,389,574</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,176,201</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,786,627</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,389,574</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,967</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(827,539</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820,572</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,012</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(142</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; development incentives</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,625</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,666</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,959</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; features</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,394</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546,280</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,644,674</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible notes and convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; notes, related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,322,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,322,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:34.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,922</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,791,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,198,506</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:34.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,769,279</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,578,211</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,191,068</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by approximately $5,437,000 or 155%, from approximately $3,497,000 for the year ended December 31, 2021 to approximately $8,933,000 for the year ended December 31, 2022. The increase was primarily related to an increase in payroll and bonus expense of approximately $2,244,000 related to increased headcount of nine additional employees during the fiscal year 2022, the increase in clinical expenses related to the clinical trial startup of THIO of approximately $1,979,000, an increase in Scientific pre-clinical research of approximately $1,127,000, an increase in professional fees of approximately $18,000, and an increase in other expenses related to research and development of approximately $116,000 offset by a decrease in stock based compensation costs of approximately $47,000 related to employee options granted during fiscal year 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by approximately $1,854,000 or 43% from approximately $4,290,000 for the year ended December 31, 2021 to approximately $6,144,000 for the year ended December 31, 2022. The increase was primarily attributable to the increased costs to create additional infrastructure to support our operations as a public company. Increases included an increase in payroll and bonus expense of approximately $929,000 related to the increase in head count over the same period last year, the approximate increase in other expenses of $896,000 and an increase of approximately $358,000 in professional fees offset by decrease in stock based compensation expense of approximately $329,000 primarily due to the 2021 expense related to founder's stock-based compensation expense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ratchet Expense</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ratchet expense increased by approximately $1,099,000 or 100% for the year ended December 31, 2022 due to the issuance of ratchet shares to certain private investors that purchased shares of our common stock prior to our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other income (expense), net</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net increased approximately $5,199,000 from other expense of approximately $4,792,000 for the year ended December 31, 2021 to other income of approximately $407,000 for the year ended December 31, 2022. The increase in other income (expense), net was primarily the result of a loss on extinguishment of convertible notes and convertible notes of approximately $2,323,000 in 2021, approximately $1,645,000 of expense for the change in fair value of the warrant liability, the change in the fair value of bifurcated embedded feature of $203,000, expense related to approximately $828,000 of interest for convertible notes for the year ended December 31, 2021, and other income increased by approximately $270,000 of income related to the Australian research and development incentives for the year ended December 31, 2022 offset by a decrease in other income of approximated $63,000 for the paycheck protection loan forgiveness for the year ended December 31, 2021 and offset by the approximate $7,000 of interest expense for the year ended December 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents selected financial information and statistics as of December 31, 2022 and 2021:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.03%;"></td>
<td style="width:1.03%;"></td>
<td style="width:1.03%;"></td>
<td style="width:13.39%;"></td>
<td style="width:1.03%;"></td>
<td style="width:1.03%;"></td>
<td style="width:1.07%;"></td>
<td style="width:12.37%;"></td>
<td style="width:1.04%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,950,927</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,574,592</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,539,131</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,526,499</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,022,040</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,327,199</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,582</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,507,793</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,181,203</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We define working capital as current assets less current liabilities.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our Ability to Continue as a Going Concern</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022, our available cash totalled approximately $10,951,000 which represented an increase of approximately $376,000 compared to December 31, 2021. As of December 31, 2022, we had working capital of approximately $8,539,000 which represents an increase of approximately $13,000 compared to December 31, 2021. We have generated no revenues as of December 31, 2022. The Company&#8217;s current operating plan indicates that it will continue to incur losses from operations and generate negative cash flows from operating activities given ongoing expenditures related to the completion of its ongoing clinical trials and the Company&#8217;s lack of revenue generating activities. Based on the Company&#8217;s cash reserves as December 31, 2022 of approximately $10,951,000 and current financial condition as of the date of this prospectus, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sale of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between April 22, 2022 and May 3, 2022, warrant holders exercised warrants, resulting in the issuance of 153,000 shares of common stock for proceeds of approximately $275,400.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 19, 2022, the Company sold 11,111 shares of common stock at $9.00 per share for gross proceeds of $99,999 with no transaction costs. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in an initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional capital to fund our operations, to develop and commercialize THIO, and to develop, acquire or in-license other products. We may seek to fund our operations through public equity, private equity, or debt financings, as well as other sources. We cannot make any assurances that additional financings will be available to us and, if available, on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows<span style="font-weight:normal;font-style:normal;"> years </span>ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:30.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,655,725</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,122,896</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,036,790</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,033,731</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency exchange rate changes on cash</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,430</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376,635</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,910,835</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2022, net cash used in operating activities was approximately $11,657,000, which consisted of a consolidated net loss of approximately $15,769,000 offset by non-cash charges of approximately $3,320,000 which primarily includes approximately $2,319,000 in stock-based compensation, approximately $1,099,000 of expense related to the ratchet share issuance, offset by a gain of approximately $98,000 related to the changes in fair value of the warrant liability. Total changes in operating assets and liabilities of approximately $793,000 were primarily driven by an approximate $211,000 increase in accounts payable, and an approximate $1,027,000 increase in accrued expenses and an approximate $440,000 decrease in deferred offering costs offset by an approximate $111,000 decrease in deferred compensation, an approximate increase of $269,000 in Australian research and development incentives receivable and an approximate $505,000 increase in prepaid expenses and other current assets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, net cash used in operating activities was approximately $4,123,000, which consisted of a consolidated net loss of approximately $12,578,000 offset by non-cash charges of approximately $7,330,000 which primarily includes approximately $2,723,000 in stock-based compensation, a loss of approximately $203,000 related to the change in fair value of embedded features related to convertible notes, a loss of approximately $1,546,000 related to the changes in the fair value of the warrant liability, and amortization of debt discount on convertible notes of approximately $597,000, offset by a gain from forgiveness of Payroll Protection Plan loan of approximately $63,000. Total changes in operating assets and liabilities of approximately $1,126,000 were primarily driven by an approximate $806,000 increase in accounts payable, and an approximate $1,261,000 increase in accrued expenses, offset by an approximate $7,000 decrease in related party payables, an approximate $15,000 increase in prepaid expenses and other current assets, an approximate $264,000 increase in deferred compensation, and an approximate $652,000 increase in deferred offering costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2022&#160;&#160;was approximately 12,037,000 consisting primarily of gross proceeds from the sale of common stock in the initial public offering of approximately $11,500,000, net proceeds from issuance of common stock of approximately of $2,474,000 in a crossover round, and proceeds from issuance of common stock upon exercise of warrants of approximately $385,000 and stock options of approximately $84,000 offset by approximately $2,406,000 of the offering costs paid in the year ended December 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2021 was approximately $14,034,000 which consisted primarily of proceeds from issuance of convertible notes totaling approximately $7,369,000, collections of subscriptions receivable of approximately $322,000 for MAIA, proceeds from issuance of common stock (net of transaction costs) of approximately $5,742,000, proceeds from the paycheck protection program loan totaling $63,000, proceeds from exercise of warrants of approximately $529,000 for MAIA, and proceeds from exercise of stock options of approximately $9,000 for MAIA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s discussion and analysis of our financial condition and results of our operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of stock options and warrants and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. We define our critical accounting policies as those accounting principles that require it to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 1 to our financial statements, we believe the following are the critical accounting policies used in the preparation of its financial statements that require significant estimates and judgments.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock-based awards are classified as equity (restricted stock awards, and stock options, and warrants). We recognize related stock-based compensation expense based on the grant date fair value of the awards. The fair value of restricted stock awards is based on the trading value of the Company's common stock. We estimate the fair value of stock options and warrants using the Black-Scholes-Merton valuation model which requires the use of subjective assumptions that could materially impact the estimation of fair value and related compensation expense to be recognized. One of these assumptions include the expected volatility of our stock price. Developing this assumption requires the use of judgment. The Company lacks company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two of the assumptions used in the Black-Scholes-Merton valuation model are historical volatility and fair value of common stock. Historical volatility is subject to uncertainty due to changes in the market over time. The fair value of our common stock is subject to uncertainty due to the possibility of changes in the results of our clinical trials, which could impact the fair value of our common stock. The total expense related to stock options is material to our financial statements on an annual basis, and significant fluctuations in the volatility assumption or the fair value of our common stock could result in material changes in related compensation expense to be recognized.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Prepaid and Accrued Research and Development Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our prepaid and accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our prepaid and accrued research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances<br />known to us at the time. We confirm the accuracy of estimates with the service providers and make adjustments if necessary. Examples of estimated prepaid and accrued research and development expenses include expenses for:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical Research Organizations (CROs) in connection with clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Investigative sites in connection with clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Vendors in connection with preclinical development activities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Vendors related to product manufacturing, development and distribution of clinical materials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. The scope of services under these contracts can be modified and some of the agreements may be canceled by either party upon written notice. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study<br />milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed we may report amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates and the amount actually incurred.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="BUSINESS">BUSINESS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Company</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. We completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved on March 1, 2022, by the Australian Regulatory Agency - Bellberry Human Research Ethics Committee. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia. In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating THIO in patients with NSCLC. Patients with advanced Non-Small Cell Lung Cancer (NSCLC) will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo&#174; (cemiplimab) manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. Cemiplimab has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study. In return, we have granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. Based on the clinical data we aim to generate by the THIO-101 trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. In addition, in the Fourth Quarter of 2023, we plan to initiate a Phase 2 clinical trial in multiple solid tumor indications of THIO administered in sequence with Anti-PD-1 or Anti-PD-L1.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Product Candidate </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-dG or 6-thio-2&#8217;-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, our research team discovered that THIO produced telomere modifications and disruption, which ultimately induced cancer-specific innate and adaptive immune responses against immunologically &#8220;cold&#8221; tumors or tumor types that were unresponsive to immune checkpoint inhibitors. This hypothesis was tested and demonstrated in syngeneic and humanized mouse models. THIO administered to mice in low doses and followed by an immune-checkpoint inhibiting agent, such as an anti-PD-1 or anti-PD-L1 compound, induced complete tumor regression with no tumor recurrence during the 14 weeks of observation. Further, no toxicities were reported in the tumor-free mice. These new findings were published in the highly reputable, peer-reviewed research scientific journal, <span style="text-decoration:underline;">Cancer Cell </span>in July 2020. Based on these recent discoveries, a new therapeutic approach has been designed to advance THIO into a Phase 2 clinical trial (THIO-101) in patients with advanced NSCLC. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA in the near future. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, we take added confidence in the potential tolerability of THIO in light of the fact that the THIO doses we plan to test represent a range of 4 to 40 times lower than the maximum tolerated dose tested in the earlier clinical trials sponsored by the National Cancer Institute in the 1970s. <span style="letter-spacing:0.2pt;">The planned THIO-101 phase 2 trial is intended to be a proof-of-concept study that may be modified depending on interim results to include both primary and secondary endpoints and be consistent with previously approved cancer treatments. In September 2022, we submitted a pre-IND meeting request to FDA to discuss, among other elements, the existing non-clinical and clinical data to support the conduct of our planned THIO-101 phase 2 trial under an IND to include patients from the United States. MAIA received feedback in-line with the proposed plans from the FDA regarding its manufacturing, preclinical and clinical development plan. MAIA also obtained guidance from the FDA on the assessment of its safety and efficacy in the THIO-101 Phase 2 trial that will be incorporated in the U.S. IND application. MAIA plans to file its U.S. IND in the first half of 2023 and commence enrolling patients in the </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="letter-spacing:0.2pt;">U.S. in the second half of 2023.</span><span style="letter-spacing:0.2pt;"> Based on the clinical data </span><span style="letter-spacing:0.2pt;">we aim to </span><span style="letter-spacing:0.2pt;">generate in the THIO-101 study and assuming THIO achieves its intended clinical effect with a manageable safety profile</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at one of the doses tested in the study, we expect to seek early FDA guidance and agreement for using this clinical trial as basis for requesting an accelerated approval. The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit, but</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology will still be required to conduct studies to confirm the anticipated clinical benefit. These studies are known as confirmatory trials. If the confirmatory trial shows that the drug provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. <span style="color:#000000;">The FDA&#8217;s accelerated approval pathway, even if initially granted, does not guarantee an accelerated review or marketing approval by the FDA. </span>The THIO-101 study protocol may need to be amended to increase the number of patients enrolled, undergo modification of the statistical analysis or change in the trial design and/or primary endpoints.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Science--Driven Telomere Targeting Approach</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive DNA nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes in cells. THIO&#8217;s mechanism of action comprises telomere targeting and induction of anti-cancer immunogenicity. The enzyme telomerase recognizes THIO&#8217;s metabolite formed <span style="font-style:italic;">in situ</span> and incorporates it into the structure of the cancer cell&#8217;s telomeres, creating a faulty structure, which breaks apart the telomere spatial structure. As a result, the THIO-modified telomeric structure unwinds, recognized as DNA damage, and the cancer cells die. We believe THIO transforms &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours. We also believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomere maintenance is a fundamental biologic process for cell proliferation and resilience in cancer cells, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in most human cancer cells (over 85% in the aggregate), across various tumor types. In contrast, its activity is detected in less than 1% of normal cells. THIO has only been shown to be active in cancer cells that are telomerase positive (TERT+) and actively dividing. Cancer cells are constantly telomerase positive due to an uncontrolled division process, while a relatively small number of normal cells are telomerase positive only transiently. Therefore, THIO activity is expected to be highly specific to cancer cells versus normal cells. Cancer-specific disturbance of telomeric structure, mediated by telomerase, is likely to lead to disruption in the cell cycle, followed by a very rapid and telomere-length independent cell death. THIO was observed in preliminary<span style="color:#2F5496;"> </span>in vitro and in vivo studies to induce cancer-specific telomere disruption, by using the enzyme telomerase which differentiates THIO from all other available cancer therapies currently in clinical use. We are also currently developing potential next-generation small molecule telomere modifying agents with the goal of identifying additional proprietary drug candidates, across multiple cancer types. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second Generation</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Molecule</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> Candidates</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with increased anticancer activity. This program may also allow us to strengthen our patent portfolio. Our current 2nd-generation pipeline of potential telomere-targeting agents includes seven compounds that have successfully undergone <span style="font-style:italic;">in vitro</span> inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO, as reflected in the following figure:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td colspan="21" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IC50, &#181;M</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell Lines</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compound ID</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MC38</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LLC</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hep55-&#160;1C</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H2081</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HEK293</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO(6 thio dG)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.92</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-*</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound #5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.02</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound #6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.01</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound #11</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.80</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.44</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.63</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound #12</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.50</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">IC50 is <span style="Background-color:#FFFFFF;">the half maximal inhibitory concentration, and it is a measure of the potency of a substance in inhibiting a specific biological or biochemical function, such as cell proliferation. </span><span style="font-style:normal;color:#000000;">Cell lines: MC38, LLC, Hep55-1C, H2081, and HEK293 are Non-Small Cell Lung Carcinoma, Colorectal, Hepatocellular carcinoma, Small Cell Lung Carcinoma, and Immortalized Human Kidney cell line, respectively. *- Data unavailable</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The figures below represent dose-response curves from which IC50 values were derived for second generation compounds #5 (X97848), and #12 (X97855) in HEK293 cells:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000004.jpg" title="" alt="" style="width:307px;height:206px;" /><img src="gjyjiv3jrhol000005.jpg" title="" alt="" style="width:307px;height:206px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below demonstrates the dose response curves for our number five next generation compound, designated as 6S-dG-dimer, in ovarian cancer-derived cell line CoC1/DDP, in comparison with cisplatin (current standard of care in this setting). The corresponding IC50 values are shown next to the plot.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000006.jpg" title="" alt="" style="width:624px;height:251px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In mid-January 2023, MAIA nominated one lead new molecular entity candidate (designated as MAIA-2021-20) and one back-up new molecular entity candidate (MAIA-2022-12) for further advancement into preclinical GLP-toxicity and other studies, and may advance one of these candidates into human clinical trials upon completion of the required preclinical evaluations. MAIA also has filed a broad provisional patent application covering the composition of matter for the new telomere-targeting molecules in the fourth quarter of 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create a second generation of THIO-like compounds. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3E677D;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OUR PIPELINE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3E677D;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our pipeline includes several potential targeted immuno-oncology candidates for relapsed and refractory cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000007.jpg" title="" alt="" style="width:601px;height:338px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules. Our initial focus is to efficiently advance our Phase 2 clinical program with THIO in sequential combination with cemiplimab. Ultimately, our goal would be to position THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer. To date, THIO has never been tested in clinical trials in combination with any check-point inhibitor. The key elements of our strategy are to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Advance our existing clinical programs, including seeking accelerated approval for THIO in NSCLC as a tumor mass-reducing and simultaneously immune system priming agent administered in advance of the immune-activating agent, cemiplimab for treatment of advanced NSCLC, and ultimately, as a cancer treatment foundation in multiple indications and geographies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Broaden the clinical development of THIO by exploring synergistic administration prior to other standard-of care immune-therapies including cell therapy. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Develop a franchise of telomere-targeting cancer treatments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Leverage our regulatory strategy to acquire additional human data faster outside U.S. for other cancer indications. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Selectively enter into strategic collaborations with pharmaceutical and biotechnology companies that have immune activating therapies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expand our existing intellectual property portfolio.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face certain challenges in implementing our business strategy including, among others, the fact that earlier development of THIO was not commercially pursued. Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Market Opportunity and Unmet Medical Need</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most cancer cells are telomerase positive (TERT+), including 73% to 100% of primary human cancers dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO across most of the tumor types. We believe successful targeting of telomeres in TERT+ cancers may represent a significant potential for broad therapeutic utilization. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TERT(+)</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TERT(+)</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Small Cell Lung Cancer (NSCLC)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic Cancer</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal (CRC)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82-89%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small Cell Lung Cancer (SCLC)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatocellular Carcinoma (HCC)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79-86%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovarian Cancer</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast Cancer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma (RCC)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate Cancer</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glioblastoma Multiforme (GBM)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bladder Cancer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuroblastoma</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">head &#38; Neck Squamous Cell Carcinoma (HNSCC)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">`86%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphoma (high grade)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gastric Cancer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic Myeloid Leukemia (CML)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melanoma</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83-86%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic Lymphocytic Leukemia (CLL)</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">`57%</p></td>
<td valign="bottom" style="background-color:#EBECEB;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cervical Cancer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Myeloid Leukemia (AML)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sources: A Survey of Telomerase Activity in Human Cancer &#8211; JW Shay, S Bacchetti &#8211; European Journal of Cancer, 33,5,787-791, 1997. Telomerase Active in Human Liver Tissues&#59; H Tahara, et al&#59; Cancer Research 55, 2734-2736 1995&#59; Highly /aggressive Metastatic Melanoma Cell Unable to Maintain Telomere Length&#59; N Viceconte et al&#59; Cell Reports 2017&#59; and Fern&#225;ndez-Marcelo T, S&#225;nchez-Pernaute A, Pascua I, De Juan C, Head J, Torres-Garc&#237;a A-J, et al. (2016) Clinical Relevance of Telomere Status and Telomerase Activity in Colorectal Cancer. PLoS ONE 11(2).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial development program will focus on Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC) and Small Cell Lung Cancer (SCLC) in areas of clear unmet need and/or areas with deficient immunotherapy effect within each tumor type. Each tumor type and area of unmet or undermet needs represent significant clinical and commercial opportunity. We believe that THIO offers a desirable profile with significant commercial potential.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incidence</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prevalence</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortality</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 (M)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020&#160;($B)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2028&#160;($B)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Small Cell Lung Cancer</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liver</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small Cell Lung Cancer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sources: WHO&#59; Global Data</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below reflects the current market for check-point inhibitors because there is no current market for THIO-like molecules. The years in the indication columns on the table below signify the timing of FDA approval in the US for the clinical indications of interest. Because the key element of our strategy is to develop THIO to work in combination with check-point inhibitors, if THIO is eventually approved by the FDA for use in conjunction with check-point inhibitors, this table provides a high-level understanding of the potential market for THIO in that combination. There is no assurance, however, that any potential market for THIO would follow the current landscape for checkpoint inhibitor franchises.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current Landscape of Checkpoint Inhibitor Franchises</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:17.2pt;">
<td rowspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.54%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Drug</p></td>
<td rowspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.3%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Company</p></td>
<td rowspan="2" colspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.52%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($B)</p></td>
<td rowspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td rowspan="2" colspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.36%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indications</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(tumor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">types)</p></td>
<td rowspan="2" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.22%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NSCLC</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCLC</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRC</p></td>
<td valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HCC</p></td>
</tr>
<tr style="height:17.15pt;">
<td colspan="4" valign="bottom" style="background-color:#1D4258;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#F7F8F9;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year of FDA Approval</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KEYTRUDA <span style="font-style:italic;">(pembrolizumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merck</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPDIVO <span style="font-style:italic;">(nivolumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BMS / Ono</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TECENTRIQ <span style="font-style:italic;">(atezolizumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech / Roche</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMFINZI <span style="font-style:italic;">(durvalumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVYT <span style="font-style:italic;">(sintilimab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eli Lilly / Innovent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIBTAYO <span style="font-style:italic;">(cemiplimab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regeneron</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BAVENCIO <span style="font-style:italic;">(avelumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer / Merck AG</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TBD <span style="font-style:italic;">(tislelizumab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Novartis / BeiGene</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JEMPERLI <span style="font-style:italic;">(dostarlimab)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GSK</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Source: BioMed Tracker 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to obtain, maintain and enforce patent protection wherever appropriate for our product candidates, formulations, processes, methods and any other proprietary technologies, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our practice is to actively seek to obtain, where appropriate, intellectual property protection for our current product candidates and any future product candidates, proprietary information, and proprietary technology through a combination of patents, protection of proprietary know-how and trade secrets, and contractual arrangements, both in the United States and abroad. However, full patent protection may not provide us with complete protection against competitors who may seek to circumvent our intellectual property. Our success will depend on the skills, knowledge, experience and know-how of our management research and development personnel, as well as that of our advisors, consultants, and other contractors. To help protect our proprietary know-how that is not patentable, we seek to put in place appropriate internal policies for the management of confidential information requiring all our employees, consultants, advisors, and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information, and which will require disclosure and assignment to us of the ideas, developments, discoveries, and inventions important to our business. See &#8220;<span style="font-style:italic;">Risk Factors &#8211; Risks Related to our Intellectual Property</span>&#8221; for additional information.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file for patents, both directly and in collaboration with our licensing partners, in the United States with counterparts in certain countries in Europe and certain key market countries in the rest of the world, thereby covering the major pharmaceutical markets. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following patent families, which are generally directed to methods of using THIO and are owned and/or controlled by UTSW:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.07%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947), issued in the US, MX, NZ and RU (all method of use) pending in BR, CA, CN, EP, HK and SG.</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756), pending in the US (method of use)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482), pending in the US (method of use)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675), pending in the US (method of use)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted). All patents are method of use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020, we entered into a second agreement with UTSW, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second license with UTSW, which we refer to as the UTSW2 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.07%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090, pending in the US and PCT (method of use)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted). This patent is generally directed to methods of using THIO in combination with immune checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property acquisition and protection strategy, to adapt to competition or to seize potential opportunities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Team</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled an experienced management team with deep research, development, and commercialization experience in the areas of telomere-related science, immunotherapy, and across a vast array of oncology indications. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key Team highlights:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our team is led by our Co-founder, Chief Executive Officer and President Vlad Vitoc. He is an M.D. and M.B.A. with over 22 years of experience in the Pharmaceuticals and Biotechnology industries. </span><span style="Background-color:#FEFEFE;color:#000000;">He has served on leadership teams in various oncology companies and business units and has a track record of success at Bayer Pharmaceuticals, Astellas Pharma Inc., Cephalon Inc. and Incyte Corporation, including development and commercialization of major oncology brands, organizational capability building, talent recruiting and development, and functional leadership.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our Chief Medical Officer and Head of Development, Mihail Obrocea, M.D., is a former practicing academic medical hematologist/oncologist and experienced pharmaceutical physician executive that brings </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">over 20 years of</span><span style="color:#000000;"> successful cancer drug development track record from Juno Therapeutics Inc. (acquired by Celgene/BMS), Pharmacyclics Inc., AbbVie Bio Corp., </span><span style="color:#000000;">Mannkind</span><span style="color:#000000;"> Corp., </span><span style="color:#000000;">MedImmune</span><span style="color:#000000;">, Inc. and Pfizer, Inc., among others. His experience includes clinical development of cell therapies (CAR-T), cancer vaccines, antibodies, and antibody drug conjugates (ADCs) and small molecules across a wide range of tumor types and clinical indications.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our Chief Scientific Officer, Sergei M. Gryaznov, is a Ph.D. who is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. He is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO&#8217;s telomere targeting activity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our Chief Financial Officer, Joseph F. McGuire has served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. (&#8220;Avadim&#8221;). Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have engaged the following advisors, who are leading, internationally recognized experts in oncology, telomeres and telomerase research, to be a part of our Scientific Advisory Board (&#8220;SAB&#8221;), which provides independent non-binding scientific advice to our management team in the roles detailed below under each member&#8217;s name:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Tom Gajewski, M.D., Ph.D. &#8211; Professor of Cancer Immunotherapy (University of Chicago)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>One of the key pioneers in cancer immunotherapies and accomplished in the field</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Key investigator on all phase 2 and phase 3 trials in Melanoma (with Keytruda&#174;, Opdivo&#174;, etc.)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Past president of the Society for Immunotherapy of Cancer (SITC)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Serves as an editor for Cancer Research and Journal for Immunotherapy of Cancer</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, will cover translational research for all cancers, for clinical development</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Tudor Ciuleanu, M.D., Ph.D. &#8211; Professor of Oncology (University of Medicine and Pharmacy, Cluj-Napoca, Romania)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Top Key Opinion Leader (KOL) in <span style="color:#000000;">NSCLC</span> and CRC in Europe</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Key investigator in more than 90 phase 3 and phase 2 clinical trials, including most immune therapy agents</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>One of the best published clinical investigators (appears in most references in the National Comprehensive Cancer Network (NCCN) guidelines)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>President of Romanian Federation of Cancer Societies</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Editor for the Journal of Clinical Oncology (JCO), Romanian edition</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, will lead clinical activities in Europe across tumor types &#8211; NSCLC, CRC, Gastric, HCC, Head and Neck, Urological cancers, and Lymphomas</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Jerry Shay, Ph.D. &#8211; Professor and Vice Chairman of the Department of Cell Biology (University of Texas Southwestern)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>One of the world leaders in the study of telomeres and telomerase</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Scientific co-founder of the research supporting our lead program THIO and an integral advisor to the program</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Highly influential biomedical researcher with over 30 issued patents and more than 500 peer reviewed publications</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southland Financial Corporation Distinguished Chair in Geriatric Research and a Distinguish Professor at University of Texas Southwestern, having received the University of Texas Regent&#8217;s Outstanding Teaching Award and the Minnie Steven Piper Foundation Professor Award</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Awarded the Eunice Kennedy Shriver NIH Alliance Pioneer Award in 2017</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, Dr. Shay will provide scientific leadership as the THIO co-inventor and a worldwide recognized expert in the science of telomeres and telomerase in cancer. Dr. Shay serves as the Chairman of the SAB.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>David Ashley, M.D., Ph.D. &#8211; Professor of Neuro-Oncology (Duke University)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Top KOL in pediatric and adult neuro-oncology</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Expert in translational research and clinical development</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Expert in immuno-oncology, having developed and clinically tested dendritic cell vaccines and other immuno-therapeutics</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Principal investigator of a number of important national and international studies, both clinical and pre-clinical</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Former Director of two major cancer centers, The Royal Children&#8217;s Hospital Melbourne and Andrew Love Cancer Centre &#8211; Barwon Health</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, will assist in translational research in Brain Cancers for clinical development</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Gunnur Dikmen, M.D., Ph.D. &#8211; Professor at Hacettepe University Medical Faculty, Department of Medical Biochemistry, as well as the director of the Hacettepe University hospital&#8217;s emergency laboratory. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Broad range of experimental and clinical experience in molecular &#38; cell biology and clinical biochemistry, translating research results from bench to bedside and from academia to clinical laboratory to mentor the next generation of multidisciplinary research projects by providing new therapeutic approaches for cancer and telomere related diseases.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Expert in the biology of telomeres and telomerase in the treatment of cancer.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under her capacity as Secretary-General of the Turkish Biochemical Society, organized various important national and international courses and congresses.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, will assist in preclinical and translational research, across tumor types.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Adam Yopp, M.D. &#8211;Associate Professor and Division Chief of Surgical Oncology and Colorectal Surgery, at Harold C. Simmons NCI-designated Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Completed a fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center focusing on upper GI and hepatopancreatobiliary malignancy and joined UT Southwestern in 2009.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Director of the Liver Tumor Program at UTSW and both his research and clinical interests are focused on the delivery of care in patients with primary liver cancer.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Much-recognized key opinion leader in liver cancer.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>On our SAB, will assist with developing THIO for the treatment of liver cancer.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our SAB is primarily compensated by way of the grant of stock options as determined by the Company as appropriate in recognition of the specific services or areas of expertise of each member.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also supported by a seasoned board of directors, whose members have significant entrepreneurial skills in company building and corporate financing as well as decades of collective leadership and board experience. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Programs</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Telomere Targeting Program</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Targeting Telomeres via Telomerase Leads to Cancer Cell Death</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:63.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are regions of repetitive nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes, that represent a critical key therapeutic target for cancer. Telomeres are often depicted in imagery like the end of a shoelace.</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance of telomeres is essential for unlimited cellular proliferation and confers immortality in cancer cells. Telomeres in human cells consist of double-stranded and single-stranded repeats of the sequence TTAGGG, which terminate in a single-stranded 3&#180;- extension overhang of the G-rich strand. Their major function is to cap and protect the ends of chromosomes and thus to provide genetic stability. This capping function is mediated by a special architecture in which the 3&#180;- overhang participates with telomere-binding proteins in a large loop structure called T-loop. The image on the right reflects the general location of telomeres as the end-cap of the chromosomes, which are located in the nucleus of the cell.</p></td>
<td valign="top" style="width:0.72%;">
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000008.jpg" title="" alt="" style="width:221px;height:216px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adapted from <span style="font-style:italic;">Transcendental Meditation and lifestyle modification increase telomerase</span>, December 6, 2015.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most successful anti-cancer drugs in the market today typically interfere with only one of the specific capabilities or &#8220;hallmarks&#8221; cancer cells use for tumor growth and progression. In contrast, our lead drug candidate, THIO, targets two major hallmark pathways:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Targeting cancer cell </span><span style="font-style:italic;color:#000000;">telomeric</span><span style="color:#000000;"> DNA structure and functional integrity&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Activating the immune system that turns immunologically &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors that are responsive to therapy. THIO synergizes with immune activating agents, like checkpoint inhibitors, for the potential to attack and destroy tumors. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below reflects the many different methods by which successful anti-cancer drugs might prevent tumor growth and where THIO stands in relation to the other approaches.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000009.jpg" title="" alt="" style="width:611px;height:320px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotech Pipeline - PLANNED STUDIES 2022 2023 2024 2025 THIOLung Cancer Colorectal Cancer Other Solid Tumors Ph 2 THIO-101 NSCLC-2L+US Accelerated approval (projected) Ph 3 TERT+ NSCLC-2L+ Ph 3 NSCLC-1LPh 2 THIO-102 TERT+ CRC-3L+ Pivotal. Ph 2 Ph 3 MSS CRC-1LPh 2 Basket TERT+ Tumors L3+Ph 3 Pivotal TBDSCLC HCC GBM Melanoma Pancreatic Ovarian Breast Prostate Ph 3 Pivotal TBD Preclinical US Potential IND</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adapted from <span style="text-decoration:underline;color:#0000FF;">Cell 2011, Volume 144, Issue 5, Pages 646-674</span> (DOI:10.1016/j.cell.2011.02.013)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Role of the Enzyme Telomerase</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Telomerase<span style="font-style:normal;"> is a ribonucleoprotein enzyme (reverse transcriptase) that synthesizes telomere repeats from the beginning, or </span>de novo<span style="font-style:normal;">. In human cells, the telomerase holoenzyme consists of a high-molecular-weight complex with a template region-containing RNA subunit, hTR, and a protein component, the catalytic subunit human telomerase reverse transcriptase (hTERT). In most normal somatic cells, telomerase activity is absent and telomere repeats are lost with cell division and with aging. Telomerase is especially important in fetal tissues, reproductive cells and other tissues where extensive cell proliferation is necessary. However, most adult normal tissues are telomerase silent. Telomere attrition, beyond a certain threshold, results in the uncapping of chromosome ends, which subsequently induces DNA damage and onset of replicative senescence. In contrast, about 73% to 100% of all cancer cells in most tumor types have detectable telomerase activity, which leads to the stabilization of telomeres and allows for unlimited growth potential along with disease progression. Successful targeting of telomerase positive (TERT+) cancers represents a significant potential for therapeutic utilization in almost all tumor types.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since most cancer cells are reliant on telomerase for their survival, and telomerase is undetectable or only transiently present at low levels in normal cells, telomeres of cancer cells and telomerase are attractive targets for the development of new cancer therapeutics. &#8220;Proof of Principle&#8221; for validation of telomere structural integrity-targeting as a therapeutic concept was demonstrated <span style="font-style:italic;">in vitro </span>in human tumor cells using dominant negative mutant forms of hTERT. In these experiments, telomerase activity was abolished, which was associated with continuous telomere shortening, subsequently leading to the cancer cells death. Research has also indicated that cancer cell specific anti-telomeres and anti-telomerase therapies may have fewer side effects than more traditional treatments, such as chemotherapy or radiotherapy. This has made anti-cancer therapies based on telomerase inhibition an area of interest in medicine. However, attempts to directly target telomerase in clinical trials have not yet produced an approved drug, as these efforts have encountered material limitations primarily due to increased toxicities that may result from the long lag period between initiation of anti-telomerase treatment and its therapeutic effects. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Differentiated Activity of THIO, a Telomere-Targeting Agent </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-2&#8217;-deoxyguanosine or 6-thio-dG) is a small molecule telomere targeting agent that uses the enzyme telomerase for DNA integration predominantly in the telomeric structure. Based on pre-clinical studies, THIO&#8217;s telomere targeting activity is believed to be primarily cancer-specific in tumor cells with active telomerase, but not in normal cells. Based on our extensive review of publicly-available information, to our knowledge THIO&#8217;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The statements above are not intended to give any indication that THIO has been proven effective or that it will receive regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In non-clinical studies, published initially in 2014 along with subsequent studies, THIO was found to be converted, in cells, into the substrate recognized by telomerase, and then incorporated into telomeres of the cancer cells. Once incorporated, THIO compromised the cancer cell&#8217;s telomere structure and function, leading to &#8220;uncapping&#8221; of the telomeres, induction of DNA damage responses, and rapid cancer cell death. These profound structural modifications of cancer cell telomeres were irreparable. In both <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo </span>studies, THIO showed a very prompt effect, causing telomere uncapping and leading to cancer cell death<span style="font-style:italic;">, independent</span> of the initial tumor telomere length.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="gjyjiv3jrhol000010.jpg" title="" alt="" style="width:594px;height:314px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres: Key Therapeutic Targets for CancerCyclin-dependent kinase inhibitors EGFR inhibitors Aerobic glycolysis inhibitors Proapoptotic BH3 mimetics PARP inhibitors Inhibitors of VEGF signaling Inhibitors of HGF/c-Met Selective anti-inflammatory drugs Telomere Targeting Anti-PD-1 Anti-PD-L1 Sustaining proliferative signaling Deregulating cellular energetics Resisting cell death Genome instability &#38; mutation Inducing angiogenesis Inducing angiogenesis Tumor promoting inflammation Enabling replicative immortality Enabling replicative immortality Evading growth suppressors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above graphic represents an established method of action from previously conducted research in rodents that forms the scientific rationale for further clinical studies, but has not yet been tested in humans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, further non-clinical research in syngeneic and humanized mouse models of telomerase-expressing cancers uncovered previously unknown telomere targeting activity of THIO specifically resulting from its breakdown of cancer cells. The THIO-containing DNA fragments, resulting from THIO telomere disruption, are packed into micronuclei and are released from the treated cancer cell into the blood stream, which enhances immune responses. An immune response was observed, attributed to stimulation of the cGAS/STING pathways in the host APCs (Dendritic Cells, pDCs), as well as activation of NK cells and CD 8+ and CD 4+ lymphocytes <span style="font-style:italic;">in vivo</span>. At the same time as the T-cells activation, THIO treatment reduced levels of myeloid-derived suppressor cells (MDSCs) in the tumor micro-environment (TME), which is considered important for an anticancer immune response. While THIO activated CD8+ T cells, it also increased the total number of CD8+ T cells and upregulated PD-1 expression in the CD8+ T cells on per cell basis in the mouse model. This research demonstrated how the THIO-produced telomere stress may have the potential to increase innate sensing and adaptive anti-tumor immunity. In short, this immune system stimulation and TME remodeling proceeded in a specific antigen-dependent manner and induced adaptive immune responses that eradicated remaining cancer cells <span style="font-style:italic;">in vivo</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above noted recent studies in a humanized mouse model also supported the hypothesis that sequential administration of THIO followed by an anti-PD-L1type of checkpoint inhibitor may overcome resistance to checkpoint blockade in advanced cancer models, suggesting that the combination therapy could benefit PD-L1-resistant patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administration of low doses of THIO, aimed to activate the immune system via THIO-induced telomeric DNA modification, followed by checkpoint inhibitor therapy (anti-PD-L1 or anti-PD1), eliminated advanced tumors in preclinical models with confirmation of cancer cell type specific immune memory. This potential for THIO to induce immune memory, if confirmed in human clinical trials, would be a distinct feature of THIO&#8217;s mechanism of action, offering the possibility that the immune system may continue to be active against the cancer cells over extended periods of time, potentially reducing the need for additional treatment.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These pre-clinical results provided the basis for our new clinical therapeutic strategy for sequentially administering THIO as a telomere-targeted agent first, to activate the immune system against the specific cancer, followed by immunotherapy or other immune-activating therapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations of Other Therapeutic Approaches</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In contrast to THIO, which targets telomeres, a challenge for the potential clinical application of pharmaceutically useful telomerase inhibitors (e.g., Imetelstat), is the therapeutic window (the range of dosage of a drug or of its concentration in a bodily system that provides safe effective therapy) and the often-observed delay between initiation of treatment and phenotypic response (called the &#8220;lag period&#8221;). Since the antiproliferative effect of any direct telomerase inhibitor is dependent on the telomere length of any given tumor cell, clinical response will be delayed until the telomeres become critically short, and thus can no longer protect the chromosomes, and as a result, the cancer cell dies. This requires a significant number of cell divisions to become apparent, and treatment may have to be given continuously for weeks to months, potentially in conjunction with other treatment modalities, to achieve an appropriate level of efficacy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO: A Telomere Targeting Agent</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO (6-thio-2&#8217;-deoxyguanosine) is a synthetically-modified small molecule nucleoside that was originally designed to be an improved chemotherapy drug developed to work around purine analog resistance, which was standard-of-care therapy in the 1970s. Sponsored by the National Cancer Institute, THIO was extensively investigated in at least 19 clinical trials with over 600 cancer patient subjects (adult and pediatric) treated, both as monotherapy or in combination with other commonly used standard agents of the time. See &#8220;THIO Clinical Trials&#8221; below for more information about these trials. A traditional treatment strategy was used where patients were treated to maximum tolerated dose (MTD), a common approach for cancer therapy drug development. Although study results were promising, development was abandoned in favor of other therapies. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events, whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered, based generally on the results of these prior human studies, we believe that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further detailed analysis of the body of prior THIO research indicates researchers were not aware of three key factors, which if they had been known at the time, may have impacted the decision to cease development. These factors have only been discovered since 2014 (with the most recent in 2019), as illustrated in the following graphic:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">THIO&#8217;s detailed telomere targeting mechanism and resulting immune activation. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">At high drug exposure (MTD), THIO can be immunosuppressive.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Proper administration of THIO to activate the immune system followed by immunotherapy to achieve best response. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomeres are vital DNA-structures discovered by Jack Szostak&#8217;s laboratory, for which he received the Nobel Prize in 2009, which are present at the ends of each chromosome which protect the genome from degradation, unnecessary recombination, repair, and interchromosomal fusion. Telomeres, along with the enzyme telomerase, are both crucial for the survival of cancer cells. Telomerase was discovered by Elizabeth Blackburn and Carol Greider, who shared the Nobel Prize with Jack Szostak in 2009. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO is believed to selectively target telomerase positive (TERT+) cancer cells, where the enzyme is activated, versus normal cells. 73% to 100% of primary human cancers are TERT+ dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO in almost all tumor types. THIO&#8217;s cancer-specific disturbance of telomeric structure by telomerase leads to disruption in the cell cycle, followed by rapid cell death. Based on extensive review of publicly-available information, THIO&#8217;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the MAIA research team showed that in mouse models THIO-produced telomere modification and disruption induced cancer-specific innate and adaptive immune response against immunologically &#8220;cold&#8221; or unresponsive tumor types. When THIO was administered at low doses, in syngeneic and humanized mouse models of telomerase-expressing cancers, followed by a break to allow for the activation of the immune system against the specific cancer, then followed by a standard-of-care immunotherapy agent like a check point inhibitor (CPI), either PD-1 or PD-L1, complete tumor regression was observed, with no observed toxicities. These effects have been replicated in multiple preclinical models, utilizing all leading checkpoint inhibitors or radiation therapy. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these studies, we hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#8220;<span style="font-style:italic;">prime&#8221;</span> the tumor environment and initiate an overall anti-tumor immune response. This represents an entirely new therapeutic approach for THIO and forms the basis for the new clinical strategy for planned future trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Preclinical Development </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes the relevant preclinical studies. Extensive preclinical studies have been performed to validate THIO&#8217;s primary mechanism of action: targeting telomeres directly and causing cancer cell death via telomerase-mediated DNA damage.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To our knowledge, THIO alone has shown significant telomere targeting activity in numerous non-small cell lung cancer (NSCLC) and multiple other cancer-based cell lines <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span>, including but not limited to small cell lung cancer (SCLC), melanoma, colorectal cancer (CRC), glioblastoma multiforme (GBM), diffuse intrinsic pontine glioma (DIPG), neuroblastoma, pancreatic, hepatocellular carcinoma (HCC), as well as head and neck cancer, breast cancer and prostate cancer.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vitro<span style="font-style:normal;">: in summary, EC<sub style="font-size:85%; vertical-align:bottom">50</sub> values (the concentrations at which half of the total number of cancer cells are dead) were approximately 0.4 &#181;M to 1.5 &#181;M. THIO was not cytotoxic in normal, untransformed telomerase-negative cells at concentrations up to 100 &#181;M.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vivo<span style="font-style:normal;">: in summary, the doses that resulted in cancer cell death were in the range of 2.5 - 5.0 mg/kg, depending on the tumor type and the schedule of the drug administration ranging from 1 to 3 days per cycle.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small cell lung cancer. The FDA&#8217;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO in Sequential Administration in Advance of Checkpoint Inhibitors (CPIs) Therapy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vivo<span style="font-style:normal;">, THIO, at 3 mg/kg/dose, (which corresponds to a 20 mg/patient/day low-dose), administered followed by a one-day break, followed by an immune checkpoint inhibitor (either anti-programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) products), resulted in complete tumor regression in NSCLC and CRC syngeneic mouse tumor models. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this low dose, THIO was able to transform immunologically &#8220;cold&#8217; tumors, (tumors that do not respond to the CPI treatment), into immunologically &#8220;hot&#8221; tumors, which then responded well to the following sequential treatment with a CPI. These potent anti-tumor phenotypic effects were also accompanied by the efficient induction of the tumor-specific CD8+ cells, as well as CD4+, and natural killer (NK)-cells (Mender, 2020b).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These responses were achieved through telomerase-dependent and cancer cell specific activation of a) DNA damage responses, and b) cGAS/STING pathways by THIO. This body of research represents the basis for the new immune-activation treatment strategy</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following represents key highlights from THIO preclinical research:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">THIO has been tested in multiple preclinical studies evaluating various tumor types </span><span style="font-style:italic;color:#000000;">in vitro</span><span style="color:#000000;"> including in lung, colorectal, prostate, breast, ovarian, head and neck, brain, melanoma, and liver cancer. THIO has also been tested in </span><span style="font-style:italic;color:#000000;">in vivo</span><span style="color:#000000;"> mouse models of lung, colorectal, brain, melanoma, liver and brain cancers. In the below graphic, the left panel depicts cancer cell colony formation </span><span style="font-style:italic;color:#000000;">in vitro</span><span style="color:#000000;"> assay results conducted with various types of telomerase positive cancers, namely prostate, breast, ovarian, colon, brain, head and neck. In the control column, cancer cells grew. In the second column, with the telomerase inhibitor BIBR, the cancer cells also grew. In the third column, in which the telomere targeting agent THIO was administered at a concentration of 2.5&#181;M, cancer cell growth was visibly inhibited. In the fourth column, in which THIO was administered at a concentration of 5&#181;M, cancer cells were also visibly inhibited. The same concentrations of THIO were also administered&#160;</span><span style="font-style:italic;color:#000000;">in vivo</span><span style="color:#000000;"> in rodent models (mice), caring tumors, derived from either brain, or liver, or melanoma, or neuroblastoma, or colorectal cancer cells were treated with THIO (at 2 mg/kg to 5 mg/kg doses), significant reduction in tumor masses resulting from the treatment with THIO was observed. Note that THIO&#8217;s activity seen in preclinical models has yet to be demonstrated in humans.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000011.jpg" title="" alt="" style="width:168px;height:199px;" />&#160;<img src="gjyjiv3jrhol000012.jpg" title="" alt="" style="width:446px;height:159px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">THIO demonstrated potential to </span><span style="font-style:italic;color:#000000;">selectively</span><span style="color:#000000;"> cause cancer cell death with active enzyme telomerase versus normal cells</span><span style="font-style:italic;color:#000000;"> in vitro</span><span style="color:#000000;">. The below graphic illustrates formation of telomeric damage foci (TIFs) in telomerase activity-positive cancer cells, but not in normal non-cancerous cells, resulting from application of THIO. These data indicate molecular mechanism of THIO that targets telomeric DNA of cancer cells through their telomerase enzymatic activity. At the same time, normal cells, that are devoid of telomerase activity, are not affected by THIO. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000013.jpg" title="" alt="" style="width:598px;height:232px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mender I. et al., Cancer Discovery (2015)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TIF &#8211; telomere damages induced foci</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TRF2 &#8211; protein associated with telomeres</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Gamma-H2AX &#8211; protein associated with induction of DNA damage</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*CRC &#8211; colorectal cancer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*hTERT &#8211; protein components of telomerase enzyme </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">THIO, as a single agent, showed </span><span style="font-style:italic;color:#000000;">in vitro</span><span style="color:#000000;"> telomere targeting activity in cancer cells that are resistant to tyrosine kinase inhibitors (TKIs), checkpoint inhibitors, IL-2, IFN&#945;, YERVOY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ipilimumab) and a host of chemotherapies. The below graphic, in NSCLC and Melanoma models respectively, demonstrates in vivo telomere targeting activity of THIO in mice models of lung cancer, derived from PERC16 cells, and melanoma derived from WM4265 cells. Both cell lines are resistant to multiple standard-of-care drug compounds, as listed in the Figure legends.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000014.jpg" title="" alt="" style="width:584px;height:235px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*i.p. &#8211; intraperitoneal injection</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*IL-2 &#8211; cytokine interleukin 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*IFN-a &#8211; interferon alfa</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">THIO was observed to penetrate the blood-brain barrier and inhibits tumor growth, inducing in-tumor telomere dysfunction and cancer cell death, in </span><span style="font-style:italic;color:#000000;">in vitro</span><span style="color:#000000;"> models of difficult to treat pediatric brain cancer, where no therapy exists. In the below graphic, this is shown through presence of Caspase-3 enzyme which is associated with cell death. Sengupta, S. et al. Induced telomere damage to treat telomerase expressing therapy-resistant pediatric brain tumors. Mol Cancer Therapeutics, 17(7): 1504-1514, 2018.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000015.jpg" title="" alt="" style="width:284px;height:218px;" />&#160;<img src="gjyjiv3jrhol000016.jpg" title="" alt="" style="width:293px;height:214px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*TIF &#8211; telomere damage induced foci</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*MB004 &#8211; brain cancer cell line</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">THIO transformed &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors that were responsive to immunotherapy. THIO utilized a telomere targeting pathway that synergized with checkpoint inhibitors and other immune-activating therapies. The tumor-specific immune activation, resulting from THIO&#8217;s primary mode of action, overcame resistance to current check point inhibitor (CPI) standard-of-care therapy, as illustrated in the following Colorectal Cancer model. The below graphic demonstrates telomere targeting activity of THIO alone, and in sequential combination with immune checkpoint inhibitor (anti-PD-L1 compound, atezolizumab), in mice model of colorectal cancer, derived from MC-38 cells. Two doses of THIO are shown to control tumor growth while anti-PD-L1 agent. Sequential administration of THIO (2 days), followed by administration of the anti-PD-L1 agent, demonstrates disappearance of tumor cells.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000017.jpg" title="" alt="" style="width:624px;height:232px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Immunological memory was observed in mouse models, where the immune system continued to be active against the specific treated tumor cell type for 100 days post-tumor inoculation. The below graphic demonstrates that the tumor-free animals that were treated with the sequential combination of THIO and anti-PD-L1 compound were followed for 70 days, with no observed tumor recurrence. Subsequently, animals were re-challenged with 10 times more MC38 cancer cells. Cancer growth was not observed in these animals, demonstrating induction of anti-tumor-protecting memory after sequential administration of THIO and anti-PD-L1 agent&#59; ref: Mender, I., et al. Telomere stress potentiates STING-dependent anti-tumor immunity. Cancer Cell, 38,3, 400-411.E6,&#160;September 14, 2020.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000018.jpg" title="" alt="" style="width:624px;height:238px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, due to the cGAS/STING activation caused by THIO, telomere targeting activity was observed in numerous preclinical tumor models when THIO was administered followed by immune activating therapy such as immune checkpoint inhibitors (anti-PD-L1 or anti-PD-1 antibody). <span style="font-style:italic;">A summary of the pharmacological aspects of the investigational product and, where appropriate, its significant metabolites studied in animals, should be included. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;">Such a summary should incorporate studies that assess potential therapeutic activity (</span><span style="font-style:italic;">e.g.</span><span style="font-style:italic;"> efficacy models, receptor binding, and specificity) as well as those that assess safety (e.g., special studies to assess pharmacological actions other than the intended therapeutic effect(s)). The results of all relevant nonclinical pharmacology, toxicology, pharmacokinetic, and investigational product metabolism studies should be provided in summary form. This summary should address the methodology used, the results, and a discussion of the relevance of the findings to the investigated therapeutic and the possible </span><span style="font-style:italic;">unfavourable</span><span style="font-style:italic;"> and unintended effects in humans.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is therefore hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#8220;<span style="font-style:italic;">prime&#8221;</span> the tumor environment and initiate an overall anti-tumor immune response. If confirmed through additional clinical studies, this could represent an entirely new therapeutic approach for THIO and form the basis for the new clinical strategy for planned future trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Clinical Trials </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to rely solely upon our self-generated clinical safety and efficacy data, if favorable, in support of our anticipated NDA filing for THIO. However, THIO, as a compound, was the subject of investigation in numerous clinical trials in the 1970s to the early-80s in a variety of solid tumors and hematological malignancies. The compound was evaluated in at least nineteen (19) Phase 1 to Phase 3 clinical trials with over 600 patients treated by major cancer institutions and cancer cooperative groups. THIO was studied in combination with common agents in use at the time, including methyl-CCNU or mitomycin, two widely used alkylating agents to treat a variety of cancers and leukemias. Studies utilizing THIO as a single agent have been published in peer-reviewed journals. As part of the existing data base of clinical experience with the drug, we expect to reference the older NCI studies in the public domain as well as reference NCI&#8217;s original IND filing in support of an IND filing, pursuant to FDA regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the THIO single agent peer-reviewed published data available from the previous clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 1 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.23%;"></td>
<td style="width:20.51%;"></td>
<td style="width:20.4%;"></td>
<td style="width:11.24%;"></td>
<td style="width:20.71%;"></td>
<td style="width:18.92%;"></td>
</tr>
<tr>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regimen/Dose Schedule</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluable Subjects</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observed Adverse Events</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Responses</p></td>
</tr>
<tr style="height:88.15pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C76-92</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric Acute Leukemia who received prior</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-mercaptopurine (6-MP) or 6-thioguanine</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO 200 to 2,250 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> given every 12 hours for 3 doses every 2 weeks</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maximum tolerated dose (MTD) was determined to be 1,750 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> given every 12 hours for 3 doses every 2 weeks</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reversible urate nephropathy, elevations of liver enzymes, nausea and vomiting, alopecia, and skin reactions</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic Responses observed in 6/23 (26%) patients comprised of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 complete responses and 4 partial responses</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: <span style="color:#0000FF;">Higgins, G. R., Jamin, D. C., Shore, N. A., Momparler, R., Hartman, G. and Siegel, S. E. (1985). &#8220;Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.&#8221; Cancer Treat Rep 69(6): 699-701t</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 2 &#8211; Single Agent Studies</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.79%;"></td>
<td style="width:17.1%;"></td>
<td style="width:19.33%;"></td>
<td style="width:9.11%;"></td>
<td style="width:11.13%;"></td>
<td style="width:9.81%;"></td>
<td style="width:9.86%;"></td>
<td style="width:14.86%;"></td>
</tr>
<tr style="height:22.9pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Protocol</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regimen/Dose</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subjects</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Overall</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Partial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Complete</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adverse Events</p></td>
</tr>
<tr style="height:14.95pt;">
<td rowspan="7" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEG-248</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Patients</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">27 (23%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11 (9%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16 (14%)</p></td>
<td rowspan="7" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leukopenia</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thrombocytopenia</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin rash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alopecia (reversible)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nausea and vomiting</p></td>
</tr>
<tr style="height:3.7pt;">
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Myelocytic Leukemia (AML)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 (24%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (6%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (18%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 (20%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 (12%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 (8%)</p></td>
</tr>
<tr style="height:13.9pt;">
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blastic transformation of chronic myelogenous leukemai (BTL)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (27%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (27%)</p></td>
</tr>
<tr style="height:2.15pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 (23%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (12%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (12%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acute Lymphocytic Leukemia (ALL)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (50%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (50%)</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (20%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (10%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (10%)</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.79%;"></td>
<td style="width:17.1%;"></td>
<td style="width:19.33%;"></td>
<td style="width:9.11%;"></td>
<td style="width:11.13%;"></td>
<td style="width:9.81%;"></td>
<td style="width:9.86%;"></td>
<td style="width:14.86%;"></td>
</tr>
<tr style="height:22.9pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Protocol</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tumor Type</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regimen/Dose</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subjects</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Overall</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Partial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CR</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Complete</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Response)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adverse Events</p></td>
</tr>
<tr style="height:21.55pt;">
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EST 4273 (ECOG)</span></p></td>
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorectal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(prior 5-FU chemotherapy)</p></td>
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIO 100 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> daily for 5 days every 3 weeks</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MeCCNU 175 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2 </sup></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">every 8 weeks</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (5%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (5%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td rowspan="2" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leukopenia, thrombocytopenia, nausea and vomiting</p></td>
</tr>
<tr style="height:13pt;">
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 (9%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 (9%)</p></td>
<td valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Omura, G. A., Vogler, W. R., Smalley, R. V., Maldonado, N., Broun, G. O., Knospe, W. H., et al. (1977b). &#8220;Phase II Study of beta-2'-deoxythioguanosine in adult acute leukemia. (Study SEG-248)&#8221; Cancer Treat Rep 61(7): 1379-1381 Douglass, H. O., Jr., Lavin, P. T., Woll, J., Conroy, J. F. and Carbone, P. (1978). &#8220;Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea: A Phase II-III study of the Eastern Cooperative Oncology Group (EST 4273).&#8221; Cancer 42(6): 2538-2545</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events. , whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered. Based generally on the results of these prior human studies, we believe that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding these limitations, the available data provides substantial information on the clinical experience with and clinical profile of THIO with an exposure exceeding 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program and new treatment strategy. All studies were conducted in heavily pre-treated/refractory patients, most of whom were pre-treated with other standards of care including chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, THIO has not received marketing approval in any country&#59; therefore, there is no marketing experience to be reported. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned clinical trials will assess a novel THIO therapeutic strategy: - evaluate the safety and efficacy of low potentially immunogenic doses of THIO administered to activate the immune system against the tumor to be treated, followed by standard-of-care immunotherapy (checkpoint inhibitor) or other immune activating therapies. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Developmental Initiatives and Objectives </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the existing data regarding pre-clinical information on THIO, we believe it is possible to enter the next human clinical study in the near term with the new low dose immunogenic approach with THIO. We plan to approach the FDA to request a modified toxicity requirement to allow us a reduced time and expenditure to IND in the United States, however, the FDA may not grant such request. We are currently working with experts to evaluate the extent and quality of the existing data supporting THIO and had a pre-IND meeting with the FDA for guidance in 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 and 3 Programs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary short-term objective is to assess this approach in a Proof-of-Concept study outlined below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This first study is a dose-finding, Phase 2 clinical trial evaluating both safety and efficacy of THIO sequenced with cemiplimab in patients with advanced non-small lung cancer (NSCLC) who progressed or showed no clinical benefit to first line treatment containing an immune checkpoint inhibitor. This trial, designated as THIO-101 study is our first human clinical trial to test the immune system activation demonstrated in preclinical animal models: lower doses of THIO administered prior to a checkpoint inhibitor treatment reverses drug resistance, enhance and prolong immune responses in patients with advanced lung cancer who did not respond or progressed after a prior cancer treatment which contained another immune checkpoint inhibitor. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial design has two primary objectives: (1) safety of THIO administered as a priming immune system agent prior to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cemiplimab</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> administration and (2) clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The study is ongoing</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in Australia and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we expect will be </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">followed by the United States. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following chart sets forth the design of the THIO-101 trial: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000019.jpg" title="" alt="" style="width:624px;height:153px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This &#8220;dose-finding&#8221; trial will assess the safety, mechanism of activity, and immune system activation of three THIO doses tested out in separate arms administered in parallel. Each dosing arm will be further evaluated for efficacy based on Overall Response Rate (ORR), Duration of Response (DoR) and Progression Free Survival (PFS) to determine to optimal (safe and effective) dose of THIO administered in sequence with cemiplimab. Additional patients may be recruited for further clinical evaluation in any of the THIO arms based on safety and clinical benefit. Each arm of the trial will enroll a minimum of 22 and up to 41 evaluable patients. Subsequently, we expect to target earlier lines of therapy (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> line) in pivotal Phase 3 confirmatory studies in NSCLC.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2022, we submitted a pre-IND meeting request to FDA to discuss, among other elements, the existing non-clinical and clinical data to support the conduct of our planned THIO-101 phase 2 trial under an IND to include patients from the United States.&#160;&#160;FDA&#8217;s November 2022 feedback indicated that our protocol is acceptable, subject to minor modifications and requests for additional supporting information. We intend to incorporate FDA&#8217;s feedback and provide the requested information as part of our IND submission to FDA, which we anticipate filing 1H 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain FDA and/or EMEA approval of THIO in combination with other standard of care approved cancer immunotherapies, we will have to conduct head-to-head studies which will compare standard of care treatment alone to standard of care treatment combined with THIO. In such studies, we would have to show that THIO added to standard of care therapies adds a significant treatment benefit by slowing down tumor progression and increasing the overall survival of the cancer patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are actively evaluating other regulatory strategies and pathways that have the potential to accelerate and/or expand the study of THIO administered in sequence with an immune-checkpoint inhibitor in other solid tumor indications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event THIO demonstrates early clinical efficacy, we plan to expand our clinical development program in multiple tumor types and assess several regulatory approval pathways utilizing our other development programs. The clinical development plan includes the initiation of an additional &#8220;basket trial&#8221; in multiple cancer types. This study uses a special design which allows different cancer indications to be studied under the same single trial umbrella. Some of the indications considered are:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">hepatocellular carcinomas (HCC)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">small-cell lung cancer (SCLC)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">melanoma </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">breast cancer</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pancreatic cancer </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">glioblastoma multiforme (GBM)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ovarian cancer</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prostate cancer</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately, we envision positioning THIO as the foundational priming treatment for all immune-activating agents over time based upon THIO&#8217;s tumor-specific immune-activation approach that enables key clinical strategies that could dramatically expand the immunotherapy market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second Generation of Telomere Targeting Agents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through the same mechanism of action as THIO, such as targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover compositionally new compounds with potentially improved specificity towards cancer cells relative to normal cells, and to assess telomere targeting activity in comparison with THIO. This program may also allow us to strengthen our patent portfolio. Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create or discover a second generation of THIO-like compounds. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Collaborations and Key Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our licensing agreements with The University of Texas Southwestern Medical Center (&#8220;UTSW&#8221;), we have commercial rights to certain U.S. patents, as well as their foreign counterparts, for the use of THIO in treating telomerase-expressing lung and colon cancer cells. We are currently using this technology to study a treatment regimen comprising the use of THIO treatment followed by cemiplimab (Regeneron) treatment in NSCLC. In addition, we have licensed several pending U.S. and foreign patent applications from UTSW directed to other indications, and we are continuing to pursue discussions with several companies to develop other treatment regimens using THIO for additional cancer indications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, we entered into a Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc. (REGN) to supply cemiplimab for the THIO-101 study. Regeneron will contribute the drug supply without cost, which represents a significant direct cost savings for our program. In exchange, Regeneron will receive development exclusivity for NSCLC indication during the study period, which means that MAIA cannot study THIO in NSCLC with any other PD-1 antagonist (a product sub-class of immune checkpoint inhibitors). All other tumor types remain open, and we are in discussions with other pharmaceutical companies to evaluate additional agreements that may be appropriate to support the expanded development of THIO. The supply agreement will remain in force until all of the obligations of the parties&#8217; related to the studies contemplated by the agreement are completed, or until terminated by either party. The agreement may be terminated in the event of unsafe use of cemiplimab, material breach, regulatory action or corruption.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our management believes that strong partnership interest will develop from other pharmaceutical companies who have checkpoint inhibitor franchises or those with cancer immunotherapy interest. We expect to continue discussions with several companies that have expressed interest and plan to expand discussions to capitalize on these opportunities. The checkpoint inhibitor market is large, and our goal is to ultimately position THIO as the foundational priming treatment to be used prior to all checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The University of Texas Southwestern Medical Center License Agreement 1</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent families generally directed to methods of using THIO (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW1 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#8220;<span style="font-style:italic;">Business &#8212; Intellectual Property &#8212;License Agreement 1 with</span> <span style="font-style:italic;">The Board of Regents of The University of Texas System</span>/<span style="font-style:italic;">The University of Texas Southwestern Medical Center</span>.&#8221; The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The University of Texas Southwestern Medical Center License Agreement 2</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020, we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second license with UTSW, which we refer to as the UTSW2 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:69.97%;">
<tr>
<td style="width:69.97%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW2 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#8220;<span style="font-style:italic;">Business &#8212; Intellectual Property &#8212;License Agreement 2 with</span> <span style="font-style:italic;">The Board of Regents of The University of Texas System</span> /<span style="font-style:italic;">The University of Texas Southwestern Medical Center</span>.&#8221; The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIO Program</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement 1 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 8, 2020 (the &#8220;Effective Date&#8221;), we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW) to develop and commercialize certain UTSW owned and/or controlled patents and related technology directed to methods of using THIO (&#8220;the UTSW1 Agreement&#8221;). The license is exclusive as to worldwide Patent Rights for all uses in the Field, which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW1 Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement includes an exclusive license to the &#8220;Patent Rights&#8221; of the worldwide patent families including all provisional applications and any </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">divisionals</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:62.36%;">
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</p></td>
</tr>
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells /PCT/US2017/34706 (WO2017/205756)</p></td>
</tr>
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors /PCT/US2019/023596 (WO2019/183482)</p></td>
</tr>
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means Licensor&#8217;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also grants the Company the first right to negotiate an exclusive license under any patent rights covering or claiming any improvement, which is any patentable invention and is conceived or reduced to practice solely by Dr. Jerry Shay or those under his direct supervision at UTSW within 3 years of the Effective Date, under certain conditions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the UTSW1 Agreement begins on the Effective Date and continue until the earliest of: (i) termination pursuant to the UTSW1 Agreement, (ii) the last date of expiration or termination of the Patent Rights&#59; or (iii) if Technology Rights are licensed and no Patent Rights are applicable, twenty (20) years after the Effective Date. The Company may terminate the UTSW1 Agreement for convenience, at any time prior by providing ninety (90) days&#8217; written notice to UTSW. UTSW may terminate the UTSW1 Agreement if the Company (i) becomes in arrears in any payments due, and fails to make the required payment within 30 days after delivery of written notice from UTSW, (ii) is in breach of any material non-payment provision, and does not cure such breach within 60 days after delivery of written notice, (iii) UTSW delivers notice to the Company of three or more actual breaches in any 12-month period, even in the event that the Company cures such breaches in the allowed period, (iv) becomes insolvent or bankrupt, then termination is immediate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTSW and/or the co-owners of certain patents have reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other education-related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UTSW1 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The Company is also obligated to pay all accrued patent expenses as well as ongoing patent expenses on a scheduled basis tied to Company fund-raising through Series A funding until Company has reimbursed all patent expenses. In the event that the Company assigns the agreement to a third party, the Company is obligated to pay UTSW an assignment fee in the mid-six figures within 15 days of such assignment. The agreement cannot be assigned without UTSW&#8217;s consent.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UTSW1 Agreement, the Company is obligated to use diligent efforts to bring licensed products to market through a funded, ongoing and active research and development, manufacturing, regulatory, marketing or sales program (all as commercially reasonable) and provide semi-annual reports to UTSW on its progress. The Company is also obligated to pay agreed upon milestone payments to UTSW. Failure of the Company to fulfill these obligations may be treated as a material breach by UTSW.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The only milestones that require payments under the UTSW1 Agreement include: (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) first commercial sale in the U.S. of licensed product for treating an oncology indications &#59; (ii) first commercial sale in the U.S. of licensed product for treating a non-oncology indications&#59; (iii) first time aggregate Net Sales (as defined in the UTSW1 Agreement) of licensed product for treating an oncology indications exceeds low-nine figure sales in a contract year&#59; (iv) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low nine-figure sales in a contract year&#59; (v) first time aggregate Net Sales of licensed product for treating an oncology indications exceeds low ten-figure sales in a contract year&#59; (vi) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low ten-figure sales in a contract year. There are no milestone payments required on any development or regulatory milestones. The only required milestone payments under the UTSW1 Agreement related to commercial sales milestones, and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement will not exceed $112 million.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW1 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten figures of sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW1 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to pay multiples of the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiples of the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#8217;s fees and expert fees. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage of the royalty obligation in any contract year. In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced below a certain percentage of the royalty obligation in any contract year.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTSW maintains direct control over the prosecution and maintenance activities of the Patent Rights, and the Company is obligated to reimburse past and ongoing patent expenses as noted above. UTSW will permit the Company to comment on submissions to government patent agencies, during prosecution and will consider the Company&#8217;s comments, but UTSW retained control over all final decisions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW1 Agreement contains a representation that UTSW has the rights and authority to grant to Company the licensed rights and is to its knowledge unaware of any third-party infringer or any infringement of third-party intellectual property rights. The UTSW1 Agreement also requires the Company to indemnify UTSW and other related parties against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses arising out of any product the Company produces under the UTSW1 Agreement, and requires the Company, beginning with the earlier of the first clinical trial or commercial sale or other commercialization, to obtain liability insurance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will have the first and sole right but not the obligation, at its own expense, to initiate an infringement suit or other appropriate actions against third party infringers and monetary recovery received therefrom, after the Company is reimbursed for expenses in enforcing the Patent Rights, is shared between the Company and UTSW pursuant to a good faith negotiation between the parties at that time. If the Company does not file suit within six months after a written request by UTSW, then UTSW may bring suit to enforce any Patent Right and retain all </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recoveries from such enforcement. If UTSW pursues such infringement action, it may, as part of the resolution of such efforts, grant nonexclusive license rights to the alleged infringer notwithstanding Licensee&#8217;s exclusive license rights.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the terms of the UTSW1 Agreement, on April 24, 2020 Company sublicensed all Company rights and obligations under the UTSW1 Agreement to Company affiliate THIO Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement 2 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 23, 2020 (the &#8220;Effective Date&#8221;), we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW), which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights (&#8220;the UTSW2 Agreement&#8221;). The license is exclusive as to worldwide Patent Rights for all uses in the Field, which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW2 Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement includes an exclusive license to the &#8220;Patent Rights&#8221; of the worldwide patent family including all provisional applications and any divisionals, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.64%;width:62.36%;">
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title / PCT Application Number</p></td>
</tr>
<tr>
<td valign="top" style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means UTSW&#8217;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the UTSW2 Agreement are similar in many respects to those set forth in the UTSW1 Agreement. Pursuant to the UTSW2 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The UTSW2 Agreement recognizes the accrual of low five-figures in patent expenses relative to the Patent Rights of this agreement and provides for deferral of this fee and related ongoing patent expense fees on a schedule connected to the Company&#8217;s fundraising through Series A funding. Once the Company has raised mid seven-figures, the patent expense fees are be paid in full for all patent expenses incurred by UTSW for the Company&#8217;s licensed technologies which accrued between December 12, 2019, and the date at which the mid seven-figures has been raised. Until the Company has reimbursed all patent expenses it is obligated to report its fundraising progress to UTSW on a quarterly basis. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The milestone payments are the same as in the UTSW1 Agreement wherein the milestone fees are based solely on commercial sales milestones and are payable one time only, regardless of the number of licensed products or licensed services developed and regardless of the number of indications or patient sub-populations treated with a licensed product(s) and regardless of whether the licensed products or licensed services developed are within the rights granted by the UTSW1 Agreement or the UTSW2 Agreement. In other words, there are no milestone payments required on any development, or regulatory milestones under the UTSW1 Agreement or the UTSW2 Agreement. The only required milestone payment under the UTSW1 Agreement or the UTSW2 Agreement relate to commercial sales milestones and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement or the UTSW2 Agreement will not exceed $112 million. In the event the Company assigns the UTSW2 Agreement to a third party, the Company is obligated to pay UTSW low six-figures within 15 days of such assignment, which is cumulative of the UTSW1 Agreement assignment fee, such that if both agreements are assigned to a third party, a total of high six-figures would be owed to UTSW. The agreement cannot be assigned without UTSW&#8217;s consent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are mid-single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten-figures in sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue on</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to pay multiple times the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiple times the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#8217;s fees and expert fees. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UTSW2 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a minimum percentage of the royalty obligation in any contract year. In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second-generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage obligation in any contract year.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the development and reporting obligations as the UTSW1 Agreement and as with the UTSW1 Agreement, UTSW has reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other educationally related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The obligations and rights as to patent prosecution and defense of the Patent Rights are the same as those for the UTSW1 Agreement. The term and termination provisions of the UTSW2 Agreement is the same as the UTSW1 Agreement, however in the event that the UTSW1 Agreement is terminated for any reason, or expires, then the UTSW2 Agreement likewise is terminated or deemed to have expired.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above description of UTSW1 Agreement and UTSW2 Agreement is just a summary and readers are referred to UTSW1 Agreement and UTSW2 Agreement, which are attached hereto as Exhibits 10.2 and 10.3 respectively, for a full and complete description of the patent expenses, milestone payments, fees and royalties payable by MAIA.</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our intellectual property, including the intellectual property licensed under UTSW1 and UTSW2, has been conceived or developed through government-funded research and thus may be subject to federal regulations providing for certain rights for the U.S. government or imposing certain obligations on us, such as a license to the U.S. government under such intellectual property, &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers. See Risks Relating to Our Intellectual Property - Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology industry is characterized by a rapid evolution of technologies, significant competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with unique competitive advantages, we expect to face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. For example, current competitors in the non-small lung cancer indication are Merck, Regeneron, Eli Lilly and Roche. There are also many other large and small companies developing products for this indication. Key product features that, if approved, would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors also include large pharmaceutical and biotechnology companies, which may be developing therapeutic candidates with mechanisms similar to our compounds or targeting the same clinical indications as our therapeutic candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Any pharmaceutical candidate that we develop must be approved by the United States Food and Drug Administration, or FDA, before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates biopharmaceutical products under the Federal Food, Drug, and Cosmetic Act and the Public Health Services Act, or PHSA, and implementing regulations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Approval Processes </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Submission to the FDA of an Investigational New Drug Application, or an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Performance of several phases of adequate and well-controlled human clinical trials according to the FDA&#8217;s current good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug or biologic for its intended </span><span style="color:#000000;">use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Submission to the FDA of a New Drug Application, or an NDA, for a new drug product, or a Biologics License Application, or a BLA, for a new biological product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&#8217;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval of the NDA or BLA.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities, any of which could have a material adverse effect on us. These sanctions could include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal to approve pending applications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of an approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">imposition of a clinical hold&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warning or untitled letters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seizures or administrative detention of product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">total or partial suspension of production or distribution&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions, fines, disgorgement, or civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. There can be no certainty that approvals will be granted.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted in accordance with the FDA&#8217;s good clinical practices requirements. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials prior to approval are typically conducted in three sequential Phases that may overlap or be combined:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 1. The drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific disease.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 2. The drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA or BLA.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA by the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug or biological candidate and, among other things, must include methods for testing the identity, strength, quality and purity of the final drug or biologic. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees&#59; a waiver of such fees may be obtained under certain limited circumstances.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews for completeness all NDAs and BLAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the NDA or BLA submission is accepted for filing, the FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product&#8217;s continued safety, purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the approval process, the FDA also will determine whether special marketing conditions or restrictions under a risk evaluation and mitigation strategy, or REMS, are necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS&#59; the FDA will not approve the NDA or BLA without a REMS, if required.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is to be manufactured, and may also inspect facilities that provide raw materials for use in the product. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to assure their compliance with cGCP during the conduct of studies of the subject drug. If during the review of the application the FDA identifies questions or concerns regarding the application, data, manufacturing process or manufacturing facilities, it may issue a deficiency letter which the sponsor must adequately address to the FDA&#8217;s satisfaction.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NDA or BLA review and approval process is lengthy and difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA does not, in its submitted form, satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA will issue a &#8220;complete response letter&#8221; (CRL) if the agency decides not to approve the NDA or BLA. The complete response letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter will typically include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be for more limited conditions of use than the sponsor had proposed, such as limitations to specific diseases or subsets of a disease, limited patient populations, second-line or third-line use limitations, limited dosages or other limitations which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which may involve clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Companion Diagnostics</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many drugs for cancer indications involving patient-specific genetic mutations or biomarkers are approved by FDA with limitations that the specific genetic mutation must be confirmed in each patient by use of an FDA-approved diagnostic test, commonly referred to as a &#8220;companion diagnostic.&#8221; The FDA issued a final guidance document in July 2014 addressing agency policy in relation to <span style="font-style:italic;">in vitro </span>companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. The FDA has also issued a Guidance, <span style="font-style:italic;">Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product</span> (2016), which is &#8220;is intended to be a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic,&#8221; and a Guidance, <span style="font-style:italic;">Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products</span> (2020), which &#8220;describes considerations for the development and labeling of in vitro companion diagnostic devices (referred to as &#8220;companion diagnostics&#8221; herein) to support the indicated uses of multiple drug or biological oncology products, when appropriate.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As stated in its Guidance, the FDA may decide that it is appropriate to approve such a product without an approved or cleared </span><span style="font-style:italic;">in vitro </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared </span><span style="font-style:italic;">in vitro </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared </span><span style="font-style:italic;">in vitro </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. To date, no product targeting TERT+ cancer patients has been approved by FDA, and the applicability to THIO of FDA&#8217;s Companion Diagnostics Guidance and policy is yet to be determined. If a companion diagnostic is required to be developed and approved in order to receive approval of THIO, the cost and length of time to fully develop and receive approval (if at all) of THIO may both be increased, as described in more detail in the section </span><span style="font-style:italic;">Risk Factors &#8211; Risks Relating to Government Regulation. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the FDA&#8217;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a Fast-Track program that is intended to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically, new drug and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Under a Fast Track designation, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if (i) the sponsor provides a schedule for the submission of the sections of the NDA or BLA, (ii) the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and (iii) the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing approval, including those submitted under a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or the new product has the potential to offer a significant improvement in the treatment, diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of accelerated approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies to confirm the safety and efficacy for the approved indication. Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy may result in revocation of the original accelerated approval. In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch or subsequent marketing of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process, and even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Hatch-Waxman Amendments and Generic Competition</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orange Book Listing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a drug product is approved under an NDA, the product is listed in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug (RLD). Sponsors of approved NDA&#8217;s are required to list with the FDA patents whose claims cover the product&#8217;s active ingredient, formulation, or an approved method of using the drug. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Extensions</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ANDA Approval Process</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Hatch-Waxman Amendments established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application, or ANDA, with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Section 505(b)(2) NDA Approval Process</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments to the FDCA and enables the applicant to rely, in part, on the FDA&#8217;s previous approval of a similar product, and/or published literature, in support of its application. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ANDA and 505(b)(2) NDA Patent Certification Requirements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submitted to the FDA&#59; (2) such patent has expired&#59; (3) the date on which such patent expires&#59; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA is submitted to FDA with a Paragraph IV Certification, the generic applicant must also provide a &#8220;Paragraph IV Notification&#8221; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the ANDA applicant, providing a detailed written statement of the bases for the ANDA applicant&#8217;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the ANDA applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA will be automatically stayed for 30 months, or until 7-1/2 years after the NDA approval if the generic application was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &#8220;section viii&#8221; statement with respect to a listed method of use patent, certifying that the proposed generic labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ANDA or Section 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regulatory Exclusivities</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Chemical Entity (NCE) Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Hatch-Waxman amendments provides a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&#8220;NCE&#8221;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2 years after the approval of the reference drug NDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Clinical Trial (3-Year) Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation and Orphan Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a therapeutic candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a product or therapeutic candidate for this type of disease or condition will be recovered from sales in the United States for that product or therapeutic candidate. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product or therapeutic candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the approved product is entitled to orphan product exclusivity, which means that the FDA may not approve any other marketing applications for the same drug for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same indication, except under limited circumstances, for seven years. Orphan product exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA, or if our therapeutic candidate is determined to be contained within a competitor&#8217;s approved drug for the same indication or disease. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, an orphan drug credit is available for qualifying costs incurred between the date the FDA designates a drug as an orphan drug and the date the FDA approves the drug.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to support a label change for pediatric use&#59; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new drug or biologic product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, continuing cGMP compliance, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or a NDA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA or BLA approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product or therapeutic reaches the market. Later discovery of previously unknown problems with a product or therapeutic candidate, including adverse events of unanticipated severity or frequency, may result in in mandatory revisions to the approved labeling to add new safety information&#59; imposition of post-market or clinical trials to assess new safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal of the FDA to approve pending applications or supplements to approved application, or suspension or revocation of product approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">mandated modification of promotional materials and labeling and the issuance of corrective information. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a therapeutic candidate manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cGMP compliance requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record-keeping requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reporting of adverse experiences with the therapeutic candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">providing the FDA with updated safety and efficacy information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">therapeutic sampling and distribution requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, foreign regulatory agencies, and some state agencies for compliance with cGMPs and other laws. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any noncompliance with cGMP requirements. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA or BLA applicant and any third-party manufacturers involved in producing the approved product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act, or the DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10&#8208;year period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation Outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. It also is not yet clear how the United Kingdom&#8217;s recent withdrawal from the European Union will affect the approval of medicinal products in the United Kingdom. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European Union regulatory systems, a company can consider applying for marketing authorization in several European Union member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the European Union on or before May 20, 2004 intended to treat acquired immune deficiency syndrome, cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the European Union on or before May 20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the European Union-level. The decentralized procedure provides for recognition by European Union national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several European Union member states, one of them being chosen as the &#8220;Reference Member State,&#8221; and the remaining being the &#8220;Concerned Member States.&#8221; The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product, or the marketing authorization holder has given its consent. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. In the U.S., third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product and therapeutic candidates. For example, in the United States, the system for FDA to collect and expend user fees paid by manufacturers of drugs, biologics, and medical devices must be reauthorized by statute every five years, and since 1992, each reauthorization legislation has included, to greater or lesser degrees, various other changes to the FDA&#8217;s regulatory systems and procedures. The current legislative authority for FDA user fees expires in September 2022, and by that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. The expected 2022 reauthorization may include new legal provisions that could significantly impact our business in ways that cannot be predicted at this time. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of reducing drug prices, containing healthcare costs more generally, improving quality and/or expanding access. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has had a significant impact on the health care industry in the U.S. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA and we expect there may be additional challenges and amendments to the ACA in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law on March 27, 2020, and was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on December 20, 2019, the Further Consolidated Appropriations Act for 2020 became law (P.L. 116-94), which includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the &#8220;CREATES Act.&#8221; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. While the Trump administration put forward various proposals and executive orders aimed at reducing drug prices, the Biden administration is likely to pursue its own proposals going forward. In August 2021, President Biden announced his support for legislative proposals to grant Medicare the power to negotiate lower drug prices, for pharmaceutical companies to face penalties if they raise prices faster than inflation, and to impose a new cap on how much Medicare recipients have to spend on medications. Such proposals may be included in upcoming legislation in Congress, but the outcome of such proposals remains uncertain.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, physician sunshine and drug pricing transparency laws and regulations such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing </span><span style="color:#000000;">practices&#59;</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes federal, civil and criminal provisions that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The Physician Payments Sunshine Act, among other things, imposes requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and, beginning in 2022 for payments and other transfers of value provided in the previous year, certain advanced non-physician health care practitioners), teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations impose specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities, which include certain healthcare providers, health plans, and healthcare clearinghouses, that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers&#59; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information&#59; state and local laws which require the registration of pharmaceutical sales representatives&#59; and state laws and non-United States laws and regulations (particularly European Union laws regarding personal data relating to individuals based in Europe) that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities to produce any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all our required raw materials, Active Pharmaceutical Ingredient (API), and finished products for our preclinical and clinical trials and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships with these third parties. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s current good manufacturing practices, or cGMP, regulations. cGMP regulations require, among other things, quality control and quality assurance as well as corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facilities </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters is in Chicago, Illinois where we currently lease office space with approximately 124 square feet under a six month lease starting in mid October 2022, under which we currently pay $3,000 per month. We expect to renew this lease before it expires. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms. Additionally, we intend to maintain our business model designed to leverage virtual technology to minimize brick and mortar facilities while optimizing our ability to attract top talented employees that may reside in any geography. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022, we had a total of 18 full-time employees, which includes one employee employed by our Romanian subsidiary. We believe that we maintain a satisfactory working relationship with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None of our employees is represented by a labor union.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Engagement, Talent Development &#38; Benefits<span style="font-weight:normal;">. We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, and opportunities for equity ownership.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diversity, Inclusion, and Culture<span style="font-weight:normal;">. Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="MANAGEMENT">MANAGEMENT</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers and Directors </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding our executive officers and directors as of the date of this prospectus: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#1F497D;width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" style="background-color:#1F497D;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="middle" style="background-color:#1F497D;width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td colspan="3" valign="middle" style="background-color:#F2F2F2;width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p></td>
</tr>
<tr>
<td valign="top" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="top" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-Founder President, Chief Executive Officer, Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td colspan="3" valign="middle" style="background-color:#F2F2F2;width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors (Non-Employee)</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan Smith</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle" style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean-Manass&#233; Theag&#232;ne</p></td>
<td valign="middle" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle" style="width:60%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Leadership Team</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a team with deep research, development and commercialization experience in the areas of telomere related science, immunotherapy, and across a vast array of oncology indications. Members of our team bring experience from multiple biotech and pharmaceutical companies including Pfizer Inc., Bayer Pharmaceuticals, Astellas Pharma Inc., Janssen - a Johnson &#38; Johnson pharmaceutical company, Incyte Corporation, Pharmacyclics Inc., Juno Therapeutics Inc., Cephalon Inc., Geron Corporation, Agouron Pharmaceuticals (a Pfizer Company), Novo Nordisk Pharmaceuticals Inc., among others. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc, M.D., MBA </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Vitoc is our Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy &#8220;Iuliu Hatieganu&#8221;, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Dr. Vitoc is qualified to serve on our board of directors because he is a founder of the Company and he has significant knowledge and experience in the pharmaceutical industry and in the management and support of compounds targeting various types of cancers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr.<span style="font-weight:bold;"> </span>Gryaznov is our Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO&#8217;s telomere targeting activity, our lead compound in development. Dr. Gryaznov obtained a M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mihail</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obrocea</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, M.D.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Obrocea is our Chief Medical Officer. Dr. Obrocea is a hematologist/oncologist with over 20 years&#8217; experience in drug development in both academia and the pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Dr. Obrocea&#8217;s research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology. He received an M.D. degree from the Carol Davila University of Medicine &#38; Pharmacy in Bucharest, Romania and completed an internship and residency program in Internal Medicine at Yale University affiliated hospitals in Connecticut followed by a hematology/oncology fellowship training program at Dartmouth Cancer Center and Geisel School of Medicine in Hanover, New Hampshire.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. McGuire is our Chief Financial Officer, and he brings over 30 years of experience to MAIA having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. (&#8220;Avadim&#8221;) from October 2014 to May 2021. Avadim subsequently filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code and announced on August 17, 2021, the completion of its court-approved sale of substantially all of its assets to a newly created company and emergence from the reorganization proceedings under Chapter 11. Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Joe received a Bachelor of Science in accounting from the University of Notre Dame. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collective experience of our leadership team includes involvement in the development, approval and/or commercialization of a number of major oncology drugs, including TARCEVA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, NEXAVAR<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, IMBRUVICA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, XTANDI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, NERLYNX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, TREANDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, TRISENOX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, and ZOMETA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, as well as numerous state-of-the-art development programs, including a telomerase inhibitor (IMETELSTAT<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), a new immune oncology platform and agent (Cavrolotimod&#59; AST-008), and novel nucleic acid based siRNA and antisense oligonucleotide therapeutics (NP/NPS-oligos). In addition, our team was involved in the development and approval of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">BREANZY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, an autologous CD19 chimeric antigen receptor (CAR T) treatment for B-cell lymphomas&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">BESPONSA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a CD22-directed antibody drug conjugate (ADC) for treatment of B-cell acute lymphoblastic leukemia&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">IMBRUVICA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, or bruton tyrosine kinase inhibitor ibrutinib, for treatment of chronic lymphocytic leukemia and mantle cell lymphomas.</span><span style="Background-color:#FFFFFF;color:#111111;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee<span style="font-weight:normal;">&#59; Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. She also held key leadership positions within Group Internal Audit of HSBC in Latin America, Asia Pacific, and United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Born and educated in Hong Kong, Ms. Louie joined HSBC as an executive trainee in Hong Kong and became an International Manager of HSBC Group in 1996. Since then, she has taken up different roles in Hong Kong, the Philippines, Indonesia, Taiwan, the United States, the United Kingdom, and Latin America, primarily in key management positions to lead, drive and execute a change agenda in a wide range of management situations including business re-engineering, business turnaround, business downsizing, and business set up.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to her current appointment with MAIA Biotechnology in April 2020, Ms. Louie was the Group Chief Operating Officer of Group Internal Audit of HSBC Group.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Ms. Louie is qualified to serve on our board of directors because she has extensive</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finance, compliance, and audit experience and expertise</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero J.D., LL.M.<span style="font-weight:normal;">&#59; Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Guerrero is the Founder and CEO of IMPERIO, Inc., a Chicago and Suburban based Real Estate Investment and Brokerage Organization with over 20 years of business experience. He has also been a Venture Capitalist for the past 10 years aiding entrepreneurs and small businesses in their startup ventures. He received his undergraduate B.S. degree in Business/Management from the University of Illinois, his J.D. at the Universidad Metropolitana de Monterrey in Monterrey, Mexico and an LL.M. (Master of Laws) in International Law from St. Mary&#8217;s University School of Law in San Antonio, Texas and the University of Innsbruck, Austria.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Guerrero is qualified to serve on our board of directors because he has extensive entrepreneurial start-up experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput<span style="font-weight:normal;">&#59; Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Luput is the founder and CEO of Optimus Realty Inc, a full-service real estate company specializing in brokering, managing and developing residential properties in Chicago, with over 15 years of extensive expertise in real estate. Mr. Luput has also successfully completed multiple multimillion dollars real estate partnerships, consolidations, mergers and acquisitions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">He is actively involved and serves in the board of directors of several charitable organizations. Mr. Luput is a graduate of Babes-Bolyai, Cluj-Napoca, in Romania with a major in accounting and Business Administration.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Luput is qualified to serve on our board of directors because has extensive management and entrepreneurial start-up experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith Ph.D.<span style="font-weight:normal;">&#59; Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith, Ph.D., is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Dr. Smith is qualified to serve on our board of directors because has extensive economics, financing, and management experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jean-Manass&#233; Theag&#232;ne<span style="font-weight:normal;">&#59; Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean-Manass&#233; Th&#233;ag&#232;ne founded Montreal-based 360Medlink in November 2010, and has served as Chief Executive Officer since its founding.&#160;&#160;360Medlink is a software development company specializing in digital health platforms with a particular focus on scientifically tested solutions that address unmet needs or unique health conditions, and serve special or vulnerable populations. He has over 20 years&#8217; experience in the life sciences industry serving in diverse roles from global strategy, marketing, commercial operations, licensing, and business development. He has globally marketed multiple products, notably with Novartis Oncology and Schering-Plough (Merck). As a serial entrepreneur, Mr. Theag&#232;ne has been engaged in companion diagnostics, where he launched one of the world&#8217;s first non-invasive liver biomarker tests. As CEO of a healthcare technology company, and an early pioneer of Digital Therapeutics (DTx), Mr. Theag&#232;ne is also a strategic advisor to both private and public agencies in the areas of innovation and healthcare technology. Mr. Theag&#232;ne holds an MBA from HEC Montreal, a Master of Science degree in Criminology from University of Montreal, and a Bachelor of Science degree in Arts &#38; Sciences from University of Montreal.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Theag&#232;ne is qualified to serve on our board of directors because he has extensive technology, pharmaceutical and entrepreneurial start-up experience and expertise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Steven </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chaouki</span><span style="font-weight:normal;">&#59; </span><span style="font-weight:normal;">Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven M. Chaouki is President, U.S. Markets &#38; Consumer Interactive, overseeing two TransUnion business lines. U.S. Markets provides information and insights to business customers across financial services, insurance, public sector, media and diversified markets. Consumer Interactive provides credit, financial and identity protection services to consumers. He previously held the role of Executive Vice President, Financial Services, responsible for the company&#8217;s financial services business, which provides solutions to banks, credit unions, capital markets, financial services resellers, auto lenders and other customers. Before joining TransUnion, Mr. Chaouki held roles at HSBC in card/retail services and auto finance. Mr. Chaouki earned an M.B.A. from the University of Chicago Booth School of Business and a bachelor&#8217;s degree from Boston University.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Mr. Chaouki is qualified to serve on our board of directors because he has extensive management and financial experience and expertise.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad<span style="font-weight:normal;">&#59; Former Director</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad served as a director from 2019 until his resignation from the Board on March 13, 2023. He is a highly successful entrepreneur has started and grown two successful companies, in wholesale and retail as well as the lighting industry. His most recent company, Luminii, is the US market leader in linear lighting, having built projects including One World Trade Center, Uber HQ, Space Needle Seattle, and United Polaris Lounges.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Family Relationships</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships among any of our officers or directors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Involvement in Certain Legal Proceedings</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the best of our knowledge, except as set forth above regarding Mr. McGuire, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past ten years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board Composition </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors currently consists of seven members, all of whom are members pursuant to the board composition provisions of our current amended and restated certificate of incorporation and agreements with our stockholders, and who will remain members pursuant to the board composition provisions of our amended and restated certificate of incorporation, as amended. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our nominating and corporate governance committee and our board of directors may consider a broad range of factors relating to the qualifications and background of board nominees, which may include diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding board diversity. Our nominating and corporate governance committee&#8217;s and our board of directors&#8217; priority in selecting board members is identification of persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. Our amended and restated certificate of incorporation and amended and restated bylaws, each as amended to become effective upon the completion of this offering, also provide that our directors may be removed only for cause by the affirmative vote of the holders of a majority of the votes that all our stockholders would be entitled to cast in an election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office and not by the stockholders, unless the board determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Director Independence. <span style="font-style:normal;">Our board of directors has determined that all members of our board of directors are independent directors, with the exception of Vlad Vitoc, including for purposes of the rules of the NYSE American and relevant federal securities laws and regulations. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Staggered Board. </span><span style="font-style:normal;">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, our board of directors is divided into three staggered classes of directors of the same or nearly the same number and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the directors expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2023 for Class I directors, 2024 for Class II directors, and 2025 for Class III directors: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our Class I directors are Louie Ngar Yee and Steven Chaouki&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our Class II directors are Vlad Vitoc, Ramiro Guerrero and Cristian Luput&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our Class III directors are Jean-Manass&#233; Theag&#232;ne and Stan Smith. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one third of our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Committees of the Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which have the composition and responsibilities described below. Each of the below committees have a written charter approved by our board of directors. Each of the committees reports to our board of directors as such committee deems appropriate and as our board of directors may request. Copies of each charter are posted on the investor relations section of our website. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee is currently comprised of Ms. Louie, Mr. Chaouki and Dr. Smith, with Ms. Louie serving as chair of the committee. Mr. Laurentiu Vlad resigned as a member of our board of directors in March 2023 and, as a result, ceased to be a member of the Audit Committee. Our board of directors has determined that each member of the audit committee meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the applicable NYSE American rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Each of Mr. Chaouki, Dr. Smith and Ms. Louie qualifies as an audit committee financial expert under Item 407 of Regulation S-K. We have adopted an audit committee charter, detailing the principal functions of the audit committee, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">assisting board oversight of&#8201;(1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent auditor&#8217;s qualifications and independence, and (4) the performance of our internal audit function and independent auditors&#59; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">setting clear policies for audit partner rotation in compliance with applicable laws and regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and reviewing a report, at least annually, from the independent auditors describing (1) the independent auditor&#8217;s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under &#8220;</span><span style="font-style:italic;color:#000000;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;">&#8221;&#59; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us </span><span style="color:#000000;">entering into</span><span style="color:#000000;"> such transaction&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our compensation committee is comprised of Dr. Smith, Mr. Luput and Mr. Guerrero, with Dr. Smith serving as chair of the committee. Each member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act. Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the applicable NYSE American rules. The composition of our compensation committee meets the requirements for independence under the NYSE American listing standards, including the applicable transition rules. We have adopted a compensation committee charter which details the principal functions of the compensation committee, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing and making recommendations to our Board of Directors with respect to the compensation, and any incentive-compensation and equity-based plans that are subject to board approval of all of our other officers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing our executive compensation policies and plans&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">implementing and administering our incentive compensation equity-based remuneration plans&#59; assisting management in complying with our proxy statement and annual report disclosure requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">producing a report on executive compensation to be included in our annual proxy statement&#59; and reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by the NYSE American and the SEC.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nominating and Governance Committee </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our nominating and governance committee is comprised of Ms. Louie, Mr. Luput and Dr. Smith, with Ms. Louie serving as the chair of the committee. We have adopted a nominating and corporate governance committee charter, which details the purpose and responsibilities of the nominating and corporate governance committee, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the Board of Directors, and recommending to the Board of Directors candidates for nomination for election at the annual meeting of stockholders or to fill vacancies on the Board of Directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing and recommending to the Board of Directors and overseeing implementation of our corporate governance guidelines&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">coordinating and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the governance of the company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The charter also provides that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used to identify director candidates, and is directly responsible for approving the search firm&#8217;s fees and other retention terms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the Board of Directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leadership Structure and Risk Oversight </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors does not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the board of directors, as our board of directors believes it is in the best interest of the Company to make that determination based on the position and direction of the Company and the membership of the board of directors. Our board of directors has determined that having an employee director serve as Chairman is in the best interest of our stockholders at this time because of the efficiencies achieved in having the role of Chief Executive Officer and Chairman combined, and because the detailed knowledge of our day-to-day operations and business that the Chief Executive Officer possesses greatly enhances the decision-making processes of our board of directors as a whole. Dr. Stan Smith is the lead independent director. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Chairman of the board of directors and the other members of the board of directors work in concert to provide oversight of our management and affairs. Our board of directors encourages communication among its members and between management and the board of directors to facilitate productive working relationships. Working with the other members of the board of directors, our Chairman also strives to ensure that there is an appropriate balance and focus among key board responsibilities such as strategic development, review of operations and risk oversight. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee Interlocks and Insider Participation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, see the section titled &#8220;Certain Relationships and Related Party Transactions&#8221;. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a code of business conduct and ethics that applies to all our employees, officers and directors, including those officers responsible for financial reporting. Our code of business conduct and ethics is available on the investor relations section of our website. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="EXECUTIVE_DIRECTOR_COMPENSATION">EXECUTIVE AND DIRECTOR COMPENSATION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary Compensation Table </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the total compensation paid or accrued during the fiscal years ended December 31, 2022 and 2021, to our Chief Executive Officer and President, our Chief Financial Officer and our other two most highly-compensated executive officers that were serving as executive officers as of December 31, 2022 (our &#8220;named executive officers&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Qualified</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc, M.D. M.B.A.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442,542</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492,220</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,508</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207,770</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160; and President</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,583</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,000</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,068</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,651</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308,750</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,110</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,128</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733,988</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,500</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,519</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700,258</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,035</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878,312</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,083</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,110</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,101</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">851,494</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Medical&#160;&#160;Officer</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,500</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,731</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907,411</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,344</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,986</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sergei Gryaznov</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339,625</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,110</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,944</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770,879</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,542</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,500</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,980</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,485</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,507</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> All of the bonuses earned by our named executive officers in 2021 were paid in cash in 2022. All of the bonuses earned by our named executive offices in 2022 are expected to be paid in cash in 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup> The aggregate grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if any. The valuation assumptions used in calculating these values are discussed in Note 7 of the Notes to Consolidated Financial Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to time-based vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>All other compensation consists of medical premiums paid on behalf of the executive officers and a 401(k) match to be paid in cash in 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2022, we entered into executive employment agreements with each of senior executive officers in connection with their employment with us, the material terms of which are described below. Except as noted below, these executive employment agreements provide for &#8220;at will&#8221; employment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Vlad Vitoc</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Dr. Vitoc&#8217;s employment agreement dated September 16, 2022, Dr. Vitoc is entitled to an annual base salary of $473,000. Dr. Vitoc is eligible to receive a discretionary annual cash bonus of up to 50% of his then-current base salary based on the attainment of individual performance objectives, corporate goals and milestone achievements established by the board of directors. Dr. Vitoc is also eligible for a discretionary annual performance incentive options award based on the attainment of individual performance objectives, corporate goals and milestone achievements established by the board of directors for the previous performance year. Dr. Vitoc is eligible to participate in regular health insurance and other employee benefit plans as established by the Company, as well as reimbursement of reasonable expenses incurred in the performance of services to the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The employment agreement also provides for severance payments and benefits upon termination by the Company without Cause (as defined below), or by Dr. Vitoc for Good Reason (as defined below): (i) payment of his then-current base salary for a period of 12 months following termination&#59; (ii) acceleration of unvested equity awards that would have vested during the 12 months following the date of termination&#59; and (iii) continued coverage under the Company&#8217;s group health insurance plan with the cost of such coverage shared in the same relative proportion by the Company and Dr. Vitoc as in effect on his last day of employment until the earlier of 12 months from termination or the date Dr. Vitoc becomes eligible for medical benefits with another employer. Further, the agreement provides that upon termination by the Company without Cause or by Dr. Vitoc for Good Reason within a period of 180 days following a Change of Control (as defined below), Dr. Vitoc will be entitled to receive: (i) a lump sum payment equal to 18 months of his then-current base salary&#59; (ii) a lump sum payment equal to 1.5 times the target bonus for the year of termination&#59; (iii) acceleration of all unvested equity awards as of the date of termination&#59; and (iv) continued coverage under the Company&#8217;s group health insurance plan with the cost of such coverage shared in the same relative proportion by the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company and Dr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as in effect on his last day of employment until the earlier of 18 months from termination or the date Dr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> becomes eligible for medical benefits with another employer. Payment in each case is subject to Dr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc&#8217;s</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> execution of a release satisfactory to the Company following such termination. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in consideration of the payments and benefits provided under his employment agreement, Dr. Vitoc has agreed to certain invention assignment, confidentiality and other restrictive covenants, including, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Vitoc&#8217;s employment and for 12 months thereafter.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Cause&#8221; means the executive&#8217;s: (i) willful misconduct with respect to the Company, which causes material harm to the Company or its reputation&#59; (ii) continuing failure to materially perform executive&#8217;s essential job duties (other than upon a Disability), provided that executive&#8217;s failure to achieve Company operating goals by itself, will not constitute a basis for Cause if executive attempts in good faith to meet such operating goals&#59; (iii) refusal to follow a lawful directive of the Board that is materially related to and reasonably consistent with the provisions of the agreement&#59; (iv) material failure to comply with the Company&#8217;s Code of Business Conduct and Ethics and material policies&#59; (v) act of fraud with respect to the Company or willful and knowing misappropriation of Company property&#59; (vi) commission of any felony or any crime involving moral turpitude&#59; or (vii) material breach of any material term of the agreement or of any separate proprietary information and invention assignment agreement between executive and the Company, provided, however, that, in the event of conduct described in clauses (i), (ii), (iii) or (iv) that is reasonably capable of being cured, Cause shall exist only if the Company provides written notice to executive within sixty (60) days following the initial occurrence of such event giving rise to Cause reasonably detailing such grounds for Cause and executive fails to cure such grounds for Cause to the reasonable satisfaction of the Company within thirty (30) business </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days after delivery to executive of such written notice. executive&#8217;s date of termination in the event executive&#8217;s employment is terminated for Cause shall be the date on which executive is given notice of termination, except, if a notice period is required, executive&#8217;s date of termination shall be upon the expiration of said notice period if executive fails to previously cure the grounds giving rise to Cause.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Good Reason&#8221; means (i) any action or inaction that constitutes a material breach by the Company of the employment agreement or the indemnification agreement between the Company and executive&#59; (ii) any change in executive&#8217;s title or reporting line or a reduction in authority or duties of employment&#59; or (iii) the Company no longer permits full-time remote working&#59; provided, in each case, executive has provided the Company with written notice reasonably detailing such grounds for Good Reason within ninety (90) days after the occurrence thereof, and the Company fails to cure such grounds for Good Reason within thirty (30) days after delivery to it of such written notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Change of Control&#8221; means (i) the sale, lease, exclusive license or other disposition, in one or a series of related transactions, of all or substantially all of the assets of the Company or (ii) the consummation of any merger, consolidation, sale of stock of the Company or other transaction or series of related transactions pursuant to which the direct or indirect stockholders of the Company immediately prior to the consummation of such merger, consolidation, sale or other transaction or series of related transactions do not, immediately following such consummation, directly or indirectly own a majority of the outstanding equity interests in the entity resulting from or surviving such merger, consolidation, sale or other transaction or series of related transactions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Mihail Obrocea</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Dr. Obrocea&#8217;s employment agreement dated September 16, 2022, Dr. Obrocea is entitled to an annual base salary of $418,000. Dr. Obrocea is eligible to receive a discretionary annual cash bonus of up to 40% of his then-current base salary based on the attainment of individual performance objectives, corporate goals and milestone achievements established by the board of directors for the previous performance year. The remainder of the terms of the employment agreement are substantially the same as the terms of Dr. Vitoc&#8217;s employment agreement summarized above. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Sergei Gryaznov</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Dr. Gryaznov&#8217;s employment agreement dated September 16, 2022, Dr. Gryaznov is entitled to an annual base salary of $363,000. Dr. Gryaznov is eligible to receive a discretionary annual cash bonus of up to 40% of his then-current base salary based on the attainment of individual performance objectives, corporate goals and milestone achievements established by the board of directors for the previous performance year. The remainder of the terms of the employment agreement are substantially the same as the terms of Dr. Vitoc&#8217;s employment agreement summarized above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of Employment Agreement with Joseph McGuire</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of Mr. McGuire&#8217;s employment agreement dated September 16, 2022, Mr. McGuire is entitled to an annual base salary of $330,000. Mr. McGuire is eligible to receive a discretionary annual cash bonus of up to 40% of his then-current base salary based on the attainment of individual performance objectives, corporate goals and milestone achievements established by the board of directors for the previous performance year. The remainder of the terms of the employment agreement are substantially the same as the terms of Dr. Vitoc&#8217;s employment agreement summarized above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Equity Awards as of December </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1, 202</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards (1)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Awards</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(2)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares&#160;or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock&#160;that</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Have Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of&#160;Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of&#160;Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">that&#160;Have Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested(3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/16/2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.56</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/15/2032</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,529</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/30/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/16/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473,797</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,109</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/15/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,078</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/01/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,695</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/31/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/03/2020</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,789</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/2/2030</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2030</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/01/2018</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805,000</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/30/2028</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph McGuire</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/16/2022</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.56</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/15/2032</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/31/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,297</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/30/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/16/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,334</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,666</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/15/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/30/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/29/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/16/2022</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.56</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/15/2032</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/31/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">772</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/30/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/15/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,085</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,915</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/14/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/30/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,436</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/29/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/07/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,447</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/6/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/05/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,476</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/4/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/16/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,022</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/15/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/31/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,131</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/30/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/06/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,269</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergei Gryaznov</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/16/2022</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.56</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/15/2032</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/1/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,529</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/30/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/16/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,055</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/15/2031</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2021</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,078</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2031</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,695</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/31/2030</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2020</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,493</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/2/2030</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/31/2030</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/19/2019</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,000</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/18/2029</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/01/2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/30/2029</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> All of the option awards were granted under the 2018 Plan or the 2020 Plan, the terms of which are described below under &#8220;&#8212;Equity Compensation Plans and Other Benefit Plans&#8212;2020 Employee, Director and Consultant Equity Incentive Plan.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plans and Other Benefit Plans</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Employee, Director and Consultant Equity Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 14, 2018, we adopted and approved the 2018 Stock Option Plan (the &#8220;2018 Plan&#8221;), which provides for the issuance of 3,900,000 shares of our common stock for purposes of attracting, retaining, and motivating key employees, directors, and consultants. On May 29, 2020, we amended the 2018 Plan and approved it as the Amended and Restated 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and reserved 1,671,000 common stock for issuance. As of the date of this prospectus, there are 1,924,500 shares outstanding in the 2018 plan and no shares reserved for issuance.  On November 1, 2020, we approved the second amendment of the 2020 Plan to reserve a total of 3,171,000 common stock for issuance. In April and July of 2021 there were amendments to the 2020 Plan to bring the plan to a total of 4,171,000 shares reserved for issuance.<span style="font-weight:bold;"> </span>The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock and restricted stock units. As of the date of this prospectus, we have granted an aggregate of 3,999,023 options to various key employees, directors, and consultants under the 2020 Plan. As of the date of this prospectus, there are 3,993,023 shares underlying outstanding options granted under the 2020 Plan. No additional options will be granted under the 2020 Plan upon the effectiveness of the 2021 Plan, as more fully described below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 Equity Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors and stockholders have adopted and approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which has replaced the 2020 Plan. The 2021 Plan is a comprehensive incentive compensation plan under which we can grant equity<span style="color:#000000;">-based and other incentive awards to our officers, employees, directors, consultants and advisers. The purpose of the 2021 Plan is to help us attract, retain, and motivate such persons with awards under the 2021 Plan and thereby enhance shareholder value.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<span style="font-style:normal;">. The 2021 Plan is administered by the compensation committee of the Board, which shall consist of three members of the board, each of whom is a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 promulgated under the Exchange Act and &#8220;independent&#8221; for purposes of any applicable listing requirements. If a member of the compensation committee is eligible to receive an award under the 2021 Plan, such compensation committee member shall have no authority under the plan with respect to his or her own award. Among other things, the compensation committee has complete discretion, subject to the express limits of the 2021 Plan, to determine the directors, employees and nonemployee consultants to be granted an award, the type of award to be granted the terms and conditions of the award, the form of payment to be made and/or the number of shares of common stock subject to each award, the exercise price of each option and base price of each stock appreciation right (&#8220;SAR&#8221;), the term of each award, the vesting schedule for an award, whether to accelerate vesting, the value of the common stock underlying the award, and the required withholding, if any. The compensation committee may amend, modify or terminate any outstanding award, provided that the participant&#8217;s consent to such action is required if the action would impair the participant&#8217;s rights or entitlements with respect to that award. The compensation committee is also authorized to construe the award agreements, and may prescribe rules relating to the 2021 Plan. Notwithstanding the foregoing, the compensation committee does not have any authority to grant or modify an award under the 2021 Plan with terms or conditions that would cause the grant, vesting or exercise thereof to be considered nonqualified &#8220;deferred compensation&#8221; subject to Code Section 409A, unless such award is structured to be exempt from or comply with all requirements of Code Section 409A.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Grant of Awards&#59; Shares Available for Awards<span style="font-style:normal;">. The 2021 Plan provides for the grant of stock options, SARs, performance share awards, performance unit awards, distribution equivalent right awards, restricted stock awards, restricted stock unit awards and unrestricted stock awards to non-employee directors, officers, employees and nonemployee consultants of MAIA or its affiliates. The aggregate number of shares of common stock reserved and available for grant and issuance under the 2021 Plan was initially 1,909,518, including the reserved shares of common stock not issued or subject to outstanding awards granted under the 2020 Plan.&#160;&#160;As of the date of this prospectus, we have granted an aggregate of 1,310,392 options to various key employees, directors, and consultants under the 2021 Plan, and 599,126 shares of common stock are reserved and available for grant and issuance under the 2021 Plan. The same number of shares of common stock in the aggregate may be issued under the 2021 Plan in connection with incentive stock options. Shares shall be deemed to have been issued under the 2021 Plan solely to the extent actually issued and delivered pursuant to an award. If any award granted under the 2020 Plan or the 2021 Plan expires, is cancelled, or terminates unexercised or is forfeited, the number of shares subject thereto is again </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">available for grant under the 2021 Plan. The 2021 Plan shall continue in effect, unless sooner terminated, until the tenth (10</span><span style="font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></span><span style="font-style:normal;">) anniversary of the date on which it is adopted by the Board. The Board in its discretion may terminate the 2021 Plan at any time with respect to any shares for which awards have not theretofore been granted&#59; provided, however, that the 2021 Plan&#8217;s termination shall not materially and adversely impair the rights of a holder, without the consent of the holder, with respect to any award previously granted.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future new hires and additional non-employee directors and/or consultants would be eligible to participate in the 2021 Plan as well. The number of stock options and/or shares of restricted stock to be granted to executives and directors cannot be determined at this time as the grant of stock options and/or shares of restricted stock is dependent upon various factors such as hiring requirements and job performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<span style="font-style:normal;">. The 2021 Plan provides for either &#8220;incentive stock options&#8221; (&#8220;ISOs&#8221;), which are intended to meet the requirements for special federal income tax treatment under Section 422 of the Code, or &#8220;nonqualified stock options&#8221; (&#8220;NQSOs&#8221;). Stock options may be granted on such terms and conditions as the compensation committee may determine, which shall be specified in the option agreement&#59; provided, however, that the per share exercise price under a stock option may not be less than the fair market value of a share of common stock on the date of grant and the term of the stock option may not exceed 10 years (110% of such value and five years in the case of an ISO granted to an employee who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of capital stock of our Company or a parent or subsidiary of our Company). ISOs may only be granted to employees. In addition, the aggregate fair market value of common stock covered by one or more ISOs (determined at the time of grant), which are exercisable for the first time by an employee during any calendar year may not exceed $100,000. Any excess is treated as a NQSO.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights<span style="font-style:normal;">. A SAR entitles the participant, upon exercise, to receive an amount, in cash or stock or a combination thereof, equal to the increase in the fair market value of the underlying common stock between the date of grant and the date of exercise. The compensation committee shall set forth in the applicable SAR award agreement the terms and conditions of the SAR, including the base value for the SAR (which shall not be less than the fair market value of a share on the date of grant), the number of shares subject to the SAR and the period during which the SAR may be exercised and any other special rules and/or requirements which the compensation committee imposes on the SAR. No SAR shall be exercisable after the expiration of ten (10) years from the date of grant. SARs may be granted in tandem with, or independently of, stock options granted under the 2021 Plan. A SAR granted in tandem with a stock option (i) is exercisable only at such times, and to the extent, that the related stock option is exercisable in accordance with the procedure for exercise of the related stock option&#59; (ii) terminates upon termination or exercise of the related stock option (likewise, the common stock option granted in tandem with a SAR terminates upon exercise of the SAR)&#59; (iii) is transferable only with the related stock option&#59; and (iv) if the related stock option is an ISO, may be exercised only when the value of the stock subject to the stock option exceeds the exercise price of the stock option. A SAR that is not granted in tandem with a stock option is exercisable at such times as the compensation committee may specify.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Shares and Performance Unit Awards<span style="font-style:normal;">. Performance share and performance unit awards entitle the participant to receive cash or shares of common stock upon the attainment of specified performance goals. In the case of performance units, the right to acquire the units is denominated in cash values. The compensation committee shall set forth in the applicable award agreement the performance goals and objectives and the period of time to which such goals and objectives shall apply. If such goals and objectives are achieved, such distribution of shares, or payment in cash, as the case may be, shall be made no later than by the fifteenth (15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) calendar month next following the end of the Company&#8217;s fiscal year to which such performance goals and objectives relate, unless otherwise structured to comply with Code Section 409A.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution Equivalent Right Awards<span style="font-style:normal;">. A distribution equivalent right award entitles the participant to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions that would have been made to the participant had the participant held a specified number of shares of common stock during the period the participant held the distribution equivalent right. A distribution equivalent right may be awarded as a component of another award (but not an option or SAR award) under the 2021 Plan, where, if so awarded, such distribution equivalent right will expire or be forfeited by the participant under the same conditions as under such other award. The compensation committee shall set forth in the applicable distribution equivalent rights award agreement the terms and conditions, if any, including whether the holder is to receive credits currently in </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">cash, is to have such credits reinvested (at fair market value determined as of the date of reinvestment) in additional ordinary shares, or is to be entitled to choose among such alternatives.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards<span style="font-style:normal;">. A restricted stock award is a grant or sale of common stock to the holder, subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the compensation committee or the board of directors may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance goals and/or future service requirements), in such instalments or otherwise, as the compensation committee or the board of directors may determine at the date of grant or purchase or thereafter. If provided for under the restricted stock award agreement, a participant who is granted or has purchased restricted stock shall have all of the rights of a shareholder, including the right to vote the restricted stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the compensation committee or the board of directors or in the award agreement). During the restricted period applicable to the restricted stock, subject to certain exceptions, the restricted stock may not be sold, transferred, pledged, exchanged, hypothecated, or otherwise disposed of by the participant.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards<span style="font-style:normal;">. A restricted stock unit award provides for a grant of shares or a cash payment to be made to the holder upon the satisfaction of predetermined individual service-related vesting requirements, based on the number of units awarded to the holder. The compensation committee shall set forth in the applicable restricted stock unit award agreement the individual service-based vesting requirements which the holder would be required to satisfy before the holder would become entitled to payment and the number of units awarded to the holder. The holder of a restricted stock unit shall be entitled to receive either a cash payment equal to the fair market value of a share of common stock or a distribution of one share of common stock, as determined in the sole discretion of the compensation committee and as set forth in the restricted stock unit award agreement, for each restricted stock unit subject to such restricted stock unit award, if and to the extent the holder satisfies the applicable vesting requirements. Such payment or distribution shall be made no later than by the fifteenth (15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) calendar month next following the end of the calendar year in which the restricted stock unit first becomes vested, unless otherwise structured to comply with Code Section 409A. A restricted stock unit shall not constitute an equity interest in the Company and shall not entitle the holder to voting rights, dividends or any other rights associated with ownership of shares of our common stock prior to the time the holder shall receive a distribution of shares, if any.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unrestricted Stock Awards<span style="font-style:normal;">. An unrestricted stock award is a grant or sale of shares of our common stock to the employees, non-employee directors or non-employee consultants that are not subject to transfer, forfeiture or other restrictions, in consideration for past services rendered to the Company or an affiliate or for other valid consideration.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change-in-Control Provisions<span style="font-style:normal;">. The compensation committee may, in its sole discretion, at the time an award is granted or at any time prior to, coincident with or after the time of a change in control, cause any award either (i) to be cancelled in consideration of a payment in cash or other consideration in amount per share equal to the excess, if any, of the price or implied price per share of common stock in the change in control over the per share exercise, base or purchase price of such award, which may be paid immediately or over the vesting schedule of the award&#59; (ii) to be assumed, or new rights substituted therefore, by the surviving corporation or a parent or subsidiary of such surviving corporation following such change in control&#59; (iii) accelerate any time periods, or waive any other conditions, relating to the vesting, exercise, payment or distribution of an award so that any award to a holder whose employment has been terminated as a result of a change in control may be vested, exercised, paid or distributed in full on or before a date fixed by the compensation committee&#59; (iv) to be purchased from a holder whose employment has been terminated as a result of a change of control, upon the holder&#8217;s request, for an amount of cash equal to the amount that could have been obtained upon the exercise, payment or distribution of such rights had such award been currently exercisable or payable&#59; or (v) terminate any then outstanding award or make any other adjustment to the awards then outstanding as the compensation committee deems necessary or appropriate to reflect such transaction or change. The number of shares subject to any award shall be rounded to the nearest whole number.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment and Termination<span style="font-style:normal;">. The compensation committee may adopt, amend and rescind rules relating to the administration of the 2021 Plan, and amend, suspend or terminate the 2021 Plan, but no such amendment or termination will be made that materially and adversely impairs the rights of any participant with respect to any award received thereby under the 2021 Plan without the participant&#8217;s consent, other than amendments that are necessary to permit the granting of awards in compliance with applicable laws.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain U.S. Federal Income Tax Consequences of the 2021 Equity Incentive Plan</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a general summary of certain U.S. federal income tax consequences under current tax law to the Company (to the extent it is subject to U.S. federal income taxation on its net income) and to participants in the 2021 Plan who are individual citizens or residents of the United States for federal income tax purposes (&#8220;U.S. Participants&#8221;) of stock options which are ISOs, or stock options which are NQSOs, unrestricted stock, restricted stock, restricted stock units, performance stock, performance units, SARs, and dividend equivalent rights. This summary does not purport to cover all of the special rules that may apply, including special rules relating to limitations on our ability to deduct certain compensation, special rules relating to deferred compensation, golden parachutes, U.S. Participants subject to Section 16(b) of the Exchange Act or the exercise of a stock option with previously acquired ordinary shares. This summary assumes that U.S. Participants will hold their shares of common stock as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In addition, this summary does not address the foreign, state or local or other tax consequences, or any U.S. federal non-income tax consequences, inherent in the acquisition, ownership, vesting, exercise, termination or disposition of an award under the 2021 Plan or shares of common stock issued pursuant thereto. Participants are urged to consult with their own tax advisors concerning the tax consequences to them of an award under the 2021 Plan or shares issued thereunder.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize taxable income upon the grant of a NQSO if it is structured to be exempt from or comply with Code Section 409A. Upon the exercise of a NQSO, the U.S. Participant generally recognizes ordinary compensation income in an amount equal to the excess, if any, of the fair market value of the ordinary shares acquired on the date of exercise over the exercise price thereof, and the Company generally will be entitled to a deduction for such amount at that time. If the U.S. Participant later sells ordinary shares acquired pursuant to the exercise of a NQSO, the U.S. Participant recognizes a long-term or short-term capital gain or loss, depending on the period for which the ordinary shares were held. A long-term capital gain is generally subject to more favorable tax treatment than ordinary income or a short-term capital gain. The deductibility of capital losses is subject to certain limitations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize taxable income upon the grant or, except for purposes of the U.S. alternative minimum tax (&#8220;AMT&#8221;) the exercise, of an ISO. For purposes of the AMT, which is payable to the extent it exceeds the U.S. Participant&#8217;s regular income tax, upon the exercise of an ISO, the excess of the fair market value of the ordinary shares subject to the ISO over the exercise price is a preference item for AMT purposes. If the U.S. Participant disposes of the ordinary shares acquired pursuant to the exercise of an ISO more than two years after the date of grant and more than one year after the transfer of the ordinary shares to the U.S. Participant, the U.S. Participant generally recognizes a long-term capital gain or loss, and the Company will not be entitled to a deduction. However, if the U.S. Participant disposes of such ordinary shares prior to the end of either of the required holding periods, the U.S. Participant will have ordinary compensation income equal to the excess (if any) of the fair market value of such shares on the date of exercise (or, if less, the amount realized on the disposition of such shares) over the exercise price paid for such shares, and the Company generally will be entitled to deduct such amount.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize income upon the grant of a SAR. The U.S. Participant recognizes ordinary compensation income upon exercise of the SAR equal to the increase in the value of the underlying shares, and the Company generally will be entitled to a deduction for such amount.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant generally does not recognize income on the receipt of a performance stock award, performance unit award, restricted stock unit award, unrestricted stock award or dividend equivalent rights award until a cash payment or a distribution of ordinary shares is received thereunder. At such time, the U.S. Participant recognizes ordinary compensation income equal to the excess, if any, of the fair market value of the ordinary shares or the amount of cash received over any amount paid therefor, and the Company generally will be entitled to deduct such amount at such time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Participant who receives a restricted stock award generally recognizes ordinary compensation income equal to the excess, if any, of the fair market value of such ordinary shares at the time the restriction lapses over any amount paid for the ordinary shares. Alternatively, the U.S. Participant may make an election under Section 83(b) of the Code to be taxed on the fair market value of such ordinary shares at the time of grant. The Company generally will be entitled to a deduction at the same time and in the same amount as the income that is required to be included by the U.S. Participant.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">401(k) Plan</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10b5-1 Plan </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our directors and executive officers have adopted written plans, known as Rule 10b5-1 plans, in which they have contracted with a broker to buy shares of our common stock on a periodic basis. Our other directors and executive officers may also adopt Rule 10b5-1 plans in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional shares of our common stock outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations of Liability and Indemnification Matters </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that no director of our company shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to us or our stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) in respect of unlawful dividend payments or stock redemptions or repurchases, or (iv) for any transaction from which the director derived an improper personal benefit. In addition, our amended and restated certificate of incorporation provides that if the Delaware General Corporation Law (&#8220;DGCL&#8221;) is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of our company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amended and restated certificate of incorporation further provides that any repeal or modification of such article by our stockholders or amendment to the DGCL will not affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director serving at the time of such repeal or modification. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation also provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation also provides that we will advance expenses to Indemnitees in connection with a legal proceeding, subject to limited exceptions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation also permits us to secure insurance on behalf of ourselves and any director, officer, employee or agent of the Company or another corporation, partnership joint venture, trust or other enterprise, against any expense, liability or loss incurred by him or her in any such capacity, or arising out of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">his or her status as such, whether or not the Company would have the power to indemnify such person against such expense, liability or loss under the DGCL. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding arising out of their services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The description above of the indemnification provisions of our amended and restated certificate of incorporation and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our policy through November 15, 2022 with respect to the compensation payable to our non-employee directors provides that each non-employee director are eligible to receive compensation for his or her service consisting solely of equity awards, specifically 18,000 stock options per year, of which 1,500 will vest for each month of service. Non-employee directors that serve as chair of audit committee, compensation committee and nominating and corporate governance committee receive an additional 5,000 stock options per year, of which 417 will vest for each month of service. Starting November 15, 2022 our policy with respect to the compensation payable to our non-employee directors provides that each non-employee director will be eligible to receive compensation for his or her service consisting solely of equity awards, specifically $60,000 worth of stock options per year granted from the 2021 Equity Incentive Plan. The stock options will vest and distributed quarterly ($15,000 per quarter) and will be valued based on the closing stock price at the end of the three-month period. Non-employee directors that serve as chair of audit committee, compensation committee and nominating and corporate governance committee receive an additional $15,000 worth of stock options per year, granted from the 2021 Equity Incentive Plan. The stock options will vest and distributed quarterly ($3,750 per quarter) and will be valued based on the closing stock price at the end of the three-month period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors may be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors will also be entitled to the protection provided by their indemnification agreements and the indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The employment agreements for the Director who is a full-time employee expressly provides that his service on the Board does not entitle him to any additional compensation. The following table shows the total compensation paid or accrued </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to sitting non-employee members of our Board of Directors for the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fiscal year ended December 31, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">earned</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or paid</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,250</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,250</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurentiu Vlad</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> The aggregate grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if any. The valuation assumptions used in calculating these values are discussed in Note 7 of the Notes to Consolidated Financial Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to time-based vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup> Steven Chaouki had 0 shares and 24,045 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup> Ramiro Guerrero had 33,334 shares and 39,045 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup> Louie Ngar Yee had 11,111 shares and 50,568 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup> Cristian Luput had 24,306 shares and 39,045 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup> Stan V. Smith had 33,334 shares and 101,529 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup> <span style="color:#000000;">Laurentiu Vlad</span> had 33,334 shares and 36,045 total options outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PRINCIPAL_STOCKHOLDERS">PRINCIPAL STOCKHOLDERS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based solely upon information made available to us, the following table sets forth information as of April 3, 2023 regarding the beneficial ownership of our common stock by:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">each of our named executive officers and directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">all our executive officers and directors as a group.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The percentage ownership information shown in the table is based upon 10,996,404 shares of common stock outstanding as of April 3, 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated, each person or entity named in the table has sole voting and investment power with respect to all shares of our capital shown as beneficially owned, subject to applicable community property laws.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In computing the number and percentage of shares beneficially owned by a person as of a particular date, shares that may be acquired by such person (for example, upon the exercise of options or warrants) within 60 days of such date are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The address of each holder listed below, except as otherwise indicated, is c/o MAIA Biotechnology, Inc., 444 West Lake Street, Suite 1700, Chicago, IL 60606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficial Ownership</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.02%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Address of Beneficial Owner</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the&#160;Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">After</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,166,444</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.08</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.18% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,828</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergei M. Gryaznov</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">910,660</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.98% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073,957</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.64</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.41% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mihail Obrocea</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,868</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,008</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.17</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,970</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,351</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.40% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,195</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(10</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.82% </p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean-Manass&#233; Theag&#232;ne</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">945</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(11)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All directors and executive officers as a group</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; (10 persons):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,905,226</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.69% </p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Five Percent Shareholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jerry Shay</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">711,666</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.46</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95% </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Less than 1%</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days following the date of the information in this table are deemed to be beneficially owned by, and outstanding with respect to, the holder of such option or warrant, however none of the persons listed hereinabove has the right to acquire beneficial ownership in any other shares of the Company. Subject to community property laws where applicable, to our knowledge, each person listed is believed to have sole voting and investment power with respect to all shares of common stock owned by such person.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Vitoc beneficially owns (i) 1,014,196 shares of common stock, which includes 210,000 shares of common stock owned by his spouse, and (ii) 2,152,248 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023, which includes 28,159 options owned by his spouse and 200,000 options in trusts for his daughters.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. McGuire beneficially owns (i) 5,000 shares of common stock and (ii) 58,828 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Gryaznov beneficially owns (i) 44,511 shares of common stock and (ii) 866,149 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ms. Louie beneficially owns (i) 928,584 shares of common and (ii) 145,373 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Obrocea beneficially owns (i) 27,100 shares of common stock and (ii) 183,768 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Guerrero beneficially owns (i) 301,709 shares of common stock and (ii) 48,299 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Chaouki beneficially owns (i) 54,250 shares of common stock and (ii) 29,720 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Luput beneficially owns (i) 292,068 shares of common stock and (ii) 53,283 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Smith beneficially owns, through The Stan V. Smith Trust Dated 1993, (i) 543,328 shares of common stock and (ii) 155,867 shares of common stock issuable upon the conversion of options and warrants exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Theag&#232;ne  beneficially owns (i) 945 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Shay beneficially owns (i) 700,000 shares of common stock and (ii) 11,666 shares of common stock issuable upon the conversion of options exercisable within 60 days of April 3, 2023.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRAN">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following includes a summary of transactions since January 1, 2020, to which we have been a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets as of December 31, 2022 and 2021, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;<span style="font-style:italic;">Executive and Director Compensation</span>.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party Agreements in Effect Prior to this Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Services</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $88,994 for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $34,560 in cash and issued her options to purchase 23,964 shares of common stock with a total fair value of $54,434 during the year ended December 31, 2021.&#160;&#160;Ms. Durant was no longer considered a related party in 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $4,700 for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $2,350 in cash and issued him options to purchase 184 shares of common stock with a total fair value of $1,100. The remaining $1,250 for services provided in fiscal 2021 were settled in March, 2022 for 226 options issued to Mr. Vitoc. The Company also issued him a convertible note in the amount of $50,000 during April 2021, which was converted into 8,557 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share, and also received 4,278 warrants to purchase shares of common stock at an exercise price of $6.00 per share.&#160;&#160;In 2022, Mr. Vitoc provided consulting services to the Company through July 2022 for which the Company incurred $36,900 for services provided during the year ended December 31, 2022.&#160;&#160;The Company paid Mr. Vitoc $19,950 in cash and issued him options to purchase 4,690 shares of common stock with a total fair value of $19.950.&#160;&#160;In August 2022, Mr. Vitoc became an employee of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Loan Agreement</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's chief executive officer lent the Company a total of $25,000 in August and September of 2018. These amounts, were unsecured, had no stated interest rate, and no stated repayment terms. The Company repaid $3,633 of the loan to the CEO during 2020 and $367 during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $21,000. The convertible note issued to the CEO was converted into 3,621 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share.&#160;&#160;No further notes to the CEO were incurred in the year ended December 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Compensation Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and December 31, 2021, the Company had $0 and $111,271, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $193,379 in deferred compensation. The Company paid $457,749 in cash and issued 268,769 options with a total fair value of $296,264 during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $743,167. The fair value of the options issued in excess of the deferred compensation balance settled totaling $10,846 was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Bonus</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022 and 2021, the Company accrued $1,094,582 and $384,750, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of 713,536 stock options with a total fair value of $786,531. The fair value of the options issued in excess of the accrued bonus balance totaled $6,531 and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the DGCL, subject to certain exceptions contained in those agreements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Related Person Transactions </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors have adopted a written related person transaction policy, setting forth the policies and procedures for the review and approval or ratification by our audit committee of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds the lesser of $120,000 in any fiscal year or one percent of the average of our total assets as of the two previous fiscal years and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm's length transaction and the extent of the related person's interest in the transaction. Certain of the transactions described in this section occurred prior to the adoption of this policy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="DESCRIPTION_CAPITAL_STOCK">DESCRIPTION OF CAPITAL STOCK</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of (i) the material terms of our amended and restated certificate of incorporation and amended and restated bylaws and (ii) certain applicable provisions of Delaware law. We refer you to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which are filed as exhibits to the registration statement of which this prospectus is a part. In addition, with respect to the description of our warrants, we refer you to the forms of such warrants filed as exhibits to the registration statement of which this prospectus is a part.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized Capitalization</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 70 million shares of common stock, par value $0.0001 per share and 30 million shares of preferred stock, par value $0.0001 per share. Following the consummation of this offering, 14,356,404 shares of common stock will be issued and outstanding and no shares of preferred stock will be issued or outstanding.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive on a pro rata basis our net assets available for distribution to stockholders after the payment of all debts and other liabilities, subject to the prior rights of any holders of outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our amended and restated certificate of incorporation our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that delay, defer, or discourage transactions involving an actual or potential change in control of us or change in our management. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized but Unissued Shares </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Meetings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Choice of Forum </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Court of Chancery of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law, for: any derivative action or proceeding brought on our behalf&#894; any action asserting a breach of fiduciary duty&#894; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation, or our bylaws&#894; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find either choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. Although our amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of certain of our outstanding convertible promissory notes in 2020 and 2021, we issued to each such lender warrants equal to that number of shares of common stock as determined by multiplying the number of shares which would be issuable upon conversion of such note by 50%, for a total of 686,489 warrants at an exercise price of $6.00 per share. As of April 3, 2023, 681,985 of these warrants were outstanding and will expire on the earlier of the occurrence of a change of control or<span style="color:#FF0000;"> </span>September 2028.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders' warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#8217;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants will only be exercisable, in whole or in part, during the exercise period ending on earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements&#59; or (b) immediately prior to the closing of a change of control.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the closing of our initial public offering, we issued the representative of the underwriters warrants to purchase up to 115,000 shares of common stock at an exercise price of $6.25 per share. The representative&#8217;s warrants are exercisable beginning on January 23, 2023, and expire on July 27, 2027.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Inc. The transfer agent and registrar&#8217;s address is Computershare Trust Company, N.A.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">National Securities Exchange Listing </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on NYSE American, or the &#8220;NYSE American&#8221;, under the symbol &#8220;MAIA.&#8221;. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="MATERIAL_US_FEDERAL_INCOME_TAX_CONSEQUEN">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary sets forth below certain material U.S. federal income tax consequences for Non-U.S. Holders (as defined below) of common stock as of the date hereof. This summary is based upon the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the regulations promulgated by the U.S. Treasury Department, current administrative interpretations and practices of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) and judicial decisions, all as currently in effect as of the date hereof and all of which are subject to differing interpretations or change, possibly with retroactive effect. No assurance can be given that the IRS will not assert, or that a court will not sustain a position contrary to any of the tax considerations described below. This summary does not discuss all aspects of U.S. federal income taxation that may be relevant to particular holders in light of their particular circumstances, and does not address the U.S. federal income tax consequences to holders that are subject to special tax rules, including, without limitation: financial institutions, insurance companies, mutual funds, pension plans, S corporations, controlled foreign corporations, broker-dealers, traders in securities that elect mark-to-market treatment, regulated investment companies, real estate investment trusts, partnerships and their partners, tax-exempt organizations (including private foundations), investors that hold common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive ownership transaction,&#8221; &#8220;constructive sale&#8221; or other integrated transaction for U.S. federal income tax purposes, holders subject to the alternative minimum tax provisions of the Code, holders who acquired common stock directly or indirectly in connection with performance of services, pursuant to an exercise of employee options, in connection with employee incentive plans or otherwise as compensation, the Sponsor and its affiliates, persons who actually or constructively own 5% or more (by vote or value) of the common stock, persons required to accelerate the recognition of any item of gross income with respect to common stock as a result of such income being recognized on an applicable financial statement, and U.S. expatriates, all of whom may be subject to tax rules that differ materially from those summarized below. In addition, this summary does not discuss any state, local, or non-United States tax considerations, any non-income tax (such as gift or estate tax) considerations, the alternative minimum tax, the Medicare tax on certain net investment income, the impact of the 1% excise tax on stock repurchases under the Inflation Reduction Act of 2022 by certain U.S. corporations, or any tax reporting obligations in respect of the ownership of common stock. This summary is limited to holders that hold common stock as &#8220;capital assets&#8221; (generally, property held for investment) under the Code.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds common stock, the tax treatment of a partner in such partnership will generally depend upon the status of the partner, the activities of the partnership and the partner and certain determinations made at the partner level. If you are a partner of a partnership holding common stock, you are urged to consult your tax advisor.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is a beneficial owner for U.S. federal income tax purposes of common stock that is not any of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an individual who is a United States citizen or resident of the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a corporation (including an entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a trust (i) the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (ii) that has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussions below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a taxable disposition of its common stock, unless:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the gain is effectively connected with the conduct of a trade or business by the Non-U.S. Holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), in which case, a non&#8209;corporate Non&#8209;U.S. Holder will be subject to tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and a corporate Non-U.S. Holder may be subject to an additional branch profits tax at a 30% rate (or lower rate as may be specified by an applicable income tax treaty)&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year in which the disposition takes place and certain other conditions are met, in which case the Non-U.S. Holder will generally be subject to a 30% (or lower rate as may be specified by an applicable income tax treaty) tax on the individual&#8217;s net capital gain for the year&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Company or has been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held common stock, and, in the case where shares of common stock are regularly traded on an established securities market, the Non-U.S. Holder has owned, directly or constructively, more than 5% of the common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder&#8217;s holding period for the shares of common stock.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the third bullet point above (if applicable to a particular Non-U.S. Holder), gain recognized by such Non-U.S. Holder on the sale, exchange or other disposition of common stock will be subject to tax at generally applicable U.S. federal income tax rates. There can be no assurance that the common stock will be treated as regularly traded on an established securities market for this purpose. The Company does not believe that it is or has been a United States real property holding corporation for U.S. federal income tax purposes but there can be no assurance in this regard. The Company would be classified as a United States real property holding corporation if the fair market value of its &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Taxation of Distributions </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussions below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; in general, any distributions the Company makes to a Non-U.S. Holder on shares of common stock, to the extent paid out of the Company&#8217;s current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, under certain income tax treaties, attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), the applicable withholding agent will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. Holder&#8217;s adjusted tax basis in its shares of common stock (and, subject to the discussion below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212; FATCA,&#8221; and the third bullet point above under &#8220;&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of common stock,&#8221; to the extent such distribution does not exceed the adjusted tax basis, such amount will generally not be subject to withholding) and, to the extent such distribution exceeds the Non-U.S. Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of common stock, which will be treated as described above under &#8220;&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock.&#8221; In addition, if the Company determines that it is classified as a United States real property holding corporation, it will withhold 15% of any distribution that exceeds the Company&#8217;s current and accumulated earnings and profits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends the Company pays to a Non-U.S. Holder that are effectively connected with such Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, under certain income tax treaties, attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder), generally will not be subject to U.S. federal withholding tax, provided such Non-U.S. Holder complies with certain certification and disclosure requirements. Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to United States persons as defined under the Code (subject to an exemption or reduction in such tax as may be provided by an applicable income tax treaty). If the Non-U.S. Holder is a corporation, dividends that are effectively connected income may also be subject to an additional &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty).</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information Reporting and Backup Withholding</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally must report annually to the IRS and to each Non&#8209;U.S. Holder the amount of dividends paid to such holder and the tax withheld with respect to such dividends, regardless of whether withholding was required. A Non-U.S. Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under an applicable income tax treaty generally will satisfy a Non-U.S. Holder&#8217;s certification requirements necessary to avoid backup withholding as well. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will generally be allowed as a refund or a credit against a Non-U.S. Holders U.S. federal income tax liability provided the required information is timely furnished to the IRS. Holders should consult their tax advisors regarding the application of information reporting and backup withholding to them.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FATCA</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under sections 1471 to 1474 of the Code, commonly referred to as the Foreign Account Tax Compliance Act (&#8220;FATCA&#8221;), a 30% withholding tax generally applies with respect to certain payments on and, subject to the regulatory relief described below, gross proceeds from a sale or disposition of, common stock if paid to (i) a foreign financial institution (as the beneficial owner or as an intermediary for the beneficial owner), unless such institution (a) enters into, and is in compliance with, a withholding and information reporting agreement with the U.S. government to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which would include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or (b) is a resident in a country that has entered into an intergovernmental agreement with the United States in relation to such withholding and information reporting and the financial institution complies with the related information reporting requirements of such country or (ii) a foreign entity that is not a financial institution (as the beneficial owner or as an intermediary for the beneficial owner), unless such entity provides the withholding agent with a certification identifying the substantial United States owners of the entity, which generally includes any United States person who directly or indirectly owns more than 10% of the entity, or such entity otherwise qualifies for an exemption from these rules. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An intergovernmental agreement between the United States and the applicable foreign country, or future U.S. Treasury regulations or other guidance, may modify these requirements. Under proposed U.S. Treasury regulations that may be relied upon pending finalization, the withholding tax on gross proceeds would be eliminated and, consequently, FATCA withholding on gross proceeds is not expected to apply unless such proposed U.S. Treasury regulations are modified, withdrawn or replaced in a manner that would subject gross proceeds to FATCA withholding. Non-U.S. Holders should consult their tax advisors regarding the possible implications of such withholding tax.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-U.S. HOLDERS OF COMMON STOCK ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE APPLICATION OF U.S. FEDERAL, STATE, LOCAL, AND FOREIGN INCOME AND OTHER TAX CONSEQUENCES THEREOF TO THEIR PARTICULAR SITUATIONS.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="UNDERWRITING">UNDERWRITING</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity LLC is acting as representative of the underwriters of this offering. We have entered into an underwriting agreement dated <span style="color:#000000;">&#160;&#160; &#160;&#160;</span>, 2023 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underwriter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity LLC</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters are committed to purchase all shares offered by us other than those covered by the over-allotment option described below, if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&#8217; obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&#8217; certificates and legal opinions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of the prospectus. After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various times.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-Allotment Option</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the representative to purchase a maximum of <span style="color:#000000;">504,000 </span>additional shares of common stock (15% of the shares sold in this offering) from us to cover over-allotments, if any. If the representative exercises all or part of this option, it will purchase shares covered by the option at the offering price per share that appears on the cover page of this prospectus, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $&#160;&#160;&#160;&#160;  and the total net proceeds, before expenses, to us will be $&#160;&#160; &#160;&#160;.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discount</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the offering price, underwriting discounts and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total&#160;Without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-&#160;Allotment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total With</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over-&#160;Allotment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underwriting discount (7%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds, before expense, to us</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to pay a non-accountable expense allowance to the underwriters equal to 1% of the gross proceeds received in this offering (excluding proceeds received from exercise of the underwriters&#8217; over-allotment option).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have paid an expense deposit of $25,000 to the representative for out-of-pocket-accountable expenses, which will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have agreed to reimburse the representative for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fees and expenses of legal counsel to the underwriters in an amount not to exceed $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000&#59;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fees and expenses related to the use of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ipreo&#8217;s</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> book building, prospectus tracking and compliance software for the offering in the amount of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,500&#59; (iii) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000 </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for data services and communications expenses</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#59;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000 </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the costs associated with bound volumes of the public offering materials as well as commemorative mementos and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lucite</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tombstones</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#59;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up to $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000 </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for actual accountable &#8220;road show&#8221; expenses</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#59;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi) </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up to $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000 </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for market making and trading, and clearing firm settlement expenses for the offering.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense allowance, will be approximately $1,111,299&#8236;.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Representative&#8217;s Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to issue to the representative or its designees warrants to purchase up to a total of 121,500&#8236; (or 139,725&#8236; if the over-allotment option is exercised in full) shares of our common stock (5% of the aggregate number of shares of common stock sold in this offering) (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. The Representative&#8217;s Warrants are exercisable at any time, from time to time, in whole or in part, during the four and one half year period commencing 180 days from the commencement of sales of the securities in this Offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Representative&#8217;s Warrants and the shares of common stock underlying the Representative&#8217;s Warrants have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or permitted assignees under such rule may not sell, transfer, assign, pledge, or hypothecate the Representative&#8217;s Warrants or the securities underlying the Representative&#8217;s Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representative&#8217;s Warrants or the underlying shares of common stock for a period of 180 days from the effective date of the registration statement. Additionally, the Representative&#8217;s Warrants may not be sold, transferred, assigned, pledged, or hypothecated for a 180-day period following the effective date of the registration statement, except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners. The Representative&#8217;s Warrants will provide for adjustment in the number and price of the Representative&#8217;s Warrants and the shares of common stock underlying the Representative&#8217;s Warrants in the event of recapitalization, merger, stock split, or other structural transaction, or a future financing undertaken by us. The Representative&#8217;s Warrants will provide for registration rights (including a one-time demand registration right and unlimited piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration may be made at any time beginning on the initial exercise date of the Representative&#8217;s Warrants and expiring on the fifth anniversary of the effective date of this registration statement in accordance with FINRA Rule 5110(g)(8)(C). In addition to the one-time demand registration right, the Representative&#8217;s Warrants shall have unlimited piggyback rights, for a period of no more than two years from the initial exercise date of the Representative&#8217;s Warrants in accordance with FINRA Rule 5110(g)(8)(D). The Representative&#8217;s Warrants will also provide for customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative&#8217;s Warrants shall be reduced if necessary to comply with FINRA rules and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discretionary Accounts</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors and officers have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of six (6) months from the date of this Offering.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we agreed that for a period of six (6) months after this Offering we will not directly or indirectly in any &#8220;at-the-market,&#8221; continuous equity or variable rate transaction, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of our shares of capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock in any &#8220;at-the-market,&#8221; continuous equity or variable rate transaction, without the prior written consent of the Representative.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Right of First Refusal</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Underwriting Agreement will provide that for a period of six (6) months from the closing of the offering, we will grant the representative an irrevocable right of first refusal to act as sole investment banker, sole bookrunner, sole financial advisor, sole underwriter and/or sole placement agent, at the representative&#8217;s sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings, during such six (6) month period for us, or any successor to or any subsidiary of us, on terms customary to the representative. The representative has the sole right to determine whether or not any other broker dealer shall have the right to participate in any such offering and the economic terms of any such participation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent permitted by law, we have agreed to indemnify the underwriters and its affiliates, stockholders, directors, officers, employees, members and controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Electronic Offer, Sale and Distribution of Shares</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representative may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#8217; websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stabilization</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-allotment transactions involve sales by the underwriters of securities in excess of the number of securities that underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing securities in the open market.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared with the price at which they may purchase securities through exercise of the over-allotment option. If the underwriters sell more securities than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying securities in the open market. A </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in the offering.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our securities. These transactions may be effected on the NYSE American, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Passive Market Making</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the NYSE American or on the OTCQB in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Relationships</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have no present arrangements with any of the underwriters for any further services.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offer restrictions outside the United States</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">China</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&#8217;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to &#8220;qualified domestic institutional investors.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">European Economic Area&#8212;Belgium, Germany, Luxembourg and Netherlands</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&#8220;Prospectus Directive&#8221;), as implemented in Member States of the European Economic Area (each, a &#8220;Relevant Member State&#8221;), from the requirement to produce a prospectus for offers of securities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year&#59; (ii) a total balance sheet of more than &#8364;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than &#8364;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">France</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&#233;taire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&#233; des march&#233;s financiers (&#8220;AMF&#8221;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&#233;s) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d&#8217;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &#8220;Prospectus Regulations&#8221;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Israel</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus&#59; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Italy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societa e la Borsa, or CONSOB), pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&#8220;Decree No. 58&#8221;), other than:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">to Italian qualified investors (&#8220;Qualified Investors&#8221;), as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999, as amended (&#8220;Regulation no. 1197l&#8221;)&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Regulation no. 1197l.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993, as amended, Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007, and any other applicable laws&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#8220;FIEL&#8221;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Portugal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is not being distributed in the context of a public offer of financial securities (oferta p&#250;blica de valores mobili&#225;rios) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&#243;digo dos Valores Mobili&#225;rios). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&#259;o do Mercado de Valores Mobili&#225;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#8220;qualified investors&#8221; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sweden</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#8220;qualified investors&#8221; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is personal to the recipient only and not for general circulation in Switzerland.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United Arab Emirates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&#8220;FSMA&#8221;)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#8220;qualified investors&#8221; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&#8220;FPO&#8221;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &#8220;relevant persons&#8221;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Canada</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="EXPERTS">EXPERTS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated balance sheet of MAIA Biotechnology, Inc. and Subsidiaries as of December 31, 2022, and the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for the year then ended, have been audited by Grant Thornton LLP, independent registered public accounting firm, as stated in their report which is included herein.&#160;&#160;Such financial statements have been incorporated herein in reliance on the reports of such firms given upon their authority as experts in accounting and auditing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated balance sheet of MAIA Biotechnology, Inc. and Subsidiaries as of December 31, 2021, and the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein. Such financial statements have been incorporated herein in reliance on the reports of such firms given upon their authority as experts in accounting and auditing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="LEGAL_MATTERS">LEGAL MATTERS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loeb &#38; Loeb LLP, New York, New York, will pass upon the validity of the shares of common stock offered hereby. Venable, LLP, New York, New York has acted as counsel for the underwriters in connection with certain legal matters related to this offering.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="WHERE_YOU_CAN_FIND_MORE_INFORMATION">WHERE YOU CAN FIND MORE INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. You may read and copy the registration statement, the related exhibits and other material we file with the SEC on the SEC&#8217;s Internet website. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is <span style="text-decoration:underline;">www.sec.gov</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, are required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available on the website of the SEC referred to above. We also maintain a website at www.maiabiotech.com. Our website and the information contained on, or that can be accessed through, our website is not deemed to be incorporated by reference in, and is not considered part of, this prospectus. You should not rely on any such information in making your decision whether to purchase our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not authorized anyone to give you any information or to make any representations about us or the transactions we discuss in this prospectus other than those contained in this prospectus. If you are given any information or representations about these matters that is not discussed in this prospectus, you must not rely on that information. This prospectus is not an offer to sell or a solicitation of an offer to buy securities anywhere or to anyone where or to whom we are not permitted to offer or sell securities under applicable law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMEN">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Grant Thornton, LLP PCAOB ID 248)</span></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGIST_PUBLIC_ACC_II"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (EisnerAmper, LLP PCAOB ID 274)</span></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS1"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:underline;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CHANGES_IN_STOCK"><span style="text-decoration:underline;">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
</tr>
<tr>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors and Stockholders</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Opinion on the financial statements<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated<span style="color:#0000FF;"> </span>balance sheet of MAIA Biotechnology, Inc. (a Delaware corporation)<span style="color:#0000FF;"> </span>and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the year then ended, and the related notes<span style="color:#0000FF;"> </span>(collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company<span style="color:#0000FF;"> </span>as of December 31, 2022, and the results of its<span style="color:#0000FF;"> </span>operations and its<span style="color:#0000FF;"> </span>cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going concern</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring losses, has negative cash flows from operations, and has an accumulated deficit of $44,207,272 as of December 31, 2022. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis for opinion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ GRANT THORNTON LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charlotte, North Carolina</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2023</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGIST_PUBLIC_ACC_II"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF INDEPENDENT REGIST</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ERED PUBLIC ACCOUNTING FIRM</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheet of MAIA Biotechnology, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021, and the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor from 2021 to 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS1">Consolidated Balance Sheets </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,<br />2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,<br />2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000027" name="us-gaap:Cash" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000028" name="us-gaap:Cash" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">554,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">54,537</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia research and development incentives receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="maia:ResearchAndDevelopmentIncentivesReceivable" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">302,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="maia:ResearchAndDevelopmentIncentivesReceivable" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">43,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:AssetsCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">11,808,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AssetsCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">10,672,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:DeferredCosts" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">211,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:DeferredCosts" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">2,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">3,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:Assets" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">12,022,040</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:Assets" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">11,327,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">1,165,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">960,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">2,103,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">1,185,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">3,268,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">2,145,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="maia:WarrantLiabilityNoncurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Liabilities" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">3,514,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Liabilities" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">2,145,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 5)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"><span style="-sec-ix-hidden:F_000050">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000065" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001878313_20221231" decimals="4"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000066" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001878313_20211231" decimals="4">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000067" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000068" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction> shares<br />&#160;&#160; authorized at December 31, 2022 and December 31, 2021 respectively,<br />&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000069" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001878313_20221231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000070" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001878313_20211231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000071" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001878313_20221231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000072" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001878313_20211231" decimals="INF">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:13.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000052">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000053">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000073" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001878313_20221231" decimals="4"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000074" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001878313_20211231" decimals="4">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000075" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000076" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction> shares<br />&#160;&#160; authorized at December 31, 2022 and December 31, 2021 respectively,<br />&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">10,955,904</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2022 and December 31, 2021, respectively</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:CommonStockValue" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">1,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:CommonStockValue" contextRef="C_0001878313_20211231" decimals="0">758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">52,729,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001878313_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001878313_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001878313_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">8,507,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">12,022,040</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">11,327,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the accompanying notes to the consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of Operations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:36.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">8,933,314</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">3,496,796</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">6,143,527</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">4,289,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ratchet share expense</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="maia:RatchetShareExpense" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:OperatingExpenses" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">16,176,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:OperatingExpenses" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">7,786,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">16,176,201</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">7,786,627</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:InterestExpense" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">6,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:InterestExpense" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">827,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,870</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,012</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian research and development incentives</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="maia:AustralianResearchAndDevelopmentIncentives" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">313,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="maia:AustralianResearchAndDevelopmentIncentives" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">43,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paycheck protection program loan forgiveness</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="maia:GainOnPaycheckProtectionProgramLoanForgiveness" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="maia:ChangeInFairValueOfEmbeddedFeatures" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes and convertible notes,<br />&#160;&#160; related parties</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">2,322,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">406,922</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">4,791,584</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">74,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on warrant modification</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="maia:DeemedDividendOnWarrantModification" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to MAIA Biotechnology, Inc. shareholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.28%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">16,219,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:15.3%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000109" name="maia:EarningsPerSharesBasicAndDiluted" contextRef="C_0001878313_20220101_20221231" decimals="2" sign="-">1.75</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="maia:EarningsPerSharesBasicAndDiluted" contextRef="C_0001878313_20210101_20211231" decimals="2" sign="-">2.37</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:61.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:16.36%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:61.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding basic and diluted</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.28%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000111" name="maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">9,276,761</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:3.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:15.3%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,278,435</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:61.21%;"></td>
<td style="width:1%;"></td>
<td style="width:1.07%;"></td>
<td style="width:15.29%;"></td>
<td style="width:1%;"></td>
<td style="width:3.04%;"></td>
<td style="width:1.07%;"></td>
<td style="width:15.3%;"></td>
<td style="width:1.01%;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">16,219,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Foreign currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">16,235,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CHANGES_IN_STOCK">Consolidated Statements of Changes in Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Year ended December 31, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:auto;">
<tr>
<td style="width:45.3%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:4.81%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:2%;"></td>
<td style="width:4%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:9.67%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:6.44%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:11.28%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:11.28%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:11.28%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:11.28%;"></td>
<td style="width:1.59%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Stockholders' Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000119" name="us-gaap:SharesOutstanding" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="0">758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000124" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">46,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="0">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">83,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000128" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">529,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="0">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">385,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">385,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares in connection with equity<br />&#160;&#160; financing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">274,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="0">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,473,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,473,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares in connection with initial public<br />&#160;&#160; offering, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,749,905</ix:nonFraction> issuance cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">2,300,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="0">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">8,749,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">8,750,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Issuance of ratchet shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="maia:IssuanceOfRatchetSharesShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">219,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="maia:IssuanceOfRatchetShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231" decimals="0">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="maia:IssuanceOfRatchetShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,099,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="maia:IssuanceOfRatchetShares" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification of warrant in equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="maia:ModificationOfWarrantInEquity" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="maia:ModificationOfWarrantInEquity" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on modification of warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="maia:DeemedDividendOnWarrantModification" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="maia:DeemedDividendOnWarrantModification" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="maia:ForeignCurrencyTranslationAdjustment" contextRef="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="maia:ForeignCurrencyTranslationAdjustment" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:ProfitLoss" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000154" name="us-gaap:SharesOutstanding" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231" decimals="INF" format="ixt:numdotdecimal">10,955,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231" decimals="0" format="ixt:numdotdecimal">1,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20221231" decimals="0" format="ixt:numdotdecimal">52,729,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">8,507,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Year ended December 31, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:auto;">
<tr>
<td style="width:37.21%;"></td>
<td style="width:1.58%;"></td>
<td style="width:1.58%;"></td>
<td style="width:3.18%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:2.25%;"></td>
<td style="width:2.24%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:6.45%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:3.18%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:8.04%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:8.04%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:9.68%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:8.04%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:9.68%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:1.59%;"></td>
<td style="width:9.68%;"></td>
<td style="width:1.59%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subscription Receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total MAIA Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Stockholders' (Deficit) Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000160" name="us-gaap:SharesOutstanding" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,433,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="0">443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="0" format="ixt:numdotdecimal">12,599,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">15,934,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">2,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">3,336,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231" decimals="0" format="ixt:numdotdecimal">1,719,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">1,616,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000168" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">8,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000173" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">283,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">529,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000178" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">15,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of restricted common shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000183" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,557</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="C_0001878313_20210101_20211231" decimals="0">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - MAIA</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - DGD</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">161,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">161,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense - THIO</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">104,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">104,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock options to satisfy accrued bonus</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock options to satisfy deferred compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon conversion of convertible notes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000200" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,375,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">11,001,136</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">11,001,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">11,001,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares upon conversion of SAFE</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000205" name="maia:StockIssuedDuringPeriodSharesConversionOfSafe" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common shares in connection with Equity Financing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000209" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">772,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">6,180,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">320,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,860,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,860,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of stock subscription receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="maia:ReceiptOfStockSubscriptionReceivable" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="maia:ReceiptOfStockSubscriptionReceivable" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="maia:ReceiptOfStockSubscriptionReceivable" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs incurred in connection with Equity Financing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="maia:ReclassificationOfWarrantLiabilityToEquity" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="maia:ReclassificationOfWarrantLiabilityToEquity" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="maia:ReclassificationOfWarrantLiabilityToEquity" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted common shares to founder pursuant to<br />&#160;&#160; THIO Merger Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000224" name="maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="0">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" sign="-">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dissolution of DGD</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dissolution of THIO pursuant to Merger Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">813,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">813,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="maia:DissolutionOfFirm" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">813,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:ProfitLoss" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:ProfitLoss" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:ProfitLoss" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">74,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000237" name="us-gaap:SharesOutstanding" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="0">758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20211231" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="5" valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:27.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss, including noncontrolling interests</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:ProfitLoss" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:ShareBasedCompensation" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:ShareBasedCompensation" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,722,893</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Loss on extinguishment of convertible notes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">2,322,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Gain from forgiveness of Paycheck Protection Program loan</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of embedded features</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="maia:ChangeInFairValueOfEmbeddedFeatures" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ratchet shares</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="maia:IssuanceOfRatchetShares" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">596,953</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">505,233</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">15,155</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="maia:IncreaseDecreaseInDeferredOfferingCosts" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">440,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="maia:IncreaseDecreaseInDeferredOfferingCosts" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia research and development incentives receivable</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:IncreaseDecreaseInReceivables" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">269,395</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">3,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">211,346</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">805,516</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">915,742</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">997,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">7,037</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">11,655,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">4,122,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible notes, warrants, and embedded conversion <br />&#160;&#160; features</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">7,369,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Paycheck Protection Program loan</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="maia:ProceedsFromPaycheckProtectionProgramLoan" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collections of subscriptions receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="maia:ProceedsFromCollectionOfSubscriptionReceivable" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of transaction<br />&#160;&#160; costs</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,473,560</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,742,171</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">385,400</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of common stock in initial public offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of initial public offering transaction costs</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="maia:PaymentOfInitialPublicOfferingTransactionCosts" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,406,170</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment on loan payable to officer</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="C_0001878313_20210101_20211231" decimals="0">367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">12,036,790</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">14,033,731</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net effect of foreign currency exchange on cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001878313_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">4,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">376,635</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">9,910,835</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001878313_20201231" decimals="0" format="ixt:numdotdecimal">663,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at end of period</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:13.4%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible notes and accrued interest into MAIA common stock</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">8,249,587</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of SAFE into MAIA common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued for accrued bonus</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="maia:OptionsIssuedForAccruedBonus" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued for deferred compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="maia:OptionsIssuedForDeferredCompensation" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="maia:ReclassificationOfWarrantLiabilityToEquity" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible note for payment on loan to officer</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" contextRef="C_0001878313_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">21,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Previously paid issuance costs in connection with the initial public offering</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="maia:PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:69.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued to underwriters in connection with the initial public offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="maia:WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12.36%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p><ix:nonNumeric id="F_000297" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000297_dcnt_0575cb53-ca7e-4291-82f0-a6453495829e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;color:#000000;"></span>NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p></td></tr></table></div><ix:nonNumeric id="F_000310" name="maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business, Organization, and Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#8220;the Company&#8221;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#8220;MAIA&#8221;) was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>THIO Therapeutics, Inc. (&#8220;THIO&#8221;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned <ix:nonFraction unitRef="U_xbrlipure" id="F_000344" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812" decimals="3" scale="-2">93.3</ix:nonFraction>% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_000345" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812" decimals="3" scale="-2">6.7</ix:nonFraction>% <ix:nonNumeric id="F_000346" name="us-gaap:StockholdersEquityNoteStockSplit" contextRef="C_0001878313_20220101_20221231">minority stockholder of THIO received <ix:nonFraction unitRef="U_xbrlipure" id="F_000347" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> share of MAIA common stock for each share of THIO common stock owned prior to the merger</ix:nonNumeric>. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>DGD Pharmaceuticals Corporation (&#8220;DGD&#8221;), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>MAIA Drug Development Corporation (&#8220;MAIA DD&#8221;) incorporated in the state of Texas on September 10, 2018, and was <ix:nonFraction unitRef="U_xbrlipure" id="F_000348" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaMAIADrugDevelopmentCorporationMember_20210731" decimals="INF" scale="-2">100</ix:nonFraction>% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div></ix:nonNumeric><ix:nonNumeric id="F_000311" name="maia:LiquidityPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2022, the Company had working capital of&#8201;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="maia:WorkingCapital" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">8,539,131</ix:nonFraction>, an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001878313_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction>, cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:Cash" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction> and current liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">3,268,906</ix:nonFraction>. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:Revenues" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000354" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_20220101_20220228" decimals="INF" format="ixt:numdotdecimal">263,729</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000355" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_20220228" decimals="0">9</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220101_20220228" decimals="0" format="ixt:numdotdecimal">2,373,561</ix:nonFraction> before transaction costs and expenses. During May 2022, the company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000357" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_20220501_20220531" decimals="INF" format="ixt:numdotdecimal">11,111</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000358" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_20220531" decimals="0">9</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220501_20220531" decimals="0" format="ixt:numdotdecimal">99,999</ix:nonFraction>. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#8221; The Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000360" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000361" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="0">5</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> in the initial public offering. On August 3, 2022, the Company sold an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000363" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000364" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803" decimals="0">5</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803" decimals="0" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> per the overallotment option for the underwriter. After deducting $<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803" decimals="0" format="ixt:numdotdecimal">2,406,170</ix:nonFraction> for cash issuance costs, net proceeds from the offering and overallotment were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803" decimals="0" format="ixt:numdotdecimal">9,093,830</ix:nonFraction>.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_0575cb53-ca7e-4291-82f0-a6453495829e" continuedAt="F_000297_dcnt_cc8d6ebe-050c-46c7-937c-59d47bc333a3"><ix:nonNumeric id="F_000312" name="maia:GoingConcernConsiderationsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern Considerations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001878313_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction> from the Company&#8217;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:Cash" contextRef="C_0001878313_20221231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,951</ix:nonFraction>,000 million in cash and cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</p></ix:nonNumeric><ix:nonNumeric id="F_000313" name="maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</p></ix:nonNumeric><ix:nonNumeric id="F_000314" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221; or &#8220;GAAP&#8221;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</p></ix:nonNumeric><ix:nonNumeric id="F_000315" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s Chief Executive Officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_cc8d6ebe-050c-46c7-937c-59d47bc333a3" continuedAt="F_000297_dcnt_1aa6b247-fef3-43bb-b1da-38ac6a2a2f0d"><ix:nonNumeric id="F_000316" name="us-gaap:UseOfEstimates" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p></ix:nonNumeric><ix:nonNumeric id="F_000317" name="maia:CertainRisksAndUncertaintiesPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p></ix:nonNumeric><ix:nonNumeric id="F_000318" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of the Company&#8217;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric id="F_000319" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</p></ix:nonNumeric><ix:nonNumeric id="F_000320" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account&#59; the Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001878313_20221231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001878313_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> cash equivalents as of December 31, 2022 and 2021.</p></ix:nonNumeric><ix:nonNumeric id="F_000321" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000321_dcnt_7ac61892-18ec-42ce-a48e-d8e0ace64894">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#8220;Accounting Standards Codification (ASC) Topic 820&#8221;, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_1aa6b247-fef3-43bb-b1da-38ac6a2a2f0d" continuedAt="F_000297_dcnt_3417753f-6388-4a5d-b17f-4fa77574db7b"><ix:continuation id="F_000321_dcnt_7ac61892-18ec-42ce-a48e-d8e0ace64894">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</p></ix:continuation><ix:nonNumeric id="F_000322" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</p></ix:nonNumeric><ix:nonNumeric id="F_000323" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000323_dcnt_69fd0d43-c83f-4645-bc25-4158ac06550c">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_3417753f-6388-4a5d-b17f-4fa77574db7b" continuedAt="F_000297_dcnt_a3fae586-a971-4b24-85f1-f0d9f192e4b3"><ix:continuation id="F_000323_dcnt_69fd0d43-c83f-4645-bc25-4158ac06550c">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular period</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. There have been no material changes in estimates for the periods presented.</span></p></ix:continuation><ix:nonNumeric id="F_000324" name="maia:ResearchAndDevelopmentIncentivePolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000325" name="us-gaap:DerivativesPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. </p></ix:nonNumeric><ix:nonNumeric id="F_000326" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000326_dcnt_877ad630-891e-4ad1-90da-ee01badd1fce">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_a3fae586-a971-4b24-85f1-f0d9f192e4b3" continuedAt="F_000297_dcnt_163b8220-75c0-43f0-b070-51d3e428cc73"><ix:continuation id="F_000326_dcnt_877ad630-891e-4ad1-90da-ee01badd1fce">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations&#59; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions&#59; the lack of marketability of our common stock&#59; the market performance of comparable publicly traded companies&#59; and U.S. and global economic and capital market conditions. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</p></ix:continuation><ix:nonNumeric id="F_000327" name="maia:CommonStockWarrantsPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), depending on the specific terms of the warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</p></ix:nonNumeric><ix:nonNumeric id="F_000328" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p></ix:nonNumeric><ix:nonNumeric id="F_000329" name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</p></ix:nonNumeric><ix:nonNumeric id="F_000330" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000330_dcnt_c6d03954-d2f5-4875-85f6-823f1f49f06b">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000297_dcnt_163b8220-75c0-43f0-b070-51d3e428cc73"><ix:continuation id="F_000330_dcnt_c6d03954-d2f5-4875-85f6-823f1f49f06b">
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p><ix:nonNumeric id="F_000333" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.94%;"></td>
<td style="width:12.11%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:12.1%;"></td>
<td style="width:0.93%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000372" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">6,545,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000373" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,797,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000374" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">796,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000375" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,311,117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000376" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_maiaUnvestedRestrictedStockAwardsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">58,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p></ix:nonNumeric><ix:nonNumeric id="F_000332" name="us-gaap:LessorLeasesPolicyTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <span style="-sec-ix-hidden:F_000377">ASU No. 2016-02</span>, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of <ix:nonNumeric id="F_000379" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001878313_20221231" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric>. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000298" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000298_dcnt_0ac7169e-2e36-4659-8ffd-b7929d050b35">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">RELATED PARTY TRANSACTIONS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consulting Services </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="maia:ConsultingServices" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">88,994</ix:nonFraction> for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $<ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="maia:CashPaidForServicesProvided" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">34,560</ix:nonFraction> in cash and issued her options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000382" name="maia:OptionsToPurchaseSharesOfCommonStock" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">23,964</ix:nonFraction> shares of common stock with a total fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">54,434</ix:nonFraction> during the year ended December 31, 2021.&#160;&#160;Ms. Durant was no longer considered a related party in 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="maia:ConsultingServices" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">4,700</ix:nonFraction> for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="maia:CashPaidForServicesProvided" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,350</ix:nonFraction> in cash and issued him options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000389" name="maia:OptionsToPurchaseSharesOfCommonStock" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231" decimals="INF">184</ix:nonFraction> shares of common stock with a total fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,100</ix:nonFraction>. The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="maia:RemainingConsultingServicesSettled" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331" decimals="0" format="ixt:numdotdecimal">1,250</ix:nonFraction> for services provided in fiscal 2021 were settled in March, 2022 for <ix:nonFraction unitRef="U_xbrlishares" id="F_000393" name="maia:OptionsToPurchaseSharesOfCommonStock" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331" decimals="INF">226</ix:nonFraction> options issued to Mr. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000298_dcnt_0ac7169e-2e36-4659-8ffd-b7929d050b35">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company also issued him a convertible note in the amount of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210401_20210430" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during April 2021, which was converted into </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000395" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210929_20210930" decimals="INF" format="ixt:numdotdecimal">8,557</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock on September 30, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at a conversion price of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000396" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930" decimals="2">6.00</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share, and also received </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000397" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930" decimals="INF" format="ixt:numdotdecimal">4,278</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> warrants to purchase shares of common stock at an exercise price of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000398" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930" decimals="2">6.00</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share.&#160;&#160;In 2022, Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provided consulting services to the Company through July 2022 for which the Company incurred $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="maia:ConsultingServices" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">36,900</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for services provided during the year ended December 31, 2022.&#160;&#160;The Company paid Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="maia:CashPaidForServicesProvided" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">19,950</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in cash and issued him options to purchase </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000388" name="maia:OptionsToPurchaseSharesOfCommonStock" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">4,690</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock with a total fair value of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231" decimals="3">19.950</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;In August 2022, Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> became an employee of the Company. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Loan Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's chief executive officer lent the Company a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:UnsecuredDebt" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in August and September of 2018. These amounts, were unsecured, had <ix:nonFraction unitRef="U_xbrlipure" id="F_000400" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930" decimals="2" format="ixt-sec:numwordsen" scale="-2">no</ix:nonFraction> stated interest rate, and no stated repayment terms. The Company repaid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:RepaymentsOfUnsecuredDebt" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">3,633</ix:nonFraction> of the loan to the CEO during 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:RepaymentsOfUnsecuredDebt" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20211231" decimals="0">367</ix:nonFraction> during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210301_20210331" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction>. The convertible note issued to the CEO was converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000404" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210929_20210930" decimals="INF" format="ixt:numdotdecimal">3,621</ix:nonFraction> shares of common stock on September 30, 2021 at a conversion price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000405" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210930" decimals="2">6.00</ix:nonFraction> per share.&#160;&#160;No further notes to the CEO were incurred in the year ended December 31, 2022.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p><ix:nonNumeric id="F_000299" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ACCRUED EXPENSES </p></td></tr></table></div><ix:nonNumeric id="F_000334" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.98%;"></td>
<td style="width:11.28%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.98%;"></td>
<td style="width:11.28%;"></td>
<td style="width:0.93%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">1,094,582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">384,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional&#160;&#160;fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">332,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">380,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="maia:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">516,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="maia:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">268,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation to former officers</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">111,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">159,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">41,157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">2,103,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">1,185,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Compensation Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="C_0001878313_20221231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">111,271</ix:nonFraction>, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">193,379</ix:nonFraction> in deferred compensation. The Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="maia:CashPaidToSettleAPortionOfDeferredCompensationBalance" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">457,749</ix:nonFraction> in cash and issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" contextRef="C_0001878313_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">268,769</ix:nonFraction> options with a total fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">296,264</ix:nonFraction> during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">743,167</ix:nonFraction>. The fair value of the options issued in excess of the deferred compensation balance settled totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">10,846</ix:nonFraction> was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Bonus</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022 and 2021, the Company accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001878313_20221001" decimals="0" format="ixt:numdotdecimal">1,094,582</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">384,750</ix:nonFraction>, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of <ix:nonFraction unitRef="U_xbrlishares" id="F_000427" name="maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance" contextRef="C_0001878313_20210416_20210416" decimals="INF" format="ixt:numdotdecimal">713,536</ix:nonFraction> stock options with a total fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" contextRef="C_0001878313_20210416_20210416" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction>. The fair value of the options issued in excess of the accrued bonus balance totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">6,531</ix:nonFraction> and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000300" name="maia:PaycheckProtectionProgramTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.78%;text-indent:-4.78%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. PAYCHECK PROTECTION PROGRAM </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2021, the Company received a second PPP Loan in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction>. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000431" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210131" decimals="INF" scale="-2">0.98</ix:nonFraction>% per annum. The term of the PPP Loan is <ix:nonNumeric id="F_000432" name="us-gaap:DebtInstrumentTerm" contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131" format="ixt-sec:durwordsen">two years</ix:nonNumeric>. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction>, and the Company recorded a gain on extinguishment totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction> for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p><ix:nonNumeric id="F_000301" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000301_dcnt_68cf8b99-e261-4f05-91f3-eac9aafb0ac8">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CONVERTIBLE NOTES PAYABLE</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2019</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company issued a Convertible Promissory Note totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000437" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731" decimals="INF" scale="-2">8</ix:nonFraction>% per annum, was unsecured, with a scheduled maturity date of <ix:nonNumeric id="F_000436" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001878313_20190701_20190731" format="ixt:datemonthdayyearen">December 31, 2021</ix:nonNumeric>. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190701_20190731" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> (before any transaction related expenses and costs). The conversion price will be set at <ix:nonFraction unitRef="U_xbrlipure" id="F_000439" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" contextRef="C_0001878313_20190731" decimals="2" scale="-2">65</ix:nonFraction>% of the price of the preferred stock issued in the aforementioned Equity Financing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Feature</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the terms related to the Equity Financing conversion, (the &#8220;Embedded Put Feature&#8221;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2019 Convertible Note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231" decimals="0">607</ix:nonFraction> for the year ended December 31, 2022 and 2021, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="maia:DebtDiscountAndValueOfEmbeddedPutFeature" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190101_20190731" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction> at issuance. The balance of the debt discount was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20211231" decimals="-3" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20221231" decimals="-3" scale="3">0</ix:nonFraction></ix:nonFraction> as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231" decimals="-3" scale="3">310</ix:nonFraction>, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2020</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company issued Convertible Promissory Notes totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="0" format="ixt:numdotdecimal">610,000</ix:nonFraction> to various investors or holders, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRelatedPartyMember_20201231" decimals="0" format="ixt:numdotdecimal">110,000</ix:nonFraction> of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="INF" scale="-2">6</ix:nonFraction>% per annum, was unsecured, with a scheduled maturity date of <ix:nonNumeric id="F_000450" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231" format="ixt:datemonthdayyearen">May 31, 2022</ix:nonNumeric>. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000301_dcnt_68cf8b99-e261-4f05-91f3-eac9aafb0ac8" continuedAt="F_000301_dcnt_cc608fdc-8228-4867-9603-448313858b46">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) a Change in Control whereby any person or group becomes a beneficial owner of more than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000452" name="maia:PercentageOfVotingPowerDefiningChangeOfControl" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="2" scale="-2">50</ix:nonFraction>%</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price is set at <ix:nonFraction unitRef="U_xbrlipure" id="F_000453" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="2" scale="-2">75</ix:nonFraction>% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231" decimals="0" format="ixt:numdotdecimal">131,000</ix:nonFraction> at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2020 Convertible Notes totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,375</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">11,523</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discounts on the 2020 Convertible Notes totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20221231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20211231" decimals="0">0</ix:nonFraction> as of December 31, 2022 and 2021, respectively.&#160;&#160;During the year ended December 31, 2021 amortization of debt discounts amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">83,608</ix:nonFraction>. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20220101_20221231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> amortization of debt discounts for the year ended December 31, 2022.&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p><ix:nonNumeric id="F_000461" name="maia:WarrantDescription" contextRef="C_0001878313_20200101_20201231"><p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by <ix:nonFraction unitRef="U_xbrlipure" id="F_000462" name="maia:PercentageOfIssuableUponConversionOfExercisePrice" contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231" decimals="2" scale="-2">50</ix:nonFraction>%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231" decimals="0" format="ixt:numdotdecimal">65,660</ix:nonFraction> (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000301_dcnt_cc608fdc-8228-4867-9603-448313858b46" continuedAt="F_000301_dcnt_84e900ff-a484-40e6-bf87-0f12fbc6a791">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2021</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231" decimals="0" format="ixt:numdotdecimal">7,390,000</ix:nonFraction> to various investors or holders, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="maia:ConvertiblePromissoryNotesToRelatedParties" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,863,300</ix:nonFraction> of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="maia:ConvertiblePromissoryNotesToSettleLoan" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction> Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000467" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231" decimals="INF" scale="-2">6</ix:nonFraction>% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price was set at <ix:nonFraction unitRef="U_xbrlipure" id="F_000469" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231" decimals="2" scale="-2">75</ix:nonFraction>% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231" decimals="0" format="ixt:numdotdecimal">2,821,000</ix:nonFraction> at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2021 Convertible Notes totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">199,049</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:InterestExpense" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20200101_20201231" decimals="0">0</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20220101_20221231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">513,035</ix:nonFraction>, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p><ix:nonNumeric id="F_000475" name="maia:WarrantDescription" contextRef="C_0001878313_20210101_20211231"><p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by <ix:nonFraction unitRef="U_xbrlipure" id="F_000476" name="maia:PercentageOfIssuableUponConversionOfExercisePrice" contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231" decimals="2" scale="-2">50</ix:nonFraction>%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000301_dcnt_84e900ff-a484-40e6-bf87-0f12fbc6a791">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231" decimals="0" format="ixt:numdotdecimal">320,460</ix:nonFraction> (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conversion of Convertible Notes Upon Equity Financing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_us-gaapShortTermDebtTypeAxis_maiaConvertibleNotesMember_20210101_20211231" decimals="-6" scale="6">5</ix:nonFraction> million, the Company converted all $<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">8,010,000</ix:nonFraction> of its outstanding principal and all accrued and unpaid interest of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">240,000</ix:nonFraction> related to the Company&#8217;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into <ix:nonFraction unitRef="U_xbrlishares" id="F_000487" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="C_0001878313_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">1,375,228</ix:nonFraction> shares of the Company&#8217;s common stock on September 30, 2021 at a conversion price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000488" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001878313_20210930" decimals="2">6.00</ix:nonFraction> per share. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001878313_20210101_20211231" decimals="-5" sign="-" scale="6">2.3</ix:nonFraction> million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001878313_20211231" decimals="-5" scale="6">3.3</ix:nonFraction> million. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="maia:ConvertibleNotesOutstanding" contextRef="C_0001878313_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> Convertible Notes outstanding. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for <ix:nonFraction unitRef="U_xbrlishares" id="F_000480" name="maia:CommonSharesUponExerciseOfWarrantsShares" contextRef="C_0001878313_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">686,489</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000481" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001878313_20210930" decimals="2">6.00</ix:nonFraction> and expire at various dates throughout fiscal 2028.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000482" name="maia:WarrantsExercised" contextRef="C_0001878313_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,504</ix:nonFraction> of these warrants have been exercised.</p></ix:continuation><ix:nonNumeric id="F_000302" name="maia:SimpleAgreementForFutureEquityDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000302_dcnt_eb723867-97b5-484a-b8b6-16e27ec1e820">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">SIMPLE AGREEMENT FOR FUTURE EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="maia:SimpleAgreementForFutureEquityIssued" contextRef="C_0001878313_20191001_20191031" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction>. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at <ix:nonFraction unitRef="U_xbrlipure" id="F_000490" name="maia:PercentageOfConversionPrice" contextRef="C_0001878313_20191001_20191031" decimals="2" scale="-2">60</ix:nonFraction>% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="maia:SimpleAgreementForFutureEquityIssued" contextRef="C_0001878313_20210901_20210930" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> was converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000492" name="maia:NumberOfCommonSharesConvertedUnderSAFEAgreement" contextRef="C_0001878313_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">5,208</ix:nonFraction> shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000493" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_20210930" decimals="2">8.00</ix:nonFraction>. 'The conversion price was equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000494" name="maia:PercentageOfConversionPrice" contextRef="C_0001878313_20210901_20210930" decimals="2" scale="-2">60</ix:nonFraction>% of $8.00 per share, or $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000495" name="maia:CommonStockConversionPrice" contextRef="C_0001878313_20210930" decimals="2">4.80</ix:nonFraction> per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.78%;text-indent:-4.78%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000302_dcnt_eb723867-97b5-484a-b8b6-16e27ec1e820">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000303" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FAIR VALUE OF FINANCIAL LIABILITIES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Derivative Liability </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000335" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000335_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.98%;"></td>
<td style="width:11.28%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.97%;"></td>
<td style="width:11.28%;"></td>
<td style="width:0.94%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:DerivativeLiabilities" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="0" format="ixt:numdotdecimal">127,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability on convertible notes payable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="maia:DerivativeLiabilityOnConvertibleNotesPayable" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,821,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (Gain) on fair value of embedded features</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="maia:ChangeInFairValueOfEmbeddedFeatures" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of derivative liability in connection with debt conversion</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">3,151,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#8217;s income reflected the volatility in these estimate and assumption changes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="maia:ChangeInFairValueOfEmbeddedFeatures" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction> for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000501" name="maia:PercentageOfProbabilityOfTheConvertibleNotesMaturity" contextRef="C_0001878313_20220101_20221231" decimals="2" scale="-2">0</ix:nonFraction>%&#59; the probability of an equity financing was estimated to be approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000502" name="maia:PercentageOfProbabilityOfEquityFinancingMaturity" contextRef="C_0001878313_20220101_20221231" decimals="2" scale="-2">100</ix:nonFraction>%&#59; and the probability of default, change in control or dissolution was estimated to be approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000503" name="maia:PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" contextRef="C_0001878313_20220101_20221231" decimals="2" scale="-2">0</ix:nonFraction>%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. <ix:nonNumeric id="F_000336" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000336_cnt_1">The fair value of the warrant liabilities recorded are as follows:</ix:nonNumeric></p><ix:continuation id="F_000336_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.53%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.97%;"></td>
<td style="width:8.36%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.98%;"></td>
<td style="width:8.36%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.98%;"></td>
<td style="width:8.36%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.97%;"></td>
<td style="width:8.36%;"></td>
<td style="width:0.92%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001878313_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> warrant liabilities measured at fair value on a recurring basis at December 31, 2021. The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</p><ix:continuation id="F_000335_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.97%;"></td>
<td style="width:11.28%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.97%;"></td>
<td style="width:11.29%;"></td>
<td style="width:0.94%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="0" format="ixt:numdotdecimal">85,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="maia:FairValueWarrantLiability" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="maia:FairValueWarrantLiability" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" format="ixt:numdotdecimal">320,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on fair value of warrant liability</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="maia:ReclassificationOfWarrantLiabilityToEquity" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231" decimals="0" sign="-" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000304" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000304_dcnt_830f1875-2ec7-4132-8afb-c627c0272c90">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s initial public offering, the Company&#8217;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#8217;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;) and amended and restated its Bylaws (the &#8220;Amended and Restated Bylaws&#8221;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to <ix:nonFraction unitRef="U_xbrlishares" id="F_000516" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001878313_20220801" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction> shares and decreased the authorized number of preferred stock to <ix:nonFraction unitRef="U_xbrlishares" id="F_000517" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001878313_20220801" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction> shares. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales of MAIA Common Stock </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000518" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220228" decimals="INF" format="ixt:numdotdecimal">263,729</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000520" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220228" decimals="2">9.00</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220101_20220228" decimals="0" format="ixt:numdotdecimal">2,373,561</ix:nonFraction> with <ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="maia:TransactionCosts" contextRef="C_0001878313_20220228" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> transaction costs. During May 2022, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000519" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531" decimals="INF" format="ixt:numdotdecimal">11,111</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000521" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220531" decimals="0">9</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220501_20220531" decimals="0" format="ixt:numdotdecimal">99,999</ix:nonFraction> with <ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="maia:TransactionCosts" contextRef="C_0001878313_20220531" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000526" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_20220228" decimals="2">9.00</ix:nonFraction> price per share they paid was equal to the price per share in the Company's initial public offering of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000527" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220228" decimals="2">5.00</ix:nonFraction>. The number of Ratchet Shares were calculated using the $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000528" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="2">5.00</ix:nonFraction> per share price in the Company's initial public offering and <ix:nonFraction unitRef="U_xbrlishares" id="F_000529" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="INF" format="ixt:numdotdecimal">219,872</ix:nonFraction> shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction>, based on the $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000531" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="0">5</ix:nonFraction> price of the initial public offering and were recorded as expense included in operating expense.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 28, 2022 the Company&#8217;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000532" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000533" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="2">5.00</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="maia:ProceedsFromCommonStockNetOfIssuanceCosts" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000535" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000536" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803" decimals="2">5.00</ix:nonFraction> per share when the underwriter exercised the overallotment for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="maia:ProceedsFromCommonStockNetOfIssuanceCosts" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803" decimals="0" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001878313_20220803_20220803" decimals="0" format="ixt:numdotdecimal">9,100,000</ix:nonFraction>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Restricted Stock Awards<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, MAIA recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:RestrictedStockExpense" contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">202,500</ix:nonFraction> of stock compensation expense related to <ix:nonFraction unitRef="U_xbrlishares" id="F_000540" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">112,500</ix:nonFraction> of MAIA&#8217;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#8217;s <ix:nonFraction unitRef="U_xbrlishares" id="F_000541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210813_20210813" decimals="INF" format="ixt:numdotdecimal">612,500</ix:nonFraction> fully vested THIO restricted shares were canceled and the founder was issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000542" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_20210813_20210813" decimals="INF" format="ixt:numdotdecimal">612,500</ix:nonFraction> MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000543" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">87,500</ix:nonFraction> MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are <ix:nonFraction unitRef="U_xbrlishares" id="F_000544" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231" decimals="0" format="ixt:numdotdecimal">52,500</ix:nonFraction> of expense related to restricted stock for the year ended 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000337" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:62.07%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.94%;"></td>
<td style="width:12.21%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.98%;"></td>
<td style="width:11.29%;"></td>
<td style="width:0.94%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br />Average<br />Grant<br />Date Fair<br />Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000546" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">58,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231" decimals="2">1.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000547" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">58,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231" decimals="2">1.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000548" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231" decimals="INF" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Stock Warrants</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000304_dcnt_830f1875-2ec7-4132-8afb-c627c0272c90" continuedAt="F_000304_dcnt_c68004c9-42af-486c-8501-c12a1bc8663e">

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders&#8217; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#8217;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements&#59; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the <ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="maia:WarrantModificationValue" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220131" decimals="0" format="ixt:numdotdecimal">144,497</ix:nonFraction> warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="maia:DeemedDividendOnWarrantModification" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction> and was treated as a deemed dividend and is reflected as &#8220;Deemed dividend on warrant modification&#8221; in the accompanying statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January 2022, warrants were exercised, resulting in the issuance of <ix:nonFraction unitRef="U_xbrlishares" id="F_000553" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131" decimals="INF" format="ixt:numdotdecimal">61,111</ix:nonFraction> shares of MAIA common stock for proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131" decimals="0" format="ixt:numdotdecimal">110,000</ix:nonFraction>. During May 2022, warrants were exercised, resulting in the issuance of <ix:nonFraction unitRef="U_xbrlishares" id="F_000554" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531" decimals="INF" format="ixt:numdotdecimal">153,000</ix:nonFraction> shares of common stock for proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531" decimals="0" format="ixt:numdotdecimal">275,400</ix:nonFraction>. Another <ix:nonFraction unitRef="U_xbrlishares" id="F_000557" name="maia:WarrantsExercisedShares" contextRef="C_0001878313_20220501_20220531" decimals="INF" format="ixt:numdotdecimal">394,501</ix:nonFraction> warrants were exercised with a cashless exercise assuming the fair market value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000558" name="maia:CashlessExerciseAtFairMarketValuePerShare" contextRef="C_0001878313_20220531" decimals="INF">9.00</ix:nonFraction> per share resulting in the issuance of <ix:nonFraction unitRef="U_xbrlishares" id="F_000559" name="maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" contextRef="C_0001878313_20220501_20220531" decimals="INF" format="ixt:numdotdecimal">315,601</ix:nonFraction> shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the closing of the initial public offering, <ix:nonFraction unitRef="U_xbrlishares" id="F_000560" name="maia:NumberOfWarrantsExercised" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="INF" format="ixt:numdotdecimal">20,520</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000561" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801" decimals="INF">5.00</ix:nonFraction> per share expired.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the closing of the Company&#8217;s initial public offering, the Company issued warrants to purchase an aggregate of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000562" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_20220801" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction> shares of its common stock to the Representative or its designees, at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000563" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001878313_20220801" decimals="INF">6.25</ix:nonFraction> per share (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants are exercisable beginning on <ix:nonNumeric id="F_000564" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001878313_20220731_20220801" format="ixt:datemonthdayyearen">January 23, 2023</ix:nonNumeric>, and expire on <ix:nonNumeric id="F_000565" name="maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" contextRef="C_0001878313_20220731_20220801" format="ixt:datemonthdayyearen">July 27, 2027</ix:nonNumeric>, pursuant to the terms and conditions of the Representative&#8217;s Warrants.&#160;&#160;On August 3, concurrently with the full exercise of the Underwriter&#8217;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000566" name="maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction> shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#8217;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction>, which was the value determined using the Black-Scholes method using a term of <ix:nonNumeric id="F_000568" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, risk free interest rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000569" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803" decimals="4" scale="-2">2.82</ix:nonFraction>% and volatility of <ix:nonFraction unitRef="U_xbrlipure" id="F_000570" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803" decimals="3" scale="-2">77.5</ix:nonFraction>%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20221231" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction>. The gain on remeasurement of the warrant liability in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">98,394</ix:nonFraction> was included in other income. Only the <ix:nonFraction unitRef="U_xbrlishares" id="F_000573" name="maia:ClassOfWarrantsIssued" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">115,000</ix:nonFraction> warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000338" name="maia:ScheduleOfWarrantExercisedTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:53.06%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:10.23%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.98%;"></td>
<td style="width:9.31%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:10.23%;"></td>
<td style="width:0.93%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants<br />Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br />Average<br />Exercise<br />Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term in<br />Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000574" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal">1,311,117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000579" name="maia:ClassOfWarrantsWeightedAverageExercisePrice" contextRef="C_0001878313_20211231" decimals="2">4.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.30</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000575" name="maia:ClassOfWarrantsIssued" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">115,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000580" name="maia:ClassOfWarrantsWeightedAverageExercisePriceIssued" contextRef="C_0001878313_20220101_20221231" decimals="2">6.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000576" name="maia:ClassOfWarrantsExercised" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">608,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000581" name="maia:ClassOfWarrantsWeightedAverageExercisePriceExercised" contextRef="C_0001878313_20220101_20221231" decimals="2">1.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000577" name="maia:ClassOfWarrantsExpired" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">20,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000582" name="maia:ClassOfWarrantsWeightedAverageExercisePriceExpired" contextRef="C_0001878313_20220101_20221231" decimals="2">5.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000578" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">796,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000583" name="maia:ClassOfWarrantsWeightedAverageExercisePrice" contextRef="C_0001878313_20221231" decimals="2">6.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000585">5.16</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000339" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000339_dcnt_5f07e582-ca99-47ad-bb93-6773e1f05e32">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000586">2.8% - 4.1%</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000587">0.6% - 1.3%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000590">4.6 - 5</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000591">5 - 7</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">78% - 92%</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000595">81% - 106%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000304_dcnt_c68004c9-42af-486c-8501-c12a1bc8663e" continuedAt="F_000304_dcnt_bdcbe251-c17e-4c8a-a21e-eee02fcb80cc"><ix:continuation id="F_000339_dcnt_5f07e582-ca99-47ad-bb93-6773e1f05e32" continuedAt="F_000339_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Stock Award Plans<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#8220;MAIA 2018 Plan&#8221;). MAIA&#8217;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the <ix:nonFraction unitRef="U_xbrlishares" id="F_000598" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandEighteenStockOptionPlanMember_20221231" decimals="INF" format="ixt:numdotdecimal">1,924,500</ix:nonFraction> options outstanding in the plan of December 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#8220;MAIA 2020 Plan&#8217;&#8217;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the <ix:nonFraction unitRef="U_xbrlishares" id="F_000599" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231" decimals="INF" format="ixt:numdotdecimal">3,983,023</ix:nonFraction> options outstanding in the plan as of December 31, 2022. There are <ix:nonFraction unitRef="U_xbrlishares" id="F_000600" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#8220;MAIA 2021 Plan&#8217;&#8217;) with <ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20220801" decimals="INF" format="ixt:numdotdecimal">1,909,518</ix:nonFraction> shares of common stock reserved for issuance. As of December 31, 2022 there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231" decimals="INF" format="ixt:numdotdecimal">1,271,413</ix:nonFraction> shares of common stock available for future issuance under the MAIA 2021 Plan and <ix:nonFraction unitRef="U_xbrlishares" id="F_000603" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231" decimals="INF" format="ixt:numdotdecimal">638,105</ix:nonFraction> options outstanding in the MAIA 2021 Plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are to be granted with an exercise price which is at least equal to the stock&#8217;s estimated fair value at the date of grant, and with a contractual term of no more than <ix:nonNumeric id="F_000604" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_20220101_20221231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. In the case of an option granted to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000605" name="maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" contextRef="C_0001878313_20220101_20221231" decimals="2" scale="-2">10</ix:nonFraction>% stockholder, the exercise price shall be generally no less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000606" name="maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" contextRef="C_0001878313_20220101_20221231" decimals="2" scale="-2">110</ix:nonFraction>% of the fair market value per share on the date of grant, and the contractual term shall be <ix:nonNumeric id="F_000607" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001878313_20220101_20221231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause&#59; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#8217;s exercise repurchase rights and various other features of awards granted under the plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.</p><ix:nonNumeric id="F_000340" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.85%;"></td>
<td style="width:0.78%;"></td>
<td style="width:1.04%;"></td>
<td style="width:9.37%;"></td>
<td style="width:0.78%;"></td>
<td style="width:0.78%;"></td>
<td style="width:0.98%;"></td>
<td style="width:7.35%;"></td>
<td style="width:0.78%;"></td>
<td style="width:0.78%;"></td>
<td style="width:1.01%;"></td>
<td style="width:9.06%;"></td>
<td style="width:0.79%;"></td>
<td style="width:0.79%;"></td>
<td style="width:0.97%;"></td>
<td style="width:8.31%;"></td>
<td style="width:0.79%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options<br />Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br />Average<br />Exercise<br />Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term in<br />Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br />Intrinsic<br />Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001878313_20211231" decimals="INF" format="ixt:numdotdecimal">5,797,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000614" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001878313_20211231" decimals="2">2.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">8.59</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000609" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">811,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000615" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001878313_20220101_20221231" decimals="2">4.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000610" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">46,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000616" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001878313_20220101_20221231" decimals="2">1.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000611" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001878313_20220101_20221231" decimals="INF" format="ixt:numdotdecimal">16,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000617" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001878313_20220101_20221231" decimals="2">1.82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000612" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">6,545,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001878313_20221231" decimals="2">2.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">7.85</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">9,773,706</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000613" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001878313_20221231" decimals="INF" format="ixt:numdotdecimal">5,449,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001878313_20221231" decimals="2">2.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000622">7.59</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">8,804,841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000625" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231" decimals="2">8.87</ix:nonFraction> per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#8220;OPM&#8221;) and the Probability-Weighted Expected Return Method (&#8220;PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000304_dcnt_bdcbe251-c17e-4c8a-a21e-eee02fcb80cc">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes at $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000626" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231" decimals="0">9</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share based on the sale of common stock from January 27, 2022 to May 19, 2022. From June 1, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000627" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231" decimals="0">5</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />During the year ended December 31, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000628" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="2">1.80</ix:nonFraction> was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000629" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001878313_us-gaapAwardDateAxis_maiaMarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="2">1.83</ix:nonFraction> per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair<br />value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to<br />arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.</p><ix:continuation id="F_000339_cnt_1">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.94%;"></td>
<td style="width:12.11%;"></td>
<td style="width:0.94%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.93%;"></td>
<td style="width:12.1%;"></td>
<td style="width:0.93%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000630">2.14% - 4.45%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000631">0.36% - 1.27%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5 - 6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">5 - 6.50</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">71.9% - 87.9%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">71.4% - 81.5%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 <span style="font-weight:bold;">w</span>ere $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000642" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" decimals="2">3.75</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000643" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="2">3.55</ix:nonFraction>, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20221231" decimals="0" format="ixt:numdotdecimal">3,447,367</ix:nonFraction> which the Company expects to recognize over a weighted average period of approximately <ix:nonNumeric id="F_000645" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231" format="ixt-sec:duryear">3.26</ix:nonNumeric> years.</p><ix:nonNumeric id="F_000341" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:57.7%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.97%;"></td>
<td style="width:13.02%;"></td>
<td style="width:0.92%;"></td>
<td style="width:0.93%;"></td>
<td style="width:0.97%;"></td>
<td style="width:13.96%;"></td>
<td style="width:0.93%;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">1,422,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,779,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20221231" decimals="0" format="ixt:numdotdecimal">896,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">943,708</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_20220101_20221231" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001878313_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,722,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000305" name="us-gaap:DefinedBenefitPlanTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000305_cnt_1">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>EMPLOYEE RETIREMENT PLAN</p></td></tr></table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:continuation id="F_000305_cnt_1">Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000652" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231" decimals="2" scale="-2">100</ix:nonFraction>% of employee salary deferrals that do not exceed <ix:nonFraction unitRef="U_xbrlipure" id="F_000655" name="maia:DefinedContributionPlanEmployerSalary" contextRef="C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231" decimals="2" scale="-2">1</ix:nonFraction>% of their compensation plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000653" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231" decimals="2" scale="-2">50</ix:nonFraction>% of their salary deferrals between <ix:nonFraction unitRef="U_xbrlipure" id="F_000656" name="maia:DefinedContributionPlanEmployerSalary" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231" decimals="2" scale="-2">1</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000654" name="maia:DefinedContributionPlanEmployerSalary" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231" decimals="2" scale="-2">6</ix:nonFraction>% of their compensation.<span style="font-size:11pt;font-family:Calibri;"> </span>The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.</ix:continuation> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000307" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000307_dcnt_5a0b76f9-f83c-4275-8161-965f9b84a1e4">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Licensing, Sponsored Research, and Patent &#38; Technology Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">THIO</span> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#8220;PLA&#8221;) titled &#8220;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#8221; with the University of Texas Southwestern (&#8220;UTSW&#8221;) to license patent families for a specific compound (&#8220;THIO&#8221;) from UTSW to MAIA. The agreement, as amended, has a term of <ix:nonNumeric id="F_000657" name="maia:TermOfAgreement" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" format="ixt-sec:duryear">20</ix:nonNumeric> years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $<ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="maia:MilestonePayment" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="maia:MilestonePayment" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>, not to exceed a combined milestone payment total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="maia:CombinedMilestonePaymentsMaximum" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">112,000,000</ix:nonFraction>. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore <ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="maia:PaymentsDueRelatedToMilestones" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> payments are due to UTSW related to the milestones. The agreement requires royalties of <ix:nonFraction unitRef="U_xbrlipure" id="F_000662" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130" decimals="2" scale="-2">2</ix:nonFraction>-<ix:nonFraction unitRef="U_xbrlipure" id="F_000663" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130" decimals="2" scale="-2">4</ix:nonFraction>% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and <ix:nonFraction unitRef="U_xbrlipure" id="F_000664" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="3" scale="-2">2.5</ix:nonFraction>-<ix:nonFraction unitRef="U_xbrlipure" id="F_000665" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="2" scale="-2">5</ix:nonFraction>% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in December 2020, the Company entered into a second license agreement with UTSW titled &#8220;Patent and Technology License Agreement AGT. NO. L3648 &#8212; MAIA Biotechnology&#8221; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of <ix:nonNumeric id="F_000666" name="maia:TermOfAgreement" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" format="ixt-sec:duryear">20</ix:nonNumeric> years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="maia:MilestonePayment" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="maia:MilestonePayment" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>, not to exceed a combined milestone payment total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="maia:CombinedMilestonePaymentsMaximum" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">112,000,000</ix:nonFraction>. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore <ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="maia:PaymentsDueRelatedToMilestones" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> payments are due to UTSW related to the milestones.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires royalties of <ix:nonFraction unitRef="U_xbrlipure" id="F_000671" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="2" scale="-2">2</ix:nonFraction>-<ix:nonFraction unitRef="U_xbrlipure" id="F_000672" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="2" scale="-2">4</ix:nonFraction>% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and <ix:nonFraction unitRef="U_xbrlipure" id="F_000673" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="3" scale="-2">2.5</ix:nonFraction>-<ix:nonFraction unitRef="U_xbrlipure" id="F_000674" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="2" scale="-2">5</ix:nonFraction>% on net sales above $<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="maia:RoyaltyPaymentsOnNetSales" contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaUniversityOfTexasSouthwesternMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. <ix:nonNumeric id="F_000676" name="maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).</ix:nonNumeric> The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000307_dcnt_5a0b76f9-f83c-4275-8161-965f9b84a1e4">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cemiplimab</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000678" name="maia:TermOfAgreement" contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaRegeneronPharmaceuticalsIncMember_20210201_20210228" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the event that</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> neither party has terminated the agreement</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation><ix:nonNumeric id="F_000308" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true" continuedAt="F_000308_dcnt_bfff0d23-110a-4400-a70d-5dd52dc366e3">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div><ix:nonNumeric id="F_000342" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's net deferred tax assets consist of the following components:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">3,294,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">3,013,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">1,183,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">1,800,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">1,499,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">244,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">109,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">6,724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">102,825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets before valuation allowance</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">6,229,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">5,027,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001878313_20221231" decimals="0" format="ixt:numdotdecimal">6,229,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001878313_20211231" decimals="0" format="ixt:numdotdecimal">5,027,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20221231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231" decimals="-5" scale="6">15.4</ix:nonFraction></ix:nonFraction> million that may be applied against future taxable income. The state NOL carryforwards begin to expire in <ix:nonNumeric id="F_000694" name="maia:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20220101_20221231">2030</ix:nonNumeric>. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to <ix:nonFraction unitRef="U_xbrlipure" id="F_000695" name="maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231" decimals="2" scale="-2">80</ix:nonFraction> percent of taxable income. The Company has unused Australian NOL carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapAustralianTaxationOfficeMember_20221231" decimals="-5" scale="6">0.1</ix:nonFraction> million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#8220;R &#38; E&#8221;) tax credits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20221231" decimals="-5" scale="6">0.1</ix:nonFraction> million that begin to expire in <ix:nonNumeric id="F_000698" name="maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20220101_20221231">2041</ix:nonNumeric>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of the Company&#8217;s NOL and R &#38; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#8220;ownership change,&#8221; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#8209;percent stockholders (or certain groups of non&#8209;five&#8209;percent stockholders) over a three&#8209;year period occurs. After such an ownership change, the corporation&#8217;s use of its pre&#8209;change NOL carryforwards and other pre&#8209;change tax attributes to offset its post&#8209;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an ownership change occurs and if the Company earns net taxable income, the Company&#8217;s ability to use its pre&#8209;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#8217;s state income, franchise, or similar taxes. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC 740, &#8220;Income Taxes,&#8221; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.<span style="Background-color:#FFFFFF;">The valuation allowance increased by approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001878313_20220101_20221231" decimals="-5" scale="6">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001878313_20210101_20211231" decimals="-5" scale="6">2.1</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results</span>.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31, 2022 and 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000308_dcnt_bfff0d23-110a-4400-a70d-5dd52dc366e3">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred a pretax book loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001878313_20220101_20221231" decimals="-5" scale="6">15.8</ix:nonFraction> million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001878313_20220101_20221231" decimals="-5" scale="6">15.3</ix:nonFraction> million and a foreign loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001878313_20220101_20221231" decimals="-5" scale="6">0.5</ix:nonFraction> million. The Company incurred a pretax book loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001878313_20210101_20211231" decimals="-5" scale="6">12.6</ix:nonFraction> million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001878313_20210101_20211231" decimals="-5" scale="6">12.5</ix:nonFraction> million and a foreign loss of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001878313_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption. </p><ix:nonNumeric id="F_000343" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000707" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001878313_20220101_20221231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000708" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001878313_20210101_20211231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000709" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001878313_20220101_20221231" decimals="3" sign="-" scale="-2">7.7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000710" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001878313_20210101_20211231" decimals="3" scale="-2">4.4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000711" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001878313_20220101_20221231" decimals="3" sign="-" scale="-2">1.2</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000712" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001878313_20210101_20211231" decimals="3" sign="-" scale="-2">1.9</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000713" name="maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" contextRef="C_0001878313_20220101_20221231" decimals="3" sign="-" scale="-2">1.5</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000714" name="maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" contextRef="C_0001878313_20210101_20211231" decimals="3" sign="-" scale="-2">3.9</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other nondeductible expenses/(nontaxable income)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000715" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001878313_20220101_20221231" decimals="3" sign="-" scale="-2">3.0</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000716" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001878313_20210101_20211231" decimals="3" sign="-" scale="-2">2.8</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000717" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001878313_20220101_20221231" decimals="3" sign="-" scale="-2">7.6</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000718" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001878313_20210101_20211231" decimals="3" sign="-" scale="-2">16.8</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000719" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001878313_20220101_20221231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000720" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001878313_20210101_20211231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#8217;s tax returns since inception remain open to examination by the taxing authorities.</p></ix:continuation><ix:nonNumeric id="F_000309" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001878313_20220101_20221231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SUBSEQUENT EVENTS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 16, 2023, we issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000721" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230116_20230116" decimals="INF" format="ixt:numdotdecimal">18,000</ix:nonFraction> shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement&#160;&#160;an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000722" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230416_20230416" decimals="INF" format="ixt:numdotdecimal">18,000</ix:nonFraction> shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue <ix:nonFraction unitRef="U_xbrlishares" id="F_000723" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308" decimals="INF" format="ixt:numdotdecimal">22,500</ix:nonFraction> shares of common stock on March 8, 2023 and an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000724" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230306_20230605" decimals="INF" format="ixt:numdotdecimal">22,500</ix:nonFraction> shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for <ix:nonNumeric id="F_000725" name="maia:TermOfAgreement" contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308" format="ixt-sec:durday">180</ix:nonNumeric> days, and renews automatically until we provide written notice prior to the end of the term.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Options</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1 to March 20, 2023 we issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000727" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320" decimals="INF" format="ixt:numdotdecimal">638,710</ix:nonFraction> options at a weighted exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000726" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320" decimals="2">4.10</ix:nonFraction> to employees and consultants.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:24pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjyjiv3jrhol000020.jpg" title="" alt="" style="width:290px;height:110px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:37%;">
<tr>
<td style="width:37%;"></td>
</tr>
<tr>
<td valign="bottom" style=" border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRELIMINARY PROSPECTUS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style=" border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:48pt;text-indent:0%;font-size:18pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:48.82%;">
<tr>
<td style="width:48.82%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ThinkEquity</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:72pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;, 2023</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II &#8211; INFORMATION NOT REQUIRED IN PROSPECTUS</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Expenses of Issuance and Distribution.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the FINRA filing fee and the NYSE American listing fee.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEC registration fee</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,549 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FINRA filing fee</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,250 </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NYSE American listing fee</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,000 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting fees and expenses</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000 </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees and expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725,000 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer agent&#8217;s and registrar&#8217;s fees and expenses</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000 </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printing and engraving expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,000 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accountable expenses to underwriters</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,000 </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Underwriter Expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous fees</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256,299 </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indemnification of Directors and Officers.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides that no director of the registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws authorize the indemnification of our officers and directors, consistent with Section 145 of the DGCL, as amended. Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director's fiduciary duty, except (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (iv) for any transaction from which a director derived an improper personal benefit.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enter</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into indemnification agreements with each of our directors and officers. These indemnification agreements require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fines</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Recent Sales of Unregistered Securities.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a) Issuance of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019 through June 2019, we issued and sold 246,668 shares of our common stock with an aggregate principal amount of $444,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, we issued and sold 873,725 shares of our common stock with an aggregate principal amount of $1.573 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July through October 2021, we issued and sold 772,563 shares of our common stock with an aggregate principal amount of approximately $6.2 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we issued 1,375,228 shares of our common stock as a result of the automatic conversion of the convertible notes referenced in Item 15(b) below. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, we issued and sold 263,729 shares of our common stock with an aggregate principal amount of approximately $2.4 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2022, we issued and sold 11,111 shares of our common stock with an aggregate principal amount of approximately $0.1 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2022, we entered into an agreement with FORCE Family Office, LLC (&#8220;Force&#8221;) for the provision of investor relations services from January 16, 2023 through July 16, 2023, pursuant to which we issued 18,000 shares of common stock on January 16, 2023. <span style="color:#000000;"> Pursuant to the agreement, we also agreed to issue an additional 18,000 shares of common stock on April 16, 2023 unless the agreement is terminated beforehand.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue 22,500 shares of common stock on March 8, 2023 and an additional 22,500 shares of common stock every ninety days after the execution date of the contract until termination of the agreement.&#160;&#160;The term of the agreement extends for 180 days, and renews automatically until we provide written notice prior to the end of the term.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a) of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only, and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b) Issuance of Convertible Notes &#38; Warrants</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, we issued and sold a convertible promissory note with a principal amount of $10,000, which converted into 2,259 shares of our common stock on September 30, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020 through December 2020, we issued and sold convertible promissory notes with an aggregate principal amount of $610,000, which converted into 108,132 shares of our common stock on September 30, 2021, and warrants to purchase 54,066 shares of our common stock at $6.00 per share, for an aggregate purchase price of $324,396.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021 through June 2021, we issued and sold convertible promissory notes with an aggregate principal amount of $7.39 million, which converted into 1,264,837 shares of our common stock on September 30, 2021, and warrants to purchase 632,423 shares of our common stock at $6.00 per share, for an aggregate purchase price of $3,794,508.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (b) of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only, and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c) Stock Option Grants, Option Exercises, Warrant Grants and Warrant Exercises</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between January 1, 2019 and August 1, 2022, we granted to our employees, officers, directors and other persons who provide services to us options to purchase up to 5,557,479&#160;shares of common stock under the 2018 Stock Option Plan and the Amended and Restated 2020 Stock Option Plan, at a weighted average exercise price of $2.47 per share.   In addition, we issued to certain persons who provided services to us and in conjunction with convertible notes, warrants to purchase up to 1,594,733&#160;shares of our common stock at a weighted average exercise price of $3.65 per share, which expire at various dates through September 2028 and vested&#160;upon issuance. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The issuances of stock options described in this paragraph (c) of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees, directors, consultants and advisors, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section 4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such information.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits and Financial Statement Schedules.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Exhibits.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:8.02%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<span style="font-weight:normal;"><br /></span>Number</p></td>
<td valign="bottom" style="width:0.44%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:91.54%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1.1*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459023001518/maia-ex11_673.htm"><span style="text-decoration:underline;">Form of Underwriting Agreement (including the form of Lock-Up Agreement).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.1<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex31_19.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of MAIA Biotechnology, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3.2<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex33_9.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of MAIA Biotechnology, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.1<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex41_27.htm"><span style="text-decoration:underline;">Specimen Certificate representing shares of Common Stock.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.2<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex42_16.htm"><span style="text-decoration:underline;">Form of Warrant.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4.3*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459023001518/maia-ex11_673.htm"><span style="text-decoration:underline;">Form of Representative&#8217;s Warrant (included in Exhibit 1.1).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5.1*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459023001518/maia-ex51_239.htm"><span style="text-decoration:underline;">Opinion of Loeb &#38; Loeb LLP.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#8224;<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex101_313.htm"><span style="text-decoration:underline;">Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2&#8224;<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex102_238.htm"><span style="text-decoration:underline;">Patent &#38; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 8, 2020.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#8224;<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex103_239.htm"><span style="text-decoration:underline;">Patent &#38; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 23, 2020.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex101_7.htm"><span style="text-decoration:underline;">Employment Agreement between Vlad Vitoc and the Company dated as of September 16, 2022.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex104_6.htm"><span style="text-decoration:underline;">Employment Agreement between Joseph F. McGuire and the Company dated as of September 16, 2022.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex102_8.htm"><span style="text-decoration:underline;">Employment Agreement between Mihail Obrocea and the Company dated as of September 16, 2022.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex103_9.htm"><span style="text-decoration:underline;">Employment Agreement between Sergei Gryaznov and the Company dated as of September 16, 2022.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex107_21.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement between the Company and each of its directors and executive officers.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex108_15.htm"><span style="text-decoration:underline;">MAIA Biotechnology, Inc. 2018 Stock Option Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex109_22.htm"><span style="text-decoration:underline;">MAIA Biotechnology, Inc. Amended &#38; Restated 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex1010_12.htm"><span style="text-decoration:underline;">MAIA Biotechnology, Inc. 2021 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1011_13.htm"><span style="text-decoration:underline;">Form of Director Stock Option Award under Amended &#38; Restated 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1012_12.htm"><span style="text-decoration:underline;"> Form of Compensatory Management Stock Option Award Agreement under Amended &#38; Restated 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1013_11.htm"><span style="text-decoration:underline;"> Form of Consulting Stock Option Award Agreement under Amended &#38; Restated 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15+<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1014_128.htm"><span style="text-decoration:underline;">Form of Employee Stock Option Award Agreement under Amended &#38; Restated 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16+<sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_4.htm"><span style="text-decoration:underline;">Form of Incentive Stock Option Award under 2021 Equity Incentive Plan</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17+<sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_5.htm"><span style="text-decoration:underline;">Form of Non-qualified Stock Option Award under 2021 Equity Incentive Plan</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18+<sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_6.htm"><span style="text-decoration:underline;">Form of Director and Consultant Non-qualified Stock Option Award under 2021 Equity Incentive Plan</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1<sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022038110/maia-ex161_46.htm"><span style="text-decoration:underline;">Letter from EisnerAmper LLP regarding the change in the Registrant&#8217;s certifying accountant, dated November 21, 2022</span></a><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr style="height:10.35pt;">
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1<sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459022020206/maia-ex211_8.htm"><span style="text-decoration:underline;">List of Subsidiaries of the Registrant.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459023001518/maia-ex51_239.htm"><span style="text-decoration:underline;">Consent of Loeb &#38; Loeb LLP (included in Exhibit 5.1).</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.2</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex232_7.htm"><span style="text-decoration:underline;">Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.3</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="maia-ex233_332.htm"><span style="text-decoration:underline;">Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_OF_ATTORNEY"><span style="text-decoration:underline;">Powers of Attorney (included on signature page to this registration statement).</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
<tr>
<td valign="top" style="width:8.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107*</p></td>
<td valign="bottom" style="width:0.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:91.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1878313/000156459023001518/maia-exfilingfees_238.htm"><span style="text-decoration:underline;">Calculation of Filing Fee Tables.</span></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:69.23%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on August 1, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Filed as an exhibit to our Registration Statement on Form S-1 filed with the SEC on April 11, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Filed as an exhibit to our Registration Statement on Form S-1 filed with the SEC on May 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4) Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on September 21, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5) Filed as an exhibit to our Registration Statement on Form S-1 filed with the SEC on June 29, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6) Filed as an exhibit to our Quarterly Report on Form 10-Q filed with the SEC on August 22, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7) Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on November 22, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8) Filed as an exhibit to our Registration Statement on Form S-1 filed with the SEC on May 16, 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Previously filed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+ Indicates management contract or compensatory plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224; Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Financial Statement Schedules.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See index to financial statements on page F-1. All schedules have been omitted because they are not required or are not applicable.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 17. Undertakings</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned hereby undertakes that:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&#8199;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)&#8199;For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois, on April 4, 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA BIOTECHNOLOGY, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Chairman</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_OF_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, the undersigned director of MAIA Biotechnology, Inc., hereby constitute and appoint Vlad Vitoc and Joseph McGuire, and each of them singly (with full power to each of them to act alone), my true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman and Chief Executive Officer</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr style="height:16.9pt;">
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joseph F. McGuire</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph F. McGuire</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Chaouki</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ramiro Guerrero</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louie Ngar Yee</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cristian Luput</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stan V. Smith</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jean-Manass&#233; Theag&#232;ne</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p></td>
</tr>
<tr>
<td valign="top" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jean-Manass&#233; Theag&#232;ne</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:6.41%;"></td>
<td style="width:0.21%;"></td>
<td style="width:43.38%;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*By:</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vlad Vitoc</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attorney-in-Fact</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II-8</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>2
<FILENAME>maia-ex232_7.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-ex232_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Segoe UI;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the inclusion in this Amendment No. 1 to the Registration Statement of MAIA Biotechnology, Inc. on Form S-1 (No. 333-269606) to be filed on or about April 4, 2023 of our report dated April 8, 2022, on our audit of the financial statements as of December 31, 2021 and for the year then ended. We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in this Registration Statement. </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Segoe UI;font-weight:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 4, 2023</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>3
<FILENAME>maia-ex233_332.htm
<DESCRIPTION>EX-23.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
maia-ex233_332.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:right;margin-bottom:6pt;line-height:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.3</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.11%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.11%;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have issued our report dated March 24, 2023, with respect to the consolidated financial statements of MAIA Biotechnology, Inc. contained in the Registration Statement and Prospectus. We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption &#8220;Experts.&#8221;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ GRANT THORNTON LLP</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charlotte, North Carolina </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 04, 2023</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:20pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:20pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gjyjiv3jrhol000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000002.jpg
M_]C_X  02D9)1@ ! 0$ L "P  #_[@ .061O8F4 9      !_^$3PD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P + (K@ !    L BN  $  $%D;V)E(%!H
M;W1O<VAO<" R,2XR("A7:6YD;W=S*0  ,C R,CHP-#HR-R P.#HT.#HT,0!4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   "00         & 0,  P    $ !@   1H !0    $   $^ 1L
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M$0,1 #\ V**W7@P]K""![S U#WSN_P"MJ;\6UFV;&'<YK="=-Y !X_-W>_\
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M]NW8YM_M]+_"^MZOZNI7_L6O'TP;JK;J9I?:26;BT?K%/OKWU>H'_FW?H_\
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MZY;4'QN:YU7NCZ%GT'_1=OVO_KHZUX(TOQ:GIT!K3Z=4AQC]7MY]NK-O]?\
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M P,# P,# P,# P,# P/_P  1" )!!$$# 1$  A$! Q$!_\0 'P    8" P$
M            !P@&!00) PH" 0 +_\0 M1   @$#! $# P(# P,"!@EU 0(#
M!!$%$@8A!Q,B  @Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34G
MX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(
M24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'
MR,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ_\0 'P$   8# 0$!
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M[?\ 5_J_;U[S7)N2./\ #_'ZD@@\G_;'WJM!PSU:E6.<==>4W;DD@"P(Y]1
M^MKFS6^H_'OU1Z=>S_JK_J_V.L(F/ _.DC2/38KR6L2JM_OOZ>]:O.E.MT)-
M,</]7RZX&<@$-/\ @K?Z 6)/-[CZ#B]O>\\*]:QG%*?L_P!GKL3DV(XY^@47
M!/\ 8)!) L.![U7RZ]1N(X5]?S_U?X.NQ-<\@EKVXL55K6%QS?@_7GD?Z_O0
M-,^76Z$XIG_5_JX]1O.>2=7UX/IY')_))NH!^@//]??@W GA3_5Y];*>5//[
M1_GZ[\INPY%K^G@V N+GD&VK^AM[T&SPX_ZOY=>*"E:XK^S_ (OKPG'Y8V '
MUX+->W'X(_K;\^[:@36G6M%.!H?M_P!7^H==&8@*0=)O_1?I8 $  A;7_K>_
MNNKC_J_V>K!*:2 /]7^;J/Y^-0U*/K>WU47L+H?P/K<W'O=1Y4Z]0U%5/7O.
MP_Y6CQP2 +\@BU_P+'^IO[\<@^O7E'R'^K_-UX3&PY(%QJ((9M))&H@'FQ//
M]?\ 7]Z)'"F>MA3Q(Q_J].N7I/JO8D$GZGTV^OXLMP>+?4^_?GGK8\SY4_E_
MJ_XKJ)YF/T)%C^ 3:Y+"QN0M[V^E_P##WXD?;U4 DXP?7_5^SKB9S]?HU^2/
MQ^!8\GC\$?0_[;WL\,]:'J/7KLU!*WY!&GZ?DV-K:@5MQ<'G_#_#0_E^SJQX
M<!4?/\OL_P!6.%>O7'A(_+-:UB03<W(X!#$_@\ 6]^ K2O"G6RYU-0TJ/\_7
M0FIA<V)O8<ZAP;7%P20;<'B_^'NU*G)ZI2@X8_U?ZOGUR$X)^AL+@\*?ROT_
M*@*/]B/Z^ZFAX\.K<"//\_\ 5Y==>86L2?Z E58G@WX'(8<V'(OS[U4'!P*=
M;X#.37_4/^+Z[TD?T"BP!)0\+<7X/)-S_L?>ZUQYUZT10\<#_)^?^JO483D7
MX(YN;CGU74 C@:21S;ZBW^M[]QP1UL8H01_J_P!6?\G7>MB./[5@?[(%K'^E
MR>/Z7]^+ 'AGK05F']&O^KAY?9U@!^GJ')'Y_%R>" 2.2??J#('5J\"3\_\
M5C'77E_J3>YL!;Z?46 )N;?X?[#GWNN> ZJ!C%2/M^7^KR_EUV1:Q%K$DVN?
MZD"][DD$?T!^OO7#[>M\2!IQ\NNE'^-KG2;D$ZA;_7Y!X]^\_EU[%*GC\O\
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MSJN.?4&Y()>XO[\. I_J_P G7B &.H_ZO\/72V !)YT_F]UN?KS<DV-N.?\
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MSI-R+G4%(_V_^W]ZIFGEULD$#U_U?ZO]6>)E^IN PN+"_-[#U?X<?\3[W7R
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M2#_B I-C?Z\>_ D\1UHT6O#AZ=<;6 M_0_FQ!^IL2/JQO_3Z^]]:TX%/\/\
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MUK_3^EOI[V!\L]>/S./LZBFHYX M;_$6Y)N5/TL 3[WBF.JT:HQ7\_\ B_\
M5\^N_,>#QQQ<?FWYYX%[_P"\?CWJHK6F>O,",>=?E_EZ[$M[\:3SZK&XN ?R
M!] ?]?\ WOWZM,GCUZE:4%/]7^S_ )NNA]+FP-@+_2Q_K;D\\CWKC@'J^ 2Q
M'^K_ "^G7C<@?I)'/'*W)N;^]4_9UO56F16G^K_5CAUZY_!/Y-[$_DFWXO\
M\1[WY=:KG_5Q_P!7V=2;D'G\'_#^A)_Q^O'T][^5>M<.HIY)XX^O NI!M]0>
M3>_]/K[]\^O$G*Z<'\Q_L_ZOS[\IXOS]>#J^OTMQ<D?\CM]#[\32E!UI06'=
M6O\ L?M_V?RZZ ^@M:]C^3^/Z?J(/_$>]$>?5E!ID8_U>O\ L==B5N01]221
M8V!(U<<6O;_7_P!;GWNN=5,=:H:%2?E_JJ/\_77FX!TB_P!>2;_@GBYYM];>
M_&IZT!0>=:^9_P"+_P G7 $@@&W/+W_%K\L0H-B?Q<FU_=A3\NGB":YR>/I_
MJ\OEQX]8/Q^+7_H03>XN2;Z>/Q_O?O7$GR/7@: <-(-/^+_,\/+KDLX5C<6N
M;&YO]?5;39K->_UX//OQU8SG_5GK8KD%<?ZC3_5YGK/YE)MQ8'AKL==KD6U!
M3_KCD?X>_9I7K1)5@OH/V_ZO3]G6 2K:RSJ.+7X MQ_3@ #GZ<@?ZWO1+<2?
MY?['7J F@Q3'EG_8X_;^SKH$?F>XO<<B_P!3P/R 0/ZD<>_9Q@];)P2>'EC_
M  ?X?\G7/3=N)_Z6((#&QMZA];$L?I:]OI[]4CAUX#46)'^K/\O\/[>HQE%E
MU%K?@-S9@>!_3Z&WUX/U'O>?3/\ J_U?Y>M48  G '^?^5,?Y.'70F!'-@;7
MN;WX-^"3:_'U/^'YO[]GU'6P,<//SX^O'Y'&?V5QU[S\7O:Y))]0OP;D_P!F
M_'^M>X]^'SX=>)-*Z@2/M_R&GK_/UZ\"UK"XO^.2VIOZV(YT_7_8?ZWO?$D]
M>U,!0 _Y> _U?LX#KQGL.?J"K%A<'Z7#6XO<7-SS<>]#)KY=>(8@BF>/Y^HX
M?\77[#UY]1]7!!L?K]!;ZFP-P/\ &]O\/>_RZU1CQ;(_V!_L^GY<.0EXO^G2
M#]2;M>X Y"VM_O/NO^K_ %9ZM1P#G ^W_8X?EZ]=>90038E;7!7^MB WX_/]
M?Q[W4^F.O4*D"HQ_J]?G_+K%YAP/P;<D?J (NIYY-^?Z?7_'WHD^0Z\ /.A'
MJ?R_XL5ZQV)O>UB+BP_QL#?U7M>Y^GU]V]*=>)4?$<?ZO]5>O>8?7A?[1MJ6
M_P#13]5//^^M[U4YZT%/ T _U>?\L_MZY>9?K;DJ?J#>QOS_ ( 7/Y_WKWOR
MX^?6F-:5%?M_U?ZO+AUT-(X8DVM^0?38?0FWI(Y(Y^O/]1[/5^WSX\?E\_VY
M^WSZP6N18K<W/-C< <@C@FY']/\ BGO77J<:Y_G^?^K\NN_/ZN?QR+:R"UB;
MFRBP%_\ 86'OU3_J_P"+ZJ0<'_5Z_;^7I3Y==?6VI3<<\<$:C]/KR>01R.??
MJ>5>K-2I!%1_J_U8_9UT#8VOS;\D$:K$\WT@D7'^Q][..O5!!I3_ (OKJP!O
M<"X/U'!^MK\  $VX]ZZW34 2:_ZO^*X]<P;G_/ $V-["P-B-1-OZ_2_!]^''
MCCJA+@87-<_Y?]5*=>\VNQ-OKSP;<@_6W]23_@;^]DTQU:CTPW^K_5]OSQU@
M\P_/'.H<"PMR03_7_8_[W[I4];"4H6I_J_EUF-^;?ZH?0DBRA;#^A)( _P!A
M[O\ ,]:XUS@_ZOS]?/'E3K 9% ;5_0&]_P"T=1_/ N3]./==5>/6RF!C'KC_
M %'_ %9Z]<FUOR2""+'\@@C\6X_VWO?5@1UV)!S^=(M]#8_6X4?J))'^'_%*
MU.,=:T:M1KC_ %?ZOM^?6'RWM?C@?4M:YL3_ +38 'C\?ZWU\&^77C7M)_U5
M_P W7C+?\$V ]/)(-K\ "WT_V/O88\"//KS#-1DT_/\ U>O7A)8D^%?KP+FQ
M//\ M_K]/>JX&.MA<G_5_J]?\N>N_(O%_J"+EB6/]3S;\ G_ 'UK[R1PSUH#
MB"V/L_E^SKHR#4?]< _DFX%](%R+6_V-O>JGTSUL$C40?]7_ !779DL/TCZ\
M  \K>W-OI8?['Z^_5/IUO(J,<?\ 5_J_:.N/^-C>UOZWTBR\V^I6_P#7C_8>
M]]>%,X^5/L_GUA]7]1?_ &X/-@2!SS_O'O77NX?;U(,H7\6XM=K $V^E[&W^
M/YY]^!/IUIJCB?\ 5_+AU''X(!X%A]2--[?UY^GOWV=>J,4!ZSD#^O/X! -B
M#< E;WY'Y'OW5CF@ _U?ZO\ 5CK ;W%[CB_U-A^/R1;_ &'_ !3W[K7F,TQ_
MJ_U?X,=9/*W^%_K:PM?Z"]_Q<\?BW/O0I_J_P\>GF8Y]!^S^?^JG7N;?X_3C
M23S_ *E;?47_ -O[K4UX=;I49.<?/RZQ $7O>_')_'/ ')(_XCWOJAX&E:U_
MXK\_]5.O6U?0?2X/^\"]A_3W[[>O 'X033_5Y?L_P]<?*1J_J/H!ZO\ 7XT\
M@:N+_7WNH].O9KQK_J_U?ZAUXRCZD,">1^!S<"UC;_6_I_O/OU?3JQ(_+[/E
M3U_,=</+8?I^M^>2OY)U?6_UM_3_ !Y][STQPR!Q_P!7_%^7V==F501_B/I>
M_-B;#\W_ *WX_/O53_J_XOK8[?\ 5Y_SS_+SZP>0&QX) _M!B2?J"P .GZ_[
M[\^J<XZI0&AJ.'#_ %5_E7'6#RS_ %/!' Y1N0QL!R+V_P!:_OV.MY.2>'^J
MG^K->N/FGNH%O4" Q L>&MJ&KTW8D_D_ZWOU/GU[&*#)_P!7^?KG^\#I)!])
M ^EOK]7//Y/'^]'WKRKGJS$DF.HJ1_J_U?ZCXSK:Y/U-K6-]7TL""OY_/X'O
M>>M D\>'^KY]<1.+W/U*ZA;@6OP/T <ZN1^??LGA_J_GUH%E!+FII_GX_P"P
M:8Z]Y_HI\FK@$'G_ !YU@,&%OP/];WZO' Z4'@HS6E. J?+[?]D&G7?W!13<
M$^HKZ@ =0!Y )Y2UOKQ]?\/?L$\.JU*C)J?]7^?%1\O+K/\ =TW]#_MU_P"C
M_?M*_P 1_8.M>(_S_:>O_]$^/U6YL!]0?\ .0; D"W(_WP]Y%<:>O7)CUQV_
M['I_J^?IUQ,[!;D$CZ  G5P!R"1P+6/(/_%/8'V=;HV!C_!_A_U>E>N@UOS_
M +#Z-;^A'(N3]?KQ[3I:Z#7U_P!7KU[Z6UD#!3^7=7S^W_+_ ).N336_46%C
M_: ^E@!RH-QQ^?9A'%BG6Q'!#Q;MSZC\_P#5_DZ[>=R"6FL%(!X4,+V(O?DW
MM_M_;+5C(4^GV]5MDM4JU:BM//AGY^IZQ*0 =.EP" 3J!X;5QR2 .3^/]Y]T
M:0@BG#IRYM[6<<1_/Y?E^767SD*3<6N;\<DWL=/!XM^/J+"WOSQ+<-IC/ 5S
MZ8QY]-&"V=B#QX^?^4\>H0%N.1>Y!-_]>P-P1]/]8>Z)%X!.OC\O^+'3T<-N
M,*,9]?\ +_J'61)"=*KP0=1^@N-(!_!^I]OB LK.3BA/^K/2*;4^A0Z@5R*G
M_H'_  _MZPEBW^N#PQ /]0JBP')_I]/^)9,"L?G^?^?K<%S%;@B4''F ,Y/"
MI&<_ZO/$96N018W_ *#C@VXM:US_ %L/Z^[+ [4) ('^K_4.E:+;3$C2PKZC
MUI_2I^=>N0E;@WY%]('/ULIY*H+"PXM[T1 &*/J##T _Z"Z?\%$)J17T-?\
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MD!O;_@UKZ1>Y-QI%PQ)_'O1MUI2N.O1^ Q)!-3QQCS_SY%.L)E!^CJ;"]]1
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MU>K>OKUQ+@%Q92 ;,?H+\<#BUU/MPPR8R.O!T.HC X?ZOGQ_U'KAP0+!EYN
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M_P O\O7K\V-^ #?_  O];->Q! _U_?NMC)H?]7[<_P"JO71E'TMR02;@'@6
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MF/D7TVN!?VQ%>&H4'LZ3W_+EQ"KR^&=7J=7D13R^?7"6LIJ6CI8JFKHH*H5
MU0S56I@+G08A'&UK#]5R>?\ >-7-XD+0A#0,#7'^SUO9=FN;^"^DNQJ9'4+\
MJ@XX?GU*$JZI50PU44@#?<I4*SQD@WC$&D-^X3>_-K#VY!?LQ'=P..'5+BPD
MM6.DT)P2"?\  1\O+KJ.4:M"K=9&M*#P)!<"S:K6N>.+'VO9HI-;,H\0_P"'
M\CT6,%TR,4U/0YSQIQ\NL<[RI3^1HJ.ECCFT+&K,TDT0)(C)NS$$7_Q-_:?Q
M)(L:S0=(K>UO9'IP8_;G]@_;U@CS%)$K1G(T4,BN3"@GI0T"L/T$23Z]?/T(
M]LON:H1XK5^W_BQT*+7ER]N5&D$$?Z:E?E0<>I-)4)61SO+.:B 7C9\=4TP;
M@AC< R*'X!/TYM[TM^DPU)33_J^?35[LVYV5PMN6/P@\2>/Y#[*=17KZ23]E
MJR D'2Z3U %:T:\QQDI$(U:]O]<_4^W#=#SP/]7SZ]^Z)RNHK5_M;Y?+_/UV
MU724CP254E/1M VI8LG/Y4DCL3'*$@0LXU$$?X^]"[\O]0Z2G;;E;@+0>$<'
MC^WAUS6I,WAF@$-4\\Q85!9HZ!03^;@.H'^M[\+L#SQTO&TNP8:<?ZOEU#.2
M@F2IIX:F@:J1R/)),8Y2+_H@)B\1M8@?GWHW"-\0P3_J\^JC;9."'(_U8J/V
M]9Y)(Z:*0U J:5&C0^:2KA=Z>XY81QW++(3Q[W^F$UHH!KY5ZK]&[2Z':H_P
M=1X:B-XH=#PU4<3$Q52S$S.2?K(A5"A2W ((/M*+JX,FGQ32O#\NGY-HB@MM
M4<8&*\2?/_5PKUDDD:1C()O#(Q7]\1^0'3PL?B7_ (Z7TWMQ^?:Y9RJ5/&HZ
M#T*2O?I SDQE6_EP\OV=<9:J*"=8Y:RACG)'^2R9!::Y;AF:\3@\&^F]S]/=
M#=#TJ?\ 5\^C8V 8!&.*X]:T^S/7,S"FUREV2(D-&SJ7H6(L;,;%V!M^/Q[J
M;I*C K_J^?6AM2$4*U4_,]8XZZFF@D\#T<K25.JI$,DE5"K B_C0*DE)$/\
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MUK:0 ?\ 4.F'VN]MB=7 ')-?/RX=9$\;QB;R:B" )Y !1K;Z!#QJ(!XO:_\
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M@XY'-OI?U6N?K8?@_7_#WZI]/]7[>MBHXL?]7^;_ %#AUUY0+\"_Y N3S?2
M3R+$^_9H/7K5#FO^K_/^?7+RC_'@$  6%N/U6' ^G'^/OU30$CKU,T4_ZO\
M4?MZZMQZ3^;$&UKCT_X_4C_7X_UO?O2HZV:G@WG_ *O\'^3KWE4VXN;@WOP
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MH?XW54^Z:JF6>M62'-F&&EF,L);T0OI'-@+?[%;S%/<0:&AF92 IH/.JU/\
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M[6_KPE2YW:YFFCCN2(HR!4+Y^E<Y^1'4US\N\I<F<N6.X[ALZ/=R1EBSN:4
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MGT+_ $)X]RE"T1L3(1WT:F1UB+8R;E<;VEM<.#"63&BG$BN:>?5JM?U_U/\
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M?7NT4^8_U#_53^77?W!%K  BX4-Q?E@3^D #@?D?[ ^_5&<=;H*@@^0_U?\
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M3[J.&!7KQI6O^K_5_J^?4;S$#FH(!(%M) -OS_:U$6_UA_K>_5).#GIVBK3
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M(!!-[V:RGZ_GZ<>]DGCZ=5H.T!:^?S ]:U_S\.N;3V4FRC@AKA03P?3;@ @
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MJA(*FCR E"&*IAJT56-S5)(%HXFXT2J:DK^18^Y/@9ELR"<Z3UAI8R6_[]!
M'QQ^N<CS^SJV7^8)-_>'X_=$;IH;S82GDBJ*[-H9?MJ6EJ:9/$U28X)H:>.I
ME/ZV:RGW&5S 4WC65^!S7_-UE)SANL;>UUU-';BX62R&F,G2'.H>?X?7)Z?O
MY=N6@VUT)WAN_.P24^#7)TF7-9FXC3XJ6"DP%4]4M.R:?-#6$69K#3^+^Q3S
MF08]CS2MJ,4X\,_8.D/M'N*W7+.[--M:VL:2(,N7']F,8\SPZ>_@5N"3"_&C
MN_/8>&DFK\7GM[5=''6T[5N.G2!JJHA:6@K(X]=/.%L19A;_ &WLJYOBD\2P
M5?/P_G_Q70G]O+BRV;9=\NX;87!3QFTU*5-2:5H?LX9'5<>^?E7V/VAM&IVU
MG,%UKC<?DT1:E]O[$H\17*(CHT15@$50C,%]1TBY]B;;]N2-E;);SJ:^?V]8
M\<T^X]WO]O<1_00VL)R(P 7%!0?J #57TIT7&I6(4P6&GCC96CCCBC:54U(@
M2XLC)&TC?4EA<_3V:WFN.$Z3FG'J&+8S3;S&916/6U149]<<<]7>8K9NR.NO
M@EA.N-_]G83JBN[)2DJZ[-UV-GR;RKD%2JK:7[6%HDEDDQ\F@N9!I^MOQ[C6
M\\:^OS&02P5@.'D:]9P;?;V5G[>VHEO%M3,87+49CF@& #\0QU-[XV=MCM;X
M0I0[+WUCNW\QT]+25#[KQM$<:]=6XB/[7)5YH)I7-!KAA!*^1UX^OLLM89;>
M[5"I!-/\/#H4<V[=8<R\D.MLRR1Q2.VH FI (P#IZ2_2N0&[_P"6QOC$;0*9
M/<.%VUNVGR./5%JJQ)5EFEI4@2%G@$A;U#U<WM[-=XCG\92U0CQD+PXZ36O^
M0= ODR"RB]F-\VJ&GU@V^X4T!KWEB/E4^M?MIU4#M#:&\=Z5&0QVQ<)FL]6X
M>G^^RM%3Q)53XRG@&F".NC<1BGGI8P \08DL/K[&5AN<=OLVUVTGQK H-33-
M/]7#K%[9MMW07V_1Q;2\I6;BM#50,F@K3_)T\]<P24_9.S(IZ.:A6#=^*CJT
MJZ>6G:GG%=#]U'(Y\BQR&8%K?07]FD>Y![=]*=N//_8Z+^3 T7-3&;:03^MC
M5PX\:=6%_P TQI&WOU ?MI(HEV?DE4R:*HO$U?4C]B12LGD)OZ2H7_:O8"Y8
M(FYA:(TH(P?E\7I_EZR8]]BLG*VW1FWTMXA*M6I/92GY\?ETW?RM/MI^V.P\
M<U?#2K2[2\C8O4GW#F%S/]P\A"E$)L- U6^M_9_[CGP?H0O#Q'_X[T'?NS63
M20[P]ZQJ+:,BH'^_#6E#^WIL^,>Y]O8/^85O.FR%=''_ !?/[JP,%?J2H^];
M[ZIG@,DQ"M22*6TC2'UGGV6:)9.6$>,?Z%'TLV=(;+W@E+RTM#=W"\,4-0,\
M1GY= ?\ /;&5>&^5N^H<G054<V=@PTFT8)H)HERDJTE-2F.D95)D+.A;5")V
M)^J@\!KE7<9?H;NBFJS,./H.J^[WMW)?[W%N-JYJ8TK1!BKU/%A7'G^?1P_E
MI7KMCX!]3[0R\,=-NS+S82FHJ.6&H>770TD$<U;S"&5D1?HRJ?ZV^GMCEK<'
M6^NIO,Q>OE7[/7J49+&R?E7:K:_ \0,S $'-!35CAT)G:G<-?TQT/\7=U8^>
M26BPV5VS'GJ>,NB9'%3P4T>0HIR@>6&*5-7(5^?Q[*K^.7<N8(BH-#**^?H/
MY=/Q[M;;3LNU1JP"4:@J16E<<#QZ.1M39NS4QO9W<&T3%-1=L;)Q^X*RHI4=
M$K?LMN4]!B*Y%G$ UU6+@C>0'^VS'GV5[W%,;RWC<$-$A'VU/^ >7KT-MBM=
MNDVO<+Z/3IG"M2AK32./S/$CUZU>LG($SF?FU:XEW%EXH6N"TK35$FJXB:4+
MH)_J?I[FN1=.QVI\]4?^ =<Z^>K+ZSF>Y$&54M@#T<^M.K9/Y6F11-O_ " A
M2=*E%!^ZM4PM)CM.,#&!3+XHRBDVU _CV$N<=R^INX:XTNIX_P!$?(=9)^QL
MP2VWA3MX11;FHU#S=C7C@>7'^?1<O@//#-\Q8*]:A@:3)[[\=Y)*EI14Y"OI
MT;R11&E!C%FN7%_I[?\ K/J>7;J$BFJ+UK^?2'DN[A/N?N=S^ZU3_&8S75_1
M&/S^8ZL(VUV1@^P>^/DG\4.PI(*O$[G!K-J+4M42"")H8):^BAC\!@::*I#3
M!E<DWM;V!K*.2YM+N=<>%+0GU[17CU-UKS)976^;AM\]M&A\5U5=1-2&)#<*
M?*E>@]_F>XB';O0O4^W*"222'#Y["XTU3P) 31TT,4%)!X_*_J9(?J+BWU]J
MN7$D%X2<_%T&_=^2V_<=N%0 ZE]?]7\NJ6:'*5&,RM#FJ4-%-CLM3Y6D6/7K
MIY()$<^-D5W)"C\*3^+>YFF4/:31'\2L/MKUA#8WDD%_%*AII*D4^6:_;UL+
MUG7.'^0%3\.>WJ0PY+#[<IZO([CKGIWD^ZHXX8FC@J#I\T'CJ5?ZJ2.;CW"^
MX276W75S9"H75BGI0?MZZ#<K6>T<S<I[)N]^%:3Z9"=0))-2&R.&13@>'5//
MS0[&3L+Y =B5^/R,E5CMNRQ;5PL<Q"04%#A(Q09.>,U")2T]/+EH)W5O)Y&!
MY4'V:<N6DLUSX\P)6I.<T! IY]8P>].XR2[@D,$Q$)4#' Z92.!'H.CK]DU5
M(?Y6&Q9TJZ)(GJ,*M'7S.'B=O*5T 71YS5Z;$VT@<W/OV_QK)SE2(UB^G2OR
M-!BE:]31:[4LGMC8V;(*^.SC]E>'Y] 1_+BWQ!M[O:KV97B&FHNPMN5N)EI1
M*4Q]!4T$]7500PPJLJ5CM154<6MFC+A/I^/8PW^S7]TF2)!X@8G S0<>HP]L
M[^.PYE&URS!898E2AX5>I'VU)X5X]'.W-LA?BG\8OD_F:B-L5GM\[MS=!M=X
MX_#-.F1ED&'2F,33(=5/*WZBMA[C%#/=7L<2U:)S0'' _+!ZF7F^WMN4.1.8
M=QM:+>^!BE5.I3C/</SI3/2"_E<Y>FFV!W!L&&:*IS,:UF3:"GG\[SNNW(<8
M?651O-4+2J;6(#&Q/U/L3\PV;P;;9N5H %K^8I_AZ _L;OD6]0\PI)+JE::0
M\:_Z$I/D.!/E7JO'X^X'<5;\J-GX!,1D8<Y2;]F?(XRJB$69QM!%E9'^YRL,
M+S04L$D9NA#-=?8GV<)_5>>22@4,^?R\SU$')G+-U-[CSEI'T+$<:1@B7TK4
M''F.C5?S3,[C:CO3;&VZ&>G2KPFSJF').SAI\9/4UE5D8A+$NI?\IIZI&6[
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MYY8?J/\ MK_3WOCUKX:U-/\ +^W'^SY"G7A,2%///U!MS9B&L#I(NWT'TO\
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M]Z^OOWGFE?\ 5^S_ %<>MU% H';_ *L?,=>^X-[%0">391J0,#JU GFQ%O\
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M31Y:HW'4U\=110T])54VK&K3TDL9<_<7]94W%_Z^SOFC;6W>.T^E4LZ."14
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MS:WT) 'TX-C[]BE#7K0!J*"I]?\ +_J^P]<ONU'(-B"!^+:K\F_]1_K'W[%
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MM^S_ %#KFM6  H#<CA!]/R/KJL;K?_6]^Q6N>/7BK4*AL4P.N/WB_G5<V^@
M %OZW-^?][]^KQ/5=!HM7KUW]VGXU?FWI7Z&W^U6Y/TY_/O9<>0/51!0FK8^
MW_5QKUT:T?2S6YOQ>_'XY%[7]ZKQ.>KE?*N!7\R?3KHU2:A];D_4B[<<\7X)
M _WCW[4?,&G6S&-2Y%0>N)J$-[:Q<D\+>VK_ &W-C_A[]J^76R".!Q_J\_\
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MM0+?F[:0"5('^\#W7(\JCKW:Q/D?YBOG^5?GDTQYR/.@LI]9!)NP/]01SR
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M-C]O'C^W\L_GU$60_7TJ5(TK8W%CJUDA5;Z?DW^GT]V,7'S7_5\_\'5 EL:
MX/YYSQP!\AY_9QK),S\LI&G2>+AN?KROT^JV!! _V(]Z\.IH1G_5_JIU;1;:
M2X)TGCQ^W_50C../43S$0'5<:6*^E2/58WN%L%!5?J/H![\8@3CCUX"!:$G
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M7_J.+^[>&*G^'_5\_P#5^SJH6W733XCYY\OG_FQ_/KOS7NOTX%_00; &Y]/
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M&]P>D@<]:;K!%[W!']WBIO\ B_/^Q]V&XFOQ8ZT?;>^(S;R5']'_ *'ZP_Z
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MQ%?R_P W6E]MMR H;>6G^E/_ $'_ *OLZBK\?/D#87Z([?)(_'6F[OK?Z6.
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MP!+P.;W^G)/O77J=9/X3C_\ E64< "S.+ 6(M9@?J/\ 7][KUZGSZZ_A&/\
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M(!75<@\\J /KQ_L/>_SZW7KUE^K6M;\$E0+C_!N #?\ K_L/>NM>G7?UL.+
MB^F]C8@&X/%K\?FWOW6^NF-C>UPIN+\VU<_72"5!^G'T]^XC'6AZ^?7>H D'
MTB]N1>Q//T! /U_KQ[]UX\.O7'#VN."=1)O<M_M-S8W%_P"O^'OW7O+TZY:M
M#?0#\<-<CZV/(/UN?\3<<\^_=>I7KAP&N!^ 3SS<@WN/4;\\?F]O\??NO4Z\
M02"+-8C2"#QP!Q_7Z_2]Q_3WOKWGUZP-OZ7_ #=00!>QL&M]3_7\^]<./7L]
M>8?4FQO8DB_( );@E3;2?K_Q7WXCKPZ[U"X%B"+?\& (N%OI%^2.3]??NO=<
M?I8_3ZW/('];>GTE;^_?X>M]=^H6))-P;@W'^)M?2JBUOZ\^]]:QUV;&UN;W
M)((']HV:_I'%S;\>]=>ZZ(  3FWU]-M(L?5;ZL2IN+7_ -M[]UX>O77-R1R1
M<C@ "Q-R5_(;\_@7_P /?O\ #UO_  ==AN?ZGC]6D:;$V-P+WO;_ )'[]UKK
MLB]QQSS8_0#FQ^@4'@7_ *_T]^Z]UX6'!(;\<@G39@;?7_#Z <^]]>Z]8$$?
M@ZK#BU[$"UC=OQ^3].?Z^]=>Z]^?2JVO]2+#_#D$_IU?7_;?U]^_P]>\L]>!
M/)N/H&XX4,+W!/J)!Y_I[]U[KKZGF]^%-B+GFQL>0+7YX_WOW[\NO>77K@@_
MGBX!+$7L20?2#?G@\_[:_OW7NO ?J_96W^JN-+ "Q !46-OZVO\ X^_?EU[%
M>O 6_200/[/"W )(YU$DW-A]??N/7NO'TDWL/U 7U7_IZAZ@?J/SQ[WU[CTK
M=I&S5P%_4P8\BUU9AR!?DAO]< ?X^_#@?MZTW$?9TM/>^M=>]^Z]U[W[KW7_
MU=_CW[KW7O?NO=57_P X4_\ 8O'Y$"P6S=4?DCZ]Q]3?6UF'/^-O9[RW_N=9
MYIAO^.OT'N:*?170^8_X^O6D,"-*7!_2?I^;WL>; J!_M_<R?Z&#U!$^)CY_
M\5_J_P!GKP^MKVL"+W(%_I8\_3Z&_N\?PGI@FA'H.O6XO^+\"W-S8'ZD6Y ]
MWKGJI%1\NNC>UK?3\ _6_-[W/U_V_O?YXZ\2*<.NAS]#R1]+Z;V!^A_%C_O/
MOWGPZ]4D8X=<A_KFUK BWTY %SS^/>NMX())ZC3<6_P (TW''Y)-[WL??JYH
M1UO%*U%1U'')%K7X^O-_K<\_0GBW'^M[]2@-1UHY-?,]9UL%']19;?7@@_7Z
M_7_6]^ )!/6BPP#BO7+_ !X%R!:QYYM:Y_Q'Y][R>K4%1ZCSZX?BW^-N1Q_B
M ;$D?ZWOW^#JGJP_U?\ %^?74@.GDFX_']!8\6^H '^]^]'TZN!4U(ZP\J"6
MT@(#(RE/(6">HQJA!.N2XM;Z6]TE36A0'C3KPP0:4_XOJ(]93*52HFHW:2]1
M$<A+,S4:+S]LBQW5)WMP&MR>?=!>):K1Z4'V?;_DZ?7:Y+HJ0,'[?]7Y\>N)
MKZ245$$6129Z1!(9C*L-+3JS6L78JMP#8"_/T]I)=V5ZT_P#Y]&T&Q,J4-.'
MJ?3'2HVMLW='8&Z<#M#:6-R6X=V[FR=%MO:^$H+Z,L^2/ E(Y5"Q_P!M[66M
MVDG)EV%;.B;HFAL)(KE3IJ:CR/KY=+_N[H'N?X\9?"[;[KZ_J.N<UN3'_P :
MV[BXY!4460Q[S#'U<\DJEE5Q)1G5SP?86Y)<"XW"O^_&S_M%Z&=S:2+MVED*
MMI7!!!&#D= S.RF5PA1T1S$FG])"*%6QORA-_8FC03Q^)7%3_AIT#;0-% $(
M)H3_ (:]8C_0<_2XO:]_U"P^AY]^^B([M6/M_9TJ:Y-0NGNK4_ZO7KO4"3^>
M/ZGAOU$<\V]J8X*UR.FC-HJW"O78^IM>US]1S8DV_P!?Z_T]MR6HH17'39GU
M$$5H?V_ZL]=6=@%0:YB0J*7\2NWUL7NH0C^O'M/%#HGB>F%:O2>8LR,K<".H
MRUU*1%%]U#/]R[I))2O+:G=;^@U)]!-P1:_-[>T4UXHO,GS/^'H2[?9EK,D)
M7_HG_5]O6%@;?B]^#Q>U_H3_ (#V(+R4265 ?(]!X1/'<ZJ#54=8SQZ1QSQ>
MQ/YU&Y)-@?Q[+D^$?8.E#=QTKQK_ *OL^?7$"P/Y-_3^/QS>]R![MZ=>*T5L
M#_5_JQURN2#?ZCFW]/2;W:_XO[\!D#KVJH8US_J_;UCDN.#<'BPL/]A8_@?G
MWX\0?+JH).H5SY<.N(!XL+&Q]5_K<6')O]#[UP!].G5XBO$\.N7_ !!M>YM8
M<J".!8 _[S[U\Q_J_P!GIROEU$D OQ;FWX ]5[?D_GWYN'6P/4\>L9!%[<W%
M@!]2/IR1;\C\>TWV];(!-/*F!Z_ZO\W74GZ""?Q;^MC^;FX/U]^.:^G54."6
M(&?]5>HWUL"0+<?339K7M]/>J]7(!HK"I/\ AI_J_;\NO6_J?]OR/\0/]<^]
MG@!Y=: ]:5_U<.O/:WTXX7@6/(-P1_2_U_UO;38EBSZ_X.GXZ&.4?9U9K_)H
M'_8R?XTV_IW!]/Z'H7M< DW^O_$?[;V5<X:?H@.(K_E3H0\G _6%C_JP_6_-
M[B3J9.O>_=>Z][]U[I,;1;3L_:K#^SMO"MIX]0&(ISIO;C^O']/?AP/6CQ'V
M]/'WW_-K_D_Z_P#)GO5?EU:G77WW_-K_ *R?](>_=>IU[[[_ )M?\G_](>_5
MZ]3KO[[_ )M?\G_](>_5Z]3Y]=???\VO^3_^D/?J]>IU[[[_ )M?\G_](>]]
M>IUW]]_S:_ZR?](>]5^77J=>^^_YM?\ )_\ TA[]7KU.NOOO^;7_ "?_ -(>
M_5Z]3KWWW_-K_D__ *0]^KUZGSZ]]]_S:_Y/_P"D/?J]>IU[[[_FU_UD_P"D
M/?NO4Z[^^_YM?\G_ /2'OW7J=-N*W-B,[1ID<)7X[,X^22:%*[%9&FR%&\M-
M*\%1&E32-- TE//&R.H:ZN"#8CWI6#JCH0485!' CA4'SR*?:#UZE&9?Q#B/
M,8KD?81TY???\VO^3_\ I'WNO7J==???\VO^3_\ I#W[KU.L-3F*:BIJBLK'
M@I*2D@EJ:JJJJE*>FIJ:"-I9ZBHGE"10P0Q*6=V(55!)-O>QG@.M&@!)..FK
M ;TVWNNC?([7SF$W)CXZAZ22OP&9H,Q1QU4:1R24SU6.EJ($G2.569"VH!@2
M.1[V012H(ZTI5OA8'[.GO[[_ )M?\G_](>ZUZM3KWWW_ #:_Y/\ ^D/?J]>
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M)^Y2I-!9A'J!#_I*_P"M[]4'SZ]UPT@@<^HD$L">% 'T++PQ_)_P]^!4>?\
MAZU7]G6)B5U&.-IX8EGDJ)81&RTJP!6D%2K.DJ,58$:5:]_?K@BV@2YD/Z;
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M]1_7\6YL+6L2/Z^]UQCAUK2"1J^('KOGZ^D6 8#DGD\FW]>/?N%>O>0 \O\
M5_/K@_I5N#?Z\\<_F_%KFW'^/O6.K &O#'6'5J,@/*BPYN2/H/J!<V'O0_GU
MXBO'AUQ#,%60$^2)TDC;Z$2*W# #Z@7Y'Y]NQ#5(H/PT/5695%2*Y^SK9$_D
M-=?]>[VV)\CJK>_7>R=]38?=>WCCQNG:N#W!40QU-%7355-2OEJ*J,0J9(E^
MA O[CGFFX;Q$C20J-8R/L/4F\J(A1W:(.1&30Y_$OY?*O2DZ[_F3?!KNOM^+
MX\;^^$6Q]DXO?&XALS"9T;9V!/!F:ZKJ)*.$5E+A<=%F,9&63A]2%"18\>R_
M;-LW"Z1YK:Z8MH)H1QH*\<C(]>C?<]WL+<HDMHH750D-0Y.GA_L]%1^0WQ$S
M7P,_F/?'C_9?<='N3;W:V_=N9;J7:6XLS#BXZ3<ART-#5;%DW'6NM)3X@350
M,;NWE6(\GB_LVV#<UFY2OHE>I1):^9SY8_.G23<-B^FOX5MQG4I6N,\14\.-
M*_+TZE?S8Z/Y'][_ ".^-G6.^>J]M=5;IWKMP;8ZXQ+[^P>Y*+-U%7N//+/-
M7[OQU5/B<#!62Q!E2=@X^G'X9Y0N!"M_*U=*LYX9IH' <>C6^M))X(Q*J@E%
M  .H#C4ZOF:]%QK?Y.'SNQ^;EP%3LG9"S8W;,NZ*_*3;ZQ+[?BQE!4BGDHCG
M8W6D&7>20:839VBU'\7]J[3F:W0(FHFK<*9R?2E?F?*G04;E6Y2)PT8!%234
M:?MU5I^PUKBE>BU_'+X0?)CY65>;H^E^OH\M!MJ3[;/;JW!F:7"[0CK=$4Z8
MBGS<^FEBS:44\<LD#$L0X8 *;^Q#<;_:6UOXLL@ (]:D_8!D_D,=$UOL%S<7
M(B2,DU.:4 ^9)-!P\STI_DE_+N^6'Q/P=)N[MW8./EV;4LL4NYMC;@HMR8S$
MU3+>&GSWVADDHXGD_7,P5"#8&_LNL>9H9GE(<TIYT!X^ASTJW3ER6WC@4J"2
MQK3(./45'Y5Z2?QG^$7R5^79RW^A'9E/F,+BPHK=X9_(0[?VS3551"E4,909
M:KTTTM72HZQE;D^36#^GAZXYC@A0N\@I]N?R J3TGM.79[B3PDC[C^0I\R:
M#\QQZ6?=/\M_Y?\ 0FX-@;=['V#C:=.S]PXO;&W-T8/-TN6V?!NK-.<?A=GY
M#,Q%Z:EKLG5V<LY4*.;V]I8>88+EE$<E:D8X'CZ4K_GZ67?+,UM;W$DL5 $)
MJ,CAZU(_GU?%E_Y5V=R7\NC$=,X#K3K.?Y5P3T,^1W*E;CZ2%Q_'*^IJ7FW*
MH%+J?!O3QE1]62P]5R0E?[NPW RAB(A7!\ZMQI3Y="K:-E'[O,3(/J"1P-0!
MH\S6G&G[.M53=>T<UL3=6Y=D[G%+!NK9.?SV"W72TSZZ*AJ-OU#T<\5)(3^X
M)Y5N#?GW(UM<>/9+FH(/4=;E!]/=-0$,#TEB ;Z?IJN-7#6Y/)^A(^I_/M4N
M .BUA4:N''A_J_U5ZXFP O\ 0GZ?D#Z\#\\?U][J:_*G7N  X&O[/]0ZY<?4
MKQ<$$D_3^I/^//OQ[?LKU8JIKBAI_J^7^JG6)P#:Y_/UMR;_ -;?2X_WGWLG
M.3U51P' ]<5!'/)L#8W(;_&W']!_A[KYT\NKK@ GT_U4ZQEV,EBUEXN/POI%
MK^D6Y/\ 7WHCSIGIT#RKCKHH"=7%["S$WO;Z7MQ?G\>_&O7L=1@2+6-P+$B_
MT'!%_K<#^GY]IO4UQU; (H,?ZJ?EUB+N;AG/U^E@+\W_ *<FWOV>%.O4(H3P
M'R_P=</\/\?2>>1?GD\7%N?>B*TH>M@T'=\N'SX=>TV'JXL?25^G^)_UO>_/
M\J]:\J$<#3'^K_!U&J>= OR2?K<\#2>3^ 2?]Z_U_;+U$L6,9_U?+I1$ 4DH
M17'^'_5^WJSO^31<_P RGXU+Q<CM_5RP'_,A>V";6)-C_07O[*N<?]P\<*_Y
M4Z/^3*&[P?/_ )]?K?I]Q+U,O7O?NO=>]^Z]TF-J?\>9MN_XVUB/_=73C\C^
MGOW^;KP_R]2+^]=;Z]_OOQ[]UOKWOW7OGU[W[KW7O?NM=>]^ZWT5OYM[_P!W
M=6?$CY$=B;!W!%M3>NT.JMUYK:^Y9Z*FR,6$S5+CW^PR,E#61RTU2M-.P;2R
MD?ZQL?=D%9(A3BZC]I Z>MXUEE5&4D&O#[#UK\_$O'?SUOF!\>]C?(#8GSDZ
M5VUL_>U!DJK"8W=?7-%-NJMEP63J\7+-42X7 U-!0TN5R%#*BQRLLD: ,5"E
M6)CS1;/;/X-@$6X"U(I2M1BA(I7^6<GC1%=1Z6E2%7+#^F0*TX9/S^SHZ?\
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M=E;IR^*J&BBG6#(XW!U]90S-#4*]/,(JF%6*.&1K68$7'M,Y*H[>@/\ @Z5
M$X''K5Q_E _S>^\>Q>Z\/TM\Q^SZ'>M%W+0XS&]=[NK]K8O:4FV>VC1Q5>.Z
M\I&PT$%-F<=O#&"L/GD5VIZZE@34BU#:E%BHN=G:[<_KK.5%*9&D&A^RA(_/
M!J*-7>FSNHXA7PV4$U)-#FAS7SP?R/EU8M_,L^5'?G0_RS_E\]?=4]C'9NRN
MXNR*[!=DX0[4P6?AW1COO\32QTDU?DX9*S&:8:EPK0E=);5]0/;E@%DO4BD4
M&(TK4>I-<\0:>E*=%][-(DCJC$%8P10^=6_(\!@_Y3U<%O7?6R^M]N9'>'8&
MZ]O;+VKB(9*C);@W1EZ'"8BCBBBDF8S5V1F@IPYCB8JFHLUB%!/M. 6- .C1
MF51D_P"K_+T!O1GS2^)OR9R.6PW0/R&ZH[9S&#=TRF(V7N_%97*4QC$C2/\
MPY)EK)X8EB8O)&CH@%R0"/>RC $TQ^75?$4G34U^P_Y1TIZOY-= T/>V-^,=
M9VOL^F[_ ,Q@GW-B^IY<B4WA7;?BQ]9E7R]/CC':2B7'X^>75J_3$WY!]^T-
M353%.O>(@8J3FM//_#PZP]N_*3XZ]";FZZV9W/W-U]UINOMK,?P#K? [NW#1
M8C)[ORYFAIUH\33SN&D9IZA45WT1LY*AK@@5IUYY$2I8\!7\O7'3MWG\AND?
MC-LR#L/OWL[:/4^R:K.8_;-+N/>633%XZJW#E(JN?'8:ED8-)4Y&MAH)GCB1
M6=EB8VL#[]3K;,%I4_ZA_D^?0N4592Y&CI,A05$570U]-!64=5 XD@J:6JB2
M>GJ(74E7BFAD#*PX(/OW#K8(8 C@>I/^^_WGW[K?7O?NO=>X]^Z]_@Z][]U[
M'7O?NO=/<7^:B_Y9I_T*/>^J])[=P']T]V?3G;^:/ Y'^XF8>JY/JX_PXM[\
M>'6AY]*7W[K?7O?NO=>]^Z]T'F=YRTVJY 2+\@?5% L";  VN;?Z_OQX]>'
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MH\I)@.RMY=@]_;2V5D9LW%0FAW+D=H8*GI\8E3%2Q?W;#RU7A$C-((3/Y=8
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MN%PRJT569!D *!4"IIQ+!.%:KBM>JR,BAT5:M4*I-2<U'^"A.?MZV9P H"J
M    .  !8 "UA8#V'S4DD\>G    !0#KOW[K?7O>NO=>_P!]^?\ ?<>]]>Z]
M_OO]<_\ $^_=>Z]_OO\ ??Z_O7^#K73W%_FHO^6:?]"CW;K72<W>!_=+=_\
MCM[-D_\ GGF'YO\ T]^/ ?9UH<3TI_?NM]>]^Z]U[W[KW0=9M@<M5VM_FX0?
MJ2;1 ?D<&Z?[S_3WZF?RZ]7'Y],G%Q*>/P;!;\V N>&N+_[S?_#WKY^75OEY
M]<!8<"UK6U&W/ /TN+<G_"WO76^N7!N=9!OQ]6YM< $6/#?3_"_OW6O3KL?7
M@W( ']JZW]/I/ (L3Q_C]/>^O?*G73?1F)Y.D_D<$DW8 >GB]N?Q[]7KW @=
M=VMZOH?K9OI=N3I-Q>P'^N?>NO=>U:B3^;_4\\6X.D6-A?\ Q^O^L??NO<,#
MAU6I_-^B)_EP_*?QBG8_W%BC=C3,U1!Y<C!H*529"!8;!;C7$5%_S["VZG_=
ME!5<ZU_+M_U?Y.C;;Q^G."V-!\^.?]6/+HI?_"><(G\L+:4<-3'4Q+N;L:.5
M9JIGGDB.H3RS-YY1)$&].A*,@G^T?Q(7,NIMAVX4.8$SY<?]*?\ CPKZ>?07
MY:H-_OM5*B9R,5^SS'^QG/D:+?Y8/POVE\U?EO\ /#IS>^]^QNL^NZRLSN4W
MC0]3U6-VUD]URP]AUZ87"Y7<M?A<]!386GK*TU+TS4TRUC'Q-X;^12C;4U\K
MJ#Z/_AZ.MU(/,Y-,U3_ >LW\N;XF9;L#YJ_*?^7#_I][AV5\9\#E<]6;MQ>Q
M,RVW]U;JCV7EY<=AZ#%FLERFW=HR5"3N]?/34]7'D&]<J*Q]F=A$#M%[*X!E
M,A\OXES]G'[.'19N0"[K:J/A5!C[&_U?/H?OY;&QF^"_\\+?_P /.KMX[KK.
MHWI\C@*O%YR<Q4V;AR&"GR=#7U\=%-0XK*[BQY*I]W'1TQ55]*6 'M-RU;+-
MLN_M-1I8X$TFG#2P5:?D /GFO'I1S2YAW;8S$2JM*Q(]=2DFN3Q)K\L4I3H'
M^O\ H+$?([^>7\H.IZ[>.ZNML1NA^U%WUF^JIX<?NS-;2H9=B4E5M_";F:D+
MX9\S55*QS>2F=&2F(?4H4%)RF2+/>B!4ZY\>M5'G3_5Z=7YL_P!R=E!H!H@_
M+N/^;/2>ZG^'E7TA_-V[%_EU=*=]=K]<]/=C"IVCO/<6,R%)#O/-; S&-.4R
M&-:MHIZ3&0[NX\-/F!C@R&Q\6D6]WY:!.W;RLA#,D: &@&%( I\Z "O']O37
M,;B2^V:55TB1V8BM?B!)!/G4FO\ Q72EJNA,3_+"_G4=!]3]#[Z[ EV+ORNV
MMD-PT^ZZRDSN=W!A-ZON/&5N!W94TB;6I=Y+#F<<U2:FHITD<2:F+L3?W*\7
MUEINZKFDT_\ (#[/7_57IKFMM5YLK$ 'P;?AP^)AQXY_EZ^IB.Q*.A;_ (4^
M=?3/#CX:QMUT$UWHZ 5DJT6WI5IYZ:O4TLD\L:S-^UXZB:/61S]?=MEG2-MZ
M@7!*T ^T"O\ @'1EO-39;*36F?\ CQ^WJ5_.FH:"I_FR_ ZHK\9CYZH1=8M]
MSD*2KFE2>;L2%Z>=WFK8(EJ*@)$MRI $G,:Z6]IMHM]%]?'32OB'_C7VGIJY
MSM%O3(\5/^.CI"?SO-M3;E_G&?&+%X[)5FV=RYK:O5^)Q^[*&DH*BNV_79'*
MTM+_ !G"15U%44M5FJ*ZF&I>)XJ5U5]!=%LUL[>%S9( <%P#_O(/^0'U]?/I
MO=^[E="0"=!I_O1]/+/02_S.OA3M'^5_\L/BOVU\>NSNV\MO3M3?.6S.[=U]
MD;JQ^0W!E<W0[HVR<_0Y7=&+PF"?*X'+)6S,U'-2Q1Q2O%X]2JS*FOKAFYMM
MR>!CC_87_/R.?LZ60]O*<"F@I>D&E>(45I45XC[?\IG_ .<_W;V+\B_ES\2/
M@I!O?<77W5>]</U1FNQY-L9?)8O^/Y7M2@QU54"JKH'I%JZ3'T58S1LLDL(9
M;21N"8R>1;;#)S-:L4[0\H''RK\QGK4))0D@5X_X>B\?S#?AOMG^27V9\8N\
M?A?VGVIA3N?=AH-Y;:W'N? 1'<_\&JJ59*.IH=K[5V-@8,+5TDDA:6;%S/,T
MITS,[-<HCOI(]_NK4']%[8+Y8#.?E7S]?L/1?<]E6],_LKT93^=1V%EMQ?)3
MX(;P^2E3N_#_ ,O[?6V]AUW8\V R>4I]@/E-R4^'R>Y,9N!,*$;+-04M5,_V
MS2QU,L:72-O:RXL8HR"%R,>?V5X^?6[6[<BFNO[/2M/^+Z*1O#%?#7-?S&/A
ME-_)&HMQX^FQ&Z(,?W-G.K,7W/M[9E/1X_.3N)\OD.T*6AR5?0OAI \L\L\N
M'JD)-/-*RN MMD6,4*]I'S.#_/K<Y:1:XU5QP'#^70A_SE_D)5=U?S*<)\4^
MVMP=Z+\9NNL=@9MS=>_'O;DV[=V[\J=P0SUNX:^@VBV7H*?-VI*><>=X:VDT
M2 _;:0?89O2#?W H=.HX_(>ORZ,2M+"W\R4'^'Y>5>BD[1RF$^)WRYZ [&_E
MN=6_S%,%UI+N'!4'<NR^_NE<_MZGSAR.:>GKE;!;&VM3[8W!A_M)4D\[P4#4
MZ+H_<TEO8O)/[KF]0&^?GY^G15:*#+\.#3_B_P#5_/HZO\W?;<V__P"=%\3<
M5C,I/M/-[QH.H*6BW1145"<UM2KR>X<$M'D,6E?395<?EJ"6O:*#R4Z&.[>1
M;CV0\FKJW#<65@1XK' _X6?3AQZ67DA^ILXR**8CQ^1/'UZ"+^95\+]J?RK/
ME+\2N[?CCVGVUF]W]C;SHZS>6X^S-TTV4W!ELUC]TT^'S\U3GL)B,%2FBRM+
M60014/ATP^ V9@1[,.4+ES=;S;%OTA"IH1BK$U\O11Q].F=SAKH;SK_D'SZ,
M-_."=\[_ #AO@#524U-+69K;?6&;FAK%2N2*M_O+@YX&EIW1/30-6R_O:U6.
M.5[,-3#VURXNG>=U ;M,KX_VA\OD#^SAU3<S_P A]L L)(\G-,CS_*IZ<OYJ
MV\]Z_,G^:_U!_+XR>^MT[,Z*QM1M' Y?"8+-Y3")GI-W8F/<NY<[DJ@3T,V9
MKJFCK(*6CII/O:,)3V920+E5T?\ =DH& "O^ =&]H/\ =<[<:JQ_83U8U\:?
MY**_#/Y?[5[I^,GR3[+VKT9!05-!O7J[?&*I-U5O8&=G'DKZ/<-7AY]@[1QN
M*GA-UJ*C$9'(L;7<MR1*[ZH5#MW8)SZ^?^?H-@GQI&45X_M].CU_S294_P"&
M]OE>P8)KZMJF1)&\; -E,(%+K-I:(V(Y<+]?I[!V\4\8>I/^0=#'EH_K<MT_
MWZW^7K58_EE]]?SB.M/C)2;7^#GQ8V?VQTDN\=RU,&\,SAL)F:Q-Q"*@FR5)
M]KG.U]HU"*&=?W$IS&RM=;^Q39!19QD_%I]?Z(K_ ).@G<"D6[:<G]Z-\_Q'
M_57RZV'-F=6?(#Y[_ /L7K[^9=UC+T7V!NC^(Q97:?7<F$Q51'@=MPU.:P5?
M205&5[$Q:U-54T[>6]1H\;$>-20?87YU>2#9MKGB>DBF0UQ4,*'\_+[/GTNL
MRC[U?(R@J64'T(9:?ZCUKK?R.OY?7Q\^4/>?=F=WY+NK'UOQ:[$VWDNK:;9V
M3PN'QM?]YN'>4%5!N#'97;F<\U&$P4,QBIOMY?NI)I6D*R*BC5;^1N5%U,2S
M,*GU/A?9T6;V@EW*#_:T^P,?\G2<[I_EO?'*H_G28;X,+4[ZI>G.WLQ)N;=-
M>VX<#!O[^/;DAER^4I<1F8=J':L%"D[_ .3PU.%JYE2R^93S[)N47U6&_P#<
M1I5/GZ?9T(=\B_Q#E[MK4/C\V_9PZ%'^;CV#C>K.]/C9_+FQ^Z.Y<#\2.C^O
MMEQ;AP/7^/7>/9F^L1F:G<E37"LPN.@V/2[FR5+AXJFG\?VRTEI=11M);V@M
MZF_<5%=1_P"/5X])(5"Q@_A) _:0!7Y9S\OY%+2HV)\6?D!\?NY/Y6W7O\Q_
M:^.I,I15/:&&[ZZ0R>%H,Y2U%=%$OV=+UQ@UPV3Q\V.<".#)12:4-_*WU]GX
M4M<PJX&:_/IFX0J6K2H/E7JRK^:]V;V!\POYC'QN^"?]]=V==]0;EVIUE4;Q
MVO@:ZJQ4F0RG9V-R.[MQ09P2TDM7'D,=A,744CK-3S1PM,?*I0,/88G/^[$
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M]^_+K?78 /U8AK:FYX/J!!/U!X-_S[]U[_!UXBP)!/JY'YYN;,#?4#_3Z_\
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MWT%_I>UO\/Q[]3UX]6^P8ZPG2+WX-N#_ +'_ &/]?I_7WIOA;TIUK H*^?7
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M5+7+72T )I))&JU"C@E;D$>P7S'L5]<L'@*\:FK?(\/V]23RMO\ 96R$3!J
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M#QDZ"7*O]OD8K: 03<?@^PORU:/8Q;K;T&J21OLKH"_LQU>;?897M_"#B-$
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MP&X&S-/%34E$VXFQY3S8^:699;0P+>WU[,&J+4A:?Q DY^SB3]@Z1R1^)(J
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MLP5;7]G0\(21D$Z:FO' \NDLXC\-C4:]1P,B@/;3\O+R/2E_FF_RS_D+V?\
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M$C20#?GZ\@<WY]WK3SZJ17'7'0@'  )_ '!M8WN;W%[<CZ?[WKK?G7KK2.%
MY/ ( !XX/(OIL?>P2*4X];_/'7=U .FXL;W '-PPL#^3Q^?K_MO?O\/7A\N'
M7( 7XMZ5LIM>U[?DBUR/QQ[T<\1UJE/+KH$6]0%[7Y%KW(6P' Y 'X][^T]>
MZ[6X(^H/%[6Y'U/-CS<_ZWNK E2//K?Y=>7U&Y'UX( '(X)!/XU#\?0^_(I
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M:^E&_P #=![F;_<":OJ/^/)UI!FY L&-[WN?Z_G_  _WU_Z^YD3_ $+/XO\
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M,) $,L1E6["Q(-_>CAM->'6JBG7<;!T1S^VVMXVA>SU$4R!R8*A(3,$G9%U
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M9G-Z;CJZ45:8/'QU8:6GHI'5A3M6$7*J5UO:]_:K8-W6QVTW,I.A%7A6O T
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M"Q VXL;>TVT7\TUVFF.J$-J8'"D#@!@G/^JO1GN>V1Q6CU^,4H"N6!KDD8%
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M>DE9<=+DI8O5%XI&<=HC/$NK]4,*X-2*T!KPQ2GK^0KUM%E2&=67](QDBA%
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MHP.";>_:F!(TXI_EZ8(>0LR&J>7^7H0NT>Z>T-M_&/X0[YPF^:^DW/V=VO\
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M0;(Q=15]MP;".36@ZYVSUI_"Z:;)8G'Q8NE@KJNI50MJX!C=EO3R!KQZ\.)
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M?7NLIL(K ?0+P2;VT_D$V]-N1Q[MY=5''I3;1 !KK7;4R'7Q86OQ>VJ[7O\
MCZ>_#@?MZ\WQ#[.EK[]U[KWOW7NO>_=>Z__4W^/?NO=>]^Z]U5A_.+-_Y>OR
M%!^OBZH-N  3WUU\!S_6XY-['V;[$*W<./Q-_P =;H/\U8L)2#C2G_'DZTA
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MR82?^'+?C4+ _P#,X"/H>#T)VP;D7/Z=7TO]/9=S:*6P'E_LIT<<F_[E^?\
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MV]=;/J-KUW7.[=PX[%)%EH_XI1XFJIDSGV^'.TZJASM2*U8I/XC'42/*C:-
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MJ?RX_P"JAZ<KKN0VEJ+'0D@C-1CY\#D8_:.KV(O\U%_RS3_H4>V^GND[N_\
MX]/=UCS_ '?S=^!P?X1-P-/)XY_K[V> ^SK0XGI^MJ7@+<MJ _21?59F# DZ
MC?\ '^V]W!H>/35*CRZX$>D"F*@Z $U$A2$NOUTL2;'F]_H/]?WK-.[AU8TU
M=O'J4&#7M]+VO^#P#Q_4<^ZD4X]7!!X=!WFK')UI -]"CT@7;2B@@@<$"_\
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M[^GW)68N;X\9ZMS%-0PX2 KN5:W&0XPK.T>9<Q,7CU?0D@_[$5\J=)&UZ_\
M4>@H[7^'U'VEN+Y3YQNP*S##Y.]0[7ZER4$.V(G38]1MFGR6-I]W8P?QEOO9
M:F+.LIC2Y #MR ??J5J>EA/:H'I_DZ$?L/X\4W8D/QUBJ=X5.&3X^[SPVXJ>
M:EQLFK=\-+M^CQ(HZRFC:?[,.M'9V+LJWY;^NZ5'$=)7:E,5J>H.[?C#M??7
M?>_.Z=P[@R1A["^/U=\=LOM.BI(Z(X_:M=NG'[I;-X3.7R=,V3@GQ:J8:F@
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MZUU[_??[ZWO76^O>_=>Z]_OC_OO]?W[KQZ][WUZG7O?NO=/<7^:B_P"6:?\
M0H][ZKTG=WW_ +I;NU?3^[V;M^?3_")[V!/];_T]^/ =:'$]*4@7U'Z@$7_P
M][J:4Z]05U=-=S>UB006NVKEF!()^MN+>U>.-<](<DTICKP8J/U6N  /]@;@
M#DDZK'^G_$^(KY=;!H*UITBL]_Q<Z@W:Q9-0XL;+& /5<'D?ZP_I[1M_DZ7+
MYCIH)OS9B3^H?I!L.5_38Z;6_P!<7]U_P=6ZZL+E[?3CZ@7L;7  N;_XCCW[
MK?RZY:N38#D $!KGBW _UC8?7Z_X^_=>\Z==<$C\CZW#'CZ&PU#ZZC^+_P#$
M>_?+RZT.N0)X-A;FX4VYY#W.HW;U C_8<WX][X=:X]<%DC= R HCJLD:,075
M6N0KVL-:C@F_U]ZH.'EU85%*=>L+<#FQ(#?7TG^EM7_(K>]]>U-ZXZ[Y_4!]
M0?H+,/P?U+;Z_P#(O?JGUZ]4^O77'%[@V%[F]N0>?\22/Q_QKW6NN5_HY X/
MXY:XY]-^ ;#^MN/>OSZW\NO%>?S8\D&Q_K8W8>H_GZ^_4%>'6N'7K_ZP)#?\
M5&FS6-Q]?>^O==   @@"S6%[@_46^@O<\GW[->/6J#B%Z[(O<GZ '^R/H"#^
M#PUOZ^_5ZL2?XNN@+&_]K\-P2>>+\DZ2/]A_O'O7'K0HM:#)Z\"#_9%K_7AN
M;<_7^H_P^OO=3Z]>*BM:=>^I*6 -_KP+"U^.;W4^]4%<C/6P2 =)QUZW-[#4
M!]1R1;_6T@7L?Z?3WOKU?7KQMP;&YX4 <CB]P>1Q_@; ^_>?5: \1CKH"QM8
M>KF_+&]@+\&U[\\>_?X>K5-/EUR_)7Z78WYU'F]K_6W/U_U^/>O3K1 (R*]<
M[K>QMP 18 WO];<\\#WO&.M 4P.'6/Z7Y-K<6) (_KQ>]OH/K_Q375J<.O&Y
M!^IM8\_6Q'-R0-(_/^\>]YZ]UV#?^H%@!87XMSI)Y/-K\'WK[.M=>MI)%R?Q
M^I2?RO/T-^+ _P#&A[\:=>]#3KH\&P(M<_@@#@W)M8V^H_WGWK2/0=;SUXW]
M/I#&_P!&%C].">18$CG\GWN@_A'6CYYZR733PO!/X XN?]?^O^PO[WCK6>L8
MY-U_J#<_U_H.1?Z'W[K?78%[C^SR=)_U1^G'-CP>1?\ V'O77O\ #USU+P=-
M^/\ :;K>_P";ZAQ_O/O?6B.L?T L!R+@\^JP YM]+DW'O75NN_\ >/K8$$VL
M;J0MK'G_ &_U][ZU\NNK'Z<V_IQ].?5]+VN?\?>NM]>)-O5<@_U/T^A_Q"EO
MZ>_=:IUT3<\$#@<$J>#?BUO4./IS_L??OSZWURXN +@WXX!/Y)M>_P!;$?[#
MWX\.M==!@+?4WO<D6-Q^2+$6Y_I?W[KW7?UOP0>">1P/]I'U' _V/OQ ].O?
M+RZZ%S8 'ZFYM_B3S>Q /'-O?J#T'7L=> "GZ"_%C;D  \_4!0/]@/?J#TZ]
MU[Z&Y):UQP... 22/K_K>[5/"IIU[\NN_J 2;&Y'T )+?@CD D>Z_/SZ]QZZ
MO]+<W-^03S<#CGZ\\\_3WO\ P]>ZY?720&U*A NI&C46X)N/]4;?4D_U]ZZ]
M\B>O$@+>QL#I!NW '(OZPJZ;\<FY_P ??NM#[>N.FUB&;EB#ZB UB;DBX^EN
M?Z?F_OW6^EGM0@I6@<_N1W-A:X\MQQ;GG_7]V QUH\>E=[]UKKWOW7NO>_=>
MZ__6W^/?NO=>]^Z]U5C_ #A[-_+O^0Y//[G5)%KVM_IDZEXL2#^;V)]F_*U1
M>6H^3?\ '7Z#W,X'T5P/F/\ CR=:07XX^I!U7%](]0(#<$?X#\_[W.0^!?3/
M^'J![@5;SJ?\W42:S/\ 4C4 H(!(O<<V _Q]I93^H%(P1TR!VL5]<Y_U5ZY*
M"@L#8<<@F]KFXO\ 4"Y]Z*C-5'[.M@D :7/VU/74G(%VX%_Q]0;7'^\>_4%:
MD=65R@.ECPZC2311>EY AMP.2 MOQ86O_A[>4A3FG3NMBH/G]O722P%O3*GT
M'+$J;6''(%R;_P")-_;RW!4@K0D'IDAJ!M/4BP(#6!-@#8BUP/QS<W]ZAAFF
MFN)P*LS:CD>?I4\/EUX*.( ^?7#2"P47)*FP +:K&Q((!%@/?I7:)J2X/^KT
MZVM6/6&0+$TL>JTB*LC+]= ;A68WM:YX_I[9>X7.EN[_ %?+IU(9"*M'V?[/
M44:B+N6)96:.RA@_T*Z6#+?\_P!?:=&U/W4K^72@A5P&H/V=8&ED2Q;T$J64
M&_(4A3<,5L;GZ?7WLS*K4\^MLB, :#]O72M)(59@P6_)N/TW^H6YYMS8@7]U
M<%J.$[>JJ$&I58]9'9D ">KCDN"EB/Q8,]K>W5(*DJ 0./[.K@ !B:\.N@SM
MR5.H?6S@B_ N#Z3_ +Q[:9X?#5$+"7\OVU/#IMM7B%Q3PR>!KC_8ZYW]+%B"
MWTT^HM<$@?@J/I>]_P _[#VXL@B0)..ZGG_L?LZT8F+%_%.C^7^Q_J^?6$33
MJQ938#5JT:E:Q_5^X)1?\B]N?=PV4E:(&//R!Z=J0C)&Y%:9^SKI"S$-I*"Y
MU?2Y^OJ-B0W_ !O^OM/AG/A1@+^7^QU32:'4U7^S_9ZXSO(JG1&TE_38*."Q
MXXO?3_C:UOZ>W'_45( ._./+_-U=%:FG_-TV5$M?#RT8C%N1:(W'%K\MSQQ_
MA[9CDD@-(G(/I_+[.O J#0@5^SK!]_=5!+*ZCU *H4GC2;%3P03Q_7W4,?$9
MV'Q<>M:2"65J5ZP&>ID/#\&Y!]*<<\\6^OOVLDE*]O3OD6ZQD3L"?40+DG4M
MOZ"_U/ORI0, !3JA96I7RZ]][.@*D@KI(;^U>RV_!O<'WZX_QBW-NX/@X_(C
MT].KPTAG\=*>+0_G7C7UZG4&=EQM71Y.AK*G$Y;&&)\5DL:\L%5054;:DK(Y
M48.6!'J ()OQ?W;7''LUSM\=?$T$+\ZFOV#IHJ[;O;WSD>%K&KY4'S.1]G1P
ML!_,E^<>U*"AQ6(^2/838ZAA2EI(ZW<^^)4AID8R!*>FI-VXRABCN;*/#=5X
M^GL)S[&)D$@MD$OGVKGYU/0FM.9-PM9#$96>W!-#J( 'I0>G1=^U>ZNS^\<_
M)NSM[?V>[ SLK2NE3GJBHJHJ0R.[LU,M14UDZ.00NIY&-AP?:W;MND@*>*BJ
M@\A3_)^723<-UENB_AR/1N(U&AJ:\"<YZ#!:Z,6&I507 L+$?4?T%R3_ %Y]
MGI>)HWB,:E#^WHA^DB+B:E)?.@'\_P#/UTM:!>S*W^P8@'BX%R;C5[;MM-J1
MX(%>G)K:"X!\1>O?=$_J^EQR%_I^1Q]0?>Y%$C^(PJW6UMXE70,+UT:I1^EK
M?T)O]/H+ V][U(0 (P!U5;2%:T)(/EY?LZXF;403SP0/3^"?Z_7D^]IV5Q7[
M>G'BB9:! !3KE'+$'593Z'.EM0+71AI8$ 7-P3[>LI$MI$>2N/\ *"/\O22X
MMI98V1",_P"$9^S)Z,=U;\NODAT;0RXGI[NO?FR\',-(P&,W'N/'4$**PET.
MF$S&)ED42)= LOI!(M8GV1;CMXO[Z\D>%6A9ZJ2 3P' '(J>CNRW2\VNTLOI
MI6#K'1U!(J:^H]/E_DZ479_SB^6O=VW5VGV?WIO//[<O*T^(;*YR>FJC.8_(
MDS9K<.98QF./00I4D'CV56VS30RDI H4GB H_P '1K=\R274*AY&64 _B;S^
M9/R'V]%362.(D011Q@BQ"H%%@!] >5)/UM:_L5V^F!8Z*I<<:\.@O.@O68W-
M6'KQ.?F:]1J@J[*Q^I!N1^/2H(L/\1_K>ZOI\2/2M!4X_GT_"H2&1 3BG5G/
M\F(EOYEGQJ-[LW^E\WL/U?Z!>UR#]"0;_4<7]DG.5?IAZ_X<I_+H1<F9O,<*
M_P"1^M^_W%/4R=>]^Z]U[W[KW28V8!_=#:1L2?[M8'F_T_W%4_)_V_\ O/O=
M<<<=5\QC_5GI3^]=6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDQO0 ;0W8WY&V<__ %Y_W%U'
M]#;^S_K^]UQ3K7G_ *OETI_>NM]1GCL6DB*AK6( %K ^H@C\@<?[#^OMU6K1
M7&.F66E70YZ@_I L+<$6X)%_Z6 -QJY_UO\ ;J.)Z3<*=(O,,QR=> ?J--B?
MS<C\V%@ /:(^?V=+Q3S]>FD\76ZG5_:-_H1:Y-_\/KS_ ,5KU;RZY6'-K\\\
MCZ"YMZ=+7_Q'OW7NN?X^GT^E[$ W'U-CQ?\ V'NW6NL=_I<V%_H=/U #%M('
M  /UXXY]UKUOKC^-7J ' M^;#Z BQ_M'_8?7WOK?^'KL*   =-@@XX%[\:@+
MVL/\/]Y]^ZUUV?TER;*%-P0+"X/(U7MR?Q]?]Y]^^?7J>771T?0@_7@#\>H7
MN0>>&^GX]V*D<1TYX;<:CKC<DA@ 2!<\<7YM^>!_K<W]T-!Q/6M)ID]<@ $"
MZK<\L#^ ES_4"W]#_MO?O+JGGUZYNH^I-R""+?4@GGZ_0V_''^/OW6^N[-;Z
M:K &WU-C_0B]R2+'_>O=BI'6NN)/('U/U'Y]/'^Q_P!B/Z>ZD@=;^SKP'IO8
MW)/T XM;\#_;C^A^OO=.M1GQ> I]O78_M?0D%>21?U7!(/YY'//OW7G_ $_B
M_EUT&)Y/T_V)^O (%OZ'_6]^..(Z])^E75QZ[L US]1?BQU?4\,.3:Q-O^*>
M_+W4T]>C/B_#UU<7'''/^!(U"PL;6Y/U][IZ]6*D5SUV?2!Z3I]6H<:C8<_3
M_7XL?=?LZ;+@&G75Q>W'-_Z#C3] 1];V_(M[W3IPJ1QZ]J/!"_X WM:XOZOH
M ..#[]QZ:9PII0]=H#S].3Q:UK6!X^@!)^O''YM[UU?SZX>0$VL?U7X"A0?H
MWX8BU[_GG\>_$BO6Z'KF>>+$?@?U-_K8G@7%_P#'_8>W'B=*ENJ@@TH>O7L;
M<'@6%@/JOJ!O8B]K?[ZWMAI%3CU<*6ZZ#+?_ &%QR6-N?J#I;_D=O\/=@P''
MJH!(QURX-P >!_4\V*W 93?\#BWX]ZU#KQQGKCJ'TL;@"X/ZK\$D_3Z#_7X'
M]/=_GTXT;*,D== @?[$<VY4$?I)*BQ%_]?Z<^_"O2=Y%3C7KG=M+27  ^MSQ
M>Q)Y_P!5^/\ '_8>_=.8&.NAR#J/ L>;%;?0_1;$FW^'^']/>NO$]=D 7!Y4
M<"U])XU$$?BS7YMQ]/?O\'7N(Z\IM_6YN2+ D"Y]7X' _P ?]X]^Z]UT=(/X
M'^QM_B"0;_T_/Y][Z]Z^G7B?1>W XX^MA_4WLNJ_%^?]O[]PSU[SIUV39K@%
M;#B]]-V)%R3Q;_6_'O76^O&P]/!^ILQ%@+_0<VL; >]]:ZZN+\?UU<D@_2_.
MH<@?[#WZOGU[RZ[O<_Z_/X%A^?QR&)O_ +W^??NMXZXOZ$#.!;ZVL23>Y(')
MO<_U//X]^../6N/V]<@>+!;7XYMRWUL".6O;C_'_ !]^'=PZWPX]>-[*3]3Z
M;CFPMR+\:M(_H?>NM=<0>206M<G@<*1<?7Z'Z?ZWO?7J_+KL_B]UX'%UM<"]
M^/K<#_"UO>O+KWKUWZC_ $N-7^Q8$ D?7Z$_G_7^OOWRZ]@=<0-7!L;L 2?P
M"1?2+ @7/)O[]UOKR^IN39@0?IR>!^H,.  +_P!!;_8^_?X>M=<KFYL+<>HV
M-N2&O:]@+_[Q_3WOUIU[R%>E7M+@UHO]& M]#<,2>+#Z:O\ ?<>]C@?MZTW$
M?9TM??NM=>]^Z]U[W[KW7__7W^/?NO=>]^Z]U5M_.&_[=X_(<@W_ 'NK#R+V
MOW)U22/U7M8W^OU/LWY7_P!SK7R^+_CK]!WF;&WS^M1_QY.M'Y;WG(O:ZAA?
MBY5KGC@C^O\ Q3W.*_V8_P!7GU!,^HR28]/\'Y_/J.1?@WMP?K87MJO]/S?_
M )'[;T FIK7I/Y4X4ZZM<"W/UN;\K?\ K_4F_NC@ ];&: G_ %?9UB<#\G_>
M+7M;GZ_T(]U^T=: ]#GK@T$,D333:HQ !))5FQIZ/3J8?=TY&JJBEC0JH X8
M'VM01B%6903\Q\^E$7<H7SZ6NZNL=][%P.S-T;RV=/MW!=HT4^X-@9:IJ5EA
MW'A*(B"JJ<?37)I56<AB#^ 1[21R0O<>$*$9'\J_YNGI8)HX#( 0<>7Y5'\^
MD3PB&PY%_I:Y/^W]MS7/@,0C%?L/3L,'B#N%13C3J(4!!)56N";FXYLQ-[&]
M[?T]NP74#9F4,2?/IJ:UE3$8(H/+H8^MNCMV=J[5[<WGM>KP$.%Z6VKC]Z;U
MILD?]R$^&FKX,=+_  HMR46HJX[C^I]E>Z7\<,B>$ H) P:?R_+I7MMF\R,9
M 32N?S%#7RX]!I@-M9?>>=Q^W=N8Q<QN#./24^"Q6*#,U1)(Q9W=1<DB)?:Z
MWNH'M-;(NNG'I!<V\T=WH#-HKP_+IHK*6:CK:^@K*,T-=CJZLQM?12AEDI:R
M@JIJ2>)U/(*O#>WX!]ET%TLNLL>#FG2VZMGB,:KYH*_S_P!7^H=8XUN)&D3_
M "6&FEGE$9M.3$-44<7(+>1^#_4'VOBECIQJ>DW@2]V#3H1.LNI^R.Y]V4VR
M.I]CYO?^ZI\7'E:W%XB&&&DP&.$7FJ*C*UU05IJ)(XV6\DC*%Y]M[A<QV]H\
MZ@:E8?SKT_#;22R+&*EF'#_5\NGCM?X^=V=$PX*O[6Z^K-K8K<-554^$RD>1
MIL]AZFLH[A(8L_BYJC'S3"1;&+7]>/::ROX9@"5'[>GGMQ'56'=]G^3H'-9N
M1R"Q9OK=C_L?J0+_ .P]J9Y(F (IU4I4T5?]7^QUS*7!]5N+$W_!'^-K@$>W
MIYT6%(AA!PZT;=EH*8ZXV=5XLW M];V/];\$6_(^OM/:SQHRLI!8>73(AF1N
MV(D=8G378NS 6 L#:P M]?=RZ)-J<T!ZJXT,NM6QZ=1S1PE@X#,"W"L[.IMQ
M]&_!O[J\D6OM(ITV\K4&B)B?V=8SCXI95NJ1 E%9R="1+;U,Y)MI '^\>]J\
M;'B.MPO*[A&B(6GGT^[+V/N3L#=&!VAU[MC.;QW=GJO^'8_:6%HFJ\O5U$KL
M*>OC0*Q7&E(F)<\ <D^VWN(HQP /S/2T6<LZX8@?+H9NU_B5\C.FMM3;M[/Z
MLR.U]J4V6BPM;GJ/*8S<-)CZV8J/%E_X)458Q,T1_5'/H<'ZCVE6]1ZZ6J.M
MIM8C/<QUT^>*>M>BX"CCB4W?6+7!X ;Z_G\7]K(I(WH">JO$Z_NXC_1KCPS\
MAZCY]#(G1&[ST%6_(Y?[OC9&/[%PW6D>)J<F5W+79_+XG,9B.I7'K>&3%+2X
MF0AG(/I/MFXN88G\),N02/L! _R_X>E,=A<2)S(M32WF14-,@&N/M/G^76+O
M3H7=G0&[=N[,W]7;;K,KN+9NV-\0S[3E:KIJ3&;UQZ97!8^K1P%BR45*X$P%
MU!-@;^VK:[1XR6%6#$>8X?ZL=:W"#Z.=+?@?"5OGFO\ FZ4G6_P\^27;VQXN
MQ]@=25^8V)-F*O Q;@;<&!Q22Y&B94J9'BR]93K]A3EU\S17:/4+VO[:EOHH
MW5&;N;@/7IV&SEF0LBX!H33H/NU^@^TNC,]'M3MW864V+GJBCAR%)!7/#5T5
M;0S^J+(8S*4C2T&1I*A#Z&B=K?GW:"ZAFH M3QK_ +'5Y["6&/6P[:@?F>@J
M:DC4:1I#?6_TN0#_ %/T]OF>)>..DZVTK5"Y/I3K$8 !<.MQRP%P+#5_O=OI
M[L)E;(ZT8&7!.>E1@-C[DW0V83;F(FS(VSM_([OW)]NC,<?MO"T,^4RE6U@=
M)BHJ9R+\>[RO%$I)8%_3JZVLC4]?]7'H2LWT9G<)\>-E_)0UF-_N;OGL#<G6
MV/QD]5 ,M39[;+HF0F>"-C*M'&91^H#V4&[T3.6EHO\ +]O#HR%IKA15BS_J
M/#C3H#6B75, \4VB0HD\+^2*0:$LR-^>6(/LU@FAN(U8./\ 53HJN8);>1HR
MII2O[:]8[&X !)O]1^3Q;Z_CVZ:@T'3 IY\.LFMUL"0+\CGZ?[#Z?3WX$I4
MTZJ55LD5ZX79;G2IY_PO]+7]T"Z0 .MJB@^?4224^0!A]!P ;\7/(M_3VT[$
M.M,'JZCL<>75H/\ )<-_YEWQK#W//;X0#^G^@3M?GT@7%E]DW-U3:@^?^RG0
MDY,'^."O#_8?K?R]Q7U,/7O?NO=>]^Z]TF=I?\>IM*W_ #H,+^/^K1#_ +;W
MX<#]G7CY=*;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF-X:?[I;N_/^_>S9;C\_PB;_7O
MQ;WL\!UH<3]O2G]ZZWU[W[KW7!T612CBZL+$?U'^O]1_L/?NM$5Z#G/ '+U_
MTU?[C/Z7' YM];?C^MO]A[]UOSZ9O3S>UR /Z6( _H=-A:WX_/NOY=7IZ==@
M!@;DDCCGG@D"P(#&]R?H.?P/>Z=:X=>]-^>+\#CZ_3FPN"#<?XGGWH]>/7N;
M"PXXXYM]22&OP3_L>?\ ;^_=>Z\ 0/H& U<W)L MQ8BXL5/TL+_CWX=>KUR'
M(N"?K<@<6#6!^FHCZ?T/OW7NN)!MS86^OUM:Y!!L1>UP/]?W[KPZZ-B>;$@"
M]@%O;ZGZV-Q_R/W['6_EUW8@ D>D "]P> ?IQ86 'U/!_P!B/?O3UZUUVH0G
M3>^HV /U_'U7@ BW^^^@WU[Y]=:2K%1_:#+Z2&!/-P.0>!Q]/>O/KP((KUW]
M3>]A86'T/H('&D"_]>??CU[RZ\AM_K@VY8J 1:]K6L+G_6/OW7CGKOZ'C5QZ
M1P+@A@;?T (/' 'O?7NN*W' N!R"+>H FQ%[JQ]0^E_H/]A[UPZ]QSUXB]N3
MQ]=)!/UXL1I-P?ZW]^X];IUYA>Y_)) %OJP_2/R38'_8_P"\GW6NN^+BU_P>
M#>YN-1T@-<V(N+_[W[]U[KNUKV6P%P"/K]2--V/+7%^!Q;\>]_EU[Y=<!]"+
M\WO8:OP+A2 +:N/\>?Q[]GKW7?YM:Y%U4+<_0?T-R.3?C_8>_>G7L9].L]S<
M6)-Q<FW'^IO:UA^>/>_LZKUA%P""H)YOJ-OR;"_!_/\ 4?X^Z]6]*=>! !%A
M?A22. &!-CQ8#_6]^Z]Y@=>_%M((%E4@ GU?4%K@'2O(^G/O?7OEY]='5?U
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M=S'V67F;Q,!2^%1R+6 M[=%F1[>LNH%@:G!H0<"@\OVTKTWMABDCGU14;30
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M3R65PI*H+V]VF6ZNF@,H5=)[J9J " *_Y<=49+.PCG,6MF8#34\"2"<8Q2H
MST5/XE]LX'HSY)=7]O;PARU9M'8V3;)[T.W:./)Y&/$5E-+!3M'2Z8Y)9H&D
MU>*%E?38>S2)9EMVB0"NG%?]7^3HCU12W2/*3QS^S[0.'SZ,MA^[?C3#B_D?
MT5N3L#M#<O1_>VY\5VQM#L>BZP;"[BZ\[-H*O,U#++L?^+22;HPQQ.82&N9J
MB'7&JV"LI)1S6!C*R##TJ16HJ>/^P>CV.9"E #0?/-!P^7G\^@I[Y[EZ>7I#
MK?XQ?'O+[KW#L/:&9S/8V\.Q-Y85MJ5NZ=U9&A6A%'B]GO/5MC]L4&@20$SR
M%I21?D69A$VO2P%.D$]WX1U(/VYSFOY9_P!CJ1\;^^>I<'UKVK\;_D+B=YR=
M&]M5>$WQ1;\V!0#*[UV9O_$XYZ/%YA<-(R+E<# &9:FF!C9H[*'4\^SB:%X;
M7ZNW%9UH &/:=7$'&*4P>FK3</&ND@NJ" @U*CNJ.%,\#Y_ETHL+VC\.>C:#
MK$=1[9SWR)WU0=I[=WWO'N;LW:M3L:ECVOL[-4V7EV#LK84^2R=%B$W'2TC4
MU;-5O5I,LC651Q[0_4W[C]3PU!7@!P)XU/G\N'1DUOLC-K)FK4'B/+_.3G_B
M^C58OY>?$3$=J_(3L[-=_P#RIW(/DILW?NSZ;:^;ZZRDN-ZCAW=3S+2)+@Y-
MQ3XO>^,Q1E$%%+30XP)"JFQL/9/=6-S<+F%/$5P10FC#SS2H/I6OSZ/-OW:Q
MLC17DT:2#6AIBG"H 'J!T13Y&]S]>]D=/_$CKG8LVZ<K6]$["W?MC>U9FL*V
M#2NQ^0S=+4XJJQBFI>:7(5,%$L@IED]!?1<VO[,VLED"AB< >?0>^L8F2B@5
M).?G7T\L]&DS7S;Z'W;W;VY1Y['[[J/CQ\@/C[L'JC>=;380T6_=IYG8N)PD
M.*W+3X25_/D:*AR.*:].TGKB8@,+W]L1;8% =A^J/G7/R-!Y8X>?Y]./?,ID
M$1'A5] ,<<BI\\\?+Y] ULWN/XP_&K=G2FYOCZ>R>Y=[[7WE45W8._<_@_\
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M%#]02>/?AM_J.W_5QSU;ZZI%#W?ZN';PZDS;VR9YIXD/]FPIV//]3<VO^?\
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M_/IH'UO>W(_!_ _IQ8<_ZW/'/OW6R/V]1SI\=A<7!%[_ $LP_H;C]7U)X/\
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MNU]AM7S_ -ZH\*VX),:,-G7IFPZ,$-7%N 8MMM3RJ7 %-'6M5$7(B(!(L;<
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M_;GZW&D'ZW;\D&U[_0FXX'OVL#RZKX;$_%U[[<FWTM>_#$<VO^ 20/I_O/\
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MZ=)/!-!7RK_JX_GT:4LW U+]"?K>_P!?2"".0#<V%_\ 8\#8N5H"1_J_U?\
M%=>\#-//_5\_]7SZQ!0(343W;ZG^T38@V((NIN1];V'O45RDK:4%#^?^;I88
MVTU/#HE?RU^;?6'Q0ZLK]^[DS=(]14:\/M*EHU->-V;E9CIP>%4%_P"\&E6(
M)XPV(-SD\B!P#*"T>X)U?#_/_"*5]3D^2CJIM^!7C_J_U>G6DU\HOG9VO\FN
MQY]^]AYNJR$U+_%*':.WZ3,#^[FQ<80;X;9-S?G^" G*<#,CV!.;ON^[_N=N
M[>-Z>4?JG_+R/3_5YY$\L\U[-L,RCPN-?.3T;^@W\7[.@9VAVF:C)4\-:O\
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M_NN\+G<C#F*+.L9&HMM98X\+24[ I%5<*..4H-)36O \?\G6QW  5K7_ #=
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M%[<D_P!/I[U3@?(]:'' J*_ZO]7Y]1"UCS] /TC]&D@#_$#_ &QO[]04\O\
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M.'#('^#(/[?/H\EI-W:JFA^WC3_)_DZ<ILSE-T)/!M":?'8BIU4G]Z:BC/\
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M/LZ?:,6!AN;'@\ 6(!-_HU]0_P /^-*+%/!@,Y^+_9(]?\G1?S&PJ+:H /\
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M#Y5<:V:H*+=&:P=/7215=3#*M47CEITD6)1J^@]Z>^C3#-W$&GY"O3MOMLC
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MRHZUW3N+:V7R5!D:2'51Z:FMQ\<,JQE'!N%>4L"=3FO17)W @EJ#R!I7[?\
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M*O=G\U;.R[5IWR&9[+W8*'.MM^FCR&2Q\?Q6V@D;8"IKZ!LI)21UM3-#'X'
M+E@;W(]^ ]3TA<$4 &*#HM?6^]^L_C^?B;W=\FL3/@.H$^*M1L';>^]P[.S>
MZ-M;&WXF>K)ZO Y7;^/PF>R.#S.<IY%9)10R"8'\#40T !*20,GCU8!O"1?]
M$ _/RZM ZNS.P]R?'G<N;ZMV)F^O-E9S$[WR^V,)E]M5V!-;1Y3&5C5&[:#
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M@XD6%OX6>L\)OWZ6(!_O%VE6WMQ[RL]BY%#@D#_5]1_J_EUCY[LP,8&QG/\
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M-_1;Z _C^@M[@$\=/V]%(P">EK,PU@'U'D@  Z3:VG^I)!_-AS^/SM>!ZTW
M=:7G_"@'*S[H^:>#V[?_ "#9'06Q,.>0/]RN<WCOO>XMQ]1_&:(GD_ZY]S%[
M8VRK;SRC\;U/Y!T]?Z/0CL$'8A'E_G/5(V.VW4<?LCZ?XD&Y'(])'U^GN58B
M5E) _P!5.EL\0)H6S3[?3H<^G=K[?@W+0R[[QFXZ_:/\7QM%NZEVJ/\ ?S5V
M, %\-A!:^W[#_<9_6_\ O(>YSG:(%0?]79\O\O08VU/%/ 5_XOHY'R#^4&[>
MS*?!;87[;;FPMG@_W&V!@*NVW,#]<)_&0>?X_N$&_LCY8Y8CWAFDD6K4R?\
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MXY_K86TV4W/'^M[K]@ZMUR)#6!&FPN5L3S]2;W-S<_G_ 'OZ^ZT.NP2!S?\
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M69T5>%4D@#Z6]L5/Y=/!JGRKU'U>@HHY8Q^1BP,LIB:\;32G5+.UK*2S$M&
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M]?)M[$U=9D<?BJ):R::#%4R5U?)+)]LL9F;3Y"VA+,9\^J\/LZ6WTN>0!?U
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MODD+202.-,/"I>U_>F6&,8 /Y=66>X<DLQ KPU5_P]899JA]--_$<G404M=
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M*5\P?\'IU=;*%8XVUY8&N":$''#C7_B^A SO\O;$5FZ^C.O.M>Y<SNG>_=N
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M-^G_ '/;BX_XN?YXO[ -]=R7S%B<T_S?(>G1];E+, ?/U^W[?7JT3:-/28O
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M16[4[!VMWGF.SL;MJ?86YMRXO?.'R4.,5*.FW'3QR1[<JZ":FDD76PUZBHL
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MZ7^U -OT@< W_3_O)'^'L&> T3$@?X/\_4E27VA14_X?\Q_V.FO(9V;S04\
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M.D CJ]PKJWX(5U/''-E-^/I?Z>UJW0-,FG15=[01G3D'Y>O4(W_/TOP?]A^
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M[)V+L75_&L$57/LNW,V1;*WM?G\^SNVYE?9U5APK08%1ZU[6/$TQ7R\N#H=
M0K+6OS/^;S_U9ZHG[9_X3Z[XV'ESE.M>^MP_P_&5F,^SQ._]A83<)89G+VPC
M'.;?W'M)OP;C^$_[;V+[;W'DJIU?ZL_\+Z1MM\9:A4 G_5ZUZ+(/Y)_RKI:@
M0S]R]9_;?=@?=C#[PL;$J 1_=SC@?U]B*#G^1AE_]6?^%]4&VVX)JOV?ZJ]"
M=M#^19N&KJ1-V3\CLU44%_\ +,7L'KA=NY(F_P#SO,_N#=A7Z?\ .H_/^P]D
MUUSU*ZG4]?\ -C_A?6E@CC(T+0_ZO\_5L'QM_E3="?']#OW:_4^.&8VU1',U
M?:7:M5_>/)83&8,!,UF1F\__ +]G &Y/.*_@]OZ<>PA=<W2LQH?\'R_H?ZL=
M*DF"XX>N.B4_*;Y<UVX\5G]D[$'\%V%E!]C5U551WW)OG&"QOF_J-A[>)X&+
M_P"+S_SL_P#G7^Y&Y>Y1 <22?\5\7H_1_;IHR*5_XO\ U>F.JB,]#/EZ\S3D
MV^[Y/^N-(X LU_\ B/<Q6;KM,:J!_A^?V^O1;?R'4>[ _P!C_53I-U-".#<6
M(O8@"YYN0;W%P?;NW=N2?/\ S]1UO-VS CSH/3Y?(=";U!U+E>Q=Q8C%8J@^
MXK\EE\7A\12U-9;[[(_CZ%3;U?Q/\\4/LMWK?#:&G^K\/]$]$EE8_558?ZN/
MS'\L?MZ-YO3K7+="U67VMFZ+;G\0_NYC*RLJL5E\QN,'^.9G.W(MMO:9%CA*
M&W]/K[ FT\SM?D*W^KXOZ(].I:V?:=-&!\_G_2_I'UZ 0Y&IE]/F-C]/]B 2
M.+\<?[[CV-/IUF76O'_5\^ENY0F,T\O2GV=8#63RU-/!87-_ZB]@1^KZD^U5
MK.#&37 _V>HLW"\)JJC/_%?+_#UL(_RH-N3C<N[LU"/^>8V=4\?I_@.S?[\!
MA92>!VE?Z$_\1"7/=P/%;T_V(_ET>[&Y95J<_P"RW6QT"=-[VU>KZL "2+V
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M?07'^M[U^76QYU.>L)XOQJTL0=(%@"2/H+%F/T_I[KU;KHFS?YK4#J-R;?J
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MU[KWOW7NO>_=>Z__T]_CW[KW7O?NO=56?SD;C^79\@_J5,W4_P"H #_F>O5
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M_N^,_P!)OV53_9Z+7,; 7_(LP-KVLUSR1Q<?UXO[/>)H,CH.&@H375_J_/\
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MI!OQ^?I?\V'! ^I.D6^G]/?OLZK]O'_5Y?\ %=0[$A02>001_K_XBVK5^/\
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M 6('/X]^H*_EUH<#GI@-E N01R "#Q?\V!-M)'/YM]?=>G.N[L#]"+$6+68
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M>>>;\CGD?CW+_P"!>H*DJ78]-]^.;_7Z<\_BW'UN!_L?]C[,2<YZ3Q#N%/\
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M'^\>]>'%D^&N/D/\W7@*$J%S\_\ 5_EZCGU<GZZOJ;'CFY(O];_U_/MQ0J@
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M6_I]#_7GW8<1UK_/U-D8ZR6  93J^NH'2"PM_9MJN1S[>ICCUI#VX_U?SZE
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M.O>G78-@;DK]./4+WL=1('-[&WT_XIOB.O>=.NN!Z23I&G\AFYL0>" #IO\
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M.5*C2"6X]7((/Z^?Z<G^GL^V^W&UII!HU*5_,_,^M.H(OKB?=-^:[O\ -O\
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ME_&N,D_R5O\ 5Z=;$/\ +CR-\+E_MB3B-S;CWWN?$CZ:ML;V[+S^=P>8_M
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M-_;? @>?3(R*UP/Y<?\ 8^VOKU)_ /U(/! XY(^OU%@;#_B?Q[L,&AX?ZO\
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MJ9\B0 38\,W)-P2!Z?\ 'Z>QGLT]ALW,MMN$#UMXM0&&SJA(."&/%CY']G0
MYU@OMZY/N[29>]M-<KY3QMY:1Y#SZ$W8G1\8J*"#-8K);BW=58C^,4FR<55X
M7^*?PHDG^-9HY\?[@=OW-^3_ ,1[[8<J^[RWW)UI;Q>6O^<[GSA'IU\^?.?M
M0]CSG>3R$@'1_*!!Y3'U].A=J>L\GM?Y _$'*ULV%JMP566[APW]W\!1G^&8
M('IS.YU?X+G% W+GOZ?Q3\V_XMN/]Q!S+<"?GF(^E?\ M'7Y#K)'VZVIMN]H
M/<\D_P#1N_[3I>.3Z];#/QOZOJ-LT']XLI0?;U^3(^T6KOR+@O:Y!/TY^O\
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M_=&]7T.9@&T<I16V_5;0Q>YMQTOV=VW:,WFM^8+^#9RPL-O'^Y'^YJPOF/\
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M7V<G_5GY=-R0EJ \/^*_P]"5U+UQN?N;LW8?5>TXE&Y>PMQ8S;6)^\.97%T
MS9&K,FX_ /\ L+\GWZ]W (I9C11DDTQ\^'1_MUCKH *D\*?:<<?7_4>MV?8V
MQ?C+_+9^-U15%XMJ;+VC203[TWY68YCG=\;B9M"UN35;/4Y2ND81I&++ A:D
M8,J$>X7GO[F[<4/Z0QY<?V"OEU,\%O# H>"%3]NKC^WY]%*V#_.3ZESW8.&V
MEV%TWVYU+M+<>2AQFQNSMVX2DAV]NAZN510S154] ,@D-3K!N:A[ W/X]OVV
MWM+0USC_ %<.O3[O/;8,$97/\7E_MO\ !T,7\Q3X-;&^8'3^4W!MO&T</=NT
MMJ5V6ZTW=148&4SGW,4<R;+SI\A_CNWMSZBE](&,XD4!6%S?;;V2WO)+9S\#
M4.*YTFA!X4\OM_/H@W3:8I]NAO$ !=:T!.!J H16M?.M<#\J:3$WF@F'GMQ;
MC@ @_@EO21?_ &-_<DV[:X_]7SK_ *O\/4/7UMX4I /;_P 53S_U?+'7J00R
M3X^3*-DAC(ZZ&/)BF>$5T.-8KKGP!*_;K5!.;U*N@(Y%O:O^'UKUNG;4 4IT
M?/;W0_PXW)T5OWOX=H?+;&X38NZ=O;-R^%?;74U9N>HK<Y<HV,KVQRX^3".\
M;!69=94?U]D$]_<([JJQZPY&20*>7SKZ]"&&.-HHE)-- J?\V.@;W5TKL0?'
MRJ^0&QMP[_K*&?O:;K/$8#<FT<4N3>AI=NKE/XCEGVG0+3"2;_-LX4 O^?=C
MN(H 6P?LZT=L,A-!Y>5?E]G^#J')T=LK%?'7K/Y ;NW#OK'TN\>[=R]<9W9N
M/V_1MGJ#"8+$4V4J<CM)MP49HHWRZU%PU0C1D1,!ZOHAN][%L8UU?$"?+RZN
MFTM%C.3\Q3B/3_5Z=#YV5\*-IT7R:ZL^.?1>_P#?>Z]S;RVO@M]9C=/:.%VI
M1[6P6S\SAZC,-/&N#IH)U;9>"AGFJ1,60RJI7@<[M]T\;5K"C/\ F _,]._N
MVM*&O[?+CC_57^73=M'XO?%WM[?VXNC^A?D5VIF.Z<-BLR=@5F_]D;/H^L.V
M-P[3IZS(Y^#!93%4T69Q<E2:1DI?N&O*=(XO;VM:66*%KAT&A?3CGU_R]67;
M"C:QY?;_ )NB:===4]@]K=B83JO8VWT;LC=>5R6 Q.T:B=(ZBCS6,;(2YYWJ
M9B88H9*FAG&E^ M[BPM[M!?HR%G/:!4_ET5WEJ_BHJ"KLU!QR36G1CLG_+W^
M75!3S9.39NPY,3C:RMPVXLWA.WMHY?;77]?A07JZ#>^4IW;';'FGTGQK4JA!
M-K>V)]VC6H2H('F*?/'KT;;7M32Z ZYKGCCR\O\ )QZ"+='QJ[ZVAVAMOJ',
M=?3#LS>_\ KMH87965I=SX#<U#F,:^0V]FMM9FE,N!SNVH,49#5US!X05+ @
M&WNZ;F)$5QY@<13CZBG3,NW>%)*M>#$<3Y'[?]6>E#NKX>=Y[-7;E5G\=UO7
M;?W)ONGZZEW/M3M';N\=L[;WAE&\$FV-[9W U+4'7_W(+:)I]"B52M](-K#<
M@P'_ !7RZK^[Z5J/Y'T_U4XYZ%;O'X!]H]:]Q;*ZGZ[R^'[9R^^=I;7W!MV<
M;PV;2[BIEKMH8O,YZ/=6,H(J:#;^+VRU2T$5;($%91Q)*;ZM7M*-TUU+"A%1
MP^9SGU'\^K/M^EL&O#.?, _R../^;H/\=\5-_;+[#Z-B[+Q.W:_J[L_L7'[0
MH.P^L.S,9OK:.8KXJ^*+-;7&;PDLL.V\U&LA22GUK*Q(X%Q[\-RU5*_#\^FS
MMH7!4ZOSK_D/2\^17P+[EZUWU\@<CL7:>VI^INI<Q6Y-MMX?LG$YSL+9.P)Z
MI/X-EMR;$2>3+MCH:=B\]77+*E-'=^+#W9-R4N%K7%>&/]6>'6Q8,#3(S3-?
M]1Z#'8WPG^2G9FUMO;MVALS;DF%W?C<GD]B8#<?8FV]M;^W+0X<LE=E-B[:J
M##E]S4N5$;/$:);-8@"X/MX[D!I4^9]/\/6Q9'BOEQX_\5G^?2BVYT'LNI^&
M'9W=6?P69I.TME?(S8?5&-HER^7P]#1T>7H\S/N'!9*A2=",E+/C%3R-^IS[
MT-S(E":A323\^('V4]?M'6CMX\-FSQ_+S_G@4_/Y=#!MO^7OOSLS>GR0PN0P
M.V/CAE>C^KTWAC^N,CW5C-P2SU[M33!LEE]UR5%=0X')TTWW+9!66"%SX!^!
M[+5WJ,A&J:,?2OGZ4J!T;_NEZNNBCJN<GR^=2#\@*XZ++U[\.?D1VEMNBW-M
MO!=>0;<SVYY=J[9R.YNU]N[#JNQ-PX%))]QX[JYMQU$=3O#Q*T;+)CQ]M4NV
MA%U?5<-R12@:N3Y"O^#_ (KK0VPG4=)) ]#_ #IT%6UNG>U-Y]K0]+8/:\I[
M9DRM5M<[-W/5Q8LID8!))6X^HIZU0T$\T$?[8CLDCVTCD>SZWN@+"1@*D.?]
M7SZ([^S$-^B,: H.ID'Q][@GZJ['[FCV742=:]1[F?9?8.Y'R4$TFVMP,\S1
M;3CQ4,:S9(&2F+,X(^WF(#?J]AB7=%%P(BV3FG'@!7^9&.C4;8S6_C!2$'^$
MUI\\@']G2[I/AM\B,EF)-M5.U-M[=_XQYANUX\GO/?&U=F[=Q&Q]R4\4U%6[
MQW-7FEAQ&3R"R)XH)6,IC(M[-FNU%L9*^8^WHC@MM5Z(P/(G_-_JSTTY'XF_
M(#'=K[/Z8J-@T^2[ [-H:7/;(@VOF<'N39>\<7#0!DWG@-ST4<F$K\3B8D,<
MU4EV0H26N#9,+Y3GRZ-38#2:D\?G_A/35VM\:^W>D\#MG<_8."VM/LS>9K,+
M@-S=?;ZPW:.V\EG:*4K4XJMW)AYITQ>5I9%.NEG-XV%K"WO2WZN*K7C3A3S_
M ,'7FV\Y!XTJ./\ EI_@Z @BQTVM8Z"3^+<6(^EQ;VO/SX]$7F:#SZQD6+#@
MGD'^HM_B3;G^ONO5P",=8W' /]>+6'^(X'(!_P!Y][%,^O3B4TCB1U$M^?\
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MU7D<0,=Z;$#^-WTWX ^G^Q]X\@WMM'I$*B2E*UQ^P,1Y]9EKS_;S.#Y<?/\
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MX\Q/!05F0R %6,QELKE:S^)Y'.9*X_C>8S>:SWJ.X@"!;\_T^ON>.5K-48
M!1^S@_SZ43#2C,/]7#]O0$5<,,( $((^MB3]";&_]H@ _P!/^*>Y-D32@I^?
M48;Y?.I85/V</X?ETS5R^.\_TXMR;W&HD@'FX!_V/M=M3";/E_Q?V=0QOM\\
MG;4\/EZJ?3Y>G4KKW;M1N;=5!000_<7K5LM'1VNNHD?2YY_WFWNN[ Q4*C_5
MV_ZO^+Z#<&W"\)!)K_ES\QZ5ZMM^/D.*B[TR6UJ^DJ:>O%9C-@;<JJND*XS=
M8V1_'L[G?X(?4/[P[5[#S><Q8X_Y0/>*O.5VQNEHV/\ 8C^765_+MBMO;&BU
MI^7F_J?GU?\ 8BBAI<90000FGIZ:E+_:,2+7-M04$GU 6'^W]AZ5JVU:\?\
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MY]01./U>&?\ 8'4<<@GFWTOR ;#G@6L1I/U]I+"B"C#_ %9ZO#5K=F#&F/\
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M3;3'(P5G _U#YCH0VUSNNFMHYT?[3Y_Q?GTCL%\8-^5E=X,G3BEI_N[6!)Y
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M*X_WW:Q_[[7]OVUY!_>+^[UN.RS$V\55'S0<1;#SN6_B/22\,^6K((8+U!_
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M>Z<IZ5;Y_P##^K">E/CWUS\?\,F(V+C2U;+&%S><RM\AN'+1JS!4 +, NM^
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M^&%M(^OU8&S7TW8V' _K[]UO[>L8:Y/A)4#F_IMJ'Z5('%Q8BXX_/O1DA0
M4K]O37@3R?$U1]@_R?\ %=<E%K D!C90238VO_A]?]\?Q[HRQR#A_AZO26,T
M_P W72J#S_:MZCS86' X-BMC_L?Z>TJ0-M1JQX?+_9;UZVU\$[?]7^#KW[BD
M@<'6+/?4!R;:KDF_TO[,$IN"U)[?S_V/3K6)QGC_ )OV=-F;I(:[;^Y**7$R
M[HCJ]O9JAJMJ8]XJ?(9ZAK:"MIZG!054D\=/3SY.&ML9)GBT)I-P.?9/<QO&
M\@48->GXJ!5ZJ*Z'W1NO#]V=8]-=7OWUN'K_ &GD]S2=F]?_ "/ZMI*2FZAV
MM74U0M5ENO.\ZRBHL%DQ@"=%+08B-WF4 %WN?9K!4*H/\(_;UJPTD3YSJ:F#
MQKCAQ%?]GHOW4':=)D_A%/\ %;'=6]M9SM+LCMKMAME-1]?)6;#D2;Y1;RFH
M>P3O\TZ[+II]OTF*F8P5<XK?+0 W4%1[=N^#"F/]GI'=%?JW&KN#8&?):5]#
M_L]+CNWJ^MZU^0/9&;[>WW\\NO\ !=B[;ZWHMC;A^'68>MP?8E=B-O+B\GM/
M>U'C=C;QK,<V)KRT1FK?MJ$I,Y2Z$DI(*F,G43G_ %?YNC"8T=1I [1Q'^KC
MQZ$K9^T*;X;;O^-G<>X.JN[ZKIO:'QX["ZEJ\KD"W<?<O6V^]Y]BTN\H*K=U
M)L:@I)9J'/8)JE16TE' E'YEAD M8O\ SZ35U8\Z_EP_/H1MU397M'LWX";^
MVQT?O+KO;P^378V[\[0YO;E+B*RFQ53UWF8\!V)N3 X:GIO[H1[OE]6FM5)?
M*;/J8W+T)"F35YK3K8H3QQZ] AF-D]AU7P@_F$8&79O8E9F-R?,#N/<^T\&F
M%RU;F\UA<GV5BJX9G#4$M/(]5234$1D,L32C1<W_ #[5^(@=& & :^O6L @5
MQIZ%JB[!QWQ?[P^0&6[1ZA[1W-1_(O;G2>0ZQS'7G7NX=]1;EI]M;#DPC=?Y
MTXBCJDVC109JK0&&O(I74R-,"@]L.5,=%X9'\^/V_P"?JR&I%3FH_P G04?)
M2IWA7;[CVONRF^6_QXV%N#HC;>)Z>V3\4<!3XM<MO?(;;R9R/6_<F_,'MG<E
M"])19*H6*EBDDAQ]''4$&1'+^TIK0>G7G/=7_5]G3+TKD<E@\Y_*PSU=L+N2
MCPVQ*/O?I[>YS/7VY),CM+=FX=I9W"X>'==,E!'/1X:2ORL1;*L!0RV=HV/T
M]^S4=+;2H5PE-5!T]]1[:R=1\(>T,;7;>W+M;M'XT_(KO7OJ"LW3L[.;<I_N
M-L]S[^WQ_%]KY'/TM%25N%W!U#N*KIUK(V,>NH!-R![6_4#2IXD+3I/>_&U&
M(_U'HZOP/I,QN/J&K[\W?B&P^\?DONW)]P;OQ<LYJY,;A)/)1;7H()=8$F,A
MHG4J4*!KVO[3N0U!3'2&'47XY_U4ZJ+[IJ^Q-Q87<R]@93YW3]W]=]W;8WYN
MCI#K#;'V/Q9P_5^TN[MNY1=R8O;.*V7+CMW9.?8[BH>AI,E'DJV625M%HV9J
M1KFG2Z4 TTTI3S_S_P#%]'HQ/;F,^.79'R5PG8G2G:O8E#\GMV2]I=1S[3V#
MDMT[4[*V5G-M108;KO=N6?&Z=D9? F66DGIMP2)3+),[0C0I9G1BF,TZ9H//
MA3H6*C>53L3YT])U.;V/V)MO#]A?$>IV+MC%X[:F:W#MS9.\*G==!G!LC<VY
M=L0U&T<'44^/I]::W$":5"G^E674 1QKU[MTE2< ]%CPFQ-_[/\ BCNCLRGZ
MVWE4]A=$?,+L[N? ;(I\0U/NS=^Q*C(8ZBWOC-N0,AJ*T;IV-)D:5#1!M<SI
M(>4/MOQ?#'ITC<@/GUKUGW?A^WNK/C-T5N7/4W:&Q*;MKLO>_<'RUWATMM-L
MSWAU?F>S8HL]2TNQ:1L;E\IMBL&8KJBEF>CAJ)J:"--*LI*>_:-8+?G\^C>W
MQ')D5TX!X8XX\^('0&[-P.XJ7I'^9]LK;N+^6>\\QV%M#:V].NMS_(/;VXL]
MVMVWM2BVGE\4[05Z[>P-/G:FEDKU%/B:>F3*1QAEE5AIM44'3,N0O"G0[?)E
M7[.S7QI^32[G^9&Q>CMN]=[YVUN#=_0])E=@=V[/W7DLECZ6.3+;)SVT]Q[R
MR6,W2M!+3RPQ4B%(J**S&Y!WQ]>DA.AA0"GKZ=)K']/+M+I[;W>VR=I?*KLW
M:6WOF7L/Y"=DK\ALOC-X]Q[XV7M1)4J]_879]-M[;&5HEH*>4Z<//1R9&=W7
M]5K^_</LZ=#5 K3AT:3HWLJD[U^8^[.X=J=>]I;=Z\KNB]EXJ/>._.M\OL=\
MWDX=U;IDEHJ_&9R"#-BHH8PL!%2 P5 5 30/:23[,=;-1D'_ %?ZCTT[D[ H
M_BS\G_D5N?M#J??^Z<#WQ@-IR; WIUGLC,]A4^[:>@I*G&U76NX*?'4E95X.
MCQ!J+-)5K#1Z:@D$V/M3 ";<D<-1Z;_T4$'-!_AZ]N#-9?X]]LXCY'YKH_?N
M"Z<W_P!08':&X=K];8"FWWO7IS=NW:U7VO35>T]G-5Y#*X/*8FMDJ9C2Q$0N
M0LP5U]IQI\4&G:>EM6\.FH:AY_ZO/TZ+ULSM?NS:6]ODIOGKFK^;?;?66X.C
MZG+=*8SY&BLK:.H[>W1GX=O4IV7A9MNX/,[7P>(J\_'$T,Z%XJ6-BMP+A9)0
M1 CB3TB-3(5Q@?ZOV]3(/BQ\M_C!MSXM]C4O=^([FPGQ^W1C*&;IW;7QYP^T
M-TXG8W8\*4>[/O=]8_=N2RVZ:K;1FDGJ'DI&DGG/D(#$^TH%-/?7_5Z].DZA
MA:?/.>EO\@I/C32]K[GR>[^A_DUUAWUE**NQ/7W:/1V"WA4Y#?./W!2B'![@
MS>X-KC([(P-?553K$[YFCBJ::^MW"KP[%_:I@UJ.J^7' \O]7^7H4=H'M3L/
M>7PEZD[LK:$=C;&ZNE[R^0%-7Q1RY9=P-2T>V]C9E9X4$6+W'_',;E9);"0$
MS?07]VN?B'\(Z\*5:G0<?)*F^/4?=6X\GV%T1\D.M/D+F/O-L;![FZ&Q&[<C
MD=^X^MQ4\>+K*W.[+7)[.VY435JQK)69K'M5A6_SB+<^_6U0P'F3_AZL.!SC
MY_ZO+H3NWL#W+N'^6OG,=V+BMP[C[NRW7_4\6;QOD@R&],C+3;[V#E*U<@:)
M7HY=QKB0YR9A70*BG=E//%VP6'#/5?.O0X_*C=>/V1\0NPZS*XC=>6-?U--@
M,?B]E;(W%O;/557E]MRT-'C*G"[<@K<H)H93XY7C%XFY')YKY =:'Q9Z+)U\
M*?M/#_RY,G1[%W?4[2QW6U?M'?--O?9>9VS18FGPW6%#MK/4.X\)N2&GR4$,
MY#T],98[U15K^NY!5=K)]7&57MTC[//I]"NEJL.)Z#WKOJKM78/S5ZSZ'SF(
MW;D^GM@=%]]R=8]XI15-3A:'KWLK)X!J78^6R3K+34FX]@HM0F/$SB22"1%T
MVB'M;:\!KSC_ #]7H2K8STQ0;[S.QOCU3_#GLO;WS'Z<[QVE3[C79N[_ (IX
M.IICOR@HLA7Y/;4NV^VL/M_<NT\+09A:A!6TLZQ2,Q)>Q]KY@M!I./\  ?\
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M,'B)MIQ2A))J1TJJPE; \^_&2=BC$C3J'RI3_"?EPZ\+:+2XH:Z33SK7U!.
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M26GE2.*DIY% "O=KA5>7DEL*QYT\:CU\@?7YBM/3I/8VT5R2D@ U?"03@^I
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MGO;[@S<_;K&\8QGT_@@_X7'P\/\ U>=LGQTZJJ-K8X;BS5"!D,D0*34;:06
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MW?E-OTN,RNY)Q)6YZKPN+J)Z:&#)K*B>+%P.78JI-YG=AQ<^V;B569NT\?\
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ME4NXAD*)@<.XYI\\T-/E3Y],.(^2-;AOE=4?*2@VLL%55=D;FWE6["_C,_\
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MOWT;$*"YH#^9^1QGYTIUOZM0'&,BGR'V=W^&O18OBUWE#\<NY<=VK+M9M[4
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M_)Q4YY'^('NP\A\QU6F3_J].G!RAD<  *"+G_7 4D&Y&D*/\>![= H!7KV7
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MVX(ZBA4[BB=Z>6I9?NHE/DC(87]JT&:'CUL0Q:Z'\O7CQ^SJKNEV7W=%U_\
MRF]O1]Z4F3["S^2@RF"[-RO6&S:$[+P%?T#42X[#8S:&.I$V[N#-;*Q)EIZ>
MOKTDERBJIJBS 'VFH/WD!7/AC_#TBNU"3C0N*5^TU/1ELE\K.VOCWTY\I?\
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M4U!60;AVY54]76?9XBKI-H=\ UV4:R_J_P!'0!N!]?I_O7M0???G[#?ZW?\
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M7O?NO=55_P Y<'_ANGY#$&_JZF%AZ2 .\^J!_06Y^OTO;@>S?EL'ZJT].[_
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MS8-(::I>:6HR&6S%1F5J0570RKI!X[6IJ&H5&:DU^61C[,="$M$VNJL 6\J
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M4Y7AVH/EY0^@'[.FAR;O8#'QC3TI'FGG\1 SG[,>AZ4O8VW?C;B,[X(^QQN
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M]?I[>44M"/\ 5\75Y2IN #CC^7;_ (>C*[E-OA[T4.0/]F:^4MRU])!ZU^'
M^H4C^U]"/K[#NR #<I*?PK_UDZ$6\'_$(<CXF]?5,=%I\HXLOUM>Y4DZ?P2#
M>Y_U_P#;>SRO&OGT&]1J#2I ^W_5C_5ZMYO]1;D@@FW N0 0.2MQ_O'NU*TK
M7_5_E_U<>KF@7%-/^#_8_P!GRZYZ5(*$ @ZBR:08V!!!1P0-2L/:0#A4YZ=5
MP !4#&?V#_57I55?8_8>0P&&VA7]A[YK=H;<KDK\'M>NW#D&P&V*N$@P9#;M
M+'ZH*N%A=50@+[0MM\+LTAIJ;-?7I:NY21JBK\*X\O\ 4.I.\.V>V]_X>+$=
M@]K]D;_VWBJRGJ\=B-U;GR.1%'44]OLJO&T-[>6EL+7#,OT/N@VR)2Q4#)S_
M +/3IW27&I3PZ[K.W>V,AF]O;DR/;'861SNV*+[#:>;;=&2ILQMK',Z.<?B:
MH6.-I-:*7B-U9EO^/=OW?$!0Z:?ZO]1ZJ-PE8@!3CA_J_P '4?.=G=H;DW/C
MMV;E[*WKN+>>+T28S<^6W+5UV;Q2T<BU-*E#FI6$=(ZSHH 2S<>]C;X5 5:!
M?3K?[PD-6*DMYGY_ZATT#=^\/'N 1[QW.)-VBK@WP\^79GWE29*85E72[AJ%
M?R9B U<0.EK\B_MZWLXHY8W+"@Z:DW"4HU$;7U'FW+NJJI-NXBHW1GY,5MF5
M*O:E+)F9A2[.J(9$J(SM98G#X77(JEC9;DWYM[5/;Q-C4.E$.X, &(H?/_)T
MZ;P[9[2[!HZ3'=B]I=B;YI,/6"HQ>.WCN?([AH*$K;1_"K$K$ZV%BPN/:'P5
M@+>%& 2:X'$^IZ;N=QE8=E2>'E0=)S.;IW9GJZ',YO=&X\QN&GIZ2EILYE,C
M+ELE18BAC6'#X[%UZMY<>F+HHDBB2X,2H%XM[I^[(C60LM3G\SG]M>/2W]XN
M40&M=(KGT&?\'3YN_MOMO?..QN*WSVQV#OC&T+0I08W>.YJ_.8_"I2*'UX^&
M-F2!JBG3Q@DDAO\ 'W4;=#'K\-1DUZ8?<)6/PDT'^K\^LV<[@[AW+MH;)S_;
M78^;V)3BF-+L_+;RJZ[;\,=,%J\?1PXNH>QAH5D$.EB0-%OP1[3?NY#?Q2!1
M\&3\ZXS]G2J#</\ $)P[4<28!(!X?M_U?+IMVAV?V-L'[FHZ^[%WQL,Y6JBR
MV2AVMN.?"1"OI?VJ8Q4](2LACU!K,+?T]G&YVD$D&E)%8YP#7RZ0[=>LDP9E
M(4\?+S\Z]/\ C.PJ3=_8V+WI\B\AV5W134531U&Z6DW2M/N[<=)B'1\=B:'-
M9EOX?3XYW0"H3]4T5P@)]H+2PA6$H651C^72G<MUG()C!8CTH>)^T?Y.E1\G
M.^*WY,]W;W[BEQK;>ASM5C:+;FV*N=9GP>R<!AX,+M3$S5CM]M45>$Q%+' 5
M0DDK_7V56]H]O=JPB.FHR :<>E,NYM/:OJ8ZJ&@)J>&!\_D.@TPO979&V]N9
MC9VV.Q=\;?VGNJ%J+<VT\%G3B-KY:GD],KY"@X65W7ZL!?\ Q]B/<'CEAC(0
M,ZC&*D5.:?:./RZ*]OF=)^ZJ@GSQ6@/^#KO&]M]MXO9LO7V)[;[,QG7<@=/[
MH4&\<I18617)+K/C QDF@E:]U%@WLD.WHSB0J-0_P'_5GHP_>#@%*X/V=,U/
MV#ON+:;['AWQNN#8AKUKY]E1YFOAVI/ED99HMP0X!0&&7B9%*S\$,H-_>OW=
M&6U$"M.-.M_O)PH7CFM*CCPK^SITW-W'V[O_  E/M/?G:O8V]MJXW0F'VSO'
M=>2R&VH/"AB6HJ*!;ZY(5_S(.H+;VJCV^%8V:JAB?S/2.2_D\5:*::>(I^RO
M_%],S[][!?([>S%3O[=%;G-BT=/A=H9N3<E5_&<)CZ%:@4E+B<G(RFDQ,4.4
MF1(D/ 6Q^@]L+;^$W8AI]G2PW)D6CG-//T_U?Y.H*[OW93Q;CHX-U9^&CW='
M'2;YIX*^44N[C%(U31UN8AA+MDYZ>=V/D-V!]KI(ENK?P'&D!@<^H'1?&76=
MI$:CE2*_;_+[.E!0]S]U46T1L#']P=E4VPDIY<;#L--V92GVA]C/<2POCF8,
M*=[W9&(0CVC7:HXSJ[2U*=4GFN2:+(:#S Z1E1N+<E=MVCV95;@S57LFDFJ)
ML?LZJR4AVYA*^&XR&1P%)<MCZG/.VII+#4+D$^WO!"&@'3UO/= 5>:@IZ?+H
M0J+Y"?(;"XW"8+%]\]OT&&PD=&</A,?OK*+A-KC"@?PW'XR(DO-1%0%8<CW4
M6$3LS, &/1A!>.* G&/M.?\ !U$Q?>?>.!QF9P6'[H[1H\)FJG)U.>V]C-Z9
M+&8;/UFX7DES-=E/4#5254DC,^G3J_I[K^[8 RM12PX?+[.E$]\64@,:8X4_
M9TQ["[9[5ZF3(X_K#MSL78-/DFAJJX;3W)7X>ARD]"99*>+(1@D2.7J7URV!
MD)O?VS)80R2:F )%/VCI$+^= %"D#[/7I(5U=5Y*IK*[+9&?+9?(5<^2RN2K
M:VIKZJMKZYS/42S5M62]3(TC$\7"^U"6R(!1NO&ZEDH'!I\^F]2 Q]2@G_$7
M_LFYN2!]/]C]?:H*JY#=4E;4  *FO7(LNDV(OIX]0)L>;G_6]VJ.%>F #_#U
M$D9"K+K75Z> PU$ W'T;4.!<^ZU4FE>_^?3R*^H$H='5J'\DK_MY[\:; 6MW
M!^5^G^@/MDZB?S<?[[\^RGFVHMT/G0_X4_U#HZY3S=C!!Q_@?_5_Q?7T&_<6
M=2UU[W[KW7O?NO=)G:%_[I;2M]/[O835Q]5_A,'UOR/5;WX<#UH\1]O2F]^Z
MWU[W[KW7O?NO=0*N@I\@D]/6PQ5-'54QIJFEF0,KJ2QL3SP0Y!M;\'WOR(ZU
MZ'HD65^ WQOK6\V!V=GM@GT_L;"WQO';N-!L!?\ @*;E_NRP^O\ R[!]?8%W
MCD&QOS1<CY5_H^9D^71I9\Q7D"UI0_.GS^0/0/[P_E]=;XK'U$N,[7[OQQJ8
MTHOLZ.KZX7'E .+I_HZ&D_2YOJ]ENV^T5JSE0V:<,_,5_MA_J/2^;GZ[MU&H
M YXT '_'#U6)U'M7)Q=4=5Q0;BQ^JFZYV*:4U7776['C9F"4W VZ"!8'^GY]
MC./[L>VRM\7G_3_[:NHO/OGNA/\ 9_S3_MGZ$0[>W #9MPX_TLMK]8]07]!X
M^FVS?_#C_;^U@^ZEM!H'DH?L?_MKZVOOEO#"JQ8KZI_VS]<AMS-B]]QX_AOJ
M.KNH1]0+?7;? !/^(]^_X$GE_P I?^,R?]MG2G_7VW;_ 'W@?-/^V?KH;<W&
M ?\ ?TXX@UFK4>K^MR?43_V;IYLH/TY/OW_ D\O\/&'[)/\ MLZT/??=J5\+
M/VK_ -L_7?\ =O- M;<6.'UY'6'3WZ;<$_[]LW-R3?\ VWU]['W2N7_]_&G^
MED_[;.DW^OCNY(_3%?M3_MGZZ7;>9N!/N'&VYM_QB[J"P)(-M1VU_7_&UOI[
M]_P)6PG'B^7\,G^#ZSKW^OENU"1&/VI_VS_X>L_]W\UP?[QX\V/%NK^GA:UE
MYMMHD$K_ (?GVS_P(O+7^_C7_2R_]MG3H][=X_WUC[4_[9^NO[OY^:4 [A@J
M"3_EI;J[J _0"P%]M\V!_P!;WO\ X$7EF@)N>/\ 1E_[;.J_Z]V] D>#_-/^
MM'6$;8W#_N[<&/.FUO\ C%O4 %P;FP.VC];G\\ _X>W/^!+Y?/&;/V2?]MG5
M#[Y;N<^%_-/^V?J0=NYB'_@/N'&K:D-O^,8=/_DW!_X]NY(L3_L?>_\ @2^7
M_P#?^?\ 2R?]MG7A[X[J!_9T_-/^V?J+_=;<'XS^&N /^:6]/DG].JX_NV2.
M3P?I;W7_ ($KE\_Z-_QF7_MLZ\??'=L_I#&.*?\ ;/U)&W=P0D34^X,>%%B;
M=8]/\<7%K;:'Z>?K[V/NE\OUIXV?]+)_VV=>_P!?'=N/A_S3_MGZP#;^X9@L
M-3N''$7.JW5_4%C87%[[<N"&Y''^\^Z?\")RUC_&#3_2R_\ ;9U<^^&\4_LA
MZ\4_ZT==2[7S,T/@GW!AZH?7_*^K^G[7Y(;_ (]FWU^O-_?C]T7ES'^,$C_2
MR_\ ;9UX>^&\5S'_ ,:3_K1T1JCQO97P\=L!/B]R]B_&<562K-N;JV5U=L_>
MF]NFAF\T<[F\-F<)G=O?WCSVP"Q.3.4Q0_W#_0_3V$-Q]@(YBJR_#D_MIZ7
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M&D6L+< _\C]^S3/5B17C_P 5_F^7^7KU[M8:?\> 0?S;EB+<_P"W]^KP-?\
M5_J^WK0H: #'^Q_@_9Z=1I[D6 /U(L2?J21SS>]A;FWU]^8CRZJ@U#)/G_JQ
MY?ZOGU@/^-E(L.2/ZBU[$@CT_P!+7_UC[]GB.'6R<-JX\!_J_P!7I\NO <_B
MPX' 4 W56!U:SP#>]_>QZ#]G3Y)%*_ZOE_JICKT3$_[ < GGZG2./J;\?C_8
M>]<&SQZT*G X?MP/3J-,#_@+V'^  X(]7IXO_C[3];P5'K\O]7^KY]8+6Y
MN2#>Q+<$V!)_)'O?6B*$4&3_ *ORZZ'!M:][7(Y(/ U<_P!FZ^]=>_HZ<TX_
ML_U>?7A_G6L?[1X!(-PPO?B]C]??LTZVH!(_AZPRG4;V)_/T.H\7_%[\?2_O
MQZT/(4SUAN?&.#P1_M/_ !L"WXM[]U8GN^=.O"]C?_6O];'@ @ 'Z$?[X>_=
M5!P*#AUA(^MP>1_K<<^D CZ-]/Z>_=>R>HL0^M_KJ/))L %!+'@D@_CZ^_>H
MZ5FI!].I YM_C;_ @#CZV-@+?T]^\OGU7CQ_U?X>L$HL0/QJ4\W /!YL3Q;G
MG^GOQXUZL : 5Z[Y-[\<VL?K]+&W!Y)/^PM[UY=>H2W^K_5_@KU'O?G\_P"M
MP/H>!S_3\?7W[CUOUJ,==3:5_P!N+<@&UK6Y:UP!_L?>R.'7N!ZB?2QN/Z_4
MF_%[C^G^\^V?\/3_ )]<>;V!_P!B /K<7X'%_P#B#[\/3K>>/78N;?3Z@'C_
M &-KG\$^_?X>M=8 /]< FQ^I' ;ZGBXM[KUOK">:FP&KE;BU@;GD7^@&D<6_
M/NK ?4C[?\G2E6/@$4_U>?5K7\DVW_#G/Q@M^8^XS]2>?] 7;5R"?S8?UO\
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MS3O5 ?J./]%/^@.O?U:VTZJQFOVM_P!!]<S_ "AOBYR/X'CKG\?P:0,3:_\
MST%N/]]^/>_ZU[S_ ,I/_&4_Z ZO_5G;#3]$_P"]-_T'UV/Y0WQ<_P"=)C3]
M"#_!9?4.#Q;/\CCWK^MF\_\ *3_QE/\ H#K?]6-L\X#_ +T__0?7'_AH7XOB
MQ_@5,3R;_P ):ZGD_G<''/\ 2_\ Q/MT<Y;U_O\ _P",Q_\ 0'7OZL[:!_9'
M]K_]!]>'\H7XP!6_W!TY(_2O\);GG\6SX!_V)'O7]<][_P!_?\9C_P"@.O?U
M8VS_ 'UY^K_]!]<O^&B_B_R1AZ,C26##$FQ^MP+[@YL?Z\<^V_ZU;QG_ !C/
M^E3_ * Z]_5G;J#](U^U_P#H/K@?Y0OQ@+6_@=* 6X8X>XXN3;_?P%K&W]/I
M[W_6S>,_XP/]Y3_H#KW]6=LQ^D:?Z9O^@^O?\-#?%^Q)PM&I/&DX@AC<+>UM
MP6LM[?6_^OQ[U_6S>?\ E)_XRG_0'7OZL;9P$1_WIO\ H/KE_P -#?%\<'%T
MGU6P_A+@_P"O<YW^I]Z_K3NY_P!'Q_I4_P"@.M_U:VT?Z$:_:W_0?7O^&A/B
M[86P>/?_ %L-)_MQ?< '/MP\X[X*_K?\9C_Z ZU_5G:\#PO^-/\ ]!]<5_E"
M_& CG!T_/U#8D^G\?V=P'BW^N?>_ZY[WP\?'^EC_ .@.MGEC;!_H6?M?_H/I
MO3^4G\956"JI<-3N #<OB2A_5IO;^/DDW'X]ZNN<I=R72E!]E#Z'S1?3IRSV
M>XVV0/LTQC_(-ZC\;'U;]OR'02;F_D8?"C>DGWE9L4X;(+4J6RVTILKMS(7%
M[#5A=P(?[)YYL/Z>P/>)NMU(3'=A?]JGR]>I;V7W)YPV*-4N)O$4?T81YMZ1
M-QU#]G5?.<_E4?%+8'S9V!\>>V<SVIF>K_D/UWD:_I:IJ^Q=XH(NR>L8FD[1
MZVS7\#W!%<;IZ\S=!E,/]!:@KA>X )7O%QOPO8Q+,?#:M*B/R"UK3/\ J^WJ
M8#[@;ES9R9><PQ;0%FMRNLF530-+H4J-"@_ *XI0,<$9MHZ\_E)_"CK2JQ>2
MV9UAB*2HPM?C,O1U>0I/[QY1,G@9SE<,W\6S99FL0>./\3[/);2XGME69ZM3
MT7A6O4%[OSUNF_[:UL]]X;+QHB'BRM_OL?PCUX_+-G^&Q5/@<?\ PR@^M/8*
MRDD"Y  9;V8@M]+?D^U(A4#4//\ U>O07NKV6=B"*$?9\N&!U/5)A#K*_<$"
MX'Z.0V@ ,#_9'^N!_O5L8!./V])8HFDI4]/?MOI3U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF-Y>K:.[ .2-OYD6N>?]QDS?U']?
MI^?]C[L.*]:'%O\ 5Y=.$MO*P']%O]!8Z1>_.IK*!S;_ (GVZ,CY]:4&BYQ_
M@_U&G^#KG #YX3R1I8ZK"W(;G2%&GG\FY)_/NA^&O3$?Q#IT]M]*>@\SMSEI
MOR D-Q8BP\8TV-OZDW_%O>\5 ZUY'[>D^2.0O-R1>Y-A;Z7M<EN?\/\ >?=.
MK]<PI *DVT\_TTD:1<7XYOR?]?\ V/O+KV./70N#P"U^+_4L;\?GZCZ_4\>_
M=>X<>BI=Y?,3J/HJ9<9G\I4[CW6>?[K8"D_B62H5;25_C( TX)/\;VX]C3EG
MV_NMR<".GAGSP/)C4=^?MJ/\O00WSG2WLA4@ZA]N.'] ^O#HK6/_ )I>Q)*B
M^:ZKW53X_P#-52[BP]?DK'ZVTW:XN;?G_B!_=>REX\99)JO\P /Y35Z#]A[I
M6X.4Q3YGU_X5T?GJ3N+KWN?"?Q_8NX:;,04M6QK:3[48^OP1;ZKF,-8$@#^M
MO\/<5[WLC6GQ*!]AJ/P_/R^SH8;)O8O*T-?\/XOZ-/+U_P W0L7)NQO];BQ%
MRUN2U_P/K_4^R&RHA(_U>?1_>$LM:?ZL=<KV)-[CD V'T-Q;D\7L"/\ 'Z>_
M<.O?(]=&X _ 8BQLUR%_5^+>D\\&W^\>]>77NO$<L3;D_J '%_Q8?ZUN 3[]
MU[AUR1'E81Q*SR&P5(P79A8VLJZF)L@M87X]^X=>'RZXCTL%8696OR;D,!<\
M?2YM_B1;GW[TZ\1UT;D_GBPO:X"@@!KA@1<?Z_\ O/OPJ>'7OEUV/R!?^C-^
MH7:][#^IN;?GWL=>/\^LX+-?TE38K<W%^/I9O^)N1[WZ]5_/'6-5=]*(K.S%
MTC6,:BY(! 1022_'TM?G^OO75@>/7EBD=EC56>1CI$:AFDU7]0$:J69@1SQ>
MXM[UU[ QY]<2"K%"-)4V]5@P*WNI'U+:N2+?7Z^_>O7OGUEU"_"L2+ VL1^/
MK8V Y'/^^-NJ_G@]> N>.20+#^EKAOKQP??N/#K?#CPZX",DV-B21< D'4>0
M1R +C_#_  ]ZH>O5'6.Q!X(-@?J3;^RH'! X'Y_I[UU;KPOS?AK7!])U%@ "
M"/2+#Z_Z_P#MO=>X]>(6P^H4?6WU)(/*D6O_ +V/];WOK7VGK+K5;"QX/U%O
M]O8V-K<_FW^\>_5'6J'-3UC U74$$H1<$@&]SPP'^OQ^.??AGAULFAZYLO(X
M%A8>@_2][GZ#FP/'XO\ 7WZAZ]7KRJS%]",X0!Y"@OH7@%G(N53GZG\\>]?9
MUXTZX VYO8V6^E@QMI*D DW''^O;_#WO/6L<.NK"U[D%N#]!<M>PYM]?I]/Q
M[U3'RZMY]=@ ?32;?4GTK?D+=6-S8$_CZ"WOWV=:^9ZRJDA0R)#*(PRJ\GCN
MB,0;!G*E%_587_']?>\^G7O\/6/\DD7X%Q8#C_5<JMQJ/(_V//O77NNOJS:K
M@"Y'-K@$'38 FP^I 'OU.O8ZY*CR.J*K2.[>D*"[$%KD(JJYU#ZW^OO?G\^O
M''75S>Q-F'!! # J%L!?U$V%O\;\V]ZX]>ZZ)/T Y%K6M^;ECR?\/];W[UZ]
M\^NR+76_J 7TW!TW)%PHL">!R?I]??O7KP-:>G7N#>VD"S^DWO\ 7Z\"Q&H_
M[U_K>_5H*]>SPIUXV 8BW]$]5A8Z1I8?06 _U[^]_EU[AY]=< <1@-;3:^D_
M51Q<6M?^MOH/?LCRZ]6OGUTMSQY6X^ITK;\6U$FQ_H/S;_#ZZZ]]@ZYZOK;F
MY-A<C3Z>1J/-R?KQ?W[%.O>=.N-CJ/#6YX=1_BP'.JWYL?K[]6M/3K?^'KUN
M#>P%S<<'CCTW-B.?]8?TO[]QZUUW90..&O\ 0MZ;?4GZ'\_ZWU]^QU[/IUZQ
MU%2;GF][$'40UFTV;ZG_ &'OWSZ]Y=>%CQ>PO;ZKSQ>P):Y^O'%O?NO=+':@
MLE;QR7C)/ ^IEO\ FX^G^'T_UO=APZJ>(Z5_OW7NO>_=>Z][]U[K_]'?X]^Z
M]U[W[KW55G\YZW_#<?R$YO9NIQ^#].]NIKCZ#D_3^O/U]F_+=#>6I(IAO^.O
MT'N9J_N^?[1_QY.M%QKDBP()O8WL/J#SRWIY_P ;^YC)_3&>H&E_M34<.L$P
M-PI(^EN1?^S;]1'-R/\ "_\ M_;N*KG_ %?+JYJ2P%,T_P V?MX_9UT+@G^@
ML;'@<$?X D"_X_'OP]2:9ZMW< ,4_P!7EP^SU_9S/U!U!3I-R#>W']?Z_P"O
M_3VYN872:\/S^73FWQ6SN.[R^?S_ -6/\G1C-UJ#\1.B3R0WR1^4J@?0>GKC
MX<,IO?CV&8:?4RYSH7_"_0AFLH# @KC4WD>-%'KCHL>D6(! ^@M?FUO\?S?_
M !]B.[C%Q2G#_BOLZ(&OM>KS)^S_ #=>F&GBRCAC_4CZ>JR_T'^^^ONEI::"
M6(S_ ,7\^KZM0'#_ %4ZC\?5>5M<$7^G-CS<&W^-K$>T_P QTC^P^7^3_5_J
MR)(U<"UA?\VM^3:WX -A]+^_8ZU0BGI_Q73=SZA;_'Z7U7!/%P/I]??B*U^W
MI9\U'E^VM>&/\@ZY<\>D7)'TU$E@02/J?P?P../\/?O,GRZL3IH*9)_U?Y.N
MB>.23Q8_X!@;$"W) X_/OP\@2*5ZJ22"6!I2F,_ZJ=1P?S]"?IQ]5N.20;CC
M_8>ZY^=>KC(S3'^3_5Z\*]>%[#D7N2WX(']0+"QL?Z^]GU_S=:7 R<_ZO]G_
M "8ZC27N/\1?TCG@_0,?R+?3W[RZTHH<D?9_J_V.H]^ >3] %M92;7O>P!'U
M'M/T]FM<T_P]>-KC\WY_H1Q_K_[#WZO6R,A1Q/IU&-B+$FX)'TN?J ;\$$
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ML'MJ>3;6,H-G3UA.J?*4=/G%2.8M=Q$VK@D^U5G$9(I&8Y!4#\Q7JFY,L<T
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MVS\5)@=R9.N@R& G@4@/F*9:4FE4DZX_41;Z,0*YM^8&U A+TBA\^!X^5#P
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MDCTD< W_ $_[#CW3RZWUT"18 A3J%V*ZK ?0$VY%O];CWKKU.O<#Z\ BXL
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M?^"VY/!^A/X+6-Q< \_GW[KW^'I6;3MIKP#:QH+\G_4R?DV^HX_UO]M[LO\
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MW&;8RF*W!E=OU,46MWBJXY%-A<@6]I+ZU!4NL8)I3(%:?(T_XOI;9W05P Y
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ML?K=V(;Z@\>R-Y@A*J&)\O\ 4,8X=#[E;E6'>6,^ZW2[=9 5+%3-3#'X58$
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MD:J45JMZR==M+CB,M0$?EC_BNFT\^.K[?\W0IX_X^T'0'S^^-FWL%V+VWO#
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MDD_11^!Q_L??NO==@E;<'\,;FQN3]3<<$<6^O(]^].O<>NOTD >L?4GDW'U
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MBWAVY@=F5%5)48G%=I[TQL=/CMS;MIHY@)IZ=!"+64!> NG>)D"H?/\ S],
M>?\ DIT::P#,;D@\7_V')+*00.>+ _U]I>M]=@AK-87_ #<&QM_K6%F^G/\
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MXL)MREV/@-DTFW:S<.=QNW-NX.BI<IE]X+44$<5(7FT.[:2OJ!]N#<Y1J)%
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M";FWUNI_) N!_B;?T^O_ !/NO==E>!SP0=7U4@'\GG\FWO?6NNB2+\7%^?\
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MZV.NK<WM^!?_ 'H&PM:Q-C^;>]=:Z]:^D6-O5QS<7N;\M>X(X_P][Z]Z]>L
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MZ7/TM8@?0B_X L#]/>L^8ZW7]O7%O\R?4+K8%B!S_4$?34!^1^?:@C_$R?\
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MMSIM;_>N?>NMU&3_ *OY==3<D?5K$CTC@<G\6MJ_WQ]^(\NK<*?,==#A";@
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MZZ(4#\!N1^1P6MQ?E05'YN.?\;^Z"?PQ4</]7RZK^]+N;&FO^\_YO]7RZXD
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MK@$\<C\<BWOU.O?9UXD$7O;_ !N;@J&X8,UR>?\ BGOWV]>X==$W/GX)2QU
MD#T@A@O N>+?UY^OT]^SQZ]_1)Z\04 )_+'^EPMK DD*3?\  /O?7NNP .+@
MBQ)'U_LFP(L";.!_OA[U3KW75R.;F]EL2.+<%0+M^;<G^GOWD>O=>L?S8\$
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MA8V_Q'']![L.!^WJI^(?9TM??NO=>]^Z]U[W[KW7_]+?X]^Z]U[W[KW54_\
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M=C)8&WU]-_P ;W(!M_Q/YL%]>J%J\.N6H'218W(]2DLI-Q?U"S, 38?C^O\
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M'+"164NF@@68."+$&Q'TO[]I8?A->O AN!!Z[4*2=+7.HQMR&*N+AE9;$AE
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M'T68DLUP"+7/UO:QY_ M?V=U-/ET38)X]W_%?ZO]68\YM;G@V!M:_!86:_\
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M4R!DH"*'TKU%JWI[^H#4""9=7UMI'"BZV(_XK[7QO/%VW K7SQ_@'3?U9B-
M>'E_LD?/JO5NU=QXK>D3"NWON'M+,]I]V[6_T/T%;M>LQ]!MC9F%WO\ Z-L5
MF=I'.'<VQ<%NBGVCA=RIN=</ER7SFDL,;D*#QM?N[96;_<+'^GD_P:OE_JQT
MD6ZWG3I\7/KIC]*<>.>%>-#\LAUE^Y=R4&)Q6"V1VAO7<M=NK%]2+VMV0*/9
M^[\?U3C<QO*/"=F]AK@<#N)]R=6;@,>\7Q[8[*8H8;"C _Q$+:@R1K]C:-FH
M6^C.D_TY!Q_VW'Y_G3T7B?=9**7&,?#'3&?05X#UQBM*U6R=H1Y/=HP7]_\
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M )^C[981.%5O7_/_ )NMU3Y(?(+9?QJZMS?9.]YXJJGI%1=N;:ID:IGS69G
M;%8NEAA)FE-5/HC1OIR/<;PVAE<T&17J7Y[-XQ4I4@C_ %>>.M:C(]<]W8;Y
MV_$?M[O+.;BQN[/D=O&;?.-V_!5Y5*7 ;32J*8+;M9C1+IB:>GG+:"HNH'L1
M6=DABGDB:I0$<1@@?Y.@=>Q3++&&C(&KSKPJ/+K:SSF$QN[,1N#:VZ*&ER&
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MT?WA>W]S?U5I&":_XWD"H%0#MP+<>'G0G@">I6/W?=U44+KXF",5!-.!/CT
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MY# 6(*C\\^]=>ZZ-S;GG4+_7ZV4W&H"]]7T_'O?SZ\.NR+$^G\6!L' %BO\
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M(;<G:NX=\;"&;P\N1R]K6S(PY*Z:$WZ+<F>\^Q\X01S\CWI:FJO8]1F10?\
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M]#QS8GCD7O<\<W(_WGWK/Y=.=I%13/\ E^?^K_+U%-A?ZG@6N>>.;#^MS?\
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M\7AE.O<;C\GBZ]-]44-=4U$M=AZILP:G<D4LD,DOBJ:ASH(U(UA[<US,B*>
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M-J!+WIUKY#UZ*#V+W_\ )&@V'\=.N,AFOD3E]S_(7$]@=J[\W)\?MFON;O\
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MI_L],F5AW5^VOV=5Q?&23LKH3X*='9G97>O:.YGWY\A-NX/7OFHI98<'M?\
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M+$^]B*(@4(_G_FZ5QW<L@(12P_+_ "GJ/3H(TAC\M4%= E88:RMCFG2[S/\
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MI9ZJLK<DU/!4(3>*GK:A:>"K:9SY)T_<*\_46]W^D7S8?S_S=4^H<@X/\O\
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M<2-&-8''B0/2OVGKGU'\6]W;.ST69[=^4':'R(H]K87)[3V+M3=&V-K]?8;
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M56_&KFUKGCZFWOW7OEU[GT@ FXO?4=5AZB2 2 +_ .\>_=>].O #^R/KSP&
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MNO5IQ_U?ZAUGY_I];"PXN00!_7DW_P /K[L:5H3T\,\ .HW-[?X?U!^ES?\
M%N?>O6G5A7SZ[ MR;?G\<C]7)/! Y_P]ZKUO-<]=3$!CJO\ TO8'G\\?2]O]
MAS[W7UZ\<C\^L'T)%OKQQ^+WXN +6'^P(]^],=>IQK_J_+K #:_U/^N;VMQ_
M0&_/OU*_93K8\Q45_P!5>L+ ?D#_  M>Y'T!M?\ '_&_;..G\XZ\%YOR+_[?
MD_3F]R;?7\>_>G7NL,A/C;Z$<7^O'%N.?J/Z?T]TS3K8P:]8(AQ<<"QM_A_L
M#;_>N/\ >??O/KW#RZ[)/.K^O'/%[?0C^U]>/R??OLZ>-?/AUU<<#@&W^N+V
M /TO>YM_MK^_>O6B0*9SUQB'!M>QM901]&-QSR3?C\?[S[]CCU;B*==^$G^I
M'%_3<D\C\_U/T/\ K>]TZ]05'K]O6+CZ@ ?2]@+<W N; KQ_A[KPZ\/]7^K_
M %<.LUN>?H5L0/SP/3<6M<BQN?Q[WGTZJ:=-=^2;"XXL1<GGECQ8\#^G_%?>
M^%#Y]4^7EUWQ>W :]@!?\?XDWN+ 7_I[]U[%:=>^@^@L0!?5<+<&_P!/5^!]
M1?WHXZ]Z9Z\P /%N"".;7OR0+7)N#[WGAUOYUSUX@B[_ (/ _(N" !P6X('X
M]ZIY =>J?/KQYNOU !)-EMZEL =)XY%_>_3K7&N.LGY;CF_^L #]=0X*CZCG
MZ>_'_<BO^KAUZ/,6>/\ L]6N?R0O^WHGQAX-RG<2A3;^UT#VR /P+#_BGLMY
MO/\ BP/GG_"G^H]'?)X_QC'J/^?_ /4.OH5>XMZE7KWOW7NO>_=>Z3.T+?W2
MVC]#_OWL)8F]Q_N(@Y'UYM_O!]^' _9UH\1TIO?NM]>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M2;WB;;1W1P3_ +][,CC\ XZI!/\ L!S[]U[I2>_=>Z][]U[KWOW7N@ZSG&5K
M!Z0=$#"UQP(E/-^#<D?0?Z_O?G^76@,?GTQD?0@7XN;CZ"QYM^038W']?=>K
MXKQZ[X'Y N. +6M]3?\  -OS^+^]=>^SKH #41^E3S;@W( N-3$74_T_WCW[
MKWIUQ^FGG\V&DZ0+Z2. HM?7S];V]^Z]^77._P!;V_U_R 2;6!] _''^^'NM
M]=7)_P +!A;DJ0%#6'!M_7_8\^_>F>M<*]=7TL1<_4J?H38,"38FXNMP#^;?
MU]^].O=<K@N..0?K8$<,/SZFN/QQSS_7W[SZ]Y=>N".?PVIM  -@?\/3R1Q]
M3[]]HZ]UUQQ>Q!!YY  )XM<LMKV_XI[]UOKHD_7^@T\  WO_ %//Z3_A[]UK
MY=<O]8<@VM8-;BY]1%A<G^E^/?NM_P"#KUPUB+?C@'Z<'U7//ZC<W/Y_V/OW
M6NO$@$@@\:O\!8?D"YTE?\/]X][Z]G'7C<A1R#R>?22?3<D_0"_/U'U]^Z]C
MCUT#^FPMR"!^/P+W-B0US^./I[UU[KW-C]?\;V4 $$?[9M7TX_I[]Y'KW7?
M 7\?XBQ)]0'^OQ:Q)Y ]^/6^O V(_#&]_421;C_:@IYU?G_>O>^J^O71''];
MEK\@6((8C6;GG_&WT-O>NMU^6.O6Y$)/U!Y'^IOR18?B_P#0?3WOY=>^?7@/
MZ\BP/+6/T^A)!.FY^GTO^3;WKKW77%R>0=)N2UKEN >=)/U''T]^Z]UR%@"M
MS<6#78D6N!]&'UOS_OC[]U[KP*<B_/TL#SP26'^)_(O8W_V_OW7ORZ]>U_\
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M -!=<O\ H'-^& O_ ,9;^4+BYX_O5U%?@_0$],"QN?\  >_?UOO <D<?0?\
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M^M]W_$/V#_H'I[^J]OZ']C?]!]9O^@;CX4W_ .9P?*H_7_F+^H[?0#_GRO\
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MRQ9_Q?\ 'O\ H+KW_0-A\)B>>X?E5_L=W=0\@_47_P!"?U]^_K?=T&1^P?\
M0/7OZL6?K_Q[_H+KW_0-A\([DGMSY4_07(W?U$#;@?7_ $*_2PYX^OOW];[R
MGE7[!_T#_J\^M?U8LL]W_'O^@NL1_P"$U_PF' [?^59N>?\ ?W=/\GZ@<]+#
MG_B?>_ZX7=.(I7Y?] ];'*]H<:O^/?\ 0763_H&Q^$EKGN#Y5'\@C=O4-P#_
M $MTG_O/O7]<+KU'[!_T#U[^K%GZY_VW_0778_X39?"3Z#N'Y5'3P+;OZ@N+
M6X!_T)?07_V'OW]<+SU'[!_T#U[^K-GZ_P#'O^@NO?\ 0-A\)3S_ *7_ )4\
MW/.[>H1?\K<?Z$_J/S_7W[^M]Y\OV#_H'K1Y8L_XO\/_ $%U%7_A-E\+SI#]
MK?*A1^;;QZ?)_P!A?I@\"_'_ !'MK]YT\A6G^KRZ3Q\NHGFW\O\ /T.OQ@_D
MC?%_XC]W["^0O7_8??V<WGUXVX_X10;WW7UWD-MUCY[9V<V/EWRT.W^N-JF2
M08+.U=CK4JPO]1;WJ3<=:M'BE./IZ&E/(_/CGHTM]G"9!/V<3G\^!KZ?X>KL
M?9-T;]>]^Z]U[W[KW2,HMJUN/I*:AHMV;B@IZ&D%+3 TFT7]-ETD7VW]%T"X
M(6]A[]\NM9X]./\ !,G_ ,]?N+_SFVE_]B_OW5ORZXG!Y3FV\=Q#CB])M(\_
MUXVP+C_#W[K77+^"9+C_ ']^XO\ '_)MI\_^NQ[]U[KB,'E?SO'<)Y_%)M,<
M?T_X]@\W]^QUK/RZ[_@F4_Y[#</U_P"53:?T_I_Q['U]^_;U[/J.O?P3)_\
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M\]=N+_SFVG_M^-L>_?GU[\NN/\#REC_O\=Q7_'^2;2_I_3^Z_//OV.O9Z]_
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MVQ2?F><V  MI' (/YO<D B_^/^WUCTZ]W>1ZY_W;H[\2S@<6&I38C\_I /\
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-U[KWOW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gjyjiv3jrhol000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ,'!6(# 2(  A$! Q$!_\0
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MCJ:/,6H?,]J-Y["@"4N">31YA'0U%O:F[S_>H F\S/6C>>XJ'?\ [5&\?WJ
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M6![_ *4 3[R>:0R-TR*A#+Z4;AZ'\Z )MX Y(H\T'G?4(D..E-\P@\B@"<R
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M]Q-&_!Y857+C.2*-X]* )O,_VJ/,Y^]4/F 4>8OK0!-O)Z$TAD]S4'F-Z_\
MCM'F'U_2@";S1G%!D..E0ECUS1NP>6_6@"7<11O;N1418>M'F#^]0!)YOO09
M./O5#O%!D3^]0!-OXSFD,G;-1>8O;-&_G.*!DF\&@.*C+D]J0,10%B4OZ"C>
M:AWGINH+GNU [$V\TFYO6HMXQRU-WK_?H F,A]:-^.AJ'S$]: Z]LT!8D+[C
MDM1N'7/Z5&7']VC>>@6@+$F\4>8HZU$7(YS1O)Z4!8E\SVH\SVJ$2'NU&_OO
M_6@"7>WI1O85#Y@(^_1N7UH"Q*9".I'YT;\]6J'?STHWKZ4#L2[E]:3>H[U'
MOQU-)YM 6)=XHWCTJ(RXX-)YG^U0,F\P_P!VCS#_ ':A,G^U1O!ZM0!+YC^@
MI-[^OZ5"7'8T;_:@";>W=J-_/WJA\SM1O- $C.?[U&\5%YON*3?CHU $V\4>
M9V-0^9G^*C>/[U $WF>U&\U7+^AH+\<4 6/,(ZTWS,_Q5#YGM1O- $N\==U'
MF>IJ$R&D+]]U $V\4>9[5#YG^U1YG^U0!-O/84;R:K^9S1YGM0!.9#2;^^ZH
M?,]J-YH F\W/\5-\P]S41D/K2;\]6H FWBCS/:H?,_VJ/,_VJ )MY["C>:@+
MCUI-X]* )_-]Q2;P3UJ'S/:C>>PH F,OO2&3MFH3(1UI#*!U>@";S/:CS/:H
M#,O7?1YH_O']: )_,/84;S5?S%]?TH,GH* )]Y%)YG^U4/F?[%'F'TH F\W_
M &J0R>]0^9]*0R=]U $V\4>9[5#YV/XOTH\W/\5 [$V\]A1YAJOE/6C<H' H
M G\SW%(90/XZA\SVHWMZ4 3><#_'2>:.S5"9<4GFC^^*0[$V\4&0=A4/F_[5
M)YH/\1IA8G\S_8HJ'S/]JB@#TKS/04>9[5#YG_32D\P8^\:LY2?S/:C>?2J_
MF+_>/YT;^>GZT#L3F3WI/,Q_%4(9V8*B%F/  [U)]COR,_89?^_9I7'RL7S0
M.KT>8"/O4AMK[_GSE_[]FHI?-B;9,K(?1EQ0'*R7S!Z&CS/:H?-[;J;YJ_WS
M3"Q8\P]EI"[=@*72M,U;7;^/2]#TRZO;F5L1V]I"TDCGT"KDFMCQ-\*OBGX-
MLAJ/B_X9^(-)MV^[<:EHT\"'_@3H!4\T5*S9I'#UITW.,6TMVD[+U9B^8>["
MCS<?Q5 )>.5H\SC.*HS)_-&?OTTR+_?I%M[V1!)':2,IZ$1GFE-G?_\ /I-_
MW[-+W2N60>8/>DW(>@ILD-U$NZ6VE5?[S1FH_-']^@5F3%P/X*#(V,@5%$))
MVV0QO(W7"KFEEBN(!F6UD4=,LI%%Q\O4>)&SR:/-P>7J#S?1:?'#=S+OAM9&
M7^\J$T<P<HX2CN]'F \YJ.430MLEC*-_=88IAD/4F@+$YD.>:"XZXK2\*_#W
MX@>.RZ>"/ NLZPT?^L&E:7+<%?KY:G%1>*/!7C7P/<BR\:>$M6T>9AE8=4T^
M2W8_02*#4\\>;ENKFOU>O[/VG*^7O9V^_8H>9_LTH?T%0>8*D2UNW&Y+.9@>
M01&:JYE8=YC'KMH\S'\7Y4&SONUC-_W[-(+2_P#^?";_ +]FCF'ROL)Y@/ D
MH\PC^(TDL-W"N^2UD5?[S(0*B,A)[47%8F\S_9-'F8Z)4&_'.?RJ;[%J'_/I
M/_WZ/^%*X6?0"Y'K1O)[TGV._'_+E/\ ]^S4<J2P?Z^%TS_>7% [,E+OVI/,
M/=JA\P#G%2+:WK*&2RE(;D$1GFF+5CO,Y^_32_\ M4&ROSUL9O\ OV:CE62$
M[98F5L9PRXI#M(DWTF__ &32107$R;X;>5A_>52?Z4OV.^'_ "Z3?]^S2N'+
M+L'F?6EWFF/;WB+N>VF4?WC&>*B\P?\ ZZ+BU1,9#V(H\S'\51QB69ML,3.W
M7:HS3_L>H?\ /E+_ -^S1<=F+YA[']*0R'NQI/LFH8_X\IO^_9I#:WJJ9'M9
M%5>2QC/%%PY9=A=_<FC>.^:B4M(P6,,S-T51S3VM[N--[VLP Y)*'B@+,7<#
MVI0^.M0"7'2D\S'3- B<OW#4GF?[5(EM>2*'CM)&4]&"FE-GJ&?^/*7_ +]F
MBX^678"Y_OT&3/%1RK-"VR:)D)YPRXI8X+N5=\-O(Z_WEC)H"S'-(!UI/,]!
M4<J30G$T;IGIN4C^=-WX_CH$3;SUH,C&FK;7CIO6TF93R"(SS43N4.QU(P>0
M>U 69.'P.<4GF<_>I$M;UU#I93%2,JPC/-'V+4/^?";_ +]G_"@KEEV R?[5
M(9!UH^QZA_SY2_\ ?LU%(LL;;98V4^C B@7+(D\P'UH\ST%1%CC%)DXP6H"Q
M-YGM1O/85"6P.309 >IH$3&1C_%32Y'5JB+#UI/, ZT 3;R>0:/-QR34.\&C
M</3]: )?-&<TGF>U1[O0?K1O/I0.Q)YGM1YGM46]J-Y]:!V)?,]J"YJ$R?[5
M-W@_Q4 3;F_O4H9J@$@/20T;AWS0%B9FYY-)O'3-1;P.@H$F?X: L2;QFC>*
MCWGTHWF@+$F\4;SV%1[V[4W>W]Z@+$V]O2F[B><5&7S_ !TA?L6- 6)=S4;B
M.IJ'<OK1O% [$WF8ZO\ K2%QZU%O]!1YGM0%B4LOK2>8O3-1ESVIOF=LT 3;
MQV%)N_V:B\S_ &J#)_M4#)O,;THWMZ5#YG^U2&3/<T 3;F]:0N1WJ'?1O]J
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M7\,>O:7<Z;&Q_P"NDF1^E<_URAT;MWL[??:QZO\ J_FFTHQ3[.<%+_P%R3_
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MY"K <$E3@'<67_@F#\'/B_X(^,VN>)_&OPXUS1=-_P"$8>U\[5]/DM1).]Q
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M&3;EZXHW^@J+<WK2%CZT 3>9[4;VJ'?_ +5)N7UH EWL#R:/,_VJAWBC>.U
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MVLS\DF8J2I4@@X(-7O#/AGQ-XUUJ+PYX/\/7FJ:A/N\FQT^W::5\ DX502<
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M_P!@;]I7P9\?/#_COXB>%(=!TO1;S[7/,^K6T[S;5.V-%@D<Y8D YP N3DG
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MZ>=0_P#2V:NO/)*6"37\R_)G@^&=.I3XCJ1FFFJ<M'H_B@>'>+_VBXOV=_\
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M,]:-]0^9_M4;QG.ZO4/BR;?[4;SV%0>8!2;Q0!/YON*3S/\ :J'S/:C>>PH
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M/4R^MA\MCA\GFYN=>"3J)ZT_:6<8P7\M_CM:_P K'3?\$6VW?'/Q9_V*9/\
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M'0TGF"HC(?6D\S_:H&3;QV%&\]A4/F?[5(9!0!/O-(9#T-0;Q1YGH* )M_\
MM4;_ /:J'S/:C>?2@";S/]JD\S/7-0F3WI/,_P!J@";>/2CS/:H?,_VJ0R>]
M $^\^E(9/>H-XHWCL* )O,_VJ#)_M5#YGM1O- $WF?[5)YGUJ'S?<4GFX_BH
M FWCTH\SVJ'S/]JD\WW- $^\]A2&0]Z@WBC?Z"@";S/]J@O_ +50^9[4>8:
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MZ'_X-U_^)I3_ ,$R?VIC_P P[1/_  <+_P#$U^GG_"-K1_PC:T?VYC?+[O\
M@A_Q#7AWO4_\"7_R)^88_P""8_[4O_0/T3_P<#_XFD/_  3'_:E_Z!VB?^#@
M?_$U^GO_  C:T?\ "-K1_;F.\ON_X(?\0UX=[U/_  )?_(GY@_\ #L;]J7_H
M&:'_ .#E?_B:;_P[&_:G_P"@7H/_ (.!_P#$U^H'_"-K1_PC:T?VYC?+[O\
M@A_Q#7AWO4_\"7_R)^8'_#L?]JC_ *!FA?\ @X'_ ,31_P .QOVJ/^@;H?\
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M/^'7O[5./^0;H?\ X.%_^)K]1O\ A&UH_P"$;6C^W,;Y?=_P0_XAKP[WJ?\
M@2_^1/RY_P"'7W[5 Z:9H?\ X.%_^)H_X=??M5_] O0__!TO_P 37ZC?\(VM
M'_"-K1_;F-\ON_X(?\0UX=[U/_ E_P#(GY<G_@E]^U9VTS0?_!R/_B:3_AU]
M^U8?^8;H/_@X'_Q-?J/_ ,(VM'_"-K1_;>,[+[O^"'_$->'>]3_P)?\ R)^6
M_P#PZ\_:M_Z!^@_^#A?_ (FC_AUY^U;_ - _0?\ P<+_ /$U^I'_  C:T?\
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M^V\9Y?=_P0_XAKP[WJ?^!+_Y$_+7_AUU^U>?^8;H/_@X7_XFC_AUU^U=_P!
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M,\ON_P""'_$->'>\_P#P)?\ R)^68_X);_M7]],T'_P=#_XFC_AUO^U=_P!
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M ,37ZH?\(VM'_"-K1_;6,\ON_P""'_$->'>\_P#P)?\ R)^5_P#PZQ_:Q/\
MS#M!_P#!TO\ \31_PZQ_:PZ?V;H/_@Z'_P 37ZH?\(VM'_"-K3_MO&>7W?\
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M(]=.T'_P=+_\32_\.K_VL1TTW0?_  =+_P#$U^J?_"-K1_PC:T?VUC/+[O\
M@A_Q#;AWO/\ \"7_ ,B?E6?^"5W[61_YAV@_^#I?_B:/^'5W[67_ $#=!_\
M!TO_ ,37ZJ?\(VM'_"-K1_;>,\ON_P""'_$-N'>]3_P)?_(GY5_\.KOVL_\
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MQ#;AWO/_ ,"7_P B?E/_ ,.J?VL_^@9H/_@Z7_XFD_X=4_M:=M,T#_P=+_\
M$U^K/_"-K1_PC:T?VWC/+[O^"/\ XAOP[WG_ .!+_P"1/RF_X=4_M:_] O0/
M_!TO_P 32'_@E3^UMC_D%Z!_X.E_^)K]6O\ A&UH_P"$;6C^V\9V7W?\$/\
MB&_#O>?_ ($O_D3\I?\ AU3^UO\ ] O0?_!TO_Q-'_#JG]K?_H&:#_X.E_\
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MW_"-K1_PC:T?VUC/+[O^"'_$-^'>\_\ P)?_ ")^4/\ PZC_ &N/^@7X?_\
M!XO_ ,32?\.HOVN?^@9X?_\ !VO_ ,37ZO\ _"-K1_PC:TO[:QGE]W_!#_B&
M_#O>?_@2_P#D3\H/^'47[7/_ $#/#_\ X.E_^)I/^'47[77_ $#?#_\ X.E_
M^)K]8/\ A&UH_P"$;6C^VL9Y?=_P1_\ $-^'>\__  )?_(GY/_\ #J+]KO\
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M6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\
MB:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_
M ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9
MO^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/
M%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#
MO>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^
M)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_
M /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\
MB&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X
M/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T
M#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\
M$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#
M_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^
MUW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>
M7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\
MT#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%K$NJZLMK\RV[2*H$.X'#D;2Q(XW.P&X ,?$?V1_B'\=?!U]\1;+X5?L[_\
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M[7HOL_B;1?L>G>*+&3Y9([J.^MP9"N 5$@&[& %;>@)V$U]%?L]?\D"\#_\
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M[2.@?"#PIH.A?L2ZUJUC8^&[&WL]4A\0!%O(DMT5)@OV8[0Z@,!DXSU->\?
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M8;<&'RYE+'"A&W#@[\=C7TC\*/B1\?\ Q=XFDTSXH?LU_P#"'Z<MFTD>J?\
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MT <5_P $[?\ DSGP?_W$/_3A<T?\%$O^3.?&'_</_P#3A;4?\$[?^3.?!_\
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M1110 FT4M%%  1DY-&.,444 )M'6E''%%%  1GFFO&DJE)%W*RX96'!%.HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK?XLZ)!JFM:MKTD&APZA&LT6F6L6TH(0PP&!.P-C<!'D'+N3ZA^T7^R?\/\
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MVS4?@-\#=8U"XU?5_@QX3NKJZF::ZNKCP[;2232,<L[,4)9B2223DDU\MP?
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MJXVY)7]H*S!_B\'7'Z7</^-=EN]O_'J #_OJC_OJE ).-I_.E"2-TC:@!O\
MWU1_WU4GV:<\+'^M*+2X_P">7_CU%P(O^^J/^^JE^R7'_//_ ,>I#:7.?]5_
MX]1<"/\ [ZH_[ZJ0V\Z]8_\ QZFM'*O_ "S:@!O_ 'U1@'J&I2&'5#^=)N]O
M_'J # /4-0.#D;J,^W_CU'/]W_QZ@!R7$Z'(D;\:E34''^L3/O4'/]W_ ,>H
MY_N_^/46"Y=CNX91PVWV:N3\2$'XW^$R#_S ]8_]#L:WR"?X?UKD?$#R1?&S
MPJ5_Z FK_P#H=E4\I7,>@4552_(/[Y/Q%6$ECD&4:I*'4444 %%%% !1110
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M_P %&OV?K;X9?$'6E5_"^I:9,6TO5BV0D2EI)5!9D=4D2:1'D!B^1P W1_\
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MP6G\?;?$7B;4;R)=0M[=[J,7SHK7T;%DCW%<0MDC@/TH ^V/CU^T/^WOX/\
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MH/\ Y$C3/^QX\-?^GJRKN*X?]H/_ )$C3/\ L>/#7_IZLJ[B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X
M?^#FO_DR[P3_ -E0M_\ TW7]?HMI/_(*M?\ KW3_ -!%?GC_ ,'+.E:MK/[&
MG@NVT?2[B[D7XG6[-';0M(P7^SK\9PH/'3\Z_0[2<C2[8$?\NZ?^@B@#\]?^
M#F7_ ),0\)_]E<L/_37JE'AO_@WN^ >J>';#4Y?VK?C-&US9Q2M''XBM0JED
M!P/]&Z<U/_P<IZ5JNL_L,>$[71],N+J1?BQ8NT=M"TC!?[,U09PH/&2/SK[W
M\$!AX,TA67!&EVXP?^N:T ?D7_P5!_X(Z_"+]D;]C/Q)\=O"?[0/Q,UZ^TN\
MT^*+2_$FLV\UI()KR*$EU2!&) ?(^;J!7Z2?\$[?^3!_@K_V2S0?_2"&O'O^
M"\MA?ZI_P3+\;V.F6$US,VI:.5AMXB[-C4K<G '/2NU_9P^+6F_LY?\ !*CX
M>?&'Q;X<U2^M?"OP;T6\OM+TRW5KN4)80YC1'907]B10!\H^-?\ E9Q\(_\
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M^":O[,WQ"UKQ_KT+VEMJFL:5 J:,'POVI4@FF5V4%B&F:.*,A7<NH9" 4_\
M@C/H[>,?^"HG[6OQ@T2[2328?%&H6JLK#$OVS6KJ:)QZC;:/S[^]?J'7R[_P
M27_8&D_8&_9F7PGXNFMKKQMXFO?[5\8WEOM81S% L=HD@&7CA4'DD@R23,N
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M,9)%E0J00P\O(/K0!V'[<'_*PM^SK_V(]M_Z4ZU5C_@YOY_95^'H(_YJ(/\
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M:3T'_:\#ZO\ I>:;_C7<5PNM''[2WAL9^]X&UOMZ7FE?XUW5 !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<TM% %2>S9/GA^[Z9J 9[[JTJAN+5)OF7AOYU7,2XE/'^]1C_>I75XWVLO\
M]>DR?[O_ (]5$DL%RT'RD?+5Q65QN4UG<_W?_'J?#/+ >,[>ZU+129?HIL<B
MRKN0TZI*"BBB@ KC_BU_Q_>#_P#L<+?_ -$3UV%<?\6O^/[P?_V.%O\ ^B)Z
M .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH X?\ :#_Y$C3/^QX\-?\
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M_&GCQCXNQ_R-.I?^!TG^-+_5V7_/S\/^"'^MT?\ GS_Y-_\ :G]'=%?SB_\
M"8^+O^AIU+_P.D_QI4\8>+3U\4:C_P"!TG^-'^KLO^?GX?\ !)_UPC_SY_\
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M1XDU#_P,?_&G_J]+_GY^'_!#_B(,/^@;_P G_P#M3][:*_!=?%/B<MSXCO\
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M_(>O?_ I_P#&I$\1^(=O_(?OO_ M_P#&I_U>E_S\_#_@A_Q$^'_0*_\ P/\
M^T/VLHK\51XC\0XYU^\_\"G_ ,:5?$?B'/\ R'KS_P "G_QI?ZOR_P"?GX?\
M$7_$4*?_ $"/_P #_P#M#]J:*_%I/$?B''_(>O/_  *?_&E_X2/Q#_T';S_P
M*?\ QI_ZO2_Y^?A_P1?\11I_] C_ / __M#]I**_%_\ X2/Q#_T';S_P*?\
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M_P"QX\-?^GJRKN*\S^)0']@6O'_,?TO_ -+H*VSM'44^4/:'8T5QN?EQ[4W
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MK8HV=H.T%GD;:VU%'."254%A-/&8:I1=52]U=6FOS+J9?C*6(5"4???1-/\
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MN[[.VG?\"L+D=&IB%&4Y.+=/X8ZVJ1YDY:VBDM&_>UOO;7S3X*?%?Q=^S?\
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M]3\;_#/Q#X-T/6KC3;[5=$NK2RU&TN&AEM9I(F5)4=2&5E8A@0<@BG?$K_D
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M,60[<^IS7/6H4*=-V>JMWZ]]++RU^\Z,/B,14JIR7NN_;2W;6[\]/N+WC?\
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M[25_5M'?A<VP-;V3IU$U5OR?WK*[MZ).Y]-T445Y)[(4444 %%%% !7Y>_\
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MS/=?CM_R95\ _KXJ_P#3C'7B0Z5[;\=O^3*O@']?%7_IQCKQ(=*SPO\ "?\
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M7MNO0\Q^,O[&_P"S3\?]>A\5_%GX56>IZG#;F%=0BNI[69XR,;'>WD0R*!P
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M3?M)>*?VUOV)_@5IGAOP,VAZW\7_ !W)_9OAM=22Z1OL\LEG&K7+QQ;2TEQ
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M?PFBB&#ITYJ;;DUM=MV]#.MF%:K2=-*,4]^5)7]?\M@HHHKH.$^W/A]\>O\
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M[XT>&KR7YQX=\.ZYIUYI\38^XL]TOGE<]V!/\JY']I/]IRU^,^D>'/AA\.?
M$?@_P!X-BF3P[X;AOFN',DK;I;FXE;!EF=O;" D#JQ;R,'"\TZ,YZ5,<-3BU
M)MNVUVW;^NY%;'59TW!*,;[V25^NMNE];*R\M#V;]G[]J71/A_\ #S5O@#\;
MOAG'XV^'NM7JWS:5]L-K>:5?A=HO+.< F-]HPRD8<#:2%9P_6:?\2/\ @FU\
M+[ZU\;?#KX,?$SQCK%K^\M]%^(6J6$6E1S#!1G%HADN$5NL;X5P,,,$U\WD@
M=:D7[M#PM.3;NU?>S:3_ *\@ACZT(1BTGR[-Q3:]+]/)W2Z'?:[\>_&/C_\
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M<K77>_R.+_X)D_%S_A:'[*>D:->:I#=ZAX-N)/#UY-!]R1+<#[.Z< E#;M"
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M^W01_P >WA+_ ,*'_P"UT[_AQC^W/_S[>$?_  H3_P#&Z_9JBJ_M['>7W?\
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M?9?"?_A0'_XW7[$44O[<QWE]W_!%_JKE?][[_P#@'X[_ /#D?]MW_GU\)_\
MA0'_ .-TY/\ @B1^VX.MMX3_ /"@/_QNOV&HI_V]CO+[O^"+_5/*_P"]]_\
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M^V8!C[-X7_\ !]_]KJ0?\$;/VR\8^S^%_P#P??\ VNOUHHH_MS&^7W?\$/\
M4O)_[WWK_(_)A?\ @C9^V6#DVWA?_P 'Q_\ C=2+_P $;_VR <FW\+_^#P__
M !NOUCHH_MS&^7W?\$G_ %)R;^]]Z_R/R?7_ ((Y_MC@8-OX8_\ !Y_]KI1_
MP1T_;& _X]O#'_@\/_QNOU?HH_MS&^7W?\$7^I.2_P!_[U_D?E&/^"/'[8G7
M[/X9_P#!Y_\ :Z=_PYZ_;#_Y]_#/_@\_^UU^K5%']N8WR^[_ ((O]1\E_O\
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M2B_:OD3<MOX=_P#!S_\ 85^E<<32.%&:OJH5=H%*6>8WR^[_ ((UP!D/>?\
MX$O\C\R/^'4/[6&>8/#O_@Z_^PIZ?\$H_P!JX=;?P[_X.?\ ["OTUHJ?[<QW
ME]W_  1?\0]R#^__ .!+_(_,O_AU+^U;_P \/#O_ (.3_P#$4Y?^"4_[5@&/
M(\._^#@__$5^F5%/^W,=Y?=_P1?\0\X?[S_\"7^1^: _X)5?M5C_ )8>'?\
MP<?_ &%'_#JS]JK_ )]_#W_@X/\ \17Z7T4?V[CO+[O^"'_$.^'^\_\ P)?Y
M'YG-_P $M_VI(#L>#P_GK_R&/_L*5?\ @E]^U %_U/A__P &Q_\ B*_22^&9
MN_W:AQ_O57]N8UKI]W_!,WX=\/\ >?\ X$O\C\XQ_P $P?VH!QY/A_\ \&__
M -A0O_!,+]I\')A\/_\ @W_^PK]',?[U&/\ >H_MK&^7W?\ !%_Q#OA_O/\
M\"7^1^<Z?\$Q/VG0,>3X?_\ !O\ _84?\.Q_VG/^>&@?^#;_ .PK]&,?[WYT
M8_WJ?]MXWR^[_@B_XAWP_P!Y_P#@2_R/SK_X=D?M-_\ /+P__P"#?_["@?\
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M5'@')Y?;J?>O_D3X]\*?L#?&C4;I?^$O\0^']+MR?WC6L\UU*O\ P'RT4_\
M?=>Y?"C]DGX8?"Z>/5_(DU;5(\%;[45#")N.8XQ\J<C()RP[-7J5(S!%W,:Y
M*V88JLK-V79:'M9?PKDN6S4Z=/FDMG)W:]%LO6UR+[(!_'_X[1]D_P"FG_CM
M1BY::Z4+]W=^=6JXCZ(@-D#SYGZ4GV$?\]/TJQ10!7^PC_GI^E#:>&_Y:_\
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M (16/_G];_OW_P#7KG?V@_\ D2-,_P"QX\-?^GJRKN*.9ARQ,<^$T(Q]M/\
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MFD'LJ?8Y/_A5L/\ T&F_[\#_ !H_X5;#_P!!IO\ OP/\:ZRBCFD'LJ?8Y/\
MX5;#_P!!IO\ OP/\:/\ A5L/_0:;_OP/\:ZRBCGEW#V5/L<G_P *MA_Z#3?]
M^!_C1_PJV'_H--_WX'^-=911SR[A[*GV.3_X5;#_ -!IO^_ _P :/^%6P_\
M0:;_ +\#_&NLHHYY=P]E3[',0?"_35_X^=3G?T\M0O\ /-:^E>%]$T<A[.Q7
MS!_RUD^9OKD]/PQ6A10Y2?4I0C'9  !T%%%%24%%%% !1110 4444 %%%% !
M103CK7S9^V?_ ,%0_P!G;]CAYO"FHW<GB?QE&BE?"FC3+OM]R[E-U,<K;@C:
M=I#2$.K",J=U:4:-6O/DIJ[,:V(HX>GSU9)+S/I/-%?BY\8?^"W7[;/Q&U)C
MX%UO2/!&G[F\NUT72XKB5D/02372R$L/[R+']*\4U3]N;]L_5[U[^Z_:O^(B
M22-EEM?&5Y @^B1R*H_ "O9IY!BI*\I)?B>!5XHP496A&3^Y?\'\#^@ZBOYZ
M?^&T_P!L?_H[3XF?^%[J'_QZG?\ #:?[8_\ T=G\3/\ PO-0_P#CU:?ZO5OY
MU]S,O]:L/_S[?WH_H4HK^>Q?VT_VQL\_M9?$S_PO-1_^/4X?MI?MC8_Y.R^)
MG_A=ZA_\>H_U>K?SK[F'^M6'_P"?;^]']"-%?SW_ /#:7[8O_1V/Q,_\+O4/
M_CU.3]M']L4CG]K'XE_^%WJ'_P >H_U>K?SK[F'^M6'_ .?;^]']!U%?SY?\
M-H?MB?\ 1V'Q+_\ "[U#_P"/4?\ #:'[8G_1V'Q+_P#"[U#_ ./4O]7ZW\Z^
MYD_ZV8?_ )]O[T?T&T5_/E_PVA^V)_T=A\2__"[U#_X]3Q^V?^V'C_DZ_P")
M7_A=:A_\>H_U?K?SK[F#XLPZ_P"7;^]']!5%?S[I^V=^V$3S^U?\2O\ PNM0
M_P#CU._X;-_;"_Z.N^)7_A=:A_\ 'J?^KU;^=?<R?];</_SZ?WH_H&HK^?P?
MMF?M@8_Y.M^)7_A=:A_\>I?^&S/VP/\ HZWXE?\ A=:A_P#'J7^K];^=?<P_
MUNP__/I_>C^@*BOY_P!/VR_VO]O_ "=9\2O_  NM0_\ CU.'[9?[7^?^3J_B
M3_X7.H?_ !ZC_5^M_.OQ)_UOP_\ SZ?WH_?ZBOP#_P"&ROVOO^CJOB1_X7.H
M?_'J/^&R?VOO^CJOB1_X7.H?_'J/]7ZW\Z^YB_UQPW_/I_>C]_**_ ?_ (;(
M_:\_Z.I^)'_A<:A_\>IR?MC_ +79Z_M4_$C_ ,+C4/\ X]3_ -7JW\Z^YA_K
MCAO^?3^]'[[45^!J?MB_M=8Q_P -3_$?_P +B_\ _CU.3]L7]KG/_)T_Q'_\
M+B__ /CU+_5^M_.ON9/^N>%_Y]2^]'[X45^")_;$_:XS_P G3?$;_P +B_\
M_CU2)^V%^UN0/^,I?B-_X6]__P#'J/\ 5^M_.ON8O]=,+_SZE]Z/WJHK\&!^
MV#^UMC_DZ/XC?^%M?_\ QVGI^V!^UJ1S^U'\1?\ PMK_ /\ CM'^K];^=?<R
M?]=L+_SZE]Z/WDHK\'Q^U]^UGC_DZ'XB?^%M?_\ QVE'[7O[61//[4'Q$_\
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MA^M_.ON8?\1*P/\ T#R^]'[%45^.R_M.?M)XS_PT)XX_\*R\_P#CE.7]IO\
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M $#R^]'ZR45^3O\ PT9^T)_T7?QE_P"%1=__ !R@_M&_M"#K\=_&7_A47?\
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M6/\ T.QJK\)/C[X!^,EB9?#&H^7>1INN=+NU"3Q#.,X&0R]/F4D<C.#Q5KQ
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M^%C^(O\ IW_[]?\ UZ.20>V@=]17 _\ "Q_$7_3O_P!^O_KT?\+'\1?]._\
MWZ_^O3]G(/;0.^HK@?\ A8_B+_IW_P"_7_UZ/^%C^(O^G?\ []?_ %Z/92#V
MT#OJ*X'_ (6/XB_Z=_\ OU_]>C_A8_B+_IW_ ._7_P!>CV4@]M [ZBN!_P"%
MC^(O^G?_ +]?_7H_X6/XB_Z=_P#OU_\ 7H]E(/;0.^HK@?\ A8_B+_IW_P"_
M7_UZ/^%C^(O^G?\ []?_ %Z/92#VT#OJ*X'_ (6/XB_Z=_\ OU_]>C_A8_B+
M_IW_ ._7_P!>CV4@]M [ZBN!_P"%C^(O^G?_ +]?_7H_X6/XB_Z=_P#OU_\
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M4M2OKA8+'3]/M6FGN)&.%1$0%G8GH "31&I"4;Q:8JE.I#W9)I^A6HKW2?\
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M^*'P7\0_\(G\6/ .K>'M0,9>.VU:Q>$RH&*^9&6&)$W*0'4E3@X)J_\ #GX
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MCHQ4X:IHZA3[U:GA;PMXG\:ZW#X:\&^&]0U?4KC/V?3]+LWN)Y<*6.U$!9L
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MTAX"HB@EF)Z #)JU!X4\53>)_P#A"8/#.H-K7VPVATA;)S=?: VTP^5C=O#
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M9%1V&TC_ ':6D?[M$1B'&.JTVG'./O?^.TVC[0=!JXQU%-?O3AG'7]*:_>J
M:,8ZK7-^/5_TC1&_ZCD8_P#')*Z09Q][_P =KG?'(W3:&/\ J.1_^BY*"9&I
M39.E.IK]*K[1)+$V8Z6HX&P2N:DI,8Q_O4P_<I[_ 'J8?N4A#:;)3J;)5 -J
M,]:DJ,]:H J.I*CH)?4:_2FTY^E-H),/QW_R"+?_ +#6G_\ I9%7D/[>WQ&\
M=_!GP3X0^,'A+Q#<6.F:'X_TS_A,HXY (Y]'ED,4RL"#GYVB (P1DFO7O'?_
M ""+?_L-:?\ ^ED5<?\ M>?#'_A<G[-'C;X;QV7VBXU'P[<&PAVYW74:^;;_
M /D5(S6V'E&->+EM?7T,,3&<L/)0WMIZ]#QK_@I]\<?C-\.O#'AGP=^S]XBN
M-,\07W]J:Y?7MN%.S3=-LGGG#;E88;<I&1\Q0*.M;_[7WQZ\1S?LL^%_$7P/
MUB^TW7/B?K.A:;X1U"!$\RV>]9+@,P;( ,"2*?0M^->=_L2>+=/_ &QOBQ??
M%7Q1!_:5CX9^#^C^$K^.Y7=!>WUY&;C475.@P5$+#N/4$5P_[*=SJ/Q(^./P
MK_9<\07*WD_P%N/$UQXE\]W\NZ>"Y%I821J>\321LN>BYQZ'THT802BUK3U?
MG=-Z_<E\SRGB*E23E%Z5=(^5FEIYZR?R/K[XJ?M)?!WX$WVF>$_'?BFZDUC4
M;??I^CZ;IMQJ%_<1J"#+Y-NCN%^5OG("DA@#D$5J?"?XU_#'XX^&Y/%?PP\4
M1ZE:V]T]M>+Y$D,UK.GWHIHI%62)Q_=90<<C@@UY'\ S!=_M_P#Q\N-9,<E]
M9V/AB#26F.Z2&S:Q9Y$BSRL9EVLP7Y2^"><4?"_9;?\ !1GXI6OA=8Q83>"-
M%F\2+#VU+<X@W^CFWR?<8-<LJ%/E:UNHJ5^FMM+?/ON=T<15<D].5R<;6UTN
MKWOY;6V?D=)\+_VXOV>?C7JNGZ3\,->UC5Y-1F,8DM?#-Z8;9\M\L\OE>7"3
MM) =@<%3T89Q?V(/$NJZGI'Q8N_$NO7%PEA\:O$4$,E]=,XMK>-XML:ES\D:
MC.%& /:LW_@E1%''^PIX-9(U4O-J;.57[Q_M&Y&3Z\ #\*\GGG\5V_[$'[4#
M^#(Y&O#\5O$ZS+&N3]D::W%T?H+<S$GL,UM[&GSSI0TU2N]>MK[(Y?K%7V=.
MM/6\7*RT^RG;=GH7[1_[=_[/_B'X >-].\!?$+4ENKGP_J%GHNNV^BWT-G/?
M"&0+'#>^4(B^Y2%(?YB!M))&?1OV;/C-X4U3P?X#^$6I>(9Y_%DWPITGQ!/#
M<*[--:O''"9S*>&8RY!!.[G)X.:YKXPZ;X0C_P"":^L66@VMLVCQ_"8-IJ[0
M4V+8AHF&>^0K ]<X/6O./$6N:/\  [P_^S'^T]KM\MCH]GX7M?#7BBZ6$MFU
MO-+1X&<CD1QS0EO0%_?D5.E4I<L4UJ[==4M.G7\Q2K5J=;GFUM&^EDDY6?5[
M;W['TQX/^-GPX\>?$/Q/\+/"^N_:-:\'M;+KUK]G=1"9T+Q@,1M?A3G:3M/!
MP:\Y^,OQ=^ _Q8^&=[<7GQ>\4:#IOA_XC0Z%?:IX6::VG.J0RHOV;=Y;;X2\
MB@LHVG&0W%?-OPS\0:A^ROJ'A/\ ;>\=:;Y/_"VO#WB:[\71F9EMX;F1I-5T
MY8^2"\J1B%%8YPQ&>U=9XR\ 7_PZ_P"";OPXTO6Y))-2U#Q=H>KZI+,H$C7-
MYJ NG#X_B7S=G_ :KZK3IU(M-ZM)>NJE^*T]43]<J5*4DTM$V_31Q^]/7S3/
MI[XO_M)?"#X&WVFZ+\0/$DR:IK!;^R]'TW3I[V\N@HRS+# COM !^8@#C&<U
MXK\!_CIHOQF_X*#^*+CP+XSO[[P_%\,X1_9MP)X%M;M+U$D#V\H4Q2CH<J&P
M?0BMGX4B:Z_X*2?%BX\50H;NU\&Z)%X5:91Y@TUEW7'E]]GVK.['&[ /:N!^
M+$FHZ;^V=\<+_P #KY>L+^SO<2V[V?$INP!Y;<<[\"/&><!>V*BG2IZQZN*=
M^FMGM;S[EUJU67+/HIM6MKI=;WZV[=CV?4OV^/V5]*URZTBY^)$C6]CJ L+[
M7+?1;N33+:Y) \M[Q8C IRPYW[1GDCFO7[>X@NH$NK699(Y%#1R1L&5U(R""
M.H-?&GP2\(_M8^(_V)]%\'^&H_@?!X%U3P+Y4TEY-J44B6\T!\]YVC_=I/EI
M&E8<"3>:^A_V1/"VM>"/V:?!OA'7?&VE^(YM.T=((]:T6\-Q:74"LPA,4F!O
M01;%!Q_#^-88BC1IQ]UZIVWO\]E;TU-L+B*U62YUHU?:WRW=_70RO!W[;_[/
M/Q#\26_A'P/X@U;5;^?4/L4T=AX:O94LY?.:(?:)%B*0 LI.78?*-WW2";'[
M.FK?#)KOXC:AX*^*/B+75M?'VHQ^(O\ A)KIFBTB]3:9K6VWH@2VC&-N"P _
MB.*Y+_@FI9VEM^S?<36UI'&]QXTUJ2X:., R/]M==S8ZG:JKD\X4#H!7 ? O
M1K;Q%\#OVKM O-<M=+AOOB1XR@FU*^8B&T5[;:99" 3L4'<< G -:RHTXRJ0
MC=6:7?KZ&<:U5QISG9W3?:VGJ=YX\_X*0? _1]*MW^&EKJ?BJ_U/6(M,T%%L
M)[#3]1N7E\LJFH7$2V^%PQW;B#CCCD8OQD^/?_"K_P!JKX6^)OBQ?7_ARSU#
MP'J#ZIX=MYY+W%_(UN%MA';!OM,JNQ1613G!(P,FO.[6[^*7[67[$_A']E?P
MO^SCXJT.6YTK1;>]\7:Q:16^E6UG:R0DWL#.XDG,BQ!EC$88B4G)&"WL7Q+L
MK:7_ (*'_"YYX%D:W\#ZX\+2*&9&S$NX'L=K,,CL2.]:^RHTI<MM;3OK=V2T
M\E?7I<Q]MB*T.:^EX6T:5W+7?5VTZVZ'=^ _VJ/@S\2]#\1:SX.UK4+B;PI"
M9->TB30[J'4+4;"Z_P"BR1K*Q95.W:IW$8&3Q7GG['7[84WQR\5^,_"/B5-8
MEN;7QYJEOX=D;PK<6\,&EPI&8HIY?+"1SC+Y20B3D9'(J9+2VM_^"I[W%O L
M;7'P#W3,B@>8PUI5#-ZG: ,GG  [54_8DT>Q\0Z!\>=!U1G6VOOCIXHM[AHY
M-K!'2W5L-V.">>U8^RHQI2=GJDUY7^7^1O&KB)UHJZT<D_.WST_$Z<_\% ?V
M4UOTB?XBSKI\FH&RC\1-H5X-*>XW%=@O?*\@C(/S[]G&=V.:]E1U=0Z,&5AE
M6'>OD2TO?C_^Q1^SS;C7-%\ _$SX2^';6%H+[3II+;4Y;"2=62<QLLEM-M\Q
M6&UAN !SGYJ^MM-O[;5=.M]4LG+0W,*RPL5(RK $'';@UCB*5.G9PVUUO?;Y
M*S\F;86M4J753>R=K6M?YM->:)J***PCL=84444P"BBB@ HHHH **** "BBB
M@ HHHH **** -3PSXHO/#UR!EI+9C^]A]/<>A_G^H]$M;J"]MTNK60-'(NY6
M'<5Y/77?#35G;SM$E<D*OF0^PSR/S(/YUE4CU-Z,]>5G74445@=(4444 %%%
M% !7SK_P5D\3ZQX2_P"">OQ*U70[Z2WFET^SLGDC."8;F_MK>9/HT4KJ?9C7
MT57SO_P5B\+:SXP_X)[?$K2=!L9+B>'3K2^DCC'(AMKZWN9G^BQ1.Q]E-=&#
MM];IW_F7YHY<=S?4:MM^67Y,_",=*Z3X4_%WXE? [QG#\0_A-XNN-#UJWADB
MAU"U52Z(Z[7'S CD<=*YL=**_0Y14HV:N?E\92C).+LT??'_  3!_;N_:[^-
M7[;W@WX:_%'XYZMK&AZA'J1O=-NHX0DOEZ=<RIG:@/#HK=>HKS/]HG_@H_\
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MI&G6^BVJW-_=:Q=-#&D9.,[@C=,<YQ6,YQIQYI.R.W#T*V)K*G25Y/IZ:O\
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MIMY>AX(__!.?X#3Z5<>#KWQ)XYN/"<RL(?!$OC2[_LFV).X&.$,#\K?,H9F
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ME[<2A8P,;B !DBO9_%'B;0_!GAK4/&'BC48[/3=+LI;O4+J7.V&&-"[N<9.
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MEUN>Q?MP?$WX'?%;]H/4O$'[.W@*ST'PO;6\5G9FQL?LJZBT>0UX8<#R]Y.
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MV>W:Q^Q=XCU;4/[0^!_Q*\(^,?#T[!X]3A\16UK-91-ROVN"=T>)]IR5 8@
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MO_"O]/OM6\0>$;C^TD:3^V-5AM(KP-&&WA,)<8# *,@@DFNCGPO+=6_G^?\
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M'O\ _P",U_0111_K!67V%][#_5/#O_EX_N1_/RG[%O[8@//[*/Q)_P#"'O\
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M5X^_\(^]_P#C52)^R=^U*.O[-GC[_P (^]_^-5^VU%'^L%;^1?>R?^(?X/\
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M%\9?^$O=_P#QNE_X9N_:'Z?\*&\9?^$O=_\ QNOUHHH7$%9?87WL/^(6Y?\
M]!$ON1^2_P#PS=^T1_T0;QE_X3%W_P#&Z>G[-_[0X'/P'\9?^$S=_P#QNOUE
MHH_U@K?R+[V3_P 0KR__ *")_<C\E;KX ?':QFM[>]^"WBR&2[F\FUCD\.W*
MM-)L9]B I\S;$=L#G"L>@-3#]G3]H./[_P "_&"_7PS=?_&Z_33XFLJ^+? +
M-_T.$@_/2=1%==)&LB[6%'^L%;^1?>P_XA7E_P#T$3^Y'Y/K^SG^T&XRGP+\
M8'Z>&;K_ .-T[_AG#]H7_HA'C+_PF;K_ .-U^KZJ$7:HZ4M/_6&M_(OO8?\
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M/\:UN?[W_CM26F1<K^/;VJ^9D\J,IM!U8G(M/_(B_P"--/A_5]N/LG_D1?\
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M$\5_] K_ ,CI_P#%5Z+11[20>QB>=?\ "">*_P#H%?\ D=/_ (JC_A!/%?\
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M@GBO_H%?^1T_^*KT6BCVL@]C$\Z_X03Q7_T"O_(Z?_%4?\()XK_Z!7_D=/\
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M  3Z?_\ )U7_ &9C_P#GVS/^V,L_Y^H^Y**^&_\ A_Y^QT>GPT^)G_@GT_\
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M'_@ML_\ Y*H_LW'?\^V'^MG#G_03'\?\CZDHKY;'_!6[]G!NG@KQO_X+;/\
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M_LS'_P#/MA_K?PS_ -!4?O?^1[+\6&*>)O ,F#_R.>./?3KX?UKM*^1/'O\
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M\*?]!7_R _\ \31_PG?A3_H*_P#D!_\ XFCEEV#GCW->BLC_ (3OPI_T%?\
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M]?E.64Z--5JJO)ZKR_X)\+G6<5,15="D[06CMU?^7Y[@!S3MO^S^M-'6G?\
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MFIR6^KZI8QW$UD8+V01"W:0$P;2"_P F#N8L><8K?LXKXS;X2_M2#X<?:/\
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MJ>7X:<59RC*[[VDTOP/2?V6/V:O&O[5WQAL?A-X+F2U\R-KG5-4FC+QV%HA
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M".G/&16E>48T92E>R3>F^W3S.?+J=2MF%*G3MS2E%+F5XW;25TT[KOH]#S$
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MI6T?KHE^A5.C2H:KTU;T797.8_9M^!I_9Z^&A^'8\4?VO_Q.+Z^^V?8OL_\
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M5& .?85-114K3J:/\$EOZ%4Z-.DVU?MJV]%MN%%%%9FP4444 %%%% !1110
M4444 %%%% !1110 4444 %3:9>OINHPZ@A/[F0-P<9&>1^(XJ&B@#US-%0V
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MM]&U^UUG6KI8R4M;.UF29V8_P[BHC4GJ\BCO7H'[;_[7GB/PM_P4\\3?M ?
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M ,%2/''@7X8P_!'X_P#PAT#XK^%;'8--L?$^WSK94QLC\QXY5D1,';OC+KG
M?:%52A'&8?"P2BFU>ZOKOT>QGC)Y;C<PJRE4<8NW+*S:T26JM?7RV[,Z?_@D
M/\?/V@;[]JK0O@^?'>N:MX1U"POO[9TB]FDNK:VACM)7CD4/N%N/.$*;EVAM
MX4YW 5T/[!_B[P'\$/\ @K'XT\ Z%]GM=%UK5-=\/Z.J,!%!MO!-#&IZ8S;"
M)?4LH[US/B;_ (*T0^'/"VHZ%^RA^R;X-^%=[JT7E:AK6E1PRW!0!L%!%;P+
MO4G*LXD R<+DY'R39:UK.FZS#XBT[5KJWU"WNEN8+Z&X99HYE;<)%<'<'#?,
M&!R#S4+"5,0ZDIQY%*-K:/775VT+EF-'!0H1I3]JZ<W*]FE;1<JOKTUT6IUG
M[0OP<\2_ #XT^(_A+XIM9HY](U26.WFFCV_:K?<3#<*/[LD>UQZ;L'D&M[X(
M?LE?%WX]?#OQA\4_!EK8V^A^"=.:ZU34-6NC;QS,JEVAB8J5:01@N02 HVY(
M+H&]UT3_ (*U67B_P_8V'[5?[(7@GXG:IID/DVNN:A#!#,5P,EDDMIU#,1EO
M+$:D]%&*X3]IS_@HEXZ^/?@&'X*^ /A]H_P[\!0L&;POX<50MR0V\"5U1%*!
M_F"(B L<MN(7;K&ICY14'!)]9737G9;Z_(Y*E')82E555R6MH*+4KO9-O33J
MTW>VQZQ_P34/_&%7[3W_ &(\W_IMU&OB8'Y37O?[&?[=$_[(OASQ9X4F^$.F
M^++'Q<L":A:ZG>>7%Y4:2HT;)Y;K(KK,00>,<<YKT;_AYS\#R/\ E&]\+O\
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MOCE\*XX_"M\VM7&H:;:Z:J^38K*[-]G5=H5H@K>7M*[2O!&.*^BI_P#@IO\
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M7QUIMU*?#=]=FX;3;FUG\B94E;YGB9N5+?,<$_+D(F_\?R!^Q9\ \G^'Q/\
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MD7;^/6ND7J*XM7>-E=&*LIRI':NJTC4H]1MUD!&Y>)%]#6=1=3MPL].4] ^
M'PVTWXN_%O2/A[J^H3VMOJ#3"2>V WKL@DD&-P(ZH!]#72>&O!G[,?C[Q'8^
M"_#/C#QMIVH:I=QVUG=ZMI-I);K*[;4#B*;=AF(7(Z$Y/&32?L3?\G-^&/\
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MC_@WBT''_)UUY_X1J_\ R71_;.7?S_@_\@_U?S;_ )]_C'_,_,:G)TK]./\
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M5^A@_P""$^B@Y_X:8NO_  DU_P#DJG+_ ,$*]% Y_:6NO_"37_Y*JO[8R_\
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MBC^V,O\ Y_P?^1/^HG%'_/C_ ,GA_P#)'Q"G6G5]K3?\$B-+MY-H^/-P>/\
MH7%_^2*;_P .D-,_Z+O/_P"$ZO\ \D52SC+]^?\ !_Y$O@7BC_GQ_P"3P_\
MDCXM3Z4ZOM(?\$DM* _Y+K/_ .$ZO_R11_PZ3TS_ *+M-_X3J_\ Q^A9OE_\
M_P"#_P B?]1.*/\ GQ_Y/#_Y(^+X_NT]/O5]HV__  21TR5_*_X7O..^?^$=
M7_X_5@?\$A],!S_POJX_\)M?_DBE_;&7_P _X/\ R%_J%Q4_^7'_ )/#_P"2
M/BFG+C'05]K?\.BM,_Z+S<?^$VO_ ,D4?\.B],'_ #7F?_PFU_\ DBE_;&7V
M^/\ !_Y!_J#Q5_SX_P#)X?\ R1\5#&>@I:^U#_P2-TQ!N_X7Q<?^$VO_ ,D4
MT?\ !)/3/^B[S_\ A.K_ /'ZJ.<9?_/^#_R(EP'Q5_SX_P#)X?\ R1\6CK4E
M?9X_X)*:8#G_ (7M-_X3J_\ Q^E_X=+Z9_T76;_PGE_^/T_[8R_^?\'_ )$_
MZA\4_P#/C_R>'_R1\7U(.E?6'Q!_X)CZ=X'T*WUE/C+-=&?7-,T_RSH07:+N
M^@M2^?./W1-NQWVXR,Y&]'_P28TQCC_A>EQ_X3J__'Z7]L9?_/\ @_\ (%P'
MQ4]J'_D\/_DCXQJ6RO+C3Y_M%L^&_B'9O8U]F_\ #I73/^BZW'_A.K_\?H_X
M=*Z9_P!%UN/_  G5_P#C]']LY;_/^#_R*7 /%B=U0_\ )X?_ "1X#\ /C;8?
M"OXFZ5\1)M)^V/IS3?Z"USY7F;X7CX?:V,;\].<8]ZQXV!;.:^EO^'2NF?\
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MT#[0!J5U=_V?]JV_ZX2#;OVGIOZ[><=LUZC_ ,.O[G_HXF^_\$G_ -OIR_\
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M_P#PC/A[_H"VW_?D4?\ ",^'O^@+;?\ ?D4>T0>QEW/,:3:*]/\ ^$9\/?\
M0%MO^_(H_P"$9\/?] 6V_P"_(H]H@]A+N>8X%!'&*]._X1GP]_T!;;_OR*/^
M$9\/?] 6V_[\BG[1!["7<\Q Q17IW_",^'O^@+;?]^11_P (SX>_Z MM_P!^
M11[4/82[GF-%>G?\(SX>_P"@+;?]^11_PC/A[_H"VW_?D4>U#V$NYYC17IW_
M  C/A[_H"VW_ 'Y%'_",^'O^@+;?]^11[4/82[GF-%>G?\(SX>_Z MM_WY%'
M_",^'O\ H"VW_?D4>U#V$NYYC17IW_",^'O^@+;?]^11_P (SX>_Z MM_P!^
M11[4/82[GF-%>G?\(SX>_P"@+;?]^11_PC/A[_H"VW_?D4>U#V$NYYC17IW_
M  C/A[_H"VW_ 'Y%'_",^'O^@+;?]^11[4/82[GF-%>G?\(SX>_Z MM_WY%'
M_",^'O\ H"VW_?D4>U#V$NYYC4EI9W=_+Y-E;22M_=C4FO2AX:\/J<C1;7_O
MRM6X;>WMD\NW@6-?[J* */:C5#NSEO#7P],+K?:\%9E.4MU.0/\ >/?Z=/KT
MKK ,=***SE)RW-HQC'1!1114E!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M] #X>06]ZY+Q+_R6_P )_P#8#UC_ -#L:Z]!A<8KD/$O_);_  G_ -@/6/\
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M--,)0%$]Y.\L81(PA />_P#@Z%\"GXH_LZ?LU_#,>*-4T/\ X2+]LGP;I?\
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MU6;?+);7[QWMQ-LN(%BGB5EQE+N7/O\ 6'_!5;]C#]L2_P#VGOA%_P %0/\
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MF^+&A^&=TFM>+O#/AN.*Q2W&<W*++)YRQ8!PTZ0]#Q@9.)_P=8?M/_$[1O\
M@B+X'FT2_CL9/B]XL\/V'BP6:LBO:/IUSJ<D,?S%E4W%K ,$G*!E.=QKS?\
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M;]E__@F%^V)X1_92_:+\"^(%M?$W@U?$ESXST]DDM=.MVFO81&T S+)(7LB
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M::IXJTZULY-0L9=:LQ;0I]FNYPZA+C4$?=M)6<+\PX7]'?\ @[9_Y0V>)/\
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MGA'2=#D\[5K?2I[>6&51Y9S")[W^SA&'VF5X&\O/E2;4%EHC]1OV-KG]I_X
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M],>AU^OL\,5S"]O<1*\<BE9$89#*1R#7$? ']F7]GG]E3P=<_#W]FGX*>&/
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M.,CAD!ZBK'PV^&GP]^#G@72_AA\*/!6F>'?#NBVJVVCZ'HUFEO:V<(Z1QQH
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MD^HW6C^$]%AL;>:[>..-IVCB55,A2*)2Q&2(U'85W% 'SK_P5Z_Y13?M)_\
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M+R2Z&B>%])BLK43R8WR>7$H7<VU<G&3@4 ?D;_P7L_Y3\?\ !/G_ +'+3_\
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M%D"I*-*%B8HS*SE217DW_! #X^_\$"[K]E2\\$_\%(/#_P *Y/CY-XPU:_\
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MX>Z>^HKJ9B(M9$O].M@MELF,;EGE0%$<8DR8V9+[:GM?_!SU^R#XD_X*$_\
M!**U^)?[,PA\7WO@76[/QOHZ^'YA>?VWH[6LT4[6C1;EG'DW"72E2=Z6Y";B
MRANL_83_ .#A7_@E;^U%^S9H?Q)^+O[0O@#X;^-8='A_X3;PCXNGCTU[34%0
M"<6OGG%U SAFB:)G8HRAPK[D63_@UU^&GQP^&/\ P1J^&^D?&VVNK/\ M#4-
M5U3PGI=]9O!/9:-<WDDL&]74$B9VFNHVY#1749!P0!ZC^T)_P09_X)%?M1_$
M6;XL?&3]ASPK<>(+J:2:^U#0KR]T7[=-)(9))[A-.G@CN)G=F9I959V).6-,
MC39GBW["W_!:BX_X**?\%3/$W[/7[&/P%TOQ-^S[X-\'++KWQ>DL[BQN+;5R
MTA1X?,3;+#,=L$=NZ12GR;BX$C1IY9^;_P#@LU_RL[?L0_\ 7GI/_IZOJ_8+
MX'?L]? S]F;X?V_PJ_9X^$'ASP3X;M9#)#HOA?2(;*W\P@!I66)1OD8*-TC9
M=B,L2>:S_'O[)_[,_P 4_B[X>^/WQ)^ GA/7?''A-8U\,>+-5T.&?4-*"2-(
M@@G=2\6'=F&TC!8GO3%U.B^*X/\ PJ[Q(0O_ # +S_T0]?E+_P &6G_*+'QQ
M_P!EZU7_ -,VB5^NE[8VFI6<VG7]K'-!<1M'-#(N5=",%2.X(XKC/@%^S-^S
MW^RMX.N/AY^S7\%?#/@30;O4GU"ZT?PKH\-C;2W;QQQM.T<2JID*11*6QDB-
M1V% =+'XL_#/]L#]FO\ 86_X.Q_VJ/BI^UM\6=/\#^']2^%T&EV.J:Q'+Y<U
MW+#X9GCB'EHQRT4$K@XQA#STS][_ /!2W_@N!\./^"?'P=^#O[36A_ 7Q)\3
M/A;\4M3MVO/'_AFX6*RT?2YHDECN,2*6EN)8WWPP.(5D$<@,J,H4_0OQT_X)
MZ?L)_M.>,5^(?[0_['?PT\:^(%MUM_[<\3>"[*\O&A7[D;321%V1>=JDD+DX
MQDUV_P#PHCX+'X.Q_L\S?"7PW-X"AT5-'C\%W&BP2:7_ &>D8C6T-JZ&(PA
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M** .'_:#_P"1(TS_ +'CPU_Z>K*NXKA_V@_^1(TS_L>/#7_IZLJ[B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)&F?]CQX:_\ 3U95W%</^T'_ ,B1IG_8\>&O_3U95W% !1110 4444 %%%%
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MU'_Y/JO[#Q_9?>3_ *Q9;W?W'Z_45^0/_$0!^V1_T33X9_\ @FU'_P"3Z/\
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MR[+[P_UDRSN_N/U)HK\NT_X+7?M4MU\!?#__ ,%=]_\ )E2+_P %J?VIR.?
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MN?\ >H61HWW"OAU?^"D_QT)Q_P (OX4_\ KK_P"2*F3_ (*/_')AD^&/"O\
MX!77_P D57^JV;=E]XO]8LM[O[C[KAF69=RT^OA>'_@HY\<5;<OAKPN/^W*Y
M_P#DBK4?_!1_XYGKX:\+_P#@'<__ "14_P"J>;=H_>5_K)EO=_<?;U%?$J_\
M%&/C@QY\->%__ .Y_P#DBIA_P42^-I_YEOPS_P" =S_\D4_]4\X[1^\?^LF6
M=W]Q]J45\8)_P4+^-;<GPYX9_P# .Y_^2*>G_!07XT'_ )E[PW_X"7/_ ,?H
M_P!4<X[1^\/]9,K[O[C[,HKXX3]OWXS,,G0/#G_@+<?_ !^I4_;W^,C'!T'P
M[_X"W'_Q^J_U1SCM'[Q?ZR99W?W'V%17R$O[=_QA;_F!>'__  %N/_C]:_A;
M]N_Q5'<8\9>#;.XC9P/,TV9X61>YVN7W'\5J9\(YU&-U%/R4E^MAQXCRN4K.
M37JF?4U%<+\-_C=X'^*MLS>%M:;[3&FZ:PN?W<\8]2N?F'(Y4D#(YKJ//G_Y
M[-_WT:^>K4*V'J.G5BXR71Z'LTZU*M!3IM-/JC2HK-\^?_GLW_?1H\^?_GLW
M_?1J.4OF,']H4X^ 7C@_]2?J?_I+)785Q7QB9I_A'XJ@G.^-_#=\KH_(8&W?
M((]*Z%IYQTG?_OHTFK!S&I165]HN/^>[_P#?1H^T7'_/=_\ OHT@YC5QGJ*3
M8O\ ='Y5E_:+C_GN_P#WT:0W%P1_KY/^^C5<H7-; ]*3:O\ ='Y5D^?=?\_$
MG_?7_P!>D-Q= 9^T2?\ ?1HL%T;  '045C_:KG_GXD_[Z-)]JNO^?E_^^C2L
M',;-%8IN;O\ Y^9/^^C_ (T?:+O_ )^9/^^S_C3Y0YC:HK#:ZNP<?:9/^_AI
M#=7?:ZD_[[/^-'*',;M%8/VJ\_Y^I?\ OL_XT?:KS_GZE_[[/^-'*',;U<?X
ME_Y+?X3_ .P'K'_H=C6@+R[_ .?N7_OX:Y_6))7^).AW#2L9(]-U (Y8[E!:
MVR >V<#\J.47.>@45SS7EYM_X^Y?^_AIGVV]_P"?R;_OX:.47M#I**YO[;>_
M\_DW_?PT?;;W_G\F_P"_AHY1^T.DHKFS>WP&1>2_]_#_ (TS[=?'_E]F_P"_
MA_QHY1\QT]%<Q]NOO^?V;_OZ?\:1]2O(QDWTW_?P_P"-'*3[1'32RK"F]JHS
M2O,V6Z5SKZC?N<M>2_\ ?PTW[9>$8^U2?]_#5* .9T6?]Z@G']ZN=^V7?_/W
M+_W\-$=W?,?FO)<?]=#5<I"G<ZFTMM[><_X#UJW7(C4=0'2_F_[_ #?XT?VE
MJ/\ S_S?]_34.++YT==7'_%K_C^\'_\ 8X6__HB>A]3U('C4)_\ O\W^-8?C
M.[N[BXT0SW4C^7KD3Q[G)VMY<G(]#R>:.0/:'IE%<=_:FI?]!"?_ +_-_C37
MU34P>-1N/^_S?XT_9A[3R.SHKB_[5U3_ *"-Q_W^;_&C^U=4_P"@C<?]_F_Q
MH]F'M/([2BN+_M75/^@C<?\ ?YO\:C.K:KG_ )"5Q_W^;_&CV8>T\CN**X?^
MUM5_Z"=Q_P!_F_QH_M;5?^@G<?\ ?YO\:/9B]JCN**X0ZOJP./[4N/\ O\W^
M-)_;&K?]!2X_[_-_C1[,/:>1WE%<'_;&K?\ 04N/^_S?XTS^V=8_Z"MS_P!_
MV_QH]F'M4=_17G_]L:Q_T%KK_O\ M_C37UK60?\ D+77_?\ ;_&CV8>U1:_:
M#_Y$C3/^QX\-?^GJRKN*\?\ B%?WU]H=K#>7LTRKKFFR*LDA8!EO865N>X8
M@]B 1TK=.M:R%P-7NO\ P(;_ !H]F'M4>AT5YTVMZT/^8O=?^!#?XTG]N:U_
MT%[K_P "&_QH]F'M4>C45YNVN:WU_MB[_P# AO\ &F_V[KG_ $&;K_P(;_&C
MV8>U1Z517FIUS6^VLWG_ ($-_C2?VYKG_09O/_ EO\:/9L/:H]+HKS%]>UT'
M UJ[_P# AO\ &F_\)!KV?^0W>?\ @2W^-/V3%[9=CU"BO+_^$@U[_H-WG_@2
M_P#C1_PD&O?]!N\_\"7_ ,:?LGW#V\>QZA17E_\ PD&O?]!N\_\  E_\:/\
MA(->_P"@W>?^!+_XT>R?</;Q['J%%>7_ /"0:]_T&[S_ ,"7_P :/^$@U[_H
M-WG_ ($O_C2]DP]O'L>H45Y?_P )!KW_ $&[S_P)?_&C_A(->_Z#=Y_X$O\
MXTO9^8>WCV/4**\O_P"$@U[_ *#=Y_X$O_C1_P )!KW_ $&[S_P)?_&CV?F'
MMX]CU"BO+_\ A(->_P"@W>?^!+_XT?\ "0:]_P!!N\_\"7_QH]GYA[>/8]0H
MKR__ (2#7O\ H-WG_@2_^-'_  D&O?\ 0;O/_ E_\:/9^8>WCV/4**\O_P"$
M@U[_ *#=Y_X$O_C1_P )!KW_ $&[S_P)?_&CV?F'MX]CU"BO+_\ A(->_P"@
MW>?^!+_XT?\ "0:]_P!!N\_\"7_QI^R8>WCV/4**\O\ ^$@U[_H-WG_@2_\
MC1_PD&O?]!N\_P# E_\ &G[)]P]O'L>H45Y?_P )!KW_ $&[S_P)?_&C_A(-
M>_Z#=Y_X$O\ XT>R?</;Q['J%%>7_P#"0:]_T&[S_P "7_QH_P"$@U[_ *#=
MY_X$O_C1[)]P]O'L>H45Y?\ \)!KW_0;O/\ P)?_ !H_X2#7O^@W>?\ @2_^
M-'LGW#V\>QZA17E__"0:]_T&[S_P)?\ QH_X2#7O^@W>?^!+_P"-'LGW#V\>
MQZA17E__  D&O'_F-WG_ ($O_C4UKXM\26C;H]7F;_KJ=_\ /-+V4@]O'L>E
M45RVA?$:WN7%MK,*P,WW9H_N?CGD?F?PKJ58.H=3D'D$=ZB47'<TC*,M@HHH
MJ2@HHHH **** "BBC- 'C?[<G[8_@?\ 8J^"-S\3/$J+>:K=2&T\,Z&&(;4+
MPJ2 <?=B0#>[G@ 8&7=%;\+_ ([_ !Y^*G[2GQ'O/BI\8?%<^JZM=_(C.V(K
M2$,2L$*=(HE+-A1W9F.69B?>O^"Q/[1U_P#'?]L?6?"EGJ;2:#X"9M$TNW5S
ML%PA'VR3;G&\SAHR1U6"//2OE6OM<IP,<-AU4:]Z2OZ+M_F?G^=YC/%XETXO
MW(NR\VMW_EY!17TA^U=_P3 ^/?[)OPBTOXV^)M:T?7-#U"XABNIM#\]FT\RI
MNB:8/&NU&/R;LX#E5/+KGYO;..*].C6I5X\U-W1Y-:A6P\^2I&S"BOH+5/\
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M_P"2AZ+_ -@Z^_\ 0K>MT5A:M_R4/1?^P=??^A6]!F;C_=IE/?[M,H ****
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MUY5HG_!3O]C#QYJ;^#M*^*[6]U>*T-K-J6DW%M!(Y!P/,= J9]7*C\Q7"?\
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MVM[+NV>9?\%(_"7A_P"-?_!6J\^&'AF[2-O$'B'P_HE]=JX9!<RP6D#-P?X
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MI ? ?_7/6/\ TSWM=&,_W.I_AE^1A@/]^I?XH_FC:\6&/]M#]C>T^),#>?\
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M./\ Q]JUJR/ G_(JVO\ VT_]&-6O7++XF=T?A04445)04444 %%%% 'YB?\
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MXUU4GWOQJ,]?QHC*4=4R9QC)6:N0V%A8Z79QZ=IMG%;V\*!(888PB(HZ  <
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M,J-M_"NBHI1E*+NARC&2LU<S[;PKX8L[BVO+/PY8PS6<(ALYH[-%:", @(A
M^5<$C P.3ZT>)_"/A3QMH\GA[QGX9T_5]/F_UUCJEE'<0O\ 5'!4_E6A11S2
MW#EC:UC"\$?"_P"&GPSMI++X<?#S0_#\,S;IH=$TF&U60^K")5!/UK:N+>WN
MX'M;J!)(Y%*R1R*&5E/4$'J*?10Y.3NPC&,59(Y;PI\#O@MX#UE_$?@?X0^%
M]&U"3/F7^D^'[:WF?/7+QH&.?K74T442E*6K%&,8JR5@HHHI%'HO@3_D5;7_
M +:?^C&K7K(\"?\ (JVO_;3_ -&-6O7++XF=T/A04445)04444 %%%% !111
M0!PWQ4_9F_9Z^-[^?\7/@MX9\0W C\M+S5-'BDN$7T68KYBCZ,*\BN_^"/O_
M  3HO+EKJ7]G2-68Y*P^*-5C7\%6Z 'X"OI:BMJ>)Q%-6A-KT;1SU,)A:TKU
M*<7ZI,^9?^'.W_!.7_HW?_R[M7_^2Z/^'.W_  3E_P"C=_\ R[M7_P#DNOIJ
MBM/KV,_Y^2_\"?\ F9_V?E__ #YC_P" K_(^9?\ ASM_P3E_Z-W_ /+NU?\
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M]GY?_P ^8_\ @*_R/F7_ (<[?\$Y?^C=_P#R[M7_ /DNC_ASM_P3E_Z-W_\
M+NU?_P"2Z^FJ*/KV,_Y^2_\  G_F']GY?_SYC_X"O\CYE_X<[?\ !.7_ *-W
M_P#+NU?_ .2Z/^'.W_!.7_HW?_R[M7_^2Z^FJ*/KV,_Y^2_\"?\ F']GY?\
M\^8_^ K_ "/F7_ASM_P3E_Z-W_\ +NU?_P"2Z/\ ASM_P3E_Z-W_ /+NU?\
M^2Z^FJ*/KV,_Y^2_\"?^8?V?E_\ SYC_ . K_(^9?^'.W_!.7_HW?_R[M7_^
M2Z/^'.W_  3E_P"C=_\ R[M7_P#DNOIJBCZ]C/\ GY+_ ,"?^8?V?E__ #YC
M_P" K_(^9?\ ASM_P3E'/_#._P#Y=VK_ /R73A_P1[_X)T#I^SS_ .7;J_\
M\EU],44?7L9_S\E_X$_\P_L_+_\ GS'_ ,!7^1\TC_@C_P#\$[!T_9Z_\NS5
M_P#Y+IP_X)"_\$\!T_9\_P#+LU;_ .2J^E**/KV,_P"?DO\ P)_YA_9^7_\
M/F/_ ("O\CYM'_!(K_@GFO3]GW_R[-6_^2J=_P .C?\ @GL.G[/Y_P#"LU;_
M .2J^D**/KV-_P"?LO\ P)_YA_9^7_\ /F/_ ("O\CYQ'_!)+_@GT.GP"/\
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M^%G_ )7+[_X_7KU%']J9E_S^G_X%+_,7]GY?_P ^8?\ @*_R/(Q^PE^RJ/\
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M_P Q?V=E_P#SYC_X"O\ (\N;]C[]GGK'X V_]Q:[_P#CM1-^R1\!(N#X _\
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M[RT\&^'=)_MCQ=:V+&.2\N-GF*A;)#*$>W"G VF64\D+C<_:._X)@?LTZ?\
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MX?RG_GW_ .32_P P_M[-O^?GX1_R/NU?^"SN?^;;O_+P_P#N.I$_X+*;N?\
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MA#_V4VU_E7M'[;WA35_''[)/Q!\.:# TUY)X9N)888XV9Y3$OF[%49+,P3:
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M*EC)U6]'LNU[.7WM'QK_ ,$1O^3<?$__ &.TO_I':U8_:Q_Y2@? O_KPD_\
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M/B&'X=>/_P#@IKX%TGQ@&C@OO#ZZ9#(;>Z(&8-SWT;$[C@;D1CQ\@)Q7S/\
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M?V:_CKX.UB3]F/Q'XPL_%V@:=-J4GA?QD;:;^UK6, R?99+9$_>JN6V,"6Z
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M:=FGH[W77]59ZGWLQRN:;3C]SBFU^''ZK+<****T)*/B9/,\-ZA'C[UC,/\
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M% !49ZU)49ZT$_:"BBB@DC/6B@]:*"F%1U)4=!(4U^M.IK]: ,7QQ_R"+?\
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M.:,/@XSPU+VL=8Z_C_PS^08O'SIXNLZ$O=FDOP6WGNOFS[3_ &>AC_@B=\>
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M%Y\+?A=JFG^+/VA?$^F!/$GB.*,26OAFW<!EA0,/7#I$1ND*K-,%00Q-QO\
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MP( /(*3K*57$<CULE'J[?E=L=:-"4:.%]HM&W*71<UMN]DOO/>?@'\ ?A/\
M\$R?AQ8?MB?MI:2NH?$2]7S?AK\,?,43V\P&5N;@'.R1<@EF!6W&#AIV2-/C
MKX^_'CXC_M+?%?5?C)\5-66ZU;59LE(5*PVL0XC@A4D[(T7"@9)/)8LQ9C]L
M?&/]LK_@CC^T#X^N_B=\8?@'\6M<UJ\"K)=W&HNH1!]V.-%U0)&@R<(H"C).
M,DD^"?M=^/O^":'BCX9VNG?L<_!+QEX;\4+K44EW?>(;MY('L1%*'C :]G^<
MR&$CY1PIY'0YX2=3VO/5IRYWI=I62[+71?B]V:8VG3]C[.C4AR1U23=Y/N]-
M7^"V1Y]^R=^R9\6/VQ/BE!\-/A?INV--LFM:U<1G[+I=N3@RRD=S@A4'S.1@
M< D?1W[6G[3WP4_93^"FH?L!?L.WJWL-\K0_$KX@*X:3592NR6WC=>&4C*,5
M^14)1<EG:NO_ &8O^"C?_!/SX/?L?V7[-7BGX4>/K>;4=-V^-KKPS;Q6[:G=
M/_KG^TI>QS%6'R=5^3Y,!?EKEA\8/^"$ _YM3^*'_@RE_P#EK45*E:KB+U:4
MG&+T22LWW>J^2-*5*C1PJ5&K!3DO>;;ND_LK1_-[GRW^S!\8O"OP"^-^C?%?
MQK\*-/\ &^FZ6MR+CPSJDD:P7?FV\D2EC)%*OR,XD&4/*#IU'U)XV_X*P_LT
M>*O!FK^&--_X)D>"--N-2TNXM;?48;ZR+VKR1LBRKC35.5)##!!R.HZU\H_M
M#ZO\$-=^,NMZM^SAX7U+1?!4TD)T/3-8D+W,"B",2!R992<RB1A\[<$=.@XN
MNZIA:&*:J3B[V75JWR3L>;3QF(PD94J<E:[Z)WZ73:O;0105&":^^_V5_P#E
M!G\</^QXD_\ 1>C5\Y?L:>+_ -ACPG=>(6_;7^%GB;Q-#/':CPXOANX:,V[
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M[O5MN[[ZZG'BJCJ5FW+FV5TK+1):+MIH?0?P<_Y,%^+O_8<T3_TH2L']A_\
MY.L\$?\ 88_]IO79>&/C=^Q5X8^$/B/X+Z=X<^*3Z7XGNK6XO[B:ZTTW$;6[
MAT$;!0H!(YRK9'3'6O.?@[\2/!'PC_:)TOXE:3IVK3^'M)UIY[2WN&B:]:WP
MP0.1M0R8(SC SG%<4(UJE'$QY&N:[5^MX)??='?*5*G6P\N=/ELG;I:3?Y,Y
MGQ6,>+]5_P"PE-_Z,:O7OV@_^3:_@FY//]CZL,^PO!BO&=7OTU77+W5(D95N
M;N25%;J S$@'\Z[OXF?%G1_'/PG^'_@#3].NH;KPC8WL%]-,%\N9IIQ(I3!)
MP!P<@<UWU*<Y5*+2^%MOR]R2_-HXJ=2"IUDWNE;S]Z+_ "3.W_;K,)^)_AU]
M./\ Q+6\ Z2=(V_=^S>6VW;[9W?K4G[%F/M?Q/\ ^R/ZU_."J/AKXU_!?Q]\
M/-&^'O[2OA'Q!--X9B-OH?B;PI<0B\^QYRMI,D_R.B'[K=5   'S%]GP?\=_
MV>?A/:>+/#OPN\!>(Y;7Q%X1OM,.M:_-;R7WGS*JQIMBVQQ6ZX=FQN=V*YX0
M"N%QQ$<!]55-MK2^EFDUK>_5=-[G?&5&6,^L\Z2>MM;IM;6MT?7:Q0_8O_Y*
M=JW_ &)>K_\ I*U:/[+Y!^%?Q>CT_=_:7_"%@Q>7][[,)/\ 2/\ @.W;GVKB
M/@%\3=*^%'BV]\1:S87%Q'<Z#?6"I:[=P>:$HK?,1P">>^*C^"_Q6U;X.^-H
M_%>GZ;;ZA;S6\EGJVE7?^IO[.08D@?KP1@@X(#*I(8 @]6(P]:K*KRK=0:\W
M%MV^>WS,,/B*5.-+F>SE?R4DE?\ 7Y'.Q].:[+X*?"G4?C)XZA\'6>J0V$ A
MDN=2U*X&Z.SMHUW/*1D9P, #(R2,D#)'6KK'[#8E_MU/!OQ(-QYGG#06U"S^
MQ;NOD>=_KO+S\N[[^.>M4O#7[1=WH/QRG^+MOX(TV&QO(7LKKPW9*(;=K$Q"
M+R,A>H55.['++DC!VUO+$8JM2FJ--J5G9RLM>B2N[^NQE"CAZ56+JS35U=*[
MTZMZ*WYFO';?L.V3/:7&J?%"^:.0J;NS@T^.*;!QO57^8*>H#8.#R :M_MFB
MP_X7!;'2O.^R_P#"-:=]F^T8\SR_)&W=CC=C&<<9K.U'5OV.+"&35_"_A7Q]
M?7ROOM]*UB]M([%FSPKO$#,4'H"&.,;AG-1?&OXI^!_B]9:9XJ72=6M?%:VE
MM:ZMN>#^SWCBC*EHE50ZLS!3@G: 2.< USX>G4^N4ZEIM6:?-;1NW3MIJ]MC
MIJSI_59T[P3O%KEOLK]?GHC=^+7_ ";!\(?IKW_I8E0?L^?\BO\ $;_L19O_
M $?#1IGQ0^#WBCX0^'?AU\4=$\3)=>%VOAIUQH-S;B.=;B42DR"52000!@=A
MG/.!@_##Q_IW@G1_%6G7]E/,^O>')-/MVAVXCD:2-]S9(^7"'IDUK&E6^IU*
M7*[\[?DTZCDFOEN1*I2^M0J<RMRI>C4%'7YG6_#TY_93\?"RW>:-7THWNW_G
MAYAV9]M_ZUYM'_G\ZZ'X3_$O_A7=_>0ZIX?BUC1=7L3:ZUH\\QC6YCSE2& .
MQU;YE<#*G.,9R.PLM>_9&T"YCU[2?"/C?5KJ!O,BTG6+JT2SD;/"NT8+E1UZ
M'.,'()KHC*K@ZU7]W*7.U)-6_EBK.[5M5N]+-:Z,R<:>)HT_?4>56=[]V[JR
M=]^FM_D3_M4F/_A+_#:28^V+X'TT:D/XQ/M;._\ VMNW\,5#^U2?^,AO$O\
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M+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5C_\
M(U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^
MRS_T5_X@?^!5C_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_
MX%6/_P C4?\ $/O^RS_T5_X@?^!5C_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE
M_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5C_\ (U']N8#N_N#_
M %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5
MC_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\
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M1\OC3Q)_W^M__C55_K5D_P#,_N8?ZN9I_*OO1\;Q]15F/^E?8:_\$W?A4O\
MS./B/_O];_\ QJG+_P $Y/A:O_,X>(O^_P!;_P#QJJ_ULR?^9_<P_P!7,T_E
M7WH^08^G_ :L1?Y_.OKI?^"=7PN7IXN\0],?ZZ#_ .-4Y?\ @GA\,%Z>+?$'
M_?Z#_P"-57^MF3_S/_P%A_JYFG\J^]'R7'TJQ'7U>O\ P3V^&:=/%OB#_O\
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MH:UJT>O>%])ETZQL89HA9R1NERI:13&7+8N7QAP.%XZY]B_X0#Q3_P ^*?\
M?]?\:/\ A /%/_/BG_?]?\:J-7DORO=6^3)G1]I92C>S3^:V,:N-_:!^"/AC
M]HWX1ZM\&O&6I:A9Z;K'V?[3<:7(BSIY5Q'.NTNCJ,M$H.5/!/0\CTO_ (0#
MQ3_SXI_W_7_&C_A /%/_ #XI_P!_U_QJ(U.22E%ZH)474BXR6CT/ OBW^Q1\
M./C)\ _"W[.?B/Q9XBM=!\*QV26LFGW4*7%VMK;&WC$S-$RM\IW':J_-@C&
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gjyjiv3jrhol000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #] IL# 2(  A$! Q$!_\0
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M0<=.2>6)))/->-O&WC?XK^-;[QQXZU^]UK7=8NO-O+ZZ<R37$K8'^ "@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU1^/=%%&#C./QK[H_.3VO]AS]N/XJ?L/?%2/QKX+N&O=%O&2/Q)X;FF(@U"
M'D@=$F49V28R#P<J2#^\'[.'[1_PI_:F^%.G_%WX1:^M[IUZNVX@8@3V4X4%
M[>9 3LD7(R.A!!!*D$_S:5[5^P]^W%\5?V'_ (JQ^-?!%RUYHMXR1^)/#<TQ
M$&H09Y('1)E&=DF,J3@Y4LI\G,LMCBX\\-)K\?7_ #/;RG-I8&7LZFL'^'FO
MU1_0]17 _LW?M(_"S]JKX6:?\7?A%KZ7FG7BA;BW8@3V,^T%[>= 3LD7(R.A
M!!!*D$]]7Q\HRA)QDK-'W<9QJ14HNZ84445)04444 %%%9?C'QEX;\ ^'+OQ
M;XNUB&QTZQCWW%S,V%4= /<DX  Y)( R33BG)V1,ZD*<'.;LEJV]$DNK#QAX
MQ\->!/#=WXL\7:Q#8Z?8Q[[FZG;"J.@'J23@ #DD@#)-?G9^U7^U9XE_:+\1
M?9+(RV/AFQE/]FZ6S8:0_P#/:;!PSGG Z*#@<DDI^U5^U9XD_:*\2_8[3SK'
MPS8R$Z9IA;#2'IYTV"0SGL.B@X&3DGR4+C^"OL,KRM85>UJ_'T\O^"?@/&W&
MT\XF\%@G:@MWLYM?^V]EUW?1()Q_'74?![X/>-?CCXWM_!/@FQ\R:3YKFYDX
MBM8<@-*Y[ 9^I. ,DXH^#OP>\:_''QK;^"/!5AYDTGSW5T_$5K#G#2N>P'IU
M)X&217Z1? 3X"^"O@#X(C\*>%;?S)I,/J6I2+B6\FQC>W)P!_"HX4>I))WS+
M,H8*'+'6;V7;S9YO!_!^(XCQ'M:MXT(O5]9/^6/GW?3UL.^ WP-\)_ #P'#X
M*\+!I6+>;J%](,/=SD &0C)VC@ *. !W.2>VKS?X1_M3?"GXX_%OQU\(_AKK
M']I7/P]^PQ:_?6_-N+JY:Z!MT;^)H_LQWD94%]N<JP'I%?%UO:NHW4W>NOGJ
M?T3@Z.%P^%C2PR2A'1);*VGYD=W;07MK)9W4"2Q2H4DCD4,KJ1@@@]01Q7X2
M_P#!6C]AAOV./V@WU/P;IOE^!_&#2WOASRHSLL9 1YUD2<_<+ K_ +#KU(-?
MN]7BG_!0#]E31_VPOV9/$'PHN(5_M:.$W_AFYXS!J,2L8N3T5\F-O]F0]\&N
MS+<8\'B$W\+T?^?R.3-L"L=A6DO>6J_R^?\ D?F=_P $-?VU'^"'QQ?]G+QS
MK*0^%_'EPHT^2X)VVFKX"Q$'L)@!$>.7\KD '/[-KTZ5_,)/%K_A#Q"]O/%=
M:;JFEWA5T8-'-:W$;X(/0HZLOU!%?T'?\$]/VHX/VNOV5/#/Q7N-1AGUM8/L
M'BF.)0OE:C" LF5'"[QMF '&V5>G0>AGF%49*O'KH_7HSR^'<:Y0>&GO'5>G
M5?(]NHHHKY\^H"BBB@ HHHH _)#_ (.,_P#DN'PY_P"Q4N?_ $IK\YJ_1G_@
MXS_Y+A\.?^Q4N?\ TIK\YJ^XRO\ Y%]/T_5GYUG/_(SJ^J_)&KX%\;^*/AKX
MSTOX@^"M6DL=6T74(KS3KR$X:*:-@RGW&1R.A'!XK^A']AC]K?PM^V=^SOHW
MQ>T:6WAU1H_LOB;2X&)_L_4$ \R/!Y"-Q(F<Y1UR<YK^=FOI[_@E5^W+=_L9
M?M"P1^*=2F'@?Q4\=CXHM@PV6YW8BO<'O$6.[')C9QR=M9YK@OK5#FBO>CMY
M^7^1KDN8?4L3RS?N2T?D^C_S\C]ZJ*CMKB&ZA2XMYEDCD4-'(C95@>001U&*
MDKXL_0 HS17CO[=/[6GAG]C']G?6/C'KD:W%\J_8_#NF[AF]U"16\I.2/D7!
MD<]0D;8R< U3IRJ34(K5F=2I"C3<YNR6K/BW_@N_^W=_8>DI^Q9\,=:7[7?Q
MQW7CJZM;@[H(.&AL3CO)Q(X/\&P<AS7Y5\UK>/?'7BSXG^-M5^(OCO6IM1UG
M6K^6\U*^FQNFFD8LS8' &3P   ,    5DU]Y@\+'!X=4U\_-GYOC\9/'8EU7
MMT79=/Z[A7] /_!*#_E'G\,/^P)+_P"E4U?S_5_0#_P2@_Y1Y_##_L"2_P#I
M5-7F9]_NT?7]&>MPU_OD_P##^J/H>BBBOE#[8**** "BBB@#R/\ ;H_:2T[]
ME']EOQ9\9KAMU]9V!M]#AR,S:A-^[@'/8.P=N^Q&QD\5_.S?W][JE]-J>HW4
MD]Q<3-+<32L6:1V.68D]22<DU^B'_!P-^U(GC#XIZ#^RSX6UMI+'PM#_ &EX
MDAB8[#J$R_N8V]6C@.[C@?:2.H('YTU]ADN&]CA>=[RU^73_ #^9\'G^+^L8
MSV:>D-/GU_R^0'-?HM_P;[?M/+X1^*?B#]ECQ#.PM/%<)U702TORQWT$>)HP
MOK)  V1_S[8YSQ^>.IZ3JFBSI::OI\UM));Q7$<<\94M%+&LD;@'^%D96!Z$
M,".M;/PE^)GB;X,_%#P_\6/!UY)#J7A[5H+^S='*Y:-PVP^JL 58="K$'()%
M=^*H1Q6'E3[[>O0\W XF6#Q4:O9Z^G7\#^F<=**Y?X+?%CPO\=/A1X=^,'@J
MY\S2_$>DPWUKNQNC#J"8VQT=6RK#LRD5U%? RBXRLS],C*,HIK9A1112*"BB
MB@ K\6?^#@/_ )/GL/\ LG^G_P#I1=U^TU?BS_P<!_\ )\]A_P!D_P!/_P#2
MB[KV,C_W[Y,\/B+_ )%WS1\.U^\7_!%__E'-X"_ZZ:E_Z<+BOP=K]XO^"+__
M "CF\!?]=-2_].%Q7JY]_N<?\2_)GA\-_P"_2_PO\T?4U%%%?)'W 4444 %%
M%% &5XZ\9:!\._!>K>/O%5\MKI>B:;/?ZA<2'Y8X(HS(['Z*IK^</]I#XW^(
M_P!I#XZ>*/C=XI^6Z\0ZM)<K#G(MX<[8H1[)&$0?[M?JM_P7S_:?'PV_9YTW
M]G70K@KJGCRZ\S4"DF#%IMNRLP(Z_O)?+4=BJ2#TK\<J^JR/#<E%UGO+1>B_
MX/Y'Q?$>+]I7C0CM'5^K_P E^85]0?\ !(O]J,?LR?MCZ*^NZQ]E\.^+@-#U
M[S&_=KYK#R)FSP-DP3+?PHTG8FOFJ\T+6M/TRSUJ^TFXAL]0$AL;J2$K'<;&
MVOL/1MK<''0U5C>2*198G965LJRG!!]:]FM3C7HR@]FK?UZ'@T*U3#UHU([I
MI_UZG]0X.:*\"_X)H?M/#]J_]D3PS\0M2OXYM<T^'^R?$H1OF%];@*SL.QD0
MQRXZ#S>*]]KX"I3E1J.$MT['Z=1JQK4HU([-7"BBBLS0**** "BBB@#\N?\
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M_:0^&&I?"3XN>&X]2TC4H]K*P D@D'W9HGQF.13R&'3W!(/X1_M\_L#?$_\
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MC.L-['%<ZVEK\^O^9[G#^+]O@_9O>&GRZ?Y?(L4445XY[P4444 %?BS_ ,'
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M1]?*DP,).H^\O0_>7(/'UV6YG'%1]G4TFOQ_X/=?TOA<WRB6!E[6EK3?X?\
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M:_.:ON,K_P"1?3]/U9^=9S_R,ZOJOR1^RW_!O(,_L4^)1_U5"]_]-VG5QO\
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M'=Z]JLEOX=\6?\2+71O/EJ)F'D3,.GR3!"6ZJC28ZD'Z?-,-]9PC2W6J^7_
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M?^%M?_\ QVMS_AW?^W3_ -&F>/?_  FY_P#XFC_AW?\ MT_]&F>/?_";G_\
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M7FGK!1110!^2'_!QG_R7#X<_]BI<_P#I37YS5^C/_!QF?^+X?#G_ +%2Y_\
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MMR-P5U&5R-READ9R/2Z*J$Y4Y*4=UJ34A&I!PDKIZ,_+/_B&ZU3_ *.\M_\
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MG_!R7_S1C_N8O_<97Y=U[V4?\B^'S_-DYY_R-*GR_P#24?J)_P &VG_-9_\
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MT2XL6O+?#%(YX6CWKV) ?([&@"C_ ,+S^"?_ $6'PK_X4%M_\71_PO/X)_\
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M^ZB2%F'N 17? YK\[?C'_P &_OPO?PNUW^SU\8_$5CKUNNZ&/Q5)!<6]PP'
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MKYK\L_\ @N  /VT?A/C_ * ]M_Z<7K]3* $W#UK@/%O[67[+O@+7Y/"GC?\
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MT^,_V3?V@-%_X*"?LZ0R6,-QK$<^O"UB'EV.I9_UK ?\L;@95P1@ONR3YH%
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M-?GSXF\+^(?!FNW/ACQ7HTUCJ%G)Y=Q:W";61O\  ]01P1R*^ZR_'4\;1O\
M:6Z_7T/YEXJX8Q7#F.<;-TI/W)>79_WEU[[H]Z_9C_;X\1?"#3(/ WQ)LI]:
MT&W4)9S0L/M5FN?NC<0)$'9201T!P !]8^$OVN_V;_%]JMQ8?%[1[9F7/DZI
M="S=?;$VWGZ9K\QB,\;*-G^S^M8XK)L+B9\ZO%O>W^1Z&2^(.>9/05"5JL%H
MN:]TNR:Z>M[;+0_4/Q'^U+^SMX8@:;4_C)X?;R_O1V>HI<R ^FV(LV?PKYI_
M:-_X*,W7B33KCP=\"[:XL8)MT<_B"Z 69TQ@^2G_ "SS_?/S = IY'REM_V?
MUH QQM_6IP^286C+FE>3\]ON-LV\1\\S*BZ-)*E%[N-^:W;F;T^23\P8L\C2
MR2[F8Y9BW)/K5C2-*U'7M6MM"T>TDN+N\G6&U@BY:21CA5'N2:CL[*]U*\BT
M[3;*2XN)Y%CA@AC+O(Q. H Y))["ONC]B?\ 8R;X4I#\4_B=9*WB.:/_ $#3
MVP1IJ,,$MZRD>G"@XZDUV8[&T\%1YI;]%W/G^'.'<9Q%CE1I*T%\<ND5^K?1
M=?2[/5OV:/@S9_ KX2:;X&5(S?;?M&K31G(ENG WG/<#A1[**] I H!R*6O@
MJE256HYRW>I_4&%PM'!86&'HJT8))+R6A^7?_!R7_P T8_[F+_W&5^7=?J;_
M ,'(NCZG/HWP?\01VK-9VMUKMO/,!\J22K8-&I]R(9"/]TU^65?9Y/\ \B^'
MS_-GPN>?\C2I\O\ TE'ZB?\ !MI_S6?_ +EW_P!R=?J)7Y@?\&V]C>1V/QBU
M)[=Q;S3:!%%-M^5G0:B64>X#H3_O"OT_KYO-_P#D83^7Y(^LR+_D54_G_P"E
M,"<=J_-;_@O;^VW;^'O"EM^QG\/]5SJ&L+%?>,YK>XYM[4'=#:,!R&D8+(P)
M&$5.")*^P_VZ/VQ?!7[%/P&U#XJ^)C'=:G+FU\,Z/N&^_O6'R+C(_=K]]V[(
MIQEBH/\ /S\2/B)XR^,'Q U;XF>/M7DU#6]>U"2[U"Z9>9)7;. !P .@4<
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MX?ZQ\,_&^F+>:1KNG2V6H6[ ?-'(I4D>C#.5;JK $<@5^5"_"K]O_P#X(_\
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MUN-%MH=5TQI TNFWBZ@WF6\F.XR"#@;D96P,XK]EJ_#K]HS_ ()[_&#]E?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR?*8[QCC>!NKZX# U_,=XO\&^-OACXNNO"/C?P[J&AZUI=QLNK&^MVAGMY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gjyjiv3jrhol000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '* 8$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=>%]+TV\M(+)Q%=[?/DDN'=V"G(&\G( (SC-:LFDZ2^M6NO':MY#"UO'.LI
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M7C&,CN#5O6/"=IK-XMS/<W".MA/8 (5QLE #-R/O#:,=J?\ E^G^8U:Z]?\
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M.N"RHKH;?[P3[@.5Y [>E4Z-1:\KMZ>I.FFO]:'6CI15!M9TY 2URHQUX/\
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M/^%<1-87-GEV0O&O'F(#C\?2OL\%CX5H6;U..=-Q98LV;?EPV%.>35F6Y5.
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M67PO<S*#@2+<JI/_ ([6&VI^"F;<?"=_G_K_ %_^)KGXXU48Z"EV*#WKZ6&
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M>T7^X/Y5YQJPSILN0/\ )KT>#_CWB_W!_*LY#1)1114C"BBB@ HHHH ****
M"BBB@ HHHH IZOJ,>D:-?:E,,QVD#SL/4*I/]*X2U\;ZII.D^&8+G3+C6-6U
MRWDNE6&14VL<.J?-P% 8#)/&.]=KXATS^VO#FIZ7G;]KM9(0?0LI /ZUY>;7
M7-2O/AZ;7S].O[6RN()99+<NL4B(J$..."5/<9[&A?U^/_ 'T_KR-Z7XJ(FE
M6DZ:#=OJ,FHG3)]/\U1)#/M) ST8$@<\<'/:K5_\0KRUN5L;?PO>WNHV]LEU
MJ5O!/&19JPSMW='?_9'6H;/X;S6[V%U/JPGODU<ZK>2F' E<H5VJ ?E SQUJ
MYK/@S4Y?$%[J^@:X--EU&%8+U)+<2A@HP'3D;7 XSR/:A_U]W^8EO_7?_(I7
M_P 5M/1]/32K,WSWEI]M59+A+<F/)&U-WWY,@_(/3K27_C37#X^\-Z98Z++_
M &;J%LUQ)YSK'(1@9W*>5V9R5ZG/'2F:C\+HY='L=)M;BTFL;:V,'E:C:B7#
M$DF5&4JRN2>>=OM5N/X?W%A<^%YM-U@HVBP/:N;B+S#-$^-V.1M;C@\XIZ7_
M *\_^ +6W]>1)_PL&6/Q#::==Z#<VT%]/);VDTLJB1Y%_O18RBMC@DGMQ6)H
MOQ.U&+PYJ6K>(=&>+;J+6=FD4\;>=(6*B(?W=NWECP>2*2P^$<EAK^GZJ-0M
M'N+/4&NFN&MV,URC$Y61B^-PSP0 /:KES\,9[K2;_3)-6B-L=2_M*PW6H8PR
MEF8B0$XD4[L8P.*7]?E_P2OZ_/\ X!%>_$&YO_".H:I9V[V&I:'<Q27MEYR3
M*\61N =>&4H2<CN*7XKNEWHVEO$=R2EW0^H*@BH]8\+:AI/@+5--1K6ZU+69
MH[518Z>EO%&K$*?E7G 7<Q+$UH^/=,C71]*M8B<6P*1@]P% _D*Z,-)1JJ3_
M *T_X8B2NOZ_KN?/CH8I65NN:B89-=%JVF_O,[2".E8S6Q4XVFOM:6(C."9P
MRBTRIMJ6( MAJD: JFXBHO:MTTUH26R@4=:@D?:47/5QC\Z8TK*N">*N^'M*
MGU_5XX(P?+5@6<#I7/7FJ<&Y%QU9[M\8?^1(4\\7<>?R:O"5QSS7TEXWTU-6
M\-2VC_Q."#Z'!KYNN[2?3+N2UN%*R(<?4=C7D9+6C[-T^IM7CK<M0'*^^:L&
M3 VYK,20@<&G;WSR<^E>PZ=S%2++RKT)JG(X;I0V>IQ43-S@5<()";N0SD")
MNW%?0/B(X\!Z"^W.R.!O_(8KPK3-*GUS4X[2%24W R,.@%?1FMV"GPM8VG_/
M.-$7\%Q7@9Q5BZD8KH;T4TF<>F)%20=&&:F%9\$C6\GV:7AAPI/3Z5?0D+D\
M^OUKS+71J/;E>E1[%'2G DGN!1(Q4?RQ4J($)4@\#\JQ?$+[K184^_*V"/0=
MS6L]PD4;/)D*#R36/!;3:OJ+2$$)@JOL*TT2NPL>E:PNWPYI9SDHJ$>_R5G@
M@C(.:TO$"^3H>G*/X-H ]?EQ6+!(JC;V_A-<198Z5'*V5XJ0\TW9518AL2X3
M)ZTBIABV*DSCBD9PJY/W>]#W @NL.@CX^:O08O\ 4I_NBO-YY< D?ZQN%'H*
M](A_U,?^Z*B10^BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Y+QRZ+%8JQP6=\'\!76UF:Q,T,495RN2<XHO8#R34-/2Y)VD!SV]
M:Y>?3#'(<$9'\)->M7VNSPG"3N7_ -[@?6N2U#QU-9R,JWL\TN?NH_ KT\'6
MK->ZC*44>8:I.(YS#(?+*C.,CFLXW<8Z$'\:]"N_'NNW.1'=/".Q$AS5BQ^(
M&IQHB74\L@[LLAS7MK%UX)>Y^/\ P#+V29Q>A^&-2\13?NL);YY<GM7K6BZ-
M8>&-,VQNH"\R2GJQS3M+\7R70W0WLKJ/O(S?,*Z6UU6691_I+L#T.ZO#QV,K
MU)6GHC:$%$V_$<R0::I<X#2JH^O->>>)?"MMKT&[(BN%'RR"O3]0E:&VWHVT
M[AS@&N7UKQ4-%MC+<7."1\JA1D_I7#1J3A-.GN4TGN>!ZKI5YHTICNT"J.C@
MCGWK/%U'CB52?K7H=_\ $SQ'>7)^Q7/D1]E6)&/ZJ:JGQQXS_P"@P%]F@A_^
M(KZBCC,1RKFBG\_^ <[I1.,DDA\A6,PSW%7M'\/ZAKLP6W41PY^9R171-X[\
M:+UU7/\ N0P__$5L:'\4]4BF$.JS>8I.#((U!'X 5GB,9B5%N,?Q_P" .-.)
ML:/HEAX7TYSE=X7=+*>IKNM1E\[1=/>)'D60(1L4G@KG-5[369+ZW6:"X#QN
M."%7_"M2\FE33X75R'/4CBOF9U92DY2W.A*R./U#0WO8\^1(KCH=AK(:UU:R
M;8UI--&/2-L_RKK;O6);5>9W+>F[K60=6U6Y<B*>?)[(QP/QJH5FA&<LMP$R
MVEWV3V$+5$\UZ<"'2;PM_M0L /TK6,FNX_X_I$/O*::UUKT7/VJ9\==LI/Z5
MK[5OH*QB_P!BZIJD@,T$RIGH8V %;'V'^R-/=TM+AMJ\[(69C^E6;3Q#=K)L
MGFE(SSECD5M1WTTJ[EN'/T:L9U)-:E(H>,7N6T#2Y+>WGD8NI94C)91L[@=*
MPK,7CH&-E<@=PT+#^E>@WTLD=G"RN58XR0?:L*]UF2V&/.<MCH&J+ZC,R..\
M R+:9AZ&,C^E.)G)P;2Y7_MF3_2JS:QJUQ*1!<3L?[J,<#\:?YOB KG[?Y?L
MTI-:)B)=MR1\MI/GWC/^%0S170./LL[OV_=M@?I37N?$,0RUQ+(OK'*:L67B
M*Z+;);B4D'D,2&H; RKJ.\A1G^Q7+O\ [,+'^E>H09^SQY&#M'!^E<_'?S2H
M&2X8@CUKHUY13[5G>XQ:*** "BBB@ HHHH **** "BBB@#D-"^(NCZ[=Z[;Q
MI/;MHQ;[0TX #*"P++SR,J?TK/B^+.DS^$X/$$&FZE+%/?"PCMTC4RM(0<8&
M[OCUKS<Z;J,<;FRMW#:UK-[I%PQ0_+%),K*WT&U_S-7;B--#\+0/)#,EK9>-
M1*P6)F*Q*S'( &2,>E-)=?+\U_F-];?UH_U1ZGX=\<6.OZA)ILEE?Z7J2)YH
ML]0A\N1X\XWKU!&?0U':>/\ 2;SQS<^$T2<7D"G]\RCRG8 $JISR0#Z5Q]QK
M\.O^-[?Q;IEO>'1]"TVX,]S);O&)9".(U# %CWZ5RJ:)XWTGPQIOBR>VTMUM
MKW^V)/*\TWKB4C>K _+@J1P.@%"MU_K7^F+T/<?$6N6_AKP_>:Q=QR206B;W
M6( L1D#C/UKG;_XGZ+I_@:S\5R0W3VMTVQ($4>:&R001G QM.>:P_'T/B.Z\
M$^([R74+2YT6YLPUI;0VQ$PW,A7)[\9KB/$&D:BG_"1:*UO(=.L+"34[<["=
MTDZ1J0/H?,X]S2[CTT_KL>HZE\2[:QU9--M=!UG4KAK2.[(LH5?:C],_-70^
M'/$=CXHTD:A8>:J!VBDBF0H\3KPRL.Q%>,ZQ+96?CR*74];UW1H6T*U59M*1
M]TC?W6PC<=ZZ?P+:>*)O DD6B31:>XU*5X+O4;4F2[@//F.O7>6/7VJFM_ZZ
MDK9?UT.DUCXEZ+HVL36$T-]+':LJ7MW! 7AM6;&T.WJ<CIG%.UCXD:-HNKM8
MSPWTD4)C%U>0P%H+;S,;-[>^1TSUKAO%'BK3;_6I/#&LS26>G6[1MJD]K8R,
MVHSK@E%*J=J @9)Y/05/\1-274[C^R8]&U&/4K9X9M%\F(R07Q.T_O%V[<+C
MD-T_2I6R&SO]=\;Z-H&J:=IES/YE]?W$<$=O%AF7><!F'9<__6I/%]P+:T@?
M/S$L%'J<5SWQ!L?E\*7)M(Q>R:[8FY>),DXSU/7 ]ZT/B),D%E9R.V"ID('J
M<"M*<.9V\_\ (3V/*_$NN.K&TMY/F/\ K7SS]*Y@.6/([U*4-Q.\DO+,2QY]
M:>MNI''4<]:^LHTHTX)(S;%5,)E14;)BK(<(.13 4=N1BM-4B2&"YDM9TEB8
MK(IX.?YUZ'X<UI;N..3( )V2+Z-ZUY_<P[%Y'6M/PM<LFH"$?==3^8Y'Z9KA
MQE!5*;E8M,^@/$5U'9:/)<2D!(SDY/UKYWUO5;C7]3>5GQ&IX&>%%>Q?%N=H
M/!+%3C?<(I^F&KPZ 8A4*<;^6_I7!EE%-^T";U+$; +MC&U/4=2:1BN.03Z4
MY% ;:!^-.E4#EN@]*]M+4S959AVX]*CXEP)  _\ "XJ8!') P*B92,C-4XZ"
M3.L\#>()-.U(:?<O^XEX!)^ZW:O9=4N!%HD$IQVQ^5?-TC/&8;E>"C $U[M=
MS&7P)I,SGED4G\C7SN8T%&7,NILF9L43ZA<LS'Y!U-:>Y(E$<:X4>E16T1AL
MD1?O'YFIX4YS_%7GI60Q0^YL@4N2.&P0:E1!C..>].*@]J5WT S[JSCN$R5^
M8=&]*BTVYDAD,$N01TK1Z''K6?J*>5)',.#G&?Y4[W&=5K4XATN%SST_E7'Q
M0/J%PQ<D1J?WC?TKH_$SD:%9DMC.,_\ ?-9=K 8-/CC_ (R-S'W-)(&"[8T\
MJ !%'3'>A8I&/S$@5-''@Y(!H+\GVJKB$2-U;/8=ZJWME'=@D$)<#[C_ .>M
M7U;=VILB $''/:E<#,TN[>-V@F&UEX(/]*]$3_5K]!7FFJ9@OH)\8W_*W]*]
M*B.84/\ LBB2L-#Z***D84444 %%%% !1110 4444 %%%% !1110!#=7=O8V
MSW-W/'! GWI)&"J,G')-,MM0LKR>XAMKJ&:6V8).D;AC&Q&0& Z''K7)?$#-
MQ?\ A/3G)%O=:PAF'9@B,X!_X$H_*N O;J]LM<^(M_8^*3I4UC<I.ELJ1GSF
M\L8W;@21VP.YH_K\O\PM_7W_ .1[K17E&E:OXCU[QE*SZK=6MK:Z3:Z@]A"B
M8EE9<E"2I(4\YQS6+X.\6^,-2UC1]0NM01K2^N72X@FN[8)L!.1'& ) RX'&
M2>#3MK;^NPKZ7/<:*\:M?&FIR^+- ^QW^J7%C?:C-!-<744<=O,G.%B3[WRX
M^]QGOUIVF>*O$5OXDTQ=7NKAK.\U"2U2_LYHKBTN=Q(C0*O,9'KGJ#D&DM1L
M]:EU&RA9%ENX$9Y1 H:0#,A&0G^]@=*X/XMV O-+L7+LIA:1@%/7@5Q=EI\L
M/P\\>32:Q<7%Q9ZI)-%YNW*2Q.K"7@9W-C![<<5Z!XO\S4-!TJY==OF1[I%/
M;<@K;#R4:BD_ZNA2[>OX'A32[6;/4TZ*<A2<TNH6[6ES)$0<J?S%4"Y5^.E?
M7P2E%/N9,O.QV;L]:2WW!^1FH4E#<' JRLL<*EBP)[5K;2Q)-<N,*#R<5!'*
M]N8WB8JY<#(].:KF4RMQGKQ6CH>GRZKKMM:*NY58%R!Q7+7:A2<GL4CV#XS?
M\B*/^ON/^35XI"PV]/X17O?Q/TY]3\%S11C+)(L@'T!KY_AW>6,G# D-7GY2
MTZ?*.>Y>CE)XQCTID^[''XU&LH!Y-.9PX/->K%6>I!5C9Q)SFK,A! :HE"KR
M:3?YCA4%:.PEN/D!^PLQSM,B@?G7M\__ "3W11_TS7_T$UX]#:27=Y::<F2S
M.'<8_P ^U>X:I9F/PCI\"@_N@./P->!FDE=(VB0(1@?05-M!QBLZRE+VZL3R
MHP:T$8,..*\B2&/*E0"*3O2^80.>:8S\<5-@&R??JAJW_'LONXJX 7;)[=ZI
M7>;BXCA3L<FFM -KQ*I?P_9J.X7/_?-0K@@$#L*T-<7_ (E5HK=,@'_OFL*U
MF++Y3'YT.#1%7&7\<9J*53M&W&:<CCH1TJ3:&Z4K-:B*J,QE"G%32$9 /6G>
M4H.>]1F++[CT%/<#,UJ)IHX%09;S017H47$*#_9%>?3OON7<=(%)'U/2O08N
M84)_NBJGT&A]%%%9C"BBB@ HHHH **** "BBB@ HHHH **** ,+Q1X?/B"TL
MQ%<"WNK*\BNX)"N0&0\@CT()'XTVY\$>&;V^:^N]$LY[IIQ<-+(FXF0#&>?8
M#CIQ6_10!2ATFP@U6?4XK9$O9XUBEE&<LJ_='IQ5.S\)^']/UF;6+32+2'4)
MAAYTC 8YZX[#/?'6MFB@#GHO OA>"^%[%HMK'=+<BZ65 0RR>H.>!ST'!]*G
M@\(^'[;6VUF'2+5-08DF8)R">I Z GU S6U10!R>O>!--U6VO8K.&"RDU.>%
M]1F5#NGC1@Q7KP3C&?<UI>(;83VL2#C&<#\*VJSM6\O;"9)X8N3CS7"Y^F:'
MM8#QSQ-X:,H9XAAQT..OL:\^N[22"38RE2O4&OHFYL;>Y5O]-L]W?]\*YF^\
M)6%^&S?Z:6_Z^%KU<#F+IKEGJC.4+ZGB?SYQ@U+%$Y;/.#ZUW5]X ,5R#'K^
MCVZ'@![U03^=6+7X:Q,=U]XAL&C_ -FZ7%>L\SHI71'(SB[2&2:=8;53+,QQ
M@#@5ZWX-\+)HEMYLWS74G+''2M+0O#VA:8F+&\T^1P/F<3JQK9,ME&1NU*Q'
M/>X45X6,QTZWNK1&L8FMJZ"2Q*$9#'!KPCQCX5ETB^>^M8RUK*<N /NFO>]1
MV?9AOECC&X<R-M%9$UG;W$;))/:,A'(,@.16&'Q,J%3F0VKGSAC<"Z\@?I2@
M=\YSVKTO6O FA3S.]CKNF6DQ.61KI<9_.N>/@F:-B1XB\/./4WRBOH:684IK
M70RY6<MM+97!]L59@!A((3?*>%0#O72P>"&=LR^)=!C0]TO5-=IX<\(:%8OY
MD6IV%Y/CEA<*V*FMF5."LM1J+,_P9X7:U']I7HS<2C*@C[HKT>^0/I<*D9'I
M^%9TDMA:C]]J=A$!_?N%7^M:5[-!'I]L9+B-4<C8^<AN.Q%?.5JTJLG*1K8Y
M&6!]/N"Z@M"W4>E6H9DD7,9!%:4C6;J=UU#M[]?\*PIETI7W6^K0QGVW?X41
ME=68<K-,G/3FF-@=361_;-E:<OKM@O;+%_\ "A+ZRNG.==M"#R1&6Y_2F*S-
M"XN @ 4;F/114UE9F/,LG+MS]*CT\Z2S#R;^WDD_X%_44^\\0:'IPS=ZM;P_
M57_HM9RD]A\K-W64\S3H%]Q_*N5DC9)MZ_ZU>H_O"NKU">W?3K27[0BQR;3&
MYSA@1D8X]*R)X;652?M4(QWR>/TI*7+(+%.*YBN."=CCJ*NH"!UR*RF2Q=B7
MOK7CC<"V?Y4];S3[>/;_ &[;@?[1/'Z5JY1:"S-,D#[QQ]:IW-SN_<P,=QZL
M.@JL)+"X3<VLP2#L 6Q_*I8(K:=O+6^M@GHA;G]*F\8["LQEO!O(13E5.23_
M !&N^3_5K]!7#SZOHFEIBXU2VAP.X?\ HM=O$P>)&4Y4J"#ZU"=W<=K#Z***
M8!1110 4444 %%%% !1110 4444 %%%% !1110 45YIIOQ$U*Z\<+;SVUJOA
MNZOIM-L[A0?,,\:@Y)S@JQW 8':G>*?&'C#0[B_U*/3=.BT2RNH[=8[HO]HO
M-VT;HB/EQ\W'T-"Z >DT5YIXN\0>/-&U*U73FT&6+4;E8+&SDBE-PV1DEL$*
M HR2>E4O%'Q&\1Z)XAO;2"#21%I_V=6MI_,%Q?&3 )@ XP"3Z]*$@/6*Y/QO
M'YD=AQT=R6/;@5S_ (B\>>(;*_UF[TNRL'T?07B2^2X+^?*7VEO+Q\HP&'7W
MK4^(=WMTRQ=3^ZD+,3[;0::CSZ#B[,X;5M8MK&$[\K'G"*OWI#7%:A?:K</A
MF^R6[\JJ<$CW--6XDU34'NY=WD(=L8]!ZU+/EQEF(R.$]*]C#8506HY2,MM-
MM7LVEO'E:8?<)8G'O5.%K^*5OL5S)L7U.01[YK7NQ_HBQL=SMSGTJC;-Y;Y=
M5VMQDG&:]#V,+:HQ;9?T_6[B&=1)MM;G^"1/N/[&NRL[J'7+;>8Q'=1D":+'
M7W%>;3*3N&UO+)ZFM/1-8;3]1AF5B7B8*_/WD/K7G8O"1:NC2$WU/I?Q*BOI
M8W $"53S^->+^+/&$:.]G92!54[693R3Z"O3OB=J$FG>#9)8_O/*L>?3(/\
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MTJ20GM4$UH]G$7L)7?:?WRXP.*SK9>G"U_Q'&H[GL'B33_#<B^;=1:\ZD?\
M+&:+!_,5W>J?84\,Z3OM)IX%6/RU:7:RC9P21U.*\D\'>(X=;L&TR\8&11M0
ML:]?UWR[?PY8^9@+&J ?@M?/UJ,J4G&1T73LT9W]H:7!'YDEBZ #C]\37.:M
MXFT<-$K>'S.KR89EN<%1Z^OX51FNI=3O!!  7[YZ(/6K-OX5L[=+GEF>Y(\Q
MRY!7W7THI12UD58AD;PW<\CPC<RYYW>:PY_&I/[6\,Z;+%%)X:DA+@_?D/%;
M8B6*,<@PH-J8)_6J:SQ733I)%L"':K.!\^?2M%9BL6+/7]$F0(-+,4;< K.>
M?RK%\3+X>2,S7'ARXN5 X*WK+FFWNBA09M,/E..&A'W)/KZ&DL;J.\B:TN!\
MK#&&'*'T-93@UJAV._U7[$_AW2O.L7D@*)LC$I!C&SC)[\<5D;]$M$,ATZ1<
M=C.QS6UK[);>'[)F^[&JX [X6O/)IKC5+T00<.1EF/2-<=_>HMJ$5H;3^(]$
MM\G^S)%4G@"X//X5&VJZ1>)O'A:XF'][<?ZT_3]&M[$;L"23JTLO+'_#\*OD
M;E)5B?2JLNP[&6^OZ!9';+H,UOGIN=@/SQQ5FWU30+B3!TV0;NC?:"<_C4DJ
MYC D;=D<J1Q7/:AH36JM=::,-C+VY^XX]O0U7(I*PK%O79]#LU\R3P]/,I'W
MENV%>LVQ!M82J[5*# STXKQ[3[N/4K7[/-R&& &ZJ?0U['"-L$8]% _2L[-.
MS)D/HHHID!1110 4444 %%%% !1110 4444 %%%% 'G_ ,3M0ETNY\*7<5O>
M7.S5@3;V:[I)1Y;_ "A<C/TKEYO&%Y-X_P!7UB+2M5TY[3PW(\=KJ,7ELS*Y
M(<*"01[^QKU+6- MM:N]*N)Y)4;3;H7400C#-M*X/M\U0R^%K&?Q4^ORL[S2
M6/V%X6P8VC+$G(QUYHZ??^0=?N_,X_POX'CU'1M'\2RZ_JXUNY2*ZFO%NB0^
M[#&/8?EV=L8K+\6^!=$7X@>&X MZ(]7N+EKQ1>RC>0FX8^;Y>3VQ74V_PPTJ
MVO8FCU+5QIT,@EBTS[8PMT8'(P.N,]LXKH-2\/6NIZYI&JRR2K-I;2-"JD;6
MWKM.[\*>E[BULS@?B/I6HZ5HNE)9ZF]OHUI=VD$5HA8R2G>!F20G) [#\35S
MQU#J\?C#PK=2:J1ISZS!%%8PIM!^5B6=LY8Y' Z 5V7B/P];>)M.CLKJ66..
M.XCN 8B,[D;<!R.E&M^'[;7)]+FN)94;3KQ;R((1\S*" #GMS0GMZW_(;Z^G
M^9Y'XTU"^U+Q=XA>2VUF6VT)86CFL+H1"R7&YIMI/[Q_]G'0=178>.M1#^'M
M'U*VN=\#QF82$ &12@(./>M?Q!\/M*\0ZFU]+<WUJTZ"*\BM9S&EW&.BR =>
MOUQQ7(_&NXM])\-:590J(D=FAA1%P%4*O ] !6V%CS5%$4G9W/,-/22_OI+Q
MXR;F60/!/(<(J@\_B*U8=<N]#NH)+V5S:@EB(<,9"<_,>,\\5A-)=)86\RSR
M+'&ZQA4;.P]<XJ2XTZZNBCZFZ12N#+O)Q\OT[U]-*FK\K.=-JY=N)9Y[J._G
M+,P#21P2'(Z\8JO(M]=R%_.0W#RDO!-C;'N&/O=JI:A%]EL=\%XQ@>/:AW'D
M?3M_]:H-'O$FGE2_G A,;$MCJ0.!5\MM4*^NH:R9_,@CNHXU>*/9E#G<!T)I
MFEW<L0 B;$MO()(OIGD5IV]U+JUK<JS)]GBQPL?[SRQTY]*SHK/[)<#S9#"Y
M<*01G"MW_E14:G3]Y"5T[H]Z^-%[)9?#]WB S)<I&?H0U?.VEV@DW/N4LN#M
M)QGUYKZ"^.0S\/ER0/\ 38NOT:O (P%C"%N3@;1W'O7%E$;T6RZK]Y(OR31W
MVJK&DBPQJ/+3)^45;T[3;#[7*MU=(PC<*JL^T-ZXK.U*"UAE5+<Y0IDC.2#5
M:\N#.WF+&J*JA1A<5ZTHMHSYM2S>SQ-J!DB<B.$[4$ARV :UX;Q7DN)H+1!#
M*% :08&37-11^;+'&Q"[R "QX%=+9>5+;1V\!2*3<8C\NY7/9L]JF<597Z#B
MVSG )=-U-;A/DECDSA#D U]&^+KD/X$TJYD;:KQQNY)QP8\FO!=5^SVNGDQV
MLLEQ'+^]D?H3VQ[&O=?%>V;P%H(>$,LBP!H^P!0<?2O"S.W-%V.BEN8&FQO9
MV27"H'FE(9\#J#_]:K[ZU$EW;VT\;1SS [0!N&![]J=Y+001K'E0%QSSVH1=
MW+@9'0^O^%>=:+=V;DKS97J0 <  XJM,G[EE !X^7/4'UJ"\<Q['8CR>01G\
MJ2.X,D;,"I"G )ZUI&&@Q\,K[5,K94X4@CI[UE:O!]DOX[A"%CG)1@.YQP:T
MY"CA8SR3R#CBJ.OONTEV".QC9<9&"#D5,HV8'9^,I_L_A/3I2<!0I/\ WQ6#
MI-FT&G)N<K<R_O'<=<GD#\N*V/'# ^$]'0J3YDD*D>Q S4&45>,# QS6"5T*
M.PZ,R,0'8$CKQUI,%78^@ZU \A0':<D<X'>L^XN99(U=5((P=O>M(TVQFH"2
MH/5B,BH(;HSW$UN;>2/RMI#MT8GKBJ=M>/-*Q<'!X !]#3M,DU+[5=+?&'R?
M,_T;RN3L]ZITTMQ7U,G4[4:;K23H,17G##L' SG\:]J@_P"/>/\ W!_*O(/$
M$B3:=N4']U.H5F&.<X.*]?M_^/:+_<'\JRJ=&*9)11161 4444 %%%% !111
M0 4444 %%%% !1110 5QQ\9)#K?B6:ZE2+1=!AC25MF6>9AN;!ST VC'J:[&
MO,'\,KJ.J^._"EQ.8#K'EW]M+C.5( 8^^UU&1Z$4=1Z&]I?Q'TR_BOY+K3]4
MTM+*V^V.U]:F,-#_ '@>?RJ/3/B/8:M<-9C3]2TZYEMY)[+^T+8QK<JHR2G/
M/'./2H%\+>*M9T?4M*\2:Q8&SN+(VD26=N00W:4DGK_L]*AL_!OB.^U33[OQ
M%J=A*FDP2Q6:6D+)YC.FS>Y)/;L*&)"V/Q(2W\)^'[J_M+K4-8U2W\Y;33K?
M>Q ^\VW/"BKLWQ-T6+1-/U1;>_D2]NFLQ;I!F>.89RC)G.[(QCW%9-MX!UW1
M[3P]>Z/?V2:QIE@UA,MQ&S0S1D[N,$$$'FI[;X?:A"NCS3W\$][#K+:K?2!"
MJN2"-J#M@8'/I1U_KO\ Y!LOZ[?YCKSXBM<^$]0UK3;*YMIM(NXTO[.^@VR>
M62N\ 9X.UL@^U4?C':0ZEX?L)5C24KO>)O3*CD4GBO0[O2]"\7@/'-/XEO88
M;.)0<Y=50@_0!F^@K6\:Z:L>DZ1;*VY;8% &_B 4#G\JUHU%3FIOI_EJ)J^A
MXSI>J2#38Q*D<D+@J8MFT<#&<^HJS?W]QME:9(+F)%_T=NF0#@@'O@55O?\
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MPT+[^.2!P#Z4IA()_P *HC2W\W>+F"&4_P#+2&Z09^HSS5@6VJIPFHZ;(/\
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MX)&FQ0%1F8G#<UAEN"C4E[2>PI3LK"&(3JT\R!GR/SI#:!?E$(,N<[<=JG7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gjyjiv3jrhol000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000008.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0""17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   ;:@
M P $     0   <8       #_VP!#  $! 0$! 0(! 0(" @(" @," @(" P0#
M P,# P0%! 0$! 0$!04%!04%!04&!@8&!@8'!P<'!P@(" @(" @(" C_VP!#
M 0$! 0(" @," @,(!04%" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" C_P  1" '& ;8# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M3Y?[IKGO#^IKJ.G)=*Q.>];GF#U-?ZTW1_EFHL__TO[^**** "BBB@ HHH-
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MV3C<U8R$0]P1P:193MW$UGF3ZTT,2?EY/I730I1OJ?CV?YM:,K2-6WD>YF"
M8KZ@^%7A&>_N(V"]7P.V<8_QXKQGP7X:FU.]3:N<XSFOM4W]S\(O"5K-X9L!
MJOB_7KR/0_!>A+]^^U.?A68=H8!^]E;@*HQG)%?-\59E1PV&J.MK%IGPN0X"
MKCL7"4/B3/7?AW\-?^&A/V@M(^%C1?:/"/PVGM_$_B^0',5WKI ?3--;L3!Q
M<2 9P=N>M?T^_ 7P,UW<?VC.A.Y@Y9NQSSSU.[O7YQ_L0?LM:=\$/AYI_@#3
M7:_U"6ZEU?Q+K$N3)J.L7AWW5PQ..#)P@[(H%?NU\-/"*:#I<0*X)3YAUK^
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M\_WT ;8"VT]R <?K7\5G_!QOXNFU[]NKPMX)MFS'X:^%T$CH.0)M4OYF8_\
M?$8%>WPS1=;,:%-KJ>KET.9G\X^JJ7Z8QD[?YUC0VI8GIUS767]N=P ZYYXZ
M>U16]DI/RG)K^J>6"B?0.G9VMH9]M8CEC6JEKQQQ6M;V)4<BKT=@6XQBLHR3
M=CBQ]16L8]K8F6X55YYKV[P3X<>2Z1EXP?G=^%4#N3_.N/\ #^CM-<@ ');
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MT9H76H-<R,22>U.MQD8&/QK)MMO0]2*T(<;B#Z5][&*BK(\;,LQ44[,VTE4
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MQBL76Q5=UI.[8L14E.MRQ6A^U_AB!;?3D@"E6"YY'; Y[^M?%'[?G[?'PO\
MV#/AC'XN\46\FL^)=78VWA+PE:.JW6J7"??+$[A#;1#F:4C"CH-U?A]\3/\
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MJ9=_$1ZNG7\:EJ).OXU+7PZV/I HHHI@%%%% !1110!__]+^_BBBB@ HHHH
M**** ,W5_P#D'3?]<F_E7@T?^K7Z"O>=7_Y!TW_7)OY5X-'_ *M?H*^@R3X9
M'CYK]D5>_P!:4C(Q2+W^M.KWJ?PH\![D<L$=PICD4'(Q7FVL?#?3-:O(45 F
MZX0MQSUQ_4UZ;G;DD[<=2>,#UJS;&0WT!P2!,FX^GS#_ /72J:1;6YI23O<_
M!W]D[X-WM]\(M?U&V PWQ.\:0$ 95A'K$R#*D$<#BO(/CO\ \$_OV=?BXLS?
M%/P%X=U25NM[]B2"[STSY\"I)GL,FOT__P""?5G:WGP&UK)4Y^*WCK..?^8W
M-7U3KGPZTO5-_E8)(.<XV]>Y]*PP4;1OL=E2I:UC^-3QU_P11_9-T#5[/6/A
M[<^*O"6HW6H)IT9L[\SVXCE#_:(ECDBDVR&-6",QV XY)XKPSQ!_P;^_"=G>
M3PY\3?&EH@+>6NHVEG,0,[L/M53GGGUK^O+QI\&VO?BMH>AZ7%*+6+3;_4KM
MH+Z%%52!!"EQ98,LL3L7*.N%1UP<FJFK?L[N0HC3E<]!Q7NT<SK1ESTJC3]3
M/G75'\<G_#@'2I'X^*^K %OE_P")3#V_X%77:3_P0$^$))_X2;XF^,[I1AY(
MK&VL[;Y>V"X;FOZM+C]GZ^,FW:PQR .*A'[/5^,X5^>O6NF>=XR2M*J_O*4D
MMC^<?PE_P0Z_8@\.3176M?\ "9^(G4C,>KZJ%A<CG+16\:$#VS7Z!?"K]DG]
MFSX&V\:_"WP%X8TF1,!;Q;"*>Z!QC/G3B1P3Z@U^G</[/U[&P5%/)&<#D_C7
M7Z?^SO+(5:167(_N]Z\NMB9SUE)LB-9[(^'TM+R^81%'(4;5"[N!TQ]!Z"NV
MT3P%J6HL D;CV(/]:^_-&^ .GVV"1N9BJ@$'J>  %SUZ9/2OG?\ :%_;1_9$
M_9!OQX4\9:I)KOBSR]T'@OPG#_:NK-N! \]8CY=JI(QOF=0,=ZXZZE*/+3C=
MCIQE-GG7CR#P#\ ?A;J/QK^--XFFZ#H\'G3/MS+<2' CMK9#AI+B9F"1Q@99
MN.F2/YVOV@/B]XU_:3\3VWQ"^,$:V.AV,\LW@[P"I+6MC ?N7.IKDK=:@Z[6
M;<-D7W5&<D^X?M@_M7>-OVQ?'VD^+_'WAV;PEX6\("27PCX/N+]+^:3491MD
MU+43&!&)HU^6",;A%EFSN(K\]_&7BF:]F8EG9B226.6;/<GUK].X)X,NXXC$
M+Y'MTL-&&J6ID>-/&,UW*PD9L;, 9(P,<?3CCZ<=.*\'U":>_D)9L]PW>NBU
M&:2\.6X _E6,ML G%?N5"BZ=-0ML=E22:LCFY+=FDVFH6M2#@#\\UORP;3_6
MJDD')_PK6W4^0S7&[ZG-R0*"<=0:S9D4C&*Z.: #)'&3FLH6@FE '3.":]"A
M&-DV?FF9YAJT9UKIWVJ7RQN^HZ=*^@O!_AJQT31;CQ/K65L]/M9;ZX<#GRH0
M2WT],=3Q6%X+\*2W<Z_)@$CGGIBOK?X?_"B3XU?%/P_^SO8QM_9T9A\4>/9.
MT>E6<@-O9,W'SWTH4 ?W 37S/&'$L,%A:COKT.+A[*7B:O.]CM?A?^R_^U]X
MS\%Z-XNL=-^'FAPZO81:E"-1N;V6[M+:X 9!/:HGS2%&!*@US?CCX.Z]\+_V
MD8M!UOQAJ'B"YT#P@FH:O%;1)9:1#?ZI(\4$%O:H2Q*0H7W2L6&[I7]!>A:3
M+J-Q'%91H%9@JJ@P%7[O '& .1C&.U?A/X[NKC4?BS\6?$MPNQY/'L^C(1U6
M+2;6" *#Z;BQ_&OP?(<SQ..Q?-4GIV/VS*80C42BMCP#QCJ+2R,93D@D%B.2
M<]3[FO.DD5>5;FMGQ1+)),VTX7=P#7*HI'/M7[OA:5SU\SQ*L;#2GU[5%)<%
M1S5-3SD^E0S2J5KO6'UT/SG,\99MW)7N<K_A74>#AY]X!U^8?SK@W?*GFO1/
MAY$KZDF[OU'ZUW.GRQ<C\HS7&1E5L?7OA_P_;^*?C'\'?AFP+K<^*IO%5ZK#
M'[C0+5Y0<=P964?A7]+'P$MKEM0C+CHX8J>""W)Q[<U_/S^RM867B#]LV_U*
M_D5)?"?PT@ATBV?AIFUF[=KJXCSU6(1)&2.A;FOZ./V=]/$DD4C'.6!/KD]C
M^5?RUQ/BO:XRH^Q^T9;"V%IOR/T'TD,EA%_N"M"H+9-D")Z+BIZ^=-0HHHH
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MO>:[L+%V;9QUWL4ULK9CEAMX]*D_L^R]ZL8%%=*DSF*9LK./YL?B>*AF-E!
M\\I2$")FWN0JJN,L[,2,*JY8DD"M%@Y 5,9.=I(!Y^G?Z5^'W_!6+]I/4KRY
ML?V(_AUJ%S93ZYIZZW\1M5TUQ'-I_A\OB'3XI%^9)M1=2AY!6$'':B%"56:I
MT]V=.%I<TK'@?[:G_!2KQO\ &[4]5^$7[)6L2^&_!5A=R:9K_P 3;$A=0UKR
MR5N+30CM/EPHV4DO3R6!\M3UK\<VN_"7P^TV72?!MNMBLLC374A8SW5U.?OS
MW-P^YIGD[EV/3/>NL\;ZOI^D6T&A>&X8[*PLXEM[6SMU"Q0QH,!$4=-O?KD\
MDY-?+>NZM<W4K$%CDG/8=:_;^&.#J5&DI25VSZ:%*-/1$OBGQ3+>,6$F><8'
MI[>PKRF]EDEERQX[5OW*EHV9NO\ C6*8%' Q7Z)A:'+#E9KRMZF UL#DY.*J
MR0!1CG'K72O;A@3CI5&6'"]*[4M+'B9AF/LTTCEI8<XJE+ P.[\:Z.6%?R%9
M=PO!7VKKPU-/<_.,YS75LYUX3*VQ<YZ=,UV'ASPI<7KJL<>1N  P2?R':I-$
MT07TRAEY+#&/>OIC2XM*\'7>FZ1!INI:YK^L;UT3P]HL)FO;WRR!(QSB..*,
MD>9*[!5'8FN3-LPHX6GSU=D?&4*,\;74*95AM-+^&GA9/%6K03W4LT\5EI.F
M6:F2ZU#4)3B&U@4XRSM@L>BH&)/%?KS^R'\ -:^"?P\FU3X@&VG\:^*+H:QX
MMO+;F(2D8M[*$]H[2'$?8%]S#KFN$_9M_94U3PMX@3XT_'HVUSXN13#H&BVC
M^;8^&K5A\Z0DC;-=2#B6<KGC:F%//Z&:!HMQJFH) H9M[8YXXS7\Q\6<3/,\
M1R_81^N91EL<)3]FMSW+X*>$QJNIQ.R Y;D]C_\ 6K^<OXB:8VG^/?BGI;KM
MEM?BSXE24=>6EC8=?8U_7C\#_ HTJU6[*;61-RJ1GD9-?R[_ +9=CH'A3]M3
MXW>#?#UW:WD,_B2S\4 V;K-%!/J5DB7%O(Z?*DRR0DM&3E<@D#-+@O&1IX]4
MXK<^AR[2IZGYF>(XB;F3L,G%<T%;&,>HKMO$:"2Z= ,$9]__ *U<RL6T\CK7
M]+X=<JU)S>=KF<RL!@\51;)SD=CBNAEB&S.*H-;[E)_G713OL?EV<UVF[F"Z
ML%[UZ%X&N1#>KCVZFN1EC!7Z=:Z?P<IBU '&?0#WKM:M"Y^1YMB;3YD?:D_B
MBW^&'C;X=?M#VQ*KH_B*/PCKK#Y?/T;Q#MMRKCN(;@I*#VR:_JW_ &?K2-(_
MWC@LK89^YP< DXZXK^2'XKV)U']E/QEMY:RT4:E">ZS64BSI(/<%<9K^I7]F
M/QC]MT33+R0@?:M/M+H#N!-$C'GKU]:_ESC7#QI8R3CLS^@.&,0ZN#@Y'Z36
M_$"X].,U-5.PF^T6J2CNH-7*^5J+4]:HM6%%%%9D!76>#_\ D._]L3_.N3KK
M/!__ "'?^V)_G7-C?X,_0]3+OXB/5TZ_C4M1)U_&I:^'6Q](%%%%, HHHH *
M*** /__4_OXHHHH **** "BBB@#-U?\ Y!TW_7)OY5X-'_JU^@KWG5_^0=-_
MUR;^5>#1_P"K7Z"OH,D^&1X^:_9%7O\ 6G4U>_UIU>]3^%'@/<!P<TN?;'M2
M45HI!<4DG@\BN6\;ZM=:#X0U76;1+QY;;3KJ6!+!5ENFD1"1Y,;%5>4<%%)
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M-CC'7Z5UXB?+!/N?E6/:G4Y+GMWQA":3^R/XQD(VR7VFP:7%M[RW\Z6\:_\
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M4)WL>@ 4$L>E1_!WP"VK:G HC<@NJ (N23GCCT/<U]!?LS?#;X>?%7XJ>/\
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M7_Y!TW_7)OY5X-'_ *M?H*^@R3X9'CYK]D5>_P!:=35[_6G5[U/X4> ]PH!
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M-'<7<Q,()!/6O0_"O@:XU&3$J,=QZ@=^*]3ZW#!KVLG9H\N6%=?]W)>ZSBM
M\&WE_<&-D+?-QCWKZU\#?!"+[&^IZLT5I:Q1^9-<W3K%"BYY)=C@8[D\'M7J
MO@?X9Z!X6T&Y\;>-;NUTK1M-M&O=3U.^8)!;01C<SR%B!]T' ZL>!S6'X6\
MR?M<ZS8_$?XF:3-9_##3"TO@OP=J4;(?$,K]-;U2+*MY6W M;5\@+^\;);%?
M] 7T4OI"5\ZX P,J^M:DN37JEHG?KH?\\GTG/ /#Y5X@8[ZNDJ-5N>FUY;HQ
MK;XH_#ZUO6\'? 72[KXE^)03 T?A]@FB6+#/S7VK2 0)Z[8O,; / ->O^#/V
M>]>U_P 6:;\8?VB]0M/$'B/3$)T#0]/1HO#NA2%<%[6!\O<W..&NIB2#]P+7
MTYHVD:5X>TV+2-!M;2PM(4$4-I8P1P0H@Z!8XU"@?A6U#%)-F-5QG'S+G&![
M=*_2,RSS$XZ5YST['R.69#A<"VJ,?F5?W>X[ <D@G/WF.,%C[_0#W&<UZE\/
MO"=SJVIHPC+@L#Q5'PMX%O\ 6[I6",><CCWK]!?A-\)3I2QWETA#$@DX]>E<
M4596/4J5+NYZM\,?"\6BV*94 @9QCUKV1!DA4&6/R@=\L>W?/I6=%;+;*(X^
M,5=%]:V"-?W[I#!;J9II9#M"+&-[,6[!0.2>E%>#4&UN3R/[S^?W]KOQ]_PM
MK]MS6)4?SO#_ ,&-%3P_I:9)1O%.LQK/J%P""0)(+410JPY7<WJ:_.OXG>(Y
M;J5_GW<GGU&>/K7JWP^\3G7?A;KGQ/N6WS^-O'/B+Q7,Y;(D2XO'AMF![KY$
M*@&OEKQ??-=WKNI'#<*#GKFOV#@+*^3#QD_M'TF$CRPLSSFZ=YI.<$#_ !JH
MT;8_S_C6LPPF#Q51X_E.,U^FTJ7+:)Y^9XB*CHS'E!.%-5'A8(3W-:DL>,.:
MI2_,#BNY1TN?EF<9BTFKF-)$2G/6LNZ CQFMN7#1XK(O02<9X[BNG"25]3\>
MXAS6UTV<Y,-[;%KU'X<: VHZO#L3*[MO/UXKSA(-UPJQ]>^:^L_@;X=-SJL)
M(&"XQNZ$CI6V8SY*4GTU/SC <V*Q2?F>L_\ "0^/;CQL?V;O@5"FE:U_8UOK
M7BSQC>*/^)'I5\3'$=.B/_'Q?2@-Y6X>7&?F(.,5];?"KX7>"_@QX%M? '@&
MW=+6V>2>6YG?S;F]NYCNEN[N4\RSS-\SNW?H, "O!O!&GPVW[<OCJ1%;.G_#
M7PO;3+U"F>2:;:?<(.*^Y_#?AZZU>94B0G<><#J?K7\B<18FKB,5.<I75[']
MJ9#A(4,)3C&-M#JOA]X?N;_4X@(RP+ GZ$U^L'PXT.+3M)50NWA3C%> ?!WX
M5#3HTO+R+! W9(K['L[6*TMQ'%^->92ARH].K.^A8Z\T445J8!1110 5UG@_
M_D._]L3_ #KDZZSP?_R'?^V)_G7-C?X,_0]3+OXB/5TZ_C4M1)U_&I:^'6Q]
M(%%%%, HHHH **** /_1_OXHHHH *8[A0#[]Z9)*D;#<0,CC-? O[:7[8/\
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M)(2Q_O$CK7G\5*KG7$E')G4M1C#FE9_%KHCIR?\ X3\HEF"A^\;:5^A'=?\
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M;IT='9Z-VU/X]\:?I?8'+*,\'DDE4J:J_1'!Z#\._'7[3>K6'Q!^/NGOX?\
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M![QVR#C?!0Q>0XA2E:\H-VE&V^A_DEXS>&F><(XN>$SK#N"O92WB^VJN59I
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M9A\NBZW(.8)D 46UXQ$<X&QR7J3X=Z'/J6JQ+\K;I%R<?K_C7Z9Z?\(?!GQ
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M7XE6S9-=^'WB5%@U2%&79)B%CBX@;)"RQ91@>O-?"/\ P5C^#GP;\,>&[/\
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M.WLE$ES;VN/^/C9.BK.J,P3."!R:^M_@!_P1XNM#O8X/CMJFB0>%+*62YL?
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MVE7&A6\4=U#I)8"ZM([W>98DSAR7VDBFL9+K$J&#A?<_H:BGANHEN;1UECE
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MU1VE91]5"FOSV^+L[O?3!AR"2<FOI3]K']L3]D&;]L+PE\7/#7Q!T*\T[7_
M>H^!M4:!I=L-U:W4=]9!RR#/F*)@H'>OD#Q+\6/@]\3=?FTSX=Z[8ZQ.$><I
M:E@5C!Y8[U'<\8]J_P <OIZ\-X^>>PQD:;=-16O0_P!3_H19U@XY?6PDII3;
M^9X7-(>365/*2,5IZY']FF,>& YXZ$?6N8GE 7C^=?PKA(*45)']\WULT.>1
MB3MK+GF<<GCBHY;K!R?2L"^NF'W3UKW,/A[O0RJ5!EY>D97/K6&[/)C;T[T%
MC,QZ]>U=/HFA37DBJ!D'U%>S)PHPYFS%)R(M'T*2_*K@]>,5]K_!;X73WTD(
MV,2QZ!>H&,G\!US6;\+?A7+JEQ$/+!)XV[?O#V/MWKV[XP?$75OA+<V?[//P
M'6WN_BCXHT\W$$Y DM?"VE.2DNLWN 1E<$6\)YDD R-N37^CW[-SQ$QM+,LS
MPL&U1:379R_X8_R\_:*\ Y?F&%R[&<O[V+<7WL<C\=7D^,OBP_L2_#F[EBTB
MPCAU#XR:[8R;3;6;E9+70K>0=;B[(W7(!S'",'[YKZQM+#3](LK?1])MH+.T
MLX([.UMK4;8HHHE 2.-!PJ*!M ZUYM\&?A)X7^"_@:/P=X:DGNYFF>^UC6+Y
MM]]JFI3$M<7EW(<F2:5B1SD*F%Z "O:-%TYK^[2"$9!YXZ?3FO\ 2O&8BK7K
M.M4E<_SUP>&I4**HP6QWWP[\)RZ[J485<$$$DYK]1OAGX,BTK3XIY-^]>>22
M.G;->"? [X?-$JW<ZJ"%!!VYK[9M;<6\"H,8QG &*FP3+("JN%9_IFD5F4D9
M(0_>16(!^H[T9/6BE9&?,P4MN+L21GY0"<CU%2!V#;@Q^4_*=Q#*OH*CHIJ*
MZC4VA6:527$C*3_<)R?J>],\U]ACSU^\ 2 ?J*/F[8J,1'V_S^-:6B:1J/JR
MV6*X,;N"% !!/ '\/XTTR2JQ9#G^[SM*CVQTIE%9678CG>XH+,-[$DGN3DGZ
MDUU7@[C7 !T$)_G7*9-=9X/_ .0[_P!L3_.N;&K]S.W8]' :U4SU=.OXU+42
M=?QJ6OB(GT@4444P"BBB@ HHHH __]7^_BBBB@ R*:XR,4UG"\=_6L;4]2M]
M/ADO[N5(8(8VDEED(5$11EG8G "@#)). .]9U)\MFT!=N+:*1"SKG /3K7X=
M_P#!2_XA_"SXNSG]E+P7X4T'QI\2YXLR:O,NZ+P3:R#)O[J]B(FBFV\P6Z.'
MD89("#)W/CK^WG\2OCEK]U\&OV&;R.VL;:=K;Q)\7;F!;C3;, $2V^C))\EY
M=+SF7F*,_P!X\#YSO4^#W[&OPLN;NVFG2XO[KS'NKGS=0UK7]7N?N[^L]U<3
ML=J@?<'W0%!K^7O&CQPHX2,LGR>"KXJ6EMTONN?J7!_!56<XXK&/DIK7L9FN
MOI7[*'[/6GZ):OJOBO7I(+7P[I:!A+K/B+59%$,8C8_>FE/S=<)RQP,FOD?X
M:?'-_P!G/XB3?&GP1'?Z VGZK;6'QA^'VI(;626UN)5@EN[JVR52]M0YECO(
MP5FC5AN8$$>]?L[_ !>\$:5^UA<_$C]M:TU?0]6TJW6#X>Z=JEJT%CX7CNX0
ML\]];;MPO)B2HO#OB5<*&0[JL?M>1^ _VMOV@/%.K> %LY-$^'_PWU?PKX@U
M_3]IBUK6=1B\V.V,L6$GBTZ,;U8CB5B < U^=\&<"?ZL9:L^Q6*<<3.:<HIV
MOS/:W8]W/LZ_M/%K+:-'FI1B[/T/Z HIK>>!+FSD\V&6-)H91C#QR .C#'J"
M"/:GU\Q_L5>*]5\=?L@_#+Q9K$CRW=YX-TO[3(_WGDAB\EF/N=F:^G*_T=R[
M$NMAZ566\DG]Z/Y>Q%%TYR@]TPHHHKL,0HS110!Y;\4_A%X7^+VEZ1IGBMK@
M1Z+XBL/$UF;9@&^UZ=)YD(;(Y0M]X'M7CGQE_9&\,_%CXECXPZ+XB\1>$-=G
MTN+0==O/#\D875=+AE,L5O.9T<+)$S-Y<T>'4' .!7UKQ00&^]]:SE14GJ=E
M+$\JT/C#QO\ L+_"OQAJNJ^+(-2U_2?$>I^)-.\66/B/3[H+>Z3JFF60L89[
M0L"I#P#9,CC$A8DYK4^'G[$_PI^&.O>&/&&G7.M7>L^%M0UC6Y]<U&Y\ZXU7
M4_$2".\N[U^-[LBJJKC"  #@"OKP,1Z\]: S*?E/XUA/!1OH.>.GT9\EV?[%
M?P;AT+PEX4U);^^T_P (76O7EI9W4I:*Z7Q)%-#=QW7'S@QSN$ ' ->66O\
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MV1\/?&7)>)<)&IAL0E/JFU<_.BZ^U!C'M+'./H*HBQO;F0?(^.GT'Y5]C3?
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MHJ3FD[A1110(**** "BBB@ HHHH *ZSP?_R'?^V)_G7*#O75>#^-<S_TR/\
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MM!KY*^*7A?0?V8?V3?$'A/P8/.EO;!= TFT$,5M+>:MJF+.-E2$*K23S/N<
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M+&3I.J_$?PS8ZW(2 @M?MBS*K9X*M,J COTKQ^(<R6"R_$XNU_9PE+[DV=F
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M[^T]^T)X._9Q^$E]\1/$S!Y%'V;2K#<%DO[Z13Y-O'_O'YG)R%0%CP*_F?\
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M02?$[1-1UKQIJ/C;3$L]6O-*LXM,\=:K<EYM/D\J5GW[=H)^X2><\YJI\1_
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M2E \-R;?+S/B-0'E P!CKFKCPSP8W"^7TK=?W:_R,Z>-XH49_P"TU+]/>?\
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M@&6>VE\.R7ET;<Q7-E))EK65+QA#(0^6C;ED))'6L9\'<&NBYK+Z._\ (O\
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ML3S_ ,*X^+(_[@#TGF^#[K[D$LDQ^[C^+/L810'_ )8Q_P#? H\NW_YXQ_\
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HX>M-'C6*!5 '(*BO1XUVK7,:=U'T%=2GW:YJTFSLIJR'4445@:'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gjyjiv3jrhol000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000019.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %?!98# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#];./6CCUI
MVP4;!7T!^:6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCU
MHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/
M6CCUIVP4;!0%AO'K1QZT[8*-@]: L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#
M>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8* L
M-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"
MPWCUHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@
M+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8*
M L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@
MH"PWCUHX]:=L%&P4!8;QZT<>M.V"C8/6@+#>/6CCUIVP>M&P>M 6&\>M''K3
MM@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M
M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZ
MT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L% 6&\>M''
MK3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<
M>M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1
MQZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L% 6&\>M
M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZ
MT<>M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'
MK1QZT[8/6C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0%A
MO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L% 6
M&\>M''K3M@HV"@+#>/6CCUIVP4;!0%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!
M8;QZT<>M.V"C8* L-X]:./6G;!1L% 6&\>M''K3M@HV"@+#>/6CCUIVP4;!0
M%AO'K1QZT[8*-@H"PWCUHX]:=L%&P4!8;QZT<>M.V"C8* L-X]:./6G;!1L%
M 6&\>M''K3M@]:-@H"PWCUHX]:=L%&P4!8;QZT4[8** L2[%]*-B^E.V-Z4;
M&]*"QNQ?2C8OI3MC>E&QO2@!NQ?2C8OI3MC>E&QO2@!NQ?2C8OI3MC>E&QO2
M@!NQ?2C8OI3MC>E&QO2@!NQ?2C8OI3MC>E&QO2@!NQ?2C8OI3MC>E&QO2@!N
MQ?2C8OI3MC>E&QO2@!NQ?2C8OI3MC>E&QO2@!NQ?2OGC]M50/$NAX'_+C+_Z
M&*^B=C>E?._[:P(\2:'G_GQE_P#0Q79@?]Z7S_(^;XL_Y$53UC_Z4CQ*BBBO
MH#\?"BBB@ HHHH **** "BBB@ HHHH **** /7/@5^R#XL^.W@.\^(6E>-=$
MTFQLM2:RF_M621,,J1ONR%( /FJ.3UK<\9_\$_/BSX:\%WWCCP_XI\/^(;?3
MX&FFM](NI&F=5Y?8"@5BJY;;N#$# !. >^_93\':'\0/V&_&/A#Q+XVL_#EC
M>>*F%QK5]M\JVVI8N"V]T7DJ%Y8<L.O0ZWP</P%_8J\,>*/%UM^T=HWC&ZU*
MUB6VTG29H@TDD8D*+LBFE)W%L;SA4!.>M>#5QV*C5FH2NU*RCRMW6G7IN?J6
M!X;R6I@<-/$4N6%2DY3JNJHN$O>VIO62T6RMKY,^,\BC-?0'[(>E>$IO">J7
M6E_LTZC\0O%;7/E6[ZA9P?V/:Q?N_D:69RBR?>;)3<1M4$#<QZ;]MOX.>%]#
M^!_AGXK2_"/3?!GB6XU9;#5-)T6:-K=4:.XD&?*4(S_NE.Y1QO*DL%4COEF$
M(XI47'=VO=?E>]O,^5I\+XBMDLLPA43Y8\S7+.UKVMS\O)S=>5.]CY9S75ZI
M\%OB#H?PIL_C-K6DK:Z'J.H1VFFR2S#S+IF69MRH,D*ODL"6VYW+M##)'U;^
MT_J/[,O[-&LVLD?[/FA:MJFN:2\<-FVGP+:V:Q>84F\LI]YY) K$88I'U^4!
MIOCY\6? K_L0:+XH'P8TQ;+Q S66DZ/YJ>7HLTEO=!+F(^5@LA4D85#\YY'?
ME_M.M4]G*G3=I.UVUKZ:_P!?<>U_J;@,)+%T\5BXNI1@Y<L5+1W5G)\KNK-:
M)WNUT3/B&O1OV=_V9_&O[2&HZI:>%-2L;*'288WNKJ^9MNZ0L$0!0220CGI@
M;>>HSYSFOL;P-H/Q-_9]_8JTC4/A?X,U;4O%7BK6;;4YETNT>X:VA++*A98D
M),;0PQHR,1S</SU%=>.Q$Z--*FUS2:2OMYOY(\+A?*\/F6-G/%1DZ-*$IR4;
MW=M(Q5NKDU\D_4^4_B+X%USX8^.M4\ >)(MMYI5XT$K!659 .5D7< =CJ5=2
M0,JP/>L6OIS_ (*._#T3:EX;^/6E:)=6=OXBT^.VU*&[MO)EAN%3?$)E)W+*
M8B4*X^7[/@UY1XA^(/P@U#]FS0?ASI/@)H/&5CJKSZIX@_L^!1<0%[@B/S@W
MF-@20C!4#Y/89K#XJ5;#PFE>^CMT?5^ET1F^24\MS;$X6511C!.4+W]]-IQ2
M\W%^FC/.B<#->O7?[-'@?P/MTCXW_M":3X7UZ2UCF70K?1[C4)+?>@94N'BP
ML#X(R/FX((R",^1QS26\BW$+;7C8,K8Z$&OH+Q?KO[)_[4.N2^._%'CS5_A_
MXJOHX%U);K3_ +9I\\BIL+1[/F7A5R79![$Y:C%5*D91M=1UNTKOI;2STWOH
MR<EP^"Q%.ISJ$JJ<>6-2;A%KWN9\RE#WD^6R<DM7OL>3_%SX.>*O@WK=KINO
MW-E?6FI627FD:QI=QYUK?V[#AXWP#QT((!Z$95E8\GFO3OC9\*/&/PLD\,Z1
MXQ^(*^(O!<S3/X=U31;[[1 +<RCS_)1FVQR$;6*@[2Q WM@D>R>#='\6:[XC
MM-+^'_[!OAU? [7$2QWGBO0U34WM#M,DK7,\P^<@LRD!@!M W8YS>,]G1C)M
M2O?6Z2T]>OEWN=4.'I8S,*E&*E2LXKD<95)+F5_L)W@NDGNG%J]W;YY^"_PB
MUGXU^-AX0TG4[73XH;.6\U+4KQ\16=K&!OE/<XR  .[#) RPS_B'H'@OPUXF
MDTOP!X__ .$FTU8D:/5/[+DL]S$?,OE2$L,'OWKZ3^",6B_"#X__ !8^&GAW
MP;H]Q8Z;H.IWEG-J%JTLZ1(L96T+E\M 0^&4Y+;02U8WP-^&.I?$WP=KO[1/
MA;X"^&_$&OW&O+IVD^$_+CMM(T^-+=#+=&&68"4'<%$9;ACO&?X<GCG&HYR^
M&T;;*[EW;V^^VG5G;'AF-3!T\/3LZ[E4YVE.32IZ-14=):_W7)MJSBDSYIS6
MYXU^'GB;X?0Z++XGMXH?[?T.'5K!(Y@Y^RRLXC9L< L$W8R2 PS@Y ^@_C1\
M%?$5K\'[KXV_$/\ 9_\ #W@SQ#X4U2S=K/1Q"VF:U9O,J>6]O%,^QU=EW,2-
MRG&3QLD^/?QC\.:=XO\ A#)XO^%7A&329O">C:IJA_L/S&BMI5GBDM(P7(^S
MHCL\<9!*NBG)QBKCCY5)1]G&^Z>J>J5]&M.IA4X7A@Z=7ZW4<':FXWC*/NSF
MXMRBTI*S35GZJZ:9\N45[QH?[/FA>'OVR=5\%^([:-O"GAB6?7]0/$D::7'&
M+B)7#C]XIWPQ. #G+=N:\4\2ZO;:_P"(]0UVSTBWT^&]OIIXK"U4+%;*[EA$
M@ &%4':.!P*ZZ6(C6E:/9._KL>#C,KKX"FY5G9\\X6ZWA;F?I=V7=W[,I444
M5N>:%%%% !1110 4444 %%%% !1110 5O?"S_DIWAS_L/6?_ *.2L&M[X5<_
M%#PV/^H]9_\ H]*FI_#?H=&#_P!ZI_XE^:/L?Q.J_P#"-ZAQ_P N,W_H!KX:
M QP*^Z/$RM_PC>H<?\N,O_H!KX7KR\KVE\C[?CO^)0])?^VA1117K'P 4444
M >F?L[?LP>*_VCTUJ3PUXCTW3ET,6YN6U(R ,)?-P1M4]/*.<XZBNZN/^"<?
MQ2N=*NK_ ,)?$/PIK4UK&7^QV5^^Z0X)"!BFT,V,#<57/4@9-=5_P3,M(;_P
M[\2[&YO%MXYK.PCDN)/NQ*4O06.2. .>HK2^ OPP_9Y_9A\9S?%B\_:_\/ZU
M';Z;-"VGZ;)"KR!BO5([B5Y@,9"*N=VTY^7!\'%8W$4\15A"7PVLN5N]TG:Z
MV/T[)N&\IQ.48/$5Z-U5Y_:3=50Y%&;BFHR^*R6METUW/D*_L;[2KZ;2]4LI
MK:ZMIFBN+>XC*212*<,C*>58$$$'D$5%FOH7X%ZWX#^(7Q2\<_$3_AGK6?'.
ML:EK$]WH6E-8Q/862S22N/M3N^Q6;.,LC ;"5R3QWO[37P2T"^_9:O/BGXD^
M ^C^ _$VBWD6VRT*:%EDADN(X<2& !&R'W '+*5X8;F4]DLPC3K1I3CJVENM
MWY7O;S/GZ/"=7%Y;5QE"JFH*<K<L[.,&[WGR\BDTFU&]_36WQ[FNFT/X0^.?
M$'PSUKXOV6G1KX?T&2.&\O99@-\[R0H(4498M^_1B2 H4'YLX4_4OB6Y_9G^
M _P2^&?Q"\8_ S2M:U+6?#UI$\*Z?!^^5[>WDN+F0.I621<#;NY)D8;E#,:O
M_#KXX_#NX_8K\0?$.7]G[1%TW2=6M[34_#<,D:VVI3YLE-PW[DA3ND5@"KD>
M4OS'J,9YE6E!2ITW;F2NVM=;::_B>AA^#\OIXB=+%XN*DJ4JEHJ3<?<4DY>Z
M]%>[2U:6FK/B7->_>'?^"?WC;7?!NC>-;GXI>%M/M]<TV&]M8M0N)(V"R1K(
M%.4P2 XS@FO 6(9V94VAF)V^GM7VK\6_AO\ "3XA_L_?"5/BK\7X_":VGA6W
M-BTEN)/M1:TM=XZC&W:O_?5;8_$5*,J:B[7;OI?I?8\_A?*\'F%/%3K4U-TX
MQ<4Y^S5W))WD]%H^O73J>$?&C]C+XF_!GP7_ ,+%N=9T?6M%61$FO-'N7?R=
MS;%9@R*-I<A<J3R1G%>0YK[$\9> -&\%?L.Z_P"%_P!G;Q/!XRTNXU(W?B35
M!>)YEHJ>2\A2)5X 2)"RLVY59FYR,> Z#\0O@_9?LVZY\.M5\!M-XROM42;2
M_$']GP,+> /;DIYQ;S%RL<HP%(^?W.#!XJK5IMR]ZTK;6=M-6NA?$&1X'!XR
M$:;]DI4O:6<N>+DK^Y":5I7LK/5)NUSSFO5K[]F33?#^AZ%K'C3XY>&=%D\0
M:';ZK9V=Y#=M(()EW+GRX6&1R#SU%>4U]/\ QL\!_!7Q7X1^&5[\2_C[_P (
MG>1_#+2D@L?^$5N;[S8O+)\S?$P"_,67:>?ESWK;%5I4YP2;2=[V5WMVL_R/
M/R3 T<7A\14E",I04;*<U".LK.\G*"VV5SP[Q[\./"?@_1DU30_C+H/B"9KA
M8VL=+ANED52K'S#YL2+M! '7.6''6MGQG\"/#_P^^%VF^+_%OQ6M8?$6MZ5;
MZGHWA2WTN:5I[.9@%=K@82-MN]MI'\! )-,\:>%_@I\-WTKQ5\-?C7:>.;RW
MU:)Y]#U#P?<VEN\2Y<F0ROB1"55&0$$ASR,5ZI^TS\;$T.^^&MP?@UX%O//\
M Z7JGEWVAM(L?FQW$?V51Y@Q;)NW)'U5E4Y.,5C*M6YH*%W>][I)Z=+-+3Y>
MC.VCE^7^QQ-3$*$7%1249.I%<SMS7A-WDNB<FD]XO8XGQ7^RSX6\&>)]-^&O
MB#]H3P_9^*II0-8T^^M)8+/3(S;/.KO>/\C9 C4+@$M*O&.:\=S7V/XXN/#W
MQ$_X*,Z=\,?%7P[\.W%C8M*;BX;2PT^H[]'$JBY+$K*(V V?*-H Z]:\<^&M
MAX-^$W[/K_'K7OA]I?B37-3\3'2=#LO$$9FLK>%(=\D[0@@2L3E,,1M.UAT(
M,X?%U/9ISNY-1:6F\K[;::==EW9T9MD.%^N5(X;EITZ<ZT7+WW94E3NVFY7=
MYV]VR<GM&-K>-YHSVKTSQW\1O@E\2[#0=:U/X;#PSK<.L"+Q'!X/LTBLKO3<
M@^9#&[XBN%&5"X*L<LS=%7W#P'X8\6^,?&5OX=TC]@WPWI_@-[Z.UDO/$6B^
M1JL5BS!&G:>>4.TH!+_*&;^$,Q^<[5<9[&'-*-M]VEMV=];]/T/-P/#RS#$.
MG0K*2]VSC"<F^97NTHWBH[2;V>UUJ?(=&:]X\*_"SX;>!O%'Q:^(WB+PS_;&
ME?#G5OLNB^'[IF,5Q-+>R0P&9MV72/8NY#G>&YZ8;#UOX[?"OQMX2;4?$/P,
M\-:/XJT?5+6ZT%O#.CB#3[Z(2*9K>]A+G>A5>",DDX&T;M]K%.<O<@VM+O32
MZ3_)J_8PJ9+'#TD\17C"34G&+3=U"4HMW2LFW&2BGNUTNK^1T5[I\1_@'H'B
MW]JOP[X7^'=F(?#7CR&RUC38[,",V]C*F^XP& 5"@CF8)@X&T8[5YK\;_$/A
M7Q1\6M?UKP-HECI^C2:@T>EVVG6XBA\B,"-'"@  N%#GCJYJZ.(C6:45NK^G
M2S\]_N9ACLIK9?&I*I)>[-P5OM65W)>23B_^WT4_AO\ #_4?B1XBDT.QO([6
M.WTVZO[Z^N(W:*UMX(6E=WV@D#Y0H_VF4=ZP0<C->G_#)F\$?L]^.OB*?M$-
MQKLMKX6TFX@88(D;[3>*W(.TPPHO&?\ 68QSD>8'A:JG.4ZD^R=OPN_SM\C#
M%8>GA\+0?VYIR?HVXQ5O^W7+S4D>K6'[-WA?P[I&FZE\=_C?IO@RXUBP6\T[
M25TFXU"[$3'Y&F2+ @##D98GL0&# <W\6/@MKOPH@TC69->TW6M%\06\DVBZ
MWI$Y>&X5& ="& 9'7*[E(X)QDD,!ZAXD\<_LQ?M1?9_%?Q7\8:OX(\:?V?#;
MZC?1Z>;O3KV1/D\P)&"X)7:<$HJCC+8W'D?CG\&/&GPP\+:'./B>GBGX?W5Y
M(NAZMI-PTMO#(23(OE%MD<IPYVAR&*-ELA@..C7J^T2JR:;W36G_ &Z[:_>[
MKHCZ',,MP/U.I/!THSIQ2<:D9WFKM*]6#E[J:OM"*BVM6M_*\UU'P<^%6M?&
MGX@6?@'0M0MK-[A9);B]O"1%;PQH7=VP">@P/4D D#)'T)X5T_Q5J.IV=G\(
M?V#]"NO!JK"\-[XTT.--2NK? :20W,\P4%LL4/S* 5QD#:+7PATOPY\%OVQO
M&WPJ\)^$-+FTY=-FN;.?4H&FN;119B;R(Y"V1&3(58')957)R"3-3,'[.:@O
M>2;6J?9:VV:OL;8/A.*Q6'E7G>E*I&$GRSBFVFURMI<R?*US*UM';5'S1\2O
M#?@;PKXD&F?#WXD+XIT\VZO_ &FNDRV>),D&/RY23Q@'=G!W?6L"OI3X%?#2
M]^+GA[Q)^T7H/P(\.Z[K7]K1Z9H?@^U6.UTBS=+>,RW,D,LJB0;63";SEW9L
M<ADL?'#X"^*=4^!6N?$SXD_ ;0O ?B#P[/:M:MX7>%;75+627RW1H8IG6-XR
MP?S"<L,*!@<5',*<*BI2>MTGJKW=NBMWU:7X'/4X7QF(PL\;1C:#4IQ2A4Y.
M2-_MRYDFTFU&4F]DW=I'@GBCX8>+?!O@[0?&_B"UAAL_$JSOI*K,&D>.+RP9
M"!PH)DP 3N^5L@#!//5]3?'_ .,MC9?!GX1ZWJ'P@\(W%OJ,<E[/8KI>U;>.
M"X@=K>WW,PACE&4<$/D'VKD_$O[/&B:U^V9I_@C0(;=O"?B2:'7K.2-O+@;2
M70SRA#'_ *M,)+$G3HO3(-.CCI.GS55;XG\HNWWDYCPW&.*5/ SY]:,6FFFG
M5@FGM\+=_2Z3UW\%KH/ GP_O?'5KKU]!JUK90^']!EU2ZEO-P615=$6%=H/[
MQWD55!P">]-^)_B+0_%GQ#UKQ#X8T6UT[3+K4)&TVQL[588X;<'$8V+P#L"Y
MQU;)[UV&G/+X&_9/U"Z,ABNO'GBB*T2.6W_UNGV"^:[HW;_2)8E..OED>M=-
M2I)4XVT;:7^?W*YX^$PM&6*JJ;YH4XS;:T3LFH^BE)Q7S/-].LY-1OX-/B8*
MUQ,L:LW0%CC->L>,/V5M$\ ^*)_!7B_]HCPAI^J6K1BXM;B.\_=ET5URP@*@
M%64YSP#S7E_A?_D9M._Z_H?_ $,5ZC^WG_R=AXK_ .W'_P!(+>IJ2J2Q,:<9
M633?3HXKKZG1@J.#IY/5Q=6FIRC4IP2;DE:4:C?PM:^ZOQ.0^+OP1\8_!N[L
M3KMSI^H:;JD)ETC7-%O!<6=\H W>6^ <J6 (('J,@@GCZ]VT6/\ MK_@G?K!
MU>YD<:+\04;21)+D1EH80T:CL,32MCIER>N:O?%+Q?\ #[]E;Q>/@EX9^!OA
M+Q)-I-M;MXBUKQ9I1NI[VYEACD8PDO\ N(]K* N" <\'DMC3Q53^&US23:TT
MNE;77;=?,[L5D>%5L4JGLJ,H0EK>34I\R4597>L)M-V]U:W>_P ]T9KZ6TOX
M(? ZT_:.\-R26D,&@^+?!<6O^&/#^M73+;F_E0^58S39+%-P+9_B.V/#YPU'
MXVZ5X@TWX?:QI_QR_9'TOPM>QP1/X=\2>!]&2.W@FW@%+IXYFC97'RC)+*2<
M*3@AK,*<IQBEO;LGJ[:+K;K;\29<+XJCAZE6I-+D<EHI2C[J4E>25H<R:Y.:
MU^O*M3YWS1FOJGX:_L\^.O!GP<\,^*OAO^SMX;\=:YXDM?M^K7_BF:":ULK=
M^8((8998OG*$,S\X.1E@1MXG]KSX)2>!/#7A3XDWOPWM_"6JZXMQ!XBT#3[I
M);2"ZC8;)(=K,$61"6\L$A  .H))3S"C4K*FNK:6JO=7Z;I::?\ !%BN%<QP
MF6O%S3]V,9-<DTDI6M:;7+)KF5TGIKORNWD?@/P/XD^)7C#3_ OA&P-SJ.I7
M'E6\>< <$LS'LJJ"Q/8*37H\'[-GPQO;Z/P9I_[5/AF7Q3)<_9UT_P#LVZ%B
MTF<;5O=NPY. /EP2>.U<;\#/BK<_!/XJZ1\3+;2UOO[-ED\VU=]OFQR1/$X!
M[-M<D'D @9!'%>D'X0?L@?%6=IOA9\?+KPG>7"2/#H7C*Q_=I)DE(_M((1$^
MZHRTKXY^8\48FI4A4U;C&VZ5]=;WT>FW;U%D^#P>(P=U"%2MS-.$ZCIOEM&S
M@^:*<F^9.[=K+W7<\=\8^$/$?@#Q1?>#/%VER6>I:=.8KJWDQE6QD$$<%2"&
M##((((R"*S<U[[\-OV=/''C?]IGQ#X0^/45[KVJ>']'EU*[M/[3);7"BQI;P
MK<NP*)('CPY(*JNTA#G;Z7IG[/'Q*^+?VSP5\6_V3O"'@VRN+65M)\2>$_LL
M,VGW2J3&9A'<,UQ&?NE=O4@X'WEB>94:5E)IZ)MII;]DW=]]/Q9TX?A#,,=S
M2HPE%.<HQ3A)OW7:TY13C!]+NRO=NT=3Y>_X5=J__"FO^%U?VA;_ &#_ (2?
M^Q/LGS>=YWV?S]_3;MV\=<Y[5S&>U>R:;87>K?L+6^EV,>Z>Z^,RQ0KG&YFT
MS 'YFO9M:_9^^(WPRU9/ _PJ_8]\(>*O#MK'"MUKWB2:UDO]3D*+YTB/).IM
M@3E54*0I7<!\VT$L=&C)QG:]W:[2T5NK]14>&*N/A"I04E%0@Y6C.;YI\WV8
MINWNN[V6BW:1\:YHKZ8UC]E7X?>!OVBO$<>OZ-<3^%-!\#S^+(M!^V$R2(HV
M_8GE!R )!)A@6)5%!)))KA-5^.WPG^)/A37/#_C_ .!7AS0;E;%I?"^J>"=)
M%K-%>*?DCN,OB6)@<,>P!(4L5*:PQBJV=.+:T;VTO^?G^IQXCAZI@>:.+JQI
MSO-13YGS<F[NE9)O2-]WNDM3S[7?AYXF\.>!M!^(>K6\<>G^));Q-)VS!GD6
MV9$D<@?=7>^T9.248X VEF_$3P?;^ O&5YX2M/%FEZY':>7MU31;H36L^Z-7
M^1QUQNVGT92.U>W_ +0OQ177?V3?AR@^&GA2R_X2!=6VM8:4T9TSR+Z+_CT^
M<^3YN/WF=V[)Z5K^./@S\,K']J#XF>(]8\#V[>%/ OA^WU!=!L&%K!<73V<!
MB@/ECY%=_,8E1U'(()!RAC9;U%;X]%;6TE%?/6W;J=V(X=HRE[/"34OX%Y.Z
MM[2C.I)VM\-H\VS:5DKNY\OT5]!?"[Q%X$_:QU:\^#7B3X->$?#.K7NFS3>%
M]:\)Z6UDT-W$C/LG 9O-C90<YZ!3@;BK(6UW\-?A=^RGX#^*<WPGT'7/$UYJ
M.I6\/]LV7F6TB"=PTDZ*5,[(JJD:L=J[V;JJUI+&.,N1P?-=*UUU3:=^VC..
MGP_"M3=>&(C[)1E+FM)?#*$91Y;7YOWD6NC36J=[?/N:*]H_:+T7PCXC^#/P
M_P#CQH/@72O#M_XC-_;ZM8:'"8;5F@F\M'2/)"<*Q..NX9)QD^+UT4:WMJ?-
M:VK37FG9GDYC@99?B?9.2DFHR35U>,XJ479ZK1JZ>S"BBBMCA"BBB@#[4^%2
M+_PJ_P -\?\ ,!L__1"5O[%]*POA4K?\*O\ #?'_ # ;/_T0E;^QO2OE:G\1
M^I^^8/\ W2G_ (5^2&[%]*\(_;;4"W\-\?\ +2[_ )0U[SL;TKPC]MP$6_AO
M(_CN_P"4-=&!_P!ZC\_R/'XJ_P"1#6_[=_\ 2HG@-%%%?1'XV%%%% 'KWP._
M8]\7?'+P#<?$32_&VAZ58VNH/9R?VI)(F&58VW9"E0#Y@ YZUK>.OV OBOX2
M\$WWCW1?%7AW7[/3;=IKF+2;QVE*)RY4,@5MJY8C<"0. 3@'T7]E_P &Z%\0
M?V$O%7@_Q-XXL_#=C>>)V$^M7P7RK;:;)QNWNB_,5"C+#EAUZ'1^$MS\"/V)
M?!?BKQ1I_P"T+HGC6^U2"%;/2]+EB#22Q++L0K%+,0&9\&0X"CU) /@U,=BH
MU9J$KM2LH\M[K3[70_4L'PWDL\#AIXBERPJ4N>=5U4G"5I;4WK):+96U\CXU
MSQFBOHW]E/2_#EU\-I'\%_LHW/Q \4S:@ZZAJ'B""W32K:-<D112S,5WA=A*
M[58F0Y8A4!Z']LOX(^!_#5M\/O'FG?#?3O#>HZMJ$-KKVBZ<J?9P[*CE,(!&
M=AWKN4#>#SG QW/,(1Q7L7'NMUT5]KW2[,^8I\)XBIDO]H0J)I*+:Y9I6DTK
M*;BHN2O=I/0^4:Z[6_@?\1?#7PJL?C)X@TA;/1=4OH[;36FF'FW.^.5Q(J#.
M$ B/+;2=RE0P)(^F/VMM8_9H^ .L7W@73_V?])N=8\1>&I)8[U;"!8M-RLL5
MN\2%<;O-#LY78V IRV%5>@_:3^*'@J#]B[0O$<OP@TZ2S\1VL=KI&EF5/+T6
M6:SG,<\1\K!:+! PJ'G@K7/_ &E6J>R<*;M-VU:V\M?Z^:/5CP?E^'^N4\3B
MTYT(7M%2LG>RYO=UTMHNK6NC/ADU[MX"_86\0ZGX2M/'GQ@^)NB^ ]+U!5-F
M=693.VX93<KO&J[AR%+[O51TKR_X*:1INO\ QC\(Z!K5FEQ9WWB:PM[NWD^[
M+&]PBLI]B"17L7_!2[6-9O/CW9Z1>32_8[/P_";*%I#L^>20O(%Z D@*3U(C
M7/05TXBK6EB(4*;Y;IMNU]NUSQ\GP.7T\HKYGBZ;J*$HPC#F<4W*[;DUK9):
M)-79P?[0'[+'Q"_9]6SU;6;FTU71=18)8ZUIK$QNY!81L",JY52PZJ1G#'!
MJW_[,GQ;T_PBOB-_"M^UXNH7%M>:(FFS&ZM%AC21IY!LPL6)(\-G!WC'6LN_
M^,'QA?X::3\-;OQ->Q^&[.8W&DVXMUC7>LK-N64*'?;(6QEB%(P,8 'I/B3]
MMS6];^'LOPYL]/\ $%I;QZ3;QZ;JD?C"<WT=\C.9;B:?:&GCD#D&%AL 1=FS
MY2J;S"$8I6D[ZO;3I\^Z7W]ZA#A.O6K3DYTH\J<8O5J5KM)I.\=+1E*VZNNJ
M\(!S17HOA7X@_!_2_P!G+Q!\/-<\!-<^,+_5%GTG7O[/@;[-!FWRGFEA(O\
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MN_'3_H1O_*G:_P#QVC_AEWXZ?]"-_P"5.U_^.T?6,/\ SK[T']CYM_T#S_\
M )?Y' 45W_\ PR[\=/\ H1O_ "IVO_QVC_AEWXZ?]"-_Y4[7_P".T?6,/_.O
MO0?V/FW_ $#S_P# )?Y' 45W_P#PR[\=/^A&_P#*G:__ !VC_AEWXZ?]"-_Y
M4[7_ ..T?6,/_.OO0?V/FW_0//\ \ E_D=A\/OB_\.]#_8D\8_"+5/$/E^(M
M5UY;FPT_[',WFQ;K/YO,"&-?]5)P6!^7W&?$#7?_ /#+OQT_Z$;_ ,J=K_\
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M+?BNZ\-FUU[^V=!\0QZ>]Y$KF+RY+:2*/YPI&6!7@L<G&T!Y/^&+?BE_T'M
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M6QS/C_QCX<E^$G@KX;>%;I)6T^.\U'Q!+"DB*]]<2[51@ZKN:."*)=RY7YB
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MCJ'6O#MSI&E>&1HMW:6UFT__ "]_Z02B;!N^5!EB_P"(YG_ABWXI?]![0/\
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MY)D \LR ?+O VYYQCBC_ (8M^*7_ $'M _\  J?_ .,T?\,6_%+_ *#V@?\
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MS1_PQ;\4O^@]H'_@5/\ _&:]SZWA_P"9'Y;_ *NYW_SXD>0T5Z]_PQ;\4O\
MH/:!_P"!4_\ \9H_X8M^*7_0>T#_ ,"I_P#XS1];P_\ ,@_U=SO_ )\2-/P1
M\8?AUI'[#OBSX/ZCXB\OQ%J6N+<6.G?8YCYL8DM#N\P(8QQ$_!8'Y?<9\._"
MO7O^&+?BE_T'M _\"I__ (S1_P ,6_%+_H/:!_X%3_\ QFL:-3"47)QG\3N_
M73_([\=E_$680HQJ8=KV4%!66Z3;N[MZZO:R\COOA[\:O@=XK_9.TOX&>,?C
M#K'@74--O)/M4VFZ?<2+>PM+*S(WDJV^-TF(*L5_>*#AE&&K_'GX[_ GQG\(
M?A[X7^'GB&\1O"VN01R:=J5G)]H2SB5HQ/(ZH(F9@B,0A)_>]."!Q/\ PQ;\
M4O\ H/:!_P"!4_\ \9H_X8M^*7_0>T#_ ,"I_P#XS7*J.!53G51[N5M+7>_0
M]J6,XJG@_J[PD?@C3;M+F<8-./V[)JW1*_5.RM<_;N^+?P_^,WQ>TWQ3\-M?
M_M*Q@\-PVLT_V66';,MQ<.5Q*JL?E=3D#'/7@UU7BCXR? OXJ_L<:#\,?$OQ
M FT;Q!X9MVF@TQ=*GF^V3P6\\4,?F*FQ%D+H2Q/R\@XZCB?^&+?BE_T'M _\
M"I__ (S1_P ,6_%+_H/:!_X%3_\ QFK]G@?94X*=N1W3TO\ E;\##VG%$L;B
ML3+"I_6$U.+3Y=6G=6DFFK:7;7=,\EM+N[L+F.^L;F2&>&19(9H7*M&X.0P(
MY!!Y!'2OI[6OCE^R9^U-HFEW?[1XU;PQXFTRU6&?5M)A9DN5!)*J5CE.PME]
MK)E"Q"L<DGSO_ABWXI?]![0/_ J?_P",T?\ #%OQ2_Z#V@?^!4__ ,9K3$2P
M>(:;G9K9IV>NYQY7A^),KC4IQPJG3G;FA.-XNVSW3371IHVOVC_VE/A[K?PP
MTO\ 9W^ .CWEGX5TV0275Y>95[M@S.%"DD["[>8S-@E\8"A?F\'KU[_ABWXI
M?]![0/\ P*G_ /C-'_#%OQ2_Z#V@?^!4_P#\9J\/4P>'I\D)>;ONV^K,<SP/
M$F;8KV]>@]$HI))1C%:*,5?1(YWPWIGP%F^ NN:GXD\07D7CZ/4E70]/C27R
M9;;,&68B,IG!GZN#\HXZ9X.O7O\ ABWXI?\ 0>T#_P "I_\ XS1_PQ;\4O\
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M9-X33]G2^T'P_P"*O"WQPU7X7^)['3_LFN1V]A?79NY@,-=Q2PMF/S 3NCR
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M+VVM_P "Q56/$-2E*E]22@Z?L[)2LH\_M$U>;?,I:W;:?VD]3J]9_:/^&/\
MPU)XR\0W-]>7_@KQIX=31=2O-/@:.:*-K*")ID250<HZ,O(Z%B W .9\/]8_
M9Y_9LU6Z^*7@WXR2^-?$%K9S0>'=/A\-W-C'!/+&R?:)FF.&559AL&2=WXC'
M_P"&+?BE_P!![0/_  *G_P#C-'_#%OQ2_P"@]H'_ (%3_P#QFI]G@N7D51I6
M2:TU25M=.VCM8T]IQ-*LZ\\(G-3E.,FI7A*;YGRVFDTI:QYU*SU*_B?XD^"M
M0_9!\,_"VRUK?KNG^*+B\O+'[/(/+A990&WE=ASN7@,3STJ/Q3\1O!VI?LE^
M%_AE9ZQOUS3?$UU=WEC]GD'EPN)-K;RNPYR. Q//2KG_  Q;\4O^@]H'_@5/
M_P#&:/\ ABWXI?\ 0>T#_P "I_\ XS6J>#5O?VDY?-W\MM3DEA^)9<U\-\5*
M-+;[,>6SW^+W5=[;Z'D-%>O?\,6_%+_H/:!_X%3_ /QFC_ABWXI?]![0/_ J
M?_XS73];P_\ ,CR/]7<[_P"?$CR&BO7O^&+?BE_T'M _\"I__C-'_#%OQ2_Z
M#V@?^!4__P 9H^MX?^9!_J[G?_/B1ZM^RO\ \D2TO_KM<?\ H]Z]$KEO@KX$
MU?X=?#NS\(ZY<6\ES;22L\EJS-&=TC,,%E4]#Z5U?E^]>!6DI5I-=V?KV5T9
MT<MHTYJS4(IKLTE<;13O+]Z/+]ZR._E&T4[R_>B@.4DV&C8:=BC%3S%\HW8:
M-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV
M*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<
MP<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW
M8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-A
MIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,
M4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<
MHW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:
M-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV
M*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<
MP<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW
M8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-A
MIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,
M4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<
MHW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:
M-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV
M*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<
MP<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW
M8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-A
MIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,
M4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:-AIV*,4<P<
MHW8:-AIV*,4<P<HW8:-AIV*,4<P<HW8:*=BBCF#E),#THP/2EV-Z4;&]*DOE
M8F!Z48'I2[&]*-C>E <K$P/2C ]*78WI1L;TH#E8F!Z48'I2[&]*-C>E <K$
MP/2C ]*78WI1L;TH#E8F!Z48'I2[&]*-C>E <K$P/2C ]*78WI1L;TH#E8F!
MZ48'I2[&]*-C>E <K$P/2C ]*78WI1L;TH#E8F!Z4F4SCBG;&]*^-OC,\J?\
M%IOA+&KLH;X<W(90W4>7K/'Y@?E4RERV-:-'VKDKVLF_N/LC ]*,#TI=C>E&
MQO2J,N5B8'I1@>E+L;THV-Z4!RL3 ]*,#TI=C>E&QO2@.5B8'I1@>E+L;THV
M-Z4!RL3 ]*,#TI=C>E&QO2@.5B8'I1@>E+L;THV-Z4!RL3 ]*,#THVFC% <K
M# ]*,#THQ1B@.5A@>E&!Z48HQ0'*PP/2C ]*,48H#E88'I1@>E&*,4!RL,#T
MHP/2C%&* Y6&!Z48'I1BC% <K# ]*,#THQ1B@.5A@>E&!Z48HQ0'*PP/2C ]
M*,48H#E88'I1@>E&*,4!RL,#THP/2C:3TI=C>E <K$P/2C ]*78WI1L;TH#E
M8F!Z48'I2[&]*-C>E <K$P/2C ]*78WI1L;TH#E8F!Z48'I2[&]*-C>E <K$
MP/2C ]*78WI1L;TH#E8F!Z4AVJ,G%.V-Z5\L_P#!8J6>']B;4DCE95DU[3UD
M56(#KYN<'U&0#]0*F4N6+9K1H^VK1AM=V/J7"GH*,#TKG_A+)/<_"KPS<7$K
M222>'[-GD=LLQ,"$DGN:Z'8WI5&;BT["8'I1@>E+L;THV-Z4"Y6)@>E&!Z4N
MQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-
MZ4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2
MC8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;
M&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8W
MI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]*
M Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'
M*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6
M)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,
M#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>
ME&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#TH
MP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!
MZ4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2
MEV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4N
MQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-
MZ4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2
MC8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;
M&]* Y6)@>E&!Z4NQO2C8WI0'*Q,#THP/2EV-Z4;&]* Y6)@>E&!Z4NQO2C8W
MI0'*Q,#THI=C>E% <K'^7_G%'E_YQ4F*,4%D?E_YQ1Y?^<5)BC% $?E_YQ1Y
M?^<5)BC% $?E_P"<4>7_ )Q4F*,4 1^7_G%'E_YQ4F*,4 1^7_G%'E_YQ4F*
M,4 1^7_G%'E_YQ4F*,4 1^7_ )Q1Y?\ G%28HQ0!'Y?^<4>7_G%28HQ0!'Y?
M^<5\'_M2?%WX9?#/_@L!\.?&OCCQK8V.EZ#X"D@UJ[:3>+*66+5?+CD"99&8
M3PD*1G;*AZ$&OO3%?"/[3WPE^&OQ%_X+#_#?P9XU\%:?J&EZ[X!DGUJSFMP%
MO98X=5V22[<%V400@,3D")!T4"LJU^56[H[<#R^TES;<LMO0]Z_X>/?L0?\
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MCB-%_P"_4_\ \;J]_P .\_V*/^C</#?_ (#M_P#%4?\ #O/]BC_HW#PW_P"
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M%28HQ0!'Y?\ G%'E_P"<5)BC% $?E_YQ1Y?^<5)BC% $?E_YQ1Y?^<5)BC%
M$?E_YQ1Y?^<5)BC% $?E_P"<4>7_ )Q4F*,4 1^7_G%'E_YQ4F*,4 1^7_G%
M'E_YQ4F*,4 1^7_G%'E_YQ4F*,4 1^7_ )Q1Y?\ G%28HQ0!'Y?^<4>7_G%2
M8HQ0!'Y?^<4>7_G%28HQ0!'Y?^<4>7_G%28HQ0!'Y?\ G%'E_P"<5)BC% $?
ME_YQ1Y?^<5)BC% $?E_YQ1Y?^<5)BC% $?E_YQ1Y?^<5)BC% $?E_P"<4>7_
M )Q4F*,4 1^7_G%'E_YQ4F*,4 1^7_G%'E_YQ4F*,4 1^7_G%'E_YQ4F*,4
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M^R[+X77^W(]5N_'?BQH;K7"XP?LL+_O6MXE9(B"DPR$;* R2%_T _P"'5'[
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M$O 5]\3OB?KXTO0],\K[=?&WEF\KS)4B3Y(E9SEW1> <9R<#)KIO+]Z^=_\
M@JXF/V!/'IS_ - O_P!.MI5THJI4C%]6D14YH4W)=$Q/^'J/[!/_ $7V/_PF
M]3_^1J/^'J/[!/\ T7V/_P )O4__ )&KU?\ 8Z_8[_9'\3?LC?"WQ)XE_9:^
M'.HZEJ'PYT.YU#4+[P/8337,TEA"SRR.T)9W9B6+$DDDDG->D?\ #$'[%O\
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MO?I;_(\A_P"&Q/V;_P#HI2?^"N[_ /C5'_#8G[-__12D_P#!7=__ !JOH/\
MX9L_9U_Z(%X*_P#"5M/_ (W1_P ,V?LZ_P#1 O!7_A*VG_QNLOK<NQV?V/A^
M[^]?Y'SY_P -B?LW_P#12D_\%=W_ /&J/^&Q/V;_ /HI2?\ @KN__C5?0?\
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M3_XW1_PS9^SK_P!$"\%?^$K:?_&Z/K<NP?V/A^[^]?Y'SY_PV)^S?_T4I/\
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MJ +E8U +851GK@#TJJ>)E*21G6RNC3HRDF]$WT_R/3_%?BC0?!&@7'BCQ1J
MM;&UV^?<>6S[=S!1PH).68#@=ZXS_AJKX!?]#^O_ (+;K_XU4G[6"8_9_P#$
M!SVM?_2J&O4/@5\#/@GJ_P $?!VK:M\'?"MU=77A73YKFYN/#]L\DLC6T99V
M8H2S$DDD\DFO0<L/1PZJ5$W=VTMV3ZH^/_X5L9FTL'A'"*C!3;FI/>4HV7+)
M=CRO_AJKX!?]#^O_ (+;K_XU1_PU5\ O^A_7_P %MU_\:KW[_AGOX!_]$/\
M!_\ X3-K_P#&Z/\ AGOX!_\ 1#_!_P#X3-K_ /&ZQ^N8'^67WK_(]#^Q.*/^
M?M'_ ,!G_P#)G@/_  U5\ O^A_7_ ,%MU_\ &J/^&JO@%_T/Z_\ @MNO_C5>
M_?\ #/?P#_Z(?X/_ /"9M?\ XW1_PSW\ _\ HA_@_P#\)FU_^-T?7,#_ "R^
M]?Y!_8G%'_/VC_X#/_Y,\A\!_%CX??$V6ZA\#^(EOFLU0W ^RRQ[ V=O^L1<
MYVGIZ5TFPUXW^SSI>GZ3\??BQI6DV4-K:VOB26*UM;>()'#&MU<A451@*H
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MJ0L;C4#(7_TN/@QJ/E?G@9/K.![R^Y?YA_9&9=X??+_Y$]L_X:X_90_Z.?\
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M (2;4Y/)GCA9D?9)<LC8(!PP(/<&JC6P,I**<M=-E_F3/*\RIP<GR:*^[_\
MD3Z,\)^+/"GCSP_;^+/ WBC3=:TNZW?9=2TF^CN+>;:Y1MLD9*MAE93@\%2.
MH-:6PU\]_P#!*)=W[ ?@$Y_Z"G_IUO*^B/+]Z=2/LZDH]FT<--N=-2[JY'L-
M&PU)Y?O1Y?O4%\K(]AHV&I/+]Z/+]Z Y61[#1L-2>7[T>7[T!RLCV&C8:D\O
MWH\OWH#E9'L-&PU)Y?O1Y?O0'*R/8:-AJ3R_>CR_>@.5D>PT;#4GE^]'E^]
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MHV&I/+]Z/+]Z Y61[#1L-2>7[T>7[T!RLCV&BI/+]Z* Y6.HJ2BI+(Z*DHH
MCHJ2B@".BI** (Z*DHH CHJ2B@".BI** (Z*DHH CHJ2B@".BI** (Z*DHH
MCHJ2B@".BI** (Z*DHH CHJ2B@".BI** (Z*DHH CHJ2B@".BI** (Z^=_\
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M^U,L_P"?\/\ P*/^9VNQO2C8WI7%?\-)? O_ **7I_\ X_\ _$T?\-)? O\
MZ*7I_P#X_P#_ !-'L*W\K^YA_:F6?\_X?^!1_P SM=C>E&QO2N*_X:2^!?\
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MTOQ%IMJTEK:/<AA;O=9P]NCS!+;++E)YHT<)DE?!?A_HG[7O[,WQ4^)7A/\
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MSEHH]M4[A_9^$_E_%_YGZ-?\/_\ _JTS_P OS_[@H_X?_P#_ %:9_P"7Y_\
M<%?G+11[:IW#^S\)_+^+_P S]&O^'_\ _P!6F?\ E^?_ '!1_P /_P#_ *M,
M_P#+\_\ N"OSEHH]M4[A_9^$_E_%_P"9^C7_  __ /\ JTS_ ,OS_P"X*/\
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M/_+\_P#N"OSEHH]M4[A_9^$_E_%_YGZ-?\/_ /\ ZM,_\OS_ .X*/^'_ /\
M]6F?^7Y_]P5^<M%'MJG</[/PG\OXO_,_1K_A_P#_ /5IG_E^?_<%'_#_ /\
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M,_Y(GX._[%73_P#TFCKGQ/Q(VRW^"_7_ ".JHHHKF/0"BBB@ HHHH **,T4
M%%%&1ZT %%&<]** "BBB@ HHS10 5\G_ +1?_*1_X>?]B;-_Z#J-?6%?)_[1
M0)_X*/\ P\ _Z$V;_P!!U&M*/\1&.(_W>7HS3_:\'_&._B+Z6O\ Z5PU[;^S
MU_R0+P/_ -B?IG_I+'7B?[7JN/V=_$18=K7_ -*X:]L_9Z_Y(%X'_P"Q/TS_
M -)8Z]+%?[C'_$_R1\?E/_)55?\ KQ#_ -.3.!_:L/[&Z7MF?VCQ:-JC6>+$
M0_:/MGD[GQ_Q[_,$W;]N_P"3=NQSFOG705^*C:EIL7[$"?%8:2TDAW>('C_L
M]GZ97I;@?+UD.3P.",'Z _:M_9G^'OQ$\2V_QE\=_%^7PK'I6F1V:W&8T5=L
MLLBL'9@=Y,A  Y.!CDUX]X=\(_L]^*=8CT+2?V^/$BW$G"?;&N+6,GT\R;:F
M?09Y/ KLP4Z<<*K.4NZ:E**^27ZGS7$F'QM7.I*<*=)-^[*$Z=.M-::N4I7W
M5E[I]3_ 4?%U?ACIZ_'.2-O$V9?MS1>3]WS&V9\G]WG9MSMX_'-=E7+_  ?^
M',WPJ\"VO@N?Q;?:XUO)(W]HZDVZ:3>Y;!.3TS@<]!745X-:4959-6M=[*R^
M2Z>A^H9?3J4L#2A4OS**3YGS2NDKWDM)/N^KU/D#]GK_ )..^,0_ZFF?_P!+
M+JNE_:Q_:'T']ESX$ZW\7-92.XN;6$0:'IC2 -J.H2?+!;J,[FRWS-MRRQI(
MV#M-<U^SR"?VCOC%@?\ ,TS_ /I9=5Y_8B;]MS]N>34]\DWPU^ NH&*W7]ZL
M.K^+#]Y\%0KBT P#G<CA64M'.:]K&.U73M'_ -)1\-PO&,LMO+93J-_^#):?
M,]#_ &%OV<]:^ /P=:]^([K=>/\ QC?R:]X_U)EC\R749R7:$M&2I6(-L&P[
M"WF.H D(KVC%.V2>AHV2>AKGC[JL>W*4IR<F?%__  5F\3?%NS\8_!?X??"G
MXP^(/!TGB[Q1<:9>7V@ZM/;Y\R2SB1Y%AD3S0AD9@I(ZG!&<U(/^"5?[:..?
M^"J?CS_OO4?_ )8U'_P5/##X_?LT;A_S4D?^E>G5]Y5M7Q5;#T*?LVM4[Z)]
M?-%X' X?&5:KJINS5M6NGDT?"/\ PZK_ &T/^DJ?CS_OK4?_ )8UY_X@_9>\
M3^$M<NO#/BK_ (+UQZ9J5C.T%]I^H>-GAGMY5.&1XWU8,C \$$ BOTNKX!_X
M+#_L=?LV>#/V:O%W[1?AKX7V]KXTOO$%G-=:XM[<,\DD]THE;8TAC&X$]%&,
M\8KE_M+&=U_X#'_(]+^Q<O\ Y7_X%+_,Y30/V3_&OBN'4+CPO_P7?;4H])L&
MOM5DT_QE),MG:J0&GE*:L?+C!907;"@L,GD5TMO_ ,$ZOVE+OP2?B7:?\%B?
M$TOAQ=/:^/B"/5+QK$6JJ7:?SQJ?E^6%!8ONV@ G.*ZWXB_L>?LW? C_ ()Z
M^.OBC\)_A?;Z/KVM?!UX=4U"*]N)&G22"*5P5DD91F1%;@#IQQQ7D'A#]M_Q
MKIW_  3/F^"$?[%GQ8N+)OA/?:5_PFD'AN1M)$;V4L9O/.VX\A0V\OG 52:/
M[2QG=?\ @,?\A?V-E_\ *_\ P*7^9M7'[%?Q7M/".F?$"Z_X+@7T>@ZU=&UT
M?6Y/$\ZV=_.&93%#,=5V2ON1QM4DY1AC@UI?$#_@GU^T+\)]%3Q)\4_^"ROB
M'PWI\EP(([[7M8N[.%Y2"1&'EU-5+$*Q"@Y(!]#7C/CW_E$A^S/_ -E4G_\
M2_4Z]N\1?#3P[^VG_P %D/%GPQ_:!\[6O"?PO\'6]UX<\,R3[+5II([%V\U
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MS?NW#3K*DCR2N)&5HL;E"@\G'(P?VEC.Z_\  8_Y!_8N7_RO_P "E_F>5_\
M#JO]M#_I*GX\_P"^M1_^6-<I\=?^"?7[9GP4^#/BCXO2_P#!3GQ]J2^&M"NM
M2:P6ZU&(W'DQE_+W_;VVYQC.#CT-?HS7DW[>/_)EGQ4_[$/4_P#TF>M*68XN
M52*;6K7V5_D95LGP$*,I*+ND_M2[>IYU_P $Q/%_B[Q]^PYX'\6>._%6I:WJ
MMU_:7VK5-7OI+FXFVZG=(N^20EFPBJHR> H X KWK%?.O_!)97/_  3[^'Y
M/_,5_P#3M>5]&;)/0UMB-,1-+N_S/(P^N'@_)?D?-O\ P5RX_P"">OQ _P"X
M3_Z=K.O2/V-Q_P 8A_"O_LF^A_\ IO@KSC_@KFK#_@GK\0"P_P"@3_Z=K.O2
M?V-ED/[(7PJ('_--]#_]-\%<W_+SY';_ ,PJ_P 3_)'HV#7\W]?TA%7[BOYO
M:RQ'0[<K^W\OU"BBOMC_ ();_LT_! _![XF?M[_M/^"+;Q)X5^&UJ8M"\.WT
MBFWU+4EC$K)*AR&_UEM$BR*T;-=$E3LKE/6/B>BOT6_9F_;\^ G[;/QMTW]E
MG]J7]BSX5Z7X5\77#:9X;U#P[H[6EWI-PXQ;QB926W2.L<(>'R<,ZDC;E:ZG
M]@/]C#P+\%?CM^U#\(_B#\%/#GQ(OOAWIMK/X/L_$GAV#5'N%>*[N+4*C1L5
MEFB-N'6, ECM&<"D!^8%%?KA^QMX?'[5GQ%U+X.?M/?\$9/"?@#PW>>'[B5O
M%%M\-9-%:W=2BA%GEAC<.V_Y3#(LBD%AE0Q7RO\ X)A?!KX-VW@7]J#5] ^"
MGA?XSW'@2Y4?#\Z[X3AU-M66(:CY)AC*.X^T"*(E8^6RO7 HN!^<>:*_6[]E
MOX>>'/VQ[/QO\+OVO/\ @E#X7^#7AV'PK)=P^/M-\#_\(]/93+(G$4T]NIWA
M2TV\-L58&61'63%?DBP 8A6W#L?6F 4444 ?MA_P2.&?^">OP^_[BW_IVO*^
MD,5\X_\ !(Q7/_!/3X?%1_T%O_3M>5](;)/0UZ$/@7H?,XC^//U?YC<51\5#
M_BF-2_Z\)O\ T UH;)/0UG^*ED_X1?4L@_\ 'A-_Z :M&1\W_P#!O'_R99XG
M_P"RH7O_ *;M-K[RKX-_X-X_^3+/$_\ V5"]_P#3=IM?>5<V9?[]4]3VLH_Y
M%M+T"BBBN$]$**^!_P!O+]HO]I;X#?\ !1;1O&/PHU;5M5\'^#?@W%XE\?>!
MH;R9X+_2_P"V)K2[N(K8,(S=11S1S"5MNU;<EF**4;T[]N_XY7VH?#_]GCXB
M? _XF:A;Z/XR^/GA.)M0T/4)K9=4TNYCN7:"7:5+PR +NB<8)4!ER,!V ^JJ
M*"<"OG+Q!_P4;\$>+-6N?!?['OPJ\3?&O7+>6:WFN/"4*V^A6=PBAECN=7N-
MMM&'4L5:(S [".I4% ?1M%<S\'[[XL:G\.M/U'XX:#HNE^)[CSI-1TWP_>R7
M-K:J9G,,0ED53(ZP^6)& "F0/M^7;7GG[9O[0WBOX2^%K'X;?!;3X]0^)GC9
M;FV\'VDS*(;!(HM]SJER6! M[6,[RNUC(YCC527. #VFBO _V+?CKXZ\5_\
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M,,DFO>(X-%)@2!0)%9H[@XENMK*Q19"I4<5[EX)_X)@?M$?"OX>77PA^$_\
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M_P $>O\ D[C]KH?]5(A_]+]:KZRV"ODW_@CV,?M=?M=?]E(A_P#3AK5?,_\
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M0?#;X<_#F/Q##'_9T:R6FVUTV>:5I57>X N)VP2>H]!7R[^UG^P1^S_^P_\
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M_:=T]I-)#&Z:/0]19'VRK$?)<6Y6Y^9@1Y)?*!G&45F'SG\./!>KZ_\ '_\
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M"_9@\6?";Q'XGLY;WP2OB"3SHM6MT0R%7;RXS;S[%<F(A@"A0N'**WS_ /\
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M<J/'OV*?B7)HW["?[7'_  4 O;^;0]7\?:_JD=BD+'%C=/$[6K12'EL7.K;
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M%_O!@$^LZIP>(-!N=<N/#%MK=G)J5G;PW%WI\=RIG@AE:18I'C!W*CF*4*Q
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M<#VUS"LD<BE9(Y%!5E(P00>H(H ^5O\ @C9_PNK_ (8>\)_\+,_X1?\ L/\
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M=B2'# 1G"N3@>8_M;?'+X0?'_P#:Y_9(\;_!GX@Z;XATUOB.@DFL9LO QO\
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MB!_W"?\ T[6=<A_P4Y_Y27?LR_\ 80;_ -*XZ[+_ (*X_P#*/7X@_P#<)_\
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M9\SA?]UI_P"%?DCYH_X*\_\ *._XA?\ <)_].]G7 ?L^?\/2?^&6?! \#_\
M"@?^$;_X0#3?['_M;^V_MWV'[#'Y7G>7^[\[R]N[;\N[..*]"_X*]_\ *.[X
MA?\ <)_].]G7I7[&7_)GOPH_[)KH7_IO@KEWJ?(]",N7#[=7^2/B?_@E4_\
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M_P!@^;_T U2BK[&?M*G+:[/F'_@WC_Y,L\3_ /94+W_TW:;7WE7P;_P;R?\
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M7]DOP3^S%\/]>NM&T]-&\,_&VX\26D%G;V:A8X+BXTQXFG>:*$ '&]2Z@D3
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M0?"_X9_%;]N[]J;0_BC\.]"\265O\1KN>"SU_2(;R*.4:IJ2B14F5@&VLPW
M9PQ'<U^HE?FS_P $WO\ E(%^U9_V/UY_Z==0KT\!_!K>B_-'BYM=5J%N[_\
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M'!J?>'RL_-GXA_\ (_ZY_P!ABZ_]&M6/6Q\1/^2@:[_V&+K_ -&M6/7W%/\
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MYKNB>&/V$OA9XE\2ZQ:Z?ING_"70[G4-0OKA88;:&/2X6>61V(5$506+$@
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M%%O?,%0DF&78"P.]ML$8PI:N\_9G7=^TA\9/^QHF_P#2R[KUWXD_#KPK\6/
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MWA\7K>ZN_A/_ ,%9O#OBB&RD5+R7P[XEDO5@9AE0YAW!20#@'&<5TG_# /\
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M_P#B:/\ A"?&?_0HZI_X+Y/_ (FCGCW#ZOB/Y']S,NBM3_A"?&?_ $*.J?\
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M R*\W\'?MQZ?IO\ P3"F^!I_99^,TTC?".^TG_A*;?P0&T4%[*6/[4;GSO\
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M?]*-OO\ I0%F-HIVWW_2C;[_ *4!9C:*=M]_THV^_P"E 68VBG;??]*-OO\
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M^EG_ .ED%>J?L]?\D"\#_P#8GZ9_Z2QUZ&(_W"/^)_DCY/ _\E;4_P"O$/\
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MBTJUU#3[ZW>WOK&]MUEAN(74J\;HP*NK*2"I!!!P:XY14D?34:DJ4KV/RO\
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M'17/_"CX@6'Q8^%WAOXIZ5926UKXET"SU6VMYF!>*.X@2958C@D!P#CTKH*
M/,?CS^QI^S!^TW=V^I_''X.:7KE[:1B.#4F,EO=",%B(S/ Z2-&"S$(6*@L3
MC)S79?#KX9?#SX1>%H/!'PN\$Z7X?TFWYAT_2;-((@Q RY"@;G.!ECEF/))-
M;E% !7DW[>/_ "9;\5/^Q#U/_P!)GKUFO)OV\?\ DRSXJ?\ 8AZG_P"DSUI1
M_C1]5^:,<1_N\_1_D?-G['_BS]K#P=_P2A^&>J?L=_##0_%GBA]:U&*[T[Q!
M<K%#'8G4M2+R@M<VX+B00J!OZ.QP<<2?\+W_ ."[_P#T99\,_P#P:P?_ "ZK
MU+_@D"I_X=V?#PY_Z"W_ *=[VOI7#?WJ[<6KXJ>O5_F>+@I<N#IKE3]U?DC\
MWOVDK?\ X+7?M1_!;6O@3X__ &/_  -9Z1KGV?[9<:/K=I'<IY-S%<+L:35I
M%&7B4'*GY2<8."/NC]FGP5X@^&O[.7P_^'/BRV2'5?#_ ()TK3=2ACE$BI<0
M6<44BAAPP#*>1P:[G!_O?I2;??\ 2L%&SO<Z)3E*-K6&L"1@5_,_7],14_Y%
M?FK_ ,0[%C_T=S-_X0H_^3:BI%RM8WPM2-._-Y'YCT5^G'_$.Q8_]'<S?^$*
M/_DVC_B'8L?^CN9O_"%'_P FUG[.1U_6*/?\S\QZ*_3C_B'8L?\ H[F;_P (
M4?\ R;1_Q#L6/_1W,W_A"C_Y-H]G(/K%'O\ F?F/17Z<?\0[%C_T=S-_X0H_
M^3:/^(=BQ_Z.YF_\(4?_ ";1[.0?6*/?\S\QZ*_3C_B'8L?^CN9O_"%'_P F
MT?\ $.Q8_P#1W,W_ (0H_P#DVCV<@^L4>_YGYCT5^G'_ !#L6/\ T=S-_P"$
M*/\ Y-H_XAV+'_H[F;_PA1_\FT>SD'UBCW_,^D/^"//_ "CF^'?_ '%__3O>
MU],5YO\ L?\ [.B?LH?LZ^'?@!%XO;7ET#[7C56T_P"S&?S[N:Y_U>]]NWSM
MOWCG;GC.!Z5M]_TKHC\*/-J>]4;7<;6?XM_Y%74_^P?-_P"BS6EM]_TJOJ^G
M?VII5SIAEV?:+=XMX7.W<I&<=^M,SLSY'_X-X_\ DRSQ/_V5"]_]-VFU]Y5^
M;7@+_@C%\6OA9H\GA_X9?\%%_&WAVPFN6N)K'0M-GLX7F*JID*17ZJ6*HB[B
M,X51V%;?_#JS]J#_ *2J?%#_ +[O?_EC73BJ&'Q&(E455*[[/_(RP>+Q6%PL
M*3HMV5OBC_F?H517YZ_\.K/VH/\ I*I\4/\ ON]_^6-'_#JS]J#_ *2J?%#_
M +[O?_EC6'U+#_\ /Y?^ R_R.G^TL1_SX?\ X%'_ #/T*HK\]?\ AU9^U!_T
ME4^*'_?=[_\ +&C_ (=6?M0?])5/BA_WW>__ "QH^I8?_G\O_ 9?Y!_:6(_Y
M\/\ \"C_ )GZ%45^>O\ PZL_:@_Z2J?%#_ON]_\ EC1_PZL_:@_Z2J?%#_ON
M]_\ EC1]2P__ #^7_@,O\@_M+$?\^'_X%'_,_0JBOSU_X=6?M0?])5/BA_WW
M>_\ RQH_X=6?M0?])5/BA_WW>_\ RQH^I8?_ )_+_P !E_D']I8C_GP__ H_
MYGZ%45^>O_#JS]J#_I*I\4/^^[W_ .6-'_#JS]J#_I*I\4/^^[W_ .6-'U+#
M_P#/Y?\ @,O\@_M+$?\ /A_^!1_S/T*HK\]?^'5G[4'_ $E4^*'_ 'W>_P#R
MQH_X=6?M0?\ 253XH?\ ?=[_ /+&CZEA_P#G\O\ P&7^0?VEB/\ GP__  */
M^9^A5<#^U9_R:[\2?^Q!UC_TBFKXS_X=6?M0?])5/BA_WW>__+&H-3_X),_M
M':WIMQHVL?\ !47XE7=G>0/#=6MTMY)'-&RE61U;42&4@D$$8(.#3C@\/&2?
MM5]S_P B9YAB90<?8/5?S1_S.N_X(L_\F%Z%_P!AO4O_ $I:OJ^O*_V,?V7X
M/V0?@38_!"V\:/KZV-[<W']I2:>+8OYTA?;Y>]\8SC.[GVKU;;[_ *5>(G&I
MB)2CLVSGP].=/#PC):I)?@-KXF_X*5_\GS?LD?\ 91__ '(:37VWM]_TKYU_
M;I_8'O/VS=?\$^)])^-]]X)U#P1-=3:?>Z;I9FF,TS6[+(CB>)HF1K<$,"3D
MY!&.:PLX0K)R=E9_BFB<53J3HV@KNZ=O1IGUY17YZ_\ #JS]J#_I*I\4/^^[
MW_Y8T?\ #JS]J#_I*I\4/^^[W_Y8UC]2P_\ S^7_ (#+_([/[2Q'_/A_^!1_
MS/T*HK\]?^'5G[4'_253XH?]]WO_ ,L:/^'5G[4'_253XH?]]WO_ ,L:/J6'
M_P"?R_\  9?Y!_:6(_Y\/_P*/^9^A5%?GK_PZL_:@_Z2J?%#_ON]_P#EC1_P
MZL_:@_Z2J?%#_ON]_P#EC1]2P_\ S^7_ (#+_(/[2Q'_ #X?_@4?\S]"J*_/
M7_AU9^U!_P!)5/BA_P!]WO\ \L:/^'5G[4'_ $E4^*'_ 'W>_P#RQH^I8?\
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M1R2#FCW/JBBOE?\ X>#_ !R_Z,2\6?\ @7<__(-'_#P?XY?]&)>+/_ NY_\
MD&CDD'-'N?5%%?*__#P?XY?]&)>+/_ NY_\ D&C_ (>#_'+_ *,2\6?^!=S_
M /(-')(.:/<^J**^5_\ AX/\<O\ HQ+Q9_X%W/\ \@T?\/!_CE_T8EXL_P#
MNY_^0:.20<T>Y]445\K_ /#P?XY?]&)>+/\ P+N?_D&C_AX/\<O^C$O%G_@7
M<_\ R#1R2#FCW/JBBOE?_AX/\<O^C$O%G_@7<_\ R#1_P\'^.7_1B7BS_P "
M[G_Y!HY)!S1[GU117RO_ ,/!_CE_T8EXL_\  NY_^0:/^'@_QR_Z,2\6?^!=
MS_\ (-')(.:/<^J*^6/CF,_\%,/AN/\ J3;C_P!%ZE2?\/!_CE_T8EXL_P#
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MFCO-/J6VVN&A>$RA?[+VE_+DD4,02H=L8R:/[.Q?9?\ @4?\P_MC+_YG_P"
MR_R/M#X,?#U?A'\'_"GPH34OMB^&/#=CI*WGE[//^S6Z0[]N3MW;,XR<9ZFN
MEKX?_P"'IO[8G_2)#XF?]_-0_P#E51_P]-_;$_Z1(?$S_OYJ'_RJI_V=C.R_
M\"C_ )A_;&7_ ,S_ / 9?Y'W!17P_P#\/3?VQ/\ I$A\3/\ OYJ'_P JJ/\
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M-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L%.HHN
MW8*-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L%.H
MHN W8*-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L%.HHN W8*-@IU%%P&[!1L
M%.HHN W8*-@IU%%P&[!1L%.HHN W8**=11<"3 ]*,#THP?2C!]*DKE# ]*,#
MTHP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]
M* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C
M ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP
M?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#T
MHP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*
M,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E#
M]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?
M2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0
MP/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,
M'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.
M4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2
MC!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH
M#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#
MTHP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]
M* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C
M ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP
M?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#T
MHP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*
M,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E#
M]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?
M2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0
MP/2C ]*,'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,
M'THP?2@.4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.
M4,#THP/2C!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2
MC!]*,'TH#E# ]*,#THP?2C!]* Y0P/2C ]*,'THP?2@.4,#THP/2C!]*,'TH
M#E# ]*,#THP?2C!]* Y0P/2BC!]** Y278WI1L;TJ78*-@I<QIRLBV-Z4;&]
M*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4
MNP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV
M"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4
M;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8
M*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1
MS!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8
M.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!R
MLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D
M6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV
M-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO
M2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4
M;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8
MWI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]
M*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4
MNP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV
M"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4
M;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8
M*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1
MS!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8
M.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!R
MLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D
M6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV
M-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO
M2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4
M;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8
MWI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]
M*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4
MNP4;!1S!RLBV-Z4;&]*EV"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z4;&]*EV
M"C8*.8.5D6QO2C8WI4NP4;!1S!RLBV-Z45+L%%','*QU%.Q[?RHQ[?RHT-.4
M;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>
MW\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.
MQ[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RH
MT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_
M*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4
M;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>
MW\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.
MQ[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RH
MT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_
M*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4
M;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>
MW\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.
MQ[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RH
MT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_
M*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4
M;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>
MW\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.
MQ[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RH
MT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_
M*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4
M;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>
MW\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.
MQ[?RHQ[?RHT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RH
MT#E&T4['M_*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHQ[?RHT#E&T4['M_
M*C'M_*C0.4;13L>W\J,>W\J- Y1M%.Q[?RHHT#E)-E&RI/+]Z/+]Z@HCV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*
MD\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV4;*D\OWH\OWH CV45)
'Y?O10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gjyjiv3jrhol000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000012.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'T!7,# 2(  A$! Q$!_\0
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M@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10
MF!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M
M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?
ME2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C
M]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5075Y:6,#W
M-[=6]G;1C,EQ=31V\$8]7EF9(T'NS 5!I^JZ7J\1N-*U*PU.!6VM-I]Y;WL2
MM_=,EM)(@;V+9HUWMH*ZO:ZOO;K;O;<O8'H/RHP/0?E5&]U73--VG4=1L+ /
M]PWMY;VN_P#W?/DCW?AFK%O=6UY$L]I<074#_=FMY8YHF_W9(F9#^!-&N]M
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MT'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:*
M$P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*E
MHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#
M\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48
M'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?
ME1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3
M]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@
M!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI
M:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@
M_*EHH 3 ]!^5&!Z#\J6B@"%OO'\/Y44/]X_A_(44 2CH/H/Y4M(.@^@_E2T
M%?S>_P#!0?\ X+:?%3]CS]M"V_9D\*_!?PMXL\/QP>$+BZ\2:GK%W;7\P\30
MK+,BVT;K&GV7=M0I@MC+5_2%7\"7_!</_E+,W_8.^%/_ *21UZ^2X>CB<54A
M7IJI".'J346Y)<T902?NM/1-];:GPOB#FN891DE#$Y;B9X6O/,\+0E4A&G)N
ME.-9SA:I"<4I.,;M)/31H_M3^)/[0;?#O]E[5?VAKG0H[NYT_P"'D'C-/#Z2
MR>1)>W.FI>Q:>TX(D$ D?RFE!W[1D'-?S-_!S_@YN\9^)/BAX7T'XJ?L[^%_
M#'P^U[Q!!HVIZ_HGB'4;W4]'BN[Y;&"[CMI96CF0,P>;S00B G(K]T/VH/\
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M \]CXMM%L]3_ +2T6.VEFE6-,J8)([N(HP)YW \C%?H;7\AG_!H[XJM? O\
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MLAA=OO;0HXKS_P#X.&'$?[<?P:+QI*AL+)9(I!NCD1]JLCJ>&4ACD'BOCO\
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M5']?-%%%>2?;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!"_WC^'\A10_P!X_A_(44 2CH/H/Y4M(.@^@_E2T %?P)?\%P_^4LS?]@[X
M4_\ I)'7]]M?QX_\%8_^";G[:O[0'_!1B#XS?![X-W/C#X9W%I\/H&\2PZQ8
M6D=NVBVZ1ZB9()SY@$# YSC=QMKVLBJ4Z>,J.K4A3B\-5BI3DHIR<J=E=M*[
M2=EN['Y[XE83%8S(</2P>&Q&*JK-L'4E3P]&I6FH1A74IN-.,I**;2<K63:O
MN?O!^U!_RC-\2_\ 9#=*_P#3%!7\^?\ P;D_#_P]\6/"_P"V)\,_%EE;ZCX<
M\:>#1HFI6=U$)H66\U.2VCG,; @R6S3F:,]G4'KBOZ5/CY\(_'WB_P#84\0?
M"/P]HQO_ (@7/PFL?#UMH@GBC,VLV^D16[V8G8^4"9E*!R=O>OR-_P"" O[$
M7[4?[).H?'&^_:*^&-Q\.H_%=E:6V@I<ZE:7[WKP:P+AR!;$[%\@;P6X/&*K
M#UH0RO,(^TA&H\13E3CS)3=I1?-%7N[/JD89G@,36XQX3JO!UZN$I97BJ.*J
M^PJ2P]/GH3@Z=>HHNG!RYN7EG)-WLC^<?Q;I_P 3O^"5'[<GC_PK&M\-,L+C
M7M*9,O;Q>-_ VK)=BW6/(59+.%KJ-0PW)E<#K7Z#?\&X=X-2_;K^,6K+'Y2Z
MQ\/?$VKB'KY(U+7S>"+_ +9^;L_X#7['?\%O?^"8WB[]LSP?X6^*WP(T2UU/
MXY>!2--FTR2:"TD\3^%F;SCIT-Q+M2.[CF'R22EAY>U01M%?'G_!"?\ X)U?
MM??LL_M%>//B=^T+\+W^'6@7_@&Y\-Z:L^K6.I37M]/=I.&06C$HBH,'=WKU
M*F/P^*RG$5)3IPQ4Z,:56#FE.<H25FHWN[IMII=6NB/C<+PSFN3\<99A*.&Q
M=;)</F=3'83$1I5*F&H4<33O.,ZRBX4Y4W"-.<923;C&=FYW?]7]%%%?'G[V
M?Y_G_!7KX/7_ .R)_P %,;'XB^%EFTS1/&'B/PY\5DU:V5H(SJ%SJUM<ZO81
ML  66*)EE ;D9&:;_P %._VDKC_@HU^UC^S=X:^&4DFI:3>^&O"FB2:)$_G*
M^OS:I92ZY.L:%@&\J2ZPN-RQ  GN?Z%/^"[7[ 7Q0_;%^%'P\\2? ?P@OBOX
MH_#O7;N=]'@N+>QN];TB[@BB2U-U/A66VD\R54;/7 ]ORO\ ^"0?_!(O]JKX
M;?M?^&?C#^TS\([CX>>%?AE;2:WX?FU+4K/4DUC6YXS!]C%O$2Z^2,2!F!3B
MOLL-C<,\%1QE6K#ZW@\/6HQIN<5.3M&,7RM\S;Y8M-=&_,_ <WX>SB'$68Y!
M@L'B?[$S[-,!CJV)IT*KPU&G&HZM5.M&+I05-SK1E&<DY.--=8G]<'P'^%^C
M?!?X*_#KX7^'[=;72O!OA#3-)@@5 @21+42W6%  &ZZEF;'7FOX*OB5_RF^\
M+_\ 9QWAG_TJN*_T-'!*,!W5@/Q! K^+OQW_ ,$QOVY-4_X*RZ#\>=.^"EU<
M_!VS^-F@>+)_&PUG3UMTT*UN)7N;PVI(F/E*X_=@;VSP.]>5DU:$9X^5:I"$
MJF%J6<Y*//-N[2YFKR;>RU9]IQ_E^(JX;AJC@<)7KPPF<8/FAAJ%2K[&A2]G
M%2FJ<9<E.,8VYI6BK;G]HU?Q%?\ !S5_R<#\.?\ L3HO_21J_MUK^4[_ (+S
M?L ?M=_M7?&'P#XH_9Z^$US\0]%L?#T>FZE=6VJ6=C]AN%MVC/F)<G<R[CC<
M.!_/'(ZD*>/A*I.-./)47-.2C&]ENY-+\3O\1L+BL9POB:.$P]?%5GB<+)4<
M/2G6JM*;NU"FI2:5U>RTZG[O?\$YO^3%_P!EK_LCWA7_ -)FK\ /^#GIS'X8
M^!L@&3'JDSCZK(S?TK^C']BGX?\ BSX5?LF_ #X<^.M-_L?QAX-^&GA[0O$6
MEF5)S8:I9VY6YMC-$3'(8V."R':>U?C9_P %]_V+?VF?VM/"OPIA_9V^&\_Q
M%O= U&5M8L[;4+6Q>SB<L5F)N2-Z\C(3..M/+ZE.&;JI.<(4_;UGSRDE"S<K
M-R>EGW(XIPF*K<!SPM'#5ZV)67Y='ZO2I3J5^:G]7YXJE&+FY1L^96NK.^S/
MPZ\&?\$:)_B[_P $Y_#_ .VU\.O%TD_CI_#.J>+=<\%26LLW]H:=I5Q-%<V]
MA(,JMTD4/FA54EE8L,[2!]F?\&X7[4G@WP]\0_%W[,'BSPCX<TKQIKEG=:[X
M5\9FPM[7Q 8M-A8:EX>U/47_ 'UQ)-*2(H<JP9 "<;E/]!O_  2V^ WC_P""
M/[ GP;^"GQO\*)X?\9:-X?U33?%?A>YF@OTMUOKRX)M9I8MT,PDMY 6VY'S8
MZBOYG?%?_!*+]O;]GC_@HG#\4_V<_A/J/B;X7Z7\5[7QGI_B^QUNRL;6YT;4
MM1EOM4TN:U=A,EI )/*>!^&48 QQ7J+&0QT<RP6)Q$$E.I/"U93C&+49-1BI
MW2FK\K2N^9/2Z1\;+A_$<-5N$.(,GRS%2G4H82AGF#HT*M:JIUJ-+VU65'EG
M.C)J57G:C%0J4XWLWK]=?\'0_@K4-3\)?LT>-+:"=K#0M8\5:=J=RL;-;6Z7
MEK&;7S9/N1-)+*X4L1NQCG%??W_! +XQ>&/B-^PUHGAFPU*S_P"$E\!^(M7T
MK6=#$\?]HVEF#;)97\MKN\Y;:[*N(Y2FPLH&<L,_H%^UM^REX9_;=_9HUCX-
M?$^U31=2\2:-8WL%]&HEF\,^*(H$F62*1 SF""[+13K$<RQ+QG %?QZW?_!*
MW_@K=^Q+\1/$%]^S"_B75M&#M%/XR^'WB&#2+?7=-CD+6Z7NEREIG54*@_NE
M<'(8Y-<V&GA\;EBP%2O3P]>A4<Z<JKM"<7)RT;LOM-6WVLK7M[.;T<TX=XQJ
M<3X7+,7FN6YG@Z=#%4\%3<\10J1ITH7=-)RT5&$TW%0:E*,I1:1_4_\ \%<O
MC5X1^#?[#'QMG\0:K8VVL^*?"\_A_P *Z1/<1Q7>M:K<SV^;>UB9@\FR$.SE
M =OR^M?SL?\ !LO\.]3U']H/XR_%\6-S_95MX'D\+/?>4_V2+4+O4DOC9F7[
M@G5"QV9W;0>,#CQ27_@F9_P6'_;@\6^&K7]I>Z\5Z9X4^W(]OKWCSQ)!J.F^
M'H"RBXNK72H]DV]D#A#L8[_?BOZ[/V"_V)/A]^PE\#M-^$O@E_[1U"XDCU3Q
MAXC=-LWB#7S%Y<UX=P$BQ %EA1^54G@9I598?+LMK8.&(IXG$XF7ONB^:$(>
M[N]MHZ=7+R0L%1S3BOBW+\^Q&5XO*<JR>BUAXXZ'LL1B*[4I*U-I.SE4NVKP
M4(KWG-M'JOQQ^%7[,OQ&;0YOVA/"OPK\0/II=?#TWQ&_L2.2WW2;Y(M.EU:>
M!V1Y3NDBB9D9SEE)KVGPYI7A_1-"TO2O"MEING^';*S@AT>ST>."/2X+!(U%
MNEBMM^X%N(]OEF+*%<$$CFOYH_\ @O?^QK^V]^TQ\0/@9K?[,/ACQ%XT\+>'
M=&U*U\0Z7H6N#25T[59KX/;3SQLZF9G0>8L@X4':3FOW._8G\"_$KX:_LP_"
M/P7\7+FYN/'^A^%K&UUY;RX%U<VEPL* 6,MP,B5K7!C+ GIUKRZU",,%AJRQ
M4:DJDI)X92NZ.KUY>9M7LK^['U9]K@<QK5\_S; 2R6KA:6%IT90S:5/EAC^:
M,'R*?LH\_)S-12JU+<CYE#1/ZIHHHKA/HPHHHH *^;/VRO\ DT;]J#_LW[XP
M?^H!K]?2=>&?M/>%?$'CK]F[X^^"O"E@VJ^*/%WP:^)?AKP[IBR+$VHZYKG@
M[6--TJR65_DC-U>W,$(=OE4OD\"@#^43_@UOR?\ @A9^TL "2?$7[26 .I/_
M  @,W ]Z[/\ X,TR/^'??Q\7(W+^U%XEW+W&?#FBXR/?!Q]#7U9_P;E_L'?M
M%?LG?\$ROB/^SA^U7\.[_P"%/CGQI\1/BBRZ'J%Y8WUT/#?C#0[?28-29].G
MN8%#F2YV1B9WVQAFVEMH_&+]GK]EC_@O-_P1;^+G[07P7_8@_9RT+]H_]GKX
ML>.;S7_!'B/5KK3QI.E7]VQ^RZQ<0RW*W$$UG9DP7$-Q"D<D,;$RDY0 'OGQ
M@X_X.P/@\"1N_P"$+MF*]P&)921VW#D>HKRK_@J1\&/AO\??^#D_]D3X=_%G
M0(?%/@FXT?2-2O\ P_=JLEAJDMF\<\5MJ,#_ "W-FTMO"TL#_*VP5K_L-_\
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M* "BBB@ HHHH **** "BBB@#\6_^"\Y_XP!\>_\ 7Y;?RKX._P"#7+_DW_\
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MKOPV\+WB:?HDL=I*^H>,O$=[?".+5;33!NG@AMUE$?EE=QCCW-GDG]T_%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_!O_@L?_P13T/_ (*:3_#/XK^ ?BEJOP0_:2^"MR+[X?>/-.#FS>YA
MECN+!M4\D-<JVFW4,,]L]N 6V&-SY;NK_O)10!_')XA_X(K?\%R_V@/!DOP/
M_:H_X*P+XH^!VMB/2_&>F^&(-;MM>\3^'BZ":RO9I;6*,N\ (&'QOQGBOZ4/
MV#/V'_@]_P $]_V;O W[-OP7MKEO#OA&R5=0U[4A'_;7BG6)"SW>MZP\7R/=
MW#N1QG:@5=QZU]ET4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5B:YXBT;PY:&]UF_@LH < RMAG;&=JH,L3^&.1S69XP\9Z1X.TR>^U"
M=//$9^S688&>XD(.P*@^;9N W-V'2OAJ[N_%7Q*\0/@7>HRW-T?+M4W-!8V[
MM\NY<A0D:X8L1G:#0!]2M\>?!HN?("WA3S!']H"+Y6TD R9Z[!U[G KUS2M7
MTW6[1+[2[N*\M9/NRPMN&?1AU5AW!KY4U3]GVYT_P_<:A#J9N-6MH6F:S51]
MF8("7"MPQ(49'TSFL_X$^*KC3?$,GAV8LUI?EEC7)(BNT8@[03A0<$8% 'V;
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
M+_>/X?R%%#_>/X?R%% $HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110
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MT[9J5A<7'DRWD!293/I*003R/9WYVI--$(1\K&2/]&/^#C;_ (*,?&'X)_\
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M;8WDDVQY=8T4,Q;[$_X*B_\ !&_]EK_@JUH?@BW^.<OBCPMXO^'<LI\)>/\
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MK$JOV*SDE!?[N[A1GN>6Z#GVH ^0_CAXLN-<\3/H,!)LM'=856,EA<7,AXD
M7J48A<\D 8]J^B?A-X+C\)>&X&N(T.JZBJ7-W, -VUU#11@]1A""PZY//2OE
M/X:Z1/XN\>V<LK^<L-T^JW9DRPE@WL^PGD<9&T$\"OOY0% 50 J@*H'0 #
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M%R/FV%2Y(..GR]CU_(?4E>+? FQ2U\$PSI&4-[,9G8C D(W+N![XSC\*]IH
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M EL'G@=:^N-$\/:1X=LX[+2+&&TA15!\M/G<JH4L[G+%FQD\XR3@"MD
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M> HO&/C3Q9;WFI'QO92W*/\ 9K30K*W?[!/NE4)B=&=@ZE0>2/YM/^".=_\
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MAU\6_P#@F+^U!I/Q'TO3M0L-!\":AXHT6:^A@:6PU_1X7N-.GLKB52]M.9E
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MZ5HKN]$D44D9M %\Z.3>RM"R.&8$$_M;_P $X_\ @JC^RO\ \%./AGJWC_\
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MS]"\%:#I:>+_  YI-S:^;ILNH^))M,OKZ*V:W.]O+DA6WB96+CDJ 9'[%_\
MP<G?!#X__M$>&?V7?VBO@9\4?V0_BUX^NXK'P%I?Q2T>ZTRSUF\N,"UM[JYO
ME@6R>]=A':%B?,?("'G'X8_\'-W_  5*\?7W[0W[.OP1\ >$?CW\))/V=/CZ
M=:\0^*;";Q#X3T7XM64<VE%-(T*YT^>UB\10O':L8;9_/@<W3!XG##;\X_\
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M 5][T4$'\JG_  :_?LY>/O#_ /P2K\;_  ;^/7PV\9?#J7QKXK^(^@ZEX?\
M&>AWWA[5[C1-?DU2PENH['4(H+E8I;:\9HGDC3=D'&"#7XP?#'PA_P %-?\
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MW#_,5[M^Q[_R!/%O_85A_P#150OC?I_D=4F_8I]>6'Z'U!_P@O@[_H6](_\
M .+_  H_X07P=_T+>D?^ <7^%=715G-=^?\ 7_#+[CE/^$%\'?\ 0MZ1_P"
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M.^()5%_&H%E=N0HND&!Y;$D NO&#U/0]J^BZ9RA1110 4444 %%%% !1110
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M?_%4?\-/_#;_ )Z:C_X#C_XJO@?_ (5K\0?^A*U__P  &H_X5K\0?^A*U_\
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MB#QY\;OBC]EL/^&B/']DOBCXC^+7E6,);:7Y=FFI:[>R2J@*R.D)E(W>:R#
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MEJVC7MOJ%A=1G^*&YMGDB?J,@-D9&1R* -RBO*O'_P <_@W\*[JSL?B3\3_
M_@>]OPILK3Q/XCTS2+FY#'"F*&\N(Y&#'[IVX(Y&1S6'\5_CSX$^&OP5\5_&
MG_A*/"MWX=T3PMJVOZ/J-QKEI%H>MW5CI\]W96$&I1RM&[7TT26Z>2S/ND'
MH ]QHK\&?^"/W_!:31/^"D'@7XH>(_BCH?P\^!VN^"/B/J'@O0="C\91W4WB
M.R@N7M[74(EU"9&+S$*H2+(9V^0.N&/[R(ZR(LB,'1U5T=3E65@"K*1P0P((
M(X(.10 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K^#'_@\RT"[\5^*OV#/"]A=-8WWB3XA3Z!9WRNT;6=WK#+IUO=+(I#1M;S7
M*3!U(92FX$$9K^\ZOX./^#RCQ)#X.\9_L!^+KF%KBW\*_$EO$D]NOWIX=#FC
MU.6%?]J1+4H/=A0!^E'P*_X-8_\ @GWI/[)A\(_'/PYJ?Q@_:'\6>$CJ6N_'
MK6M:U2?Q)I?B2]TI9+<Z&/M9@>RT^4QQH+F.4RQ1JD7E(BEORX_X-;/B%\6_
MV8_^"@_[9?\ P3(\3^(KS6_ /@R'Q#XNT."^O+BZ6PO_  Q?6FG6XL8II'CL
MXKG2+^VN)X;<(C7+7#D?=K^A;]G_ /X+Z_\ !-SXK?L@6OQ\O/C_ ."? E_H
M7@5I?$/PP\3ZU9Z;X]L-9TK2Q!-I-CH4[K=7[7%W$8K.2"-A@YD 50[_ ,[?
M_!L9I7C7]K#_ (*G_MS?\%%8/#T]C\+M:A\3^#],U*5)5C?5O$=]875A!&S@
M+)(VAV%O-*$+".226,[6C9: /SO^-O[ ^L?\%'_^#DOX\_LS6/C"\\#>'-7U
M/4/%_P 2-4T^]GLKR]\ ^&+#29O$>F1>1)']KFU"WGAA6WFWI(!C82J$?W%?
MLV_\$2?V&OV0/#GQ:TO]G'P7J7PRUOXR?"+4/A)XM\8:;J4T^N?V?J.GS64^
MN64TLBFVU1'GEO(@DBQQ3NY0KDM7\VG[ S9_X.Y?VF>>3\)/BY^.-"\-_P N
M*_K$_P""I?Q+^)WPB_8&_:9\??"""ZD\=:'\,O$<FF7-D'-UID4VFW,5WJL'
MED.LMC S2HZG<C88<B@#\ ='_P""6?\ P;5_L0Z;>?#3]JOXE?!?XC_%*&YN
M6\0^+?CUX\GN/&<\\[LV)[;3;R>*VGC+%3('DD^5%^39@_CE_P $E/%?P7_9
MH_X.)==^#?[!WQ7M_&G[)/QD;7+'2XO#FI75]X930EB^WVFD1+.4$WV&X#M#
M=RPFX"L4#A  $_X()_LQ_P#!'G]I_P#9S^(/[1?_  4L^*'@SQS^TJWQ#\2/
MKVD?&CXBR63Z1X6LYS<Z3K$%A?W/F:G_ &J7N9,*91"\?E0P#S$"^3_\$]?$
MO[&5Q_P<I^ KW]B#2K;PS^S?H>L>(]'T/R5\C3+RYLK*2WGO],!5?,L+F5#]
MFD&X.H!#L#N(!^B__!T)'&W_  5/_P""7CNJ\26@W,!\JCQFDF<D<!617]BH
M/4"OOS_@ZG\:Z'<?\$A=.\/V<D>HS77BSX92O-%B2&W:TT] NYC_ ,M-]Q'(
MOILSG(%?ES_P<]^,H/%7_!3[_@G4NG+)'::8+&W@F(V37$DWB>&9G"Y)4!I3
M%'@_,N&[X'W5_P '*G@76K/_ ((XZ;XEU)/L<(\6?#,);R\73FZLK1(3*AY&
M[R)/PQZT ?%7_!%3_@W_ /@#^TK^S=X.^/O[6]KKGQX\0?$W1OLN@:5J^MZE
M_P (W\.=!AA0:<-)DCE)69(60R0A5CWJJ*H"*H\O_P""0/PBU/\ X)Y?\'%7
MQ#_89\+:Y?7_ ,)O%7AWQCJ<.AW5S+/80VVFV=[KF@QI;.[0F2S(EB\\IYLB
M11*[$* /ZV_^"$UK;6O_  2X_98%M"D0D\$022%0,N["/<SL!EC[GMQ7\TWP
MV/\ QV%M_P!DX\7#_P M#5^* /[SU544*BJBC@*JA5'T   _"E) !)X &23V
M ZFEK@/B;XB/AKP;J]_$^R[:W:"SYQF:3 X]PNZDW9-O9*YTX/#5,;BL-A**
MO5Q-:G0A_BJ344WY*]WV29\V?&KXI7&K7\_A?0[EHM,M&,=_<0N0;N8'E%93
MG8G*G!QG\:^<>E.=WE=Y7)+RN\CDY)+R,78Y/^TQIM>7.<IR<GUZ=%Y(_IW*
M<JPN38&C@<)!*%.,?:5++GKUK+VE:H^LI2O;I&-HQT04445!Z05Z)\._B#J7
M@75X9HY))=)GE1+^R+$H8V;!DC4\*RDY.W'<UYW13C)Q::=FCGQ>$P^/P]7"
M8NE&MAZ\7"I"2NFG]I/>,X_%"2UBTFC]4=+U*UU>PM=2LI5FMKN%)HG4Y!##
M)''=3D$=B*OU\U?LY^)9+S1K_P /W,F6TR57L5)R?LS@E^O. Y'^>:^E:]2$
MN>$9=UKZ]?\ @>1_,N>99/)\UQF72;DJ%7]U-[U*,TITIZ:7<)+FMIS)KH%5
M+^_M-,M)[Z^G2WM;=#)++(P5551GJ<9)Z =2:LNZHK.Y"HBEF8\!54$L2?0
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MN VVIVT=M?W6G3174) *.MQ:2X]5P: /JJBBB@ HHHH **** "BBB@ HHHH
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M_P#H=1+XH_+\R(QE&$XRBXRC.SC)---<MTT]4UV9^K5%%%:',%%%% !1110
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M_B#;&U@N7%QKVN/'\0O%_FP>']%5TNM6N(_-BW16V6 =<]17]-_[*W_!QO\
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M_8R\*:9X?M-3\(V-O>ZEX?@U31G2X\3+K,%O'):V,=U GF^9?&-+@0F-'!E
M/[??L-?$C_@A!_P47\6?#+QY^S5X(^#7ACXY?"RZL/$.A^'+'PYIW@'QWH&L
M?9@6TN*(V]FVOQV>&,?V19-ZCSD50Q6@#\U_^#IC_@KQ\-_ GPND_9 _9[^.
MGQ!\!?M8>"OBAX:U3QE:>#8M4T+[%X52/SKN*;Q):R".03KL:.U!7S@'&UAT
M^^?^"2__  7U_8/^-GPZ_9A_93OOC1XV\2?M0ZWX8T?PQJEKXC\*:KMU?Q;'
M&RSHWB*=EM[F1E4,93N=B&<_*17QA_P>#?L\_ S1?V*?"OQQTKX4^"=/^,6N
M?&_PEI&K_$NTT.T@\7ZEI<JI'/87^L1HMS=VTJ*@,<[. %^7;N;/Z[_\$@/V
M%_V-M _8\_93^-^A_LU_"/2?BXOP[T?67^(EKX3L$\5MJTL69M1.KE&N1<.%
M7+AL KN4!F8D ^V_VUO^"DO['?\ P3Z\+P>*?VH/BYI'@E+QHQ8^'[7;J_BV
M_20@+-9^';:9;^:$LR*) @#%U";LU^;WP5_X.>/^"17QR\>:5\._#OQO\3^&
MM<UO4TTS3+OQ_P" M5\(Z#-++)Y<4DFLZC,+6&-OOMN)*)\QR <?S2?L4?!G
M2/\ @N5_P7>_:1^)W[6C2^-_@Y^SQXA\6Z-H_P /&N9DT*XG\&:G<Z'X>TXV
M;%H%T<W.E33:G:B/%XQB+D[(RG[R?\%QO^")G[$GQ)_8*^+'C+X0_ CX=?!C
MXI_!_P .77C7PMXI^'WAVQ\-R3P:+$;B\TS6$L(XUOK2:WC=$\P%U9V#%U8;
M #^F#_A+O#C^%)?'%GJUEJ?A6/0[CQ)'K6E7$.HV%WHUO9R:@]]97-J\D-W"
M]K&TL3PR,L@QM;FOQVTW_@X._P""6.I?#+XF_%8_M!QZ;X>^$_BJ]\&^)].U
M?0[C3_$]QKM@\D<\&@:!-/\ ;-:B9HR(9K;"R[D* AA7P!_P;._M*_$#]H;_
M ((U^--/^)&NS^(-7^#Q^*'PVT6[N6=YXO"&F^%;A_#]I+(Y8R-;1>?$6));
M;N[X'\Z/_!NE_P $N/V??V]OVROVF/BG^T?8GQIX+^!WQ%\1WOA_X77,D@T+
M7/$DOBB]A-]XBMLF&_TY8&7-HRCS64ACRK( ?V7?L<?\' __  3&_;B^(<OP
MM^#OQIO](\9BUFO+73_B;X<N/A]!J<4 9F73+W6[E(+N?8I?R5*MCC).,^9_
M';_@Y@_X)+?L^?%[6?@OXR^-WB+6O$_AS47TG7=4\#>"-2\6>%-.U".01/;R
M>(-/F^QLT+D_:#E1 @#MD&OY5/\ @Z)_X)[? W]FC]KC]D'Q1^RMX6T;X!-\
M9(H?#&OVG@*U&@:9IVN/KHTJUU[3;;3WB-K*+!B+E8BBR/(XV[&*U_1Q:_\
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M2,2NTJ 3_J/^&[B6[\.Z#=S,7FNM%TNXE=N6>6>Q@DD8GN69B2?4T ;5%%%
M!1110 4444 %%%% $+_>/X?R%%#_ 'C^'\A10!*.@^@_E2T@Z#Z#^5+0 444
M4 %%%% 'Y??M(?\ )3]1_P!P_P Q7NW['O\ R!/%O_85A_\ 15>$_M(?\E/U
M'_</\Q7NW['O_($\6_\ 85A_]%5"^-^G^1U2_@K_  P_]M/LNBN2\:>+]/\
M!6B7&L:@=P3]W! I^>:=@=B@=<9'S'TKXNUKXX^.]4O&GLM1;1[?S/W=M: %
M?+!^7>6&2Q'WO>IJ5H4]'=RWLNWY'O9#PEFG$%.I7PWLJ&&IR</K&(E*,)U$
MDW"FHQG.;C=<S4>6-TF[E[XW^-K_ %SQ-=Z'%/+%I.DNULULK,HDND.)'D P
M3[#I[5X?7E>L_$76]'\<WEMXL!N[/6[HW46J$'>);A@-K-C:,G&>F*]35E=5
M>-@\;J&1QR&5@""".#U[5YCJ>TE)ZW3LT]UVTZ*VQ_1V&R&?#^6Y9A%"DJ$L
M)2G2K4&I4J\^6/MI\R2;J>T;Y^=*:TNK6.8\>^+K^QT/0_#UQ<22Z9?:TGD0
M.S-Y-SM.&3).%P,X]:Z_X%#'Q.T(>DH'Y/7FWQ#T2ZU.W\.WL<;_ &;3-:2X
MEFP1'N"D>7NZ%L<XY^E>D_ LY^)VAGUE!_-S790;:5[_ !:>FGZW1^(>(E+"
M4\ZC]74(UJF$IU,;&%K>W<VH2DE_R\G247*^KW=V?JS11178?G 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8WB+P]HGBW0-;\+>)=-M=9\.^)-)U#0
MM=TB]0R6>J:1JMK+8ZCI]U&"I>WO+2>:WF0,"T<C#(SFMFB@#\X/$G_!(;_@
MFGXJ^&^D?"35OV./@LWP_P##^J76M:%H%OX;%O#I.J7K,UY>V4\<_P!J26YW
MR"4/-)&RNP"#@CZ5_9S_ &2/V:OV1_#%UX-_9L^#'@7X.^'+^X%U?Z=X,T>/
M3EO[H#!GO)RTMS/(Q^9@\Q3=\P4$#'T510!\XZA^R'^S-JOQSL/VF-1^"W@:
M\^/>EV?]GZ?\5)M,9O%MI9YS]GAOO."*F3WA+#UKZ)FAAN89;>XABGMYXWAG
M@FC66&:*12DD4L3ADDCD0E71U*LI*L""14M% 'Y>_$?_ ((M_P#!+KXK^++S
MQQXV_8Q^#FI>*=3U";5-9U:#0Y;";6KRX<R32ZHEG<PQ7!=V9CB.,Y8C., ?
M9WP'_9D_9_\ V8/"3>!/V??A)X*^$OA"1S++H'@W2(]-L)I",%YUW223L03E
MII')R<YS7NE% 'YN?$7_ ()!_P#!-3XL?$N?XO?$#]COX.>(OB#>:E_;&I^(
M+GP^T4VKZF)!*EYJ<-M<0V]U+'*HE3=&J%QET<9!]]^&/[$?[)7P8^(.M?%7
MX4_ #X;> OB)XB\,KX-USQ9X;T*/3]4U3PLA4KH=VT<AADL,JI,7DC=CYB<F
MOJ:B@#\M?&'_  11_P""6/CSQG=>/O%'[%?P9U'Q)J%]/J>K7/\ 8<\%OK&H
M7,IGGO-3LX+N."YGDE8N[!4#'DJ3DG]$_AU\-? /PC\':+\/OAEX1T+P/X)\
M.VJV6B>&?#EA#IVDZ;:KTAM[:$!0/5F+.> 6( KMZ* /SJ\;?\$E?^"<7Q%^
M+2?'/QE^R-\(=:^*8UN'Q)/XMGT%H]0O=>MKE+RVU:\\BXCCFO;:ZC2XBEV*
M!*H9E>OT.MK:"SMK>SM8D@M;6&*VMX(QMCA@@18HHD7LD<:JBCL *GHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKR
MWXE?$FP\#V#11,ESKEU&PL[-3DQDC GG Y6->HSC/TH T_'WC[2_!&EO<3ND
MVHRJRV5BK R228($CJ,D1(V"V<$CI7QC;V_B?XJ>*229;FZN9-TDAW&VL+;.
M3U&U5C7H.N!Z]&:7I'B_XFZR9!]HOY'N!]JOI-QMK!9#E@,_*$09V[>0,5]N
M^"?!.E^"M*CL;&,/<NJM>7C*/-GEQR-W41J<A%],$^P!1\!?#S2/ MB8[5?M
M.H3@?:[^09E<]XXR>5B'8=<<'CBO0:** "BBB@ HHHH *IZA8V^IV5U872+)
M;W<+PRHPR"KC&<>QP1[BKE%!492A*,XMQE"2E&2T<91=TT^C35T?FCX[\)7O
M@WQ#>:7=(WD-*\MC<[2(YX'8LNP]/DSLQGM7&U^E'CGP)I'CG3&L[^,1W4:D
MV=ZBCSH),$KANNPMC</2OAKQA\,O%'@ZXF^UV4EUIZ$F/4;9&>%D_AW  L'P
M?FXZYKSJM&4'>*;@]NMO)_H_U/Z!X5XNP>=8>EAL55IX?-*<(PJ4JDHPCBG%
M**JX=MI-RT<Z5^:,KN*<6K>>44$$?>5E]F5E/Y,!0.>G/TY_E6!]M9]G]P5:
ML;*ZU*\M["RA>XNKJ5(H8HP2S,Y SQG '4GVK7T'PKK_ (FN5MM'TRYNF+!7
MD$;+'$#_ !NS #:.IQT%?:/PP^$%EX,1-3U3R[[774'?MW0V><';!G)W#D$_
MD:UITI5&M&H]96TMY=WV^_8^:X@XGR_(,/.52K"MCG%_5\%"2E4E.WNRK)/]
MU23:<G*TI)6@FW==E\./",?@WPO8Z80IO'C6>^E P9)W&<,>YC!V_7-=Y117
MI)**45LDDOD?SGB\56QN)KXO$2YZV(JSJU)=Y3=W9=$MHI:)));'R=^T+X7F
M^V6?BB"%WBDB2SOI4!(B6,;8RV <9XYZ5UGP4^(D&IZ='X9U6>.'4-/14LF=
M@JW-N,XC4G_EH@P<9Y&0.<"O<M8TFSUS3;O2[^,26UW$T3@@$KN! =<]&4\@
MU\4^+?A1XI\(:@;O1HKJ_L$D9[:\M2WGP+G=F;:<Y'3'I@&F<Y]I:UKFF>']
M/N-2U2YCM[:WC,C%F4,^.BQJ3EF8\# -?$_Q%^)FI>/+U+#3DGM]'64);62[
MO.O'+86294'S$GE1TV\8K!>T^(?C6XMK*Y35=3:,!(EE#I%"N=H9P=JLJXYW
M9.%/TKZ;^''P<T_PN+?5M:V:AK@0,$(W6MG)U'DJ>KJ"021C/K0!@?#/X+V=
MK9Q:MXMM4NKRX"R0:=*"8K:(C($R]Y#P<=0,YZBNZ\=_#GPYJGAO4!::5:VE
M[:6KSVEQ;1B.53;HS^4&!^ZP!!S7J]9.O2>5H>L2_P#//3+Y_3.VVD.,^^.*
M /B[X(:W?:5XW@TM>(-662"\C)Z- ,QE>W!P3_D5]SU\!_"..6^^(VD2Q@J!
M)=32,/X %)QGW ]Z^_* "BBB@ HHK$\0>(-,\,Z9<:KJMPEO;0*3\S /*^#M
MCC!Y9VZ#L.] &)X]\96/@O0KG4+EM]TZ/%96R,!--.RX5E!YVQDAF.,=!WKX
MN\'Z#J7Q&\:!KLSS)/=?;M8N^24A$A9 7/&X *A7/(Z"HM>UK6_B9XM\N$SS
M&]N3#I=FY;%K;;AC>J\+M'S%B!QQ7V=\/? ]IX'T5+)"LM]/B:_N0!\\Y'S*
MC'YO+4]!G!/- ';VMM#9V\-K;HL<-O&D4:*  %10HX'';)]ZGHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_%6D+KO
MA_5=+9=YN;.98EXYF$;&+K_MXK\R;VSN-.O+JPNE*7-G/);S*005DC8@CG\/
M:OU6KY,^.7POG>>3Q?H-N9 ZYU6TB7D$<FZ4#JS=&X-<V)IN24TM8[KJUW\[
M?D?I/AWGU' 8JOE>+J*G1Q\H3P]2;M"&+C[BA)MVBJT7RINRYXQN]4?*5%'/
M0@@C@@@@@^A!P0?8BBN _;PHHHH *^F_V<?#<MQJ6I>(YHR;6VC6VLY"#_Q\
MY'F@9]%->$>%?"NJ^+]6@TK3(7<R./M$X4^7;0Y&^1FZ A<[1G.>U?HMX1\,
M6/A'0K/1K%%"P1@SR@8:XN"!YDS^I8]/0#UR3TX>FY2YW\,=O.7EZ=?^"?GW
MB!GU' Y9/*Z4T\;F"C&<(ZNCA5)2G.?\KJV4()ZRBY.UM3I2 P*L 58$$$9!
M!&"".X(X(K_/@_X+D:!8^'?^#A3_ ()X&S*6\.H>)/"5^(58(L$DGB.R VC/
MR^9+G9TW,,#)XK_0@KXG^.7_  3N_8]_:+^,7@;]H3XM_!/POXN^-GPQ6,_#
M_P"(=^+S^V_#,]M,MS:2V1BN4MR;>Y2.5?,A?E17>?A!P/[4?CI_$G[$G[8.
MDZE,IU+1/@?\3\NYP9K,>&]302DG Q$_EQL3CEP*_F1_X-*/")^)/_!.']L+
MX>6TL/G^.+GX@>#XV=@R13>)]!UC2('E .0@:_20YQN3D<&OZ7/%6A6UKJ'B
MGP5XXTU=;\,>);2^\/>,]#N-RV_B'POJA,=]I\Y&"8[R$X<J<^A]?;OV/_V/
M/V4?V0? EYX=_9/^$GACX2^#_%%Z=<U+2O#*W0@NM1N ))))_M5Q<-YJ,Q4@
M, #GC&* /\^+_@D!\4?V-?\ @E[^V%^U/^QG_P %3/A3X0T#1?\ A*=1MO /
MQ5^(OA*:\T73Y=+U.<!9+BXM6:31]2L#;&VO;7S$CD9E^?:ZG^E'Q[_P4D_X
M-Q?A]=>'+?PTO[._Q%\7ZYK>AV&@^&_A]X)_M76'O-2O[>#3[EBEB(X42YDC
M=22SDH?E 4FOV>_:N_X)I?L-?MO7%A?_ +3_ .SE\/OBIK&E0R0Z9KNL:=);
MZU9+(&!>/4+":UEED4.P1[KSRJG8/D 4?-7P6_X(-_\ !*3X">*M*\<> ?V0
M?AU'XPT.\2_T?Q!K,5[J][IEU'()8I;1;FY^S(T;*A0M Y!4'- &)_P6^^$>
MJ_';_@D9^TWX;^&NB7%[J)^#A\0^%?#>F6K&YNK>"RMY[73;2SA0MYB6DR[8
M8X\@1,H7-?S[?\&_7_!=G]@W]E#_ ()P:-^SE^U-\4(/@_\ $WX"ZMXLM8/#
MFOV5^VI>,;;4=2OM72+1H(+:39>6UR[6,L%TT)25E#8966O[EVLK-[,Z?):V
M\E@;<6C6<D*26K6HC\K[.\#JT;P^6/+,;*4*?*017Y'^.O\ @@W_ ,$F_B1\
M1[SXJ^+?V-/AAJ/B[4]2EUC5YUM[^WL=7U2:;SWOM0L(;Q8I)O-PV(C#%Q@Q
MD<4 ?Q'?!O\ ;JT__@HA_P '*7PI_:7TKP5K/P^\+Z\-)\+>"]*\16[V6I:I
MX;\+P2V6D:XT<T<1D&LV[/=QE5R5!!PR.!^F/_!V?(B_M>_\$P0SHI'QB\)2
M$,P!$:^-O#X9R"<[%)&YONC(R>:_K63_ ()K?L-P_&/P#\?K/]G#X=Z=\6OA
MAHEKX=\#>,-,TR33[[0-(LHA#:VEK':316S"&)519)H9)" "[L<D]%^TI^P-
M^R+^U_XF^'7C#]HWX)^%?BEXD^$^KV^N_#_5=?6\-QX<U2TNX;ZVN[,VUU N
M^&[MX9U$BNN^-<@CB@#ZJM[:.^\/P6<O,5YH\5M)[QW%DL3_ /CKFO\ .B^'
MGQKD_P""#?\ P<"?M%>*OVC?"FL:1^SU^T?=WNE6/Q$BT^Y;1+3P=KMY:ZI:
M^)89MFVX;3]0M94NK2)FFC256==K-C_1RCC2*-(HU"QQHL:*.BHBA54>P4 5
M\O\ [4'[%7[*_P"VAX6M/!O[3_P2\$?&'P_87'VJPM?%6FF:>RN ,+);7UK)
M;7L84X=8_/,(<!_+W9) /YM?^"O_ /P<4?L :U^P[\6_A-^RC\7](_:)^,OQ
MR\*ZE\./#OAKP);:E=7.@KXBMC;3ZUJ236<39M$;]W9Q+)/*V\(A=55O=?\
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MQKXCU/&39VCR <]2"!^(ZCZ5\R_L[WMQJ5GXJOKN1II[C5%<NQ+':PRJ@GD
M X]\5S5JKIRT7O2779+37S=[]3]!X0X5AQ#&O7Q=6=+ X5TJ<E2LJM>M*,9\
MBE)-0C&#3D[.3O%1ZGW9\=OC1X4\1S^&K&TNKJTMW^T&4WL7D0M,6 B!Y(+<
M9!///2O(P0P5E8,C ,CJ<JRGHP(Z@]JY/QEX4MO%VD/I\A\JYC/FV<X^\DJ\
MJN<< G))_P#K4GPM\/\ CF?3[W1KS2[W5)='D14N;2-[C=%)_JPQ'3"YXSCK
MV KSY5)SJOFC=2MRN*ZI)--:]KI^I^\9?D^3Y1P]2C@L5[%X&K.-?#XRK34I
M0KUG*&(IU9>S4USS5.<6N9>[T-'7O#FE>);3[)J=JLY7FWDQB6*7^%E8#)P<
M8&<=NG3[!\"?LYZ'/X8\.7=YK.I$OI\,DMJ8HPOS<["Q8/\ = &<9]#W/SO=
MZ5J'AR]M#JUD8I@R7'V.9MDZA2&0R1D949'(.<]*])@^._CRVEC$5Q9"QA5$
MCL_LD0 CC  3S,;N@QFM::I1DW5BV[6V=UJGKJOU_P _G>(I<29A@<'AN'LP
MIT:,:E7$3J2Q$?9OFBJ<84/W=91<GS2E./)'W8OFW:Z?]I?PQHOA3X;Z%IVB
MV<=K"NNPEV S)*VQ06D?J<G)QG'-?/'P)_Y*;H/_ %T7_P!#KT_XW?%&R\??
M#[2+>2%;+6;;6HGGM0VY7C5%!EC)Y()!./>O,/@3_P E-T+_ *Z+_P"AUW)Q
M;@X6Y=$K=-=K=#\!S'"YC@\5BJ.:QJK'*KSUG6DZDZCGRM5/:7DIQFM8R3::
MV['ZM4445L>,%%%% !1110 4444 %%%% !1110 4444 %%%% !117&_$/Q]X
M7^%O@7Q;\1O&NIPZ/X4\$^']6\3:_J,[*J6VEZ-937]VZ[F4/*88'6&/(,LI
M1!RPH [*BOXLM$_X+9_\%:?^"E?C_P"([?\ !)_]ECPPOP,^'&L7FD6GQ2^)
M%RL%EXQ;3K@K-]EFOD6W6_GC,;K96Y;RXI(MQ\PL*^O/^"7O_!=?XR_&W]J#
MQ=_P3U_;U^"]M\!/VK]&MK^W\%3K))%I?C[6K6.1A86<$JQP,KQPR7EK<VC2
M1S0?*SF1'CB /ZD:*_FQ_P""8G_!7OXY_M!?\%&/VN/^">W[47A#0_!_COX*
MWVL7_@RYL?)MVU/1M.O842T(&W[1<O87ME=KMW%D=L'<"!UO_!:7_@K9\5_V
M&/C3^Q[^S'^SKX5TCQE\9/VG/&=G9+9WYAF_L[0?[;M='F#PN28I;A[I'B8@
M,8PSC*KF@#^B&BOYF_VS_P!O#_@LKK?[1M[^R=^P=^QMI<MYX/\ !OA76_%'
MQ_\ B/<-IW@35M>UC3(9M5TK1[J^4:8\6F7?FHS0NT@82>=M00Y^>/V0/^"U
M'[?7P:_X* >"?^">/_!5/X(>$O!_C'XH627'A/XD^";V.311<S6LL^G):?9E
M^QZE::BZB&1TD\R!S&X548%P#^NNO(_CW\6K'X$?!GXD?&+4M&U7Q#8?#KPK
MJ7BBZT31(&NM5U.+3XPYM;&W0%I9G+#Y5!.T,1TK^>[_ (+F_P#!;'XJ_P#!
M*CXS_L[Z-X4\!V'C?P3X_CU";Q5ISHC:G>R)#+]ALM//^M22:= @,>"2<#G
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M;1_!-G&5C2[U9ES<:A(@,@+ 9CASG8J\C<N"U &9\,?AA9>"K-;V\5+K7[E
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M'6NN74$D]KI]Q>V2VJ7LUO&#))$C+O,:@L0<"@#^43_@W&_: T#]E3_@C/\
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MM@G# CD'D4 ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0O\ >/X?R%%#
M_>/X?R%% $HZ#Z#^5+2#H/H/Y4M !1110 4444 ?E]^TA_R4_4?]P_S%>@_L
M]>-;#P-X'\9:I=CS9WU:**SME/S2SF$A-PZ[ Q&2,\>E>??M(?\ )3]1_P!P
M_P Q7GWA9KK[%>(N_P"QFX1G !,?G\[2>V[&<=^U859N'/);V27SLKGU/#66
MT<WS; 8'$MK#U+U*R3Y74A1INJZ2?1U.51NM==-=5Y'\7O$OCVS\3WVJV]Y<
M6.E:E<O<VZV*_NHS(Q=T<8(!R>IP/TKSZ3XWZOH^A7D.L.+C[3LLXKT#-PCW
M'[L,W?@G/ XQ7US=6EO>PM;WEO'<0/PR2H&&/8D''X5YQXD^%'A+6-(O;6QT
M."/4),36CAF;-U&=T0"D 99SC P/3G%>+4I57*4H5'K=V;?W+]%IV\S^QLHS
MO(%AL#@,UR>GR8>5"E]8PT*,'[.FX1C4J3ERU$XQ7OMRJ*23=E=H\_\ @[X5
MO9;\^++]'6(*6LI)0V^X>4?.Y#=05.1Z].E?1IP3D)$&!R&$4892.00P7((.
M.<YXKF;?4=.\*:3H^D^)+ZUT?4+;3X$EMI_D^8<;AM&WD$=\_E6]I5W::\\<
M>B7,>J/*XCC6T/F%G8@ ;1SU//IBM:2C&*@G[V[5[RN]]/P/#SS&8K,L96Q]
M2E.&%3=+#U5"?U58>DW&#A6<53E&27.Y)\K<FTK'I?Q#\17>O_!31HKQVEDT
M7Q-!8+*Y)9T,89<D\G;T'H.*X+X$_P#)3=!_ZZ+_ .AUZM\7?",_A#X,^'K:
M[7R[[4/$$%Y>1?\ /*7RU"I]0IYKRGX$_P#)3=!_ZZ+_ .AUZL5)*FI;I1O]
M_P"=C^3L^J86KG&;5,#R_598ZJZ3C\+^'GE&VG+*ISRC;2S5M#]6J***W/G0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P_$WB31?!WAS7O%OB2_A
MTKP]X8T?4M?UW4[D[;?3M(TBSFO]1OIVYVPVMI;S3R'LB$T ;E%?.O[,G[6/
M[/W[8WP]F^*G[-_Q)T+XI> H-;O_  Y-XB\/S--9)K.FB,WED68*?-A$T;$8
MZ.#7T50 4444 %%%% !114-Q<0VEO/=7#K%;VT,MQ/*W"QPPHTDLC'^ZB*S'
MV% $U%?,O[.'[8_[-/[7,/CNX_9S^+?A;XJP_#/Q(?"/CE_#-T]R/#OB)5E<
MZ9?;XTV7&V&1L#(PIYKZ:H **** "BBB@ HHKGO%GBKP_P"!O"_B'QGXLU2V
MT3PQX5T;4?$'B#6+QBEII>C:3:RWNHW]RX!*P6EK#+/*P!(1"<&@#H:*\ _9
MO_:C^ G[77P\'Q7_ &<_B5X>^*OP^.L:CH'_  D_AJX:YT[^U]*=$U"Q\QD0
M^=;-(@D&WC<*]_H **** "BBB@ HHHH **^6?BQ^VK^S)\#_ (T_"G]GGXI?
M%CPYX1^,7QM;;\,/!&I3LFK>*S]K:P']GQA2'!NT: 9(S(,5]34 %%%% !11
M10 5\Z?M"Z]<V.CZ;HL#M&NJR/)*RY!*VYX0D=FSR.XZU]%UXG\;?!]UXD\/
MQW^G1&:_TAFD6(#)>W;F8KW+*!D =: /DWP-;6]WXMT."Y_U(O89/7YXW!3Z
M\BOT>K\TO#M[_97B'2KN8-%]FU" 3AP5,:"4>;N!'&U<GI7Z36MS#>6\%U;N
M)(+B-)8G7D,C@$$?G0!/1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !117+:/XX\&^(-5U+0]#\4Z#J^LZ.VS5-+T[5+.[OK!N?ENK:&9Y8
M2,$$.HVG@XH ZFBBB@ HHHH **** "BBB@ HHHH *0D $D@ <DG@ >I)X%+F
MOD;XR?%ZX:XN?"OAJX,4<6Z+4K^%OF9NCV\3 C !&&*G/O43J1IQYI?)+=L]
MG(\DQF?8V.#PD4K+GKUYI^SP])-)U)M:OM&*]Z<M%U:]>\7?&7PCX4>2V^T-
MJE_&2KVEB0[1MT&]S\N,]=I/'>O$]0_:4UII&.EZ+9+%GY1=F3?CWV-UQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#U_XJMI=7TZST[4/M.M>';/>MS8RW-](;F:=/+_=PL<%A7@O_!6_XZ_LH?M
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MKGB+7+V&PTK2["$9DNKN[F98XXU!&#DEB0%!) K\==)_X+Y?\$M?B7X^\1?
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M;*[9YRU?VNS!&BE61MD;1N'?=LVH5(9MYX7:N3N/W<9[4 ?CU^TY_P %Y/\
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M (,\U5?^"3.54 O^T#\5&<@ %F%QIR L1U(557)YVJ!T K^G?XD_$3PI\)O
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M?PXS7<0VMM;&0V]M! 96WRF&&.(RO_>D**N]O]ILGWJ>@#_-2_X)Q_M00?\
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MS&C%MI&*U/\ @Z>\#^//%WC7_@GK+X-\">,O&4>G?'7P]+J4GA3P[J6NIID
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M %%%% !7A7QO\?R>%=%32=-D":MK"NBR _-;6X'[QB.H9U)"G';WKW6OSO\
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MBCFC8$,DB!U(/7@@UYCK_P 'O!>N"5A8#3;B7.ZXLOE;)[[2<?7&,^U>IT4
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M$5:[79U)N5OE<^#8_BW\18B2=8U"3(Z26SX'N/D/-64^,OQ 08:^N'.>K02
M_P#H&*^Y'T?29#E],L&/3)M(/_B*KMX=T)B2VD:>2>O^BQ?T6F<I\61_&WQY
M'D-<&3)_CB?C'886KL/QY\;PX+Q6\^,\2QNN<^^WMU%?7?\ PB'AK_H#6/\
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MSD\!AC:C$Y:OIX'(!'(/((Y!!Z$&@ HHHH **** (7^\?P_D**'^\?P_D**
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MYEY'JEAJ=EJ*F3+1/+-&6;RPS?V(U_%%^R@ O_!WK^V&5 4M\%M?W$#!8_\
M"*>%1EL=3A5!]0HSTK^UV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZ<'/I62C)NRBVWY,^DK9CE^'INK7QV#I4TK\\\314;>7ON_RO\ D>=@$D*
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M_P""</P*M_V??@+/XIN?!-OK-_KHF\7ZM_;.K->ZC-)-/NN_*B_=AI"$3:<
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M>*-*TOP]91^)=!\(78BNOM=T;749]0M7%E)N\V>W;#M&)1#G(^%O^"Y7B/\
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M82(JR,49C&G[*444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $<TJP0RSO]R&.25_\ =C4NWZ U^>VOW#>-?B%<M9%C'J>L*MFK
MY<K#'(-ZX')Z-Q^. !7U]\6_$_\ PC7A"^>)PM[?HUI:+G!)< 2''7 C)Y'T
MKYU^ WAU]4\52:Q+%FWTB,W$4S#*FZE<J\:>C#<21Z#GUH ^S=.M8[&QM+2)
M=L=O;Q1*H&,;4 /ZYJV6"@LQ"JH)9B<  #)))X  Y)/ %+7D_P =]8U;P_\
M!?XJ:WH2/)K&E^ _$][IR1Y\QKJ#2;IXMF,G<",C'0B@#^3S]N?_ (.$_P!K
M'QY^V;J?[!O_  2$^!6D_&SXI>#+^_TOQ?XY\16,.N^'+G4]/5TU2UTZW:YL
M[:RBT2X5(KFXU"ZBCFD>0([F)XDZ_P#8H_X*N_\ !97P+^VK\(_V4/\ @I[^
MQ_:Z)IGQQDFLO!_COX;>%EM],T6XBC+"ZUS4M%N]8TE+17V1LT]W!*7=E\K*
M%J^-O^#/_1M"\1?'7_@IO\0M?T^QN/B+#\5HH8[R[2.75=,L]9\1^*;K54M9
M90UQ''<WFZ"X:,@$1+&YPP%?W%^,8XX/#^N:U!86MUK.C:#K5[H\\MK#-<V]
MY!IUQ-!]EED1I(6>:.,'RV7<<9S0!_+9_P %5/\ @X*^*'P7_:CTO]@+_@G)
M\'8/V@?VI9;^VT_7M1N(1K'A?0]7N4)/AV2QMRD@O[11+)>7-S+':QM&D+30
MF5"_P#\3?^"V7_!P%_P3ROO!7Q2_X*,?L=>!?^&?M<U^.RUFZ\%^'=/LM0M8
M2@DDM!JVDZQJD&G3JA4J=1$"EB%\W<P5N*_X-K=*T?XD_P#!:/\ X*?_ !"^
M(VGV>H?$30K6[U;07U9([B_TS4]1\?75AJ=Y8M/ND2Y%B!$7BP\46,%0HQ_4
MW_P6[\+>#O%G_!*K]MBR\;V5A<Z1:?!;7=1CN+Z&&0Z;>VUQ8_9[^TDF4_9[
MN,L4CEC*R;9&0'YJ /;/@S^UG\+OVWOV&Q^TI\(+UKGP9\1_A;XAU2UMIW1K
M[2;L:5>17NE:@B8,=W97*20R*R(3MW!<&OY:/^#/C_D?/^"IW_9?+#_T\^,*
M]H_X-6=6\4W_ /P2'^.=GKBW T?2M8\66_A<S-(T9L)="UF2Y\@/\JH)PNX1
M_+N/K7B__!GQ_P CY_P5._[+Y8?^GGQA0!]V_P#!7W_@X \6_LH?'W1OV%OV
M'?A-_P +[_:]\0#22\2P?VUX=\.7&KY-KIMW86C>9<W@7=)>!I$2S2/,[PHV
M\_FI\7/^"RW_  <6_L$6.@_&C]NO]C?X>#X 7&L6J>()?"WAO3K;4=.M)Y(V
M>SDU/2M:U(:;.(W2$2:E%!%&[[Y)UVD'R#_@AGI6A_$S_@X9_;P\>_$J*#4?
MB%X-\:?%JS\$KK!2ZO+"Q_MW5M,E;3X[HNZB+2K6TD#Q#-N&#QLF03_99_P4
M[\(>!?'/[!/[47A_XC6>GWOA:?X3^)KFZBU-(&MDNK.S:YT^4/<#;#*EY'#Y
M<JLCACL5OG((!Q_[//\ P42^'?[7W[ EY^VE\"3"4?X:ZYXF;PQJDT=W=^%O
M%>EZ7/=/X=U[R %,]K.D;3(%4M"ZY .:_CA^#G_!T+_P54_:DLM6_9R_9Q_9
MN\$_$+]KBZ^(6K1Z-KGA_P +/>>$-/\ A_I\TL!AO]'N+R**/5?-00KJ%W=6
MT+C,RXD_<#Z@_P"#7&\U67_@CQ^W]I]QYK:#I_C7QZ-&D=G,:2S> M]W! "2
MJH&6WD8( #)*Q/))KJ/^#,SX:> [GX;?MV?%FX\,:5/\1K#]HBW\%V7BR:UC
MDU:S\,7.@'5I])M;EU+P6\VH+]HE\LJSDE2=I8$ _7[X!_\ !2[]I7]FW_@F
MIX__ &N_^"MW@+1?A9\3OA]K&K:7#X.\-VUOHD_B^XA:==$TK3;3?/;PZIJ8
M2$';)<0JQDV33;0S_C3\.O\ @K3_ ,''?[;7AC6/VCOV+/V-_AII/[-LNIZO
M)X.MO'&@V5SXDUW2M-8R206\U]J%I/J%Q'"/+$UFABG=XGAFE\Q!7K?_  >=
M>)/$]I^Q1\'_  Q9I,/"NJ_%#3]0U:5"RPG4;)F6RCEVX5SM)*JQ."<@9P:\
M\_94^,7_  <O>"_V;O@/H/P/_9A_9I;X36'PQ\(/X%<6.R;4O#EQI-M<:9J&
MIF!0KZA?6DD5Q=N.6E<ECNS0!^HG_!$C_@N'J'_!1;7?B9^SC^T/\/(O@]^U
MK\%))8?&7AV-TMM*UYK>]GL+Y-'T]_\ 2;>YTRYM;E;J*0\Q*DBJ P9][_@M
M[_P7%T7_ ()BZ=X.^#WPF\%'XN?M8?%N-1X'\%Q$3V?A^WN7,.GZQK=A&#<W
ML=_>!;6UM8 6;<TA5@,I^/G_  22_P""4/\ P4Z^'G_!7C5/V^_VJ? /A+X:
M:%XUC\:ZM\1=-\+OY&EZIK?B2QVP?8+2,J/DO=TKEUP-Y^7."/%/VCOLOQ6_
MX.XOV>=!^*6FVU]X?T34;*P\/Z9K2+/87]MI.A>([C2(S;W&867SLRHH7YY8
M5ZL!0![-K/\ P5B_X.6OV<=$\-_M#?M.?L0>#=6_9QO+W0[S7]+\%^"[23Q;
M::#K<MN;801:1K&I:Q;W36TX9/M.GC<<L[1[6KY]_P"#FW]J'_@HU\:_V7],
MGN_V?])\'?\ !/'QU-\+_&6G>.]3MX?^$YM_&5S9F\LM%U5)9H;W3U%W<3QJ
MOV619_*E5_+\D9_T%;BQLKRV:RN[.UNK-E5&M+BWBGMF1,;$:"5&B*K@;5*8
M7 P!@5_+S_P=T(EO_P $DM9MX$2&!/C!\.$2")%CB1([FZ"*D: (JH#A54 *
M.  * /@O_@B/^T?_ ,%Z9O!7[)/P[_X9:^';?L-"#3=*D^)US;Z;::[!X%5B
MTFJQ3)J<UU<7 #8C5K&+?\^)0R+&WVG^W=_P5+_X*]:_^UYXZ_91_P""8O[&
MB>)(OAG;VQ\1?%3XF:%]H\-ZLTV1+<Z-/J,VF:<T$3;1\MS)(BLN8I&S7ZJ?
M\$1'+_\ !,/]E/+;L?#ZQ4'.X !$X!&1P2>/7-?D9^W!_P '"'QDLOVQ-;_8
M2_X)<?LP1?M0?'WPK>2V'C#5KQ7_ .$=AU"SR-5M$:REMY%_L1MOVJ2[E1'<
MLB.&5D4 ^,?#G_!>W_@K;^P3^U)\)?@__P %=/V=O!NA_#GXL:II^D:3XC\"
MZ)::9<Q/J]]%8PWMMJUG?7MEJ$=G-.&N;=A'/"BG?$T:/L_I#_X+.:E:ZS_P
M28_;(U>QD$MEJGP(OM1M)5(99+:]ETNY@<$<$-%(IR/6OX6_^"[GQK_X*Z_%
MRP_8KN/^"DO[-?PO^!?A/3OCPDOPRU3P+%<MK&J>(IETTZIH^K75U-<2?9[+
M3#'=16Z3>2)B9@OF22,W]I/_  4BFEG_ ."%_P =I9Y&EE?]E#2B\CDEG/V/
M11EB<DG  H ^&?\ @T9_Y1AP_P#8_:C_ "N*_J<K^6/_ (-&?^48</\ V/VH
M_P KBOZG* "BBB@"*:"&XC:&>))HG!5DD4.K C!!# CD'%?-WQ'^"5K<076M
M>$HA;WB;IYM,7_57"CYG6W7&$<XS^>,U]+44 ?"_PR^(M_X-U6/2=2:0:3-<
M?9[J&;=FRD#%2P!QM"M^>/?-?<<,T=Q#%/"XDBFC26-UY#(ZAE(^H(KY&^/7
M@F#3+F+Q38QI%;WTBPWL2+@?:OX) %P%#=3[YKU'X%^(Y-9\)_8+B5IKO1Y?
M(ED9MQ,<F6B7GGY5&![4 >VUYW\3O"D'BKPO>P%%^UVD;W-K+MRZ-&I9@IZC
M<!7HE-=%D1XV&5=61AZJP*D?D: /ACX,>))/#OC"/3YR%MM7<V,_F$@1/&YV
MR<X 9BH!/O7W2#GD<@\@CO7YY^.],E\+^/+V.#]TB:G%<6A3(Q$9E8D'J,DG
M./3VK[YT6[2^TG3KN-@ZSV<#[EY!/EJ&_P#'@: -.BBB@"%_O'\/Y"BA_O'\
M/Y"B@"4=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO/?BWX_M?A3\+/B/\
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M67[+;W*QL(KA68!UVLI)%?TXJRNJNA#(ZAE93D,K#*L".""""".HH =1110
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M;]GE=%3X70VJMXH?6OLT@_LI;;.#=Y8?)GK7K/\ P;6? ;XS?LW?\$I?A/\
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M#3=9>RB748-9L;+4;?5K76-(BN[FS8Q/#>R60@E7<1$90S':N:_/[]E+X?\
M_!S'^SC^S-HW_!.WP!^SW\+O"O@?P?I&J^!O"7Q_O]4T27_A'O!EW)?*MW J
M/,]]J$GG.UM+N%ROG/F-3'0!Q'_!L)=ZI+^P=_P60M]3T]=$N1\4=6N;SP_$
MVZWT/47\$:]]LTNVYP(K&8O:KM 5A$#CN?IG_@T6^ GP?F^$_P"U#\;[SP+H
M>J?%34_C=KND/XOU;3[34=2T_2[>]OF6QTB>ZBEDTV&1QYDRVS(9)"S$C>X/
ML/\ P0K_ ."77[;'[%7[*O\ P4K^%7[1_@[3+/Q]\>O&$^K_  [U"SUZQOK;
MQO)<>$]7TV[U5WMSC35N]3N(I/+N0K(;E^-J9/UG_P &Y7["O[3W["O[/?QK
M\%_M/^!;/P)XF\7?%_6_$^@V%IK-IK*W6BW=U=R073RVA98BZR(0C?-@Y(!X
M !^67B#PKX<^&7_!XOX&LO NCZ=X9T_Q9^SW9ZSKEAI%K%86=[JVO>!=:;5[
MZ>WMU2)[B]FACGD?:"9%4C& *X'P%H'A[]I[_@ZS\>_\+YL++Q'%\&O#UW%\
M-?#'B:*+4-+E&CVDZV-U;Z9>K+;RBQ^V2W$8\LJDH1]ORXK]-?B/_P $[_VL
M]=_X.5/AQ^WWI7P]M9_V7-"^">A^$=4\>G7+".>WUJS\)ZOIUU:?V,S_ &^1
MA?75O$CK%Y11G<N" #Y?_P %>O\ @D1^VA)^V_X _P""I_\ P3"U?0G_ &BO
M"MKIVE>)?AEK,EMI]AXB@LHIHKF_:YNY(;6Y74+>XECN;.25/.EBM]SJ &H
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ML*Z&BB@ HHHH *K7EI!?6L]G<QK+!<1/%(C $%9%*GKW /!Z@\BK-% 'Y_\
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M:EXJD6]G7;(--3/V4'J!,.I93C(4\]\'-?1MO;P6L206T,<$,:A$CB0(BJH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME'P4A,/P[T4,I5F^T.V<\YE.#S_LXKU>@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+Z>P- 'V;X6TV/2/#^DV$8VB&R@+#&,/)&KOQ[,Q%=!2    #  P .P'04M
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MW=G8I/RBNKH *X7XA^*XO"/AF^U#S52]DC:"P5L'=<R A3CT7U]<5W)( )/
M ))] .2:^&OC/XN;Q/XF.FV3O+8:2WV2(199+F=WYD"CJR.2OT ]Z ,GX:^%
M[KQWXN2:]9Y;2"X.H:G+(#(DA#;S:L3T+DX4'MTQ7WS%&D,4<,2A(XD2*- ,
M!4C4*B@=@J@ >PKS7X4^$%\)^%K1)HU74]0C2ZU"0#YF=P6B7U&R-E!'K7IM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &?JNJ66C6%SJ6HS+;VEK&999&(^Z.RC.68D@ #^5?%_CGXPZ[XJN38:
M%]HT[30[)&ELQ-Y><X5PR88!L9*<8!Z5UW[0GBB[-W8^&(6>*R$8N[J0942R
MY($18X#)MZCIG\J\9\'^+;;PE<S7ZZ;;:AJ! 6V>Z59(;=3SN"'/[S/1L=*
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X]^T+XXU;X9?
M7XT_$?04CDUOP%\*_'WC'2(Y@##)J7AKPMJFL622@\&-KFSC#YXVDYKV&OFS
M]LK_ )-&_:@_[-^^,'_J :_0!_%S^Q]_P7S_ ."PO_!1WX7#X5_LA?LS^&=8
M^-.AZOJ=_P"-_C1JXEMO NC: [SG2-+B>18[1M2.84D5HQ)N.,E=I/ZA_P#!
M&K_@L]^TK^T!^U/\6_\ @GG^WW\--*^'_P"TC\++6XO+/7-*=XH/$DUO=+#<
MV#69"PB-80US:7$._P U'52Y</&G _\ !G!I^G1?\$N_$^HPZ?9PZE=_M!^/
M8;S48[>-;V\@MX-+^S0W-P!YDL5MOD\A&.V/S'P.:^71;V^G_P#!VC UE$ML
MVJ> Y9]1,7R&[G**/,G(_P!8<8'/:@#](_\ @J9_P6;^-/P@_:C\"?\ !.S_
M ()[?"G2_CC^UOXZMTF\17.HW$J:'\,K>Y=DMY]7:/\ <QNJ8N+AKHHD<8*J
MV\JLGY_W_P#P6)_X*W_\$P_V@OA/X&_X*P_!OX=:Y\%?B[K]CHA^+/P[U%)]
M)\+C4[N.!)8KNS+0SW%B7(G@F(4JC@Y8 5^<'BSX2_M-_%;_ (.=/VW/!/P#
M_:.TG]F#XKZY+J=QX)\;^(='BU?^W=%&AZ";?0-$M+D8-S<[)1&\&6#P2XY)
MK]-/VJO^#?'_ (*C?MR^$=$^'?[4_P#P4B\/^/\ P5H>M1:Y86DO@**"2ROH
M@0+A)8BLVU=QD\M'7+J,Y&10!]W?\%@_^"M'QF_8X_:#_P""9'@OX#V^BZOX
M _;"\<:!:^)K[48XVFN/#'B'Q!X5TVQDL2P;RWDTWQ)]N#!@,PA0Q) /Z]?\
M%$OC_P"+?V7?V-OCK\=O MM;7?BOX>>"]1US18+P V[WEO$S1^:&X*@C.#UK
M^2#_ (.+?!*_!']H3_@@=X*U?6DU+3OA/XM^'G@G4?%$X%O!?#P9XC^&FE7&
MJS9^6!;J'37O2&^XI;/"FOZ/_P#@N#X\\%>&?^"77[3FK^(?%&BZ1IVO?#NY
ML]"NKZ_@@36KS4X,Z?::66;_ $R>[61'@2+=O0@Y&Y<@'S/^Q+_P4U^.7[0'
M_!&_QK^W-XMTK1X/BSX?\,>+M1L[.W5%TZ2\T9D6S=T7]V!E\L,8..1VK\&O
MV=/^"ZO_  6L_P""D/AK2O"O[$W[/GATZQ\,IO.^,'Q2U&T1]#U"].I*8O#=
MDS@6RW4VF$2XB)E53N8+\N[[&_X)=[E_X-E_BP>03X"^([J?9A$RL/J""#Z8
M-?4__!I?H^DZ=_P3*-YI^FV=G>ZO\4/$UUJUW;P)'<:E<17-Q##->RJ T\D,
M($4;.24C^4<4 <S^W[_P71_:#_9TUK]GK]B7]GKX+Z?\9_\ @H=\4?#&C/\
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M1OA;HEQ+/I.EZS<K!87MTTEJ6EFE.JR[+&T=1&XVRR'R263\UO\ @V%O(O\
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M>W%?H3%%'!&D,*+'%$H2.-%"HB*,*JJ.  .E?)WQL^&]U!>MXLT2W::"<_\
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M-2,DNGZ2Z3W#2[B;J<D/$H?H<,/F'UKV/XP?$VST33YO#&A3AM5N(O+FFM9
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M%% $HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-;W-PEK?R-J"2+<1&[CB199%DW&/*9Q7ZD?\$KO^"-O[!VA_\$U/@WX-\=?
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M9Z9XWL9K+QMK.MF6,O<WBWMO;W;P&V\QG*QB#S0?)S%M8_N_0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !59[*SDD\U[2V>7.?,>WB:3([[RA;/XU9HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\
MC1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_
MF?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_
MQHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&B
MB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:**
M#'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?
MS/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C
M1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/
MK^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OY
MG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\
M:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@
M Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7
M\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/
M^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT
M8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ
M_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\
M&BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH
M ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q
M]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_
M,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\
MC1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_
MF?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_
MQHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:** #'U_,_XT8^OYG_&B
MB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ Q]?S/\ C1CZ_F?\:**
M#'U_,_XT8^OYG_&BB@ Q]?S/^-&/K^9_QHHH ,?7\S_C1CZ_F?\ &BB@ P/3
*\^?U-%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gjyjiv3jrhol000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000007.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ,'!6(# 2(  A$! Q$!_\0
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MCJ:/,6H?,]J-Y["@"4N">31YA'0U%O:F[S_>H F\S/6C>>XJ'?\ [5&\?WJ
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M6![_ *4 3[R>:0R-TR*A#+Z4;AZ'\Z )MX Y(H\T'G?4(D..E-\P@\B@"<R
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M]Q-&_!Y857+C.2*-X]* )O,_VJ/,Y^]4/F 4>8OK0!-O)Z$TAD]S4'F-Z_\
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MQV%)N_V:B\S_ &J#)_M4#)O,;THWMZ5#YG^U2&3/<T 3;F]:0N1WJ'?1O]J
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M7\,>O:7<Z;&Q_P"NDF1^E<_URAT;MWL[??:QZO\ J_FFTHQ3[.<%+_P%R3_
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MY"K <$E3@'<67_@F#\'/B_X(^,VN>)_&OPXUS1=-_P"$8>U\[5]/DM1).]Q
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M&3;EZXHW^@J+<WK2%CZT 3>9[4;VJ'?_ +5)N7UH EWL#R:/,_VJAWBC>.U
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MVLS\DF8J2I4@@X(-7O#/AGQ-XUUJ+PYX/\/7FJ:A/N\FQT^W::5\ DX502<
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M_P!@;]I7P9\?/#_COXB>%(=!TO1;S[7/,^K6T[S;5.V-%@D<Y8D YP N3DG
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MZ>=0_P#2V:NO/)*6"37\R_)G@^&=.I3XCJ1FFFJ<M'H_B@>'>+_VBXOV=_\
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M,]:-]0^9_M4;QG.ZO4/BR;?[4;SV%0>8!2;Q0!/YON*3S/\ :J'S/:C>>PH
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M/4R^MA\MCA\GFYN=>"3J)ZT_:6<8P7\M_CM:_P K'3?\$6VW?'/Q9_V*9/\
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M'0TGF"HC(?6D\S_:H&3;QV%&\]A4/F?[5(9!0!/O-(9#T-0;Q1YGH* )M_\
MM4;_ /:J'S/:C>?2@";S/]JD\S/7-0F3WI/,_P!J@";>/2CS/:H?,_VJ0R>]
M $^\^E(9/>H-XHWCL* )O,_VJ#)_M5#YGM1O- $WF?[5)YGUJ'S?<4GFX_BH
M FWCTH\SVJ'S/]JD\WW- $^\]A2&0]Z@WBC?Z"@";S/]J@O_ +50^9[4>8:
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MZ'_X-U_^)I3_ ,$R?VIC_P P[1/_  <+_P#$U^GG_"-K1_PC:T?VYC?+[O\
M@A_Q#7AWO4_\"7_R)^88_P""8_[4O_0/T3_P<#_XFD/_  3'_:E_Z!VB?^#@
M?_$U^GO_  C:T?\ "-K1_;F.\ON_X(?\0UX=[U/_  )?_(GY@_\ #L;]J7_H
M&:'_ .#E?_B:;_P[&_:G_P"@7H/_ (.!_P#$U^H'_"-K1_PC:T?VYC?+[O\
M@A_Q#7AWO4_\"7_R)^8'_#L?]JC_ *!FA?\ @X'_ ,31_P .QOVJ/^@;H?\
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M/^'7O[5./^0;H?\ X.%_^)K]1O\ A&UH_P"$;6C^W,;Y?=_P0_XAKP[WJ?\
M@2_^1/RY_P"'7W[5 Z:9H?\ X.%_^)H_X=??M5_] O0__!TO_P 37ZC?\(VM
M'_"-K1_;F-\ON_X(?\0UX=[U/_ E_P#(GY<G_@E]^U9VTS0?_!R/_B:3_AU]
M^U8?^8;H/_@X'_Q-?J/_ ,(VM'_"-K1_;>,[+[O^"'_$->'>]3_P)?\ R)^6
M_P#PZ\_:M_Z!^@_^#A?_ (FC_AUY^U;_ - _0?\ P<+_ /$U^I'_  C:T?\
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M^V\9Y?=_P0_XAKP[WJ?^!+_Y$_+7_AUU^U>?^8;H/_@X7_XFC_AUU^U=_P!
MW0O_  <+_P#$U^I7_"-K1_PC:T?VYC?+[O\ @A_Q#7AWO4_\"7_R)^6I_P""
M7/[5Q_YAVA?^#E?_ (FD_P"'6_[5O?3="_\ !RO_ ,37ZE_\(VM'_"-K1_;>
M,\ON_P""'_$->'>]3_P)?_(GY:?\.M_VK/\ H&:%_P"#E?\ XFD/_!+?]JWM
MINA?^#I?_B:_4S_A&UH_X1M:/[;QGE]W_!#_ (AKP[WJ?^!+_P"1/RS'_!+?
M]J[_ *!VA?\ @X7_ .)H_P"'7'[5O;3="_\ !PO_ ,37ZF?\(VM'_"-K1_;>
M,\ON_P""'_$->'>\_P#P)?\ R)^68_X);_M7]],T'_P=#_XFC_AUO^U=_P!
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M ,37ZH?\(VM'_"-K1_;6,\ON_P""'_$->'>\_P#P)?\ R)^5_P#PZQ_:Q/\
MS#M!_P#!TO\ \31_PZQ_:PZ?V;H/_@Z'_P 37ZH?\(VM'_"-K3_MO&>7W?\
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M(]=.T'_P=+_\32_\.K_VL1TTW0?_  =+_P#$U^J?_"-K1_PC:T?VUC/+[O\
M@A_Q#;AWO/\ \"7_ ,B?E6?^"5W[61_YAV@_^#I?_B:/^'5W[67_ $#=!_\
M!TO_ ,37ZJ?\(VM'_"-K1_;>,\ON_P""'_$-N'>]3_P)?_(GY5_\.KOVL_\
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MQ#;AWO/_ ,"7_P B?E/_ ,.J?VL_^@9H/_@Z7_XFD_X=4_M:=M,T#_P=+_\
M$U^K/_"-K1_PC:T?VWC/+[O^"/\ XAOP[WG_ .!+_P"1/RF_X=4_M:_] O0/
M_!TO_P 32'_@E3^UMC_D%Z!_X.E_^)K]6O\ A&UH_P"$;6C^V\9V7W?\$/\
MB&_#O>?_ ($O_D3\I?\ AU3^UO\ ] O0?_!TO_Q-'_#JG]K?_H&:#_X.E_\
MB:_5K_A&UH_X1M:/[;QG9?=_P0_XAOP[WG_X$O\ Y$_*7_AU1^UO_P! S0?_
M  =+_P#$TG_#J?\ :W_Z!F@_^#M?_B:_5O\ X1M:/^$;6C^V\9V7W?\ !#_B
M&_#O>?\ X$O_ )$_*3_AU-^UL>NF:#_X.E_^)H_X=2_M:]M,T#_P=+_\37ZM
M_P#"-K1_PC:T?VUC/+[O^"'_ !#?AWO/_P "7_R)^4?_  ZF_:W_ .@5H'_@
M[7_XFC_AU-^UQ_T"_#__ (.E_P#B:_5S_A&UH_X1M:/[:QGE]W_!#_B&_#O>
M?_@2_P#D3\H_^'4W[7'_ $#/#_\ X.E_^)I/^'4O[7'_ $#= _\ !TO_ ,37
MZN_\(VM'_"-K1_;6,\ON_P""'_$-^'>\_P#P)?\ R)^47_#J7]KC_H&Z!_X.
ME_\ B:3_ (=2?M<?] W0?_!VO_Q-?J]_PC:T?\(VM']MXSLON_X(?\0WX=[S
M_P# E_\ (GY0_P##J/\ :W/73-!_\':__$T?\.H_VN.VE^'_ /P=K_\ $U^K
MW_"-K1_PC:T?VUC/+[O^"'_$-^'>\_\ P)?_ ")^4/\ PZC_ &N/^@7X?_\
M!XO_ ,32?\.HOVN?^@9X?_\ !VO_ ,37ZO\ _"-K1_PC:TO[:QGE]W_!#_B&
M_#O>?_@2_P#D3\H/^'47[7/_ $#/#_\ X.E_^)I/^'47[77_ $#?#_\ X.E_
M^)K]8/\ A&UH_P"$;6C^VL9Y?=_P1_\ $-^'>\__  )?_(GY/_\ #J+]KO\
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M6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\
MB:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_
M ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9
MO^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/
M%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#
MO>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^
M)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_
M /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\
MB&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X
M/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T
M#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\
M$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#
M_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^
MUW_T#/#_ /X/%_\ B:/^'3/[7?\ T#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>
M7W?\$/\ B&_#O>?_ ($O_D3\F?\ ATS^UW_T#/#_ /X/%_\ B:/^'3/[7?\
MT#/#_P#X/%_^)K]9O^$;6C_A&UH_MK&>7W?\$/\ B&_#O>?_ ($O_D3\F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%K$NJZLMK\RV[2*H$.X'#D;2Q(XW.P&X ,?$?V1_B'\=?!U]\1;+X5?L[_\
M"96<OCZ]>YO?^$NMM.\B3./+V3*2W !W#CG':O9OV'OC?J/Q:^$[>'?&ADC\
M6>#[C^R?$=O<#$N],K'*P))RP4JQ.,R1R< 8KQG]DC]J'X%_ J^^(GA_XJ^.
M/[*O+SQ]>7%M#_9EU/OCSMW9AB<#D$8)!H ^@OAG\3_VBO%/BR/2/B/^R[_P
MBNEM"[2:Q_PFUI?;& ^5?*B4,=QXSG KS/\ 96NKO6?VU?C=JVLIFZANK6VA
M9AR($9T0?39''^0KT?X>?MG?LU_%?QC9^ /A_P#$?^T-6U#S/LMI_8]Y%OV1
MM(WS20JHPB,>2,XP.<"O,?BIJ&J?LE_M9WG[1>L:->WG@7QKIL-GXBO+*WW_
M -DW48CC21E4?=.Q><Y/FR8RRJK 'T_7S;_P5/\ ^38X?^QFM/\ T7-5KXG_
M /!1#X,)X1N-/^!NMW7BGQ9J"_9M"TK3]&N=QN'!".PDC7<%.#M&68X ')(Y
M/]O6?XC7/[#FA7/Q;M[*+Q))K5D^K0Z>A6*.0I.=GWF^8 @,02I8,5XP* /K
M2O+?VU_^35/&_P#V!C_Z&M8W_#Q+]CG_ *+!_P"6_J'_ ,CURW[9'[4WP*U3
M]G+4_#5AXX\R^\7>&_M7AZ#^R[H?:XC,5#9,6(^8W&'*GCW% 'K?[,7_ ";?
MX!_[$W3?_26.OEOX%_ 5/C_^R[\0=!TMO)\0:9\2[^_\,WJR;&AO$@@(7>"-
MH<90G. 2K=5%>[_L5_'+X7?$?X/^'O 7@SQ/]LU;PUX5TZ#6[7[%/']FD$*Q
MD;G15?YD8?*6''I7+_\ !-4_\6Y\<<_\U(O_ /T3;T <G\2_CX_QY_X)S^++
M[7HOL_B;1?L>G>*+&3Y9([J.^MP9"N 5$@&[& %;>@)V$U]%?L]?\D"\#_\
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M[2.@?"#PIH.A?L2ZUJUC8^&[&WL]4A\0!%O(DMT5)@OV8[0Z@,!DXSU->\?
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M8;<&'RYE+'"A&W#@[\=C7TC\*/B1\?\ Q=XFDTSXH?LU_P#"'Z<MFTD>J?\
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MT <5_P $[?\ DSGP?_W$/_3A<T?\%$O^3.?&'_</_P#3A;4?\$[?^3.?!_\
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M1110 FT4M%%  1DY-&.,444 )M'6E''%%%  1GFFO&DJE)%W*RX96'!%.HH
MR]!\#>"_"MQ-=^&/".EZ;-<?Z^6PT^.%I.<_,449Y]:U  #FBB@ H Q110 $
M9H"@444 !4'K0 !THHH ",TR>W@NH'M;F%9(Y%*R1R*&5E(P00>HQ3Z* ,SP
M_P""_!_A(2+X4\*:;I8F;,W]GV,</F'U.P#/XUI[1110 4$ T44 %! /6BB@
M HHHH H>'O"OAGPE9OI_A7P[8Z;;R3&62'3[1(4>0@ N0@ +$ #/7@>E7Z**
M *$_A7PQ=:_#XLN?#MC)JEO"8K?4Y+-#<11G=\BR$;E7YFX!Q\Q]35^BB@#*
MM_ W@JSLK[3;3PCI<5OJCL^I6\>GQK'=LWWC*H7$A/?=G/>KFCZ-I'A[38M&
MT#2K:QLX%Q#:V<"QQQC.<*J@ <DG@=ZLT4 0:GIFFZUI\VDZQI\-U:W$92XM
MKF$21R*>JLK @CV(JL?"/A4^'?\ A$&\-:>=)\KRO[+-FGV<Q_W/+QMV^V,5
MH44 <OH'P1^#'A358]>\+_"/PSIM]"<Q7FGZ#;PRH<8R'1 1^=;VK:+H^OZ=
M-H^O:5;7UG<+B:UO(%ECD&<X96!!Y /([5:HH Y7_A1GP3_Z([X5_P#"?MO_
M (BM7PUX%\$^"_._X0[P?I>D_:=OVC^S-/C@\W;G;NV*-V-QQGID^M:M% %'
MQ#X9\.>+=/\ [(\5>'['4K7>'^RZA:I-'N'0[7!&1ZUA_P#"C/@G_P!$=\*_
M^$_;?_$5U5% &/X;^'W@/P=-)<>$/!.DZ3),H69]-TV* R*#D!BBC(^M;!YX
MHHH  ,=****  \T444  &*0* <TM% !UH*@T44 8^I_#[P'K>K+K^L^"M)N[
MZ/'EWMUIL4DRXZ8=E+#'UK8 QTHHH  ,4444 %%%%  1GK1110 8YS1110 '
MGB@ #I110 $9HVC.:** "C'.:** #'O0 !THHH  ,4444  &.!00#UHHH  ,
M'-%%% !1110 4444 %%%!( R: *>M^'= \36!TKQ)HEGJ%JS;FMKZV2:,GL=
MK BG:3HNCZ!8QZ7H6E6UE:Q_ZNVLX%CC3Z*H %>6_P##>'[)/_1:;#_P#N?_
M (W77?#3X\_!SXQ&2+X9_$33-6FA0O-:V\^)D0$#>8FPX7) W8QDXS0!UU9-
MGX"\#Z?K;^);#P;I4&I2$F34(=/B6=L]<R!=QS]:YSXF_M*? _X-:Y#X:^)G
MQ!MM)OKBU6YAMYH)6+1%F4-E$(^\C#KGBK?PK^/'PD^-OV[_ (59XUM]8_LS
MROMWD0R+Y/F;]F=ZKG.Q^F>E '74 8KD?BI\>O@_\$K6&[^*7CVQTG[1_P >
M\$FZ2:4=V6*,,[*.[!< ]^:Q_AI^UK^SI\7];7PW\/\ XIV-YJ#C]S9SPRVL
MLW<A%G1#(0,G"Y( )Z4 >C$9H Q6+X_^(G@OX6^%YO&?C[7H]-TNW9%FO)8V
M94+L%484$\L0.E:FFZC9ZOI\&JZ=.);>ZA66"10<.C#(//J#0!,5!.317/:Q
M\5OA]H'C_3?A=J_B6*'7]8@:;3=-:-RT\:AR6!"[1@(_4CI7'^(/VTOV8/"N
MO7WACQ!\7+*UOM-O)+6]MWM;@F*:-BCH2(R,A@1P<<4 >HD9H]Z\C_X;O_9)
M_P"BTV'_ (!W/_QNNQM/CE\)+SX:)\8H_'NGQ^&9%<QZQ<2&&)MDC1D#> 2V
M]&4+C+$8 .10!U>,T#CBO']*_;X_9%UC5(](M/C/9K-)($5KK3[J"+)/>22)
M44>Y8#WKURUN[6^M8[VQN8YH9HU>&:)PRNI&0P(X((Z'O0!2\0^$/"GBZ!+7
MQ9X9T_5(HVW1QZA91S*A]0'!P:MV-A9:9:1V&G6<=O!"NV&&&,*B+Z #@"IJ
M* #:,YHHHH 3:*7I110 %03F@@'M110 8% &.*** #'.<53UKP_H7B6P;2_$
M6BVFH6KD%K:^MUEC/U5@15RB@"KHN@Z)X;L%TKP]H]K86L?^KMK.W6*-?HJ@
M 5:(SUHHH ,8Z4!0#FBB@ K-\0^#O"7BZ..'Q7X7T[5$A;="FH64<PC;U <'
M!^E:5% $=O:VUG EK:0+%'&H6..-0JHH&  !P *D QTHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK?XLZ)!JFM:MKTD&APZA&LT6F6L6TH(0PP&!.P-C<!'D'+N3ZA^T7^R?\/\
M]H#2X[DI'H?B2UNH9M/\5:?:@7<!1P<%E*EQM!QEOE;##D<\3_P3!U2"Z_9F
M_L3:4N-)\07EM>0M]Y')63D=N''X@UE_M9?"CX]>"] \7?'7P_\ M=:]IVGV
M:-=V?ANWLV2.($JJPK)Y_')Z[.IZ4 ;_ /P43M)K#]C;6+.ZOY;J2&;3DDNI
M@N^8BXB!=MH"Y/4X &3P!TKV'X7?\DS\._\ 8#M/_1*5\Z_M0ZSJWB/_ ()G
M:7X@UW4);N^OM#T*>\NIVW/-([0,SL>Y)))J]X'_ .">OP]UKP7H^LS_ !K^
M)4+W>EV\S16_B2)8T+1JQ51]G.%&>!D\4 .^-@S_ ,%)?A/D?\R_>?\ HJ\K
MVS4?@-\#=8U"XU?5_@QX3NKJZF::ZNKCP[;2232,<L[,4)9B2223DDU\MP?
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MJXVY)7]H*S!_B\'7'Z7</^-=EN]O_'J #_OJC_OJE ).-I_.E"2-TC:@!O\
MWU1_WU4GV:<\+'^M*+2X_P">7_CU%P(O^^J/^^JE^R7'_//_ ,>I#:7.?]5_
MX]1<"/\ [ZH_[ZJ0V\Z]8_\ QZFM'*O_ "S:@!O_ 'U1@'J&I2&'5#^=)N]O
M_'J # /4-0.#D;J,^W_CU'/]W_QZ@!R7$Z'(D;\:E34''^L3/O4'/]W_ ,>H
MY_N_^/46"Y=CNX91PVWV:N3\2$'XW^$R#_S ]8_]#L:WR"?X?UKD?$#R1?&S
MPJ5_Z FK_P#H=E4\I7,>@4552_(/[Y/Q%6$ECD&4:I*'4444 %%%% !1110
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M_P %&OV?K;X9?$'6E5_"^I:9,6TO5BV0D2EI)5!9D=4D2:1'D!B^1P W1_\
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MP6G\?;?$7B;4;R)=0M[=[J,7SHK7T;%DCW%<0MDC@/TH ^V/CU^T/^WOX/\
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MH/\ Y$C3/^QX\-?^GJRKN*X?]H/_ )$C3/\ L>/#7_IZLJ[B@ HHHH ****
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M>?&'Q;X<U2^M?"OP;T6\OM+TRW5KN4)80YC1'907]B10!\H^-?\ E9Q\(_\
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M^":O[,WQ"UKQ_KT+VEMJFL:5 J:,'POVI4@FF5V4%B&F:.*,A7<NH9" 4_\
M@C/H[>,?^"HG[6OQ@T2[2328?%&H6JLK#$OVS6KJ:)QZC;:/S[^]?J'7R[_P
M27_8&D_8&_9F7PGXNFMKKQMXFO?[5\8WEOM81S% L=HD@&7CA4'DD@R23,N
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M,9)%E0J00P\O(/K0!V'[<'_*PM^SK_V(]M_Z4ZU5C_@YOY_95^'H(_YJ(/\
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M:3T'_:\#ZO\ I>:;_C7<5PNM''[2WAL9^]X&UOMZ7FE?XUW5 !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<TM% %2>S9/GA^[Z9J 9[[JTJAN+5)OF7AOYU7,2XE/'^]1C_>I75XWVLO\
M]>DR?[O_ (]5$DL%RT'RD?+5Q65QN4UG<_W?_'J?#/+ >,[>ZU+129?HIL<B
MRKN0TZI*"BBB@ KC_BU_Q_>#_P#L<+?_ -$3UV%<?\6O^/[P?_V.%O\ ^B)Z
M .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH X?\ :#_Y$C3/^QX\-?\
MIZLJ[BN'_:#_ .1(TS_L>/#7_IZLJ[B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-\7>+_"_@'PU>^,O&
MWB"STK2=-MVFOM0OYUBA@C'5F9C@#^O%?FS^UO\ \%Z-1^W7G@O]CWPM"+=-
M\7_":>(+8LTG!'F6UJ<!<'#*TV[/1HA75A<'B,9*U-?/HCCQF887 QO5E;LN
MK^7](_3C</6@'-?SV_$?]MS]KSXMWMU=^/?VCO%]U'>,&N+&WUJ6ULR<8XMH
M"D*?14 K@CXS\8,=S>+M2)/4F_DY_P#'J]B'#U24?>J)?*_ZH^?GQ524O=I-
MKS=OT9_2?17\U[>,O%^/^1LU+_P.D_\ BJ=_PF7B_P#Z&K4O_ Z3_&K_ -79
M?\_?P_X)/^M<?^?/_DW_  #^DZBOYL1XR\7_ /0U:E_X'2?XT\>,?%W_ $-6
MH_\ @=)_C1_J[+_G[^'_  1?ZUQ_Y\_^3?\  /Z2Z*_FU_X3'Q=_T-.I?^!T
MG^- \8^+L_\ (TZE_P"!TG^-'^KLO^?GX?\ !#_6Q?\ /G_R;_[4_I*HK^;G
M_A,?%W_0TZE_X'2?XT?\)CXN_P"AIU+_ ,#I/\:7^KLO^?GX?\$7^ML?^?/_
M )-_P#^D:BOYN?\ A,?%W_0TZE_X'2?XT?\ "8^+O^AIU+_P.D_QI?ZOR_Y^
M?A_P0_UMC_SY_P#)O^ ?TC45_-[_ ,)CXN_Z&G4O_ Z3_&G1^,?%W_0TZE_X
M'2?XU7^KLO\ GY^'_!)_UNC_ ,^?_)O_ +4_I HK^<'_ (3#Q:>OBG4O_ Z3
M_&GCQCXNQ_R-.I?^!TG^-+_5V7_/S\/^"'^MT?\ GS_Y-_\ :G]'=%?SB_\
M"8^+O^AIU+_P.D_QI4\8>+3U\4:C_P"!TG^-'^KLO^?GX?\ !)_UPC_SY_\
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M1XDU#_P,?_&G_J]+_GY^'_!#_B(,/^@;_P G_P#M3][:*_!=?%/B<MSXCO\
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M_(>O?_ I_P#&I$\1^(=O_(?OO_ M_P#&I_U>E_S\_#_@A_Q$^'_0*_\ P/\
M^T/VLHK\51XC\0XYU^\_\"G_ ,:5?$?B'/\ R'KS_P "G_QI?ZOR_P"?GX?\
M$7_$4*?_ $"/_P #_P#M#]J:*_%I/$?B''_(>O/_  *?_&E_X2/Q#_T';S_P
M*?\ QI_ZO2_Y^?A_P1?\11I_] C_ / __M#]I**_%_\ X2/Q#_T';S_P*?\
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M_P"QX\-?^GJRKN*\S^)0']@6O'_,?TO_ -+H*VSM'44^4/:'8T5QN?EQ[4W
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MK8HV=H.T%GD;:VU%'."254%A-/&8:I1=52]U=6FOS+J9?C*6(5"4???1-/\
M)L\CHK[7A_X)H?L4WOB/_A M/_X*F>$9=<8[(U_L:'[.\G9!+]M\LL3Q@.3G
MC&>*^>_VL_V/_C%^QK\0T\!?%?3H7CO(3-HVM:>[/::C$" QC8@$,I(#(P#*
M2#@JR,Q3QF'K2Y(O7LTU]UTKF=;+\5AZ?/..FS::=O6S=OF>64445L<9)3HZ
M]W_8J_8 ^*/[9&HWFLVVIP^%_!>D*QUKQIJD&ZWA95W&*)2R":0##,-RJB\L
MP)0-E_MQ?LE?\,7_ !N7X.#Q_P#\))NT:WO_ .T?[+^Q_P"M:0;/+\V3ILZ[
MN<]!BLUBJ$J_L5+WNQL\%BHX7ZPX^Y>U_P"M?GL>/5(.E;GPK^%_CCXT_$/2
M?A9\-]#DU+6];O!;V%I'W;!+,QZ*BJ&=F/"JK,< $U]=ZQ_P2S_9I^'6MVOP
MY^-/_!1SPGH'C"2-!?:3'I22164C '8\CW2;1@@@R"(D$': 14U\51H22F]=
M[)-NW?1,>'P.*Q47*FM%I=M)7[7;6OD?%%.CKU?]L']COXH_L:?$B/P+\03;
MWUGJ$!N=!UZP#?9M1@!P2,C*2*2 \9R5)4@LK*S5/V5?V3OB_P#M=_$1? /P
MKT7='#LDUC6;D%;33(6) >5\=3AMJ#+.5.!@,1I[>C[+VO,N6U[F$L+B/K/L
M.5\][6ZW_K_,\UJ0?=KZ&_;X_8)L?V);;P7?Z7\9X_&5MXQAO9K>X@T46D<4
M< MRK*PN)A*'%QD$$ !>^>/GD?=I4ZU/$4U4INZ?]=2,5AZV%K.E55I+=73W
M2?339A3HZ[/]G7X(Z]^T?\9]#^"GAG5[2POM>FECM[R^W>3&4A>4EM@+=(R.
M!U(I_P"T'\!/'7[-'Q9U3X1?$&&,WFGLCV]Y:DM;WUNZ[HKB)B/F1E/U!#*<
M,I OVE/VGL[ZVO;R,_85O8^VY?=O:_G:]ON.+J0=.M=K^SU\"/$'[1?Q!?X>
M>&M9L[&Y31[S4#/?;_+*6\+2LOR@G)"X'&,UE?"?X6^.?C9\0M+^%GPUT-]1
MUK6+CRK.U5@N<*69F)X55569F/ 52:/:4XR:;V5WY+^D3[&K)1:7Q.R\WII^
M*,,9V\4Z//>OHF7]D+]E/PO)-X8^)/\ P43\+6/B2W9HY;'0?!NHZI8+(/X?
MML85,9X)"G'OTK@/V@/V7/B#^SPVEZMK6IZ3KWASQ!"TOAWQ=X:OA=:=J*J<
M.$DP"KJ>&1@""#C(&:QAB:,WRI[[735_2Z5_D76P.)HTW.25EO9IV]4F[?,\
MW.>QJ1?NUZ3^SY^RQXZ_:!L]8\56NN:/X:\)^&XU?Q#XP\37AM["R+'"1[@"
MTDK$@*B@DEE!QN7/H>G_ +%GP'^)%Y;^#_V>/VY_#'BCQ5<+MAT'6O#-[HB7
M4N.(;>XN-R32,WRJIV[N.F>*EBJ-.7*WMOHW;U:5E\R:>!Q5:FI16^UVDWTT
M3:;UTT3/G>G)UK>B^&7BVW^*47P?\1:;)I.M'7$TJZM[Y2#;7#2B(A\9X#'M
MG(Z9XJ]\<OA%K/P%^+VO?!_Q!JEK>WN@WGV:XNK/=Y4C;5;*[@#C#=Q5>TC?
MEONK_(Y94:B@YM:)V?KKI^#.73I3J:GW:]J^&'['<FN?#FP^-?QT^+^A_#?P
M?JEPT>DWVL0RW5]J:H<226ME"/,F120"Q*CD'D'-$JD*2O)_UY):L*.'K8B7
M+35[:O9)+NV[)+S;/&QTIT=>\:_^Q3H/BCPOK'C']E3]H71?BA;^'[/[7JVD
MV^E7&EZM%;K_ *R=+.X!:6)"1EE8GY@ ,D"O!XSD9I4ZM.JGR]/5/[GJ9XC#
M5L-95%OLTTT_1IM/Y,D3I4O\-1)TJ7^&K.4<GWJE3K42?>KT#X._"3P/\2;"
M\O?%GQ]\,^#9+694AMM>ANF>X4C.]?(B<8'3D@U,I1A&[_S_ "%3I3K2Y8VO
MYM+\6TCB%SC@_I3EZ5]!:;^PMX3U7P'J/Q,T[]K_ , RZ#I-Y%:ZCJ2V^H;(
M)I?]6A!M]V3CL"*XKXD? CX<>!O"%QXC\/?M1>#_ !-=0M&L>CZ1;WJSS;G"
MDJ98%7"@ECDC@''-8QQ-&4K*_;9_Y&]3+<71ASS22M?XHZKRUUVZ'FPZU(,]
MS78>-O@KKO@7X0^!OC'J&K6DUEX[_M(Z?:P[O-M_L5P('\S(Q\S'(P3QUQ7'
M9P,FMHRC-77FON=G^)PU*=2C-1FK.R?R:33^::8].E._&NQ^+GP5USX.6/A*
M]UK5K6Z7Q?X2M=?LUM=V8(9RX6-]P'SC8<XR.>M>C_"K]B?1_BYX-NO&'A_]
MIKP9'_9/A]-7\064T-[YNE0[ SB7$&"4)*G86Y!QD5$L11IQYV]/1G13R_%U
MJSI1C[RULVETOU?;4\,3[U/'6MCX@^%M&\%^,+KPWH'CG3O$EK;K&8]8TE95
M@GW(&(42JK?*25.0.5.,C!KU3P7^QW#!X(TOXG?M$?&C1/AOHNN1";18=0M9
M;W4KZ \B>.SA^?RCV8D9R#C#*2ZE:G"*DWOMH[OY;F-+!8BO4E""OR[NZ26M
MM9-\J7G>QXN,]S3T^[7MNM_L;:9XE\-ZIXM_9C^.VB_$JWT:U-SJ6E6NGSZ?
MJT<"XWS+9S@M)&I(!*L3D@ $G%>))]VBG6IU?A>WR:]4]498G"XC"R7M%OLT
MTT_1IM/Y,E'6G)31UIR5H<<MR1.E3#I7KW[(?[,OP_\ VHM=N/ NH_'+_A%O
M$8#2:;IMSH N(]0C"Y;RY?M"?O%P28]N=HW L P7B_C-\%_B#\ O'UU\./B3
MHK6E_:_-'(N6ANH22%GB; WQM@X/!!!4@,K 91KTI5723]Y:V_K?Y'14P&+I
MX2.*<?W<G9--/5='9MI^3M?H<NM.IJTZM3@D.3I4PZ5U7B[X/:UX+^$_@SXM
M7VJ6LUGXU_M'[#:Q;O,@^QSK"^_(Q\Q;(P3QUQ7*CI0I1G&\?-?=H_Q*JT:E
M&7+-6=D_E))I_--,>,YY/Z4^.NJO-$^#L?P1L=?L/&FHR^.I/$#Q7VA2696U
MAT[RB5F63;AGWA1]_.&(V#;N;H(?@WX9?]D*3]H W]__ &POQ%_L 6OF)]E^
MS?81<;]NS=YF\XSOVX_ASS6;JQBM;[VVZ_Y>92P56=U%IVCSNS3T^75=5N>;
MT]/NTRG X7FMF<)(,\<_I3JU/'/@;Q9\-/%UYX$\<Z.VGZKI[JMY9O(CF-B@
M8#*$J?E8'@GK671%J4;H*D94ZCA)6:T:>C371KN.3I4J?=J).E2I]VB6QF/7
M..OZ4+UH4\=Z%ZU)F2)TIU-3I3JKJ!)0.M% ZT?9)D.7.3S3B..M(IY-*>E4
M024Y.M-IR=:G[) ZG+G'7]*;3E/'>A_" <_WC_WS3E5G9412S,< >M-&2?XJ
MT_#%H+C4#,ZY6%<_\"Z#^M%^6-QQCSR2-K1=*CTVVVD R-S(W]/I5]/]6*:.
ME.3_ %8KE;N>E&*C&R.\^ /PNT#XJ>)=6L/$^KWEG9Z3X=N=4FDL(D>5Q"4R
M@#D#)#'J1R!S70^"OA1\#/B]X@3P+\-/'7B:SURZ@E;31XBT>!;:XD2,OY1>
M"9VCR ?FVD  \$X!L_L5_P!F_P#":>+/[9,_V/\ X5_J7VO[*%\SR\Q;MF[C
M=C.,\9ZT>!OB1^S=\(/$</Q"^'^E>-M2UO3TD_LVWUIK2*U\QXVCW2&++D ,
M3@8Y'6O/K3K>UG&%[I*UK6OYW/K<#A\#'!X>I74.64I<[DWS<J:^&SW2O:RW
ML8%O\,=+'[/NH_$"ZM;I=;M/&4>E+%YGRB,P%RI3'WMP]:X62&>VG-O<P/'(
MOWHY%*D?@:]O\"?$;Q?X0_9*\0>*?#^JF#4[SQ\L;:@JCS8_,MLN\9_@<X(W
M#D!FQC.:ROB!XCUCXF?LP:/X_P#&MU]NUK2_&4VD0ZI-S-+:FU6?9(W\9#G@
MGH/J2:IUJD9M26G-;?R[=OF8XG X.IAX2I-J:IJ;7*K/WFG=WO>VNUM+7.0^
M$'@+1/B%XJDT[Q-XOM]$TRQT^:_U"\D&Z0PQ#+)$G_+20YX4<X#'!V[3V%I\
M+O@O\2O#FN7/P8U[Q-#JWA_2Y-3FL?$D-OLN[6,CS-C0GY'7(.&SG( ZDKY,
MGWNE>QZ1:K^SA\-M6N_$;%?&'C+16L+/1L?-ING2D%YI_P"[(^T;$X*XR>I"
MO$<\9)QD[NUE^?X;]O4SRSZO4@XU:2Y(J3G-WOJO=2ULG?9+=[Z)V\C^\*]5
M\1?#'X&?#_1/#<_CCQ-XL:^U[PY:ZKMTK3[62*,2@_)F25#D%3VZ8YKRH# Q
M7OWQ@7X'GP_\/3\39O%BWW_"O-.\G^PH[9HO*P^-WFD'=NW=.,8I8B4HSBE?
M6^V^P971I5,/7G)1;BHVYFTE=V?5'C_BZ#P+_:\,'PUN-:N;5X5#?VQ:Q1S&
M;<>%6)W!7&W'.<YXZ5FO9WL433RV,RQJ^QG:,@!O[N?7VKOOA^/AX/VA/!H^
M&CZTUA_;VG^8=<6$3>;]I7./*)7;MVX[YS[5Z5X&^*7CKQ;^UGJ'PT\4Z_)?
M>'=0U;4].N=#G5?LQMU$VU0F,*044[AAC@Y)R<S.O*FM%>RN[NS_ "W-</EM
M'%U%SSY7*:@N57C=I:W<D[7?F_R/GB"WN)87FBMI&2/'F.J$A<],GMFGS6EW
M;S"VN+62.1L;8Y(R&.>G%>Q? C7=7\!?!OXL:UX:O/)O+%M*2UN&C5BF;F9-
MPR"-P!R#C@X(Y J+P)XL\2VGPI\6_'6^URXOO%$5U9Z5I>K7K^=+91N2TCJ7
MS@E/D#=5R<$9.:EB)<TK+9I;[MV\MM14\KHRITG*HTY1E-^ZK*,'-.SYM6^3
M162N]7U/(I[>XM)/)NH)(W'\,BE3^M>I^(/@_P"$=-\<_#'P];"Z^S^+-)TF
MXU;=/EM]Q*%DV''RC'3KBK>BZYKGQG_9_P#&=W\0]3;4[[PG)8W6BZE>?-<1
M":1UEB,GWF1@HPI)&>>PQO>,/^2K? KC_F7_  ]_Z/%8U*TW*VS5T_N37YG9
MA<NP\:/M/BC/V;BVK-)U'"2:N^J:WU5O1>?ZOX8^'?A3XG^+_"VOV&M7%AIC
M7T&CKIC(TB3I)MB>8MC]V!G<1SG'%<;;6EY/&KPV<K*TFQ66,D,V,[1[X[5[
MSX0_Y+O\:/\ L6?$'_H^.N>\->.?%?@;]E-+KPAK,NGW%UXZFADNK?"RB/['
M$VU7ZID@9(P3C'0D%TZ\]DKOW=WW7H%;+:,KR;Y8KVCTBK^[))+=7WT[>9Y5
M)')%(T4L;*RG#*RX(K1\,^#O%'C+5+?1?#.A7%Y<73,L"1K@,5!8_,<*, $G
M)XQ7IGQ"OK#QEX#^%_C[XA3>=<WUU=VFO:EM DN+6&Y15+D=66,M\W4YR237
MHNFW?QGLOVA;FUU."XC^'D<,P</ HT<:7Y)V$''E?=V]#GJ#QD5,\5*,+I*^
MN[[.VG?\"L+D=&IB%&4Y.+=/X8ZVJ1YDY:VBDM&_>UOO;7S3X*?%?Q=^S?\
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M]3\;_#/Q#X-T/6KC3;[5=$NK2RU&TN&AEM9I(F5)4=2&5E8A@0<@BG?$K_D
M6O\ V']+_P#2Z"MS\*J+Y=42US*S/CWPS^U5XCMO^"0LWQJU?5+Q?$MCX2N-
M :ZBU O>)J2SMIL-PTC'=YQ<Q3G/S?,3W!K>_8D^+/C/X:?LU?$#PQ\?_$]U
MJNN?!W7-7MM:U*_O'FFO+2*/[9%.7D)=E='8)N.=J*.V*\1T[2;^#]M?4/V#
M(;=O[-D^/<?Q(FNH;/$1L/L'VXVC*?E\L2B&+TW9]A5_]OF7Q+\-OV@O&WPD
M\%Q36\W[1GA?0;#3[R.,D'4X-1CLI8?[H5K*5]S'G+*.,YKV_8TYOV27QOG7
MDKJWW+F9\_'$5*<?;-_ N1^;2?YOE1['^S!\9U^ /["/A/XO?M&>*]8U;6?%
M$C7L$*R3:A?ZK<WTTDEG9VL;,6:1H3$JQKA5PQ) #-7=_"[]L;P9\0_B#:_"
MOQ+\,O''@77M3M9+C0K'QUH2V?\ :R1KOF%N\<LB.\:X9T)5@#G! ;' ?M3Z
M%9_#O]H3]F65REGX+T/Q%?:3(LS@0Q7DE@L6G*1TW9CD53V/UJY^WI);:M\2
MO@%X/T%?.\2R?&33]1MK>W_UXTRVCE>_D]1&J%"_8@=\5R^SI5I)M:SYG?M9
MO2WRU\GT.R-2M0@TGI#EC;^:Z5W?SO9>:ZG1>/\ ]NKP%X)^,VL? #2OA-\0
M/%'BC1;>UN+BP\*Z#%=![>:,/YP=IT"(FZ-6,A3YI%"[^2.-T;5GU[_@JCI>
MMRZ/>:>UY^SA'.UAJ$:K<6Q?6"WE2*K,H=<[6 ) (.">M:?P. /_  4:^.K8
MY_X1[PR/_)5ZKW'_ "EOAX_YM[/_ *>FIQC3A=17V+OYI,4IU*BC*3_Y>62M
MVDT=%XH_;L\":7XWUKP3X$^#_P 1O'7_  C=R;77]6\$^&5O+*QNE/[RV:1I
M4+RH,%DC5R,XY(('BW[ /[1WP_\ AQ\(KS6-7M=3N-/\??M!:CI&BWUG:#RX
MI[M8G@,P=E>-&QC(4D'J!S7H?_!+*=M/_9DO/"?B*]C;Q-H?C36;7QBK.#(F
MH"[=G,G<DJ5^8]0/:O"OAEX3_P"%F_\ !.7XT:UX(U.-;S1?BEK'B;P[J5JW
M,4ED]M=K+$1_$8XV53_MUM&G1CSTK:7BK_?K^OH8RK8B7LZU]7&32MML[?IZ
MGU_XU_:C^&7@/]H/PG^S3K2W[>(O&%G<76GR0QQ_9K>.))&'G,TBL"YB=4"J
MV6&#CK69\4_CQ\)]2U[QW\ ?$V@ZQJ4>B?#FXUGQ9)8QIY"64J2(;3S!*KK<
MO$&=5PHV\[P>GR7XMU>X_:;\$_$+_@HOX-TFZDF\$^)O#M[X'L;B-5>&VTE$
MFOT<G[T1-Y<L0I&XP#&<8KU#X-W5K\4/@?\ M&_M5Q+(\?Q DU>WT.Z+82YT
M?3;"2TM) G5&+?:-V>3QFH>%ITXJ3W5D_P#%=/\ )OYHJ.,J59.*M9W:_P "
M37XM+Y-'I'A+X^?L]?L^?LD^"?''AW2]<M?#.I:=9VW@WPZENUYJU_+.I>&T
MCC#OOG?GC?M!_B Q7CWQP_:&L?C#^T]\!M"N_A)XX\'W]GXWEN$L_&F@BT:Z
MA-N 7A:.21'VD@,NX,I9<CFJ7@^>+18OV*?%7B*:.#08=+O;*XN+A?W*W]SI
M,:62$] [2*P3OGITX]&_;8U'3!^U!^SKI;3Q_;&\;7<L<7\?EB! S?3)7\<>
ME7"G"G6V;;4W>_;F7Z7?J9U*E2IA]TE%P5K;WY7\M[+T.V^)7[9G@KP+X_OO
MA?X5^&/CKQUK6CVZRZ];^!= 6\72MZ[HTG>26-0[KEE12S$*<@<9['X,_&CP
M#\>O EO\0_AUJ4EQ8S2/#-#<0F*XL[A#B2WFC;F.1#P5/L02I!/RQ^S+\/?V
MA=;^)GQLT7X<?M+V7@FZMOB_JUUJ.@7G@.#4+B2*X*O;WF^69&$4L?W!@KB,
ML"=U>K?L+> -'\%I\1+[2OCO;>.[G4_'MS+X@NK'PY_9L-KJH1!<HJB1T<G*
M,60[<^IS7/6H4*=-V>JMWZ]]++RU^\Z,/B,14JIR7NN_;2W;6[\]/N+WC?\
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M[25_5M'?A<VP-;V3IU$U5OR?WK*[MZ).Y]-T445Y)[(4444 %%%% !7Y>_\
M!P_KEW)XH^%OAOS#Y,-CJUSM[%G>U7)^@C_4^M?J%7YH_P#!P]X)OGL?AC\2
M8(&:UAFU+3+R7;PDCB"6$9]Q'-_WS7J9.TLQA?S_ "9X^?*3RNI;R_-'YDT4
M45]P?G9]/?\ !'#_ )2+> ?^N>K?^FJ[KR']JO\ Y.B^)/'_ #/VL?\ I;+7
MKW_!'#_E(MX!_P"N>K?^FJ[KR']JL9_:B^)/'_,_:Q_Z6RUP0_Y&,O\  OSD
M=TO^13'_ !R_])B?7G_! V.2;XK?$R&&-F9O!**JJ,DDSCBOE,?L6?MCD9_X
M9,^)G_A":A_\9KZN_P""!,\MI\6OB5<V[;9(_!4;QMUPPG!!YKQ__A\/_P %
M%QQ_PT*O_A):3_\ (E<\7BO[0K>Q2^S>[:Z/LF=4E@WE=#V[DM9VY4GU6]VC
MWC_@GI\&?C#\(/V)/VJ(_BS\*?$GA=M0^'<QL5\1:'<61N0FFZGO,?G(N_;N
M7.,XW#/45\#_  ^_Y'S1./\ F+VW_HU:_1[]CK]K[]H?]K#]B?\ :<N/C[\0
M!KSZ%\.;I=+8:3:6ODB;3=1\S_CWBCW9\I/O9QCC&3G\X?A\-OCS1./^8O;?
M^C5J\'[3VM?VEKW6VWPKN1CO8_5\-[*_+9VO:_Q/M?J?9G_!?K_D\7PW_P!D
MSL__ $X:C6CXUU;4_P!G+_@B-X/TWP'<2:;J'Q6\53#Q1=02%9+FU<W190RD
M$*\-K:QLO1HVD4C#D5G?\%^C_P 9B^&_^R9V?_IPU&KGQW2Z^+'_  1&^%OB
M[P__ *8W@GQ<;7Q L'/V&/S+RW1I/0DRVF/^NZ^M<M/7!X5/;F7Y.WXG96_Y
M&&,:WY7;[XW_  N?"@7"[:^\-6U*^_:5_P""(<OBSQW*UQJWPB\90V&CZA+\
M\TUMYEM$L18\A5BOU3 X(MH\Y(S7PAD=<U]V>%X9_A%_P0F\2)XQC-O)\1_'
MT;^&HS]Z95N+3)(ZJ"NG7##U 4CA@:[L?_RZ?7GC;]?PN>5EFOMD]O9RO^GX
MVL?"=/MI4@N(YI;=)E60,T,A;:X!^Z=I!P?8@^A%?7G[)G_!4#X<_LT_ S2?
M@_XA_8UT7Q?=:;-<O)KUYK4,,EQYL[R@%6LI2-H?;]\Y"]N@\^_;L_;5\(_M
MC7GAFZ\*?L\Z;X!'A^.[2=-/U".X^V^<82"VRVAV[/*.,[L[STQS<:N(E6Y7
M3M'76Z_+?4QG0P<</SQK7EI[O*_FK[:?B=5\9/\ @H3XJ^/\_@?X#_"_P7;_
M  ^^&VD7VFI_PB&CSY2[F6:-R9I %,J++EU4CE@)'W/@KTW_  7*_P"3W$_[
M$S3_ /T9/7RA\,R/^%D>'^?^8Y:?^CEKZO\ ^"Y3#_AMQ.?^9,T__P!&3UE[
M&G1QU.,%96E^<3H>(K8G+:TZCN^:'R5I:);)>2-C_@AQX;TRU^,/Q ^,VIVR
M3?\ "(>!Y#;JT88H\S[BZ^C>7 Z\=I&'>OC#Q!X@UOQ=X@OO%WB;4I;S4M4O
M);O4+R8Y>>>1R[NWN68D^YK[8_X(;ZG::QX[^*GPC,NRZ\2> R]NW;$4AB;\
M?]*4_0&OAZZMKG3[F2QO[>2&:&1HYH9E*M&X."I!Y!!X(JJ/_(PK7_NV]+/]
M3+%?\BO#V[SOZW7Z6/N;X[-+\7/^"*OPO^('B&9KK6/!WBAM-COIHQN2S$MU
M;I""!]T1+:+ZGR5SD\UY%K/_  4)\3Z3^R7HO[*?P)\!6?@2T:V8>-]:TB9C
M=:],?E9BY^:,2(%\SYBS8$:E(EV-ZY\3)&\!?\$-/ >BZJLD-UXJ\;R2PVT\
M91S%]JO95< \E2D*,&Z$2*>XS\-1FL\'1IUHRYE=*<FNV_;UN:9EB*U"I#D=
MG*E!2?7;OOJK7/MS_@J6,?LH?LI_]DU/_I!I-?%(Z5]K?\%2_P#DU#]E+_LF
MI_\ 2#2:^* 1C%7E_P#N:]9?^E,Y<[_Y&$O2'_I$3Z#_ ."6'/[??PY'_40N
M_P#TAN*Z*''[9O[*M_X7D19OB3\$[.:XTF0L/.UGPJ')D@R3\S6;'<BY&(FV
MHK,Q-<[_ ,$L/^3^_AS_ -A"[_\ 2&XKS3X/?&;QE^SW\<=-^,7@.X5=2T/5
MFF2*7/EW$9)62"3'.R2,LC8(.&."#@@J4Y5,3)Q^)*+7WRT]'L/#UHT\#"-3
MX)2FI>EH:KS3U7I;9GK'_!+O_DYRX_[$;7O_ $@EJA_P3D\?^#O W[1,EAXU
M\8+X;M_%'A74] L_%$CA5T:ZNH"L5T6)&S# +NR "^20,D>^?!?X/>#/!G[9
MMC\:/@Q%_P 6[^)?PY\0:QX555"_8)/L<@NM.<+PKV\IV[1D!609)!KX+16;
MA5)^7/%*')BY5%LG&/R^+\F%3VF7PHMZN,Y/R:M!KY-:I]CUCXN?L1?M4_!#
M4[ZU\:_!/76L;'YVUW2M/DO-.DB/W9%N8E:,*1SABK#.&53D#S635M5GTR'1
M;G4[A[.UFDEM;.29C'#)(%$C*N<*S!$W$#)V+GH*[3X9?M5?M)?!N*WM_AE\
M<?$VDVMJP,.G6^K2-:#V-NQ,1'L5(KU_]I[5=,_:._9%\*_MC>(?"=CI7CA?
M&EQX5\57^EV*V\7B';;?:HKYHUPHE4?(S*/F8MT541-?:5J<HQJ)--VNN_H_
M\SAE1PM:G.5!R3BKN+L]+J]I*U[=FE]^@W]KJ&]^$_[(WP*^!.F3K%;:SX=E
M\:ZT(!M%[<WS?Z.\G]YHH,Q ^GX5\VPR2P21SP2LDD;!D=&P58="#V-?2G[<
MUP?'G[._[/'Q<TRV?^SC\-_^$;D;J$NM-D\B0'TW'+ 'J!QTKYJ7[HIX+^!K
MO>5_6[N+-/\ >K+91C;TY8V_S/3O#OQ3\>_&C]J/PS\1_B=X@;5=;OO$^DK>
M:A);QQM*(Y88DR(U4$A$5<XR0.<UTG_!1K_D^+XC_P#8>_\ :4=<9\-?!WBW
MP/\ '_P9HWC3POJ&D7C^(M+N$M=3LW@D:)YXV20*X!*L.0W0CI79_P#!1K_D
M^+XC_P#8>_\ :4=0N58J*CMRNWWH*CJ2RV;G>_M%>^]^66YYA\./!US\1/'^
MA?#^RG$4VN:U:Z?#*PX1II5C#?@6KV7_ (*7>*UUG]K?7O!ND+]GT'P7;VOA
M_P .:9&NV*PM;:!%,2#LOF&0_C["O(_@[XPM/AY\6/"_C^_B:2#0_$=CJ$R1
M_>9(9TD('OA:]4_X*5^$K[PC^VUXZCN4?R=2U"/4K*=E^6>*XA24,AZ,H9F7
M([H1U!J_^8V-_P"5V^]7,Z?_ "*:C7\\;^EI6_&_W(\K^&?Q,\=_![QK8?$?
MX:>(YM)UK369K.^@569-R%&&U@58%6((8$$'D5D2SRW5Q)=3E?,D<N^U HR3
MD\#@?0<5-X<\/Z[XMUNU\,>%M&NM2U*^F6&SL;&W:6:>0]$1%!+$^@%17-G>
M:;>3:=J-I);W%O(T=Q!-&5>-U."K \@@\$'D&M_=YF^IYDI5/9I._+?3M?2_
MSVO\@3I4O\-1)TJ7^&F8CD^]4J=:B3[U2IUH,I;'T+\+O^4;_P 4O^QZT7^3
M5X G:O?_ (7?\HW_ (I?]CUHO\FKP!.U<V'^*I_B_1'?F'\'#_\ 7O\ ]OF?
M1GQWTC5M5_88_9W_ ++TNXN?+7Q9YGV>%GVYU1,9P..A_*O"QX1\68_Y%?4?
M_ *3_"OI?QO\=?C%\%OV&/@$/A/\1M4T#^TE\4_;_P"S;@Q^?Y>J#9N]=N]\
M?[QKS#_ANG]L+&#^T5XH_P#!B?\ "LL.\1R/E2MS2ZO^9^3.C,(X%UH>TE)/
MV=+:*:_APZN2_(ZK]NN&:VT7X*6]Q"T<D?P3T=7CD4AE(DGX(]:O_L)?\DL^
M/?\ V2>\_F:C_P""@_B'7/%H^#WBCQ-JDU]J.H?!K2KB^O+AMTDTKRW#,['N
M222:D_82_P"26?'O_LD]Y_,UG_S+U?NO_2CH7+_K$[;6?_IL\T_98^'VG_%3
M]H_P5X UBV6:QU'Q%;K?PMTEMU</*GXHK#\:T/VO_B9K?Q8_:7\9>*=9U&2X
MCCUZYLM+5EVB"R@E:*"-5Z+A%!..K%F/+$TW]C;QC8> _P!JGP%XGU65([6'
MQ);Q7$TC86-)6\IG)[!0Y)^E4?VG/!VJ> ?VC/''A'5[2:*2T\47OE_:(RK2
M0O,SQ28]'C9'![A@:ZI:X[7^73[]?T/)VR7W>M37Y1]V_P!\K?,J_ ?XEZW\
M'OC'X;^)7A^YDCN-)U:&5@C$>;$6VRQ''\+QET([AC77_MR?#C2?A/\ M8^-
MO!6@QQQV<>JK=VT,,85(4N88[D1*!P%3SMH'HM<!\+O!^K>/_B1H/@;08#)>
M:MK%O:VZK_>>15R?0#.2>P!->G?\%"/%^D^./VRO'FN:*Y:"/5(K$L>\EK;Q
M6TGX;X6Q[5,O]\5OY7?[U;]2(_\ (EG?I4C;YQES6^Z%_D>.C); %>B)^R7^
MU)_T;GXX_P#"7N__ (W7GB$JX8'H:][7_@IO^W 1_P EM_\ +;TS_P"1JNM]
M9T]BEYW;_1,YL&LKES?7'-;6Y%%][WYFO*UO,Y'2_P!EW]K31M0M]8TCX">/
MK2\M)UFM;JV\-WD<D,BD,KJP0%6! ((Y!'%?:O@?PKXP_;M^"S?!S]KKX.>)
M/#7C'0H&ET'QI>>&IK=)&P 9 S(JACA1+"2%D 5EPRCR_ER+_@IE^W#*RQQ_
M&EF9FPJKX:TW)/I_Q[5]??#/XU?'/]GCX)W'Q\_;L^+DUQ<:C;A/#W@>'1[*
MWN-Y^8;S%"CF9ACY,A8DW%\L<1^1C_KG+%R4>:_NV;YK^6GWWT/KN'EDWM:D
M:<JKI./[Q3C!0Y>CDU*Z=_A:]Z^W4_/WXU_!'XA?L^_$&[^''Q(T<VUY;MNM
MYX\M!>0DG;/"^/G1L>Q!!5@K*RCDZ[W]HW]H_P"(?[3?Q"D\=>.[ORXX\QZ5
MI,#'R+"'/W$!ZL< LYY8^@"@<%7M4?:^SC[2W-UML?!X[ZJL7-89MT[OEOO;
MS/=?CM_R95\ _KXJ_P#3C'7B0Z5[;\=O^3*O@']?%7_IQCKQ(=*SPO\ "?\
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M7MNO0\Q^,O[&_P"S3\?]>A\5_%GX56>IZG#;F%=0BNI[69XR,;'>WD0R*!P
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M3?M)>*?VUOV)_@5IGAOP,VAZW\7_ !W)_9OAM=22Z1OL\LEG&K7+QQ;2TEQ
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M?PFBB&#ITYJ;;DUM=MV]#.MF%:K2=-*,4]^5)7]?\M@HHHKH.$^W/A]\>O\
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M[XT>&KR7YQX=\.ZYIUYI\38^XL]TOGE<]V!/\JY']I/]IRU^,^D>'/AA\.?
M$?@_P!X-BF3P[X;AOFN',DK;I;FXE;!EF=O;" D#JQ;R,'"\TZ,YZ5,<-3BU
M)MNVUVW;^NY%;'59TW!*,;[V25^NMNE];*R\M#V;]G[]J71/A_\ #S5O@#\;
MOAG'XV^'NM7JWS:5]L-K>:5?A=HO+.< F-]HPRD8<#:2%9P_6:?\2/\ @FU\
M+[ZU\;?#KX,?$SQCK%K^\M]%^(6J6$6E1S#!1G%HADN$5NL;X5P,,,$U\WD@
M=:D7[M#PM.3;NU?>S:3_ *\@ACZT(1BTGR[-Q3:]+]/)W2Z'?:[\>_&/C_\
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M<K77>_R.+_X)D_%S_A:'[*>D:->:I#=ZAX-N)/#UY-!]R1+<#[.Z< E#;M"
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M^W01_P >WA+_ ,*'_P"UT[_AQC^W/_S[>$?_  H3_P#&Z_9JBJ_M['>7W?\
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M?9?"?_A0'_XW7[$44O[<QWE]W_!%_JKE?][[_P#@'X[_ /#D?]MW_GU\)_\
MA0'_ .-TY/\ @B1^VX.MMX3_ /"@/_QNOV&HI_V]CO+[O^"+_5/*_P"]]_\
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M^V8!C[-X7_\ !]_]KJ0?\$;/VR\8^S^%_P#P??\ VNOUHHH_MS&^7W?\$/\
M4O)_[WWK_(_)A?\ @C9^V6#DVWA?_P 'Q_\ C=2+_P $;_VR <FW\+_^#P__
M !NOUCHH_MS&^7W?\$G_ %)R;^]]Z_R/R?7_ ((Y_MC@8-OX8_\ !Y_]KI1_
MP1T_;& _X]O#'_@\/_QNOU?HH_MS&^7W?\$7^I.2_P!_[U_D?E&/^"/'[8G7
M[/X9_P#!Y_\ :Z=_PYZ_;#_Y]_#/_@\_^UU^K5%']N8WR^[_ ((O]1\E_O\
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M2B_:OD3<MOX=_P#!S_\ 85^E<<32.%&:OJH5=H%*6>8WR^[_ ((UP!D/>?\
MX$O\C\R/^'4/[6&>8/#O_@Z_^PIZ?\$H_P!JX=;?P[_X.?\ ["OTUHJ?[<QW
ME]W_  1?\0]R#^__ .!+_(_,O_AU+^U;_P \/#O_ (.3_P#$4Y?^"4_[5@&/
M(\._^#@__$5^F5%/^W,=Y?=_P1?\0\X?[S_\"7^1^: _X)5?M5C_ )8>'?\
MP<?_ &%'_#JS]JK_ )]_#W_@X/\ \17Z7T4?V[CO+[O^"'_$.^'^\_\ P)?Y
M'YG-_P $M_VI(#L>#P_GK_R&/_L*5?\ @E]^U %_U/A__P &Q_\ B*_22^&9
MN_W:AQ_O57]N8UKI]W_!,WX=\/\ >?\ X$O\C\XQ_P $P?VH!QY/A_\ \&__
M -A0O_!,+]I\')A\/_\ @W_^PK]',?[U&/\ >H_MK&^7W?\ !%_Q#OA_O/\
M\"7^1^<Z?\$Q/VG0,>3X?_\ !O\ _84?\.Q_VG/^>&@?^#;_ .PK]&,?[WYT
M8_WJ?]MXWR^[_@B_XAWP_P!Y_P#@2_R/SK_X=D?M-_\ /+P__P"#?_["@?\
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M5'@')Y?;J?>O_D3X]\*?L#?&C4;I?^$O\0^']+MR?WC6L\UU*O\ P'RT4_\
M?=>Y?"C]DGX8?"Z>/5_(DU;5(\%;[45#")N.8XQ\J<C()RP[-7J5(S!%W,:Y
M*V88JLK-V79:'M9?PKDN6S4Z=/FDMG)W:]%LO6UR+[(!_'_X[1]D_P"FG_CM
M1BY::Z4+]W=^=6JXCZ(@-D#SYGZ4GV$?\]/TJQ10!7^PC_GI^E#:>&_Y:_\
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M (16/_G];_OW_P#7KG?V@_\ D2-,_P"QX\-?^GJRKN*.9ARQ,<^$T(Q]M/\
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MFD'LJ?8Y/_A5L/\ T&F_[\#_ !H_X5;#_P!!IO\ OP/\:ZRBCFD'LJ?8Y/\
MX5;#_P!!IO\ OP/\:/\ A5L/_0:;_OP/\:ZRBCGEW#V5/L<G_P *MA_Z#3?]
M^!_C1_PJV'_H--_WX'^-=911SR[A[*GV.3_X5;#_ -!IO^_ _P :/^%6P_\
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M+B__ /CU+_5^M_.ON9/^N>%_Y]2^]'[X45^")_;$_:XS_P G3?$;_P +B_\
M_CU2)^V%^UN0/^,I?B-_X6]__P#'J/\ 5^M_.ON8O]=,+_SZE]Z/WJHK\&!^
MV#^UMC_DZ/XC?^%M?_\ QVGI^V!^UJ1S^U'\1?\ PMK_ /\ CM'^K];^=?<R
M?]=L+_SZE]Z/WDHK\'Q^U]^UGC_DZ'XB?^%M?_\ QVE'[7O[61//[4'Q$_\
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MA^M_.ON8?\1*P/\ T#R^]'[%45^.R_M.?M)XS_PT)XX_\*R\_P#CE.7]IO\
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M $#R^]'ZR45^3O\ PT9^T)_T7?QE_P"%1=__ !R@_M&_M"#K\=_&7_A47?\
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M6/\ T.QJK\)/C[X!^,EB9?#&H^7>1INN=+NU"3Q#.,X&0R]/F4D<C.#Q5KQ
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M^%C^(O\ IW_[]?\ UZ.20>V@=]17 _\ "Q_$7_3O_P!^O_KT?\+'\1?]._\
MWZ_^O3]G(/;0.^HK@?\ A8_B+_IW_P"_7_UZ/^%C^(O^G?\ []?_ %Z/92#V
MT#OJ*X'_ (6/XB_Z=_\ OU_]>C_A8_B+_IW_ ._7_P!>CV4@]M [ZBN!_P"%
MC^(O^G?_ +]?_7H_X6/XB_Z=_P#OU_\ 7H]E(/;0.^HK@?\ A8_B+_IW_P"_
M7_UZ/^%C^(O^G?\ []?_ %Z/92#VT#OJ*X'_ (6/XB_Z=_\ OU_]>C_A8_B+
M_IW_ ._7_P!>CV4@]M [ZBN!_P"%C^(O^G?_ +]?_7H_X6/XB_Z=_P#OU_\
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M4M2OKA8+'3]/M6FGN)&.%1$0%G8GH "31&I"4;Q:8JE.I#W9)I^A6HKW2?\
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M^*'P7\0_\(G\6/ .K>'M0,9>.VU:Q>$RH&*^9&6&)$W*0'4E3@X)J_\ #GX
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MCHQ4X:IHZA3[U:GA;PMXG\:ZW#X:\&^&]0U?4KC/V?3]+LWN)Y<*6.U$!9L
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MTAX"HB@EF)Z #)JU!X4\53>)_P#A"8/#.H-K7VPVATA;)S=?: VTP^5C=O#
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M9%1V&TC_ ':6D?[M$1B'&.JTVG'./O?^.TVC[0=!JXQU%-?O3AG'7]*:_>J
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M7[;W@WX:_%'XYZMK&AZA'J1O=-NHX0DOEZ=<RIG:@/#HK=>HKS/]HG_@H_\
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MI&G6^BVJW-_=:Q=-#&D9.,[@C=,<YQ6,YQIQYI.R.W#T*V)K*G25Y/IZ:O\
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MIMY>AX(__!.?X#3Z5<>#KWQ)XYN/"<RL(?!$OC2[_LFV).X&.$,#\K?,H9F
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ME[<2A8P,;B !DBO9_%'B;0_!GAK4/&'BC48[/3=+LI;O4+J7.V&&-"[N<9.
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MEUN>Q?MP?$WX'?%;]H/4O$'[.W@*ST'PO;6\5G9FQL?LJZBT>0UX8<#R]Y.
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MV>W:Q^Q=XCU;4/[0^!_Q*\(^,?#T[!X]3A\16UK-91-ROVN"=T>)]IR5 8@
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MO_"O]/OM6\0>$;C^TD:3^V-5AM(KP-&&WA,)<8# *,@@DFNCGPO+=6_G^?\
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M'O\ _P",U_0111_K!67V%][#_5/#O_EX_N1_/RG[%O[8@//[*/Q)_P#"'O\
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M5X^_\(^]_P#C52)^R=^U*.O[-GC[_P (^]_^-5^VU%'^L%;^1?>R?^(?X/\
MY_2^Y'XFC]D[]J3 _P",;?'G_A'WO_QJG+^RA^U'N_Y-N\>?^$C>_P#QJOVP
MHH_U@K?R+[V2_#W!O_E]+[D?BHG[*/[40Z_LX>//_"1O/_C5/7]E/]J =?V<
M?'?_ (2-Y_\ &Z_:BBC_ %@K?R+[V)^'F"?_ "_E]R/Q:3]E7]I\'G]G+QY_
MX2-[_P#&JD3]E?\ := Y_9S\=_\ A(WG_P :K]H:*/\ 6"M_(OO9'_$.<%_S
M_E]R/QB7]E?]ISC_ (QT\=?^$E>?_&Z&_9<_:80X?]GGQPOU\*7G_P ;K]G:
MIW_,R\_PT+/ZW\B_$F7AS@?^?\ON1^-Z?LO_ +2@'/[/GC;_ ,)6[_\ C=2+
M^S%^TG_T;[XV_P#"5N__ (W7[#<^O_CM )W8)[^E5_;U;^1?B3_Q#G!?\_Y?
M<C\?T_9<_:8/(_9X\<?^$G>?_&ZD3]ES]I<#G]GKQQ_X2EY_\;K]C57:NT4M
M3_K!6_D7WL/^(:X'_G_+[D?CDO[+_P"TMN_Y-Z\<?^$I>?\ QNI%_9@_:4[_
M +/?C;_PE+O_ .-U^Q-%#X@K/["_$7_$-,#_ ,_Y?<C\=U_9@_:4 P?V?/&_
M_A*W?_QNG+^S%^TGG/\ PSYXW_\ "5O/_C=?L-11_K!6_D7WL7_$,\#_ -!$
MON1^/J?LR?M)#K^S[XV_\)6[_P#C=2#]F7]I#'_)OWC;_P )6[_^-U^OU&!Z
M4?ZP5OY%^)/_ !#' O\ YB)?<C\@1^S)^T@3_P F_>-?_"5N_P#XW4B?LR_M
M'@<_ #QI_P"$O=__ !NOUZP!T%%'^L%;^1?>P_XAC@/^@B7W(_(4_LU_M%(V
M'^ GC0?7PO=__&Z=_P ,W_M#?]$'\9?^$S=?_&Z_6R^&9O\ @/I4.#TS_P".
MU7]O5OY%][)?AC@/^@B7W(_)D?LW_M#=/^%$>,O_  F;O_XW3Q^SC^T*!C_A
M1'C+_P )FZ_^-U^L>/?_ ,=HQ[_^.T?V]6_D7XD_\0QR_P#Z")?<C\GHOV;_
M -H=FPOP&\9'_N6+K_XW4O\ PS7^T5_T03QI_P"$O=__ !NOUBLABX_X">U7
M*/\ 6"LG\"^]A_Q"[+W_ ,Q$ON1^28_9L_:)Q_R07QG_ .$O=_\ QNE_X9M_
M:)_Z(+XS_P#"7N__ (W7ZUT5/^L%;^1?>P_XA;E__01+[D?DL/V;OVB#_P T
M%\9?^$O=_P#QNE_X9N_:'Z?\*&\9?^$O=_\ QNOUHHH7$%9?87WL/^(6Y?\
M]!$ON1^2_P#PS=^T1_T0;QE_X3%W_P#&Z>G[-_[0X'/P'\9?^$S=_P#QNOUE
MHH_U@K?R+[V3_P 0KR__ *")_<C\E;KX ?':QFM[>]^"WBR&2[F\FUCD\.W*
MM-)L9]B I\S;$=L#G"L>@-3#]G3]H./[_P "_&"_7PS=?_&Z_33XFLJ^+? +
M-_T.$@_/2=1%==)&LB[6%'^L%;^1?>P_XA7E_P#T$3^Y'Y/K^SG^T&XRGP+\
M8'Z>&;K_ .-T[_AG#]H7_HA'C+_PF;K_ .-U^KZJ$7:HZ4M/_6&M_(OO8?\
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M/\:UN?[W_CM26F1<K^/;VJ^9D\J,IM!U8G(M/_(B_P"--/A_5]N/LG_D1?\
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M$\5_] K_ ,CI_P#%5Z+11[20>QB>=?\ "">*_P#H%?\ D=/_ (JC_A!/%?\
MT"O_ ".G_P 57HM%'M)![&)YU_P@GBO_ *!7_D=/_BJ/^$$\5_\ 0*_\CI_\
M57HM%'M)![&)YU_P@GBO_H%?^1T_^*H_X03Q7_T"O_(Z?_%5Z+11[20>QB>=
M?\()XK_Z!7_D=/\ XJC_ (03Q7_T"O\ R.G_ ,57HM%/VD@]C$\Z_P"$$\5_
M] K_ ,CI_P#%4?\ "">*_P#H%?\ D=/_ (JO1:*/:R#V,3SK_A!/%?\ T"O_
M ".G_P 51_P@GBO_ *!7_D=/_BJ]%HH]K(/8Q/.O^$$\5_\ 0*_\CI_\51_P
M@GBO_H%?^1T_^*KT6BCVL@]C$\Z_X03Q7_T"O_(Z?_%4?\()XK_Z!7_D=/\
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M  3Z?_\ )U7_ &9C_P#GVS/^V,L_Y^H^Y**^&_\ A_Y^QT>GPT^)G_@GT_\
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M'_@ML_\ Y*H_LW'?\^V'^MG#G_03'\?\CZDHKY;'_!6[]G!NG@KQO_X+;/\
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M_LS'_P#/MA_K?PS_ -!4?O?^1[+\6&*>)O ,F#_R.>./?3KX?UKM*^1/'O\
MP4I^!GBC4/#=WIWA/Q8JZ/XB2_N/.L;8%HQ;SQ$+BX.6S*.#@8SSZ]&/^"J?
M[/9Y_P"$.\9?^"^T_P#DJC^S<=_S[8?ZW\,_]!4?O?\ D?3%-DD"C ZU\TG_
M (*I?L^8X\'>,O\ P7VG_P E5'_P]-_9^SD^$/&7_@OM/_DJFLLQW_/MDRXP
MX:Z8J/X_Y'TMR>32\^]?-/\ P]._9]/3P?XR_P#!?:__ "35F#_@IO\ !&Y&
M8? 'C9A_>_LVU _]*:K^SL=_S[9FN+>');8F/X_Y'T;S[T<^]?/ _P""DOP;
M(R/ /C+_ ,!;+_Y+IW_#R'X/?]"#XQ_\!;+_ .2Z7]GXS^1E?ZT</_\ 00OQ
M_P CZ%Y]Z.>G-?/B_P#!1WX/'_F0/&7_ ("V7_R71_P\:^$#' \ >,?_  %L
MO_DNCZAC/Y&'^M&0?]!"_'_(^AHXPG)^]3J^>T_X*._"+H_P^\8_^ MES_Y-
MT[_AXW\(?^B?>,O_  %L?_DNL_[/QG\C-UQ5P[_T$1_'_(^@J*^??^'C7PA_
MZ)[XR_\  6Q_^2Z7_AXS\(ST^'OC+_P%L?\ Y+H_L_&?R,?^M7#_ /T$+\?\
MCZ!HKQ?P?^W=\#_%$[0:FFL:#A@J-K%BA63/H;>27'U; KUC0O%/A[Q/IZZO
MX=UNUOK63A+BSF$B$^F5)Y]JQJ4*U'XXM'I8/,\OS!7PU6,O)/7YK=?<:%<?
MXE_Y+?X3_P"P'K'_ *'8UUOVB+^_^E<EXC^?XT^%;E?]7'HNK*S>A+V6/Y&L
M3N.PHJ,W,(ZO^AH^U0?\]/T- $6H=4_'^E5L_P"]4NH74&4^?U]?:J_VF#^_
M_.K6Q#W'Y_WJ,_[U1FZ@'\?\Z/MEK_SU_0TQ%BV/[]>O6KU9L%[:K,I,O?T-
M7/[1L_\ GM_XZ?\ "ID5$FHJ#^TK+_GO_P".G_"D_M.Q_P">W_CI_P *DJY8
MHJO_ &K8#_EX_P#'3_A2'5]/'6X_\</^% 7+-%5O[8TX<FX_\=/^%)_;6F_\
M_/\ XXW^% 71:KC_ (M?\?W@_P#['"W_ /1$]=,=;TP=;G_QQO\ "N3^*-_:
M7EYX5:VEW"#Q7!++\I&U1#,,\_44!<[:J-SD7#?6G?V]I/\ S]_^0V_PJE=:
MWIAF+"Y_\<;_  JHDR:)\_[U26Y/G*<FJ/\ ;FF=KC_QUO\ "B+7M)$JDW7?
M_GFW^%43S(W**H'Q-HHZWG_D-O\ "D_X2?1?^?W_ ,AM_A469?-$T**S_P#A
M*="_Y_O_ "&_^%!\5: .M_\ ^0G_ ,*+,7-'N:%%9W_"6>'_ /G_ /\ R$_^
M%)_PEWA[_H(?^07_ ,*+2#FCW-*BLS_A,?#G_01_\@O_ (4G_"9^&O\ H)?^
M07_^)HY9!S1[FI164?&OAD==2_\ (+__ !-)_P )OX7_ .@G_P"0'_\ B:?+
M+L'-'N<[^T'_ ,B1IG_8\>&O_3U95W%><?'#Q)HVL>$=/M--O/,DC\8:!<,O
MEL,1Q:M:2.W('1$8XZG&!DX%=A_PG?A3_H*_^0'_ /B:.678.>/<UZ*R/^$[
M\*?]!7_R _\ \31_PG?A3_H*_P#D!_\ XFCEEV#GCW->BLC_ (3OPI_T%?\
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M]?E.64Z--5JJO)ZKR_X)\+G6<5,15="D[06CMU?^7Y[@!S3MO^S^M-'6G?\
M?->W$^9#;CG%.IO_ 'S3JH!RC/:G#I3%_#\:>.E !3DZ4VG)TH%+8=1114R(
M"I*CJ2B),AT=.IL=.JB20=**!THJ5L*6P]/NT].M,3[M/3K3EL9O8=0.M% Z
MTD024Y ".13:<HR*: D6GQ  G%,%/BR"<BH,9#L#.:EJ+!W9Q4M4@8]>_P!:
MD3[M1KW^M2)]VI,I;DM*/NFDI1]TU7V29;#ZF3K4-3)UJ3*1(G2G#K34Z4X=
M:#.1(.M3*,CI4(ZU,O3M^-!E+<>GWJD49/2HT^]4B]?\:")#Q4E1CI4AYH)'
M1\=!4J?=J*/BI4^[52,QZ#OBI(ZC3\*DCI="&3#I3@,-T[4T=*<OWO\ "D1(
MD3I4PZ5"G2IATH,I;CHZ=38Z=09RW)$[5)4:=JDH)EL/3[M2U$GW:EIF4AT=
M.'6FQTX=:);DDE.3I3:<G2J,R7^#\*>JY&<4S^#\*>.G\-03($Z?C4PZ5"G3
M\:F'2GT)')UIU-3K3J:W)D.4<9Q3L#TIJ\^E+M^GY41)'Q_<IZ?>ID?W*>GW
MJ.YF/IRKD9Q3:<.G\-'V0%"X.<4M-'7^&G41)D ZU)48ZU)5$A4@Z5'4@Z5(
M!4UAI]QJ4_DVXZ?>8]%J)$>5UBC7+,V%'J:ZO2]/CT^W6!.>[-_>/K2G+E1M
M1I>TEKL.TO0K#3U#+'ND[R-U_P#K5H)UJ..I$Z\US;GI1C&,;(5#\M6[&QOM
M4NX=,TRSFN+FXF6.WM[>,N\KL<!54<L2> !R37T!^T!\7OC5X&U/PQHOP\\4
M:G9V!\$Z;*T-G%N3S"C G[IYP!2^(OM^J?$KX*^,O&>FQ6OB[5KZW?7E6%8I
M)XTO46VGD0='>/.3@'C& % '#]:G**DXK6]M;[)O71=CZ>6248UITHU)-P<4
M[P25I24='S.[NU9-*Z3?0\"N+2[T^[EL;^UDAGAD:.:&9"KQN#@JP/((/!!Y
M%(GWJ]I\6_ ?PAX]^)OB+1/"'QHL;SQ7<:I?3P^'O['G5'=9))&A%RWR%PH/
M;&1@'&2/%E#*VUASWK2E6C5CIY=&M_4\['8"M@9^_:S;2::>VZ?*W9JZNGJK
MJZ+NGZ)K6J0S7>F:1=7$5NNZXDM[=G6(>K$# 'UJ'(QFO0-6_:.^)-[/HNC_
M  [O;SPWI^D6D-OI^D:/=,$DD&-SR  ><SOR0P;.>Y+$W/VM[+2;'XTW@L+6
M*WNIK&UFUFW@0*D=X\2M)C''.58GNS$GFIC4J>T49*UTWO?:V_WFU;!87ZK*
MM0J.7(XIWC9/F3?NZWTY7HTFUKILO/#I&K1Z7'KLFEW"V,EP88[QH6\II ,E
M ^,%@"#C.<&I(]$UIM*_MM=(NC9JVUKP6[>4&STW8QG\:[_XTRCP?X1\ _#9
M8U=]-T,:M?QRQ[<W%X_FF.1>N5147GG'I76?"_X@?M+_ !"^*FC>*!%JT.@3
M7D:W5O#;21:/#8AMLJ[6_=;!&&&22V1P2V*F6(E[/G25M=W;;;IU.JGEE"6,
M^K2E+F]U6C&]G)+FOJM(MV\^Z/#X_N5T/@#XB>,OAIK"ZYX,UV:SFS^\13F.
M9?[KH?E8?4<'D8(!J#XC#P^/B#KP\)^3_9?]M77]G?9_]7Y'FMLV_P"SMQCV
MK+3I6CY:D=5OT9Y_-4PF(O3E:47HT^W5,^WOV?\ ]HG0_C5I36D\4=CKEK'N
MOM/W?*Z]/-BSR4SC(ZJ3@Y!#'I-<_P"2I^'O^P5J7_H5K7PAX1\5ZYX'\2V?
MBSPY=F&\L9A)"_8^JGU4C(([@D5]I^$O'.F_$G6_!OC72AMCOM#U%VBW9\J0
M/:AX\X&=K!ES@9QD<&OF\PP:P\N:'PO\&?L7"?$4LXHNC7?[V'7^9=_5;/U3
MZZ=\_2FTY^E-KSXGUKW*]_U3\?Z57JQ?]4_'^E5ZHB6XC_=IE/?[M,H)'1_?
M%6",+G%5X_OBIST[4%1$II7C[M.IIZ?PT%$;]137&".*<_44UNH_I03]D1_N
MTRGO]VF4$C7Z5@^-/]=HO_8:C_\ 1<E;S]*P?&G^NT7_ +#4?_HN2@#8;O5>
MXZU8;O5>?[WXU2 CIL?WQ3J;']\51)(_6FTY^M-H*(SUILE./6FR4$]1IZ5'
M4AZ5'021U&>M25&>M #7'?%, [XI[_A48Z]J: Q?&G_(,M_^PK8_^E4=>??M
M2_'CQ)^S_#X(\0Z?IME<:1KGCJQT/Q#)=0R,UI;7&_\ TA&5@%VE,'<"#O'3
MOZ#XT_Y!EO\ ]A6Q_P#2J.O-OV\OAW+\3_V1?'7ANT\S[3#HK:C9^5]\S6C+
M=*J^[&+;_P "KHP_*ZT5+9NWWG-BN=4).&Z5U\M?Q,']OK]KSQ)^R7X'T'5_
M _A:SUK6-8U211I]X)-OV*"!Y;F4>6004 CYY #$D<5T/[5/[1\_P5_9]_X6
MM\.AINKZIJUYI]KX3L[MG:'4YKJ5-JKL(9LPF208(X2O'? U[HW[=GQRMK[7
M7631=%^!<4&IQV_W['5=?@_?*K]-PM 5X'!/U%<;\&O%FN_'.3]F_P#9W\0Q
MR?;O FK:CJ'C6QCA!DTZ;0]UK8F0]@SE4;&<EQ[&NV.'IQC'F6L=9>EFU^"_
M$\V6*JRE+E>DM(^3NDW][O\ +U/M_4M?TKPOH@UCQCKMA80QHHNKRYN%A@5S
MQ]YS@ GIDYJW;75M>VT=Y9W$<T,T8>*6-@RNI&0P(X((YS7S5X>\">#_ -H[
M]N?XH6WQK\.VWB+3_AQI^BV'A/1=8MUFLK87MJUQ<3&!P4>5G50'()VJH_A7
M;=_9[TG3_@O^V+\0OV>? MN]KX1NO#=EXETW1XV/V;2;J21H9XX5_@24XDV#
MY05PH XKFE0BHO75)/;36WGY_P!=>R.(DY+3W6W'?6ZOTMM=/KV^7N5E\2/A
MYJ0T\Z=X\T6X_M9G72_)U2)OMC*2&$6&_>$$$';G!!S7GW[)/Q6\:_%6R^(<
MWC;4H[IO#_Q6UK1-+,=ND?EV5NT8B0[0-Q 8_,<D]S7DW_!*?X$?!L?LL^%?
MBY/\--'N/$]U>7TS:]>6"37431WD\*>5(X+0@(@&$*C.3U))P?#_ ,3?$?P>
M_9!_:3^(/A%Y(]2L_B_XDBL;B)B'MY)Y[: 3*1T:/S=X]TK:6'AS3I1U::5V
MNM[&"Q53DIUIZ)IRLGTM<^C/VC?B[!X$^#7CO5O!'B[3U\3^'?"=YJ%O:":*
M6:W=(2R2/"<G;G;]X8.1ZUH_ GXC1^.?A9X1O]?\0V<_B'4_!NFZKJ5K'(BS
M$S0(S2^4O*H7)P<!<\"OGGXL_L:_L[>&?V -6U&V^&VEOKFF^ WU7_A*%MP-
M0GO1:F5I7N?]8RNY;,98H5;;C  "^"U'PP^)'[-7Q>+^38^*_A=!X-URYFGV
MQH191WMDN#QN:995S_\ JJ/8494;1>MWT[*_</K%:-=.:TLM$[[NU]EL?5UG
MK^A:CJ=YHFGZU:SWFGF,:A9PW"M+;;UW)YB@Y3<O(R!D<BN+^,_BOQ9>>#?-
M^"GQ1\'Z5J-GXDMK34KWQ!,);= )!YUH=C?+.P*J%.&^; VDAA\H_LN_%34?
M '[0%U^TW\0-:NH?#7QST?Q#JEG;W4(WV8TB=Y;=92/NJM@LF#R#D=>SM2\*
MZEI'_!/#POXW\1VJIK7COXHZ=XJUJ1&)\Z:]U)9$?GOY'DC\/QJE@U3JJ[ZI
M;==;_<TT3]>]I2;2Z2>_16M]Z:9]P:WX@T'PSILFL^(];M-/LX<>;=WUPL4:
M9.!EF( Y]Z\@\)_&SQEK_P"W-KGP;CUZWN/"MK\.;;6+"&&&,YN)+A$\P2@;
MF4H>!DKWKC$\(>$_VD_V_P#QQX=^,7ANWUS1_ACX=TR#P[H>J1B:R,]]%Y\U
MTT+Y1Y,8C^8$84'&54C@QH'AG]EO]L;XS:[\'?#MOIL.D_ FYURQTNW3_1X+
ME7$FV./I'&73=L7"@LV  <5-/#T[..\G%/;36UM?1E5L14O&2TBI6WU=KWTM
MM==S[+F\5>&+;7HO"MQXCL8]4GB,L&FO>(+B1!G++'G<1P>0,<5?SFOSY\!>
M$/A5XN_9;BL-2_8E^*>O>,/$NB_VI/\ $D>&[6XNYM5GC\U;V&\-VLWE"5E9
M0-H9 -RDLV?L;]E?5?B=K7[//A.\^,^DW5EXH725AUF&^4K,TL;&/S) ?XG5
M1(?=ZSQ&&C1C=.^MNGWK5Z&V'Q4J\K-6NK]?N=TM3IE^(_P^D6S>+QWHS#4+
MIK:P*ZI%_I,RMM,4?S?.X;@J,D'C%8/P;U+XA:C?^+O^$Z\=^&M;AA\6746A
MQ^'FW/IUFNW9:W7_ $\+_$.H)ZD$ >%?\$X_@%\'=1^%\_Q8USX=:3J7B)_&
MFIR6^KZI8QW$UD8+V01"W:0$P;2"_P F#N8L><8K?LXKXS;X2_M2#X<?:/\
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MJ>7X:<59RC*[[VDTOP/2?V6/V:O&O[5WQAL?A-X+F2U\R-KG5-4FC+QV%HA
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M".G/&16E>48T92E>R3>F^W3S.?+J=2MF%*G3MS2E%+F5XW;25TT[KOH]#S$
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MI6T?KHE^A5.C2H:KTU;T797.8_9M^!I_9Z^&A^'8\4?VO_Q.+Z^^V?8OL_\
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M5& .?85-114K3J:/\$EOZ%4Z-.DVU?MJV]%MN%%%%9FP4444 %%%% !1110
M4444 %%%% !1110 4444 %3:9>OINHPZ@A/[F0-P<9&>1^(XJ&B@#US-%0V
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MM]&U^UUG6KI8R4M;.UF29V8_P[BHC4GJ\BCO7H'[;_[7GB/PM_P4\\3?M ?
MSQ# UUX7O!I6CWEQ9K+&K16/V.Y 5LJZ^8USM;H00P[5K?$G_@KQX@3X>ZA\
M,_V2OV</"OP;L]9##5+[PVL;7;Y4+NB:*"!(I"N5\PHSJ""C(P##X[)).2:4
M*56M6=6M&RMRI;Z/5WZ>1%;$4<-AXT</-R?-S.5FM4K)*^NFKOW/JK5?^"S/
M[=FM:7<:/?\ C;1&@NK=X9E7PW;@E64J><<<&OEFHZ]B_9(_:9\$_LU:WK.K
M>-?V</#'Q&CU2UBBM[7Q-#$Z63(S$NGF0R8+9P< <"MXTJ>&IMT8*_965SEG
M7JXRI%8BJ[:ZN[M^I]'_ +#A_P"-3O[0X_Z>&_\ 2>&OA9NG2ONG1/\ @L[X
M*\.^&-0\$>'?V O 6GZ+JO.J:/93Q16MYP!^]B6U"2< #Y@>!7C'[5W[:OPS
M_:.^'EIX&\&_L<^"?A]=6VLQWTFM>&[:%)YHUBE0P$I;QG83(&/)&8UX[CEP
MOUJG6FY4[*3O>ZTT2_0[,=]1J8>FH5KN$;6Y9:ZM]M-SVS_@KY)>_&?X5?!'
M]K;1K59-*\0>$A::A+;.)([*\9$G$#,. ^YKA,=08'!P17G7_!''X<:_XX_;
MH\.^(].TV233_"UG?:CJUP.%A0VLL$>3ZF6:/CJ0&/0$C&_9._X*-^,_V=OA
MW>? OXA?##1?B1\/;R8S+X5\2 ;;:0N'/E,Z2*(R_P"\,;1L-_SKM8N6Z[XM
M_P#!5RYU3X6:M\(_V7OV:/"WPCT_Q!&T>NW7A_RFN+A&7:VPQ00(C%,H7*NP
M5OE*D UE[+&4\,\+&&CNE*ZLD^ZWNKFSQ&7U<7''3J--6;A9W<HI;/:S:OK]
MQYE\3? /Q*_:_P#VK?B?XC^ /@W4O%4$GB'6-8633[<MBP$\KQO_ +S1A0B?
M>=L*H9B!7DNA>)_%'AC4H=6\.^(]0TZ\M6W6]U97CPR0L.ZLI!4CVKI_V>/V
MA_BG^R_\2K/XJ_"/7OL>HVRF.XAF3?;WUN2"]O.F1OC; R,A@0&4JRJP^II?
M^"LOP&UR];Q9XR_X)I?#S4O%$T@GNM=:2VW37'4S'?8O)G(SS(6_VN]==26)
MH^Y"GS1LDM4G\[_H>;3C@\1%U*E7V<[MNZ;3OJK6UOZ_>;7_  4E:Z\??L _
M ;XT?%:!?^%@7D,=O->386XO+-[9Y&D<=6R4@DY^ZTS8QO(/P:.M>I?M8?M?
M_%_]L;Q]%XW^*5[!#!8PF#1=#TY62STZ(X+"-222[D O(Q+,0HX5$5?+1UJL
M%1G1P_++>[=ELKN]EZ&.:8FGBL8YPO:R5WN[)*[];'VE_P %+/\ DSG]E'_L
M0;G_ -)-*K7_ &*O$6C_ +=/[*&O?\$_?B3J\2^*/#\#ZM\+=6OYB/+*9/V<
MMM)VHS,I&&/D3.%4>2N/GK]HO]KC4_VA?A'\+_A/?>"(-+C^&6A2:;;WL5\T
MK7ZO%:Q[V4H/+(^S X!;[_7CG@?A3\3?&'P9^(VB_%3P#J36NKZ#J$=W9RJS
M!6*GF-]I!:-URCKG#(S*>":YXX.H\&H/22;:?9\S:^_KY,ZZF8T8YDZJ]ZG*
M,8R7=<L4_FFKKS2/KK_@LQIFH:-XB^$>B:I:M#=6?PWA@N(6^\DBN%93CN""
M*^8_C%^S?\;_ -GIM(3XQ_#R^T+^WM.6]TLW84B2,]5)4D)(O&Z)L.FY=RC<
M,]M^W'^VQJ_[;GC/1?&.K_#ZW\/MHNEO9K;V^H-<"4-(7W$E%QUQC!KN/@/_
M ,%2/''@7X8P_!'X_P#PAT#XK^%;'8--L?$^WSK94QLC\QXY5D1,';OC+KG
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M^++'Q<L":A:ZG>>7%Y4:2HT;)Y;K(KK,00>,<<YKT;_AYS\#R/\ E&]\+O\
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MOCE\*XX_"M\VM7&H:;:Z:J^38K*[-]G5=H5H@K>7M*[2O!&.*^BI_P#@IO\
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M7QUIMU*?#=]=FX;3;FUG\B94E;YGB9N5+?,<$_+D(F_\?R!^Q9\ \G^'Q/\
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MD7;^/6ND7J*XM7>-E=&*LIRI':NJTC4H]1MUD!&Y>)%]#6=1=3MPL].4] ^
M'PVTWXN_%O2/A[J^H3VMOJ#3"2>V WKL@DD&-P(ZH!]#72>&O!G[,?C[Q'8^
M"_#/C#QMIVH:I=QVUG=ZMI-I);K*[;4#B*;=AF(7(Z$Y/&32?L3?\G-^&/\
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MC_@WBT''_)UUY_X1J_\ R71_;.7?S_@_\@_U?S;_ )]_C'_,_,:G)TK]./\
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M5^A@_P""$^B@Y_X:8NO_  DU_P#DJG+_ ,$*]% Y_:6NO_"37_Y*JO[8R_\
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MBC^V,O\ Y_P?^1/^HG%'_/C_ ,GA_P#)'Q"G6G5]K3?\$B-+MY-H^/-P>/\
MH7%_^2*;_P .D-,_Z+O/_P"$ZO\ \D52SC+]^?\ !_Y$O@7BC_GQ_P"3P_\
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M"OXFZ5\1)M)^V/IS3?Z"USY7F;X7CX?:V,;\].<8]ZQXV!;.:^EO^'2NF?\
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MT#[0!J5U=_V?]JV_ZX2#;OVGIOZ[><=LUZC_ ,.O[G_HXF^_\$G_ -OIR_\
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M_P#PC/A[_H"VW_?D4?\ ",^'O^@+;?\ ?D4>T0>QEW/,:3:*]/\ ^$9\/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M] #X>06]ZY+Q+_R6_P )_P#8#UC_ -#L:Z]!A<8KD/$O_);_  G_ -@/6/\
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M--,)0%$]Y.\L81(PA />_P#@Z%\"GXH_LZ?LU_#,>*-4T/\ X2+]LGP;I?\
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MU6;?+);7[QWMQ-LN(%BGB5EQE+N7/O\ 6'_!5;]C#]L2_P#VGOA%_P %0/\
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MF^+&A^&=TFM>+O#/AN.*Q2W&<W*++)YRQ8!PTZ0]#Q@9.)_P=8?M/_$[1O\
M@B+X'FT2_CL9/B]XL\/V'BP6:LBO:/IUSJ<D,?S%E4W%K ,$G*!E.=QKS?\
M8Q_X.D_^")O[#?[,_A']F+X*?L[_ !NT_1?"VCP6KR0>"]%234+H1J)[V<IJ
M:B2>9P9'? +,QZ#  !^EO_!-'_@K5^QW_P %6OAKJ'CS]E_Q5?+J&AM$GB;P
MCXAM%MM5T=I-WEF6-7='C?8VV6)W0E67<&5E'G/_  4M_P""ZO[-W_!+3]IC
MX=_L^_M#>!]=:Q\=:;_:-UXPL'1K71;47#0R22P@--+MVEML2LS=%!) K\B?
MV7?^"EO[)WQ9_P"#GOX:_M3?\$]O 7B[P=X6^+\/_"/?$[P_KNFVNG?VGJEZ
MMQ'-/Y5I/-&T32IIUXY+!GN89)&&6W'Z._X.$/AYX*^+'_!P!^P[\./B1X9L
MM:T'6+[2K?5]'U*U2>VOK<Z]\\$T;@K)$X&UT8%64E2"": /3]1_X/#?V/M'
MFLO&.L?L4?'BU^'NI7QM=/\ '=QX?LXX+I@3GRU:Y$;\*S;5E+84_+D$5^H?
M[.?[17P:_:S^"7AW]HG]GWQS:^)/!_BJQ^UZ+J]GN"RKN*.C*P#1R)(KQO&X
M#HZ,K ,I =^T5\)O 7QT^ ?C+X-?$_P[;ZKX>\3>&;W3M6T^YCRDL,L+*1_L
MD9RK#!5@""" 1^7O_!ESK.L:I_P2G\966IZK<W$.F_';5K?3X9YF=;6$Z1H\
MICC!.$0R2RR;1@;I&;JQ) /I7_@II_P7^_86_P""8?CNS^"7Q"E\1>./B1>K
M"_\ P@7@&RBNKRS68 PM=/))'' 9 5*Q[FF8.C"/8ZL?,?V4?^#HS]B'X[?'
M[3_V8OCU\)_B)\#/%VL310:2GQ,TF.WLYYI2!#"\JOO@:3(VM+&D9Z>8"0#^
M37_!'+_@N!^P[^R?^U!\:OV]?^"@OPQ\=^,/C-\3/$TEUHFN>%_#]E>Q:'93
M-*]Q% UW>PO!O,B0A5!"P6\<:L%+*?3?^"Z__!?;_@DY_P %7?V);[X0^#?@
M'\3X?B=H>I6U_P##?Q1XF\+Z;#'I4IN(1>QM/!J,DJQ3VJR(T81D:1('9<Q(
MR@'[N_\ !0_]M+PG_P $\/V.?&7[8_CCP;J/B#2_!<5D]UH^DS1QW%Q]IOK>
MS4(TGRC#7"L<]E/>O@*#_@[B_9/\;V&C:7^SS^QY\:/B;XFO-#AU'7M#\'Z!
M'<+HC29_T:20,6DD7C<R1F(%@ Y8,%X?]K']I/Q-^UM_P9I2?'+QI=W5UK-Y
MX!\/Z9J]]?7#2S7MUIOBBRTV6ZD=N6>9[1I23SF0U]E?\&[OPW\#?#?_ ((W
M? V/P/X7L]-_MSPK_;&L26MNJ/>WUQ*[2W$K 9DD.%7<V2$1%'RHH !M_MN?
M\%H?V1/^">'[+W@G]HS]J0:_I>H_$#1;>^\-?#FQL5FUVY=X(I98?*=XTC\C
MSD6621T16(7)9E5OD_PQ_P '>7['>F^,=%TG]HS]D+XW?#'0/$3J=)\6>(/#
MD4EJT!Q_I+(D@D>( @DP+,V",*<U[Y_P59\3_P#!&#]DS]H'X8_\%#/^"B\F
MDVWQ*\(6MQ9_#0FUN=0OK\1>;,@6PA5UD%O+,\D5Q*JQV\\R-YJ.R5\ _P#!
M3?\ X.@_^"3?[>/[!_Q2_9.'P/\ C%=:CXL\*W,/AF;6/#.F16MMK$8\W3[F
M1TU)I$2.ZCA=BJ,=JL-K E2 ?KM^U]^W1X?_ &:OV-V_;,^&7PM\0?&#1YH=
M-NM%TGX;QB]N=7M+V2)8KFWV!A)%LE$NX9&SFOY_?^"2_P#P5UUO]E/_ (*2
M_M:_M&VO[!?Q<\<3?%CQM?:C/X1\*:,TVH^&3+K%]=>1?($)CD4S^400/GC8
M=J_7[_@V"\1:WXF_X(=?!&]U_4YKR:WAUZTBEG<LRP0Z_J,4,>3_  I&B(H[
M*H':OD[_ (-W?^4X/_!17_LJ>K?^I+JU 'U[_P %(_\ @L+\"OV)?V8O@C^T
M+^T!^REKWB*'XJWEC<Z3X8O+>U%YX=O7LTNE\];D82>+S3&2H#*P;I7VYXP\
M8>%/AYX3U3QYX]\2V.C:'HFGS7^L:QJETD%M8VL*&26>61R%CC1%9F9B H!)
M.!7XT?\ !Z'_ ,D$_9Z_[*K<?^DJUWG_  >2_'OQC\+?^"86@_"OPEJ4EK#\
M1OB39Z;X@,9QY^GV]O<7AA_&XAM6/J(R.A- %GQK_P '='[&DWC+7-(_9N_9
M0^-7Q6\/^&W)UGQAX9\,I'9) ,_Z0JR2>:L1 )!G2 \'(&,U]D?\$T/^"N7[
M&?\ P5:^']]XP_9?\7WT>J:)Y8\2>#?$5HMKJVD[\[&DC5W22-L';+$\B9&T
ML&!4>K?LE_LO?";]C#]G'PC^S%\$=!AT_P .^#]%AL+3R[>..2[D51YMW-Y:
MJ'GFDW2ROC+R2,QY-?C]^UW)X7_8$_X.Z_@GXG^ V@)X?M/CIX+LXOB1I^E_
MN;?6;S4[W4[&2:2-,+DRV=A=/Q\\\)E;+LQ(!]P_\%*/^"\'[-7_  2Z_:I\
M!_LV_M"^!M>-GXTT(:Q=>,;%T>UT>U^T30LTD(!FE8>2S;8U+-D!02<5\VWO
M_!X7^R#H]QI_B[Q%^Q-\>=.^'NJWGV;3?'5YX?LT@NFR>8U-P$? 5F*I*S84
M_*2,5Y/_ ,%\/AWX*^+/_!QK^Q/\._B-X:L]9T+5(=%CU32-2MDFMKV$:]<L
M89HW!66)]NUT8%64E2"":_8S]K7X0^!?CW^R_P#$#X,?$O0;?4M"\2>#]0L=
M1L[B$.I1[=\.,CAT;:ZL.5=58$$ @ TOV??V@/@[^U1\&/#O[0GP \>67B;P
M?XJT];S0]:L&.R>/)5E96 :.1'5XY(G"O'(CHZJRLHZ+Q5X1\*>.]!G\+>-_
M#&GZSI=UM^TZ;JME'<6\NU@Z[HY 5;#*K#(X(!ZBOR?_ .#,'Q'KNM_\$HO%
M6F:OJ]S<V^C_ !PU>TTN&>9G6T@.EZ3.8HP3A$,L\TFT8&Z1VZL2?UPH ^/?
M^"L7[,7[-?AW_@E[^T5K_A_]GKP/8WUE\$?%$]G>V?A.SBF@E72KAED1UC#*
MP(!# @@C(KY]_P"#7W]GOX!>/?\ @BW\+_%'CKX'^#]:U.XU3Q")]1U;PS:W
M,\@76KU5#221ECA0 ,G@ "OKK_@KU_RBF_:3_P"R%>*__33<U\Z_\&J'_*#_
M .%/_85\2?\ I\O: /NJUT?X*_LZ^ =6UW3]'\,^!_"^F6\^JZY=6]K;Z;8V
ML<<6Z:ZF90D:!8X\M(V,*G)P*_,;Q]_P=U_L5+XWUSP_^S=^RY\9OBQH?AG+
MZWXO\,^&XXK%+<9S<HLLGG+%P<-.D.<'@#DV?^#Q/XX^._A-_P $H+'P3X*U
M1K2W^(?Q/TW0?$31DAI=/2UO+\Q @C&Z:SM\]B@92,,:\2_8P_X.D_\ @B;^
MPW^S-X1_9A^"O[._QNT_1?"^CP6KR0>"]%CDU"Z6-1/>SE-4423S.#([X!9F
M/08  /TN_P"":'_!6G]CO_@JW\-[_P =_LO^*KY=0T-HT\3>$?$-HMMJNCM)
MN\LRQJ[H\;[6VRQ.Z$JR[@RLH_.K_@N;_P K&G[!?_86TK_T^U\K_LO?\%+?
MV3OBS_P<]_#7]J;_ ()Z^ O%W@_PM\7H?^$>^)WA_7M-M=._M/5+Y;B.:?RK
M2>:-HFE33KQR6#/<PR2,,MN/U1_P7-_Y6-/V"_\ L+:5_P"GV@#]F/'WCWP7
M\+/!&K_$KXC^*+'1/#^@:;-J&M:QJ5PL-O96L2%Y9I';A455+$GH!7Y6>+O^
M#O#]CB?Q/KD/[/O[(_QN^)?A?PS(W]M>--!\-Q164<(R?M 623S$C(!(,ZPG
M .0*Q/\ @\O^/GBCP7^P;\/OV:?"VJW%FOQ3^)$2ZXT3#R[K3["+SOL\@(Z?
M:Y;*88(.;8=1FOU*_9G_ &<OA-^R1\!?"O[-_P #O"EKHOA?PCH\=AI=E:PJ
MFX*,O-)@#?-+(7EDD.6DDD=V)9B2 >3_ /!-G_@JY^QW_P %5/AA>?$7]EKQ
ME>-=Z-)''XF\):_:K;:MHKR!C'Y\2NZLCA6VRQ/)&Q5E#;D=5\C_ ."CG_!?
M;]E__@F%^V)X1_92_:+\"^(%M?$W@U?$ESXST]DDM=.MVFO81&T S+)(7LB
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M::IXJTZULY-0L9=:LQ;0I]FNYPZA+C4$?=M)6<+\PX7]'?\ @[9_Y0V>)/\
ML=M!_P#2FCH&Q@W/_!VG^RYXSO+71?V7_P!C#XW?%K4(]%L;WQ /!OAM9(-*
MGG@$CVA;)D=XGWQ,_EK&S1L8V=<,?N3_ (* ?\%+?V4_^"9WP'C^/G[57B^Y
MT^TOIOL^AZ#I=L+C5-8NMF\V]M"64,P7EG=DC3(WNNY<T?\ @D1\/O WPR_X
M)>?L_P#ACX>>%K'1[&3X0^'[Z:UL+=8UDN[K3X;FYN&"CYI)9Y9978\L\C,>
M2:_+W_@Y;CT[0/\ @LQ^P_XY_:3^P_\ "E(=?L8]1?7A'_9<$R:[;/J3W7F_
MN_(^SM8M*'^4Q1MD$ BI*-3]J+_@\&\,Z9^SAX@U[X*?L1_%CPGX@\1:/)%\
M+O&/C;1+;^R)KI@ +A_WNV01J6D"QF4,RJ&^4DCZN_X(:7?_  6)^(WA_P#X
M:,_X*#?MF_#CXJ?#7QSX(LM1^':>";"TAFMKB5ED9YOL^EVF"(R8V0N^UU8$
M @FO3/\ @M1\6_V64_X)(_&Z\^,GCCPG=:#X@^%^JP>&UOM0MY8]2U5[21]-
M%KDD2S_:A!)$4R5=%<8VY'PS_P $MOB_\>?V+O\ @TI\6_'G5-6O-/U"Q\,^
M++SX8S0(8[C2H;N\FM[2X&Y>U_+-=*2"&21"#@B@#Z&_;5_X.;_V(/V5OVA[
MW]DSX5_#CQ]\:OB#I=Y+9ZQI/PUTN.XM[*\BSYMH97<-+-'AMZPQR*A5E9E9
M64=E_P $UO\ @X3_ &'/^"DOQ4NOV=?#MCXH^'?Q/MO.\GP+\0M/CMKC4#"I
M:=;62.1TDDC56+0OY<V$=A&51V7\F?\ @@U_P7@_X)._\$FOV.$^''CSX%?%
M*\^*?B35+B^^(7BCP[X7TN>*]VSR+96\4\U_%*8(K;81&RA5EEN& ^<D\%_P
M7$_X+??L*?MT_$GX._M<?L(_#KXA>#_C?\*_%4=TOB?Q/X;TVTCO;",B>!)9
M+:\GDG:"YB0QHP"!+BY!/S8(!^@/_!V#_P % -3\&?LI_$#_ ()_Q_LL>/M0
MMO%?AKP_JDGQ4L]/9O#^F%==@F^SSS;<+(39A -P^:XC]>;_ /P;W?\ !6+6
M?B%\(/@1_P $_)?V&?BQI-M8^!S9#XJ:AH[+X?F%I9RSB59MF"DOE[$.>6=1
M7NO_  <^W/VS_@A5\:KS9M\ZW\,/CTSXETHUZ=_P0V_Y1"?L\G_JF.G?^@52
M)D9/PW_X*8? ?QK_ ,%B_'W_  31TCX W=G\0/"/@VWU+5?B$8[7R[^U:TT^
M[6W# ><0HOXQACM!C8CM7-_\%&O^"\G[,_\ P3'_ &N/!O[+W[0_@C7EM/%G
MA==>NO&5BR/:Z7:F>ZAP\(!FE?-J<*BDL74#FODW]FS_ )7.?V@/^R0V7_IC
M\-UR?_!;+X<>"/BU_P '-?['?P_^)'AFSUK1+_PWHYU#2=1MUFM[I8]9U241
MRQL"LB%D7<C JPR"""13$>K?\1@/[(6A7^F^*_%_[%7QXTCP#K%UY&E^.+WP
M_:+#<\_>13<;)  "Q"2LV <*2,5^J7P'^._PB_:<^#WA_P"/OP%\=V/B;PAX
MJTU+[0M;T]F\NXA;((*L T<BL&1XW57C=&1U5E91Q_[9_P &_ W[0/[(7Q.^
M"_Q(T2WO]%\1> ]4M+N"YMTD"$VSF.9 P($D<@22-\91XT9<%01^?'_!FEXL
MU_Q'_P $EM;T?6-3FN+?0?C-K%AI,4DA9;:W:QTVZ,: _=4S7,SX'&Z1CU)J
M9%1/6_V_?^#D3]B?]A[]H"3]DSPSX&\<?%[XF6LGDZGX9^&^FQ7*Z?<;=WV:
M65Y%W3[3DQPK*4PP?8P*U\/_ !A_X.$OV]/^"EO[8OP__8B_X)5^(K;]F_Q-
M=6=\OB+_ (7AHMD)M0U1%,B6"F2UO1'B%"R#R8Y))'93T0->_P"#4K7O"/P]
M_;H_;%\"?M+ZYH]C\<;KQG!%.NN7,$>I7PCOM4.IK;>81(ZBY\AY@GRDFW9L
M[5(N?\'*FJ^!OBW_ ,%8_P!B7X?_ +*^OZ'>?''3?'4::E<Z3Y=Q=Z7#_:FF
M3:8;TQAF6**07UPJOPB><Y 5R2AG[#?L>>'OVFO"G[,?@WP[^V5XZTGQ-\4+
M31U3QIKV@PI'9WMYO;,D2I! H7;M'$2#CI7+_M_?\%"OV7?^":GP,F_:!_:F
M\:R:;I9N/LFE:;I]O]HU#6+PJ66VM8<C>Y5226*HH&7=1S7N2]*^-?\ @L+X
M3_X)%Z5X3^'O[2O_  5D?08=,^&_BHW7@A]86YN&NKR7R_,M!8VRN^H1.88)
M)(3%(F(%:3$8?()JY\EVO_!X+^R?IW]E^+?B)^P_\>/#O@?6[E8M*\:7F@VC
M6]QG/S*//5)  "Q$<CM@' )&*_4CX ?'_P"#_P"U)\&_#_[0/P"\>6?B;P?X
MHL!>:)K5@3Y<\>XJRE6 :.1'5HWC<*\;HR,%92!^1_[3W_!VI_P1_P#CU\$O
M'7[/?B;X+?&;7-'\5>&]0T6X\SPCI@MKF.>%X@XWZDLB#+!@VT.I ( (KL_^
M#,;Q3XD\0?\ !*/Q3I.MZW=75KH?QOU>QT>":4LMG;-I>DW+11@_=0SW$\F!
MQNE<]2:LR<?=N>P?\%@_^"[?[%W[!VOP?LK:U%XB\=?%*\O-+NI/!?@>QCN9
MM.7[3!<PK=.\B+%)*B@I"N^4B2-B@21&;XF_:K_X.5?VM/VQ_C7\*_V(_P#@
MG-IEU^S3\0_$OB:>S\6:Q\=/#]H$CD>&/^S;2-I8[H1K/(TROOM YD^R!'56
MESB_\$\O$GP]^&/_  7G_;G\+_M.:G#I/Q*UWQC=2?#<^++C9=76E-X@6[$-
MH\Q^8/8'3IHXE.XVT64'EQMCT;_@\>\6? _XB?#+X%_ CX<ZAI^M?'ZX^)D<
MGA'2=#D\[5K?2I[>6&51Y9S")[W^SA&'VF5X&\O/E2;4%EHC]1OV-KG]I_X
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M],>AU^OL\,5S"]O<1*\<BE9$89#*1R#7$? ']F7]GG]E3P=<_#W]FGX*>&/
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M.,CAD!ZBK'PV^&GP]^#G@72_AA\*/!6F>'?#NBVJVVCZ'HUFEO:V<(Z1QQH
MJ*,G@#% 'X1_\%3=2^$WP-_X.H/AM\:_^"H-CIUY\#[[P-;+X)O/$6C->Z38
MQQV-U$B3H$=7\K5WEG8$-Y7VJ&5PJ$-7TU_P6:_X+5_\$HO!O_!.;XH?!+X%
M_'/P/X^\6>/OA]J7AOPSX<^'<\-X(#>VSVS7,LMNK0VR0)(92KLK,(]JC)R/
MT4_:B_8\_9>_;6^'3?"G]JOX&>'?'.A[F>WM=<L1))9R,I4S6TPQ+:R[25\V
M%T< D;L$UY=^R9_P1I_X)A?L.Z_=>+OV9_V.?"^AZS=1O&VM:BUSJ]]#&\3Q
M21PW&HRSRVZ21NZ.D3(KJQ#!A0!\F?\ !I[^UU^S?XU_X)B_#O\ 8]\+?%C3
MKSXE^#]/U_5/$WA&)9?M-A9R^(;MXYG)0)M9;J C#$_O1[X^1?\ @DI^WE^R
M'^PA_P %J_V_-=_:[^.>D^!;3Q%\6];@T6;5XYB+N2/Q'J;NJ^6C=%=3SC@U
M^V'P(_81_8K_ &7/&-_\0?V;/V4/A[X!UK5+%K/4-2\'>$;3399[9I$D,+&"
M-?W>]$;9TRHXX%9/QC_X)I_\$]/VA?'UY\5OCE^Q'\+/%GB?4O+_ +2\1:]X
M%L;F]O-D:Q(9IGB+RE8T1%+$D*BJ,    _+;_@\>\2:)XQ_9B_9K\6^&M1CO
M--U3XD->:?=QYVSP262.CC/."I!Y'>OI'_@Z>_87^)/[;'_!,&ZOO@UX?N-8
M\3?##Q1;^+8='L83)<:A91P3V]W%$@Y9UBN/M&T?,PMBJ@LP4_;OQ@_8Z_92
M_:"\*:!X%^.7[.G@WQ=HOA5T?PUI?B+P_!=V^ELL8C4P)(I$1" *-H&  *])
MQ0!^?_["O_!QO_P3-_:=_9ET'XG_ !=_:I\%_#GQI%HL/_";>$?%FI+ILMGJ
M2QC[0MJ)F_TJ!G#-$T3.Q1E#!7W(OQ7\(O''A+_@NK_P<N^%?VQ/V;/#]_>?
M!G]FWP9:V=]XVNK:6*'6;R&34)[1HEDC5HF>[OCLC?YFAL))#MW!%_1K]H7_
M ((-?\$B/VI?B/-\6_C+^PWX5N?$-U/)/?ZAH5U>Z+]NGDD,LD]S'IT\"7,S
MNS,TLJN[$G+&OH[X*? ?X*?LW?#ZT^%'[/\ \)_#O@OPU8LS6NA^&-'ALK5'
M;[\GEQ*H+L>6<Y9CRQ)YH _';_@M8?\ CIH_8:_ZYZ/_ .GNZK]F?B9_R3?Q
M!_V [O\ ]$M7->/_ -D_]F7XK?%OP[\?/B9\!/">O>-O"/E_\(OXLU;0H)]0
MTK9(TJ?9YW4O%M=F8;2,$DUWMY9VNH6DEA>VZRPS1M'-%(N5=2,$$=P10!^0
M_P#P96?\HL/'G_9?M5_],FB5^OE</\ ?V9_V>?V5?!MQ\//V:?@IX8\!Z#>:
MD^HW6C^$]%AL;>:[>..-IVCB55,A2*)2Q&2(U'85W% 'SK_P5Z_Y13?M)_\
M9"O%?_IIN:^=?^#5 _\ &C_X4_\ 85\2?^GR]K] /''@CP?\3/!FK?#KXA^&
M+'6M!U[3IM/UK1]4M5FMKZUF0QRP2QL"KHZ,592"""0:RO@U\$/@]^SM\/;/
MX3? ;X8Z'X/\,:<\KV'A_P .:;'9V=NTLC2R%(HP%4M([,<#DL3WH ^$/^#H
MS]AWXF_MO_\ !+34[+X-:+>:MXD^&_BFT\96>@Z?!YD^J0007-M<PQKU9U@N
MY9PJY9S;A%!9@#%_P3O_ .#A+_@EE^TS^RWX:\8?&C]H/P'\-_'=AH-O#XX\
M+^,Y8M+:#48XPL[6AF)6Y@=U9XC&[OL=1(J.&0?HZ1GJ*^1_VCO^"$'_  2,
M_:P^(4WQ5^-G[#OA6Z\074TL^H:EH-S>:(U_/+*TLL]R--GMUN9G=F9I90[L
M2<L: /$/V+?^"V8_X*$_\%8-7_9D_8C^ 6F>+_@#X1\&M/XM^,#6,]C+8:ON
M<Q2PF1=LUO*P6VCMVCCF=EGN4=H8&5_ES_@XE^(O@OX&_P#!=[]B3XX_%G7$
MT/PEX?N+.]UC7KR-_(MH+?6A),Y*@D[$96( ) 8<<BOV5^ O[-_P"_9:^'\/
MPJ_9P^#?AOP/X=MY/-72/#&CQ6<,DNQ4,T@C4>;*RHNZ5]SMM!9B:H?M!?LB
M?LK?M8V.G:=^T]^SCX(^(,.CM(VD+XQ\+VNHFP:39YAA,Z,8M_EINV$;@BYS
M@4 ?FS_P<A?!/3/^"JO_  2&\._M>_L-ZI:^.H_A]XF_X2S2=0T>&9I=2T9%
MN+/4%M8R@+/'((IV# 92RDVY8JK>[?L<_P#!QC_P2X_:2_9QT7XM?$/]K'P9
M\/O$JZ1$WBWP?XNU9;&ZT^^$8\^*%9L&[CWYV/#OW*5R%;<B_:7PH^$?PN^!
M/P]TWX2_!CX?Z/X6\,:/&\>E:!H.GI:VEHKR-(RQQ1@*@+N[' Y+$]Z^8OCM
M_P $#?\ @C]^TC\29/BW\5OV%?"LNO7$S37EUH5W>Z-'=S-(9'EG@T^>"&>1
MW)9I)$9G).XF@#\^_P!EGX@Z;_P6[_X.5--_;^_9_P##-W<_!#]G/P1_8MMX
MNU33Y8HM=N_*U 6WE)(JM#(;G4IIT5@6$-DK.(VE5!K_ /!4PY_X.U/V.<?]
M$^L/_2_Q!7["?!WX)?!W]GGP#9_"OX#?"SP]X-\,Z>7-GH/A?1X;&TA9V+.P
MBA55W,Q+,V,LQ))))-8_C']E/]FGXA?&K0?VD/'?P'\)ZQ\0/"]JMMX<\9ZE
MH<,VI:9"K2LL<%PREXU#32D!2!F1O4T <3_P5)_Y1D_M&?\ 9"?%W_IENZ^)
M_P#@SV/_ !I]A'_53M<_]!MJ_3SQCX/\*_$+PCJO@#QUX>L]7T/7--GT_6-)
MU"W6:WO;6:-HY8)48%71T9E92"""0:Y_X&?L\_ G]F/P./AG^SO\(?#O@GPZ
M+R2Z&B>%])BLK43R8WR>7$H7<VU<G&3@4 ?D;_P7L_Y3\?\ !/G_ +'+3_\
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M%D"I*-*%B8HS*SE217DW_! #X^_\$"[K]E2\\$_\%(/#_P *Y/CY-XPU:_\
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MX>Z>^HKJ9B(M9$O].M@MELF,;EGE0%$<8DR8V9+[:GM?_!SU^R#XD_X*$_\
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MQDUV_P#PHCX+'X.Q_L\S?"7PW-X"AT5-'C\%W&BP2:7_ &>D8C6T-JZ&(PA
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M** .'_:#_P"1(TS_ +'CPU_Z>K*NXKA_V@_^1(TS_L>/#7_IZLJ[B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)&F?]CQX:_\ 3U95W%</^T'_ ,B1IG_8\>&O_3U95W% !1110 4444 %%%%
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MU'_Y/JO[#Q_9?>3_ *Q9;W?W'Z_45^0/_$0!^V1_T33X9_\ @FU'_P"3Z/\
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MR[+[P_UDRSN_N/U)HK\NT_X+7?M4MU\!?#__ ,%=]_\ )E2+_P %J?VIR.?
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MN?\ >H61HWW"OAU?^"D_QT)Q_P (OX4_\ KK_P"2*F3_ (*/_')AD^&/"O\
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M#_Y$C3/^QX\-?^GJRKN*\?\ B%?WU]H=K#>7LTRKKFFR*LDA8!EO865N>X8
M@]B 1TK=.M:R%P-7NO\ P(;_ !H]F'M4>AT5YTVMZT/^8O=?^!#?XTG]N:U_
MT%[K_P "&_QH]F'M4>C45YNVN:WU_MB[_P# AO\ &F_V[KG_ $&;K_P(;_&C
MV8>U1Z517FIUS6^VLWG_ ($-_C2?VYKG_09O/_ EO\:/9L/:H]+HKS%]>UT'
M UJ[_P# AO\ &F_\)!KV?^0W>?\ @2W^-/V3%[9=CU"BO+_^$@U[_H-WG_@2
M_P#C1_PD&O?]!N\_\"7_ ,:?LGW#V\>QZA17E_\ PD&O?]!N\_\  E_\:/\
MA(->_P"@W>?^!+_XT>R?</;Q['J%%>7_ /"0:]_T&[S_ ,"7_P :/^$@U[_H
M-WG_ ($O_C2]DP]O'L>H45Y?_P )!KW_ $&[S_P)?_&C_A(->_Z#=Y_X$O\
MXTO9^8>WCV/4**\O_P"$@U[_ *#=Y_X$O_C1_P )!KW_ $&[S_P)?_&CV?F'
MMX]CU"BO+_\ A(->_P"@W>?^!+_XT?\ "0:]_P!!N\_\"7_QH]GYA[>/8]0H
MKR__ (2#7O\ H-WG_@2_^-'_  D&O?\ 0;O/_ E_\:/9^8>WCV/4**\O_P"$
M@U[_ *#=Y_X$O_C1_P )!KW_ $&[S_P)?_&CV?F'MX]CU"BO+_\ A(->_P"@
MW>?^!+_XT?\ "0:]_P!!N\_\"7_QI^R8>WCV/4**\O\ ^$@U[_H-WG_@2_\
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MNB:8/&NU&/R;LX#E5/+KGYO;..*].C6I5X\U-W1Y-:A6P\^2I&S"BOH+5/\
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M_P"2AZ+_ -@Z^_\ 0K>MT5A:M_R4/1?^P=??^A6]!F;C_=IE/?[M,H ****
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MUY5HG_!3O]C#QYJ;^#M*^*[6]U>*T-K-J6DW%M!(Y!P/,= J9]7*C\Q7"?\
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MVM[+NV>9?\%(_"7A_P"-?_!6J\^&'AF[2-O$'B'P_HE]=JX9!<RP6D#-P?X
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MI ? ?_7/6/\ TSWM=&,_W.I_AE^1A@/]^I?XH_FC:\6&/]M#]C>T^),#>?\
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M./\ Q]JUJR/ G_(JVO\ VT_]&-6O7++XF=T?A04445)04444 %%%% 'YB?\
M!=O]C?4O[5L_VS/ NF>9:M!#IOC:.%3NB=2$MKP]?E(*P,>-I2' .YB/S6!S
MS7]+'B#0-$\5Z'>>&?$NDV]_IVH6LEM?6-Y")(KB%U*O&ZMPRLI((/!!K\F_
MV\_^"+/Q*^%NK7WQ,_9.TB\\4>%YIC))X6@#2ZGI8/\ #$O+7<0/ VYE 905
M?:TE?491FE/V:H579K9^7;_(^-SS)ZOM7B:"NGNENGW\[]?ZMY5_P4^_:N^$
M?[5WC3P-KGPDN[Z:WT#P;'INH?;[$PD3B1F(4$G<,$<U\P8]JEOK*]TR\ET[
M4K26WN()"DUO/&4>-AU5E/((]#46<]*]^C2C0I*$=D?-XBM4Q%9U)[L^D/A+
M^T_\+/!O_!-?XI_LO:U<WR^*O%GBBQOM'CCLRT#0Q3V+ONDSA3BWDXQZ>M:?
MA3]K;X1?";_@F1K7[-'PZN]2D\?>._$1G\63-:F.&UL]X&Q)<?O 8K>)"GK<
MR\\<_+E%92PE*5[WUES?-6_#0VCCJT;6MI%PVZ-N_P ]6K@.E?5'A;]K7X,^
M+_\ @F'K'['OQBNKU/%&@Z\=2^'MTFGM-#$-XEV,X8;6;S;R+)!"K.#CY:^5
MZ*TK48UK<W1IKU1C1KU,/S<O5-._9GZ!_P#!/7]J/_@FA^QMI]K\1E\6>/F\
M:ZOX5AL/%%O/IRSV4<Y,4DP@"HK8$B8!+'Y?7K7C6BZY_P $YOA?^V;\._'G
MPR\2^-KKX?Z#(NI^(9-=LTDNC?P-));QQHL:AHC(MOO!'*E^0<5\PT5A' PC
M4E/GE[RL]?\ @=.AU2S"I*G"')&T7=:>C?7K;4]5_;;_ &@Q^U)^U%XM^--H
M91IVHZAY6BQS+M9+&%%A@RN3M9D0.P_O.U,_8L_:!;]E[]J#P?\ &B=I/L&F
M:H(]:CC0L7L)E,-SA01O81.[*"<;U4GI7EM%;^QI^P]E;W;6^5K'+]8J_6/;
M7]Z]_G>YZO\ MO\ CCX-?$_]J+Q9\3?@+<73^'?$5\-2C2\LV@DCN95#7(*G
ML9O,<8XPX':O*#115TX>SIJ"Z*Q-2HZM1S?5WTVU/M[_ ()9?M<?L6_LH?#7
MQ+JGQ;&L:=\0M9OYK6U\1:3HHNYK33/)B\M83(&C1O.\UR-A#E8]X<*H$7B4
M?\$6O&7B"\\6>+OC!\<-2U34;E[B^U"^\J2:XE8Y9W9K<EB3W-?$U%<DL#!U
MI5%.2;WL_P#@'9',:D:$:3A%J.UU^.^YZI^UAI_[(&G^+-+C_8[UWQ9?:0VG
ML=6D\6(BRK<^8<!-J)\NS'8\U],:;^UK^P?^W-\)_"O@K_@H7=^)O"OC;P=9
MBS@^('AV%I6U2V"@8E*Q3MN8@,RO$P#[FC=!*Z5\)T5I4PD*D(IR=X[.^OW_
M / ,Z>,G2J2:C&TMXV]W3;2_ZGVY\6/VP?V,_P!F+]FKQ1^S!_P3VBUS6KSQ
MQ$UMXK\?>(K?9)-9LKHT2B2*-F/EO)$H$,:H)&<%G):O)/\ @FO\7/V8?@5^
MT7_PM+]J+0YKZQTG2'E\-^58-=?9]4\Z+RYC&" 2L?G;2P(5BK !U5E^?J*F
M.#IQHRIW?O;N^K^8Y8ZM*O"I9>[LK>ZOEZZ]S] _VA_C'_P23_:E^)UW\6?C
M'\:OC3J&I7 $=O#';PI;V-N"=EO!']G(CC7)XY+$LS%G9F/SY^U/H_\ P3?T
M_P"'UK-^R)XL^(5]XF.L1K=P^*HXUMA9>5+O9=L2'?O\K'/0MQ7S_111P<:-
MN6<K+I?3\AU\=+$<W-3C=];._P!]SZ<^!.@_\$G;SX4Z/<?M!^-?BA:^,6AD
M_MRWT&&(VB/YK[/+W0L<>7LSR><U[]\>OVB_^"0_[1?@;P#\/O'OCCXH16/P
MYT$:3H+:;IR1R20"*"/,Q:)@[[;>/E0HR6XYX_.6BIJ8&-2ISN<KJ[6NU^VA
M5/,)4J3IJG&S23TWMWU[ZG>?M(6?[.UC\4KBW_9;U7Q!>>$1:0FWG\3*HNC-
MM_>@[44;=W3CI7!T45V1CRQ2O?U.&<N>3E:U^BV/K+_@E)^T?^R'^RYX[\1_
M$[]H[1KN;Q!'#;0^#;^VTMKHV2L)A=,HSM1V'DJ'QN"EU! 9PW<?%+Q7_P $
M>OC5X^U+XH?%+XW?'#6=<U:?S;V^NH;?+'H%4"V"HBC"JB@*J@*H  %?"M%<
MD\#"=9U5*2;TT?3[CNIYA4IX=47"+BM=5U?5Z_+T/:OVL]+_ &#=.L-%;]C7
MQ+XWU"Z:>?\ MY?%T<:JD>$\KRML:<D[\YSVKVCX(?MB_LC?'_\ 9ET/]D?_
M (*$Z?KEBO@^0+X-^(6@0^9<65L.!"^U)&7"!8L"*5'1(RRJ\2.?BVBKGA(U
M*:@Y.Z=T[ZI^OX&<,;4IUI3C&-FK.-O=:]/QWO<^]K7]K'_@G_\ L"> O$EM
M_P $_=3\2^,OB!XFL6LX/&WB2SVKI,) X42V\(;:X$@00D.X7S'*HJU\(Q%B
M<LV2>2?6JXZU8B[55##PP]VFVWNWJV1B,54Q'*FDE'9)62OO]Y/%_6O8/V&?
MCOX1_9G_ &H/#/QL\=Z;J5WI6C+?K=6^DPQR7#>?87%NFU9'13AY5)RP^4'&
M3@'Q^+^M6(OZUT3IQJTW"6S33^:,*=25&I&I'=-->JLRQ%_6IXNO2H(OZU/%
MUK5&9[%^UE\>?"'Q[U/P!=^#]-U*V7PK\+](\-Z@-2AC0R75J)?,>/8[YB.\
M;2=K'G*BN\TKXY_LS_'OX$^%_A7^U!-XFT'Q-X%LVT_P[XR\.:=!>)=:;OW)
M;74+,C'RA\J;3TY)R6#?-,7WJL1G!K#ZK3]G&*NN79K=?U<ZEBZOM)3=GS:-
M/9[?Y=-3Z4TW]H+]ESX7? 'XE? ?X3>'_%U]-XRTW3XH_%&M06ZO=7$%SYC!
MH4EQ;6ZJ"4"^;(S2-O8 (%YG]B_X\?#WX$^-?$TGQ5T36;SP_P"+O ^H^&M4
M;P^T7VRWBNC&3+$)B$9AY>/F.!NSSC:?&8CS5B+[OXU4<)2]G*#;?-J]=;V2
M_07URK[2$TDN71*VEKM_JSU#PS\0/@]\*/VIM!^)WPFLO$UUX/\ #_B33M1M
M+?Q%]G_M.2*%HI)E?R2(MQ=9-N"!C;GG-:_[4?B?]E?QKXD;QG^SW%\0(]2U
M?5KR]\01^,EL5A4ROO46XMB6&&9\AR>-O)YKR*,\"IX>#DUK]7C[2,[NZ5M]
M_4CZQ+V<J=E9N^VS\NQZ?\3/C'X:\;_ #X6_"K2K"^CU#P3;ZQ'JTUQ&@AE-
MW?&XC\HARS (<-N5<'ID<U[CXHUGX/P?L-? 'PY\;- U232=0_X2IH]8\/LG
M]H:;,FI?*R++^[FB;>1)$=K':C*ZE"K_ ".AP*]'\?\ QV/C[X#_  [^"7_"
M*_9/^$!_M;_B:?;O,^W_ &ZZ6?\ U>P>5LV[?O-NZ_+TJ*V%YG34;V4G)Z[7
M4M?O?](WHXKE]I*=KN*BE;1V<-/_  %?TSU'P9\7OV5_V7+"X\:? "[\4>+/
MB%)9SVVDZ]X@TV"SL=&\U2AN(X SM).$+ ;B4.[G'(/!_LE?&#PY\!OC]H/Q
M4\7:9>WFFZ:+I+RWTW9YY2>TFM\IO(4D>;NP2 <8R*\R3I5B+K6T<)3Y)QDV
M^=6;;UMM;RW=K=S)XNISPE%)<CNDEI?37SV6_8](/Q'\%?"#XZ:?\3?V7+GQ
M!%8Z+-#<::?%ZP&Z>0+B5)1;$(8VRRX!!*L>0:[_ ,2WW[!7Q1UUO'SWOC;P
M)<7C_:-8\+Z;I-O?6JRG!=;.7S$,:$YP'7"EN%50%'@$9JPG6KEA8RDI*332
MM=/5KSZ/[M.@HXJ44TXIIN]FM$_*VJ^_7J>C_'+XH> ?'#Z+X2^$W@/^P_#/
MAFRDM]-:^\N34;YI'WR7%U,@^9V;D("4CY"8!-</'_2H$ZU8@Z_A732IQI4U
M&/\ F95*DJLW*7^1]+_#3XM?L*>#_@YX@^%U_9?%J3_A,K/31XBFABTL^5-:
M2^</LQ+C:AD)'SJQ*XZ'FO,/"WC#X8_#W]HG1/'G@F#7I?"NB>*+&_MX]46$
MZ@]O#-'(X81D1ESM;&"!TR1R:X"/H*GC/-8TL'3IN;YF^;>[OT2_))&U3&5*
MB@N5+EVLO-O\VV=5\6O&&F_$'XM>*?'NC03Q6>M>([V_M8[I561(YIWD4.%)
M 8!AG!(ST)ZUT7CKXJ>'_%?P*^'OPOT^SO(]0\*3:PVHS31H(9!=SQ21^60Q
M8X"'=N5<'&,]:\[B(SUJQ$1Z]ZZ/84_<7\NWW-?DV9>VG[_][?[T_P TCVGP
MG\7?@_\ $+X2Z7\(/VA;/6K>?PTTR^%_%>A*DTL$,IW&WN(I&'F1JW*[3N "
MJNT EM_X2?&+]FO]GKQ:=2\%VWB?Q ]UIMU:ZEKE]8V\3(KPNJ1V]OYAVY<Q
ML\K/N CVJ,,P;Y_C(QC-6(ZQEE]&I&4;OEE>ZOI=[^:UUM>U^AO''58RC))<
MRM9VUTV\MM+VO;J>C?LM?%;P]\$_CIH?Q/\ %5G>7&GZ;]I\^'3XT:9O,M98
MEVAV5?O2 G+#C/7I6/\ "KXC>(/A)\0=+^(OAAH_MFEW!=(YD#)*C*4DC8?W
M71F4XP0&R"" 1S,72K$?6NOZO1G.4I*_,E%]FE?_ .29C&M4C&,8NW*VUWN[
M?Y(]FU ?L5^*M5_X2P:IXV\.QSN9;[PS9Z?;W 1B<F.VG+J%0=%WJ3].E54^
M/^C>&?C=H?Q-^%GPZLM%TOPTL<&GZ6@437< #+(UQ* =\TBNX+X.T%0-VW<W
ME:=:L1=*SC@:>TY2DK-6;NK/?UTTN[OS-)8RI=."47=.Z6MUMZ>BLO(]@\0)
M^QWK6MW/C"S\0^.;6&ZD>>3PZNFVQD5V))1+@N55 3@$JS #G)J7XH?%KX/_
M !1^%^D63^'M>TWQ-H%G]ATFUM7@;3$M1<%E5V8^<[K$=N[&2PR<Y)KR!/O5
M:B/%5' 04HR<Y-Q=U=[:6MMK?K>[\P>,FXR2C%<RULM_/?2W2VGD>N?"_P")
M_P %&^"4WP:^,FG>*1"OBC^V;6Z\,_9MQ;[.(=C^><  9/ .<CD8YR?@U\1/
M"?PR^(M]XBEMM2FTR33;^TLU5(VGQ-$R1%_F5<C(W8/K@&O/XB.N>U68OZ5I
M]1HM5(W=I[J^FN]NUR?KE3F@]+PV=M=-KG6_"3XE7WPK\7KXC@TR'4+6>UDL
M]6TNY_U=]:2#;)"Q[9'(.#@@$@C(/8"S_9$DU#^WDUOQM'9_>_L#[#;F4-_<
M%QOV[,\<KNQWS7E<9YJPE:5,)&I4]HI.+:L[.UUY[[=U9^9-/$RITU!Q4DM5
M=;/^NFWD=9\4OB1=_%#Q.NMMI<6GV-G9Q6.CZ7 =R65I$"(X@V,MC))8]2QQ
M@8 O?%KQYI'Q U;1]0T>VN8DT_PU8Z=,+I%4M+#'M8C:Q^4GH3@^H%<;$>*F
M0\CGM6U/"T:?)RJW(FE\[?Y$RQ%6?-S/XFF_D=KX,\?Z/H/PE\8> KRUNFO/
M$$FG-9R1HIC3R)G=]Y+ C(/& >>N*O\ @'Q#\(;KPR?!OQ0\,WD+)<//9^(M
M#V?:4+*!Y4J/Q)'D CD$<XQN)K@XCE<#TJQ']X?2E+!TI<]FTY-2NG9W24=/
MDEIL5'$U(N-TG96LU=6NWK\WON>HV/C+X2?#+P[JL'PVNM8UC6M8TZ73Y-0U
M*UCM[>VMY,;RB!F8R$#&20!G/L?/HNE5XSR*L1>E;8?#1P_,TVV]V]WV[))=
MDD9UJTJUE9)+9+;_ #_$LQ?TKUG]E;X77/C3QK'XNU"U;^R]%F67S&R!+<#!
M1 ?]DX<_0 _>%9GPD_9L\:_$"XAU+6[2;2M(W O<7$>V69<9Q$AY.>/F.%[C
M=C%?5/A30-!\':%;>&_#U@MM:6L>R.->?JQ/<DY)/<FOE^(^(:.'P\L-AY7G
M+1M;1777O^6_8^@R3)ZE:LJ]96BM4GU?3Y?F:E%(KJWW6S2U^9GW1S?QF_Y(
M_P"*_P#L6[[_ -)WKH%;=$K?WES7/_&)=_PB\5+Z^&[X?^2[UN6C;K&%O6-3
M^E3("2BBBI *#115QV ;G_>H8\=Z7\#^=(W3H:); -I.?>EH_"E$!"?K29_W
MJ<?I2?@?SJ@&/U%(2<]Z5_O#B@GVH)^T-S_O49_WJ&=5&3_Z%49N5[#-!0X5
M@ZPZI\0M%+'_ )AU]_Z%;UKO+(1P<5SVK$GX@Z,2?^8???\ H5O3,SHI+G(P
MB_G4))8Y8YHHIL /2HZD/2FI&\GW11$!M.1&?D=*E2W"<MS2T<P#5C5!@"G4
M45($=!Z44'I5=@"HSUJ2HSUHB 44442 :_6L7Q=_K]'_ .PQ'_Z!)6T_6L7Q
M=_K]'_[#$?\ Z!)3CL!L4U^M.IK]:8#:*** "HSUJ2HSUH)^T%%%%!)&>M%!
MZT4%,*CJ2HZ"0IK]:=37ZT 8OCC_ )!%O_V&-/\ _2N*K.L^&/#GB$1_V_H-
MC?>3N\G[9:)+LSC.-P.,X&<=<"JWCC_D$6__ &&-/_\ 2N*M@]* WW,>S\">
M"=-N%N].\'Z7;RJ<K)#I\:,/H0*U*<_TIM.[>X62V*^IZ=I^KV,VEZM80W5M
M.FR:WN(@\<BGJ&4C!'L:YWP7\%?@Y\-KZ75/AW\)O#.@W4XQ-<:+H-O:R2#T
M9HT4G\:ZA^G2FT^:25DR7&+E=K40\=ORJG_8.B_VK_;W]CVWV[;L^V?9E\W;
MZ;\;L?C4?BKQ;X5\#Z'-XF\9^)=/TC3;8 W&H:I>);P19.!N=R%&20.3UJEX
M#^*/PU^*5E/J7PT^(.B>(K>UE$=S<:'JT-VD3D9"L8F8*<<X/.*I1ERW2T#F
MCS<K>IM2_>Z=ZY7QG\%/@W\1M2CU?X@_";PSKMW#\L-UK.@V]U)& >@:1&('
MXUU4GWOQJ,]?QHC*4=4R9QC)6:N0V%A8Z79QZ=IMG%;V\*!(888PB(HZ  <
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M,J-M_"NBHI1E*+NARC&2LU<S[;PKX8L[BVO+/PY8PS6<(ALYH[-%:", @(A
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MBM/KV,_Y^2_\"?\ F9_V?E__ #YC_P" K_(^9?\ ASM_P3E_Z-W_ /+NU?\
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M]GY?_P ^8_\ @*_R/F7_ (<[?\$Y?^C=_P#R[M7_ /DNC_ASM_P3E_Z-W_\
M+NU?_P"2Z^FJ*/KV,_Y^2_\  G_F']GY?_SYC_X"O\CYE_X<[?\ !.7_ *-W
M_P#+NU?_ .2Z/^'.W_!.7_HW?_R[M7_^2Z^FJ*/KV,_Y^2_\"?\ F']GY?\
M\^8_^ K_ "/F7_ASM_P3E_Z-W_\ +NU?_P"2Z/\ ASM_P3E_Z-W_ /+NU?\
M^2Z^FJ*/KV,_Y^2_\"?^8?V?E_\ SYC_ . K_(^9?^'.W_!.7_HW?_R[M7_^
M2Z/^'.W_  3E_P"C=_\ R[M7_P#DNOIJBCZ]C/\ GY+_ ,"?^8?V?E__ #YC
M_P" K_(^9?\ ASM_P3E'/_#._P#Y=VK_ /R73A_P1[_X)T#I^SS_ .7;J_\
M\EU],44?7L9_S\E_X$_\P_L_+_\ GS'_ ,!7^1\TC_@C_P#\$[!T_9Z_\NS5
M_P#Y+IP_X)"_\$\!T_9\_P#+LU;_ .2J^E**/KV,_P"?DO\ P)_YA_9^7_\
M/F/_ ("O\CYM'_!(K_@GFO3]GW_R[-6_^2J=_P .C?\ @GL.G[/Y_P#"LU;_
M .2J^D**/KV-_P"?LO\ P)_YA_9^7_\ /F/_ ("O\CYQ'_!)+_@GT.GP"/\
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M^%G_ )7+[_X_7KU%']J9E_S^G_X%+_,7]GY?_P ^8?\ @*_R/(Q^PE^RJ/\
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M_P Q?V=E_P#SYC_X"O\ (\N;]C[]GGK'X V_]Q:[_P#CM1-^R1\!(N#X _\
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M[RT\&^'=)_MCQ=:V+&.2\N-GF*A;)#*$>W"G VF64\D+C<_:._X)@?LTZ?\
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MX?RG_GW_ .32_P P_M[-O^?GX1_R/NU?^"SN?^;;O_+P_P#N.I$_X+*;N?\
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MA#_V4VU_E7M'[;WA35_''[)/Q!\.:# TUY)X9N)888XV9Y3$OF[%49+,P3:
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M*EC)U6]'LNU[.7WM'QK_ ,$1O^3<?$__ &.TO_I':U8_:Q_Y2@? O_KPD_\
M0[BOI+X(?L]?"']G'PY=>$O@SX2_L?3[R^-Y<V_]H7%QOF**A?=/([#Y448!
M XZ9R:=XM_9_^$OCGXH:%\9O%/A/[5XE\-1E-$U+[?<1_9E)8D>6D@C?[S?>
M4]?I5RQ=-XR=6SM)/UU5B(X.K' TZ+:O%Q;[:._8^-?VH? GP7^&'_!2FW^(
M7[3_ (4M]0\"?$/P_'%'J&IQL;6POX8HH,G;S\H@CR> HNMQ.%-=Q\<-$_X)
M3?!GX:WWCY?!'P^UVYCM6;2]%T?5XYI]1FQ\B+Y;N54G&Z3:54')SP#]0_%+
MX1_#;XU^$IO OQ4\&V.N:7,=S6UY']Q]I7S(W&&BD 9@'0JPR<$9KS/P1_P3
MA_8L^'GB>U\8>&O@99_;K*3S+5M0U*\O(T;& WE7$SQDCJ"5)4X(P0"+CC*<
MH1YW).*M9/1VVZJW;J9RP5:-2?LXP:D[WDM4WOTU[K8\4_;8^%MK\0?^"8^@
MZQ\*OA'=>%=/T*ZMO$@\*,@:6RMW6<3'"%N!]J:<YP0F2P0@J/?OA#^VW^SC
M\5/ACI_Q$?XN>&])>>R234]-U/7(8)M/FV_O(G65E;Y6R V,,!E<@@UZU)''
M*ABD165AAE9>"/2O"=;_ ."9/[#>OZW/X@O?@+:QS7$S221V6L7UM &/]V&&
M=8T7_950H]*SC6HU*?)5NK-M-:[[IW?EN;/#XBC5YZ+3NDFGIMLU9/OM8\1_
M8;^)OA3XP_\ !3#XO_$/P/>M=:3?^'\6-T5*B9(YK2+S #SM8QEAG!P1D#I7
MW-7!_#S]F+X$_"?X@:A\4/AS\.[71]:U33X[&\FL[B98C;H(PD:0;_)B4"*/
M&Q%^[[G/>5GBJM.M43A>R26ODK&V#HU*%)QFTVVWIYNY\&?L)_'+X3_"O]L7
M]H+PK\2/'.GZ'<^(/'$TFE2:I<K!#-Y%]J D3S'(4/\ OTPI(+<XSBMG_@J=
M\>_AY\5_AIH?[,WP:\4:?XJ\5^)O$UH([#0[R.X$2*6"AW1BJ.TC1@*2#C<Q
MP!D^[Z[_ ,$__P!D+Q--XBN=>^#%K=3>*]4&I:Y<3:E=F66Z$DDGF1OYNZWR
MTLF1$45@V""  +_P8_8F_9>_9]\1-XN^$_PEL]/U1H]BZA<7=Q=S1+@@^6UQ
M(YBR&()3:6!P<BNQXK"^V59*7,K::6NDEWN<,<'C?J[P[<>5WN];V;;VM:X?
M%_\ 9RT_X@_LB:A^S9%-Y^WPG#IVF7$V5'VFVC0VTAP> )8HV(STR*^&?V<?
M''B7]M#XA_ S]FWQ+IMU_9_PKM;B_P#%GG1 1S_99MMM&T9R&58H[6 DX)-Q
M*,#J?T ^//[2'P?_ &:?#MKXI^,7B=]+L[Z\^S6DD=A-<&2;87VXB1B/E4\G
M ]Z^=_\ @E'X%G\41?$+]K[7?#ZV-U\0O%5T=)@$("Q6:S/)(8SGE&GD:,@C
MK:@\YI8>I*GA9SDNONOS=T[?+\@Q5*%7'4Z<'T]Y?W4TU?YZ?,^PJ***\P]@
M**** "BBB@ HHHH ]%\"?\BK:_\ ;3_T8U:]9'@3_D5;7_MI_P"C&K7KEE\3
M.Z'PH****DH**** "BBB@#XG_P""W_[4^H_!3]F^T^#GA*^DM]9^(D\UI<31
M]8M+A53= $'Y6D,D,7((:-YNA K\<Z^T_P#@N_XPG\0_MK6OATDK%H/@RRME
M7L6DDGG9OJ1*H_X"*^+*^YRBC&C@8M;RU?S_ . ?G6>8B6(S&:>T=%\M_P ;
MGUE^VG_P2E\;?LD_ [1_CWH_Q(_X2[2+J:&/6UAT!K1M*$R PR,1+*&C+GRR
MQV8=HP V_P"7Y-SQFOVH^-/[0'@O2OV@_!/[&OQOMX[GP+\7OA;#IKQR C[/
MJ3221PD,#E/-!\L, 6$H@8%0K-7PQ^SY_P $Q/%-S^WUK'P%^+UN1X-^'\_]
MK>*-;F'E6]WI8_>6WSYVI]H4 $;@459^<Q'&."S"7L9/$/5+F3[K;[T]/N-\
MPRR'UB*PJT;Y6NTK7Z]&M?DSGM:_X)C^-?"?[ ,O[<OC/X@)I[M;6EY8>$?[
M'+R36ES>0V\,KW'F@(7683!1&WR%<D%B%^7P<BOU(_:1_:O3]KW_ ()S?M%^
M/-#7R_#>D^--)TCPG"JE<V$-[II68@A2#*[/)@@%0ZH<[,U^;'PE^&NN?&3X
MI>'?A1X:'^G>(M:M]/MG*[A&TL@3>?\ 94$L?0 UTX&O6J4YRKZ--_)63M\K
MG+F6&P]*K3CA]4XK7N[M7^=CZ-\,_P#!*GX@>)?V"[K]M>/Q[Y-Q#H]SJ\/@
MZ31"LDEA!,RO.;AYEVY@22X4"-@R! "2_'RCFOURN?VN/!_PW_X*>>%?V(],
M,$?P[TCP''X(?3;ID:U^W3PQS1#DGS<K':VFUN0SR @YY_,G]J#X)7_[./[0
MOB_X)7WG,OA_6I8+.6X(,DUH?GMY6P ,O"\;G 'WJSP&*K59RC5ZKFC_ (7T
M^6GWE9EA,/1IQE1^R^27^))._P ]?N/J;]FG_@D'\,?VF? .B^)/"?[=WAPZ
MYJ&@6^IZIX5T_1(;R[TGS%4M'*J7X<;&<(69%YX(!.*^>_VQ?V</AK^S3XVT
MKPM\,OVD]!^)EKJ&E_:KC5/#ZPB.TD\QD\EO*N)QNPH;E@<,..]?3'_!OK_R
M<WXR_P"Q#;_TMMJ^"<U6'>(>-J0E4NHVTLNM_*^EA8J.%67TIPIVE*^MV_AM
MT;MK<]4_8R_9:\0_MC?'W3?@AH6MG28[JVN+K4-9-B;A;"WBC+>8T8=-P+^7
M&/F W2+S4_[;7[)WB#]B_P"/=Y\%M:U_^V(%T^VOM+UK[$+87UO*G+B+S)-F
MV59HN6))BSP"!7T3^P1$?V5?V!?C'^V]=K]GUS7+<>%/ L^UHYD=B%DFB;.'
M7SI8W.!D'3WYZBK'[<LC?M<?\$X_A)^V;9AKKQ!X07_A%_'4VX2S%N(A/.R@
M;=TL:2!3C']H@<YS4_6ZWUZW_+N_+_V]:]^_EV+^IT?[.O\ \O;<_P#V[>UN
MW][O8^$Z*,\<T$@=37J'CGLW[&G[$'Q6_;3\87FC^"KNQTG0]%CCF\2>)]68
MBWT^%B>PYDD*JY5,@'8=S(/FKWS2/^"1'P1^)-S<^$O@!_P4A\!^+?%D<+O9
M:"MC'&MT5Y;YX;R=PH7)+)')C'3'(^</A]^V%\8OAE^S7XN_97\*3Z?#X;\9
MWB7&J7*VS)?1$&+S$CFC=?DD2)8W20."A90%W-FY_P $_P#PKXU\6?MI_#/3
MO $5PU]!XRL;R9[=B#%:PS++<NQ_N"%)-PZ$9'.<5Y]>.,]^I[3E2V5D[V5[
MMO\ 0]/#RP/[NFZ?/*6[NU9MVLDO+O>YYU\1_AWXT^$?CK5?AI\1= FTO7-%
MO'M=2L9\%HI%/8J2KJ1AE=2592&4D$$_37P+_P""6,WBWX*V/[0'[3O[1WAW
MX0^'-<\MO#1URW6:XU%&!8/L>:%4#( R ,[LN6*JH!:Y_P %$-"\*?'S_@K?
M<?#7P[?0B+6_%&@>']1OK>577[2\=K;2G(S\T9/EL.H:)@1D58_X+A_$'4]=
M_;'C^%\?^CZ-X)\,V5GI6GPL5@B,T8N'D5/NHQ#Q1G:!E8(Q_"*CZQ7Q'LH0
M?*Y1YF[7LM-K]VR_JV'PWMJE1<RA+E2O:[UU=M=$NG4YO]IS_@F1J_P>^#/_
M  T;\"?CIH/Q6\#6[B+6-8T"-8Y+!R^TEHTEF5HU)0,0^]2_*!06KPGX%? _
MXB_M'?%/2O@]\*M&%[K&K3%85DDV10QJ"SS2/_#&B@L3R>, %B ?KS_@A?K'
M_"7_ !/^(W[,_BI7NO"OC+P!<2:MIS2$*[)+%;G&.5+0W<JDC!.%]!CYC_9<
M_:J^+G[&/Q$U+QW\*HM,75+S2+C2+Q-6L?.58W=&.-K*RLLD:,,-@E!N##BK
MIU,5^]I74I1LTWI>^U[=K,FK1P;]E6LXPE=-+6W*U>U^Z:WV/IB3_@D?^SQH
M/B&'X=>/_P#@IKX%TGQ@&C@OO#ZZ9#(;>Z(&8-SWT;$[C@;D1CQ\@)Q7S/\
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M?V:_CKX.UB3]F/Q'XPL_%V@:=-J4GA?QD;:;^UK6, R?99+9$_>JN6V,"6Z
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M:=FGH[W77]59ZGWLQRN:;3C]SBFU^''ZK+<****T)*/B9/,\-ZA'C[UC,/\
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M% !49ZU)49ZT$_:"BBB@DC/6B@]:*"F%1U)4=!(4U^M.IK]: ,7QQ_R"+?\
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M.:,/@XSPU+VL=8Z_C_PS^08O'SIXNLZ$O=FDOP6WGNOFS[3_ &>AC_@B=\>
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M%Y\+?A=JFG^+/VA?$^F!/$GB.*,26OAFW<!EA0,/7#I$1ND*K-,%00Q-QO\
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MP( /(*3K*57$<CULE'J[?E=L=:-"4:.%]HM&W*71<UMN]DOO/>?@'\ ?A/\
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M!G\</^QXD_\ 1>C5\Y?L:>+_ -ACPG=>(6_;7^%GB;Q-#/':CPXOANX:,V[
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M[O5MN[[ZZG'BJCJ5FW+FV5TK+1):+MIH?0?P<_Y,%^+O_8<T3_TH2L']A_\
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M=]^FM_D3_M4F/_A+_#:28^V+X'TT:D/XQ/M;._\ VMNW\,5#^U2?^,AO$O\
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M+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5C_\
M(U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^
MRS_T5_X@?^!5C_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_
MX%6/_P C4?\ $/O^RS_T5_X@?^!5C_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE
M_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5C_\ (U']N8#N_N#_
M %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\ $/O^RS_T5_X@?^!5
MC_\ (U']N8#N_N#_ %>S+LOO1^1M%?KE_P 0^_[+/_17_B!_X%6/_P C4?\
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M1\OC3Q)_W^M__C55_K5D_P#,_N8?ZN9I_*OO1\;Q]15F/^E?8:_\$W?A4O\
MS./B/_O];_\ QJG+_P $Y/A:O_,X>(O^_P!;_P#QJJ_ULR?^9_<P_P!7,T_E
M7WH^08^G_ :L1?Y_.OKI?^"=7PN7IXN\0],?ZZ#_ .-4Y?\ @GA\,%Z>+?$'
M_?Z#_P"-57^MF3_S/_P%A_JYFG\J^]'R7'TJQ'7U>O\ P3V^&:=/%OB#_O\
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MH:UJT>O>%])ETZQL89HA9R1NERI:13&7+8N7QAP.%XZY]B_X0#Q3_P ^*?\
M?]?\:/\ A /%/_/BG_?]?\:J-7DORO=6^3)G1]I92C>S3^:V,:N-_:!^"/AC
M]HWX1ZM\&O&6I:A9Z;K'V?[3<:7(BSIY5Q'.NTNCJ,M$H.5/!/0\CTO_ (0#
MQ3_SXI_W_7_&C_A /%/_ #XI_P!_U_QJ(U.22E%ZH)474BXR6CT/ OBW^Q1\
M./C)\ _"W[.?B/Q9XBM=!\*QV26LFGW4*7%VMK;&WC$S-$RM\IW':J_-@C&
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gjyjiv3jrhol000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000020.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #] IL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHKD_BG\=/@W\$=.75?B[\4=!\-P2*3"VL:I% 9,
M==BL07_ &G&,I.R1,I1C&\G9'645\4_%G_@O+^Q#\/KN73O!<WB+QG-'QYVB
MZ3Y-N6]-]R8R?J%(]":^<_B-_P '&OQ,OI6A^$W[-^BZ;&,A9O$&L2WCL/7;
M$L(4^V6^M=]/*\=5VA;UT_,\VMG.6T='43]-?RT/UB+ =:3<*_$CQ/\ \%YO
MV]-=+#1]0\)Z*K?=^P>'1(P_&=Y!^E<?J/\ P68_X*1ZBLD3?M&&&.0YV6_A
M72DV\] PM=P_.NJ.18R76*^;_P CCEQ)@%LI/Y+_ #/WHW"DWBOP6T[_ (+)
M_P#!2/35$<?[2$DJ;]S+<>%]*DS[9:U+8^A%=;X:_P""[_[?>A$?VMKOA?6A
M_%_:'AM$)_[\-'1+(<8MG%_-_P"01XDP#W4E\E_F?M[17Y)_#S_@XQ^,6FW"
M)\4OV>/#NKP9PSZ'JDUC(!Z_O!.I^F!GID=:^A_A9_P7Y_8R\:W$-CX_TCQ1
MX/DDP)+B^TT7=M&?]ZW9I"/?R_KBN6IE>.I[POZ:_P#!.RCG66UM%4MZZ?GH
M?<M%<1\(OVD?@-\>[8W?P;^+WA_Q&%C$DD.EZE')-&OJ\>=Z?\" KMZX91E&
M5I*QZ491G&\7=>04445)04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 445PW[0/[1WP=_9@\ S_$GXT^-;;1]-BRL*R?--=R8R
M(H8Q\TKGT XZG R:J,93ERQ5V3*4:<7*3LEU.X+J.]?.7[6W_!4C]D[]D9IM
M"\5^,3KWB2/<O_",>&]MQ<1L/^>S9$<'.!AV#<\*><?G%^V__P %L?CK^T-)
M>>!?@.]WX#\(2'8TUM<8U2_4'K),O^I4_P#/.,Y[%V!Q7QIX9\*^+?B%XFM_
M#'@_P_J&M:QJ$VVVL=/MWGN)Y#R<*H+,>I/XFO?PF1MKGQ#MY+]6?+X[B)*7
M)A5=]W^BZ_/[C["_:9_X+F_M<?&DW6A?"N2U^'NB3,5C71V\[4&C]&NG'RGO
MF)8S[^OQWXH\7>*O'&MS>)?&GB2_U;4KALW%]J5X\\TGU=R2?SK[P_93_P""
M!OQR^)D-GXL_:3\3Q^!])F_>/HMJJW.J2)V5N?*MR1ZEV7H4!Z?H3^SQ_P $
MQOV+?V;K6*;P;\&K#4]4C8,VN^)E%_=,P_B4R I%_P!LU0?CS77+,,MP*Y:*
MN_+]7_PYQPRO-LR:G7E9?WOT2V_ _$;X0?L4_M8_'J*WN_A-\ ?$FK6MUS;Z
M@-/,%JX]1/-LBQ[[L5],?#[_ (-_/VS?%%O'=^,_$O@_PR).9+>ZU.2ZFC^H
M@C9"?HY'O7[/+$B*%1=H7A0.U. QP*\ZIGN*E\"2_%_U\CU*/#>#A_$DY?@O
M\_Q/S#\(?\&W^E1A9O'W[5EQ,3C=;Z/X36/'KB22X;/_ 'P/QKN-/_X-VOV6
MH47^T?C)X\G?;ABDUFBY]0/(./IDU^@E%<DLTQ\MY_@O\CNCDN61VIK[V_U/
MS]O/^#=S]E6:+%G\8/'L#X/S&XLV&>W'V?\ K7%^+O\ @W!\,S1L_@+]JB^M
MF'^KAU?PLDX;V+QSQX^NT_2OTVHHCFF/C]M_A_D$LERR6]-?>U^I^-/C[_@W
MQ_:\\.Q37/@CQYX-\1+'DQPB\FM)I!Z 21[ ?J^/>OFSXN?L"?ME? U;B?XD
M_L[>);2UM5+7&H6=G]LM44=6,UN7C ]]W%?T4D9X(I"H/45U4\]Q4?C2?X?U
M]QQ5N&\%+^&W'\5^.OXG\P6C:[K7AK5(-=\.ZO=6%]:R![>\L[AHI8F[%64@
M@^X-?67[-7_!:G]LOX">1HWBWQ%#X^T.-ANL?%!+7*IW$=VO[P''3S/, [#L
M?UA_:#_X)Y?L?_M+V=P?B9\%M+_M&X8O_;VDPBROED_O^=%@N?:3<I[@U^?O
M[4O_  ;\?$CPH+KQ-^RIX]C\2621F1?#FO,EO?#'\$<PQ%*?3<(_3GK7I1S+
M+L='EK1MZ[??T_ \JIE.:Y?+GP\KKRW^:Z_B?8O[)/\ P5Y_9)_:FE@\.R^)
M&\&^)IF5$T'Q-(L8G<\8@N/]7+\W 4E7/]ROJ?<,9K^9+XA?#7Q_\)O%-QX'
M^)O@W4M!U:UXN-/U2S:&5?0[6 R#V(X/:OJ#]B/_ (+#?M$_LISVG@[QS>3>
M./!:.JMI.J71-W91XQ_HUPV2H P?+?<G&!LR6KEQ61WCSX=W\G^C_P _O.S!
M\1-2]GBU;S2_-?Y?<?N=17F'[+7[7WP+_;!\#+XX^"OC".\$:K_:6E7&([S3
MI&S\DT6<KR#AAE6P=K$5Z?7S\X2IR<9*S1]13J0JP4X.Z?5!1114E!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !03020*^2_^"G?_  4Q\+?L1^#_
M /A#/!IM]4^(VLVA?2M-D^:/3HCD"[N/;(.R/JY'9036M&C4Q%10@KMF.(Q%
M+"T74J.R1T'_  4&_P""E/PD_8:\*?V;.T>N>.-0MR^B^%X9.4!! N+EA_JH
M0?\ @3\A1PS+^)'[1W[37QD_:K^(EQ\3/C1XNFU*^D9A:VX)6WL8B>(8(LXC
M0<=.2>6)))/->-O&WC?XK^-;[QQXZU^]UK7=8NO-O+ZZ<R37$K8'^ "@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU1^/=%%&#C./QK[H_.3VO]AS]N/XJ?L/?%2/QKX+N&O=%O&2/Q)X;FF(@U"
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MQRXZ#S>*]]KX"I3E1J.$MT['Z=1JQK4HU([-7"BBBLS0**** "BBB@#\N?\
M@X>_:.D#^#_V5]#GPI4^(-?VM][EX;6/])V.?]C'0U\K?\$D_P!F./\ ::_;
M,T'3]:M1)H?A9?[>UQ6CW+(D#+Y41!X(>8Q@Y_AW5Q/_  4#^-L_[0G[8_C[
MXF'4A=6<VO26>DNK906=O^XAV]L%(PW'4L3U)K]+?^" 'P$C\!_LO:O\<=2T
MT1WWCG6F6UN&^\UC:%HDQZ#SC<?7 ]!7UE1_V?E"2W:_%[_=^A\/2_X5,\;>
ML4[_ "CM][M]Y]\4445\F?<!7Y]_\'%'_)JW@O\ [*!'_P"D-U7Z"5^??_!Q
M1_R:MX+_ .R@1_\ I#=5W99_OU/U_0\W./\ D6U/3]4?CW7W#_P1)^ OPQ_:
M4\9?%+X2?%OPW'J6CZEX)B#*P DMY/M2;9HGQF.13R&'3W!(/P]7Z)_\&Y__
M "<!\0/^Q.A_]*TKZS,I2C@9RB[-6_-'Q64QC/,*<9*Z;?Y,^9?V]_V!_B?^
MPQ\3FT#Q%')J7A?4I7;PSXFCA(CNH\Y\J3LDZC&Y._WER#QX-7]*WQY^ OPO
M_:0^&&I?"3XN>&X]2TC4H]K*P D@D'W9HGQF.13R&'3W!(/X1_M\_L#?$_\
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MC.L-['%<ZVEK\^O^9[G#^+]O@_9O>&GRZ?Y?(L4445XY[P4444 %?BS_ ,'
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M1]?*DP,).H^\O0_>7(/'UV6YG'%1]G4TFOQ_X/=?TOA<WRB6!E[6EK3?X?\
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M:_.:ON,K_P"1?3]/U9^=9S_R,ZOJOR1^RW_!O(,_L4^)1_U5"]_]-VG5QO\
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M'=Z]JLEOX=\6?\2+71O/EJ)F'D3,.GR3!"6ZJC28ZD'Z?-,-]9PC2W6J^7_
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M?^%M?_\ QVMS_AW?^W3_ -&F>/?_  FY_P#XFC_AW?\ MT_]&F>/?_";G_\
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M7FGK!1110!^2'_!QG_R7#X<_]BI<_P#I37YS5^C/_!QF?^+X?#G_ +%2Y_\
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MMR-P5U&5R-READ9R/2Z*J$Y4Y*4=UJ34A&I!PDKIZ,_+/_B&ZU3_ *.\M_\
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MG_!R7_S1C_N8O_<97Y=U[V4?\B^'S_-DYY_R-*GR_P#24?J)_P &VG_-9_\
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MT2XL6O+?#%(YX6CWKV) ?([&@"C_ ,+S^"?_ $6'PK_X4%M_\71_PO/X)_\
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M^ZB2%F'N 17? YK\[?C'_P &_OPO?PNUW^SU\8_$5CKUNNZ&/Q5)!<6]PP'
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MKYK\L_\ @N  /VT?A/C_ * ]M_Z<7K]3* $W#UK@/%O[67[+O@+7Y/"GC?\
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MT^,_V3?V@-%_X*"?LZ0R6,-QK$<^O"UB'EV.I9_UK ?\L;@95P1@ONR3YH%
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M-?GSXF\+^(?!FNW/ACQ7HTUCJ%G)Y=Q:W";61O\  ]01P1R*^ZR_'4\;1O\
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MIQEBH/\ /S\2/B)XR^,'Q U;XF>/M7DU#6]>U"2[U"Z9>9)7;. !P .@4<
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MX?ZQ\,_&^F+>:1KNG2V6H6[ ?-'(I4D>C#.5;JK $<@5^5"_"K]O_P#X(_\
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MUN-%MH=5TQI TNFWBZ@WF6\F.XR"#@;D96P,XK]EJ_#K]HS_ ()[_&#]E?\
M:PT_PCH/@_6M>\,S:Y;W?A[7+33WG$EH9U^64QJ0DL?W6R!G&X *PK]Q1G'-
M 'Y+_L:S1^&?^"X'BZT^(,BK?77BSQ/'8R3\;II'G>,KGINBSM'HP K]:!GO
M7Y__ /!4G_@FI\2OB/\ $2']KK]E!9?^$OMF@EUC2+.X\FXN)8<"*\MFR )E
M"J"N1N"@KELAO-O#?_!;;]K;X/:2WPZ^/W[*_P#:'BBR7RC=W8N-*F+8P&FM
MS"^YLXSL,8/8#.: /:?^"]FM^$;/]C[2=#UF6)M4O?&EL^CPEAYG[N&?S9 .
MNT(VTGUD7U%>L?\ !**QU73_ /@G_P##F'5T99'TVXEB5^OE/=3-'^!4@CV-
M?$?A3]F/]N;_ (*N_&_2_BM^U-HMYX1\#V(!B6:P>SC2UWAF@LH)"9&>3O.^
M1@ EFVJA_5;PUX>T7PCX>L?"OAO38K/3]-LX[6QM(5VI##&H1$4=@%  ^E '
MY@_\%R?^3R/A3_V!;?\ ].+U^IE?EW_P7,\(_$?5?VFOA[XI\$_#_5M933?#
M2R.VGZ9-/&)$O9'",8U.#TXZX-:(_P""SO[<!'/[#G_E,U/_ .)H _3,]*_(
MW_@I(Z^$O^"P_A'Q/\2SCP]_:OA>]4W',?\ 9T<\:S?\!WQW&?QK[5_X)V_M
MI?'+]KF?Q5%\9/@7_P (:NAK:'3S]EN8_M7F^;O_ ->!G;L7I_>Y[50_X*D?
M\$]Y?VU?A]8^(?A_=6]IXX\,I)_9373;8;^W;E[5VQ\IW ,C'@'<#@.64 ^J
MHY$E0.C!E;D$'K7B7_!2/5_"6B_L,?$ZX\9A&M9O"EQ;VR/CF[D&RVQ[B=HS
M^';K7PA\+/\ @IK^W;^PKHEO\%/VFOV==0UZ'3(1;Z3<:X9[.Z\M> HNA'+'
M=1@# 8 G ^^> ,SQWXD_X**?\%A/$&F^$[#X9R>$OAY#?++YK6\T.FQ?]-II
MY #>2*"<+&,#/"KDM0![C_P;XZ;K<'[/OCC5;E6&GW'C!([/=G!E2UC\TC\'
MB_+VKA?^#B&TU/\ M7X77Y#?8OL^JQ@]O-W6Q_/;7WY^S+^S[X._9=^"FA_!
M/P.9)+/1[?$UW,H$EW<,2TLS8[LY)QV&!T%<I^WE^Q[X?_;5^ UU\+;Z]BL-
M6M;A;[P[JTL986EVH(^;')C=69& ]0V"5% ';_!G5_#GB#X#^%]:^&SQG2[G
MPG9R:)Y. HA-LGE #H,# P>F,&OSC^./Q9_X+H_L_>!-3^*WQ-\16^F^'=-D
M7[1>*N@SF-7D$:?)&&<Y9E' .,\USOP;_:E_X*!_\$J[5O@W\9O@-=Z]X-MK
MB0::MXLBPQL6R?LE_&KIL)RWELK$%N F2#8^._[<'[;'_!33P?<? 'X(?LI7
M%CX?U&2(ZI+;PS73DI(KKONY%BA@3<H/(!XQN[4 ?='_  3$^-GQ+_:%_8[\
M/?%3XN>(?[4UR^OM0CNKW[+%#O6.[DC0;8E51A5 X'/>O8/BE\,O!WQD^'VL
M?##Q_I,=]H^N6,EI?6\B]58?>4_PLIPRL.58 CD5YI_P3V_9U\8_LK?LI^'/
M@QX^U&SN=6L6N;B^;3V9HHWGG>;RPS ;MN_:3@ D''%>UT ?A+J'[(WQ<TS]
ML1O^";\'Q'?^S[KQA'(&\]A:.OV<R+>M%G'FBU)^7KG*@XYK]M/@[\*/!7P-
M^&6C?"?X>:4MGH^AV2VUG$/O-C[TC'^)V8EF;NS$U^>GB'P!X[?_ (+T6/C.
M/P3JS:.NI1EM6739?LP']C%<^;MV_>XZ]>.M?IB,B@ HHHH **** "BBB@#\
ML?\ @M[_ ,$Y)K:\O/VTO@KH.Z&7!\>Z59PDF-NG]HJH_A/ EP.#^\/5R/@W
M]E+]J'XE?LB?&?3/C)\,[[;-:MY>HZ?(W[G4;1B/,MY!Z,!P>JL%8<@5_1QJ
M6FZ?JNG3Z5JEC#=6MU$T5S;7$0DCEC88964@AE(."#P17XJ_\%8?^"8.K_LG
M^*[CXT_!S1YKCX;ZM<YDBC4L= G<C]P_?R68_NW[9",<A2_TV5XZ%:G]6K>B
MOU7;_(^1SK+:F'J?6\/IK=VZ/OZ=S]:/V5?VI/A;^UU\(K'XO?"S5EEM[A1'
MJ6GNP\_3KK:"]O*.S+G@]&!##((JG^V9^R=X(_;.^!6I?!?QK<R69F=;G2-4
MA7=)87B ^7,%_B7YBK*<;E9AD'!'X7?L7_MK?%S]B7XHQ^/OAS>_:-/NBD7B
M#P]<2'[-J5N&R58?PR#G9(!E2>X+*?W5_9/_ &O/@Y^V/\,8?B3\(M>63;M3
M5M(N"%NM,G*Y,4R?R895@,@GG'GX[ ULOK*I3^&^C[>IZ>79E0S2BZ-6W-:S
M7?S7]:'Y+^(?^"#W[>>F>.3X8T/1O#>J:6TVV+Q)'X@BBM@F?OM&^)Q@=0L;
M8[;J_2S_ ()N_P#!/W0?V"_A3>Z#+K\6M>*/$%Q'<>)-8AA*1-Y88101 _-Y
M:!WY;EF=C@ A1]&[1C I0,<"L<3F>*Q5/V<VK>77U-\'D^#P5;VD$[]+N]O0
M****\\]0#R,5P?QH_9Q^%?QYTM;+QYH(:YB4BUU2U(CN8,]@^#D=]K KGM7>
M45=.I4IR4H.S\CGQ6%P^,HNC7@I1>Z:NCX0^)W_!,_XL>&GDO?AOKMGXBM=W
MRV\C"UN@/HQV-QWW ^U>5:S^RU^T9H4ODWGP7\22-_TYZ:]P/SB#"OU#V#O1
MM KV:6?8R"M)*7X/\/\ (_/\;X7Y#B*CE0G.GY)IK\5?\3\M]-_9E_:&U:40
M6OP4\4*Q./\ 2='FA'YR*H_6O2?AQ_P3>^.GB^=9_&4ECX:L_P"(W4PN)V'^
MS'&2/^^F7\:^_P *!THVCTHJ9_BY*T4E^)GA/"W(Z-12KU)U/*ZBGZV5_N:/
M+O@1^R)\)/@&BW^@:8VH:P8PLVM:CAY??RQ]V('_ &><<$FO4@,445X]2M4K
M2YIN[/T+!X'!Y=AU0PT%""Z)6_X=^;U"BBBLSJ/,?VM/V5/AM^V+\&;[X-?$
MZ*5+>>1;C3]0M3^^L+M0PCG3/!(W$%3PRLP/7-?F[)_P;E?&X>*OLL7[1/A4
MZ'YG_'\VGW(NPN>OD8V9_P"VM?KA179A\?BL+%QIRT^\X,5EN#QLU.K&[76]
MCRG]CG]D+X9?L6?!VW^$OPV62XW3?:=8U:Z'[[4;LJJM,PR0HPH"H.% QR<D
M]/\ '3XX_#;]G3X8ZI\7/BOXBBTW1])@+S2,PWRO_!#$N1OD<_*JCJ3V&357
M]H+]HKX3?LP?#6\^*OQD\4QZ7I=J-L8(W374I!*PPH.9)&QPH]R2 "1^&'[?
MO_!03XH?MU_$8:OKGF:3X5TR1AX;\,1SEDMU(P9I<<23-W;&%'RK@9ST8/ U
MLPK.<]KZOOY+^M#FS#,,/E=!4Z:7-;1=O-^7YF-^W/\ MI_$']M[XT7'Q*\6
M[K/2K0-;>&="$@9-.M=V=N0!ND8_,[]2<#A54#Z9_P""+/\ P3EE^-7C.W_:
MJ^,>@?\ %(^'[P-X;L;J-@NKW\;<2]MT,+#GJ'<;>0KBO)_^"97_  3:\7_M
MN^/H_%'BJWN-.^'.C70&N:LHVM?2+AOL<'?>P(W.,B-3G[Q4']S?!_@_PQX!
M\+:?X)\&:';Z;I.E6D=KI^GVD>V."%%PJ*/0"O4S+'4\+1^K4-'L[=%_FSQL
MHR^IC*WUO$:J]U?J^_HC3HHHKY<^Q"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR?*8[QCC>!NKZX# U_,=XO\&^-OACXNNO"/C?P[J&AZUI=QLNK&^MVAGMY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gjyjiv3jrhol000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000010.jpg
M_]C_X  02D9)1@ ! 0$ L "P  #_[@ .061O8F4 9      !_^$3PD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P + (K@ !    L BN  $  $%D;V)E(%!H
M;W1O<VAO<" R,2XR("A7:6YD;W=S*0  ,C R,CHP-#HR-R P.#HT.#HT,0!4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   "00         & 0,  P    $ !@   1H !0    $   $^ 1L
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M$0,1 #\ V**W7@P]K""![S U#WSN_P"MJ;\6UFV;&'<YK="=-Y !X_-W>_\
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M]NW8YM_M]+_"^MZOZNI7_L6O'TP;JK;J9I?:26;BT?K%/OKWU>H'_FW?H_\
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MZY;4'QN:YU7NCZ%GT'_1=OVO_KHZUX(TOQ:GIT!K3Z=4AQC]7MY]NK-O]?\
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M P,# P,# P,# P,# P/_P  1" )!!$$# 1$  A$! Q$!_\0 'P    8" P$
M            !P@&!00) PH" 0 +_\0 M1   @$#! $# P(# P,"!@EU 0(#
M!!$%$@8A!Q,B  @Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34G
MX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(
M24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'
MR,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ_\0 'P$   8# 0$!
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M[?\ 5_J_;U[S7)N2./\ #_'ZD@@\G_;'WJM!PSU:E6.<==>4W;DD@"P(Y]1
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MR>/Z7]^+ 'AGK05F']&O^KAY?9U@!^GJ')'Y_%R>" 2.2??J#('5J\"3\_\
M5C'77E_J3>YL!;Z?46 )N;?X?[#GWNN> ZJ!C%2/M^7^KR_EUV1:Q%K$DVN?
MZD"][DD$?T!^OO7#[>M\2!IQ\NNE'^-KG2;D$ZA;_7Y!X]^\_EU[%*GC\O\
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MSJN.?4&Y()>XO[\. I_J_P G7B &.H_ZO\/72V !)YT_F]UN?KS<DV-N.?\
M7_&CQP,UZV"*5)IC_5_J_P!0Y>8"WTN!8D$%A<\ V8"Y_P!Y'^M[]7ACSZT<
MGS_;Z_ZN%/\ !U'8'D<WO_J6N+VL1ZOK?\_[ \>_<16O6S@T\Z_/_5_D_P '
M7C-8D@6L1JN#8_BY^@)%Q_K^]BG&G6B2:T_/T\NNO*--^.3P!<,+"]QPWZF7
M_;#WK[0>M5H*\,G\N'R_U#KPE6WXO<&UV^OUM:P6W!_WWTV2V33/^KY]/"A\
MQ3_5_+'Y=>M;FW'-K-<V( O=;W M_@>?Z^[8]?+K>:$A:5^?\_L]?\->O&07
M)L 5M^6%A]0?J>#;_;'W6IR ,?ZO\O3!"BA]/R_U?[/7O-Z1].#S<7-K<<6!
M;^MC^?S_ $\/SZW4X_U?ZO\ 4/LC>5?TWX'#@ W-[<?F_!]^SP'3E,<>'\_\
M/7+S):]K7O?^IY/XN&TW!_K[\:];4 X R?\ 4//KH#3Z3 3:U["W'XY)_P!C
M_OK^_5'3&?2OY?ZOS_/KP!L; CTW7F_( _'%C87^MP/?M6>MT &/3K&1_9N!
MSI-R+G4%(_V_^W]ZIFGEULD$#U_U?ZO]6>)E^IN PN+"_-[#U?X<?\3[W7R
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M2#_B I-C?Z\>_ D\1UHT6O#AZ=<;6 M_0_FQ!^IL2/JQO_3Z^]]:TX%/\/\
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MUK_3^EOI[V!\L]>/S./LZBFHYX M;_$6Y)N5/TL 3[WBF.JT:HQ7\_\ B_\
M5\^N_,>#QQQ<?FWYYX%[_P"\?CWJHK6F>O,",>=?E_EZ[$M[\:3SZK&XN ?R
M!] ?]?\ WOWZM,GCUZE:4%/]7^S_ )NNA]+FP-@+_2Q_K;D\\CWKC@'J^ 2Q
M'^K_ "^G7C<@?I)'/'*W)N;^]4_9UO56F16G^K_5CAUZY_!/Y-[$_DFWXO\
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MUI_2I^=>N0E;@WY%]('/ULIY*H+"PXM[T1 &*/J##T _Z"Z?\%$)J17T-?\
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MD!O;_@UKZ1>Y-QI%PQ)_'O1MUI2N.O1^ Q)!-3QQCS_SY%.L)E!^CJ;"]]1
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MU>K>OKUQ+@%Q92 ;,?H+\<#BUU/MPPR8R.O!T.HC X?ZOGQ_U'KAP0+!EYN
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M_P O\O7K\V-^ #?_  O];->Q! _U_?NMC)H?]7[<_P"JO71E'TMR02;@'@6
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MF/D7TVN!?VQ%>&H4'LZ3W_+EQ"KR^&=7J=7D13R^?7"6LIJ6CI8JFKHH*H5
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M;I*C K_J^?6AM2$4*U4_,]8XZZFF@D\#T<K25.JI$,DE5"K B_C0*DE)$/\
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MUK:0 ?\ 4.F'VN]MB=7 ')-?/RX=9$\;QB;R:B" )Y !1K;Z!#QJ(!XO:_\
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M@XY'-OI?U6N?K8?@_7_#WZI]/]7[>MBHXL?]7^;_ %#AUUY0+\"_Y N3S?2
M3R+$^_9H/7K5#FO^K_/^?7+RC_'@$  6%N/U6' ^G'^/OU30$CKU,T4_ZO\
M4?MZZMQZ3^;$&UKCT_X_4C_7X_UO?O2HZV:G@WG_ *O\'^3KWE4VXN;@WOP
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MH?XW54^Z:JF6>M62'-F&&EF,L);T0OI'-@+?[%;S%/<0:&AF92 IH/.JU/\
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M[6_KPE2YW:YFFCCN2(HR!4+Y^E<Y^1'4US\N\I<F<N6.X[ALZ/=R1EBSN:4
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MGT+_ $)X]RE"T1L3(1WT:F1UB+8R;E<;VEM<.#"63&BG$BN:>?5JM?U_U/\
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M?7NT4^8_U#_53^77?W!%K  BX4-Q?E@3^D #@?D?[ ^_5&<=;H*@@^0_U?\
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M3[J.&!7KQI6O^K_5_J^?4;S$#FH(!(%M) -OS_:U$6_UA_K>_5).#GIVBK3
MT_['GU[2#I TVU$ :A(0>#HN1]/P5X'/U]^/GZ]4_P '_%=<=/#'[@ L38D*
M+FWHO<^K3R/Q8W_'NU>MFE#0 ?E7_/\ ZOMZYH#]=1)-^05*@7U6'!*_3\?D
M>ZU)IU6@]<=<//SJ8"XY4J 3^ ?]4 PT_4_46]^H/,9ZL/2N.HQE=OQ?5=B+
M M<6%[<$$ _C_>O?J_+_ %?;UL*IIW 8/S_U?Y^I=[ @V"O^D'2WZC=1;590
M!]/H/>CYUX=5'E0"O7A*XN2.+_2X')TGTD :3I%OK;_$^]U%#4XZVH&!P-.H
MG%OJI_20;%N;V(&DZ0=()_KQ_K>_#%2?]7^K_5Y]*2=5-)Q\L^1_U4X\/EU[
M2">+"_\ :T\AF8G@_P"L/\?K[]D4IQZ\HR:Y%?Y_ZOS^T4/7$3GC_*5(X_LW
M(!!-[V:RGZ_GZ<>]DGCZ=5H.T!:^?S ]:U_S\.N;3V4FRC@AKA03P?3;@ @
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MJA(*FCR E"&*IAJT56-S5)(%HXFXT2J:DK^18^Y/@9ELR"<Z3UAI8R6_[]!
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M''F.C5?S3,[C:CO3;&VZ&>G2KPFSJF').SAI\9/4UE5D8A+$NI?\IIZI&6[
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MYY8?J/\ MK_3WOCUKX:U-/\ +^W'^SY"G7A,2%///U!MS9B&L#I(NWT'TO\
MT]^KQZMZ?ZA3/K0_YN'70F)!_H6XL;L&! L02!R1?^EO]X]4$C&>JUQ4F@^P
M?F/\O6'C4O N?J";D76]K6"^FX_P/^Q]Z^WKP!!) -!7Y_YAC&?L/6,BI:UF
M/U)%R 0.0!;6.&('XY^OOV,XZ]4&FIJ8/[/+_5CAGKF9;#A5%B>-5C?D'\DL
M@-_\1_B/>P:9IULBI*@Y]:?[/#YU_EU',S :0SD"UB#IO:^K]0 M87U?UY_Q
M]ZQY@#_5]O5J#516J!\AQSY4'_%]23<7/^U74CD"Y%R1<$6)M_Q'X#) (IY_
MZO\ 9_/I%4_ZO]7GUX2F]K<7%K<I_9"@CZ%@5OQ]?>ZCU_U?ZCUL4X:?\/IZ
M?ZL]1@#8+;2I^CL1J!-N--P/T6!_'^N/>J5' \?]7^K_  =>J3Y^77O*3Q]N
MVJQN;@ ?4$7MZ5L>1P#;WL$5-!_J_P!7[/3JI!H,\?\ +UQ%0/[0 8@*38<F
MY%P0!P?Z_0?[UZO^K^?^JG5@JU!!]/\ -_J^WKFJFP*E; #TE>"Q' ( U6*_
MU_!O]?>SYTX=5].NA.1SINP! Y8?I_&GU'4 3S;CGWHT/'JXIP /V_ZO]7V]
M>()') )(/(L-5[GDLI)(;FW'T^MO>L9KU4_+_5_Q?7A?20*@B[<W)4@_6P;F
MP^O^O[]Z8ZN:'-/]7^KR^?7B2HY')-K?CEKA64&_/]+&X]^QCCU4UZZ^Z/U5
M2 I)  M<_P"%@"02;G_?#WL\#6OSZV*5%#1?L_U?ZOEUR6H(M;@$ZB?]N1Z2
M#H5AR/\ 6/OU!0 C'7C2IH<_ZO\ )^?7#[BW%@=-B+_1A<W)XX.J_P#7GWKS
M&./^KUZT1\\#KL3GBP4A0VN_(_3P!Q8*!^/S;_;^-*9'6P 6IJ%/]7^#KM1>
MX)TL0=2Z;  _2Y#?@'C^GU_J?>C3CY=:S^?^K_5_L]1O.]B ?J0";<$$<$G3
M>QM_L;^[>F,=;-*&A-1_J_U4_P G7N+G]))'Y:WT(N;V'];$?U]ZK@5Z]YDC
MJ/Y?R.0+'25M9@+#ZDW')OQ_K>_9/6^P8/\ @_R=<B-7TLH'U%@"P/)/]GTF
M]_Z6][R*FO5: T]?]7^K]O7OI:P/U):_(8:EM]/K]!?W[US_ *O]7#KV/3K'
M]RU^0#P;D7:]R+\DGA;$_P!+_D'WJI%.-/V?ZO\ 5\^K44U./\(_U?LZY#BW
M#$$7?ZW #?@$$!38<_U_U_>\$UKY_P"K_#U7Y?ZO]6.N8%N6N+V8WL=0+<<$
M$&Y_)_K_ $Y]ZP13KWS_ -7^K_9ZQ"=@O( /)Y^@)X7B[\-;\\<?CWXX(!XU
MZN-)5FX8_P!0X_ZO2G78O;A;ZKC@->XT7((%K 'ZCWK@1GK52013_5_J_P!5
M>O&8\^E3=>;$BYTBXU6 O?G^G^V][KC./]7V];I4T%":?ZA_FZ\)C<:K?4 *
M5N"1>W.D \"]Q[W4>7']G50 15OEBA/\_P"?'Y==,CV*BI/' _4QX_H?TZ2/
M]Z^OOWGFE?\ 5^S_ %<>MU% H';_ *L?,=>^X-[%0">391J0,#JU GFQ%O\
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M31Y:HW'4U\=110T])54VK&K3TDL9<_<7]94W%_Z^SOFC;6W>.T^E4LZ."14
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MS:WT) 'TX-C[]BE#7K0!J*"I]?\ +_J^P]<ONU'(-B"!^+:K\F_]1_K'W[%
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MM^S_ %#KFM6  H#<CA!]/R/KJL;K?_6]^Q6N>/7BK4*AL4P.N/WB_G5<V^@
M %OZW-^?][]^KQ/5=!HM7KUW]VGXU?FWI7Z&W^U6Y/TY_/O9<>0/51!0FK8^
MW_5QKUT:T?2S6YOQ>_'XY%[7]ZKQ.>KE?*N!7\R?3KHU2:A];D_4B[<<\7X)
M _WCW[4?,&G6S&-2Y%0>N)J$-[:Q<D\+>VK_ &W-C_A[]J^76R".!Q_J\_\
M!UQ-0G)LQM_51^+BP-R3:_\ K^_8J*=> /<:_P J?LZ]]P@_U1%BI) X5>#8
MW_(_K[W7T!ZH%(KPIZ^>.NC5QB]@PN#86X"C^I)X/]+_ %]Z!K3'5F!\FK]O
M_%=<A4(1;7>]K>H+:QM<?7B_O50.O4SG)_+R^76+[M0"MBMC<$6U$?3_ %CS
M_CR?Z>]ZCQZ\%P0&-<=<S6HH-E;3<FX53;G^H?\ /];'WX$5XGJK CS[<GKK
M[K@+IM8W^@)/&JPN#<?GZ>_5/'K8"CMR#_J/^K'6+[V-0->I@;?I7C\<?XEM
M7]??JUKUXA1X=?Y</]7IUR-;&MR5:_T-@#8<_P!2+'WZM:"G7B-(+>?[>'7'
M[R,BPN0./TJ+?4V^O))!_P!Y]ZJ0!QZ]H!+4.!_A_P!7\^N!JU-BRLQ(^FF_
MT%[ 7OS]3;WZM. ..MUJH)X'_5C]G^7KK[J,W8%N!]+D6_USQ]/R/?JT%-/6
MB-53JQY_X?Y==BK4']+?0@^EA?3_ *GCF]K>_5ZMD@T'=_AIUD%4]PH4_4$$
MV%R?P ?J1_O'O=>O,!45SG_5_J_P]837@V)##BUB""0!QZ3;^OT]^#?LZJ4'
ME7]O60SW(LHM;FUOK>P;_7_K_A[T/7SKU8Z< <*?ZO\ B^N(JE/(YL!_MC8#
M5>U^#?\ UO>B32F>M *:D&I_R'A7_#]G77W7^J!L!^ #<$<6Y!N/?L?AX=6H
M:5;B/3K$:^/DL)%''!5;W O_ *KZ "U[VO[]J&.KE&J2:A?\WI_JX]=??QM8
MVD )N%TJVE2I8,=+L1?_ &_O=?09ZKH;%7.G_5Y_Y.N1KXR0+.0S WTK;U E
M54EK7-O?@12AZ\R,#4>OE_JXXQZ]</OHR;:6!X_"V;@V'ZK@67Z^]5IFG6Z:
MQ0$#KPR%,WU9B> ?2+:K@!18\$D_G_D6S3\NK*C8%#J'R_U4_/KWWR7Y1QR/
M]2 HX+ G4; $WO\ Z]_>B>JJ":UIG_5]G7OO5)8!6/TM:WI%A]23IN#^+W][
MJ >&.M4U"A(^7^K]O6,U<8_$EA]./^0N1>XU:OS8W]ZKULC.3C_5_AZZ_B$0
M7]+V'TU  7;D<!KZ2I_I_7W[4/+K:Q^3''E_Q?I_J\NN/W\)-]#@$ \Z>2WT
MN"PL !_K?X^_5/&G7M.:>?GY=2!.H/"D6N22!_K'BY-R!_0^_$\.O 9(QQ\^
ML'\1@/Y86X%P/Z#5;U7Y'Y/OQ-1QQUX0L2: @_YO\_#KA]]%;_-R&Y/(TV'U
MX^MAS?\ VWNFJG53(K4 !K_J_P!7V=9OND%^)!8VM91<\?@/;C5S?WOQ!^75
MO%4D&A'6(5T1)L)!:]SI!MP;FP/) _H;>]:AZ?9UH2+4?$ /]7KUX5L1N KD
MBWTTWYX/]OD_UY^GOVL5IUK4H!-#7_ >NS6Q^HE) !<WLI (MQ97M<D_3WH.
MHX=>\0$U88_9]G6,Y&$,4TREA;U:4()^GU#D@DC^GO>OCCJZR4TFAX>771R4
M!YTR6YY] N!<WMJO8 ?T]ZUCRZH74X^?Y]=?Q&*_Z91^FUU7Z_4<:[D&_P".
M?]?W8R 4'^;KRNM#6N!^SK#/6>4K:,CACR5L>/J/58Z?SSQ_L/="P-,9SUIF
M#9_V?]7^K[.HOW# ?0'U7L%_%B"/IZO3Q8@'_;>ZU!KG_5^WINE*5%3_ *N'
M71G:[<BP%^">4 MSSJOS_L>?R1[WCAUX@>M!_J^?^?''KEYOJ&'_  6Q'CU6
M(5;@6OZ?K86'OU1P _XK]O6R!VFN?\O^K\NO><+K !LP)_#&UEM_B0+?3GCG
MWZ@QZ]:J#4T&?R_GUX:C].&  4>FW]H_@@ V(^GTY'Y]ZJ*X'7J-YG_5_J^?
M7 3D:=7T!'T4'DWY5@!<&]_IS?F_O=<9Z]05.<=1S.;K^\#P+M_0MS:W/()_
MXFWTM4@C(H?]7^K[>G RD@%:>?R_P?E\L\?+E8D7MZ1=N+^D7N+\WL"O]?>\
M>?#J@KY=>L?38 _4&Y(Y/].--RHM^1[W4"E.'52#GUZP W%P5Y)(%QQP#;C5
M<$'_ 'P]Z[:BG5L^8ZXF8W!)^EVY ^H!O^+L;M]>;B_]?>R?V=>&G!_%_J_U
M8\OV==F?EN!8*">1;C\+J^EP/S_O1]^H/,9Z]C^+'V>?IUW?3?\ 0 /IP" ;
M-<,3?C43]23;F_O1]:]:%*D=<02#Q;\ @_T!8V!N"/4?][O]?>N()I_J]>M\
M* ]=&H8V!'Z1?D!;ZA9;7Y(6W-R?IS[W4?ZO^+Z]PQ^?^JO^&G7O,Y'(5CSR
M#>_^J902%!U-_O'OQ-*#_5Z=>H#G%/\ 4:_Y_+KM9AJ(/)73P5!L20 W]2.+
M_P!!_M_?J@5%,=>H*CNS7_5Y_L_P]>\WTU?1M5_[)( %A:U_J.3^??B:$XX'
M_5_J_P _5@%H!JK7]OE]G'KL3>JX.DM8<W%PQ'^J!('^QO?WNOIUJBZC4_X:
M?YQ^WJ,9V %@#S<AC9A^3J+ V^HOS^?];WKUI7_4/MZWCMP#^WUZY"9@+E;V
M%^-0(_(51P;W_P !]3]/>SQK3'[?MZT*:0//\_\ 5QZX?<5'%P@(!%[D:;$W
M TJ;7*W^O(O_ *_O5*>>?RS^WKW;@>7^#]E<?ZL^>#S&][ZOP  2?TJ"5-E4
M6# G_8_ZWOQ..%/]7^K\^K40$YJ/]7SZZ]6FPIK&U[<W5K73\@ #3_7Z_CWO
MB> S]G6@!I/=^6?Y_P"2G7$$7(+*"?H+&X%[-<M8WO\ UY_V_OQ'#/5014_Z
MO]7^?KJW(U![78"RE1I4*3:P8V):Y%N?]ZWD$4/1A52NIA4?ZO\ *<CUSPZE
MF=?['U;\$/91Q] 3^3_KV]Z-0,'_ #]6HNH5!^SR'J13S/I]M>HPY'%2W)']
M3P+:3^IEL+_2UO\ >/>J\1Y?ZO\ 5_Q?6Z"F2"YS6OY?['[?3/7E6S#Z:C?U
M:])NQM8?7\_ZQ_K^/>\D^M/LZT H &FBFE3G\O\ (?LZC"=A8@!6 .FRFRW!
MM;F118<FP_40>?>A3_5_J_U?+JS:@#@@?ZO3A_+\^I:SV-U'J 4M>WT:]OTZ
M;FP-K#DC^E_>N(SP_P W6]6EM*CA3Y<?,_,_X>H@G55Y46##^P=04@WU"]^2
M3>W/NV6K@]4H$"TJ1_J_/[*4\SU)N;\G@'ZJ?3] &TDD\Z0?R;_[Q[UY#[?]
M6.MDFKT/E4?LSGUX_MZP>;]14Z0""?J" #JXU \>G_'@_7Z^_5^6.O,:#5G4
M3Y_GYG_5Y9ZZ,]CSS_06.GZJ!_JE(N/H1^/>_GFG^KYU\^M5J#6A(H./#^5/
MR/"G7;5 8%>--Q8VL%/TYU*@^OY^O/!]Z%3Y9ZL2 I!'#''A7'H*_G^WKA^D
MWN;$LY*BVCA5(XMKN;_U^EO=LGR\O]7V>75*TS6HKY8_S?.G[./6#2=-B?H2
M0#< 'U-HN?R"O)M]+^ZXS4=68$ $,3]OG^W[!7\_/KD)B;&X -BW#<_2WT O
MI_ /^P_I[U6E#3_5_J_U'JPJU17)\_LX&G&E*>7GP&>O"H4*03:VGT\GC_%B
MOU'^P_V/OU3U6B@$$\>/^'Y?+T_, ]="< '@64CEA8D:K%BP-N+?X?ZWO8;B
M.O4IIJ, ?(TH?\GEY^@X]=&Y-S<FS!P-)M:_ %C=1>_^/XX]^X>?6B-6I0.T
M?97S^7 G_5Q'78()-A]=8)L+V'ZA;\L !^".;W]^&:XZL0,4'"OS]?7_ &?\
M'7O.OI_(4\:@W]1K M?BX_(M[\>/#KP-!10:#[?MX8],'UQYFF#SDWM;DWO9
MM0+?F[:0"5('^\#W7(\JCKW:Q/D?YBOG^5?GDTQYR/.@LI]9!)NP/]01SR
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M-C]O'C^W\L_GU$60_7TJ5(TK8W%CJUDA5;Z?DW^GT]V,7'S7_5\_\'5 EL:
MX/YYSQP!\AY_9QK),S\LI&G2>+AN?KROT^JV!! _V(]Z\.IH1G_5_JIU;1;:
M2X)TGCQ^W_50C../43S$0'5<:6*^E2/58WN%L%!5?J/H![\8@3CCUX"!:$G
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M7_J.+^[>&*G^'_5\_P#5^SJH6W733XCYY\OG_FQ_/KOS7NOTX%_00; &Y]/
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M&]P>D@<]:;K!%[W!']WBIO\ B_/^Q]V&XFOQ8ZT?;>^(S;R5']'_ *'ZP_Z
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MQ%?R_P W6E]MMR H;>6G^E/_ $'_ *OLZBK\?/D#87Z([?)(_'6F[OK?Z6.
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MP!+P.;W^G)/O77J=9/X3C_\ E64< "S.+ 6(M9@?J/\ 7][KUZGSZZ_A&/\
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M(!75<@\\J /KQ_L/>_SZW7KUE^K6M;\$E0+C_!N #?\ K_L/>NM>G7?UL.+
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M.1[V012H(ZTI5OA8'[.GO[[_ )M?\G_](>ZUZM3KWWW_ #:_Y/\ ^D/?J]>
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M)^Y2I-!9A'J!#_I*_P"M[]4'SZ]UPT@@<^HD$L">% 'T++PQ_)_P]^!4>?\
MAZU7]G6)B5U&.-IX8EGDJ)81&RTJP!6D%2K.DJ,58$:5:]_?K@BV@2YD/Z;
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M]1_7\6YL+6L2/Z^]UQCAUK2"1J^('KOGZ^D6 8#DGD\FW]>/?N%>O>0 \O\
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M:KTTTM72HZQE;D^36#^GAZXYC@A0N\@I]N?R J3TGM.79[B3PDC[C^0I\R:
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M6)CS1;/;/X-@$6X"U(I2M1BA(I7^6<GC1%=1Z6E2%7+#^F0*TX9/S^SHZ?\
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M=E;IR^*J&BBG6#(XW!U]90S-#4*]/,(JF%6*.&1K68$7'M,Y*H[>@/\ @Z5
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MF51D_P"K_+T!O1GS2^)OR9R.6PW0/R&ZH[9S&#=TRF(V7N_%97*4QC$C2/\
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M>'6AY]*7W[K?7O?NO=>]^Z]T'F=YRTVJY 2+\@?5% L";  VN;?Z_OQX]>'
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MH\I)@.RMY=@]_;2V5D9LW%0FAW+D=H8*GI\8E3%2Q?W;#RU7A$C-((3/Y=8
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MN%PRJT569!D *!4"IIQ+!.%:KBM>JR,BAT5:M4*I-2<U'^"A.?MZV9P H"J
M    .  !8 "UA8#V'S4DD\>G    !0#KOW[K?7O>NO=>_P!]^?\ ?<>]]>Z]
M_OO]<_\ $^_=>Z]_OO\ ??Z_O7^#K73W%_FHO^6:?]"CW;K72<W>!_=+=_\
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MVO@:ZJQ4F0RG9V-R.[MQ09P2TDM7'D,=A,744CK-3S1PM,?*I0,/88G/^[$
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M]^_+K?78 /U8AK:FYX/J!!/U!X-_S[]U[_!UXBP)!/JY'YYN;,#?4#_3Z_\
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MWT%_I>UO\/Q[]3UX]6^P8ZPG2+WX-N#_ +'_ &/]?I_7WIOA;TIUK H*^?7
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M5+7+72T )I))&JU"C@E;D$>P7S'L5]<L'@*\:FK?(\/V]23RMO\ 96R$3!J
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M#QDZ"7*O]OD8K: 03<?@^PORU:/8Q;K;T&J21OLKH"_LQU>;?897M_"#B-$
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MP&X&S-/%34E$VXFQY3S8^:699;0P+>WU[,&J+4A:?Q DY^SB3]@Z1R1^)(J
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MLP5;7]G0\(21D$Z:FO' \NDLXC\-C4:]1P,B@/;3\O+R/2E_FF_RS_D+V?\
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M$C20#?GZ\@<WY]WK3SZJ17'7'0@'  )_ '!M8WN;W%[<CZ?[WKK?G7KK2.%
MY/ ( !XX/(OIL?>P2*4X];_/'7=U .FXL;W '-PPL#^3Q^?K_MO?O\/7A\N'
M7( 7XMZ5LIM>U[?DBUR/QQ[T<\1UJE/+KH$6]0%[7Y%KW(6P' Y 'X][^T]>
MZ[6X(^H/%[6Y'U/-CS<_ZWNK E2//K?Y=>7U&Y'UX( '(X)!/XU#\?0^_(I
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M:^E&_P #=![F;_<":OJ/^/)UI!FY L&-[WN?Z_G_  _WU_Z^YD3_ $+/XO\
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M,) $,L1E6["Q(-_>CAM->'6JBG7<;!T1S^VVMXVA>SU$4R!R8*A(3,$G9%U
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M9G-Z;CJZ45:8/'QU8:6GHI'5A3M6$7*J5UO:]_:K8-W6QVTW,I.A%7A6O T
M^9..D.X;>+GG6:-%[C+)QI3"CCC@.C[YC^2%T3GWW/L?ISYA#=O<>UXYZK.;
M5K\AL/)QT%=(NH4&?QFW8$S6W0E7H5 Q6R-Z@;GVG'-DYG\22 HE>%6K3R-,
M>7V=+]TY4BN=QA=;E?J!H;25\AQH?4_8>J_/A)_+U/R.^2G<_P ;^\-S;LZN
MS'36V*BMR46TH]O39.3<U%N6GP63HZILO152U5$L<WDC:E41:>5(^OLVOM_D
M:UBN(E#%Z'.H"A^RO\^BE.6D;=+R*5RJASD!6_*E1_J\NC_[)_D:]0[@W!V5
ML/*_+&K'8>U:^JDP.S]N2;-JL[MS:\R*VV-P;ZP=1!/EY*?)U (E8)'$5X4\
M\!UN8)E8%8?($Y/Y@?Y/(]':<J(ZL&G H2 =(SZ$^@)X\2.D-TS_ "1=O97-
MY#87R#^2>-V-VY)79EME=;=<Y#;.2SV5VIC@ST^\<W0;A6OKV@R-$%FTPHD<
M:GBQ]NR<Q25B>)2R 9-2/R'S_ETG3E)6#QS3+'(3@:0:_,G I^9/RZKQW5_+
MY[KQ_P RY_AKMZII\GN&GR./FQV^ZFC2/#)L>LD.1_O#F*90!451QE++"4BX
M61P;<>SE-]#0B0.=)'SQ_J/'HC?EETF*,G>&I^'/S^=<$=6G#^1W\=Z?*4O6
MTGS,J(>^*O"-68[KRIJ]BK+D'*_<QU(VW4P/NZ;'VD]4L;:U0 W ]D-US'+&
M[.T)$5>)))_U?ZJ]']IRC"R(OU:M/G 7'#^+_8^5.J_NDOY:^3W3\U=W?#CO
M/=F:V+E-M83,[CP^Z=FT-'4/FL+344M30U]-%E::IQLF/:)6:22=&(('(_!]
M)S'KVT-'1B:BE6''''-:>GGPZ+(.6&CW+PY5T@&I-%/J> IQ]?3/0]_*7^57
MT1\8]C]N[CSWRH6/>6W\=!N#J+J#+5^QJ+=6YZ R4].7RE-+$F;R+U]0Y$(@
M"Q VXL;>TVT7\TUVFF.J$-J8'"D#@!@G/^JO1GN>V1Q6CU^,4H"N6!KDD8%
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M>DE9<=+DI8O5%XI&<=HC/$NK]4,*X-2*T!KPQ2GK^0KUM%E2&=67](QDBA%
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MHP.";>_:F!(TXI_EZ8(>0LR&J>7^7H0NT>Z>T-M_&/X0[YPF^:^DW/V=VO\
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M0;(Q=15]MP;".36@ZYVSUI_"Z:;)8G'Q8NE@KJNI50MJX!C=EO3R!KQZ\.)
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M?7NLIL(K ?0+P2;VT_D$V]-N1Q[MY=5''I3;1 !KK7;4R'7Q86OQ>VJ[7O\
MCZ>_#@?MZ\WQ#[.EK[]U[KWOW7NO>_=>Z__4W^/?NO=>]^Z]U5A_.+-_Y>OR
M%!^OBZH-N  3WUU\!S_6XY-['V;[$*W<./Q-_P =;H/\U8L)2#C2G_'DZTA
M.+VN0/P#8FUAS] /Z<7L;^YCL\1X/G_EZ@:XKXOS_P!CK@Q"S4 2-5:7)XYY
M)S:6*3151)''74Q]#QHO"$^U5ZY7;'44^)O\'5;"VBEW))69@X45\A2O^K[>
MMHS^<MK3X!?&*?0*C[+.=<35%+-/&LE:W^C.HBBCC@%B2KR:D4?I"^X:M=7U
MQ8 4U-Y?ZL^O4VWQ3]VPHS-72O$Y.!_J'0:_\)[\IB7@^3&W$G@GW(TN$KWB
MG=8VR5))B] E,1(E:.GE(B:2^D7_ *^Q9SN)9=BVDH@T^.P)IZK6GY^7Y] W
MD6&"VYCW8ZVUM;*0">.ES7K#T]\A\_U;\HM][;Z-_E$-M3O&FK=STF\-R8K=
MF4HYLAM:.N.1J<Q596LJ9<;5S9>JIX98DNTBE@%-N/<=6EDRU=3I+>9)/EZ$
M]2?<[S-I,/A!D'E05P?4#\^EQ_*M[ER'=GSM^7W:^8V$G5&<WCB**IW!LBMR
M7\0R.-RN/KJ?&R1Y"8*K4[(::^BP))O;V?;E$\.U(6SH! /V*3_J^70<VV^6
M3=7D4!2REJ>7Q+_G_;TOOY9<]'BOFY_,/V_E::HQV^\IV%4[BPN.R%/+329/
M;%0:V"OJL?+.JM-#49">F> J2%B#>Z40<M6<R!C(Z(7'HWD0/3Y=+8[)$WB3
M<BO^-.6)_AS2H \N'10_Y=?5'=VW_P":?W%F\OLC>>%Q6.K=_-NC*5E)61X^
MF2LFD6BCGJYD%/FXJZ26)Z=P6\1Y'T]I?IK*?99MVG>0;D"P #47M^'M\SQ-
M//I3#+<W-Y'<31JLBT&%]!2E/\/1ZOB]EMOYO^='\S:S U%/44M+U#M[&5WV
M,4=5'3[CPF7P>+W#%)6J!X!/6ZWD3DL_U]K-RCFAY:V6>%299;=7;SR6\O2@
MZ:VZ6.YW?=!*0'CF(%,# )_/_+T2KXDU5:O\[7O\BIE0P[GWO12%JJ;S/0I2
M021T-1 7:.;&!YO(B&X5Q<6]LV>UI<;7+?7&KZA>%"0N" /\/3>X[S-:;M!M
M]NJ> Y )*@MD$FA_+'6#+5D]7_/RQ4L^0D\U-FLK!%5QUE142MC5VM 8</)&
M6$5)0Q-^VL5K>,>TVPV1OH>8)KL&MK<*D87 *E:G5ZFOGU3?MVDLKS8K6VT>
M'<PL9"14A@X T^@IQ'Y]6*K5[9Q'\YO= RR4\>=W!\7X(]IUS.)JR+)T&1IJ
MJMAHZ5R(YHCBXI24 +6O[M;+.\;1@ QY^7$^9Z,;KZ97\8D^,#GS'PXH.BJ?
M(3N5.F?G_7S[9_E<4787>F5SRT?67=F/W9EX,QOS#-#&E)G8&2J?%XJG,)"R
M1.JA&!!''LLO('D4+)W(]*BI!J#PJ#7'2JVN8XI"8XP'4$!J<0?/(\^G#XX_
M(+?GR _FVRU?9/3AZ(WIL+IG.;&W)M*?+#,UV=JZB-<BN2J*HJJT3XNFB*12
MJ-$B$@WN?8LN-MBL]C%U!*SR&I%3VTH"!3[>/GT$(=XN+S?C:S0HB @$ =U0
M34U/#[.JEOYM#PQ_S(^SCF5J<A04^XNN=:2U+""+;\ZX"MJ*:.4LPBI8Y':0
MJM@+<^S'V[C.Y7EQ!?BD:AP-.#B,$5/V\>DG/U]+MUM;O8Z=;,E=8J,R$&GV
M#K8 _F.[OZZP7QOZ3["S/P\Q?S"ZWQ,F&F6.?(UL5)L2B;:T!QFYH(<;,LF0
MIJVJ1*8-9@LA'T-O8)OX)O$=30T8@Y/J1Y>?0OL)X!%"XCP46F/D*T^5?\'5
M6?RI^9?:N9^"NR^M<]\"*SH3H_L3(;=I>N<LV[ZO)TV+I]DUU'E<930TM5)-
M6Q"KH:01Q&9P/&Q^I'!OR]9@W*LSTH. .:&GG^5.D^^;B8K=M"#C0$C%17R]
M<]+C:O\ PH8W)@-O;=VQ3?%BEK:/;^#QN(FF3L?Q3K'C:*+'T\CTS#4@E2"[
MQ@D<V]GE[RRIGEGCNB=35^$8!S^T>O0;'-<\%E$OTB%54CBPK0?+_!P\AU1G
MV_VF_=7>NZ>UI<=2X2?L?ME=[-A6R<U6<=-GMQ4N0KH!5,#KAIZJ9TA0DE(E
M47]C+:I9[&P9+=5TBGQ"OX:?Y.@K!=&XNS+-\;,2=.!DU/\ AZV0OYWLNOX4
M?&8AC(TV9P5.L\;BQ27:-.M1&MN4DDC-D8?0_3W&NWW-W;;Y*4C31.X#5'E6
MIIZ=2!>^$VT1.7.I(B5SY_,=$2_D\_!WI_Y(57:/<G;>-S.Y<3UO?!X/K/ 5
M]7C1E\U'AX\SE'R$=++#59"@RU!4T\5'"'4>?R?UM[&O,]_+M>WVKVJJ7D4$
MU%?(UI_+^?0)Y<M4W?=;B*\=@B%OA-":$4J?VU/V=6T_RMMZ=99W=/?V,ZK^
M"Z_$;;NW=P';YS'W&5DR?8]2*^6FG@EP^2FD*5<,2F:5U'(_-CS$227=]9R[
MG,/\<1684X KPJ/2GEY]2PQM;*[CVNV4+9R$*Q;BP;B ?+UJ.'02?R>J2IQ_
MR;_F$4%30UM$])VUF:J&.OIGHIH*6;/;B!2*FF5'IZ>I6%)8&4$!'%OQ[.Y[
M)386=ZQ/CR::Y-.X5-!T0VK)'NEU:1G]-!)]M%-!G]F>M?+;H[#I?G]4UW4]
M!2Y;M2+Y,YF?:-!FF\E%)GFW94FD_BU;,[-!))8QJY:WBL1:WL>['M-HG+TF
MX4?Q]!)!/;@^G02W/>KN'>EV^,1_3E@,CNRN<^O5\?SXWO\ ":I^2?5.?^4_
MQO\ E/FN\NIMO[4R=3D.C=LY;-=75]71T$6X8]LUN3@@GAW1BL1FIV5#K6[H
M&N;>P% ["XE-K(I 8_'Q/K4>70^:!)H +R(JP483(P*BA''TJ:]%QV]\Z5^6
MG\TKXB;PW)U_G^J.L]I5-7M3K3![]HYL#DJ[*Y6D:7^]U5+7Q1+]Y3ZXZ=X#
M;E H_K[-WMXXK)T1B[4)_P!@4\N@6;W>'W^W'A1)M^M020=04+Q)(XU_PTZ-
MA_,O[%V=U%\DNO,SN+^6A!\F,[E*+%5W6_<T6:S<)IL]A\@9Y,&\=%4_;8FL
MHJEA+$K@+*6-P1[)5M4DC;]4@ZLK_J_F>I N;DP^!!:J)(VB#.6_CX46@PO^
M?JOG^81\F^W>]?D)\2NO^Z_BU4_'K?FP=W8/<E)39#<W\9K=P83=V2P$2P4D
MP/A*8F'$WN#J,LCQGE+ ]V7;XS'(Z2,STQZ @G_4>@9O-Y>1S)X5O&E"*DU)
M(H*<?0</7HP/_"B3"Y')9SXSY.#"UM=CL/MO=%5ELA3X^HJJ6@QCPH%;)2I%
M)!0 $BVIE+7]M<HJ#S7=K+_8"TF...H \#Z=+N:$NY.6B\(74-!%?]+BH\NA
MO[8\!_D%I(TFJ$=4T<EY;R1I$N]$JA(P6SS,I,21A>19OQ[+%9[C>C"5[69:
MTXY3^711LC7X]G=UW1A'^\(K&1UQV:A<$+5>)%,T\^FGM6LFA_X3]X^::::(
MIUIB:V-U=X9)8ERP6-9'@"LRGR$E3]1P?:/FR.6TNK6.S-6K$#JSACFGY<.C
M/E6:ZO.4#?787QQ-Y"@\O+[>HGP!J&G_ ).'R&@J%66EI\#V9#325FHT?VHI
M(*@1)&]S34L<]0T@  TL;_7V=[E916MRD:$FI/$^7KU;;+^6ZMKF1P* #X1Y
MDC'^#I!=([FPN,_DZ;8VW\VNENQ-Y]#[OS<.*ZR7HO'5F?[93#5&5K7I<_F<
M?0^5\/48^N@D*5)6SQ,NI2+'V@,0:6D3 3 9!J!3[?4=&:.?  DC_28X*T)!
MH/+T/[?GT5WO[YY]0[.^%60^('Q1^/WR#VIUQNJ"2#>79O?>U<QBJ^HCK,K1
M[HK)9*YJ:-,CDY'Q<-.9!H58(M%OJ?9E:1B-T:Y=6D0XIP&#D^I-3_+TZ)[V
M2:CQVT;*CCN)XG(P!P %!\^/1)=E?RZ_EOOSXGY7Y4[7;!P=-R8:OW#3[8J-
MWUT.:S&#Q4^BKR=%MY:@4$]+5K&V@,NMK'CCV(K;= ERMJJCQ66H[<?97UZ#
MUQMT[VS73,? 5Z'N(.:9T^8SQ_V>J_:B6FG=YJ9:>&*J\=2M'!*TOV4%13TQ
M@I7).A9HTC]2J?2?K]?9P]Q+-+ )%4$:N IQ'^QT0- D2.RDD-3CG]GV]6??
MR82?^'+?C4+ _P#,X"/H>#T)VP;D7/Z=7TO]/9=S:*6P'E_LIT<<F_[E^?\
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MV]=;/J-KUW7.[=PX[%)%EH_XI1XFJIDSGV^'.TZJASM2*U8I/XC'42/*C:-
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MJ?RX_P"JAZ<KKN0VEJ+'0D@C-1CY\#D8_:.KV(O\U%_RS3_H4>V^GND[N_\
MX]/=UCS_ '?S=^!P?X1-P-/)XY_K[V> ^SK0XGI^MJ7@+<MJ _21?59F# DZ
MC?\ '^V]W!H>/35*CRZX$>D"F*@Z $U$A2$NOUTL2;'F]_H/]?WK-.[AU8TU
M=O'J4&#7M]+VO^#P#Q_4<^ZD4X]7!!X=!WFK')UI -]"CT@7;2B@@@<$"_\
MO(_/OQ^7IUL?,^?3':_Z;$$7#  \"^D$<GG_ 'U_=.K=>L6!-A^2226Y%N K
M6-['C_ >_=>Z\2/2.!S<&Q_(X//-@MO]<^_=>'6.4R&2'0L)19A]WY064TJ1
M2S5&A3ZFG*1V07)9C8<GWOY]:X#H&MJ]1C;???;G?TNZLCFLOV)MK;.V,1A9
M:=J3&;2VUMN&!8,112F055+/E:J$5,QBBDL[&YN3[WYDXZU3 '04]N?%9^T-
MX=S;OH^R*W;D?>GQNW!T+V#@8]N1Y/'U575TKIMC=E)E9,C1Y.6NV]!455*L
M1IQ$8ZYB'NO">Y36B_;U=#I/GTY=F_&&D['ZCZ=ZK_OCD<)3]+=A=<;TQ^Y*
M?;N-KJC<U1UECZJCCQV0Q<^?#+29DUC7F-C&0&4GD'<"T )8].\"13_57J#B
M?C-NW;WR%[Q[AP7<=/3;"^0N'QB[ZZ@K.MZ>JS>/W#B-IY_:V*S>*[6AWG!&
MV-IESTLSXM\'/J_1]PM@WLQ+CPF0C@N#^SK> @'E3^?^H="K\?NG8^@>F^O>
MG4SS;G39N,I-KID)<90HF4IJ&$K#YI3):DIJ:)0$E-E)M8D^TM>.>DU#CI3=
ML[ I>U>L-\=<5N8?"4V]=O9':XR"TL^0J,(M5"R+50QPJ?-&">";J?Z^_8\^
MMY&!TD:OHW:^;^/5/\=MRSUN;VFO3VV^I-Q96E=,=N/-8S!;;Q.WH,QA_,W\
M/H:E*C$B<Q2D.PX(^@]H5C(=RPK4_P":G7LDTKCHL6#^%O:DF[/CSE^U_E;D
MNR-M_&G?E#N?KG;N)Z>QFTIZC#TF*7'TF'WWG*??.2&Y<C!3Q1Q29&GHJ5#I
MM]F;Z_9E$Q52H/E_J\_+JRFIX?ZN'0L[0^+%!LKJGY)=80;PJ<G!\D-Z]O[[
MK<JN'2&3:E7VIM/ ;;.,I(:BOJFJ(,4F )$JI3(_F($2@:Y+S.&?5\ATR2?&
M TX"]=[[^*5#O/I+I?I3^_60IH.D-\=:[TI]QC T=;5[C?K9:L)C?LI<U@8H
M8\@*FSU'W/D"(NF&;A0Q0$4(STNJ E?]7\ND/NGXD=F4F[NQZ[HCY(CI_KSN
M7-UN[.SNM:OJBG[ -;N'/P30;DRG6V[ZO?>RGZQJ\Y2-H;7CLJ(I@K>+2 C)
MKE=9BIY-7U_GTDMSWRUR:?/_  4Z6&#^(>S-I[S^,6XMG;DRM#A/B]L_L+8>
M"V]EZ.')UF[L;O;'[2Q[9[-;BCJ<,E-N&&3:K353KCIHJV2INHI]'[AM;R*L
M(C/PT'V^7^JO\NF9"=1-<YZ,%V)AMZ[AV/N+"]<[QQG7N]LG2/1[?WKF]E_Z
M1<3@*J0A9:ZMV/\ WIV5_>*F:'4@0Y6C5&8.68+H8JG35=1R4P&X_P"H=+82
M=!^SUZ(SL/X';UV_\5MY_%'>/R(H]\8/.[LI]R[7W'BNFJ/8%1M)1VM4]OYK
M&5\/^E#>(W'3Y3=-94+"T4E%X$D!(D4"ZFC4(/$=:D8'N Z,_OKHBBWWOOX[
M[^GW)68N;X\9ZMS%-0PX2 KN5:W&0XPK.T>9<Q,7CU?0D@_[$5\J=)&UZ_\
M4>@H[7^'U'VEN+Y3YQNP*S##Y.]0[7ZER4$.V(G38]1MFGR6-I]W8P?QEOO9
M:F+.LIC2Y #MR ??J5J>EA/:H'I_DZ$?L/X\4W8D/QUBJ=X5.&3X^[SPVXJ>
M:EQLFK=\-+M^CQ(HZRFC:?[,.M'9V+LJWY;^NZ5'$=)7:E,5J>H.[?C#M??7
M?>_.Z=P[@R1A["^/U=\=LOM.BI(Z(X_:M=NG'[I;-X3.7R=,V3@GQ:J8:F@
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MZUU[_??[ZWO76^O>_=>Z]_OC_OO]?W[KQZ][WUZG7O?NO=/<7^:B_P"6:?\
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MII2O[:]8[&X !)O]1^3Q;Z_CVZ:@T'3 IY\.LFMUL"0+\CGZ?[#Z?3WX$I4
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M?A22. &!-CQ8#_6]^Z]Y@=>_%M((%E4@ GU?4%K@'2O(^G/O?7OEY]='5?U
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M=S'V67F;Q,!2^%1R+6 M[=%F1[>LNH%@:G!H0<"@\OVTKTWMABDCGU14;30
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M3R65PI*H+V]VF6ZNF@,H5=)[J9J " *_Y<=49+.PCG,6MF8#34\"2"<8Q2H
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M$1'A5] ,<<BI\\\?+Y] ULWN/XP_&K=G2FYOCZ>R>Y=[[7WE45W8._<_@_\
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M%#]02>/?AM_J.W_5QSU;ZZI%#W?ZN';PZDS;VR9YIXD/]FPIV//]3<VO^?\
M8VM[M^[5H>X5_P!7S'3YNZ>I_P!7V=1QO/-?VHJ %A>QIY@6 !/)U'@J+#Z6
M'M-)9E"05Q_J^?SZK]9P 8UK_J\N@ZW_ /(+873NVO[Y=L;PV9L#;$%7CZ&J
MW!NG,#&8W^)$L1B!(I#?WANUQC;WXY]EN\2[+M"EI)B#4^3_ -'A0-C/V_+H
MXV2#==^(18L?:G](^>G-5\_V] EU;_,$^,?<VX!M+KCNO8NXMW5]8:+#8"II
M,UL[)YPV/JPJ;[3:G]XR "/]QBG\'V6;=O'+VY,R_4BOJ1(/7^B/3HYW'DS?
M+%#*(33CC03Y>0D)\_+HU<>[,E)HBDBHP$5R/V)&-R=;7\C+?ZGB]O8FL+=+
M^+Q5)U5_RD>=/3H(-?OM*F.YPQ]/]@'U]>IS[HR-B?% Q8@7%*Y M8)?T6(X
M^MO]8^V[:T D>-Q08_P$^72*+<ZR&0CM'#'Y>G^#I9XBNCFH*"HG\ %52Z[\
M$_JY%M!)#&W'T_V/M 1-&0)!G\O\GY=&JLB=I(IURK#33#5)3?<AKV<SR1D_
MH#$*I6S +_L"+^[,&(7..E<=G:WFHA\^?'_/\NG45*$7MQ<\EB01<V/Z6/Y^
MG^VX]Z^C4GYD?ZO/I+]17-,?ZOEU+!!'Y%_ZAE/^\@$'VWVPKDX_;_GZ=KJZ
MY>W.M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)K=
MM_[I[J_%MO9JQ-^?]Q4_)^M_Z>VDX4_U>77O/IYJA<7L&]# +_B>+DZOZ?X6
M/Y]J4^WKQ. ".TD?MZF>V^O=>]^Z]T'><L<O5C^D<((XYO"H_P ?Z^_>?6AP
M_/IH'UO>W(_!_ _IQ8<_ZW/'/OW6R/V]1SI\=A<7!%[_ $LP_H;C]7U)X/\
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MNU]AM7S_ -ZH\*VX),:,-G7IFPZ,$-7%N 8MMM3RJ7 %-'6M5$7(B(!(L;<
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M_;GZW&D'ZW;\D&U[_0FXX'OVL#RZKX;$_%U[[<FWTM>_#$<VO^ 20/I_O/\
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MZ=)/!-!7RK_JX_GT:4LW U+]"?K>_P!?2"".0#<V%_\ 8\#8N5H"1_J_U?\
M%=>\#-//_5\_]7SZQ!0(343W;ZG^T38@V((NIN1];V'O45RDK:4%#^?^;I88
MVTU/#HE?RU^;?6'Q0ZLK]^[DS=(]14:\/M*EHU->-V;E9CIP>%4%_P"\&E6(
M)XPV(-SD\B!P#*"T>X)U?#_/_"*5]3D^2CJIM^!7C_J_U>G6DU\HOG9VO\FN
MQY]^]AYNJR$U+_%*':.WZ3,#^[FQ<80;X;9-S?G^" G*<#,CV!.;ON^[_N=N
M[>-Z>4?JG_+R/3_5YY$\L\U[-L,RCPN-?.3T;^@W\7[.@9VAVF:C)4\-:O\
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M_NN\+G<C#F*+.L9&HMM98X\+24[ I%5<*..4H-)36O \?\G6QW  5K7_ #=
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M%[<D_P!/I[U3@?(]:'' J*_ZO]7Y]1"UCS] /TC]&D@#_$#_ &QO[]04\O\
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M.'#('^#(/[?/H\EI-W:JFA^WC3_)_DZ<ILSE-T)/!M":?'8BIU4G]Z:BC/\
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M/LZ?:,6!AN;'@\ 6(!-_HU]0_P /^-*+%/!@,Y^+_9(]?\G1?S&PJ+:H /\
MD"GT_ECJW_\ EG?$ZH^0':E!_',*,GL3;%(,SNVFJR1C<Y^<%LTWM?Z?Q3G_
M )4/^F_W"?.O,27DYMG':*?X(SY*/3UZ([=9=K4W"-W'_9'G7UZW/JG,=1_$
M?IQ=P;[RN%V)L?;-'CJ(U8HS8C2/X+A\)AA_Q?38\8S%@6M[@_;[7Z=5AMU[
MR,Y-*5/F-6DYP2#\AT.K</O,9GF-?V?,>6FOP]:O'SY^:]1\H.RH,WC<7DMJ
M;2VQMM=L['VM5Y?[[)4>,S>8&=SF9S0L;9[=)^Q_W&<_\6&C]SI[<<LPW32/
M*U6J"2<9TR#@K"@[?G3))ZM#5)!"1BG^0G_#_J\NJWHI9=/W '(L&-K>D:;?
MTXXYM[EV*[V>ZY=^O>/N/S?_ 'Z5]/D/+_/T"M\GW6UMRT<A_8OJH]#ZGUQT
MJ-LP5]?G*"CH1?55$FX''T'U;]7^]<?D^X#]Z?:O9>8N4OWJD/ZGVR?[^@3_
M '\ODOIT=^V'O)O?+MT%$W;]D?I*?]\-_%_J\MF/^5UU96Y#=^2[,>CIA!2G
M&[%Q-9]H/^+9L5=P'.D'T-<]A9HXL\_\N+_6]\^_97D8;;$TS'/F?G6>O^B'
MU/\ @ZRG^\/[IR<Y;@D/&OE_M;;TA3^#_5Y[$PEC2\GE#QPD<6*#U@\_0M<,
M"?S]#_A[R*<Z,GSZ@$CP(""O=3/[?S]>G;WOIGKWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[I.;P_X]+=/%_P#?NYOC_P AM3_B/?O7
MKW2C]^Z]U[W[KW7O?NO=!YG;'+S*+7*17/-[>%01>XO]!_Q4?C?7OPG[>F'U
M,.1_7D7)_+ '^SQI_/\ M^?=>K=<3J;C@$E;#2+<EA^;\W/'_$\6OMB^/:.2
M,8_X\>DEQ*5NP!QSG\@>H&8QM'FJ"NQN3HJ:OQ.2I#A\M35@U"MQQ! -@UO3
M;G_8_P"O[KMEZUG=-H\C6OY-\N&>M[]:B>V!?(\Q\JKP^>/]7#JCCN'X<=R_
M'W>D_8W0J97<F-QU0^4VE+B5BRF[\$TD2Q/B1AGM-E6CM='36SZ[$"USDYRO
MSWR[S7R_)MN^R%99-0-11"M3^*BTRI!!'I0GR@#>>1M\Y?NUNMLTB%*$=U&#
M</5O)AFH\\"@J'&/[I^?V6JZO'4>0[6J<C4_;TTE+3;+J5CB%. @=!X%5-?U
M8V'M4>6.28G$KB%80:AF:G\S_J'2"UWCF8,4E=V8T!%:U ^7KZ>O1Z/B;\/M
MSX'>DG=O?-2F5W])525^%Q,<D=3-CZVJ1#49K,K -"9I77]I ;(AM>Y/L!\]
M\]0?10[5MH_W7Q)I!H14?IU'PD8(-"IX9^P<<K<J,+^ZW&Y_W*G>I%0>&L"F
M1Y4K4&A&,=6;#FP,E^3:ZG^@U6_J+_7W"2MXA\>N3_Q74RK"+1 JXI_J_P O
M2/WYF]T8#;&8S.R]BR=G[PQT<;X38^-W5!LVORWKM+.N<RU/6X>G5%.HK-%)
M-8W)+#EISW?GTT/7_5_/HF?5OS$[^[,[!W/L2+X.;TPB=?;NI=J]EYS(=_;!
M>DVQ6Y*D^\_B--'C]O19+<214EW"ZH;VX'Y]K(R7-//[/\W3,H6,*1P^T#_#
MQZ-;U%VE1=QU7:-/M_ ;CPL/5';.8Z;R4N3FI*Z7*9/"X?:>Y3N"DD%/((:0
MP;OIR S'BG()//MFYC*X45/_ !?\NGK6340SL O'_4?,]%EWU\TLE@.CL_W?
ML?X_;R[.QNW>PLEL/=&T<=OO;NW<IBOX-7)@8\SKW!0U&+R5/79"0:Z,*CT2
MDL22.*PL&BC;S(ZU--IEE3%%8CR'S_P=*S>7RDRFVH.N]K4'1VZ=_?(7L793
M[W3HK$[LPK-LK:T:A:BIW;V57T,NVZ#"RR.E,\Z4S+/)*H4 @$N#/EGK:QF3
MAPZ6/2/R*':6:W+L#>'7.[.C>Z-ET5!E,[UOO')X_<J5NV\](8Z+.;0W7B$@
MH-S;;AO]N)HXH33RKXB/S[<2W,Z,X&!C_+TU/$T+*<]PK_/H7]Y[PV-U]M/)
M[RW[NK;FQMG881+F-S9[)18O%8BD->M#2UM5-5))!Y!DGB2$MP)).+7]H*&&
M3.!U=",>9Z!*G^9OQ)J,#N/>,7R+ZREVSLZJI\9N/*4>;J_NL7DL@',-35$T
M"9NNJ,E+&3'-10>)0"-5B+KO&$J: :D?X/*G3[ZA'QQ7Y?Y^A4JNW.KX.OJ?
MM^K[&V3'U548H92FWV,GKP<^%E6GBAGIVBC:2IKJF>.:(#Q-5B0W"AA[;QY]
M,YX=>Z[[EZE[7V8W8/6/9FTMY;'I!4??;EI,F7PM$E"&.3ESM=E(J4P5$<JO
M(8ZZ%;*W#$6OL_;UY?B4>5>BUX[YN]4[[[JZ>ZLZ-WUU]V=B>QI^V*/>>Y\-
MF,M69+9U1UUL'<.[* 8'&3Q4F,R<<U9AQ!(S*\2JY*G@7]QZ=<-0DB@]/SZ!
M[Y!?/>/I78_2+XS?GQLR_9O='<V:V12YVOKM_P 74N'VIB,QN>+<6Y:_'8:I
MES%3F<+D,>F-J3%4)&<_4S,(Q&OIU7S%*=)'"U/K_J_XOSZ.+M?N#$#&]K[D
MWOV1U$^WNLLM3R3Y3:V6SD4NU:!\6M:S]C/NVIK ^4A8F:*GA5$%.UQ&6]O&
M,:%-#7I[2  !QITH.I^ZNG>]]OUVY>H.S-I]B[?Q=0<;E,SMW)5%938/+Y.*
M*835L&1@I:^C6:*'4D\R_;>.X'"FR9VTTJU.M?9T VY/FWU'7]F]7=:]2;\Z
M^[9S>].RLGUWV+0X_*9:2OVU28_%39.JK<33T HL=F)DJX+3M>6FN0%'U]N(
M3) 7XKUORZ5/R%^8G1?QBW5U/M/M3>F,P&:[6RDU'CI*NI>BIL3AH56*LW:M
M-38RJIYZ2$_Y*U+$8JB647' O[1C^TIY5ZW7B0V>EYOGY'_'SK#=6V-F;[[F
MV%L[=NZHJ7(;=V]FLNM+7Y;'5823&^*:6DJH<919:.6,$UK1.XLW /LT7"<*
MKTU*^G3W $U_/III>Y\W)\K%^/KX##-M^JZ;I^U8=S0R5,V>K<C5YJMQ=1B1
M2TLR8/(XB*DI$2"4*KG4"K#GV72@^)2GGU9"&4UK7AT[8'Y&_'_>'9N3Z;P'
M<.R,YVO@ZIH*W8-#FZ@Y^GFBU?=0PU]1$E-)D*94U?:TL\C*5YOS[6+7PSC'
M^KUZ?,=$=@#3U_R4'315?*_XT4&^J7KRH[\ZQIMZ2;JJ=K1;?7/5E+72;J\E
M'338G*9*>)L=BMR/-64T;4TU1&U:&\8(U7#8^7'IK/ICI]ZZ^071W<.X=P;5
MZM[3V-O_ '5M N=R[<VQE*J2HV_0P-_#?NX<57P0RT\LE72Z6FA:57>_-N?>
M_LX]>IZ\.HE%\E>@\GVQ_H,QG=>Q*SN*CCFB_N+!D)J?<L-93HU358N.,0K@
MZZM2%20DD\E09+  FP]ZZUZCIGS_ ,H^A<9NW*=8TG='6M/VM2C-XC%[(R&?
MKC/2YW%[<?>,U+NM\?2M)@H,7B=-;.)'BC./*LG[A)]^ZWG]O7'(?(_J#KWK
M#8_97<_;G4> PNZXS'C=ZXJMR5-M#<&2F21GQ^QXG6NW"*&B,>MJETD&JQ)%
MP#0-JD=?+K5".)S^7\^A@QV],/DMCT>_-MYBAW;MM\!)NC'YO;589:3<^-H8
M)LFCTF9,C>5JM8?&TDH'[BD,@*D>U3QCPPV:Y_S];H5%">B"[=^?6^O[A8'N
M_??PV[&Z^^/&5H:3*U_;&,[&VCV%)M_"5M8U"N<KM@XK#09RHQ<E4%::59F>
MF#ZP %(*6.;0CYQ7_5]G6]1%/6G^KSZ&#?'S,Z^V)\F^H_C9N#"9J&;M_8 W
M_B>W(JV$[%VXF5RV0QNW=K92.O>6OI,SN;['RT\LC&)7E,:V(:S23":4*.!X
M9\CT^\!\(O0XK7UKC\OY=#5@>V:#+]V=B]'+@\M0YKKG:.U=VY/<&5JL=487
M*+NZI>BIL?C*580].($ :H<@:DLH/Y]J[JW,5FESY%P/Y])MO;5>-'F@1OR^
M?^3H*.IOEUL7MCNSMOH[';>W#MRIZOFAI=O[MR61Q[8#N:"F6*+<F1V/'!%J
M:':6=J*?'58!T:JGQO8-S6!QI7T/3=RU)=/GTF/G1\M\7\0>CQV/)4;&3<^=
MW5MW8NSX-ZU.X,3LVIK\K4+'D:K/#;JG)QXW;>KR5$"LHE'$9^GM+.]&!Q2H
M'^K_ &>CJ"W\2RN&"_#$[$XH*4I4<<^HZ7=#\JNE<!M_K6'M7O7I[&[[WEM/
M;6Z,?!@*_-T.!W-!D\FN%&X-K8ZIBK,]#M=<G5P144E7ZON#IF;1:[J4KQST
M';%ZJ-+@B@X<#QX</R\^E7!\F?CU/V<.D*7NSKT=K1M-24VRJ++5,.47(TU)
M1MD<6D=3"^WGJT1K&A2<2.;Q %HB/:E3Y^7RZ6S1AN \J9_U5^WI+]_?,+XU
M?&RIDQO;79F(Q&ZCA&KJ'KS'4>0S6]<_!5E*9!@=JTE/639/.5+R*(()*B!$
M/*K87]MGB>M+P  Z<MU_*?X]]=4.!G[2[2VYU=DLQA,=NG&;3[+;(XK>E/BJ
MV1:2"LW-MBE2NG("H+\A*.4G4?2?>JUZW0].Z_);XW5N_,)UEC^\>M,AOC>6
M(I\KM;;B;JFR.0SE%5H*NC%#EG5L.),G&EY8#(*B5;#0.1[]CK74KL7Y)] =
M3[OQ.Q.S^X-A;,W?N!*2OQ.W=VY2IIZL?Q.JCI$2.*AC9,-2PO\ LTS5$T*V
M-])!U>]^HIQZ\*<1UG[/^0'1'2\M%0]N=J[#V'45>-BRW\"W)EJV&?*4%-,8
M7S,.+H(JYI<8KD,*R,,K7LS &_OQI^77O/Y]!)WA\X?CIT;U/LGN?/\ 86VL
MSLCL/<>/QVR,WB<FB8K=='EY(TJ\O'-38VNJIZ;;JU0>KI7$<LK^1 +@@^J?
M+KWV]+_=7R?^-VQJG96+W;WEUQMK)=@TF)R.SJ3+UKR5>;Q>4T24=3 D% )Z
M;%9.-@](:MH?$&M]0?>OEUOS^?0\P>.H29X%29/$))Y$:/*TLE&\T==MZOI,
MG(2M2E110ET:-FT*=7XO[WU[_!UD-QI)'-[ ?I^EP;EKD+;\?C_#W7C]O6^E
M9M(W^]M]-2M]?RS/_@!8VXXX]V'PG[>JGXAZTZ6GOW7NO>_=>Z][]U[K_]7?
MX]^Z]U[W[KW56O\ .0X_EY=^Z?IKZDOQR/\ C.W55^3R3I%O^*GV<['FZM\>
M9_9I;H.<R_[A3^N/^/)UHW 'RDL#:XYN;_XD?758GZ^Y?M!^F,?ZL]05.29#
M0^?^;KL6$HYX(O\ D<+]%N MU'(^GY^OLU>[U _ZO\G3MK;:;4CSQ_(]"9U!
MUCN+NCM78G5.TR%SV^-Q8S;M+>C'^X]1J)S7-A:US]>!;\>RZ3=$MZL[40#B
M?L\\=:V/;6EN&H*L2. ^3>IZW5]B; ^-W\N'XZ9FH\D6V-I[-QTM?NC>-8ZR
M[P[%S$8(IY*NL!\E57Y&H(1:$'1 +:E8D7A6]O3=,H7@?Y</D.)_E_.?+*S%
MJK.WQC_9^?IY?G7AT&GQ!_F/[-^6O8V[NM<1U%V!USE]L8VBS<U3NN?"U463
MP647R8O*+(F(I\IHKX"K /,Q4&U_J?;<>Q),/$:ND?/Y>6/V=;FWV6"B@"IX
M'\_MZ<_YC'P8VC\KNI]PSXS%8^E[RVA@ZK(]<[MI:1!D<@M3205,FS,R5U X
M#<4TS1,>+M&QL+^S+9;SZ6[>/.A6(X9X-0\/RZ2[A8&XVW6 #4*?VE3Z]:1L
MYEBDJ(*B %OK?D'\BQ!( )N?]M[E>UOQ*@TGC7_+\NH%&W-%?-4</^@?MZ=]
MOQX7(9K%0[NSF9P^W*F0PYC+[?Q<.7W-BT4FYQ>!9XX,DH%P&) :WUY]F"@4
M) \CTZVJN!7(_P!6 >CMUGQB^+E+T;BN_C\H.ZO[AYW>]1LBFII/CY13;AGR
M^.IUJC35N+:O$-'"=8NZN21S;Z>P!"MRK$ZCJU&N3CNZ$[&%Z#SH/\''X>@"
M["Z@V_LSHWK7O?!;^J,Y2]C[_P!^;-VYMG+;5;;E=3X_:=/C)ZFKR$$89*:6
MKCR2%5O]0?8CM+T1=KY- ?7_ %4Z:-H) 3BM:?ZL?+'4VOZ(VUANC>C>]MS=
ME;AQ6U^VNR-V[)RF$PNTQN#<FVJ':U+4U&1FP6,E,<>4GK/"9 &8 17:_O6X
M;NGB1JHSI]..>G;?;'HYIV?;\OL/ET.W8WP5QF*^0&QOCMU)VQF>QM];HVKB
M-]Y[=.]=E0;(VSLC8E=AX\\,W3Y..:1:Y<'MZ2]9&]M,J,GJ(Y0QWSS!S(FD
MU\C6OH?D3Z=.26:PE:&HIQ^WB*4'^KATU[9^)W0?;NX]W=6?'KY65_9W;6WL
M?N#*[8VYN#JB/9NSNW)L3#$^2H^OMU-,TT\F/6CD80.D;5/C+ 7-O>IY9X[>
M65T 54J:-D9X?L_F>MQK$\\:**JS4&/\E/\ +T2+;FVMW;RW5B=D;;Q-9E][
M9+<O]T<7@8(RK93=DTC8@8JU@0!4O9?ZGV(=KW%/HZLH\N(^70<W/;V6[)4F
MIK05X4/^JG1E<G\#?FE@DBCKN@-V8JI3*0[=G^WJL;D(J#+5-/)71UN0QE--
M+-B*66"G:,25 1+O]?9&NZQ-<C2U0:4]#]GV]'+;7(MNVM2"*_(BF/Y5'00]
MI]#]L=-UV"PG:77>:V1D-XXI*O;]/-509*'<.*:I^V%1@ZW&//1Y3,25J%6I
M8V9@."+W]KCN\,VIXS5:D<*<./3=AM,JW#+*E/A-#Y@\.ESOOXC_ "BZYV=7
M;\WOTUN7;NW<#_!ILKGZK(T%.=OP98Q1X_[_ &U1S/D,&N>^\BB:6>-0K#FW
MM')NL;.4#9IY=4W3;9%[P*I7_*>E[W+\%>VNG^HNH^U:S'Y7)8OL6FR,^8V[
MB1B:O.;#JZC(XN';>#P,D-3)59^EW.M>)I*B)7,:7!MS[U;[@LSRI4ZE4?SZ
M<FVQOH[<@ =YR3QP.@R['^(GR;ZUV5DNP-_]3Y[;FRL0:'^*Y;%Y/'9&AV?-
MDT7^'KN'&T4L^1AEKED'-0J!68>TL]ZOC-$)#K&:>@Z40[5(8EDT]IQ7Y]&4
M[2_EZ]F56'Z)S/QUZUW?O.F[%ZDQ.ZMZ3S;HQE'D!O5IY14/MUZN>.:6F_A4
M2'Q4X=B;^U,-\J*#(W%J#[:?RKTEGVMV9@H.!4_/C4_8.B<=>?'GO+MW,[GV
MWUIUIF\QEML,LF]:&OJ8,+C:6G^Z-!'C9:_)24]-39..H0R%)&60AKV]O3<P
MP?3;$Y^ 7G<:>5?/Y#TZJ=DECP/B^W/V^O\ FZ'?X^?$NNW+\L</\<_DEM?>
M&R%K]L[JS&5HZ6N*;@%#@=GYO<6+JL9617IZK$Q5N)CU2(2IU6O[42;E'-_7
M5X=.GQ8ROD*'T],=-?0LAH:D4/VX_P!G_+T'5/T9O/<NQ\#D]@]/;NRN5W!W
M!G^NME]IY?L*B7:VYZ[$O8;0P^WJIH8J#/X^C97J*R1]$BL%M<^TESN(AN((
MR^!"II3A7SKYUZ5V]@9K4R%,:R*_8.'Y<>'7'?OPS^3O7FV\EOS?O3>7QFP(
ML[0[57=M-F,+N=/XCEY4I</MG%S8BJJ7I,A-4.L?VZ7E60ZB+<^WX][MI"8E
M8%Z$T(\A@_Y.DO[GF4"01'PJ@5%>-*TSYT!ZB[^^(OR>ZNV7/V!V-TSG=M;?
MAEQC93<4U90Y=,6^2IBN'.4@Q\LM7B\A$FGRBI1!;Z\^T3;K%+-X2G(-#CAT
MJ;:W6T9]) 8"AJ:_ZO7TZ4?0OPR^1G=57USN/$]4[LR75FZ-WXO:>0SU#EZ#
M#Y5<:V:H*+=&:P=/7215=3#*M47CEITD6)1J^@]Z>^C3#-W$&GY"O3MOMLC
MX!X<:_(#H.^\.H*?:/R6[-Z(ZMI-P9:CVYV57==["I*J)LYN;+U#5:4"MBZA
M%)SV4FDDM+)8JBG\>]I=ZXDDJ>Y:^G_%=-W.W,HTL*%>.?E\_3/'IQ[.^)GR
M0Z,VY#OCM'J3*[#VD,@<349LU..S.,H=RM$SKA\DF-GJ&PSUL*^-$GT,KGZ>
MZ+NT(8HK90YQUM]J?Z:)G&&7]O#I72_ 7YHK@DW)%\>=XT.)J=JKO6D5LWCZ
MC)R[2-)#EY<WB,+YOO\ *T$%#.KQQHC$!V/M3%O$!(HPH6IP\_3I.-HN$<^(
MA&-6:_#BA^P\:]!7UE\;^].[L'N3*=0]3YC=V)V?EJ/';@@_BE%AJ"@;+SS5
MBM5Y/*2T]+-5QL?)+0*YE!.D+[O>[A"\.FNEO+UJ?LZ5-M,SF&BU4$DT.,>O
M0E?-KX_;?^-79.R]BX<;ADK\ST[L'>>[Z7<54,FV%WYF:>H_CT&&E6QQN!1%
M$4<'.I[$>R?;2QN'U,3W'_ <=/7]K]/;*VD!M/\ A;_BCT3>8W8+8?0$7M;Z
MW-B?Q_L#_P 5/OLZ):DU!X_ZO\/7M8:_U!"VXOQ8GZV%[7;G_7][QBG6J"E1
MZ?ZO]7'UZQ V-N&)X#7!%B"/ZV^G^O[U7KPJ*C'4<2D'D?XB][\_BQ!N1_3W
MZH].MT\R<4ZXGBUOK<FWX/)N.!Q<_P"Q^OOUA\.1_JSTIAS Y'#_ &?^*ZM&
M_DKV_P"'-/C./]I[@'U^I/0?:YL3]+@$?T_P]AGF/^SD(_U?#T?\H"ET01BO
M^1^OH">XYZEWKWOW7NO>_=>Z3>S1;:.UOK_Q[N%/)N><=3'Z^_=:'^7I2>_=
M;Z][]U[KWOW7NO>_=>ZB2TR.I7A06O?\_I(-B2;F_/\ OK^V;M#<0E:Y_P!D
M=>B_1D5UXU_R=:LG_"B7Y5YV@HNI?A%UWF*O'Y+M*5NS.YCCJH^6LZSP^57#
M;(V>#(A(_O/V#AZW(>GZ# :3_P #;"8_9WE@7MWXI3N3 ) Q435H2P.13(QQ
M'4:^X^_"SM?#UBA'KZ&,U^$C'D/L(J.BO?''KVBZGZ*.[H(&_O=O"K_NSL6K
M-C]ADLW_ ,OD6U$+>]O];_7]Y.\W[T!1%;M4 GYUTBG#\SCRIUA_RK8M>7#2
M,IU$D#RI0-7@1Z$"GK7HX&W>BZ';FP*>LFH0#54=B31FZ\'D_P!GZ?[ C\^X
M8?F&DC ?ZL?Z7\^LJ=BV!EA1B,Y]/5OZ753WR*Q&+89^:BK33U-+6?Y56?9W
M!)]-[WY!_P!?V-=H<R/Q'^K5T*HZ\-/5?E7C8,1DZ_*UN*@^RQ9_C&'RM-2?
MQ/[_ "8( _)L6 N3P?8O-H64'_5_ASTO0AAPS7_5^SIFJ]E9J6T>5HH:JGJ:
M.U'E?LCCC07&J]PPM;Z6XX]EWTI*FG^K^?7IK6J@$5I_J]?]7^ 0_AMOG*].
M_()MAUM=DCLGN&B.VJO$UE6!C/[SC_BQYFUS]/\ BU_3_E._I[!V[[;5O]7R
M^?1!<V9:OK_J^?0N?-'IVAGAK\I#3TWA((O>UN 1?!@7]/\ A];^P[&YFN0*
M>O\ @Z9VBS,9-?3^6?F?\/1@?^$\WR@HMC=[[]^(6YZ[.5&R]]X;)=E=78W<
M&8/\-H=\X*XSP&#MQ_>O;K_Q(?\ :B]AKGW93- &5>\^?G2J4\_7AT+C9&55
MH*@?Y?M/E_/K=AA\$K&H@X)TG[OZ@G3R0MTL!_4#GV CCCGY=)^()'^;KJH)
M#"PN?[0!M]/H3P1?Z?UMQ[VM.M-6F.'_ !?6JY_PI9[ J)J'XK]4035 Y[,[
M(S%,*T>K2-A[&P>D@_DMF^?\?<@^U=N0;IZ#BJGUJ!*W^!A^SHTLEPN<5^W&
M1_D_9UJ@T>-J)O\  V'/]2!QQ?BX'T^GN=[,Z9LG/_%]+)HR0<?ZORZ6VW-N
M3U>0@@AA^MAPI(!T_G_ ?[W[]/<+8PL6_P!6?L/KT&KB(RX'^JO6W1_)NPFW
M>B_CWO;NKM?*X;9>PLKEQN4;KSY&,QE#MDX;!;'P;<\7W3N#[[_M<??T7^'O
M'[G2X:^F 3XC3T]$]0/3_5YZMK0K4TJ/E3Y_/_5_@)M_,I^?='\F]\X"CV'_
M !C#=9]>4F3I-HTN4K/X;D-UY3.?\7W>.<PH-\#?;Y_AF$QA_P!S/\'^]X_R
M[^' [Y,Y/GV]Q),!JKP!&,.*?'G.<@<?3H1P1!*>E/\ /_J'53<57-5R>>;_
M "@:@/J;W(L3S<?G_#@?Z_N=43P8M/G_ +/Y]([VZC1\C_#QP.-/]1Z>:>:>
M67PPP@,%)I203<:3Q]/I[W9A98V+'_5GJ&.9>8OWR:+C_4F,JO\ #U8%\7^@
MMW[SW#0;=VU1U W-G 3F,K3$?\8XQN;-O[YYHV)#"Y_@F+/_ !>;_G&4&0]Q
M3SKS7%LCE5;^1](_Z#?Q=/<K<OR7)+D=O'CC\8_B^7IUN@_&3IG&=.]=8#"T
M%!#0FEP^.HJ2B0K_ )%C@JL%X^C-<D?\%/\ 4^\6QU/!/1F/?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF]XV_NCNBXO
M_OWLR/\ 8G'5 !_V!Y]^]>M$TZ4GOW6^O>_=>Z][]U[H-,V+96M^H],9!LMB
M-+$BWT/J(_%[_P"W]^.#^77AP_/IKL/J38V;Z6/^V(&FR_ZXM]/=>/#JWY==
M +S,/5?3ZA;](X8:[<?7_>/>^O5\NN(%[_V@>.;L;W!/X-S>_P#@?Z^_=>_P
M==M?_7'%N1^"3< ?VK,?K:_^]ZSU[SZ]SZ>2;GD7L"]S<CC^GY ^IY][].O#
MUZ\+6-M1L-+74&QL02!>Q%AQS_6WO77L^?7$V 8@  6!5B0+Z0"#R 2#^+>_
M=>'EUEF57A=9-++9V", RWMJN;?6X_'O9 H<#K0H72HQ4=$V^-5%E*+Y#_/*
MHJ:&HHZ;(=P;'R&#GJJ6K6GS%+'M6M@R#TS6\<Z1O(%8CBQM[M Y5CG!/^7I
M7<QH88=4:U S^P=%*Z0^'.P^Y>P?E)O+>6[?D)M#+3?++>%#'0]<=W=@]<;4
MFP\6P.J&H<^VWZ%XJ"HR575M+ TT2^%X8@I;4/:6\<,,U],&GK_/JMM1"-(7
MA7(K^7'AT#N6W;UI\>/Y<^[=L[XW%FMNT<W<VYMN;2J-Z#>FY\_G'QF]J;)9
M=J?-T.$R65RN1@Q\1EJ:NLB5)0&"NQ*@F5O+ NW6:&,:EB%<"I-:9^?SZ)+Z
MVFEO[R5"2#*2*&F"/P_+^?1F,[W?L+J+O#8?RXW#6UU=\:^T_BIBMG8SN3$[
M4W)D\)M/-X?.87-(-RK2XS^\6+P-9C</*ZPC'&9ZD*QCN/:"C,Y8,:?LZ-K9
MC'I5\DGAZXZ>NH=P0?*;Y/;W^2/266W/A^G<-\=*7IS9G;_]TIJ$[FWKN#=,
MNZY=Q;)P&\Z6EK=PX+;]/5@>:KIH8HJI6C:/@,RSO6.@<T;]G5;Q]5Q$:U 6
MI'H?3_5Y])3YG=5=J;-^ GR&VWV#WMO'Y09C-97K1:*?>&P-H8.KQ\$?<6Q)
MJJ@H,1L"@C.1I10)+(_D!"^,N>2?:55&LASJ8=&$"Q'23&H&?GZ_ZOGT).5Z
MWV+)\\.@<K1=>[8%/%\3]^T[U:[8IAA7GBK* 8]<L$H8Z)*N.,%8TG5JE5-A
MQ[57,82T4HH#F4YI0TTG_BQ\^FM2$T*8X_S'^K[.BDTF/_N1M7K??FZML[K7
MHCI_YV=L[M[&QD&W9Y\=LW:57UO78K;V[\OLHT]16Y78N'WMG*:K5Z>&00,6
ME5&;TE19Z#"5= 6(\Q]M?]7V=$EYK\>J.0,\#ZTI_J^WJ3NV#'_(7&_,KM/X
MR;>RVX^EMZ=<]982/'[2V7E=MTG<>Y=G93'5V_AL?"5--A<ID#'B*<P3R2P0
M%VB8>K4+E4NLW,.EJ)J&/4?['1M"56&36H+Z3D^OK7Y\.E/M[O#X[=W_ "L^
M%$GQVPL591;#VMWY@-W5&%ZWSVU$V%ET^/VZJ(;'RV0R6%Q4%;D8*Y'ADYDB
M>>VB5@1[,=*#4-.:_P#%G]G20L_%BW^0\,?M]>D%L/ ,_3?P!IJC;<I%%\[.
MYI:N&NVU/7-%1R[S[N=*BOIY\?)-CL/,M2IA6IM%I,1YL#[<(BSVCAZ=4J>-
M?]7KTENZMB;TS$7S1K]L5>]=J8':G\P+8?8._MR[*V5C=X5U+UYBL!7TN0R5
M-L[=5+_ ]V4N%>='EB*S0$"ZCCVBKCXCT83 +%"0,E?L-:#SZ4_66QJ3N7:W
MRSW=T9\D.WOE#N3,?&_<_4V+W3!TUM3HOK[+Y/+1UN1AVIA3M? [0RF6WY13
MXNFA662D5Z>*1M,A$S7;(#>=1]G2 5$A&:?,U\OLX=*F@[E^.O9>[_@7L#IG
M;;4_8O578#XCL7;U%U=F,%GNHZS';#@QV8QV[*N?"4%$DTN1C(EECJJ@%@26
MOS[JU0-*-1:\/+JY)#*#7(_U?D<]&E^=>\>ONM-P_%G??8]5C,-LS!=^Q-N3
M/5V!K-TT^WZ;)TE*M+2U4..PV;K)\?D)IBD:!-",3=@1[:*T(/E7I92D=0M3
M0?+UZK<[/QN,VGW#\E=J]P_)KM7IJO[MW_5U/6FQ,+\:MB]I2?(':6X<'''M
MRHZUW3N+:V7R5!D:2'51Z:FMQ\<,JQE'!N%>4L"=3FO17)W @EJ#R!I7[?\
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M*O=G\U;.R[5IWR&9[+W8*'.MM^FCR&2Q\?Q6V@D;8"IKZ!LI)21UM3-#'X'
M+E@;W(]^ ]3TA<$4 &*#HM?6^]^L_C^?B;W=\FL3/@.H$^*M1L';>^]P[.S>
MZ-M;&WXF>K)ZO Y7;^/PF>R.#S.<IY%9)10R"8'\#40T !*20,GCU8!O"1?]
M$ _/RZM ZNS.P]R?'G<N;ZMV)F^O-E9S$[WR^V,)E]M5V!-;1Y3&5C5&[:#
M&:2IBV]GYG%10DJCM=CXD-A[72&J$%JX_P G^3I&I;6"W"O#\^JN-A?,3H#?
M/P2PGQ4ZWW-E.S?DGGNF*SK2EZ9VGL3?HSAS]745=+G&GK:_;>*Q46,Q5 WE
MF*UK*53A3R?:"(1D.,&IZ,] 6C&,#YX^WH>,CT)1;V^0]#TIO-,JU!)_+YZ[
MVW#N-J.2HAV[OS#=G;DJ<'N*@RM.HCI\AMK)1H\M.)2[IJ#&TA]N!(U-0@!I
MTGD8E6 <TK_D].@@ZS[W[1V+V3\W=W]G;'W51]K]-=#=7].U&07;.2K]O]@[
MXILK4XC:^Z-ISTX\V=I<Z)8*W(A+?9EB!9?=I9':(1LY,=10>5?LZ8LT*W#.
M!FAZ;L7U)\T?BY0?&CM3LZI^-67VATCN1]N;JP'4FT>TSVA7[2[\W9AZ3L-,
MS7[HKLEBLTJ]GY>@JJUZ%56+[2,QVC63V]"G:5T ?/I2_ALY)!)/D0*<.CC?
MS)Z7^*?&W;JT5 ^9J#WCTG.D(Q<F7K)X&S\[5)>-*.2:D@CIP@=G]-AZC^/:
M*Y":30<#_GZ,XG(AFI_OMACYE<'[>G&DVKCIOYEW8&6EV7056+QGP[_AV&R=
M=M.G?!T>4I=_;/KHL5BZ^2D:FAEGI*>1BD05B$N+6]KX%5K9'* M45_9_GIT
M0QTU.?,G_/U4IV=V,,U78R;=_<V2VYNGK7Y-8+<'9?Q4V/\ &;&T>UNL]N_W
MNS\6%W;F>S/[KMOXT&7BJJ?(UD]#DZN2>JKP3&(2 I;9N6N0AD)-1CRZ71C5
M2JU_/'[/]7R\^EI\E.^.O=A=_?*+I#+/U-6XCY*;DV5N>3NKM+(YNCR_4T57
M08]1+MW:N*V/N7+;OQ<" -0M1U6/D@EMYH^&(?N" =(%#^SIR:'])67M]?+_
M %$=6 [(PFT]T?//'96IH\;V1MR@^&/7>,H-\[BQ\.<H]U;:J\U44^0S)RTM
M+58NIKLC24L=6\"-]PY<@\W'NML'SK)-:?X.BI&)=0:C'^?HJF&ZTPV$_EM]
M5/CMDQ8O<J?*'9%=3U^*VO4ONFFGF[MUC(#[>G3/XNCJ<$KI.TCB,0.5^C>S
M9A$)31!31C'^K/1I!H(&I03_ )*^?SKY^G0;=SXRGV9WK\K-F]V?*KMWIC/=
MV]MYO+]==>XSXQ=<=OOW3U_N ^+;.&ZQWCG-KYF=YL%2H:/34UN.%*\BB-BP
M<J63F@ #$'_5^SIRBL%*PU%/6G\O/H[6QNLJ3#?,3XJ;?R^V]P;JH=B_$7-;
M>CSO9^VX)\Y3,:^"*II-V,ZUF$P>ZZND</44ZNZ*%*@^D7UMX!:Z$S?@'J:&
MO2&\(7P3$:'7\LBG#H%-Q';_ %M\2>S\GG\-'A-F["^<.=S<K5>U<C)2;9V7
M'V)N>>KS%%2Q8S*L,6M,L4C/2TTL/J T'4/=;H@%J&@KY>F>G;85"8J=/^;K
M-\F>V.GML]B[E[*V7O\ I*+</=?6.TX=B=8=J_'W)[QZO[[&/H_/MBHZMW1C
MMO39K&O7Q)]K44LXQ=.DTOK "FVUK0,6X]4*D%@%(H<_ZO\ B^K0NL^U=K9C
M^X_7&1EP^TNX*/J?:6^L]T[15;M5;'P.;PD%/6U,<,M'%CYZ.CSU>^+C6"5I
M8$D#$>D^W:"AKQZ;/'Y=#5?\?7^R&X])_(N;D 7N/S;W7J_2SVH++6_4?N)Q
MJO\ VI;<"X_'^''NPX'[>J'B/LZ5_OW7NO>_=>Z][]U[K__6W^/?NO=>]^Z]
MU5E_.2_[=W_((_CR=3VMJO\ \SVZJ L#8_7BPM_Q'LYV;-Y;_P"V_P #=!SF
M7%C<5/\ #_QY.M'&QX)]0M<CZ?4@GC\@_P"O_C[E^U-8SG'^R>H*G!\:OG_L
M#_5^7[.OJQ]-KD@6N?K<?C@+P?9M:6>M:GA_Q?SZO)=%+>AXT'^'[.K#/Y6.
M2Q>.^?OQVFRM13&@&7WS1T8JAS_%,WUKOO!X2]_^SB4_7ZC_ %O8,YCC,(=1
M_+_:_P"?\NA!R,XEN?G_ +$G6W1\DNG.E.X^O8<+WQD\;A]F4.<Q&7&8R65A
MH,71Y''5*3T4&XJNIEBITJIY8U24.0K'2/<41(8Y*T_+J:Y',BX;%?\ 5_@_
MV>JC_B]OWJO%?S3_ )79NDWGLK$[7JMG[/V/M7(1;DPL&T<VN/IHZ>EI=L,C
M"GGKF &H(Q-^/K[%D)#6Q 4^1IY_G_EIT$+C4LQ.H4R/.G^H^6.K_IY(Y&IF
M@=)89<=BC'*CAUEC;&TK121R)=9 ZL"".#<6O[($0_5S34R7;_+\\=#*U*G:
MQ&14!(_\"]?.P[:R6,R_:O9N4PLU-48C)]C;ZK<354G _A@WGG!@C8:18_7_
M &'N6-@M_%6IS_Q;?/J!=RE$5\P'Q8]?X1_J]>D*0FF57CBDBFL)(I8HY89.
M?J871HY&/UN1<^SX<!CHI-.XUH/\W1ZLV(I/Y9>S*&66DFE7Y29V88C[_'OD
M8:>3;6+CHZH8TP,*6G65#I*H!Q8_3V'7MZZBH\SZ]'43T=:U^$?X3T(</=.]
M>G_@;\=SLU]DM5YCM;M9<Y1;JV!UEVM4K0P8S")2-%C^QMN[GI]O&2:1_71Q
M4QDTV8L%%D4U@92#1JBG D?X"/\ 9Z,H-P6$M0K]M >-?.A_V/EUWWSN/L'O
M;X7?#N>JH\9NKL'+=R=CX./:FPMO[(V=/7BGQ-=!CF@V1M&CVU@IZV0D)))H
MA8PWNS?3V6WEA,)5[3PJ?]5>C6RW&%HY:.*@@?R^SY]&Y[#HGZK^?.'7M.B'
M7NUN[/BM0]-;9["R1Q='M"BWSGMC18VGHOO:/(Y$(V+S3_:54DBJL#*UKVN7
MK1%(9D;45J#0>?F.FKF:I5  !@TK7[.'RSGHLGQ)^)_=GQO^2&![?^0.WH.L
M>J/C?75&Y]W]A9#<F%K-O;K?";.RVWL52]>5%)7R56;J=P_Q**1AH+#4>0MS
M[67DL<MA=0HPUM'PSZXQ3Y=(;8:+RV9A0J_J/2GE7S/[.BF?'#<D>YOG'U%N
MQ7BQ5#F?DSM3=%#44]2V-H:3#9#?-/-#D:AT>)(%6D?4W*@_GVHVVSE%C\%1
M0>7R^WI-N=Y%]2VEZ-W9KP.?.G1YMJ;LS>+[I_F\5])NBLQBY/8FX*-JG'YE
M(,E55;;YPE%0'&E:SQ5J_93,K&,$O&S!B1?V2FRE^J4:.%*8X?YNC9;R+Z4M
MXF2#6AX_(XSY<>D/TCOW9NS^E/Y<>X.Q<C1P[*V-\K.Q:>NCW T%92;:HXX,
M141RR4TIJ5P^TY\A4&5'CB#I/Y61PWT72VDIED4(:Z1FF/\ B^F=KNT$E=0(
MKPKPX_+%?E\O3HPO8U%W3UIN3YB]ETGQ8^/FS-O[HV/V(V8[ZS?</<^Y,9W3
MM?>N2FR.)_N_3;A[FW!B-T9O)X^I2KBIFQRQX^2T=,L*(J L-JYI&'+.IR*#
M&304P!3ACJVZWL/B.4"@E0*ZC7XOM_:"/RZ++N+K";>'1?\ ++W--39'#]74
MN0S> [&[>P.3Q]/)UJFY>SMITZ5==N3[O^-[8R..QTTCP2-3U+QTZ65A>X46
M412>X0L=80&E,TKQ'D>E"W,7T5KPIK-#7SH/SZ.IG.H=SX#'_P Q[#;2^,&W
M=@XC<?3\V'V-W&O</8&]NSOD/28[)X6H_B%7B=V]F9C!9TUF,IWJ!404E)(B
M#Z$#0U)XF\5*R,1K(I3 ^1] /7I9;W$)C8KIKIKDY/\ LYX'Y_;T!_>/QZ[\
M[6?^6]E.G\#D,O0;%ZFVK3SY'$;OQ&//5>8I<^U7F<ANJIER(3;*_P .1KU%
M-#$2O&F]S[4VZB-9B]%[J9%*U7Y<?]0Z3W5Q'J7N!Q4=PQW?/A]GY_;-^3$4
M'RCZQ^9^ROBS5XW>^[:CY;5.]]W;1VQDZ/$;F[;V_/CX\?19G;T%944L^?Q=
M%EUEF^Z:9VC\FK0>1[#PL;B*+899"51;NIQ@9.>E=SN%L2X!5A7UXX'K_GZ%
M+KIFVW\G?Y>?36YLBU5WCUO\>>U<1V-!5;UQ69RF/J<[LO<[;,V'D\Y'#3T+
M9/"J9%\#NL9,X5U?0I]GR*6'/#5!C:6,UIBGY^O11*XD>J5)R!GUQ2N///&G
M$=%CJ.@.P>T/ACUY\>L1BJ?#=B9WYW=A8>;%YC*86BJ]ITF6I:3[K/5!->U,
MR4D*,\DL0C10H\; W]IMT5FGMFP%%NN>/^KY=*=N=5MWC(JQD]0.-3_J_P /
M2^7 ;@Z%^0WQOV5_H5W-T_\ "GX[=L;:;,]J;DV_M]<5OOLRIF3%S=R[T:AS
MU;6LV6JR4IZ@,ZPT[#2BD7]V,<C0L%>K$-0 "N.-*X_;CIF.X@\9"=/Q#SQ3
M\NZ@^6?0]3NPX>[.H<3\R=YO\7.@.IMN[LV[N+%;I[:R_=O=&XT[MPFY<TD^
M(K-BXK<7<VX\!NK-U<#+5))58V5H0NE"B^GVDBAD^L@JQ(!(./EY^G2N:[@-
MG=4 H:4H>'V?X*-TG-Y=2]P=Z]A?R\^TOC\_]Z>G]C;&ZCVM'FL?O.@QM-T[
MN/ ;DC;L'^^#&MHYMH_Q%?!(HA0^;R!"=)L31PJ"56!&#BGQ8K0>N,=,VEW&
MQC'B#43BIX9'_%X]:]%MRFVMO;]_FK;IVONG>-?LS;V3^2]?CI=T8S<-9M[(
MTM$V3BJ:C*8O<='D@V'QF8\/A,E//"I62XY]^2)Q;HZQFNBH7S^ROKUZYNH2
MY1I%I6A-:^7'_5]O1P]]]3[VI/AS_,)VWB/B)MOH(Y?.;4RNVZ&B[0W?OWL;
MLW"[6W;04V=WY]AOGLK<E/40FGC>8Y2D2G\L9)>&0DD$TL+_ %# 25.LC/KZ
M?;Y]/K/"UDA4#X*D@_(_M\A^SK!O;<%7!_-4^$$N,W+XJ"DZ*Z;H)I$W3#+C
M*?$5'5D]/7P5E+%+#14PDEB\=0ID!>13J4< *HH)" 5X9\O3C_JX=)6GC\5E
M<@F@\_V>ORJ./D>@#[,ZWWY\A_AI2;#^.F/IMY9KJKY8]PYKMKK';.<P.(W'
M_N?S-*NS=[U&VZMJ>ES%-3Q031)7,TTE&L>I;Z_:^W @:;Q.TLE 2..?AK_.
MF!Z=+)[M!';G4-(>I%?EQS^7KP^70,_S0\5F,!WEU+A]S5W\3W7BOBWT[A-Q
M55/FEW-2T]?B:*HAKL?5;A6HGDRV7II]"2%A&(]!4+;W7:BOBOI6@UMY4S0U
M/^SY],[Y.DEM36"=*^=?Q CAY@>G#AU6Z+CD3-_3@<< ?T](_P /8@QY] ^M
M#VCKD !(3P1SS_2QL?H1Q_L+<>_9(ZV  >.*?ZO]7V=0?S<C_;6N>;&_/TY_
M ^A]ZX=5\ACKJU^#8C\@G_'@W-_ZCWOK2T].N!U6!YX+6-_QQRO]JW/^M[U8
M8  .?^+Z60D?3N:?ZJ]6@_R5K?\ #G/QIO8<=P'U#\GH'MG^FKBWL-<Q_P!D
MWV?] ]'_ "D?\:SQK_D?KZ!7N.>I<Z][]U[KWOW7NDQM G^Z6T/S?;V$N>3_
M ,N>$WO^.?Z^_#@?LZT>(Z4_OW6^O>_=>Z][]U[KWOW7NL1DN5L-6HD AOS^
M+@7XL>?K8<^[ 5!->JN=+!:9_P!7^KY=:#_\W3<E1N[^<+V[BZ^>T'7NV^C-
M@XD6%OX6>L\)OWZ6(!_O%VE6WMQ[RL]BY%#@D#_5]1_J_EUCY[LP,8&QG/\
MUA^?[?EU8ENFMHMN=+=#5H*_88[<62HJP!3ZLE_!RWUX_P ?9AOTC7+NOGI'
M^$?YNH\]O]M42(3ZG_ _S'4[>OR+AEV]!A()M-Z.U)5?>6_+ *38$6_V'^\>
MPQ9<N"Y;5_J\_P"E\NLE%O!9Q:0/]5?L/KU4OVMO^;)54^W<;08W)'[L5FXZ
MK< _W&4!_L_QNP'T'^Q_WCW*5CMBP\*_ZJ_/Y]-(,UZ#/:^W=O8C=$^+BQ>:
MIC5T?VF'%7B/]QHQBB_&:Y-A_K^UMQ>& %:X_P"*^71@@)H13IHR^!Q4-33[
M)J(:G>M?_%OXQ6#[P8_&8$DD_7U6 !_')/LN@NM9^?\ Q?R'6YKL:#3_ %</
MET&4V'I_]-W4E/#]S4Y;_2CL4'[0W6B WE@C?BU_IR ;>T-_(K''^KAT0S7?
MQ5. /]1X=6)_)6&"OV!7'P$?:_\  2W'].1SI/)M]?K[#%EMWAW2DC_5I/SZ
M?$WA.0.'^KY?/JF[X:[GGV+_ ##OC)F\9/\ OMV[_!:G_@V]\-G=C-<>GFV>
MY_U_>N=T1(%'GFO[4Z%VU3B1*G@?]G_5\NOI1]>9A<YM2ARGJ*VU&VH\6/-F
M-_1;Z _C^@M[@$\=/V]%(P">EK,PU@'U'D@  Z3:VG^I)!_-AS^/SM>!ZTW
M=:7G_"@'*S[H^:>#V[?_ "#9'06Q,.>0/]RN<WCOO>XMQ]1_&:(GD_ZY]S%[
M8VRK;SRC\;U/Y!T]?Z/0CL$'8A'E_G/5(V.VW4<?LCZ?XD&Y'(])'U^GN58B
M5E) _P!5.EL\0)H6S3[?3H<^G=K[?@W+0R[[QFXZ_:/\7QM%NZEVJ/\ ?S5V
M, %\-A!:^W[#_<9_6_\ O(>YSG:(%0?]79\O\O08VU/%/ 5_XOHY'R#^4&[>
MS*?!;87[;;FPMG@_W&V!@*NVW,#]<)_&0>?X_N$&_LCY8Y8CWAFDD6K4R?\
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MXY_K86TV4W/'^M[K]@ZMUR)#6!&FPN5L3S]2;W-S<_G_ 'OZ^ZT.NP2!S?\
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M69T5>%4D@#Z6]L5/Y=/!JGRKU'U>@HHY8Q^1BP,LIB:\;32G5+.UK*2S$M&
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M]?)M[$U=9D<?BJ):R::#%4R5U?)+)]LL9F;3Y"VA+,9\^J\/LZ6WTN>0!?U
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MODD+202.-,/"I>U_>F6&,8 /Y=66>X<DLQ KPU5_P]899JA]--_$<G404M=
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M*5\P?\'IU=;*%8XVUY8&N":$''#C7_B^A SO\O;$5FZ^C.O.M>Y<SNG>_=N
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M-^G_ '/;BX_XN?YXO[ -]=R7S%B<T_S?(>G1];E+, ?/U^W[?7JT3:-/28O
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M16[4[!VMWGF.SL;MJ?86YMRXO?.'R4.,5*.FW'3QR1[<JZ":FDD76PUZBHL
M+G!M+DN!],?#TY/F#7T\ZCSZ8AOK=,B<:BU>(I3[>/'R_GT<#,_,'X[;U[B^
M5-;E=^9W;.S^^_A_L'H;;^\#L#<&9^RWS@MN4^+R#9?:\4)J?X>*F(@5FD1@
M#5JX]IH["YBA*"W8L9"?/@3QSZ#R^>.G+S<[:>>*0W2T5/5>(\L''\^D?UKW
MW\-\YL[X;[=[HWMNK'T_QPV-OV7^'Q];;EW%B9^QJW,UL^UJ;+4%/22U53MS
MR>&KE5>64M&6'M!)872R%X[-BQ(KQ&//\P. \^GTW"T,.E[Y:*II32<^0XC#
M'B>(\@>D-L7OWK;ICY-4_P EZOY!U?R.RN_I=S[<[6Q^U^KM]]2;DVUAMST:
M4U%N/8.8W='!1P#:7BB6GHH0L86E "?N:2HDM+F2SN(Q:-XA3 XU->%!\L](
MQ=VZ7$3F<! V6!I3'\J'_B^DEW7VUU7+UCN[!X;YA_)?Y+;[W%NG&9+;,.YL
M9OO9^QMI;<QN93*G'[OP^ZCX=S;AJ504XEH?\DC4:^18A-9;=? AI=O=6 H"
M5S2GV?Y>A"=TV\6VB/<8B30D:_3\Z=&1P7R)^$NZ/ESU]\U]]]J]@;#W13XW
M;F7[.Z4H>K-T[EKJS?5+118Z+^$]B8>GGP,VT8O&'EI%9I(PUFY^BV:RO2&C
MCM3A<'/[".(Z"]E<VJ7"N\]%J/,<*\1Z_G_Q=;NP>Q\-MCY([=[/R,U4-M8C
MN:7>M75PTUJZ' 5&?ER'FH**B43IG!2$%G(L19?J/9A%82_2QCP6!"]-7]Y&
M^Y7<BS!HV>M12G[>CY8CY.?'_:/:/RNQ6W.]^Q<5U[\G,KFNQ,#W/L#86\MG
M;NZEWG5;JSN=I]M[BP51%!N;>> G&7U2_8 J9+L+?0E,UA=Z$9K(B11PI6G'
M@?GC]O2^UW"T5B/JU /JP%>''_-FA'$])S;?R@Z3ZT[Z^*N\ZWY =^?(G$=5
M9_\ O'VUVIV#2[PCQ^0JZEVI*$[*ZQS8?/TL.W:2=EDUH9)D9F_2/;%G83+]
M1XMJR%D/E2I\AJ]?GY=++[=+)U@5;Y'*N/Q:J#UH3PQPQ7ATEJ_M#XO[QZ_[
MV^-FZNV=Q;=VG5_(6O[SZ8[VHNL=VYBGR.4SU355&<PFXM@4<39/%TR4]=IB
MJ-"Z98P?TD^U[6SLJMX1#:14<?Y^?V^?26VO;89,Z4X5+ 9_P#AT,/77S)^/
M75?9W2NS<%N3=V;^/O17Q^[FZXPNZ,ELS*TNY]_;\[0@RE579"MQU'"N2V]A
MY,ADW@B,^D+&@<\DGVD>QNSD6[\?0^O1LNZ[6B,)-PA!H<%AZ4_R?M_9T0G$
M=K[+QGPK[5Z,EJ\E!OO>W>6V-_XR@I,4TF+KL#28 T.9^[R C,>+:AKV,=+'
M<:J<?3Z>S!K:4TI&=-*?.O0<CN41ZF4 U)^7ET=_97SFZ;V9VCU%D*>KW[BM
MHTWPUI/C7V#O39M#)B]S["W'D-VUF=3);2IO&F8RO\%GIJ6>IJJ:\4L;,JF]
M[(&L9&$@:!J%CCC48_U4\NCN&]M@ ?JE#4'G3S/SZ+SW=VMUG4]:;3VIC/E9
M\C_EKNYNQ8-U9;)]A-N_9_6&V]KXK)15,.+GVINTC<.;W T*<21WIB0- N;^
MTRV%P)J_2%5T^0\_M'^#I5-N%H8TI>H?]O7^7#^70U5_S'Z+F_F:9'Y-G)[D
MK>G<A@'V[%NB39D]5N/"[CR&SXL%1;WQNT<I TZ2;7R?'D1 TD<0=3S?V?/:
MR/;FB@29QDXK^WA_/H.)=1+* 91HQY@>0_P']HZ]V1WM\?MV?%O??4V\OF#W
M;\@.P\WW3LWMC^\>X=D;^Q$E;B<6*ZAKML]=5NX4#;#SM%058=*FJ*T9DB73
M>P!"TFVW8OHVCLW\,$BH7AZ?D>A+^\;)]LG1[U?%-#357Y?M ^SIPWO\O.G:
M3I3MK8=3WYOOY44V;QNP:?I'97;?4>0Q_874>3VGE:')TF:W?VQ5TJ8C=ST%
M/1-CVCQ3DRP3ZV%DX4K8W>/\584\P#FO&GI^?1:MY "U;A<@_B'EP^W[/Y]/
M6[/E[T3V9N7;?<FX_E_\L.KZ)MFXJ+L/XF==4&^/#F-\;=H(Z:DI=F]B0!]H
MX'96XIX@T\<Y,M.C$?@'WIK"=J(;$E.-:?MQZ_/I7%N$"U87BAO(ZZ&@X?.@
M]!T37X2]X=?]&?):J[4[&R>;H]L5^T>SL!,(*2?=&<R60W+MO*4>$&9KU2;S
M115%5&LDI-F:_/L27$*ORU>6X ^J94HOGBE<?+H(64CKS?#=L:68DD.L_#0\
M,\,^74SMKO;K/>OQ?^(G5^)R>8GW?T_V3V+NKL-)=O5%+%_"MR[CHLGA/LJR
M2,1U:+1TK"6F0ED91<>KVFF@9N8DN%'^+?NT)J%::\]M>%<C'0N6]M%Y9EMV
MN8_JCN&O22-6G'=3TP<]('YK]M;*[S^2F\>T>N,AE<EL[<&W]@4E%+E\'/M^
MMCR&W-DX/;>5CJ,94I'./'6XMQ%(19X0I'MK9H)8+1$D0AZ<.'F>B+>YXIKY
MGBD#1^HR.'\^BJ,18C4!]/\ "X)'^V)%_9MPZ)^()K3_ %?Y?]7S;?I):X_'
MU)M?D<?06]^ZO7 ^SKJ7ZFUP.2.;6L!;Z7'%O]X]^].M>1IPZ\ ;_E@+@\_C
M7<GGG@#GBWOWY=* *M@\.L1 XY!X'T^O]HFWU%@!S[W]O6B 10=8B>.#:Q;Z
MDW/]"+VY'T_K[U8?(9_XOJ\.;9JD^7^'[/\ 5^?5I?\ )3*_\.<?&@\WMV^2
M"> ?] 7:_P"!JO>_^Q^GL,\R?V,HKG_HGH_Y/Q>5^8_P/U] ?W'/4N=>]^Z]
MU[W[KW2;V:;[1VO_ .&]AOS?_EW4_P#B1[]Z?9UH?Y3TI/?NM]>]^Z]U[W[K
MW7O?NO=>]^/7ND)OH7HJ"\EK92$BW!%E)MJ' L?ZCG_>U]E\9QC'^7I!>GM7
MNSG_ "=::?\ -3_DC;O7L/=WRA^$>*QU7_>^MRF\^T.@OXN<;][N8J^<S>\N
MK2X<7W0[7;%\7/\ Q;>;8\35R=S9^YWHQ(I3.<TU8PK=V:'T^SB&-SLA/'H(
MKQ]/EZ^0.?*O^"@7K7Y5;MV!F)L+6KD\;EMLY?)X?*XG*T9QN0PN2PCLF;Q&
M8PKQJ/X\K*5^OU_K8^YF',T/,,=&>K?X*>1[1GMKCR_G$6\<A&[9F513%/F#
M3(JZT I3)X]6 [2^<V$R,4$.5I[5(/\ RAWO>]S8$64W'^/LQ^@A<8./]7SZ
M(1RA,#P%?R_Z"_U?SZ$:3Y>]=P4W[\U3>X/%RP%^.2 ;K]+\^_?N:-C0-_A_
MZ"ZH.4YE[J>GI_D;^?\ ,] SO3YR[5HJ:>'&0&I' _U7TM<6Y)(%O]Y_UO;[
MQQ0U:O#H4;;RX\3#5D?\7_2_U?X*ZNW/E1N'?-5-!]]4K]Q5?9T=+3E_XER%
M_HK$ $6X^OLNDWJ&WJBL?R_Z)ZD[;=MTH.P?ZJ\,G_4>CZ_$+^5YN?)5=!WU
M\T:"GVEUYMBB.\L5U#E:L?Q/-_P+_<X,KV@0;;?V]I-SC/J3QE/X=S>&]YYG
M;?'T+P/E_O)J:JO\)Q7H4V*4^T?[/4CY3_(7='<>ZZC*Y6<XW$XVLR=%L_:H
MH[?W3QGT.DWL-P@C_<W]/8@Y8Y6>X&LK3]G]+^F/3I?/*$% <C[>B(Y&*>LE
M\TU1<@$$$6LIL/KS_3GW*<8^H(%<?ZO\W04O+I8%:OQ?\5\OGURHX!#):F@Y
M!(8<FQ-[\G_6'-OQ[,DL%7+'_5^WH"W>\ZFH!P/Y>6.'^#AT9GI_'G)9RA\\
M)^PIO\MK/Z&Z\\6-B!Q8?GV3[M;),#_Q7\/0@Y:9XY.'Y_:'Z,+5[NFGKR;C
MZ7^U -OT@< W_3_O)'^'L&> T3$@?X/\_4E27VA14_X?\Q_V.FO(9V;S04\
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M.D CJ]PKJWX(5U/''-E-^/I?Z>UJW0-,FG15=[01G3D'Y>O4(W_/TOP?]A^
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M[)V+L75_&L$57/LNW,V1;*WM?G\^SNVYE?9U5APK08%1ZU[6/$TQ7R\N#H=
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MA92>!VE?Z$_\1"7/=P/%;T_V(_ET>[&Y95J<_P"RW6QT"=-[VU>KZL "2+V
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M?07'^M[U^76QYU.>L)XOQJTL0=(%@"2/H+%F/T_I[KU;KHFS?YK4#J-R;?J
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MU[KWOW7NO>_=>Z__T]_CW[KW7O?NO=56?SD;C^79\@_J5,W4_P"H #_F>O5
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M_N^,_P!)OV53_9Z+7,; 7_(LP-KVLUSR1Q<?UXO[/>)H,CH.&@H375_J_/\
MXOKF3:3Z:E)Y6X/U)(L0?\3]??LDUS_J_P!7[>MX%*@?G_JS_+'V=2,;D<AB
M*Z@RV*K9L?D\7D*3*X^NI6T34N0H)(Y*>>-A8DQM&./R./S[>6>5!I5J>7#_
M %>76\G/GQ/VUZ.EO#YR[CWBV^L^_1/1>-[AWUM48#>/=<6-SM7N7/4<M)38
MW(Y!-H5U-_!,1N+)T5'&D^1@03M8D&[$D)?NT"1B2Q7/;Y5J36OG7]G0B&XO
MH05 /K4>@'#RI3U/2FV]_,.W-MG>>PNU,W\<.B=W]N]>[(QVQ*3M+-3;H7.;
M@V=0T,N/DPU9MRFC;$09>HQM1]O#5QJ)XT6X-^?>FVM7UU+:3Y#%/L/\^MQ[
MI)&8R&7%2":4_,4_R]%_[!^26<WOT_@>C*'8^S=J[!V]VIN7N?#IMFKS,^2Q
M=;O#'U.+DVS)-FTBDEQV)AK27(+,"OU/M1'L(N:N%R,>?'UQZ]/P[K,L3JDF
M*CR'^'^70C8[YT=C_P"D^K[)FV;L+(T6>Z=P?1&]>M"*VJV9V#L/;./IL=32
M;J:8"JQV1J&I$D2II_7&ZAD(('M0NPS( $_+!-.D$VZ3EF'C]N*\/]0_U#IO
MQOS:WUL_<G4>4Z7ZKZKZ-QW2U5NBMV]LO:.)RF?Q66DWE#246[*/=.Y,Y%+E
M-RT&>QU#&LL4S2*@C&D >]R;/=+!)XTA>,K1J@BHK7TP:GI5!=KK634!(IU#
MA@\,<*C\NDQO[Y-TF\.MMW=8["^._2/3VV-\[QI-X[]FZWQN<S69W)F:2K%<
MDS9/<%.9<!0)7#R?:TCK"A/TX]E<6T0QZM*L?2M<?+[/]1Z4S[I*P#&8?R]<
MGRX_\5T@/D%\@=W?)#>VW][[LQ&WL#7;:V#LGK^)-FS5E72U+;&IUI(VJY*I
M5U:J$%3S:Y_P]JTMF3"5X]%,U])2E>VGRX>7^?H0>O?EI7[,ZPVUU!V%TSUC
MWIL+9V]:_?/6D/9=1N+&5'7.5R#1S5$>"RFWAY:W#5<\*M)0RLU.[7N+D^Z2
MV+R$N&96)%:#C3RS_AZ4VUXJPJ&:I -*D"A/GP/3M'\W>P:T=MXSLWK/J+M+
MK'NO(T.6WET]F<#7[1V&N4PE%1XG!5FWJK;\$60PQQV&QM-3B2G"&5(_5>_N
MDFW!PX"E6/ YJ.ED6YRPA-$@H/+&?\/^7J=AOG#O7;?<NRNXL)U%TQB,1LS8
MF8ZSPW4NW\7F<1UZ=H9W UVWJ_'5&>B@BR];E9L;72!JF=C,YY+$V]L2[1"R
M >&:GSS7[?\ 5CJ[;U<. 'F#*#@8I^W_ &.F*+YBY2BZVVWU=2]']1'%["[+
MS/:&PJO*IGMP?W2RNY:F&3,8JJP.4ISCMS8*MCA6*U4K*H%QS>]%VJ  4B/\
M\]5&[W2X\<4/V?ZOV=0]^?+[*;HZ\[(ZLV#T;U?T5C.XMR83+]KU.QJC=V4J
MM\UNWIS68D146567&;:Q-'5R-)'1T0CA4M;Z 6LFV(&U$$C54#T^SIJ6_=J$
MD<*5QFOGP'K\^BD.J$6(O8 <$$<?UM;V)<^9IT'ZC%2=7^'[>N!8K900!:P-
MKD_DW^OY/Y^GOV<UX=;!%,'/E_/_ "?Y.N)))N0+ GZ?FUQSS_R/WHUS4YZ\
M!BH!H/V_/K!,2+6_+&]B/P2 /J+@>_8Z\H(\J$G/^K_)U&+GD&PN+&X'Z@?]
MZXX]^R3UM--0.'77XL+ _4<_GD'_  XO_O'OQQ3TZ=5%X>?'K#K(N ;L1]/I
MSR#;\D6_'OW'''KV@!C04)Z[UL!^KD6OQ<B]^3_0#VG?XB:=:H/E3_53[,==
M:B1:X_)N!R.+6_J;@>]<,]>%0*'\CUB9 03S]%_/-O\ 7M_OA[]ZCK?Q $C_
M %'SZCOR+?@$7_' ^G/^O[V>M8"X.*]1?,?]C8<-:Y%C^""/K[UY=6H <_X.
ML''E)_UN3]>-0%[@B_'^L/?L\.MU[?RZP_CFX_M$6_%OZ?UY_P!?WX]*0.%.
MI!OQ^?I?\V'! ^I.D6^G]/?OLZK]O'_5Y?\ %=0[$A02>001_K_XBVK5^/\
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M 6('/X]^H*_EUH<#GI@-E N01R "#Q?\V!-M)'/YM]?=>G.N[L#]"+$6+68
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M>>>;\CGD?CW+_P"!>H*DJ78]-]^.;_7Z<\_BW'UN!_L?]C[,2<YZ3Q#N%/\
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M'^\>]>'%D^&N/D/\W7@*$J%S\_\ 5_EZCGU<GZZOJ;'CFY(O];_U_/MQ0J@
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M6_I]#_7GW8<1UK_/U-D8ZR6  93J^NH'2"PM_9MJN1S[>ICCUI#VX_U?SZE
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M.O>G78-@;DK]./4+WL=1('-[&WT_XIOB.O>=.NN!Z23I&G\AFYL0>" #IO\
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M.5*C2"6X]7((/Z^?Z<G^GL^V^W&UII!HU*5_,_,^M.H(OKB?=-^:[O\ -O\
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ME_&N,D_R5O\ 5Z=;$/\ +CR-\+E_MB3B-S;CWWN?$CZ:ML;V[+S^=P>8_M
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M-_;? @>?3(R*UP/Y<?\ 8^VOKU)_ /U(/! XY(^OU%@;#_B?Q[L,&AX?ZO\
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MJ9\B0 38\,W)-P2!Z?\ 'Z>QGLT]ALW,MMN$#UMXM0&&SJA(."&/%CY']G0
MYU@OMZY/N[29>]M-<KY3QMY:1Y#SZ$W8G1\8J*"#-8K);BW=58C^,4FR<55X
M7^*?PHDG^-9HY\?[@=OW-^3_ ,1[[8<J^[RWW)UI;Q>6O^<[GSA'IU\^?.?M
M0]CSG>3R$@'1_*!!Y3'U].A=J>L\GM?Y _$'*ULV%JMP566[APW]W\!1G^&8
M('IS.YU?X+G% W+GOZ?Q3\V_XMN/]Q!S+<"?GF(^E?\ M'7Y#K)'VZVIMN]H
M/<\D_P#1N_[3I>.3Z];#/QOZOJ-LT']XLI0?;U^3(^T6KOR+@O:Y!/TY^O\
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M_=&]7T.9@&T<I16V_5;0Q>YMQTOV=VW:,WFM^8+^#9RPL-O'^Y'^YJPOF/\
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M7V<G_5GY=-R0EJ \/^*_P]"5U+UQN?N;LW8?5>TXE&Y>PMQ8S;6)^\.97%T
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MGD'^HM_B3;G^ONO5P",=8W' /]>+6'^(X'(!_P!Y][%,^O3B4TCB1U$M^?\
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MU7D<0,=Z;$#^-WTWX ^G^Q]X\@WMM'I$*B2E*UQ^P,1Y]9EKS_;S.#Y<?/\
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MX\Q/!05F0R %6,QELKE:S^)Y'.9*X_C>8S>:SWJ.X@"!;\_T^ON>.5K-48
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MI^7F_J?GU?\ 8BBAI<90000FGIZ:E+_:,2+7-M04$GU 6'^W]AZ5JVU:\?\
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MY]01./U>&?\ 8'4<<@GFWTOR ;#G@6L1I/U]I+"B"C#_ %9ZO#5K=F#&F/\
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M3;3'(P5G _U#YCH0VUSNNFMHYT?[3Y_Q?GTCL%\8-^5E=X,G3BEI_N[6!)Y
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M*X_WW:Q_[[7]OVUY!_>+^[UN.RS$V\55'S0<1;#SN6_B/22\,^6K((8+U!_
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M>Z<IZ5;Y_P##^K">E/CWUS\?\,F(V+C2U;+&%S><RM\AN'+1JS!4 +, NM^
M !S?W&/,?--SS82UU=>( **,X%0?,#S!-,#SI4]2'R]RY#MHT6\"QBN0  *Y
M%>T_8//RZ':VHB_^  !_4UK:OH#;C^O'L'6RKMF7R//^?V^O0CO&TCM_G^77
M92?_ "BJ9Z:FI;>:2:JE6"GQU#C:2E2NK*@NRHM.1%)*SFPNQ/X/NAG0EO7/
M^?IR-5*K7ACAT5_K_P"9OQI[7WY7]8;![(DR&]\;%D)S09C:6[-N87++C)'%
M9+MW=F9Q--MG<C1QHQ6*@J:B5U%P/;\0#T).*=6MCXVOQ ="D\/ECYU'SZ2F
M._F"?$#,[FPFT\9VY)+7;DKZC"XO-3[/W+1[-I\OC]PYO;62Q^4WM58V+:^+
MR,64V_-3K3U-3%*\KP:0PE7WN91&*^9Z13L5F,6: _Y :'I>]T?+GX\?'C.X
MG;_;N_:C#9C-O2I3T&V=K;IWW-C5R*M)B*O<?]T<9EGV_C\M #)!4U@BI&56
M)D"B_M/$[.I+_%7_ (KI4T:H5$52M*_Y^I_:/RFZ#Z=V?M;?>^=_P_W9WLD+
M[/J=JXK([YSFYH)D#-E,=M;9L.9RU3A*%7(JJF*-XJ>1=$A#7'M[[>'5*'R!
M)Z8:OY%]<YRHZ"W!LGNG:2[*[5W/N'%4-#4;3RN8S/8E5MK;60RN:V?0STD$
ME9U]N7"+!]PRU,8DD5/"5UE5-E4FM!Y?\7UX5/\ J_U?Y>B(]#_S#,GW8ORU
MW?6=W;*Z]V+U%O#+8'9$>=^/6_(DVQL^AWE#MW;F]MVYK*T%(=R9S=5+*89\
M)&!58Z=Q)*@"W][\$L13CU;25I48/^KCT>7MGYG_ !NZ&S>U]K=K=E3X_<NY
ML?CJNGQNV]E;GWF\-+7T,4E-N+.1[3Q^4_N?A,M,_DI9,E]O&$)NVE2P\\78
MP/PD$=>56+ C)!_9U+[>^97QNZ,_N^>Q>Q&B7<E!09/''9.VMQ]E+'C\MH-!
MF,E_<G'9@8[ S*P6&LD(AF]1++H;VU&J0CM/GULO(3I48^SIAW?\@LS#\B_B
MCU]L3(;5SG5_?>T>TMW9K,+2R5V5JJ3:.S,KG]O/M[(ZXXZ%7KZ)/N59"S+J
M0@'VXSESW4Z4VR++ESC\QZ=)WXS_ "I?L+K/;>Y>Y,G@,-NO>_>O=W56RZ;!
MXJ3&X_/-UQV1O';6!P"I)-4_;YZJV]MPSRRE_P!YZ>5@-)L#,V41".K&A0$U
M/F:UI3[.'2>:,6[.4%14_9T:+$=D;*SN^-X]:8;/KD=];#IL76[LQ*T-9'%A
M(LSH.)I?O6B&/K:NH# 2)'*TL ]3+8&Q=,H2@4UKTTDKRDAR .@/'S9^+Q[1
MAZ='9IAWW4Y>AQ259VIN^38]/N O-#%M]NPAB1LVIJJRK#4JK'5,PE%FL2/;
M<-#D_%7K9@$3F5 :T_U#K/VK\P_C3TQV%C>N.R>PYMN;\K*2/)5N'Q&WMP;N
MH]K4E1;[2'?.6V_CJ[$[/IQ&PD@;(2T^J!]8.GGV\<@+@]:N!]7F6M/ECI%U
M'SIZGI?EWA?B9''DZ[*[EZS_ +\XS<^*VYO3)8VJSM350#'[>H\S18.7:TV"
MJ<--]X,L*S[?R@07N;^TEQ#&@1@23JZNI=4" 54'_4>EQU/\B>OMRS8?:U?W
M!A-_[QWGO/L?;NRWV_LFNVFF6K=B/]QF]G4]+6)'CZC-[/QZEZF?S?Y6#=+Z
M3<P@?3%6N1\_]CIAG?7I4"G^JOGT[[L^5?06Q*3L"KW7OU<4O6F<@VEN^&@V
M]N//9.BW5+0)ESAL7B<5C*JKW%DTQ,R/4P4*SM32ED/*GV7RDBXB<?A:O\OY
M]+([=9$+9UCY\:?ZOSZ!/M+^83T7LKXK;T^5>SLADNP-L[6IIH*/;T>UMX8G
M)56Y=++0[9W+BJK"INO:<M82LR3U-&D7ANQ( ]NR2-*26ZJRD4IBG'H3Z_YD
M?'S!=3;1[LW'O7)XW9F]Q6OMW&2[(W<N_<I%1QTD53/CNOH\7+N^IH<=5O(:
MB8T@TPR0D\R"]%B4=U<=)V9P2H'=]G2CB^4GQ_EZ:J/D!+V?BH.I*3_)I\[4
M8_*TF:@RZ%F&$J=G/2C=$6Z:JVF#$_:_=2B[:>#[;\"/2RYH6U?GUZ5/'55<
MG'ICH'.D_F+MGY#=[YW9_56?ILQU=B.G<+O]I,SLK<FT-Z1YW(9_/86<5-!N
MBCQN6IZ*V)71!+3H?JZ%D96-'E*O'*O$''IPIT_&[PIX*CMI3/&E:_M_GT*G
M<ORX^.OQZW%@-H=K]@56$W%N&&EJX,9BMJ;CWE68RDJUD%#5;HIMGX[,5&T\
M9E)$;[:KKA# ZQL=5@3[>C7Q(S,Y[ZD>GSQTP!1RBK@Y/Y\>DAV?\F=RTNY-
MD]9?'#K_  W?':6^-ES]CT\V0W93[8ZZV_L.&>*F;/;HW+CQ7-0BNFJ8XJ2*
M,-*\E]:@W]T1V#:13I5H71JJ>A$Z-[0[-WU_>3;_ '-T[6=0[\V@^,^_BPV3
M_O=LK=-%FP6H<GL/<%2*.7+X^C2(_=-(B2+(6 4J+^U4FH1!O.O259")&4$4
M Z#/IGY<OVS\C^TN@LCL"+:N(VL^4DZF[&BS<^7Q7<-%M/+R;8WO4T@2D6BQ
MK8S<=/*L(6:3RQ)<?CVB90Q(I0]/:R,GSZ3-=\EOD+O?L'?.%^//QZV9O_K_
M *IW%3[3["SN\^S_ .Z^^/XVI6;(0;6VK04]=29(M1@BCCJI8&FG*JW!/MR/
MCI'#%3Z=:))&2*?ZO]7ET(?;G>^Y=L= T'9&V-N2;!['[!S.QMN;"VCV'CHL
MD^)WINVNABGVQN.AH9FD23&T-!D6\B\M((]0%C[<F/A_ <CK250T'I7H-,K\
ME/D+N??W8.QNA_CYU_V=@NEJ_%;5[6S>\>SCM'-YC=U3A3EJ_#[%VU3P5YJU
MEJ*:1*=*R2(O(5 6W(U$P>FH4'GUYP),O3/3;\A/E%\I.L^MO]-W7?QHV)G^
MM:;:^W<UF\?VSVO7]?=H8+.Y[,8;;M3MG,[?QN*RU!#5X/-Y8QS3I)*DH3T_
M4'WL)I9J9R>M  "FKACI097NOYD;7Z$[$[8WCT#T%1;JVCAX=S8#:&*[QSU=
MB]Q8$4LU77R5^:."-7BJVGBA'VZK"XG:ZV%A[MJ-*4Z]Z4./S_S=!]N_YU]D
M=6]??$K?7:/0^)IX_D%4TM7V-_<+>M7N+#].]>Y3%4^4I^PVJZK'4]9GH\/'
M6TXKJ,QQE%E=B?VN6WD52*\>GH_A8!\?ZO/HUF6[UIL?WIT]U#AL-1[@P_;_
M %EO[L[&[U.6>B%#A]FU.W(:&6GIVC-%5T6<I<Z:@.\J:(D5A]3;WBOQ0"AZ
MWQ!+'AT7'%?+OY!=DT]9V=T/\6\5V+\=J.;,KBMT9GL8;=[4[(H=O5TF/S.:
MZ]V)#35%)6T$=7!*D!DE!E,14\W]V#2,.\#P_+'GTRR>18Z@?]7^HGH^&VL[
M3[LV_@MTTF.R^)H=PX2ARL&,S5(U)F<55U:1O48W-TLA26EK*)]<1 4QN5)4
MD>]XZT*B@'E_J_GT]*O'YO\ 6UP0#_3^EAP?Z#WZOKU<N:'KF6N>!<\?0<6/
M'YN>/]M[]U4 >O7$$@+P23_L.222+V('^M_M_>OMX=>]>N(YX&DJ#]3J](O]
M1ZN+_P"'^Q]^ZW_AZY$#ZW](^A!X%[<<?6UOH+<>]XZUUUQ>XL3_ +>ZD$@C
MZ"X_/]/?NO=>"V;Z-^+_ (-S:Q%K$W^G^/T]Z^76Z\3TK=H@VK6NQNR:A:PU
M,21_AP/I_KGW8<#U0\1]G2T]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW56G\Y
M;G^71WY<V.KJ?GB_'?'5)])/]1_B?]C[-N5LWUI_MO\ CK]!_F?_ ))\_P"7
M_'DZT9P;$'ZDCZFS$Z03PO!^@_VQ_P!A[G*GZ:@?ZL]0-.?U,FM?\W4<WN18
M?3Z64A5LH)'!-VX_/T]I!V TX].;75K9ZC&/\)_/_5Y=/VS-W;AV%NG;6^]H
MUM3AMR[1W#C=R[<RM-I/V>3PN9.=P8L38"P_I;WX6R7 .M:@_P"#KVV3O#=4
M7A_EH3_JIUMY;'[M^.'\VOXY?Z'<]O&MV#O^MI:6H[ Z[H,W%0;MH,ACFBDK
M:O;51(C-F]BT\JEDRFET87!^H]Q#?;8UK(9!32.'\N/<3Q. *CJ=K'<Q<IH*
MFO\ Q?#'H,UZ#\_R*/CE!!0T^.[C^1-*,=E<=G*N@H]\5%%B:PO+Y?)X8Y$H
MIZ;6HN5TZOZ#VF@WAK8_#D4_U5ITKN-H%POQ>9\O7CYCK#_,,_F(; ^-_3F2
M^-W2>]8-Z]S5NUI=AU66QN23+P]88.@@-)E<ON/.QKH??T%.JA<:27LH# $:
MG$6U[<U[>23R"C,U<?Z4CUX"E?(D^7J$MUWB.WL8+6'*HE//^,-_#QS3S%/M
MQJ368<,2/U6]3"P^G]0+M>_YMQ?W)$-@(5J,_P#%GY]1E=.UW(VHG_4!]GI7
MY8ZQ2JO) )UDFY^G(^@'-AS_ *WO1&:UQTEUG\Z_['6)Y-.EP\$,]T8/5 +#
M*(@1&6E5=#M&/T!OH?;;!!4TSTH2VF8 @G2>'SZ<Y-M9JAQ>.W&^,W#1XW+O
M6T%!G)\9##@<Y5P2FGKTI\L"U#455+(#&2C:TTZ6%Q;VR9T0=I_P=5^EG'EW
M 9X],E53-(9*6GALXHQ3BAG"PT,-5'(KFJFJI%!FJ)8KG5'?D#_ >[QO!<!B
M],'^72VT$T*FI.3P/^K_ "=8:,47W54^,3[9:J.*-8J%(IXVJ::GDCK/NFJ"
M'6.KY#N!R./;;HGX<GJ\KR4)\O\ 5_DZ[I((/)$+8Z,K2+&U/2M#*M%!'*=*
M4D4X7T"_(4G2">?;<:#Q8P_P5Z+Y;B2)))$.1GKC6K#,)**IB 1Y/.L$4I<K
M.K+]M%4'6@=YXU+1.K?M("0#[5//#%BH_ET_'M\D\1N17AQSZ5_U?LZX2M%9
MZKR2$F>""LJ4I6$D4H(2"ECC$8%5'"0/6;^]Q2PS$@T^?#I*C33N(*8X>?7%
MJ:.B-255Z96G>.JJX*:DD@JZR9'B\M3#/+K4K3.(R0+*J*/Q[8:2&I%1Q^71
MB(I1P\A\_LZD8C"93)>5=O8RLF7&02563J<7CI\G1X/%T0+UN1R"X^"61Z!H
MK^0R6"W^ONOBP\!Q_+_4>MB.4#CC/K_J'3*T-*D+A:":!"C)-CW:(P2QQK''
M32R55,),A!+1LK32*PO(LUFX]U::(C2OF/YC[.J/#,K*2#6GSS7K%X:&6='B
MCAG9)8&@1:.%(%DB4NQ"'0U-13?B,C2PY^OM#X49<$]/B68)BM*'UZR4]/2^
M9?M8X?N$BCH?+*:.EI:77/YZ=B$D#M'!4@-< V_I[61E"IB(%#]GETG(F5UE
M->/S\^G'-;9RN"GPK;BVWE,!4YFBJ,[A:?<&%R&'R>=I:UF$>32.HI4I/#2L
M/+%4ZOWTMP?;4LD46%_R=>#ROJP<?;TR24J$&66D\DJ0QQPO(M+!)&T3$I5X
MZ.:4*U46)LXXY/'/MA?U<CB>G1#,^#7^?GUS^TIVC5I0DU2I5YS50I_#*F41
MZ%J7JI=$;5P')86]0][\-!4=.CQZUJ:_ZN/4(QT[/%(L40,+TR1.K1.!44KR
M,DSSL&C3RK*Z2 7#QL1^??A&F0.MDS^8]:X-.I#NPBE:#_**F"0*+K%2TZO*
MQ8TU#50%D:&7Z.EN1]?;HF2*)D^=>F#;SR3*QQ4 >9X=01# 4DAC^P9_O(WI
MIZ,B.!*V>2GJ:LT6LZ(DHV$E.P)MPX'U/M LJ.X_V.EC0W"*6H:G[?\ 5\^L
MD<%+-9EI:-J6"6H/@J BK1U@D<O-2T,3,DBLKW U:2;<'V;@1"&K4!Z0P23K
M<LVD_">NFA@IHA#3^<4L5(\:8^>&".J9M3R/61TT1?AG8N=1LQ//MFL''!I]
MG2YC,]17CGS_ -7^K/4.""FCLT;4J 48EK:N*G5*S%Q)&(Q4I$H5:C(LZEV*
M\EF8^]_HT'28PRL>.>N[O(T,<44QEG,%(NE/NE$]5?[+)U$E-K\,%4/\ZCV2
M'\GW[ZE >/3WT[XZ[#LT3RPK&ZHW,D4GGB9>;M&R>HH?QKL??OJ5(%".M?3N
M,U_9UGQ=#5[AR5)BL+15^3RM944U%1XZBI9:VMR.2JV:.CQ..IJ197JLE72&
MT4:!B;$'VK%PGT^EF]>O?3O\04U_U?ZL==Y;&9' Y:IPF=PF:P6<QU0^.R6'
MRM%+197&UL+&.J@R&/J52IHY:64%6255Y'''M"+A!)QZ]].WQ#@?]7ITVSVI
M!+,[1IXK(QFO)/4*S (U/24:SU#?N,NKBRJ2;\>U\UU'X"#SU?Y.M?3N!J%?
M\G74<B2&>)9EF,$&NJGAB>3[6HX(A2G4&>J@TW!=5.D_4>T7U*G-?\'3@MV\
MEJ*_/K!)/$\-.T8CTS7_ +50)!HYN\<J(8[Z?I[V)E<T#9/7DB*Z6(..K2OY
M)#$?S./C"> "G</U' 4=!=L\FW-K+S;_ 'GV3<WC_%A7Y_X4Z$G*)_QFO#A_
M@?KZ"GN+>I4Z][]U[KWOW7NDUM!@-I[3!)]6WL(!].3_  F!N;\_1?Q[\.'7
MCY=*7W[KW7O?NO==$@"YX'^^'^]^_#NX=>../1=?D3TWCN^>J]S;!JJP8_(5
M8^]VCG13"V!WIAV#8+,7N 6AS=KVYM].?J0;CM7CC)_/]GSZ7V.XM;&J@^8/
MS_D1C_!]O5 NX<)!L:C@Z#[/ZXBZ[W9CNS-K9FK[;Q6&RM=N/:76N;#MO=O]
MP""3MO8#C#VP^HY?##2/XGC <$;X]_N#>.6B!,_GQ[.&/1GX:L4^>3B@UMX3
M*NL&JD?9Z_/CC@:4^70B]=3=>9;L>A^*G;];C^]^M,[5Y3;?1_;FTJD'&X7*
M?W-CWQG,3A<W@-P:\%M[<NW<U0C-8L'^#8?,?9\-C+?P\:[0L&\ )<"I\CD4
M^(^5!Y?M_/HMOM4%7&">(\SP_;3A\QP\NCW;&^"'Q>V9A_L(NI=N[R$B2^/+
M]CX_#;SRE!C@WC_@^%$NWU&Q, K(0!BQ8G_#W)DGMY9Q$1A>T^I.?/'ZGK\Z
M_/H%WO,%US!<_O+;P%9&R,'! 7BZCB%.0.B\]B_RN^JH\_%W+\:\UF.F?DYM
MJJ;+[([2JJO,[DQQ5\0N 79^]=FYYUVQG]N';8_AO%\R+WOQSI^1X=H3QH</
MZUQ]N7;U^S[?*6>3O>*7< -FWQ?%@TD$4TGN+-\21*,4%16OG5>#3J/YJ=^=
M+8ZBQ7S ^*':M!7XVB^TRO;GQMI$[GZFS@L"V87#Q@=E[?5B1_N,RN';D?G\
M&L>]%!E*#U'^:G2N;V]Y5W$N-FE#2MW*K>+CSH"T@QCB02/4U'2Y/\SSXAR:
M:=-U=JQYDZ@V!_V5OY&R;E^ITC^"MTRG' N0/S[7+S0%%"3_ #_Z Z)V^[GS
MS?DOML=8_D;?[.+W()X'B.DMFOFAWUVU3UNW_BI\.NW,AN:KI5_A79_R<QG^
M@?J7!,07_C.<P>X+=FY]--[XW%X<<&_OUSN,LX.E3H'GY>7G3J]ER!#L5S'N
M%S<*(_- 1JJ5*^4K,!4\=(QZ#/2R^.GPLI]A;Q/?7R#W?-W[\K:Z@KZ2I[/R
MN.?'[>V+BLXUY-H=7;+9QMG8NW&C91?2<QEVY)-[#4.SI>ZIIVJQ-2?Y5 !&
M!BIX <:=%O./N5#N<";1RJ@BT(% %20:J^3-&!D*U!@X)J2RT&7Y;5DN.Z(W
M/!% 6&<W#UKMBJ!!/WVVL[V5L3 Y[#9H?V=6W?O?H>?K_C["ONQ.=MY:G,)P
M=/S_ -%AX5!]>/1/[8[<=XYG@\?)[O\ JU+Z%?X?\O6N;V!F*VHS51//IUM5
MDU=C==7(///J_P!C]?\ 8^^09M6W?>[PN:S/2F!Y(OV#@ORZ[9<N&'E_EVV"
M+11J\S_OQ_\ 3?Q=!#5541C:"$:R ;D%;?GC@GZ_XVL?9_;16D3AKJ'6WVL/
M+Y?E^SI_Q-PVVX"W+U'V+Z?*OKT'V2D6O_R))2;"P!-N#I) T?4VY/L9;7=[
MC"^C;$*H?P]I\B>+C[?/_)T$^?N5MMYGMU:9,_:WK'Z.O\'^KS&CI+KV+#WW
MKNG%U&2Q]/6+1XC%48"Y'=F2:_\  ]G84@:KWOQ:_P#R\O?9WV9]UI^9=GE=
MFSCT_CG_ .%)_#UP#]XO92'V]WB-5 TU/K_!!_P^7_?G'\OL/ILCI/=O8=!!
MA9ZW;M/V;G-QXO>67W#B\2-Q[)H\J 5P6&_@=@&P&UMN'^&#^OV/M'>D[OND
MS2MV#/\ Q@?Z7^'HWL42+:8Q&N3_ -!GU^WJR'9GPG_NEB\C48GM;<6-SV3P
MX%52FCRYV1_>8;S.^3F,ULO^\C:;;>_W&?PSZ?P;V4W,2,3I((!_;PX9SZ<>
M/1KIK0GT_9T[5OP]S0Q H<9\@.Q*?/';IPE3E,O5YC<6-SK#=_\ '1F<UA3N
M,@L0M'C.".*"D]^MX1'1F6N?\_"IXTS3TKZ=;TG@#4?ZO\O72_$;=4V4>;+?
M(CLB?#KN4Y<8NE_BN/\ )BO]),>_/[H9C-+N1FSJ;I>2MQ6;U!6S16CL,>M"
M* VJ. 'G_J_U4'[*=;-U@$G-./\ J'^K[>A&Z=^/E;U7NP;BF[6WYORA.R!M
MJEP.ZLMELDW\3_C'\?\ XU?^\3$C3]?SR?>VJ>'&O^K%"/\ B^J_5<<T'[/\
MG1_MN<X3'$?3[:PL#8W>]_J;&_\ C["]U^*GH/\ )T(?Q'I]'T]TC^ =>/7?
MN_6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[I,;T'^_/W;]?\ CVL]:W/_ "ZJG\< FX_/NPXCK5./4^3U,Q)OK'%Q
M^;*+<:2?H/R/;O#\NM@G33Y_+_5_E_P]2HCRY-O^!LJ@\?32WT%AS>X_VY]M
M#S^SJI\OMZG>Z]6Z#O-D_P 6K!>Y\<(L/I;QBW'T+?C\<CWL\?RZT.'EQZ8C
MR"=1 MQSQ<$<$F_/-^/]?W3J_GURM8 !C?F[ &UB/JP#6''/!X'O?6OGUT%O
M^&%M(^OU8&S7TW8V' _K[]UO[>L8:Y/A)4#F_IMJ'Z5('%Q8BXX_/O1DA0
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M.IICOR@HLA7Y/;4NV^VL/M_<NT\+09A:A!6TLZQ2,Q)>Q]KY@M!I./\  ?\
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M,'B)MIQ2A))J1TJJPE; \^_&2=BC$C3J'RI3_"?EPZ\+:+2XH:Z33SK7U!.
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M26GE2.*DIY% "O=KA5>7DEL*QYT\:CU\@?7YBM/3I/8VT5R2D@ U?"03@^I
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MGO;[@S<_;K&\8QGT_@@_X7'P\/\ U>=LGQTZJJ-K8X;BS5"!D,D0*34;:06
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MW?E-OTN,RNY)Q)6YZKPN+J)Z:&#)K*B>+%P.78JI-YG=AQ<^V;B569NT\?\
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ME4NXAD*)@<.XYI\\T-/E3Y],.(^2-;AOE=4?*2@VLL%55=D;FWE6["_C,_\
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MOWT;$*"YH#^9^1QGYTIUOZM0'&,BGR'V=W^&O18OBUWE#\<NY<=VK+M9M[4
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M_)Q4YY'^('NP\A\QU6F3_J].G!RAD<  *"+G_7 4D&Y&D*/\>![= H!7KV7
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MVX(ZBA4[BB=Z>6I9?NHE/DC(87]JT&:'CUL0Q:Z'\O7CQ^SJKNEV7W=%U_\
MRF]O1]Z4F3["S^2@RF"[-RO6&S:$[+P%?T#42X[#8S:&.I$V[N#-;*Q)EIZ>
MOKTDERBJIJBS 'VFH/WD!7/AC_#TBNU"3C0N*5^TU/1ELE\K.VOCWTY\I?\
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M4U!60;AVY54]76?9XBKI-H=\ UV4:R_J_P!'0!N!]?I_O7M0???G[#?ZW?\
MV?VW_;/TH_J!L5-/C5_*3_K9_L]2)NQ3$<A#493"_P"XRC(RYJMI]\$T L#?
MGK>X ^OUYO[]_K[<_ FOMW@?\O\ ;?\ ;/UL\@[$<>-G[)/^MG^H]84[!O-C
MX3E=M_<9.E6LI*7^X_?%Z[&$7 XZY -K_P#%T^EO\/;]U[J\U"Z5ARAC_GJA
M_A'_  G_ &.G[3D#89]MD7Q:''E)_&?^&#TZ"3OCY'Y7J_J3=V^ML-MS<6>Q
ME:-L[<Q5)M'MX&NWSF\U_ \'A]7]WKC<!W /^+7]/\??M_\ ?/F>SMD#\HT%
M<_XU$<:E_P"7<^OK^SH>>SOL/LFY[B[B:O#RD_@G_P"7@>GI_@ZA_'_!GIO8
M1VQ6Y/'Y'?N3K<EO[L_<%5L7OD;DSF^M\?[G,WF\VQZX+#;VDVM];4'^V#'+
MW.WNO9D,>433_GJL_P"E_0/KT*?>0<O<Y3A4G[OLE](#GX/X#T,IW]Q04\64
MPO\ N<I?]Q'VVQN]_P#+Q^?X(/\ 1Q86/UY/L87?NK[JA1_R$,_\]5GZU_WS
MU!EM[>[%M<.IIN/RD]2/]^GUZ[/9</VM=6S[BVZ<?BJPTE;5_P!T>^?X9093
MB]A_HY%@3]1?@?X^TEG[R<VWVX(DUL*9_%#_  GT@'F.J0^W'+]E9LT<M3]D
MGJ?60^IZ8<[NW<6<V?7SUNULCA(*4]9YFDJZILP/]R0WG@KX7_<]MZSN?X'_
M +>O''O(JSW_ '"^LDEEC[L^:?Q'T4>7G]G0%AMH+*Z*QG'V'T^9/K_A^SHV
M/RKV;#T5NOIW^9%L9WH-R=9+LCK/Y%XFZ_P[L#H'?&[\!LS+YB0!M2;EZL&?
M&74$7TT'\._I[QFYCVLV]ZDU" K4(IDCM'KP_P A'K7K/'V^WD\UG>^2BHTS
MHF@G #*LDW'2I)JNK!/PL?+3U=@L4$U&J@C_ ">YAN&(82L"X!)6S*?P2;\\
M#\F@#Q0@L,Y_P_GU!DW^+1W>VEJCLI^W5_E]>EI[OU;KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I,[OM_=/==P+' 9GZ6-S_"Y@+@
MWL;^[#B.M>M./4UN7(YMZ;V)TW^MP1JL-0MQ_P 5/MT^O7D!  IG_5_J'4N4
M &G.IC:L/'*D,WDX^@-@"?\ 7!_H?;7Y>75?/\^IWNO5^@ZS8)RU;_K?4<FP
MQ0U"P^H*GWH]6QC_ %>?3&5%_5Q8 6'TO8CZD<F_'];_ (O[]U[[.N[@CDA2
M;#B_]-/ 4$?3^GX/O77O+AUX-SJT@!23_MR!I:]R+GZ<_P#%??NO?GU[Z?DZ
MN+_6P_M W&DCZ?[;W[_#U[CUQ@!M_:(N3]"NGU+>PULM^;D?X^_#KQ_GUUSJ
M%C:UKWL2 0/\"%L#]+<?X>_=;\NLQ)_PO]1I4$*O]3<DD7'X_)]^ZK^?42K\
M@H,PD:ZI'P]?%!"%UF6<T.0$46BX\C--(JZ?[6JWY]D6]Q7,D;?3Q,[E#P%<
M^72ZTD52"S  $<?]7V]5+?'+X0;\S?3FQ=H]H=N]G;,ZCI,YG<[N;XUUVTJ.
MEJ\AEHMU5.7IIZ_?-=64^XHL97^B2.F&-(*GTN0 ?8GFF_Q6UH 91"H/\50,
M@^G^'H/6B3B>8NKA3,Y&.WCQKQ-1PQ3H?>Q/A#7[SWMW+7;4^0^_NH>N?D=3
M;D@[UZ]V;MO&Y*'=^X,QM1-JKN+#;QRF3I,]MAUV[300RB*@J*6=T*%Q<CV4
M6LDX>LB,,^8-/Y]"">12@X,0,9%?^+^51T]TWQ)W%B\C\9]SXSY#[PI-W_'+
M:M=LN?-S; V_D#V9LROJX?/A<KB%SJ46&RHI(41<A%/(5 +^._(73]\X<?PB
MOGGJEO(!8/&?C+G!-#2F#3/2@H?B%LV@Z:[NZ5AW9N&7!=W[ZWKO[.5>3HZ4
MU^*SF\UQ1KH8*NAEF7(0T_\ !X0M0Q4OQ8"UO:@NHC.17HC>.8RBBMISY?X/
MY9K^73GVW\4]@=Q[L^/V\<WG-R8VKZ!JL8]'C\=1P)2]A8;#TU+_  ?;.\EJ
MF5CB*#<-)%D0$UN)D!L /:)%8.Y/F.C;4/!1?.O^3KCU[\2ME[ [C^0G<)W+
MN7<4WR#AEPV=V;DX\5#MO8^-RE+(-Z+L:>"5ZI:?=N6F:OEU*X,S$"Y]N_X.
MFC7'RZ +;W\O_=^%@V'@$^7_ &D^S>F.P,'O#HW:K;(VQ3XK96.Q&6&3BPFX
MVI-PU+[\B^W,E*D\T5#44J2:A%J&EM/72P4YIU=3D57KCLGJQNP/YBN_?D#)
MUQV3LS975O6R; Q^3WQM+.;<PW9'<>0KZVBSW:&U,;FJ.DBW1C:G86-PN-@R
M]"\T""@4!KGF\&!DT^W'5V:H*^?1N>T^E,+VOF>F-RYG-YN@K>DNR,/VSA:'
M$T\,<.;K<960M_",A]WH,;R&($K^H+<_3GWZ<E@",D>G28@^(2!C_-T@:+XC
M;3QG3O<'2D&[MP5&%[A[ SO9&6S%11XUZS%9;<F],+NRLQM+XZPAJ6CJ< L:
M,1H:-P>+CVF0,."4Z=\5AI'F!_D_V>ARW!L7&[BV!F^N:RLR5+ALMLO,;(J<
ME34U)+62PY3#386#.BC6HE@J*ZDAF+!.!P/:I./SZ]X\BN3\_3HK^ROAHFW\
M5\;Z3>'=N[>R,G\5]QU.2Z^R]3L[#[=^\P5;L^IV=B]M5M#%EZA)%PF.J6)J
ME9I7)LT2A02P!7<5D:H4(!7RX^O34A9W)*D_ZL]+_</Q7ZYW?6?(6;=M1G\W
M1_(\;4DW%14YHL>^T:[9\4,&V<OMK(/5*YKL7711UD9:-1'-$#8KS[5;B0\2
MHE& %,&I/3R5730TIY],_2_Q[['V!NF/=O9?RB[4[ZK=NXD;=Z^P>Z,%C]F[
M<Q-(94OD=P4>+RN8CW7G*H0(#D*TTKQ(EWCY'MF/$2CSKY\>MO0@X_U?LZG]
MY_&^L[)W=@>WNM.V=V=%]X[8VWDMDTG9&$V_C=\09;:F5J8LOE-N;BV5E,OB
M*7+TT&1I$>EJDJ$0E0 2UA[V?D>J#TICI ;@^&%;'C.M:WKWY#]G[1[@Z\GS
MT]-W)6XG$[VR68H=WR15._L=D]NY^LP>)QN)S>0#M0TL%;.]%$P"AQR=</SZ
MJ]=#<1CRX_EQZ:L+\#\?C^N]\]5YWO;LG=NWMX=L;?[D>LRNW-O_ ,<AW+CL
ME2Y3*QG.Q99S7?Q2JI(RDD@B-(BV3R6/OU!Z]>M#H7(-?G@_ZOSZ,-N_X^[,
MW[V)FNP=WUU;EH]P]19GI+/;0 ,6/J]IY?<.Y=P29&#--+#5IDT;<S(FB(LC
M1@CD>]^?3\AH %H1\ORZ!CJ_XA9_9.5QU/O'Y*=I]K]7[1QV2V[UMU/G,-0[
M3QF%V]DJ*7%5.-WAG\5596OW[3T6(E,5**FFH=+ &Y/'O731/"G'J'U_\.-T
M]?YS;.,Q_P HNX9OCWL7+?QG8'10I<;CGQ HJB:6DP67[(H<K5[CS^VX35R/
M!0SXV&)4TQ>7]H#WO&?3I0K9S34?.O\ L=#UU3T=@^I]U=Y[HQ6X,GFI^^.T
M:SM3-PU]'!21X3*5%#344>'QP@GF,]!#'3@^631([$W7VH+(UDZ:OU QH/,@
MC]O\NDI+_7H]/TP@'[#3)X<,\?7H/>WOC;N#>_:F-[EZO[SWET;V#'MN396[
M:C;FV,5NS%;PV@];3URTG@S>5PM-B\E234J>"ICFDD1A<1-;V66",FHNE":5
MK@'I;N,@D5?#8$_T<GT\\?SZ0.PO@OB=H8[IC'Y'NK?N]L;\?^Z]Q]R[%7<N
M)Q=-D:BIW7M[-XJKVMFYZ*IDERF$6LS]14M4B,5,<A5!$4NP51R/'<2,/A*4
M_GY?L'21 O@C&:G[?EC]O0E9SXL["WAFOD;F-XU>Y<M3?)W";#Q>[,'2M1XA
M-L+UWMZFVUAZW:.7ADJ*RER\2T*5$;5,<1N"HN&/MN660."%8CJW$"HQT%W7
M/PUW9MWL3J/LOL_Y1=F]SY+HF3=V.ZPP64V?M[:='2;9W/LO*[0JJ+,UF.S.
M9.5R]/@ZWQKD93!-4.GC\.J3A0DOZ;KI^(>?6JGRQT,'?OQW_P!-%3LG=VV^
MR-P]+=Q=6U>Y?[@=E;1Q5'G?X;1;A%+!FJ3<6W<C6XS$[KH,@M%$Z**E7!+D
M?4V02*Y<,%./05Z<!%*'^?\ DZ"W:WP8V?2;+[\VEV7V=V)VU6?(C<6%WAO3
M=.2-'M#-;;W?MW&5-%!G-B_P2?)-B0U16&IIXE:5("@C#M<V5VM$()/[?^+Z
M]6O$_P"K'^;I4]>_&_L/;N2W!E^WODYV?WK/DMF[JZ^P%)E<+C-H[<P.%W72
M3X_S5> P6;W ^XLW'3%2V2J#&5L"^EVTKMLENFR<]2L?\2-LXWICICI5-[9^
MIQ/1N_=L=A[9S<V+II,GG<KMFHKJR'%92F2H2CHJ)WR#)Y(Y9+J+\^_>76L@
MG[.@U[%^"^0W-G>VZ;K_ .2G9'2W6'R &<K.U^K-O[:Q.YZ*;<F:Q+8G*9O;
M&Z*[*TM?M7^*1",SPPTM1%4"(*&4"X;(_4&3PZ<+5MBI(K7R.>'I3_+7H8L+
M\9=NX?L'X_\ 9E/NO<39#X]],Y7IO;V.JJ:F%'N#%YJ';E#/E\W3TCRU..KA
M#MI'6*$2I>0ZREA=5JHE 1TYMLB1!@^!CB:8'^K_ %'IER7Q*P&4V]\J\ -\
M;FQU1\K:ZHRV7S$5!AQ6;*JY*=H(JO"P+7R4%8$GTL8JN2"2118@#GVA(.IJ
MJ:=);@ SDHM5TT_R?R'4/:WQ1CILCTUGNQ.SL_VKG>H.J=S=/551D-JXS;&-
M[#VON^@HL/DL?G\7197(?PN2.AQT7CFIW>'6-3R(./;R?">/39#&I/27ZV^&
MF=Z\W)M.'_9D>W\OTAUG4O6=<="-28O#QX>I,J_8T6XNQ:/*U^3WM@]NTO[,
M$,]'3K)IU"1@>7B>T]PX=;49!TGCT)G?7QNR':NY=K]F;![:SG2?=^RH*[$X
M;M3:VVL=N6+);;W P.8V[G]G9C+X>BR5+&=+++YU(*:@+J 6\].C'ECI$9?X
M;K7;)V;1TG=W9]%W1U_NC>^\=H_(FNFH,QNO$[DW['CFWQ0KLTSTN'EV5N#(
M46B#%&J:FIH(H]-0P)9O<?/KWV=1-R?#ZKWY\>NV^C.T^\>S^Q\YW=14XWCV
MQG*/$BKQ>4Q$]+5X-MF[ CRM3BMOXRA-'&DE/'6%)^0''OU,$5P>EEM,T5Y'
M(H73X++4F@J13T^+\LG'SZS4GQ&RO^ENB[<K^]-_ON',]'XOI3LV+#83![:/
M8-/M:3(5>U]V4^;I\GDI^O,KC*_+S-(E'%6I4(R@L I(\2.(.3TFB.BTY<@9
MCIB+ZJ@5 )/QC@HH!2A))XXZ=NJ/BQN/:/;&,[B[4[]W=WWNC;&"W#LWKN7=
M>S<#M=NO]J[B,"9R.NJ<;D<E7[US4D-'"J5$HB64@R*O)LXM &!/^?\ XKKS
MM61V7@6/[/Y='!/I-M1=5X61P4:4)I_<=%;]MRI!MP03^?PUU7I6[28'[X?V
MM2'Z#\%PUR"U^?\ '_>A[\.!^WK3#(^SI9^]]:Z][]U[KWOW7NO_UM_CW[KW
M7O?NO=55_P Y<'_ANGY#$&_JZF%AZ2 .\^J!_06Y^OTO;@>S?EL'ZJT].[_
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MS8-(::I>:6HR&6S%1F5J0570RKI!X[6IJ&H5&:DU^61C[,="$M$VNJL 6\J
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M4Y7AVH/EY0^@'[.FAR;O8#'QC3TI'FGG\1 SG[,>AZ4O8VW?C;B,[X(^QQN
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M]?I[>44M"/\ 5\75Y2IN #CC^7;_ (>C*[E-OA[T4.0/]F:^4MRU])!ZU^'
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MF]NFAF\T<[F\-F<)G=O?WCSVP"Q.3.4Q0_W#_0_3V$-Q]@(YBJR_#D_MIZ7
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M&D6L+< _\C]^S3/5B17C_P 5_F^7^7KU[M8:?\> 0?S;EB+<_P"W]^KP-?\
M5_J^WK0H: #'^Q_@_9Z=1I[D6 /U(L2?J21SS>]A;FWU]^8CRZJ@U#)/G_JQ
MY?ZOGU@/^-E(L.2/ZBU[$@CT_P!+7_UC[]GB.'6R<-JX\!_J_P!7I\NO <_B
MPX' 4 W56!U:SP#>]_>QZ#]G3Y)%*_ZOE_JICKT3$_[ < GGZG2./J;\?C_8
M>]<&SQZT*G X?MP/3J-,#_@+V'^  X(]7IXO_C[3];P5'K\O]7^KY]8+6Y
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M/NK ?4C[?\G2E6/@$4_U>?5K7\DVW_#G/Q@M^8^XS]2>?] 7;5R"?S8?UO\
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MS3O5 ?J./]%/^@.O?U:VTZJQFOVM_P!!]<S_ "AOBYR/X'CKG\?P:0,3:_\
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M'M/T]FM<T_P]>-KC\WY_H1Q_K_[#WZO6R,A1Q/IU&-B+$FX)'TN?J ;\$$
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ML'MJ>3;6,H-G3UA.J?*4=/G%2.8M=Q$VK@D^U5G$9(I&8Y!4#\Q7JFY,L<T
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MVS\5)@=R9.N@R& G@4@/F*9:4FE4DZX_41;Z,0*YM^8&U A+TBA\^!X^5#P
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MDCTD< W_ $_[#CW3RZWUT"18 A3J%V*ZK ?0$VY%O];CWKKU.O<#Z\ BXL
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M?^"VY/!^A/X+6-Q< \_GW[KW^'I6;3MIKP#:QH+\G_4R?DV^HX_UO]M[LO\
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MW&;8RF*W!E=OU,46MWBJXY%-A<@6]I+ZU!4NL8)I3(%:?(T_XOI;9W05P Y
M)R,^6,Y_S="-@_DGT9L3Y'_&+=-/\@>\^Z<-U[75E=VMW)V-_>?/XJ3(YC&?
M8U=5L+9>X\ME<IB\?1+'9H_N!42LUVD/L,I:2K/41]VDFE1^ST_/H4K>6_AB
MLE.X#A6GSX_GQZ9]R]L_%'LOJ7?WQWWCWED=J8?$=Z;B[AZ)[^/76X\GMZJI
M,LVC([:W3UH,N<[35\E.H\=3!5QJ)5_3I-_:AK:X"A_#[J96HX_;2F/LST67
M%[ 68:LAL&@I3/E7CGUQT+.S/F?\=.O._/A_@\9N3>%7\:?C9U[N_:[[[RVW
MA'G]Y;HWRF0S5?5T6W(!'D,3CJS)9;QA7J"5AB2[!M3-=K1J$**'U_P_YNO6
ME]&0"Q%?L^VG^?HG77/=W5^UOCO\Y^N,QN'+1;O[FRF!FZ]PT&V:B3$Y.CAW
M'FJVHR.0RIK'H\97"&KA(=X9)XM/ID%R"H6U8*/3I+/<HUQ(1_&Q_P '^'H<
M>KOFAU;TQL3X(3T3YK<^[?CUD]^8_M3;8ILGC1#B=\925*S*X#*FKE3*9J#$
M>.2.KC2.4N%&KTBVQ:,:U%!]O^QU=;A37/\ JS3IM[;[:^/QV1WV^&^<_P L
M?D9E-^PU4/3?565R_:FU,3LF',5\V4K1V%-G=WY3$[CCP6HT\,-'#31216N.
M/:86DH4EH AU'S!K\\#S'^;I7+N26J^('U# _;FE*^7Y#/03_)OOKK;M/K/X
M7[7V3N"NR&6Z2ZJ7 ]BK-A*C&TE+F9][RY9Y:(4T\,N1J8*6<6T.DCE?U7Y]
M^%HX+,!]F>JQ\P+505%?L/RX9_U'HWN^OF+\9.S>V?DMM#<.?W%0]0_(GJ?J
M3:&&[8JL'/--M'>756V[))7;(FEGK,Q0M7UU1Y M0E2RJNF0$&_OI'%"!4Y_
MU<.ED?,&%H!2H\C7]NKJM?N.@^+.#VGU[MKX]]@[I[FW;'2YC)=A=E9[:C;6
MVOE)::40Q4.$V9FQ7YREBI(QXP*JLE237<)86]K]JAD+M4:37AQI@GC_ *AT
M0SW:-=3R5J&;CPX_F?\ #U8;\7OE-T#TMA>O4K_EUW!MKKC;F,R.7[3^(78/
M6%#VGALWN7*8V2CCPNS]P?;0;5VSL[-CQR> T3U%&[%TDO:Q7O,#K-\':0,@
MT/'S\Z].Q725#>)WBN*5' >1-,^>#T6[#=H]$;U^'7>?2&Z.PI.C]][F[\JN
MVM@;1AVQF=_XW(X"@P&\Z;"[=I-P8?(8>#!9+,/N$/X*I)Z>%(-(4,0?:RVC
MG$::(B8R&U'533@4J*9S\P1T;[?<1 7;-)GP6ICY&N:^7V9_+*<^:_?W7/<.
MX_C/FNJ\U6Y.'I_X^['VMO#'YS"56#6#>^$R2"HQL>+J)JJ>LH/&OG6:*10)
M"2>."3Q1/]9DYU"G15+=P_U<V0#X?$>N,UZ/9A/DK\#A\N?]G+K._P#>^-K-
MQ]89[ 9/J*HZKR;9*@[(J^M3M:2*+>R9#^'OLI95,BAH&GN#=[6]FNYQ7)M7
M4(NK-#7!%17%*@@>5<GSZ,EN;4-RAXI/A@/P J33'GYGCCAY=$\VUV%\5^Z?
MC#U;TEW7VON#HS?72W86\\IMK=U'L3*;YP.^>N=]YMLAEL7B*7&Y"@K,#G8X
MU#Q3I(JZSZP1<%A+5BD;*O$#[?\ !TFN;E?J+CNP&-/S_/\ U>G3[TYW#\,^
MM>S_ )2[1P>^-X]<=%]E]%Y;JS:G8>Y]HIOW<,F=R4F*D?.9C:NWTPF=:@R4
MM(= DK9*B,$WD-K'TEK)166+60P\]/Y\/+TZK'<+5E:8(60^6H?9Q%*^O$=)
M;9&^?C%O7X>[R^(O:_>&7Z[J=B=RQ;VZU[=I>N]Q;PP796WZO!97"U<(V2<S
M'5[>JJ>DR32PQ22R274AV/T]UGAD15/SZ;\2-SGT_G^W_53HU=-\R_BQA?G!
MU+VIMG?>[,ATUUW\.<_T-_>[(]?)3Y_);MJ]HU^$CJH]GSR29"BQ,M54@LIJ
M2 IMS]?:6.*X=>Y:'TK6GYT_U</GT;(]NAHC54#CI ).#PKPQ3CT4GX6?)_8
M/5.(^0/6/9N\^P>J=E_(;$5/]W^T.MZW.XW?G7&X\)N'^*87*'!X')XZHCPU
M5"")XA+Y_$[!)%:Q]NFRE?)%?]7E_J]>DES>1H" <C&/6H_U<>-.D;\F^P^K
MLQUIUGM7:?R6^0'RL[ 7<&8S&_NQ.RLSOK%[$GI&HIZ+!XG:NR=^;BW36T]?
M0%UF%9Y49YE!/I!!56=LZ%24TG\O\@STS/=@J.ZN!\_M\Z=$:"&.%8V65"BJ
MI6H<R3*54*5FD-]<EQ9B?J?9WP '^KAT2D@LQ' U_P /7!OS_0GF_P#JA_L!
M^#_L/>_RZ]YX..LGE'TL"";_ %(%K&U_KQ;_ !/O53^5>M #\^H,)O?BW%OK
MS^?J1;FWX_'NHZN?/UZ\0. !P;_UO<@ 6_J.?]Y]^H//IW.<XZZ)M].2/]<G
MF]Q]/I_O?^PM[]]OKUZO75['\VMQJ!O?3_KA@ ?K[VW^Y(]?]CIF/^RKY?[/
M^K_B^K5?Y(H'_#GOQ>7\A>\PIOJNQZ#[6^@//(-N/Z>R[F^HMQ_J\TZ/N4/[
M<BO^JC_ZO\G7T(_<6=2IU[W[KW7O?NO=)O9UO[H[6L;_ ._=PHO>_(QM,#_M
MC[]U[I2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJVOE!\\L)\>-
MW;<Z>VETYW%\A>\=S85-S4?5W4VWCEGV]M7-YC/83#[MWIG3'#MW ;;GS^"J
ML?K=V(;Z@\>R-Y@A*J&)\O\ 4,8X=#[E;E6'>6,^ZW2[=9 5+%3-3#'X58$
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MD:J45JMZR==M+CB,M0$?EC_BNFT\^.K[?\W0IX_X^T'0'S^^-FWL%V+VWO#
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MDD_11^!Q_L??NO==@E;<'\,;FQN3]3<<$<6^O(]^].O<>NOTD >L?4GDW'U
M(('!)')O_P 1[]PX'KW'RZ]]>.&TW'' *"UN;?32+<GZ?ZWO?7OMZ9\[@\1N
MK:NXMGY5:A,3N>@RN(S!1R:J6BR44D%1]DZ\0ZHYFTW/I-C_ (>V9;6"2--7
MQ4'$=+K>XB1W)D[<_P"JO0.P?&OJB+HJ@^.N0P$V?ZLQN).)I,/E:QY<E1QT
M>6.X,%FJ3)(D3KNK";B9:NGG C$>BWJ'!=$SL K'A_Q71781I'&V0&)/E\\5
M^WUZ0W6GPTZRZTSF8W%6;U[J[AR>;VMDMCQY+N[LJNWK6[.V9E:>2FR.WMCT
M\%#B8,%15<,A4Q?NL ?3(I-_=M"/4$X_;TS+%<)=>*L/8>)&/S'SZC];?"/J
MSKGL/ [[I]^]Y[KI-G2"?KWKSL/M"LWKU/U?5O"*9\AU[M.JQE+482J@HN!K
MJ)S)(2K&T89],JQ*SC^S_P!7ETN:5I_"X:@ /G^?12^A_P"6_B\ML>MB[RSW
M>FQX,GV]V9N3>'1VV>TC0=0]L;?RV[SFL+F.S=A8R&IILU59>DLA\.0I7AB1
M>-0]UB83_P!D:D?ZL];*2 5T#[?V\.CH]N_$WK;N2MP&=&Y.T^G=ZX7;<>QZ
M'?716\6ZSW<FQ)*H5XV7D\O3X[,1U^V8:@VF0Q"69KC6H]VDHA42&A_U?\5T
MTKJC 8+9X]=T?Q#Z3I]E=:;+@Q^Z:''=5[_@[-VS40;@,&X<AO2DC,+;@WGG
M/M:AL_6Y1 !4:8XO)91=0/>Q0T*Y/3VL4-./^K_/TO\ .=']=;D["WSV!G,3
MDLQFNP=CTW7^[*#(YJI;:&4VGXJY:B@I\?2+0Y"CR#+4E&D6=>&X(^OMWP)B
M11>W_5PZ\K"I%>@AZL^%75?5F],=O>FWIWIV =NT==2]:[0[<[,J=\;'Z:QE
M=2)CZC%=;[?DQ]#_  B2HH5,"^:>J5:<*I)8:O;%5%>[ILDUR!Q_;TDH/Y>'
M0]!O:;<E#N3NY-C-NF3?%'\<3VGD_P#9:Z3>+5LV0_O#!UO'1Q5.-R+U$IED
MECR#*TCL!$$(4;T\2IZ]JQ2@_P O^K\NE)V9\(>I.SMZY;=M5O;OC8]'NZ*E
MB[$ZSZW[3K=N=1=EQT@BB$&_MI3X[)1Y>FGI$>A CDA#4]3)= 23[5141&!H
M"?V_D?\ 5Z=-LKD@T!7AGR_P=#KV/U)M'M/J[/\ 36X!7XK:F=P<&W:FFVYD
MI,;5;93%:(J$[=F$$J19#&Q0IHJ'#ZI5OH(]E$T,IDQ'C%>'^H]/I-$JFL@U
M9_GT'&TOBIUYM#.]*;MFWAVWV#NOH#96Z]B;%W-V7O%-S9NOVWO6JV]5Y;^]
MY_AM!#GMP8]]L4\%#*O@BBI'L0S*+&23A(7C![B,#\_\W'[.J*C&1)"M$!R>
M&*==[E^(_2N[,1WIA,YA,S44/R,W71;O[ )W34H8-QTM-/34&=VV\5*D^&;$
MBH:144R_N 6N!;VE_5;XA3I4SP:1I:M!^?E_FZ0/77P6ZUZ]['VGVT_;?R:W
M_P!B[5Q>3V_D-W=F]MS;WR>_-I9&6HD@V9NVNFQ.+^^VMC)ZF5X8$AC<"4@L
M;"VC"C98=W2-RU5('[,#H6NA/CWM7X\)O6EV;NSM3<.#WGNO);N7:F_=Z#/[
M7V?D*YED?&['QBXVD;#8!90&C@+RL+&['V]?GQK2&&++*E*?F/\ -TDL(7@N
MY7=*(SU\O0CU^8'2'[A^&O6/;>\)]^'=G<G4N^<OBZ'![XW9T-V)/L"H[-VK
MB%9:7:78<AQV23,X@Q.T81(8F*\.[6!%=O'A(?&PU#3SSY=*;S4[ZH148K]G
MGZ?E^?4G</P_ZFS.,Z5H,/6=B=;_ .R^[B?<W6M1U?OBIP%?!]XD,65QFZJ_
M(T67J-R4NX3&7R41\0FM9&4&WNL@9F)%?MZ='PQ]N?\ !UW4_#+HN;;R[5EH
M-U/AZ;O;&?)BC2+<C"H';.(R,U?3U+U,E%?^#2R5#.]&=6OZ>1?=P* U\^J@
M$ @'/ ]#%#U7MI.WZGO1I\G-V%7[%'6=55'(^#;[[:ARG\5B!V['2-%2S22\
M&=9W93<Z/=V*M%(HXTP.MFM#08Z":J^)74>0V(.NZF/="[<;MB+O*$C.C^(I
MV#'DH,L\%>_VWA?"&JI$72G[FEK_ %]MPO)%?;-<^'B!'!SP)&,>?E_@Z9"&
MF1GU_P E.EKA>A-@[?S7=>X<=39=<I\@Y<G)V>9,S(U-6)E,/_=]Z?"1_;C[
M9J:BO8N3]?ZCE/;">*PDMF '^-LX'F03EJ^E*8ZL%.*<:\/ET&&__A3U7O?9
M_5.T\?NON+K#)]'K44O6O97378DFPNT,/@:Y67.X ;L_A>26:AW#%(\-7 :<
M>>G8Q^1 2?:MZR7$DA."1TZ&"1JHH33@?+I/X/X#]([:V7W3UQBMP]S3;3[[
M@H?[]TE=V$\KT><Q$5$D>_=LU\F-EEQ&_<H:"*6KJF2>&>I#R>-%8(KQ==(S
MD=)PK:JL,?ZO^*Z?MU_#+K;>'6W7NR<UOKOQMS=51&/KSOJ@[6FH?D7M:*II
M1BLBE%V'#AA!4/58IFB(>B*>(FUF 8)DJK.QK0BG^K_#T])72FE14'_5_J]>
MIN"^%71.+ZDW1TAFJ3=N_-M[^R)S^^=];^W17[F[/W1N<U!K(=R97<DC4B1;
MCI*P^:*IA@1?(+M&;D>VI&GKVI45]>M(#YT!I_J_U>73!UA\'NN.L>R]J=PG
MLCO[M#LG:&*WAM7#;L[G[5GWA71[9W=58&HKJ/)1C"TD5134J[?B6E1"ICXO
M<#@PBG9(BC.:$'CGI0'4J*@#[,>O0\OU!LN7NC&?(>HILI+VCC-BY+KVDF$R
M+B!@ZAF*-/3ZK-4W/! -S]?96L<JY(_XKJK,"-(\^@3[8^$/4O;&\,_OMMX]
MU]89W=R8J#LG_0SO^?9%'W-C\!2QXZCQ/95 M+74V4I&Q-/%1!8O 9((M3DN
M2?:E0!ZCATG8.PH:4^?0F4/QPZLP^]NJM_8#"UNW<UTMM/*[&ZXQN,S%6N"P
M>VMQPA<C15:U*U576&F92Q=Y&9Y9&;\#WHJ1+JIV].1M2/2<9_S?ZO7K)3?'
MWKJFV[WOMP4V>7'_ ".RV\<SV/"F5\=1+4;QQ<^,RJXO)>(R8H2TTSJH5) S
M/<_3VI+J5 !S3IX.!2AX?['07[X^$G56],7T_2X7>?>?4F>Z4VAMS8.S-^=1
M]J5.QM__ -QL1BL3C%V9F=P1X3*1Y+;\E/AXEK8_ CS$^EU!();<I*^8U.JO
MD?+JZ,H9BQ!'S%<G->FK;/P!Z#VG@EV?B,IVD-H4O<>V^_,)MS);W?*83 ]F
M;8GJ*LYFACJ,>M0K[BR53)/7,2QD+\:;6!K:RI$G=QI2AX_M_P!5>DTA\0UQ
M2O$?ZO\ BNAKVWT+L+:V3[ISV%I\W3Y3Y"5--5]E+5YEI82]+AZG;X;$:*<^
M&>2BJG:Y^E_:/<=4P(A!8_L\Z\#T];LB,"] !^WI/8?XK=4XF?X_5$7]ZEJ/
MC(<W2=6F;-1S4ZT.>I9L=7#<D*TB'+5$E-52/'(IBT6%P;>W#IH #W =,>&@
M(X4K_+KC0?%;JO#=1[KZ-Q<6XUV#O;<>5W-G))\[Y<TN3K=QT.ZB(9S2I"].
MV5Q4>E2/0C ?@GVCDB<U(%?^+Z4)X5*%A3[/EU7=\Q?COVMNSOS'[CI^I/E5
MO?96.VE@ML]?[D^)?;W7^Q*_&4&W\?*2G9T78F*R/W6=AK/&:"?'QP^)@6+L
M=-GK82*GZF#J\_3K1>,$:.%/3H_/Q"VWWCMOJ2"@[TS&\,CE3F,E+M#&]FY^
MBWAVY@=F5%5)48G%=I[TQL=/CMS;MIHY@)IZ=!"+64!> NG>)D"H?/\ S],
M>?\ DIT::P#,;D@\7_V')+*00.>+ _U]I>M]=@AK-87_ #<&QM_K6%F^G/\
M6WT'OWY]>IY=>+6Y^C7:VDEO3]+V)'UMS_QKW[KW#I5[3Y6ON+F^.)L3]=#F
MYX_'Y'NR^>?]5.M-P&//_+TM??NM=>]^Z]U[W[KW7__6W^/?NO=>]^Z]U5;_
M #FQ;^71\A ;<MU*?QQ_QG?J@ 7N.+L0. ?9QRW_ +EVP\N[_ _0=YD/^(SG
M[/\ CR=:*A)!_P""DM]5%QQ?^NHWO^?<P'X%/4$R]LA%<#_5_J_9U%'/U(M>
MPN"?J."3=OI<GVHJ?RIU<T\^(/\ D'VY'6$6O];<@@W N+_U MQS]?S[]GX@
M,_ZO]7^JG6J@5#-C_)_J_P!7F,A.F?@@6M]!87(N+!K>KC_86_UO>MRA4@G_
M %>76MO4U U9_P"+Z,5NY0/B!TCP03\DOE,0+B_'6_PX']D_F_\ K^PY#$GC
MR*1C0OKZM_FZ$,R-X"4;.MO\"T\^BVR@@?7Z@VYN+&Y!N?H&L3]!];>SB.[5
M> S_ *OET3B%W.6%/]7^;KKBY!6][$D,/K<7M]#?G_7X]F"(+@5/#_5]GIT]
M3P:CSZA2EFIU62=*2FBE1JBJCB6:>GB-@TS*5!1-0TW^G!_I[26^8Q7A_L](
MV9H&:&G#/E_J_;_DZM1Z-^#/5'= Z\V[AW^5XSW9.T<E55G;-!U;MR#XX[:S
M<=//5P87<N1J*5L_E1(:.,'(1RH=4H4*0MR'+S=I(+Z6W0J54D4_%Y</EZUZ
M&=E9)-M]O<,IU,H(S_A%./I0TZ"S97Q8Z.PWQN[8[\^1._NS,,_6_=C]+9#;
M75N,VO5RYII(S71UN/R^=H:Z2F>AE+&56NP%DO[K^]'=RH&*5KC_  =;?;D*
MEBV:\,\/6OY]+'(? #;>=^0?6>R-E]KR5/1?:?3<W?L_8N[,%3T6=PG66WRV
M/W)05^%P"TN*;<V*R= 5AF:,^21[DZ3[40;BZL7''212@\_\G2"?;D*J0:&H
M-<_[&>E[L^C^.E#\#?G]4='[V[?W%$N0V;@MRT?:E%MK#5>6I\5FE@H,I3UV
MR*'%4U51-&EXHJL32Z#RY]AH[A*]XIF"^,M*4 Q^9S^SHW:PA6W8Q,XB)X$G
MN/'-*"@XBHZ3O\I&MV-ANYNU\]N"L[%Q6]Z#H?L?*8K*=;5U!056,VSBZ..?
M,UF.W'DX*K.4&>I::2&II$AF2'SR/9;7'LSW2[D:R/:"IXU%1_JKUK8K6-+R
M,U(.*4-//Y^71;>S.K]N9WXW[N^8M)V1VKN7*5WR$?8%'#OZ3"Y#=6=Q.3H,
MCD%W3NBN^S*U^X':C\<DMM3!%N;W]^LIV6&$D'X?V=/;C$C7-PJG <BGY?['
M0_[4^ ?7FY_DC\:.DLAV;O:@P'=O0=7WMN?=,5%C:K-8FKQ&,K,D,*F*GA;$
M5%"(Z1M+21%Q*Q%[ #V8R7K+&=*ZB/+&>B1;12^7T*3QXTX?97CT&&Y_C7\?
M]Z=%=H=Q?&3L;MC<^0Z3[%Q6S-U[/[FQ&U:),_3[NSF3VSCZW;,^!H*1J""F
MW!C4?[>4LC(X^I /M$MQ*DA=ACU]/2OS^SI9:6,-ZQ@)S2M#ZCC2E/V9X]*[
M=OQ1^+'4>]\-T)VU\A^R<-\BLGUI2;HW+N+%XS!OTCLK=V9QB9?!;)W0V3I)
MMR":II94@J&IYTID+'T, ?;BW<LA7M 3-?7[1Y9^?3\NS) KG-3PSC\QQ/RR
M.GS$[1^+M#_*^WUG=QXSLZNWUB^]Y=JKNK;]%LVFJ9]]4N.J9*''87-'#MEU
MZAJZ.(324@FN\IU7X]V\2<NA33X5<UK7\O*O25X(8_$UJWBZ<4I3RXU%?7@>
M/3]NGX0UV[^S^N,7O?Y$=DY;KC;/Q-VO\CNW-Z[HK:?,9?9FS::..'%]==;8
MS(^;%XZ@IJRNA@IP(Q>22W'LC7<&2ZG330>(1Y?MZ.&L5:UA:M2R#A4>9_S=
M%ZW#\<NB=]]*/W[\8]_=J9?"[1[.VWL'M3;';>$VNF[\;BM^5XI,#NK$5.)Q
ML%%]LSI*(TE1IP_U8J18V3=)- UD:O*E/3Y]%+[<I<@*:5 /GDFGRIT9_=OP
M ^(E#\@>P/B1M?O?N8=][?V+D-U[5W1NK:FS)MB5F:Q.U(MW0[<J!38PUE+-
M]@E;_E)D/C'!_5<(TOY+AD#"AJ#_ #ITI.W1A*AJJ*?X,XZ(#\4^CL3W]W&>
MH-S;CSNVLID=O=@#:=?CDQE729;?6S\#D,QC,=7T^6@J#28K<U;1"FC:'22T
M@ ]BF6X9+*H]#QIT@FVQ=7#/R)^S_5]G0UT7P0R%7\',K\FGS.?C['Q_:<FV
M(>G):3&(9-CG-2;8I=\QU/VRSM'-NQHZ<$<:&M[(-NW%TO@F@Z2:UQ2OI_EZ
M-;';8BH;Q!J! TFM3@FM>'RIZYZ%;%_RWMN9;MK?>TX=X]G;@VQU%TQM3L3N
MM-@[:Q>6[,DWKN3&1+1]>=5X.$4V ^YH<]70"HJ*F)I/'&[M>UBY<;FPEG)8
M4U'TITV^WQ^(ZTQJXU/^KA\N@][H^"]%MGKKI[NK:$/=^V-C[Y[.I>K=T=?]
M[[3VMM7NW:>XJBLI(9LA'58NEBQN7VO54-1')3!H!(TWE!X )31;LYJ"RU\M
M/IY=6;:U!^$Z:^9\S3TQ_A^WH3M\?R_^@:SY7U?PVZ>[1[JW-O[ 5ZY7L/>6
MXL)MREV/@-DTFW:S<.=QNW-NX.BI<IE]X+44$<5(7FT.[:2OJ!]N#<Y1J)%
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M";FWUNI_) N!_B;?T^O_ !/NO==E>!SP0=7U4@'\GG\FWO?6NNB2+\7%^?\
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MZV.NK<WM^!?_ 'H&PM:Q-C^;>]=:Z]:^D6-O5QS<7N;\M>X(X_P][Z]Z]>L
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MZ7/TM8@?0B_X L#]/>L^8ZW7]O7%O\R?4+K8%B!S_4$?34!^1^?:@C_$R?\
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MMSIM;_>N?>NMU&3_ *OY==3<D?5K$CTC@<G\6MJ_WQ]^(\NK<*?,==#A";@
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MZZ(4#\!N1^1P6MQ?E05'YN.?\;^Z"?PQ4</]7RZK^]+N;&FO^\_YO]7RZXD
MZC<,+?KYM]+'@&_ %OH23[:;=M'G6G^KT/5Q-<-Q3^8_U>O7,K<%K$,1R #;
M2POQ];D _DBUO:CK5?V=>!(/!"\7%@>18GG\<W/U/]/?NO?EUV6M:_TU G_5
M?6Y _KZ3^;<_CZ>_=>ZZ/ X])%B+<&_((#>F_P#L>3>X]^\^O?;UV6!XN65B
M18B[<_4W%B5N/Q_O?OW7NN@#9KV%B 5((LI-[,;_ $TW_/X^OO?SZ]\J]>NH
MM;43];+;2;$VN%L/2/\ 7]ZZ]GKNQ-U (/\ K6!4Z0/ZD^HC_#CW[KQIUT.>
M2>+F][C@F^H "Z@6X^GUM]?KOKW7?ZK%N>#R 5]-[&PN!8*#_7\7^OO5.O?X
M>LW%C8?@"WXY! !^O];?7W8=5/E7K .> !^1:P/T&LKI !X(X_Q-OS[KU8^O
M7A#;5;FW];CC2%^B@6L./>Z=>KUG-^2/J>!_:YOZ0IN /]A_O'O?5?MX=80!
M<FQN0+CD:E^AOS<:KC_;_P"O[UU?CURY(4<_@'C3:Q&K2+6OZ;@?B_\ 3WJG
M6NN!^IYN ?I8D &]P0/Z#_7%C[]^?7L]<BQ ) # ?[38V^K \'A@.>>/]X&S
MCKU*]<3>Y OI/U NIY_VG@'D^]?EUOKO2"HY6Q:P-A_9_-[6X'^Q_'O?6ORZ
M\?H0Q(8?4J25 (^C 64W(_XU8>]5\NO>G75SS]3<#BWUL0/J;$_0?@WN?>_R
MZW3KH?4#5^0/J/K?@&S"]S<7M;GWKK5>NPVD@E00%N1]/I;ZW;D<BW^!^GO?
MSZ\?//7;<7Y/-F(# #DL#JMP ;#Z_P#&_>NO==#E2P!N-)'#&W^J//)!)Y^O
MT]^\NO>?'KUOU7)!XT@:A>Y(XM879@#_ $YY]^IQZ]^6.NQ]3J#64J.5)LH9
MK@$\<C\<BWOU.O?9UXD$7O;_ !N;@J&X8,UR>?\ BGOWV]>X==$W/GX)2QU
MD#T@A@O N>+?UY^OT]^SQZ]_1)Z\04 )_+'^EPMK DD*3?\  /O?7NNP .+@
MBQ)'U_LFP(L";.!_OA[U3KW75R.;F]EL2.+<%0+M^;<G^GOWD>O=>L?S8\$
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MA8V_Q'']![L.!^WJI^(?9TM??NO=>]^Z]U[W[KW7_]+?X]^Z]U[W[KW54_\
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M=C)8&WU]-_P ;W(!M_Q/YL%]>J%J\.N6H'218W(]2DLI-Q?U"S, 38?C^O\
MA8#!_P!7^K_#U4X(%.@]SM_XI4:KGU+ITF]E""P)"VYM].2/]ARV>/Y=.KP/
MV]-!O]"3]"/J>5/UM?3S]?\ >?>NK"G7?#7 %K7L2K6L1=A]3_:'^/\ A_C[
MKWG7K@2"00.&(!N3?DJ;&Q+<>]=>^7GTW9?.X7;E!/E-PY3'X7$TP:KJ\IE:
MH8S&6)568:B2&#'FW%O]C[46]EXQH%J?]7S'^3\^J3[I:PU)&/S^7R_S]!)2
M?(?HC*5O\,H^W.NJG(3U0-)2+N_$,>1=;!>;CZ#ZGZ6]GB<LO(A80DCY<?R&
MNI_U?F13<W6<;JM0!^=/+U2@X_Y>AS!M$L\)YU'@L0H8"]E(N!;CC_B/8=^?
M1_YT/6)?IR0/H"#]"&-OU:N>>?S_ *WO76^N2J?2;:N0JL 0I)%AI/YNU^/]
MB![UP\^/6PKL"54D=<3<"%K668N(&(XF*$"01W($K1Z6U6^GY]^/;QQU[/Y=
M=*5:(S1L#$55O(>4\=[!]8708SQS]./]?WL9':*]:/&AZ]$PE"-$1(C.0&!,
MBZHRFL!ELI\8<7'^M]./?B",L*=>X5'RZXM(JH)';3!)(T*,]@CS7*B)6N$>
M52+:;W%C[T"&.#7KWS\^O7!8PF*TJAG:(D:D6-"6=D^JA4N3Q8<_CWNAX:>O
M5S35G_/U*"/Y!%HD$S2-$J$$.TJ@$QA226<7X'U_/O?GUZAH#IQUC"2.;JCL
MXF^W*E6;]]]6BG87(\S<V0^HV^GO6?3K55X5QUBB9:@1&%O,97ECA:+2_EE@
MNLR1^-&,K1D'4H)(^AM[UUZH]1UZ/]^PA;S%G,=HQY+S*#JBNESK!%BH'U]^
M\NM@USUQ656%XV1U\K(MBK^N,KY$])(U)K (XMJ][_P=>SY]9@&)L003=?4+
M\@!VO_JF%KD?6W^P]^XY\NM5 Q45ZQ>6*P(>-D=I5U!P _VR>24 AF6\2*7;
MZD#D^Z%T%:N!^8ZWY5\^NW81LJR-H)\P7R>EBT0#3Z06];0K(NKGT@@VY'NX
M[CVY^SKU:CCUR0-(594NS%% 4$EFG>>.+2+$LTDE/(%^NHQG\@@>H?3KU1PK
MUT>))W^BTT:3SL;?L1N2(Y)> (8V"FQ;@@&QX-M?/RZ\!44\^NQ?D!3?4JVM
M9F;\"_)%S?@7O;WL D!A\)\_+JQ5O0]< ZOY-#!C' L[!6U%()5$BSM^$B>,
MA@WT(/!]UJ":5ZJ32N>O,ZC22Z 3 >.SC3)K8JK(7_7J (6WU(]V*D<1@]:#
M!AVMUS7]Q;1@/I8PDKZB)E74\0 !O(/]3]1_3CW[K?VGKH VDO8:)6A;TCT2
MKI+1L/Q(@^H(! /OWY=>K7AUS*R:_&RL'>-Z@(QMY(8QJ>4"^HQ(%Y8746Y(
M'T]3KV*=<1=E=EY"QK(S:B$2)_0DC,;G1(S6!-@6/'O7#KWIUU(&@N9@(=/+
M"7T +J""^L+8-(N@'CD$>]:E\CUXD+4-CKF5*+&[7167R([ !7B()UJ6  0D
M?J6_O=1ZCKU=7#/6-G6,.69$\<(G?R.JZ*>X432#C3 S-PQX/]?ZZ+*.+4Z\
M.XT7)ZYK^YXTC):225Z=8D]3R5$2!YH$6Y5Y56S,HY ^H]^5E;X6!^P]>((^
M(=<+@.4N 5=XBO =9(P2ZLO+!D"DD'](4_3W:A%,8ZUJ6OQ"O7EOI3G5Y0GB
M'+"164NF@@68."+$&Q'TO[]I8?A->O AN!!Z[4*2=+7.HQMR&*N+AE9;$AE
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M'T68DLUP"+7/UO:QY_ M?V=U-/ET38)X]W_%?ZO]68\YM;G@V!M:_!86:_\
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M4R!DH"*'TKU%JWI[^H#4""9=7UMI'"BZV(_XK[7QO/%VW K7SQ_@'3?U9B-
M>'E_LD?/JO5NU=QXK>D3"NWON'M+,]I]V[6_T/T%;M>LQ]!MC9F%WO\ Z-L5
MF=I'.'<VQ<%NBGVCA=RIN=</ER7SFDL,;D*#QM?N[96;_<+'^GD_P:OE_JQT
MD6ZWG3I\7/KIC]*<>.>%>-#\LAUE^Y=R4&)Q6"V1VAO7<M=NK%]2+VMV0*/9
M^[\?U3C<QO*/"=F]AK@<#N)]R=6;@,>\7Q[8[*8H8;"C _Q$+:@R1K]C:-FH
M6^C.D_TY!Q_VW'Y_G3T7B?=9**7&,?#'3&?05X#UQBM*U6R=H1Y/=HP7]_\
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M )^C[981.%5O7_/_ )NMU3Y(?(+9?QJZMS?9.]YXJJGI%1=N;:ID:IGS69G
M;%8NEAA)FE-5/HC1OIR/<;PVAE<T&17J7Y[-XQ4I4@C_ %>>.M:C(]<]W8;Y
MV_$?M[O+.;BQN[/D=O&;?.-V_!5Y5*7 ;32J*8+;M9C1+IB:>GG+:"HNH'L1
M6=DABGDB:I0$<1@@?Y.@=>Q3++&&C(&KSKPJ/+K:SSF$QN[,1N#:VZ*&ER&
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MT?WA>W]S?U5I&":_XWD"H%0#MP+<>'G0G@">I6/W?=U44+KXF",5!-.!/CT
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MY# 6(*C\\^]=>ZZ-S;GG4+_7ZV4W&H"]]7T_'O?SZ\.NR+$^G\6!L' %BO\
MASIY/OWG3KW60_Z]N#>W%_P>#:Y _P +>]^76L>8ZP@FY)/-^/U"YMQ:_P!3
M<_0VO?\ VVC]G6_RZ]ZK6)N+V&KD<"]PW^Q_I;\^]=>Z[LW/]0.+EB2"=(MR
M2;>_=>^SI9[5 "5UC_NR*X^MC:0\\GD?Z]O^(MZ_;U4\17TZ5WOW7NO>_=>Z
M][]U[K__U]_CW[KW7O?NO=53?SJ/^W;WR'XN;]3 "P(-^^.IOJ/S_P 4/LWY
M:Q>6H_TW^!_LZ#W,8K8R_E_QY.M#Y]0"'@$<\BW((N?5:US_ $^G^M?W,.="
MDG!'^K_5Y]0PU/$(7B#_ )/]7V=<;D\<$ E>!]2.+ CGD&_]./=(S4'IC<+D
M3,*9_P!0^0Z,C\/>\Q\</D_TYWE60?<4&QMVC^\=+26N-LYS##8N<*C\[@.W
M<Y7?7Z^P_N4!?AP_XKH^V3<1 M&I7_HH^0ZW'/FS\4ZOYZ=9]2UW6?<..V%B
M(:;&;ZPVZZ)),U#FL'FJ>GS.VJZA2F!EKI):&IADI9P/[2M[C&RN&M9#$YPI
M*\?3'4U71DN( \<C $ XSQS_ #ZI)^0/P'^7NQ?DM\?]B9#Y(]F]R5>Y\GCY
M,%VQ!M_+5,O5D5!-I:&>O ,= 3"I*B_Z3_7CV/=JWC;DMW,MNF@<5)&<&N/.
MO0#W;;=Q>2D=W(6/ BN,CSKBG\NMAWN?N+!_$/XT;C['[0W*-PS=<;.J*&.N
MRS-2U>_=W4E%%3X3;<D3"_FW?GD U$\D'Z@'V2%A?;O=26\"QQ$BB@@A1I-*
M?ZL=&)#V.SVT5S,9)@&J2#5N\<:U)'&OG3KY]><SF5W'GL]N/.3?<Y?/9C*9
MC+U5S_EV3SE@"06N+?CCV.X;.J?ZOG\^H]N+S]3%/]0'R_U5ZQX;*U6W\UM_
M<F/$)R.W<SB-P8Q:I/-3'(X#)T67HA4PJT9FIC5T*"1%92\=P&%[@VBGD@$P
M0"C*0:BO$$?Y>B\4+(:YJ/Y4/^K_ %#I4]L]G[F[H[&WKVCO>/$#<^_\G49?
M<$6$H9L?AFKJN/QR2T&/>JJ7I0E[H#(Y5OS[(]MM(H6X&E?\O1A+,TOGD#]O
M1H-F?S!.[MG477,=5LWI+?N^NHL'6[;ZA[9[*Z^?<G8W7VW)Z-DHL;M7<\&X
M,9AGJ<;+I^U2LQU5+3,JV?CV87.VV,O=))(/4!@ 3\\>@ Z46M]>6A)@5<^H
M)_E^W\^@VPGRS[8P?5.ZNH*^@V-N[;N8[$A[8EW-O?!9/*=A;0WOY#6C/[?S
M=%E*2BIZO)5#VG62&9]  ]) /LL?8]OBMEEA>7#'BP(/\N(\NE4O,&Z&X:XE
M2+QRH HI  'RK^WATO\ (_S"N[:_LS=W:$^S^DOXAV#L'%;'[7V1-L_*0=<=
ML83$TL,&,S.]MO/N*>NK-QQ&ZFNIJND>, 6 N?==MV6RN<2O)Y?B]:_+Y8Z:
MNM_W*[%95CQ7@*>G[.'02=N_)SL;N*LZS7)X+K_KW;G4-"L77'775&UZS:76
M.UDEJ%J9:S 8^MRF7K,ID<C(/\MJ9:IY'4VXL+*+;:+.._$*M(5T,<M4_P"#
MI/=[S?S6IMV"+"7#8%#V_/TZ&:;^9+\GY?DQA?EC+7[%F[5P.S9-C8VCGVU6
M2;(&"J,='CZYJC;W\8$\V0R+@U4[_<A'JW9](!T^RF^V&T9A5I#FN6_V. X#
MY8Z<7F+<54(@CX4^'Y4X</Y?/CT"G57RJ[6ZCWAV-N_$)M/=U/W#CJ[%]K;#
M[#PE1N+KOL+&U]8,@U+N+ 09#'5,S4=8JO3SPU4-3"46TG'MZQVFVC6@9P_D
M:Y%12HQQ_;TW%?7$;%JC)J1FA_XKI0Y_YM=WY?>O3^^MM1; ZIEZ"2II^I-I
M=5[0AV_LG:U)D9(WS=*V-R59F\EEX=PQPB&N^]K*EYX"5N!:RBQVBRAUJI<U
MK6I]3GR]?]CIW]\7K.&94H"/(GAY<?\ 5Y]*7?GSX[0WUU?VIU!1]4?'#K39
MG=E9!E.SUZJZUR6V\QNC+4\WF7*39.OW7F7I*GS%G*0K% "3IC X]J)=DL%*
MS:I#(M:$G_#C/3\^]W\\#6YT",CTZ#?H;Y3]D?'K"=G;9VC@.M]V;8[CQF'P
MG8FVNS-KU6Y\-G<)@IZNHI\5]O29;#S4E+5M5$5'B=)'5$TLI!)9GM([ND;D
MA *8-/\ 5_L=(]MN9+!9V0 NSUX>HZD=B]Z[U^4>:ZMV%NK+]2="[ V0D&V]
M@8+:&W]Q;6ZAZRHZW(1U5=DDP>/_ +Z;AJZFJG77-4325%0Q 'D"C3[<MMCL
MK-&>$R:SQJ:U_D.E=SOM[=L$G6,K\A3_ "]#A_,O^1V![\[NVIC-E;U@WYL3
MISK+9?76!WG!Y!C]S[@QV,5-UYK!?<10Y*4Y6KB0U355-3%_$EC=1=(D9BOH
M;E=6H$FA\JCAYC'V].27+?NZXA)6A %1Y@'!!Q^6*]%+V/WEO?KSJONKIW;D
M&W_[G=^4N"I=\O7XZIJ<W1_W?F::BJ=KU\5=!%BZJ9V/G::*H\@X 'LX^F@O
M2OC@_D:=(;>\EA%5(J/7_4#Y=&IV;_,V[XV3DNN=ST?6WQLSG875NS:#KG:W
M:FZ>K<CENPI>O\9%74U+L[,Y--V4N,KL*M'D9824HHJGPD*LH Y*[K8]O&L!
MI:$4^(?YN/2\;]>I1@$-#Z?Y*](3:_SJ[!VS%CH)^D?BKO&#;&_<AV7UQ#O;
MJ"?*3=2;LR,_W4U1UY7T&YL9E:6@AJK2PT^2GR4<<HU#F]V'VJ655741&.'S
M X5QGY]);/=+E;B62BU8UX?ZL>G24V]\RNU<51_('&[HVUU;V_0?)[-1[E[;
MI.V]L97/19#<U,?]QVY,'_!=P;>DPV9Q#Z6I9%+HA1;JW-Z?N1QIHQ4@^1P?
MD<<.CV;>[AHG!5""*<,C'$9_U5Z0W0?R%['^..]LOO78<&T\ZVXMM9;9>ZMI
M=@X([EV3NG:>:4?>;?SV(IJO%UM9C[*NC351R*5!UW%_;DFVAA28GY$$_P";
MH/\ [PGCEJH75]GIT8;)?S%>Z:W;G5FTL?U=\;=G[<Z/W]1]E=346SNK\KC8
M>O\ ,TJQ+48_&S3[OJY3MC,&"(UT=2T\TC11Z94 M[8;9[<BC%^%./V_+_5^
MSHXAYDW!0441T^:_[/$#H"XOE+VEB]S_ "'W+3T>SH,[\J<-N7!=FXU\3D+1
M8?=[#^-U>PDCK;X=)0MXWGGJ1&/H/=H]J@MI8[A=6M#JR<8SG'22>]ENP[-3
M5G@*>5.'Y_MZ&7KG^8QWEL'&]2Q56Q^ANS]Q]'8V6DZE[)[7ZVKL]V1UMBDD
M9Z3"4F>I-RXFAR&%QR62F%323S0QJ+2\7]K3MUK?,7F=A7C0T_/SZU;[A=0$
M!:9/ICAZ?[/1,]^[VSG8V]=Z=E;J2A_C>^LY7;ASTV(@G@Q5)DLQ*LLAIX&\
M\D=--*MT76^D&US[L-NM++N@UU^9KQZ3W<\]R*2:?RQ7I*&Q34 % 4<!RX%E
MTFS:5N&*W^@M]/;@9FR:=)8P$C1:8_P=<5)87N!R..?I].1>_P"?\?;ZQU[C
MTZ&&!C_+UW9BRI&L4E1*WBIJ:24TZU$I!:WW CD$"QJ+\CU<6]UN%$"H1Q)Z
MT6."O"G7!K2113@JJ3%%"VE8,X$PEBAD**',+0GU< _T]L(]<GA7I](ZI5CG
MKH*!R/\ #ZV)M^>/ZCCV^ A'S^WI%-)*C*% H2/\/422WD<DC\W!/-K<7Y%S
MQ];V_P /=:$>G3Q.3G_5GKJPO?U?[P."M_\ 'E?>V_W)_P!7IU6*@BI_JX]6
MN_R0R!_-$^,'U;T]Q7 /]>@^V"./R1_AR/9;SA_N,/\ 5YI\NCKDZGU'YC_G
M_KZ%/N+>I6Z][]U[KWOW7NDQM 7VEM$VO;;V$(/UM_N(A%_I]2#[WZ]:/ETI
M_>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4-BZ6-K$$Z?I>Y!_"^D
MJBDFYY]IK'6J&*7%.'#YGR_+JLV"&7_5_JST"':O3VUNSDI/XJTL%=0.S462
MH[KDJ Z$1@/4I /-A:U_<&>Y7L)LWN ZRW=QI>G'2YP/#\Q<1U_LQ_JXC+ES
MF27;0VB.HKPP,YX&A]?,= @?AKMM!SO7<"V)_P"47$:K_P"JMI4D7-OK8^\6
M/^3?/)5/]RO^,3_]['J3/]?G=AQMU_WI?^M'7?\ LG>"M_Q_6XC:Y-Z/#CD?
MJ^MB>&O^+_["WNG_ ";VY)'_ !*_XS/_ -['JP]^MU_WP*?Z9/\ MGZQ'X=;
M=*_\?]N$V]5A0XH\7XM^V#]/]A?VXW]W_P EFE;FO^UF_P"]CY=;'O\ [L :
MVP_WI/\ MGZZ_P!DWVJ;C^_&X1IU:1]GC"+L/U$Z#I^I_P!?Z^]G[@')1I6Z
M^SMG_P"]CU[_ ((#>/\ E&7_ 'I?^V?I5;)^-&R-GYBAS+/D<YD<;4_?4;5[
MH?LJRS#4H1EL#P?\/]?W*_M7]T?:_;F\6\$^MS0_"R^4J_\ *7+BDA\OG\P"
M>9/=W=>8(6@<]M*'X2?PXQ$F>T9Z-+'H:/6R:UM]-37TEO\ 5?4$<>\O/II(
M85BAX#[/6OF?GU&T(%V[._'_ %#RIZ= 'V;T7MOM4ID/)48C==+2M2TF:I"#
M)IN0;,TBJ -)(!OQQ_KXW^]?W8^3?=JT>>$".]7A7QG%=4 R#<Q+\,-,U_;Q
M'G(WN-?<L3A94#0D\,5_'P.@C\5?V=$?W#U%VIUIECF::FD\>/F,D>X,'5*T
MWB9%!\U.;MH&H7'TY_Q]\NN9?8SW7]EMS>7E2(F.H_4'TH%0BTIXL\WG*X'G
MY^0TY&+SWL/-MKX,[KK8&J,"33B00$ .%SQ_SH&*LZVS-9N//;KZ_P )CM\[
MDI9I6[8VQBH:'<,&7J#A'_B\N(D@EP7\;W(^%H3E_&R?Q@* >+ 3M[:??;66
M[T^X-H%B_BJ2<++4A;:R!([8ZFE!4$Z<CH*;][(6,L?BV-RS2"O:0:9(Q5I:
M@#-*9QFI->AO[ 23M:EVHG:==M?O[K%,WN5]X;4ZOZFWACZPXU\/@&V?A]W;
M(;<G:NX=\;"&;P\N1R]K6S(PY*Z:$WZ+<F>\^Q\X01S\CWI:FJO8]1F10?\
M&($I\#C4!4 D U(K .\;1S-RM>1Q)#12!7,6#I7AJ+5^(UI0TJ:>BDV9WQ#@
M]P=5].]>4.\ZW:U;OG,X>NW3VE09H1F@5-\YP=.=:YX [=WOG.KJ;"?PQLBN
M7RVD84X\'(O]])CY4DLEM POY*L/+/R_A)]5_+TZ*"8SQ(X>GG_J\OG^?1I=
MB]N]:]D9_=NWMB[H3/U&QXMMU&5K:"GJEV^\6<S&X\# ,1G8R<#N1H\_M'(4
M$AQS.J34+4A-Q?VUJF=2=O-/V'U_BS0 -GT\QCI.;>!Z5/\ A\N'#U\_ET8+
MVHZ]U[W[KW7O?NO=>]^Z]TF]Y?\ 'H[I_P##>S/YM_R[JC\_X>]CS^SK1\OM
MZ4GO76^O>_=>Z][]U[H.\X#_ !:J%[DK3G^E[Q* +6MP/\;^_>M.M# !/KTQ
MVL2" 38^H?IY)Y-[<@'Z7/!Y]UX]7^?7F''TLH4&XLQO]"05X%_\/K[]PZWU
MT1]0386M8 7/(+$@*;#^G(_'O8ZUZ4Z]R2;@ZC_4WM?@#402;@GG\?X?G77N
M'7(-8'U6L0+'_$<7*V&D_7Z?GW[K?GUUQ9K#_68'5J_+7((&H _ZP]^ZU^?7
MB+ "W)*E6%Q<WTI:_!%O\?I^??J<.O=)3L/%5^?ZZWYMK$Q1U&6S^T\]B,7!
M-**>":NK\7/3TD<T[*5@5YY0"Q!TCD_3V1WMG<W 4P(* >M/Q5_P?YNC';9H
M8(BLIR6)X?(#_#_GZK8Z<^*G>FSJSX(S[BV_AJ4=";+[)PO9[P[JI:NEQU?N
M3<6:R.&@BI8((WW$DU'6QEGB9!$S$'D7]B,. $!.: ?G3H+QQRR.--,5_P"/
M'/\ /CT8C8'3O8VWMY_.C(YO'Q083OS=,.5ZVK,3N&,SY'%_W2R6%?[NGEAD
M.WJZ/(U2_N"Q(N?H/=@#0"N1T>1H5IK4!:U_P=%_VM\7>]<9LK^5[AJ[;NW%
MR/Q=K83W; FXHG3;V*CVE@,-_N-E"Z-V9,5^.DUR* KN-=K-PU*O<">'1C;7
MEO%%<H7(9@-..)HU?L'#HSVPNJM_;?\ D[\D>T<O0TW]S>S-D=:839^63)TS
MU^6RFT:??5/7+E,-'"L>+>ACW'&L4T876E0X'T-U2S1JE&)K]E>@Y=0S325B
M (^VGK_J_P"*Z+!5_&'Y"83XP=5X7:^W=HUW<O2_>Q[@QO7LV>@I,'N[!X[>
M-!N8;9HMRF":EPF>S]!0>""MEAF2DDE+.C@:?:*X_4$AC&2,#ATJL@T7A^.V
M0?M%*_YNGK"=9_*CM#M'NSMGM3I?:W4%)OSXW5G5^V-D1]E46_-P#>DN(DHT
M>MW3C\9B:08K[EN2U,+*/S]?9>EO-JJT>:>OG_JSUZ] G)$/=6M">VA)Z</]
MEJ[>7X<?'3I,8W'#?G7N]^L\SO?'+N"DBHXL9M:7<LN9J(\^E-JR:Z\G3^.G
M3395(4_6ZM(9@*:?Y]>V^WEA_M@*5\C4>73UN/;'RGZ$[\[D[3Z,Z5P?R<VC
M\@Z_8N7RNW*OLS"=39CJ[/[$QF6I(*F2NRFWL]3[GP&5.4:]/'%#4*R*1,H#
M!WRC # I7I=<LK,%!S3&/]7IT"%1\2.^^MMH_%#<&U-@;2[=[-V/\E:OO+O7
M 8#>0Z^Q$&3W;6TT^:S>VLAN"+.BLI,!&C:Z0JS5!6R,E[C1&GCT7K#)KU #
M37U^W_/TIH^NOF?T+CNU^B^F^D-C=S]7=Q;T[$W'MOMRK[,I=BQ].4?:E1E<
MINY-Y;'KL5D<OV"U)N3-Y"O@2FK:&-H:B.-Q(R-=IF&DTSGI>HT!3(U/RK7'
MKT WR,Z[W;TO_LI?0WQOW!5R=W].=:[FR=9OS#]@=6]1;CI=JY:ODEW!%CMP
M]R;0WKUG4[>RVZMRJ9<3+B9JQUIZ>HCFCDI=1UHD8!E&/]7^#JA&KS[?]0\N
MFO8NVMZ=P=6[IZ!VAUKD]M][;([WZS[O[IES/<&RNS9>S<9+F*>:?>F-[2V1
MM';&PI<M4B8B?%4N-4H)+:R5(]^9&5-1%.DDL,I(51^VO^KRZ-_5[4^9GQT[
M+[H_V7SJ#;G>.P^^-W4N\<1GLGV/ANOJCI7,U&&I\=N"+=.#KL'EJC?6/J\M
M%)6K'0SX^18I/&LE[$56-R01Y_9UM::5!XCH-^Z/C9W3F.Z\=V9O'XL],?.;
M![CZVV%LJNVGO;<6#P6RNEMXX7-5E=N3?NUML=AX3>D&2H<G%FB*B*G%/7SI
MC@HJ5#K92OY\.K@Y^*G^7_-T%>#^)GRNVU\-=B]/T?1.PJ7L;I+Y=;2[CVIL
MG9W86+V]LC?.RL!O_';O%?MJHGQ]5#U[0TL5$(EQC>=F.IE(N1[K*X"X!Z4V
MLJ1F4N_Q"GKFO1[OE#U%V/W1C_C?4[5VG'3UG7W<>(WSO/"93=]&XQ&'CIZ0
MULW\2>C0YQJ*6-T6*-4+J ?R $;$DB@.FO\ FZ8F;66((S\O^+Z6& ZKWC1?
M.CL+OJOH<;+UYN+H[KK8F%S]371SY*#.;<W?OK+Y/!T6$C59L=24M!F:285+
M.PD>H95&I2?9@L\(B*DG63^7IUZ,A 0?Y?[/1(ZSX/=JYWXQTVR,]L;J3)]A
M;+^2^[.]<'USO2*+=_7V^<;5;IQ.2H*.>HK/+'B<GG\!3U%/_E'EBII)-3J3
MQ[K, ^%/ETJFN(6+,@QZT^VOY<.A;^-_2>\\9N[>F[\E\%_C9\+\.^PL_M?#
M;<ZYBV-G^R]ZY?-PU$,CU78>RMJ[3I<)ME3(!]N*19FO=Y'Y]LPJRL"R@4X?
MZAT6SJSA]#5QTF\%\7^[Z#X*;;Z&K,%A5[0Q?;51NJ;$UFY::L2@VS_I&W'G
MZ*:EW&L"4TN3I\%7P2#]LO=RC$L+^]W:O*X9!@+3JMJKK2$_&<]&'[2Z2WEV
M!\D>O]YO30R=8T'1._.J]WYD9&A&>AEWS38O&9"CAH*JFF:J2IH(YI&GC*%6
M2P(+ ^TICD8]M:_ZO]7V=*;@&U ,N!^WY]$[K>D_FSN'HFG^">Y^I^OY.KM*
M8:N^64/8-*V,EV53;@_B@QV)Z<7%KN2#<E5C0M.*B;*20)(FKP6-P]'!*&6J
M"@\Z^7GCJL3+/&9$8XIY?Y?/HUNR>D-^[<^;&[^XSB*&GZDJ/CUM'JW:V0_B
MT%7D?[R;>W++D8S4X>6)ZM8,=0LL@=I-$K>FWU]J,\:8ZV10$'CT5FMZWFW-
M_,R_N3MK/8C-]2XBBP'R5[+P^*J*"JQ6,[=VEC\YM7"T>5CI9Y8:6MW=!N)Z
MJ:&7QLAQ\1(-P1JG'/6JT ]?]7_%]&H^;W3N^N\NJMKTO7&VL%V9D-K=F;:W
MUN#J;<6:;;NVNW-NX*K-5F]E9?(5<53B6EW H,6NNI:JE46UQ2#@I)+6=I3*
MH'AD^OI]O2E)4$84GHK?1'QV[HVMW;V%O&F^%75'QEZV[=Z!RFRJS9?6V]]C
MI1;2WS2U;28S^^%+M#9^W*+>M7FIX%G@KH(*04=*XBE$KJ7*V%A&._'\^B^9
M'=NPU/2WB^+/=T?P&ZP^/<V*VXO;6U=T8;,9FGCS=.:#'T='V#5[EGJ<-F_&
MU.U:,3,J!'5XR)'4J6"L%1N86#!6.O[/*F>DUO:W&M0RB@'K@T./\O2NR6TO
ME=T1WIWGN7I+IS;7R Z[^3FY\;N[)U^0[)H^N<YTUN*@VZ<+Y,G29+%YB+>>
MVQ):1::D%%4\']\?0E,\BBO$_P"K_5CHYB&FFLT/[?3 _P _0S?#'J_L+IGX
M];&V5VCCL+ANQ<7_ !UMPP8#('*XY(<QE:JJ-'3U;L\,EX90=0%U_P!A?V_:
MNI )KCIF='D)\*A!'1JE,:@1HKA!Z5'U(15LHX(!LH'T'MRM2<]4TE0.O,--
MG4_7BQ(7\6Y)O:_O1]:];'I3/7 DZ-7/UM>X8$@ 7%QQ:PN?Z>]=>%,]>U3:
M;64$_0@_IM<6X(N>!_K_ )][SU[!Z]Z2/H01P6-[G@_C22!]1^/I?WK[.O?/
MK-_@#R?H#R""?QJY/(_KQ_MO>^M=8AQ]#I/UX%A9>+G^T#?\?X>]=;_+'7K7
MN ?5?D\&VK@:KV-E_P!M?Z^_<>O==+SJ'! U$6X'T)-K^D?\4]^Z]Y=<O620
MO'UU$#3J)/UL!R>/\??L^77L>?7&]A;ZDFU_S>Y!M:[$G_6X_P!?WX=>_P '
M2NVERM?P0?\ (+\V^D<AMQ:UA^/R./I[L.M-7R_U9Z6?OW6NO>_=>Z][]U[K
M_]#?X]^Z]U[W[KW55/\ .GX_EN_(7D 7ZFOQ^?\ 3UU3^/RW/UN/9MRU_N;;
MCR[O^.OT0<R?[@2^N/\ CR=:'5B);#FYMP0 0+?T-KV'N8SE17A3_+U"I!$A
M]?\ 8Z]-QZKFW]"3R=1!)!N0"H_I]![9L^_'^KSZ;%IK-2:G_5\^N@G(_(^E
MK'Z\B_!!O?\ V)_K[O>6ZDZCU7PGA  I_J_;_G^?5COQ0_FF_*+XH-0X&EW$
MW;G76,I<7C\9L3LFOW%6P[2PN&I8*##8?KS<M1+-4;7Q>*H*>*&EIHVRV!@B
MC5(U50H <W+E:TE+$6R!R:D@"I)H:G-?6O0LV_FJ[C"*;F30!2E<?( 4(IPZ
MLCK?^%%.Y(L7)#AOBGAJ//ROY(,ID>Z?O,=++<>N7"+UT [V/U.6)Y]DT7(S
MRM59& ^W[?\ AGRZ.)>>C&G<H)KZ?9_PNOGU3!\K?FU\@?F9NF+<W<&Z87P>
M'KB^U=AX*E>AV9M9S92^'P[>MMQ  ?[E,L<QP+>Q1M^P0VI+(H!)^RO'T8]$
MVY[Y+<)1F) %/L&#CM'SZ*@6M$1R;F_%KDW'(#&_)!/^N/:VXN!;C1_J\OD>
MB2*#Z@EC7_5^8].HT44TLVB"-YI&>*&""%#+-/-,VB""GB4%Y9)=8 4"]^/S
M[<) 5O2A_P O3(XC/GT/6^?B7\G^M=ES=@[YZ,WWMC:4'\($^:RF/,=+BHL\
MBR8BNW%H+38'&Y!)%$<U2L:EF ]E-O?1,*JP.?6O#HTALI0P!5@U <CR/"GK
M^75AD_\ *YK:39?Q"I7V!WM5=@?(*JH,EV3O(9[;6(V/U%@YLW"&QZ;4K&&6
MR.5?",:C[N)B@%A:Y]H+K<GD:;1*OA+B@XUKQ/\ @I^?0@@L BQZD(8BM?4?
M+/\ DZ /Y6?$#;_1NZ.^]O[9^/7R;CVWTS2TU11]HY[?NULOM+&4IJDI?]).
M]Z;%QN]+A-Z5C"3'T3L)XXW56U'DVM;W5M2:W%3*]/4_8/LX])KVQ*S,0E.U
M:X.*CSJ?/[.BX0_$#Y1R=:Q]Q?Z#M_5/7<.VTWDV\X<&\D.3PQJ# ^6_AS#[
MY]K)-5CRS+'XUCAUDV(]JMGO41@"X#&GG]O\^D8L:@5C/#T_+I/97J//S[!Z
M,W!MCJ#MN3,]HS9R/ ;B>MIMQ;0[7J8I32+C>K,#CXFKL;/BZO\ S\<MR0#]
M/;GURQ;CK9A30WGPKTQ<61*$*OF/7_/_ )NLO;/Q:^2/2&,Q^:[9Z:W=L?#9
MC,?W=Q.:RT$9P]1N!=(GP<U?3M-%1Y:F+V>&4JZDVM[<>]@FUZ7&H4KGUX?M
MZ97;)E 9T.DG!IZ?X:>?2PSOP1^9NVMMY'>&=^-W96-VKA\%+N?)Y>IQ15Z;
M;D5.*@YXT%_O3BFC(*S:-!4WO[2?O""/(D6@)''T\O\ /TK&V3##HU<'AP!\
M^GZF^"7=,_P_Q/S$IZ"KEVAD]R9&"?;BT*)-C^N:'&5=:W:391Y%CFQ[UM*:
M3[)0:A6]973S[I;WT9E\-I!K]/D<]>N+*2*/6(SI]?GT W4?1/<??.5R>%Z=
MZVW1OZMV]C8LYN7^"T)9,#@J@*:;)UT\ICIXTJM0\:LP9B;>S"XNU106;!Q_
MFZ1P1-*Q4+4@5H/3SZ4-+\6_DE4]C97IN'I;>Y[4P=(V6S6QVQTD>6QN%\,<
MR9AI)=%,:"KAD5H)-?CD!X)M[U93QM%+*Q&D-_*G'IRY@:-XXUXLO^7_  ]-
M6Y_C=\A-G=C[:Z=W#U+O/ ]J[W.(I]I[.J:"]9G9MP5<5'B$I98C)!5TU>TP
M3RQLRQR, 2/=WW&!DJL@*$8-?+K:6,RL08R''RSTH>R/AW\H.E-G5.^^U.@]
M[]9[+Q>0APU=G<KCH3B\)+4R.QH<F\+/+&]3)"TJ5#Z0=&D&[#V7R74#B1DD
M!<<?/CTK%I,:0F,Z6Q6E.'_%=8-M?$OY.[NZZ';NVNBNP\QUA+1UN6I=YT^%
MD7'Y#"T#::G+8RG<+65]+':Y:)&6PO?CVHM[Y#)X7B#Q*5 KFGK]G2.>SE@C
M,C1'PZTK3%>H'5?Q3^2_>F!.Z>H.E-\[YVNN1JL1)N'%X[Q8I<A1)52U4%/4
M5)B%8]-'2D2K%K9)/01?CW2\NU4A78 MP!Z];VDD]="DBF:9]?\ -U%ZO^+_
M ,C^Z6W9_HJZ6WIOM=C9"3";R?"8]G?;>>65H$Q.92?QFAD>9""\FE0/];WY
M=[\-50#(%!D>72H[=)'4D$TXX]2!_AH.@]3KK?<G8#=5Q;3S-3V1%N(;0JMF
M45*U=G8=S,="XR&CI@[5'[_I:1-2+>Y-A[O^_JX(H?M'2.37\-*GI?=J?&?Y
M$]&R;?B[=Z?W=L-MVY#^$;;.3I%GAS66C81S8>EJ:,ST_P#&-;A8Z8L)9"WZ
M?=5W*.[X4%/F.JBUF!I(C CC4=9^U/BA\I^F^O,YV5V-T9OS9FU<-08ZMJ\U
MGL8T>+H_XTLE3B(,VL7DFIXLC1Q,'215,4C#5;2?>Q=0M2CCT_,=*EM)%_!Y
M5X<?GT?# ?R^NC\U\B>C>E?[Q]A1;4[?^&^8^1^79<E2M5X[?6,VG5[F_N]B
M\@Q9CM1S2$,%()4VX]LRW0$$]0*UIQXC_/\ +I:EH[2+QI]GG7'GGR_S=5,X
M# Y3=>X,+MO:6,SFXLEG<M487;V)I::2NK:Y9:EZ:AP\T4*,\[M(HC:?E1]?
MI[K:W ]<?['5+B'P*@X_U<>K #_+^[*V!\=_DOW!\BM@=F]7;IZMP.T,KUE@
M\@U%3X_-:L]2XS*X^6EC=FJGI(:T3%S;TKI_/OT]ZDB@I(".'Y@''6XK9RP1
MXR"<Y&:&E#T7[:_PW^6.]=AP=D[0Z [&W/LBKQ=9N&FW'CL3KI:S!TK339'+
MTL!*U=114ZQL5>-&5RK*#=39J*\C545F&NGK^WIN:S<2RZ5.@'TX>7'IFZD^
M+'R0[WV[DMV=-=-;P[(VWC,M)@*C+;?I4^W3<,&K[C"2FI:$KD:2-2TL:ZF0
M#VN6_@6FIP ?GU06DK$=AK3..'0U_'G^7_WM\BZ/Y$2[?QF;VU7?'C#9*KK<
M978(R5FY]^X6HF63KHP5!BFP^1%(%F::4+&-92]UM[8W.\C$,.F0?'_DZ=BL
MI"^8C4#R\NETG\N#M7=OQMZ4[<Z3ZL[4["[8WQGM_;;[7VI02T=?A-G5F%KL
M+_":&FC615AJ)ZB=D9E)L#_0^RY;U$J9'4+Y5^SI>EJ[J JU/F/Y#JO;<F!S
MNR]S9O9F[L16[=W7M[)R8?+X'+024N1QF6I[C(T&0@=5:EEHSZ1JMK)X]F$<
MX8CUZ*;F$K2B^8/2=DL7>PM<D7)T@<#@D$'\?2_M=Z],D9IUF/$ZFP)4?0?\
M%X)']FW^/O34^I'V_P"3JL=? -!_JKU:K_(^'_8S[XP"]R$[BNWY%N@>V";$
MW!-OH!_M_P ^RWF[%J*4\_\ "G1YR?F<UKQ'S\GZ^A5[B[J5.O>_=>Z][]U[
MI-;1YVGM/Z_\>]A"./\ JU0?6P-OK_A[\.'6CQ'V]*7W[K?7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U$M'-3V!*J+\@$E""0;@<D#_>OZ>V]23*0C5!
M'H?]CKQK(:GC_EZ@B-X%\\+K(@]5]**?H;BS$V%B>?K_ +#VG*W48*QL2OG@
M#_#U4Q^&U6'=U(%2MO\ @7^3_NC^EK@<?3D?[[Z/"> <&_D?\W3QDBQ^GC[3
MUW]P+D?>?0_B#D?G^AX_V'O7U$/#5_AZ]XD-*^'_ #/7&Y)U%[7L S1@_IYM
MZO58&WT_/^W]ZK;#_4>K5AI73_A_S?ZOMZYAREE,A6RBZ^,6%@ 3QZN/K_3W
M[_%ZD4_P]>)B'E_AZP0SQLOC2L)M^/$X;@EK\B_^O[<"SR\ %'V@_P"7IMKN
MV<FBY_/_ #=9ZDR*#HF(X L+<6(%B3_:.JYY'MB2\BLU'CBI_,?X ?4=:T2,
M:H:?D/\ +^?3?%XZNG>(>J0V*-H*?FY]/IT_I /NB06T:D6@ ?T[O\OY];N)
M(K@D(#3_ (KUH>N%#!$%^W#>G\:4L1=3R3R3ROY]O",./\8AJ?6O^8_9UJ.W
MN;5:(VE/R_V?7HN._/CEL3=C3UU"G]U\S-4K4U%=B8W>FKF!"DR8^:H99+*"
M3J4'_$D<X?>Z_P!T7VY]PH&GVF#P+VI(.JX8"IB! 4W<8^&,@4P/MH>I'Y>]
MT-YV615O'\2 "E.W4:!LZO#8GC7(J<?/HG6[>E^S^LZJ3<5'YLIC\?6&KI\W
M@IQ_$J9"J^0YC"-Q*@! )6_)]X!;S]WOWH]HKMI>2KC5&".ZED*'2/\ ?UQ*
M1_;.,YK7/#3D'LONERGOT M]TM =0(*L9<@ZJCMC \A_F]6_,=M2]F8G"8#M
MZES>0QV%S_\ %Z/<6P\H=F[AI&.$W+LC+:RA5RFZ,)N"MQQL<385[6M>XE3V
M@^^Y<[/?I%[B.98*5K15(&F4GLMK%JZ:Q@BHX5KIU'H$<Q>RTUC TD+#Q/*O
M _"1W>.>-0:BOGBO UW0O7FW-JUVZ=R[ W#4Y7KS-[,ZTVELJ@R.8S.5JMK;
M=V/)O0+B%&XC(\6$+9S]M0S&UR?H/?3GE3W,V[W-VA=QY3E41*>Y@&_C9!VS
M11G)B<8K^P"N/>[\OW&W7+1/'4^E<< >.HXS4^?RZ.O['/1?U[W[KW7O?NO=
M>]^Z]TEMZ?\ 'G[NM?G;.?-K"Q/\)J!SP23;^OO?EU7\1_U>G2I]ZZMU[W[K
MW7O?NO=!YG?^+O,/H#'$0?S<QJ2+<W TW_K[]Y]>\C]O3"NFW/-SP ;<#C@D
MVM<D_0<@V]UZM]G79'U%^!^&(U6 8W86!OR?]]]-_P"#KWIZ]<CJO<@L!8BX
M%AS]6'I!+'D>]?/SZ]3K&;:@3P /Z7#>GZ'4/J?]O_L??NM]=CEB2/\   ,+
M$@W_ ">-.KGGCW[TSUKKLE2 +EK$ C4&)!%S8FP%K<_TO^/?NO=<>;ZB=1))
M*\_4B_TY)4#Z\<7]^Z]\NN((N0;,=#-I%R2JBS/;A@JWY-N![3RRB(!2>/2E
M$\^O*59'>,B15!9G0:E15 +,Y5M*A +DG@#V8^$PH?D/]7#HJM1W8KQ/^'KL
MC0L;,K:774C6LCJ/HZ.18J1^1<>],VD''1FP[3^?7ETZE4,H:RL$N+LLE_&0
M#8E9%L00/5^+^VW;413IBN!UR] ,JNRAH@Q-R%\80^K7JY14!YOPON@'KUJO
M ]<8Y Y0.%7RW:$\6F=4,I2._$I$2EC:_')X!]^ ^6.MGRZY$ /XQZ9250QL
M=#ZRH94,9Y9V#7  ^GO7#/6\U'6(Z!<.53U%?W"%NUXN 6(N094X^OJ']1>K
M2JI'R/2N/TITWT6:PF4->N-S.%R9Q-2]!E5QN5Q]>^+KXD,DU!E125,IQM;%
M&"QAF"2!!<J!S[4HWB1JPX=)IV_5=?*E>G!Y(4#L\L*I%)XI':50L<Y^D#$L
M-$Q_"FQ/]/;,E:$=>1ACJ#E\OC=NXC+[AS4HI\3MS'5F;S$K4[U'V^+QB2+7
M.*=#YG,15ULH+!P18D$!(X_U?GT\TE(R!PKT!6Z>H_C?\K=@;8W?O78.U^UM
ME9'&'*;1W-NBGS.$6@QU3D&IACY,CBYL=F88EJ:9RZRA8ULNJR\DP@X U(/R
MITSXM<# _P!7K_@Z6'3W77377>S*?!]$[>VAMO8-?4@8J78^0CS>)RU9#)X9
MX:C<,E;D:RK@AFN/^!!"M_0^Z7)(J20>M:_(CN'0JZH2!X8T1 "\4*'4L<2\
M (Q)9HHE %SS8<GVV@[5^SK9!.?7KF=2O'&RVFGOX8REI)S9"PAC-FD $BW*
M@_K!_(]VIUJA/GUP33*K-%^Z@+ZF3UIJB'[BL5U &+3ZKFZ_GW5E)'7C@BO7
M,"RBUN0"MK%65E#*X/U=2IO<&Q'/T]UTGSZJ*>77% '4/&5= 2 T1#J6'U0L
MFI21_0?0CWX(<]>R:"O7;W5F#ZD+E>" #ZC90 WY9A8?UO[<IZGJP4^0ZXAE
M+K&O,EM8B!740>3)XQZV4C\VM;^GOU/GUO2>)Z\2K)K)&D!2I+$ Q%BHDU&Z
M^,R#3<\%A;WNE.DNO1>1J:?#_EZXK)%J8B:'5&R)(-:%HY)&5$C<#28Y7<@*
MK $DV'U'NW@E1J/^K^72S=#XD:@<33_ ?MZRE=$A0_YPAV,=K/H0D2/H(#%8
M[78VL/S;VT9AK\/S/3%@H%G(['@HZXI/%8LLJ>C02ZO'I4N"$!8L5O)8Z1]6
M_ ][%:FG6]:MZ5Z"O9_3'577N=WMN;8'7>VMI;E[.KZ/,;URN*CR,E5OVNQI
M9Z2GSK5LLL@A2*29E$;0Q^2W!_._7'6PI*DCR/0H0^&.,()G95L2*BH@EEB\
MK:EIV:((EHB="BUP!;D^WA\*^G6\@4\^LXC8.ZJC-*C!&C5&,HU+K \0]:L1
MS8C]//MAZ]QIFO6L$ >770(=;W4'DCZ?4%M?TN/0;WXXL?=(5)>@'EU[6(\D
MXZZ!#)Y3I,2VO,"#& YTJ=:^DA[64_D\<^V+B,DZJ4Z=4AO/CUX6)(!4LAT.
MEUNC,2^AQR5-A^1>W/M^U0@"O^K_ %?GUII G' _U?9UVH)T-8$&P!4$BUN;
M?G_B.?;AP3CINH-2#UQTE26N #I%M0OPIYY! )/]/S^??LT)Z]4'KEP3<$$'
MD@GZ'4#] !<<_4C\>]=;_P /7$V(_P!@/HUKC0/I<?0<C\C_ %O?NM=<ASJ_
M)'U%@;:KBPMJ'!-[?BWOWGU[Y=>N3Q<J#<#5>_ U"]B?I>W]?Q^??OMZ]UXB
MWJ!"DD#5Q8\'^AOZB.?Q8^_=>Z[M8D7^HL"/J2#8$DL.>?I]/?NO=<38@?4?
MXDM>]R 20/T\?TO>_P#K^_=>'7,BXU,>#:_-R!^3P +M_L";^_=>_P /70NR
MA1?BPO=@I(%^1P#;3^/^->_>7RZ]CI6;1_Y3/H.5X]0(]3?XE3_C^0?=A\/Y
M]5;XA]G2T]^Z]U[W[KW7O?NO=?_1W^/?NO=>]^Z]U5;_ #HS_P!BW_D(5YL>
MIC>_ _XSQU41QQJ%C[-N6\7MM48[O^.OT1<Q"MC(//'_ !Y.M#4GQ7U7YO<@
M$_2_(X/J%_\  >YC;^S_ -7KU!DO]J?]7EC_ (OKE]--KFQ_ Y_UQ<'C43Q[
M:X=.DU"@&GS _P!7V?RZZFYTCCZ_U!L>+C_"P_UN?>SC/E3II:5%#_JX\.L'
M]#QS8GCD7O<\<W(_WGWK/Y=.=I%13/\ E^?^K_+U%-A?ZG@6N>>.;#^MS?\
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M\7AE.O<;C\GBZ]-]44-=4U$M=AZILP:G<D4LD,DOBJ:ASH(U(UA[<US,B*>
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M-J!+WIUKY#UZ*#V+W_\ )&@V'\=.N,AFOD3E]S_(7$]@=J[\W)\?MFON;O\
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MI_L],F5AW5^VOV=5Q?&23LKH3X*='9G97>O:.YGWY\A-NX/7OFHI98<'M?\
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M+$^]B*(@4(_G_FZ5QW<L@(12P_+_ "GJ/3H(TAC\M4%= E88:RMCFG2[S/\
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MI9ZJLK<DU/!4(3>*GK:A:>"K:9SY)T_<*\_46]W^D7S8?S_S=4^H<@X/\O\
M/U@E<NV0E-5E9),E4!*YQG,LDV2HH%B^SCKZ\5(J9!!+$6,)!B:P%R+^]BV4
M,*#]G_%=>\9R#5C_ *OLZPGG4>3_ +4!:_TX8"Q%C:]O^*>U/3/"O^QU,-]3
M6L;F]^?K]-+"Q^E_K_Q3WIO]R1G_ %4ZK'4P^1_XOJU7^2(I_P"'1/C"-14Z
M.X6#'@!O] /;%S];V_K_ $]E_-_^XH]*'_"G1YRA7ZBGG4?X'Z^A3[BSJ5>O
M>_=>Z][]U[I-[._X]':US<_W>PO_ +K:;^EOI[]_FZT.E)[]UOKWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9Y*>.LI1]V;V-RX!#'UK8%5*\
MD+;_  O[+9H(-P%8Y/M-#_E(].GY$1WTHN/+IOE2."!$CD\*D,"V@R!K2HX8
MAC(4*ZR#;DW^OO8-EMH D>C^M&_V?7IVW:. G7D_G_D^WI4>S'I'U[W[KW7O
M?NO=>]^Z]TF-W@_W2W=Q]=OYNWUY'\(F'^]CWX\!UH>?2G]^ZWU[W[KW7O?N
MO=!IFR1EJWZ#TQ&Y/YT6!Y^JBW-^/Q[\>/Y=>7A3Y]-]Q<"UKCGZW^E^-5N;
M?["P]^ZWGK"2;V'.H+RM^2#<A01]/5_MOK[KUOYGKLC@D'ZF[>HD-<D@ ?T?
M^O _IS<>_?X.O>G7CI+'@_10"ER.;,&]1!!]^Z]UX!N"+\M<7/ZC?]0!%BUO
MSP?]L??NO8KPZ]PP]1( ]1/!Y!Y!%O5_3@>_=>/70OP?Z7(M8VN+"Y(X"GWO
MKW2-[+HZVMZO[&I,?139*NR.S<_CJ.@74R2SU.,EC0*OXDDU_468<6Y]D>^Q
M:'10!72/^/='.WZ?"+'(#GR^758/QW^$&]=S](]%[=[1[_[-@Z:VZ*#.+\9<
MILW:F+PZ;JQF\<_GJ6FRO8@HD[.RV)DR)2J6CJZJ6F5M!50--ATUS$%Q&E2@
M^W"C-/\ 5@#RZ!R&0-0.U0QS6@X\/LI_.O1]-K]([>VSWYV1WW29VKJ-Q=B]
M?8G8=5MB6CIUVS@]O[>JZ62)J+)0Z:BJKJLT2Q&%[A@;&_LEN)$ TZ1PXTX]
M'%N6(&IJK7H!:OX)Y>CSF7PG7GR>[CZLZ,WINJKWCO#H3#;=VO48A\YFJTYN
M>DPW8]3 V]=I[=IY)M'\+Q<\-'<$M&7N?::$HVH(M,^G5Y:C2-(QYCH1/DW\
M2]E?*KKK8_7NY]V;BV?2]?[SVQG\=GMGU4\FY,C2[2DB4[8K<GEI'R4-/NGQ
MTZUM0KVE2F5'#+Q[>\NFOGT[]V_&>@[=;K_<FS>Q-R]"=H].46;H=@]D[+QN
MW=R5&&AKL%/B),5GMH;AIY]O;OQ]/!*T[4M=#/23N-,B,I(]^%*@>76P:'A_
MJ_U?X.D-6?#*HS73W9'6/9/?G9G9V[.V:W:F5WIV=N/%X>ER5/5[?: T-+MK
M:&)6+:FW*,QP@?;TT4<('   ]ORLK U _P /7@ *4%!Y=#=N;HG"[GW;T/NN
MJW'F(ZSX_P >1I,%3G'4D1S7WN/P.+DFJXH8UA:<P[=5GXT@N0. /9;-!&37
MPA4?+[?+JPD:A[S_ *O\GRZ"?;OQ)BH=\?(.IS_:^>WCTY\CH,G/FOCG7;*V
M?BL32U=;15=!EZW']ATE%_?24U5-6.LD-1/X0AT*-)/MZ!1'$$44&<=5< FK
M $XSTF.N/AUNW8VY]G-N3Y5]M=E=4];UR;@ZGZ8J-O[9VKAMIYVE8#'T6:WS
MMN"DW7V%B\8@ 7'Y>:HIV"^E0&-W?MZKI485:=-.\/@UN7*97M.#K;Y2]K=)
M=8=TQ5T_8W4FU-D["W%M[*;KRWBI,YN#:.X=UT=3N/957N*.C%154N/EIX?-
M.[&Y<WJ5##('[.K5'IG[>C==7]=8;JSK#8G3N&FK,IB-H;7&U:)<GXJK,U\-
M,*J6LJ\O+1!*5:RKDJM2 <"4_P!3S8$J!0_LZKI!KC'1/L!\$3B^@]X_'C=7
MR#WMO39M;N5]S=4[H3:&R=K;EZ(SJU[Y7&U&#.!HJ>IW-5X:O8-&^1DE)*W]
M^:C9;/6Z#A3I;]4_$O<^S.\*#OOM3Y(;^[Z[#INK*KJKS[@V3M'9.,I-NY'-
M9S)P&##[-I*##Q9N&7,RB8>+]?U)_&@*8ZM7 "_#UZD^&FV8/C!N_P"+PWSN
M2MV]N+>-9O>LW!44V"Q^2HLB.R]O]@18F,4<""1:>MPT<*R,3(\4K*?2 />\
MTI7KVMJU!/0I[MZ(PVZ>T^D>VJ[/YNDR/1F.W)@<3B%QF)J\5N?#[PVE6[0R
MQS]0D25E!]O19%VBEA.OR6N>3;PJ,@]>+,W%B3T6Q?@%5PS'9&W?DOVMM#XT
MY[<-5NW<GQ=H-J[1J<+EYLG7G,2[<QO:]?3R;^PFUJ>LD*"@HJF*G>&T;H1[
MV"U?B-.M$BF1W>O1F*7X_P"V*'OBD[\I<C7XZJQG4U/U+BM@4V+I*?&8/$XJ
MOEEQ@QR1H(Z6""GJ0JA0+(+ 6]ZKQJ3UX:A3J%\A>A,-\B]B8[9&XLWEMN8S
M$;_V+V**NA@A:2>MZXW)C=SQT9,:AG2KDQ@2Q]-V_I[UQ/5M;>;'IK^07QRC
M[T&R]P83L?='3/;/7,U2_6O<NS<1C,IN/:LE0%,E#4[8RB-M;<6 K8 3-1UT
M,J27(<$$CWO(^WK6HFO<:'Y](S#_ !'Q^1ZN[+V3WEV[OWO_ #?;,>/GWGO_
M '''1[5IH:K%M34^&K=F;)V>M#@]A55"F/IYUAQ\,-,97<E/6U_<#4'/5&57
M<2-&-8''B0/2OVGKGU'\6]W;.ST69[=^4':'R(H]K87)[3V+M3=&V-K]?8;
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M56_&KFUKGCZFWOW7OEU[GT@ FXO?4=5AZB2 2 +_ .\>_=>].O #^R/KSP&
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MNO5IQ_U?ZAUGY_I];"PXN00!_7DW_P /K[L:5H3T\,\ .HW-[?X?U!^ES?\
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MCUT#^FPMR"!^/P+W-B0US^./I[UU[KW-C]?\;V4 $$?[9M7TX_I[]Y'KW7?
M 7\?XBQ)]0'^OQ:Q)Y ]^/6^O V(_#&]_421;C_:@IYU?G_>O>^J^O71''];
MEK\@6((8C6;GG_&WT-O>NMU^6.O6Y$)/U!Y'^IOR18?B_P#0?3WOY=>^?7@/
MZ\BP/+6/T^A)!.FY^GTO^3;WKKW77%R>0=)N2UKEN >=)/U''T]^Z]UR%@"M
MS<6#78D6N!]&'UOS_OC[]U[KP*<B_/TL#SP26'^)_(O8W_V_OW7ORZ]>U_\
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M -!=<O\ H'-^& O_ ,9;^4+BYX_O5U%?@_0$],"QN?\  >_?UOO <D<?0?\
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M^M]W_$/V#_H'I[^J]OZ']C?]!]9O^@;CX4W_ .9P?*H_7_F+^H[?0#_GRO\
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MRQ9_Q?\ 'O\ H+KW_0-A\)B>>X?E5_L=W=0\@_47_P!"?U]^_K?=T&1^P?\
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M?T_X]@\W]^QUK/RZ[_@F4_Y[#</U_P"53:?T_I_Q['U]^_;U[/J.O?P3)_\
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M\]=N+_SFVG_M^-L>_?GU[\NN/\#REC_O\=Q7_'^2;2_I_3^Z_//OV.O9Z]_
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MVQ2?F><V  MI' (/YO<D B_^/^WUCTZ]W>1ZY_W;H[\2S@<6&I38C\_I /\
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-U[KWOW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gjyjiv3jrhol000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 3P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T3P;X-\+7
MG@;P_=77AO1Y[B;3;:2666QB9W8Q*2S$KDDGDDUM_P#"">#_ /H5-#_\%T/_
M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)K7N=0M+2>V@N+B..:Z<QP1LWS2, 20H[X )JI)XBTR*]N+22699($9W
M8VTNPX )"OMVNPS]U23[4 4_^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFM>PO[?4K1;JV9S&Q(Q)&T;*0<$,K ,I![$ U9H Y__ (03P?\ ]"IH
M?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\
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MBRB:088&9R@]2$)VJ3W( )[T 9?_  @G@_\ Z%30_P#P70__ !-'_"">#_\
MH5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-
M=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <_
M_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#
M_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30
M_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/
M_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $U\[
M_'FPL]"\<V5KH]I!IUN^FQR-%9QB%"QEE!8A<#. !GV%?5%?,'[1W_)0]/\
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MQ8FQBGMF185-[#MS$=K!<Y.WY3@XX[:FOV/BN?P3JEK9:C:/K<B_Z/-:P-;
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M!+Y.#SM&0<#'=AEECAR5W.[:U25DNNEW_7XQ+GZ'>:1K6F:]8K>Z5?07EN<
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M %%%% !1110 5AW7^A>,K"X^Y%J%M):2-U\R6,^9"OMA#='/ [$YVBMRN?\
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M5!U(]/O2_-F-\+K%M/\ AIH<+*ZEH3-AU4'$CM(/NL1CYN.<XQD*<@=?7/\
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M]<_[\V7_ ,CT44 '_"/:I_T.>N?]^;+_ .1Z/^$>U3_H<]<_[\V7_P CT44
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MM4_Z'/7/^_-E_P#(]%% !_PCVJ?]#GKG_?FR_P#D>C_A'M4_Z'/7/^_-E_\
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<_KNN:W>74<0A60M;QX0$D#"0@=6/;/-%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gjyjiv3jrhol000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 4(# 2(  A$! Q$!_\0
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M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
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M3P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH \_O=(\*V<-TO\
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MZ4 9>@Z-K&F:GJ5U?ZI8W<=_*+AXX+!X2L@CCC&&,S_+MB'&,Y.<XXKH***
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M_<UK]S8GNCTNBBBN<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC'&*S_\ A%O#W_0!TO\ \ X_\*UJ*;BGNB(UJD/ADU\S)_X1;P]_T =+_P#
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MS3/*W)SRSDL?Q-8W@3_DGGAG_L%6O_HI:Z"@ HHHH **** .?\=_\D\\3?\
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M'4=ZU: "BBB@ HHHH **** "J&J:A8Z;'#/>K(Q\S$2Q6[SR;L'[JHI;IG)
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M9A@?.:** #0IH],U:*]O;_6[M883!%$GAS4HU"<8RIW)D #YE12><YS75_\
M"9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W
M_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6
ME_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",
MT?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_
MX(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_
M  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W
M_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_S
MZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,T4
M4 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_
MX(;W_P",T?\ "9:7_P ^NN?^"&]_^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9
M:7_SZZY_X(;W_P",T44 '_"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_
M^,T44 '_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",T44 ?+7BSP?X
EHU/QCKFH6?AG6Y+6ZU">:%_[.F7<C2,5."H(R".#S1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gjyjiv3jrhol000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '&!&<# 2(  A$! Q$!_\0
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M>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZUS_P?7O_ ,>H Z"BN?\
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M Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J .@HKG_\
MA#=+_P"?K7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_ /A#=+_Y^M<_
M\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\ GZUS_P 'U[_\
M>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\
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M?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J
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M /A#=+_Y^M<_\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\
MGZUS_P 'U[_\>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\
MQZC_ (0W2_\ GZUS_P 'U[_\>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-T
MO_GZUS_P?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5S_A[_D.>+/^PJG_ *16M=!7/^'O^0YXL_["J?\ I%:T =!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ'&H#"WR.'?/'0Y [\<8K?\ AIK-_P"(/A[I.J:I<?:+V=',DFQ5W8=@.%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7/^'O\ D.>+/^PJG_I%:UT%<_X>_P"0YXL_["J?^D5K0!T%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <_9_P#)0]9_[!5A_P"C;NN@KG[/_DH>L_\ 8*L/_1MW704 %%%%
M !1110 4444 %%%% !1110!Y_P#!+_DD.A?]O'_H^2O0*\_^"7_)(="_[>/_
M $?)7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOTN:%UXC\77OB3PKI&DZE!"=3T47-S+-;JZH^ 3+@ $GT7(7)YI--OOB!?\
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M?_!+_DD.A?\ ;Q_Z/DKT"D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KG_#W_ "'/%G_853_TBM:Z"N?\/?\
M(<\6?]A5/_2*UH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G[/_DH>L_]@JP_
M]&W==!7/V?\ R4/6?^P58?\ HV[KH* "F3,R02.B[F5257U.*?378I&S!2Q
M)"CJ?:E+9C6YX-X!\ >&OB!H=UXB\2WEQ>ZQ<W$INE^T[/LQ#$ 8'3C!YXQC
MTKK/@S(UO:^(=%M[Y[_2M+U$PV-PS;LH1DJ"."![<<US6C?#_P (?%7[7K\E
MC?Z%>K=/%>65O<H?G&"259,J3GT'>O7_  [X<TOPKH\6E:1;^3;1DG!.69CU
M9CW)JEHNVFWW$RU?S_ST-6N#^*O_ " ]&_[#=G_Z'7>44NJ?9I_<Q]&CS?XB
M_$FU\-:I:^'TU"+3KFZB\R>_EB>46L9R 51 2SG!QG@=35/3O$W@IO!\]MX;
ML3XGM[":.>_BEMW,K;F^:<^9'^\<$%L#T[5ZI10M >IYA-XDTKQ_XK\--X6>
M6Z.F7C7%W>?9I(T@B\ME*%G4<L2!@>E:]_\ "#P)J>HW-_>:%YEU=2M-,_VN
M<;G8DL<!\#))Z5W%%/I8.MSS_P""7_)(="_[>/\ T?)7H%>?_!+_ ))#H7_;
MQ_Z/DKT"D 4444 %%%% !1110 45SVI^.?#FCZC+87^H^3=18WIY$C8R 1R%
M(Z$5#:_$/PM>WD%I;ZIOGGD6.-?L\HW,QP!DKCJ:?*^QT+!XAQYE3E;O9G3T
M444CG"BBB@ HHHH **** "BBN;\?>'[OQ5X)U#1;&2&.YN?+V-.Q"#;(K')
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MCNJ*Y2'Q1=R?%&X\+F&#['%I:W@D /F;R^W&<XQCV_&C0?$EYK'B7Q7I=Q%
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MUX&2!SC/%7?L?C#_ *#NA_\ @FF_^2J2VM\_Z^X.ORM_7WG045S_ -C\8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_@QA_\ BJZ"B@#G_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
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MLG))8CM@52G^'.L2?#KQ#X>%S8_:]2U.2\A<N_EJC2*X#';D'"GH#]:79/\
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MJ:ZBF_\ ($%%%%(84444 <_>?\E#T;_L%7__ *-M*Z"N?O/^2AZ-_P!@J_\
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MV/QA_P!!W0__  33?_)5=!10!S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\
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MSN*'..BL,?,"O:5S]Y_R4/1O^P5?_P#HVTKH* "BBB@ HHHH **** .?L_\
MDH>L_P#8*L/_ $;=UT%<_9_\E#UG_L%6'_HV[KH* "BBN;\:>-+/P/I,>I:A
M97UQ;/)Y9:T1&\LGINW,N :3=AI7.8\0_ WPCXAUB34V-[8RS.7F2TD54=CU
M.&4X)]L5VWAWPYI?A71XM*TBW\FVC)."<LS'JS'N37D/A_\ :,TM-*4>(;&_
MDU#>VYK*"/R]N?E^](#G'6NX^&OC6]\<)K6H26S1:9'=!+!GCV,R8Y#8)!(X
MZ'O5)-*RV)D];L[NBBBD,HZGH]AK'V3[? 9?LEPEU#\[+MD7[K<$9QGH<BI;
M^PM-4L9K*_MHKFUF7;)%*NY6'N*LT4=+!YG-^'? /A?PG<27&B:1%:SR##2E
MWD?'H"Y) ]A724447 \_^"7_ "2'0O\ MX_]'R5Z!7G_ ,$O^20Z%_V\?^CY
M*] H **** "BBB@ HHHH **** "BBB@ HHHH X" ?8_C9<G.!?:>.,]2 O\
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M>A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
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MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 !>?\ )0]&_P"P5?\
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ML%R!DA23C)'/N*COO%GAO3+R2SO_ !!I5I=1XWPSWL<;KD C*DY&00?QK/\
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M?F_V3JMC?^3CS/LEPDNS.<9VDXS@]?0UC^(_AWX5\7:C'?ZYI?VNZCB$*O\
M:)8\("2!A& ZL?SJQX9\$^'?!WVK^P-/^Q_:MGG?OI)-VW.W[['&-QZ>M %B
MQ\6>&]3O([.P\0:5=W4F=D,%['([8!)PH.3@ G\*V*X_1/A;X-\.:Q!JVDZ-
M]GOH-WER_:IGV[E*GAG(/!(Y%=A0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5S_ (>_Y#GBS_L*I_Z16M=!7/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?\ I%:UT%<_X>_Y#GBS_L*I_P"D5K0!T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '/V?\ R4/6?^P58?\ HV[KH*Y^S_Y*'K/_ &"K#_T;=UT% !1110 4444
M%%%% !116+XLU]?#'AJ\U8P^>\("Q0[L>9(S!57/;)(H8+4VJ*X#3_$OC+2]
M?TNR\7:=HZ6FJN88)M.E?,$NTL$D#]2<$97C-=_3L%SS_P""7_)(="_[>/\
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MQ)IER&*F!X9)<CU#(I&/K@^U/^SL7:_LI?<S24>6*DVM?-?BKZ?,]+HKA?\
MA<?@'_H/?^2<_P#\11_PN/P#_P!![_R3G_\ B*7U#%_\^I?^ O\ R,^:/<[J
MBN G^-'@2&!I(]7DG8=(X[24,WTW*!^9KMM/O[75=/@O[&=9[6= \<B]&!_S
MT[5G5PU:DKU(-7[JPTT]BS1116 PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_#W_(<\6?]
MA5/_ $BM:Z"N?\/?\ASQ9_V%4_\ 2*UH Z"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP]<:M_PGWV#R;MK;RO['MY<X1&W9^7^_C&.U>WT4 >(:=>_$._\ BAJW@O\
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MS6K5PJPTDM.OY?\ #DJFE*YY_P#\(E\0_P#HI_\ Y0+?_&C_ (1+XA_]%/\
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M5X7N)=-T>^COM(U..:""\B$1N3"X),>2<JP)P>]/HN;O^&G_  1==.WXZ_\
M ,D^%M*^'7C+PS+X?%Q:VNIW#V5Y;FY=TF)C+*Y#$_,"O;UIFOQ>(/\ A9OA
M*XU:\@%I)J$Z6MC; [458VP[L?O.0?3 [=35N#4=3\=^+-!F_P"$:U?2-/TB
M5[JXEU.'R2\FPJJ(,Y8?,3GVK5\7V-W<^-?!4\%K/+#;WDS3R1QEEB!B(!8C
M@ GCFFKWC?O^']7$]G;M^.O_  #M****0PHHHH **** "BBB@ HHHH ****
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MD G=G)^M5?WT^SN2OA:\K'B/AZVNI?BO!X*DB_T#2-7N]14$G[I4%./8X/\
MP*NO_9X79X4UE,$;=3<8/;Y%KT>W\)Z':^)[GQ)#8A=7N8_+EN/,<[EP!C:3
MM'W1R!VI^@>&-'\+V]Q!HUG]FBN)C/*OFN^YR "?F)QT' H@^6-O*WSNOT0Y
M:MOS_P _U9KT444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Y_P]_P ASQ9_V%4_](K6N@KG_#W_ "'/%G_853_TBM: .@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y^S_Y*'K/_8*L/_1MW705S]G_ ,E#UG_L%6'_ *-N
MZZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\ #W_(<\6?]A5/
M_2*UKH*Y_P /?\ASQ9_V%4_](K6@#H**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M?O=&UC_A(;C5M)U2QMOM%I#;217=@\_^K>5@P*S)C/FD8(/04?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
M\$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8
M?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\
ME5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R57044 <_]C\8?
M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R57044 <_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5=!10!
MS_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E5T%% '/_8_&'_0=T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gjyjiv3jrhol000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\!*L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /%4;;C_ )ZQ?]^S_P#%5+10!%MN/^>L7_?L_P#Q5*HFW#=)&1W 0C^M244
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17)>*/B3X:\(:A'8:G=2FZ=/,,4$)D,:?WFQT'7WXJ;6/'_AW1/#UEK=Q>
MF2SO]OV3R(R[SY&0%7K]<XQTZT =/17+V?Q"\-7OA&X\3QW^W3+8E9V="'C<
M8&TKUW<C [Y%+X3\?:#XS:YCTJ:83VX#203Q&-PIZ-@]0?\ /6@#IZ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XGQIXKU#0-1M
M[>S$)22'>=ZY.<D>OM0!VU%<IX)\17OB"&\:\$0,+(%\M<=<_P"%=70 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ_>B_(_XT8N/[T7Y'_&I:* (L7']Z+\C_C1BX_O1?D?\:EHH BQ<?WHOR/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!F>(=3&D:#=WF<.B8C_P!\
M\#]35'P7IATWPU;[Q^^N/W\F>N6Z?IBLWQ:3K'B'2?#R',9?[1<X_NC/] WY
MBNR  & , =!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\BI:* (O+E_Y[G_ +Y%'ER_\]S_ -\BI:* (O+E_P">Y_[Y%'ER_P#/<_\
M?(J6B@"+RY?^>Y_[Y%'ER_\ /<_]\BI:* (O+E_Y[G_OD4>7+_SW/_?(J6B@
M"+RY?^>Y_P"^11Y<O_/<_P#?(J6B@"+RY?\ GN?^^11Y<O\ SW/_ 'R*EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSC\CR,U['X*T&7PQX-TO1IYA--:P[9'7."Q)) SV!.!["MZB@ HHHH ****
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M %ZEHH BVS_\]4_[X_\ KT;9_P#GJG_?'_UZEHH BVS_ //5/^^/_KT;9_\
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M>?\ AOXAZC=^+D\+^)_#S:+JD\!N+4+<"9)5&21D=#A6_P"^3T[T?@1/-<>
M;AYY7E;^TIAN=BQQA?6@#TZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;>R $MB6*@;L =-PSUZ,/0ULR^+O'WC+Q/XAM/!LVGV5CH<AA/VA SW+@L,
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M5<XRK @C\C5FB@#QA?AU\1M/T"7PCIGB/3/^$?=F5+B176YCB8Y*\#'<]_Q
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MM.TO3]'M!::98V]G;@Y$5O$$7/K@=_>@#RSPU\./&%MJ6D+K%[H,.FZ9A?\
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M;!Z@_P">M '3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPM.CSU9>\MTFNY/;:9J'B.:._P!5Q%:J<PVN#@CU(S_^OZ5TZQS(BHC0JJC
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MC[=*IZ;IWCJ)?%/]H:U8RFY#_P!A;$ ^R_ZS;YG[L9QF/KO^Z?Q[&B@#Q_\
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M2Q7%C<MI6C,=S1ZBI:.0?[,7!Y]05SZU]&RPQ3*%EC210P8!U! (.0?J#3Z
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M[]O3J\[^,"JOA?3-J@9UJT)P.IW&@#?\9ZUK6D:=:IX?THW^I7ERMO&71C#
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MIZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M='17F<D>QK'!8:.T%]QEQ>&M#A&(])LA[F%2?S(K+_X5]X;_ .?)_P#O\_\
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M/3?Z_CSU^]7HUAJ%GJEG'>6%S'<6\@RLD;9!_P#K^U<>)P$J"4FDXO:2V?\
MP?)ZA'#X6>GLU?T1YA_PJK5,_P#']9X_X%_A7<V_@KPY;8V:5"V/^>A9_P#T
M(FM^BN-4XH*.78:BVXQOZZE6WTRPM,?9K&VAQT\N)5_D*M4459V**2L@HHHH
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'QYT
MC3X/!DNIQ6<*W]S?6ZRW&WYV ! &>N.!Q4_Q-GBTKXE^ =8OY%BTV*>:.29S
MA(V8+@L>WU_V3Z5Z=J&F6&K6WV;4K&VO( P?RKF)9%W#H<,",T:AIEAJUHUI
MJ5E;WELQR8KB,.I(Z'![T ?,FMQ2:GX4\=Z[9!IM+D\31RK(@^5T!DRP]CYD
M?YBO1] U&S\2?M WFJ:-<I=6$&BK'+/$<H69E(7/KS_XZ?2O4H-*TZUTW^S;
M>PM8K':4^S)"HCVGJ-N,8-,TO1-*T2%XM*TVTL8Y&W.MM"L88^IP.: +]-8,
M5PK;3ZXS3J* (MDW_/8?]\4;)O\ GL/^^*EHH BV3?\ /8?]\4;)O^>P_P"^
M*EHH BV3?\]A_P!\4;)O^>P_[XJ6B@"+9-_SV'_?%&R;_GL/^^*EI"0 23@#
MJ30!'LF_Y[#_ +XJ*XE%I;O<7-Y%##&,O)( JJ/4DGBN)\2_%;2=*D:RTA#J
MVH$[0L)_=*?=AU^BY^HK M_!?BSQW<)>^+KY[.R!W)9(,$?1.B]QELGZUZ$,
M#R153$RY(_\ DS]%^KLCGEB%?EIKF9<USXJR377]F>$K=]2NV.T3&([ ?]E>
MK?H/K5?3OACK'B&[75/&>IRR2GE;=6!('IQ\JCIP/TKT70O#6D^'+40:99I#
MQAI,9=_JW7\.E:U$L<J:Y,+'D7?[3^?3T5OF2J$IN]9W\NG_  3.TW1K;1[1
M;73HXK>$?PI'U^IZD_6KFR;_ )[#_OBI:*\\Z4DE9$6R;_GL/^^*-DW_ #V'
M_?%2T4#(MDW_ #V'_?%&R;_GL/\ OBI:* (MDW_/8?\ ?%&R;_GL/^^*EHH
MBV3?\]A_WQ1LF_Y[#_OBI:* (MDW_/8?]\4;)O\ GL/^^*EHH BV3?\ /8?]
M\4;)O^>P_P"^*EHH JW%I]KMY+>X,<T,@VO')$&5AZ$&O.M1\#ZOX2FGUGP7
M?&- "\^FR\QN!UVY/Z'GT/:O3Z9-$L\$D3YVNI4XZX(Q75A<74P[M'6+W3U3
M]49U*:GON?/8^,?BO=C?9]?^>'_UZ^@MDW_/8?\ ?%><GX(>&CG%[JN?7S8_
M_B*;]B\>^".;&8>)-)3_ )82Y\]%]NI_+=]!7LXY8#&<JP;4)*^C5K[==OO[
MG-2]K2O[35?>>D;)O^>P_P"^*-DW_/8?]\5ROA[XCZ#KT@MGE:PO\[6M;OY#
MN] >A^G7VKKZ\*MAZM"7)5BTSKC.,U>+(MDW_/8?]\4;)O\ GL/^^*EHK$HB
MV3?\]A_WQ1LF_P">P_[XJ6B@"+9-_P ]A_WQ1LF_Y[#_ +XJ6B@"+9-_SV'_
M 'Q1LF_Y[#_OBI:* (MDW_/8?]\4;)O^>P_[XJ6B@"+9-_SV'_?%&R;_ )[#
M_OBI:* (MDW_ #V'_?%*J2A@6E!'IMJ2B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M='D]]\;H;3RXQX?N!<C(N(9YO+,3#L/E.?QQ]*Z?P'X['C9;\_V=]C^R&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\D_\]I?S'^%2T4 1>2?^>TOYC_"CR3_SVE_,?X5+10!%Y)_Y[2_F/\*/)/\
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M^Z&SG*CUKN?)/_/:7\Q_A4M%8XG$SQ-5UJF[*A!0CRHB\D_\]I?S'^%*L1#
M^;(<=B1_A4E%8%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"-2"<^@W;3GT5JX^>V\3_#OQ[X<\2^((=)M["14TB8Z:7V"(+A2^[N  >/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !2!55=H4 >@%+10 @ 4    < "EHHH *0@'J <'/-+10 4444 %(%"C"@
M=>!2T4 %%%% !2%0PPP!'H12T4 %(JJ@PJA1Z 4M% " !>@ YSQ2T44 ( %
M"@ #H!0%5<X &3DX'6EHH 0J&&& (]"*6BB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gjyjiv3jrhol000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000009.jpg
M_]C_X  02D9)1@ ! 0$ JP"K  #_[@ .061O8F4 9      "_^$/BD5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )X!.P "
M$@   +*':0 $     0   ,0   #P *OR;P !    J_)O  $  $%D;V)E(%!H
M;W1O<VAO<" R,BXQ("A7:6YD;W=S*0  ,C R,CHP-3HQ,R R,3HQ.3HT. !4
M:7)T:&%D978@06-H87)Y80   Z !  ,    !__\  * "  0    !   $0: #
M  0    !   ".P         & 0,  P    $ !@   1H !0    $   $^ 1L
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M^56&E];Z_<YS;9&Q\;@8WS_T?>JM^14US15>YY!:70]I!:9W,^E[7;?TC?\
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M@Z-TA&6%=H97=X=(B#F LN*SPW6EQ6=8:'C8<)#RXZ2UIK;'J,@I_\0 <Q(
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M 5"F*:A2C$P@A[2BB""-<E54?S:7_P J[P      0)    $"0    0$4 )
M              $"0         F")   ! D                   $"0
M  0 D         !)FD
M
M
M
M
M                       7*S<2IK45VP       /2I!""!(@ !ZN5%!,R@
M(UVR9(@  2( $)N"$G @
M                         =%=#Z/099M>BE6NYC1A3,2")*B,0A$D@1$(
M@D4X_FY6LR&*\_I)_.VN\VK@  VAL%JZ9WF!JBSY5B[4<VK7#,OD"443!,(1
M",RA!&1$$6XW&B9U]U&QK>(>?RMK6NQ0
M                                  "9$NC.C] L^-ZVBLTGK^!K
M     #<.[[J1L'-Z&FYBY3RRX$/55+867;M756=CZ]X,T]_:X!4Y=U%*EQ+(
M$B"-1 5&80B$C"D%VR9?0OI^>Y[^;_(=!T)"
M                                      "IHJ=>==[+8N.N4\8OH
M      %3;J=8^G^XV[E'R[QJX@N4.Z.BTNI>"^?S]M!E5-V3V?9V6ML#OVKC
MNADS=+6L:79IMV_K3:Y^N](<IB9O':56BEB<AVM<IH,1BWB>+4W,@XAOZS=<
MRY+.LS&M.^,W&Q7DO2[+8'FB
M                         !-KJ=,]S[=;N8>#\/N(1K/ICE;GGB^\Y5-S
M_34:5SG<9NP^0MKS^XND_/MWC.G_ %W6T?4OCF3KSF[OLC<&-86'9,/R,G,.
M ]AH]CA,7'1O8^IVG3O)<!=L5HUSW32[)Z;4Z>XNYK8[A#(=A+KF_O<&V;RF
M-BVKZ[N9X%N<*LQ2QKY/2EK9XI<,CHJ7 ,?491=-5S*CVF^HM>86/,O48-!R
M9LZ]G '9_6Z[37&');'<H
M                      $^JIU)V7M=LY4XOQ*YA[O&WK]_ ?.'7=,7Q[-S
MN>5D5TJYARO&)D^9;'\Y_C5XYBV1E7R-K#M]'<R9^MKV)D03%QU3W?L%JY8X
M7Q^ZR8MO=VIVQNM;J;B30;#;(5^PO/JWB;C7%#J,VCZ5VN)I[G+6W=D6S51K
M:=D:3-N@]OLYLGB^JSG2GJNIP';WF6OU_I[J(V3S?K;V5<5;_F=F0MRB.V.M
MUVIN)N2V.V0
M            )U5UVAVOK^-<C\5Y+DM!9MJ"Y9       'J";3=72U#K[T3W
MBT<3<'X'=PC7+IC=:[ K5AY-RY]PK^5^;8       !&LC<.Z>CUFI^.N4V^S
M,9FW6
M       >Z2X7\QV!W7MN.X5K^:N'/_)^>7*EII>8QP)(Q""010))A""MS:F]
M]UZ-:]A;/HJ#DS@O&\CQJO# $:CL7<X>N,BVFLL?+O(])M;$IHK?-%0@ )$
M !+VAMS?X&+="9UC!]$Z?.S/GO5W<N
M                                  "_Q<AO'K?4[3.NU0G1+W5,(57?
M<J*4BNW$A>]KL_?:'I_T39N%?&OF2[IA/U./1Z/T_!W[%<?5>@   *A+HCJ=
M5K6]U6['[R+<-K[B<8ZZ[OB-)_.[RON.E/./91BJ/FJ[";72FT5Q02MQDPUU
MQU_-M*:[(S
M                 )M-:LHI>X/4%'52E5U(55H)73%A]&?H[ZSL_P Z_GKY
M,O%I0A%3Q-IYD    !(DFS=?9/W+S[AWX[>(=UW%27:WC%"$ DF36J9O/6)9
M0JJ4-VT
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M@ C&$ A*,!$A&(C749<=9[GK9O+G>];/
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M7E_.MK;YK786)6Z]V\W;F*[KK\ !66KCM?S;R*@X<].]9KP
M                       #Z!^<X.*\"^CYV54]<(420!M*C)ILGBY3T5-C
MQL&BO#<:N7<F]3%GMZ*W0MS#RL B(#O?@+&-<.=XR78^IK\?6GYET=A^./U9
MTEUPK)M5D[96WG'J3L+8HTXJ34!.M9(DJA)O:]U-Z?[=([$PO1<*Z/\ *;6@
M]KX_48YN;KO09=AYOSN?N?:\-I7G_!Z#<F!:W-K^ ;'E&\>O?L'XTY&_/_\
M,GL/T7D6Z 5-&4]55I5-H2]1;2[T(10C,KEB77TK\:^?[9A%.TK.!O:O:9_<
MOG/FMJY([;O;EA&\R_<BS"" ;LMY=@@FON-BC&==W:,EV>NX9IBY8SWH2C)U
M+K^JUE^FZ\?,@]52A2=_^2^16_C+TOUBX89GW
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M "OHM.\O*?.[7J3J-_5<U]AU]5;9M
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MT2^BZ/H.9HNGP*5;%E[BJ:0A,O40E6<:/'GJ'H%3C&3D>@
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M7:B\)4=>.E@ JEQOBQZFYZN^4HCU5 DF$8/$UO--+S(
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MN.KT1?)VK(<7IGK)L,=BPMUS1,?IYMJRGCP
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M%1,(Q A":DU>5<R"AIH04$TID770.)Z2Y[R_-D5+RMH*Q"*D$%2(*7B9
M                                            5EG.2JK:1<Q0
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M $R<>5;KDU.'[-<*:YKF!N56VY;>(H
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M("))"F$"*))/>:\DM6=;QE)^=G] OA&9P9[9XC<-5V^24ES%
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M;\\4]TO>N.XX"?B?3ZNQ_:G\Z?L?+/-1P%[;X/3?F+_4#\YJG5-CC
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M5?,VW\PF6ZW0D39
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M3C*.UJ(W.K.A=+.='463Q[PM@
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MIUF34FON \7,=3U60   $^C*3:*U-=Q'B:0
M                                'J*U5:RWBYCJ:JR    K+.<B/U3?
MF[Z_B5)TEZP=5>Y?0'+'U;_'GF^E^ ?IS14'8/A.UG_&C]TOQAR;._H;\^,G
M_+;XS^Y]5];<;L?E]\$,GGOJ<0#ZL8NZX<LEK%O/V2Q<CX#]R=%/.'.'[:_A
M=^SW>G;^0>\*TO;>-?\ XS?T"<E?)?A^\V9VE^KGXL;E_.1^7WZ:W36O*=#,
M"7<QU/59   $156<Y$4=[!
M                     $V+B?:RDBNPE5V  "2,'<?F'0ROJ9\R]IB/QN^O
M.1N6BNIYV[=.9W?:[_6)\G?5W*GWA_ #F^Q?SG_M#\CV+Z8_NC_'=LW7NJ]#
ME:,\J^BK)Q?H_=;G9>IZ&G^=_GGWUJSZW><?7'Y*MQVLO$M:3'3/VUQ+GY7[
MOH>$J_SN?:5O]NO2GZP_A=]WN>?RD_<WGCB_XG^NZ'\ZWI?S!U;DU=+O7Z%\
M:M$RQJ;A\^/!?H.?;\,IJK(   F16J+66EU4*>YB
M                                       #TE56,Q*KMI%S&  >KQUG
MRO3:[[ \-VF1?)SZLXG(J744O-RAXHJ==97H.M_TK^2_5?)5S^H/YHNM/L#]
M'_A?LGY7>/\ ZC6.5A:UQ1XE]D47Z,?O_P# 3)_C?\,?O9RG]W/.?UZ_F;\%
M7Z/JS^>W.P?T_P#Z L'._,K]%+6L^46J^!J^@'PD[+Z$_<MPK1?SWX*=U\R=
M)>:*$:X1MWFZ>PY&'4?K/GE-\]_G7V^JD30   *FF\]V[ZFN8KQ50
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M8R@0@E& DFE!*=5?C:]+MO?-_&=//\6)00
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MYB3R3R7<U-/KK3Q;H) 0)("( (","2IR;S/-OJ/.].DT,CD+SCK*F%$@
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MWNASG=O)Y]##=W\IY1O:VX:WJLY. ;^]*YN3B?!["9JW!VGH
M                         ^@GD/3XSP%[+R^32+$@^E&RVG.?2?F]ZJUS
MU=6MJA7D/#V)RV\NTZ,S0.I-KW>W-A7=%:X\=F46H>PM7;&;&LO/%E_5[, +
M\RGZF_SI]-TY^<[[\X;-M![C69;*JQDJJDBI"*5YMY:-G"2\_-4V3:4.#9
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M9>^=7O\ 6?"%O6[=YJV&LR7)NKAO_.Y&GY:X;KZ@
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M>NPUVY3^F]3N=/<87-5NO";^->>V?0/+Z;D+C/3:FQX58
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M% F!( 1,$@C@G/=9[T_RW43J3%L%R$+8
M                         3(J38N)EJ^DUVTFYCH(='WN<D]$XWAL-&3[
M!(Y?K[BNE10        ^J>-MOG]\K,G4_0$ #W%Q,HO)M-PB%/>Q4N:
M
M    !Z2J;.:B/%S'2IMKG54^SN5\#T_Q4Q/O2HIYE"(        ?0;'V7&NM
MZK6:\@WL+I4)D5)]K+1B7FJ$BYC/$VP
M                                   !Z$*SI+5<-XVIB<3)M6]TU3XH
MH)N$D:JWN9+4@RFK3^<HG'H]54[RNBA[U]]=<G-H->4]UZYGR>\K:*J@ !FU
M-VQ=K6=AH'&YIR:F3L<!#H:WD<Z<]W,?HGU%7GT>HD!&3,>H(B%R1J:K,;X%
MOZWJOR@
M         $U6ZCL><6_Q@Q5<W[/TZ=0[&PBD2 I!"N"2?9H0$JJ\"HUY"DZ2
MQ/-9&68N))XRW'J-: 9K3=L?>-G9<Z_-G(U'4P        !D5-RA^C-C:<J_
M,3)T_7
M         5S(=R8'AMKX-S_:KH !UAI[6ILY[/>WS:?+[NR8QC8MTE[;64-L
MY>*W!.NLRL%LV;UT-SE_ OGYOL+=M'=H!4TR^@.@\ I_G_T/T-4>4O=FP^@>
M'LN9_GCLM7TP !N/>6+5U5INNPVOTE^95YVNH_>%CR=2Y5^JJK^//TA7BY/W
M!I]OJ'YB=9I-]V_760!M6C(Q?<M%[6'(M[!WN
M                                      !7Y=YVGS_SKYX=VOT)Z  Z
M'UEO ,DZO<9-DFFSJ/U@XEENFPHJKGRUR1J_J<3U=;4S\/TUJY<^[FSD-)<H
M!66JW7%OR*AYVQ_3:[$]CMDNS;=P8V9RCPIGZ[JX #:&]QK5O74]132]-=]S
MLO7V#+<.J?CEZ_9\&R<++:91:<THR7(.TU6:2L*  '<]C8\K<,7]=U2
M                                                        !<J[
MSN+4^!^>"]G[MZ .RK&SU]],>ARN>=0:*N[[PXRJT_-/UO5] ]E<?TF-S-M8
MT_F&AP?6F,K8;[GM/:<%M[+7WR[S>8ZC"XKCM:KPRCXCH]QK*:8(EWC9V',/
M!E_6]/  3+U3[ -?RUG>O[S(KKSU6HN;^IU_2^C,; Q7N_K.EOVY?&M)SU\W
M^\HZ1^?61I]D@ !W?8V?.7"%_6=&@
M                              76U2^@^N^>9'SHVWT5/E*0!74W4$*2
M[:+QL77W;+>)SJ;4%[6Y'ZBXR>J*39.-=P[1N1CYX%=;A]$\'YYI_F]LOH>H
M .M;6=IC"IHR3G^YB;# /5Z"85&40LRR>QD4^'V[%16YN4A<QE'KH  !W;8V
M7-'(UW#WUA=5F^@
M                !<8K?1'1_.]!I7/[Z=S1L.[J83*(   "")) ]Y=+H3F_
M-I&_==S-!P/U'N5SQ*,KV !VY9V/,]YB;?QW=P^IK1-'I("!(@    SVF[B7
M8%K.T-H.O%V/S)=P]O@
M                      76Q=; KT'G==7GM$$9@2)%(E  B$9D2D:JY#1_
M2^DS\%UVXJ9<XJCD  "X16Z>MY',=5,6LD$8@3" 2C&"$B (S#%#/N<;F+O(
M
M
M
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M !YC?J$;"%["(V 1\+T-K@;R U?Y X6$1N(@->=6"@&]>^KA5ZM7^ K_ !Y
M-K"(>=[ -JL4:^$:"U7"K!0VH!+0=-"):N6O@KX:N6AZ0H.D0'I"A$M?\84
ME&@Z*N6O@$.H@C<M"(4 D !,4* 2B "6]RC0"%[ (#TW"P"'35RW#IM<M@Z:
MN%[E&KEMU%KX+"(!0VJY0JQ;?!?X:N4!^$1^&OA"OA&CVH5!N(F&@O0#73:@
M$:$1Z1$0  &O,0]]7&KB(&$PCYW$!$/,U>?4/ON-6 *$PC1DBH4I/R:%133T
M]2I05*+ER7(@<+*9$A%-#T]EG4,+>6<2)G,NO&TR1"&!V!94#,0BS*%)D1%
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M&H0-:WD "%%((4!AH#&MUC0'\@,-A.(T)JZS6ZS" F-;J$*,8:ZC!76:A,-
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MM>PB( -_(!$*Z@H!L-P !$1"]J ;4 T(A0B T:U7#P4, EZPH.FO(:^$0^
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M7* C:KDKRJY:\A#X:N4* 2W 0L%JN4:#I + %#8! HUTF"ND: IK@ V !
M0$2F 1 :Z3"%A"OB&@*-6&@ P5TB 6,:AN-!<!ZC5:X>85TC5S6^(*\Z$:O0
MF\J\P#SO<: :OY7"@M7F%=0U?X@,(!>KWJ]?X#RJ] (T![5Y5Y@ C0#<"C7O
MH1 * 1O< #JO0#Y#Y  ^?2%!YB(!5J#S&P4(A0 -6 1\JL #Y!04(!0AYB 4
M V#JL "(T-7&_N"_E[P$: P7ZJO0C7G5S4 U\0UU7$1-0 /J[A7RQM8(EM7R
MIM0Q;0 ^5-;C$MK?*6P5\J; /RIKU?*VH@,4V$/E3:WRYK;Y:V"OEK2_RUF-
M!%-!KY4TO\L9U\N9W^7-0KY>T ?EK,*^7,@KY0U$?E+6_P I:V"*:#7RQK8(
MYK88QM7RQM0Q300^4- $(MJ%!%M:^6MJ&,:](Q38:^4M@'Y8WKY6V$/E32WR
MMJ!0B6EQBVI:&-;6^6-A'Y:VKY<VL$8W,'RUK?Y:V&OEC6OEC>OEC>AC&H#\
MN:T,<T ?EK:@CFM?+6H5\K;!7RQL %C6G4,:V"AC&E?*VO4,6UZOE;6OE38P
M_*VU!&MAKY8V&OEK>ACFPC\L:C7RQL _*FUQBVE?*FHU\J;4,6UM\L:@(QK:
MBQC:WREK8(MI7RIK0Q+2XQC6WRQH%!&-1H(UJ-!%-*^6-;?*FM%BFHU\K:V^
M5-.D8IK;Y8U$?E;2ABFEOE;7I^5-@KY4VKY4UH8EJ(_*FM?*VEOE36OE32OE
M34*"*:V-&M[=LB-$.0:ZB6N2UTQKR ;DH.B]RUU$JY:ZB7 Q;=1:$2T!R#0B
M01ZBT-AI-JFY/\I:5]-XD-!C>(V^FL3H,;Q*WTUB-?3F(7^F\2KZ;Q&WTQB0
M"&,XB%?3V)U],XC<<?Q"OI_$+_3>)T.-8G<<;Q.OIC$;_3.)7^FL3&@Q[$+?
M3^(#0XWB?5]-8E7TSB-!C.(U],X@-?36(C7T_AU?3N'6^G</M].X<%!C6)
M8SB-?3&(5],XC?Z=P\ #',/KZ9Q&OIC$0H<9Q(0^F<2"OIG$:'&<0&AQK$!$
M,:Q$!'',0M]-8;?Z>Q&_TYAU!CF'=7T]B(&^GL1O]/8C7TWA]?3N'U]-X;8<
M<P\0'&\.N&.8?08_B%?3V'W^08@-# 8A8<;PX0'&L1$?IK$J^F<2KZ>P\!''
M\0L&/X?0X_B%@QO$Z^FL2L&-8A?Z9Q *^F<0O],XA7T]A]PQW$*''<."@QS#
MQ#Z9Q&@QC$  <9Q"AQO$QH<;Q !^F\0KZ;P\"_3N(#7TOB5?2^)T&+XE;Z7Q
M.WTYB%#C>'5].8<%?3>'!7TYAPT&-X>%!CF'4&-X?7TWA]!C>'U]-X=08YA]
M!C>'6^F\.H<;PVWTQAM@QG#J^F<-N.-8<(?36&T.-8=7TUAYJ4B8Y)0&"!:!
MBC0L4:%DC7H4J%DC7H4:!BE7H$:]"C;Y>E;T*->@1KT"-"P1L+!$:] C<6"-
M$B(AV/TQA]6"K!5@JP58*L%6"K!5@JU6JP58*L%6"K!5@JP5:K!5@JP58*L%
M6"K!5@JP5:K58*L%6"K!5@JP5:K58*L%6"K!5JM5@JP58*L%6"K!5JL%6"K!
M5@JU6"K!5@JP5:K!5@JP58*L%6"K!5@JU6"K58*M5JL%6"K!5JL%6JP5:K!5
M@JP58*L%6"K!5@JP58*L%6"K!5JL%6"K!5@JP58*L%6"K!5@JP58*M5@JP58
M*L%6"K!5@JU6"K5:K!5@JP58*L%6JP58*L%6"K!5JL%6"K!5@_\ F8!5B%$Q
M@)XVJWZ  /Z"J@JB01*(F+76%=85W KK"NH*$X5UA766NL*%3RZPKN%KK+_)
M(: D))(KC$HE0\]C%OGF,C03>-!7SO&J^=XU03>,V&<QFOG>,W";QJOGF-4,
M[C-?.\9L:6QL1?JX@_1>1IFI?98,C.E%HA%L7YYC10"=QVAR+&AKZAQJOJ+&
MJ^HL;&@R'&J^H<;H,AQH*'(<;N&0XW7U%C5?4.-A1L@QH]*PJ0@JW$AOX^ @
M%1#%-<K^15>G_7QG(WN-.LCB&J8=5 :CJF4%I'K/#K.""7Q%?J2[_2CX"%O
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M6<W?ZUG:^N)V@S:;KZVG IYM#)W97DW(/A_DHC:C 0P]M.NT0:*02U\5>=A
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M5]:;AKZUW!7UKN&WUKN*OK3<%?6FX+?6NX;*Y9-1XP4_'3;?Q]_@ 7'V%?\
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MC;V55>@Y)UJ=6.,52.:+$736613-+%;';I&(<DQD4/C^/R*A(V2ZR>R[)W%
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MT]L]VX!5]X%3,<#=0AX6"AM9$W21(O6H(W]K;T6_R3&VZL:FZ(L8M*&ZQ;'
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MQL;H6Z%'SL$VJQUBU!G-+9)L5T9U/_O.>D'#I5HH#B-\"AU&,'2/M+$[8HD
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MWD%#0  U8!H H;@ V&K4-[^=7O5QZA ;A<:'W6->UZM\0@(58>D M72(5<;
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M0!TT-[#8# (C7E>XA0^=!Y#U>8&M0B%[A5[T @%!:_F:KA75Y7$ N%@'PZ@
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MT-8>0NA1K[AM##7W":', <A-#@'W"Z("ON#T/7W#Z%K[A]#B'W$:&K[A="@
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M5P*K[.4^SFN3)Y;,?PL0\S  _HV :N-1L&YS')-[95'X9@4&;TM2L2I(MSN
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MS#'L:BL?5;X=J%O,I&%FWR?%_I@W'[8.%:Q=PV80>1) 8IPV_)?+,=W6)87
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MCV\/@,@S!/67&S'<5>;3W(?)*4,)C!Y4 "%)J&*;/\&P[:$9B&O,NUN/4'Z
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M[;"4X><&]J\?()IH4Y5F.A5Q,EIN+Q(JVT\!Q0V8;4R.5-WG2JB:)AI0 (8
M\BW6,Z<O71ELIQ6*/!; Q*;@5WS \(GD3!05\BCBU(YG%>I-(,W"23UDYE5(
MF.-,Y$_)$-F$:::$ZL@(%52"KDJZ=73O=.KDJY*NG5R7N2KDKJ)5R4H5?J?0
M^/R"4:NLBN W_>I @,(\?/Q.(&HHA?P 1* &Z!$*'R#VH-<BSEXP5*J):M2
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M'6/_ !\IS%,PQ+9.JT\)W1@&=O/6,*]:PKUD?7K6%>L85ZQA7K&->L8#7K6
MUZQA7K8^O61].Y5DRJ;WIJW'E':&4;75BXIOCS+V$'"0D/'J"!VZZ9NTI7;4
MKMJ5VE*[2E=M2NVI7;4KM*5VU*[:E=M2BMG*E%9)MZ<.17'^0JF</5<@Q+%L
ML;?;]J2WV_:DK[?=1U]ONI!H>/VH[_;]J2AX_:CK[?M1C7V_:D$?M]U'0\?M
M1U]ONHQIGHK4T>9A#,(U%(S1ZBU5%-7V2',F;USRO7.Z]<\KUSRO7.Z]<\KU
MSRO7/*]<\KUSRO7/*]<\KUSNC/'0_P#Q&__:  @! 0 !!0 4?/L^8(")?3T#
M<1KLA78KL -=@*%N% V&O3UZ?X@;W'TU"W"WIRT*!>D6X4#8*!O0-RUV*[-J
M!(**D%"@4!%  $4!$10Z:[(UV N#?R[-Q%O7I_+L (F0 *! ! $"]0(UV!$>
MS>NP-^P80].80[5"@(CV/+TXC0H":@1$!].- @-^SY]@:!   $!ZO3WHJ A0
MH&N* T"!J[ UV##79$*[)A 41MVC5VAN"(B (FOV36[-"@:NR:@1$:[1@ 4#
M5V!OV!KL#78&@1$1!$XT#<_2"!J%$U^P:NP:PHFOZ<0'TYJ%$X *)Z! :[)A
MKTYA#L'$H(&HK<0H&YJ!N<:].<U=@P5Z<X4"!@KL&$3(#0-U*! ;"@>XH'&@
M0.!!;&Z01N4C<3&!$0+V_,42T#<U_3GKM5V@H$@"NR4*%(!H4@&A2 :%$M"F
M AT!7;"NW7;+7;"NR6O3>7IP"O3W 40"O3E !;EH&X6]. 5V KM!79"_9 3=
M@1HR%Z%$.GLV$&XC79*%=D0KL5V H6]P[ !78 *[ !0-RC0M@"O3B-=@*[ !
M0-Z% +]@*!$*%$:[(6%N%"WM7I_+L"6@;C0(=0]D>GL7'L6H$!"NR-=BP"A7
M8&W8$!%N-NQY=@**C:NSY=FU=H; B-"A79-0HB(]@UQ1-78&W8-7:,%=H:[
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MC0H -/@+&Q7-IVJ[V/FA1/I_C9M78.(ZZY$R\OF''CCZH\;:IV<D3,>7_,Z
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M%=@U=@1#TYA 6Y[^G/843 (H"(BW, ^G,-"@:_8\Q;^8H&L#<U>G.-=DXB"
MUZ8UP0&XMS]((G"NP8*[)QH$!"@;GH$#6[!K @(#V#7%N-"B-=@;@B(#V1MV
MC"(I"-=JNV%=L KM^?:KM %=FNT CVJ[05V2W!$H@*):[):%$ KLA?LA79"_
M9 *%$*[(5V@KM%H4BT*(5V@N*05V:[%>GKL7 4*%"U C<.Q7IZ].-NQ7I[UZ
M>NP-O3C0H 6A;A78"NQY]CR['F"%Z].-=BNP T#>@0 !,@-"C8.P%A;^8H!8
M&X5Z<*!$ KLB ]L;=KS[5J[8T*5"E>A2&_:H4J!(1#LB% C>NT-^R-"@-^P-
M*)EH2%KI"NDM 0!$"A5@H +0@%$)Y=  ( %=(4)0KI+8"EN !0% 1[0#31,!
M'LFKN%KN)A0*%"A4)7=+7=*(BJ6NZ2P*D$!4( ]U.NZ7J'MW_P"._4 UUA1E
M2V%4MA/5PH.BKE"@-13>?=+7>(-=TH4"A1#J)0F(%=1*ZB6*LF(]TMNLM^X3
MJZDZ Q*[A;]P@ *A:[A;]P@!W2#7=+766NHE@Z0#J3"A$@4)R"/42KEKJ(-=
M:8AUDOU$MU$H#$N)B!0"00ZBUUDH5"B/42@.G766_66NX%@5*%=P!$5 "A.2
MP'+;J)?K)?J( =9;]T $% KK  [H4!RUU%&@.0*$X4*H7ZP$>X%@4+746W44
M:$Q*ZBA0G"NH+@?SZBUU%KJ+U 8M7( =91KK3&A.0# 8E 8E=:8B!BUW &NL
MMNX6W62NX2XG(%=Q.CEZA,D(4*= D%Q3KM^7;N';O0$\DTK5VO/M>7;KM6'L
MC<4AH4J!&P]JU(&*BKWR4/,S0%?>9H"OO-T"-?>7H *^\S0%QYDZ O\ >;H
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M (&X*;\P35:,=RZU/'Z'G.6&&K.YW>>)[53Y1<G\'S,N9\OM1S^[4.:^*8Q
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MSNY$<-/P087A*O/;@,CMC4W&;?,-R)UA*PL+F,'E.'ZT>:YXXX6SW!F7._\
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M'(+*6' /:CB3P_B@V<0<UJ?9V-8;XZ%V0CK?9>W<+<ZVV-^\_DHCPB.21DP
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M!U#7Q4/57Q5\56-7Q!7Q5<]Q$;W-7Q5<U7-5CB%CT/4(B!Z$3WZCU_R5<UP
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M(6OGD(%?/(6OGD)7SN%KYY"T$Y"C7U'CU-9:+?*?NQC 4.TJH)4TR#^H( (
MF4@%$P!^IF>0?26'\6,9(T@6Q'*(JNTWC5*'C''CFV4?2$5C?(G&LQR#(P<S
M,=J& V1FS;8^2PV-*;3WKA"^.O-M: P7$(#)>0F?;X[PE4]A4B36024>E$\>
MY?-=V8N1YJSBV@,-$_J.7*#1%5)Z_-V&W4'8*'4A74A74@(W0JZ-71H!0JZ
M5=&KH6[;>A3;T1AV01?%]1^Z($,=3],5$RG]A0A5"$$1+^GR8>O&6E=&P<1!
MZV6-=),;@P* K>&THG(9K$<!TB.,ZJU@MN_5&Q=Z\R,5U5DNZ^*<)M2(@]/-
M./VKL'P/:NPN5>9.=X8KNY)FQBR,GKQ],T-_!^U07%5$7 E427*]CVDF/'Z2
M(WWC[$L7(C9:$M*%7CI::D&K)VB_:&?O4T(I5\NP\$!7.X34[BI3BJ G,F';
M+['D8.V4![9:\BATA72%"6] 4 \+7%B=<[8! ?W);J%/V%O^UBFM<@UM!Y?D
MDQB64O,YV0CR:+F<BS<#FBL?"Q>0-)W#,5R]Q+[%BL@R:'UQK.;CI<_L6-W?
M#,RE4?OY?*8M]%+RIP(ODJR:CF<1B6[M\XGO'EUV7FM<.B%L?P)$$W%.4$6:
MT64"H#O[2J6VJS/$L[]+ECC-M+QF^L0SS></R(R;4D%N+(LIV%L[;L)K>/9[
M&;8AE</F&I6[K'<3XDLM;[0QR%F]E(Y"N];MEJVUR!TIHIO(=(,5%64P@Y,1
M9$CPZ-8)$JLN64?*1LLGXN\<CWLT=DV,16$CG30C5%-:88NG\;'MUFC"GQ3'
M9]93"!"I@JN"0HNBKB1<YDP&X>!+V774"FK@YZ.'D)S6 XC2"G<I8Y@'P[ZA
M);]R5 1-[&>9](8<M%9(WEAG\G<1,"6<CR0,9G6O5ZR[(,$C8"-RW%)F>:[8
MU:_@);+H/&(Y?-L,:S/L.43+E!J:_I:<O(F*475QDKE@A&MSE##5(I5W (KQ
M0Z^;2J[8%Q!D(4+(!#?F82&M=?8_+-IW$4) 0,X>]A:?A(_.<:Y'_@ZB.47)
MO4&I<=TKA9B%.3.\HEX1]K_$./J2VA,@WF;=._&G,3;NQLXUJA&<KMZ;.SGC
MC&+[)C]5X@GBNO>0#W#=.0F%;#**$>W6;MLLQG=_X.V,OR+U_J7%]4XG&Q[U
M6-,DZ>K22J:;7%=E&5WSZ21= VQA9JZITAWSP;6<0RG&UVQ6:2Y1R6":&!F<
M[E%S'P4N]FDX044!14BVO@K8U*M1[:1$PH&[@L4H#9<]U4GR[1X5P8A4P(KV
MSLW*+H9 LPHP8KJJ-2F*8[I%ZL'@2R0_N2Z0+)%'J#QWWJQUL-1IH?&\BQV4
MU1 0>I9?%7#_  "=Q4)!6/@3M7SG4DG(81BFN,QQ+ ,RQ;8(JOL7S@,K]@H'
M,X\)%!^*S7$W*<@K&KNV4Q!2TZP=8J9Q4#%K1:*!#)(>'*R#;2FH=+F=%TZW
M(!Z3"U1RAC!X9CD X\RE-V:VRK<CO+G$9K[D=R\TGQMV3H/5TKQM8Z2A=;[I
MY/-8:!9QF0Z&P*:B-L95/8#A&/;&BGFK\AV DO$X.ZR![BU.?^RXC&SX7C5-
MTBFBD1_K9FSRCDEXGG&+9TG,L%FB\RQ;H.YABR4+-,SN5\A]$T*8I@IXB=RT
MOX 6OAKX*N2NL.L3@*@"!@ 0/5TSC_Q@((I%$5"!1%DSE!%$ZG@DV44E?W.R
M;</^@,81HI0*'Z>[,>2RC4G&&39O,)*5L>D#@J5BU=I+>"R22Z47J# ,;S+(
M<+QC(E389($DM;RV/?*LCV6&V<(P"6B("&:RCC+<SE9[6V88'AF#X1@,',ZF
ME'NSFKE%ZVIXBY5,6306? )0#8,P;%,<XW)QDQDGBX:G6H[0#OW[)ZJ)HY,X
MKX^LZFY& ?OV+9-R>3\%H\1D1'I)TGKI/5AJPT #5AM8:L-6&O.K#5AKI/72
MI11$Q?4]UQ%13"#C?W3M](B94 [RE=U2N\I7>4KNJ5WE*[RE=Y2N\I7>4KO*
M5WE*(HH<;*"(  !^KHQ9YAVW49_$Q:2*N9K@\Q1*2<8AD:&6XS19N&-,TJBH
M<<IRE77[;1FQPY-:>R;D!@VO=T0'+GC%K3()3)\BR..V5Q@U;LZ(6QR>QO8,
MP**@> J@X<7D4A,5!RWW;-(1&-<9<5/C&J?U19I MZ-(HE1(%=JNS7:KM4"5
MJ[5=JNU7:KM4+=.@;IV01>*$2231)_$]^J/=9[<:SV/0F</,RC$DIQ:<C<(;
MR9DIG\I&(;DV]C7XJ>'WVE<6_ 2@;PF-;:\R)=_ASKYS3QF@_;Y+PWPV2SK<
M6H,"WQJO@IQBY3<6]@R?6LBDX(=-HS].V]>F5_DLLXR+?3!BUC&/G0WKSL%Z
M\[C?P"_@-_ +UYT-_ +UYW&_CYT-_'SN-_ +V_BNV<%1V-@.I,Y6R;6IDWZ"
M,*@\.6*2^<-L>EET_P!21?HQK18'J-%BV1"(*.U5MBY"VAH7C=!*91.?S/<^
M/S6K-F8_(Q&=QK*#=2$ED.SL)PK%7+=MDJL3*.>[X3OY-E=B_E@\?R9?D9F_
MQ\[1P3.<2V=A-/':;)ND5RK1!;@\(]ZEU.VK(;.?OMGYMAF)0V!XI_,GLMZB
M71Q2&S-K"2"_'W.\JQ.(V##%=:]GFZ;PR;7&8V1A(PRCV/%ZBV?MM3_B]T#A
M')/QYB\"-,\UQQ38?'SA[QYYR?\ V'W:JOXA?R@[2U_O1+O)*D KAN990$-V
M[68,:TGJQ?$X,%TT%$5D7"7\O56(B5=+*IM_C&*8[AD0P8,(IAMK54!MS%,4
MS)_@4A NY43L<3QK&'B)52D62NJD>-R QEA2?$5FT:W;MF1U!HS,/_LF<MEI
MG77Y)/R;_D:Y![Y_'7PFY'; =6]2T[CAW^$WGO(\A]9"Y1)6\=Q+88QT_IMZ
M\?\ @M&&35!<.[_+=F$VFOCC/&(UN_\ 8V?JS%MKX]+KY#K%]!95'9F\IXJ+
M1832:J!&4*=B3JZ>;KDC3A:Y_P#V/PHRN2P_Y+-'?B$@],_D:_-7QSQGC7SP
MRU@:"F^#N(\K]K[@RO;F69!%ZLT>:&5]@0 :*1RDI_%,FS"*Q<$/JN0$(&4
MWR]W88]V-?+W=?+G=!'NPH(YW0Q[NOESN_R]W0QSROE[NXQ[L:4A=C0[:$R]
M1T]\,^,Q+$&6:Q6%O"Y 12&?NY$J#?((E7"Y&:?/\A!Z# TW&*NWKV6-ED,Z
M \CDRJ,@BT<O_F$S"Q&11>4<?,TUK+XSR1AR23"<C):/-#.GU-D'B1O(0YM
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M:K?2(#,2L0>M<Y82H%]_JQ;@U/A[M6IFH\_B:]3,I9C*@W$0(C'?;A'Z7X5
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M '5KN\Y_)J_D^4CR='):/ZS?[-7_  EH_K-=_)J_X2W]IS^35_PGAM/]:?\
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M KA!L /F^ID<IUNHD>$.H\2V/_E]0_+-5^$M?\W&F_+-7^%M=\W&GC^6:O\
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M +8B2"8F3@8K:?1<1_CZ3GHNCTZB$&\%2$8Q%\$Q<#!N_P .:GB&L)-*G
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M8$.&89:B5+Y[-Y(.49>LRB8%6IJ%JLU-#G:JKB*CE:66JU0*^<@QD>09NS%
M^KXN]!#2H+)':TPP!J=B"4SY\I?JJV0AL0T7VUW"J/RC:?45J69BM,,:50HT
M9JA DBX$P 0%9A?;5FM0RM3 D$K-PDY I8N(B] W-?(!RXW<G+T'E]T*HZ[>
M\/!R6TM37.$%0A1!!@LU-5!"%RLM47UHQS>J#:IW:0CVG3!6()50.VHBNM[L
M%DI@,Y,W&\ 6J=Y$J*-+1-,&64$]K4%!(4PS#/"R%@$K,"#;(_JB/C+'(!C
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MJ3@. 5S*VGXSI>(-5TNJI"IIZA1I*DZA:E&KV:4Z:5Z)HA:U+$'*ZDJRDLC
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MTK(9[1F8SC(>+O%Y<1 FI= NY+NJW/-AR_2W3Y!8UIN5??/.=TD;'W7U8?,
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MG=[I=B=Y\1MIJE)YBK?=!'5>XCGMPZB;B*5_2:E2>B=K[  S)&'1T^2T W$
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M-_: D2-\",)BT@3%NL;(*SD,8F%8J,TA1.08D0LPS-=-A0U;'L'#%$[.HUR
M%V:%8KE++.;+E$F8B#HGU0'$4<($*D',:;/*]6&!IJQS+*K&60Q@\3U5:J[+
M0HK6JA*=6H0AS9&(1'(^]M,+(5<[0HFVMH,2*M/(:@&;*,WJB?5Y 54RI(#A
M20#FK24>E0>$%1W K9PI94HPH.0Q+%R<47JEVJZ<%Z6<K)5E8,CE6E7&988&
MXW[[+V^B@WR,\S=RB>46U6A/#<U"K389"]Q(7,#FN(ZRB^[+,W@6U.AUE%J6
MOI.U-T8=973[XA'BC"QEMNB/I>9JRB\^7===T##Q6H4%'4T$Y3S5[R/>OS>"
MU(YS&GF/4_RF.QGP6JG-!U$3ZEV3W_%X;?-/Q9>"2^J_2=W;)+=E5R8QU<OV
M(D<N-N^W#Z7 )3A?L<#MU&7VE,QO,DR3-Y>-V6;+IE/5$Q=RJI.()W\I]X&O
M2G-R_LE!Q)&_W[55!_&8G\7_ ,G>,2WU7-9 SB-*3%VFN[6)WK,D;Y\%J2U^
M\G;KI9@>STJ?WTC? B^#OPW39ZE7@G;-J?\ /!/O<<C#DYL-\VUVB/!^Q&D"
M1\LKQVM$L?\ *MC.\L;]V XEJ%X_V-2IV<CL$;U:P&.1MS'DW6(CK>?R],G?
MNNL2;XN-^WBNZ+#OA6IS4U2.BEB9(2M6#;R)(15$*#+/RR3JPTC.P'/E+).%
MTQ. ]\_X2+1U#CS<_1RVN-W_ +!V=,];>>0>FV5=VWC./ZGC?97)B)\@(\L"
MU;B&@JEEHZL%1A';:2G38]8\M%8$<MV^U.MH*,T[\#1'Q5'QEDWD]-@-8MW-
MEG=]29Y)-EU.H?)4D"\5!$DB\3A>,1?TWV<S==YS93T^:RK74=GCT[MQ$\H\
MXW]WZG Z=?3:H5'FNM2H"6!T13L89B A.%-<RL9O)6.(\/[V:/4T]4[4GIU%
M*]H$J*S$FF:89U<5\](*6+J^9RJ*'/"N+]VDH5.&52YIU49%9P2X<5#4H272
M]9905.9$S8VI'4\/I@&FK K6%10"@C"BN5B*0#*0K!I! (MJTXQQA4HO3(A#
M4J$,R5E7)4HJY4D5"2RGJ.59LI!S:?5<*XC[.<TMG[:HA7L],O50ZA7#J%ZH
M,J9>6"P3I^$Z?@J5:J5:C)4KNQ8*U1F",*>IIER(D!ZKH"S#( PLC:KN^11N
M'WY)$DR<H<"?"3$ 838TZ&F52U][,9$'?FEN3&XV7A7#^/:;/3O(3V@OFS9V
M#@TV<LN5PF6_K9064J+4]5H">R*]6"PD$'E@@&>2\'DL]'0U^UX6;TJ01((!
MB&O!#&\[B)!RLLKI.#%4T(J9F%2,M0JU/*,P9H(,R2(,@3!-G;B?"*JT(%\T
MRHO&#BHTGK1"5 <;%=73@B_&1AORY=P&V/>_AQ59T?!ZPW&*FJJY*7Q2)%34
M,?7O[.(O,%J<D/U5Z%JZ@?5U!A4B;IY\1S66V-JE,UO6-(S'[FQ;ZK?,<W/9
MV-3*7H5:<Q-U5::DCK;LEXB^\2,;4=13K_+)1I4UE9'R25$D]:\D/,#U2(S/
M:O1IZDN*E$))6#.>M4=O6/K-5;J_%@=-J-9JU+M$RF32#,"I5B%8N"JD#K"Z
M\@YL5+56U2NR:?34EA&50NF>LZ$CM6!8]H T1)3,?7RKQG5',J5G#!>K!<@F
MK410[Y148@Y6ZT*)D^X;<<[S]R^'=IK"0VJIT\LF65FKJI#I(#5&K&XR358G
MKV?BG&NKFZ#\1DPIL.1=P\]FR\(ONN[7WSMSVS?HK'#Y7S=4\M@/TU/_ %/_
M $=O)8#]-"/WGSW6G]-W_O/P6G]-;_W'_H^:Q_WU?^\_]&T_IK_0_P#1VCEM
M'Z9W?N/C^+;+^F;_ -Y^#S6_GJX?YGX.2S#],F/WD>CP_!8E^X5P'_;O!R>]
M?XK'_@(B?]>\7Q<=N>PX=W08=@YO\"AO\N2<6? CS :*CPT %R>UK,HR4J8.
M7.P#/+@'Y)( J_&,F0*2M 51R8<]X\>\F^;S_A4M3,$^+Q>BWJ3T'TQY[?B;
M?ME]-OQ-I^R7TV_%&_;+Z;?B;?ME]-OQ-H^R7TV_%&_;+Z;0=&W[9?3;\4;]
MLOIL8TC?ME]-A_%&_;+Z;?B;?ME]-B/9#^V7TV_%CCO9?>]%NO4"KR+CX_0+
M95%VWCL?U,[;[0-Q\<WBQKZO413JAX<P <E6%-S-'587Y1RP3A6I\1[Y4]76
MI"Y=)3J:@N2PN%2G2>@!UE$]H>4<EM7INZ'=K3:'4$75:E:K5J8KZBOHDI9H
M%^96 W1$E-7KN^6MKKIG2I36JU%J25%:F X0T5I+UA<\$&Z;C=PCO/H@%.H5
MA47ZBK38TZJWJOQQG$ #*RG=>,E]IIMUMMO-,VH?I&BQJTVS*59T*DP,:;*"
M;E7E@<D@T^/_ *7IT:^II :AA1S4U=%ITA45?;*9".E,=1%C,&)/6 M0X)0U
M;ZG0T1\B&!5<S/6J5"%-2NH9JE8D &0JTQ>5NU-?BO#NQI(5S$5,P :.L6IY
MB(SK)PB<V^/X[Q?LM2,K2*>M-YGLX:FR3UJ,C<& )B ;5>**6-0G%INOJ9F:
M:JF *3"0K7B)SA5=M/PSB6:B#?3*T"5!7,""Q,WWDE@8( D>K4I5> -3IDB
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MJ.S:%58)+9C5UFN?Y5S?=R"%N&4#U1$"-_-9J>EJQ3&%R^'$'?/TOUY'N_\
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MST>[K:5-6UV>N6 6\>JH2HI,3ZP/,K6?OE\XG'M1WJ^=:LS-6XCJ!V2JSFI
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MU335F:^HJ$PP1'J->9:9B\8FZ-;3IG,>H=UWK;R3RV[ST="D5?9Z.6^CZQ0
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M=VN ?-/W<KKWEHC4=6JY&=F%&HL-6<4E4)1J%I*Q,R>J+;IW;;76OVZ;1'6
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MH*C*Q)X9\Y' .&9NY2C*0*E,&D'TATCW5-14K5 *KFK.0F\J 0,UM1\[&JH
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M5*F8$"U;NY\TFKR]X)$&$4LIK!V4'4MDIL49V#9B1DA1F92M?N;Q?NE3KO5
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M-80?+S#;T68[XVVW]&$ 7_!T;<EL(.VW@M<3=MMYK$0=O!T^6Q)N:?-X+8$
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M)_K+_L_$?S>Q_P#,2>3^(<1_-K!A\X8G^0<1\WLUW/'@M/\ S$__ #?Q&?\
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M'_R_$/S:Q![QC\GXA^;6D]XL?]7XA^;6)_K'_L_$?S:Q_P#,'_8.(?FU@?\
MF"/R#B/YM\-KOG"/Y!Q'\WPL"?G"Y/\ X#B/YO8SWCW_ /9^(_FTV#'O'!C_
M +/Q'\VM_:01_)^(_FUKN\D'^3\1_-K0>\8Q_P"S<1'_ -VM [QR/Y/Q'\VM
M?WB_V?B/YN=L;91WCN_D_$?S:Q [QW\VGXC^;6C^L=W\GXC^;6)'>3_9^(_F
MUC_Q'_L_$.G_ +-8_P#$?^S\1_-[$?UB@_R?B/YMZ+?VCO\ Y/Q'\WL?^(O]
MGXA^;6D=Y?\ 9^(?F]C_ ,27_P GXA[VF\EI_K)_L_$/S;;QV_M)_L_$.G#V
M:P7^L=W\GXA^;6D=Y+_Y/Q#\VLWL_>]4IW1_%->=U\SICOM [Z)N_P#@]=^:
MV_MJN'_9-=^:[<EO[:)^1Z[\UM/]<T_(]=^:_3L0>^B?D>N_-;['_C->3\3U
M_P":V_MFOY'KOS7RV!_KFGY'KOS6P/\ 7-)'^IZ[\UM [YKC_P!CUWYK;^VB
M'_Y/7?FO38D]]$_)-=^:VG^N:3'_ &/7?FMC_P :)'\CUWYK]*T'OHL_R/7?
MFMI_KHOY'KOS6U_?5)_D>N_-;7]]$C^1Z[\UL5UO>U:E+&!I->M^ ,C3<A/C
MYK?VD'Y-Q'\VMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&
MV-L;8VQMC;&V-L;8VQMC[F-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8V
MQMC;&V-L;8VQMC;&V-L;8VQMC[F-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V
M-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8VQMC;&V-L;8V
MQMC;&V-L;8VQMC;&V-L;8_\ ZY@-4=N@Z$\T\ODY[#M?XNO[)]L/+S?JH$VD
M?1B;&V/GMS^&V-L;7&WK6%]A?;UK8VQMZWN#]<C<1XM63AG *3=?4U>S=!>5
MA8<&J2T* L7F"0;B:.LX;J>\=?,1VCO6X=2/(46D:E2)80K!9RGEN?)\S6A"
M\_$.)$^2N+'_ ,F]!^7\3_#V_N;T'Y?Q/\/;^YOA_P"7\3_#V_N;T'Y?Q/\
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M?T>FQG6OAS695K,U7E,$<\"0?'8&G@3<,;K]\03<21= B^3%H,SXCT']<!3
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MYD9E ZIO %X!-^H<Z/M*_; ! 6'5)<YY!4$F-Q '(+IH)0I"IGK.)+1*J5
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M-S<B#DL*NNU=2I4Y79F(PY8W >+]0!!O%E-;2I,S($-A$2"#S?#8'V-9Z?\
MI6';:!#X3]T.2U2O2BCITO)ZQY;X&8DDL<+SR3%JC5-(C:QV+$P0%!!(1 *K
M0%ON)OD"[+8+6T2,HYR,8^NYAXK?B">,_=V).@4>$_=6@Z)3X?\ I64^R 1M
M]5]+=:_3+M^SM^+C;]G:5TJSM]?9J2+"=!/G/ZYOOWD-H&KC]B=N2WXY]K81
MK9_86^_R.BP^5\EOOODM]]\AM46E7NI1DZN.9>MC[\\W);O;\QW%>*!7XBE.
MKPAG3,M&M1J5M3JE!6'7,$#9691D%4J#G*.R-6AU)!&4XCFYK??_ +6T(M_2
M;=4_J9!NV\-M)PVI5*\/[16K7"\(1"P=S0V PAOB@$3(W6PN\'T-QCQ6$-OY
MK$3 /18$-YO3^M;#Z+#W,/='T$6@V,BT?02+5]3IM!6J:99EU1F41,R0<HB.
M>WM&6_P?4Q;2\;TBD5:#@@G#U"L$ &X@D'?>>FW$.]7">#KH^'UU#/34I4RL
MM*E39R_94H+-3+-* LS%LQ+2_P"C^&:8KK<K&XAI"4S4<@-U;D5B=T1B;K $
M7^"P#"[P<W)]'&6\7X?!$>2Q@VR*).^XDQ?)Z!CR^"V6H"IY((.')=T8V83$
M=/+;4ZI9[>LV9C)DPI4+,F5$FZ^\SB+C#6];R6R!ED'<9WG&/")/1>2/H;K1
MO&VW@L".3;;GNL3-_P!!/JG]D;=;B.4_O;&WJ>46]3RBWJ>4>FWJ^46]3RBW
MJ>4>FWJ^46]3RBWJ>46]3RBWJ>46]7RBPSU9!YH]'):30S_LH]_;P_X="4T+
M,=PD^:RBI551F@[R($S ! G&"?/%C#GQ?#;U:GB7[NT!:GB7[NWJU/$OW=O5
MJ>)?N[7K4\2_=VN6IXE^[L.K4\2_=V]6I/0OW=O5J>)?N[>J_B7[NWJU/VJ_
M=V$"IXE^[LL.(@F^[ <H4K?X)PW6 J(58[71NOO@\WT$S?:=WO6$X_0Y;:*E
MQ'54J5"B*V6M3U!I:B@&#L0$))JFH84!4> 1# W'B7&=3^C2#3T@HH]6FK%^
MU*5Y5&=TNO<O3.8'-+4UD<5.GU&BS'V-R"M!6(.JJ+60Y":59J=/(TT5A0PB
M:F9F[L<:XB-%1XN6U09*34:^<#5:1*;5/813I1[.SL$-$,R!D9LYS&GPGBO!
M^'T.#)^F!1K4Q3%/(N@+Z17%!!)[:FB4:C.&<O*@G,&UA71:'Y+4ZC)E6E"T
M!I785"AR4G5:B(RU*S!03D=Z:DBVGJ#3E-*=)0%,YZ15U5*:EE6C4JTD5G#?
M)T7R+<8EOHW=R67,3E:Y2+S(.#3=<&,_70 *E+253AU2H+225 ]4DP%@$W1)
M+,!-F&HS=I.)R^J <+LHY9))O,#UI"/7 4S^YP2% O,W3/A83.ZVK->L[T5>
M"Y !<)4K"3 -."8 %*I46 &S7J6+*T(JF+JADE0RA5"]F#F8$DL&:>NI5%FN
MVFJIFS$7!1&4I!6")$9X(%QQ)N@'45[P8,Y0#DY,+CUB+QFF\'<A2J7$-.8D
MR21/K$WF\F;KIB1-J@I$9)W8<\1NW77<WT)M)F1;E'FM$^X HOG#?;64^Z%&
MIQ364JF3Y,55IYBQ$&N]+L@L!B'#%&42I(9;5#P?YBZ-9!AGXYHJ8:X8#V9[
M@<PZQ7"ZXBU_S-*/_P";Z3\%:?\ DTO]+Z3\%8'_ )-)_2^D_!6_N:2?^]])
M^"M_<TD_][Z/\%83\S2Q_P![Z3\%;^YI?Z7TGX*T_P#)I8_[WTGX*W]S*?TO
MI/P5K_F;7^E])^"M?\S:_P!+Z3\%;^YE8_[WTGX*P'>+YL*VDT8/6:GK=+J6
M7HHTU#->0"0;IDW D5],W>3V?6)ZU-]/7S@@L"("H21DO )*S#!3=_AQ:-,@
M$G$W7#>3$  ;3;LM-)H[VP9O+<IC D&)F6)C]6!W6F 5Y#./3..-XBXW@V5T
MOH$P#R&^YH&/.+CB#N6+9K"[EVVW6P^@.NTW A4TIIO44C4T Y6D6SL*9?M&
M"&Y@BDX" 2)KZ0< I=NA3,/:]-U"]R*Q->$:H2!21H9R>IF@V[L@(5KZA-8Q
M4]FF0T'*,7[2L@"$SUSE,3",9![QT-&!76DRJ&[33HSLD&HM.B-2[U"H%Z4_
ME$P=$,"RY>&:90],5+]=HT^3:Y&E]2I7.2H0F,Q-QQ-M'4U?!5IU*W;@ ZC3
M9YTH;M2P;4@Y552*A;U&4 M+JC:U*7#_ )7155IB:FG #5*;UC):HJA,B.V:
M62! <,UM%PW4:4^V:Q0\*U%E=!!ILM16=&0@^NA@$$,T@VIG@NIJ+KV=$1J#
MT"#VJ5&!2LFH:9%.J&(FFN0]HZ96LFIXOQ%=17-&FQ=ZU)P%JU,E +6-54J9
MRL*:50P;KFRJ_%>]^KTE,:?1T\S@UZ 90:XTHS4A5-7*:T4U/9$,2((!S6XC
MW7TC"JVEK5DSN:=%6%)@K,,^I8 $Q<S+EF%+B^W%.WH+2;3CK!W0'J4B[FFJ
MEWJ@*!!I*]Y6-X%8 77?XWNR<+ E2($X&X 3C'ANOQP((L*;$!R 8D_&P@^"
M<2>6;"NMZ+)(P8 &&ZOK0#C==,P<;!*9ZUPP,;]IG&\F+[!,YDW1>+L!==%X
MNN Y,;*14$'#'HOZ;26@$'EW3FW3=!]%BKCK>/GW<WBZ?<O]R_'W9L3%UN>;
M:SO1Q.L*?!:0DDS  )0X9F)!$ 9"20% ,@V''^.YQ\W\#L*!E#6P K5A-.H%
M-1(IA1.6]2*9)K,SL2Q-Y-_C/T6D.Y,WE%M*IQ3-Y3]'!:";9JJ1J5(*5%)#
M*RE2I!#J3! ,=6#,%&,VK?-GQ*N!Q!:8J:.H>S45Z93MJ^159AVE-RR9'8LU
M)!64%9568&Y/O(Z3\ILW['_#510PSN;\9"R0+H$9B#-Y!CGL%&'N4J*'K,0/
MAZ!C8TJ1SKD#AKE!4C&_ ;K\<(M4)I@*H$DLH'6O$$F#X)M3%>G%/.%:""5S
M7P0)*R,)%V^^Q5J<KUA<R_%OQO (Y#$BX6:I4IPHB;P2,PD9A)*SS@<]NT$+
M2@F3R+ZQ $L0/L2.>9%@E%"U,E5!,3F90Q!PY;ICEFXV+]EU0LW$$Q,3 ,D3
MOB(OF+)3U"D4B2"5*D@A2P!B8-PQ WV"K3EL@87CU3<(OOGD%\W19UJ4"85C
M<ZW9;C)O]7>MQZ+350"3&(-XO(,3?!YK1[C43$/@?J3B#-\3,$@29%]UD(8%
M3\,ST6N%NM@?H=":?=)ZW%-/3KJ']J=5!K,ZJSIV76*@@*J5$F\->;N*MK>Z
M!;0:BK2J+375NK4FIH%^^&B^96'K*4N^+A;@%6MPP^THNO1F%1@K)JJG:P%[
M+--/K((:\ WB0!Q]&TNIIU&K/4I]EJGI(/:&9B*ZI0^6[-B33;-3RCDO)U6I
M'=JH#6H44FEJGI54-'*24JFE5 2J5(J4S3,JT![KT<=TG2K3.J*EM8S1[8O6
MN.F6>RJ=:F ZPGR33<XX.E+3LJZ.CJ*>H*.B/6]I1*:5 _8L:;TDITUIN.T?
MJ>LLS9M=I$UE755PBT U9J]8B@ :G7RAB6(:H5R4Z: D*I%M(G'%&G2G7IU*
ME5A5-0G3K7(#C3T S=JU5*1(I$4U$Y&GJK1X%Q=Z[U:*(T(13H"C4#(E(>Q:
M%2K L6'8)E:;VF1QONI^@ZU+VRFB95U#'3#)K?;NT[+V9 :[,HIU*G:@N.M"
M^H>*\>TN@:BNK>JT&KVF7M7INPDT*<J&3*)$Y1!)/6/&=1Q;4>R5*US9)-55
M>@-.RTV?05U4LM._)5T@&8!F<S4.I$7G+R[O![LG?8*R@";_  B.6XWDB<,-
MUC674148%3(GJMZP,N3@($=:6!8M%OE6)HMF$Y0!!S 0<28DWF_>01:B2R$H
M"IS#-(8DDJ,P(@$B9@&#ED#,!G&5A?"A097=UR!= @"9-QG E=3%0@JUV(81
ME -0Y9WP6/Q@ 022E.J!*[U!&!OC/ O)B.L+E#"\$U,L$@>.(DP!>8DW"\X>
MX+8W_0WBP\MN$]TZ-)6[CLW:ZF;LRH%=*<EZ58=I7IRS(#$ SV=S#@^F_$AY
M>MGW];UB=_H^A-,N%0*6+1, #I$WP.8F;5T10>S;*3(%\W1)F_=RS;C6N;*#
MI:U&D5S*&FHSBZ6,L&2\!7,$N0$!8\<1Z3*-*5!4WD%5$C,J0T8$J()$W7PB
MTM68[9J1E "&"LUP#M(A>4;L9LNLH5BU$OD8$!65MTC,UQ&!/B&ZNWM*JZ4V
M8+B3E4L3B(&Z;\28,681?[IS#;Q^YHN\'"0B]Z>'5&J:.HP0A2X6E73K]3+5
MI9E(<0'"."I0,-'WDX54S<&>F'HGK"5?JD]=4>"1/74'="_X:7.!=30= RS/
MA:?%[KU!3S5,A /U)._ SC$<_@MD:EURF4LK9)696(%V4X;B"9$V:F%8#,I!
M+EB(!WD7DDD[E!O"S)/?/@3($H<9]FSS?E&G(<@1E/78 SG&4"):XCO3KE1A
M1XDU$Y"TE#21Q 8*LKGJ5&@(A@HI)RDM4IMI_P",L5ZV8[B9A1AF!$R6@"!!
MM5;4ZHTJ+H0S"]C*N( [*H(/4D H#\:3,5ZJD+5*B!>3F R@@P0(#'$DR-TQ
M:@QH361 H,D#JF0T"#,78QOB+K5:]/296JOF?K2"8CJP@RC,2QQ)P)M3IJ06
MS D"1"J<P!( -Y8F5PBZ)FS,--UC3=99I,.+I;(I,1(D$F;F!Q5/9X(),EL[
M 0!E#900+K\Y8GEP]U:J>NID<Y!4CR@6KYC 9BV^3)+2O5W2,,+2!$6*##Z$
M"^+7"+1MMM=8'?8187V,6TVNTQ K4F##GN8$&XW$$@\UN _/IW?IC]"=X%;M
M5OS4J^GR::'DJ,S]FX.2F 7IU"P.8.U33.;TC(.DRWFWGH_4:U6M4"TU$DQ?
M=!B!,@DX"\VU'%]8I&OUS=HTF[*$.0*1$[XD7R.3Z,3A8<OT)IU3F4_'N'(?
M5$\L>6W:Y_9"H,U^O4&\?>B8N'4PDDYL1;YZ>+Z:OVFD7]$TZ;01 &EJAH4A
M(7.N8$B9GE-JE'H\T^]]#5IY9+D7_8S=!NCEF,!R395-/KC(229)(!$^$$6[
MT:=M.0W$JE)YS3E[,$,L% 3*NP!#4R&@RV![UZE!V7Z9/RF#2!@K7)F"!B%Z
MHRR2H))E:E2N[I0+E59R53M#@@. D7A1?%]N^E'2UC[#JSH2%:"Z"@E5<I<*
M@:36=B,MTJ+U7.]1ZM-JCU$9/6BYA%W5)G<+[AN,6)00NZ2"?"8$\]PZ/H:7
MALG#$<M3TVLUM)2<2E/7ZI 3SF)/.?\ #2$/F+(D\G5!4_;+)Z?H"+1;O7Q_
MM *7#%T[$95,]NY0=:<RA2),!IO%QFW>/A;?*4N&5::,64#/VU.J9"2X]>FX
M$,Y@!NKF*JXH5LU(TB02@&["#,<S23R$[Z];35 6IN<RE<H&$93U@T8 9;V'
M(01HA2JL=54J5@Q**H/9O!,*Q @R% ]:?B^J&JO6*TU0L;I-QPC,HON@YNF"
M+SK4JYJ84&Y9%Y(@D,2"+LUT7]4L;OHLDD9H6[&^!/@O-J].LHJZ8U"0+B1>
M8RF<8.^\<@QL7TY.3*94^L,3=U;\#'*1 )Q$QOZ-\1N,\H^A@W[>?;IN-HWV
MB;<U@3:["V%N^OS2\4T]0\,JI3JZ2NZRE"NM:I58 J5:"42I",(5:XALY1AP
M8ZPUWT="F]5XR#-J*8*@ NY@3 ,F?6.68'ZAP;N]IE:E1J$FOG..12P1"::Y
MRQ6"93E* *TTPBY5&&-U]^\DXR3B3T_01NMS^YA!VVQ\%I/T(X?WIU@K=[*I
M/8Z%.U9G8%"4[6C2JTT^3JTZI+LIRF$%1V56?6_.W4;@?<%G4#A*-1KNX51\
MH^JT[4&5NWI4ZE-F5F'6I]D$)>M\[O#:2%.&UZ?"*M$$EHC3ZBF[%B7,M51K
MI@ ".05*T\GFCGY>3Z&K4]G8ZI4[2;R,LL"L@QZH#G>0# $6U/9:K,],(6!4
MK&<"(.8SCA=SV[T\4[6H:?"JFG! I%W/;U'3JA"[L%RFY4<F22JF\]Y>'UZ.
MF>IPXZ0RU3J%=2M8DATJ*C_>QZE2JLYD.5@ZV[_T=.H8:5^&]FYDY17;4E\+
MLI[$(Q?M M,9P T$M31@U*HQ@RI@4T4A6ZP*Q(425+&8!,V==128Z92>J,3R
M"2;A,2028MJ:%)8I" !,Q*BZ22<>7#Z&AB3?;1<5U-/+5U=?4UB-P[77:FI
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MH:OA'M>JI#K1J-0:GAIT'QO&";L,;%&[B52W/I-63BUTL@$W?56IU.(]S@E
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M5QNN@"XR021;),NK&1S1(NR7"")ZURF_$Y141&"!JD+U)G-36"P0$B6P)N$
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MD&3;14J=1,NG:KV9"LL=JV>H1UI!9KV),L9/5S$66N>%(&4Y1!*-<"N6 9B
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M3]9V)"*.KO@E3? < L3$ FZW&==W!&?1:N]EJ A"X<,U0!@Q(.>J5#92H=A
M5BMJ]'4\2>C3I%QDHE*94BY@YIT4<PJ*5+LRX5*9QG-7U+NPWLS$^]:3>!:X
MF8M3+T<P=@BDW@$QSW&(()P(GEM4H<)S:>O3=E)SO54E6B8>M( #$DYE!,P+
MHL:?LDT(D.&IY3<LWLY(OD 7DP8)BU>EWJ1AW7TXO((DYUU! ^2J4ZN;MJ:
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MTD?+58!*I5<M2G4+*3)IL0 >%]OQ\5.)ZJ@7KTQ1 [%D:$0L&8.2I#'*$@$
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MHVBP!'6G;=;='@^#GM)!RSMR>.Q48C;P^'HW6))&[EVNWV@D@;>+QFQ!4A6
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MIK23-/:U!449BV4A:0R5,XJ25RW\4J:C3]GQ!*&HI54Q5:JB00V#*U)Z;H
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M0/7"U1+*I!))F^VJKCA6DKTZ=6F4#.N<@AU;-3&D+,M\MVU0L*JTV4@ "VG
M^9W1P,V&I4;^4Z%AY[:+AG#?FYI<,KUT>*B:D/>FFJ-$#24IS!&%YND^%B#C
MS1[W@^&S CK>+R[7XVXC02.UJ4F43$$LA$E@<H!9A>;AB<+?,?IGT]9TX,.+
M!UIC3.Q]H6GV9":ESIWRE7O;,PS0I!06^;^J.XCE-/HWIU9XAIRR_+5'>DY#
M)F]II5&IEE0JDGJJ(GOEE^:^E3X;J=7P^HE ZS292M+3UZ5641S30K4J*2H]
M>";Y+#N]Q).#^SLC<0IM56IIV:G3J)772#**H9E0&GV=-0135<L(! X#P?\
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MH!^VF^/L;<1('K,C#G!I4DY]Z-O]%EF\D'HN;I&W3:5QVY[:-UP!*STA"/\
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MR;P0;TX"NGB7#1UY#"KFF36$ %FN#8"\D]:S</7AAT-=@#V1J5JLC,KCKEG
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M!4Q)$'>#!O'*#-XW\UQLR/B-O$<0>2U]M7Q#44\RH548@%F=5'657WM(Y8.
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M5X=4(@Q$P3.+8VXIKOT<NG>D*>8(S/FZVI62SZ>B%).G)N$7QN$EH=D&XGT
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MEO\ U SYMIMAA^LHDV>H"J:9?6J.80=)F"9P%^Z0 ;&%J:FI)DF*:870 "Y
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M1Z;"C6H,@452F0KFU>G[R\06OJ*>HT,U*:Z:M0#5-9E 7L-/0K4LRA/XOJJ
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MC D'GH<-TOS[!]"F8Q^@]$&+N69B["L]]Z 87+?,DVG_ /ZD7_Z:X=^%M?\
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MZ'YON&TW&]4(.\;FYSX[)0T'#$HTQ@! C'WR3CO/+;/I$ANECOYXY#;Y4W?
M>3Z(,K$,-XL?XPYZ3-OQAO';\8:WXPWCM^,-;\8;QV_&&M^,-;\8:WXPUOQA
MK?C#6_&&\=C.I>_G(GQ7?_JC?__:  @! 0$&/P ,8#7.N>\-!$=1R/T<<N6F
M!R(<Q#/+/S\ (AG0!# B CG3&-- TY<"&"^@<F[QTQGGP&.W73(!CEC/R\#R
M =<9$?G#OP' <N[ F'0=1$<<PTX -"]F,_2 :CC'JX#0,B8,:B',,YSZA]?&
MO3C/:)@TY9#0   ,/;\G "&#@/:&>_&0 !R&0X+]4 $1'/5H&"]6.>  2AS
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M2B'/)L\@ P#H  'ZW&N=  <YS_7&Q@<>UIQ[( .,B @!B@ #D,#Z,8UX$0*
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M-,:"'L@/&A@Y>S_7:B YZC (8QZ>,#H 9YZ .N.\"A@0#@1Y9Z>\,Z@ " Y
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M,8#0.6?7QC//LTQS ->P,XXU_%V9TSQICEVAV\^-.7=C7N]>>/K&^8OZO'8
MB.0'.>0".1P&1T#D'9P("9/(8*/M#G.@"(@!<AS^3@?TSX# #J.<!KGY/7QI
MCG@1$QAQ@  !Z0TR.?U.,8 1$/ZX-!P&NIBB/3GU9Y<#@<ZB.,CVCG X 1'(
M#CT<^,XSH&<F'ZP#U#K[6G?SQP8!Z0* \L_L38  T'3 >D,Y]'!1P4 QWAG
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M<#J'(="&'0=<B.!U#/HSP.>D1U ,CD1QS  Y]O&/9#0>W&!Z== #!1[O3QG
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M8V1Q]7"@YU$?:R.!QRSW\"?(CU<M5!QH)<!DQ\9%3N[<<8$1P;0V"*C]40P
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M1Q@"E]'+)1 0$.X-/3QJ;.NFI0TP; ^V82]N?F[^ UY9'7 "4PB.0#&0''&
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MF'O'C&<B&G+Z<Y]'&,B.@CD/7IG4<?I\9R;/: 8$1Y>GO'@<&-Z<@(#@ SH
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MP%<0]?!VJK*3:4!#?#A4W#(L3H,O@>@A^GF. QGVX+<O&0'V8"#'MP.IKZ&
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MCZ,<::>K3..0>K/&@#S <Y .WN !#C  (<QY!VAIV@(<QXY"'/ :?3D>T1X
M,"  (=W(/1D<Z\M>#  =( 7(=A=!( XY]@]G+CF']E^MQD.H0QG40'( (:::
M8$ [^?JX#4?6(@(  8 HAD,]_<&>"G2$!'.NF S[P7O*H'M"?C;%4^2J"N[3
M3(/2(B8B]8.7V@*0 RH;.H<74Q@\,0I%O.4N>KJ,%=L!@+DH  "(@ #G&,\M
M.'4#4MC;EN=&'MKZ6^/UXEB(V:R*L9"(J1@&C*M-(F.BFT*90O6!A!0.0" B
MO9)^J2NW\O)S4:"]3FR37OD8FC9G; %2&F8"!2*FH"6, <X@(ZXP.-KV:#D
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M9$,E3-0$RS9 K<"<N@0+J YXKLZ_I3"?E:\*AV+]^59NW+T'4<?OTU<D-\<
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M!_8\:"&![,X#GG.@!P YY9[=!] CC/&<AW#\OJ#3]+CF//GGGV=W9QS^GF.
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MU\@X# CG AC =FF0 !P&1](<&UR(AD0]D!#&.WJ#]CV^C@1R/(39$ #VM1U
M1' "(?3P8 -C&,@7 ".F"AG(CD #/HXYX#'=Z=  P](C@.WGZ>.0@7L[<Y
M''M" 8''&<9Y9 .?>&-1'(9^GNX'D/I$ UR B C@P8$>KY^_@0 W;H(@ @(X
M <#KGES[=>,@("(YSD0'F7(!D>H>WF.. UR.-,B Y$-   $P9 1#U=O&H9#G
MGLYCVYTR(\&UP(#D!'4P@&G>/,"CZN.K(9$ '.?9 0#MR.HB'+3NX'M]/L@
M%  P.>H/U^,Y+SU#(#H(@.@9UX  ](B. #)C (#GVA'4!QSY\N!#73EG ER'
M+(#@<  <8P& Z?:[\9UR Z8#NU^GCD7/3C./1@>W&!XT$ U[M,CCF'+ B/ #
MH'+/LXQCMYZ?CXUU' AD0+V=H:=@AQIV8QH&/3H'IUX[,X[O7R[@UX[.\--
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M  ,".=/2(CCEP #RT'M[^W(]_'+LR(9QG3OSD>,<OEU'4>GD/>/ \M QVAR
M=--,_*'&,<B&'N$0Z@#'IYX'EQS+^'R<?PART_<HCC Z9U <9#/HXR60Y_\
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M 1<'P(B.0$/9T$>,@U#(A_TR<1$!$=1R @ #V9_'Q^[^S.?=.TN<X <\@''
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MY\9]T#D _GQT'MTZ Y?I\?N7U_MDPAGO !3#.<_I<8]UT'O<:!@ _K.8_)P
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M'_ /\?'\J.0UU^Q=OY#KR&B_)Z.,!NART#^\RW!VYQ@*( ACY<\8^W)NP?\
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M^O+C^4,,AG7[*;BB.F,\J,(<9_C?'T_WB[B8'L /\!L:<?ROC_X";AX NO\
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M;7-(;44ET8ALD!M4:L6P7%Q&'3,(B;XY'+9 -"\A_(^4_9\I1R"8+6C>USC
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M" @'VC\PG8/>.]0\N/YE7E[SD/\ MC\PFN,Y$<;UYUX_F5>7O_PC\PN<Y_\
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MUG;FHF,("I8+4NW/DPCT1L:B[?&R"/2=D9\1C!5B"06CJ/0H,ON54I$(=4'
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M[.YVZLOMDUDMK?,%4(Z)A=N=XZE)UJ!O.T4!--VU.M*#;;R;JDG'2/VRI9Y
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M(1\HRNMO9R<!67U'BWR-AE4GD53I9A+Q$E5(Q8KGJBZ^YBIEZB=BETHF([7
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MP"3>#EU%<X\)*/>G'Y0*F!@SP6;&COJG5G!@_OTW!^&[?TE,%% 'V;9<EX"
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MF"A _<,M3=IX:UMJZY.40 "3$I%&QV#C@>GS<[MK!_5%\I#8HCSS[)O,6&-
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M-9H*%+!7^JB(9^JC+QQDY!AE)3I)GGWAIKH(!V#W\=78'9^'HSQ\FGH'_$X
M.7> <^\,AC0->!'OU^Z-WBX6->P2C>8>(":VTIA.NV59(F:9?1=37GDKC,MX
M,@B9\HTCSE2(03F-@!,!X56(K39\@S8/WIGFXFVK*.C"R;=9:,CIF;6N)(6(
MFYKP!%E'O%4Y!Z "8B8AQ'LG#MXQG92"GW;F(D&L+#?9Z6KET"I#%6V3M5LK
M;6"B1/TF,]-UJ)*=*9FFAE2[@P%==QUM94)XK&K3"\O0:^ZFY**C4)&SLZO7
M@O$W)6E2!((F69LO&DV*8D^(,F*YS-20:1D*=&.;##,K)'(3.Y^U43TPLC$Q
MTU%O9@DO<TBP9)QI+-C1Y9'P#R!5/R91$H@$-8K%\/:?&#;EM5*[&S-,>VZ$
M?[:04I.2(S52DK= +Q48HI%+E?' 3*1J1 4,D<[IBT>2,0C!)G?0,P-?EFYY
MJO(L&,@HWDY+J^.'F2P_PGX7%.7?Q %!C^A,3=?1@1:4!.*:/;5/OV,7#L8R
M9@YEA*.)!5-"/=Q=GBI9:N/XXYCE,5Z5Z+#I$3=8D 1X&0IDM,1E_AK15JY"
M3&WEOK+MF8;;#6Z0#X==ZG=U.DXIUY4G7'E68E)[S[X\:&(F15I)6RVP=^M<
MK$1TY*6*:W4JLHR11?NI:'@(]SN=9;$2C6AS)I0P D$=*R20'Z6!C%?E59D4
M?2<6R8,6<ZC7K"U/.UQ:UP#A.<"O*/IBD$FS7>+BF\N<K0SY2/*Q\4Q2=8J"
M4HN8BJN6DF=DUFWTG+STC1J)!M8R!N"-#1DPE)Z[E021=RKUF!@D/AZI57.A
M'"8 Y-.-94*U3F%4?V%A-3-IM,2T0%[5HD\Q/HP<9%K35CNAH9AT>(%?8R8E
M]Z0,( 4Y1$Q/\[-@1]&"F,'I')@^Z(!S'U=@<,#*52)<*N*I8KXI&(WNAO9>
M*K=-I)MRY\]KAH^WFFJ?)_8<II!&.DTV$I()@)622IPZ>$I&%KE?1CW#>F.&
M;J?W*VQJ2$@.XS*8D:9'19K==8,LE-6%&MO!3CD1/(%!'VDPR&7=WDJ6W:P[
M6*L4X\B5;32?MPE 4VR2U1MTRIMV%B^WZ415K)#.6<D[-%@1@=,14$I SQ_$
MS>KS-3<!465?*:G6[S.41[0J@X$QHFG57,QN@-'A;DHWCCEBJ]UA*F8E$[5G
MX8"8*CMM+V3<-S3++,QU0JVS4CO0P=*B^&RRE?B"?Q(+7<9J$@TK)!O&9'[^
M)3C"G(.% ]@>)&'9Q%(<J1+2*6<S".[^SI:,L,XJO'P\='[AEOGV!E[!,+1+
MLI(]G)GDE/=' BF/AGZ8=W]E(:.+8GUF91D?9]PMLZA-@>FA.EN+V4@+9<H2
M>A86HFK#X95^_02CXP6AO>SE]G,C7)]&.)*QIP3<_"IF$M$4XZRBIXL58*[+
MSL!-1HB7!';%XJF8,X,(@(!QK]S\/1]T![N!^7N$,<\\@X^?'=^&G$'4*O /
MYZT622:14+"QA >R$O(R72$;'1B1<G,JL8P% N<F$=,\N'NVVTC^'LOFF*06
M^Z&]238[QGM+)%624/0MF%5DG#$U@AP.HG*6=/K$5"=$<8@ *IGLM+OGLK)2
M+DSM_(R;I1^^>NUAZE%GC]P85EE51R(F,81'M[_OND>89Q\HB(]G9Z^#8U!3
M&1'^MQZ.\/O\".!]0]PYSV:\2;&%=-9VAV9-)K?=K;.V3G-O;_&D,HN9A8H!
M8O094G5A&01%.2CQ'**I3!K&>:/8A-X?:B<DCPVX&W<F[-)6786^"8C5I4YJ
M8PW5L=&L2*8K5^Q%(F$B *,5@!^S6$>E93!#?F@Z<\AR<,EU#4 '7Y/Z-13)
MB)4]R?-^H_D9E\"AA?P?EXVWG#0T-"^VGUH?QE;D13]94"B)#1T"TR  IQU#
MS'3L[ P'H^Y1ML*\LDWF+Y:(.J-'+KQ?<6 3,DBW4E)/PQS\+AB&%VO@!$$T
MQ'7 </=M-LK!'[DUT]'KNYU7W0D58':ZH3&U]MA8B7C+G8I2[V%M 4F*0/-A
M'/?B4F4"2A199%02@;<%X\KE>C8O:Y*N'M\U+[H;80D F-QA):ST\]5L4Q<6
M4'>QM,)"N5XK[/J2@29.@6GB>\MNO9FM;KUU:OTJ_;M[8[=W%2MW*AS5YI!=
MR9*,!FRM=4AYBRV';2?FH18YHXMCC& &4$.HA@*(<)L9^C)7&OS4!NZ^A%]N
M]Y-H)!(I]KZ?(7"PFF;?"*[@U^#E]OH8C:3F(%\5A+*Q_P"U2^Z*.DU 1OEM
MJ[*/KYR5=1^1I;:3.V&K!<H<\]3R[@4R"L4S=]M?M3%$\2-+8(Z-]]*(=.1#
M'$CN$W<4VG4&/K=SN7VBNEH9L)"4KVW48=:V2-7H,&2P[L7&$8+A[HK(1M=?
MQ;!?J!X[;%2=&)5ZQMK7;!9ZY>Y;:C;ZFR$G,59S+.-T]PMJ-K]QI*KRQ/"@
M"0ICJ;B8COB*<>042C^VCG9O#%7W"7J48-<:Q9IL6K6[T!Y;3UE.U&IOVN)0
M(RR*WY_23V/J9A/)QIHDYQ##H2XXJ]9W@@W$!4IA:X15B>4R[;=V2QU&VPFV
MMON<14+U&0\U9EMMK>=6L'*:,L+*-D3$(Z#I R9N@S".IYWSQ/;:J[M$!M+U
MA9NYHEREH6!J<G&O1G!1F'5AF;.QCT8Y#KE#2BWN7N@+$,0LW 7>A!9'+?;_
M '-M#8NW^]6S[YC"'VW8'/9).>L\*KN+ KA0?#$\O7>N/F.CI*!V@B!^(]3<
M.#AXPTJ_DX4&T;=:);GL3/PA6JLO6;?&4VP6&3IEJ:)2*8FCI<D?(% P_D_9
M-TZYSZ>?W+QY0;&)%ZSO^P4-0S.UC>%4O,)58YQ);76F-,<BJ;8;$Y2-6I42
ME*)XJ5/DP"F3A1)PD=%9!;P%T5 P8IL 7 YUR _/SX_3^CC7/I'.FOTAC''R
M8^\HY&%?DIS<&$JFX\$B[1FPA(JJ%OKR?BURRT:K3WBMM.O7IHZC%1E*L0;*
M*:ADG2:[M[M19"8J=YM<#=7D3!VIE6IQC.UB,LD5$*)6%6EV- (M-&S/ >-0
MCB@H;HZ1(8F>)F7?U$QK).)7(LC(-+ #2!00NMZC+:4T;"FA3.$0BSMG#$H"
M_.42+ (X$@@;<%FR:7VMM[9<MP+?7F%*W8EZE&-)&^ @$@RN3%A B-X0@$FJ
M1&/2>+..3E,8Y3] 2EK;5ZTQKV1VYI&WR#ZD;AGI=DB?L' 4J&;R<=:"U^;,
M$?-)U ??V(,P,+-ST>]8]LSN24V^D$)IU)[R2 NBW9%Q&$4WHI(5ZRE1C1IH
M..B*FA%ZRR^]AAAF/4< >\;</F,"^BG-*J$Q6;1-0EP<PMKLRTE78RH-[!$6
M8D6=6IR4+2:]%Q\<D4D@DF9H<YB*>\G(-6L=:K>Z%]FF[N)3J]:4O=RO6YTK
M'50RDTM[O;HE!&<)/)$2<.P5C8Y@Q8&)XI&F .!F<#.U>1VVB(FYU!Q,O[ ]
M([L[1_13;C+N0W#4JNU\&WF;#(R]O%D+[[-F6BHUF5,T>_.!NJ4B-OGQ+.VE
MR4I=ZZ9+,H^L0H4=[-/6T?5XEELUL01"+EB315#@%?CC%D4U#]3L775Q;F!Z
MG;&K&UR4O,/()IND0M02F%[LC=H2P%J)Z89 ;(VDFC9E(NQ']](TIDR%9F-X
M@6]E$4U[%(6JM3-9;^_6AO+.(MO+;MP.ZI5SG3J4&:2603@2QH^(!04*85?8
MT3XLC>TVA&H3<J_FEE8AL:4?6B*9O:=4J\H>KO'>P]YACEGUX50 2:V2F+*H
M![E)/G1!(]*83!@RP!TAD!QT#@VO(<@/;C[NG,,9Y=H#R#BJL#[2/94J-<L]
M,NTC.[DA-6!]3;EM+.[,SM5VZM<O1U[%1H96%G#R)223VS%))M&(!^T&96)I
M-A9]L;2#6O6;RVLZ'MPUW4,TG9"+V?J>],:ZM,MN$EM2M"^$I+6]H628%CHS
MQ ?":/%H!#XJGF(7V;N[RY;A[9[R;8/]WG*-IAMDH&P;U;H>8&4N%5BHF6H_
MP2USY:);GX1 L[,*46;JZFCHT>8!WFG4(F_P$#O!<X&_.HW:;>N6VON$5.5H
M)GX5#N[ZQKD^,U3';6;>?$6 QB9SF]U,F[:"E[46VEMNYR>M+6VP=O/-V'>6
MRS3*'^!WUSN,X6VVF)>#6W?H5PF%GITCR/VWD2 5T[4*S]\=B<CJJVC9"<DM
MORN*G8U0;;GU6 W-G]P*=)W0(BTVZ^5_9&"@+4W- [@O(LS4M98R L&C,/B
M>ZY-2=R+#4GZ4M6'&Z#R:^QE\E:7(RBN[%PNUODSU>3)$3I*Z,(:ZJM"IR))
MEC)II%+(LWJ)U&HRUTAZLC2HZ095U@C MG$4^=G5A8**AEI>7DX* JL%*6"P
M'BOB$H[9Q,8FM)/%# U( X'UZ?=_3[>SG\WWF?P_4X_#3TZ\;L>:19LF7<1%
MRCLEL0HH8XJ0VXENC59*[;A0ZZ2@IA+[:[>*!X9A*(HRD\Q-CJ#A59=?Q5E!
M)XBGAID\7I*4"B)03 I.@I0#3GC[T:O.W5KMG28BJV*ZWS<A_#DFX^EU& CS
MF-+.H@9FO*RQ7$Z=G&D*DJ0WOKTGUL:[JT^'B*HLKL]N(3;"XR]@W*VVVYA&
MMLD).=804>A);E6ZJIN0LIZJ\&/ O4*PIB&AAP-?NLO%P;DBN^[?8Z2VR3W1
MVUJ6ZLA;VT]$04G!1<7/2SF8B)=66>E8_E8M]\-#]\%43,!ZQI>SGBN*6>Z[
MLP6VXK2 L+1(U09JU-ZJ)Y+W):N1D\ZKXJB*G1\.*^4*(E A3%Q50VWWIN+R
MIO=Z'>Q]TG+GLY7JS-5^=)4+5=R2]5K=<WPW"1O$0,/3WI5/WQC#D4%L'M>\
MATQN\&TVX4WN!M^ZNBFWUE:W*BQ>VMWJ-Q-#FGH@DE6(6^[E0BU?LD*@\&+?
MIR@F.HP=D.U;BF7JW/M<MN] U"=J%*W"MM3V];1!+7;K>?;:E+7:54DREF(
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M+WO82S5WRU69SM3.V^&W*I\+0!VTVQ0KVW5AIU]9R*AY(8V33F8N9=1[UET
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M[.-!U'TZ!R]8<?A\_'S]_P#BXXKUQKKH6$]5IJ/GH9X4 $4)*)<D=ME0 2B
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M=!SB) %0H 7WKK!.@R<O%V.3<UF%GY*0ARJHL6#B0=R:)(YL*Y2J+F+[@.3
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M/4?EV8[]<=V0SZL\#@!P(8YCW '+JP.@>C@ [N[M]&,C]/':'R:CD-.\->-
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M_J.WOY<^/K8'.GLB/&2]G;IW#\O'M8#/J'L#NSP"K@OCG'/4GU'2[, '6F4
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M /T+QKLQY2_^*ML&& T#LHG=Q_(OY2N6,_[U78/MR(_]HO;^+@1+L[Y2M?\
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M:G9%],2SU=0"E\22E)-0R[A0>D/:,(B/:.G]'OS>?\EV?(/'U/\ +!P/Y/\
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M=0CG7.O(2ESIQ)[<S'NL'<X=%Q8-K+FHQ.,A6KM% 5*&;*8, !62E)\)G#B
MBFJ4#AJ4.+3L+NXU<U_??8U^-5MT9,+"6<DX&/7+!>.58JA$2S=92(=A)A@
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M/**@X$L=$0S=O"Q292AH1,A"AV!SSJ3OSK^+MQP(]!ATY9'L'4<AZ/T#'?Z
MSIW<?-IC&?GQV<9[![<\_2'H^]W-TY;*[E#_ /8537NX$ YAZNX1[^6G#B[3
M4[*1[$)EY ,T(.KHV(Q)-O'IR8+6%9>?KX0\6JFH4"*D!^<1*?\ )^SJWO4=
M8D4ZA\&DS3\JXC"^-#6./538_8\&II$3/I25^)ME61P,F!DE>O0$U.EJ)[*5
M6,>;=$OC9\WA3G3!P:"@IQ2 #HE!R*(SK=,78CTCH/3KCBKUY66N*9[/)P,:
MUGWVW@,:>L:<8MGQ#PMC&WJHSA"@Y 2B!$@,F FR'9$/*O9UWL9*2]GBG#B9
MA"1;Z,+5(M"=F9)6+BINPKN8E""7!4QR=0@)3%P.-8^)@+V^<GG2KM8I69JK
M>#?_ !IJ*)&+*7;FLLM Q,3+@8X>^E?OA3$/;:E#B-BY)R+B;=1K)].1((G2
M-7G+U(CMA&+.C%*3XE\,4(90H!A,V0U$-/Z2\^G3_%]?'X?1GNX'///Z!_7<
M^0=V,Z\].!R7T:F#Y._]+B[VZG[7T>Y3UY@(VKN9*UK3+=[#UA.0/-O8R(6@
MW"*B?VE<D9G4,.1 S%M@0* @-(WMW\\L,)4D/+);3KT.Z-=P+!-,+O-J1+8A
M:,K72[;K+DK=530B9$0-,DS+BU$O4521RMYIM]U7\KY=MJ]Q3;;>4&@,8M2Q
MCOOYA8.;D(26W&@H"KN5TY^=+,K?"Z7U',4?VW(9C1=F$V[-9@I+S!^7V"V=
MAGSK[)[?[,[>[PVB7EJ3+FA[I,[X%?3D^6CPE4G2_#PBTS1J)4S !I$#![52
M8;G[?O=LK5.6<=O65OAUV,YL7;=S#10S*%-B+K$S%F4KDZM7D6<D2*ELB'AB
M,7)I#[/ 8'/3C(=(YR 9[>>>_/&W>[VQUU8P?FHC7@M-S:E!)"Z9/:BE#-/L
MZZW$=F,F5M:2HBI$JQJH'D96'\-18 ' BI9-Q[*_G'8F= PC57(I140S.<5#
M1D.P*'1$M2'#)"%P4/3G/%=M05NNV8M?E&4DK6K='$GZG/MVQDU%8J<B%BD3
M=0\N3)%$QZ1$I]!*.!XWFW%V(J]0I+=KL<.WECJ,.=)Q);:R$G86<C*[8/I)
MR@C.?#F<O<'+J- Q4V)RO 5(0J:@AP(FTTY::!]SEQYEF.Y[.K#4]DKYM[OV
MVG[:UBE8^E22]3N<6>]1SY\@HE RU>9TE7]\FARO2$,8!,4/R2TLZV0VOINT
M>T=6]Z@-NX.O5]O%S<[7V#Y4[6U7V021D9>8MUC%8I@*]=G^&)%!ID1*=12)
MME+GI6L62!=C(PT]#OQCY>,> 4R0F82"9B'+DAQ 0S@2B(:Y'.S4YY\-P6Z]
M%V[AU&->1<,/<*;)W$4EDH=_=(Z'%*%@F\^J0H2\H1%, *T; (%( CPH@^$5
M'!@('6 =(  (";ZJ *$#!% [>SOXAZ)M/3G&X6]5Z92GP>J,UUF(U>L@M8:Z
MIN3-34S _9FOP-6L ,8W]]^D/V]KCB3FE=[=L%+7)1$LD%"DZ5;S4B --Q4,
M(14)<QW!/9% *E A)0KX(R7 3O<#']H?Q^;45PD5YJO+;,R%&?UJ MK"Q4G<
MZ'(^)/3^T!IFMJMJW9("U0;,0AL*?%XB7^J(CTF+M;Y@V%";[PRFW#1'=7:N
ML+SJ=<D+5(P\<J>R;/7*2) 7@O5]O6814S'#' 49:/#I.$:83<7G:U]Y9]N&
M-:N$.[@9YE9K1<+/((FR4[-VFJD2L))3%>.8?!/X.0Y' V!$57+@?'24\/Q0
MPHGX?0/AD_-@!CB80[ #E\O <OQ^G@/1W\]?DR/'I[ R!0$VH8#!L?LNS] #
MY> T[1[OD^G@N P&H_/\H_>[F?\ PE=R_P#^"*\9'ZVG<.H!CNQR'A"24KLB
M^L$4_1D8N08V92)8JB@H0XL;)$*0<S\9BS &.A!:..('$#'-IB:I!(I 0F[9
M&6M61(N=N=NK#QLK&D9E9])4O"$LPH., (=F@<69NM7"O8ZQTR-JQ(Q[-FZ8
M=[$UDE6;3T:I\- 1,1 G4#;'3C)1$0U"$W"3I4RE:(F3KC];Q+JW4A'0P3-H
MT(1.,)5$9='Q#QI1$PR1S 4<:"(&XKDA+H/YN6KQ[&T7DI>QR;]::KMB 0<5
M^0.IE045 <."F<%,"A@6U^J7%$KC* FDHVASKV8CQL5Q-9S^ ]/!=<2W31A:
M^6,B"_ P$"$SJJ.!#'$_:5&OPIQ8)9Y)> #@[\K8SXYE' >\'U5ZQ.(>UJ&>
M>F?Z3 SC4?G[.>==>.[OY9T](@/8/Z#W=N?3V?BX[^SF :AGT=H\53:ZI-BJ
MV.^V2)K\>4P*]#8TFJF 24D**9C%AX,I!>JG ,$2*8XYZ=-A_('LJHYBG6]9
M9&DV"T1Q2C8:QM#"PKZ6WQW##"@MX2=L:4J,<4LD4B8RDU[ A[F''E4V_P!B
M&!:]>8#S$[8U?8,L6^C&+*&E(2I74A#30V.OI%%0T2=(3&'(#,B81P'&PK?R
MG;@;4;=6RM;@W[_?JUG<EE"/MTS21KG9 E7&Z V"L6RQ_%D*VF^"9^(C%3'2
M^9  "&.D+;M.,6KY8A\R'ES96Q7;MQ"1FW,UO>.V4D2 &FA""C7)R[UFP%.>
MX8E/:,81D_K9X>;*;1.@?>8*S1172CT4BN66U=;G 36%])"<I@5M)"" PHA[
M(%$LGGK5( OY^=E7\O.2SL\C)RLH[=O9)^_4.8YY%9\J)E5E5#&$>HQA$/D#
M[M[HU:M4U%53=")C(>_U]%Z8(:S,8>383$,G(QYB"4RT1)L,E4#VP*(D 0(8
MP&^[::%"V66C*C>'->D+A L'XL6%B=5$TL>JFEBA@9$D(M-.CD)CHZS@/UBE
M$,C]S">0P :X[<"(Z:<0GE>\Q-B%.D'$(G;N^3\@Y4"BE6<G<$J\W*E*D5&K
MK]) )(F,)H;.#?O=GW'S 6K:F0>1=OL?E=C6VW5@BJ^V82@&VTO%7EKNI#RZ
MTXH6]SW\6VY4C)&DHZ)B/@Y6.2E*##J&3A/,?!S6^%8\OVYU#O%F"5A4;<]>
M;;7>)W I=@4N$"@B4MY^RL].Q]D($H65'#%Z(X*)@X;--J+7M]8H)@ J)-J)
M)UUO'Q &4(!QG(&O")X$2J !,F'.2\1M#;+A$;5><Q[<;-2&39D@O%T;S*UR
M*9O[5" BL\:(P4!OO7J\!2= :2[,I0+H(\,-ZJA%"PI&]0/GLV#<2C'LMSHY
M54)L Z4B$3&RQADY'43'4D3/AT*4 X()1P<F<:9^L(Y#70,EX$ ''+33OSW9
M'(\%,4>S30==!#F(::<>T/4//0, &O/3U<!U&R 9P&.8]O+@P%Y#C.@=GK =
M. Z<Y#.H:YR'</9C@1-J.GXO5P4!P)2YP'+.<9Y=O!@+H XSV\LXYAZ1X 0Y
MZZ_K>@.,&'(CTARQH'9@-.6.  QL\].D SKG&>88X$"FP&FF,X'Y=1UX#I'4
M,XT$>?KX$3#J.->S3U!C7@ $= SC0 Y^H.!,F/LCS ,AZ '(ZZ"/&YY3#@"[
M([F^'@>:IH-4$RZ8QD3>D._@>H<B.,\^S@.LV0UQI\^H:]@<& !P!L9T[AR'
MS< )=!#.O/Z/5P(F'(CC7E\X>K@.H<@&<8P'/GRX,!1P \PT[^_GP @.!UUY
MY[.W0.!$VHZ:\ODQH'(.  PYQR# !^+'])7X=X>D>.S.1Q]';G]!_4R ^GY^
M/5J'S\O5QN)YDY]H4[&G-U*+1UQ;D4!*R2<1\5M\LF(]*B*\#7A:,1$, =*:
M<?U(\;S>=V7DWLB._<LM2-E&ZY; *U2\OM+L%E@*A\)A1.J:$4W4M!26,(@W
ML];QH8HCX@B/V(W)KC:QPK>9BIB%R^GHR2@+3 B/P.9A9RMYM,!8SB&!+#@)
M1SQ9[#M[M_->;&!W5C)-DG,[E;ZR&U5EVIMTM+DE)J[SLQ"N2I[NT$+ 89,&
M*89,'U@ P9$F]-PM\SNWO% 2!)G:VMWN35K^V*^]TY'D@U)VE[6P)W$#$IH5
MIQU =03'4AX\N/AIS$ -L+\??**W'W%W"W26=>9S:=P]:P&[-)IZ]G.$MN-7
M'-@>M2;AU8\&5L:15CR9C%GQ$R]9A-X>XFRMX H3M!L#B'3>HM/<&=BBE" O
M!6>-3$ZH$CK!!*-7I2&.)B YZ1]H#?=]WB63V4<#H#>,8/7BF=<ATD3$V-.'
MD.G5;(>3CVXNWD;\$D?BC5J4?:54C_"\<I?:SJ&/3PHV<$5052R D<(F0-D,
M:=)AR&0'C _>),F+==T\6."+=LV1\1PX,<##TE+D<FQZ^-D+]YA]T3;#TIUM
M$K,;T6>2;P]TL!-[9F1E9**VEVSH<%++SU@G(:KJHDD54R&C624:Z?E=B43>
M$7;&]3"L+YE_+\W16VIW48?"$;<\ICJ*=P,$R&<23;6$WV3&0/\ O:B/AS'2
MT"0,($R*T5M_Y6MI=SBV*1*#^8VZ6BMBKK*G&U_"*])W?Q(FR5PR5KA@%^ 1
M/P@" ^$?VD(](V7>??F/HNS=KME4K%*JM%1MD$Z?U2CP"T[/%B;E,K+5(+%/
MJ6!,F!Z@-^T?:# %S88YY>VU,M[5]7K]LE:2)F&7A-S**J,_1I2$G6HE=5\Q
M[2:/+D#  #( (XQQ,+V*&9QVX2]&-<5(Q-DI%JU#?:D0R4I/PJ:;DZQVXKS2
MCPH 8W4$-.AD=<\%F[-3+'#0IG8L4Y63C%FK SX $?!*=4I2"H %$,9[/DX1
MGX*F6"2B7QG";.09Q3E=BY$ARQZP)*D+TF,4^ 'MR;A:*K4#(S+YHW.Z=MHM
MFHX4;$R'MF(D F H&P ]@9X8UJ9K\I&S4N5BZBXUXT40?OO?G@L8\2)G)UB5
M4_4!-/:'ESX"<GJ;88F+25%LJ^D8QPV9@NH/21(5E2] ''.0#GIPC/5^EV.7
MB7YU2,G\;$NW+-P=)[\-6(DJD7I$2.  HAV"(!PZAJ[7968DXU,Z\BPC62KI
M\T3*J1EE1-,OB%*"YR$''[(W"$)88.4A91^V;.H^/D6:K9X[:O'!F2:B:2@=
M8D44*<I<AJ)1 . G9^G6&'BDU1;*OY&+<-FGCJ#TD2\90HD PCJ <].$9ZOT
MNQR\4^,H5G(1L2Y<M'!TGH1RQ$E4B 43%<8((=@B <.82O5V5F)2-3.O(L8Y
MDJY>M4RK$9"*B21?$* +G(4=-##CAO#6&NRL/)2:1%X]C),E6SURF98[/*:2
MI?$.4ZY#E#L$Q> G)^GV"'B4CBT7?246X09 H?0J8G4+T@80 1QSTX&<@*=8
MIF*6.#5!]&Q;EPR%0FAR HF7I$Y0P(Z9UX<PU=@I28DF"#IR_CXYFHY>-FR;
MM-DH95-,!/T$65(4>P!. <-H2PUR5AY.23(O',))DJU>NB&6.SRFDH'B" K$
M.4,AJ8.%9^P4NQQ$2Q,D5Y(244Z;LVYE'@QJ)5E%2"4#'<Y( =HE$.!G*_3;
M!,QBJP-D7D;&.'3;QD_9.EXR),"< #J$!#(!STUXW*JDS4$I.9;5N3< I\/.
M[FVB"*Q(NPP:9,]*?Q8BJ1/$P)T<&Z?KCEVC8ZHYJ;F=4&8C8,[)6,;-F+]V
MHHD$8@KU"#0H@*:8ZATEQV!PK/3],L43%,3)D=OY&*<MVC<ZKX8U(JJJA1(4
MQG.2  \S!C@9V IMAEXM14&Z3V.BW#EH*R8X.F"R10()@YB ZX'AY6H:NRLG
M-Q)'J\I$,FBR[]D#%T#)Z*B*8=8 @L(%4T]DPX'EPW8V:O2T,YDDTW<:A)LE
M&IW2/7TF42*J&3D$^0[<X]/"L_8*78XB)9&3*[D9&)=-F;<ZCT8U(BJJA!+D
MSG) #M$!#A:;K=0L$W%^]%9B]C(URZ9D>  =2'BI%Z 4Q@>D<#@0X6J\1 R4
MA/,_?_?(EHT6<R#;X:"AGW6BF '#W?PQZ_ZG YX;L++7I:&<R21'4<WDF:C4
M[M'JZ142!4,F()LAG7.,8X/.S=(L\;%,CF(\?O89VBS;G.(%*55=0OAIB(#G
M7&G'5@>G.,XT^?\ HP*M-V]O-I3*.#*UJK3<\0OH$T1&K@ _+QKL=O!H&O\
MM97+0/3^\O'\AV\'/3_:RN6O_P!A>/Y#MW\]W\65R[?_ '2^CC^0_=_N_DRN
M(_\ VEX_D.W@[_Y,KE_L+KQ_(=O!IGEME<N7?_ O'\A^[_/&FV5RYXU#2%[.
M/Y#MX,__  LKEWX_["CW<8_B/W?SGE_%E<N>O+]Y>/Y#MW\Z?^3*Y#SY?]9>
MW@!_B.W?[/\ R9W+'=_V%P.O'\AV\'^YE<O1_P"X7T_-PJ^D=FMUF#)']T.W
M>WEL9M$M<!XBRL,1$G/M'A1!=)1%9(1*JDJF)3D,',HE' @/S?<#CU8SR^CE
MKW<=GXNWN_0= YB(<PSKKVB/;GC3/JYXYYU$.8_BXA*O5FQD]P-SJ5"PCA$[
M#JE7=O\ , T5)=!: @4#FGZQ6)I]'Q:GM&#W!J;VA# TK92PU>X^6YO4:O7Z
MA (715S-TN,^SL4M P<0XO%<9IVA<#$P<QI"(C"  ZF# \&L&W5UI]X@$\@>
M4J5EB+)&$'7V#EKY"#V\N>./J!C(\A)C(8$W[''9Q,;?UBPGE=KMD%I6LP(-
M1.6,?W*6.V<[ASB:9B@4JBMC(:/ZN0IQY.$:[M:7:T];*H[56C9[;"K*R#X1
M$S[KFKC7&=8NLVL3J$"F6DU!*7 !@ * 4.8W$V?KE4WMH1EX93<6B3CR/KEI
MH+X[A8U6EJE-HV">+)5^<4!]%N_C!TB>]O %G[8&XF+5;+K#U2!@G!6PQQ#I
MO;?./EQ*8L?6:T8R?CX V3J*&(FF',>Y_8E+K'[C7>ZUMC8Z%;E8!@O$T821
M!SJ@X@9I:U5RR&/.G*F(B)3 !=!#.F^U8VXG5F-Z4C;HM,*QK^H21+G;V$&M
M=X2$7D9NJQS")N=2@9\IHD:](46)EC9]^3!BS W&T%EK\#/O-R)91E,;@QRY
M%9VUS\=57*T-9J=NE6[L^=1.W3F:N,6X^'^Y/Y:3C8YJ)R=*;QFZ=[L[W;E5
MJO6:*V8;L:_MQM%]D-N6UHL<'N %PD!2E5Z'4-OS7.8@"U8S.&*9@S LI+-A
M Y3=77Y;HW:K;*5HKSS&;>QMR?;(1,<WK^Y52>N@^'@^E_C\Z%!@X7XI%R9A
M+B*+%_#WHR IL@9NN*FA,$96F*O@//LG+59:/L+-Z](<4PA7$A49:R5H+#@<
M^XQ\K)Z?LA 0ST@!R*<M0SU#Z, (XUXU-KWXXK.\-WVP2W=0H1UY^M5!W: J
ML4I>6 D4J\S)21(.QC(Q]>D@%X5H4F':S=/)L%Z#/ZR?^)^FU>0*+1]#0FV4
M):"23(^AD'J.Z"VXK)4IRAKTIE !Y<4;>F%$I%JI/)R#Y(3&;,I*-,@NWE(9
M8K=-10R%ACUC)' "@.#CV9$*QN5$$C*5MRX9J6>KMC]%LM6YD58D3DA9HX*&
M]VJ4"U2_?,H= BIU#D0$-9B^6NNUD[UV87LO9;(++(")C?5+8@ @G-TXP'!(
M1Y='&[=J!,3)U[:AM#S<2U$"$3Q,WU #5E0WAJD-[)9H-,9SQYJ:LO0;/ME#
M[D6J-\R>VM>L"4E+_%6<PK7*+NG*Q4Z-<JQC@I8&T)(D' $  =E#.!XW9KL:
MA[O7[++!N'64B- CV"$9>R?&GL;%)%_)C#UJ;6>Q:9@P&&(AV#P/X<L\:#GY
M/6'=Q@,^@,Z8 ,@&N=!_0?E^81QKGMY<"83])AY^R!LXT# 8[N#&4<^$(@&1
M\$5,Z'#."]V,=G/@4MNMK[]N"J4<'2IE3L5G4(/<8D)&NC%UX'P_*OYANWEL
MSN$;'_\ +H\M>/YM6^?^Y9=1]'_8;@,>6K?+T?[5ET[NS]Y@QQKY:M\^6G^U
M;=?Q?!AXT\M.^8Z9_DLNN<?W&'&1[N QY:M]-/\ [EEU' _W%]/'\VG?/M_\
MEMUY:9Y0W9Q_-IWSY?\ P++KR[_X&[N!_P"#5OE_N673N_\ K-Q_-JWR'_XE
MMUU' ?\ N&SKP'_!JWS#_P");=>S/_N&X_FU;[_[E-V^3_K*(=OIX4D9S8#>
M2$C$_P ^^E]N[=&L$^GM5<.8I) H:=HAQ\!,5I(P:#P7 U*V1D?/P)'XX(JH
M:*E4EB,EQZL&.3H/IJ..)*/2G(:$FCE]Z@89^*C1I/+F,H4(>/DU1.DPDS%,
M LP>G(13ZOB 80ZG49+,G$=),')VKQBZ0%J[:.DQZ5454CE*=,Y3!R,''I[]
M [!]0?T34@X K%JU8,59FQV*;<@PKM2KT>43R$]898Q#)14.U*;)CB Y'
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MN@V>-&C9J/P]DQ9,BC\,'V0R.@"8 Q]/ ",OV&T]P+H..?U@R. [ XSXX@&
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MA(["P5MG_,)M?28J<WOVEB]RF\LSFZO<Q/0(<9/:W<XD+)V%]'-1(8I8L@F
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M$ 2&*(;TOHJ-E)BQV^@>5:40C(ULL]D)B2LK[8BX+?"8I IW$P ]8B D Q@
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MS>'XLVCF=MW L<CM#8X!I%Q+]@=*-M$\FWK<+#P4-+IQ1P]^.5%)3PCF 1,
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M!SUR<F)ZVE<PIY),I39-!)03MZ0/V1DPR(!KQACY-_+JV6[UZE&O@]0E&&3
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M>/Q]R,6,IUINLC8[CO G)O-JXD(;<PSRVPX1LQ$VC:M] 046GM+)WQE&MW#
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M5N8W0B8JIL8*(#@0I<;%;9O+"RK?E.A*(SD(EYLJ=U7]Y"&$ZJ$S+;T(]$;
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M+HP*/2]0F(<Q#/\ !@ZW=HW D7J;S;[?;88STT0EMA*[Z2%GKM'C:I-4R/\
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M(G;D8.#A! #@8]8>#DPZZYYCGC>>#CV!F32R7;;+:V'9@X%0(][1)ZN/E2F
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MGLTY8UXAO*]O3.MV96+OPMF;?,#AHBJY,D9Q0)R6*HCX3$$T"C$"83FZOWO
M0*+$$1BY O1X/+5(<]?[8#\P4.D! I?V0_)RX !:![(FP;WA4<Y#F @3&H_A
MSX#]K<^>%U=<ZAD0 N=2]_R\9"2#3& %FL&<?((]G'\)".<].&BY0#'+40T$
M #TCP'[Y &FN&:P:B//ZH#J \NSC^$N\1$&:XCSQS 1 0[_5V\:27,<?N-;0
M._0"X#7.._C^$0QR_<BP9QJ C[(CJ8 ].O=QI)<AU$&JN.K'8&@Y'MY\9&3-
MG3/[46Y9 ,ATAW9^?@O[Y:CCDS6[\  >SG3'R\?PCIW^Y+X$1TUTSH <>Q*>
MT8=/V@;I'!1,(>T Y$<<] X#$J(XQH#$X (Y[<"(Y$ X]ZF@ZG1?JA@_:)4L
M?M0H$_-@3LUQWYXDKKN,[*,BN0&](HL=()GG+C8@\?QHZ-53.T53JH+-2EG)
M0 ,M$J'(FD4YS%(;='?S=J9<MF3AS)OY272$P_$+4YCQ3J- JB4DJL84D?";
M) EU*!&0C4QAT(F4W>/R!GV<CZM!_HF @.!#D/#6&WVI[;=%LP;>ZQMR0D0K
M&Z40T 1 0"W-FZOVN,43>P2;1DNG7I$.!/![W6NG%$0\-AN1M:]<I-PR(B!Y
MG;^>MBRW5V8C2<?SIJ!_N<;V]GI_B][PX_G34#'HVXWLU#_<^X_G2[?YT_\
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M)G3C]3OTSW]OZ"J',/8YY >0#^ <,95@J9!XR<-'S9P3 &;/(XY1(8!QH)%
M 0]7&PWG.IM?BY2?HKW;O<%2+*Y4.*->W,KQJ?=*@4Y$A.(C8+8T*;GHS$>P
M.&L53]@D/*U7>HY)2V;I%^QTG&Q@IY!2>B=P'$Q;3%(F4>DT+6&/48=0  '$
M7=/-9YD-W?,;/MS$-(1S0BM(KK\R(=98A5VLZN5J4@1,(AUA*0A@#ZH%SI/5
M39_R];=TEG<*Q-U6SOF$.U7MUAJ-B34@;% 35Y<'-;C5SPIH!,4LR!Q NF>G
M7=?8&9<+OF-1E2.Z=./ Z/M#19V.1FZ5+@/1TG67@%R-50((E+(MU" (=..
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M#FZ)(LE'ED@,I[\4!9LV<=YC]O7QFMAB;M(67W)NS8P4=8HZ9DU3SU4DXR)
MR",+/PZSAF<I"FZ/$ Q.DQ0$-IHC;<_E:J6Z/F$VHDMU:#:?-MMK4):BKMH:
M15B)O;=6^R[IU'TW=*$F&"_A@^B)2(>J,#I"Z:G.U4,_WHL3(RU4VU<D=00(
MBF+*9N9O>B(B<062$L36"I_$%,!D#>[ &@\3%8;CF9@HJ*>NP= <0$)X)TP
M "0 T+"/._/!'->W-<14/^4]\AEZXTG 'V1 I@7=N#K>RX,<XXY]73R .)NR
M,[$P@HRM0$C+S#EU&(2,@M&Q'@'F/VN](*)<-^LH=)OV6=1  XW(\T#I9O&6
M?=AK,^9NTMK8"4S'-*^6,*G4*DE$)&J0+BMM#$,BPIA$ ++S(&#)>)J_,6MN
M3MEQLMEM5Q=66:A)-H^E)Z75ES*QA8:M5KW#J,L(J (&#J^H!0P'!R)5_<SX
M_P#"B^"[/;JP:$^.?#@ QSQ!J&5P:("7UZ/>?$%(,=0&U!<;Q%WJ3D/>"@U"
MKV&!AV96F! Q51EZS9#F5 1TQ[.,<>.,9</L'U%$8PDW$!;/#^'" I_&_LY\
M$\0)<<]?PW'A:=/5KPP&B15UBS 5?XJ6WV"OSY3&T!,8X\16ZUT@ :CUE,.>
M7!DA@MROM1\($I7Y;=6@K_QSW$/;-#C1_BGPOXF #X?O?B>'IUY]KA\-WBKM
M*.A.G\-"J6&"K[8J( /B?$#2U8LQSJ9^J) *'?GGP*XQEM&B]0&^&%FX@MK\
M/X>(>'\;^SHPWB_%=>OX=T^%ITY]KAA]AHJ\Q;HJBGQ,EML%?GFQD/\ ._AY
MXBM5E0JF<9ZP$.X0X\-6O[DC8_A8B#U.WUD(09P&'LF&*4H9G81/Q3&2>]"I
MX.G5G7A\-VB;K*NC')\-+5;#!P#<J( /7[^:6K-E.<PCRZ"E#OSP*R<?;/L-
M[P!@C33$3]K :"SP*0SA:\$-XX2.H'^&]/AZ=.=>&(T6,O$:]!4XRH6NP5R6
M9F;B&"_#31%<K2A3CIGK 0Y\84KVY8V/X7D'A+;5_@8SH, ]HT0I0S./@XR_
M,GO J>%IU9UX>C=HJZRCH3I_#2U6PP< W*CJ"GQ \K6;*<YQ'ZO0!0[\\'69
MQEM"C=13)QCJ;B?M9X?P_I.D><3KH0XJ?%<B!PCNGPO9Z>K7A@-'BKS%NRJG
M"3+;+!7Y]J9  ]CX<:(K594*ID->L!# :#KP"2\#N4-G"). /D[=6BP SGN'
ML'&'/13R81@R.!$GO8G\/(=>?:X>FO<5<943$0",+4[!"0 %, F!3X@I+UFR
M@H42<N@I1SSSP=9I&6T*+U%,G&N9R)&V>'\.P=(\XG70A_$&4R/7\.Z?"TZ<
MZ\-OL1%7F-?BX-[T6US]?F&9FF/9! \36ZZH183<^H.G&> (\K^Y1[$$:<3/
M6MOK*<(::!AE,WPE:B*NBQ0R@!DGO1E 1R'4(X'A\:\Q5PE3"FC\,)4[#"5\
M"G 1\3X@I+5FS H7HY=!2CGGP"[:-MH4<%V1C1BTU%#;/<A9)E?$+.DKY84%
MOB0&$AQC1+X?2 ER B+;[#Q5XC7GO!O>2VNP5^8;&;?L02/$UJNF(L)L9ZLA
MC/HX CNO;E&L(1B@G>MK?620IIH&.4S?"5J(HZ+$C* '407(J ED.H1P/#X;
MS%7&5$2(_"RU2PPD !3@(@I\0/+5FR]91)J D*4<\^$5FD9;0I@+,S.8Y>;B
M3V@&WAD^($1FB5TL0"O5D4SFCQ -,EYY0^PT3>XQZ#D?>2VNQ5Z>:BT#D"2D
M16*T<JW7CF EQG@82!V[I3%^[AS1LM:I)K*66?>F,B8'S]B$T^=P$$HH41P9
MBP253*'YP>8^C_$#N >S^DCYN_O'N]7'Z>>?/\/7P;'?]/Z!\PZ>CEG\!X^?
MECY1]&O%&OBRX(T^6<?8K<<FHM5:7/*))R[[V$U5!&NJD:R12E+U&.R O[+B
M$M]@KT;9/+__ ,H!&LO+=YC(2RF4DZ67<A>/<PFQMKE(:=9VP3IV6$5?TN6(
M!2PI"2:2AL&,.8Y*6\O)IIC%A[K$0$INMOR_K\!'='4>$AJ>&Z)*W7 TTT
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MQTH,A.3'@&KZ2G2G[@ " #TF >\>%WK&6;R+9F]E(9TN"*:(EDH66/!S>42
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M'ZG%.@)M[*0&TU@WHH[;>BQ0+,<Q-,2>QBA)66$"&+\$&?\ :U  ^+ T#41
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M?CEZ]>7R<<M/7QR^GCE](?J\<N.7Z_'+Z>(+<K:^R/:Q;Z\X*=N\9F.+5^Q
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MN-6AJ'7U:U5&<; 5:N(LH<9%W,+^]! 0T.K.3;N3<K*+R,@*\F^$Q0.H8"E
M,AST[0'L^0.S@0 <#C7ZO=D UP'+ABQV)N4^+B1?E,EM^<QIZJ69_(>$10BE
M07,JR/,KI$(F59J4DE@O2FH4<AQ7=F?^4G\KD3$3$E6XJVN$X./A]S(:+&<1
MEPBEY>EVYTK/4>6:MS )Q92TG)@4VH (]/#)UY0_.78MK7BRYR1]!BMT:XLQ
M6.'B=)F^TN_M<M$\ E\10 ",)' (#IC3AHU([\O>[K) @]:]J8VG:B4 ^?9Z
MD*"AN/6P Q5"YQ&Q6.D/9U'";>:\D4?84E!.'QVC^9/;LL;TI' -(>[P=<L
MY#'UA+ZN/*/O:X\IN[=;IFR%EE'UN;(3-)L4DY9/WB*8*PO1<FYIHJ)B 8V3
M%-C.,YU,ZJ'DI\QTRN!Q1(E9[5Y;J6T-Z3F-O_/3B91*;_L<(^OA$1\ONQNS
MC5<3$<FN6]EIW1L#0H"(%,\J])V[KT-U& =0":  [^(^8W^\Z3/:*'-X8N*K
MMR-$V'J<^*9CJ""-CO8VW=LBJH!@WPFSD$  .D"]KR>VKA97?;=M6+58N+Z5
M&6F;"\\,$ "*M^]VYQ5K9+H*D*4"J1Y9=/I+C.@!P]VBW"BB^72NNUI5Q!.-
MJWDH=K?($BQ/!?1VZO6F^E6"0" JI1Y8<<*%"18@<P$ ZSDQU#**"HHHH.3+
M";41$0R.1,.NH\^-0#LTT_& AKQTA\G CW8^7@ $>_ _)W<,FHB4YW3E)%-0
MR3I4H")RD_-1J*L@?JP'LID$PCRX+),MN[JZAE'YXUO.-ZU.#".G9) \2*"+
MQ:/32,K\2(*70(@?Q/8Z>K <,ZK(,#3=DD[%(59"'KD39',X\DXB+@Y<Z43$
MS$# K393(3212^X@K[75V8ZE):%H%W2GMNY!O+3 H4^4>*U5_$@$HV4GHX8M
M0D6*/@@?H>IE+T@/5DH#PM!GVROYK2JT^-KP!*C/FG1CGGMEF!BBQAG)8I0P
M^RIT 01'0<<H=F.VE[%W8??1K[7[*3I7<X$:'5(A#(A' >4%L'YSP@/X?[+'
M#N7>4NQ1T3%6V)I<_(R%?L A!STTF<46TK&Q,8YF4Q2)X0&*"(G*9XU*)>IR
M0!0L!ZC9!KKR4"$86#X))!!O90 ZPB6$L:/!HK+& N03*?Q,?L>&A+C5+)53
M238'<>WLD))0AGC(%>CQH_XFBDHNEXG[(H"'IX0JT;(PR<8R8RL7&OG-,H\C
M8(F/F571Y2.A;=*UUQ:X1-8\N[4,#)^F.70B'3D1XAZ76&?Q"<GW1&4:V <=
M:AR'$,CU  :$USV<2>T6R+XHQ2S4T3N#NBP,9*>W)>&3S*QT5)ZKQ.WRACX!
M@0X%D 3ZE1, @''U!+Z>KJ[O1QJ0#?Y(2\<L=FF<B&OX^WCY^>H!GY,]O'+Y
M-<C\N.-0Y!^'9RXUS\X_1QR_'\O';\@CQ^ED=?H[..79Z?7CY^.7TCIQR#YQ
M_4X^7T\OF]''08W4F(\\"&,%*;L$1')OQ<-++19^1@)5N4Y2.F9^GQVAQ 3L
MGZ:A#HR4:H)/:25*<@XY:!AWO3MW$L*W+1"\>QW?VYB@ (Z"D9DP!%WRIEQU
M)TNR*@":D>(]<1(^P'4D<AN/P[@']/\ HUY</+_$@+6P[^)./-YO2[ I2NY"
M->R=BV^\NE,6, &$8ZJ52$G+(EJ'4>ZZXZ R8W?C'R% .[T?= 0TSW8[.?S\
M:^O\.?W1]./HX# 9'7'9V<#\G&/OR[*7]T9/:KS35J5\NFX"*B@D9,U[^4B>
MV%R7Z<F,&V&\;:!L   ^U\,$O(P\3M6G$#,YBM34I 3K,VIF<I"OU8R01$P:
M"*3I$Q1$-!$/N@=1/QDRJ)"HD)A_+%*.H9  QU '%LV[J;G=R/LLTWK<+2G#
MJCU6G1.V^Q<)/#:&?DX7-4-V'$;N#LY4[6NG*P]B7A(N6!>+:D5C>@Q/A\/4
M_<K89TU\FVX'EZ7%N@T(Q^U]SWWNFZOQ 0^T"*IZX6&G&J*A_:'Q2#AD8OM#
MM4]N3;=Z.DMF5Y*5@4H.M5*?+?IFV^5C838^6-:)64W!KKJJ-J]>=C@D@$A)
M89>,D!2Z8\Q<F@;?(1=J)<(S9OR_4Q1S.; [+;SU^)L6Q=4;5J6A86!W6N3F
ML_!MSO<V:@652)"7J7A88,'H&U5FXQIN4$M&6;SIA#0\I3:NI%3M:\SE(GF%
M8F)B8'<X5(:?@)^29L9..+'RB1XQ,[PDBH<"1X7RX0;?<]>5WLW<L&]UQ83,
M%5FK/:*S/MIMVZ7"T_;>1:WA1:\5YO8=VA\62?!6##%P+( C>H1(38F*8)RY
M'NV6SR- G%9A0JAG,D&Y&YMQ(I#] G$D*2&N+0A -@P'(;3&!'[S=ZX6+;9J
MA)[94AU=;-OE)R:L@TI5>.600:1,9!K1#@8>8=MD7B@2$4)Y(46[H@^S[/"5
M\VYM\1:Z;(;94DL;/0QCNFHJIMGJ3U!P19-%=.715)TJ%.'4 B'9KQU&'7T^
MD,=_=P5E0]Y=TJ:RR(@RJ]^M=?9:AKEE$RS='.,=G",;'[\R[UFW7\=-2Q5:
M@VE]U@.1,>9L=.D)TX:]JVGHX63/N; O/' ,K.]MMNSG;CGFGT5M,/7D!X("
M.]2+?&H>'MOM,8,#@>;NA* /KX7)/^8K=]5!Q[+AE%W>:@(Y?.F#1$"O#,C%
MQ_T+A>0E'SR1?.3"=P]?.57;MP<<>THLN8ZAS>L1^YYF7E9J](\YT=L2C".;
MO3:A9@;J4MQ+%%-M=ZY?6D1-@T^SL2B_?FDH05 !DR>)=8=#HO!Q(44R"/Y,
M@CD0#/(1[=!^]@I=?Q10BIJ*E%@2QUB$>](L/3H; B 8#TCP_*S2LC=I);7V
MVE>[.&C(.E[.;O3VY,4 E&0$?@B,7*M4SZB;Q"#TE.7!AL,_),+&"$ENCNC;
MXM!U4:G8"MXV\55.*A)B5B)B8+7YJ?JLO'$.>+. 14D7/4)1#IXH%@9A:'+>
MLWK;JT3X)U.JU<SIE2*LA5A")AH&;- D(*2*ABLR!&I_ML0ZL9,#^J.$;!\5
M7H\C66KL#@9AX\EO7!;DF.)?B@#X!8N,<CT].?B1@_QX;E/9A"Q>XW"Y!8X!
MS)56L6WX1FM3<'[_ #51G)3[-39R"LS$6)S GTD$ ./24HGECEMI/#W!V$OS
M,K&I5F+!R.VM3+39^,&'B)QM U\2E$SZ*!@42>'U,0]R*('!6P"UMA;#(5*F
MT1Q60B(8U581U2M$%-DMT3+!-E6^-+$KX'&/-%](2+YVH#_!@ S:(8!)@NWW
M2W5N1W,@H"@'A;FWI PI#@8/;E$5X%WXH@.,'#&>P#$UP B/9S H!S_2XW/W
M"(!DK-N7*--GJ:N'M':0";;XUN=*% "FZ14AU6$64<A[$@ZYXT*4 _JL\NP0
M'N]/WD'6?+W6=V=R)67L>W]5I>],%<-K]SME]R7UL'P7IYV,J,37YWR]"DX!
MRHFQGI"RR20-?='Q&0Y5XF'^]M?+/5"R^7GS06[;J33@MW]O2EONRFW;N4 W
MPK<^E[-W0WV6F9>/D,C'K1$F4X)E%X(*IE9;A#4W+SW]/;R06JC6J;E,I2/9
M[ERD3"U!4EKG-M8#:696FYBU1Q3Q<%99.6C??,/6:?N3\S*%VKF/,5L2Y.]6
MW,A9YW3Y'<:9EJI<=MJY\;EJY(PQ]K$IR: !()D)./9/ZU*$8O$F,FH\*4AF
M5Z@%-K)*)K]'W#W!;V"KN]T@M6Z%4I^ZT7MQ+RAH>W0S>#;I5I60*^3\!A#F
M)"@8\@ OP%/B9=0S*)=*QS]&JLFT;5]W)XDM>DZQ!SDQ1EY:F;66"M4F8JZD
MVVBY5_:7]>AR2H.DROW(,GITINHU1TA&R,%%?%G1UZANW>#>%\1;18)_"MG-
MMMS+64 5< 871H\K F,&4*)@ 7%;F[SL_2[K_'5N'Y>:[2;+-W=:=N&[&V;"
MLJS=9A)&K4&S5A)";^U;(L8_DY2-CECF-U*-P$./+C:86Y[1[AS^]\5NJY/M
ME<2[RP$?"AMY#VY:9<2TY78:L*J#6QAN@P-)(I32_NX$!]&B[4" W$LNV-^K
MVWMK5(A5[W,U&R1%1L:JQ5ED20EGD8HD)-F.@P7, ,U#F$"''D40^\KDO* H
MXJLG[Q5[[%D#28HD\B,5;(H?9'\_#+* &NAL<7>A.%A=?9B>>Q+=V Z/6")^
MN,?=&H 5S%F34QGV>K^C416VQNJ-J_E;\C,9#%#JP6/<>2K8": ,B8<F,M*G
M-G^NX,4.08QGTAGO^[OEN8YVIV)W'NU/WAV1ID4KOWOI*;,0,'3[S5]Y)::/
M!*DWS\OT)8+*M-T./)T&?2ZI&HNC^XIE+[P'FF?4';J_;Q;,I[HQ'E\V6MU$
M;W>S5W:RVWJ/L,NCNW-S])7,6=H6V4U!,8HLA*B2*F(R<+(F IR%(7:Y6V;"
M;17*9?[][V4K?*6W+WEM6W=ZI^VVU$/MA,3\EM_5(G?';@MNE*#$2]C?2XQM
M?LIDTVC?K+GV#;)VB4HFR5BVPO.Y^\,1N+NSO!OA*;5;I0.VE3N</$15DH-
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M:O4]N8V'V:2W(:52EK0]AF:M)U_=>3EI2V4ZT$F+D\GYR"5+,'CRB:1(_"/
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M2GT<+BM3QG@LHT4VYP5[^,D:/\='WSX%\6"*\3/[6Z=/O-C=J57"C&*MVX4
M6W30%ZOLQM_"K#/[A7-;ZHA&TZ@Q$A*+"/L@BS,(X#C?K>TS46R>[V[^Y6Y!
M6@@!?<D;M<)JR,VP@ !CP"R $'  'L\=/8;3Y^_MX[-0#':&>[3GG'X#QV:
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M=V!"BLJ^*=13I#J$1YPVZQ$(^\WBJPC2,I,Q?WUEFPI+R&C&L-39R&+&6.!
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MW@IS=;D#0,LLT="S*4$QX3 P:EZLCWB8,ZXTS]Z2'ED=CY"X-J+0[M$6.?W
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M5(,T;U:*<R= VG)N.YH,*JR)6*Y:MRX#;^ N\V5K&0C!,X&D/"-[L  4"@4
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M_]H " $$ 08_ /\ YA#Y<?AGCD/T?J__ )A/U>WCEIZ_3^D'W.6O+37Y]-.
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MZXXT O\ 9#_F![.! P ']2(#G(=HB& P(?+QH4O+( 8X@.>X>DAP#'H$>/;
M U  $!$P"(YTY (#IP& +V9R80]>/8'..$P B8E.<2F$5#@8I03,8!*4$3@8
MPF+C B4,:YSH/(/G'_,\%*8/:-U8Z>HP8+VG,"92DR&/E' <:%*)<<Q.(#GN
MZ>@0Q\O&!YAC/=KRP. SRXRF!##C0#F,F'+3V@(IC^QX$S@B*0AKA-8RQ0U'
M(]9T$!^KCL]'IX 2%*)1SJ93&0T$#$Z2*=0#Z1#C*A0  Y]*G6   "(G,)B)
MCV=F>.I$B:AAY HJ=(N,A^R*BL(>SG]CS^?@>HI<AV%/U9#7M,0@=0_-Z>,A
MP D*42B #[9CD-KC02^$(AIWZ\>V #@ ]HH&P(^DGMF*'RF^3@0* :8YFP/5
MSZ1]@P=.!Y@.>#$-C(%*;J#JP;J$P#@!SC EY9'GP)TT@5(5,YQ*13"QS%+D
MJ:1#$\,QE!TU.0 '@PH@F=3IRF!SBF0QNXQRIK"0OI IO5Q@ SRSD1* !VZX
M'(^K@1Z"B<"Y @''!A#LZQ(&,^K@1( "(")<&$2:E' Z@4W:'<.>!$A$A,&>
MD#*G*!O9]D#&!$XER?F( . [^7&42)G/V HJ9(N,AKUE16$! NOU>>GIX$3$
M*(AG0AQ,)@ .8933#K-W<O3_ ,TB.@AZ_P!;NX_ ?U>/0 #G]+MXU#YM0]6<
M<^.7K#.H?)Z>,"&NO: \L?J\?0'KX^?T<N?/ <<A_ <<^/P]7&/7\GIX_#\.
MS[@ /I^7.G/3OXU]'+OSW:\8SVXY=FN@9SW\:]X8$-._0<X'LX#EJ'/Z>7R\
M=H:ZCZ.X.W ]_&@ZZCC&<@'+NYAQR[,]_+'9KKP&@Z>@>>O?D/EXUP.G;KW:
M8UYB&>!S@ ]7;Z\Y'@=.6 ''RY[!_P 3@.0XQZ!^<.P XR(@.@Z!K^ 8XU'(
MZ /> "&?EY?+]_[1@#(<A$ Y=NNO X$#8QJ @/, '7';@0'U#]PXET,!3" B
M&0 0 <9#MU^YH !J(Z::B.1'UB(\")1 =1*(@(#J0PE,41#M*8! 0[!X[^,F
M,!0#M$0 /E$=.!]KJUSV:!D=- #0,<>R "/8 B)0^< ,(?-QCMYXTSC//'!>
MH0#VO9R(!DPE,& SVX$>-!S^'ZO >UJ.G3D-<!D<!SR &XY9U#'>'8//NX$V
M R(  CC40*(B "/,0 3#\_ AJ&0$,AS#/=Z>$@3!,2"H8' G,<IP1\%7 H]
M:J^/T!J(!T"8<Y /N'#Q4P$HJ";J.7V!'*H]0=08 I1R/+3[@!DPB8QL".38
M$>H_/L*'9\@?>:G HB7ZHB4- R/5@0SIGU<"(!G&-,CRR "/(W(-> $3] %,
M Y]D 'F'2/4 Z#GU\"/5U9'(<M/0& #3Z>/9 !'N$1 /G #?BX#3.O;C3O-\
MG&1SV<@$PZCCD4!'@ILX$WL8R.#8 38QR$0P/R9X''/LUQ].!_%P(?LA*(
M&U$>D1P41%,1'3O ?2'&1'&-1UTY:Y'NX$I3E,;(@( 8!$!* =0"&<@)<AGN
MR'">F<G'7N_)G'/Z7!NKZN!SSY8UY:\ON"(_\]6+_8K*%#Z ^X(%$2F'0#
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M!@'J''5V^R4=.8\(D 0*4Z@D$.0B4$%3 4@@("40$@#IV!P8A@*=,Y1(<A@
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M@E#&@E#J 0*!38 O08G3J <Q ,?)P =9BB0P&]D"Y 1(8,&!0AP !*;M#@P
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MG U_'Q^:[?\ GINSEC\KV<:_C,(>G_/<\8#ESYFU'_1> YY]1!]>?RH:_I<
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M?Z)D>/S!N_'6D.N/2J >CU<#A$?[)'^VCKKQCP#8_P <ACM[ 5[>-$3!ZC(
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M,0% !5LLFFY15 H^T0Y"G*.@@ Z< W7;$<,GS57QF[YJJ *HF\,HH.63MN
M50BH@8BH%-ICI'7I*NSC)%A%M7"<>U:)5Z2;K])G"+,IV\$@R^*-F1'2P@)U
M&R1"I$,O^Y^E8P-@\85#( Y*H#=P+4R8G$@ 5[X7N8K"(9\,%/$Z?:Z>G7@5
M%O$Z0Z^DJ**[E904T5%S%2;MTU5UE?#2,($(4QC8P "(XX22Z5SJ+$$Y")ME
MSX+ICQE 3\)KUB."^*8G4(#CZIL?>2[82S:)H67AX-XN[JMI9,%Y*>>MHZ.)
M#R;N&0CK"U]]=D2<.8]5RV9F$?>%$NDV(UE*&F%7DN#L[%G"UFS69T=!@[C&
M+YXNVK41++,H]DZF6Q5G*Y4T$@5 QC@4!$'-;:.'KJ39',B]4;PLVM#LW(1L
M1,$9.[&G'&KS:17BYUHX2;G=%7625ZDR& I^F1M==HC>#FK//JQTM+5G:.=;
MV2P24[(MI-_+R0PE2^.2D([EI0CE[,J@>,(NH95PY*8#F":L:59B6=V0KQ33
M=^-2EF2RM>Z&"ON#G<=2&1CWR"2+5LH=D$@H=-)$AS)@5,!+$S8(6<K::,)6
M+%6CW9"Q 4BHH*+OZFM7T[3$-$%>D%%G;-!)/Q$Q,8 53$SQ=\K)J(,8E>86
M6BZ]8IU%5!$[!-*/8JP<5(DD[')J2C<K");"K*21E !JW6$!PT?($<IH/6R#
MM$CUD\C7A$G*1%DR.XZ10:R#!R4AP!1%=)-9(^2G*4P" ?H)E%#%(F0ICG.<
MP%(0A0$QC&,80*4I2AD1'0 X55=MS(,5"+-TH]TDGXKA(3JHG=OB>(J4$7B&
M!2;F IR)FRL *F\)#]'(8X>&Y1!3W1ZF1(7;)14O295JHJFJ4AC   8HE,10
MOLG*8HB47#%X3#IL1)4JZ:+DC5XU7%4B2R2RB0-O>2J('*L@110Z/L&-@JJ0
MF_HTZSX1XZJ$1;IA^3,<;/*,O>71SIK,@7;GBJX^;@@J@N*:Y95<BA>I$HA]
MR6G'B;I5I#1C^5=),FZCMXHVCFJKQ=-HT2 573HZ2(@FF7VCGP :CPWMMLK\
MO69-NC)H3U681TY;)5K-P#A^QG(^M,8:#^T-T9"YBG"T:NSC06E(_P -TFW*
M50"EJ1R+6!=:[($=04>UI-V=S)$ FZY77RE@@VU>5F:>$!,VQDC+?%T&(PW4
MJ9][N1LZ,CNW)ULKE:>VUHL]:T362LW.&J$LM'UQ_-,58FS+P;>,N<*BLV3)
M(K0#B1,Q\4J:OAK*)$-*A&3*E=>0-SKE5E27BEVZOKJ+2MR8UANG%P]D0J$C
M*QES>"O&P4^T%U"N7P^,@=\FW50/8:K&J3 RU9\'X@=]5[1$0CWQ%%$'(5BT
M2T,QK-T&'=I^[R?P=X_^%.CIH// 543(: JRT5;YB:L4A',&PP53FG=;C??I
M:(C%E;-N"Z:LMN:FX9H3!':<?)2[66E42^#%M'[Q5NU6LTM/.!C&]44M[Z8>
M*Q,NRCFM>KEJM\(F^*Z=(*(/ED6-445<E;J*' !(MX::3EOUC205DQG08#("
M<*]81KX"!2*_"AN'PK[(!9A9'!V$0+[XJ+']M W]W 5>'85EV\?"V?,4&[E_
M!6*#C+#'NO@"ZE@I,M-1+"-OU5(RLC4Q9>$5D(HRJQ4O>/$ZBA'IKO 9JRTQ
M(P$8@_0<Q[A_+13>8>O6C1N]1;KK],? .W2:A2BDNT1%=(QT1*<PR\8O(PK9
M.Q,H$ZMSIMLJRR[DTXQBE&K.)M3*K2;A.95<@VCWZ956:JRQ%4Q<D*)#R2D$
M>3<M8QT@U&1=5^P1,1*E=,&DFUD:O,2\6QBKA!.6;U,R<E$K/8\Y^HA5A4(<
MI?N-+,55)L:N&6<2*RHHII*5EP"86-!PN:/D'96[5L@21(FW\%5=W'H)F4!(
MR@&^_1Z5$RHE4ZUR&24,HIT>VB"2I'"141(L4IC=1% ,4!+@,Y!-TV5*B]01
M5;(JK@Y<-0;NG#)9V55BB\9IKK'*R*":AAZD1$1+[)CE.5,!$2$(0A>H3'/[
M 8R=0QA$XB !J.N<B(CGADZ6;,'+MJBW0,]<QZ"KTR;7K50]W<Y*=J8CL_B_
MLR@.<  CU 9FLBT<-U'(N%D'S4KQNH!G8NSE%%0Y2>(!QR0PY AP W2.,< 0
M#D%$B;<A"BF?Q0%!0QA,=7QNDX&3Z0 .D,& 1$1 >D'S==-FNU=+BLBU59)G
M:I=0)KG\= 3BF[44DO$<&/@AA,H <R@83C**P[!@@V'XDX,BA%0P&5 "NECH
MN%U$6K9PL<1Z5%3Z&P)C#J(*/'+21E/=E#*KL6*K-HNY%),""P8O)AZ=FV/X
M(?DC/# 8PY%0.?#8'Y%T7 @<YT'0F.Z0\0XG\)PJ:;L(**$,(ZE=JD H@4N
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M'Q%DT9Y-2U6")G;.N^=+J.9*/9P;=P0Y""R+X13?=.FH4ITU"F(<AP Q3D.
ME,4Q1R!BF*.!#M#B!D57:+QXM%LBRBJ/@AT3"+=-*6;K)(&,FV=-I BB:J7-
M)0HE' A^C+M':*3EJZ15;.6ZY"JHN&ZY#)+(K)G 2*)*IF$IBB @(#@>';-Z
M"95F:V&W0IXJJT8<3IL73HQ4442.7)FZ@F(0/9  SSU_0;->K.Y,T@*I"R$Y
M**IE*HX.VCVYUQ:L4#'3][DGIR@BV0*/6X<*$3)DQ@#BP;SWL$AW*\PDI'[A
M6-)!RD]:05?",2:T6G13Y _2_@Z_!J&4:*+$*[(F]\!83"B7'Z,L\:J)+B<1
M8JKHK%6()HYPZ240R0YDRJ-':BR9PT,4X"4VI<!][4S6&1GVT147\C8&+.KV
MJZT2:^UBT>:#BY@ELH=JK$R5@PKLM,,UXU45V;[XD510H':IYK)V5@F9*(J=
M?N=<C&]FE+#;[(X9VR9I\TBK,WJW6"=LTVYAU:RLB55TJJLX0<I H?K;]:T7
M$#-12K0E :TV?$(*3*XDGD:R]TBY6*=J6M=W$,$3/7IEFC@\BX6!9+I=I&24
M.XW#<HURLQ%OW*HSZ@6*]MJQ#JVB0@EXV0CXYC+RGNZ,C.1<,,DHHW9N%S($
M$Q@*!>H1XML/M73MO]LGUJCC(+OJY18>/CUI-M%GBX20GHBO&K:EA1B$.@A4
M3ND3BW+X1%4@$!"8B]['5&W23FV*L(\@V^W982A*P)WIWIFCFH6FS[CN9!](
M'*@5\HXD56JX,FXI-6YBJBK5ZKL[8MK=LZO6$JX@T@9O:.;ML<R:5*7@GU?B
MZZSJ>[.U3"O0L?'0PM"-2HKID*9,2=":0HJ-"2*[5U($:H$?NF315@S<O"I$
M!TNT8+O9)=DU67 QDT3N7!TR"!14.(=0_>J'=IE25*_E$2%+G MFTF[;LE!S
M^R69I)G'TF_HU)L@=$<N(^:DB/.@IB^[J22P3[5J;J ,G2C)AOD0T'/WQ'ID
ME5",HF8<&Z)!R@0?"-'J>$:/*(,'9U2D'I65]MOTB!-%5,7"'FJM&Q,I KU2
M6KR,%;%YL+#6;%*NV,:$LXD:M74*[95Y& ?MW3!,9%BD@*"A9$_C*%;%9VZO
M-8"SPUU?UN18UNR3D]7"*?9E:T0S]I.R=8HKBQLWM5DV@NDC1ON[*5.JW(=P
M+,KH[-*YUUHO#I;55J7@;?'WJ7E+/:';>F0BUJ"[1RE.K3JFSR\X_4*P5C7<
M[[XBBJY6.P7\)J>T&F*]!%K,0YC8V >05J?S%KG)B5&+38Q<E67U3@XFNJNU
MY= A%3S#A(HJ%.L9%'J5+ TR2JU,#=N9=$(YJ<7N#.2%3B6$Q ;N3M.E75T=
M;9Q4NHTGPVC>-UP+ ];-<Q^D'!4BF6G8E_7H&,J$><D?#SRMCG2VB;G/AL9+
M+-TZH^HD; *0I6+Q8Y7\?8)/VT!24127(Y2:_>R]AF71&41!1;^9E7JF?#:1
ML6T5?/G2F $>ANU0,<<:X#ABF8R#&10CD&ZYH\ ,T*X!L5-4$?>$0.JW27R9
M(3D = $Q1U*+=O;4VT:J*12J3:)TT:XY<E0355*D=RZ4=Q_68%>DK@.D"I:J
M9,0#?HL>[3%+WQ<?AYD/$:IN';,PF6/X/O'2HJ$>)3+F(F8#"F4XX,( 42.2
M)K)$.90"%7(":@E(<Q 4Z ,82D5 O47.#=(AD '3]!V6V:)X^W56G[4WF]Z&
MUKE31K"?/4Y"+3:;1U67;OX-"\MKA;%E(Q<$U6<@@ND@<6)SD<M4_P!%,(%,
MJ<"Y*BF)/%5-@PE3("ATR 8_2.!,8I0P(B(  B'6<XID(?*:9.G)R"F "#C(
M'R)5!-CH, <A'N &+5JFU;MFS;P2())HMBI_E$$T$4TP*0@-TVY0P  !2B4
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M1&G<'");!NY$0+=/J\,(VV/JJY-U%$,J-JG6(DSC74!.^/C&@!Q(V.:\R\A
M-H%A(.Y:897"76JL4VCFX.Y"7F9>3EF:;5O',TCJK IX2"*>3&$"@(\-4X7S
M>[*2[[WL7L:P1\QSF5,^;"'5X*T0#!4'J&0Y=9B  CW:A+K+1=ZCF[4XBW8L
MJH]AW8CDH+*%@D(>X*KIB&0*S16 <ZE'EPT:;F;4J =:15;NWL-[S6A2;"0O
MN_P1C/.YB)L?Y7J ZRDQ&EQR3SS 2/U:Z[$IU/AUF-'L5P1*)2E5,[9R$C#@
M943>RE[UX^@B*8!S@=Q]YQ87?<EJ5G)0L&H:/EJG0W:"!D&#MFJVB(=G9;6W
M:']N3,T2224-^1(<Z1'BGZ(HS;LU4$RD((RJRK/W<05(J!@9($6<.U7;90"B
M)5T4D1 =#FP(<% ZAW"H ('<JD0*NKJ&JGNZ*"6@  >R4 P ?<9R+<"B=@=4
M'1/!566<1;@@ ];MP1(LJ5<BJ2+@H$3.=8S<$0Z?$$Y4UD5$UD5DR*I*I'*H
MDJDH4#IJ)J$$2G3.40$! 1 0'[T(<\,P-&!.IV<&1D"BA]H4K.6Z)S71VR1;
M80)'Q?K^]AXF>K7A(C9HBW(B_D)-,J("F4LA++O7,DZ$I1 #*O7,BNHIG(&.
MH)N>!X@4(".=-TZO&6*$KWODW/3)XB$M,Q&SDK",E9J3D%4H9)[#,TV+3J]W
MBV35%FR(W:)D0*RG562!YB-CI2)8R!BY<M8V:<Q#R59)'S[*#]U ,CJ!VF;$
M[N(2YR2MR9ST F@@V/6=RMR*7%239JJ]7:,[57*=;(*N79BS6DG!D4)EH_11
M,NH)"EZS9;LV;=!HS:()-FK5LDF@V;-D$RI(-VZ"12)(H(I$ I"% "E*   8
MXG(.*D=TT(R?;-6;ENKOQOD]/%M64N\FFK>I.GVXKEW1D4G+TR/3"J, %@1)
MD.6:"*"9*Y7'5M=1B:ZCA,]RO]\W(EDS*$3)X*=@W%LEJGR,DR) ";<'(():
M]!"Y'/WA&*"GAN'W43J(J5-=!F02 ]>)?E"K =%-4I$SD*?H<*I=0=(B(  !
M@ T  T  #D !_1I9LY12<-W"2B"Z"Z9%45T52"FJBLDH!B*)*$,)3%, @(#@
M>#)/4EIFOJ.$DV,@T3>/9Z+!R9-)%E+1Z*#A:78MW B4)%$WO!$E$P<H&!%P
M_40D(M\SDF#H@*M7S!RB\9N4QR *(.6YU$5B"(<RF$/T<6]0*W?D.@J<;.X(
MLM6&@F(4K8[-9 Z/VJ<>.H(B@R6(@4$%DUW;9;PB*F @=2BIBJ.7!B)%6=N
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M#MS![@7#;QZU^)@QW.(SL36XQ<PS052%J?=)@M?;%49)BJ)DOAKHI5DE?8R
MAEE3M^-J9;8NR=+=.SW7;F)7A)F-DCQ;F1$]DVHNM2FI&OU218.U)5%VU>/9
MSV$OR10\0YCW+RV[F0^ZNWJJ< NL> EHF5(1-\2,E$HRX;=@#-*/?K03YI[N
MZCRM)E:'(3QEB]*0G;1%];MZ=)N$T?=9DSL#U644,@U$XD<NO!?0QU%E5! K
MDAVR:92@9T*IP2#(:@.H"';]T14\004,1$"HE<'7-XA@*?P"-$UG)E$T^H_L
M%R %$1$H )@2<$!T!3>(F7W]JK'NU#HJG0ZE&KE!JHF*YDQ,7)" 8H@8 Z1#
MA1-9-9-NY%9F5-+*+I#PQ>$.\.^;/NHB+M)-,4?# BR1C (B!A$$SF%5 6G@
MIE(B"!P<%< =0553NO>13,B=,Q *F")3%$HB)S 8"E8>[BF=$B3=-9)=19=<
MY#>"3Q2R!W2PG.@F)CF$X+&7$ #K 1ZN%U5'I1CTD!118)L3-\+J^[*BX<O%
MQ7&0,F4@E2% 6Z:0'.50JQ^@R*+=N)014]^=+'=&>NU0/\0:JBDD=17I3242
M<K 0HJ 5'V 3(*9!("B?O3$[AP[=E:+EBG'N[-J9!PHR(]0&8!1TJ@<A055(
MHB581P5-+JR4PD50*45&W04S910Q4RJE][*<Q728'.LED$S !02-[0E4 .D4
M4FZK=(3&%505VZKCK;HJ-@633!-PW*FJH540*<QC 0<#T' !#@Z8MS%BRH=!
M5#(-NI1W@BOO)'99DRWNO0<4?",R*?Q2";Q.CISP06":CU@N].=VT5<F,Z8E
M>*J*JNH]5P<P+MD'*@&,T,8OAH&-X _DTVRBA4U"',B<J:Q"F 3HJ&236*FL
M3ZR2@HK$-TF !Z3 .,"'Z.HA&HA(N4S+)'Z%028-7":+DQ4W[\"J@C^V4"I*
M$1(X<I"J4PHB3)@,LH)%7JY$B.G14@3%4$A4,DD0HF4,DT0,L?PDQ,;IZS"(
MF.8YS?T<<.#MB)NW34C)>0:F4929VB:AE4VX2;,Z#]-)-0XF*!5 Z1$1#F/
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M#\+RSJ C'J[%L8Z6(^,,^6\ @B@S:*O/ 3!98P 1(IE4R=9@ 1 ->!$J:+=
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MVM/RO&IC B[;*!X,C$O@3356C)=B81682#<JA1,F?F4P'()B&*8W 9#D.0]
MX$,AW#@>#>P3VCE4-[(>T<G0!#FTU.4$RX'F'2'=PYD3(()K"W*#IV5 HN%&
MS4%5")J*)D%=9-'Q#B4FN!,. R(\ Y\%+W@$O!!?PR>,"(FZ_"!7'7X77KTY
MQG7A-'PDO"3%+PDO#)X9!0,51#PR8Z2BB=,IB8#V1* ARX>OBF$RKX&X* *#
M(G05LF*9"E70:I.URB Y_+**](Z$Z0TXS@,@ @ XU !QD,]PX#YN"F$"B)1R
M41 !$!P8N2CV#TF$/4(\*MET4EFRR1T%FZJ9%$%4%""FHBJD<!34243$2F*(
M" @.!TX(4B9"%2)X:92%*4$TP H F0   (0 (&@::!W<%DQ9M!DBM#,"R MT
M??BL3K$<'9E=]'C@T.NF4XI]70)R@.,@ _=25413.JAXG@*F(454/%)X:HHJ
MX\1$5":")1 1#@!.I(%Q_P YEI1MW<P;O$@'EQ]=Y_=!^/XW/'UWG]T9#M_]
ML\?7>?+(R ]N>USQ]=Y_=&0_UUQD5)#/];+2I0_L2O  >  #O!P10@=4@_/H
MH.3"(G<F$3ACV3#[1?V(AP @K(:9QF7E1#7T"]$!]'=Q^=D?[L2W^O>,];S^
MZ,ACYO><<?7>=G_7&0[/_;/'UWG]T)#_ %SQ]=YV_P#7"0[?_;/^)PX2<)>]
M(NB]#AN[.H[;*$Q@2"V<G50*0>T * #V\%33*4B9"E(0A"@4A"% "E*4I0 I
M2E*&  - #^D[I24\(_6D;JP4>HA%2'51'J*;I*NF42"8 R4#9#4 X8M6L&K!
M-RG*1O%H(P!30HE,(I.BMT5GL0B+90O64&YEL"8!Z1$3 !<-ES]#DA.H#MP
M4SH@!G0 9P7**1E!*8! %,E$2D$.D1=*J1KHB'0P;HD\5D90Z@2<BU=NBB$F
M9'W1-IX+D,D37%$V!*=4/ 3?%+&"H9U,QSU4[QK!':G!D_BW8N$/<SM':PH@
M90R"CD#.$U6XFP/Y(%2,$T5 9(@W3",8M(11)5%!1'P$0;S+96/(@U\,#%
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M56:ZS4YVSYDN7\JS>(B9N];&*JF.!$"_<'*?BF I_"P;PCI*&153$Y'!1!5
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M"/48"=89$.60[_O3$-G!NT/K%$! 2G*.O2<A@ 2CS 0SQ@V.LHB4V- $0_9
M'4;I X" @&1$ '7]$N(L':K)TY^!,Q5;JE1<C'+V.)">*@<P@'6%>*[,/]84
M>(Q[#&%4+;(O[1*NA.)@=3!$64'[RD Z$27:PJ)3!KDPB/;P&G+.->\X>CLX
MSWX[O3Z [N%3% 0!-,B6-=1ZSYY]H%(7Y_NO&M5DJ]'3C!RRL;(]CI\U?&9W
ME7=(S\.*%8@+YMS)OW;:PL&2Q"%DTBJ^&*(A^5 Y+=2:8E4*+,7\=]I6:OU)
MA)N!?([A;LSKJ9+N6TC2;GV^Q. EUG))$!&UHOTD4F"" 1Z:9&['<?>;<+:C
M<F!VYC*=?JS#NJ58[1OLTW'5E;LWG*)N)_$W%;JR,YM_7*_$0J4;$Q$16G#D
MR-B=R<DI640DFJ>UM8+![L;Y4C>6I6RSQVZM ;;?NJ R@X"J6N1<-('=>M6C
M;E&HVF94C6Q&LHHY/'IJNVH$=M3K LG4Z//;A;KQE;C8>]58LL2P,;?]K8'<
M"OV."EZ'NL6[5VSFG*\A&RB?N3ETJ8TD=LF@^6%\E'N5:IL/';,0NX6Q%::P
MH2$8:R19#SJZSI*OQM584;< 5ZC.QL*JK&/7;N?LL:[DG"*[]0K^0]Y<.+G<
M+FRI-G\M$767E?VYK,_L;+[<6VCS#R-KZ5FBY8VY%4.]W&C[>J)'2<K%K$:
M5J=L86 HKM)?9&FQU=H;[R]M@F(^9<,]L-S)"T0,L0QH;:I]292D1M\JU.+
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M;0,-![ETQ*SP=RV^=3B_P]S!2D7'C'1DE)RYR_$B1Q8M>QC8;55E7*LVC0Z
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MU_HP_J<1I)*18M7+]T,3$J2;MHW=OWCHIW81; RQDE';I9%D)P13ZE#D1ZA
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M>':_9.S^94]NW@JXW:@[/65%3<B(H\?3ZIMU-VZ&V^6BW?VXLU=G:>Z1<M&
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MK87",=&WB#58K)(1"\26 F9VU2\ 9HE#H@B_&#9-6SIXHJ=8$W(+$$Z*<Q.
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MB8,?<=-TES-E5VZR*;DJ::IFZBJ9B$7*DJ!DE#)&,!@*8!*(A@=.![P'EC7
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M*) (<_05-P)B=1O P<QC= Z" @ @/>&O]-R[/:0:4ULSPJJ)9J[O9<C"$()
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M[R8C@J:!ET&JJ!SMC8!44BG,AXQ0=%R7J,4#"7VB=!M>!Z3"3(YZB= B;),
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M$NY!ZH0BRY&+-84$7"_A-U7#EP[<3EIF4F)[3:Y RYW\Z]9I*]((HN'3PD)
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M HB03I )@* #TF QU$P-V#D3%[Q'A1$O4/658 ZU5%#95$YARHKXAP#)M U
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M,+MAM_9]R(M*KL3/$JO/PI6L/.%EIW=.DC66@KUZ55<E91UPDRHM3 G'*+>
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ML<RB8MBAU>"RCHYLDS8M$>LQC^$V;(E(7(B."ZC^@^\-C=(GZO>&YA_(N,@
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M3--;W3U23 JS(NA!\5!I& 5,KWI_IX.N4ZH  &;&2$V41,BJI^4*7)B ?)A
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MDF0!,8P &>&CC9_9M]7J4Z4!-7<KS$_:7:=ZNQ>Q?CM)VD[%K5EWNU8%(:8
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M   "@=0P@4,$+U#T@ ?\P$%0H]:1RJ)*D,)%4CE,!LD4*(& #8P<OU5"")3
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M4BA(2#F276OVZ.YNZTDFX=K*+JHL9C=&W7"6BXTJBH^&S;+HM$2 4J:92E*
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JVPM;IHHP<V;;S:6@TJPN&*V/&9KS5;@(R25:*X#J3,J)#8U#_P"9&__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gjyjiv3jrhol000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000016.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *= Y4# 2(  A$! Q$!_\0
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M /2OW^U[_P"%A\9O_H)*/^(C_P#;W_Z5^_VO?_"P^,W_ -!)6K_Q#H?MW?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX-?^#I?_ )/I^#__ &:;\/\ _P!7!^T)7]Y5!4MH^GZ(****" HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '\;_ /P<;_ /Q-\-_P!J#X6_\%$_
M'-[X=U?]G6[^ G@C]BRW\$Z%>ZK)\6D^-4_Q"^./QRA\4R:1<:5HWA8?#I?
MUC=Z2^I#XA2:_P#\)++#:CP:VG%M;B_*'X@?"+3?@?\ LZ:#9_#&TLO#.E?#
MW5=7\2>*[4:AJVM/J/@*U3QCXG\4:+HTGB$ZK+)K&I33PR637,^E^7,KPIK%
MA;8W_JA_P7,^#/QGN_\ @JW\//CKH_B7PK\%O@\O_!/;PE\)G^.GQB%UX3^#
MM_\ $H?M(?%OQ@WPFL?B-K'A76/!LWQ+NO"[1>,+7P2FHQ^)I/"VE:GKJV2Z
M5;2SR_BGX7^.'P\^'$G[2?PY\:_ CX_^*KV;]FWXF>'_ -E=_"'@N>]T_P"'
MW[5GB;1-$OOA%\1_$MP_BW1;W6?!_AC7;_6I]?TS4;;QW93F\CMG\ >(XHH;
M:V"[/3K>VSM:UE]ZO;\3^E;_ ()$_P#!+3_@FW^TU^SG^R=_P46\5_LYWVL?
MM+Q>/]6^*.B?$S4OBI\:=#O;/QU\!OCSXL\.?#C7)O GAGXJP_#*3_A'(OAU
MX;2/3)/#-SH^M1:;'-XBT_4KB_U/[3_4)7\6G_!"#XG?L?\ P7@^!GCWQ#^S
MC\>OBC_P5K^/!UCX ?M1^-/A!I^J^+=3\$?"3QM\?;6V\&_$[XT?!0_%/0M
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MXJ\+:WX GAL[_4=5U'5Y9/#>EWVC_P"@Q0#5K:WO]_S04444""BBB@ HHHH
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M%9VWP^FL/[1-G\+_ (BQ:G_PETOCB:VL_M-QX?\ L4FB2^3_ &LUVR6//?\
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M)I^K_;;7_A&K0"-KJ^>9I+IK>PF62'R0I:^6O1-ZNWY_IH>W?\&XVHWFJ_\
M!>K]LN_O[.SL+N?]@W5O-M=/C,5G%Y7CO]BZ&/R8S-<;=\4:22?OGS*[M\N=
MJ_W^U_-)_P $$/\ @GS\!-%TS2/^"LWAGQA\5-0^/'[3_P )/B5\&O&OA2_U
M?PN/@SIGA?PM\:M)\,6U_P"$O#0\!V'CS3M>>#]GWPDUU=:W\0-<T^6YU#Q+
M+!I<,%[I,6C_ -+= GO]WX)!7^</^W-^SA^UQ^RA^UM^W)XM^)WPWM_A&O[:
M/[4WQL^(/[(NM^&_&7@ZZO\ XT>"/#7QH\6^-/$WB'5Y? GC?6K_ ,(7.G>!
M/B/X1UE;+XC+X&U:[?Q+>:?9Z==ZC;:QIUC_ */%% )V_KYG^<7X-_;2^"/P
MF^ VH_ WXJ_$^[C^.WBRYT;Q9%X<UWP]X_\ %-TT*1^%H=86V\4Z7H&I^'K>
MRM;[PEXH\JUNO$!N))+2:9#<#4+.2Z_+#XP>&-&\.?!;]H/QW=:WKUOI/C_X
MKWGQ,T_43=B4#2O''C7PE/ISZ=;6UBVH:?ITRRHMMIU[%_:%I'*Z7JJ=V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0(**** /X-/^#I@X_;H^#Q/_ $:;\/O_ %<'[0E?WEU_#]_P<B_%;QA\'?\
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M_B?P_JFH>'KC4O"GAB_FTFXLY+SP]HMPTFFVW"_\+\_X)A_]&Z_&W_P:WO\
M\_B@KE]?N7_R7G_5F?[%=%?XZG_"_/\ @F'_ -&Z_&W_ ,&M[_\ /XK]E?\
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MD/A#6_L/B#1?MUG_ &EI]M]IAW_Y[7PC_:^_X* _![XP>.O#O[)?[4%Q\+/
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M^"7[2G_"G?\ A=?@K_A-/^% _';X>_M+_"3_ (J/Q;X<_P"$3^-OPK_M?_A
MO&O_ !2>O:%_;W]A?V]JO_%.>)?[9\):I]J_XG.@ZCY%MY/NU%% CX0_X*E_
M\HQ_^"C/_9B'[7G_ *S]\0J_CN_X(Z_\GS?\$6_^R&_&;_UB2_K^Q'_@J7_R
MC'_X*,_]F(?M>?\ K/WQ"K^.[_@CK_R?-_P1;_[(;\9O_6)+^@I;+_M__P!)
M1_H 4444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!_*?\ \%R_^"H'[>?_  3P
M_:V^'DOPMTWQAIO[(/B?]G3PE'>>,[OX?^#X?A<_[2.M?$OXMM<>&%^+OB[X
M2^,+8^/F^&'@G3]5'PX@\603GP]&WB>/P]%&+G4KG\Q+_P#X*[?\%?="URQL
MKS]H/Q+J$46JZ9'J=LW[-OP)L773Y_*GN9+@I\()9;2$0.$:?*;%D642)\N?
MZY?^"DNB>,=?^!OA2S\$_P#!-KX4?\%1]5C^+&AW-Q^S_P#&'QW\#?A[X9\'
MZ>GA#QU%+\8K'6OV@/"GC#P;=:[X?N9K3P5;:7IFF0>)IM/^(.IW=G?1:59:
MS;W/\*_BGQ?\(M5^&'A?Q7\,?VE=9^*^LKXC-Z\LW@3XA>#[_P 6Z?IC>((I
M=(U#5?$\HFBM)K^TLM#9-0^TPK$D%W]FEL[=5 4E?7K=+R\G_GWN?M)_P1%_
MX*F?MZ_M>?\ !67]I/\ 9F_:/^-<OC;X+> /V2M4^)OA3P#-\+_@_P"$9=%\
M<6_C']F72K?6V\1>"_AUX6\8WW_$N^(7BZ-=-U37+O2&761*U@\MAI<MG_85
M7\3O_!NI\.?V8;C_ (*)_&OX^^'_ -K8^(/VN?''[)7B_P /_%+]B(_ ?XAZ
M6?@[X'T[XI?L^:=IOQ"_X:5O[\?#/XA?VOI_A/X=ZI_PB?A[1[35]/\ ^%H_
M89YGF\$:X]S_ &Q4"EH_NZ>6H5_&Y^W+_P $2?'_ .ROIW_!0_\ X*$?"7Q/
MX\_;$^*OQJ^.2_&?P7^RG\,O@/XGM?&]M_PMS]H/47\1>&M$USPEXV^)FL^,
M/^$+\.?%K4O$&I:Q;_"R'SM(\"7]_+I6AVNH7-YHO]D=% )_\$_AG^#'_!.K
M]H_P?_P3;^-W[5<WP@^.,/[1^I_%+0O&_AG]E2Z^!OC^T^*OV#XEW7P3M]=T
M:PTNX@D\0ZNG@:U\5^+VU35?^%72/,G@[6Y+JVT4VMT^C_'_ ,'O^")_[0'[
M1'Q L/@AXV^&_P =OV?M#_:KU'7OCE\0?CIXN_9U^)=]X;^#7BW5]'OOB->^
M#O$FDZWJO@O1+S4KO6_!MAX+62\\5>"3'J7BFRFM_#R7,%OH^H_Z+%% )VVW
M[_=_7F?P\_\ !R7X\L/AS_P4&^%6OZAX8/BV*Z_8V\#:.NF+K$^B&&2?XV_'
M6]6_^UV]E?O((UL7M_LY@5'-SYAE!B5'_IY_X)I?L$6__!.OX%>+/@G;?$__
M (6RGBCXM:[\4CXC_P"$*?P)]B?6_!W@/PD=%_LA_&/C<W/V8>"%OO[2_M6W
M$W]I?9?[/B-F;F[_ )0O^#I?_D^GX/\ _9IOP_\ _5P?M"5_>50.2LHONOT0
M4444$A1110 4444 %%%% !1110 4444 %%%% '\(_P"S3_R67_@K?_VF*_;J
M_P#4X\,5_=Q7\*7[)MI-X@_:*_X*O>$]+3[5KVJ_\%AOV\YK&PRD/GQVOBW0
M[R=OM-RT-E'LM[&ZDQ-<QLWE;4#.\:O^K\7_  68_P""G+J3+_P0_P#*;=@+
M_P /*_V?9,C ^;*_"X 9)(QUXSWH+DK\O^%=;?F?TG45_+W\0?\ @N[_ ,%!
MOA=HMMX@\:_\$6/[(TJ\U2'1K>Y_X>-?!._WZA<6E[>Q0>3I/P@U"Y7=;:?=
M2>:\*P#RMC2K(\:/_4)03:W_  ]_R"BBB@04444 %%%% !1110 4444 %%%%
M 'XR?\'!_P#RB#_:YR<#_BP?)_[.=^"U?%7_  ;S_M ? ?X/?L%ZAX<^+GQL
M^$?PL\0:E\8+OQ%IFA?$;XD>#?!&LZCX>O?@U\%+"RUZQTOQ-K.F7MWHUY?:
M9J5G:ZG;P26,]UI]];Q3O-:3I'^S?_!1']C]_P!O;]CKXP?LG)\1V^$C?%;_
M (5_CX@IX3/CEO#_ /P@OQ2\$_$HX\+#Q/X-.J?VJ/!QT0_\5)IOV(:D=1_T
MS[)]@NOY\M)_X-<_%VEZ5IFD_P##Q_Q'/#I6GV6F6W_&.VIQ1Q6MC;1VT$,$
M'_#2LBV\"+'^ZMXV\N%3L3@9(-6MJ[._9[?U<_I&_P"&V?V,_P#H[?\ 9C_\
M/U\*_P#YJZ/^&V?V,_\ H[?]F/\ \/U\*_\ YJZ_G(_XA@/%?_21CQ#_ .(\
M:E_]$C1_Q# >*_\ I(QXA_\ $>-2_P#HD:!V7\WX/^N_]/3^C?\ X;9_8S_Z
M.W_9C_\ #]?"O_YJZ/\ AMG]C/\ Z.W_ &8__#]?"O\ ^:NOYR/^(8#Q7_TD
M8\0_^(\:E_\ 1(T?\0P'BO\ Z2,>(?\ Q'C4O_HD: LOYOP?]=_Z>G[^_%']
MH[_@G[\:/AG\1/@[\2_VG?V8_$GPY^+'@7Q=\-/'_AW_ (:,\ Z/_;_@GQWX
M?U#POXJT7^U] \=:5KNE?VKH6JW]C_:6BZGIVK6/G_:=-O[.\BAN(_R>O?\
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MXK_Z2,>(?_$>-2_^B1H_XA@/%?\ TD8\0_\ B/&I?_1(T!9?S?@_Z[_T]/W
M_:E^-G[&G[2_[,?[1G[.(_;=_9C\%G]H#X$?%[X)#QB/C#\*_$G_  B?_"U?
MA_XA\"?\)-_PCO\ PL#0?[>_L'^WO[4_L7^W-&_M3[+]A_M73O/^V0_RZ_L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?DG_P %)/\ @J9%^P_JGA7X5_!OX'_\-8?M1^(;#0_B!??L_?\ "RF^
M!/\ 8OP#U:X\=>'+KXQ_\+6\4_#WQ;\/-1_L[XA^$M+\%?\ "O8=1A\:7?\
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M3?\ )QO@+_LB?A;_ -3KXJ5_3)0-_HOR04444""BBB@ HHHH **** "BBB@
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MXGUU_%+Z[XGL+N&RE\-PZ2VDPWD[ZY'>1PV%P#D[J-NBU_ _4VBBB@@****
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M99A4<W7JX7VV84*6+Q.!I*$HX=1HU)Q5.A2Y:<).=KTX3A_03^T3_P %$?\
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MFW/[2O[-7PX_: \40>(+F_\ AKXHM9OA;\/])^/GAO3;S2? 7P!UOXPZ[?\
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MQ+X1T#QKX3\6^./B+K'P AN?%7PV\8?"/PWX<\=^((M/\5/\.?B7\U_L!_\
M!2CXM?\ !,CPY^W3X:T+PL_A7X@_&'X+2_#G2+KQ;H<>@^.?@!^T_P#"[Q3K
M/A;POXD\::7X[MM0T32-,^#NE?$3XTZ]X_\ AAXR^&WB#6/%/Q.\$_#KX=:O
M-X!\/WWCG7[+>OEM/%0SW#X.I',<50S# SCB\14IU,4L/5IKVTIXF6LJ=&JY
M4\1.$W!>RYZG+LN/#9I4PW^JV)Q</[,P-2EG-*O1PU*MA\#4J7IO!3>#A%<L
ML1:I6H0G3<W.I.=-+G/TT_X)\_\ !93_ (*1_'"7]N=?BC^T=_PDX^#O_!);
M]M+]IKX<#_A4'P&T7_A'/C?\)6^#8^'WC;_BGOA?I)U?_A'QXKU__BF]=_M3
MPCJOV_\ XG>@:E]ELOL\/[!'[<__  7M_P""B_Q8\>?#7X#?M=^&='E\!_#9
M?'7B+Q7\3?@/\&M'^%6A2-XDL= T+PUJ/C3P7^RWX]N=-\=^/'U/5=2\)^'=
M5M88]<\.?#CQ_JNE;G\+ZG'/^9W_  2G:W>[_P""G#6D@EM&_P""$7_!1MK6
M4$D26YE_9[,,@)P2'C*L"1D@\U^WO_!IG_R-7_!1'_L7_P!C3_TX_M<UIFL<
M)@X9_6P^!P-XYQ0P^&Y\)0E'#T:N#4Y*E3<'"*>MHVY(RE[1+VD8R7/E53&9
MA#A:AB,PS*$<3@LYJXMT\9B*=;$2P^/JJDJM93]HW!1C!2YN=4XNDI*$I(L_
M\$^/^"JO_!1/P1_P5/TC]AS_ (*/?%S0?%&G:CXC^)/[.>OKK?A7X7?!'PKH
M/QBLK;^W_A-\4O!FK_\ "DOAKXT^(&@_&:^\)Z=X!^!WAW4&\(6_Q/TG]HCP
M-XUT>RU34X_"N@:PS]F;_@KA^V]_P4(_X*\>'?A+^S1\;-<\&_L2Z_\ %_5O
M%ECI&E? ?P/\2-._X9@^!^@QZAJ7B7Q5XB\4_"7P1\4_AQH7[5%WX2TS1X=9
M\9ZQIFN_!3QI^T;X9\(6%SXCUKP[X=T;7?!_^#F;]EB[^"'[6'P>_;<^%5UX
M\\)7_P"T19P6'C3QMX.@\=:6? /[0_[/>G>#[?X:>/K'XL6WBBXL_!7Q \:?
M#.W\.6WP\\)>%=/\#7>F-^S/XI^(FC7/B'7]2\6:EHGW1_P:X?L?WG@;X-?&
M3]M/Q5I'AU9/CIJ=E\)/@=._A[PQ>>(]'^%WPAUW7['XFZ[HGC6QUW5/$&C:
M!\2OBX/^$.\2?#G4=#\(R_VG^S;X7\8WB^*=)UCP;>Z/RX^&7PRRKG%*AAE4
MSC#87"4,/&C35/!XFFY1S.I1H<O+1_W6"HUJ:A.$J[DG^\O4[L)4S.6<T\AG
MB,7[++<=B<TJXMUZKJ8C+91A4R_"U:SFYUX^WQ$Z5>%27)*%!147&#BOQ ^'
M7_!9_P#X+@_%V7QMJOP\_:B77=*^"?P!\2?M!?%;0[7]G?X"ZIX@N_A]HGQ*
M^"7POUC7_#MCX>_9YUN1AX%O/C#9>/?&UWJ]UX;\+^'/A7X<\?\ C#6-;B'A
MJTL;W]?_ (/_ /!>;XBVO_!&_P"./Q=^*?CW0]?_ &Z/"'QEU7]F#X;:O!-X
M'M_%/B?Q3\:M'U7XB_"+XW:O\-_"/PANO OP^T+X8_#Z+XN#PKI'CCPB_@3X
MU:I^R/XET"Z\<KXO\<W^EZ+^5O\ P;>_#3P3\:?VWOCC\'/B7HI\2?#CXL_\
M$P_VE_AG\0/#RZGK&B-KW@GQW\7/V3?"WBK11K/A[4-)U_23JFA:K?V(U/0]
M5TW6+ S_ &K3-0L[V*"YC_+KXI?LV_&SX4?M/_$3]A;1I_&_BGQ_I7[1EI\"
M?#GA#7+:Z^#^D_'+XB:;XOUGX;_L]?$N\\#^+_$X\*Z$WQ&T3XB2^(/A-XH\
M2>(M1TS0/ /QNU.\T?QS-X3\7:IK6K>O7P.5XC-,UP]2AA<+#),S_M"I[*A3
MIJME4:$98C#2C3A%.G3K0@VY:QC7<8-)V/(H9CFN#RC*,QC7QF,EFN"S#*^6
MKB*M94\S>/Q7]G8I>TG)NK*$9479J].E%.[2:_I:_98_:Y_X.%?VJ/V-_%GQ
M:^ 4L_QIUSXB?&>[\">%/'WB+X>_LL_"&X^$7@[X&Z=X7UOQ/XF^%T?C[3_A
M[X%^-]K^T9XR^(.K_"#5?$.H:%XKT'X+W'[,WQ*T#3_,\>_$:VU[X5?//[2?
M_!8;_@I[_P $Y_VHM!\*?%']L?\ 9\_;G\+_  U\.Z+XN^,?P\^$^B?!FT\&
M:CXAM+3Q/X+^-?[/'C#QYX(^#OA[QU\,/BC\+OB3X8\966@WL1_M:RM]-^%G
MQ!^(WP\2V\3>,O@%9\'_ ,%[OV</VA_V3?A[^P1^S;HTUY?_ +%?P6_9E\#>
M"O"?B;PYX+\/^ OA#XU_;OL)?BO_ ,+P^*7BOP;X7O\ 5;[1_BY\4/"5QI7Q
M#L1X[UG7+N\@\5?&V]^&WB'7-7O_ -H/5K[\<OV\M-_9HU75X=7_ &)_AA\5
M/"/[.LGP0\%_#?2_&WQ9\1>(_$GC+XR?'/PW\*/"OC3XW>(/&<-S9P_#[P/\
M6/"M_P#%SP9X!^)WPZ^"MS??":VU'0M&^)G@0VWA#XL>'(3RX3!T<5@:M>>#
MPCAC<!FV+I1P^ HQA1K*I5J4:/U]U'66*PT8>SI83"TZ-.-"G4J5%5E"K5>N
M88W$8#$K"QQ^-^L9=6R2C5K8K,Z_^TQJQ@\35H8"-.-.OA:LIOZSB\;6KNG5
MY</3C34J:/UU_P"#LO\ Y/4T'_LP+PA_ZMO]J"O] VO\]3_@ZA\5>&/'7[5G
MP]\;^"/$>@^,?!?C'_@G)\.?%7A'Q=X5UC3_ !#X7\5>%_$/Q*_:8U?0/$GA
MO7](N+S2M<T'7-*O+34]'UC3+NZT_4]/NK>]LKB>VGBE;_0KKP,]_A9%_P!B
M/"?^G*Y]3D?^_P#$G_8V7_J)0"BBBOGSZ0**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _D\_X+L? KXH?#C]KOX=?\%![[Q!X3D^ %U^SA
MX1_8U7P=IL]_<?%4?&*?XF_%[XVCQ,^D7OANV\,#X??\(58OI;:BOCTZ\/$9
M2V'A Z>SZRO\_7BKX6>)?#6A>'O#6LWVBW5]\(_$EG\2==EL9[UK2[TO1?[0
MUZ6#19)=-M)KK5&L]7@BAM]0@T^R>Y29);M(ECFD_P!,BO"_CE^S5\%/VDO^
M%/\ _"Z?!?\ PF?_  H/XZ?#_P#:5^$W_%1^+?#O_"*?&OX6?VO_ ,('XT_X
MI37M"_MW^PO[=U7_ (ISQ+_;/A/4_M7_ !.=!U#R+;R0=]O5;>6WW:G\N_\
MP;]_\$\/C9X:_:^^(W_!5[4?%'PNG_9X_:;_ &:/&GP:\!^#;/6O%C_&C2?%
M'AGXJ_!SPY?7_B[P[-X(M_ UAH,M[\ /&,MI=:-\1=?U"2UU+PS)-I<$UYJL
M&C?U^444 W?^NP5_$;\9/^#<G_@HMXO_ &GOVZ/C%\/OC9^R/H?@?]JK]H_X
MC_&#P_I.M^,/BH?$5MX:\3?%KQWX_P##5CXI@7]GK6K'2M=T_3O%EO#J-MX?
MUK5=/&HK=P)J>H6D5O=2_P!N5% 7W\S^$.\_X-U_^"TVE:1/X6\!_M6?L1Z)
MX3OO(O-1TJ\USX@74EQJT<L&^Z6[O/V1]4OHXS!8:8@CBO8HMULQ\@&69YOI
M;]DW_@W:_; 3XD^$?#__  40^(W[,/QY_9/OI]?N?C'\,/AKXX^+GA[Q3XMF
MC\'ZB_@A]'UKP]\&O@]KEC_8WQ2L_!WB6^6P\>^'$GTK2;NTN%U2TN+C0M1_
MLFHH"[^[R]/QTWW\S^$G_@Z"UK5-"_;P^$5UI-U]DN)/V1_ -N\GDV\^Z%_C
M)^T!(R;+F&9!EX8VW!0PVX# %@?ZEOV1/^"1W_!/7]A#XJZW\;?V4OV??^%5
M_$_Q'\/M2^%>L^)O^%K_ !N\<?;/ >K^(_#7BW4="_L7XC_$GQAX>M_M'B'P
M?X=U#^U+728-9B_L[[)!J,5C=WUM<_RJ_P#!TO\ \GT_!_\ [--^'_\ ZN#]
MH2O[RJ"I/W8^G^04444$!1110 4444 %%%% !1110 4444 %%%% !1110!_,
MW_P6F_Y.-\!?]D3\+?\ J=?%2OZ9*_F;_P""TW_)QO@+_LB?A;_U.OBI7],E
M WO\E^2"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 45\/?M\_M4?&+]D7X1>%/B+\$_V
M2/B7^V7XH\0?$[2? NI_#/X62^*8M?\ #GAW4?"/C?Q'=?$"^;PE\-/BGJ)T
M73=4\+:/X9G6XT"QL?M_BW33)K4%P+6PU+O?V+OCW\2/VG/V;O /QL^+?[//
MC?\ 95\?^+M1^(=GK?P(^(SZ]+XP\&0>#?B=XS\"Z%>ZJ_B;P1\.M:,7C?P[
MX9TGX@:3]K\'Z4@T7Q3IRV<NK6(MM:U':="K"C2Q$E%4J[J1IM5*<I-TFE/F
MIQFZD+.2LZD(J>\'))VPCB:,\14PL7+VU&$*E2+I55%0J7Y'&JX*E-NSO&$Y
M2C]I*ZO]24445B;A17\S_P"W1_P<3_\ #%O[87QX_90_X8]_X65_PI/5OA[I
MG_"??\- _P#"'?\ "3?\)Y\&/AI\7O/_ .$6_P"%(^*O[&_LK_A8G_"/>5_P
MD>K?;O['_M;S+/\ M#^S++Y.G_X.Q)UAF:V_8#BEN%BD,$4_[5;V\,DP4F*.
M:>/]FRY>")WVK)*EM<-&I+K#*0$;W:7#6=UJ%/$TL"YT:M*%>G)8C"WG3J05
M2$E!UU4O*+34''GUMR\VA\_B.*LAPN(JX3$8]4Z]&HZ56#PV,:A-.S3J1P[I
MV3WDIN/6]C^Q&BOD7]B']M7X-?M^? +2/VA?@BVMV'AN_P#$OB[P?K7@_P 8
MS^#E^(?@3Q-X0UNXTZ;0O'^A^"/&'CC2_#&L:WH3:!\0O#VDW6O/JE[\//&W
M@GQ-<V=C%XAMK=?KJO#DI1;C).,HMQE&2:<6G9IIZIIZ-/5,]Z$X5(0J4Y1G
M3J0C4ISB^:,X3BI0G%K1QE%IQ:T:::"BBOFC]L+XX_$+]F_]G7X@?&?X5_ /
MQG^T]X\\'R^#(]#^!WP^?6X_%WC5?$WC_P +>$-6DTI_#G@WX@:R%\*Z)K^I
M>,]1^Q^$=5!TKP[?"Y;3K0SZK8W1I3KU:5"FDZE:I"E34I0IQ<ZDE""<ZDHT
MX)R:O.<HPBM92239-6K"C2J5JC:ITJ<ZLW&,YM0IQ<I-0A&4YM13M&$92D](
MQ;:1]+T5\)?\$_/VL?C1^V#\*/'GQ!^./['OQ/\ V*_$WA+XMZI\.]%^''Q6
ME\5S:[XQ\+V'@+X=^+K;XE:6WB_X8?"G4!H.H:WXSU[P; MIH6J:?_:G@?5S
M'KT]V;S2](^[:F<90G*$K<T)2A*S4ES1;3M*+<9*ZT<6T]TVATJD:U*G6IMN
MG5IPJTVXR@W"I%3@W":C.#<9)N$XQG%^[**DFD445^6/_!2?_@K7^SG_ ,$V
M-&T71O&]KK'Q0^.OCCP_KFO?#_X&^";[2;766TVST[78M"\9_$[7=1G>/X:?
M"S7_ !II$7@>V\6+H_BSQ7JFHR:_?> OAUX_M?A_\05\,ZX;#8C&5H8?#4IU
MJU1OEIP5V[)MMWLHQBDW*4FHQ2;;21GB<3A\'0J8G%584*%)7G5J2Y8QNTEK
MU<I-1C%7E*348IMI'ZG45_()HW_!U_I$VMZ%!XC_ &%-3TSPU/KNBP>)]5T+
M]I&TU_7M)\,3ZI:1>(]6\/\ A[4?@;X8TWQ)K^EZ*]]?Z'X<U+Q5X3TWQ!JM
MO::/J'BOPQ9WLVNZ?_3E^R;^U!\+_P!L[]GCX8?M,_!MO$8^'OQ3TC4+_2['
MQAH4WAOQ7H.K:!K^K>$/%_A3Q)I+S7EFFN>$/&?A[Q!X6U.]T'5-?\):O>:1
M-J_@WQ/XH\*7VC>(M3Z<?E>/RR4(X[#2H>T3=-N5.I"7+;F2J4ISAS*ZO'FY
MDFFU9HXLMSK+,V53^S\7#$.E;VD.2K2J13VE[.O3IU'!WMSJ+AS7CS<R:/HF
MBBBO//4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _C2_X+R? ?P-^T3_P4S^'/@7X@_&_PK^S[HFE_L*>$/%MKXY\8
MP:3<Z3J>JV7Q_P#C!H\/A."/6_%_@BS&HWMIK=[K$3QZO<7(MM%NE3398FEN
MK3^RVOX0_P#@Z(U*]TS]N[X0SV,WD2O^R3X B9O+BDS&WQB_:!<KMFCD49:-
M#D -Q@'!(/\ =Y05*]HZWT^[8****"0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH _F;_ ."TW_)QO@+_ +(GX6_]3KXJ5_3)7\S?_!:;_DXWP%_V1/PM
M_P"IU\5*_IDH&]_DOR04444""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y\_^#D7XT?&+X&?
ML3_!OQ7\$_BQ\2_@[XHU3]K?P7X;U/Q)\+/'?BGX?:_J/AVZ^"?[0&JW6@7V
ML>$M5TC4;O1;G5-&T?4I]*N+F2QFO])TV\D@:XL;62+^03XL?M]_MUVGPS_9
M%N;?]MW]KW2I_%7[)'Q!\0>*=3TS]I3XRV&HZUKEM_P4C_X*/^ [?Q)JM[;^
M,DGU#7[#P-X'\%^$;+6+UKB_M?#'@[PKH$,ZZ3X>TFSM/Z^_^#D7X+_&+XY_
ML3_!OPI\$_A/\2_C%XHTO]K?P7XDU/PW\+/ GBGX@Z_IWAVU^"?[0&E76OWV
MC^$M*U?4;31;;5-9T?39]5N+:.QAO]6TVSDG6XOK6.7^0#XN_P#!/_\ ;QU+
MX7?LDZ?IW[$W[7.H7_AO]D3XB>&O$5C9?LW?&2[O- \1WW_!2'_@I!XYLM U
MJV@\&23:7K=WX)\<^"?&-KI5\D%]<>%O&'A;Q!% ^D^(-)N[O[K*'A8X/*I5
M(X:4E0S]U(U52?,TJ3I1JJ6KOJH*6ZNHGY[Q!]=>(SY4'BHIX?A]494?:^[)
MYE2]LZ7+IS*&M3E^S\>A]B_MG>-_^"P?[%VB?L=_M#?&;]NC]H;0O'?[8'A3
MQ#^T7:_"R/XF_%OP]<_!;Q[X6\7>$_'%_P##'XC_  +\5V&@_#2UT_1M!^)G
MPL'B7X4R^"!\/-*\3S_$[X$ZI\.[SX<>!]#\0_$O^[/]C/XP^*/VA_V/_P!E
M+X_^-[+0=-\:?'+]FSX&?&'Q=IWA6TU"P\+Z?XH^)GPP\+^-=?LO#=CJ^JZ[
MJMEH-KJNMW<&CVFIZWK.H6^GQV\-[JNH7*2W<W\YO_!SG^SG^T)\?/$'["<W
MP*^!'QE^-,/A#1?VL(O%DOPE^%_C?XC1>%Y?$=[^S"_AZ/Q%)X/T/64T237E
MT#76T9-2-LVJ+HFKFQ$XTV\,/[\_\$Y/"_B;P/\ \$]?V#_!7C7P[KO@_P 9
M>#_V,_V7_"_BWPEXHTC4/#_B;POXF\/_  1\#Z3KWAWQ%H.K6]IJNB:[HFJV
MEUIFKZ1J=I;:AINH6UQ9WEO#<PR1KX><5HXG Y%BFJ'UJMA\PCBY4:=&DY.A
MC(T\/[2G1C"$&J3?+[L>97>J2M[F2T)X/-<^PD)8IX.G++*F&CB*U>O%3K8:
MH\3*G5Q$ZDY.<XQ]H^>3323LDDOX9/\ @JEXL\=^ ?\ @O\ ?'OQY\+?#7_"
M:?%#P-^TK^Q'XT^&?@S^QM8\1_\ "8_$7PI^S?\ LD:_X&\)_P#".^';FS\0
M^(/^$D\4Z?I.B_V%X?O+37=8^W?V;H]U;:C<VTR=S_P5'_X*#?\ !3_]H_\
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M?3OB[XSTWX@>)OB#XS\*6UO\)?A;:? CQ[X9TNYTW0O'//\ _!*[P7_P4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_?\ ^"4W_1U'_F#_ -H__P"=!039]G]Q^NU%?D3_ ,/W_P#@E-_T=1_Y@_\
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M#_@LM^S#\(?^"=?[/'P\_;P_:]\>ZU^U;X>_X6U_PM34_B=H'[0?QH\<7/\
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M6WNK:7^SK\5=+&KW?CF\\5Z/<Z<_C"SU 6>CZ;<MX;M[<QZIJ/XX_P#!'_\
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M6YM] L/%'C'XNZ? LOP9\(O-#X6\-W$.MWL$BWOB3Q?X#_L)_L=_%+_@IO\
M$;X':W\4?C':_P#!/;Q'X2\%^'_V3OCGI%UHUM\7?BA^T+XJ;X)Z1_P@?BG3
M[[X5WUSHFA'Q3X@^-6F6^JZ[\&O 6D0P>$?#EQ<^+GM;B&]\4?FM_P % #::
M;X/L9[:5Y%?Q]H$0,P)&&\'^(';A(XVR&3 )XQG@Y!K[,UR']B^']EWQ3JO@
M[XN^.=6_X*,:CX&^(UC^T9\ K[1M8B^%_@'X-M9>*DTOQ9X6\02_#33=!O\
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M*02N"05!]ATK[IH)N_/^O^&7W'\"7[<W[!W_  33\"? +]INV_8.^/\ \?\
MXU_MI_ OXF1?!W3_ (0?$U;'2O!$GQ&\'?%;PCX7^,WAW6];U'X"_"70[_\
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MI,>G'S(KJ>Z^+7[.<UVCA;O4VBCCD>T6(2R0-ME?+R%6:,"ST2>_2_6RO?\
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M;3_^=G7]AE%'^LV8?\^<N_\ ""AY>7E_6EC_ %2RW_G_ )I_X<<1_F?QY_\
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M=?V&44?ZS9A_SYR[_P (*'EY>7]:6/\ 5++?^?\ FG_AQQ'^9_'G_P .@/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\56/ANW^&"^'XOAAJRZ1;:V?'HU&[U.P/AYU_);X9?M[?\ !P%\0HK5[/\
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M3<:@/$MUOGTO^DVB@#\3/V?O^"%W[$'AK]GGPWX+_:!^!V@^./C;X_\ AO\
M"7_AK'Q?X5^+_P ?;3PQ\4?CAX5TFQU7QUXR\.0V_C3P>F@:#K'Q,G\2>(]'
ML?#GA7P'8C3]0M[-O"^D6,,.BV7P/_P4H_X("_%7Q9%\ H?^"0^L? ;]EB/P
MK;_$:T^.*_&[Q_\ %_Q1_P )C;W<'P_MOA/'X9/B7P%^T2UO_P (Q!8?$9-:
M>(^%'N?[?TEKEO$#P0MHO]5=% [_ -,_F5^(_P#P;^>'=._X)[/X/_9NT'X2
M?#[_ (*@:[X*^#>L>-/VCO$GQ/\ CAJGP@UC]H(ZG\-Y/VG/'=OX>U;3?&>A
M6F@_$;2=,^)5KX5TNR^!.G:5ID_B'1VTSPEX':&*XT/Y?\$_\&]/[64G_!.'
MX_?#7XM_$#]FCQ3_ ,%+?$/Q7T/4_P!GO]H71_''Q:L_A!X%^#EKK'P5NM8\
M)^*M%L_A!X?TF[UZZTW1?CC;V]S<_ _QC<+/XR\-D>)+;[+;S^%?["J* 3?]
M==M/338_.7Q'_P $E?\ @GUXMTN+1?$'P _M#3(-035(K;_A:OQLM=M]';SV
MB3^=8_$BVN&VV]S-'Y32F$[]YC+JC+^#?_!.7_@WX_:]\&?&WQ1J7_!53XB_
MLT?M+?L\S_"O7+#P;X$^#7C3XJ^'/%&D_&:7Q=X'N?#WBV_OM ^#OP"O9=!L
M/!%M\1-'NK67QCJ5L^H:]I<S^&KR6"'5-&_K^HH"[_KIZ!1110(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _BK_X2;_@Y8_Z/#_: _\ %6GP1_\
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M5:?!'_YV-'_"3?\ !RQ_T>'^T!_XJT^"/_SL:_M4HH#F_NK[OZ\_Z6O\5?\
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M (2;_@Y8_P"CP_V@/_%6GP1_^=C7]JE% <W]U?=_7G_2U_BK_P"$F_X.6/\
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M #L:_M4HH#F_NK[OZ\_Z6O\ %7_PDW_!RQ_T>'^T!_XJT^"/_P [&C_A)O\
M@Y8_Z/#_ &@/_%6GP1_^=C7]JE% <W]U?=_7G_2U_BK_ .$F_P"#EC_H\/\
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M3_P>ANR_\%./@9M9E_XP)^%G0D?\W$_M0^E?Z:U?PR?\'-O_  1P_P""B_\
MP4._;L^%'QD_9%_9W;XM_#7PU^R/X"^&&N>)%^+OP)\ FR\<:)\9?CSXLU+1
M/['^*'Q,\&:]<_9M!\:>&;_^TK32KC1YAJ7V6WOY;VSO[>U"HO5]-':_<_SX
M)3&VH!9F&/L8(#(7&?/(!QR,XR,]?SK_ $%O^#8?XN_M:? [_@C3\7/%/[)W
M['+_ +;_ ,3M0_X*;^/= UKX4R?M$_#C]G ^'_ =W^RO\ =1U'XA#QY\3=.U
MC0-5&D^(-)\.>&_^$1M((]8OCXL.LV\RV6AWZ2^5_P#! '_@WP_:>^!'[9_Q
M*\;?\%1/V"/A'KWP#U']F'QEX6\(6?QHU/\ 96_:/\*Q_%^\^*WP:U;0+FP\
M#Z3XS^*%UI7B!/!FC_$"*U\5OH-G;V.G3:KI#:O;R:Y'9:A_<[\&?@!\"/V<
M?"]_X(_9Z^"?PD^ _@O5=?NO%6I^$/@S\-_!WPO\+ZCXHOM.TO2+WQ)?Z!X(
MT;0])O-?O-)T/1-,NM8N+234;C3M'TNREN'MM/M(H0<FKZ+\=.G_  VEC_&:
M7_@JU_P5 ECN"/\ @I#^WLDPMYF\H?MA?M#'RR!A6$@^(87/W6!&"-WL:+/_
M (*J?\%1A:O)+_P4A_;W;*,0S?MA_M",1M,F2/\ BXI/''IT&*_;']DC_@U5
M_P""@?C!OVFS^U_^SKX\^% \-?LB_&?Q;^S ?A_^T%^R??GXC_M@:+_PC0^"
MGPI\9_8?&OQ(^P^ ?& N?$Q\1:A>?\()8VQTZS^T?$CPOO3[=Z]^QC_P:>_M
M1^-/@)^W'K?[:WPD^+_P@^/7@/X11:O^PAX'^'?Q\_97U/PO\:OC#)X-^+M]
M<>%/B;=:?J'Q0M=+T!/&VD?!_1UN-1\7?": Z=XKU^7_ (21X[>?5/#8.\7;
M_@)]%]W>W;T/@']B[_@XL_;'_9D^!'[<GPE^+7C_ /::_:K\:?M3?".W^'?P
M<^,7Q&_;(^*D7BC]DCQ1'X-^+OAM_B5\-$\3:+\1=6DU^75OB)X7\4,OA?Q1
M\-=0_M'X:: #KS7+:=J&@_$FM?&C_@K5^V#^R5^U-\1_%/[3O[77QQ_9-_9[
M_P"%'M^TU9_$O]KOQGXK\$:,OQ;^)<6A_!4ZW\,?B!\4GOO'?]I?$CPS;3::
M/#GA+Q2?"^KZ38>(-8_L.*VL]2'V O\ P; ?\%PL'=^Q$RD]=O[2G[(/O_U7
ML]J_J*O_ /@W9\7_ +/G_!"W]J[X"_LS>&OB]\0/VX_VY?A#_P $^-6^.7P6
M^(7Q6^ W_"->$_C!\"/BYX(^)7Q*\*_#3Q=;:?X!\$Z9H/AJZ\3?%-7N?$7Q
M*\;0:UIWAO0;7P[XDU2^E6X\0 >ZM%9:[[]8]=?/YH\]_P"#,#X__'WXO^$/
MVY_!7Q>^-OQ>^*7@SX->&_V*_"WP=\)?$?XE>,O''ACX4>&)-+_:1TF3PY\-
M= \2ZUJFE>!-!?2O"WA?3'T?PO::5I[:?X;T&R-N;;1]/BMO[@J_D;_X-8/^
M"8?[<G_!-]?VZ8_VS?@B?@XGQ@'[,*?#,M\2_A#\1#XD7X=#]H5?%Y/_  JG
MQ_XX&CG2!XX\*Y_MT:5_:']J?\2L7OV'419_UR4$2=W]WY!1110(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%OX/_P"$?@U2WU_4=5_:(O="U"UU,6&GZ3J/P(^,MQ>:HFB7WP-U?XU_T7_
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MPW>?%;QQ::'\6IO$/_"%ZQX$^'WP=O-(UO5-? _K=>7^?E^#/[LO@S_P7/\
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MK@%M>EM-4_3OZ_U8_P!<&BOP&_X?X)_TA>_X+\_^*XI__GO4?\/\$_Z0O?\
M!?G_ ,5Q3_\ SWJ M_5_Z[_U9G[\T5^ W_#_  3_ *0O?\%^?_%<4_\ \]ZC
M_A_@G_2%[_@OS_XKBG_^>]0%OZO_ %W_ *LS]^:*_ ;_ (?X)_TA>_X+\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGI_5S^8__@B'^UQ^V7XE_;W_ &2[7XX?\%2/VF_%>K?MP^&OB+\;?C-^PO\
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M\M]IWB+3O"OA6XTW2?"VMGX@:O\ $<&NO_!W_P"&N>__ /!$7]H?XP_M7_\
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M_MCQ#J&DZ!I/]JZ]JUA8?VEK>J:;I%C]H^U:E?V=G%-<1@'[-?MS_P#!R_\
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M$NB7'B?XF:?\'O%?C/X;)XET\:II/AKXD_8P^%+> /BE^Q;^VU^T9\-FO?\
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MG3M,^(OQMB_X:]UKQ;JOPM^+?_"H/^$>\,6$'BW0/%^I:F!]Y_3S\!?V]/\
MA?'[4GQJ_9>_X8P_;Y^#7_"F/^%A'_AHGX]?LZ_\*[_9;^+'_"OOB#H_P_\
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MA1\>OB+8?$+XPZ;:_L[^-]<\,>!/B_XF^.7PS\6>&/#OB?P6_B#QR#Z=;_\
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M\<>%M5T?1[G1VTNT^W*_(?\ X(+^'OV=/"W_  2,_8HT?]E+XB^/_BO\%4\
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MB_VK]K_LO^VM6^P^1_:-YYWOE%% !1110 4444 %%%% !1110 4444 %%%%
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M-/\ 3_\ P2I_Y1>?\$W?^S"/V/?_ %GGX=T!T7J_R1][T444""BBB@ HHHH
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MCWP-^W[^QO\ M"_L>_$.\_LC0/CE\/;[PWI_B;[-J^H?\(/XYTR\LO%/PO\
MB+_8NB>)O!M[XE/PX^)>@^$O'8\)3>)M(TCQ<?#W_",^(+A]!U;4K>8 _C3^
M/7_!:[XS^"?VQO\ @J'_ ,%1_!/Q4\?_ !0_8:_9/C\'_P#!/[_@GO\ !36O
MB1\6O#/[+OQL_;A\7V5E!K_CZQTK]GJXU'X$_M#^!/ W@?PA^T]^T+J^M_%;
MQQ_PE>K_  \\;_LX:1HFL> _$_B'X.WWPN^?/C3_ ,'%/_!1;]I']D;_ (*F
M?LZ_%>U_9_\ @7\;_@1^SS^S_P#'?X9_M%?\$Z?C[J-S'X:#?MF_LC_#SQAX
M8T_XM?"CX_?'KPIXOD\7^%OCSIMG=:U\-_BUH7_"'#0O&OP_\8:1XAU+Q#J%
MGX,_;?P9_P &N?@31/\ @DA\6O\ @F!XQ_:L;QSX@\9_M=6/[87PT_:0_P"%
M&ZOX:;X2>/8/!GPV^&=];_\ "H=-_: GLO'W]H?#7PM\0/"1G\0^/[;2+7_A
M9IUZ'PU_;W@S0[^?R;1?^#5?QVO@G]N7PEXM_P""@?PBU"?]MWX.?"GX7:U?
M_#?_ ()@? 3X"Z;\-M2^$?QW^!?QAT+Q%X+\-?"+XK>&]+\/:#K6D_!V_P#"
M_C?X<_#P_#?PM\1?%'B;1/BS\1QXP\:?#KPVT@-=/\O3<_"?]D[_ (.8OV^?
MV5?V6/ _P _;)^'P^.GPS^.W[('[3GB3]G+]HO4_BQ\9-0_:N\5^,/$GQ$^/
MGP_^'7C[XI?%C2?VB--\;R^ ?#GQV\ >./@U?6?A#6/@/\<O GPXT#0?B+\,
M?&<M[X.\)V7Q#^F/V7_^#B[]OWPQ^Q=^R[HG[.?[.GPC^*/[4O[9_P#P47^.
M/[.O@&P^-'QU_;'^-_A.*W\ ?"W]BZU\-^%;/5OVJOVOOB'\1-*U[X@>/_VF
M=$BM-4N/VB/!_P 'O >G>%M5N)?AS+K?CKQ!XUT[[B^+O_!G-_PM3P!^R-X&
M_P"'B_\ 87_#+'P \2_ S^U/^&1/[4_X3O\ X2']I[]I#]H__A*/L7_#3VG?
M\(Q]C_X:"_X0W^Q/M?B'[1_PB/\ PD/]KP?V_P#V'HO;^"/^#2_QW\*_A5^R
M=X3^%G_!3<^"_BA^R%^UW\9OVP/AS\7/^&,='\1+_P )O\3/#O[(>F^%K%O
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M6[_PN3Q]^V5XX_X2G_A(O^%X>)_^$!_X1S_AK?\ LO\ L3^PO&O]K_\ "O\
M[;_:^E_\)7]D\-@?\#U;_K].I^(G[)G_  <H?M,^ _V-?A)\&_A?^S>/B3_P
M4D_;2_:]E\-?LO>"_B_\2?VS?B)\#+KX,:UJGPS^#_ASXC7GQ7_;._:E^)WC
MOQ@OQ ^.F@_%GX(^$O"7PZ^/_@[X2^"/%W@3Q_XT\>7'@C5?#.H:+\9?W2_X
M)3_\%Z[_ /:$TW]K_P"'W_!4;0_V8_V!OC+^PU\7_!OP"^+'C?6_C]X5\$_!
MKQS\8?&_B?\ :/LY/ /A&W^(GB?5=)\/Z]X)TC]G_6+*>#2_C=\68?B%-IWB
M3QGX=N-#\.6D>F6_P/X4_P"#0[Q1\/=)_93\1_#[_@IYK^@?M"_LA_&'Q+\2
M?A;\;M7_ &7-0\=:;H7A>'Q;X ^*OP=^&/A?X.>-/VIM:^'/A'P_\)OCC8?&
MSXP7+6-E=Z=\2O$_Q]\2KXST">/189=7_3?_ ()[_P#! /X>?LR>)_VW/&/[
M;GQ-^$7_  4WUK]MWXP?#OX^^-+;XU_L;_#/POX4\._&'P=J'Q_U+7/'VG>
M]8\8?%GP4NO>*+C]H3Q9%:3>&]!\&P>$M.EU31]&@?2==DLK$#3IV7??2_\
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M_A4D^H^%]536_P#@U0_L_P"''_!-(?!W]O)OA)^TY_P3D_X3P:-^TN/V7_\
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MT[Q;\-_"7Q#\"Z)\5=+LO$&A^+/AGH<OCG5OBA\._B3XQ^$6@_KS_P $>_\
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MMV%S#H.EZ9XNUE/L-M+JLUQ\XZ1X2\7^(UDGT71]5U6&V7S+K^SK"XNA'&K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_SW?\ @K]^T5X3_8R_X+^>.?B%^P]^U]^US\-_
MVUOVA_A[\$_@7^TSX(^#_P"PA\#OVO$T4>+/AIX2G^'7@?X+:3\:/BK\+_\
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M<> *!K9^GZH[:OP7_P"#G(@?\$._VW2PRH7]F\D>H'[7/P$R/Q%?O17X-_\
M!S8(3_P1 _;9%P2MN6_9L$[ $E83^UW\ _,( Y.$W' !/H":[LLFX9EE\XI2
M<,=A)J,DFFXUZ;2:=TTVK--6MN1-VA-V;M&3M%7D[)[+J^R[G^1)JB+%&TUM
M)L!4L$'9N>,@^HYX_&DTU[R&"/4#<&.>"19(".SJ20PR1R#[5M>)9_#*7GE:
M+.]Q8B*, O'*I,Q5=R[9$4XWYP0,?A65%87MXL9".MKNP,$!<' S@'V]*_MS
M#4H\3\15\SR3 8W,*F.R65%\*91B,9*CE^8XFI&E+'YK2H3<,'AJ$I2G3BU&
M+6J5EI\G1K1J8&C*K"6'A5M.7URBJ=;V;CK2E3GKSR6DXN_9[GKWBCX^^-_&
M7@O3O ^N!;VUM([2VM[QI,2>7:&/RLKY?4B(9_><=1Q7F TF]@1)A;-=MPV$
M5CM]N%;^AQ^MJ71)+%H9N7A 4\$';D#MUS^E?17P-\<:-X-\1VU[XBT:QUS1
M3*OVF*^M([T*@ ! ADCE8],X"'GWS7[7X>^!N/RREGV49QEF<T>(L)*AB\@R
MS+,+A*LJ52M[*IB,QIX:=%TLRI5ZB<UB:T*W*H6>J.GP_P"&^#JW$&2\./-L
MHX X9SK-Y/-L_K82M5RW*ZF-G%5L=BL-0G"I&FI<LJT:4H*,??LDK'ABZ6]T
M(IK\M%%D$QE2"#^)'.,^]=Y86&FSVT<4>(DC'$NT$G&><<=_\*[[XKZ]X3\8
M^+]3OO"5E!8:1(_F06L-I]CB0*6!"0F*$*.0.%X^E>9PW$%NXMG8)@A0HSSN
MY POKG-?Z8>&7"G!_ N-HYOB,+D&?Y;Q)EV"PF89[F\G]>Q^;1C1]OEU3%SJ
M-9=2PV)@^>EA?8U(U(<L$HZ'RW&&"AEN?9UDF7YSA\ZPF39KCL'@LWRJ_P#9
M^:8/#5YTJ.9X-2YG*CC*<8U:3FY>Y))NZN=%HFB2ZQJ\.B6&V::Y/R2N,!<G
M&".?;G=C\:E\:> M1\$ZDEIJ4R2.Y/"J .F>NYNHJSH\_P!DS<6\LME<*_[J
MZA9X957 ^[(F'7OT.?:LCQ-J>I:I>6O]J:A=WSR31Q)/=3RW#YD8(/FD9F &
M>23TK]$\0>#*F4\.4N,<=CLF?#E"<<3@LLP_MJ=;*:<J]O95:\I^UE05N:-;
M'.M&K&RA)+0^%HU<TEG--4L31CED<-..*H5*#>)K8A*\:U.LFH0C%:2II)MJ
MZ\L>ZMC+;D>6 NP@'OTZ^_K_ /KKD6L[G3B\R@NDO"J>.1QZGKG\:_6L?L=^
M%/#G[-$/Q@\5Z["E_>:-J.H65M%/YY+V[W2PH4@:3:6\E.& Z^U?FCJ-FDXD
M\H@QI(YC!P,KGY3@X.2,?_KK^>\HQWAS])'+L\XI\,,SS+,,QX$QN*X>J9I2
MPL<-0HYW@E"ECJ%*LOW.,I4(.K!4Y0D[N+>Z/%X#\3N'N-)Y[#A^M6Q>$R+.
ML3D688BKAZM+#5,?@YN&(I8:K/2LJ4XVG4@[)V7D>)7^F7RS-.82/.<D#!P
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M50P&.KX*OA,*\/AJ]6GCL7S?4Z4J5)SIU<32BU-X2FH\U65/514FK:'[>?\
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MGXH\6^"?#/[ W[0&@?'?X>^'M>_9F\#>/ET.36/A!XAU36?$=YHVG:OX2O/
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M** "OX OV7/^38_V</\ L@7P:_\ 5<>&J_O]K^ +]ES_ )-C_9P_[(%\&O\
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MY_P3XU.?0_'WB&;Q-?2Z4=&TZ>4Z;J4Y-NWV>!I"NQG96$@&2. 5/3K7U7\
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M?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>+X-8_LK7XM5T33?TWH$%%%% 'P+_P %6_\ E%Q_P4F_[,%_;$_]9X^(M/\
M^"5'_*+S_@F[_P!F$?L>_P#K//P[IG_!5O\ Y1<?\%)O^S!?VQ/_ %GCXBT_
M_@E1_P HO/\ @F[_ -F$?L>_^L\_#N@?1>K_ "1][T444""BBB@ HHHH ***
M* "BBB@ HHHH **** "OX OV7/\ DV/]G#_L@7P:_P#5<>&J_O\ :_@"_9<_
MY-C_ &</^R!?!K_U7'AJOZ.^CG_R..)?^Q;@O_4JH?SY]('_ )%/#O\ V,<7
M_P"HT#W6BBBOZR/Y:"IK?_CX@_Z[1?\ H:U#4UO_ ,?$'_7:+_T-::W7JOS
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M4K3]O)UIV527*K(_2.'\3*M3FY-1I48J$O=M44UUEZ)6T2_*W^W9_P $K?\
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M_%NG^+;K;>Z]<HOUW7P)_P $O?BY\=/CK^PO\#OBK^TI\//C_P#"GXU>*O\
MA99\9^ ?VHK'P?IOQUT$:)\8/B!X<\-GQU9> ?V=_P!E'PE =5\):1H.M>&E
MTKX!> BWA#4?#\E__P )1J;WOC/Q%_.?_P '8?[4O_!5']E_P-\//$_[,_QI
M'[.7[%7B";X5?"[Q=XQ^&&MQ>%OVB_B;^T3\0->^,_Q#N="T3QQI/VOQ[X ^
M'_PH\ ?L[^$KG4]3\&ZQ\*KSQ5=?&G4/"FHZC\7/#5SXDT3X: )7=C^RNBOY
M$OV@/B3^V)_P4K_X+C_MP?\ !)O1_P!MWX^_L2? 7]EC]D#PK\;/@SX@_9!U
M.P^&OCK4OCMJG@[X 7FE>+OC9XUM85^)?Q*\ VUW^U#XCMO$7P<\*_$;X6>#
M/$ND^!OAW-$="\<:-?>.]4^^?^#;K_@HC\=/^"DW_!.0?%G]I74?^$J^-GPL
M^/7Q0^!WC;XE"S\'Z&/BBVE6'@_XH^'O%/\ PAW@'P5X%\)>"O[&\*?%C0OA
MR=%TG3=0&I'P(?&%[JKZCXHN].TT#^OR_P S[Z_X*M_\HN/^"DW_ &8+^V)_
MZSQ\1:?_ ,$J/^47G_!-W_LPC]CW_P!9Y^'=>!?\%E_VD/A[\.?V"/V\_A#X
M@\._'K4/%?CS]@7]J/\ L35O ?[*W[4'Q3^%]C_PE'P9^*/AC3?^$S^-_P ,
M?@_XO^"_PY^S:E8S7/B+_A87C_PO_P (AX>>S\7>+/[$\*:CI^M7/OO_  2H
M_P"47G_!-W_LPC]CW_UGGX=T!T7J_P!#[WHHHH$%%%% !1110 4444 %%%%
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MD_#[P+\3M1L/[2TC2O(\"_!/XT?#3XS?$_6_M6N:AIME+_PC7PU\!>+?$?\
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M%U:4IV6*HTN9*[A!J;1@)JL-A++'; O"X(CR!G##OSZG\/6O]I/_ ();-O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S O\ @IS^Q_\
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M^"</_9AG[('_ *SW\/*_R>/^"NU_;>)/^"CW[>NEV%JT=WH'[</[8]G?2E5
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MT7PWXI\5^+-1\$:;XJMO!0\5^)K;P]!KM_\ LO0(**** /@7_@JW_P HN/\
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M?M:7/'%XS$N-5UJ3C&,'.JY)I,_)O$'%XO/,+F&99SGBP57'8>OE>5912R7
M83+X9UB(3653PLGAO:4)M\E!U83A22<IN2?O'ZI^,OV#O@WI6DVT_C#6K.#Q
M+KZI-HZ7FN/!)%#+A8O+MY+U 1YOF'_5GGITKXY_:!_8<TG]F+X@?"75_B_J
M7BF\^"NN>,- A^(5]X#M+'4O%2>"))Q=^((O#2W<UII_]NW&EV]Q;:7+?7<-
MM!=31W$[[(B*\M^)W[5'Q'^._B/P]J4]@VCP>&8;:T1;2\DN5:."62;._P"S
M6VU_WHXVM@ ')Z5[;^TC^U=IOQ-^&MCX,6ZN=>U&.2V+3WUV'-DUM:3VY,:>
M1DD^;C[RX]S7^=7AA]$#QNR7Q9X>EQ#XBXGB'AMU\SCXCX>$I5JW#^%K8:"H
MT\C>*KU,!A,/B93K0K5*5&:Q2HQ34Y1U_7_H:>#&)GX-^+_$7CO])NIPOQ;P
MMEV79MD/A16P6"S? <6YA6GF,<%EF&Q%*&(Q,(T?8X5598*I35*5=5L0^2!^
MS'[8?_!?C]A#XD_\$^?$?_!.[]G/_@G[\2O OPETSX2^(/AM\%];U;XNP^%]
M3^&6I7FCZA;Z-XJ(\+-KOB'Q%"==O6U;QSX?UOQ7=6GQ-LKG6-'\8R7MKKNH
M*?X[K+5=5\+:C;:IH[O:ZE:R+)#+Y*2[9$(*MY<Z.C'/9E(->EVEXEF98YT\
M[+-C/ Y[<@YQGUR.N,Y%8U[>6JZA;7KV*2)')GR2V!)R."=AQGN,$8/3-?UK
MXA_15\*^"O"_,<;X<YS7H9EC'[?,.&,]Q>89U.%>K4ITL;C?[2S.I5P6%=>E
M^]K\G)&LY<LN9J)JLXQ6.G4H8[!4L70E1G3Y>2C3I8BFX?[O.DURRA+X;3BX
MJ+ULDS[!\9?MX?&'XS_ O3O@-XQAA\41)::7I]B(M'TRWN0FF/:R08:SLX;@
MLJVB9RQ)P<Y&<^:?"+Q7X]^$,6KZ);>"=8GU+68S,;==,NIY8X9HE@1L)"[*
MN8C@\=_>O'M4U:ZL=?TWQ'I.G6UA-;B*2*VBE5@?D^\6"#DJ3GY>OKQ7V+\+
M/VGD\/\ FZEK7@VQU[6;F-+*)I;Q8_)C5 J'+6$O&]W;M@G(K^4>&O 3,^"^
M'N(<!X6>&$>):6=X>GG>-X<R2IA\/EV)SF=?#SQ..P&85YQC4JUH4E5Q%.C)
M4*2I*+C[]CYVGP'X.\+^!O&T>&N'*N7\:8WB3#Y[E'A_E,*.!X<SS$8R>'EF
MF(Q6886,*&5XJC.C&JI^TI4:T:<8I2DT?%MU8Z[HNH/>WFGWNFW%S*QD>19H
M9$,C%R 6PXP> #@<?6MW3?&_CKPS!J<>CZW=Q6>KQE+R-UBNEE1R,C_2(YF4
MGN5*G(SUKNOBKH_BZ6Z?Q1KT:6>GZI<_Z);PG?'$9%>54SA03M5QG ] *\C2
M=HE3>=\7 V=CT ]<=O\ ZQK^^^!<EI9OPC'"<0RAEV&K6Q>#AE<L-##Y)B;1
MP^*I8S#8=?O:=.N_:58J//[>"E02E9F.!Q.&XARW#XK&T,JS&5:,(XJBE',,
M,JU&4*GL55KJHJE7#58I*>W/'F7<P=3MXK^-[N\N0MXY+$LP3S"><A.%Y)/0
M?2N*TB(?:)5F0L"K889&.<#I^/\ 3FNZ\56J26BW,8,;;/E51GGD]>/ITKF?
M#T&7W.=^4?<&SP?\?RY_"OYU\6^$H4O''A/AO#Y1@J,\%@EBJF=TIRK4,]PV
M*HT::Q68X'%2:IXF*3TA'VBIR=2:3=S[K+ZRCE=:HIRY6U"-*W+['D>D(.-K
MQ2MI:VR71'^U?_P2M_Y1@_\ !.'_ +,,_9 _]9[^'E?Y(W_!3[5Y=._X*G?\
M%*8R!Y<G[>G[7N-P&./V@_B)G!(]^W]:_P!;G_@E=_RC"_X)P_\ 9AG[('_K
M/?P\K_(]_P""K-GYW_!3[_@I#(SA/^,\_P!K_P OW(_:#^(8[D=_TZ5_G-]&
M''<3Y/XD5\_X1Q%?#9QD63XO,(.C4IT8U</]:PN%Q%"M5J.,(4JE/$.*;NG4
M]G&SYCZ_.HT:F#]C72=.K5C!W3=G:3326K::OIYGQ7)I<]Z)+L0-Y3L9"RJ=
MIW'(P1D?ECKQZ5/;^3%874,QVR!9!&A.,G9@<<9R?UKUO18?"T'P[MFN+\'7
M9&M8Q;$C.TR1AR1OSPFX_=QQ7G?B#3(HY ;1Q([)N  '<MQP3_GUX-?[$<-\
M/<-9[P!6\7_#C$?VUCEAL3D/'629YA5@<RP/$.84&\7A,/@*D</B,73H.O&O
M@J]"-7#XB3<E)N.GSW$^0YIPMF&695G-; 2_M3*<!G^75<KQ]#,*2R_%N:H1
MQ53#RG'"XQ*C-8C"U7&M13CS1CS*_#:;=/!<,A7".^.1VR1P2,]^W/->N0Z=
MIME:07S*@,R1NREB>7 /<\<MZ<<#K7E"VTCS[2-LB$<8_IZ#'^17J&F!+ZS2
MRG8B544*3S@H <=A_#_G'/T/T/:<J-3BC(,TR? 9SF2H2_U%Q&?4*,*6"SAX
MAU*^&@IIRHUJKDZ7L)2A"]G)VO;YO/W=4*L*DZ<+IXJ-.3;G3Y59O:Z2UOJ_
MP*>IKNN$CC)BMY(U(()V\DC//M@=?R)KA+M)(+@Q'/D9XD8?3N1]:]+^P2S7
M2V(P[QJ&''.W) XSQT]>GM6EHOPRUWXE^(;3PKX6A:?5+C+A$C+D(C+&V55@
M<;Y5[C/2O2^D)DE+%9/QQQ2\53P.-X)Q5+,,VP4J_P!7^JX>I3BL9E3=UA(8
M&@Z<JDOJZ=2TEWU\VAG. RJC4K9ABJ.&P6'PTL1BL57ER4</0@N=XFM-JZ2B
MG>4GT[GC;PH1B%@6_C8'/R]_T[XR,?C1Y;RQA$_>)&&W,.Q([X_SVXYKU?XH
M_"7Q)\$=:N_"GBZ!H=:%DEPR-$T0V7%NLZ85F?)"3(2<UQ_P]TO3-9&IP:E?
M?8Y%$9ML\^82)"P W)]TA1U/7Z5_#>:<6\*93E_#6=8NM2JY5Q=DWU^O+AV3
MQN'PF%E4I?45:$9TJRKU90K8Z?(Y4X0DYNZT^\X&P$O$2OEU+A7&Y?F%/-J<
ML1E..K8RCA\#CJ2PT\2JE/%UG"DO:TZ<H8?FDO:U)0@K.2/.1&T4TCLI^\P"
M'O\ -Z?0#)Y_I1<>:VUX_E3C>@/''7CJ,_S_ %V->TXP:C<VT$PD^SSRQJP_
MC1795;J>J@&L2830)O)R5^\OTY/YCTK\CS"DL%ALQI8>GC99%*7UVAFF%G1Y
M:R<E7]M"I22J)1ORU<%HIT[N4-#MK8>MAL3/#8F,:>+PU6>&KT9/F<*E*7LY
MP;5XNTHM1G%M/1IV=VQ68[I&C*(. 2" ?7';MU[9%?1W[,G@WP9\2_BYX;^'
M'C/4+33=,\=Z7XS\):1J-[<QV5I8>/=;\#^(K/X67%U?RS01V5JGQ.D\(?;I
MY)XX&L3<V]X)K&>Y@F^;Y+A[V-(U3RP#R!GG/KP/3_ZYYKZ2_9"^%7A#XS_M
M'_"/X2>/OCGX8_9J\+^.O%4&C7_QT\9Z9J>K>&?AU=&SO+O1=5U:RTFYLKOR
MKW7;;3=%AO7O]-T_3+K4X-3U?4M.TFTO;ZWY\ES>AA*^+=&O6Q&28K*JM.OQ
M!++ZKK4\1B,/*I4J8/ 4*;Q-2I0J+EI4U3J3G*FG&+<E?*I3;C&Z2J1FK4N9
M6<4TDI5):)-:W;2L['C\?AC7=+\376AZY8ZAX=U71]6N=(U>PU&VGT_4M(U3
M3KJ2TU"QO[6X6.XL[VPNX9;:ZMITCF@GBDCE171E'ZD>+O#?Q ^-WPX\+>!=
M+^*%S\2K_0FANM'\'VTUC/<6S1VL]N)1#91?:IC&+@0@2AQNE!^\5K]:O^#@
M7_@C]\+?^"?'PI\"?M._\+YUGXR?&?\ :C^,&DZ7)!H7A+1?A]\,[&WT[X8C
M7/B%XQTK18]=\<ZSK$WC'Q=:QZ]9R?\ "4V]EI4'B5;,QZHT U&Z_GJ_9+^(
MFH_#;XW^$?$,MS)'&+A+:Y6:9UB:)[BVD*Y.0"QB'\)XX/:OJ\K_ +,Q7"^4
M>*WAGA9\2YSP4\US=4>)<KC_ &;C\WA@W2KY?@J]:A#'935H5>>EAL51>&G5
MY>=-PBF/-^)N%^%> O$>MG/@[P9XD<=TN',5B?#3/>(ZF*6-X%SO#X>M.68Y
M/+"2BU7Q]'EP]=J<6X*,6VFT>8_$+X:?$CX/^)D\-_$7PKK'A/49I+<A=3L;
MBSD\J=8Y$EC-Q#$2/*D5U8<8P1VQ_LN_\$OUV_\ !-+_ ()X*',@7]AG]DI1
M(>3)CX!?#\;R?5OO?C7^?!_P4>_9YC_:)^$/AG]I;PXD:II.A17NJ6%O:K/)
M/;:)#Y%PXN5>(J&CLGP?(; &,M@D_P"A/_P3,\K_ (=N_P#!/KR$,</_  Q#
M^RCY,;=8XO\ A0_@+RT/NJ84^XK^0.-/'+,/'CPMX8XDS>5'!YYEW&O%&59_
MP]A8REA\AS2C2H*>#EBYWECJL8QDHXA2J1E33_>-W1_/OT3O&["^./ U7/ZN
M$PN5\4955_L;C3)<&ZDJ.39_@J^(HUL(I5[U6I*+J4GS3@X7M.33M]O4445^
M'G]5GSE^U]\*?'WQP_9=^/?PI^$WC36/AS\7?&7PN\76'P?\>Z+\1_B+\);C
MP=\7K;2I]3^%?B/4/'OPGNK;QYI'AK2/B!8^';WQ?9:/%JUKXC\*1:SX8U_P
MUXK\.:SJ_AG5OY'_ /@V[_X*(_M ?%?]L#QS\%OCU^T;XK^*W@OXV?L^3^-/
MAZOQZ^,'CCQQXOB^*7PJ\1Z+J6E>$/@U#XX\<WNFI/XJ^%_C[XL>-/B3H6A>
M']1\2:UHWP?\/^(?MNFZ!X!UT77]MM?YV_[>!\2?\$H_^"ZVM_M 6(^(,'@R
MU^/_ (<_;1TV^M1\,/B#X_\ 'WP*_:*U+6I/VI]!\(:!=_V5H>F?VUJNL?M3
M_ SX<:1XP7PIXQT;1](\/:Y!XG2_;0?B9J/T&54UC<NS?+U34L0J-/,<(U%.
MIS82<5B:--V<I2KT)I*"WY&U:6_S>=SG@\;DN9JI*-"EC'@,9'GDJ3H9A'V5
M.K5BGRM8>NH23:NG/KL?4O\ P5?_ &O_ -L[]IC_ (*V:A^R'^P3^T!\8?A[
M=:1)\+OV4/#</P2_:'^*W_"L=>^*9EU7Q=\3OBSX[\/_  5M[EO!7_"F-7^(
MNO\ @'X^SP:+XUU_P+X8_9T\1:_XIN[1="O/"GA;^G+XR?\ !3__ ()T_L->
M+-+_ &9/C+^TI<^&?'?P]\#>"X[CP]J^G?'WX]>,-*T&XTD6WA=?B)\1].\.
M?$_6]3\>ZKH>GVGB'5O^%C^,+_XG:WI>LZ'X]\4&]M?&VBZ_KG\M_P#P;8_"
M/Q#^TY_P4*^.W[8WQBU+0/&_C7X'^$M>^)?BG7YKK4/"?B>Y_:=_;&U_QS83
M?$C2?"'@;2]#^'][H.J^"]'_ &G=,\4:%JB6.@>']2\=>#KSPGX,N;JSL]8\
M%:^C?M@_LR_M"?ME?'^'_@E+_P $A_ W[37[1/QI;XVZ]X>^-_[0?C[Q]X[\
M ?$KX>?$N>WU7]ISXE>-OV:_BQJWA/X:_!KPM\9M+\4>._ACX7U;Q/\ %GX8
M7;:)\6O#/@KQ)IVC7OQ5\1_LVZOZ.,P>%K8NOAG2J/"Y'@\%@ZM7#U\)@Z$L
M5*4(XG$8G%XI3492JRJTX4:="M5KU*4:=*,8IREY6"QV)I85YC&O2C7S[-,1
M5PT,30QF,J+ 45.&%IX7 81QG5G[*FJDIRKX>C"G4]K4E:R?]>_[)_[='[*/
M[<.C>-==_9<^,&E?%&T^'.N:=X?\;6::!XQ\&^(?#M[K6F#5M#O+WPI\0?#O
MA3Q0?#VO6R:A!H'BRWT>;PMKFK>'_%FA:3K-YK?@[Q3I^C_Q2?\ !'+]KS]I
MOXS_ !;_ &P/"WQ__;P_:<T?X>:;_P $G/VPO&MS\1O%WQ4^-'Q93X):YHWB
M;]GG3H?C[X;\%IXPEUC4/'7PKT/7_$FN^';CPI-I_C-Q)J.D^'=6L;K6)'>U
M_P &M312_P#!2+QC-$9Y$?\ 8'^,+12W95[MHI/CQ^R*ZFXD7(:=P$:<J2K2
M@D9&#7Q+_P $C?\ D-?\%(O^T%O_  4,_P#2O]G:MZ66TL$\^P$9.?U;.N&J
M%.O.%)UHPQ%2O4E;GA.%[3C&:<'3J."<Z;C[BP6:XC,:G"N-J15*6)P?%#Q%
M"G.K&A.>%P4Z:T4U/E<J7M()S<Z7-:-1RCSO^J/_ () ?&SX _#ZV_;(^('B
MC_@LSXR_;>\"^%M(_9@C\7Z]^T]HGQJ^!W@C]FY_$WB;XW>'/"M[8>*_VF_B
M#K/AN>Z^.OB&^@\,SP>&[G2+I=6^'OA;3M9.IW6N^%;>W\A_X*K?\%QOV,_B
M)^PE\7?!7[&?[7OC[3/VD_$^M_!6#X;7WPX\"?M+_"KQ?;Q6/QT^&FN>.!:_
M$&X^'G@^U\)VT_PVTOQA:ZM)J?B71K?5].GN_#&Z]N];M])O_P"(K2?&'Q$@
MT+XF?#>R\%IJ'P=\0>+_ -G/XC>,/B"_ASQ!=GPM\6?AWX:_:V\*?"3P@GBR
MWO$\*:&_CGP5\7?COK8\/ZUI]SXA\3CX=MJ7AB\L=.\(^+8=0_II\5_L8?LA
MZ!_P;16'[4'@3PSX6^*/QZU+Q5\./B=J_P"T _@_Q5X-\>:-\1O$_P"U=X4^
M 7Q.^%<+:[JUSJLO@?X,^%M1\4_!$Z'9/#\(?B#XD\#R_M%:)X/A\8>*K7Q5
M5PRS 8;,\'6Q<\57KXW/ZU'"QIPPWL(K"8^G2?URE&E!2]O4E%.G0C1C&DY2
MA3E94WG3S?,<5EE3"X&E@J%+"\/+%XN5>>,E5?UBC5<88.I.O4G'V5.$I>VQ
M%2NW4Y82<5>9^G7_  06_;3U/3/^";G[6/[2O[;/[1WCCQ'X5^$/[5GC6WUC
MXG_&WQYXT^(^J^&_!MG\ _V9[_3/"F@SZ[>^)?%&HMJ7BOQ/?0>$/A_X5MM0
MU?Q1XW\5C1_"F@:KXJ\3066H?>FD?\%XO^"3NM:SHFA6W[7&E6=WK^MZ-X?L
M[S7_ (2_'SPMX?L[W7=3M=)L[SQ%XK\2_"O2?"_A+P]:W-Y%/KOBSQ5K&C>%
MO#&DQWFN^)=9TG1-/O\ 4+;^27]D[]I#]B;X-?\ !)3Q3X%_:Y^ &K?M3^(_
M'7_!3'X@^.O@?\$+'XA?$'X.:9<:I\-/V5_V4?"OQ%^)'B3XM>! 9?#FE^!_
M!GQE?2-/\/R6?B74_&7BGQOX=T^R\+1Z%:>*_B%\.OG3_@HOXT\=_$GP'^Q1
MX\B_8)^''[$'[*^J_"7Q]HW[%B>&4BU+XD?$GX2:)JG@35/%\GQ6\<:WK%I\
M1_B-8Q?$KQ7KWQD^&7CCQA\,/A_:^---_:(\6?$32=9^+.H^._$?Q0\284LC
MPV-QN,C56(H2Q69\01PU55L)1H6P6(KRC##X22J8K&1@XRC7J0^K4:"4::E*
M1<N(,7E^58&=&6%Q'U7*,GK8BA.ACL1B)_651A-U\73=/"X#F@[T75>*JUZC
MO[*,=7^]'_!Q+_P4Y^(7PX\=> OV4_V2OVG/'GPS\8^$QXL3]K3PW\-[#6_
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M?\,O%DGQ"^-^N:C\-IK+6? 5O:6L&OFU^'?PKU/XA10Z+\,]$NKS1/3OA/\
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M/ /P@^''[4>E:E\0/B?X@M?"?@?2=?\ AG\:_ 6G:UXGU"VN)M'\/MXI\?\
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M>+_ G[,GQVTOXC>,_ WA_3O%?B'PO=>$/B+X!UL>&=1U"32?[?T/3_B7X/\
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M5.G3IK:G"$%K)Z1BHK6;E-[;RE*3WDV[L****184444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7\''_!<_6/">O_ /!53X_?#[_@I=K7PC_8X_9/
M\>_\$YY/@M_P3X_;-\2?L&:=^V)J.J>+]7^+O[,_CSXW:E;?V#X9\<>-)_B[
MX9M)/V@OA9X3GN/$/PXOOV;O"_C/2?BE\-]*\'>+_B]'X[^,7]X]?QG>,?\
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MX*TJ\U07WB;4_,UFXU&:U-G9R6]A:_IS0(_DO_X*V^$?^"J_BC_@LC^SU?\
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M<7AZ;R+ S=.AB:U*',\7F*<N6G.,>9J*3=KM)*^B/?/^&JOVFO\ HX+XS?\
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M *&M-;KU7Y@?U(_\$L?^48G_  3D_P"S#OV0O_6??A[7WC7P=_P2Q_Y1B?\
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M2A.@U3P"C'!^RK5Z%2A&-+V/+"M1JTZO*Z24)Q<VJB^-29^ 7_!/+_@AH_\
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M$4JMO:I*W/9M/^=VZ_X-TOV;_$_[$GP4_9E\>_$G5;_XX? "V^.-MX"_:O\
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M;;F**0XDW@-MP<9!(KACJ$5X]O9^4CSSR)! '48\R1@@&6&%&XCYCC 'UK?
M\4\-87PZXPAA.(*7#6+XJP>7YC@,USS)9T<9D-7"RI2Q%##TL6YU(QE0BJ$$
MY-^TFY2O<Y\OH_6<%@,51P^/P2>&BZD<9!TL?&,()<V-HUKJG62BY5(S6EV]
M]3>\&1>'O[6O9-?8^0EO<?97XQ)*5<1L1G&6^4CK@FL.[2WEO9O+C7R"["-O
M^F>\X;'TQ]>O-=@GAR/P5XITK3OB'Y5MI=XL=Q<2VCB[,5G/&6C8?9?-8,"T
M8*@9'IUJ'XH:=X8@UV.7X=WEQ?>'7LH',\BSQ,+PRS^<A2X6.0!8Q"<[=IR>
MN./SO(N*<FEE]'!Y/ALTXNKXC#4^(L=0PF2M\F$I3AA_KF)KJE."ABY2E5Y5
MROD][9%8?'8>MG5+V%3'8C#YIET*^%S"$)5<CC#"R<'3AC(-4J>+JRDY>R;;
MG&/-%63.9MIX[<26<%PV)5(*C@8Z= ?\,FO9_@4UI+\0-%\*7_A]=?/B&6YM
M(-S8,#K97$ZR;?*DW*HA)/SKBO!H[.572= 25ZDD9]<'KZ9'YUZ[\'/C,GP;
M\>:;XHU#3K2^BAED59IX$N)+,W%O+:^;#\CNC!9CAHP"!GTKYOQ]SS,^%/H_
M^)>8Y!PS5X?XHHY'FZX6GD4)87#TGBL'5KX6M7K3=JM2&/5&479S<H\L6D[/
MDXOP&.QG#>?X?)L++-,TK93C?J6#IXJ6"KU\R6'DL(X8BCRSBXUG";2:YU'D
ML^8R_P!I3P#)\/OB+=Z<2L GMXKN.R0!?(1Y)D"CYCQ^[ZX Z\"OGBUD>SN_
M/<;\AE"<C@]QUST-?J[^T]\!W^(WA#3/VBM$U$ZO%K>GCSK>.X#O;-"9+AHS
M#(ZR(%6=2 $QSP*_(:ZOIQJ@0K)Y<;8(P1CM@@\^OTK_ "H\'O'O*^,/#3AK
MCC,.+<9GG&F7<1TLCSJE5E3GF&4<2X.V&QU7,\"DZE*C!P<Z;Q%)PJQBY-/5
M&O@IQ5A^->"\%&.-AC,UR;#_ -C\24W3E0JX3-\#^YQ6$G";]ISTZE.<8U)V
ME4MSI[V_VR_^"5IS_P $P?\ @G"?^K#/V0/_ %GOX>5_D7?\%5['S_\ @J1_
MP4D<N"3^WM^U]A.X_P",@OB$/7KQ^5?ZZ'_!*W_E&!_P3@_[,+_8_P#_ %GO
MX>5_DB_\%2[(/_P5(_X*03)*0S?MZ?M?%D+$*,?M!_$,8YXZ#/'?BOQKZ._#
MW^LW'>(P$LOCF5/^S*E6K1>*^K2IP>88&E[:FN:/MYPE4C^YWLW46M,_>\VK
M>QPJGS\C]HDGRWN^63L]'963U.HTO3?AGX%UWP5^TI>_&SX<ZO%X<^!/A/P]
M??"71]1FO?'^J:U/\"[/X8R^''LT3[+"T>LWWFZJ\KRKIMC;74\\1:V;;R^@
M>+OA#\.O!-O\&?\ A-[S7+SXD_ SQ#;:[/IU[X>F^&'AWXD^-&N]>T:76KR2
MY_M&/7/#%WHOA71+VZB(MX8HXGD6,K*L?@47PI\-77@B^\:?\+0T*"STE-+@
MU:T?PQXK::QUO5;62>TT5I(]-*7,LD\,UJ;^T$^GJZ>;)<)$Z,W*V_P'\=:E
M+X3N;G2_[*T_Q-K'A?28]0FNK">735\6WT=IH^H:KI%M>/J^GV=YYC2VDE[9
MVJ7B(5MWD9ES_8V=^,O!645>*8\,8C)\DS'),YQ6%S_+N*L'Q)PKFE?/LUH9
M77XKP&54.+J&5XS.,?F>39=D4WE>1T,7]6P4\/C*%%K.,/.MZS^BMXNU%PZG
MD&9<4TN(LDP&?9-B>"LTX3XVP6&X;H8_'95D>;YUB^!\RSS"\.97ALZEG.$C
MF?$M?*Z5?'Y?F>%K5_:9%F$,+]IZM^U!\-?AGH_P9O\ PW\/?#WC;XKZ3\ ]
M#\.P?$B/QQJ'E^"[Z\@UK3;_ ,.ZAX1LK&33[V_TF*YFG#7&HV\['4(RZ+&B
M^;\M_M!^(],\0>)OAO>Z'JMEK$=G\$O@[I.HR6-S'<K::QIG@;2[35M-N6C+
M>5?Z?>I);7MNV'@GC>-P&!%<M;_".U@@EN_&'CG1O!6G7&NZUX?\-:CJ6F:U
MJ<7B2[\.WW]GZS/%'HEI?2Z596-Q+9(]UJRVL;F[/D&46MRT?ET]A<:'JNH6
MD]S:7:Z;>W=D]W87*WNGW+6LTEO]HLKI/DN;2<IYEM.J@2Q,D@"[B*]S)?'R
MMQK*KPCAJSKY7AL=DV;2SC*\EQ6!P> 64NE@<?B(YP\!ALLX@KX/%8>>!SVI
M2QN.Q64X^A4RW,WA<7AY8>G\YG7@9Q#X;4,MS[/\N66U\RCB<.L)C.(<HS#.
MXPQM..9Y:\TX<H9OC<\X7P69Y?B%F_"\LSRS*<#Q'DV*IY[D,LRRW$PQM3I[
M;SE4R2.-A!PA[G'UYSQV_3K8@C:/,]T/*C/0#C)[<DXS@9'Y=*Y2+4+=[@2W
M%TZ0*,*JER"V3_ ,^H[9XQCC%27.KM>.L:RNZ Y5#N' X/!QS^?7I7[ID_CC
MP=3Q6+RZ5#-*^.R#ZO4R;ZWBJ-?+L]KXZ5GBISY_:O#TG"]'!4&_B:E'8^/E
M@<1*;2CRQE&]2:IRCR);0C/X922^)]--SO\ 2=*.L7N+ F0@J2K'*J<@9ZX]
M_P!.YK^B+]F/X.:'\'?V=Y/$UM;:9XEOOB-%#_:JRP11OHXL(9BOSE[@MO\
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M/V6_@QX'_P"#8'XQ_M#6WA'2-?\ B]\;?CO\._BAK/CCQ/X?\)ZGXE\(:QX
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M>,+35?AY\0O MW?>'?%/CW5X_A5HW@/X8 UU7>R_%??Z']5W_!&WP?\ L<^
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M_P!G:_\ OIG[6-?@=7UW^W%_P4C\6_MJ>&?@KX#\(?\ !*W_ (+.?"M_A_\
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MB'_BNW]M;_YQE?K_ /KWP3_T5W#7_A[RW_YI/R;_ %(XR_Z)3B+_ ,,V8?\
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MAS1-2AUS2?!7Q+\$R1Z_JWCSPE\19O$7]OQ?%?Q;XH\7Z]JD<WC;Q?XYN/\
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ME_ KX;>!O"/PNUKXB^'?!OPX_99UG7-*EU7X0?"&70+#_A'-;^-4<&@V=GX
M\:_$_P"(/CCQ_P"$O".AZ%=^&HM?\3_#\#7L?W4T5^4O_!'/_@J=X4_X*[_L
ME:E^TSX=^$'B+X&:OX2^+_C+X*>//AWKGBC3_'-CIOBWPMHGA#QE;7GA;QK9
M:1X7N?$N@ZEX+^(7@^ZN+O5_!G@_4=-\4/XD\/1Z5J6E:-IGBKQ%^K5 !7R+
M\'?V+_A=\$?VK/VR?VP?"FN^/M0^)G[<*_L[K\6-$\0ZIX>N_ WA\?LS_#G5
MOACX#_X5YIFF^%M)U[2?[5T'6+J[\6_\))XF\6?;]72"XT?^P;)'L)/KJB@
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M#:LVHO9LX-V9&+GS!/\ @WA_X+L:QJ_@'4?%7[&WVV#X<^'[/PGX:M8?C_\
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MP1V_X*5ZO8^(?B'XA_8>_:_?Q'<7MSK%]IT?[,?QE@U+4=0U:[:XO7LM'MO
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M?O66EY<[OZ+4****_$#T#X\_;Z^#_P"T!\>_V2_BQ\)_V7/BC_PI?X[>*_\
MA!/^$&^)?_";>-?AU_PC7]A?$OP;XE\3?\5E\.],UCQCH_\ ;'@[1_$&@?\
M$GTVY_M#^U?[*U#R=+OKV>+^;;_AT!_P7^_Z2B?^;L_MI_\ SLZ_L,HKU<#G
M&*R^C*C0IX2<)5'5;KX:G6GS2C"+2E-74;4XVBM$VWNSQLQR/"9G7C7Q%7&P
MG"E&BEA\75H0Y8SG--P@TG.]22<MVE%;)'\>?_#H#_@O]_TE$_\ -V?VT_\
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M]_TE$_\ -V?VT_\ YV='_#H#_@O]_P!)1/\ S=G]M/\ ^=G7]AE%'^LV8?\
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M)_-T#2/A*-.\46^HZ;XQ/B+P&U_X-W/^"F7[&.D_\%&/V:O^"77QU_8_T_\
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MXX_$SXG>/]:^,-UX6\9^*CX ^(GA+5O#/PM3P=_8G10 4444 %%%% !1110
M5Q/A7_D._$O_ +':P_\ 5<> *[:N)\*_\AWXE_\ 8[6'_JN/ % UL_3]4=M1
M110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^('[:'CKQ/\ "/\ 99\'^!]:_:4@\1?L>?%/Q-KVO^!/V<[/]N&Y\;> =$\
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M-_!MOI6J?L_>%K[Q/X8\2V>N>&KSP7\1M6\(:6"TOY>5^_GY>1_0I\5?C?\
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M8?\ JN/ % EL_3]4=M1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gjyjiv3jrhol000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1!*D# 2(  A$! Q$!_\0
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M4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4** +]%4**
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M_HHHH **** "BBB@ KX/K[PKX/H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBK%U8W-FD+SQ%%F3?&?44KJ]A.232;W*]%%%,84444 %%%% !1110
M 4444 >M?L\_\C_?_P#8+D_]&Q5]+5\T_L\_\C_?_P#8+D_]&Q5]+4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!;A_P!2M25'#_J5J2@".;_4M52K<W^I:JE %:]T
M^RU. 07]G;W<(8.(YXE==PZ'!&,BDN=,T^]NK>ZNK&VGN+9MT$LL*L\1XY4D
M94\#IZ5P'QQFE@^';/%))&WVR(9C8@XY]*K_  [T_0O[?EN-.T7Q;83PP'Y]
M85EB8$@$#+'+4 >AZGHNEZU$L6J:=:7J(<JMQ"L@4^V1Q4EOIMC9V/V&VLK:
M"SP5\B.)5CP>HV@8YKYY-Y=?\,YQ3&YG,IU7!<2'<1D\9K2T2:#3?B5X=BTJ
MW\2:#;7#NEPFNEU6ZX&U$4YR<^IZD?B >Y)I&FQZ7_9::=:+IY4J;18%$6"<
MD;,8P22>E,30])B^Q^7I=DGV+=]DVVZ#[/NZ[./ESWQBO#/&%UH\?Q;\2'Q"
MNMRV,,$#(--9OW9\M,EN0 /ZUN^$]6UO0?A%XBUSS;I[4/))HWVQQ)*D1P%9
MN3W.<>H/8T >I+X<T-(%@31M.6%9_M*QBU0*)NGF 8^__M=:LVVFV%G=7%S:
MV-M!<7)#3RQ1*KRD9P6(&6/)Z^M>-OX%$7PS'C%=?U7_ (2$6 U+[7]K;!.W
MS-F/3''U_*JGCC6IM=TGX<7U]#?S"^25KJWT[(EF.(\A ".2<D?6@#VJ31-)
MEN+JXDTNR>>[C\JYD:W0M,F -KG&6& .#Z"JD'@[PQ;7$<\'AS2(IHF#QR1V
M,2LC Y!!"Y!![UYA\-+D6_Q+O["U.L:;IS6 =-,UEF\Z23</G53T  /?//Y=
M'\*+B:>;Q?YTTDFS7)U7>Q.T>@ST% 'HU%><_&#6GM?#]CH5M=K;7>M726XF
M9]@BB!!=R>PY4'V)J+X1ZU/=^'-2\/RWD=QJ&BW$END^_>LD9)V/GN,AA] *
M /2Z*^9FMKC1)D;Q6WB71]<6ZS_;\;&XMV^;TR!C'H3].U>@_&'P]9/X/O\
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M^1_O_P#L%R?^C8J^EJ^:?V>?^1_O_P#L%R?^C8J^EJ904444 %%%% !1110
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MP='&&7]RN ?0@8%>P4 >?^ ?B'!KO@VXU;6KM()K1G>[<PM'%&A=@@4D8;@
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M"R"_>V:-KAM[  1 $Y&,8 _AS6IX>\9:'XHDN(=,NF:XM\>=!-$T4B ]#M8
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M^S@M+=3D101A%!^@J/4='TO6(TCU33;.^2,[D6Z@64*?4!@<5:CFBF!,4J2
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M\6>*?^$<M+&:&&.Z:YU&&Q=?,QY>_//&>1CI70RS10)OED2-?[SL * /+X/
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M==6,Q98KF%X7*'# ,"#CWYK%F\&:=/X&'A%IKH:>(%@\P.OF[5((.=N,\>E
M'%Z[J-Q;_$:SU.)=US'X4GN% '5QEA^M8;^#-"O/@K/XEN"\FM363WLFHM,W
MF-*<Y0G.,'E"/?UKU*7PM:)K=OKD3327MGI[64,3NHC=>OS?+G.>^<>U>,7N
MDV]]H5UI%EX>\7VNJ3NP71/,<Z?!*6_UF[ &T?>&3C/MS0!N7NBVOB#5_A9I
MM\':TETAS,B.5WJL"-M)'.#@ ^V:G?2;3POXP\8Z-I,9M]-N/#,EX;8.2BR#
M*9 )],_G7>V'@ZVBE\,WMQ--]MT.R^RQB-AY;[HPC$@C)Z<8(J>]\'Z??ZY?
MZM+-<BXO=-;3)%5EVB(G)(&W.[WR1[4 >:NAT7P5\/O&D0(_LM(H+PCO;2C:
MQ/T)X]VKJ?"/_%1?$'Q'XH;YK:T(TBP/4;4^:5A[%B,'W-)XPCMO#GP]C\)V
M>E:GJINK-[*T6.+S,,  ID88"\D'./X372>"_#R^%O"&FZ. OF01#SB/XI&^
M9S_WT3^&* .>^*>CWNM6.DP68MKOR[OS9-*GN?)^W*!]T'(R1UQ[UB>!9-(L
MO$.M6$6C:GX=U*:Q\Z329I ]LRCCS(SC).>/3KCIQWOB;PGI_BJWMDO'N8)[
M67S;:ZM9?+EA?U5O\]!5/0_ MEHU_=:C-J&HZGJ5S!]G:[OI@[K'G.U<  #/
M- 'E?AR)-:T/X;^&;]W&D7BWL]Q$'VBX:-W*H2.< \X[YKIK#P[I?AKXYV5M
MI">1;S:3+,ULKDK&Q;!*@] =HX]JE\5>&K#PYX8\/Z0FDZMJ.EV,SG[?92_Z
M;9,3N5UVKR"20> !@=\54\!Z"UQ\19?$%K;:V-.AL3";W6BWGW<K,.0&Q\H4
M8X':@##\+>!M$U?X6ZSK&H6[SWZB\-O*TK?Z.$+%0@S@?-ENG.36KYTFJ1?"
M>2]8SO,LBRLYR7_<@')[YKT32?"&GZ/X6N/#UO-<M:7 F#O(RF0>9G=@A0._
M''YU!#X%TR&/PXBSW9'A_/V7+K\^5V_/\O/'IB@#S"P\.Z19>&_B;<VUA%'-
M9SW=K;N,YCBV#Y1[5K&VC\1:KX!\,ZD7;2#HB7LEN&*K<2+& H;')QUQ7=KX
M(TQ=.\0V(GN_*UZ:2:Z.]=R%Q@[/EX'IG-1ZGX#TO4]+TFT^T7MM<:1&L=E?
M6TH2>,!0OWL8.0!GC\J .4UC2/#'@K3O$Z6OB&YTRWN;:-Y=.LY TD&6"[XU
M)R"^=O8?-U&!CC=3TZ/19O"^HZ9X,N_#^S4[>);^XO!YTX;.4:($GD DD^F.
M]>GI\+="?2M4M+^>_P!1N-4V_:;ZZFW3G:<KM;&  0,#';!R*@F^%&GWRVYU
M/7]?OYK5U>UEGNE)@*D'Y1MQDX )(/3M0!BGPMI?B?XT>)(]7A:YM;>TM7%N
M9&5&<I@,P!&2!NQG^\:PO[+M4^''Q"T=T,MEI&I3-81R,6\C &-I/ID_F?6O
M7;3PY9V7B?4=?CDG-W?Q1Q2HS#8 @P-HQG/KDFJ<?@G2DL_$%JSW,D.NRO-=
M!W'REA@[, 8'IG- $O@G3++2O!VEPV-ND$<EM',ZIW=D!8_4FM^N3M/ D%KI
M&FZ=_;FMR1:==K<PN]R-[!1@1,=O,>/X?UKK* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** +</^I6I*CA_P!2M24 1S?ZEJJ5;F_U+54H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXGUZ_TJ^%G_ &98
M&T,<6V;( WMZ\5]L5\'U+BFU+L9RIJ4XS?3]0I1MVG(.[MS2451H.1GC^9&9
M>,$@XIT1F.Z*(N?,'S(I/S <\CO3EG?R/L[.1#N+D =3C_ZU.AF>RGBGMY1Y
M@3.['W20014L52UO=U?ZE>B@DDDDY)K2OY-+;3;!;**5;M5/VEFZ,>V*&[-*
MQ,IV:5M_P]3-HK0N-,6WT:TO_M4+M<.R^2K?,F/45GTXR4M@A.,U>/I]QI:E
M;6D-G836KEFEC/FY/1AC_&L]2H8%E+ 'D9QFFY.,9XI0 6 )P">OI2BK*S80
MBXQLW<LZ@]G)=LUA#)%;D#".<D'O56M#6-,72KSR$NHKE"NY9(^A':@Z+?C1
M1JY@/V(OY>_/?Z>E3&<5%.^Y56/U9JG5=GMJ^O\ F9]%%%:#+,3V@L;A)(G:
MZ8KY3@_*H[Y'O5:BBDE825K^84X[=JX!W=^>*7]V2V"1A>.^3Q_]>I;*SGO[
MR.UMDWS2'"C-#:2NQ.22O+1(@'##(SSTJW>Z=/8)"TP \U=P [>Q]Z@N(9;2
MZDADXEB<JV#T(IKS228\R1WQTW,32U=FMC:$J7([J[=K/H,I=K;=V#C.,U-<
M1K'(KQX\MQN09R<>])<W#74[3,JJS8R%&!TIIW,5)NUB&G*[*&5<8<8/ -6+
M"W@N;H1W%RMO'M)+D9Z#I56BZ;L%TWRD_P"Z2WDCDB<7 8;6SP!W!%04I&,<
M@Y':K>EV<5]?)!/<I;1D$F1^@Q2;44VQ2E&"<GL>G?L\_P#(_P!__P!@N3_T
M;%7TM7S7^SX OQ"U!0P8#3) &'?][%S7TI5%A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"W#_J5J2HX?\
M4K4E $<W^I:JE6YO]2U5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI4;*UR(T^5-7>KO_ %Y!1115&AZU^SS_ ,C_ '__ &"Y/_1L5?2U?-/[//\
MR/\ ?_\ 8+D_]&Q5]+4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!;A_U*U)4</\ J5J2@".;_4M52K<W^I:JE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?!]?>%?!] !1110 4444 .
M#%0PP/F&#D>^?Z4VBB@ HHHH *56*L&4D,#D$=J2B@"W#J5W LXCF8-.,2.3
MEB/K59&9"64@'%-HI<J)4(J]EN%3VIMA-_I2N8\'[AY![5!10U=#:NK#UWQA
M9D8K\Q"L#@Y'_P"NGK,S1^3(Y\LL7Z9^;%0T46&FUL.+L4"$_*#D#TIM%%,
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M?,,YP0/P%5OA9J=[K'PWTF_U&YDN;N7SO,ED.6;$S@9_  4 =A1110 4444
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M\9U72[D[&1-@E@/W&QZ],_[PH [:BJ&M:O:Z#HMYJMZQ6WM8C(^.IQT ]R<
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MBW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\
M!?+_ /$T 8-%;W_"$>+?^A7UO_P7R_\ Q-'_  A'BW_H5];_ /!?+_\ $T 8
M-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\ !?+_ /$T 8-%;W_"$>+?
M^A7UO_P7R_\ Q-'_  A'BW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!
M?+_\31_PA'BW_H5];_\ !?+_ /$T 8-%;W_"$>+?^A7UO_P7R_\ Q-'_  A'
MBW_H5];_ /!?+_\ $T 8-%;W_"$>+?\ H5];_P#!?+_\31_PA'BW_H5];_\
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M^NY/+MK:)II7VD[44$L<#D\ ]*XO_A<W@#_H/_\ DG/_ /$5O>-_^1 \1_\
M8+N?_135\6T ?6G_  N;P!_T'_\ R3G_ /B*/^%S> /^@_\ ^2<__P 17R71
M0!]:?\+F\ ?]!_\ \DY__B*/^%S> /\ H/\ _DG/_P#$5\ET4 ?6G_"YO '_
M $'_ /R3G_\ B*/^%S> /^@__P"2<_\ \17R710!]:?\+F\ ?]!__P DY_\
MXBC_ (7-X _Z#_\ Y)S_ /Q%?)=% 'UI_P +F\ ?]!__ ,DY_P#XBC_A<W@#
M_H/_ /DG/_\ $5\ET4 ?6G_"YO '_0?_ /).?_XBC_A<W@#_ *#_ /Y)S_\
MQ%?)=% 'UI_PN;P!_P!!_P#\DY__ (B@?&;P 3@:]G_MSG_^(KY-^:-B",''
M<4^WF-M<QS* Q1@P!Z&ETT$]KH^M)OB[X&M]OG:T\>X9&ZRN!G_QRHO^%S>
M/^@__P"2<_\ \17S7XC\42^(4MU>UB@$(Q\G4UAGR_)7&=^>:BG*3BG-69GA
MW4G3YJJY9=KW/K#_ (7-X _Z#_\ Y)S_ /Q%'_"YO '_ $'_ /R3G_\ B*^3
M 2 0.]2VUK->3K#;QEY&Z 5;=M6:-I*[/J[_ (7-X _Z#_\ Y)S_ /Q%'_"Y
MO '_ $'_ /R3G_\ B*^4;FUGLYC#<1M'(.JFH:$TU= FFKH^M/\ A<W@#_H/
M_P#DG/\ _$4?\+F\ ?\ 0?\ _).?_P"(KY+HIC/K3_A<W@#_ *#_ /Y)S_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZUI3VCW:ZG9M;(VUYA.I13Z%LX!Y%3S7MI;>3Y]U#%YS!(M\@7>QZ!<]3]*
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MOF[ 5#15M'/!J+O84 DX'4T$%20>HI!D'CK2Y//O3%I82BBB@04444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@,\UQ:R1QQ"0)N8CCYCP.?6MJL;Q9J5SH_A+5M2M&C6XM;5Y8S(I*[@,C(%
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M>"5/#QJ<U[]]R%"0ZG..>M:T/B*]L[>6VMVB,4@PQ:,$_@>U9J11M;O(T@#
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MW/OFM(RJJNE%>Z]V&$H.O6G[ZBNUM;G%A HVRC:1R*NQ:]?V]JUK%<R+"W5
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MQJ$]:GE!#'(Q4)KCJ+WF-:'K'[/7_(_W_P#V"Y/_ $;%7TK7S5^SU_R/]_\
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MKK8<^:FU?0J[=W*J3@<\4 )MR6.[TQ6AIVK'3X98_L\<GF#!+#D5156GG"J
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M9!S]>/QKT6@ HHHH **** "BBB@ KPC]I#_F6?\ MZ_]HU[O7A'[2'_,L_\
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MFV+C(%1J^P],BF]\4,/ES4VL585GX..]0FE-(:B4FRA*2EI*QD,^EOV>?^1
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M]&Q5]*UE+<9;A_U*U)4</^I6I*D".;_4M52K<W^I:JE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8/C?_ )$#Q'_V"[G_ -%-7Q;7VEXW_P"1
M \1_]@NY_P#135\6T %%%% &KI%_;6D<R2VBSR.,(6'2J\UC+CS %RQ^XM06
MMRUI=17"*C-&P8*XRIQZCTJ:?4KBXNWN&*J6;=L084?05DXR4KQ-*$,/'FE.
M]V6(O[0\-:G;W,EN(Y@!(BRJ""".N*JZE?RZGJ,][,%$DS;F"C _*FW5W->R
MAYG+$# R2<"F6\<LERD<*>9(3\J@9S3C&WORW(J-1;L]"9KZ<::M@R*(0_F
ME?FS]:K%\QJFU1CN!R:VM;G5X8XI[9K>\C/S*5XQ6(%8J6 X'6BFTU>UC*E-
MU8J30 X(.,TK$%L@8'I3[> W$NP,%XSDU-:K;PZG$MT=T"N-Y7TJFTC:2E&G
MSVT(F6'S,J7,8 SGKFH3UXKNO&>J>&Y](M;'2;-!<1'(GC&/E/4-ZFN%K.A4
M=2',TUZG/AZJJTXSLU?H]PHHHK8V"KEEJ+V44T:QQL)5P2PSBM3PAX9;Q3JK
M6*3+$PC+[G8*H [DUEZMIYTK5+BQ,T4QA?;YD1RI^E9>TIRFZ75:D2BIWC):
M?A]Y3ZFBBBM2PHHHH **** "BBB@ HHHH WO!'_(_P#AS_L*6W_HU:^TJ^+?
M!'_(_P#AS_L*6W_HU:^TJ "BBB@ HHHH **** "O,_A)K^C67PPT>WN]7L()
MT\[='+<HK+F9R,@G/0BO3*YP?#_P>HP/#&D_C:(?Z4 7?^$J\._]![2__ R/
M_&C_ (2KP[_T'M+_ / R/_&J?_" ^#_^A8TC_P  T_PH_P"$!\'_ /0L:1_X
M!I_A0!<_X2KP[_T'M+_\#(_\:/\ A*O#O_0>TO\ \#(_\:I_\(#X/_Z%C2/_
M  #3_"C_ (0'P?\ ]"QI'_@&G^% %S_A*O#O_0>TO_P,C_QH_P"$J\._]![2
M_P#P,C_QJG_P@/@__H6-(_\  -/\*/\ A ?!_P#T+&D?^ :?X4 7/^$J\._]
M![2__ R/_&C_ (2KP[_T'M+_ / R/_&J?_" ^#_^A8TC_P  T_PH_P"$!\'_
M /0L:1_X!I_A0!<_X2KP[_T'M+_\#(_\:/\ A*O#O_0>TO\ \#(_\:I_\(#X
M/_Z%C2/_  #3_"N;U_X;:5/XD\-S:;X;TU;""XE;4 D,: H4PNY?XOF[<T =
MA_PE7AW_ *#VE_\ @9'_ (T?\)5X=_Z#VE_^!D?^-4_^$!\'_P#0L:1_X!I_
MA1_P@/@__H6-(_\  -/\* +G_"5>'?\ H/:7_P"!D?\ C1_PE7AW_H/:7_X&
M1_XU3_X0'P?_ -"QI'_@&G^%'_" ^#_^A8TC_P  T_PH N?\)5X=_P"@]I?_
M (&1_P"-'_"5>'?^@]I?_@9'_C5/_A ?!_\ T+&D?^ :?X4?\(#X/_Z%C2/_
M  #3_"@"Y_PE7AW_ *#VE_\ @9'_ (T?\)5X=_Z#VE_^!D?^-4_^$!\'_P#0
ML:1_X!I_A1_P@/@__H6-(_\  -/\* +@\4^'CTU[2S_V^1_XTO\ PD_A_P#Z
M#FF?^!<?^-9\GP^\(.NT>'=/B_VH(A$W_?2X/ZU%_P *W\)?] G_ ,F)?_BJ
ME\W0ZZ"PCC^^<K^25OQ:-7_A)_#_ /T'-,_\"X_\:/\ A)_#_P#T'-,_\"X_
M\:RO^%;^$O\ H$_^3$O_ ,51_P *W\)?] G_ ,F)?_BJ/>-N7+OYI_='_,U?
M^$G\/_\ 0<TS_P "X_\ &C_A)_#_ /T'-,_\"X_\:RO^%;^$O^@3_P"3$O\
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M^3$O_P 51[P<N7?S3^Z/^9J_\)/X?'_,=TS_ ,"X_P#&D_X2KP[_ -![2_\
MP,C_ ,:S%^'/A)6#'1HWQ_#++(ZGZJS$'\14_P#P@/@__H6-(_\  -/\*:OU
M.6NJ"DO8-M>=E^39<_X2KP[_ -![2_\ P,C_ ,:/^$J\._\ 0>TO_P #(_\
M&J?_  @/@_\ Z%C2/_ -/\*/^$!\'_\ 0L:1_P" :?X4S WH9XKF!)H)4EB<
M;D=&#*P]01UJ2H;6UM[*UBM;6&.&WB4)''&H55 Z  =!4U !7A'[2'_,L_\
M;U_[1KW>O!_VD/\ F6?^WK_VC3CN!X32KUI**V3$2\]ZL22L;9(N-H.?>JZ'
M<>:<:WY4U<EI-ZB=NM %(.34H [54(\PQA- P3S3R^&)P.13"#UQQ0U81LVN
MHBVLM@BVR-QN]1539F3Y>2350.Q R>E:&GWWV"ZBN@BN4.=K#@UU86$8IRBM
M3F=/V:<H+5E:5F5]K @BHXY0C[F ;VK0U?41K.I-=&%(@W5(QQ62WWB!TK.K
M5E+21I2;E!<ZL^J)"YQN"8YZU8M;N.V9&,(=@<G/>KGV>W?0%G>Y02A\>6.O
MUK'/#8!R*Y(S4[HF#C5336VA)/*LEPTBJ%!.<>E/+1^7A%^9NN:CCA>7=M_A
M&32C9MZ$-5Q2>AI9;+H&6BW(5&34:J68+ZT\GNQR:B+^E7**CU+2'R*(F*YR
M1Z5"3F@\TVL)2N4E9!24N:;64F,****@#Z6_9Y_Y$"^_["DG_HJ*N@^,?_)*
M=:_[8?\ H^.N?_9Y_P"1 O\ _L*2?^BHJZKXIV,^I?#C5;.U3?-*80B^O[Y#
M232=WL%F]$?)&*,5MWNC76B7_D7Z*DRC)0UERCSIV9< &NU.,ES0=T'*K6^U
M?8K]#4T2[R!G&:B88-(K%3Q3C*Q%M=3=;0F2#SS*I'7&:?)9V2V0,<H:8C+#
MTK-@NYGVQ>8=I]34EY9/;J&\S<6[ TDI?:D>C4G2E3<L/2LDM6];$,=E),QV
M#@=ZC,1#;0,G-=#H,^GQEHM1+Q+L/(ZYK >5([UGC.Z,/D9[BB%9N<HN)RU:
M5.,(.+O?=@UN\>"RXS4^2RD+D''W:6\OQ=NK1)LP.E'F!0LN#YAX-7SRY.9*
MS,:DXTYM0UB%J4$HC?)W5/<W4<:-;^4<C[IJM>:=<V:I+)PL@R"*:T8^SK-O
MW2>_:N9VF^9NZ"A7G;W'[MK#;=@+D&Y0LGI33&IE;:<*3\M1/*SG)-(-W;/%
M;Q33N3)+VG,M2>2)8Y%5SD'K5N[L8@D;P$[6'0UGRN7(ZY%3><9(T3D;15W=
MTQSY%)O7R_X(QD,;;<'-7(-6O+2U:V25Q"QR4SQ5+>V<DY]Z=')%N(E/%.KR
MRA[Z'AY5(S3B[/N,:1G?>Q)&>F:BFD!;Y1@4R1@7.W[O:FUSRJ*UD#O=W"BB
MD-9@%(:7%(:0'K'[/7_(_7W_ &"Y/_1L5?2M?-?[/8QX^OO^P7)_Z-BKZ4K.
M6Y2+</\ J5J2HX?]2M25($<W^I:JE6YO]2U5* "BBB@ HHHH **** "BBB@
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MM9[N9=T<:DY;C. <8SCMUKB8O#/B37/$5YK=WX?@T,1:)+I\5K'<QR&YD96
MY7@*,X&?0?@NG^"=9M;'X=)_9JI)I$TCW^)8_P!T&Y)SGYLG^[F@#>T?XK>'
M-4;6GENH[2VTR;9YKDGS8]P428 X!9@ .M:S>/O"J:0VJMK=J+$3&#SLG#2
M9*J,9;@YXS7G&K^#/%,VC>.]'M]#\Q=4U'[=9W(N8@) 9D;9@D$':"><=,>E
M=/XM\+ZE%K?AC7=#TF#4$T<2))IID6+<&0*&4GY<C'Z+0!H^(?']I8^&+/6]
M$DMM2M[F^BM-RN<#<3GW!'H:[.O%6\ >)9?#5[(=-BAO-1\01ZB=.BG0K;1
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M(/6J'_"YO '_ $'_ /R3G_\ B* .\HK@_P#A<W@#_H/_ /DG/_\ $4?\+F\
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M^+?^@CHG_?\ E_\ C='_  SSXM_Z".B?]_Y?_C=>M?\ "YO '_0?_P#).?\
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M_P!_Y?\ XW1_PSSXM_Z".B?]_P"7_P"-UZU_PN;P!_T'_P#R3G_^(H_X7-X
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M?\+F\ ?]!_\ \DY__B*/^%S> /\ H/\ _DG/_P#$4<\AG"_\,X?]37_Y3O\
M[;2?\,W_ /4U_P#E._\ MM=W_P +F\ ?]!__ ,DY_P#XBC_A<W@#_H/_ /DG
M/_\ $4N9@<)_PS?_ -37_P"4[_[;1_PS?_U-G_E._P#MM=W_ ,+F\ ?]!_\
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MVT?\,Y?]37_Y3O\ [;7<_P#"YO '_0?_ /).?_XBC_A<W@#_ *#_ /Y)S_\
MQ%'/(=CAO^&<O^IK_P#*=_\ ;:</V=67IXK_ /*=_P#;:[?_ (7-X _Z#_\
MY)S_ /Q%'_"YO '_ $'_ /R3G_\ B*%4FMF*R.+_ .&>I,8_X2S_ ,IW_P!M
MJ/\ X9S)_P"9K_\ *=_]MKN/^%S> /\ H/\ _DG/_P#$4?\ "YO '_0?_P#)
M.?\ ^(JI5ZDOB8**6QPW_#.7_4U_^4[_ .VTG_#./_4U_P#E._\ MM=U_P +
MF\ ?]!__ ,DY_P#XBC_A<W@#_H/_ /DG/_\ $5'/(=CA?^&<?^IK_P#*=_\
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M6<8445L^%O$EUX3UV+5[."WFFB5E"3J2AW#!Z$']:F;DHMQ5WV!&-17TI?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2_@S_P E9T3_ +;_ /HB2OK2@"W#_J5J2HX?]2M24 1S?ZEJJ5;F_P!2U5*
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M^TJ^+?!'_(_^'/\ L*6W_HU:^TJ "BBB@ HHHH **** "BBB@ HHHH ****
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M .-T?\,\^$O^@CK?_?\ B_\ C=>P?9W]5H^SOZK0!X__ ,,\^$O^@CK?_?\
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M_P#?^+_XW1_PSSX2_P"@CK?_ '_B_P#C=>P?9W]5H^SOZK0!X_\ \,\^$O\
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MNC_AGGPE_P!!'6_^_P#%_P#&Z]@^SOZK1]G?U6@#Q_\ X9Y\)?\ 01UO_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gjyjiv3jrhol000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %_ ?$# 2(  A$! Q$!_\0
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M^U7>GGPMJ?\ :EL-[6@()$>,EF/;@CL>HKK?#/B&V\4:%!JMHCQQRY!C?JK
MX(H<6MQJ:>B->BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (;NUBOK*>TG7=#/&T<B^JL,']#7EOP[\ ZUHOBA[W6X\6]A"\%@QE5
M@=S$D@ D@8+'G'WZ]8HJE)I6)<4VF>)ZYX)\5ZG=ZTMWH_\ :5Q/*7L[^34
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M/J_Y2?\ QZO3**.>0>SB>9_\*S\3?]%'U?\ *3_X]1_PK/Q-_P!%'U?\I/\
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MVM-+@F5I(8T+2,QRQV@=NW2N2OO&7BIM N'L-35;YO&;Z1 [P(RK 20J$8Y
M..>OO0![-17DZ)XY'CV;P<?&1:"33UU(W[6$7G(N\QF-0/E&6YR0< <8[U+7
MQOXGD\+V6DK?0MKMSK\NC#47@7"HAR9=GW2V,#'2@#V.BO,Y-2\2>$/%5KHN
MH:XVL6FJV-U+:SS0)'+;S0IO/W1AE(]?Z<VOA<_BG5]%L_$>N^(C=PWML0M@
MMI&BH0V ^\<DD DC 'S>PH ['6M=TOP[IS:AJ][%:6JD*9)#U)Z  <D^PK,\
M/^/_  OXINWM-'U>*XN47<861XW(]0K@$CZ5S6KVT>K?'C2K/4E$MG9Z,]Y:
M0ORAG,NTMCID+_(5U.MZ)X?NM:T;5=3>*WU"TGVV4IF$3.[#_5]M^?[OU]Z
M-+2M9T_7+62YTVY$\,<KPLP4C#J<,.0.AJ]7S_9^,+WPWX1MM/L+K[#-JGB"
M]1[T6QN&MXD<%RL8!W-\PQQZ_4=9X+\8ZC-XHN]&.J7&M:>;$W-O?7MBUH8I
M5.#&YV %2.=V.* /5**^?=0^(.LZ=8QZK!XY&JZE#<*+JPM--S8A"X&T3;!V
M(^;.37?R>,KOPUXE\766NW/G6UK9C5=-W*JDPXVM'D 9P^%&<GF@#T.BO"IO
M''B..?1="U?Q#<:;,^G#4+^]M]-\^9FD8E(514(0*N,MCJ#S5VT^(_B!O#5Y
M8Q3_ &G4FU:WTS3]4N+,P"19\[9&C( W+M;/&.GX@'K5SK%A::M8Z7/<!+V^
M$AMHMI)D" %^<8& 1UJZS*B,[L%51DDG  KR:32M<TKXP^#4U;77U>!X;XP2
M2VZ1.C>4-X.P8*_=(].16S\9Y[B+X>2QQ2O%#<74$%S(AP5A9P&_ \#\: +R
M?%GP+)J LE\16_FE]@8HXCS_ -="NS\<UV8.1D5BWWAO0I/"DNAW-G;Q:.L!
MC:/ 58T ^]D]".N[VS7"^*-9CT5M%TRQ\:VVCZ"+$")[9#>WEP0=JX&UODP/
MO#DD$4 >J45XII_C;Q?>?#_7'L9[B_O-.U1;87JV %P+4X)D\D@ N!V([\],
MU=\/>+[V?2O$TEEXR35X[329;B&.ZM!!>VTZJ>J;0K)TYYYP/J >O45X\=7\
M9Z#X(TCQOJ/B(7T<HMI+S3C:QI&892H&UE&X.-P)/3.>,#%/\6^)M0B\3:I9
M-XY73'@"_8=.TNQ-W*3MSF8[#@D_PYQ@_F >O45XK=>.?$U]X%\(ZN]S=V5C
M>K-_:NH:?9+/)&4)5/E(PH8@DD#Z>AEN/B+J6E?#>ZU"U\0V&N7$NHK965\D
M!5XE<9!FBVCYP%;  YXZ]P#V6FR2)%$TDCJD: LS,<!0.I)]*\>T#QU>V/BO
M3[.3Q#?:_I=W'+]KEN=(>V:T=5W!E.P94X(V\XKM+#Q;X/\ B'%>Z%8W[WJR
M6[&XB$4\!,9(4_,0OJ!P>] %S1?'WA;Q#J+:?I6M6]S=@$B(;E+ =2N0-WX9
MKHZ\A\21W6F>/O!\>H:5%IWAK3[P6VG75LXD=Y&7:B/R"BG'/!Z<^WKU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y_I?PQ_LW2_#5E_:_F?V)J$E]O\ LV/.W%CM
MQO\ EQNZ\].E>@44 8(\-8\?MXI^U]=+&G?9O+])3)OW9]\8Q^-+XR\-KXN\
M*7NAM=-:_:0A694W;&5U<'&1GE1WK=HH X"?P)XB_MBWURR\7+;:RUF+.^G.
MG*\=PH8LK!"V%89 [YQVYS#8?"S[#H]IIYUR2<V_B%-;,TMOEI"N/W9^;J?[
MW_CM>BT4 8(\-_\ %?GQ3]KZZ6-.^S>7_P!-3)OW9]\8Q^-<\_PPC?1+FS75
MY8KTZS)K%G>Q0@-;2L<@;22& Z'D9]J[^B@#B+/P)?SZPVL^(]>_M/4$M)+6
MT\NU$$5L'!#,%#'<Q!ZD^WIC>\*:#_PC'A;3]$^T_:?L<7E^=Y>S?R3G;DXZ
M^M;-% '*^+O!:^)+BPU*RU*;2M:TYB;6^A0/M!ZJRGAE/H??U-9UAX#U.Y\0
M6.L^+/$;:S+IQ+6=O':K;Q1O_?(!.YO3TKNZ* /._P#A5:KHL%O!K4D.IV>I
MRZE97Z6X_=,[9*%"Q#+TSR,X'TK1T_P5J4LNJ7'B3Q%/J<]_9M8A((OL\4$3
M [BJ D%CG[QYKLZ* /*[KX3ZS?>%8_#-QXRQI-L%^S1Q:<JME3E?,._Y@.>!
MC)P2>*Z#QK\/+7QK>:/<75X8&L9/](5(\BZB+*S1GYA@$J".N.>*[2B@#D/$
M/@R[O_$=OXCT+6/[*U>*W-K([6XFBGBSD*RDCH><YJF?APUYX9O;#5M>O+W4
M[JZ6]&HXV&"9?N&./)"JOH.N3[8[NB@#A+#P+K1\8Z7XDUSQ3_:,VG1RQ1P)
M8K"A5UVYX8X;G)/.>!QBNJU[1++Q)H=WH^HQE[6Z38X4X(YR"#Z@@$>XK1HH
M \U;X=>*;G2_[!O/'L\NAE1$\:V*+</%T\LRYSTXS@Y[U>NOAW<6>O6VK^%M
M832)8;!-.,4MH+A/*4Y&,L"#T[\X]S7>44 >=67PONK+3=7@7Q3>_:[Z^CU"
M.]6())%.OWBP#8=6/\. ![]:K:GX)U"UL?$?B37=:75-4_L*YLX1#9K;HB;&
M)R 268G\LGVQZ=10!Y/X4\":KK'@_P ,PZSXDDN-"C@MKQ=-%J$<G:&6-Y,Y
M**3P,=!CL*V&^'NJVNJZU+H_BAK"QUJ=I[N+[$LDJLWWO+D)^7.3C(..U>@4
M4 >>67PWU+1_#^B6>D>*);:^T@S"*<VVZ*9)&+;9(B^"1GALTU?A/;W.AZQ;
MZIJTMQJFJ7*7<E]#"L(BEC^X40$@8R<\\Y/2O1:* ..TCPGKR>(+;5?$/BF3
M4_L<;);V\%M]FCRW!=PK'><=CP*Z#7]%M?$>@WNCWN_[/=Q&-RAPR^A'N#@_
MA6C10!Y[:_#S6+BXTF/Q%XI;5--TB5)K:U2S6$R.@PC2MN.['Z]Z]"HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBLV76K>&YE@=9-T388@<#@')/;KWII7 TJ*
MR!XBM&B=T25C&VUUP 5_7W'YU)+KUC"Q1Y,2!"X3N0!FGRL+FG16)%XIL)(/
M-8/&"N[#X!]AUZGM5AM=M$3<X=/F*X9<'/THY)!<?KFH3:3H5[J,%K]JDM86
ME$ ?:7"C) .#SC/:N5O?BCI=A)*\EM-+;%U2WD@8,9CY0ED(!P %5D[DDG %
M=.NL6MQ!&Z*9(Y25!!&"O()^E<Y!X=\(O9VVBV=N\:V;O-']GG>.2(MPWS@A
MN<XQGG'M2Y6 ?\+)LTO+R*73KH6\1?R;I,%)ML GQS@JQ4GC!Z=><4ZX^(<"
MZ3J.H6FD7UQ#8VCSM,0%B,BQ"0Q%N2#A@,[<9I=0L_"QDS>0.!=7#XD,C;7D
M>(Q-SGCY 1SQ^-5KC1?"*B;?:7'^D0&W:W29\."@0G8&QN*+C=C/'6GR2[!<
MT]'\=Z9K.NMH\,4ZW 5OG(!0LH&]00<C&>I !P<=*ZFN5T^WT+3-2EO;1)H;
MB4?O(?M+;!G +;-VT$[1SC)_&M5=?LVW$;PJG!)&/_U^E'*PN:M%9TFLVL3,
M')^5=S8YQ^%-77;*1%>-]X;^[SCG!S^-'*PN:=%9W]M6O(^8L#C:.?\ ]50P
M>(()KBZA^SSH;=@-S@ 2#NR\\@4K,#7HJL][&E@;L\QA=PY'/I62WB[3XT\R
M4,D>[;O+*1G&>Q_#ZBFHM[ ;]%8TWB6RMV43!T#L50G'.,Y)_NCCJ<5'_P )
M9IPG2%O,221BD88?ZQP,E5/0MCG'I246]@>ANUGZ[JJ:%H%_JLD9E2S@>8H#
M@MM&<9[5GKXPTUKL6P$IF*EPFWYF ST'4].W7Z4^?6=+U"![*YB9X;C,$D<J
M8!RN64@]MIY^HJG3DN@KHQX_B';+X<O]2N8K6.ZMA(8K);HAYBL8<C$B(P.#
M_=/&",YIEO\ $>(WIM[W1KRU!"!9-RNH=H#-L;'0X#=,CCJ,XIUJGA.ST>_M
M8X#- ^[[29G:1WRH4_.Q)/R[5X/' I$TSPNEK!MM9W5GCE4RSMO+>68ESN;.
M=C;>?44N27898L/B'I=])9XMKN.WN!&INF4>5'*\0E$;'.<[3G.,>],N_B+I
MZZE%:Z=;2ZC ;B&"6]A=?(C,F2/F&2Q &< 8[9%5]/L?!\%S!>6UJX>U5(XD
M$K.C%8]J/M!*EMG 8\X[U--IOABZU,:O)8R17D$JE8UE*!Y(@2A* [2P&X#(
MSU%'*P)-!\;R:S=Z5'-86UK%JELUS;_Z6SR;.JY7RPN2,D@,<8KL*XJPLO"V
MD7ZZC:V\JM%N\G]\[Q0;RH<(I.V,G<,C .,UKMXLT\3-'\YVC.Y2IR.>>#G'
M'7I35.3Z"NC>HK!/BW3Q*8REP"J[FS&1M&,C]*E_X2:Q641/N5V90JY!8[AD
M'&>F/Y4>SEV"Z-FBL/\ X2O3_LK7/[T1+(T99EQD@9XSU!J?3]=@U$QB*&9?
M,)V[@.@'4X/ /('T-)PDN@S5HHHJ0"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+\1 P:M)(
M)'^=1NQ@;1Q_$> #CGJ>:[2N%\412G628W=7=0 P0<+CH.Y.?Z5I35V)E,*B
M2[+<_,CX$2R?,65NF.!CIS[UH2P6UW+N+!"R\G>""3PI*_R]:S%\Z98FD5L
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MTFFT^&&\NP9IVM\8* X#$\Y*@C(]R!5*$PQ6Z+,7210T/VN,,7A?@[5./FP
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MV)+&S#JH8$T\L 0"0">@SUH 6BD+ $ D GH,]:&8*,L0!G&2: %HI&947<Q
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MFM;F.W9@8T)#(ZJ-RLO0G:<AO4#W-5U3)78O2(\.R*-C&S;K@JT4F.!C++G
MR,\*0?3-5IKY[F:X33'"1-BTG^1E *H=VS(R4YP"<#OFKGVCS;R>."?>EO"!
M D2YP-FT D G=RP/IC%8UU>2+9@M9Q[[B789!O<HYP.0<9!Z9 XSFJZ78):V
M1;T&V?3IYS)=QS,ZK)B8[22<*4'^QD#"Y.#V&!72Z+':W%S9W%M+C:J_*QY
MRP*],DYS^5<SIV;J62=Y8IH[IU\HQ[1O8##A6/&.!QP>*VM EFNO$\+VUW$]
MI!&\5TIR").,*O'S#.22<=!BIFN6.@+5ZG>T445R%!1110!R'C2YO)M4\.Z!
M;7L]C#JMU(MQ<V[;9!''&TFQ6ZJ6( R.<9I(]-_X0Z34+JRU6>YM18M*FDWU
M[N/F(2=ZRROE%.<-G@=?:MO7_#UEXCLH[>[,T;PRK/!<6[[)8)%Z,C=CU'T-
M8J_#O39H-475+_4=4N-1MOLDES=RKYD<6<A8]J@*,\].2.: ,'2_B=?W<NJP
M"RL-3GM=,;4(!I4SNKE6"F(EEY.6'*Y&*6#XF7K>%-9U98-*OIK P>6ME<L-
MYD<(4='4/&PSU(P?P-;D?P]M&N[B[O=9U>]N)[!M/9Y98TVQ$JPV[$7:P*@@
MCU.<UE>(OAT]QX=UE;>]OM4U;4([>W,]W+&K"*.96V@JJC@9.3DDB@"W+XTU
MC2_[7LM7TW3EU*SLX[V$Q7NRWDC=RGS/(!MVL.?4=.>*R[/XGWT^F^('2RLM
M0N=,B@FBDT]Y6AD21BI)RF["8+$J#D XK=?X<Z;<V=_%J&HZG?7-Z(E>]N)4
M,R+$V^,+A0H ;G[IR<YS3E^'UH9M0N;G6M8N+R_BBCFN6F1'4QMN1DV( I![
M 8]0<G(!B'XHO!X4EU.1-+NIS?1V5O):73&!F<9W2 KYD>T!L@KD[>.M7-"^
M)VG36=_)K]U8V7V.>.'[5"[FWG\Q69=A90P/R,""/X>M7?\ A7.F26EZMU?Z
MC<7UW<0W3Z@TB).DL0Q&R;5"C;S_  ]SG-;>AZ$NBBY=K^]O[JZ</-<7D@+'
M P  H"J!Z #K0!PWQ!:]BTI_$^EZEJLT<L<,MG-:3,EK81##-+(BG,JL"2?E
M;@8XZUU_B_79-'\%7^K6+(\PA7[,W5=[D*A]QE@:JZUX#L=:O;V=M1U*UBU!
M42_MK:55CN@HP V5)''!VD9'%:/B'0(M;\*7NAHP@2:W\J)@.(R/N''L0/RH
M YB]UW7="O;CP_HMC:7D>DZ3%>2W-]<N'D'S@C@'+-LSDG'7-,U+XCR6Z:?-
M!+X<MX[RRANQ%J6K&"5?,7=C:(SQ[YYKH+'0?MPGU74XYK;4M2TV.RO(%D5D
MCV[\[" ><R-SD\8XZUJZ=I%IINE66G1IYD5G;I;QM* 6*HH49..N!0!YWKTG
MB+Q#>:7?6EC>7NFKIKRN-$UDV\4DS2#I(-IDPJG Q_%6FNMP+8>"]?TJ>Z>Q
MO)DT^1+F1F=XY00"Y).761%YYZMSS6[K7A"WU>^6]AU'4-,NOLYM7DL)%7S(
MLYVD,K#@DX(P1GK5:Y\,_P"E^&-*LK80Z)H[?:2VX$EXTV1(.<G[Q8DC^$<Y
M- '5T444 %%%% !1110 4444 %%%% !1110 4444 %<=KX6/6)CMD=GC#;$(
MS@ @G''&.,YZUV-<1XD)76<;I55OF;>WR  #H.^<'\C6E/<3*"6Q)WJD97!D
MCDBR"P YW#/4X '7-6(@QN8KIY$4.@"J1M8C')(/.>GIC%55DCM=TVW#J@6-
M5R0?O?-TR1R.<T[:A=$>2(,4)"XRI(R PZXP??KGUK9DD=W>0'4XX/.1;DH?
M*5<[MH)!R!\I'*\'\<5+/:3RA/M20(#(QCYQN7HH''J?O#UIJ)I^HZM8V]Q!
M']F@A,TA";E8X)4!N^1D\>F#5B>66:Y:86YB)1?)5@08P<X7'3GC(Z#'-*[3
ML.PPJYW74G[LJ(P"'_U:#!"[6^Z3C]0:6/SU8S-F0A623<5)EPWRY(Z8-31N
M@::V6%)+=550DA!C);WYR<^N, BG?89EL(5G)EFC1C((L E2P("_3I0V MNT
MLBA3MD"C=+\@7:3G!'Z\\U'$QAN)HG):-50(.,.6!SP>YZU:CC+12;E8, 0J
MC 5@/SSP!UJHD2R^:Z@C>-JDXQ&>W7KP3SZ>](":2-/LXB\WDQ$(2/X<@ Y.
M>0/YTY6&V26-!YBG!YP"/Q[?X4^.$B,[60QAOE56XR >03T.:7R0 3(NWD!5
M5N@'))]><GI2N!&C89@SD*V&W+SGV^F<U'<$F2*2)\K%A0I(V')[_P"/Z5*\
MB6L94I*ZR8.]!U[CGM_]>K$K(4C7*F#&TJ#DG/\ ];FB^H[%4R7D%];3"-9[
M#:PER<,F2,,!CG SWJ.[6=C"+2-AAL$%MHA7GYS]<=JOKF0IOVX09*XXZ8Z>
MH_K48D),<;?(Q<,H4\ 8R<_Y/447L!JW+,OAB9FC>5@GRHN06/&.G/7'2O/+
M,WT]NC 6\Z,-RQV_S%67.5QG&00WID'KVKT+4ID7PK=2F*1E$7*IE6;ITQS7
MFVF6(UBT>XMKQKKR(TBFMX_F0$$_+N &>&Y]-M72LDVQ,V8;47EBK#:8(VW0
M892?F&6&XY  8 ]L<]J@L95%O $E^U($ D:)QACC&XE>!\OJ.?6LFSGO1JGV
M9[>T@L)(>;PD+)(X;;\VTD 8P<X'0]JT)+""UTN&%[B98[%XHXI&RI<AB5 9
M?O*6XR.>QJGN'J4;EHHM;CU.*W8;D^S,ZR+GRE/RQN.-N"">,\*/K6GJ%D(+
M*2XMXX(FBQLN)'9RP*@Y/!.,YY'3 ]*K0%9+Z*Q@S*UG,%FDN%(5\[L].I!/
MJ?3UQ6?6+<6*7=T]])I]Y="U6V6WVEV)VLN1SCY6QGJIQVHDU'4<4Y:$VJR3
M6VDVEY/;2W,BR1L;<*I:/=A=W&1M7'7T.<]:NN4-WLN9D7"1%H@ORM(#N7&3
MU#<$#V]*RCJ4EK>WT%NUI]H<K-;V[,P"A4PV <;0>,GG !/-:VDO-J%P)+J.
MXBE-H&GMWDWQ] 5);HP^G)R,U*DV]=AN-EH68[%IK.1&CD6$W6\Q$JIR,#NI
M+8SG)Y_.EDG>TE&TS-"&)0[@<$\9P1G@Y& /7(-4-,\16&LBUGLH97B2>0HV
MPC!'52!W)XYP"%]JJZSJS2WMO9QFX;4;<)>F)8V,4B;@"KG!R1\Y' H<K*^X
ME&[L:(LKM4E95C=BYC1$4(4Q_$<>P7('7/()XJO?RVR6RS320I-LC5O,52,M
M\FUB!U)/!RIQ6C]G_P!(N;I%\Q5?>D:*'=LX&5(.0H!(QVP:P/%JK-91:0UK
M<275P/, @0.T2PG<N[VR0?[Q!//%-S=K@HW=AOA[47@C:SFLA8RQW312HRNO
MFG9Q@KT'!.22/O=#6[?B,PH[QI#&2DC(ZX8N6P!D@]1T';&.]9UQ;?VU8P_:
M+J:PN)8UF#A@ KJ!@%=WS?+NX/J,Y(JYJ5Q<:7<6$]O;75]<%A'<-&H*^2>6
ME*#H>0?P[T-VWU"UWH,LK9+&-;>(M'8VTI\J-5WDI@':S$_,"QSD=OIFM/PO
MYUAK,L#H[V][-]HAV*,0<8V''8XSGD9S5*ZCB4+YSE!*59E>3YM@& <8YX.1
M@8X ..]SPY$K>(562VG22V+01"3"JJKC++@<YSCTXI245&P7DW<] HHHKE&%
M%%4-;E2#0[Z62YN+:-('9IK==TB#'5!@Y;TX/- %^BO&H=6UAK33WM=3U:7?
M*6L(P'<ES,@,,[%?FVQEB=W R<$[0:]*L=>N+CQ'<Z/=:7):M'"9XI3,KB5-
M^W.!ROK@T ;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7'^(/WNIRAGEC1-BE@QQSR2 ._O785DWITY+F0R
M0AIV&#M;!/''?TXS5P=F)G+20O-:B*(^7)C8Y4]%[D9Z?S(-0W2V[V[B6Y=+
M0,O.X;5R< ?-R<YZ?3%=$;S1U55^QL$*GS&Z",=]QSZCMGI3DO\ 2I)(W-L5
M^?\ =R;AACC&00?<BM.<+&9'"(K>*U$'DLB'(!VGKG@XZ$CK433)LV2;64KQ
M)CT.=PZCC^AK;CUK2]4@PT<VQ225F4H?E]0>2*5KW28N!&=K(7)!/(Q]<]*E
M2"QCRNOD2*W& )&VMT.!C!'3]:EE6W>1.BS*BL/WGR@9R<#_ #UK1>;1FD5/
M++N<,%$AW'H!QGGI^E$FI:3;0S2O"WE* SLF7/)YX!)X/6CF[!8S=IMP1G(+
M@':>>3][IUY.?I35801R0C$J;]HW#)"_3TY^E;(U;2BC21LDB ;MZ2 C^=,3
M5=,G>,F-D+MA&<[2Q'X\]OK1S>06,>.4H8A*RHR':2>@53_(\8H'S.WDR QD
M_,_ISG'^?6MM[O35MU?R28=N-RG[H_G^50Z9JVCZI"EQ9HYC924=\J&!ZXS]
M*.=#MI<SUD,,T<3@-D<A>%7M^ _P-.$9,WFJW.W@*V5//&1ZX_2M,W^GI)A[
M>12A.UFYS[CG/2B;4=, S)&WR,8P <'WQSQQS1<1E(S,)4";2S;0QP%/7D>M
M96HZF]EJEE#+N:&]9K0%(\[9\@IGO@C(]*ZPWNFVZ_<V(C $E\*G?/)J&YFT
M>[D2":T\\QN)4RO",.0P/J/44FV]BHV3U)]5@9O"]S!Y43L8=H61@JD\8R3Q
M7$>'DMK&S:.V -TSS+#NY+ '#NP4[3EF[]C[5Z&7@NM.9IHLP,/F1^<CWKFY
M?^$;.LP3&Q?[;'"421'8"&//(&#@<CH.:(O381YQ<336>FQZM.\,NVYCA6$#
M<LCYZN?NYQD8&%Z>F:WYM3U.6RE34;R"2&PQ-YRH#*J$DIO7^(G@';Q73-+X
M?CG8)I4KW(W7(16SG'7G=@'CI[&KC3Z))*B_8BS;."I]N 3G^?>MG55]A<NA
MPEDOVR[G>U>VB4A%+J-@1@2WRL5SNR>W][@]15RX,-K;1(Z_NX;C,JR.% <@
MR @A3DGD8 R>.:[2.70]@A2!O*MDVA1G 'H!GFH[M?#\B9NK<&,1X8ESA5!)
M'&>W)![<U+J>0TM3S6\N#+8W$\.FI<SPF,VLX8EMK,!MW, %(SR!VZ=ZT+VZ
M&B[+N#1(PB2):NBMAF#=V["-<<>N!7>NFAOIT<*6PEM9<% )",D=.20<\ 5(
MUMHZ>4S6 \QQL_V@,YY.?6CVB:"VIR2(Z6EO;G"2#]^[QP!#(6// ^4DCYL8
MKE]5U&UMM7L]?^Q2?OY(]/?[2Y5HU\PY?\3D#!'&*]5*:-M!^SO^ZZ#+ #;C
MWP>U*;'1[BV(FM T>[=AW+<]CUX/3W%*4E8<=&<==W,T4A6 2_(N'@$>YBIX
MVA1D+R#GG!/:J%SJLUO$RO9S2V20M--<N6RN'"E>,%B!AAGCCBN_7^R+947[
M.0K,,98MTS\QY_4\TL T;[ 3Y/DPN!NBD9E( P0",\=!1[306ES@[.ZM]6U>
M19&ECDL#\QC*HBEB0KJNT[F4YXR#GJ*L6<>);A[HHXAF( @<-,F.6!*L1SW.
M.AQ78R6^A1/)>?94S-N=W1B-Y(Y[\DBJMIHWAJP,\EMI@A$[&>4[F&Z0COD_
M>P:;J=@.,_M+3-?EM;AGF@O)5G@#J-I5"-PW@CE2 3COZ5N>%[RUDUA+83RS
M3)M?S@I_?A@<,W'3 P#ZCO6R%T"6!9&T\[B=H1P=^5!X&3U[=:MZ-<Z1<SR)
M9)BXMR%E3>6,1('RDY(XP. >*3J)+E"S>J-VBBBL .5\8>*-0\.2V2VFDR7D
M=QO#.J.P#X^1/D!P6/<X%=1&S-&C.FQBH)4G.T^E>9_%JTCD-E<S/$8H8)B\
M3WJ0EQ\I&U64[B#@C'<#VKTBUP;. C=CRUQN.3T[F@":N;'_ "4L_P#8(_\
M:M=)7-C_ )*6?^P1_P"U: .DHHHH ***BN(/M$1C,DL>3G=&VT_G0!+16=_9
M*_\ /]?_ /@0:/[)7_G^O_\ P(- &C6=KNIG1M$NM06!IV@3<(E/+\XP/?FC
M^R5_Y_K_ /\  @T?V0O>^O\ _O\ F@"IX3UY_$GA^#4I;1K5W #1/U!P#T[9
MSQUXQ6Y6:NCHJA5O;Y5 P )R !2_V2O_ #_7_P#X$&@#1HK._LE?^?Z__P#
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M6Y<;8Q$D.<H"3D[O7C%6T#PE\KYH9RX!/R@'\.HY_2JUP]QND4O%(J*?,C"
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M5!<2VLT>RPG$7F0DKO5B2 1@9Q['U%=SIL,=OIEK#%)+)&D2A'F.7(QQGWH
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M9&*G.1PV.G'3I]*8'4Q[AHK'Y'(Y (R#S7*V]PES+)%]MF,@;)$@ ,9[*<=
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M*%%<]2O!PY=%%23L[7V[==.IE!O1)W.A_P"$S\,?]#!IG_@4G^-'_"9^&/\
MH8-,_P# I/\ &M7[':_\^T/_ '[%'V.U_P"?:'_OV*\6^'[2^]?Y&OO$RLKH
MKHP96&00>"*6@<# HKG*"BBB@ HHHH Q_$7B6P\,6D5S?B8QROL7RD#'.,^H
MJ[I>HP:OIEOJ%L'$,Z;TWC!Q[U!K.@Z=K]O'!J5OYT<;;U&XC!QCM5JQL;?3
M;&&SM(_+@A7:BY)P/QJ5S<WD=4GAOJ\5%/VE]>UO\RQ1115'*%%%% !1110
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MU<_>QU(IH\3:;.ZLULI=6VKF3D8Z_EGH*->P7,^PCC^SK%AA#&[( Z[22",
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M%<5V6DVUPEQ'*S ,QS+NC )Z_+QZ>M5-,U31[G4)9$TM[>ZN%$<\DBX9@
M3UXZ<XZ9Z5JVVL65[J*6ZHP=>8RY*DG'.%],8Y]Q4)23;*D[I*VQLT445)!P
M7Q%\'7WBF2SDM(K646T;@)*J [F*X^9D;C&3@8Z?EV>G64.G:=;V=O#%#%#&
M%6.%=J+]!Z5:HH I7FKZ=I]S:VUY?6]O/=/L@CED"F1O10>O;\ZR!_R4L_\
M8(_]JU3\6>%K_6]3AEM6M1#+$EO<-,3NB59EEW( .2=N,<=CGBIY_!?GZO+J
M:^(M;BN)%,8\N:,!4+;M@!3H#0!U-%<S_P (E<_]#9X@_P"_T7_QNC_A$KG_
M *&SQ!_W^B_^-T =-17,_P#")7/_ $-GB#_O]%_\;H_X1*Y_Z&SQ!_W^B_\
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M1*Y_Z&SQ!_W^B_\ C='_  B5S_T-GB#_ +_1?_&Z .FHKF?^$2N?^AL\0?\
M?Z+_ .-T?\(E<_\ 0V>(/^_T7_QN@#IJ*C@B,%O'$97E**%,DA!9L=SCO4E
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M Q@#WQTKM-.F0^%%<QH5(VJJ+P<M@<?7K7E5Q9KK?Q&-FBR)96>ZUE;>1#L
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MFNUI%544*BA5'0 8 I: "BBB@ HHHH **** "H[B86]M+.RNRQH7*H,L<#.
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M=Q^)M1GC>"ZC,-Y9S6[ EE&QT /_ "S8JKC(RO;J37J:*L:*BC"J, >@I:*
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M\91>&;)8[@^=(9KE4VB-E!+H2.&;<0..*4[K<:3:T/2:***Q("BBB@ HHHH
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MFI#92SRLT91#PS+TY_NYZ?7%=]_9]D7+FTM]YZMY0R?TIILK")53[);JK'
MB&"3^%'.%CSV.*>,M*8PS*&W['_B( P 1D=.W%1F5 A)B#S%F(01AAG&,;NQ
M'K7I/V&T(P;6# _Z9BA;&S10JVL"J.@$8&*?.%CS=X_-AWK^\;@;FPV& Y.0
M?EQC'L:C=0(U> 1'C:P7!';<Q..3GL>M>DC2M."%!86H4G)40K@G.<]/6E_L
MRP+[S8VV[&,^4N<?E3]H%CS@1QR6KQ-)^\67#*S9#,>0#2E8[J2&0Q^7N<'
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gjyjiv3jrhol000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X!($# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOBS>7UG\-M5.F)<M>
M2A(H_LZL7&7&XC;R/ESS7GO@+4-/T&^U=IIO%4&OV>D2W'V'7)08I5"ABR*
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MU_\ GWD_-?\ &I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_\ GWD_-?\
M&CS7_P"?>3\U_P :EHH B\U_^?>3\U_QH\U_^?>3\U_QJ6B@"+S7_P"?>3\U
M_P :/-?_ )]Y/S7_ !J6B@"+S7_Y]Y/S7_&CS7_Y]Y/S7_&I:* (O-?_ )]Y
M/S7_ !H\U_\ GWD_-?\ &I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<=HG^F_$/7+SJMO&MN/;I_5#78$@ DG '6N/^'X,]IJ>I,/FN[Q
MF^HZ_P V- '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO\ -^ZB5.'/8 >M %VBHOL\?^W_ -]M_C1]GC_V_P#OMO\ &@"6BHOL\?\
MM_\ ?;?XT?9X_P#;_P"^V_QH EHJ+[/'_M_]]M_C1]GC_P!O_OMO\: ):*B^
MSQ_[?_?;?XT?9X_]O_OMO\: ):*B^SQ_[?\ WVW^-'V>/_;_ .^V_P : ):*
MB^SQ_P"W_P!]M_C1]GC_ -O_ +[;_&@"6BHOL\?^W_WVW^-'V>/_ &_^^V_Q
MH EHJ+[/'_M_]]M_C1]GC_V_^^V_QH EHJ+[/'_M_P#?;?XT?9X_]O\ [[;_
M !H EHJ+[/'_ +?_ 'VW^-'V>/\ V_\ OMO\: ):*B^SQ_[?_?;?XT?9X_\
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MDLL<$32S2)'&HRSNP  ]R:RX?%?AVYN?LT&OZ7+.#CRDO(V;/T!S0!KT444
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M1110 4444 %%%% !1110 4444 %%%% !7SKXVN[2Q^/MY/>^'9-?@6Q3=9)
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MN/GNKIW)]N!_/-=?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;GUW?"?ASQ;K'Q1/C7Q+ID&CI#:?9X[:.97:4X(R=I/')//HO'>@#UNBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH IZEI.G:Q;?9M3L+:]@SGR[B
M)9%SZX(ZU'I>A:1H<;QZ3I=G8J_WQ;0+'N^N!S^-:%% !1110 4444 %%%%
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M3Q)\;?"7A?42S:3Y!N7ASA9&_>$@X]1&J_B?6@#TK0_'7A?Q)=M:Z1K5K=7
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M;9;-HK&-PZ6PD1VV@CJ<;<GU% 'I%%%% !1110 4444 %%%% !1110 4444
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M!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_\\#_ -]"CS)?^>!_[Z%
M$M><>)/#NGR^---M8ED#WTCS7/S]1G/'IT:O0O,E_P">!_[Z%<A$[WWQ/FD\
MLG[#:!0,C@G'_P 6: .LL;*'3K&&SMP1#$NU03DXJQ47F2_\\#_WT*/,E_YX
M'_OH4 2T5%YDO_/ _P#?0H\R7_G@?^^A0!+147F2_P#/ _\ ?0H\R7_G@?\
MOH4 2T5%YDO_ #P/_?0H\R7_ )X'_OH4 2T5%YDO_/ _]]"CS)?^>!_[Z% $
MM%1>9+_SP/\ WT*/,E_YX'_OH4 2T5%YDO\ SP/_ 'T*/,E_YX'_ +Z% $M%
M1>9+_P \#_WT*/,E_P">!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_
M\\#_ -]"CS)?^>!_[Z% $M%1>9+_ ,\#_P!]"CS)?^>!_P"^A0!+147F2_\
M/ _]]"CS)?\ G@?^^A0!+147F2_\\#_WT*/,E_YX'_OH4 2T5%YDO_/ _P#?
M0H\R7_G@?^^A0!+147F2_P#/ _\ ?0H\R7_G@?\ OH4 2T5%YDO_ #P/_?0H
M\R7_ )X'_OH4 2T5%YDO_/ _]]"CS)?^>!_[Z% $M%1>9+_SP/\ WT*/,E_Y
MX'_OH4 2T5%YDO\ SP/_ 'T*/,E_YX'_ +Z% $M%1>9+_P \#_WT*/,E_P">
M!_[Z% $M%1>9+_SP/_?0H\R7_G@?^^A0!+147F2_\\#_ -]"CS)?^>!_[Z%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7CGC?_DX;P3_U[G^<E>QUP/B+P1J>K_%3P[XHMY[1;'38MDT<
MCL)&.7^Z I!^\.I% '%6?C'XC>([SQ=#H][IEO!HEQ*1+- "[*I?;&O!'(0Y
M)'I5'Q!X^OM>^%7AG6;RQTZ:\EU7[/,)K99$RH;YE5L[21CI[UWGA#P#JN@2
M>-&N[BS<:Y.\EMY3L=@;S,;\J,'YQTSWKRCQ=H[>$O!7AOP5>7MK<:VFK?:V
MAM2[ 1OD*<E1WXQ0!V7C'XF:T?']YX;T76-(T.WT^/,MYJ72:3"G8,@X^]CI
MV8YZ"HD^-M^?A4=9^R6[:Z+X:<% _=%RN[S,9Z;>V>OM6MXF^&>N#QW=>*?"
M\VCR/?1;+FUU:$NBMA1N7Y3_ '0>V.>H.*DOOA+>:K\-1H.H:M"^L+<_:X[J
M.!8XU< J%PH!*[2>3SDY[8H 6S'QAM;UK2^DTJ]@NK5R+R,*HLY<';D<%AG&
M<!N#GM@^??#'Q-K'@SX7:[X@#VL^F1W#16]HP/F&[;RAN8_W-IZ9SP:]'\/^
M%/B'<>*+'4O%GB6'['8QE!:Z=(ZBY//,@PH/8]#TQ@5@Z%\'O$-OX8UOPCJF
MI:=_8ERQGM9H S3+< IM9@0!MVI@C/?CUH SM ^+7B&TUW0!K&LZ+JUEK#K'
M+;V0 EL2Q4#=@#IN&>O1AZ&MF+QCX]\7^,M?M_"4FFVVG:'+Y1CNXR?M+ L,
M;L$_,4;IC Q4WAKX<>,+;4M(76+W08=-TS"_Z#:*TUT!C&\NGL!GKU[\T^7X
M=>,-$\6:Y>>$=9TZWTW77+W*W:,7@8DDE !@D%FQR.N".,T 0_LY$MX#U(GJ
M=5D)_P"_45>PUP?PH\$:AX#\-7FF:E<6L\DUZUPCVS,1L*(HSN P?E/K]:[R
M@ HHHH **** /(O%,WBK2-/UCQ#JWC%-&NHI)&TK2XC&T4T:_=4@C+NW3VSZ
M=.JNOB)8:)I^AC7;>[AU/5+-9UM;>W:1O,PNZ,*.=V6P!7'^)O%_A+7=+U;3
MO&6DK9>(+$RP6ML8VDF)/^K>!PHSN..GISQ2:)!JB^,/AFNO"1M2CTN[,GFD
MEP=O&[/.[:1G/?- '2CXP>''MW,5KK$MY$S">PCL'-Q %QN9UZ*HSU)]?0UK
M77Q!\/VWA[3M:6XFN(-2.VRAMX6>:=NZJ@YR",'T-8W@R)!\4OB(0BY,MB#Q
M_P!,2:\\\'S'0_#GPX\47T,LFC62ZA;W$L<9?[*TDKA7( )P<8)]J /6_#WC
M_1_$FMRZ-:Q7\&HP6YGGM[NV:)H@&"X8'O\ ,#]#7#CQ'K-QJ6E:I%J5RMEJ
MOBMK6&,/\AM(P8P .P9D8G%9=_XYL)?B!XE\1:0LOE0>%S%;SM$R?:)3.JHR
M@@$C<P7/^R:T?&OA46WA;X>>&!<2VI&H0VTDT#8=6,;;V4]B26/XT =_%X^T
M"5]89+AS9Z0#]KOMG[A6'5%;^)O8 _J,YEO\5M GO]/LY+75[6749TAL_M5B
MT:S[S@.I/!7)'/N.*\[N[;4+3P+K7PW>U674]'DCO+:.*,+_ &C9B4/D =6'
M<=21W(-:OBSQSH7BS6? ]OHXGFDCUZVEED:W=!;]1Y;%@!N.<X&?N&@#VBBB
MB@ HHHH **** "L'QMJ[Z#X(UK4XGV36]I(T3>DA&$/_ 'T16]7.^.Y/)\%Z
ME(="77$1%9]/9L>:H8$]CT^]C':@#@_!&H?VOJ.FJ?BE-?7X1);C31'&%=L
MN@./F'4<=A5VV;Q+X\U+Q'?:;XCN='M=,O)+#3X($0K))&!N>7<#N!)''85C
MZ[K?ASQK<>$;'P;"LFIVVH0W&8+<Q_88$^^'.!M'08[X^F;NA^*],^'%[XLT
MC7W>VG;4Y]1L5\MC]JBE *A"!@G(P?<^QH Z/PI\0[;5?#7AFZU)&CO]8=[8
M+&GR^='D-GG@';D?6ND;Q#8)XH_X1YF<7WV(WW*_((@^SKZYKQ1TD\#>&/AK
M<ZW')$T6HSW5TJH6:)9,MR!S\JL"1[&M@:W9^._BIJX\/7#2QOX3GLH;DH45
MI3*.5R.@+@9]0: .IN?C#X8M89;IH]4;3D9HUU!+%S;2N,_*C]">/I[UW=O,
MES;13QYV2H'7(YP1D5X'K'C+2(?@:_A26UN8]<MK1+6>P>U<&)D89D8XV@<;
MLYZFO<](XT6P_P"O>/\ ]!% %VBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,'QK?:EIG@K6+[2%#7]O;-)%D X(ZG!ZD#)Q[5Y%H2W=T]G
MJ+?&;2TN+C8\L'E1([$X)0Y8'VZ?A7J?Q&LYM0^'>N6EO#<S32VQ6..V0M(S
M9&  .ON/3->1:(NFPK817'P4U5+E#&KW'E2D!AC+Y*YZ\\T ?0M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOCFZ^S>$;S
M!PTNV,?BPS^F:T]$M?L6A6-MC!C@0-]<#/ZUSOCS_2CHVE_\_5X,CV&!_P"S
M5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#R_[2N'GV,"QZ(,=N?7H>U 'JE%5-,U"#5M*L]2M23;W<*3QDCG:P!'Z&K=
M!1110 4444 %%%% !1110 4444 %%%% !37=8XV=CA5!)/M3JR?$]U]C\,:C
M-G!\AE!]V^4?J: ,;X>HTFE7M^X^>[NW<_3C^I-=?6)X0M?LGA/3H\8+1>8?
M^!$M_6MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /(] 'L%'48->/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\
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MA_\ ?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z
M/4=6TJ'5K=(I3C9(&##KCN/Q%7E4(H50 H& !VKR#_A'OCG_ -#GH?\ WY7_
M .1Z/^$>^.?_ $.>A_\ ?E?_ )'J%"*DYI:LMSDXJ+>B/8**\?\ ^$>^.?\
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M"/Q=J=K>W6!L\J/YT'H[\!C_ ,!_$UU5 !1110 4444 %%%% !1110 4444
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MZFC[-#_<_4U+10!%]FA_N?J:Y/X@A8_#\=O$O[RYN$C SUZG^8%=C7'>*/\
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MU/8C@\],T >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAM88F.61%4GZ"N6T[X9>$-*UB/5+/2%CN(7,D*F:1HXF/5E0MM4_0<=L5UU
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M_"S6+C7?AOI%[<P1PR;&B"Q1A$*HQ0%5' &%''UKL:BM;6WLK6*UM88X;>%
MD<4:A511T  Z"I: "BBB@ KSOXP*J^%],VJ!G6K0G ZG<:]$K.UC0]-U^UBM
MM3MO/ABF2X1=[+AU.5.5(Z>G2@!^LZG'HNAW^J3#='9V\D[*#U"J6Q^E<C\)
M-)EM/!BZO>D/J6N2MJ5S)Z^9RH^FW!_$UV.J:9::SIEQIM_$9;2Y0QRQ[V7<
MIZC*D$?@:EL[2"PLH+.UC$=O;QK%$@).U5& .?84 35YO\4%AN-?\$V6H[3H
MT^J$7*2'Y'<+^Z5AT()SP:](JAK.B:;XATR33M6M([JTDP6C?/4="".0?<4
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MTZ.VU63R(+C3Y7813$9".&')/3(XKK->U&XTG0[N^M-/GU"XA3,=K "7D8D
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MJWV22QM;6>+RU"/EDSD8*CJ2 "<XS7M-M=VU[&9+6XBGC!VEHG# 'TR/K4U
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M_P#K4;YO^>(_[[_^M4M% $6^;_GB/^^__K4UO,?&Z ''^W4]% %;8W_/N/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_ -G'_DGFH?\
M85D_]%15[!7C_P"SC_R3S4/^PK)_Z*BKV"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X7XB^+YM&M8M%TC=)KFH?)$L?+1*>-WU/0?B>U;_BOQ-:>
M%-"FU&Y^9Q\L,.<&5ST']2>P!KD_AWX8NY[J7QCX@S)JM]EX5<?ZI#WQV)'
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MGFN#&X65*JW%>X[N+6JMZFU*HI1UWZENBBBN$U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKFO&OC:P\"Z7#J.I6=]<6TLOE%
MK1$;8Q&1NW,N <&@#A/V<?\ DGFH?]A63_T5%7L%?/7P \;6&GVG_")-9WTV
MH7M])<))"B&)$\M 2Q+ C&P]CVKZ%H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY<, D7RH]ISN ]:N>3XN&'>(FK)='OO;82Q--SY$STRBBBO+-PHHHH ****
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M7DO\C!X>FY<S6IY__P *VUQ/]3X_UE/9F=A_Z,H_X0/QA%_JOB!>-_UT@/\
M\6:] ^S0?\\D_*C[-!_SR3\J7]JXGJT_^W8_Y#^KP_IL\_\ ^$4^(47^J\;1
MM_UTMQ_@:/[$^*4?W/%.F2#TD@4?RBKT#[-!_P \D_*C[-!_SR3\J/[3J/>$
M'_VY'_(/81Z-_>SS_P"Q_%>+_F):)-_P$C_V04>=\5XO^771)OQ(_P#9A7H'
MV:#_ )Y)^5'V:#_GDGY4?VCWI0_\!_R#V/\ >?WGG_\ :_Q5C^]X<TB7_<F
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M 4444 %%%% !1110 4V21(HVDD8*B LQ/8"G5#>6XO+*XMF8JLT;1DCMD8H
MXCPM\38_$FM6EE)HUS86^HQ2S:9<RRJPNDC;#94<H>,X.>/PSWM>0^"/!_B>
MUU_PTNLZ;':6GAJUN84N5N%D%VTI(!51RH"G/S5Z]0 4444 %<=X_P#B%8^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]:DKYAB\+Z7J/P_\?ZY=1/)?6.JS"U?S6 A^9"2%!QDYP21V'I7T'X.GENO
M^@7$[M)-+IMN[NQR68QJ23^- &W1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEG=6::38+:W;F2XA%L@29CU+KC#'@<GTJ[!!#:V\=O;Q)##$@2..-0JHH&
M!P !VHHH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gjyjiv3jrhol000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjyjiv3jrhol000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '8!$<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRVUY/!)-J]E'(\<I4NK Y4D'D'N*T!\.K:73?%EA=WSRP>(;IKAMD>PP$XP
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M;?[9Y&/OLQSLW=MW3=VKH]&T_P#LC0]/TWS?-^QVT=OYFW;OV*%SC)QG'3-
M'C&O7=S81?%ZYL[B:WN(YK$I+"Y1UX X(Y'%=A\1-0O+/POX7EMKR>"2;5[*
M.1XY2I=6!RI(/(/<5H3_  ZMKQ_&"W=\[P>)/*+(D>TVY1< @Y.[G!Z#I6++
M\+M>U*/28=:\;2WD&DW$4UK$M@J*=A'W\-EFVC )/&2><F@"K<:5?>*OB_XC
MTFXU_5K32;:UMI3;6=T8][E>.>PY8D#&3C/2LF/Q3K?AGX>^,K1-2GN[K2]7
M.G6-W=-OD1'90"S=R 203WQVXKT[3_"_V#QOK'B3[9O_ +2@AB^S^5CR_+&,
M[L\Y^@KF-?\ "5AH?A'QI<:HMUJMEJMT;V6WM(0LL()7[N6(8KC=GCITH P/
M&GAC4/!UAHE_8>*]=EEFU.VM[Y;B]9EN-S?> _A.1T'8XKUS5+W^S=(O;[;N
M^S0/-M]=JDX_2OG^^D_X2>]\+:7I_C>[\3RI?P2Q6JV8B%M"OWY)F'+,!QD\
M]?7GZ(EBCGA>&5 \<BE74]"#P10!Y'H7A36O%/@RU\4'Q?JMMXAO!]JBD%R1
M:P@MD1^5TV[>WK^52^.;VW/BFSL=9\2:JR+8@_V/H$<@EDE)YD<K_">RGV]\
MVV^%6JKI+^&X/&%Q'X6=R39&T0S",MN,8FSG&>^/;I6A>?#R_M/$QUKPKKZZ
M.TMI'9S0RV8N$*1@*A7+#!  _*@#B?#NMZHG@CXC60O-92/2XBUB=28K=P!H
MV.&.<@C:,<\>U)JVF:OX>^'6C^.$\4ZW/K&+2:99KHF!DDVYC\OI@;A]>3WK
ML=/^%LMC8>++:3Q%-=MXB@5)9I[<%XY-K!GX8 @ESA<#  &>]:VN^!O[:^'E
MKX3_ +1\GR(K>/[5Y&[=Y6WG9N'7;Z\9[T 8$MM=>//B-XBTJ[U?4;+2=#CM
MXH[>PG,!EDE4L7<CDXQ@#IT]\Y?B^\\3^!_ EKHXURZU"[OM6%G;WL,9DNH[
M=LG;ZM+Q@=^>.@-=;K7@C47\37'B+PUKYT>_NX5AO%>U6>.<*,*VTD88#C//
M3ZYIK\*+ ^$)M(GU*ZDU*:]_M)]5 "RB[[2 = .V,]SSGF@#D]&O=2TGQEHG
M]@67CE]/N9O(U./6[:5XMK8 E#'.T@G)/ X],U?^'FB7_B'6-6UW4?$>M%=.
MURX@M;-+LB$HK9(<?Q [@,9'"XZ5TNG>"=<D\0V.J^)O%3ZLNG9-K;16@MDW
MD8WOM8[C[=C6QX1\+_\ "*VFI0?;/M7VW49K[=Y6S9YF/EZG.,=>/I0!3^)G
MB&[\+_#_ %/5+ A;Q0D<+D9",[A=WX D\]P*R[7X?ZGHVHZ3J.G^+M4DNHY5
M&HKJ%RTT5VF/F 4_=;T]/PKK?$6@V7B?P_>:-J 8VUTFUBAPRD$$,/<$ CZ5
MQ\'PYUB\OM*'B3Q9)JVFZ5*L]M:BS6(O(GW&D8$EL?K^)H \]LM=NO%K:KJV
MIGQT9WN9(]/_ +#@D^S6R+POW<!FSUSZ5M7&IZUJN@?#6X\0VMQ;ZHOB"*.=
M;B$Q.VTL Q4@=1@_7-=0_P .M:TVXU*/PMXMDTG3=1E::6U>S6;R7;[QB8D%
M<^G;UJ_)\.[<:9X7L+;4)(X]"O4O-\J>8]RRYSDY&"22<\XZ8H X18_$$NB?
M$5/#?VC[;_PD3EQ;/MF,7&\1GLV/QZXJ[X U/3!XUAL[+7?$5C*]NXGT+7T=
MWE<#.]&8X4C!)[D \>G2S_#)+BQUZ!M9N(I=3U7^U(9[>/8UM)V'WCO'7TZ]
MJDTWP)JTGBC3]>\3^)/[7GTQ9%LHX[)+=4+C:S-@G<2.W&#0!O>,]0DTKP3K
ME_$666"QF>,KU#;#M/YXJI\.;&+3_AQX=@A "FPBE..A9U#L?Q+&MK6--BUG
M1+_2YSB*\MW@8^@92,_K7+_"^[F_X1)-#O5\O4M#D.GW,>?[GW&'^RR%2#0!
MF^"O^2N_$7_?L/\ T4U<[XW_ .$CD^-\=KX6\E-1NO#XA-Q,<+;1F9BTGU&
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M>6,';P.!]:I?$?XB6GBGQPVCZI<7D/A73[AD>.Q56DN70X+') Y(('H.<9H
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M9_%.QDNK!=2T+6=)L]1<1V=[>P*L4C-]T$ACMSVS]>E<%J&D7NL>%OB;;:=
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M%XJU#PU;VLRI:6>G0;);M,</Y@4EB>,#WXK%TR.6?]GOQM;)%=?:(M5=GAN
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MN(T9VSM49.!FO/? /Q&B\4:EXB@NI]BVEW*]L6MWB1+5-H!9F& V3D@G/7@
M4 >B45QME\4_!^H:E#90:HP,\GE0326\B0ROG&U9"H4G/OSVJWKWQ!\->&M1
M;3M4OVBO1$LJP) [LZL2!M"@Y/!^G>@#IZ*X63XP>!X[&&[76#*LH8^7%;R-
M)&%.&+J%RH'OC/;-=!>^+M!T_P -Q^(;K4H4TN5%:.XY._=T"@#)/MC/!]*
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M;7T,W3?V:-!^U"WP,>;YP7=G&>G'6@#MR RE6 (/!![T*H50J@ #H .E>/\
MA*V\8^,X=6OQXZO+!+?5)[1($LXG 5",<G'KC\*U_&3^(O!/PEUJ[/B6XO\
M5(YHGAO7@1&C5I(U*A1D$8W<_P"U0!Z0$569E4 MRQ ZTZN*^'GC"?Q+H$]O
MJ:>1K^F'[/J$#  [QT<#T;&>.,YQQBG?"C6=0U_X;:7J6J7+7-Y,9O,E8 %L
M2NHZ #H * .Q5$3.Q57)R<#&32X&<X&?6JNI:G8Z/8R7VHW<-K:Q_?EF<*H_
M$UBP?$+PC<V(O8M?LFMS,( V_GS""0N.N2 <<=J .C5$3.Q57)R<#&33J**
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MH8#;)-O;B,G)7;G;U[XS18Z'INFZGJ.HVEMY=WJ+(]U)O8^85&%X)P,#T H
M\'LF4_"+P79WS$:*_B+R;[<Q"^4)7(5_]G/)SZ"NP\8:;H5A\5_ 36%M:V]\
M\THD2W15S$$^4D#WR!^/I70^)/"[Z7X&_L?PMH5E>VJW'F3Z9=NS">)B2X5F
M;Y7R002>,<=JY+PSX$DF\:Z/JEKX.'AG3-,,DLAGNA-/<R,NU5'S$A5Z\\4
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MWK^OZ]#!^-G_ "3"^_Z^+?\ ]&K5&XT;3M8_:$E_M&SANDMM 26))D#J'\[
M;!XR 3^=>@:WH>F^(]+?3=5MOM%I(RLT>]DR5((Y4@]0.]"Z'IJ>()->6VQJ
M<EL+5I][<Q!MVW;G;U[XS5&)XAKEK!IVC_%^PLXEAM(YK-TAC&%0O@M@#@9-
M:.OP:MJ/Q;T"UM8=(N&@T)9K.#5V?R&<DARH4'+X'3T7/85TGQ(\-7$FCZK9
M>&_#TMUJ'B1HUO;L7&$C\LKM9@QP.,CY0.G-=7K'@O0_$6G65IK-DMRUHH$,
MJNT<D9  )5E((Z#C/84 >7V=IK>B:GX_GCN=#@O&T9I)=/T5Y?W,P3Y),,@
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M=>,DGL49=N(&<[<#TX)KH#K]U=>-O%::;J^@^$XK2=8[NYN8%DNKHJ"-Y#,
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MX.NOV@],N;5K=-$R@$L*A;:2Z1#MP1P0"4''?ZU]#7^G66J6CVFH6<%W;/\
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M<1G<$SQG'X5H>)_B/I_AK6;72/[-U+4KZ[MOM%M'81"3S1N(P.<YP"V<8P*
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MM;NPU*Q8+=6-['LECS]T\$@J>Q!_F*Z.@ HHHH **** "BBB@ HHHH ****
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MOGG=0X*Q)GUY_#-4)+!=$\:>#+S3?!<_AA)=22V,TEZ&>Y1L!E:,$D<=SZT
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MDF7)\K9U P,[J\AUSP9I/ASX1:'XKT^.2/7H%LKDWWG/O9GV J><;1NP!C@
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M<8&+W#,S%=F!A@VX<_CTQ4.FZ+>:'#\(]-U.(I=17-T[QMU3<"X!]P"/RKW
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MZ@'[Y^7ECR#VP3Q6EX7\'6'A8WD\,]W>W]\X>ZOKV7S)I<= 3@  =@!7144
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M3W,%M'%-,;& ^8ZJ S9/)R03S7T?10!X+X_U2S\5S_"W4(+$QV-W?L!;3(I
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M,^"O#W@^*5-#TU+4S8\R0LSN^.Q9B3CVZ5OT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% &1JGB33='UC2=*O)'6ZU5W2U54)#% "<GM]X5KUYG\0?^2H?#?_KZNO\
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MK.IP:O;:W%/LE2U$#P21*&/"G!0@XYY]^.:/P&_Y$.[_ .PI/_): /4****
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MNL3XBTS2;&6VO3=RSPS20W*L;9XTW[649Y/3!(Q5[4M8%EJ>F:=%$LUU?RL
MA?:$B09DD)P>GR@#N649 R1YKH]SX;NO&W@J/0=/-M-:0W,%V/LC0M$P@_U4
MA(&7!SD9)'/KSV5SE/BQIS2_ZN31;E(,GC>)H2X'OC;^5 &W;Z]H]W=I:6VK
M6,US(&9(8[E&=@I(8A0<D @@^A!JG-XT\*V\TD,WB;1HY8V*.CW\096'!!!;
M@BO-;/2[*#P3X<OXK*%+Y_%(9[@1 2'_ $R1>6Z_= 'TKK+SPWXFEO9Y(8/!
MAB>1F0S:5(SD$\;CYG)]3ZT 7=0\7WXOM1AT/0CJL6F1H]U(+GRRQ90X2$!6
M\Q]A#8RHY SDUJP:\DFM6NGR6TL'VRR^UVS2@JS8(\Q&4C*LH>,X[[CTVUYI
MK5CH&FZ[XGB\5:?+/>:CY<FD^5;NXE;R$0K;X!V2[T ['&SM74LEXM]\.[>_
M8MJ\:N]VQY.%M&64D_\ 71D_$B@#NJ*** "BBB@ HHHH **** "BBB@"GJW_
M "!K[_KWD_\ 0369X%_Y)]X:_P"P5:_^BEH\7:Y::+H<_P!H;=+<1M%#$I^9
MR1@_0#/)JG\/M6L[OPK8:= Y$VG6T5M(CGDA%"AOH<5?LY\G/;0CVD>;DOJ=
M71114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA;G48TUJ-TO+=+D^4Q<8+A<8W8[^]:4_A+2+OPA#X7N[<W&F16\=NJR-\VU
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MTKJ*RH[/U?YG+A/AE_BE^84445J=1S?@O_D'7W_7_-_,5TE<WX+_ .0=??\
M7_-_,5TE94/X:.7!?[O'T"BBBM3J"BBB@ HHHH **** "BBB@ HHHH ****
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M/^OB?_T<]:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M._.#^%>KT455"BJ,>5&F#PD<+3]G%WZA1116QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%-D++&S(F]@"0N<9/I0!X_P"*8([_ ,>ZRL^D
M>*=9C@$**=,N6BBMB8E)CQN4$G(<G)^_C QSZKHR+'H>GHL$\"K;1@17#;I8
MQM'RN<G+#H3GK7D6N:CX<NO$%Q?:OJ_CSPWJ=T$5["#S(U;8-HV>6C*PZG.X
M\D]*]/\ "M\][H<.ZQU6VC@"P1OJH N)U50/,89)R?\ :P3R<"@#;HHHH **
M** "BBB@#*\.?\@8?]?$_P#Z.>M6LKPY_P @8?\ 7Q/_ .CGK5H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_&.BM?\
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M*J:(B(H55GG 4#  \UZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J*XN8+.!I[F9(8E^\[L !6'XE\6V/AV+RS^_OG'[NV0\
M_5O0?S[5SMGX5U?Q5<)J7BBXDB@SNALH_EP#V(_A[?[1[XQ6T*6G--V7];&4
MJNO+!79SGB7QO=ZEK<,VGRF&VLI2UOC^)L$;S]02,>A([FNEB\=^(# EP_A6
M=X&4,)$#@$>H.T\&KNM>&]%MM3\,P1:9;K'-?M X"GYE%O-+@_WOFC7KGC([
MUVE;3K4>5)0V,H4JMVW(X_3?B/HUVRQ7@FL)CP1*N5!_WA_4"NMBFBGB66&1
M)(V&5=&!!'L15'4]"TO6$VW]E%,0,!R,,/HPY%<A+X)UG09&N/"^JN%)RUM,
M1S_[*?Q ^M9\M*>SY7Y[?>7>K#=77XGH%%<##\0;S393;^(]&GMG!QYD*\,?
M8'M[@FM6/XB>&G0%KUT/]UH'S^@-2\/572_IJ4J]-];$_BS7]4\/P6D^GZ&N
MIQS3)!(3>+!Y;R2)'&.5.=S/^&*T;?4I(]%2^UF"/39 I::(SB01\]-P SVZ
M#O7F/C'QP^L2I:Z7))%91.LGF#*M(X((/J " 1[C/I6AH>CZIXZ5=0UZ]F^P
MQ-MBB5=HD(ZD=@.V?J.,5K]5<8J=1V7XF?UE2ERP5V6;W6-4\=74FEZ&KVVE
M [;B[<8WC_/\/4]\#-=GH>A66@6 M;./&>9)&^](?4_X5<M+.WL+6.UM(4A@
MC&%1!@"IZRJ5;KEBK+^MS2%.SYI:L****Q-0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ON'Z4M1S3Q0 >
M9+&A/W=[ 9H ^7X-<U#0].(3Q%XYL[-"6.[2D5$R<GK+@#)_6OI'PY))-X7T
MF6:2XED>RA9Y+E-DK$H,EUR<,>XSP<UYKJ>I_$S6])NM+FT?PW!'>1- \IO@
MP0,,$XW'L?0UZ?HMF^GZ#IUE)<FZ>WMHXFG/_+4JH!;\<9_&@"]1110 4444
M >9_$'_DJ'PW_P"OJZ_]!CKTRO,_B#_R5#X;_P#7U=?^@QUZ90 4444 %%%%
M !1110 4444 %%%% !1110 445S=[XO2QOQ9R:/J32/(R1%8AB7;U*\\CO43
MG&"O(RJUH4E>;L=)14-K.;FUBG,,D)==WER##+[$>M35:=S1--70A( ))  Z
MDU']IM_^>\7_ 'V*=-#'<020RKNCD4JR^H/6N'L?#6CGQMJ%H;)?(@@BDC3<
MWRL>_6LJDY1:LMSGKU:D)144G=VWM^C['=T445J=)'<7$-K \]Q*D42#+.YP
M!^-<-X>\5:3H_A=FGN5>43R$0)R[98D<>GN>*9\0M3COTM]"L#)<7IF#O'",
MX !^4^_.<>W-8/P]T*34M5CU.2)'L("PW. 5=QD8'N#S[8KAJ59NLE36VE_4
M\3$8NK+%JG05[:7WM>U_NL:]VOB#Q?9W%W.3INDQQLZ1#.Z7 SSZ_4\>@-=-
MX*LK:V\,64D,*))-'ND<#ESD]35O7]2LK'3+B*YN8H9)8)!&KM@M\O;\Q5'P
M9J5E/H%C9Q7,3W,<.7B#?,O/<?C6L(1C4U=W8][#Y:J>%=>2<IW7O-=+/;LK
M]CI****Z2#C?&VBZ>T":@8#]JDN(HW?S&Y7.,8SCI73Z=IEII-K]FLHO*AW%
MMN\MR?<DUC>-6']CP#(S]KAXS_M5T8(/0@_2LHQ2FW8]"M5J2PE.+D[7?7M:
MWW"T445J>>%%%(S*BEF8*JC)). !0 M%5/[5TXG O[7_ +_+_C4EY!)<VDD,
M5P]N[C E3[R_2E?L7R--*6A/17&Z';ZE<:[J$,VMWCQV$Z *0,2 C)!KLJ4)
M<RO8UQ-!4)<O-?9]>NO4****HYPHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \8\4Z]8:?\0M<BO?&VH:"5$ 2"PLFD60>4I+.=C
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M/#:1QW-P+B91\TH39N_#M7DC>-=69=+76;2)M1TZ7=.4.T,X&""!D Y[CCT
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MS*!(N2.5)'(]:W* ,KPY_P @8?\ 7Q/_ .CGK5K*\.?\@8?]?$__ *.>M6@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9'(]_P"*;F77=3FY=IG;8I]N<M]3^0KI+3X<^$+&\@O+70K:.X@D62)P6RK
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M&U%(H[XPH;A(3E%DVC<%]LYQ0!:HHJCK.L66@:/=:KJ,PAM+6,O(Y_0#U).
M!W)% %ZBN<N/&VCVWA>PU^1IS;:AY:VD21%I9G<95%4=6//Y5=T#Q%8>)+.6
MXL3*#!,T$\,T922&1>JLIZ'D4 <3\0?^2H?#?_KZNO\ T&.O2G;9&SX)V@G
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MOF&5(!&>0*QO4YST.3!K#.S3=GZW]#V*BBBNH\,**** "BBB@ HHHH ****
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MDWO*5DH^:2;NWTO:WF>-QW%J)(S-*1$6 8H,L!GD@5W6GZ_\.;,J?LMQ(_\
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M^_VK?TWP]X@M_$<NJ7NHZ--%<0Q03PPZ;)'\L9D*E29FPQ,IR2#P!P*ZP
M 8 Z 5,:"6YO7S2<TE35OQ_0X$?#_68?^/?Q9=KZ<.O\GIZ>'?&]G_QZ^)(I
M0/\ GOEC_P"/*U=Y15^RCT.7Z[5?Q6?JD< 7^(]J^/+M+M1W'E@']5-1W.O>
M.([29;KP_"8S&P9H@<@8Z\,:]#IDT2SP20OG;(I4XZX(Q1[-]&QK%QO[U./W
M?\$^;@3BO0?#6L>+K?P_:V^E:+!<6J[O+FD!^;YSG^(=R?RI]W\)KEM3+V>M
M0QZ?N7$4UJ7EQ@;OG#@9)SCY>..M>A:1I<&BZ7#I]LTC0P[MID(+<L6YP!W-
M8TZ,D]=#T,7F%&I!**YM>IQK7OQ&N#\FGVD /<%./S8U*NF_$.Y7]YJ]G;@]
M5VKG\PA_G7=T5M[/S9YWUOM"*^7^9P!\%>);GFZ\67 SU5&<C\MPH7X9,_\
MQ\^(+N7/7"8_FQKOZ*/91']>K]';Y+_(^?[[P_J=I?FW_L^\(DG:* M"V92-
MS?+Q\QVJ6X[ GM76^%?A_;ZGI<D^KQZA:7"S%%C_ -7E=JD'#+GJ3S[5V'B'
M1]<U+5-,NM-U+3K:*PE-PB7-D\S-(8Y(CDK*OR[93QC.1G..*Z"(2"&,3,C2
MA1O9%*J6[D DX'MDU$:$4[LWJ9I5G#E2L^YQ3?"W1<?)=Z@I]Y%/_LM0M\,8
MU_U&MWD?U7/\B*[ZBK]E#L<_U[$?S'GP^&]\GW/%%T/7$;#_ -GI?^%<ZC_T
M--U_WPW_ ,77H%%'LH#^OXCO^"_R/G[7],ETK7+JSDGDN6C909F4@N2 ?4^N
M.M;W@?PI9>(C?&_:Y3[/Y>P1L%SNW9SD'T%>DZ_X3T3Q1]G_ +9LOM/V;<8O
MWKIMSM)^Z1G[J]?2K^FZ;::1IT-A8Q>5;0@B--Y; SGJ22>34*@E*YTSS6<J
M7(E9][_\ P(OAUX:C^]9/+[O,_\ 0BM>W\.Z+:*!#I5FN.C&$$_F>:TZ*U4(
MK9'!+$59?%)OYC4C2-=L:*J^BC IU%%48A1110!%<6MO=QB.Y@BF0'<%D0,
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MHH **** /,_B#_R5#X;_ /7U=?\ H,=>ED!E*L 01@@]Z\T^(/\ R5#X;_\
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M*B[F [GBM< *H    P .U+10!#>6D%_97%G=1B6WN(VBEC/1D88(_$&N?M?
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M;)K6HI0I*!>*Q\ZZ26GSW"BBBM3@"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 9S]*],KB_%WC2ZT;7++0M*M[*2_N+>2ZDFO[CR8(8UX&2 22QX'X?@ 6_\
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M60@G:![#DT <%XL^''AM++3CIOA>S\PZI9B;R+;)\DS+YF<#[NW.>V,UO_\
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M/_GP7_OX_P#C1_PB>A_\^"_]_'_QH VJ*Q?^$3T/_GP7_OX_^-'_  B>A_\
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M .$3T/\ Y\%_[^/_ (T ;5%8O_")Z'_SX+_W\?\ QH_X1/0_^?!?^_C_ .-
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MBBB@ KP"3PA>:K>VN@VVD:YIL<>MBYELI)-]A;1 Y>6.38N[<.%7MDU[_10
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MSD$A020!DUXEHU]=>*/B#%X@\7:;K4"6<_EZ/IRZ?,8H<D 2R-MQGID^V>@
MKV^B@#SWXD:7<W6J^#GLK*241:[#-<-#&3M4=6;';W->A444 %%%% !1110
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M7(=6;4#.H$* HTD93[Q;,8"X!!#<D8H ]1HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *0G )]*6D;[C?2@#RZ#XXZ5-8#4?^
M$<\1#3N=UV+0-$N.#\P..#[UZ+I>K6.M:5;:GI]RD]G<H'BE7H1_0@\$'D$8
MKQ#X?_$3PIH'P>72]2U!&OECN%-D(W9G+L^U>!CD$=^]9MHKZ=X0\$^'M8M[
M2T^UK<W0N-7FD2UB4L2H>-64.V,$!CQN'J: /HW<..1STYZT9&<9&?2OG3P[
M:W>H?"_7+VQO#<WGAW6FO;!@2%V(%+*!G(0KN.WV%=+I4P\:#QAXY:_N--L9
M++^SM.GV,S6Z!09)-J\\,>H_VJ /9@P/0@_0TM>#>"+W3M%\7:#9B'3-0NKM
M6BCO]"U&1MR@<M<PD]3G))[@^E>\T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !17"^*/BEIOA;Q(-"ETC5[^], G L8%D^4Y[;@>WI5_P?
M\0M$\:O<P:?]IM[VU_UUG>1>7*@SC. 2",\<'COC(H ZNBBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>maia-20230330.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4007525+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:maia="http://maiabiotech.com/20230330" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://maiabiotech.com/20230330" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://maiabiotech.com/20230330/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20230330_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20230330_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20230330_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20230330_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" id="Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100090 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram" id="Role_DisclosurePaycheckProtectionProgram">
        <link:definition>100110 - Disclosure - Paycheck Protection Program</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable" id="Role_DisclosureConvertibleNotesPayable">
        <link:definition>100120 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity" id="Role_DisclosureSimpleAgreementForFutureEquity">
        <link:definition>100130 - Disclosure - Simple Agreement for Future Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities" id="Role_DisclosureFairValueOfFinancialLiabilities">
        <link:definition>100140 - Disclosure - Fair Value of Financial Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan" id="Role_DisclosureEmployeeRetirementPlan">
        <link:definition>100160 - Disclosure - Employee Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100220 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables" id="Role_DisclosureFairValueOfFinancialLiabilitiesTables">
        <link:definition>100230 - Disclosure - Fair Value of Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100240 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails" id="Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails">
        <link:definition>100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" id="Role_DisclosureAccruedExpensesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Accrued Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" id="Role_DisclosurePaycheckProtectionProgramAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" id="Role_DisclosureConvertibleNotesPayableAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" id="Role_DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails" id="Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
        <link:definition>100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" id="Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
        <link:definition>100360 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" id="Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails">
        <link:definition>100380 - Disclosure - Stockholders&apos; Equity - Schedule of Unvested Restricted Shares (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails" id="Role_DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails">
        <link:definition>100390 - Disclosure - Stockholders&apos; Equity - Schedule of Warrant Exercised (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" id="Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails">
        <link:definition>100400 - Disclosure - Stockholders&apos; Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" id="Role_DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails">
        <link:definition>100410 - Disclosure - Stockholders&apos; Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" id="Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails">
        <link:definition>100420 - Disclosure - Stockholders&apos; Equity - Assumptions used in Calculating Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100430 - Disclosure - Stockholders&apos; Equity - Summary of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeRetirementPlanAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="maia_ResearchAndDevelopmentIncentivesReceivable" name="ResearchAndDevelopmentIncentivesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_WarrantLiabilityNoncurrent" name="WarrantLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_RatchetShareExpense" name="RatchetShareExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_AustralianResearchAndDevelopmentIncentives" name="AustralianResearchAndDevelopmentIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_GainOnPaycheckProtectionProgramLoanForgiveness" name="GainOnPaycheckProtectionProgramLoanForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ChangeInFairValueOfEmbeddedFeatures" name="ChangeInFairValueOfEmbeddedFeatures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_DeemedDividendOnWarrantModification" name="DeemedDividendOnWarrantModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_EarningsPerSharesBasicAndDiluted" name="EarningsPerSharesBasicAndDiluted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" name="WeightedAverageCommonSharesOutstandingBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" name="IssuanceOfCommonSharesUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" name="IssuanceOfCommonSharesUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" name="IssuanceOfCommonSharesInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" name="IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" name="IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" name="IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_IssuanceOfRatchetShares" name="IssuanceOfRatchetShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfRatchetSharesShares" name="IssuanceOfRatchetSharesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ModificationOfWarrantInEquity" name="ModificationOfWarrantInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ForeignCurrencyTranslationAdjustment" name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_MAIAMember" name="MAIAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_DGDMember" name="DGDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_THIOMember" name="THIOMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" name="IssuanceOfStockOptionsToSatisfyAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" name="IssuanceOfStockOptionsToSatisfyDeferredCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_StockIssuedDuringPeriodValueConversionOfSafe" name="StockIssuedDuringPeriodValueConversionOfSafe" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_StockIssuedDuringPeriodSharesConversionOfSafe" name="StockIssuedDuringPeriodSharesConversionOfSafe" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ReceiptOfStockSubscriptionReceivable" name="ReceiptOfStockSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" name="TransactionCostsIncurredInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" name="IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" name="IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_DissolutionOfFirm" name="DissolutionOfFirm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" name="GainLossFromForgivenessOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_IncreaseDecreaseInDeferredOfferingCosts" name="IncreaseDecreaseInDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_ProceedsFromCollectionOfSubscriptionReceivable" name="ProceedsFromCollectionOfSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_PaymentOfInitialPublicOfferingTransactionCosts" name="PaymentOfInitialPublicOfferingTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" name="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_OptionsIssuedForAccruedBonus" name="OptionsIssuedForAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_OptionsIssuedForDeferredCompensation" name="OptionsIssuedForDeferredCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" name="IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" name="PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" name="WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_PaycheckProtectionProgramTextBlock" name="PaycheckProtectionProgramTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" name="SimpleAgreementForFutureEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" name="DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_GoingConcernConsiderationsPolicyTextBlock" name="GoingConcernConsiderationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" name="ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_CertainRisksAndUncertaintiesPolicyTextBlock" name="CertainRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" name="ResearchAndDevelopmentIncentivePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_CommonStockWarrantsPolicyTextBlock" name="CommonStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ScheduleOfWarrantExercisedTableTextBlock" name="ScheduleOfWarrantExercisedTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_THIOTherapeuticsIncMember" name="THIOTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_MAIADrugDevelopmentCorporationMember" name="MAIADrugDevelopmentCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_OfferingAndOverallotmentMember" name="OfferingAndOverallotmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_ConsultingServices" name="ConsultingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_CashPaidForServicesProvided" name="CashPaidForServicesProvided" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_OptionsToPurchaseSharesOfCommonStock" name="OptionsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" name="OptionsToPurchaseSharesOfCommonStockTotalFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_LeighAnnDurantMember" name="LeighAnnDurantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_RaduVitocMember" name="RaduVitocMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_RemainingConsultingServicesSettled" name="RemainingConsultingServicesSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" name="CashPaidToSettleAPortionOfDeferredCompensationBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" name="StockBasedCompensationExpenseRelatedToAccruedBonusBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" name="IssuanceOfStockOptionsToSettleAccruedBonusBalance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" name="FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_PPPLoanProgramMember" name="PPPLoanProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" name="ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" name="ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_TwoThousandAndNineteenPromissoryNoteMember" name="TwoThousandAndNineteenPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandAndTwentyPromissoryNoteMember" name="TwoThousandAndTwentyPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_RelatedPartyMember" name="RelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandAndTwentyWarrantsMember" name="TwoThousandAndTwentyWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" name="TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandAndTwentyOneWarrantsMember" name="TwoThousandAndTwentyOneWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_ConvertibleNotesMember" name="ConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_DebtDiscountAndValueOfEmbeddedPutFeature" name="DebtDiscountAndValueOfEmbeddedPutFeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" name="MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_PercentageOfVotingPowerDefiningChangeOfControl" name="PercentageOfVotingPowerDefiningChangeOfControl" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_WarrantDescription" name="WarrantDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_PercentageOfIssuableUponConversionOfExercisePrice" name="PercentageOfIssuableUponConversionOfExercisePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_ConvertiblePromissoryNotesToRelatedParties" name="ConvertiblePromissoryNotesToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ConvertiblePromissoryNotesToSettleLoan" name="ConvertiblePromissoryNotesToSettleLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_CommonSharesUponExerciseOfWarrantsShares" name="CommonSharesUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ConvertibleNotesOutstanding" name="ConvertibleNotesOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_SimpleAgreementForFutureEquityIssued" name="SimpleAgreementForFutureEquityIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_PercentageOfConversionPrice" name="PercentageOfConversionPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" name="NumberOfCommonSharesConvertedUnderSAFEAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_CommonStockConversionPrice" name="CommonStockConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_DerivativeLiabilityOnConvertibleNotesPayable" name="DerivativeLiabilityOnConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" name="PercentageOfProbabilityOfTheConvertibleNotesMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_PercentageOfProbabilityOfEquityFinancingMaturity" name="PercentageOfProbabilityOfEquityFinancingMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" name="PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_WarrantLiabilitiesAbstract" name="WarrantLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_FairValueWarrantLiability" name="FairValueWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_FounderMember" name="FounderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_BlackSholesMethodMember" name="BlackSholesMethodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandEighteenStockOptionPlanMember" name="TwoThousandEighteenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" name="AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" name="JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" name="JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" name="JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" name="JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" name="MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TransactionCosts" name="TransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_ProceedsFromCommonStockNetOfIssuanceCosts" name="ProceedsFromCommonStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_WarrantModificationValue" name="WarrantModificationValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" name="ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="maia_WarrantsExercisedShares" name="WarrantsExercisedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_CashlessExerciseAtFairMarketValuePerShare" name="CashlessExerciseAtFairMarketValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" name="ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" name="ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsIssued" name="ClassOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsExercised" name="ClassOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsExpired" name="ClassOfWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" name="ClassOfWarrantsWeightedAverageExercisePriceIssued" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" name="ClassOfWarrantsWeightedAverageExercisePriceExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" name="ClassOfWarrantsWeightedAverageExercisePriceExpired" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePrice" name="ClassOfWarrantsWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" name="ClassOfWarrantsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_DefinedContributionPlanEmployerSalary" name="DefinedContributionPlanEmployerSalary" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_The401KPlanMember" name="The401KPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_CombinedMilestonePaymentsMaximum" name="CombinedMilestonePaymentsMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_PaymentsDueRelatedToMilestones" name="PaymentsDueRelatedToMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_AmendedPatentAndTechnologyLicenseAgreementMember" name="AmendedPatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_PatentAndTechnologyLicenseAgreementMember" name="PatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_NetSalesUptoOneBillionMember" name="NetSalesUptoOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_NetSalesAboveOneBillionMember" name="NetSalesAboveOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_UniversityOfTexasSouthwesternMember" name="UniversityOfTexasSouthwesternMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_RegeneronPharmaceuticalsIncMember" name="RegeneronPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="maia_RoyaltyPaymentsOnNetSales" name="RoyaltyPaymentsOnNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" name="PercentageOfRoyaltyPaymentsOnNetSalesDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ClaimExpirationTerm" name="ClaimExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" name="ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" name="OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" name="EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="maia_MoneyChannelNycIncMember" name="MoneyChannelNycIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>maia-20230330_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4007525+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="maia-20230330.xsd#TemplateLink" roleURI="http://maiabiotech.com/20230330/role/TemplateLink" />
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:type="locator" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilityNoncurrent" xlink:type="locator" xlink:label="maia_WarrantLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="maia_WarrantLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="maia-20230330.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="maia-20230330.xsd#maia_RatchetShareExpense" xlink:type="locator" xlink:label="maia_RatchetShareExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GainOnPaycheckProtectionProgramLoanForgiveness" xlink:type="locator" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:type="locator" xlink:label="maia_AustralianResearchAndDevelopmentIncentives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="maia_DeemedDividendOnWarrantModification" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_InterestExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_AustralianResearchAndDevelopmentIncentives" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_GainOnPaycheckProtectionProgramLoanForgiveness" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="maia_RatchetShareExpense" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="maia-20230330.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IncreaseDecreaseInDeferredOfferingCosts" xlink:type="locator" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:type="locator" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_IssuanceOfRatchetShares" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCosts" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10270.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="maia-20230330.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>maia-20230330_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4007525+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="maia-20230330.xsd#TemplateLink" roleURI="http://maiabiotech.com/20230330/role/TemplateLink" />
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="maia-20230330.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:type="locator" xlink:label="dei_EntityPrimarySicNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPrimarySicNumber" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
    <link:loc xlink:href="maia-20230330.xsd#maia_DissolutionOfFirm" xlink:type="locator" xlink:label="maia_DissolutionOfFirm" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ReceiptOfStockSubscriptionReceivable" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:type="locator" xlink:label="maia_ForeignCurrencyTranslationAdjustment" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ModificationOfWarrantInEquity" xlink:type="locator" xlink:label="maia_ModificationOfWarrantInEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetSharesShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetSharesShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOMember" xlink:type="locator" xlink:label="maia_THIOMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DGDMember" xlink:type="locator" xlink:label="maia_DGDMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIAMember" xlink:type="locator" xlink:label="maia_MAIAMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:type="locator" xlink:label="us-gaap_ParentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_MAIAMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_DGDMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRatchetShares" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRatchetSharesShares" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ModificationOfWarrantInEquity" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ForeignCurrencyTranslationAdjustment" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="13490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="13550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="13770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" order="14590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" order="14810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="15030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe" order="15250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe" order="15310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReceiptOfStockSubscriptionReceivable" order="15690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" order="15910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="16130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" order="16350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" order="16410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DissolutionOfFirm" order="16570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WorkingCapital" xlink:type="locator" xlink:label="maia_WorkingCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OfferingAndOverallotmentMember" xlink:type="locator" xlink:label="maia_OfferingAndOverallotmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:type="locator" xlink:label="maia_MAIADrugDevelopmentCorporationMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOTherapeuticsIncMember" xlink:type="locator" xlink:label="maia_THIOTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:type="locator" xlink:label="srt_ParentCompanyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_OwnershipAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="maia_MAIADrugDevelopmentCorporationMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_OfferingAndOverallotmentMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_WorkingCapital" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:type="locator" xlink:label="maia_UnvestedRestrictedStockAwardsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="maia_UnvestedRestrictedStockAwardsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RemainingConsultingServicesSettled" xlink:type="locator" xlink:label="maia_RemainingConsultingServicesSettled" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidForServicesProvided" xlink:type="locator" xlink:label="maia_CashPaidForServicesProvided" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConsultingServices" xlink:type="locator" xlink:label="maia_ConsultingServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RaduVitocMember" xlink:type="locator" xlink:label="maia_RaduVitocMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_LeighAnnDurantMember" xlink:type="locator" xlink:label="maia_LeighAnnDurantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_LeighAnnDurantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RaduVitocMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_ConsultingServices" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_CashPaidForServicesProvided" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_RemainingConsultingServicesSettled" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="12300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpensesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:type="locator" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:type="locator" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:type="locator" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PPPLoanProgramMember" xlink:type="locator" xlink:label="maia_PPPLoanProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="maia_PPPLoanProgramMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesOutstanding" xlink:type="locator" xlink:label="maia_ConvertibleNotesOutstanding" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercised" xlink:type="locator" xlink:label="maia_WarrantsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:type="locator" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantDescription" xlink:type="locator" xlink:label="maia_WarrantDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:type="locator" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:type="locator" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DebtDiscountAndValueOfEmbeddedPutFeature" xlink:type="locator" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:type="locator" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesMember" xlink:type="locator" xlink:label="maia_ConvertibleNotesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RelatedPartyMember" xlink:type="locator" xlink:label="maia_RelatedPartyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RelatedPartyMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AwardTypeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyWarrantsMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="maia_ConvertibleNotesMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpense" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_DebtDiscountAndValueOfEmbeddedPutFeature" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" order="12100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantDescription" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantsExercised" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleNotesOutstanding" order="13280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="13430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="13510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueWarrantLiability" xlink:type="locator" xlink:label="maia_FairValueWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilitiesAbstract" xlink:type="locator" xlink:label="maia_WarrantLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:type="locator" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_WarrantLiabilitiesAbstract" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_FairValueWarrantLiability" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="maia_NumberOfWarrantsExercised" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:type="locator" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercisedShares" xlink:type="locator" xlink:label="maia_WarrantsExercisedShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantModificationValue" xlink:type="locator" xlink:label="maia_WarrantModificationValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCosts" xlink:type="locator" xlink:label="maia_TransactionCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:type="locator" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_BlackSholesMethodMember" xlink:type="locator" xlink:label="maia_BlackSholesMethodMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FounderMember" xlink:type="locator" xlink:label="maia_FounderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOMember" xlink:type="locator" xlink:label="maia_THIOMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_FounderMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_RangeAxis" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="maia_BlackSholesMethodMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_PlanNameAxis" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardDateAxis" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_2" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_TransactionCosts" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="13110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="13150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="13170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="13210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantModificationValue" order="13280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantsExercisedShares" order="13430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfWarrantsExercised" order="13580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="13730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" order="13770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" order="13810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="13850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="13930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="13970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="14050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantsIssued" order="14090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="14160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="14230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" order="14410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" order="14430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:type="locator" xlink:label="maia_DefinedContributionPlanEmployerSalary" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_The401KPlanMember" xlink:type="locator" xlink:label="maia_The401KPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="maia_The401KPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="maia_DefinedContributionPlanEmployerSalary" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_ClaimExpirationTerm" xlink:type="locator" xlink:label="maia_ClaimExpirationTerm" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_RoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentsDueRelatedToMilestones" xlink:type="locator" xlink:label="maia_PaymentsDueRelatedToMilestones" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:type="locator" xlink:label="maia_CombinedMilestonePaymentsMaximum" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MilestonePayment" xlink:type="locator" xlink:label="maia_MilestonePayment" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TermOfAgreement" xlink:type="locator" xlink:label="maia_TermOfAgreement" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:type="locator" xlink:label="maia_RegeneronPharmaceuticalsIncMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:type="locator" xlink:label="maia_UniversityOfTexasSouthwesternMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesAboveOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesAboveOneBillionMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesUptoOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesUptoOneBillionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOTherapeuticsIncMember" xlink:type="locator" xlink:label="maia_THIOTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneBillionMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesAboveOneBillionMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasSouthwesternMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_TermOfAgreement" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_MilestonePayment" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_CombinedMilestonePaymentsMaximum" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PaymentsDueRelatedToMilestones" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_RoyaltyPaymentsOnNetSales" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ClaimExpirationTerm" order="12600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:type="locator" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardsExpirationYear" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TermOfAgreement" xlink:type="locator" xlink:label="maia_TermOfAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MoneyChannelNycIncMember" xlink:type="locator" xlink:label="maia_MoneyChannelNycIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_MoneyChannelNycIncMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="maia_TermOfAgreement" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>maia-20230330_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4007525+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Addresses, Address Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses Address Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_AddressTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Address Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AddressTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:label xml:lang="en-US" xlink:label="dei_BusinessContactMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Contact</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_BusinessContactMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Contact [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:type="locator" xlink:label="dei_EntityPrimarySicNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPrimarySicNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Primary SIC Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPrimarySicNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Primary Sic Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contact Personnel Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:type="locator" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable" />
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentives receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndDevelopmentIncentivesReceivable" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilityNoncurrent" xlink:type="locator" xlink:label="maia_WarrantLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantLiabilityNoncurrent" xlink:to="maia_WarrantLiabilityNoncurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australia research and development incentives receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentives Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 0 shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 10,955,904 and 7,584,980 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RatchetShareExpense" xlink:type="locator" xlink:label="maia_RatchetShareExpense" />
    <link:label xml:lang="en-US" xlink:label="maia_RatchetShareExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratchet share expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RatchetShareExpense" xlink:to="maia_RatchetShareExpense_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:type="locator" xlink:label="maia_AustralianResearchAndDevelopmentIncentives" />
    <link:label xml:lang="en-US" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Australian research and development incentives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AustralianResearchAndDevelopmentIncentives" xlink:to="maia_AustralianResearchAndDevelopmentIncentives_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GainOnPaycheckProtectionProgramLoanForgiveness" xlink:type="locator" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness" />
    <link:label xml:lang="en-US" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the gain on Paycheck Protection Program loan forgiveness.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_GainOnPaycheckProtectionProgramLoanForgiveness" xlink:to="maia_GainOnPaycheckProtectionProgramLoanForgiveness_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:label xml:lang="en-US" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of embedded features.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ChangeInFairValueOfEmbeddedFeatures" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:label xml:lang="en-US" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend on warrant modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DeemedDividendOnWarrantModification" xlink:to="maia_DeemedDividendOnWarrantModification_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_EarningsPerSharesBasicAndDiluted" xlink:type="locator" xlink:label="maia_EarningsPerSharesBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="maia_EarningsPerSharesBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings Per Shares Basic and Diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_EarningsPerSharesBasicAndDiluted" xlink:to="maia_EarningsPerSharesBasicAndDiluted_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:to="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RatchetShareExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratchet share expense</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RatchetShareExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ratchet Share Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian research and development incentives</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Australian Research And Development Incentives</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck protection program loan forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain On Paycheck Protection Program Loan Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Embedded Features</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of convertible notes and convertible notes, related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income Expense Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend on warrant modification</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend On Warrant Modification</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to MAIA Biotechnology, Inc. shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_EarningsPerSharesBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_EarningsPerSharesBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Shares Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Common Shares Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with initial public offering, issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon exercise of warrants shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with equity financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with equity financing shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon cashless exercise of warrants shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetShares" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of ratchet shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfRatchetShares" xlink:to="maia_IssuanceOfRatchetShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetSharesShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetSharesShares" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetSharesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of ratchet shares shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfRatchetSharesShares" xlink:to="maia_IssuanceOfRatchetSharesShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ModificationOfWarrantInEquity" xlink:type="locator" xlink:label="maia_ModificationOfWarrantInEquity" />
    <link:label xml:lang="en-US" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of warrant in equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ModificationOfWarrantInEquity" xlink:to="maia_ModificationOfWarrantInEquity_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:type="locator" xlink:label="maia_ForeignCurrencyTranslationAdjustment" />
    <link:label xml:lang="en-US" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency translation adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ForeignCurrencyTranslationAdjustment" xlink:to="maia_ForeignCurrencyTranslationAdjustment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Out Of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Out Of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Out Of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables From Stockholder [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:type="locator" xlink:label="us-gaap_ParentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total MAIA Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Parent [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIAMember" xlink:type="locator" xlink:label="maia_MAIAMember" />
    <link:label xml:lang="en-US" xlink:label="maia_MAIAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MAIA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MAIAMember" xlink:to="maia_MAIAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_MAIAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MAIAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M A I A [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_DGDMember" xlink:type="locator" xlink:label="maia_DGDMember" />
    <link:label xml:lang="en-US" xlink:label="maia_DGDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">DGD.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DGDMember" xlink:to="maia_DGDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_DGDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DGD</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DGDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">D G D [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOMember" xlink:type="locator" xlink:label="maia_THIOMember" />
    <link:label xml:lang="en-US" xlink:label="maia_THIOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">THIO.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_THIOMember" xlink:to="maia_THIOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_THIOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">THIO</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_THIOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T H I O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Exercise Of Warrants Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with Equity Financing, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Equity Financing Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ratchet shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Ratchet Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetSharesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ratchet shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRatchetSharesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Ratchet Shares Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of warrant in equity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Modification Of Warrant In Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Translation Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to satisfy accrued bonus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to satisfy deferred compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe" />
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of safe.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe" />
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of safe.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ReceiptOfStockSubscriptionReceivable" />
    <link:label xml:lang="en-US" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Receipt of stock subscription receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ReceiptOfStockSubscriptionReceivable" xlink:to="maia_ReceiptOfStockSubscriptionReceivable_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" />
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs incurred in connection with equity financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:label xml:lang="en-US" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ReclassificationOfWarrantLiabilityToEquity" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of restricted common shares to founder pursuant to merger agreement, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of restricted common shares to founder pursuant to merger agreement, share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DissolutionOfFirm" xlink:type="locator" xlink:label="maia_DissolutionOfFirm" />
    <link:label xml:lang="en-US" xlink:label="maia_DissolutionOfFirm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution of firm.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DissolutionOfFirm" xlink:to="maia_DissolutionOfFirm_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancellation of restricted common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Forfeitures</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancellation of restricted common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to satisfy accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock Options To Satisfy Accrued Bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to satisfy deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock Options To Satisfy Deferred Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of SAFE</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Safe</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of SAFE</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Safe</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of stock subscription receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receipt Of Stock Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs incurred in connection with Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs Incurred In Connection With Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares to founder pursuant to THIO Merger Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Restricted Common Shares To Founder Pursuant To Merger Agreement Value</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares to founder pursuant to THIO Merger Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Restricted Common Shares To Founder Pursuant To Merger Agreement Share</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DissolutionOfFirm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of DGD</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DissolutionOfFirm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution Of Firm</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" />
    <link:label xml:lang="en-US" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) from forgiveness of paycheck protection program loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IncreaseDecreaseInDeferredOfferingCosts" xlink:type="locator" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IncreaseDecreaseInDeferredOfferingCosts" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCosts_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from paycheck protection program loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from collection of subscription receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:type="locator" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of initial public offering transaction costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:type="locator" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" />
    <link:label xml:lang="en-US" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible notes and accrued interest into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsIssuedForAccruedBonus" xlink:type="locator" xlink:label="maia_OptionsIssuedForAccruedBonus" />
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued for accrued bonus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsIssuedForAccruedBonus" xlink:to="maia_OptionsIssuedForAccruedBonus_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsIssuedForDeferredCompensation" xlink:type="locator" xlink:label="maia_OptionsIssuedForDeferredCompensation" />
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued for deferred compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsIssuedForDeferredCompensation" xlink:to="maia_OptionsIssuedForDeferredCompensation_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:type="locator" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible note for payment on loan to officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:to="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Previously paid issuance costs in connection with the initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" xlink:to="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued to underwriters in connection with the initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" xlink:to="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain from forgiveness of Paycheck Protection Program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From Forgiveness Of Paycheck Protection Program Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Offering Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Australia research and development incentives receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Receivables</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Paycheck Protection Program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Paycheck Protection Program Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collections of subscriptions receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collection Of Subscription Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock in initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Initial Public Offering Transaction Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on loan payable to officer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Related Party Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net effect of foreign currency exchange on cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes and accrued interest into MAIA common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Notes And Accrued Interest Into Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE into MAIA common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued for accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued For Accrued Bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued for deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued For Deferred Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible note for payment on loan to officer</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Note For Payment On Loan To Officer</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously paid issuance costs in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Previously Paid Issuance Costs In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to underwriters in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued To Underwriters In Connection With Initial Public Offering</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_PaycheckProtectionProgramTextBlock" xlink:type="locator" xlink:label="maia_PaycheckProtectionProgramTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck protection program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaycheckProtectionProgramTextBlock" xlink:to="maia_PaycheckProtectionProgramTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:type="locator" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple agreement for future equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:to="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple Agreement for Future Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement For Future Equity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business organization and principles of consolidation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Organization, and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Principles Of Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_LiquidityPolicyTextBlock" xlink:type="locator" xlink:label="maia_LiquidityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_LiquidityPolicyTextBlock" xlink:to="maia_LiquidityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_GoingConcernConsiderationsPolicyTextBlock" xlink:type="locator" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern considerations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_GoingConcernConsiderationsPolicyTextBlock" xlink:to="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern Considerations</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Considerations Policy [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:type="locator" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ImpactOfTheCovid19PandemicOnOperations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:to="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of the COVID-19 Pandemic on our Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impact Of The Covid19 Pandemic On Operations Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Certain risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:to="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certain Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Off Balance Sheet Credit Exposure Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:type="locator" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentive policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:to="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Incentive</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentive Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonStockWarrantsPolicyTextBlock" xlink:type="locator" xlink:label="maia_CommonStockWarrantsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonStockWarrantsPolicyTextBlock" xlink:to="maia_CommonStockWarrantsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unvested Restricted Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:type="locator" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:to="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Warrant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Exercised Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used in Calculating Value of Warrants Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity and Information Regarding Outstanding and Exercisable Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:type="locator" xlink:label="srt_ParentCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ParentCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA Biotechnology, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ParentCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Parent Company [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOTherapeuticsIncMember" xlink:type="locator" xlink:label="maia_THIOTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">T H I O Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_THIOTherapeuticsIncMember" xlink:to="maia_THIOTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">THIO Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T H I O Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:type="locator" xlink:label="maia_MAIADrugDevelopmentCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">M A I A drug development corporation member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MAIADrugDevelopmentCorporationMember" xlink:to="maia_MAIADrugDevelopmentCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA Drug Development Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M A I A Drug Development Corporation [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_OfferingAndOverallotmentMember" xlink:type="locator" xlink:label="maia_OfferingAndOverallotmentMember" />
    <link:label xml:lang="en-US" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering and overallotment member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OfferingAndOverallotmentMember" xlink:to="maia_OfferingAndOverallotmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering And Overallotment</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering And Overallotment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage by parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority stockholder ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Noncontrolling Owners</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_WorkingCapital" xlink:type="locator" xlink:label="maia_WorkingCapital" />
    <link:label xml:lang="en-US" xlink:label="maia_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WorkingCapital" xlink:to="maia_WorkingCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payment Arrangement, Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:type="locator" xlink:label="maia_UnvestedRestrictedStockAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UnvestedRestrictedStockAwardsMember" xlink:to="maia_UnvestedRestrictedStockAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ConsultingServices" xlink:type="locator" xlink:label="maia_ConsultingServices" />
    <link:label xml:lang="en-US" xlink:label="maia_ConsultingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConsultingServices" xlink:to="maia_ConsultingServices_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidForServicesProvided" xlink:type="locator" xlink:label="maia_CashPaidForServicesProvided" />
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for services provided.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashPaidForServicesProvided" xlink:to="maia_CashPaidForServicesProvided_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsToPurchaseSharesOfCommonStock" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase shares of common stock total fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_LeighAnnDurantMember" xlink:type="locator" xlink:label="maia_LeighAnnDurantMember" />
    <link:label xml:lang="en-US" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leigh-Ann Durant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_LeighAnnDurantMember" xlink:to="maia_LeighAnnDurantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ms. Durant</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leigh Ann Durant [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RaduVitocMember" xlink:type="locator" xlink:label="maia_RaduVitocMember" />
    <link:label xml:lang="en-US" xlink:label="maia_RaduVitocMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Radu Vitoc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RaduVitocMember" xlink:to="maia_RaduVitocMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_RaduVitocMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mr. Vitoc</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RaduVitocMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Radu Vitoc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConsultingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConsultingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for services provided</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Services Provided</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock total fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Shares Of Common Stock Total Fair Value</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RemainingConsultingServicesSettled" xlink:type="locator" xlink:label="maia_RemainingConsultingServicesSettled" />
    <link:label xml:lang="en-US" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining consulting services settled.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RemainingConsultingServicesSettled" xlink:to="maia_RemainingConsultingServicesSettled_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining services settled</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Consulting Services Settled</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of unsecured debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Unsecured Debt</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation to former officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Defined Benefit Plans Current Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:type="locator" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" />
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid to settle a portion of deferred compensation balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued deferred compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid to settle a portion of deferred compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid To Settle A Portion Of Deferred Compensation Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Recorded Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense related to deferred compensation balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:type="locator" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" />
    <link:label xml:lang="en-US" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense related to accrued bonus balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" />
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to settle accrued bonus balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" />
    <link:label xml:lang="en-US" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of stock options issued to settle accrued bonus balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued bonus expense</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to settle accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock Options To Settle Accrued Bonus Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options issued to settle accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Stock Options Issued To Settle Accrued Bonus Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense related to accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation Expense Related To Accrued Bonus Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_PPPLoanProgramMember" xlink:type="locator" xlink:label="maia_PPPLoanProgramMember" />
    <link:label xml:lang="en-US" xlink:label="maia_PPPLoanProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">P P P loan program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PPPLoanProgramMember" xlink:to="maia_PPPLoanProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_PPPLoanProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">P P P Loan Program</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PPPLoanProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P P P Loan Program [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from unsecured loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Unsecured Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:type="locator" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" />
    <link:label xml:lang="en-US" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of outstanding principal and interest written off amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of outstanding principal and interest written off amount</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Outstanding Principal And Interest Written Off Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt Amount</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:type="locator" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt conversion price percentage of the equity financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Short Term Debt [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Short Term Debt [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Promissory Note [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Promissory Note [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RelatedPartyMember" xlink:type="locator" xlink:label="maia_RelatedPartyMember" />
    <link:label xml:lang="en-US" xlink:label="maia_RelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RelatedPartyMember" xlink:to="maia_RelatedPartyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_RelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyWarrantsMember" xlink:to="maia_TwoThousandAndTwentyWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand And Twenty Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Warrants [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty One Convertible Promissory Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Convertible Promissory Note [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty One Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyOneWarrantsMember" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand And Twenty One Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesMember" xlink:type="locator" xlink:label="maia_ConvertibleNotesMember" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertibleNotesMember" xlink:to="maia_ConvertibleNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Debt [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of the conversion price</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Conversion Price Percentage Of The Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_DebtDiscountAndValueOfEmbeddedPutFeature" xlink:type="locator" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature" />
    <link:label xml:lang="en-US" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt discount and value of embedded put feature.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DebtDiscountAndValueOfEmbeddedPutFeature" xlink:to="maia_DebtDiscountAndValueOfEmbeddedPutFeature_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and value of embedded put feature</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Discount And Value Of Embedded Put Feature</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:type="locator" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" />
    <link:label xml:lang="en-US" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum gross proceeds from equity financing required for conversion of debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:type="locator" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of voting power defining change of control</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum gross proceeds from equity financing required for conversion of debt</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of voting power defining change of control</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Voting Power Defining Change Of Control</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and derivative liability at the issuance date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative Fair Value Of Embedded Derivative Liability</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantDescription" xlink:type="locator" xlink:label="maia_WarrantDescription" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantDescription" xlink:to="maia_WarrantDescription_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:type="locator" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of issuable upon conversion of exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant description</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Description</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of issuable upon conversion of exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Issuable Upon Conversion Of Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory notes to related parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertiblePromissoryNotesToRelatedParties" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory notes to settle loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertiblePromissoryNotesToSettleLoan" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes to related parties</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Notes To Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes to settle loan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Notes To Settle Loan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">write-off of the unamortized debt discount</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares" />
    <link:label xml:lang="en-US" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common shares upon exercise of warrants shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonSharesUponExerciseOfWarrantsShares" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercised" xlink:type="locator" xlink:label="maia_WarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsExercised" xlink:to="maia_WarrantsExercised_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesOutstanding" xlink:type="locator" xlink:label="maia_ConvertibleNotesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertibleNotesOutstanding" xlink:to="maia_ConvertibleNotesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Shares Upon Exercise Of Warrants Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class Of Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Original Debt Amount1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Shares Issued1</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_SimpleAgreementForFutureEquityIssued" xlink:type="locator" xlink:label="maia_SimpleAgreementForFutureEquityIssued" />
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple agreement for future equity issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_SimpleAgreementForFutureEquityIssued" xlink:to="maia_SimpleAgreementForFutureEquityIssued_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfConversionPrice" xlink:type="locator" xlink:label="maia_PercentageOfConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfConversionPrice" xlink:to="maia_PercentageOfConversionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple agreement for future equity issued</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement For Future Equity Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:type="locator" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" />
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares converted under SAFE agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:to="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonStockConversionPrice" xlink:type="locator" xlink:label="maia_CommonStockConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock conversion price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonStockConversionPrice" xlink:to="maia_CommonStockConversionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted common stock under SAFE agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Shares Converted Under S A F E Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Conversion Price</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:type="locator" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability on convertible notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Derivative liabilities, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability on convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability On Convertible Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Derivative liabilities, Balance</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The probability of the Convertible Notes outstanding at maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:to="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of probability of the an equity financing at maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:to="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of probability of default, change in control or dissolution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:to="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of the convertible notes maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of The Convertible Notes Maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of equity financing maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of Equity Financing Maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of default change in control or dissolution</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of Default Change In Control Or Dissolution</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilitiesAbstract" xlink:type="locator" xlink:label="maia_WarrantLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantLiabilitiesAbstract" xlink:to="maia_WarrantLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueWarrantLiability" xlink:type="locator" xlink:label="maia_FairValueWarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="maia_FairValueWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_FairValueWarrantLiability" xlink:to="maia_FairValueWarrantLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liabilities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Warrant liabilities, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_FairValueWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_FairValueWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Warrant liabilities, Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_FounderMember" xlink:type="locator" xlink:label="maia_FounderMember" />
    <link:label xml:lang="en-US" xlink:label="maia_FounderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_FounderMember" xlink:to="maia_FounderMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_FounderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_FounderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Founder [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_BlackSholesMethodMember" xlink:type="locator" xlink:label="maia_BlackSholesMethodMember" />
    <link:label xml:lang="en-US" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Black sholes method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_BlackSholesMethodMember" xlink:to="maia_BlackSholesMethodMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Sholes Method</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Black Sholes Method [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:type="locator" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandEighteenStockOptionPlanMember" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Stock Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">January One To January Twenty Six Two Thousand Twenty Two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">January One To January Twenty Six Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">January Twenty Seven To May Thirty One Two Thousand Twenty Two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January Twenty Seven To May Thirty One Two Thousand Twenty Two</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">January Twenty Seven To May Thirty One Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">June One Two Thousand Twenty Two To August One Two Thousand Twenty Two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June One Two Thousand Twenty Two To August One Two Thousand Twenty Two</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">June One Two Thousand Twenty Two To August One Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" />
    <link:label xml:lang="en-US" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">March One Two Thousand Twenty One To June Six Two Thousand Twenty One.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March One Two Thousand Twenty One To June Six Two Thousand Twenty One</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">March One Two Thousand Twenty One To June Six Two Thousand Twenty One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCosts" xlink:type="locator" xlink:label="maia_TransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TransactionCosts" xlink:to="maia_TransactionCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from common stock net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Common Stock Net Of Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders shares cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Unvested balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Unvested balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Unvested balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantModificationValue" xlink:type="locator" xlink:label="maia_WarrantModificationValue" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantModificationValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant modification, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantModificationValue" xlink:to="maia_WarrantModificationValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantModificationValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant modification, value</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantModificationValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Modification Value</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock upon exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercisedShares" xlink:type="locator" xlink:label="maia_WarrantsExercisedShares" />
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsExercisedShares" xlink:to="maia_WarrantsExercisedShares_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:type="locator" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise at fair market value per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashlessExerciseAtFairMarketValuePerShare" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise at fair market value per share</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise At Fair Market Value Per Share</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="maia_NumberOfWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfWarrantsExercised" xlink:to="maia_NumberOfWarrantsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right date from which warrants or rights expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right additional purchase aggregate of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsIssued" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsIssued" xlink:to="maia_ClassOfWarrantsIssued_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights exercisable period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or right date from which warrants or rights expire</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Date From Which Warrants Or Rights Expire</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or right additional purchase aggregate of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Additional Purchase Aggregate Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assumptions, contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Issued</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsExercised" xlink:type="locator" xlink:label="maia_ClassOfWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsExercised" xlink:to="maia_ClassOfWarrantsExercised_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsExpired" xlink:type="locator" xlink:label="maia_ClassOfWarrantsExpired" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsExpired" xlink:to="maia_ClassOfWarrantsExpired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Warrants Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants Outstanding, Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Warrants Outstanding, Ending balance</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price, exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:to="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" />
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" />
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Options Outstanding, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Cancelled/forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled/forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years, Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years, Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, recognized period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:type="locator" xlink:label="maia_DefinedContributionPlanEmployerSalary" />
    <link:label xml:lang="en-US" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employer alary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DefinedContributionPlanEmployerSalary" xlink:to="maia_DefinedContributionPlanEmployerSalary_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_The401KPlanMember" xlink:type="locator" xlink:label="maia_The401KPlanMember" />
    <link:label xml:lang="en-US" xlink:label="maia_The401KPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The401 K Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_The401KPlanMember" xlink:to="maia_The401KPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_The401KPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401 (K)</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_The401KPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">The401 K Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution to employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee salary deferrals</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Salary</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_TermOfAgreement" xlink:type="locator" xlink:label="maia_TermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="maia_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TermOfAgreement" xlink:to="maia_TermOfAgreement_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MilestonePayment" xlink:type="locator" xlink:label="maia_MilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="maia_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MilestonePayment" xlink:to="maia_MilestonePayment_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:type="locator" xlink:label="maia_CombinedMilestonePaymentsMaximum" />
    <link:label xml:lang="en-US" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined milestone payments maximum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CombinedMilestonePaymentsMaximum" xlink:to="maia_CombinedMilestonePaymentsMaximum_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentsDueRelatedToMilestones" xlink:type="locator" xlink:label="maia_PaymentsDueRelatedToMilestones" />
    <link:label xml:lang="en-US" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due related to milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaymentsDueRelatedToMilestones" xlink:to="maia_PaymentsDueRelatedToMilestones_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended patent and technology license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Patent And Technology License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Patent And Technology License Agreement [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and technology license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PatentAndTechnologyLicenseAgreementMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent And Technology License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent And Technology License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesUptoOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesUptoOneBillionMember" />
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales upto one billion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NetSalesUptoOneBillionMember" xlink:to="maia_NetSalesUptoOneBillionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales up to $1,000,000,000</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Upto One Billion [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesAboveOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesAboveOneBillionMember" />
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales above one billion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NetSalesAboveOneBillionMember" xlink:to="maia_NetSalesAboveOneBillionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales above $1,000,000,000</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Above One Billion [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:type="locator" xlink:label="maia_UniversityOfTexasSouthwesternMember" />
    <link:label xml:lang="en-US" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of texas southwestern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UniversityOfTexasSouthwesternMember" xlink:to="maia_UniversityOfTexasSouthwesternMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University Of Texas Southwestern</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Texas Southwestern [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:type="locator" xlink:label="maia_RegeneronPharmaceuticalsIncMember" />
    <link:label xml:lang="en-US" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron Pharmaceuticals Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RegeneronPharmaceuticalsIncMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Pharmaceuticals Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined milestone payment maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Combined Milestone Payments Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due related to milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Due Related To Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate of royalties on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_RoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_RoyaltyPaymentsOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="maia_RoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payments on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RoyaltyPaymentsOnNetSales" xlink:to="maia_RoyaltyPaymentsOnNetSales_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_RoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_RoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments On Net Sales</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClaimExpirationTerm" xlink:type="locator" xlink:label="maia_ClaimExpirationTerm" />
    <link:label xml:lang="en-US" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Claim expiration term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClaimExpirationTerm" xlink:to="maia_ClaimExpirationTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty description</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales Description</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claim expiration term</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Claim Expiration Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets before valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OperatingLossCarryforwardsExpirationYear" xlink:to="maia_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Experimentation Tax Credits Carryforwards Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" />
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforward limited percentage of taxable income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:type="locator" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward limited percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Limited Percentage Of Taxable Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Experimentation Tax Credits Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Experimentation Tax Credits Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pretax book loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other nondeductible expenses/(nontaxable income)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:loc xlink:href="maia-20230330.xsd#maia_MoneyChannelNycIncMember" xlink:type="locator" xlink:label="maia_MoneyChannelNycIncMember" />
    <link:label xml:lang="en-US" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Money channel nyc inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MoneyChannelNycIncMember" xlink:to="maia_MoneyChannelNycIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Channel NYC Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Channel Nyc Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>maia-20230330_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-04-04T20:11:21.4017515+00:00 -->
<!-- Version            : 5.0.1.785 -->
<!-- Package ID         : 0d6f55c80e5c4ed783cf7a63abf6e745 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://maiabiotech.com/20230330/role/TemplateLink" xlink:href="maia-20230330.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="maia-20230330.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:type="locator" xlink:label="dei_EntityPrimarySicNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPrimarySicNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilityNoncurrent" xlink:type="locator" xlink:label="maia_WarrantLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:type="locator" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="maia_WarrantLiabilityNoncurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Liabilities" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquityAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="maia-20230330.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="maia-20230330.xsd#maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" />
    <link:loc xlink:href="maia-20230330.xsd#maia_EarningsPerSharesBasicAndDiluted" xlink:type="locator" xlink:label="maia_EarningsPerSharesBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GainOnPaycheckProtectionProgramLoanForgiveness" xlink:type="locator" xlink:label="maia_GainOnPaycheckProtectionProgramLoanForgiveness" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:type="locator" xlink:label="maia_AustralianResearchAndDevelopmentIncentives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RatchetShareExpense" xlink:type="locator" xlink:label="maia_RatchetShareExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_RatchetShareExpense" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_AustralianResearchAndDevelopmentIncentives" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_GainOnPaycheckProtectionProgramLoanForgiveness" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_DeemedDividendOnWarrantModification" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_EarningsPerSharesBasicAndDiluted" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:href="maia-20230330.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
    <link:loc xlink:href="maia-20230330.xsd#maia_DissolutionOfFirm" xlink:type="locator" xlink:label="maia_DissolutionOfFirm" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" xlink:type="locator" xlink:label="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ReceiptOfStockSubscriptionReceivable" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe" />
    <link:loc xlink:href="maia-20230330.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:type="locator" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:type="locator" xlink:label="maia_ForeignCurrencyTranslationAdjustment" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ModificationOfWarrantInEquity" xlink:type="locator" xlink:label="maia_ModificationOfWarrantInEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetSharesShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetSharesShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOMember" xlink:type="locator" xlink:label="maia_THIOMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DGDMember" xlink:type="locator" xlink:label="maia_DGDMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIAMember" xlink:type="locator" xlink:label="maia_MAIAMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:type="locator" xlink:label="us-gaap_ParentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="locator" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_MAIAMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_DGDMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRatchetShares" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRatchetSharesShares" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ModificationOfWarrantInEquity" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ForeignCurrencyTranslationAdjustment" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="13700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="13760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" order="14580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" order="14800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="15020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe" order="15240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe" order="15300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReceiptOfStockSubscriptionReceivable" order="15680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" order="15900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="16120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue" order="16340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare" order="16400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DissolutionOfFirm" order="16560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="maia-20230330.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:type="locator" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsIssuedForDeferredCompensation" xlink:type="locator" xlink:label="maia_OptionsIssuedForDeferredCompensation" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsIssuedForAccruedBonus" xlink:type="locator" xlink:label="maia_OptionsIssuedForAccruedBonus" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:type="locator" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:type="locator" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:type="locator" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IncreaseDecreaseInDeferredOfferingCosts" xlink:type="locator" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfRatchetShares" xlink:type="locator" xlink:label="maia_IssuanceOfRatchetShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_IssuanceOfRatchetShares" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCosts" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_OptionsIssuedForAccruedBonus" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_OptionsIssuedForDeferredCompensation" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="maia-20230330.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram" xlink:href="maia-20230330.xsd#Role_DisclosurePaycheckProtectionProgram" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram">
    <link:loc xlink:href="maia-20230330.xsd#maia_PaycheckProtectionProgramTextBlock" xlink:type="locator" xlink:label="maia_PaycheckProtectionProgramTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="maia_PaycheckProtectionProgramTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable" xlink:href="maia-20230330.xsd#Role_DisclosureConvertibleNotesPayable" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity" xlink:href="maia-20230330.xsd#Role_DisclosureSimpleAgreementForFutureEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity">
    <link:loc xlink:href="maia-20230330.xsd#maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:type="locator" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan" xlink:href="maia-20230330.xsd#Role_DisclosureEmployeeRetirementPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="maia-20230330.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents" xlink:href="maia-20230330.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonStockWarrantsPolicyTextBlock" xlink:type="locator" xlink:label="maia_CommonStockWarrantsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:type="locator" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:type="locator" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_GoingConcernConsiderationsPolicyTextBlock" xlink:type="locator" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_LiquidityPolicyTextBlock" xlink:type="locator" xlink:label="maia_LiquidityPolicyTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_LiquidityPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_GoingConcernConsiderationsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_CertainRisksAndUncertaintiesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_CommonStockWarrantsPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:type="locator" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ScheduleOfWarrantExercisedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WorkingCapital" xlink:type="locator" xlink:label="maia_WorkingCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OfferingAndOverallotmentMember" xlink:type="locator" xlink:label="maia_OfferingAndOverallotmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:type="locator" xlink:label="maia_MAIADrugDevelopmentCorporationMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOTherapeuticsIncMember" xlink:type="locator" xlink:label="maia_THIOTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:type="locator" xlink:label="srt_ParentCompanyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_OwnershipAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="maia_MAIADrugDevelopmentCorporationMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_OfferingAndOverallotmentMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_WorkingCapital" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails" xlink:href="maia-20230330.xsd#Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:type="locator" xlink:label="maia_UnvestedRestrictedStockAwardsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="maia_UnvestedRestrictedStockAwardsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RemainingConsultingServicesSettled" xlink:type="locator" xlink:label="maia_RemainingConsultingServicesSettled" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidForServicesProvided" xlink:type="locator" xlink:label="maia_CashPaidForServicesProvided" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConsultingServices" xlink:type="locator" xlink:label="maia_ConsultingServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RaduVitocMember" xlink:type="locator" xlink:label="maia_RaduVitocMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_LeighAnnDurantMember" xlink:type="locator" xlink:label="maia_LeighAnnDurantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_LeighAnnDurantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RaduVitocMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_ConsultingServices" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_CashPaidForServicesProvided" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_RemainingConsultingServicesSettled" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureAccruedExpensesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:type="locator" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:type="locator" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:type="locator" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:type="locator" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PPPLoanProgramMember" xlink:type="locator" xlink:label="maia_PPPLoanProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="maia_PPPLoanProgramMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesOutstanding" xlink:type="locator" xlink:label="maia_ConvertibleNotesOutstanding" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercised" xlink:type="locator" xlink:label="maia_WarrantsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:type="locator" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount_li0l2" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:type="locator" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantDescription" xlink:type="locator" xlink:label="maia_WarrantDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:type="locator" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:type="locator" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DebtDiscountAndValueOfEmbeddedPutFeature" xlink:type="locator" xlink:label="maia_DebtDiscountAndValueOfEmbeddedPutFeature" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:type="locator" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ConvertibleNotesMember" xlink:type="locator" xlink:label="maia_ConvertibleNotesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RelatedPartyMember" xlink:type="locator" xlink:label="maia_RelatedPartyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:type="locator" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RelatedPartyMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyWarrantsMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="maia_ConvertibleNotesMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpense" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_DebtDiscountAndValueOfEmbeddedPutFeature" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantDescription" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount_li0l2" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_li0l2" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantsExercised" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleNotesOutstanding" order="13270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="13420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_CommonStockConversionPrice" xlink:type="locator" xlink:label="maia_CommonStockConversionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:type="locator" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfConversionPrice" xlink:type="locator" xlink:label="maia_PercentageOfConversionPrice" />
    <link:loc xlink:href="maia-20230330.xsd#maia_SimpleAgreementForFutureEquityIssued" xlink:type="locator" xlink:label="maia_SimpleAgreementForFutureEquityIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_SimpleAgreementForFutureEquityIssued" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_PercentageOfConversionPrice" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_CommonStockConversionPrice" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_li0l2" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FairValueWarrantLiability" xlink:type="locator" xlink:label="maia_FairValueWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantLiabilitiesAbstract" xlink:type="locator" xlink:label="maia_WarrantLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:type="locator" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilities_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_WarrantLiabilitiesAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_FairValueWarrantLiability" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_li0l2" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:type="locator" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:type="locator" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="maia_PercentageOfProbabilityOfEquityFinancingMaturity" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:type="locator" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:type="locator" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="maia_NumberOfWarrantsExercised" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:type="locator" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantsExercisedShares" xlink:type="locator" xlink:label="maia_WarrantsExercisedShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="locator" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" />
    <link:loc xlink:href="maia-20230330.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:type="locator" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" />
    <link:loc xlink:href="maia-20230330.xsd#maia_DeemedDividendOnWarrantModification" xlink:type="locator" xlink:label="maia_DeemedDividendOnWarrantModification" />
    <link:loc xlink:href="maia-20230330.xsd#maia_WarrantModificationValue" xlink:type="locator" xlink:label="maia_WarrantModificationValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TransactionCosts" xlink:type="locator" xlink:label="maia_TransactionCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:type="locator" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_BlackSholesMethodMember" xlink:type="locator" xlink:label="maia_BlackSholesMethodMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_FounderMember" xlink:type="locator" xlink:label="maia_FounderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOMember" xlink:type="locator" xlink:label="maia_THIOMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_FounderMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_RangeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="maia_BlackSholesMethodMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_PlanNameAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardDateAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_TransactionCosts" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="13160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantModificationValue" order="13270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantsExercisedShares" order="13420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfWarrantsExercised" order="13570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="13720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" order="13760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="13840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="13920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="14040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantsIssued" order="14080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="14150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="14220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" order="14400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" order="14420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:type="locator" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsExpired" xlink:type="locator" xlink:label="maia_ClassOfWarrantsExpired" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsExercised" xlink:type="locator" xlink:label="maia_ClassOfWarrantsExercised" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ClassOfWarrantsIssued" xlink:type="locator" xlink:label="maia_ClassOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsExercised" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsExpired" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice_li0l2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="maia-20230330.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:type="locator" xlink:label="maia_DefinedContributionPlanEmployerSalary" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_The401KPlanMember" xlink:type="locator" xlink:label="maia_The401KPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="maia_The401KPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="maia_DefinedContributionPlanEmployerSalary" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="maia-20230330.xsd#maia_ClaimExpirationTerm" xlink:type="locator" xlink:label="maia_ClaimExpirationTerm" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_RoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PaymentsDueRelatedToMilestones" xlink:type="locator" xlink:label="maia_PaymentsDueRelatedToMilestones" />
    <link:loc xlink:href="maia-20230330.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:type="locator" xlink:label="maia_CombinedMilestonePaymentsMaximum" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MilestonePayment" xlink:type="locator" xlink:label="maia_MilestonePayment" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TermOfAgreement" xlink:type="locator" xlink:label="maia_TermOfAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:type="locator" xlink:label="maia_RegeneronPharmaceuticalsIncMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:type="locator" xlink:label="maia_UniversityOfTexasSouthwesternMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesAboveOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesAboveOneBillionMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_NetSalesUptoOneBillionMember" xlink:type="locator" xlink:label="maia_NetSalesUptoOneBillionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember" />
    <link:loc xlink:href="maia-20230330.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:type="locator" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="maia-20230330.xsd#maia_THIOTherapeuticsIncMember" xlink:type="locator" xlink:label="maia_THIOTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneBillionMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesAboveOneBillionMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasSouthwesternMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_TermOfAgreement" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_MilestonePayment" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_CombinedMilestonePaymentsMaximum" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PaymentsDueRelatedToMilestones" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_RoyaltyPaymentsOnNetSales" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ClaimExpirationTerm" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" />
    <link:loc xlink:href="maia-20230330.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="maia_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:type="locator" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardsExpirationYear" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="maia-20230330.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="maia-20230330.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="maia-20230330.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="maia-20230330.xsd#maia_TermOfAgreement" xlink:type="locator" xlink:label="maia_TermOfAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="maia-20230330.xsd#maia_MoneyChannelNycIncMember" xlink:type="locator" xlink:label="maia_MoneyChannelNycIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_MoneyChannelNycIncMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="maia_TermOfAgreement" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285884642448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001878313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAIA Biotechnology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1495913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">444 West Lake Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-8592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Vlad Vitoc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">444 West Lake Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-8592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885803328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 10,950,927<span></span>
</td>
<td class="nump">$ 10,574,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">554,321<span></span>
</td>
<td class="nump">54,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndDevelopmentIncentivesReceivable', window );">Australia research and development incentives receivable</a></td>
<td class="nump">302,789<span></span>
</td>
<td class="nump">43,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,808,037<span></span>
</td>
<td class="nump">10,672,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">211,203<span></span>
</td>
<td class="nump">651,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,022,040<span></span>
</td>
<td class="nump">11,327,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,165,505<span></span>
</td>
<td class="nump">960,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,103,401<span></span>
</td>
<td class="nump">1,185,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,268,906<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,514,247<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 10,955,904 and 7,584,980 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">52,729,942<span></span>
</td>
<td class="nump">37,618,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,207,272)<span></span>
</td>
<td class="num">(28,437,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">8,507,793<span></span>
</td>
<td class="nump">9,181,203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 12,022,040<span></span>
</td>
<td class="nump">$ 11,327,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885986112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885753440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 8,933,314<span></span>
</td>
<td class="nump">$ 3,496,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">6,143,527<span></span>
</td>
<td class="nump">4,289,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_RatchetShareExpense', window );">Ratchet share expense</a></td>
<td class="nump">1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,176,201<span></span>
</td>
<td class="nump">7,786,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,176,201)<span></span>
</td>
<td class="num">(7,786,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,967)<span></span>
</td>
<td class="num">(827,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_AustralianResearchAndDevelopmentIncentives', window );">Australian research and development incentives</a></td>
<td class="nump">313,625<span></span>
</td>
<td class="nump">43,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GainOnPaycheckProtectionProgramLoanForgiveness', window );">Paycheck protection program loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="num">(203,000)<span></span>
</td>
<td class="num">(203,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">98,394<span></span>
</td>
<td class="num">(1,546,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes and convertible notes, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,322,943)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="nump">406,922<span></span>
</td>
<td class="num">(4,791,584)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="num">(12,578,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to MAIA Biotechnology, Inc. shareholders</a></td>
<td class="num">$ (16,219,857)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_EarningsPerSharesBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (1.75)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding basic and diluted</a></td>
<td class="nump">9,276,761<span></span>
</td>
<td class="nump">5,278,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_AustralianResearchAndDevelopmentIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Australian research and development incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_AustralianResearchAndDevelopmentIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DeemedDividendOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DeemedDividendOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_EarningsPerSharesBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Shares Basic and Diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_EarningsPerSharesBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GainOnPaycheckProtectionProgramLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the gain on Paycheck Protection Program loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GainOnPaycheckProtectionProgramLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_RatchetShareExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratchet share expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_RatchetShareExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885915664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (16,219,857)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,235,830)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285888352464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common shares in connection with initial public offering, issuance cost</a></td>
<td class="nump">$ 2,749,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285880640496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>MAIA</div></th>
<th class="th"><div>DGD</div></th>
<th class="th"><div>THIO</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>MAIA</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>DGD</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>THIO</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Subscription Receivable</div></th>
<th class="th"><div>Total MAIA Equity (Deficit)</div></th>
<th class="th">
<div>Total MAIA Equity (Deficit) </div>
<div>MAIA</div>
</th>
<th class="th">
<div>Total MAIA Equity (Deficit) </div>
<div>DGD</div>
</th>
<th class="th">
<div>Total MAIA Equity (Deficit) </div>
<div>THIO</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>DGD</div>
</th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>THIO</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,616,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 12,599,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,934,113)<span></span>
</td>
<td class="num">$ (2,002)<span></span>
</td>
<td class="num">$ (3,336,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,719,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,433,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">529,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">529,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,428,935<span></span>
</td>
<td class="nump">$ 161,460<span></span>
</td>
<td class="nump">$ 104,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,428,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,428,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,460<span></span>
</td>
<td class="nump">$ 104,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing', window );">Issuance of common shares in connection with Equity Financing</a></td>
<td class="nump">5,860,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">6,180,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
<td class="nump">5,860,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares', window );">Issuance of common shares in connection with Equity Financing, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(12,578,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,503,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,503,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">9,181,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758<span></span>
</td>
<td class="nump">37,618,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,437,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,181,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted common shares</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">27,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted common shares</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSatisfyAccruedBonus', window );">Issuance of stock options to satisfy accrued bonus</a></td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation', window );">Issuance of stock options to satisfy deferred compensation</a></td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="nump">11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">11,001,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockIssuedDuringPeriodValueConversionOfSafe', window );">Issuance of common shares upon conversion of SAFE</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockIssuedDuringPeriodSharesConversionOfSafe', window );">Issuance of common shares upon conversion of SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReceiptOfStockSubscriptionReceivable', window );">Receipt of stock subscription receivable</a></td>
<td class="nump">322,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,002<span></span>
</td>
<td class="nump">322,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TransactionCostsIncurredInConnectionWithEquityFinancing', window );">Transaction costs incurred in connection with Equity Financing</a></td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue', window );">Issuance of restricted common shares to founder pursuant to THIO Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare', window );">Issuance of restricted common shares to founder pursuant to THIO Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DissolutionOfFirm', window );">Dissolution of DGD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098,110<span></span>
</td>
<td class="nump">$ 813,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098,110<span></span>
</td>
<td class="nump">$ 813,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,098,110)<span></span>
</td>
<td class="num">$ (813,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">83,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options, Shares</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">$ 385,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">385,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,319,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,319,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing', window );">Issuance of common shares in connection with Equity Financing</a></td>
<td class="nump">2,473,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">2,473,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares', window );">Issuance of common shares in connection with Equity Financing, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering', window );">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</a></td>
<td class="nump">8,750,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">8,749,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares', window );">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRatchetShares', window );">Issuance of ratchet shares</a></td>
<td class="nump">1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">1,099,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRatchetSharesShares', window );">Issuance of ratchet shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ModificationOfWarrantInEquity', window );">Modification of warrant in equity</a></td>
<td class="nump">450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,507,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 52,729,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,207,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,955,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DeemedDividendOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DeemedDividendOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DissolutionOfFirm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution of firm.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DissolutionOfFirm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with equity financing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon cashless exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRatchetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ratchet shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRatchetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRatchetSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ratchet shares shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRatchetSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted common shares to founder pursuant to merger agreement, share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted common shares to founder pursuant to merger agreement, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSatisfyAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to satisfy accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSatisfyAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to satisfy deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ModificationOfWarrantInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of warrant in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ModificationOfWarrantInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReceiptOfStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReceiptOfStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockIssuedDuringPeriodSharesConversionOfSafe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of safe.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockIssuedDuringPeriodSharesConversionOfSafe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockIssuedDuringPeriodValueConversionOfSafe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of safe.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockIssuedDuringPeriodValueConversionOfSafe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TransactionCostsIncurredInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TransactionCostsIncurredInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883217056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (15,769,279)<span></span>
</td>
<td class="num">$ (12,578,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,319,427<span></span>
</td>
<td class="nump">2,722,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan', window );">Gain from forgiveness of Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRatchetShares', window );">Issuance of ratchet shares</a></td>
<td class="nump">1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(505,233)<span></span>
</td>
<td class="num">(15,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IncreaseDecreaseInDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">440,379<span></span>
</td>
<td class="num">(651,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Australia research and development incentives receivable</a></td>
<td class="num">(269,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">322<span></span>
</td>
<td class="num">(3,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">211,346<span></span>
</td>
<td class="nump">805,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">915,742<span></span>
</td>
<td class="nump">997,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,655,725)<span></span>
</td>
<td class="num">(4,122,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCollectionOfSubscriptionReceivable', window );">Collections of subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of transaction costs</a></td>
<td class="nump">2,473,560<span></span>
</td>
<td class="nump">5,742,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">385,400<span></span>
</td>
<td class="nump">529,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in initial public offering</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment on loan payable to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,036,790<span></span>
</td>
<td class="nump">14,033,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentOfInitialPublicOfferingTransactionCosts', window );">Payment of initial public offering transaction costs</a></td>
<td class="num">(2,406,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Net effect of foreign currency exchange on cash</a></td>
<td class="num">(4,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">376,635<span></span>
</td>
<td class="nump">9,910,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">10,574,292<span></span>
</td>
<td class="nump">663,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">10,950,927<span></span>
</td>
<td class="nump">10,574,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock', window );">Conversion of convertible notes and accrued interest into MAIA common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of SAFE into MAIA common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsIssuedForAccruedBonus', window );">Options issued for accrued bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsIssuedForDeferredCompensation', window );">Options issued for deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer', window );">Issuance of convertible note for payment on loan to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering', window );">Previously paid issuance costs in connection with the initial public offering</a></td>
<td class="nump">651,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering', window );">Warrants issued to underwriters in connection with the initial public offering</a></td>
<td class="nump">$ 343,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible notes and accrued interest into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from forgiveness of paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IncreaseDecreaseInDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IncreaseDecreaseInDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible note for payment on loan to officer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRatchetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ratchet shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRatchetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsIssuedForAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options issued for accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsIssuedForAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsIssuedForDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options issued for deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsIssuedForDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaymentOfInitialPublicOfferingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of initial public offering transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaymentOfInitialPublicOfferingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Previously paid issuance costs in connection with the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromCollectionOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from collection of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromCollectionOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to underwriters in connection with the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285888482864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Business and Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/>NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business, Organization, and Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#8220;the Company&#8221;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#8220;MAIA&#8221;) was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>THIO Therapeutics, Inc. (&#8220;THIO&#8221;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>DGD Pharmaceuticals Corporation (&#8220;DGD&#8221;), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>MAIA Drug Development Corporation (&#8220;MAIA DD&#8221;) incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2022, the Company had working capital of&#8201;$8,539,131, an accumulated deficit of $44,207,272, cash of $10,950,927 and current liabilities of $3,268,906. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses. During May 2022, the company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#8221; The Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in the initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter. After deducting $2,406,170 for cash issuance costs, net proceeds from the offering and overallotment were $9,093,830.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern Considerations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $44,207,272 from the Company&#8217;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $10,951,000 million in cash and cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221; or &#8220;GAAP&#8221;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s Chief Executive Officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of the Company&#8217;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has no cash equivalents as of December 31, 2022 and 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#8220;Accounting Standards Codification (ASC) Topic 820&#8221;, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the </p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular period</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. There have been no material changes in estimates for the periods presented.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), depending on the specific terms of the warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only </p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.11%;"/>
<td style="width:0.94%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:12.1%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,545,628</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796,985</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <span style="-sec-ix-hidden:F_000377">ASU No. 2016-02</span>, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of January 1, 2022. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285969551968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">RELATED PARTY TRANSACTIONS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consulting Services </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $88,994 for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $34,560 in cash and issued her options to purchase 23,964 shares of common stock with a total fair value of $54,434 during the year ended December 31, 2021.&#160;&#160;Ms. Durant was no longer considered a related party in 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $4,700 for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $2,350 in cash and issued him options to purchase 184 shares of common stock with a total fair value of $1,100. The remaining $1,250 for services provided in fiscal 2021 were settled in March, 2022 for 226 options issued to Mr. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company also issued him a convertible note in the amount of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during April 2021, which was converted into </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,557</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock on September 30, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at a conversion price of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share, and also received </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> warrants to purchase shares of common stock at an exercise price of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share.&#160;&#160;In 2022, Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provided consulting services to the Company through July 2022 for which the Company incurred $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,900</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for services provided during the year ended December 31, 2022.&#160;&#160;The Company paid Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,950</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in cash and issued him options to purchase </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,690</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock with a total fair value of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.950</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;In August 2022, Mr. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vitoc</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> became an employee of the Company. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Loan Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's chief executive officer lent the Company a total of $25,000 in August and September of 2018. These amounts, were unsecured, had no stated interest rate, and no stated repayment terms. The Company repaid $3,633 of the loan to the CEO during 2020 and $367 during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $21,000. The convertible note issued to the CEO was converted into 3,621 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share.&#160;&#160;No further notes to the CEO were incurred in the year ended December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891485600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ACCRUED EXPENSES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,582</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional&#160;&#160;fees</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,589</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,277</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516,961</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,140</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation to former officers</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,269</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,157</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,103,401</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,185,595</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Compensation Agreements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and December 31, 2021, the Company had $0 and $111,271, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $193,379 in deferred compensation. The Company paid $457,749 in cash and issued 268,769 options with a total fair value of $296,264 during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $743,167. The fair value of the options issued in excess of the deferred compensation balance settled totaling $10,846 was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Bonus</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022 and 2021, the Company accrued $1,094,582 and $384,750, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of 713,536 stock options with a total fair value of $786,531. The fair value of the options issued in excess of the accrued bonus balance totaled $6,531 and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891388976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaycheckProtectionProgramTextBlock', window );">Paycheck Protection Program</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.78%;text-indent:-4.78%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. PAYCHECK PROTECTION PROGRAM </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2021, the Company received a second PPP Loan in the amount of $62,500. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of 0.98% per annum. The term of the PPP Loan is two years. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $62,500, and the Company recorded a gain on extinguishment totaling $62,500 for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaycheckProtectionProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paycheck protection program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaycheckProtectionProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891387648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CONVERTIBLE NOTES PAYABLE</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2019</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company issued a Convertible Promissory Note totaling $10,000 to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at 8% per annum, was unsecured, with a scheduled maturity date of December 31, 2021. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $5,000,000 (before any transaction related expenses and costs). The conversion price will be set at 65% of the price of the preferred stock issued in the aforementioned Equity Financing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Feature</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the terms related to the Equity Financing conversion, (the &#8220;Embedded Put Feature&#8221;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2019 Convertible Note totaled $0 and $607 for the year ended December 31, 2022 and 2021, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $1,000 at issuance. The balance of the debt discount was $0 as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $0 and $310, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2020</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company issued Convertible Promissory Notes totaling $610,000 to various investors or holders, including $110,000 of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at 6% per annum, was unsecured, with a scheduled maturity date of May 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000,000</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) a Change in Control whereby any person or group becomes a beneficial owner of more than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50%</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price is set at 75% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $131,000 at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2020 Convertible Notes totaled $27,375 and $11,523 for the year ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discounts on the 2020 Convertible Notes totaled $0 and $0 as of December 31, 2022 and 2021, respectively.&#160;&#160;During the year ended December 31, 2021 amortization of debt discounts amounted to $83,608. There was no amortization of debt discounts for the year ended December 31, 2022.&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p><p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $65,660 (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Payable issued in 2021</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $7,390,000 to various investors or holders, including $1,863,300 of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $21,000 Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at 6% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $5,000,000 (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Prices</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion price was set at 75% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Put Features</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $2,821,000 at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Maturity Date</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense on the 2021 Convertible Notes totaled $199,049 and $0 for the year ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $0 and $513,035, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p><p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $320,460 (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conversion of Convertible Notes Upon Equity Financing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $5 million, the Company converted all $8,010,000 of its outstanding principal and all accrued and unpaid interest of approximately $240,000 related to the Company&#8217;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into 1,375,228 shares of the Company&#8217;s common stock on September 30, 2021 at a conversion price of $6.00 per share. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $2.3 million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $3.3 million. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 there were no Convertible Notes outstanding. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for 686,489 shares of common stock with an exercise price of $6.00 and expire at various dates throughout fiscal 2028.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, 4,504 of these warrants have been exercised.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891474512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple Agreement for Future Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_SimpleAgreementForFutureEquityDisclosureTextBlock', window );">Simple Agreement for Future Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">SIMPLE AGREEMENT FOR FUTURE EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $25,000. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at 60% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $25,000 was converted into 5,208 shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $8.00. 'The conversion price was equal to 60% of $8.00 per share, or $4.80 per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.78%;text-indent:-4.78%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_SimpleAgreementForFutureEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple agreement for future equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_SimpleAgreementForFutureEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285888401344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Liabilities</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FAIR VALUE OF FINANCIAL LIABILITIES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Derivative Liability </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.28%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability on convertible notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,821,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (Gain) on fair value of embedded features</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of derivative liability in connection with debt conversion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,151,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#8217;s income reflected the volatility in these estimate and assumption changes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $203,000 for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately 0%; the probability of an equity financing was estimated to be approximately 100%; and the probability of default, change in control or dissolution was estimated to be approximately 0%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.53%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.98%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.98%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no warrant liabilities measured at fair value on a recurring basis at December 31, 2021. The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.29%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,735</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on fair value of warrant liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,546,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,952,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891456144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s initial public offering, the Company&#8217;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#8217;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;) and amended and restated its Bylaws (the &#8220;Amended and Restated Bylaws&#8221;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to 70,000,000 shares and decreased the authorized number of preferred stock to 30,000,000 shares. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales of MAIA Common Stock </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9.00 per share for gross proceeds of $2,373,561 with no transaction costs. During May 2022, the Company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999 with no transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $9.00 price per share they paid was equal to the price per share in the Company's initial public offering of $5.00. The number of Ratchet Shares were calculated using the $5.00 per share price in the Company's initial public offering and 219,872 shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $1,099,360, based on the $5 price of the initial public offering and were recorded as expense included in operating expense.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 28, 2022 the Company&#8217;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5.00 per share for gross proceeds of $10,000,000 in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5.00 per share when the underwriter exercised the overallotment for gross proceeds of $1,500,000 prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $9,100,000.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Restricted Stock Awards<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, MAIA recognized $202,500 of stock compensation expense related to 112,500 of MAIA&#8217;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#8217;s 612,500 fully vested THIO restricted shares were canceled and the founder was issued 612,500 MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued 87,500 MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are no unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $52,500 of expense related to restricted stock for the year ended 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:62.07%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.21%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:0.98%;"/>
<td style="width:11.29%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,333</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Stock Warrants</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders&#8217; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#8217;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the 144,497 warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $450,578 and was treated as a deemed dividend and is reflected as &#8220;Deemed dividend on warrant modification&#8221; in the accompanying statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January 2022, warrants were exercised, resulting in the issuance of 61,111 shares of MAIA common stock for proceeds of $110,000. During May 2022, warrants were exercised, resulting in the issuance of 153,000 shares of common stock for proceeds of approximately $275,400. Another 394,501 warrants were exercised with a cashless exercise assuming the fair market value of $9.00 per share resulting in the issuance of 315,601 shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the closing of the initial public offering, 20,520 warrants with an exercise price of $5.00 per share expired.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the closing of the Company&#8217;s initial public offering, the Company issued warrants to purchase an aggregate of up to 100,000 shares of its common stock to the Representative or its designees, at an exercise price of $6.25 per share (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants are exercisable beginning on January 23, 2023, and expire on July 27, 2027, pursuant to the terms and conditions of the Representative&#8217;s Warrants.&#160;&#160;On August 3, concurrently with the full exercise of the Underwriter&#8217;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to 15,000 shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#8217;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $343,735, which was the value determined using the Black-Scholes method using a term of five years, risk free interest rate of 2.82% and volatility of 77.5%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $245,341. The gain on remeasurement of the warrant liability in the amount of $98,394 was included in other income. Only the 115,000 warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:53.06%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:10.23%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:9.31%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:10.23%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants<br/>Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Exercise<br/>Price</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.30</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,000</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(608,612</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,520</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796,985</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.04</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000585">5.16</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000586">2.8% - 4.1%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000587">0.6% - 1.3%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000590">4.6 - 5</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000591">5 - 7</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">78% - 92%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000595">81% - 106%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. Stock Award Plans<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#8220;MAIA 2018 Plan&#8221;). MAIA&#8217;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the 1,924,500 options outstanding in the plan of December 31, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#8220;MAIA 2020 Plan&#8217;&#8217;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the 3,983,023 options outstanding in the plan as of December 31, 2022. There are no shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#8220;MAIA 2021 Plan&#8217;&#8217;) with 1,909,518 shares of common stock reserved for issuance. As of December 31, 2022 there were 1,271,413 shares of common stock available for future issuance under the MAIA 2021 Plan and 638,105 options outstanding in the MAIA 2021 Plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are to be granted with an exercise price which is at least equal to the stock&#8217;s estimated fair value at the date of grant, and with a contractual term of no more than ten years from the date of grant. In the case of an option granted to a 10% stockholder, the exercise price shall be generally no less than 110% of the fair market value per share on the date of grant, and the contractual term shall be seven years. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#8217;s exercise repurchase rights and various other features of awards granted under the plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.85%;"/>
<td style="width:0.78%;"/>
<td style="width:1.04%;"/>
<td style="width:9.37%;"/>
<td style="width:0.78%;"/>
<td style="width:0.78%;"/>
<td style="width:0.98%;"/>
<td style="width:7.35%;"/>
<td style="width:0.78%;"/>
<td style="width:0.78%;"/>
<td style="width:1.01%;"/>
<td style="width:9.06%;"/>
<td style="width:0.79%;"/>
<td style="width:0.79%;"/>
<td style="width:0.97%;"/>
<td style="width:8.31%;"/>
<td style="width:0.79%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options<br/>Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Exercise<br/>Price</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br/>Intrinsic<br/>Value</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.22</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">8.59</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">811,831</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.77</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,500</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,888</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,545,628</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.55</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">7.85</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,773,706</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,449,715</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.24</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000622">7.59</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,804,841</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2022, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $8.87 per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#8220;OPM&#8221;) and the Probability-Weighted Expected Return Method (&#8220;PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, </p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/>of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes at $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share based on the sale of common stock from January 27, 2022 to May 19, 2022. From June 1, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/>During the year ended December 31, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $1.80 was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations of $1.83 per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair<br/>value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to<br/>arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.11%;"/>
<td style="width:0.94%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:12.1%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000630">2.14% - 4.45%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000631">0.36% - 1.27%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5 - 6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">5 - 6.50</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">71.9% - 87.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">71.4% - 81.5%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 <span style="font-weight:bold;">w</span>ere $3.75 and $3.55, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $3,447,367 which the Company expects to recognize over a weighted average period of approximately 3.26 years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:57.7%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:13.02%;"/>
<td style="width:0.92%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:13.96%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,422,799</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,779,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,628</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943,708</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,319,427</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,722,893</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883140560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Defined Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Retirement Plan</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>EMPLOYEE RETIREMENT PLAN</p></td></tr></table></div>Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to 100% of employee salary deferrals that do not exceed 1% of their compensation plus 50% of their salary deferrals between 1% and 6% of their compensation.<span style="font-size:11pt;font-family:Calibri;"> </span>The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472162&amp;loc=d3e58407-109430<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235042<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891485600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Licensing, Sponsored Research, and Patent &amp; Technology Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">THIO</span> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#8220;PLA&#8221;) titled &#8220;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#8221; with the University of Texas Southwestern (&#8220;UTSW&#8221;) to license patent families for a specific compound (&#8220;THIO&#8221;) from UTSW to MAIA. The agreement, as amended, has a term of 20 years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones. The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in December 2020, the Company entered into a second license agreement with UTSW titled &#8220;Patent and Technology License Agreement AGT. NO. L3648 &#8212; MAIA Biotechnology&#8221; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of 20 years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and 2.5-5% on net sales above $1,000,000,000.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%). The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cemiplimab</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five years</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the event that</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> neither party has terminated the agreement</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891458144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's net deferred tax assets consist of the following components:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294,955</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,013,721</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,941</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800,935</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499,300</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244,848</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,673</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,724</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,825</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets before valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,229,768</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,027,154</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,229,768</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,027,154</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $15.4 million that may be applied against future taxable income. The state NOL carryforwards begin to expire in 2030. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to 80 percent of taxable income. The Company has unused Australian NOL carryforwards of $0.1 million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#8220;R &amp; E&#8221;) tax credits of $0.1 million that begin to expire in 2041.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of the Company&#8217;s NOL and R &amp; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#8220;ownership change,&#8221; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#8209;percent stockholders (or certain groups of non&#8209;five&#8209;percent stockholders) over a three&#8209;year period occurs. After such an ownership change, the corporation&#8217;s use of its pre&#8209;change NOL carryforwards and other pre&#8209;change tax attributes to offset its post&#8209;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an ownership change occurs and if the Company earns net taxable income, the Company&#8217;s ability to use its pre&#8209;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#8217;s state income, franchise, or similar taxes. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC 740, &#8220;Income Taxes,&#8221; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.<span style="Background-color:#FFFFFF;">The valuation allowance increased by approximately $1.2 million and $2.1 million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred a pretax book loss of approximately $15.8 million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $15.3 million and a foreign loss of approximately $0.5 million. The Company incurred a pretax book loss of approximately $12.6 million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $12.5 million and a foreign loss of approximately $0.1 million.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.7</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.5</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.9</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other nondeductible expenses/(nontaxable income)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.6</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.8</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#8217;s tax returns since inception remain open to examination by the taxing authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891429280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.78%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SUBSEQUENT EVENTS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 16, 2023, we issued 18,000 shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement&#160;&#160;an additional 18,000 shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue 22,500 shares of common stock on March 8, 2023 and an additional 22,500 shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for 180 days, and renews automatically until we provide written notice prior to the end of the term.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Options</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1 to March 20, 2023 we issued 638,710 options at a weighted exercise price of $4.10 to employees and consultants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285884692448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Description of Business, Organization, and Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business, Organization, and Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#8220;the Company&#8221;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#8220;MAIA&#8221;) was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>THIO Therapeutics, Inc. (&#8220;THIO&#8221;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>DGD Pharmaceuticals Corporation (&#8220;DGD&#8221;), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>MAIA Drug Development Corporation (&#8220;MAIA DD&#8221;) incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2022, the Company had working capital of&#8201;$8,539,131, an accumulated deficit of $44,207,272, cash of $10,950,927 and current liabilities of $3,268,906. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses. During May 2022, the company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#8221; The Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in the initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter. After deducting $2,406,170 for cash issuance costs, net proceeds from the offering and overallotment were $9,093,830.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GoingConcernConsiderationsPolicyTextBlock', window );">Going Concern Considerations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern Considerations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $44,207,272 from the Company&#8217;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $10,951,000 million in cash and cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock', window );">Impact of the COVID-19 Pandemic on our Operations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic on our Operations</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221; or &#8220;GAAP&#8221;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s Chief Executive Officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CertainRisksAndUncertaintiesPolicyTextBlock', window );">Certain Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of the Company&#8217;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has no cash equivalents as of December 31, 2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#8220;Accounting Standards Codification (ASC) Topic 820&#8221;, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.51%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the </p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular period</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. There have been no material changes in estimates for the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndDevelopmentIncentivePolicyTextBlock', window );">Research and Development Incentive</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), depending on the specific terms of the warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only </p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.11%;"/>
<td style="width:0.94%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:12.1%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,545,628</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796,985</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <span style="-sec-ix-hidden:F_000377">ASU No. 2016-02</span>, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of January 1, 2022. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CertainRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CertainRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business organization and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GoingConcernConsiderationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GoingConcernConsiderationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ImpactOfTheCovid19PandemicOnOperations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndDevelopmentIncentivePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development incentive policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndDevelopmentIncentivePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285888396624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.11%;"/>
<td style="width:0.94%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:12.1%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of stock options</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,545,628</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon exercise of warrants</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796,985</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285889176448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,582</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,750</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional&#160;&#160;fees</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,589</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,277</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516,961</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,140</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred compensation to former officers</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,271</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,269</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,157</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,103,401</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,185,595</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891484768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.28%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability on convertible notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,821,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (Gain) on fair value of embedded features</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of derivative liability in connection with debt conversion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,151,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:63%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.28%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:11.29%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,735</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on fair value of warrant liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,546,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,952,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities</a></td>
<td class="text">The fair value of the warrant liabilities recorded are as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.53%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.98%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.98%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:8.36%;"/>
<td style="width:0.92%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value at December 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883143040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Unvested Restricted Shares</a></td>
<td class="text">
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:62.07%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.21%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:0.98%;"/>
<td style="width:11.29%;"/>
<td style="width:0.94%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,333</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,333</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ScheduleOfWarrantExercisedTableTextBlock', window );">Schedule Of Warrant Exercised</a></td>
<td class="text">
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:53.06%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:10.23%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.98%;"/>
<td style="width:9.31%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:10.23%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants<br/>Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Exercise<br/>Price</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,117</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.30</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,000</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(608,612</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,520</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796,985</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.04</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000585">5.16</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used in Calculating Value of Warrants Granted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000586">2.8% - 4.1%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000587">0.6% - 1.3%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000590">4.6 - 5</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000591">5 - 7</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000594">78% - 92%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000595">81% - 106%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:61.44%;"/>
<td style="width:0.94%;"/>
<td style="width:0.94%;"/>
<td style="width:12.11%;"/>
<td style="width:0.94%;"/>
<td style="width:0.93%;"/>
<td style="width:0.93%;"/>
<td style="width:12.1%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000630">2.14% - 4.45%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000631">0.36% - 1.27%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5 - 6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">5 - 6.50</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">71.9% - 87.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">71.4% - 81.5%</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity and Information Regarding Outstanding and Exercisable Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:46.85%;"/>
<td style="width:0.78%;"/>
<td style="width:1.04%;"/>
<td style="width:9.37%;"/>
<td style="width:0.78%;"/>
<td style="width:0.78%;"/>
<td style="width:0.98%;"/>
<td style="width:7.35%;"/>
<td style="width:0.78%;"/>
<td style="width:0.78%;"/>
<td style="width:1.01%;"/>
<td style="width:9.06%;"/>
<td style="width:0.79%;"/>
<td style="width:0.79%;"/>
<td style="width:0.97%;"/>
<td style="width:8.31%;"/>
<td style="width:0.79%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options<br/>Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Exercise<br/>Price</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br/>Intrinsic<br/>Value</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.22</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">8.59</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">811,831</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.77</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,500</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,888</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,545,628</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.55</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">7.85</span></p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,773,706</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,449,715</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.24</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000622">7.59</span></p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,804,841</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;">
<tr>
<td style="width:57.7%;"/>
<td style="width:0.92%;"/>
<td style="width:0.92%;"/>
<td style="width:0.97%;"/>
<td style="width:13.02%;"/>
<td style="width:0.92%;"/>
<td style="width:0.93%;"/>
<td style="width:0.97%;"/>
<td style="width:13.96%;"/>
<td style="width:0.93%;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,422,799</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,779,185</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,628</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943,708</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,319,427</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,722,893</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ScheduleOfWarrantExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ScheduleOfWarrantExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285891466368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Net Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's net deferred tax assets consist of the following components:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294,955</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,013,721</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,941</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800,935</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499,300</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244,848</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,673</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,724</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,825</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets before valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,229,768</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,027,154</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,229,768</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,027,154</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.7</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.5</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.9</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other nondeductible expenses/(nontaxable income)</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.0</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.6</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.8</p></td>
<td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881547984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Common stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,207,272<span></span>
</td>
<td class="nump">$ 28,437,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,950,927<span></span>
</td>
<td class="nump">10,574,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,268,906<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of transaction costs</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,999<span></span>
</td>
<td class="nump">$ 2,373,561<span></span>
</td>
<td class="nump">2,473,560<span></span>
</td>
<td class="nump">5,742,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in initial public offering</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember', window );">Offering And Overallotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">2,406,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 9,093,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority stockholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">MAIA Biotechnology, Inc. | MAIA Drug Development Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=maia_THIOTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=maia_THIOTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=maia_MAIADrugDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=maia_MAIADrugDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285884681632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881711392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember', window );">Ms. Durant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConsultingServices', window );">Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidForServicesProvided', window );">Cash paid for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStock', window );">Options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue', window );">Options to purchase shares of common stock total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember', window );">Mr. Vitoc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConsultingServices', window );">Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidForServicesProvided', window );">Cash paid for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,950<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStock', window );">Options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue', window );">Options to purchase shares of common stock total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.950<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_RemainingConsultingServicesSettled', window );">Remaining services settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="nump">8,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">4,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="nump">3,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayment of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashPaidForServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashPaidForServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares of common stock total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_RemainingConsultingServicesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining consulting services settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_RemainingConsultingServicesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285882117952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus</a></td>
<td class="nump">$ 1,094,582<span></span>
</td>
<td class="nump">$ 1,094,582<span></span>
</td>
<td class="nump">$ 384,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">332,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">516,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Deferred compensation to former officers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">159,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,103,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,185,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883256272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,271<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidToSettleAPortionOfDeferredCompensationBalance', window );">Cash paid to settle a portion of deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability', window );">Deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,750<span></span>
</td>
<td class="nump">$ 1,094,582<span></span>
</td>
<td class="nump">$ 1,094,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance', window );">Issuance of stock options to settle accrued bonus balance</a></td>
<td class="nump">713,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance', window );">Fair value of stock options issued to settle accrued bonus balance</a></td>
<td class="nump">$ 786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance', window );">Stock-based compensation expense related to accrued bonus balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashPaidToSettleAPortionOfDeferredCompensationBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to settle a portion of deferred compensation balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashPaidToSettleAPortionOfDeferredCompensationBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options issued to settle accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to settle accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense related to accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total fair value of shares issued during the period under a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285888794320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program - Additional Information (Details) - P P P Loan Program - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from unsecured loan</a></td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument Term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount', window );">Extinguishment of outstanding principal and interest written off amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of outstanding principal and interest written off amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=maia_PPPLoanProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=maia_PPPLoanProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883984960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,967<span></span>
</td>
<td class="nump">827,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantDescription', window );">Warrant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. <span></span>
</td>
<td class="text">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,322,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">write-off of the unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonSharesUponExerciseOfWarrantsShares', window );">Common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsExercised', window );">Class Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleNotesOutstanding', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">$ 99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,373,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,473,560<span></span>
</td>
<td class="nump">5,742,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Share converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=maia_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember', window );">Two Thousand And Twenty Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfIssuableUponConversionOfExercisePrice', window );">Percentage of issuable upon conversion of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember', window );">Two Thousand And Twenty One Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfIssuableUponConversionOfExercisePrice', window );">Percentage of issuable upon conversion of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember', window );">2019 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DebtDiscountAndValueOfEmbeddedPutFeature', window );">Debt discount and value of embedded put feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">write-off of the unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember', window );">2020 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,375<span></span>
</td>
<td class="nump">$ 11,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt', window );">Minimum gross proceeds from equity financing required for conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfVotingPowerDefiningChangeOfControl', window );">Percentage of voting power defining change of control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Debt discount and derivative liability at the issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">write-off of the unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember', window );">2020 Promissory Note [Member] | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember', window );">2021 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,049<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">513,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Debt discount and derivative liability at the issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertiblePromissoryNotesToRelatedParties', window );">Convertible promissory notes to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertiblePromissoryNotesToSettleLoan', window );">Convertible promissory notes to settle loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt conversion price percentage of the equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertibleNotesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertibleNotesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertiblePromissoryNotesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory notes to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertiblePromissoryNotesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertiblePromissoryNotesToSettleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory notes to settle loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertiblePromissoryNotesToSettleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DebtDiscountAndValueOfEmbeddedPutFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount and value of embedded put feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DebtDiscountAndValueOfEmbeddedPutFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum gross proceeds from equity financing required for conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfIssuableUponConversionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of issuable upon conversion of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfIssuableUponConversionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfVotingPowerDefiningChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting power defining change of control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfVotingPowerDefiningChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=maia_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=maia_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285882865440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple Agreement For Future Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_SimpleAgreementForFutureEquityIssued', window );">Simple agreement for future equity issued</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfConversionPrice', window );">Percentage of conversion price</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_NumberOfCommonSharesConvertedUnderSAFEAgreement', window );">Converted common stock under SAFE agreement</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonStockConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_NumberOfCommonSharesConvertedUnderSAFEAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares converted under SAFE agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_NumberOfCommonSharesConvertedUnderSAFEAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_SimpleAgreementForFutureEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple agreement for future equity issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_SimpleAgreementForFutureEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881339328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes and convertible notes, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,322,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantLiabilitiesAbstract', window );"><strong>Warrant liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DerivativeLiabilityOnConvertibleNotesPayable', window );">Derivative liability on convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes and convertible notes, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,151,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantLiabilitiesAbstract', window );"><strong>Warrant liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_FairValueWarrantLiability', window );">Warrant liability</a></td>
<td class="nump">343,735<span></span>
</td>
<td class="nump">320,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,952,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities, Balance</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DerivativeLiabilityOnConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability on convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DerivativeLiabilityOnConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_FairValueWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_FairValueWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885954912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity', window );">Percentage of probability of the convertible notes maturity</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfProbabilityOfEquityFinancingMaturity', window );">Percentage of probability of equity financing maturity</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution', window );">Percentage of probability of default change in control or dissolution</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of probability of default, change in control or dissolution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfProbabilityOfEquityFinancingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of probability of the an equity financing at maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfProbabilityOfEquityFinancingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The probability of the Convertible Notes outstanding at maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883156288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285876158016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Aug. 13, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of transaction costs</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,373,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,473,560<span></span>
</td>
<td class="nump">$ 5,742,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsExercisedShares', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashlessExerciseAtFairMarketValuePerShare', window );">Cashless exercise at fair market value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares', window );">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants and rights exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire', window );">Class of warrant or right date from which warrants or rights expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,394)<span></span>
</td>
<td class="nump">$ 1,546,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted', window );">Percentage of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage', window );">Exercise price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember', window );">2018 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember', window );">Amended and Restated 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,983,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember', window );">Black-Sholes Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 343,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">77.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=maia_FounderMember', window );">Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantModificationValue', window );">Warrant modification, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,447,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=maia_THIOMember', window );">THIO | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=maia_THIOMember', window );">THIO | Restricted Stock Awards | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Founders shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts', window );">Gross proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts', window );">Gross proceeds from common stock</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock', window );">Class of warrant or right additional purchase aggregate of common stock</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">61,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,712<span></span>
</td>
<td class="nump">283,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants', window );">Proceeds from issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,400<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares', window );">Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | January Twenty Seven To May Thirty One Two Thousand Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | June One Two Thousand Twenty Two To August One Two Thousand Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | March One Two Thousand Twenty One To June Six Two Thousand Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashlessExerciseAtFairMarketValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise at fair market value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashlessExerciseAtFairMarketValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right additional purchase aggregate of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right date from which warrants or rights expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DeemedDividendOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DeemedDividendOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon cashless exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantModificationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant modification, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantModificationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=maia_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=maia_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=maia_THIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=maia_THIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285890752864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Unvested Restricted Shares (Details) - Restricted Stock Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested balance</a></td>
<td class="nump">58,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(58,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885809248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrant Exercised (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Beginning balance</a></td>
<td class="nump">1,311,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsExercised', window );">Warrants Outstanding, Exercised</a></td>
<td class="num">(608,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsExpired', window );">Warrants Outstanding, Expired</a></td>
<td class="num">(20,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Ending balance</a></td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceIssued', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881715824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">106.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881667248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="nump">5,797,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="nump">811,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="num">(46,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Cancelled/forfeited</a></td>
<td class="num">(16,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable</a></td>
<td class="nump">5,449,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/forfeited</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">2.55<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Options exercisable</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="nump">$ 9,773,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Weighted Average Remaining Contractual Term in Years, Options exercisable</a></td>
<td class="nump">$ 8,804,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285885814048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.90%<span></span>
</td>
<td class="nump">71.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">87.90%<span></span>
</td>
<td class="nump">81.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285883218912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,319,427<span></span>
</td>
<td class="nump">$ 2,722,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,422,799<span></span>
</td>
<td class="nump">1,779,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 896,628<span></span>
</td>
<td class="nump">$ 943,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285890825200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan (Additional Information) (Details) - 401 (K)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Contribution to employee</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Contribution to employee</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DefinedContributionPlanEmployerSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer alary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DefinedContributionPlanEmployerSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285882162496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember', window );">Amended Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentsDueRelatedToMilestones', window );">Payments due related to milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember', window );">Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CombinedMilestonePaymentsMaximum', window );">Combined milestone payment maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentsDueRelatedToMilestones', window );">Payments due related to milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription', window );">Percentage of royalty description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClaimExpirationTerm', window );">Claim expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember', window );">Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember', window );">THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CombinedMilestonePaymentsMaximum', window );">Combined milestone payment maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patent And Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patent And Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Patent And Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Patent And Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | University Of Texas Southwestern | Patent And Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_RoyaltyPaymentsOnNetSales', window );">Royalty payments on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClaimExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claim expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClaimExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CombinedMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined milestone payments maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CombinedMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaymentsDueRelatedToMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due related to milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaymentsDueRelatedToMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_RoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_RoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesAboveOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesAboveOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285892226528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,294,955<span></span>
</td>
<td class="nump">$ 3,013,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,183,941<span></span>
</td>
<td class="nump">1,800,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">1,499,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">244,848<span></span>
</td>
<td class="nump">109,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,724<span></span>
</td>
<td class="nump">102,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total net deferred tax assets before valuation allowance</a></td>
<td class="nump">6,229,768<span></span>
</td>
<td class="nump">5,027,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (6,229,768)<span></span>
</td>
<td class="num">$ (5,027,154)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881339424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, increase in valuation allowance</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax book loss</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income (Loss) from Continuing Operations before Income Taxes, Foreign</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome', window );">Net operating loss carryforward limited percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and experimentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits carryforwards</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear', window );">Research And Experimentation Tax Credits Carryforwards Expiration Year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward limited percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Experimentation Tax Credits Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285881714048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other nondeductible expenses/(nontaxable income)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="num">(16.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation loss on extinguishment of debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140285879270304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2023</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Jan. 16, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Scenario Forecast | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_MoneyChannelNycIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_MoneyChannelNycIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>maia-s1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:maia="http://maiabiotech.com/20230330"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="maia-20230330.xsd" xlink:type="simple"/>
    <context id="C_0001878313_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:MAIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaMAIADrugDevelopmentCorporationMember_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20220101_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_0001878313_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_0001878313_20220501_20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:OfferingAndOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_maiaUnvestedRestrictedStockAwardsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:LeighAnnDurantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210401_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210929_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-29</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210929_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-29</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="C_0001878313_20210416_20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PPPLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190101_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRelatedPartyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapShortTermDebtTypeAxis_maiaConvertibleNotesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">maia:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20191001_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_0001878313_20220803_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210813_20210813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-13</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_20210813_20210813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-13</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_0001878313_20220731_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandEighteenStockOptionPlanMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardDateAxis_maiaJuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardDateAxis_maiaMarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaUniversityOfTexasSouthwesternMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapTypeOfArrangementAxis_maiaRegeneronPharmaceuticalsIncMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapAustralianTaxationOfficeMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20220101_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230116_20230116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-16</startDate>
            <endDate>2023-01-16</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230416_20230416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-16</startDate>
            <endDate>2023-04-16</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230306_20230605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="C_0001878313_20220101_20221231" id="F_000000">S-1/A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="C_0001878313_20220101_20221231" id="F_000001">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001878313_20220101_20221231" id="F_000003">0001878313</dei:EntityCentralIndexKey>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="C_0001878313_20221231" id="F_000378">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <maia:ClaimExpirationTerm
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      id="F_000677">P10Y</maia:ClaimExpirationTerm>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="C_0001878313_20220101_20221231" id="F_000377">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001878313_20221231"
      id="F_000050"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001878313_20211231"
      id="F_000051"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001878313_20221231"
      id="F_000052"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001878313_20211231"
      id="F_000053"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      decimals="3"
      id="F_000586"
      unitRef="U_xbrlipure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="3"
      id="F_000587"
      unitRef="U_xbrlipure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      id="F_000590">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000591">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      decimals="2"
      id="F_000594"
      unitRef="U_xbrlipure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="2"
      id="F_000595"
      unitRef="U_xbrlipure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      decimals="3"
      id="F_000588"
      unitRef="U_xbrlipure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="3"
      id="F_000589"
      unitRef="U_xbrlipure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      id="F_000592">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000593">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20221231"
      decimals="2"
      id="F_000596"
      unitRef="U_xbrlipure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="2"
      id="F_000597"
      unitRef="U_xbrlipure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="4"
      id="F_000630"
      unitRef="U_xbrlipure">0.0214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="4"
      id="F_000631"
      unitRef="U_xbrlipure">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      id="F_000634">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000635">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="3"
      id="F_000638"
      unitRef="U_xbrlipure">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="3"
      id="F_000639"
      unitRef="U_xbrlipure">0.714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="4"
      id="F_000632"
      unitRef="U_xbrlipure">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="4"
      id="F_000633"
      unitRef="U_xbrlipure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      id="F_000636">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000637">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="3"
      id="F_000640"
      unitRef="U_xbrlipure">0.879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="3"
      id="F_000641"
      unitRef="U_xbrlipure">0.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm contextRef="C_0001878313_20210101_20211231" id="F_000584">P7Y3M18D</maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm>
    <maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm contextRef="C_0001878313_20220101_20221231" id="F_000585">P5Y1M28D</maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001878313_20210101_20211231" id="F_000620">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001878313_20220101_20221231" id="F_000621">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001878313_20220101_20221231" id="F_000622">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:EntityRegistrantName contextRef="C_0001878313_20220101_20221231" id="F_000004">MAIA Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001878313_20220101_20221231" id="F_000005">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="C_0001878313_20220101_20221231" id="F_000007">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001878313_20220101_20221231" id="F_000006">83-1495913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001878313_20220101_20221231" id="F_000012">444 West Lake Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001878313_20220101_20221231" id="F_000013">Suite 1700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001878313_20220101_20221231" id="F_000014">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001878313_20220101_20221231" id="F_000015">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001878313_20220101_20221231" id="F_000016">60606</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001878313_20220101_20221231" id="F_000017">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001878313_20220101_20221231" id="F_000018">416-8592</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000019">Vlad Vitoc</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000020">444 West Lake Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000021">Suite 1700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000022">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000023">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000024">60606</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000025">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0001878313_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20220101_20221231"
      id="F_000026">416-8592</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="C_0001878313_20220101_20221231" id="F_000008">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001878313_20220101_20221231" id="F_000009">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001878313_20220101_20221231" id="F_000010">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001878313_20220101_20221231" id="F_000011">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="C_0001878313_20220101_20221231" id="F_000002">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.</dei:AmendmentDescription>
    <us-gaap:Cash
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000027"
      unitRef="U_iso4217USD">10950927</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000028"
      unitRef="U_iso4217USD">10574292</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000029"
      unitRef="U_iso4217USD">554321</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000030"
      unitRef="U_iso4217USD">54537</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <maia:ResearchAndDevelopmentIncentivesReceivable
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000031"
      unitRef="U_iso4217USD">302789</maia:ResearchAndDevelopmentIncentivesReceivable>
    <maia:ResearchAndDevelopmentIncentivesReceivable
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000032"
      unitRef="U_iso4217USD">43666</maia:ResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:AssetsCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000033"
      unitRef="U_iso4217USD">11808037</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000034"
      unitRef="U_iso4217USD">10672495</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000035"
      unitRef="U_iso4217USD">211203</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000036"
      unitRef="U_iso4217USD">651582</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000037"
      unitRef="U_iso4217USD">2800</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000038"
      unitRef="U_iso4217USD">3122</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000039"
      unitRef="U_iso4217USD">12022040</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000040"
      unitRef="U_iso4217USD">11327199</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000041"
      unitRef="U_iso4217USD">1165505</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000042"
      unitRef="U_iso4217USD">960401</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000043"
      unitRef="U_iso4217USD">2103401</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000044"
      unitRef="U_iso4217USD">1185595</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000045"
      unitRef="U_iso4217USD">3268906</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000046"
      unitRef="U_iso4217USD">2145996</us-gaap:LiabilitiesCurrent>
    <maia:WarrantLiabilityNoncurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000047"
      unitRef="U_iso4217USD">245341</maia:WarrantLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000048"
      unitRef="U_iso4217USD">3514247</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000049"
      unitRef="U_iso4217USD">2145996</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001878313_20221231"
      decimals="4"
      id="F_000065"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001878313_20211231"
      decimals="4"
      id="F_000066"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000067"
      unitRef="U_xbrlishares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000068"
      unitRef="U_xbrlishares">70000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000069"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000070"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000071"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000072"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001878313_20221231"
      decimals="4"
      id="F_000073"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001878313_20211231"
      decimals="4"
      id="F_000074"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000075"
      unitRef="U_xbrlishares">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000076"
      unitRef="U_xbrlishares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">10955904</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">10955904</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">7584980</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">7584980</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000054"
      unitRef="U_iso4217USD">1096</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000055"
      unitRef="U_iso4217USD">758</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000056"
      unitRef="U_iso4217USD">52729942</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000057"
      unitRef="U_iso4217USD">37618438</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000058"
      unitRef="U_iso4217USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000059"
      unitRef="U_iso4217USD">-28437993</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000060"
      unitRef="U_iso4217USD">-15973</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000061"
      unitRef="U_iso4217USD">8507793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000062"
      unitRef="U_iso4217USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000063"
      unitRef="U_iso4217USD">12022040</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000064"
      unitRef="U_iso4217USD">11327199</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000081"
      unitRef="U_iso4217USD">8933314</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000082"
      unitRef="U_iso4217USD">3496796</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000083"
      unitRef="U_iso4217USD">6143527</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000084"
      unitRef="U_iso4217USD">4289831</us-gaap:GeneralAndAdministrativeExpense>
    <maia:RatchetShareExpense
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000085"
      unitRef="U_iso4217USD">1099360</maia:RatchetShareExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000086"
      unitRef="U_iso4217USD">16176201</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000087"
      unitRef="U_iso4217USD">7786627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000088"
      unitRef="U_iso4217USD">-16176201</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000089"
      unitRef="U_iso4217USD">-7786627</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000090"
      unitRef="U_iso4217USD">6967</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000091"
      unitRef="U_iso4217USD">827539</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000092"
      unitRef="U_iso4217USD">1870</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000093"
      unitRef="U_iso4217USD">2012</us-gaap:InvestmentIncomeInterest>
    <maia:AustralianResearchAndDevelopmentIncentives
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000094"
      unitRef="U_iso4217USD">313625</maia:AustralianResearchAndDevelopmentIncentives>
    <maia:AustralianResearchAndDevelopmentIncentives
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000095"
      unitRef="U_iso4217USD">43666</maia:AustralianResearchAndDevelopmentIncentives>
    <maia:GainOnPaycheckProtectionProgramLoanForgiveness
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000096"
      unitRef="U_iso4217USD">62500</maia:GainOnPaycheckProtectionProgramLoanForgiveness>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000097"
      unitRef="U_iso4217USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000098"
      unitRef="U_iso4217USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000099"
      unitRef="U_iso4217USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000100"
      unitRef="U_iso4217USD">-2322943</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000101"
      unitRef="U_iso4217USD">406922</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000102"
      unitRef="U_iso4217USD">-4791584</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000103"
      unitRef="U_iso4217USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000104"
      unitRef="U_iso4217USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000105"
      unitRef="U_iso4217USD">-74331</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000106"
      unitRef="U_iso4217USD">-450578</maia:DeemedDividendOnWarrantModification>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000107"
      unitRef="U_iso4217USD">-16219857</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000108"
      unitRef="U_iso4217USD">-12503880</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <maia:EarningsPerSharesBasicAndDiluted
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000109"
      unitRef="U_iso4217USD_xbrlishares">-1.75</maia:EarningsPerSharesBasicAndDiluted>
    <maia:EarningsPerSharesBasicAndDiluted
      contextRef="C_0001878313_20210101_20211231"
      decimals="2"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">-2.37</maia:EarningsPerSharesBasicAndDiluted>
    <maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000111"
      unitRef="U_xbrlishares">9276761</maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted>
    <maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000112"
      unitRef="U_xbrlishares">5278435</maia:WeightedAverageCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000113"
      unitRef="U_iso4217USD">-16219857</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000114"
      unitRef="U_iso4217USD">-12503880</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000115"
      unitRef="U_iso4217USD">-15973</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000116"
      unitRef="U_iso4217USD">-16235830</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000117"
      unitRef="U_iso4217USD">-12503880</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000119"
      unitRef="U_xbrlishares">7584980</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="0"
      id="F_000120"
      unitRef="U_iso4217USD">758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="0"
      id="F_000121"
      unitRef="U_iso4217USD">37618438</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="0"
      id="F_000122"
      unitRef="U_iso4217USD">-28437993</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000123"
      unitRef="U_iso4217USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="INF"
      id="F_000124"
      unitRef="U_xbrlishares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="0"
      id="F_000125"
      unitRef="U_iso4217USD">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000126"
      unitRef="U_iso4217USD">83995</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000127"
      unitRef="U_iso4217USD">84000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="INF"
      id="F_000128"
      unitRef="U_xbrlishares">529712</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="0"
      id="F_000129"
      unitRef="U_iso4217USD">53</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000130"
      unitRef="U_iso4217USD">385347</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000131"
      unitRef="U_iso4217USD">385400</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000132"
      unitRef="U_iso4217USD">2319427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000133"
      unitRef="U_iso4217USD">2319427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="INF"
      id="F_000134"
      unitRef="U_xbrlishares">274840</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="0"
      id="F_000135"
      unitRef="U_iso4217USD">28</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000136"
      unitRef="U_iso4217USD">2473532</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000137"
      unitRef="U_iso4217USD">2473560</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231"
      decimals="0"
      id="F_000118"
      unitRef="U_iso4217USD">2749905</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">2300000</maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares>
    <maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="0"
      id="F_000139"
      unitRef="U_iso4217USD">230</maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering>
    <maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000140"
      unitRef="U_iso4217USD">8749865</maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering>
    <maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000141"
      unitRef="U_iso4217USD">8750095</maia:IssuanceOfCommonSharesInConnectionWithInitialPublicOffering>
    <maia:IssuanceOfRatchetSharesShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="INF"
      id="F_000142"
      unitRef="U_xbrlishares">219872</maia:IssuanceOfRatchetSharesShares>
    <maia:IssuanceOfRatchetShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20221231"
      decimals="0"
      id="F_000143"
      unitRef="U_iso4217USD">22</maia:IssuanceOfRatchetShares>
    <maia:IssuanceOfRatchetShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000144"
      unitRef="U_iso4217USD">1099338</maia:IssuanceOfRatchetShares>
    <maia:IssuanceOfRatchetShares
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000145"
      unitRef="U_iso4217USD">1099360</maia:IssuanceOfRatchetShares>
    <maia:ModificationOfWarrantInEquity
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000146"
      unitRef="U_iso4217USD">450578</maia:ModificationOfWarrantInEquity>
    <maia:ModificationOfWarrantInEquity
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000147"
      unitRef="U_iso4217USD">450578</maia:ModificationOfWarrantInEquity>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20221231"
      decimals="0"
      id="F_000148"
      unitRef="U_iso4217USD">-450578</maia:DeemedDividendOnWarrantModification>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000149"
      unitRef="U_iso4217USD">-450578</maia:DeemedDividendOnWarrantModification>
    <maia:ForeignCurrencyTranslationAdjustment
      contextRef="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20220101_20221231"
      decimals="0"
      id="F_000150"
      unitRef="U_iso4217USD">-15973</maia:ForeignCurrencyTranslationAdjustment>
    <maia:ForeignCurrencyTranslationAdjustment
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000151"
      unitRef="U_iso4217USD">-15973</maia:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20221231"
      decimals="0"
      id="F_000152"
      unitRef="U_iso4217USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000153"
      unitRef="U_iso4217USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231"
      decimals="INF"
      id="F_000154"
      unitRef="U_xbrlishares">10955904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231"
      decimals="0"
      id="F_000155"
      unitRef="U_iso4217USD">1096</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20221231"
      decimals="0"
      id="F_000156"
      unitRef="U_iso4217USD">52729942</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20221231"
      decimals="0"
      id="F_000157"
      unitRef="U_iso4217USD">-44207272</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaapReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_20221231"
      decimals="0"
      id="F_000158"
      unitRef="U_iso4217USD">-15973</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000159"
      unitRef="U_iso4217USD">8507793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000160"
      unitRef="U_xbrlishares">4433644</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="0"
      id="F_000161"
      unitRef="U_iso4217USD">443</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="0"
      id="F_000162"
      unitRef="U_iso4217USD">12599585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="0"
      id="F_000163"
      unitRef="U_iso4217USD">-15934113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20201231"
      decimals="0"
      id="F_000164"
      unitRef="U_iso4217USD">-2002</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20201231"
      decimals="0"
      id="F_000165"
      unitRef="U_iso4217USD">-3336087</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231"
      decimals="0"
      id="F_000166"
      unitRef="U_iso4217USD">1719787</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20201231"
      decimals="0"
      id="F_000167"
      unitRef="U_iso4217USD">-1616300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000168"
      unitRef="U_xbrlishares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000169"
      unitRef="U_iso4217USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000170"
      unitRef="U_iso4217USD">8999</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000171"
      unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000172"
      unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000173"
      unitRef="U_xbrlishares">283616</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000174"
      unitRef="U_iso4217USD">28</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000175"
      unitRef="U_iso4217USD">529397</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000176"
      unitRef="U_iso4217USD">529425</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000177"
      unitRef="U_iso4217USD">529425</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000178"
      unitRef="U_xbrlishares">15278</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000179"
      unitRef="U_iso4217USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000180"
      unitRef="U_iso4217USD">27498</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000181"
      unitRef="U_iso4217USD">27500</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000182"
      unitRef="U_iso4217USD">27500</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000183"
      unitRef="U_xbrlishares">5557</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000184"
      unitRef="U_iso4217USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000185"
      unitRef="U_iso4217USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000186"
      unitRef="U_iso4217USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000187"
      unitRef="U_iso4217USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000188"
      unitRef="U_iso4217USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaMAIAMember_20210101_20211231"
      decimals="0"
      id="F_000189"
      unitRef="U_iso4217USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231"
      decimals="0"
      id="F_000190"
      unitRef="U_iso4217USD">161460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_20210101_20211231"
      decimals="0"
      id="F_000191"
      unitRef="U_iso4217USD">161460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231"
      decimals="0"
      id="F_000192"
      unitRef="U_iso4217USD">104999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_20210101_20211231"
      decimals="0"
      id="F_000193"
      unitRef="U_iso4217USD">104999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000194"
      unitRef="U_iso4217USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000195"
      unitRef="U_iso4217USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000196"
      unitRef="U_iso4217USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000197"
      unitRef="U_iso4217USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000198"
      unitRef="U_iso4217USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000199"
      unitRef="U_iso4217USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000200"
      unitRef="U_xbrlishares">1375228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000201"
      unitRef="U_iso4217USD">138</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000202"
      unitRef="U_iso4217USD">11001136</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000203"
      unitRef="U_iso4217USD">11001274</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000204"
      unitRef="U_iso4217USD">11001274</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <maia:StockIssuedDuringPeriodSharesConversionOfSafe
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000205"
      unitRef="U_xbrlishares">5208</maia:StockIssuedDuringPeriodSharesConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000206"
      unitRef="U_iso4217USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000207"
      unitRef="U_iso4217USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000208"
      unitRef="U_iso4217USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000209"
      unitRef="U_xbrlishares">772563</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000210"
      unitRef="U_iso4217USD">77</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000211"
      unitRef="U_iso4217USD">6180426</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231"
      decimals="0"
      id="F_000212"
      unitRef="U_iso4217USD">-320000</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000213"
      unitRef="U_iso4217USD">5860503</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000214"
      unitRef="U_iso4217USD">5860503</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapReceivablesFromStockholderMember_20210101_20211231"
      decimals="0"
      id="F_000215"
      unitRef="U_iso4217USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000216"
      unitRef="U_iso4217USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000217"
      unitRef="U_iso4217USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000218"
      unitRef="U_iso4217USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000219"
      unitRef="U_iso4217USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000220"
      unitRef="U_iso4217USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000221"
      unitRef="U_iso4217USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000222"
      unitRef="U_iso4217USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000223"
      unitRef="U_iso4217USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000224"
      unitRef="U_xbrlishares">700000</maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare>
    <maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="0"
      id="F_000225"
      unitRef="U_iso4217USD">70</maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue>
    <maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000226"
      unitRef="U_iso4217USD">-70</maia:IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000227"
      unitRef="U_iso4217USD">1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000228"
      unitRef="U_iso4217USD">1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaDGDMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231"
      decimals="0"
      id="F_000229"
      unitRef="U_iso4217USD">-1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="0"
      id="F_000230"
      unitRef="U_iso4217USD">813805</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000231"
      unitRef="U_iso4217USD">813805</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231"
      decimals="0"
      id="F_000232"
      unitRef="U_iso4217USD">-813805</maia:DissolutionOfFirm>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="0"
      id="F_000233"
      unitRef="U_iso4217USD">-12503880</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20210101_20211231"
      decimals="0"
      id="F_000234"
      unitRef="U_iso4217USD">-12503880</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20211231"
      decimals="0"
      id="F_000235"
      unitRef="U_iso4217USD">-74331</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000236"
      unitRef="U_iso4217USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000237"
      unitRef="U_xbrlishares">7584980</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="0"
      id="F_000238"
      unitRef="U_iso4217USD">758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="0"
      id="F_000239"
      unitRef="U_iso4217USD">37618438</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="0"
      id="F_000240"
      unitRef="U_iso4217USD">-28437993</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapParentMember_20211231"
      decimals="0"
      id="F_000241"
      unitRef="U_iso4217USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000242"
      unitRef="U_iso4217USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000243"
      unitRef="U_iso4217USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000244"
      unitRef="U_iso4217USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000245"
      unitRef="U_iso4217USD">2319427</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000246"
      unitRef="U_iso4217USD">2722893</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000247"
      unitRef="U_iso4217USD">-2322943</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000248"
      unitRef="U_iso4217USD">62500</maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000249"
      unitRef="U_iso4217USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <maia:IssuanceOfRatchetShares
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000250"
      unitRef="U_iso4217USD">1099360</maia:IssuanceOfRatchetShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000251"
      unitRef="U_iso4217USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000252"
      unitRef="U_iso4217USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000253"
      unitRef="U_iso4217USD">596953</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000254"
      unitRef="U_iso4217USD">505233</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000255"
      unitRef="U_iso4217USD">15155</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <maia:IncreaseDecreaseInDeferredOfferingCosts
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000256"
      unitRef="U_iso4217USD">-440379</maia:IncreaseDecreaseInDeferredOfferingCosts>
    <maia:IncreaseDecreaseInDeferredOfferingCosts
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000257"
      unitRef="U_iso4217USD">651582</maia:IncreaseDecreaseInDeferredOfferingCosts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000258"
      unitRef="U_iso4217USD">269395</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000259"
      unitRef="U_iso4217USD">-322</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000260"
      unitRef="U_iso4217USD">3122</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000261"
      unitRef="U_iso4217USD">211346</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000262"
      unitRef="U_iso4217USD">805516</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000263"
      unitRef="U_iso4217USD">915742</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000264"
      unitRef="U_iso4217USD">997126</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000265"
      unitRef="U_iso4217USD">-7037</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000266"
      unitRef="U_iso4217USD">-11655725</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000267"
      unitRef="U_iso4217USD">-4122896</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000268"
      unitRef="U_iso4217USD">7369000</us-gaap:ProceedsFromConvertibleDebt>
    <maia:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000269"
      unitRef="U_iso4217USD">62500</maia:ProceedsFromPaycheckProtectionProgramLoan>
    <maia:ProceedsFromCollectionOfSubscriptionReceivable
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000270"
      unitRef="U_iso4217USD">322002</maia:ProceedsFromCollectionOfSubscriptionReceivable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000271"
      unitRef="U_iso4217USD">2473560</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000272"
      unitRef="U_iso4217USD">5742171</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000273"
      unitRef="U_iso4217USD">84000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000274"
      unitRef="U_iso4217USD">9000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000275"
      unitRef="U_iso4217USD">385400</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000276"
      unitRef="U_iso4217USD">529425</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000277"
      unitRef="U_iso4217USD">11500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <maia:PaymentOfInitialPublicOfferingTransactionCosts
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000278"
      unitRef="U_iso4217USD">2406170</maia:PaymentOfInitialPublicOfferingTransactionCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000279"
      unitRef="U_iso4217USD">367</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000280"
      unitRef="U_iso4217USD">12036790</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000281"
      unitRef="U_iso4217USD">14033731</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000282"
      unitRef="U_iso4217USD">-4430</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000283"
      unitRef="U_iso4217USD">376635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000284"
      unitRef="U_iso4217USD">9910835</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000285"
      unitRef="U_iso4217USD">10574292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001878313_20201231"
      decimals="0"
      id="F_000286"
      unitRef="U_iso4217USD">663457</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000287"
      unitRef="U_iso4217USD">10950927</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000288"
      unitRef="U_iso4217USD">10574292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000289"
      unitRef="U_iso4217USD">8249587</maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000290"
      unitRef="U_iso4217USD">25000</us-gaap:ConversionOfStockAmountConverted1>
    <maia:OptionsIssuedForAccruedBonus
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000291"
      unitRef="U_iso4217USD">786531</maia:OptionsIssuedForAccruedBonus>
    <maia:OptionsIssuedForDeferredCompensation
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000292"
      unitRef="U_iso4217USD">285418</maia:OptionsIssuedForDeferredCompensation>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000293"
      unitRef="U_iso4217USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000294"
      unitRef="U_iso4217USD">-21000</maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer>
    <maia:PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000295"
      unitRef="U_iso4217USD">651582</maia:PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering>
    <maia:WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000296"
      unitRef="U_iso4217USD">343735</maia:WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000297">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-weight:normal;color:#000000;"/&gt;NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business, Organization, and Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#x201c;the Company&#x201d;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#x201c;MAIA&#x201d;) was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;THIO Therapeutics, Inc. (&#x201c;THIO&#x201d;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;DGD Pharmaceuticals Corporation (&#x201c;DGD&#x201d;), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;MAIA Drug Development Corporation (&#x201c;MAIA DD&#x201d;) incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2022, the Company had working capital of&#x2009;$8,539,131, an accumulated deficit of $44,207,272, cash of $10,950,927 and current liabilities of $3,268,906. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses. During May 2022, the company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#x201d; The Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in the initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter. After deducting $2,406,170 for cash issuance costs, net proceeds from the offering and overallotment were $9,093,830.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern Considerations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $44,207,272 from the Company&#x2019;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $10,951,000 million in cash and cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impact of the COVID-19 Pandemic on our Operations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d; or &#x201c;GAAP&#x201d;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s Chief Executive Officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Certain Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The financial statements of the Company&#x2019;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#x2019; equity as accumulated other comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#x2019;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has no cash equivalents as of December 31, 2022 and 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#x201c;Accounting Standards Codification (ASC) Topic 820&#x201d;, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;General and Administrative&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s research and development expenses consist primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#x2019;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#x2019;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;particular period&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. There have been no material changes in estimates for the periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Incentive&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Derivative Financial Instruments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock Warrants&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), depending on the specific terms of the warrant agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When warrants are issued for services to non-employees, under ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:61.44%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.11%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:12.1%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,545,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,797,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued &lt;span style="-sec-ix-hidden:F_000377"&gt;ASU No. 2016-02&lt;/span&gt;, as amended, Leases (&#x201c;Topic 842&#x201d;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of January 1, 2022. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#x2019;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000310">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business, Organization, and Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#x201c;the Company&#x201d;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#x201c;MAIA&#x201d;) was incorporated in the state of Delaware on August 3, 2018. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;THIO Therapeutics, Inc. (&#x201c;THIO&#x201d;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned 93.3% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining 6.7% minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;DGD Pharmaceuticals Corporation (&#x201c;DGD&#x201d;), incorporated in the state of Delaware of April 1, 2019. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;MAIA Drug Development Corporation (&#x201c;MAIA DD&#x201d;) incorporated in the state of Texas on September 10, 2018, and was 100% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812"
      decimals="3"
      id="F_000344"
      unitRef="U_xbrlipure">0.933</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaTHIOTherapeuticsIncMember_20210812"
      decimals="3"
      id="F_000345"
      unitRef="U_xbrlipure">0.067</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="C_0001878313_20220101_20221231" id="F_000346">minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000347"
      unitRef="U_xbrlipure">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_0001878313_srtConsolidatedEntitiesAxis_srtParentCompanyMember_srtOwnershipAxis_maiaMAIADrugDevelopmentCorporationMember_20210731"
      decimals="INF"
      id="F_000348"
      unitRef="U_xbrlipure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <maia:LiquidityPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2022, the Company had working capital of&#x2009;$8,539,131, an accumulated deficit of $44,207,272, cash of $10,950,927 and current liabilities of $3,268,906. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses. During May 2022, the company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#x201d; The Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in the initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter. After deducting $2,406,170 for cash issuance costs, net proceeds from the offering and overallotment were $9,093,830.&lt;/p&gt;</maia:LiquidityPolicyTextBlock>
    <maia:WorkingCapital
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000349"
      unitRef="U_iso4217USD">8539131</maia:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000350"
      unitRef="U_iso4217USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000351"
      unitRef="U_iso4217USD">10950927</us-gaap:Cash>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000352"
      unitRef="U_iso4217USD">3268906</us-gaap:LiabilitiesCurrent>
    <us-gaap:Revenues
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000353"
      unitRef="U_iso4217USD">0</us-gaap:Revenues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_20220101_20220228"
      decimals="INF"
      id="F_000354"
      unitRef="U_xbrlishares">263729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_20220228"
      decimals="0"
      id="F_000355"
      unitRef="U_iso4217USD_xbrlishares">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220101_20220228"
      decimals="0"
      id="F_000356"
      unitRef="U_iso4217USD">2373561</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_20220501_20220531"
      decimals="INF"
      id="F_000357"
      unitRef="U_xbrlishares">11111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_20220531"
      decimals="0"
      id="F_000358"
      unitRef="U_iso4217USD_xbrlishares">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220501_20220531"
      decimals="0"
      id="F_000359"
      unitRef="U_iso4217USD">99999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801"
      decimals="INF"
      id="F_000360"
      unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="0"
      id="F_000361"
      unitRef="U_iso4217USD_xbrlishares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801"
      decimals="0"
      id="F_000362"
      unitRef="U_iso4217USD">10000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803"
      decimals="INF"
      id="F_000363"
      unitRef="U_xbrlishares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803"
      decimals="0"
      id="F_000364"
      unitRef="U_iso4217USD_xbrlishares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803"
      decimals="0"
      id="F_000365"
      unitRef="U_iso4217USD">1500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803"
      decimals="0"
      id="F_000366"
      unitRef="U_iso4217USD">2406170</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_maiaOfferingAndOverallotmentMember_20220803_20220803"
      decimals="0"
      id="F_000367"
      unitRef="U_iso4217USD">9093830</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <maia:GoingConcernConsiderationsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000312">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern Considerations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $44,207,272 from the Company&#x2019;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $10,951,000 million in cash and cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.&lt;/p&gt;</maia:GoingConcernConsiderationsPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000368"
      unitRef="U_iso4217USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="C_0001878313_20221231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">10951000</us-gaap:Cash>
    <maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000313">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impact of the COVID-19 Pandemic on our Operations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.&lt;/p&gt;</maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000314">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d; or &#x201c;GAAP&#x201d;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s Chief Executive Officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001878313_20220101_20221231" id="F_000316">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <maia:CertainRisksAndUncertaintiesPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000317">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Certain Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/p&gt;</maia:CertainRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000318">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The financial statements of the Company&#x2019;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#x2019; equity as accumulated other comprehensive loss.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000319">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#x2019;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000320">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has no cash equivalents as of December 31, 2022 and 2021.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000370"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000371"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000321">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#x201c;Accounting Standards Codification (ASC) Topic 820&#x201d;, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.51%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000322">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;General and Administrative&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001878313_20220101_20221231" id="F_000323">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s research and development expenses consist primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#x2019;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#x2019;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;particular period&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. There have been no material changes in estimates for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <maia:ResearchAndDevelopmentIncentivePolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000324">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Incentive&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.&lt;/p&gt;</maia:ResearchAndDevelopmentIncentivePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000325">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Derivative Financial Instruments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. &lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000326">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <maia:CommonStockWarrantsPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock Warrants&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), depending on the specific terms of the warrant agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When warrants are issued for services to non-employees, under ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.&lt;/p&gt;</maia:CommonStockWarrantsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000328">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000330">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:61.44%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.11%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:12.1%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,545,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,797,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:61.44%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.11%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:12.1%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,545,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,797,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon exercise of warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="INF"
      id="F_000372"
      unitRef="U_xbrlishares">6545628</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000373"
      unitRef="U_xbrlishares">5797185</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20221231"
      decimals="INF"
      id="F_000374"
      unitRef="U_xbrlishares">796985</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="INF"
      id="F_000375"
      unitRef="U_xbrlishares">1311117</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_maiaUnvestedRestrictedStockAwardsMember_20210101_20211231"
      decimals="INF"
      id="F_000376"
      unitRef="U_xbrlishares">58333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000332">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued &lt;span style="-sec-ix-hidden:F_000377"&gt;ASU No. 2016-02&lt;/span&gt;, as amended, Leases (&#x201c;Topic 842&#x201d;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this new standard as of January 1, 2022. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#x2019;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="C_0001878313_20221231" id="F_000379">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000298">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;RELATED PARTY TRANSACTIONS &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Consulting Services &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leigh-Ann Durant, a former member of the Company&#x2019;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $88,994 for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $34,560 in cash and issued her options to purchase 23,964 shares of common stock with a total fair value of $54,434 during the year ended December 31, 2021.&#160;&#160;Ms. Durant was no longer considered a related party in 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $4,700 for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $2,350 in cash and issued him options to purchase 184 shares of common stock with a total fair value of $1,100. The remaining $1,250 for services provided in fiscal 2021 were settled in March, 2022 for 226 options issued to Mr. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vitoc&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The Company also issued him a convertible note in the amount of $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; during April 2021, which was converted into &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,557&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock on September 30, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; at a conversion price of $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share, and also received &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; warrants to purchase shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share.&#160;&#160;In 2022, Mr. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vitoc&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; provided consulting services to the Company through July 2022 for which the Company incurred $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,900&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for services provided during the year ended December 31, 2022.&#160;&#160;The Company paid Mr. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vitoc&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,950&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; in cash and issued him options to purchase &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,690&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.950&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;In August 2022, Mr. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vitoc&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; became an employee of the Company. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;CEO Loan Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company's chief executive officer lent the Company a total of $25,000 in August and September of 2018. These amounts, were unsecured, had no stated interest rate, and no stated repayment terms. The Company repaid $3,633 of the loan to the CEO during 2020 and $367 during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $21,000. The convertible note issued to the CEO was converted into 3,621 shares of common stock on September 30, 2021 at a conversion price of $6.00 per share.&#160;&#160;No further notes to the CEO were incurred in the year ended December 31, 2022.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <maia:ConsultingServices
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231"
      decimals="0"
      id="F_000380"
      unitRef="U_iso4217USD">88994</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231"
      decimals="0"
      id="F_000381"
      unitRef="U_iso4217USD">34560</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlishares">23964</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231"
      decimals="0"
      id="F_000383"
      unitRef="U_iso4217USD">54434</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <maia:ConsultingServices
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231"
      decimals="0"
      id="F_000385"
      unitRef="U_iso4217USD">4700</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231"
      decimals="0"
      id="F_000387"
      unitRef="U_iso4217USD">2350</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231"
      decimals="INF"
      id="F_000389"
      unitRef="U_xbrlishares">184</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210101_20211231"
      decimals="0"
      id="F_000391"
      unitRef="U_iso4217USD">1100</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <maia:RemainingConsultingServicesSettled
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331"
      decimals="0"
      id="F_000392"
      unitRef="U_iso4217USD">1250</maia:RemainingConsultingServicesSettled>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220301_20220331"
      decimals="INF"
      id="F_000393"
      unitRef="U_xbrlishares">226</maia:OptionsToPurchaseSharesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210401_20210430"
      decimals="0"
      id="F_000394"
      unitRef="U_iso4217USD">50000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210929_20210930"
      decimals="INF"
      id="F_000395"
      unitRef="U_xbrlishares">8557</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930"
      decimals="2"
      id="F_000396"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930"
      decimals="INF"
      id="F_000397"
      unitRef="U_xbrlishares">4278</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20210930"
      decimals="2"
      id="F_000398"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <maia:ConsultingServices
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231"
      decimals="0"
      id="F_000384"
      unitRef="U_iso4217USD">36900</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231"
      decimals="0"
      id="F_000386"
      unitRef="U_iso4217USD">19950</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231"
      decimals="INF"
      id="F_000388"
      unitRef="U_xbrlishares">4690</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRaduVitocMember_20220101_20221231"
      decimals="3"
      id="F_000390"
      unitRef="U_iso4217USD">19.950</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <us-gaap:UnsecuredDebt
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930"
      decimals="0"
      id="F_000399"
      unitRef="U_iso4217USD">25000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20180930"
      decimals="2"
      id="F_000400"
      unitRef="U_xbrlipure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20201231"
      decimals="0"
      id="F_000401"
      unitRef="U_iso4217USD">3633</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20211231"
      decimals="0"
      id="F_000402"
      unitRef="U_iso4217USD">367</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210301_20210331"
      decimals="0"
      id="F_000403"
      unitRef="U_iso4217USD">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210929_20210930"
      decimals="INF"
      id="F_000404"
      unitRef="U_xbrlishares">3621</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210930"
      decimals="2"
      id="F_000405"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000299">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;ACCRUED EXPENSES &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2022 and 2021, accrued expenses consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bonus&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional&#160;&#160;fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;516,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred compensation to former officers&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,103,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,185,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Deferred Compensation Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2022 and December 31, 2021, the Company had $0 and $111,271, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $193,379 in deferred compensation. The Company paid $457,749 in cash and issued 268,769 options with a total fair value of $296,264 during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $743,167. The fair value of the options issued in excess of the deferred compensation balance settled totaling $10,846 was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Accrued Bonus&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2022 and 2021, the Company accrued $1,094,582 and $384,750, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of 713,536 stock options with a total fair value of $786,531. The fair value of the options issued in excess of the accrued bonus balance totaled $6,531 and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000334">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2022 and 2021, accrued expenses consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bonus&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional&#160;&#160;fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;516,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred compensation to former officers&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,103,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,185,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000406"
      unitRef="U_iso4217USD">1094582</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000407"
      unitRef="U_iso4217USD">384750</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000408"
      unitRef="U_iso4217USD">332589</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000409"
      unitRef="U_iso4217USD">380277</us-gaap:AccruedProfessionalFeesCurrent>
    <maia:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000410"
      unitRef="U_iso4217USD">516961</maia:AccruedResearchAndDevelopmentCostsCurrent>
    <maia:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000411"
      unitRef="U_iso4217USD">268140</maia:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000412"
      unitRef="U_iso4217USD">111271</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000413"
      unitRef="U_iso4217USD">159269</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000414"
      unitRef="U_iso4217USD">41157</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000415"
      unitRef="U_iso4217USD">2103401</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000416"
      unitRef="U_iso4217USD">1185595</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000417"
      unitRef="U_iso4217USD">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000418"
      unitRef="U_iso4217USD">111271</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000419"
      unitRef="U_iso4217USD">193379</us-gaap:DeferredCompensationLiabilityCurrent>
    <maia:CashPaidToSettleAPortionOfDeferredCompensationBalance
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000420"
      unitRef="U_iso4217USD">457749</maia:CashPaidToSettleAPortionOfDeferredCompensationBalance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="C_0001878313_20210101_20211231"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">268769</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000422"
      unitRef="U_iso4217USD">296264</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000423"
      unitRef="U_iso4217USD">743167</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="0"
      id="F_000424"
      unitRef="U_iso4217USD">10846</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001878313_20221001"
      decimals="0"
      id="F_000425"
      unitRef="U_iso4217USD">1094582</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000426"
      unitRef="U_iso4217USD">384750</us-gaap:AccruedBonusesCurrent>
    <maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance
      contextRef="C_0001878313_20210416_20210416"
      decimals="INF"
      id="F_000427"
      unitRef="U_xbrlishares">713536</maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance>
    <maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance
      contextRef="C_0001878313_20210416_20210416"
      decimals="0"
      id="F_000428"
      unitRef="U_iso4217USD">786531</maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance>
    <maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="0"
      id="F_000429"
      unitRef="U_iso4217USD">6531</maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance>
    <maia:PaycheckProtectionProgramTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000300">
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.78%;text-indent:-4.78%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. PAYCHECK PROTECTION PROGRAM &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 31, 2021, the Company received a second PPP Loan in the amount of $62,500. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of 0.98% per annum. The term of the PPP Loan is two years. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $62,500, and the Company recorded a gain on extinguishment totaling $62,500 for the year ended December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;/p&gt;</maia:PaycheckProtectionProgramTextBlock>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131"
      decimals="0"
      id="F_000430"
      unitRef="U_iso4217USD">62500</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210131"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlipure">0.0098</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131"
      id="F_000432">P2Y</us-gaap:DebtInstrumentTerm>
    <maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount
      contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231"
      decimals="0"
      id="F_000433"
      unitRef="U_iso4217USD">62500</maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20211231"
      decimals="0"
      id="F_000434"
      unitRef="U_iso4217USD">62500</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000301">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;CONVERTIBLE NOTES PAYABLE&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Convertible Notes Payable issued in 2019&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company issued a Convertible Promissory Note totaling $10,000 to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at 8% per annum, was unsecured, with a scheduled maturity date of December 31, 2021. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $5,000,000 (before any transaction related expenses and costs). The conversion price will be set at 65% of the price of the preferred stock issued in the aforementioned Equity Financing.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Embedded Put Feature&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the terms related to the Equity Financing conversion, (the &#x201c;Embedded Put Feature&#x201d;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense on the 2019 Convertible Note totaled $0 and $607 for the year ended December 31, 2022 and 2021, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $1,000 at issuance. The balance of the debt discount was $0 as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $0 and $310, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Convertible Notes Payable issued in 2020&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company issued Convertible Promissory Notes totaling $610,000 to various investors or holders, including $110,000 of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at 6% per annum, was unsecured, with a scheduled maturity date of May 31, 2022. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) a Change in Control whereby any person or group becomes a beneficial owner of more than &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50%&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Conversion Prices&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The conversion price is set at 75% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Embedded Put Features&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $131,000 at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Maturity Date&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense on the 2020 Convertible Notes totaled $27,375 and $11,523 for the year ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt discounts on the 2020 Convertible Notes totaled $0 and $0 as of December 31, 2022 and 2021, respectively.&#160;&#160;During the year ended December 31, 2021 amortization of debt discounts amounted to $83,608. There was no amortization of debt discounts for the year ended December 31, 2022.&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $65,660 (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Convertible Notes Payable issued in 2021&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $7,390,000 to various investors or holders, including $1,863,300 of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $21,000 Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at 6% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $5,000,000 (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Conversion Prices&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The conversion price was set at 75% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Embedded Put Features&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $2,821,000 at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Maturity Date&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense on the 2021 Convertible Notes totaled $199,049 and $0 for the year ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $0 and $513,035, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $320,460 (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Conversion of Convertible Notes Upon Equity Financing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Convertible Notes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $5 million, the Company converted all $8,010,000 of its outstanding principal and all accrued and unpaid interest of approximately $240,000 related to the Company&#x2019;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into 1,375,228 shares of the Company&#x2019;s common stock on September 30, 2021 at a conversion price of $6.00 per share. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $2.3 million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $3.3 million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 there were no Convertible Notes outstanding. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for 686,489 shares of common stock with an exercise price of $6.00 and expire at various dates throughout fiscal 2028.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, 4,504 of these warrants have been exercised.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731"
      decimals="0"
      id="F_000435"
      unitRef="U_iso4217USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190731"
      decimals="INF"
      id="F_000437"
      unitRef="U_xbrlipure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="C_0001878313_20190701_20190731" id="F_000436">2021-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190701_20190731"
      decimals="0"
      id="F_000438"
      unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_0001878313_20190731"
      decimals="2"
      id="F_000439"
      unitRef="U_xbrlipure">0.65</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231"
      decimals="0"
      id="F_000441"
      unitRef="U_iso4217USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000440"
      unitRef="U_iso4217USD">607</us-gaap:InterestExpense>
    <maia:DebtDiscountAndValueOfEmbeddedPutFeature
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20190101_20190731"
      decimals="0"
      id="F_000442"
      unitRef="U_iso4217USD">1000</maia:DebtDiscountAndValueOfEmbeddedPutFeature>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20211231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20221231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20220101_20221231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndNineteenPromissoryNoteMember_20210101_20211231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">310000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="0"
      id="F_000447"
      unitRef="U_iso4217USD">610000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaRelatedPartyMember_20201231"
      decimals="0"
      id="F_000448"
      unitRef="U_iso4217USD">110000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="INF"
      id="F_000449"
      unitRef="U_xbrlipure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231"
      id="F_000450">2022-05-31</us-gaap:DebtInstrumentMaturityDate>
    <maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="0"
      id="F_000451"
      unitRef="U_iso4217USD">5000000</maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt>
    <maia:PercentageOfVotingPowerDefiningChangeOfControl
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="2"
      id="F_000452"
      unitRef="U_xbrlipure">0.50</maia:PercentageOfVotingPowerDefiningChangeOfControl>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="2"
      id="F_000453"
      unitRef="U_xbrlipure">0.75</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20201231"
      decimals="0"
      id="F_000454"
      unitRef="U_iso4217USD">131000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000455"
      unitRef="U_iso4217USD">27375</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20200101_20201231"
      decimals="0"
      id="F_000456"
      unitRef="U_iso4217USD">11523</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20221231"
      decimals="0"
      id="F_000457"
      unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20211231"
      decimals="0"
      id="F_000458"
      unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000460"
      unitRef="U_iso4217USD">83608</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyPromissoryNoteMember_20220101_20221231"
      decimals="0"
      id="F_000459"
      unitRef="U_iso4217USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <maia:WarrantDescription contextRef="C_0001878313_20200101_20201231" id="F_000461">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </maia:WarrantDescription>
    <maia:PercentageOfIssuableUponConversionOfExercisePrice
      contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231"
      decimals="2"
      id="F_000462"
      unitRef="U_xbrlipure">0.50</maia:PercentageOfIssuableUponConversionOfExercisePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyWarrantsMember_20201231"
      decimals="0"
      id="F_000463"
      unitRef="U_iso4217USD">65660</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231"
      decimals="0"
      id="F_000464"
      unitRef="U_iso4217USD">7390000</us-gaap:DebtInstrumentFaceAmount>
    <maia:ConvertiblePromissoryNotesToRelatedParties
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000465"
      unitRef="U_iso4217USD">1863300</maia:ConvertiblePromissoryNotesToRelatedParties>
    <maia:ConvertiblePromissoryNotesToSettleLoan
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000466"
      unitRef="U_iso4217USD">21000</maia:ConvertiblePromissoryNotesToSettleLoan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231"
      decimals="INF"
      id="F_000467"
      unitRef="U_xbrlipure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000468"
      unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231"
      decimals="2"
      id="F_000469"
      unitRef="U_xbrlipure">0.75</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20211231"
      decimals="0"
      id="F_000470"
      unitRef="U_iso4217USD">2821000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000471"
      unitRef="U_iso4217USD">199049</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20200101_20201231"
      decimals="0"
      id="F_000472"
      unitRef="U_iso4217USD">0</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20220101_20221231"
      decimals="0"
      id="F_000474"
      unitRef="U_iso4217USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001878313_us-gaapLongtermDebtTypeAxis_maiaTwoThousandAndTwentyOneConvertiblePromissoryNoteMember_20210101_20211231"
      decimals="0"
      id="F_000473"
      unitRef="U_iso4217USD">513035</us-gaap:AmortizationOfDebtDiscountPremium>
    <maia:WarrantDescription contextRef="C_0001878313_20210101_20211231" id="F_000475">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </maia:WarrantDescription>
    <maia:PercentageOfIssuableUponConversionOfExercisePrice
      contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231"
      decimals="2"
      id="F_000476"
      unitRef="U_xbrlipure">0.50</maia:PercentageOfIssuableUponConversionOfExercisePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_us-gaapAwardTypeAxis_maiaTwoThousandAndTwentyOneWarrantsMember_20211231"
      decimals="0"
      id="F_000477"
      unitRef="U_iso4217USD">320460</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_us-gaapShortTermDebtTypeAxis_maiaConvertibleNotesMember_20210101_20211231"
      decimals="-6"
      id="F_000484"
      unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000485"
      unitRef="U_iso4217USD">8010000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000486"
      unitRef="U_iso4217USD">240000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_0001878313_20210901_20210930"
      decimals="INF"
      id="F_000487"
      unitRef="U_xbrlishares">1375228</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001878313_20210930"
      decimals="2"
      id="F_000488"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="-5"
      id="F_000478"
      unitRef="U_iso4217USD">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001878313_20211231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">3300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <maia:ConvertibleNotesOutstanding
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000483"
      unitRef="U_iso4217USD">0</maia:ConvertibleNotesOutstanding>
    <maia:CommonSharesUponExerciseOfWarrantsShares
      contextRef="C_0001878313_20210901_20210930"
      decimals="INF"
      id="F_000480"
      unitRef="U_xbrlishares">686489</maia:CommonSharesUponExerciseOfWarrantsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001878313_20210930"
      decimals="2"
      id="F_000481"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <maia:WarrantsExercised
      contextRef="C_0001878313_20210101_20211231"
      decimals="INF"
      id="F_000482"
      unitRef="U_xbrlishares">4504</maia:WarrantsExercised>
    <maia:SimpleAgreementForFutureEquityDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000302">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;SIMPLE AGREEMENT FOR FUTURE EQUITY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $25,000. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at 60% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $25,000 was converted into 5,208 shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $8.00. 'The conversion price was equal to 60% of $8.00 per share, or $4.80 per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.78%;text-indent:-4.78%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</maia:SimpleAgreementForFutureEquityDisclosureTextBlock>
    <maia:SimpleAgreementForFutureEquityIssued
      contextRef="C_0001878313_20191001_20191031"
      decimals="0"
      id="F_000489"
      unitRef="U_iso4217USD">25000</maia:SimpleAgreementForFutureEquityIssued>
    <maia:PercentageOfConversionPrice
      contextRef="C_0001878313_20191001_20191031"
      decimals="2"
      id="F_000490"
      unitRef="U_xbrlipure">0.60</maia:PercentageOfConversionPrice>
    <maia:SimpleAgreementForFutureEquityIssued
      contextRef="C_0001878313_20210901_20210930"
      decimals="0"
      id="F_000491"
      unitRef="U_iso4217USD">25000</maia:SimpleAgreementForFutureEquityIssued>
    <maia:NumberOfCommonSharesConvertedUnderSAFEAgreement
      contextRef="C_0001878313_20210901_20210930"
      decimals="INF"
      id="F_000492"
      unitRef="U_xbrlishares">5208</maia:NumberOfCommonSharesConvertedUnderSAFEAgreement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_20210930"
      decimals="2"
      id="F_000493"
      unitRef="U_iso4217USD_xbrlishares">8.00</us-gaap:SaleOfStockPricePerShare>
    <maia:PercentageOfConversionPrice
      contextRef="C_0001878313_20210901_20210930"
      decimals="2"
      id="F_000494"
      unitRef="U_xbrlipure">0.60</maia:PercentageOfConversionPrice>
    <maia:CommonStockConversionPrice
      contextRef="C_0001878313_20210930"
      decimals="2"
      id="F_000495"
      unitRef="U_iso4217USD_xbrlishares">4.80</maia:CommonStockConversionPrice>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000303">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;FAIR VALUE OF FINANCIAL LIABILITIES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Derivative Liability &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability on convertible notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,821,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss (Gain) on fair value of embedded features&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Extinguishment of derivative liability in connection with debt conversion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,151,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#x2019;s income reflected the volatility in these estimate and assumption changes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $203,000 for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately 0%; the probability of an equity financing was estimated to be approximately 100%; and the probability of default, change in control or dissolution was estimated to be approximately 0%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:46.53%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no warrant liabilities measured at fair value on a recurring basis at December 31, 2021. The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.29%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;343,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;320,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Gain) loss on fair value of warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(98,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,546,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of warrant liability to equity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,952,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000335">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability on convertible notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,821,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss (Gain) on fair value of embedded features&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Extinguishment of derivative liability in connection with debt conversion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,151,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:63%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.28%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:11.29%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;343,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;320,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Gain) loss on fair value of warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(98,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,546,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of warrant liability to equity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,952,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="0"
      id="F_000496"
      unitRef="U_iso4217USD">127000</us-gaap:DerivativeLiabilities>
    <maia:DerivativeLiabilityOnConvertibleNotesPayable
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000497"
      unitRef="U_iso4217USD">2821000</maia:DerivativeLiabilityOnConvertibleNotesPayable>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000498"
      unitRef="U_iso4217USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000499"
      unitRef="U_iso4217USD">-3151000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000500"
      unitRef="U_iso4217USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <maia:PercentageOfProbabilityOfTheConvertibleNotesMaturity
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000501"
      unitRef="U_xbrlipure">0</maia:PercentageOfProbabilityOfTheConvertibleNotesMaturity>
    <maia:PercentageOfProbabilityOfEquityFinancingMaturity
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000502"
      unitRef="U_xbrlipure">1</maia:PercentageOfProbabilityOfEquityFinancingMaturity>
    <maia:PercentageOfProbabilityOfDefaultChangeInControlOrDissolution
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000503"
      unitRef="U_xbrlipure">0</maia:PercentageOfProbabilityOfDefaultChangeInControlOrDissolution>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000336">The fair value of the warrant liabilities recorded are as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:46.53%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.36%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000504"
      unitRef="U_iso4217USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231"
      decimals="0"
      id="F_000505"
      unitRef="U_iso4217USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000506"
      unitRef="U_iso4217USD">245341</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231"
      decimals="0"
      id="F_000507"
      unitRef="U_iso4217USD">245341</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000508"
      unitRef="U_iso4217USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="0"
      id="F_000509"
      unitRef="U_iso4217USD">85260</us-gaap:DerivativeLiabilitiesNoncurrent>
    <maia:FairValueWarrantLiability
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231"
      decimals="0"
      id="F_000510"
      unitRef="U_iso4217USD">343735</maia:FairValueWarrantLiability>
    <maia:FairValueWarrantLiability
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000511"
      unitRef="U_iso4217USD">320460</maia:FairValueWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20220101_20221231"
      decimals="0"
      id="F_000512"
      unitRef="U_iso4217USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000513"
      unitRef="U_iso4217USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20210101_20211231"
      decimals="0"
      id="F_000514"
      unitRef="U_iso4217USD">-1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20221231"
      decimals="0"
      id="F_000515"
      unitRef="U_iso4217USD">245341</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000304">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the Company&#x2019;s initial public offering, the Company&#x2019;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#x2019;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;) and amended and restated its Bylaws (the &#x201c;Amended and Restated Bylaws&#x201d;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to 70,000,000 shares and decreased the authorized number of preferred stock to 30,000,000 shares. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales of MAIA Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During January and February 2022, the Company sold 263,729 shares of common stock at $9.00 per share for gross proceeds of $2,373,561 with no transaction costs. During May 2022, the Company sold 11,111 shares of common stock at $9 per share for gross proceeds of $99,999 with no transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $9.00 price per share they paid was equal to the price per share in the Company's initial public offering of $5.00. The number of Ratchet Shares were calculated using the $5.00 per share price in the Company's initial public offering and 219,872 shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $1,099,360, based on the $5 price of the initial public offering and were recorded as expense included in operating expense.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 28, 2022 the Company&#x2019;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5.00 per share for gross proceeds of $10,000,000 in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5.00 per share when the underwriter exercised the overallotment for gross proceeds of $1,500,000 prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $9,100,000.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;MAIA Biotechnology, Inc. Restricted Stock Awards&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2021, MAIA recognized $202,500 of stock compensation expense related to 112,500 of MAIA&#x2019;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#x2019;s 612,500 fully vested THIO restricted shares were canceled and the founder was issued 612,500 MAIA restricted shares. Additionally, in accordance with the founder's original award, the founder was also issued 87,500 MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are no unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $52,500 of expense related to restricted stock for the year ended 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:62.07%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.21%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.29%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;MAIA Stock Warrants&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the holders&#x2019; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#x2019;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the 144,497 warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $450,578 and was treated as a deemed dividend and is reflected as &#x201c;Deemed dividend on warrant modification&#x201d; in the accompanying statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During January 2022, warrants were exercised, resulting in the issuance of 61,111 shares of MAIA common stock for proceeds of $110,000. During May 2022, warrants were exercised, resulting in the issuance of 153,000 shares of common stock for proceeds of approximately $275,400. Another 394,501 warrants were exercised with a cashless exercise assuming the fair market value of $9.00 per share resulting in the issuance of 315,601 shares of common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the closing of the initial public offering, 20,520 warrants with an exercise price of $5.00 per share expired.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concurrently with the closing of the Company&#x2019;s initial public offering, the Company issued warrants to purchase an aggregate of up to 100,000 shares of its common stock to the Representative or its designees, at an exercise price of $6.25 per share (the &#x201c;Representative&#x2019;s Warrants&#x201d;). The Representative&#x2019;s Warrants are exercisable beginning on January 23, 2023, and expire on July 27, 2027, pursuant to the terms and conditions of the Representative&#x2019;s Warrants.&#160;&#160;On August 3, concurrently with the full exercise of the Underwriter&#x2019;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to 15,000 shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#x2019;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $343,735, which was the value determined using the Black-Scholes method using a term of five years, risk free interest rate of 2.82% and volatility of 77.5%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $245,341. The gain on remeasurement of the warrant liability in the amount of $98,394 was included in other income. Only the 115,000 warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:53.06%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:10.23%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:9.31%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:10.23%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;br/&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000584"&gt;7.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(608,612&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000585"&gt;5.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000586"&gt;2.8% - 4.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000587"&gt;0.6% - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000590"&gt;4.6 - 5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000591"&gt;5 - 7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000594"&gt;78% - 92%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000595"&gt;81% - 106%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;MAIA Biotechnology, Inc. Stock Award Plans&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#x201c;MAIA 2018 Plan&#x201d;). MAIA&#x2019;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the 1,924,500 options outstanding in the plan of December 31, 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#x201c;MAIA 2020 Plan&#x2019;&#x2019;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the 3,983,023 options outstanding in the plan as of December 31, 2022. There are no shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#x201c;MAIA 2021 Plan&#x2019;&#x2019;) with 1,909,518 shares of common stock reserved for issuance. As of December 31, 2022 there were 1,271,413 shares of common stock available for future issuance under the MAIA 2021 Plan and 638,105 options outstanding in the MAIA 2021 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options are to be granted with an exercise price which is at least equal to the stock&#x2019;s estimated fair value at the date of grant, and with a contractual term of no more than ten years from the date of grant. In the case of an option granted to a 10% stockholder, the exercise price shall be generally no less than 110% of the fair market value per share on the date of grant, and the contractual term shall be seven years. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#x2019;s exercise repurchase rights and various other features of awards granted under the plans.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:46.85%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:1.04%;"/&gt;
&lt;td style="width:9.37%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:7.35%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:1.01%;"/&gt;
&lt;td style="width:9.06%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.31%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;br/&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,797,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000620"&gt;8.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;811,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,545,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000621"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,773,706&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,449,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000622"&gt;7.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,804,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2022, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $8.87 per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#x201c;OPM&#x201d;) and the Probability-Weighted Expected Return Method (&#x201c;PWERM&#x201d;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes at $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share based on the sale of common stock from January 27, 2022 to May 19, 2022. From June 1, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;During the year ended December 31, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $1.80 was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations of $1.83 per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair&lt;br/&gt;value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to&lt;br/&gt;arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:61.44%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.11%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:12.1%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000630"&gt;2.14% - 4.45%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000631"&gt;0.36% - 1.27%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;5 - 6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000635"&gt;5 - 6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000638"&gt;71.9% - 87.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000639"&gt;71.4% - 81.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 &lt;span style="font-weight:bold;"&gt;w&lt;/span&gt;ere $3.75 and $3.55, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $3,447,367 which the Company expects to recognize over a weighted average period of approximately 3.26 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation related to the Company&#x2019;s stock plans are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:57.7%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:13.02%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:13.96%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,422,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,779,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;896,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,319,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,722,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001878313_20220801"
      decimals="INF"
      id="F_000516"
      unitRef="U_xbrlishares">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001878313_20220801"
      decimals="INF"
      id="F_000517"
      unitRef="U_xbrlishares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220228"
      decimals="INF"
      id="F_000518"
      unitRef="U_xbrlishares">263729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220228"
      decimals="2"
      id="F_000520"
      unitRef="U_iso4217USD_xbrlishares">9.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220101_20220228"
      decimals="0"
      id="F_000522"
      unitRef="U_iso4217USD">2373561</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <maia:TransactionCosts
      contextRef="C_0001878313_20220228"
      decimals="0"
      id="F_000524"
      unitRef="U_iso4217USD">0</maia:TransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531"
      decimals="INF"
      id="F_000519"
      unitRef="U_xbrlishares">11111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220531"
      decimals="0"
      id="F_000521"
      unitRef="U_iso4217USD_xbrlishares">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220501_20220531"
      decimals="0"
      id="F_000523"
      unitRef="U_iso4217USD">99999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <maia:TransactionCosts
      contextRef="C_0001878313_20220531"
      decimals="0"
      id="F_000525"
      unitRef="U_iso4217USD">0</maia:TransactionCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_20220228"
      decimals="2"
      id="F_000526"
      unitRef="U_iso4217USD_xbrlishares">9.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220228"
      decimals="2"
      id="F_000527"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="2"
      id="F_000528"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="INF"
      id="F_000529"
      unitRef="U_xbrlishares">219872</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801"
      decimals="0"
      id="F_000530"
      unitRef="U_iso4217USD">1099360</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="0"
      id="F_000531"
      unitRef="U_iso4217USD_xbrlishares">5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801"
      decimals="INF"
      id="F_000532"
      unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="2"
      id="F_000533"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:SaleOfStockPricePerShare>
    <maia:ProceedsFromCommonStockNetOfIssuanceCosts
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220731_20220801"
      decimals="0"
      id="F_000534"
      unitRef="U_iso4217USD">10000000</maia:ProceedsFromCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803"
      decimals="INF"
      id="F_000535"
      unitRef="U_xbrlishares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803"
      decimals="2"
      id="F_000536"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:SaleOfStockPricePerShare>
    <maia:ProceedsFromCommonStockNetOfIssuanceCosts
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803"
      decimals="0"
      id="F_000537"
      unitRef="U_iso4217USD">1500000</maia:ProceedsFromCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001878313_20220803_20220803"
      decimals="0"
      id="F_000538"
      unitRef="U_iso4217USD">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RestrictedStockExpense
      contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231"
      decimals="0"
      id="F_000539"
      unitRef="U_iso4217USD">202500</us-gaap:RestrictedStockExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20211231"
      decimals="INF"
      id="F_000540"
      unitRef="U_xbrlishares">112500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210813_20210813"
      decimals="INF"
      id="F_000541"
      unitRef="U_xbrlishares">612500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001878313_deiLegalEntityAxis_maiaTHIOMember_srtTitleOfIndividualAxis_maiaFounderMember_20210813_20210813"
      decimals="INF"
      id="F_000542"
      unitRef="U_xbrlishares">612500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_20210101_20211231"
      decimals="INF"
      id="F_000543"
      unitRef="U_xbrlishares">87500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231"
      decimals="INF"
      id="F_000544"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001878313_srtTitleOfIndividualAxis_maiaFounderMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231"
      decimals="0"
      id="F_000545"
      unitRef="U_iso4217USD">52500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000337">
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:62.07%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.21%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:11.29%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231"
      decimals="INF"
      id="F_000546"
      unitRef="U_xbrlishares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231"
      decimals="2"
      id="F_000549"
      unitRef="U_iso4217USD_xbrlishares">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231"
      decimals="INF"
      id="F_000547"
      unitRef="U_xbrlishares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231"
      decimals="2"
      id="F_000550"
      unitRef="U_iso4217USD_xbrlishares">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20221231"
      decimals="INF"
      id="F_000548"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <maia:WarrantModificationValue
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220131"
      decimals="0"
      id="F_000551"
      unitRef="U_iso4217USD">144497</maia:WarrantModificationValue>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapWarrantMember_20220101_20220331"
      decimals="0"
      id="F_000552"
      unitRef="U_iso4217USD">450578</maia:DeemedDividendOnWarrantModification>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131"
      decimals="INF"
      id="F_000553"
      unitRef="U_xbrlishares">61111</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220131"
      decimals="0"
      id="F_000555"
      unitRef="U_iso4217USD">110000</maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531"
      decimals="INF"
      id="F_000554"
      unitRef="U_xbrlishares">153000</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220501_20220531"
      decimals="0"
      id="F_000556"
      unitRef="U_iso4217USD">275400</maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants>
    <maia:WarrantsExercisedShares
      contextRef="C_0001878313_20220501_20220531"
      decimals="INF"
      id="F_000557"
      unitRef="U_xbrlishares">394501</maia:WarrantsExercisedShares>
    <maia:CashlessExerciseAtFairMarketValuePerShare
      contextRef="C_0001878313_20220531"
      decimals="INF"
      id="F_000558"
      unitRef="U_iso4217USD_xbrlishares">9.00</maia:CashlessExerciseAtFairMarketValuePerShare>
    <maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
      contextRef="C_0001878313_20220501_20220531"
      decimals="INF"
      id="F_000559"
      unitRef="U_xbrlishares">315601</maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares>
    <maia:NumberOfWarrantsExercised
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="INF"
      id="F_000560"
      unitRef="U_xbrlishares">20520</maia:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220801"
      decimals="INF"
      id="F_000561"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_20220801"
      decimals="INF"
      id="F_000562"
      unitRef="U_xbrlishares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001878313_20220801"
      decimals="INF"
      id="F_000563"
      unitRef="U_iso4217USD_xbrlishares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="C_0001878313_20220731_20220801" id="F_000564">2023-01-23</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire contextRef="C_0001878313_20220731_20220801" id="F_000565">2027-07-27</maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire>
    <maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20220803_20220803"
      decimals="INF"
      id="F_000566"
      unitRef="U_xbrlishares">15000</maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803"
      decimals="0"
      id="F_000567"
      unitRef="U_iso4217USD">343735</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803"
      id="F_000568">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803"
      decimals="4"
      id="F_000569"
      unitRef="U_xbrlipure">0.0282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220803_20220803"
      decimals="3"
      id="F_000570"
      unitRef="U_xbrlipure">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20221231"
      decimals="0"
      id="F_000571"
      unitRef="U_iso4217USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001878313_us-gaapValuationTechniqueAxis_maiaBlackSholesMethodMember_20220101_20221231"
      decimals="0"
      id="F_000572"
      unitRef="U_iso4217USD">98394</us-gaap:FairValueAdjustmentOfWarrants>
    <maia:ClassOfWarrantsIssued
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000573"
      unitRef="U_xbrlishares">115000</maia:ClassOfWarrantsIssued>
    <maia:ScheduleOfWarrantExercisedTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000338">
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:53.06%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:10.23%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:9.31%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:10.23%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;br/&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000584"&gt;7.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(608,612&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;796,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000585"&gt;5.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</maia:ScheduleOfWarrantExercisedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000574"
      unitRef="U_xbrlishares">1311117</us-gaap:ClassOfWarrantOrRightOutstanding>
    <maia:ClassOfWarrantsWeightedAverageExercisePrice
      contextRef="C_0001878313_20211231"
      decimals="2"
      id="F_000579"
      unitRef="U_iso4217USD_xbrlishares">4.03</maia:ClassOfWarrantsWeightedAverageExercisePrice>
    <maia:ClassOfWarrantsIssued
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000575"
      unitRef="U_xbrlishares">115000</maia:ClassOfWarrantsIssued>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceIssued
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000580"
      unitRef="U_iso4217USD_xbrlishares">6.25</maia:ClassOfWarrantsWeightedAverageExercisePriceIssued>
    <maia:ClassOfWarrantsExercised
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000576"
      unitRef="U_xbrlishares">608612</maia:ClassOfWarrantsExercised>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceExercised
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000581"
      unitRef="U_iso4217USD_xbrlishares">1.80</maia:ClassOfWarrantsWeightedAverageExercisePriceExercised>
    <maia:ClassOfWarrantsExpired
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000577"
      unitRef="U_xbrlishares">20520</maia:ClassOfWarrantsExpired>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceExpired
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000582"
      unitRef="U_iso4217USD_xbrlishares">5.00</maia:ClassOfWarrantsWeightedAverageExercisePriceExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000578"
      unitRef="U_xbrlishares">796985</us-gaap:ClassOfWarrantOrRightOutstanding>
    <maia:ClassOfWarrantsWeightedAverageExercisePrice
      contextRef="C_0001878313_20221231"
      decimals="2"
      id="F_000583"
      unitRef="U_iso4217USD_xbrlishares">6.04</maia:ClassOfWarrantsWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000339">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000586"&gt;2.8% - 4.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000587"&gt;0.6% - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000590"&gt;4.6 - 5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000591"&gt;5 - 7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000594"&gt;78% - 92%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000595"&gt;81% - 106%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:2%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:14%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:61.44%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:12.11%;"/&gt;
&lt;td style="width:0.94%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:12.1%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000630"&gt;2.14% - 4.45%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000631"&gt;0.36% - 1.27%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;5 - 6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000635"&gt;5 - 6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000638"&gt;71.9% - 87.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000639"&gt;71.4% - 81.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandEighteenStockOptionPlanMember_20221231"
      decimals="INF"
      id="F_000598"
      unitRef="U_xbrlishares">1924500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231"
      decimals="INF"
      id="F_000599"
      unitRef="U_xbrlishares">3983023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20221231"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlishares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20220801"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">1909518</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">1271413</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001878313_us-gaapPlanNameAxis_maiaTwoThousandTwentyOneEquityIncentivePlanMember_20221231"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlishares">638105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_20220101_20221231"
      id="F_000604">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000605"
      unitRef="U_xbrlipure">0.10</maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted>
    <maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000606"
      unitRef="U_xbrlipure">1.10</maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001878313_20220101_20221231" id="F_000607">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000340">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:46.85%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:1.04%;"/&gt;
&lt;td style="width:9.37%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.98%;"/&gt;
&lt;td style="width:7.35%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:0.78%;"/&gt;
&lt;td style="width:1.01%;"/&gt;
&lt;td style="width:9.06%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:8.31%;"/&gt;
&lt;td style="width:0.79%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;br/&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,797,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000620"&gt;8.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;811,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,545,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000621"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,773,706&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,449,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000622"&gt;7.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,804,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001878313_20211231"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">5797185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001878313_20211231"
      decimals="2"
      id="F_000614"
      unitRef="U_iso4217USD_xbrlishares">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000609"
      unitRef="U_xbrlishares">811831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000615"
      unitRef="U_iso4217USD_xbrlishares">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000610"
      unitRef="U_xbrlishares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000616"
      unitRef="U_iso4217USD_xbrlishares">1.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001878313_20220101_20221231"
      decimals="INF"
      id="F_000611"
      unitRef="U_xbrlishares">16888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000617"
      unitRef="U_iso4217USD_xbrlishares">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000612"
      unitRef="U_xbrlishares">6545628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001878313_20221231"
      decimals="2"
      id="F_000618"
      unitRef="U_iso4217USD_xbrlishares">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000623"
      unitRef="U_iso4217USD">9773706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001878313_20221231"
      decimals="INF"
      id="F_000613"
      unitRef="U_xbrlishares">5449715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001878313_20221231"
      decimals="2"
      id="F_000619"
      unitRef="U_iso4217USD_xbrlishares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000624"
      unitRef="U_iso4217USD">8804841</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231"
      decimals="2"
      id="F_000625"
      unitRef="U_iso4217USD_xbrlishares">8.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231"
      decimals="0"
      id="F_000626"
      unitRef="U_iso4217USD_xbrlishares">9</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20221231"
      decimals="0"
      id="F_000627"
      unitRef="U_iso4217USD_xbrlishares">5</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapAwardDateAxis_maiaJanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="2"
      id="F_000628"
      unitRef="U_iso4217USD_xbrlishares">1.80</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001878313_us-gaapAwardDateAxis_maiaMarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="2"
      id="F_000629"
      unitRef="U_iso4217USD_xbrlishares">1.83</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      decimals="2"
      id="F_000642"
      unitRef="U_iso4217USD_xbrlishares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="2"
      id="F_000643"
      unitRef="U_iso4217USD_xbrlishares">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20221231"
      decimals="0"
      id="F_000644"
      unitRef="U_iso4217USD">3447367</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001878313_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20221231"
      id="F_000645">P3Y3M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000341">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation related to the Company&#x2019;s stock plans are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:91.23%;"&gt;
&lt;tr&gt;
&lt;td style="width:57.7%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:13.02%;"/&gt;
&lt;td style="width:0.92%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;td style="width:0.97%;"/&gt;
&lt;td style="width:13.96%;"/&gt;
&lt;td style="width:0.93%;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,422,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,779,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;896,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,319,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,722,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20221231"
      decimals="0"
      id="F_000646"
      unitRef="U_iso4217USD">1422799</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="0"
      id="F_000647"
      unitRef="U_iso4217USD">1779185</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20221231"
      decimals="0"
      id="F_000648"
      unitRef="U_iso4217USD">896628</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="0"
      id="F_000649"
      unitRef="U_iso4217USD">943708</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_20220101_20221231"
      decimals="0"
      id="F_000650"
      unitRef="U_iso4217USD">2319427</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001878313_20210101_20211231"
      decimals="0"
      id="F_000651"
      unitRef="U_iso4217USD">2722893</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DefinedBenefitPlanTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000305">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;EMPLOYEE RETIREMENT PLAN&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to 100% of employee salary deferrals that do not exceed 1% of their compensation plus 50% of their salary deferrals between 1% and 6% of their compensation.&lt;span style="font-size:11pt;font-family:Calibri;"&gt; &lt;/span&gt;The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231"
      decimals="2"
      id="F_000652"
      unitRef="U_xbrlipure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231"
      decimals="2"
      id="F_000655"
      unitRef="U_xbrlipure">0.01</maia:DefinedContributionPlanEmployerSalary>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231"
      decimals="2"
      id="F_000653"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231"
      decimals="2"
      id="F_000656"
      unitRef="U_xbrlipure">0.01</maia:DefinedContributionPlanEmployerSalary>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231"
      decimals="2"
      id="F_000654"
      unitRef="U_xbrlipure">0.06</maia:DefinedContributionPlanEmployerSalary>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000307">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patent Licensing, Sponsored Research, and Patent &amp;amp; Technology Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;THIO&lt;/span&gt; - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#x201c;PLA&#x201d;) titled &#x201c;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#x201d; with the University of Texas Southwestern (&#x201c;UTSW&#x201d;) to license patent families for a specific compound (&#x201c;THIO&#x201d;) from UTSW to MAIA. The agreement, as amended, has a term of 20 years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones. The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and 2.5-5% on net sales above $1,000,000,000.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Also in December 2020, the Company entered into a second license agreement with UTSW titled &#x201c;Patent and Technology License Agreement AGT. NO. L3648 &#x2014; MAIA Biotechnology&#x201d; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of 20 years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $1,000,000 and $50,000,000, not to exceed a combined milestone payment total of $112,000,000. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore no payments are due to UTSW related to the milestones.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The agreement requires royalties of 2-4% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and 2.5-5% on net sales above $1,000,000,000.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%). The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cemiplimab&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;five years&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in the event that&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; neither party has terminated the agreement&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <maia:TermOfAgreement
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      id="F_000657">P20Y</maia:TermOfAgreement>
    <maia:MilestonePayment
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000658"
      unitRef="U_iso4217USD">1000000</maia:MilestonePayment>
    <maia:MilestonePayment
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000659"
      unitRef="U_iso4217USD">50000000</maia:MilestonePayment>
    <maia:CombinedMilestonePaymentsMaximum
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000660"
      unitRef="U_iso4217USD">112000000</maia:CombinedMilestonePaymentsMaximum>
    <maia:PaymentsDueRelatedToMilestones
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231"
      decimals="0"
      id="F_000661"
      unitRef="U_iso4217USD">0</maia:PaymentsDueRelatedToMilestones>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130"
      decimals="2"
      id="F_000662"
      unitRef="U_xbrlipure">0.02</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20181101_20181130"
      decimals="2"
      id="F_000663"
      unitRef="U_xbrlipure">0.04</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="3"
      id="F_000664"
      unitRef="U_xbrlipure">0.025</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaTHIOTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="2"
      id="F_000665"
      unitRef="U_xbrlipure">0.05</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:TermOfAgreement
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      id="F_000666">P20Y</maia:TermOfAgreement>
    <maia:MilestonePayment
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000667"
      unitRef="U_iso4217USD">1000000</maia:MilestonePayment>
    <maia:MilestonePayment
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000668"
      unitRef="U_iso4217USD">50000000</maia:MilestonePayment>
    <maia:CombinedMilestonePaymentsMaximum
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000669"
      unitRef="U_iso4217USD">112000000</maia:CombinedMilestonePaymentsMaximum>
    <maia:PaymentsDueRelatedToMilestones
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231"
      decimals="0"
      id="F_000670"
      unitRef="U_iso4217USD">0</maia:PaymentsDueRelatedToMilestones>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="2"
      id="F_000671"
      unitRef="U_xbrlipure">0.02</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesUptoOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="2"
      id="F_000672"
      unitRef="U_xbrlipure">0.04</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="3"
      id="F_000673"
      unitRef="U_xbrlipure">0.025</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="2"
      id="F_000674"
      unitRef="U_xbrlipure">0.05</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:RoyaltyPaymentsOnNetSales
      contextRef="C_0001878313_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_maiaNetSalesAboveOneBillionMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaUniversityOfTexasSouthwesternMember_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20201201_20201231"
      decimals="0"
      id="F_000675"
      unitRef="U_iso4217USD">1000000000</maia:RoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaPatentAndTechnologyLicenseAgreementMember_20220101_20221231"
      id="F_000676">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).</maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription>
    <maia:TermOfAgreement
      contextRef="C_0001878313_us-gaapTypeOfArrangementAxis_maiaRegeneronPharmaceuticalsIncMember_20210201_20210228"
      id="F_000678">P5Y</maia:TermOfAgreement>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000308">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;INCOME TAXES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company's net deferred tax assets consist of the following components:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,013,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets before valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,229,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,027,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,229,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,027,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $15.4 million that may be applied against future taxable income. The state NOL carryforwards begin to expire in 2030. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to 80 percent of taxable income. The Company has unused Australian NOL carryforwards of $0.1 million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#x201c;R &amp;amp; E&#x201d;) tax credits of $0.1 million that begin to expire in 2041.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The use of the Company&#x2019;s NOL and R &amp;amp; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#x201c;ownership change,&#x201d; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#x2011;percent stockholders (or certain groups of non&#x2011;five&#x2011;percent stockholders) over a three&#x2011;year period occurs. After such an ownership change, the corporation&#x2019;s use of its pre&#x2011;change NOL carryforwards and other pre&#x2011;change tax attributes to offset its post&#x2011;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an ownership change occurs and if the Company earns net taxable income, the Company&#x2019;s ability to use its pre&#x2011;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#x2019;s state income, franchise, or similar taxes. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with ASC 740, &#x201c;Income Taxes,&#x201d; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.&lt;span style="Background-color:#FFFFFF;"&gt;The valuation allowance increased by approximately $1.2 million and $2.1 million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred a pretax book loss of approximately $15.8 million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $15.3 million and a foreign loss of approximately $0.5 million. The Company incurred a pretax book loss of approximately $12.6 million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $12.5 million and a foreign loss of approximately $0.1 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss on extinguishment of debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other nondeductible expenses/(nontaxable income)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#x2019;s tax returns since inception remain open to examination by the taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000342">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company's net deferred tax assets consist of the following components:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,013,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets before valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,229,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,027,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,229,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,027,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000679"
      unitRef="U_iso4217USD">3294955</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000680"
      unitRef="U_iso4217USD">3013721</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000681"
      unitRef="U_iso4217USD">1183941</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000682"
      unitRef="U_iso4217USD">1800935</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000683"
      unitRef="U_iso4217USD">1499300</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000684"
      unitRef="U_iso4217USD">244848</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000685"
      unitRef="U_iso4217USD">109673</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000686"
      unitRef="U_iso4217USD">6724</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000687"
      unitRef="U_iso4217USD">102825</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000688"
      unitRef="U_iso4217USD">6229768</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000689"
      unitRef="U_iso4217USD">5027154</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001878313_20221231"
      decimals="0"
      id="F_000690"
      unitRef="U_iso4217USD">6229768</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001878313_20211231"
      decimals="0"
      id="F_000691"
      unitRef="U_iso4217USD">5027154</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20221231"
      decimals="-5"
      id="F_000692"
      unitRef="U_iso4217USD">15400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231"
      decimals="-5"
      id="F_000693"
      unitRef="U_iso4217USD">15400000</us-gaap:OperatingLossCarryforwards>
    <maia:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20220101_20221231"
      id="F_000694">2030</maia:OperatingLossCarryforwardsExpirationYear>
    <maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20221231"
      decimals="2"
      id="F_000695"
      unitRef="U_xbrlipure">0.80</maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapAustralianTaxationOfficeMember_20221231"
      decimals="-5"
      id="F_000696"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20221231"
      decimals="-5"
      id="F_000697"
      unitRef="U_iso4217USD">100000</us-gaap:TaxCreditCarryforwardAmount>
    <maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear
      contextRef="C_0001878313_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20220101_20221231"
      id="F_000698">2041</maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001878313_20220101_20221231"
      decimals="-5"
      id="F_000699"
      unitRef="U_iso4217USD">1200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001878313_20210101_20211231"
      decimals="-5"
      id="F_000700"
      unitRef="U_iso4217USD">2100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001878313_20220101_20221231"
      decimals="-5"
      id="F_000701"
      unitRef="U_iso4217USD">15800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001878313_20220101_20221231"
      decimals="-5"
      id="F_000703"
      unitRef="U_iso4217USD">15300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001878313_20220101_20221231"
      decimals="-5"
      id="F_000705"
      unitRef="U_iso4217USD">500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001878313_20210101_20211231"
      decimals="-5"
      id="F_000702"
      unitRef="U_iso4217USD">12600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001878313_20210101_20211231"
      decimals="-5"
      id="F_000704"
      unitRef="U_iso4217USD">12500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001878313_20210101_20211231"
      decimals="-5"
      id="F_000706"
      unitRef="U_iso4217USD">100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000343">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss on extinguishment of debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other nondeductible expenses/(nontaxable income)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:12%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:67%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000707"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000708"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000709"
      unitRef="U_xbrlipure">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000710"
      unitRef="U_xbrlipure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000711"
      unitRef="U_xbrlipure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000712"
      unitRef="U_xbrlipure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000713"
      unitRef="U_xbrlipure">-0.015</maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt>
    <maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000714"
      unitRef="U_xbrlipure">-0.039</maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000715"
      unitRef="U_xbrlipure">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000716"
      unitRef="U_xbrlipure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001878313_20220101_20221231"
      decimals="3"
      id="F_000717"
      unitRef="U_xbrlipure">-0.076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001878313_20210101_20211231"
      decimals="3"
      id="F_000718"
      unitRef="U_xbrlipure">-0.168</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001878313_20220101_20221231"
      decimals="2"
      id="F_000719"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001878313_20210101_20211231"
      decimals="2"
      id="F_000720"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001878313_20220101_20221231" id="F_000309">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;SUBSEQUENT EVENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of Common Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 16, 2023, we issued 18,000 shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement&#160;&#160;an additional 18,000 shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue 22,500 shares of common stock on March 8, 2023 and an additional 22,500 shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for 180 days, and renews automatically until we provide written notice prior to the end of the term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of Options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From January 1 to March 20, 2023 we issued 638,710 options at a weighted exercise price of $4.10 to employees and consultants.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001878313_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230116_20230116"
      decimals="INF"
      id="F_000721"
      unitRef="U_xbrlishares">18000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230416_20230416"
      decimals="INF"
      id="F_000722"
      unitRef="U_xbrlishares">18000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308"
      decimals="INF"
      id="F_000723"
      unitRef="U_xbrlishares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230306_20230605"
      decimals="INF"
      id="F_000724"
      unitRef="U_xbrlishares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <maia:TermOfAgreement
      contextRef="C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaMoneyChannelNycIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20230308_20230308"
      id="F_000725">P180D</maia:TermOfAgreement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320"
      decimals="INF"
      id="F_000727"
      unitRef="U_xbrlishares">638710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001878313_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221221_20230320"
      decimals="2"
      id="F_000726"
      unitRef="U_iso4217USD_xbrlishares">4.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;T$A'II!^;I[G4!?47PQN$Q9A9G(,JZ,#0QM$,\WI"BE*LV(X1 ?4@[M),2
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MD?BR=KEG$*]RI.Q*:$CY_?7QH=^%CO9 ,18&+CEZV#UF(0MB/W#6 F>CP-_
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MWDSPY/7%)[[9:O-B.I_MZ(8],?UY]RCA:=IZR7C!2L5%B21;WTQN\?6"!&9
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M[(Z$Y?\3Q-3<T&&Z[W">'F5<@CACY^-3EB9IRI[62W;R>72$]WS8N?/ ._F
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M^X>W+\K\Z>.%>"'<Y&69/^Y?/J3);;K=+5#]_"[/R]<OKBK_:[[]?=_'I_\
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M 9*"]UN;TNZH5=B7YQQ[P01MVC6RG=>44D,L3YL1G[1-,80$SCUX"%R$2L]
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MS)[VDM$XWTOFF[[UW2]LMKT73_%^3W=$_7'MDF0V[B=<<Q]7[5 /&"<# CB
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M[MQZ\+SB5V6$8MV8G-A:4BB0@'>:M:B._;)_64V>]O6Y'-J\8]%O^9V<3'8
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MM+EAUV4*Z5. ,=+I.84=IXOP1<0K2$8LXCX+@S!\ 2_J-48.+_H.WDKLQ;H
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MFDHDK346!LND23!R*"-H2XLOF#"L$MJ2(\%*5;[_AEM09I+,CCJH"E&.V.J
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M;3D^^/;'SYR-.^'0IQNVV^88T#_M#U'+YNSPN+PY@7T2>B-11@$9F@:CV63
M='.J:6ZLJMQ)8JTLGDO<98X'0="T -]G2MGNAAST1\OS?P!02P,$%     @
MY8J$5IKJ>;< !   *@D  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
ME59M<^(V$/XK.^[+)XH=A^32%)@A)+V[MKDP2:Z=3J<?A+T&32S))\DA_/ON
M2H9 )C#3+Z"7W6>?9Z5=>;@R]LDM$3V\J%J[4;+TOKE,4U<L40G7-PUJVJF,
M5<+3U"Y2UU@497!2=9IGV7FJA-3)>!C69G8\-*VOI<:9!=<J)>SZ"FNS&B4G
MR6;A7BZ6GA?2\; 1"WQ _[6969JE6Y12*M1.&@T6JU$R.;F\&K!],/A3XLKM
MC(&5S(UYXLGG<I1D3 AK+#PC"/I[QBG6-0,1C6\=9K(-R8Z[XPWZKT$[:9D+
MAU-3_R5+OQPE%PF46(FV]O=F]0D[/6>,5YC:A5]81=N<C(O6>:,Z9V*@I([_
MXJ7+PX[#17; (>\<\L [!@HLKX47XZ$U*[!L36@\"%*#-Y&3F@_EP5O:E>3G
MQS.QIG,NGF!FC>\R1<.%%6J8>@K 9FG1@5U%L/P V$D.MT;[I8,;76*Y#Y 2
MLRV]?$/O*C^*>(U%'TY/>I!G>7X$[W0K]S3@G1[$FWNXEJZHC6LMPC^3N?.6
MKL:_[ZF-6(/WL;A<+ETC"APE5 \.[3,FXQ^_.SG/?CG"=+!E.CB&_G\/YBC8
M^U0'?9A-_IY^NIG^#K/[N\>;Z>/GNR\\_'@_N84[#;\)W5*E;@Z ?OT286I4
M(_2:2K) JJ@2!#@LC"YA-IO!'T9HD#I8"F5:[<%4\/UYWCO+LCY\I8MAPZ9'
MJQSO;;QZY$:+Z#S5:F%;I-V(0\W$>:%+J1?06*D+V8@:A ^;5GADF*S_\\4/
MT!"ZT+I5?7CL@O F&[ZR<^!7!M8HK",S$W;QQ:-FQ ZV9LM. #EHXX%:X(($
M:YBO@\G#U60_(V1GYK5<$*,2O*$Z?2+@;RV155P7]1H:L::6YH/P'2F4O(WX
M'LQQ(;5FL0XYG(HU55FC0KBR4[PKJ@=$5-9AC7I5:Z5?!\.8AUTU2JPI!" 1
ME?,:6=96&CH'LH+6D0!>9^ZR6C,7?*&'P-&A,%E#<?9V"PJ(5@H05%4*?0R[
M24S "UDFDG;G* [$V/?>7K2JK>L]JI0$04L'[@?QC!>I#.-6-T*^YGESN78O
M[1?SC&I.ROBV1Q)OPNUY1.:RRU7)O86N$;%HI5OR,3,F43"V%+I :NU^"9.'
M*0P^9#^=93T([>C6E 12""[QF-V;/1#7BU)HCU+AZ+GI':N*G:L$*W):T<G0
MU2;RU<&ZC!'>%#>Q#L6]H*>=D_5&FC>>U%/L#B/D@"&XKNB@V9G:=\SGIH/T
MX;W6F.Z\7PKM(KS2#@IF&9^R[>KV0V 2W[]7\_@5<2OHN"B--5;DFO4_G"5@
MX\L<)]XTX36<&T]O:Q@NZ6,&+1O0?F6HW783#K#]/!K_!U!+ P04    " #E
MBH16C_Y"N?8+   3-@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6SM
M6UMSVS86?M]?@5'=K3W#RKI8LM(DGDD<9S:=;>.MTW9V=O8!(B$)$Y)@ ="*
M]M?O.0?@12(DVXV33G?S8HLD<.Z7#T?BL[72[\U*",L^9&ENGO=6UA;?G9Z:
M>"4R;OJJ$#D\62B=<0N7>GEJ"BUX0INR]'0T&$Q/,R[SWL4SNG>M+YZITJ8R
M%]>:F3++N-Z\%*E:/^\->]6-G^1R9?'&Z<6S@B_%C; _%]<:KDYK*HG,1&ZD
MRID6B^>]%\/O7I[A>EKPBQ1KT_K,4).Y4N_QXDWRO#= @40J8HL4./R[%9<B
M39$0B/&;I]FK6>+&]N>*^FO2'729<R,N5?JK3.SJ>6_68XE8\#*U/ZGUWX37
M9X+T8I4:^LO6;NWHO,?BTEB5^<T@029S]Y]_\'9H;9@-]FP8^0TCDMLQ(BE?
M<<LOGFFU9AI7 S7\0*K2;A!.YNB4&ZOAJ81]]N)2Y;="6SE/!?M166'8-=]P
MN'IV:H$\+CJ-/:F7CM1H#ZGAB/V@<KLR["I/1+)-X!3DJH4;5<*]'!VD^$K$
M?38>1FPT&(T.T!O7RHZ)WG@OO;EEKZ2)4V5*+=B_7LR-U1 8_PYIZVB=A6EA
MLGQG"AZ+YSW(!B/TK>A=_/6KX73P]("D9[6D9X>H/\PMATE-^G^Y?/OC+U<_
MO7OS\N]7[,>W[ZYNV/6+?[[ J[U\F#2F% F3.1A_^(2]R=GW9;JABXC9E8"M
M6<'S3;60;]&ZUBJ#!TIOB"RSRG(0;,F.AH-H,!C #:9RX)(G\E8F)4_9,1+M
M$;-=J7HG??8.G@8?LKG22,@*<(-EW++9UZP0FO$\+[.(K;EA96Y$#!Y/X%+:
M%0B+U2TI4Q <,KO4TFY8PH&86C"(.I'-@8"/O.$AYC%$/)0^- "4F!+2E5L9
MXVU81Y5K(9"!B*#NQ2NP' @(1D5EQ:W([98M81M51^OH7?U6HF"O9<[S&*P7
M,= %2@[Q\T3X4@L!5=)&K-!2:;2LW2?N-R:@N',G%&QC.;@#G 2$@%\!3H$;
MC6G7JDR31DF>IANOJ"5Y@/,UU%2AP=#LQJKXO7.J67'8CZ;E+$ZY@8_0%H26
M[F91[S&T!VX%X@O4!5ZY+^;.BUT+G=Q_-Z[:W>X\O7L7B-16!P=PB+B<LX5,
M(*XUSPUW5+>4:CTP#;_&L$6I"V4HWC27!KG$O)"0)1$^,R7'T%!LO9+Q:DLC
M#>$)C<RPI59@2KZ$ %ABZ!9:Q4(DQ#Y7EJ4"'D.\Y>QH@CE'>7<\%PO,%Z34
M%EZ+E*).?(!V;X Z>CY6QAJ?>ZV(!BUB 4JE*9N#=P4EW73R=65[][R^V/9N
MXQ"*7A0&HQ?HPMVN/ZX@$Q/H)NRZM.RU2R62IS)'(B Z,_(-Y192Q3NF5LDG
M1,>KC4:1B]._?C4;C09/0RSIT?#I"5M#*I!UXU1P#0E =H)^(M+-+L=PQ5B!
M44%]:#PE*DX$,FC?AO90G$D73Y@O"434+4?D0F[0Y#V7L4'38+6;RT6I8Y)D
M 77X@"S(VXB":U@,\F>"8U],T)\++C6[Y6GI&+<$8:GD<YFB,5?(38@<:MO<
MB-]*T ?)</U>)-]:]2U]LDQPB&$M"@6\L;P *96XK(@A/I<0;A /#4>,<;7,
MY7^:0(':9"E0T"P 24%B3"V?L/LL0::D.H44=5(E<() ( $@H$KO 5X[+ZAH
MT"!M&E B>(;ZH<PEY3.5^,5"$.YLJJBF-@-^<&57RR5$9$HQ6^5,T%E]Z,&>
MA$]2Z* '?$LM%X0Y&I""1]/!.5LHQW4#L<L$HK1.MQO1:FQ[$9C$%$[\=!-2
M&E<ZAWG!@XZ0]Y)R2.4)FZ/!XA=[*\]YBA<5@VW^Z&)4SX3:=J-(G[V"1N<]
M<D_5O3-YE8D[BF?XSV5Z9=\Q()L=B]T/78T&E7SX.0BN#D KT\)6TP9<W7+(
ML1(S %J%59IZ[DJE$-TF@KMQ6B8.C_D]H.,=7.H,@7IAL<T=P^$CK;1U<O=(
MG8[>O1-XJE6Y7 ',@,YI #R0MA6T"FWJ KOIQP&['_BF=O5!QAP;9 CFT!H"
M.@VF:;D+X%6GR]RXA<>P ?HE5%A?SQI,A+CO$Z.BB)6%+Q;8JU NXMP5=R-%
M2H'AT$4;4P O\2%&4 $71^P1,,4^\Z=&D0\Z5H]5E@'AH/&9;_X^R+]A]<F?
M=#]FDIW@*84:#BH#C*W& S>VU?F&Q(?P,@[*@?YE <T-6 K"?"*'UAQ#-V%J
MG4,4 O<,M2:$-1E\W8V%-J2^5=3Z*%HE94_(=1 ?>HFT-1A/Z27/?0F*\-:Q
ME">5EE9F%--5D&.Q<;9IHRR5MW&;"\&Y"-L/(<[P_*GQ% A,K3AT+NSMH(9O
MI!2\')AKG'<XG[I8%5"G#1;C5GPW84JGGRZ^NVS$NT;8:,)@$]JKQYGGGP9G
MWA6._ISG3C"E$<X^/(XARK"CD]8 $.JB0T''/;[QSJ9PV[;ZUI&.SQ7BO% 7
M-5N@=T6;'@/X=M(A<H"T4J-[D W6_0/0V=38V74=X9!?C0J"-G\8S Z0V NS
M'P-E>_G".#L<0\3]?P==>PM\&GQ=)RVA+.HVPW$''S9@.6CQ8R-\),Q./@-@
M#\G0!\3AT^@5TD A=D#)P220KI1B D@41,70/*C,(M]C>=)IZ.P?)4#!A0R4
MN*:#4 (@=RI1[0%#" <I>*37THC=48]P#)J.5G$ %MM(:_^Y):AV?208G4?C
M\XE#U\-A-!F-[W. &58HO@/'7[4#P-Q7"@_O[SYF=-C=Z] Q/'S4,-MGC=DX
MF@YFOD@1 L[5703N<^CKLU^Y!N@&R]]T<0E5F(.A'CRUT#8'QT!43_ZX)E)Q
M/$'-> SAA!@R2:@N0X(U*"5N0YOM_@G=LL6%<B#<#_S8#"N1EP79%E# H<SZ
M=@['BKFCLH?W=ML%S)B5J95%NJD<W5#8=Q!P^8:9184,Y:,\;#5:KZ'3"7!D
M=^*]0< 9837D",J%CC%!'1Z"O,3JY'IC!TCA^8F4@YK7U/\N\^[TX=VNWWY_
M"Z@<</_Z/YU$T^E@JZC?OQ?TV4W=0-$PU:Z(=6+1(5YJNI^]S_X!_>F> XKA
M?6O9QPPOH-@_^1WCBV@V'4?C1QU@#(,##)>X-8;ET)\<)CG\O1>>6RP\X2Q5
M>/97.X?$RZNWK; >G; ZTP)B0&2"\?>/1"BOFY$(9IT[PH6'(G!4@+A%.Q)^
M?2WFNN0@^G!"[AQ70QOV?9F#2#-W]Z" 7T8G=X].'F=R$K3^)YF<R"]SDS_K
MW 01XAV#DSB@_P.G)GM#\<O4Y)--34(V?^#4I$OB#YR:!&/HR]3DHZ8FHV@V
M.C0W"=F\P2+3SS(W"<CPD+E)2(4_[]SD4=#9@7%+R%K--[!/GD2#LR?5N./C
M1BV/^X6K"7[C.AF.H\%XLLO[ 9.,@#T>/LD8?LI)1J!&?YED/,XD8_B'3#+&
MD"QG6Z.,Z;Y11K TWC'*&/X?C#*"=KG<<GRWS/V,H=D)Y>ZZ0-%PT#T5G21"
M&]6_9< :%N  >W;.@SN'09;)-"54V2X\3=/ L\?1+!HTO].0UASXN2:N!X2M
MZ4>Y<%WF!9>M7W%B92E F \R<[_Z.AJ=.=(["''W?!/\ 4^T=R!<E?90@\8^
M.,3A?C0:S>XX5FV7S)S=B,+Z+C*HNI#%,\-N@:"Y81_TJBM%?^LX $;R/:5J
M=7<7#SJG4:7"Q"FE66$*;--MJD?>MC38N3^NG,U2# FU2RC:K:#1P?;K^(9)
M[=>@-<): ]@0WZK%HEI=YDVF;B=Q-VS&C3I]]B+XY<@0B>(7%>Y@$A"F%<>M
MSOTVY.8H=/3ONHSB<7_P1:TCG]]1=W3?[>NDWT\J]].X&$_T"_D!9TWUS[NW
M:&*#\GV-6B3&&O=;[N[2MEZ[TQN;[H?OI"05QFL:36N0<*@UAP]=GZL7^W9Q
MT%C3V30ZFSW99Z)J<+<C;YW\J X 84)DMIXK)W[X$/A-VFQO,$?L+)H,SKPR
MIB5WTVHK,9)^Z"V0T]:+.C2RPM>1L,2!T]P[._7=^HVG%^Y%GV:Y>UWJ!ZZA
M.1J6B@5L'?3/)STW6JHNK"KHM9^YLE9E]'$E.. P7 #/%PH<X"^00?T>V,5_
M 5!+ P04    " #EBH16MS;F!5($   B"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6R=5M%2ZS80?>]7[+BTW,YD;,<!2FF2F0#)+3.77DJ@G4ZG
M#XJ\B378DJ\D$_C[KB3')!!XZ$MBR[MGSY[=E31<*_U@"D0+3U4IS2@JK*W/
MDL3P BMF8E6CI"]+I2MFZ56O$E-K9+EWJLHD2].3I&)"1N.A7[O1XZ%J;"DD
MWF@P354Q_7R.I5J/HGZT6;@5J\*ZA60\K-D*YVCOZQM-;TF'DHL*I1%*@L;E
M*)KTS\Z/G+TW^%/@VFP]@\MDH=2#>[G*1U'J"&&)W#H$1G^/>(%EZ8"(QK<6
M,^I".L?MYPWZS.=.N2R8P0M5_B5R6XRBTPAR7+*FM+=J_1NV^1P[/*Y*XW]A
M'6P'QQ'PQEA5M<[$H!(R_+.G5H<MA]/T'8>L=<@\[Q#(L[QDEHV'6JU!.VM"
M<P\^5>]-Y(1T19E;35\%^=GQ7%1UB3!9:432V@+5&6:-;33"]%LC[/,PL13'
M62>\Q3P/F-D[F/T,KI6TA8&IS#'?!4B(8,<RV[ \SSY$O$0>PZ#?@RS-L@_P
M!EW6 X\W> <O9 ;_3!;&:FJ,?_<E&2".]D.X83DS->,XBF@:#.I'C,8_?M\_
M27_]@.!11_#H(_3_698/,?<S/HF_FU]=WWR9PN3S[71Z/?W]#F9?;V%V?W=_
M.X7I'_=7=W_#E82OW*H%:JI _Y<>V +A0E4UD\\@C&DP!P8FD&8[I)>!- ;%
M/T7SR6SZDE?TDS<ZR(Y[:9K&<'A'P+LF-/KD2X2!-30-S H.7,E'U'YCL HH
MFR5J31QH7/@#".GYX:/S5DM@<A-^*2237,A5#%?+G23PJ48M4'(7!TI!]KGS
M\" ]8,:-.@F:A]P+5>8D1L6>0=4A413T06]3HT6--7OV61 ISDS1H_FVQ=:Z
MVU)R:&JW0\$C*QL6=BOKXUC: %T*IN%%X!+#?;#-27=5-M[Z'9;O"?F&50Q.
M]RWJM18<B6I9P@+!T.% A$[2'QP7AQR^=R^O] \-T9:!D3@^/N'2ZMM*["FY
M*1A%MJAIQV,6@SRMP [312#W($W!7$[[Q':"U*U+UY6'Q@.;&"X;=.UC0^J6
MR%#]A6L 4I8+"IR':ODDE74YL');)B;SMZI1T#6=,N[?.;[4M"UR.Q&O>HSR
M4$V9 XD$BO-&]T J5V2N&OJZAY)!6")S6 8*"K9 =.<D5SK?4I_ST.&4G:-*
M+2-R#]-6@!(REA:<-*0)33I9R?;,[+(WK/1B$UA%Z]V<T7Y,NS(-6+NCSC9E
MW6K #9/*)T(@[;3#FD@']:PG3+4X[F7I:5?2G1$]-+O1Z6&.-1%WN](@]6=#
M/W333G=NG +F;F^^;D9/Z> T[K:BMR-!!N1%JA';=B"\@V\T'Z3G>O'@*#[=
M6HMAWZ&0;)W;%>J5OYVX-$FH<(1WJ]T%:!+._1?S<'NZ9GHEI($2E^2:QC_3
M?4.'&TEXL:KVMX"%LK2+^L>"+G&HG0%]7RIJ\/;%!>BNA>/_ %!+ P04
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M,S#P8!0 1TH$UBK ?UE4'S)7WD\;K+ELK^9B ^_YU(0$AJ1%I*FOU'4Q14%
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M<M<EOSI3'@V#Z"!L\'!_T \.^\-6/PJ# >PH9D5?BW>ML6N)3>OUNZ.@_VX
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M%P7U5+QX!2\K;9XSU<+ ?""6/B"3MNA@;RV%GDFT.10-="5H6^=>I:0ABH'
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MPA=E?BFG5 -5T?A^-TV;TYKI"+@G"#56H_' 'T]GTFSC=@G\7SHH$9,!8A3
M^R36F92AA.)P2=-@664G+6_WEN;941W;J8N#1U2+.$ 8?)(KL./#2+:G1X_5
MWY\82!9IK$.9ON[]?,J>55H*6I)&J!5SDWWDSAFKTVY2LNTVB8%M@@X& _\<
M#\%X>*[=W=]_KRD+IV-_1-Q<9](P#N<CU)+@%#.2BQ 5RJSAI:8)8<"]:N-<
MF?UQHXHO:"7K2-F?JIP5:QB,_<G@U%0$_);'9A(GYY A_!+9MI&*Q<A:&<AA
MR'UPP&F2,.J;/$,.*@3@_J&#45L>:N80;-NJ0.(AM:+VK)"[5G;D5VVY23W
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M)7H"<Z]GN 4A/,C)^#TPZ7BD3SQ?G^B?0^VNECVS<*O%#UYAD],/E%10LZ/
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MXLN/>!-LQ2\<$AN"+?@R5S)3C@[@]Z7%PT1S0P:Z-U#G_P=02P,$%     @
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M-XIW7^M9P[_LRA2I8)E-GY[F9].+K"7#(WM-BU[1<B@&*#[2M-E7%V0T&GF
MN;=HB),@H="Z%/&8YJ=GI_F3IQ-B&AB;D>.I6R4A4&';+NY439L0*'VK4L**
ME+#)))],)G^1KHN+_.+B8KAO&$>DDX@L006-^L^^(DK.1?6<4/_\K^M7V>6*
MA)D,9=;31HODD&G^B(DWJQD%3@]ADHZ==1Q,)/S-3TY.\-^AE3RY?R63DS"0
ML[>F)O4D)5GW,XJ$Z*&Y!D^/LW=#LSNZ[3 3)=D>VA\:XO0_0V+^Q(VS=IPB
M1]0H,LF=R*W8"Z^ S-#;QG1P09=S^H=THNP+5E:2J,<G3_/)V0D_S_;"M&T/
MCR4"E;-Q"02P&>$Y'1]8X(8$W&HB_JN+_.3B-#\_/3D^8/Z?!O/_]* -_\%B
M*HH/R)%*I&9*KX]C'N'+1V/1@BOD760_<*\772JRM3.M:^*37M/6E9!UE2VL
M>Y_GH?3"$#MOEX8L+XR07JTKB2=H2DJZ*A^)TBXK,J).F]GITQ?MW"DZ?9WZ
M#2>G-=(8A#)]TW)\,'-QEZCE_:LH+8W1A9  ,JS*/TB^Y6N.C59(@XC6EM*B
M1!;ZCDTX3=HMR5[W6##L:+>AR6V&27?\%_L-L*K1^"&ZCGS$?^VX+S &HZ1.
M6.UQPY'0)!R<G#UK!]ZUL?UBN1L?D,ZT$FW=&SBH-:G)G:%DDL)0Y_(GK*@K
M4U68A;:*E\0A 'Z K[I1%1C,G%HA51^C5%SG3FQ20RF'E-S27/QY](B)"7+.
MD72=YJ35T![9+1]YG/V^--7NAM'.=A9&NJ+5L;2S8QR;Q9/GN1I,"C'RD'L6
M/WP[.CU%W!5+*N\T:4[MG7E#[@%1@7=[8+-MV(U8ISD;?L"2!5\X 2I[B<[Q
M;*TY!(IR4KH0.Z6[XY!Z3'.&_"<G!C5:4#1 2;76HC@DE+PQ,[V?:\*9W'T!
MSN38*"R1="GQZDC4&[A49#LT-PF&D3"]HRE!7&E[XJN:D6:.BM-8  5MVC)9
MVPQ2[#[V<R)33$K;Z_*0U3\+5O_LH)U^0T07G6-^=O7NMS<OCR87V7L2$KV"
M+R;2*/9\MS[D"O[#4\#M^\#O](1-P8D(P.^V(8__(]EQROD&R(+/[W[_\5U(
M[R E/8='Q/3*SHB/2WF56-DL*'*"DA6J%V.N2*5O,P -II; H2&9N3%-3V+=
MF 5M!CMT^O;W?JDHO;ZBG5/9UZ#,31]6]Z[O9N1O/B;$B)MI3/N1 WP)?&BS
M:^55FB*5OF;-%8<E<SNTT"V!#</&NKQQ3;+$K!4"CRG9I4BT(>^7,.W'=UE1
MD;<S<Z/+X29X,D4RUVY+<L;IV,,RR61JD!L7]&0+HJ$GMH6Q]#2) YSWI'YF
M?+O#3%X9F GZQE8WK!?N>6\6V,F1I[=-Q^Y!.8](SEU[_==MQYY DB#,O5(+
MXI]DVTK4TJ]); .'$4[@HO-^<R^M.:P+\BD>0&68MH%BJI+B,F1$%*L5G1\Z
M*BZ-(,8GIX#")<EB@IV[D67Q^A/?&U([?HC<A6:]5PZ R2BB-? 42+<@1P.>
M.UE?;RG8?42EN9JI2XI*&D<J7")15! A/]#\M=LI0X1@ WL?,NT1+2?YCBQ:
M\-JR#X%E[)N9 " LY+R[6"BVUQOQP38+G]O]L[G%CK(U'^<!\3JP88?S[VJ6
M1XQ9D&5C+*LE$>.PD-:@.%@@7\E( J4K," 4._HHU.4VQ"K:)"M:Y9T=C(TI
M*#SMPD*.&BV1UHITC0C@O4"T*,%;\?&HM+=(D"6 2-CE\ [LB8<M)'?8D)^K
MU 9&+"AQZ5/9J%G1 <>I:7@(/86MK?5!L&/, =]S'GS/^4''\ +1.J9-0> Q
M__(%P_R'<@S#&!1% ARB,-3XX?CZ."/GP>G8!E]3? L?$Z']=81<O5_BMWZX
MO'SOTVO:#/=5\NDWQ]F_;$^YJ>TK1.U*-*<T;=&W7,>!,BER%ANLN;,+C=A$
M"&M[27KN665P1$[02'8D/VIT9S\UD=D':B:!T#]:T@ +%I' TC@IQ$DFG8QQ
M@JP(66&DF>YN.?K%AV3K%CL@:;)9NC(K^&8*B'C8-*/" .!>Q>ZJ)0]?D,5'
M8 $]5]E<F29;IW(3M$"1SG6L*)\N-XXM!R.SBZ =%P?%^EHO.-5_4TOI<(]N
M?/8@/M BIK;RK<242.RP3V02H#5DI=R>4A; B0Q)-=C" :_8MA9: LL,%I/X
MP +&>5 (N"$G(;@DTB%*PWKY;K81F&QI]#P!-DM=&(CYT4I]Y,R)/V';MR3N
MD3, !%)@2MHSLLF% TZ1RP/$T0W/7Q=;"*<7^NT@_3 !^>@[5_S.JSO*J3F#
M?C>GC!@/WZ#B.?K*5E9-!*H%_ =$/50-88I;9!PZ(<AM4? F,GYXB;8'O <X
MY($B5UL1.V2!0L5PHB.3TGGDU2#:M%!\BN\<G.SJ* ?$=W(2"Z,G!V7O@X35
MKYS['LT</G,(WE,QSFH0=&SG7I^LNX ++ LMG'\T\##*)&,4%<!LR(8QXT@&
M(1LA*@GRUZ_6LL,<>BJ)!]D^KL2H230;JTQ[K?/ ;;%Y%F%>D<LF"8G5Y$B#
MJ4?Y,#J%&'Z?@D2=W,)*<P>9VG44W%O5(.,&F%\43:\JD1JR"**,\%FMYOPC
M$47F&X>NC*;%2D"<&VI]ZV$ LD2:8:M.W3F4SI?;]G,=)BQD+;[V SB/YHNP
M2E+2X1%NR)E8Y'?L1O&X;>!^*D.D,[PS8]RPI00-9BQ"YX5IBGX%-*#0#IY(
M8D[15HB5Z"N'*&#52N+%/_K2F]X (!3$7-YRL$6PZP2B3.'(Z,(=2,&@CX=F
M1/Y<5(@8 G&Z6B.@J1VB*,MU!A1@1]=+9,[T<\AG #Z'/*<2$^JR'?K-XSCI
MGC"\QD$ZJK6=@TU 24B79%BP/SIY?F.XKP-ZQJWPP?0IX$"LA8?]\23I])@<
MM$97@KAFOW *#T(_!!36[+%O?VG$U(5%VQ84B5E+0=$?;&GLP#0T8<1^,&),
M)CP8 =91&%2!FQ@$4/$ ,YN3T+NZ'CD48C*G&/!^>G1G@G,"@+A3:$SH=5"(
M%U=G?!@OP^,)\+[52Q"ST["<G*;M6.(1#7:LN_G  +F0PY."9*B34$=WAM6>
M& $$*/0.N+EJ>^/31U\E+1A$^*@WB#C(-M2ZRF%7C7)?=4O3E)2!-^14R'GT
ML"S$UH;&(!YV.E09P%&R1QU"TK1I@>%KHLT-R8ZIT0O \)8>=9Z)3<A!X9Y&
MX9X>%,77MM$D/]D5F\YBD_V*Z+S:&W?^A>$$*QIS37O<^=P--NR2N&7SPBTA
MECM,_%0N2"*Y+3RRYK[*6= Z1PH)"41U0=)<+%6] -+EG*F#<R(N1?:S(GF
M#YBIBO=$FOZD786SB?W&6J%XM]#;$Y5]0'#@E6S)XXR:--$C^0KO>):$17<)
M?V,&E(,9/BO!PKCL26D9N;'6\3>4"X:E'O$1D$%Z 5V$-YJK1P?%+7:%30ZV
M93VGH/GHA6/D-3,2-I"9Q47#NO.V'$U+% P8>6)4%/]WIAKKUDA-K*5QA[+
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MO)I-(C!M<VTG3M>AH1VTH_88AB6]1VC\!EHO-!5(-_$!^A=N]0]02P,$%
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MT2!- '[/A=![QQ08EG[R#U!+ P04    " #EBH16=73.X.H#   ?"@  &0
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MSC ,IGF.- NGY_X),-8.'Q1^.L,7'!BZ@.<3C1VI79""[DTX^A=02P,$%
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MYRR,LM_.AKDH:9G?,&A*9=>E,@Z42B<W29PO,^+$<S[OB'?4\<:Q>/=(_BK
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;,U7VV[;.!#]%4(+%+M
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M>N/UGA>/-YZ>.\L)(>+N$PX]K*^<6=M'I*QY?+6@.6THS8'27"C-@])\*"U
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MH9/ZJ!:@6DAI8B3:=L!8W@YXVXV(Y/C@L*!5 52S4<U!-1?5O$:3KCQ./B1
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MZ;7ZN$'"ME=VH'AF&HX55]B^F-<M=J0@] +\ON9<'08Z0-GCCO\#4$L#!!0
M   ( .6*A%8IZK-32 0  $(4   9    >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;+U876_;-A3]*X0V#"V01"(E^2.S#33.@@YH@"!!VX=A#[1$VT0IT25I
M._GW(R59LBR)G59A+[9(\1[><^\E><39D8MO<DN( J\)2^7<V2JUNW5=&6U)
M@N4-WY%4OUESD6"EFV+CRIT@.,Z,$N8BSQNY"::ILYAE?4]B,>-[Q6A*G@20
M^R3!XNV.,'Z<.] Y=3S3S5:9#G<QV^$->2'J\^Y)Z)9;HL0T(:FD/ 6"K.?.
M!WB[1)XQR$9\H>0HSYZ!H;+B_)MI_!G/'<]X1!B)E(' ^N] EH0Q@Z3]^%Z
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MMP3'1)@!^OV:ZY.C:)@)RFO#Q3]02P,$%     @ Y8J$5N/%7KH, P  1@D
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M7KPZ^;KPOY5^Q]>-_VVT__JKFG_S^CZY27](\IMLO?56Z74QU.#EM/BKW&^
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M?,_W:P@MSD_'%CJ=HM8=@]=IJO6&<$!SHNNY8%3M1$',6IYQ5;TUJ-TAT?R
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MOK_JU.)9:RN[D6QKND//3$I&S>4&2 A<!ZCG*\;DVXV>H&@P3O\!4$L#!!0
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M9&+#G/&//^"^_[-)=TM@C2QTRRQT;>B0U3D3@H5(T1=$I63J M9- !U',KV
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M?CR9WRB^RD[X9EPIGF272T;![.H!\'[.N7J[T1.4A\3C_P!02P,$%     @
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MC6Z8L,?X;!2.,L29^$$DL@#RC>Y DP_D&:])6G(@,B.?L@S<)MM1\D2-ZST
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M0=D).)Y):?8-NT!3I<;_ 5!+ P04    " #EBH16B+ZHB) %  !L-0  &0
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MO#,]+.G9G"[LAQY+3!I+3(R6>+<K!BM)WNV55#Q=1^GF%0ERGJI^$QAI0TV
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M8."+M:JE_]MNE($S*^MJ&>#0W0_\QBE9^K52H:X&Z7!X.JBE-LFWK[N^YFZ
M#VQ01=#60&-LN-/JR>_/QT/QJ+U>ZDJ'[21I/U<J$;4VNM9_5#E)AHGP:_OT
MKW7ZCS5!5HO"V:J:)*/NQ)UR01>OFA<1\E8N?=L2Y/)& L@D.1U"AROM?&BO
M:/N7P/BHX.+NJ EVIJN@W*4,ZA]GFXTV][$;>(H!>HPV#KN_71#/W/\)HUVM
M=*$N;='4RH0NCDY5$=#XM=[X1!A9JTFRNT1(4XJI"1 D<66ZKN#:^*1PZZNR
M>^H N"B&[DS#"7=5MN!\D!?6E,IX50KXY&VE2^ HQ7=925,H@2!3 C(](N2O
M%$%F!&3&#KE'6T2(^ ]>V)7XN5$.0>8$9'Z42.YP$>28@!P?$;(WW*<$Y.DQ
M(3,$^8F _'2T[^2%]&L$^9F _,P+>2U#XU1D^MYX;93W;<9<-'4MW1:GH"\$
MY!=>R)O8"$&<2P=I_-9)XV4K1X_S^)!*Y$->PO.B< T03I\W\7O9XR(%PVR8
MN=Q"+\6#V!<4\>.]DS5&I/0RXO?+8RQ$X*[B&B ]#/-6M@Q[0$HM(V:W+'2]
M ;;S>Z?:&2R@%S%KVGDS_=U@3$HN(V:[S*1VXDY633N;9]J GK6LQ \M8Y&(
M,2F]C)C]L@BV>%C;JE3._Q7C!Y499J.L,F+6RA0&VFZ5$C<J:-<-]AS*',Q'
M"67$;I2ZUJ&S2,S2,'4"%-@*!KJ?<BBAC)B-<F4*6RMQ*Y_[3)0_1LP"631+
MKWXW<3RGCS%\N+2FO)$R>X/4;Z_:2BF-I,P:H3%QO962*Q5FE;RTL/AP&T7B
M/V) 2B4ILTK('-T?;DHE*;-*WLK1;\:2$DG*+!*<9]Z$HTR2,IN$GC YQJ2$
MDC(+A<8<8TQ**2FS4@[7_^)$G)<8D[),RFR95^GG1"R@V[*IVA#CG1+*.=D[
MKU7:&)8Z7@>IZ IC4L[)CK=TB<08DW).=JSE2Q=6C$GNC[WW(F:&%C']73S*
M/-DQ%S&]0B.CW),QNX?&Q.D]HRR4,5N(QL3I/:,LE#%;Z,UR8Y^4,"9EH8S9
M0@<P=RD>8U(6RKC7.A1F;Z;GE(5R9@L=&G3OFWH3\'9%3EDH9[;0H6B^WA_-
M*0OES!8BH]D?=,I".;>%J&CV,<GW-,P6.K0/)#ZT.0EC4A;*V5_5$-M!X@1C
M4A;*F2W46ZCMIPX8Z1KN>(DQ*0OES!9Z@8E+XOC>&&-2%LK?<7OMQ0)CNEIA
M"^64A?+WWG'KAQ2_ZZ0L-&XM--C]7J!4*UBEEM=P"P_MA:R*N1/Q3_<:(Q_'
M;<954U47T/;3_+"RW/W\8/?3B6__ 5!+ P04    " #EBH16.(-O)L0!   -
M'@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[;L) %(7AK2 O
M(,-]F(0(J-+01MF 18:'8K#EF2BP^R!2D(-2I$%S*FML^?JO/EOCV6MLF[SK
M#FF[Z]/HN&\/:5YM<^Z?0TBK;=PWZ:'KX^%\9=T-^R:?E\,F],WJH]G$H./Q
M) R_9U2+V>^9H[=3'_\SL5NO=ZOXTJT^]_&0_Q@<OKKA(VUCS-7HK1DV,<^K
M<&ROIU.X'.3A/+D:+=_GU;!\ERJ4#E((TO)!!D%6/L@AR,L'U1!4EP^:0-"D
M?- C!#V6#WJ"H*?R05,(FI8/DC'*."9(NL&:0&M!KH7 :T&PA4!L0;*%P&Q!
MM(5 ;4&VA<!M0;B%0&Y!NH7 ;D&\A4!O1;V50&]%O95 ;[WYV";06U%O)=!;
M46\ET%M1;R706U%O)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;
M;C9+"/0VU-L(]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/1VU-L)]';4VPGT
M=M3;"?1VU-L)]/:;S6X"O1WU=@*]'?5V KT=]78"O1WU=@*]'?5V KUKU+N^
MI]XIG]J8KCT_:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%     @
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MH<BJ4&15*+(J%%D5BJS#_Y3UW9C57_^3;.YII8OZF,_:'[_33U!+ 0(4 Q0
M   ( .6*A%8'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ Y8J$5B/>1/ON    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( .6*A%85=(>]Z@(  .L)   8
M  " @8(3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #E
MBH16= Y_6Y,%  !5%0  &               @(&B%@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ Y8J$5I@;7.VR @  30<  !@
M         ("!:QP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( .6*A%9QUN ?8 (   $%   8              " @5,?  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #EBH16])POPG 2   \$@$
M&               @('I(0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ Y8J$5KAJ]$.F"   HR@  !@              ("!CS0  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .6*A%;_)K_-[B
M *!B   8              " @6L]  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #EBH16'_XV%38%   +#@  &0              @(&/
M7@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .6*A%8N
MIK 'E04  &8.   9              " @?QC  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ Y8J$5IKJ>;< !   *@D  !D
M     ("!R&D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6*A%8R&H9N! (  * $   9              "
M@?N7  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ Y8J$
M5M+;&*DB"   C1(  !D              ("!-IH  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #EBH16>O"OQ<T)  #T&0  &0
M        @(&/H@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( .6*A%8QMG;LIP,  #L(   9              " @9.L  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ Y8J$5@:22EUD(@   6\
M !D              ("!<;   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #EBH16K 9EI5<#  #M!@  &0              @($,TP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .6*A%8@ERM7
MW0(    &   9              " @9K6  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ Y8J$5G5TSN#J P  'PH  !D
M ("!KMD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #E
MBH161\KML(\%  ![#@  &0              @('/W0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .6*A%9*! 31&@0  %0)   9
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M970S,"YX;6Q02P$"% ,4    " #EBH16S=7%M)T$  #Q&0  &0
M    @(&H @$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M .6*A%:YH-\ &@,  )P)   9              " @7P' 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ Y8J$5BIH:V9A$@  E/X  !D
M             ("!S0H! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #EBH16!]T:M"T#  #O"@  &0              @(%E'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .6*A%8IZK-32 0
M $(4   9              " @<D@ 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ Y8J$5N/%7KH, P  1@D  !D              ("!
M2"4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #EBH16
MK8.Q\*8"  !Y"0  &0              @(&+* $ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( .6*A%8^CJO#VQL  /2X 0 9
M      " @6@K 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ Y8J$5L0.D^'+ @  5P<  !D              ("!>D<! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #EBH16&*W4K*D#  !I#@
M&0              @(%\2@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( .6*A%;O1R;R#00  $@4   9              " @5Q. 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ Y8J$5BY*T0U(
M!   KA,  !D              ("!H%(! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " #EBH16R,M:V/P#  !L%   &0
M@($?5P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( .6*
MA%;@_L8W)0,  *D+   9              " @5); 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ Y8J$5O@5!M/1 @  B D  !D
M         ("!KEX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " #EBH16O;SXW)8)  !?80  &0              @(&V80$ >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .6*A%8\[LP0#P,  #T)
M   9              " @8-K 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ Y8J$5B;(:G^0!   ,!8  !D              ("!R6X!
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #EBH16=-BL
MN&<#  "Q"@  &0              @(&0<P$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( .6*A%:(OJB(D 4  &PU   9
M  " @2YW 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MY8J$5OS:?&%1 P  SA4   T              ( !]7P! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #EBH16EXJ[',     3 @  "P              @ %Q
M@ $ 7W)E;',O+G)E;'-02P$"% ,4    " #EBH16\=Z.*$0$  "^(0  #P
M            @ %:@0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y8J$
M5CB#;R;$ 0  #1X  !H              ( !RX4! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ Y8J$5H"$^)W  0   !X  !,
M         ( !QX<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-
)#P  N(D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Paycheck Protection Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram</Role>
      <ShortName>Paycheck Protection Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Simple Agreement for Future Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity</Role>
      <ShortName>Simple Agreement for Future Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Fair Value of Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities</Role>
      <ShortName>Fair Value of Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Employee Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan</Role>
      <ShortName>Employee Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value of Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails</Role>
      <ShortName>Accrued Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails</Role>
      <ShortName>Paycheck Protection Program - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Convertible Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails</Role>
      <ShortName>Simple Agreement For Future Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity - Schedule of Warrant Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrant Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stockholders' Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Retirement Plan (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="maia-s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 31 fact(s) appearing in ix:hidden were eligible for transformation: maia:ClaimExpirationTerm, maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm, us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 -  maia-s1a.htm 21, 22, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  maia-s1a.htm 25</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1/A" original="maia-s1a.htm">maia-s1a.htm</File>
    <File>maia-20230330.xsd</File>
    <File>maia-20230330_cal.xml</File>
    <File>maia-20230330_def.xml</File>
    <File>maia-20230330_lab.xml</File>
    <File>maia-20230330_pre.xml</File>
    <File>maia-ex232_7.htm</File>
    <File>maia-ex233_332.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gjyjiv3jrhol000001.jpg</File>
    <File>gjyjiv3jrhol000002.jpg</File>
    <File>gjyjiv3jrhol000003.jpg</File>
    <File>gjyjiv3jrhol000004.jpg</File>
    <File>gjyjiv3jrhol000005.jpg</File>
    <File>gjyjiv3jrhol000006.jpg</File>
    <File>gjyjiv3jrhol000007.jpg</File>
    <File>gjyjiv3jrhol000008.jpg</File>
    <File>gjyjiv3jrhol000009.jpg</File>
    <File>gjyjiv3jrhol000010.jpg</File>
    <File>gjyjiv3jrhol000011.jpg</File>
    <File>gjyjiv3jrhol000012.jpg</File>
    <File>gjyjiv3jrhol000013.jpg</File>
    <File>gjyjiv3jrhol000014.jpg</File>
    <File>gjyjiv3jrhol000015.jpg</File>
    <File>gjyjiv3jrhol000016.jpg</File>
    <File>gjyjiv3jrhol000017.jpg</File>
    <File>gjyjiv3jrhol000018.jpg</File>
    <File>gjyjiv3jrhol000019.jpg</File>
    <File>gjyjiv3jrhol000020.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="489">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "maia-s1a.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 489,
    "http://xbrl.sec.gov/dei/2022": 27
   },
   "contextCount": 192,
   "dts": {
    "calculationLink": {
     "local": [
      "maia-20230330_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "maia-20230330_def.xml"
     ]
    },
    "inline": {
     "local": [
      "maia-s1a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "maia-20230330_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "maia-20230330_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "maia-20230330.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 519,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 33,
    "http://maiabiotech.com/20230330": 3,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 39
   },
   "keyCustom": 114,
   "keyStandard": 226,
   "memberCustom": 35,
   "memberStandard": 26,
   "nsprefix": "maia",
   "nsuri": "http://maiabiotech.com/20230330",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:PaycheckProtectionProgramTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Paycheck Protection Program",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram",
     "shortName": "Paycheck Protection Program",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:PaycheckProtectionProgramTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Convertible Notes Payable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Simple Agreement for Future Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity",
     "shortName": "Simple Agreement for Future Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Fair Value of Financial Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities",
     "shortName": "Fair Value of Financial Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Employee Retirement Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan",
     "shortName": "Employee Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Fair Value of Financial Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables",
     "shortName": "Fair Value of Financial Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_maiaLeighAnnDurantMember_20210101_20211231",
      "decimals": "0",
      "lang": null,
      "name": "maia:ConsultingServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
     "shortName": "Accrued Expenses - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20211231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "maia:PaycheckProtectionProgramTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails",
     "shortName": "Paycheck Protection Program - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "maia:PaycheckProtectionProgramTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapDebtInstrumentAxis_maiaPPPLoanProgramMember_20210101_20210131",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
     "shortName": "Convertible Notes Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20190701_20190731",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20210901_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:SimpleAgreementForFutureEquityIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails",
     "shortName": "Simple Agreement For Future Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20210901_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:SimpleAgreementForFutureEquityIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:ChangeInFairValueOfEmbeddedFeatures",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
     "shortName": "Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:ChangeInFairValueOfEmbeddedFeatures",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "2",
      "lang": null,
      "name": "maia:PercentageOfProbabilityOfTheConvertibleNotesMaturity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
     "shortName": "Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220801",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220801",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails",
     "shortName": "Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "maia:ScheduleOfWarrantExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stockholders' Equity - Schedule of Warrant Exercised (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrant Exercised (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "maia:ScheduleOfWarrantExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "INF",
      "lang": null,
      "name": "maia:ClassOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stockholders' Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
     "shortName": "Stockholders' Equity - Assumptions Used in Calculating Value of Warrants Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stockholders' Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
     "shortName": "Stockholders' Equity - Summary of Activity and Information Regarding Outstanding and Exercisable Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
     "shortName": "Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "maia:DefinedContributionPlanEmployerSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
     "shortName": "Employee Retirement Plan (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapRetirementPlanTypeAxis_maiaThe401KPlanMember_20220101_20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "maia:DefinedContributionPlanEmployerSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:PaymentsDueRelatedToMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapTypeOfArrangementAxis_maiaAmendedPatentAndTechnologyLicenseAgreementMember_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:PaymentsDueRelatedToMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Subsequent Events - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20230416_20230416",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "maia-s1a.htm",
      "contextRef": "C_0001878313_20220101_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary Sic Number",
        "terseLabel": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "maia_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated two thousand twenty equity incentive plan.",
        "label": "Amended And Restated Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "Amended and Restated 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_AmendedPatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended patent and technology license agreement.",
        "label": "Amended Patent And Technology License Agreement [Member]",
        "terseLabel": "Amended Patent And Technology License Agreement"
       }
      }
     },
     "localname": "AmendedPatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_AustralianResearchAndDevelopmentIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australian research and development incentives.",
        "label": "Australian Research And Development Incentives",
        "terseLabel": "Australian research and development incentives"
       }
      }
     },
     "localname": "AustralianResearchAndDevelopmentIncentives",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_BlackSholesMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black sholes method.",
        "label": "Black Sholes Method [Member]",
        "terseLabel": "Black-Sholes Method"
       }
      }
     },
     "localname": "BlackSholesMethodMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_CashPaidForServicesProvided": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for services provided.",
        "label": "Cash Paid For Services Provided",
        "terseLabel": "Cash paid for services provided"
       }
      }
     },
     "localname": "CashPaidForServicesProvided",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CashPaidToSettleAPortionOfDeferredCompensationBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid to settle a portion of deferred compensation balance.",
        "label": "Cash Paid To Settle A Portion Of Deferred Compensation Balance",
        "terseLabel": "Cash paid to settle a portion of deferred compensation balance"
       }
      }
     },
     "localname": "CashPaidToSettleAPortionOfDeferredCompensationBalance",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CashlessExerciseAtFairMarketValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise at fair market value per share.",
        "label": "Cashless Exercise At Fair Market Value Per Share",
        "terseLabel": "Cashless exercise at fair market value per share"
       }
      }
     },
     "localname": "CashlessExerciseAtFairMarketValuePerShare",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_CertainRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain risks and uncertainties.",
        "label": "Certain Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Certain Risks and Uncertainties"
       }
      }
     },
     "localname": "CertainRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ChangeInFairValueOfEmbeddedFeatures": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of embedded features.",
        "label": "Change In Fair Value Of Embedded Features",
        "negatedLabel": "Change in fair value of embedded features",
        "terseLabel": "Change in fair value of embedded features"
       }
      }
     },
     "localname": "ChangeInFairValueOfEmbeddedFeatures",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ClaimExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claim expiration term.",
        "label": "Claim Expiration Term",
        "terseLabel": "Claim expiration term"
       }
      }
     },
     "localname": "ClaimExpirationTerm",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right additional purchase aggregate of common stock.",
        "label": "Class Of Warrant Or Right Additional Purchase Aggregate Of Common Stock",
        "terseLabel": "Class of warrant or right additional purchase aggregate of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right date from which warrants or rights expire.",
        "label": "Class Of Warrant Or Right Date From Which Warrants Or Rights Expire",
        "terseLabel": "Class of warrant or right date from which warrants or rights expire"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "maia_ClassOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants exercised.",
        "label": "Class Of Warrants Exercised",
        "negatedLabel": "Warrants Outstanding, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsExercised",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants expired.",
        "label": "Class Of Warrants Expired",
        "negatedLabel": "Warrants Outstanding, Expired"
       }
      }
     },
     "localname": "ClassOfWarrantsExpired",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants issued.",
        "label": "Class Of Warrants Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantsIssued",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price.",
        "label": "Class Of Warrants Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePrice",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price, exercised.",
        "label": "Class Of Warrants Weighted Average Exercise Price Exercised",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceExercised",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price expired.",
        "label": "Class Of Warrants Weighted Average Exercise Price Expired",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceExpired",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price issued.",
        "label": "Class Of Warrants Weighted Average Exercise Price Issued",
        "terseLabel": "Weighted Average Exercise Price, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceIssued",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average remaining contractual term.",
        "label": "Class Of Warrants Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageRemainingContractualTerm",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_CombinedMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined milestone payments maximum.",
        "label": "Combined Milestone Payments Maximum",
        "terseLabel": "Combined milestone payment maximum"
       }
      }
     },
     "localname": "CombinedMilestonePaymentsMaximum",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CommonSharesUponExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares upon exercise of warrants shares.",
        "label": "Common Shares Upon Exercise Of Warrants Shares",
        "terseLabel": "Common shares upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "CommonSharesUponExerciseOfWarrantsShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_CommonStockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock conversion price.",
        "label": "Common Stock Conversion Price",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "CommonStockConversionPrice",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_CommonStockWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants Policy [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ConsultingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services.",
        "label": "Consulting Services",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServices",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible notes and accrued interest into common stock.",
        "label": "Conversion Of Convertible Notes And Accrued Interest Into Common Stock",
        "terseLabel": "Conversion of convertible notes and accrued interest into MAIA common stock"
       }
      }
     },
     "localname": "ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt conversion price percentage of the equity financing.",
        "label": "Convertible Debt Conversion Price Percentage Of The Equity Financing",
        "terseLabel": "Percentage of the conversion price"
       }
      }
     },
     "localname": "ConvertibleDebtConversionPricePercentageOfTheEquityFinancing",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes.",
        "label": "Convertible Notes [Member]",
        "terseLabel": "Convertible Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_ConvertibleNotesOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes outstanding.",
        "label": "Convertible Notes Outstanding",
        "terseLabel": "Convertible notes outstanding"
       }
      }
     },
     "localname": "ConvertibleNotesOutstanding",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertiblePromissoryNotesToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory notes to related parties.",
        "label": "Convertible Promissory Notes To Related Parties",
        "terseLabel": "Convertible promissory notes to related parties"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesToRelatedParties",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertiblePromissoryNotesToSettleLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory notes to settle loan.",
        "label": "Convertible Promissory Notes To Settle Loan",
        "terseLabel": "Convertible promissory notes to settle loan"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesToSettleLoan",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DGDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DGD.",
        "label": "D G D [Member]",
        "terseLabel": "DGD"
       }
      }
     },
     "localname": "DGDMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_DebtDiscountAndValueOfEmbeddedPutFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt discount and value of embedded put feature.",
        "label": "Debt Discount And Value Of Embedded Put Feature",
        "terseLabel": "Debt discount and value of embedded put feature"
       }
      }
     },
     "localname": "DebtDiscountAndValueOfEmbeddedPutFeature",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DeemedDividendOnWarrantModification": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on warrant modification.",
        "label": "Deemed Dividend On Warrant Modification",
        "terseLabel": "Deemed dividend on warrant modification"
       }
      }
     },
     "localname": "DeemedDividendOnWarrantModification",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DefinedContributionPlanEmployerSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer alary.",
        "label": "Defined Contribution Plan Employer Salary",
        "terseLabel": "Employee salary deferrals"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerSalary",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "maia_DerivativeLiabilityOnConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability on convertible notes payable.",
        "label": "Derivative Liability On Convertible Notes Payable",
        "terseLabel": "Derivative liability on convertible notes payable"
       }
      }
     },
     "localname": "DerivativeLiabilityOnConvertibleNotesPayable",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business organization and principles of consolidation.",
        "label": "Description Of Business Organization And Principles Of Consolidation Policy [Text Block]",
        "terseLabel": "Description of Business, Organization, and Principles of Consolidation"
       }
      }
     },
     "localname": "DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_DissolutionOfFirm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution of firm.",
        "label": "Dissolution Of Firm",
        "terseLabel": "Dissolution of DGD"
       }
      }
     },
     "localname": "DissolutionOfFirm",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_EarningsPerSharesBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Shares Basic and Diluted.",
        "label": "Earnings Per Shares Basic And Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerSharesBasicAndDiluted",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation loss on extinguishment of debt",
        "label": "Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of outstanding principal and interest written off amount.",
        "label": "Extinguishment Of Outstanding Principal And Interest Written Off Amount",
        "terseLabel": "Extinguishment of outstanding principal and interest written off amount"
       }
      }
     },
     "localname": "ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock options issued to settle accrued bonus balance.",
        "label": "Fair Value Of Stock Options Issued To Settle Accrued Bonus Balance",
        "terseLabel": "Fair value of stock options issued to settle accrued bonus balance"
       }
      }
     },
     "localname": "FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_FairValueWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value warrant liability.",
        "label": "Fair Value Warrant Liability",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "FairValueWarrantLiability",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation adjustment.",
        "label": "Foreign Currency Translation Adjustment",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAdjustment",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_FounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder.",
        "label": "Founder [Member]",
        "terseLabel": "Founder"
       }
      }
     },
     "localname": "FounderMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from forgiveness of paycheck protection program loan.",
        "label": "Gain Loss From Forgiveness Of Paycheck Protection Program Loan",
        "negatedLabel": "Gain from forgiveness of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "GainLossFromForgivenessOfPaycheckProtectionProgramLoan",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_GainOnPaycheckProtectionProgramLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the gain on Paycheck Protection Program loan forgiveness.",
        "label": "Gain On Paycheck Protection Program Loan Forgiveness",
        "terseLabel": "Paycheck protection program loan forgiveness"
       }
      }
     },
     "localname": "GainOnPaycheckProtectionProgramLoanForgiveness",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_GoingConcernConsiderationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern considerations.",
        "label": "Going Concern Considerations Policy [Text Block]",
        "terseLabel": "Going Concern Considerations"
       }
      }
     },
     "localname": "GoingConcernConsiderationsPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImpactOfTheCovid19PandemicOnOperations.",
        "label": "Impact Of The Covid19 Pandemic On Operations Policy [Text Block]",
        "terseLabel": "Impact of the COVID-19 Pandemic on our Operations"
       }
      }
     },
     "localname": "ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_IncreaseDecreaseInDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred offering costs.",
        "label": "Increase Decrease In Deferred Offering Costs",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredOfferingCosts",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares in connection with equity financing.",
        "label": "Issuance Of Common Shares In Connection With Equity Financing",
        "terseLabel": "Issuance of common shares in connection with Equity Financing"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesInConnectionWithEquityFinancing",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares in connection with equity financing shares.",
        "label": "Issuance Of Common Shares In Connection With Equity Financing Shares",
        "terseLabel": "Issuance of common shares in connection with Equity Financing, Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesInConnectionWithEquityFinancingShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfCommonSharesInConnectionWithInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares in connection with initial public offering.",
        "label": "Issuance Of Common Shares In Connection With Initial Public Offering",
        "terseLabel": "Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesInConnectionWithInitialPublicOffering",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon cashless exercise of warrants shares.",
        "label": "Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares",
        "terseLabel": "Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfCommonSharesUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon exercise of warrants.",
        "label": "Issuance Of Common Shares Upon Exercise Of Warrants",
        "terseLabel": "Issuance of common shares upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponExerciseOfWarrants",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon exercise of warrants shares.",
        "label": "Issuance Of Common Shares Upon Exercise Of Warrants Shares",
        "terseLabel": "Issuance of common shares upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponExerciseOfWarrantsShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible note for payment on loan to officer.",
        "label": "Issuance Of Convertible Note For Payment On Loan To Officer",
        "terseLabel": "Issuance of convertible note for payment on loan to officer"
       }
      }
     },
     "localname": "IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfRatchetShares": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ratchet shares.",
        "label": "Issuance Of Ratchet Shares",
        "terseLabel": "Issuance of ratchet shares"
       }
      }
     },
     "localname": "IssuanceOfRatchetShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfRatchetSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ratchet shares shares.",
        "label": "Issuance Of Ratchet Shares Shares",
        "terseLabel": "Issuance of ratchet shares"
       }
      }
     },
     "localname": "IssuanceOfRatchetSharesShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of restricted common shares to founder pursuant to merger agreement, share.",
        "label": "Issuance Of Restricted Common Shares To Founder Pursuant To Merger Agreement Share",
        "terseLabel": "Issuance of restricted common shares to founder pursuant to THIO Merger Agreement"
       }
      }
     },
     "localname": "IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementShare",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of restricted common shares to founder pursuant to merger agreement, value.",
        "label": "Issuance Of Restricted Common Shares To Founder Pursuant To Merger Agreement Value",
        "terseLabel": "Issuance of restricted common shares to founder pursuant to THIO Merger Agreement"
       }
      }
     },
     "localname": "IssuanceOfRestrictedCommonSharesToFounderPursuantToMergerAgreementValue",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSatisfyAccruedBonus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to satisfy accrued bonus.",
        "label": "Issuance Of Stock Options To Satisfy Accrued Bonus",
        "terseLabel": "Issuance of stock options to satisfy accrued bonus"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSatisfyAccruedBonus",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to satisfy deferred compensation.",
        "label": "Issuance Of Stock Options To Satisfy Deferred Compensation",
        "terseLabel": "Issuance of stock options to satisfy deferred compensation"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSatisfyDeferredCompensation",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to settle accrued bonus balance.",
        "label": "Issuance Of Stock Options To Settle Accrued Bonus Balance",
        "terseLabel": "Issuance of stock options to settle accrued bonus balance"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSettleAccruedBonusBalance",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January One To January Twenty Six Two Thousand Twenty Two.",
        "label": "January One To January Twenty Six Two Thousand Twenty Two [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One.",
        "label": "January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January Twenty Seven To May Thirty One Two Thousand Twenty Two.",
        "label": "January Twenty Seven To May Thirty One Two Thousand Twenty Two [Member]",
        "terseLabel": "January Twenty Seven To May Thirty One Two Thousand Twenty Two"
       }
      }
     },
     "localname": "JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June One Two Thousand Twenty Two To August One Two Thousand Twenty Two.",
        "label": "June One Two Thousand Twenty Two To August One Two Thousand Twenty Two [Member]",
        "terseLabel": "June One Two Thousand Twenty Two To August One Two Thousand Twenty Two"
       }
      }
     },
     "localname": "JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_LeighAnnDurantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leigh-Ann Durant.",
        "label": "Leigh Ann Durant [Member]",
        "terseLabel": "Ms. Durant"
       }
      }
     },
     "localname": "LeighAnnDurantMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_MAIADrugDevelopmentCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "M A I A drug development corporation member",
        "label": "M A I A Drug Development Corporation [Member]",
        "terseLabel": "MAIA Drug Development Corporation"
       }
      }
     },
     "localname": "MAIADrugDevelopmentCorporationMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MAIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MAIA.",
        "label": "M A I A [Member]",
        "terseLabel": "MAIA"
       }
      }
     },
     "localname": "MAIAMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March One Two Thousand Twenty One To June Six Two Thousand Twenty One.",
        "label": "March One Two Thousand Twenty One To June Six Two Thousand Twenty One [Member]",
        "terseLabel": "March One Two Thousand Twenty One To June Six Two Thousand Twenty One"
       }
      }
     },
     "localname": "MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum gross proceeds from equity financing required for conversion of debt.",
        "label": "Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt",
        "terseLabel": "Minimum gross proceeds from equity financing required for conversion of debt"
       }
      }
     },
     "localname": "MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ModificationOfWarrantInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of warrant in equity.",
        "label": "Modification Of Warrant In Equity",
        "terseLabel": "Modification of warrant in equity"
       }
      }
     },
     "localname": "ModificationOfWarrantInEquity",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_MoneyChannelNycIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money channel nyc inc.",
        "label": "Money Channel Nyc Inc [Member]",
        "terseLabel": "Money Channel NYC Inc"
       }
      }
     },
     "localname": "MoneyChannelNycIncMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NetSalesAboveOneBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales above one billion.",
        "label": "Net Sales Above One Billion [Member]",
        "terseLabel": "Net sales above $1,000,000,000"
       }
      }
     },
     "localname": "NetSalesAboveOneBillionMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NetSalesUptoOneBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales upto one billion.",
        "label": "Net Sales Upto One Billion [Member]",
        "terseLabel": "Net sales up to $1,000,000,000"
       }
      }
     },
     "localname": "NetSalesUptoOneBillionMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NumberOfCommonSharesConvertedUnderSAFEAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares converted under SAFE agreement.",
        "label": "Number Of Common Shares Converted Under S A F E Agreement",
        "terseLabel": "Converted common stock under SAFE agreement"
       }
      }
     },
     "localname": "NumberOfCommonSharesConvertedUnderSAFEAgreement",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_OfferingAndOverallotmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering and overallotment member.",
        "label": "Offering And Overallotment [Member]",
        "terseLabel": "Offering And Overallotment"
       }
      }
     },
     "localname": "OfferingAndOverallotmentMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward limited percentage of taxable income.",
        "label": "Operating Loss Carryforward Limited Percentage Of Taxable Income",
        "terseLabel": "Net operating loss carryforward limited percentage of taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwardLimitedPercentageOfTaxableIncome",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "maia_OptionsIssuedForAccruedBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued for accrued bonus.",
        "label": "Options Issued For Accrued Bonus",
        "terseLabel": "Options issued for accrued bonus"
       }
      }
     },
     "localname": "OptionsIssuedForAccruedBonus",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_OptionsIssuedForDeferredCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued for deferred compensation.",
        "label": "Options Issued For Deferred Compensation",
        "terseLabel": "Options issued for deferred compensation"
       }
      }
     },
     "localname": "OptionsIssuedForDeferredCompensation",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_OptionsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares of common stock.",
        "label": "Options To Purchase Shares Of Common Stock",
        "terseLabel": "Options to purchase shares of common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseSharesOfCommonStock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares of common stock total fair value.",
        "label": "Options To Purchase Shares Of Common Stock Total Fair Value",
        "terseLabel": "Options to purchase shares of common stock total fair value"
       }
      }
     },
     "localname": "OptionsToPurchaseSharesOfCommonStockTotalFairValue",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PPPLoanProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "P P P loan program.",
        "label": "P P P Loan Program [Member]",
        "terseLabel": "P P P Loan Program"
       }
      }
     },
     "localname": "PPPLoanProgramMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_PatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and technology license agreement.",
        "label": "Patent And Technology License Agreement [Member]",
        "terseLabel": "Patent And Technology License Agreement"
       }
      }
     },
     "localname": "PatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_PaycheckProtectionProgramTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program.",
        "label": "Paycheck Protection Program [Text Block]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgram"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_PaymentOfInitialPublicOfferingTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of initial public offering transaction costs.",
        "label": "Payment Of Initial Public Offering Transaction Costs",
        "negatedLabel": "Payment of initial public offering transaction costs"
       }
      }
     },
     "localname": "PaymentOfInitialPublicOfferingTransactionCosts",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PaymentsDueRelatedToMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due related to milestones.",
        "label": "Payments Due Related To Milestones",
        "terseLabel": "Payments due related to milestones"
       }
      }
     },
     "localname": "PaymentsDueRelatedToMilestones",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price.",
        "label": "Percentage Of Conversion Price",
        "terseLabel": "Percentage of conversion price"
       }
      }
     },
     "localname": "PercentageOfConversionPrice",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfIssuableUponConversionOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issuable upon conversion of exercise price.",
        "label": "Percentage Of Issuable Upon Conversion Of Exercise Price",
        "terseLabel": "Percentage of issuable upon conversion of exercise price"
       }
      }
     },
     "localname": "PercentageOfIssuableUponConversionOfExercisePrice",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of probability of default, change in control or dissolution.",
        "label": "Percentage Of Probability Of Default Change In Control Or Dissolution",
        "terseLabel": "Percentage of probability of default change in control or dissolution"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfDefaultChangeInControlOrDissolution",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfProbabilityOfEquityFinancingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of probability of the an equity financing at maturity",
        "label": "Percentage Of Probability Of Equity Financing Maturity",
        "terseLabel": "Percentage of probability of equity financing maturity"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfEquityFinancingMaturity",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The probability of the Convertible Notes outstanding at maturity.",
        "label": "Percentage Of Probability Of The Convertible Notes Maturity",
        "terseLabel": "Percentage of probability of the convertible notes maturity"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfTheConvertibleNotesMaturity",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales.",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "terseLabel": "Rate of royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales description.",
        "label": "Percentage Of Royalty Payments On Net Sales Description",
        "terseLabel": "Percentage of royalty description"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSalesDescription",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "maia_PercentageOfVotingPowerDefiningChangeOfControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting power defining change of control",
        "label": "Percentage Of Voting Power Defining Change Of Control",
        "terseLabel": "Percentage of voting power defining change of control"
       }
      }
     },
     "localname": "PercentageOfVotingPowerDefiningChangeOfControl",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously paid issuance costs in connection with the initial public offering.",
        "label": "Previously Paid Issuance Costs In Connection With Initial Public Offering",
        "terseLabel": "Previously paid issuance costs in connection with the initial public offering"
       }
      }
     },
     "localname": "PreviouslyPaidIssuanceCostsInConnectionWithInitialPublicOffering",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromCollectionOfSubscriptionReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from collection of subscription receivable.",
        "label": "Proceeds From Collection Of Subscription Receivable",
        "terseLabel": "Collections of subscriptions receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfSubscriptionReceivable",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from common stock net of issuance costs.",
        "label": "Proceeds From Common Stock Net Of Issuance Costs",
        "terseLabel": "Gross proceeds from common stock"
       }
      }
     },
     "localname": "ProceedsFromCommonStockNetOfIssuanceCosts",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock upon exercise of warrants.",
        "label": "Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program loan.",
        "label": "Proceeds From Paycheck Protection Program Loan",
        "terseLabel": "Proceeds from Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgramLoan",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_RaduVitocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radu Vitoc.",
        "label": "Radu Vitoc [Member]",
        "terseLabel": "Mr. Vitoc"
       }
      }
     },
     "localname": "RaduVitocMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RatchetShareExpense": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10150.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratchet share expense.",
        "label": "Ratchet Share Expense",
        "terseLabel": "Ratchet share expense"
       }
      }
     },
     "localname": "RatchetShareExpense",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ReceiptOfStockSubscriptionReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of stock subscription receivable.",
        "label": "Receipt Of Stock Subscription Receivable",
        "terseLabel": "Receipt of stock subscription receivable"
       }
      }
     },
     "localname": "ReceiptOfStockSubscriptionReceivable",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ReclassificationOfWarrantLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liability to equity.",
        "label": "Reclassification Of Warrant Liability To Equity",
        "terseLabel": "Reclassification of warrant liability to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityToEquity",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_RegeneronPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals Inc.",
        "label": "Regeneron Pharmaceuticals Inc [Member]",
        "terseLabel": "Regeneron"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party.",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RemainingConsultingServicesSettled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining consulting services settled.",
        "label": "Remaining Consulting Services Settled",
        "terseLabel": "Remaining services settled"
       }
      }
     },
     "localname": "RemainingConsultingServicesSettled",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ResearchAndDevelopmentIncentivePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive policy.",
        "label": "Research And Development Incentive Policy [Text Block]",
        "terseLabel": "Research and Development Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentivePolicyTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ResearchAndDevelopmentIncentivesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentives receivable.",
        "label": "Research And Development Incentives Receivable",
        "terseLabel": "Australia research and development incentives receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentivesReceivable",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Experimentation Tax Credits Carryforwards Expiration Year",
        "label": "Research And Experimentation Tax Credits Carryforwards Expiration Year",
        "terseLabel": "Research And Experimentation Tax Credits Carryforwards Expiration Year"
       }
      }
     },
     "localname": "ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "maia_RoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payments on net sales.",
        "label": "Royalty Payments On Net Sales",
        "terseLabel": "Royalty payments on net sales"
       }
      }
     },
     "localname": "RoyaltyPaymentsOnNetSales",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ScheduleOfWarrantExercisedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant exercised.",
        "label": "Schedule Of Warrant Exercised Table [Text Block]",
        "terseLabel": "Schedule Of Warrant Exercised"
       }
      }
     },
     "localname": "ScheduleOfWarrantExercisedTableTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage",
        "terseLabel": "Exercise price percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted",
        "terseLabel": "Percentage of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_SimpleAgreementForFutureEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simple agreement for future equity.",
        "label": "Simple Agreement For Future Equity Disclosure [Text Block]",
        "terseLabel": "Simple Agreement for Future Equity"
       }
      }
     },
     "localname": "SimpleAgreementForFutureEquityDisclosureTextBlock",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_SimpleAgreementForFutureEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simple agreement for future equity issued.",
        "label": "Simple Agreement For Future Equity Issued",
        "terseLabel": "Simple agreement for future equity issued"
       }
      }
     },
     "localname": "SimpleAgreementForFutureEquityIssued",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense related to accrued bonus balance.",
        "label": "Stock Based Compensation Expense Related To Accrued Bonus Balance",
        "terseLabel": "Stock-based compensation expense related to accrued bonus balance"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseRelatedToAccruedBonusBalance",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_StockIssuedDuringPeriodSharesConversionOfSafe": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of safe.",
        "label": "Stock Issued During Period Shares Conversion Of Safe",
        "terseLabel": "Issuance of common shares upon conversion of SAFE"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfSafe",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_StockIssuedDuringPeriodValueConversionOfSafe": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of safe.",
        "label": "Stock Issued During Period Value Conversion Of Safe",
        "terseLabel": "Issuance of common shares upon conversion of SAFE"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfSafe",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_THIOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "THIO.",
        "label": "T H I O [Member]",
        "terseLabel": "THIO"
       }
      }
     },
     "localname": "THIOMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_THIOTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "T H I O Therapeutics Inc.",
        "label": "T H I O Therapeutics Inc [Member]",
        "terseLabel": "THIO Therapeutics, Inc."
       }
      }
     },
     "localname": "THIOTherapeuticsIncMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_The401KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The401 K Plan.",
        "label": "The401 K Plan [Member]",
        "terseLabel": "401 (K)"
       }
      }
     },
     "localname": "The401KPlanMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs.",
        "label": "Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_TransactionCostsIncurredInConnectionWithEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs incurred in connection with equity financing.",
        "label": "Transaction Costs Incurred In Connection With Equity Financing",
        "terseLabel": "Transaction costs incurred in connection with Equity Financing"
       }
      }
     },
     "localname": "TransactionCostsIncurredInConnectionWithEquityFinancing",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_TwoThousandAndNineteenPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen promissory note.",
        "label": "Two Thousand And Nineteen Promissory Note [Member]",
        "terseLabel": "2019 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandAndNineteenPromissoryNoteMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty One Convertible Promissory Note.",
        "label": "Two Thousand And Twenty One Convertible Promissory Note [Member]",
        "terseLabel": "2021 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneConvertiblePromissoryNoteMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyOneWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty One Warrants.",
        "label": "Two Thousand And Twenty One Warrants [Member]",
        "terseLabel": "Two Thousand And Twenty One Warrants"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneWarrantsMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty promissory note.",
        "label": "Two Thousand And Twenty Promissory Note [Member]",
        "terseLabel": "2020 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPromissoryNoteMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty warrants.",
        "label": "Two Thousand And Twenty Warrants [Member]",
        "terseLabel": "Two Thousand And Twenty Warrants"
       }
      }
     },
     "localname": "TwoThousandAndTwentyWarrantsMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandEighteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock option plan.",
        "label": "Two Thousand Eighteen Stock Option Plan [Member]",
        "terseLabel": "2018 Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockOptionPlanMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UniversityOfTexasSouthwesternMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of texas southwestern.",
        "label": "University Of Texas Southwestern [Member]",
        "terseLabel": "University Of Texas Southwestern"
       }
      }
     },
     "localname": "UniversityOfTexasSouthwesternMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UnvestedRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock awards member",
        "label": "Unvested Restricted Stock Awards [Member]",
        "terseLabel": "Unvested Restricted Stock Awards"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAwardsMember",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_WarrantDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant description.",
        "label": "Warrant Description",
        "terseLabel": "Warrant description"
       }
      }
     },
     "localname": "WarrantDescription",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "maia_WarrantLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liabilities [Abstract]",
        "label": "Warrant Liabilities [Abstract]",
        "terseLabel": "Warrant liabilities:"
       }
      }
     },
     "localname": "WarrantLiabilitiesAbstract",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "maia_WarrantLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability noncurrent.",
        "label": "Warrant Liability Noncurrent",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityNoncurrent",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WarrantModificationValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant modification, value.",
        "label": "Warrant Modification Value",
        "terseLabel": "Warrant modification, value"
       }
      }
     },
     "localname": "WarrantModificationValue",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period.",
        "label": "Warrants Exercised",
        "verboseLabel": "Class Of Warrants Exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_WarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised, shares.",
        "label": "Warrants Exercised Shares",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "localname": "WarrantsExercisedShares",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued to underwriters in connection with the initial public offering.",
        "label": "Warrants Issued To Underwriters In Connection With Initial Public Offering",
        "terseLabel": "Warrants issued to underwriters in connection with the initial public offering"
       }
      }
     },
     "localname": "WarrantsIssuedToUnderwritersInConnectionWithInitialPublicOffering",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WeightedAverageCommonSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Common Shares Outstanding Basic And Diluted",
        "terseLabel": "Weighted average common shares outstanding basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageCommonSharesOutstandingBasicAndDiluted",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://maiabiotech.com/20230330",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r187",
      "r434",
      "r435",
      "r438",
      "r439",
      "r499",
      "r546",
      "r599",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r187",
      "r434",
      "r435",
      "r438",
      "r439",
      "r499",
      "r546",
      "r599",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r371",
      "r507",
      "r528",
      "r547",
      "r548",
      "r558",
      "r569",
      "r573",
      "r604",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r371",
      "r507",
      "r528",
      "r547",
      "r548",
      "r558",
      "r569",
      "r573",
      "r604",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "MAIA Biotechnology, Inc."
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r330",
      "r371",
      "r399",
      "r400",
      "r401",
      "r506",
      "r507",
      "r528",
      "r547",
      "r548",
      "r558",
      "r569",
      "r573",
      "r595",
      "r604",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r330",
      "r371",
      "r399",
      "r400",
      "r401",
      "r506",
      "r507",
      "r528",
      "r547",
      "r548",
      "r558",
      "r569",
      "r573",
      "r595",
      "r604",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r372",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r202",
      "r372",
      "r578",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r202",
      "r372",
      "r578",
      "r579",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r593",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r192",
      "r193",
      "r194",
      "r235",
      "r236",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r405",
      "r406",
      "r407",
      "r421",
      "r422",
      "r430",
      "r431",
      "r432",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r475",
      "r476",
      "r480",
      "r481",
      "r482",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update Extensible List",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r572"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses Current",
        "terseLabel": "Bonus",
        "verboseLabel": "Accrued bonus expense"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r163",
      "r526",
      "r536",
      "r540"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r572"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r587",
      "r588",
      "r589",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r95",
      "r96",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common shares in connection with initial public offering, issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r30",
      "r38",
      "r128",
      "r288"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r136",
      "r145",
      "r162",
      "r183",
      "r217",
      "r226",
      "r230",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r434",
      "r438",
      "r457",
      "r572",
      "r600",
      "r601",
      "r644"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r158",
      "r164",
      "r183",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r434",
      "r438",
      "r457",
      "r572",
      "r600",
      "r601",
      "r644"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r542",
      "r543",
      "r572",
      "r580"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r160",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r40",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r127"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r152",
      "r153",
      "r191",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r420",
      "r430",
      "r431",
      "r440",
      "r442",
      "r443",
      "r453",
      "r458",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r487",
      "r488",
      "r510",
      "r511",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r152",
      "r153",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r420",
      "r430",
      "r431",
      "r432",
      "r440",
      "r442",
      "r443",
      "r444",
      "r447",
      "r453",
      "r458",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r487",
      "r488",
      "r510",
      "r511",
      "r529",
      "r530",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrants and rights exercisable period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrants exercise price, per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "periodEndLabel": "Warrants Outstanding, Ending balance",
        "periodStartLabel": "Warrants Outstanding, Beginning balance",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfWarrantExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r140",
      "r149"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r250",
      "r251",
      "r545",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r587",
      "r588",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r572"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 10,955,904 and 7,584,980 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r169",
      "r171",
      "r178",
      "r524",
      "r527"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r125",
      "r126",
      "r234",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r125",
      "r126",
      "r234",
      "r541",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of SAFE into MAIA common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion Converted Instrument Shares Issued1",
        "terseLabel": "Share converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion Original Debt Amount1",
        "terseLabel": "Debt Conversion, Original Debt, Amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r181",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r282",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r137",
      "r138",
      "r143",
      "r187",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r478",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r60",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument Convertible Conversion Price1",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r129",
      "r131",
      "r266",
      "r478",
      "r554",
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r165",
      "r553",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r17",
      "r187",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r478",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term",
        "terseLabel": "Debt Instrument Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r128",
      "r131",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument Unamortized Discount",
        "terseLabel": "Debt discount",
        "verboseLabel": "write-off of the unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense related to deferred compensation balance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.",
        "label": "Deferred Compensation Arrangement With Individual Recorded Liability",
        "terseLabel": "Deferred compensation balance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement With Individual Shares Issued",
        "terseLabel": "Options issued"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability Current",
        "terseLabel": "Accrued deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r135",
      "r144",
      "r581"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r104",
      "r635"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net Of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r104",
      "r635"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r104",
      "r635"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r104",
      "r635"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r104",
      "r635"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "auth_ref": [
      "r367",
      "r508",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined benefit plan.",
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Employee Retirement Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Contribution to employee"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r166",
      "r167",
      "r456",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities",
        "periodEndLabel": "Derivative liabilities, Balance",
        "periodStartLabel": "Derivative liabilities, Balance"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities [Abstract]",
        "terseLabel": "Derivative liabilities:"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities Noncurrent",
        "periodEndLabel": "Warrant liabilities, Balance",
        "periodStartLabel": "Warrant liabilities, Balance"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives Policy [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Net effect of foreign currency exchange on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r185",
      "r410",
      "r425"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Other",
        "terseLabel": "Other nondeductible expenses/(nontaxable income)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative Fair Value Of Embedded Derivative Liability",
        "terseLabel": "Debt discount and derivative liability at the issuance date"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized compensation expense, recognized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r154",
      "r173",
      "r174",
      "r175",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r208",
      "r244",
      "r306",
      "r405",
      "r406",
      "r407",
      "r421",
      "r422",
      "r450",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r492",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment Of Debt Amount",
        "terseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r38",
      "r64"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r454",
      "r503",
      "r504",
      "r505",
      "r554",
      "r555",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r280",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r454",
      "r505",
      "r554",
      "r555",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r280",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r503",
      "r504",
      "r505",
      "r554",
      "r555",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r38",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10120.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "negatedLabel": "Loss on extinguishment of convertible notes",
        "terseLabel": "Loss on extinguishment of convertible notes and convertible notes, related parties",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10140.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r184",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "U.S. loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r134",
      "r141",
      "r150",
      "r217",
      "r225",
      "r229",
      "r231",
      "r525",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "terseLabel": "Pretax book loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r184",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r411",
      "r412",
      "r418",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r408",
      "r409",
      "r412",
      "r413",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Due To Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Receivables",
        "negatedLabel": "Australia research and development incentives receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r130",
      "r142",
      "r176",
      "r216",
      "r477"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r29",
      "r215"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r183",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r435",
      "r438",
      "r439",
      "r457",
      "r551",
      "r600",
      "r644",
      "r645"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r139",
      "r148",
      "r572",
      "r586",
      "r594",
      "r640"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r159",
      "r183",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r435",
      "r438",
      "r439",
      "r457",
      "r572",
      "r600",
      "r644",
      "r645"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Long term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line Of Credit Facility [Line Items]",
        "terseLabel": "Line Of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r11",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line Of Credit Facility [Table]",
        "terseLabel": "Line Of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-Term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r17",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-Term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r252",
      "r253",
      "r254",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners",
        "terseLabel": "Minority stockholder ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Minority Interest Ownership Percentage By Parent",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r112",
      "r168",
      "r170",
      "r200",
      "r201",
      "r583"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income Loss Attributable To Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r217",
      "r225",
      "r229",
      "r231",
      "r552"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to MAIA Biotechnology, Inc. shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r306",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Schedule of Unvested Restricted Shares"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off Balance Sheet Credit Exposure Policy Policy [Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r217",
      "r225",
      "r229",
      "r231",
      "r552"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r54",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r107",
      "r108",
      "r110"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income Expense Net",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total MAIA Equity (Deficit)"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r2",
      "r307",
      "r308",
      "r329",
      "r561"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Pension And Other Postretirement Defined Benefit Plans Current Liabilities",
        "terseLabel": "Deferred compensation to former officers",
        "verboseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r572"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively, 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, warrants, and embedded conversion features"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from sale of common stock in initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of transaction costs",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.",
        "label": "Proceeds From Issuance Of Unsecured Debt",
        "terseLabel": "Proceeds from unsecured loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from equity financing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r94"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r584"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds From Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r157",
      "r168",
      "r170",
      "r179",
      "r183",
      "r192",
      "r200",
      "r201",
      "r217",
      "r225",
      "r229",
      "r231",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r433",
      "r436",
      "r437",
      "r452",
      "r457",
      "r525",
      "r552",
      "r570",
      "r571",
      "r583",
      "r600"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Receivables From Stockholder [Member]",
        "terseLabel": "Subscription Receivable"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification Out Of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r354",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r354",
      "r495",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r493",
      "r494",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments Of Related Party Debt",
        "negatedLabel": "Payment on loan payable to officer"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments Of Unsecured Debt",
        "terseLabel": "Repayment of unsecured debt"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r98",
      "r151",
      "r652"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and experimentation"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r67",
      "r147",
      "r535",
      "r540",
      "r572"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r154",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r244",
      "r405",
      "r406",
      "r407",
      "r421",
      "r422",
      "r450",
      "r531",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r373",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r373",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r177",
      "r183",
      "r213",
      "r214",
      "r224",
      "r227",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r457",
      "r525",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r72",
      "r74",
      "r82",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]",
        "terseLabel": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r85",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Activity and Information Regarding Outstanding and Exercisable Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions Used in Calculating Value of Warrants Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule Of Short Term Debt [Table]",
        "terseLabel": "Schedule Of Short Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule Of Subsidiary Or Equity Method Investee [Table]",
        "terseLabel": "Schedule Of Subsidiary Or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "terseLabel": "Founders shares cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Shares, Unvested balance",
        "periodStartLabel": "Shares, Unvested balance",
        "terseLabel": "Unvested shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Unvested balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options Outstanding, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options Outstanding, Cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options Outstanding, Ending balance",
        "periodStartLabel": "Options Outstanding, Beginning balance",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Fair value assumptions, contractual term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Sale of common stock, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short Term Debt [Line Items]",
        "terseLabel": "Short Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-Term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-Term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r65",
      "r154",
      "r173",
      "r174",
      "r175",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r208",
      "r244",
      "r306",
      "r405",
      "r406",
      "r407",
      "r421",
      "r422",
      "r450",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r492",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r208",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r65",
      "r66",
      "r67",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Issuance of common shares upon conversion of convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Number of common stock sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Forfeited",
        "negatedLabel": "Cancellation of restricted common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Issuance of restricted common shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedTerseLabel": "Options Outstanding, Exercised",
        "terseLabel": "Issuance of common shares upon exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Issuance of common shares upon conversion of convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Forfeitures",
        "negatedLabel": "Cancellation of restricted common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Issuance of restricted common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common shares upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r105",
      "r106",
      "r111",
      "r154",
      "r155",
      "r174",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r244",
      "r306",
      "r405",
      "r406",
      "r407",
      "r421",
      "r422",
      "r450",
      "r467",
      "r468",
      "r472",
      "r492",
      "r532",
      "r533",
      "r586",
      "r594",
      "r640"
     ],
     "calculation": {
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r182",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders Equity Note Stock Split",
        "terseLabel": "Common stock, conversion description"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Common stock, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r473",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r473",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r473",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r473",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary Or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary Or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credits carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebt": {
     "auth_ref": [
      "r3",
      "r138",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured debt"
       }
      }
     },
     "localname": "UnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Deferred tax asset, increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerShareDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants And Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://maiabiotech.com/20230330/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235042",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472162&loc=d3e58407-109430",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001564590-23-005432-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-23-005432-xbrl.zip
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M0UW JS"1[K14/;^PE3(:$GV(\17-5:=.E9_>O\;AC!^V,F^5JNG)?$)/T/N
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M%3SO4B0JYS%Y">:$E+DZ*M ^>WCR5=RUD0:$^SW!XA4'2:SVM2%_7->'0?0
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M9POB52X_$\Q4.)[^::H@D&5Q2A-M@-;9Q[[ "R"<"6<[3@7AF@-#4B\JLK'
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M!)_YU**@O?^QN.YP.A><#"9XHRFI7%%0TE5;!N,:('TMEG 4P2>H6>"_EV]
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M;<2+O<--ID=4)JHO88] IPN@9?*T'G E+/HZ!UC/#<9U.&%;I:&6CZT[9:O
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MI!/AE?'PF2,^!7:,H7#!Y=7^^#'?&624KXAH8"U7DDA'?!<F^$%2)G"=Z<"
M#F+#3:.I/&!6!M_?]*"#V@8WN2@& 'R6079K&%;*S=^[ZA@I[&@YU9KOZYC<
MN[$XP^.ZD%TB/^/>C?@R20DX8#NE/H_"Z<O2=#'WJ:]1TV_PQU&.1K%P8L@/
MU"F*03X,DJ(8-5H1627WS$=>#C[96E3]S%%P+N4&V#0EH2)]-O%\D-&/@^M3
M(L3<Z'(JV+"*KWI 47]D?28NN*SSUHM=Q1?D&P@70N[:)L&Q%<:/\!"GZ%.@
M.17=[461F88\$A;4/-''<<YQU3C!X;^P'YCGJ'(\A<=YMK&"&#X';MWW0[$L
M\W8S76O_H^7>>IS'W)B'-=OQ0GF<CW*!TE;[<Z@)A9?\@-:#/:-80< QN&/L
M;)/UT-?>5SM4V5926:\X^5LRC\,&$S>>.8VR#G0P=)M&D46Q5>#7=HF)K>9J
MN[4;D5!NO6-M#2U,/R:/RET7S4",>$'K8$:'RZAHIY"_44>Q3QK$F_#EZ-8K
MN[U!<N\$K.:MTN]477 O4PB[]_>96/3%0'=3,Z8+PMA9N" @WJ3/%M31SF^?
M+*,<BB;K&R=P*7LJ>TRU!,@K)'P0KLCR\(4_@PM-?EV5,I4(FH\/E\SC.WIZ
MX/045O%P'@NU?QPA0@<5'RS2PAU@G\!'5("+TQ.HWP6')QE=]V,JF(4)!X&;
MXEF#6MJM#9.'!>*830<NA?>T*U2%L,^)J.P6.3U<$3*\.0^VIC <=/@KZ+PF
MH1S5G\F0Z<\V%LO%#':^$ ([("7203?/,>G00;,L+ZX7!4-95S*O__&HT(MY
MY3<>?U>T^G5)<T1<Y5Q*/W/:<"_R.J,VW%"5'91S8ER1QX9)J:3C*50T27HJ
M$)TZ6@97KW(\OZC2%CK( /-**G8-ZVX4@25$!TW1SM,N!#V9M+ ._WO_VX]K
M!2'\":VO2T'7BG5OK$@P+]NA9EF>4R1#.5-G$_F7U3P&FS>JJ@84)3XGFV0X
MF8WP\,TE[&+2#EU+V#0(Z@%^"=!!GS2K:!GV#)/ I,QE/:UA0[9"=C<>&9XG
MY#)^F@N.>5DM0[;4 VI*-/NJ<'LJ(?["%3KH2!L"?)@"H99 U!#>U*S#%0,(
M6E=J8.66YD" VLZ!^Y3M6,2X1-+G;=[WT]&JK^<?1TUN831U6]" \MST1VRX
M$L(.P,VFTT&G#80?5Q/(-N-C/^;]3EZ7KW\N7&@5R-GEPKS9R]9JS1+C]\U_
MD]TM(/AM?!>\JOY[C=Z7MZ%FO]\Z["AZ"0[/5;5"CR$'T 1MV41KV5<4D;E1
MC9O3\0&FMT/LU>T,11T6QHV8'I787GUMKBW.5'IR_S>R B$%),XD,O"$\SHT
MQIZM;GL'<\KU-=ZRLSMR:_[&CVMK+2HB)4>-C\6C.FA'"=EK:LXQ"+>ORU7*
M;+53>..!+Y%Z.MYO+1[:9*IL6N]CNF4!F1L=ZTF$7-J/2CKHP#N8:O#I2)CW
M6 P016/C((<"_23/W^7HY]BCBCSEQ*B8(NO95=-P#B7T(ZLO, G':">O%<S@
M47?='K,WS"NX5_ARHQ^R+WF3EO'<2$7@?DNJ:0Y0Y(\]93/6M;IR1I==MYH;
M,PV/1G$VBB^#":\1BL2-^%D!CG'D^.>5)+N6NG[$O1;(*.87(Z!C:2>,'.?0
MK"U$-A(6R)X5&ZZ(]:])U_F]<>G,F$+<[.SLX]3>E*./)4#7VA<P2@RB>0A-
M0!'N<1CB2%^H[Y"R3X>MC\7ON/I??V&ZTN+-Q//7XO3DK?EU\8=\#UE].$#(
M6I-,;WLHF0TYR!^X'D56=<&?OU@1.6SZ:,C^0DE$M(W;TO/M<\ZO"_E$C7UN
M==:(%_E "?=1X^:PD;II%A(=%-&($X_5T/)QUU#@:/:T?"^S[&GENRWEEJ#&
M&]1T].P-X4'BV3G>9MA+<Y,5&#=2/ C5$K!]YF*Z_=#%<JL3:XUN,G-K\D^Q
M+>A$\-'&:R>A,_<I]@1<M/7I#RDWAZ4WTF3WWBF+!2=\\L?T@D<V:2>-YK#C
M**THTE?J=^2UH!?2B#OV<T855>\A62&GH5+KUU=6V=U]*XXH61SU.%^,F]VD
MG')^0"BNR06J2-K ;I[KGC%,JQ9\VJ RQ$F&V8B[M_1BUQ&;)S_NV![_Q02B
M7I[0=#M[%T 3QNV'H#-"OVD7E@)K(Q? #N6#GY/=BP,Y8MJJFW""CW((.B_R
M )NF,8O(7<Q9.S>+=_P(I3WKAJUO::3;-XH47C(%RAU+.*YZN,GA*B/P],]!
M1Y5)S_M0TY_095_E+5N\"W4A]=*/A.T2LM&[A2R4DFH^BZ,/&]=2%E[< '^K
MB"I&W .\9SX:^,'.!-%!M_LW^1X499,*V.5?!PL5_I@FS:41Z2"NPSD0",<*
MOD0=.:9<=4M('J]_>>^N%5.:YAT'2#-T7/YUOB&3N84*BR(QD7)69)HK'NN)
M&@NWI6)1+G5:_KFN!S6INE5IX F[IVR)TL9**%_W]&M0;%FR62G3P1O.9__Y
MV ]=7W;E4YH-/?JB/E>L1/R/61D=/14<0P$Q)",=V1D(+<&OZQ4 4/WO<H"C
M]9-!#?%+B6^L.SNNA3X*[3M89\6WP7Z#K?>K:*SAY'/6R#%H6?S4B\_6[1JP
MF<FQQ)<;?!:^/;Q[[[(3KI5)C ^ 9I54QV-V2NN=![V%]UJDP4LTW92,A\BZ
MB#V+!B&+E4;4Q\18U'08K') ^!11<W'-E\AE;KGF7Y-);BJ;T'_!O:"@^ EW
M/NF&GR!B92[E F;HAH\"K,?@[68L1"BH67U5%7X]'JXUH-4^;GUE;>,S2JNK
MMG9O_C2L'D\P (]7W:16-1YK*5CAO=8T)WU,I((8D%9G(3_WMU8;O-5E]S4!
M8LZ.;3ZY_NN[;=E!JU+(P=Y^9B#7@N .K<!DI7)G?8O2P/7UW^\O5_CG #,5
M1[(D(!4QC;B1J.''B#BU&/5_,C,KP34=E-BGP<AOE!!,'Q10AM(,F6=9J-&_
M&6'.VF+1"1F#:JHA=B$AB%L?'#UB9TYPI\-!Z=D_<'E-E(*5,J.]DP?(;T ]
MFJ;S@(K20=::@UNQ3*[@LQ26@B 6.Q.2G6GO=, X6OK5OFU(@4-4=5&7Y*SC
M%1V]HKX#;FN_U?MO50O:]7+J<K-TY[&M1J"@\)G !']9$)"#[VKHEV$W];K5
MV6"NC3-SNAA5PAW[CP_':D/=P:/*1M1/%(W:O4A*.NR<:\EI9V_QDX%@\4[?
M<73M9&*)XO[V+)P-B&I*6\=%:EAD&3A^L_KY=\)ZXO(0(]8R#YQN$HPA%V*%
MC 08_[IZ8F%:^ZDQU8[<+>\7!93O&DVDICI3_PXW+NUA1A-) )&WF4.>BQFA
M5XJV_NTQ();Q^SO9+&UQ([[UY*D TYM"3#] H8XSLF.;)#@Q-'_"$F'?M_XA
M%6*8YR<U&5JB-(7\@.EYI-#>I80J.QA2*4QGBT:KU=M,X>>#^61?J2X8W31^
MF]_D4H/QJ[M<&SPU+LTU #U-&\"6545><*V QF6"X;*;NL[?LGN>'WB\*G,F
M8-)0+GA HG<X^OIJ(@N"K;*Z),RC#S?+]HG'^=[#?4:DE=JF;F\S_;XRC\BN
MHJ*'GLNUXX=RN9(=7+K3+%*VQS>4>NMU<0I79>)%\[0WYI!N 0MPHV2CGO-E
MG7]^RBPXOGLTD;)J?CU>TF2XPLV#3;<\>79CRS]RZ$2-JZACA,F&WK>U-8R_
M9&?YNE*7?FSTO.5,V/GN^CC#(\]513.;&Y>H#!?A>!DP?4VY#WQ\7#2KFD4'
MW>@?/^KZK>5H5>'78*]/<WF*HPGM_4TF"^^HO+Z+@&^4=X9VP@-7R9L(GV7N
M@ZH^_YTZ31N2"Z#@3)"<N9P^[72GEX0O?]JOXR-6ZZ6<L<<<(=PE^?O*D><^
M5]RF\Q^\M4[PF5Q!&3MXE7M96CHL%>B<%*U_%_473Q%,I8.N.](69*GM%G\G
MD3D, >NLA>1"X@FHUM-C959CDVZ5VSTL7<EW*SGXT3X77R?N&2"M+$8/DXZ'
M$P[.S?__,P[OP02/AOCY .CY"O$J;_CUL:,F!E5_G6]^>V>RP?P9NLE*A6+2
M>^F@>0=HZGQB82=VWLQHD0[*OB8N5+!M0V,;)WN, R'-[_ EZ!:JA5KD]Q)8
MT"^WD 2/]9N3'%E,G:[GI>).GM<V/)'<V$*MA;K#CB';H$P57#&-E^4FG_HL
M#+>H068::;M1G=6=U#'JGF=G+M^C3W00%'H&<BFH>XZEE<-FUCFQXIDB!]Q^
M0+1N0.;#LV0+]VFF'\R?3'Z F'ZT^3\> 7O<'S=P%:K'4[AZYG#;7(ZZ*P3D
M3M46C( 2J:=&HYYPG:(-X\NCHAK97#J77?U]9!17VU3(E]&G.30^-+5P[_,.
M3NHBAG=NSABQ+PFS$7ZAI^D@5E?CD>5@LXR M-"/M>MW+L;?NB2QPPJB2,YC
M 9'<M2OB:VC"Q?I0(HON%L)[SF6V9L"QNFI<Z<.3XPYEZHU.GO>2.2&/\F]N
M-6%*0!TW+1=&<$6/5!T)'=H+!V59(C_JA7DSW:;>87[ZP;Z9:'//9_[^WZ>P
M,Q%D*8("N+71:319&$KZ%;R-'J6#2#<8H:,^"#-M$4[1(U21NAETQ?%46*"T
M^K=?3;U6B,"85?W5OMMF[I97'EQXJ,"4<'+5_O"$J$5"8FR],UD]2*FE69AG
MH,+F%<)U09\SW5%T+9:DUSY[ZLSQ.WQ[F(L 8]@=LZ7F(]DI%PC89GW9$=B#
MQJ@6-8[B5*&U$KR(X??;)5%7I3M- Q;Y5'I!SQ+060@'1I'<:*,T,#!*?D;1
M@ GK%UQ/=IVZG I+)KZ,+A&MC493'W\OC'WU]X:.\6=3[@*2NM[@]75?_<JA
M\MB1#0]9Z3]N-J_2):7</[]]L7'B0@PE'BB9V00D BG<V-G 2'?*?0+/7%,C
M;]]"DC1<IKP@UD9=8D%N?[L^]:ABS_MXKV]JH"-Q9>"AQ.-!%GH$\? =-//2
MR4LC2V/N/$KZ"AL.[":%KBD3ZR8I4\^A\A2&(Y(\Q?"[#OJ;5)UL3#_\7-.W
MR2"X<<4?F,? .P6Q N8_MUY>H1!AZ;1S!*[$PX>847OGK#2X"XKCJ=E!.H5C
M[M@G382U;USI5<[26[NK'=;4:QVJUYGVE1GCB@Y:0?+T05TP0D$P6-66AK;W
MC!__TPD=<^T$R1>D]S5+XW&B&-@D>F-X];+;MBYIFW'[(%K?/Y]TV8=Z8$:<
MX!O%Q167!RJ$P+I\]:5UB ]I*E$4Q,TK4O9R*:E.5[N".DH9'UJA]8\9OJ"#
M3BB_@CX>5ZUW/K_%O]I3%\$^>7Q55NIGW>#M+/$<->-C.$ E_#YA#D:1ZDOB
MKG@U,YCS&O.@TO%I ?K1$L,!^3>X;6Z.PG6(O%'0)T91$&$BXJQN@25P]D[5
MH$BU:&?52:<SG0(:&YR<H:O;>-)#Z@OL4\RX&RDND51*;;A.7I>]4U43,RO$
M9191M"%;W_BH,F8D;MPZC^_AN%6IU\D [X/(+.87-X2U&/V*@3TI(@##/#Z2
M84CI%_[&QPQ3B6"(RGB]!T-J.VBC33!CVN2!9U8ALAUZ[GJ1B%':RLI<D]K+
M -)0'Y_HVQ[I"#-0LM$G3#IV.HS&142%HYP3^2R!EN:Q=RG7IZYOBT29EB0?
M]R>+,GMQ,HE<B-N9?0Y9P71A =GXRNP0LCY"OK2O&)'^LQYB.F37%G '?L*\
M<SD\P6W7%'N-X9AK(:>!Z'Q:'Y13PV0:#5HYZ%I..YF4;M3_Y"-ST:A7G./]
MN+G5&% I]GL5A>?W-Q%2VSH=I,UZN),ESF( 2S"2#4-56C1]9&D=@E5RM6$!
M?1G,IC1:*Y4<'+)9UIX_J]W362=_EZ"08=&MSZB0#&K5X"TZJ(43]5?A/L,]
MNXU@'3" !&Y=@6Q "4B<0;49C:;03MN)[:3'Y@PVMH4(BR9Z#O3\D%6%4(Q9
M=!EW^%8^L(&:1D]=#N&8LE7+^2"V@-__2ZKN@!(NO36BG8C% - 'U# _.\F6
M1-[Q\H9 TW#8 ^/S=HHM=R,:?.&BYR'A0@7+F]%0KGIIHN,,K82 :S]X-.7*
MO_%1^MUGSQ^(OLYL/>$XA;>>^3].=W+O&V-9L7 Z"& ,BC8/QU;L20T%[SDN
M$+XS9V5!4TT_7:#S'"7>*TF(E/)-+'!>QLC"7H)YM^>UVF].MZWA-BC!"C8.
M);WJ'YZI6FLCR_9^7:V*_?LS-/?K047K0V*CV);)I<UM%2^6' 68"ZI)K9Z9
M;$%1H69*[7"-X=N(*VGXC,?]TVF.FG_C:^:U?+VKH]&J(GQCG&S*3#<@C!$=
M'J/:#SG-&%'2NSCJ\>8:*#.R@PXB6,??;[*&9,] QV2-P^]6_UG_VW\!]NJ^
MCDB5RT![G??6S)WSZ_;A=! +"!!HIRGV-W++AM<+Y#_%.Z=;DW5)]FBQCK<U
M[@$;([F>7MZ9U9"W>Z@FMI!8HS#:Z?*ZL#O9L2T\)QE\;Z[#0PP[H7E"\QLS
M49G&RD3P)8T#>JB95UAW3#2O\*6T X&L3Q4=K]#&6V;WD)YLH3TIX&'A07)6
M%JI3>)C6P!@2O[617J@F)()Y#L/OAF+'-S6R#58XP-WRV<)SEDM_B73;. :T
MJ?SB5!CF/H!F1=I='K2[X^#Y/)RV](FK&SK^5^OP 4&-YT5DM(*BFD'A>*HF
M0\X)QKC1J%DPY>PP*;8?Y8D;M9XLW!$H,N[.M[)IUHA76M&*ON 'WEKU8@/)
MO7ST@)LZ^10Y@>>BH!@#M<FID1\HN$-0*O'/'@?"FSV\\VR62QOJGZ9VVI:_
MN/L\*R7EQRKL:R.4(!X!$0=D'P A<PV<'/IWAJ3F*P:D-L[Z_!2( W\6TN*\
M"8H[)<&\Q49CO4@V IA)-< @P6B.Z[F8Y="<=F6463__C3_+5;'?E#_ +ZO'
MA7$>GW=R9Y_%.A405DEQ#+D+H3RDOJ6#W#B@S6I<X;M%(2T*;N_VD,+#TM?W
M,O1<G&'O[O._3N[8L[G@+/"<M1GKK>/="T+JT]K+=&?0@ Q+;!'D0F=!J/\L
M[FR'HRC%,TWWXYQD9OJ77WU+/UBI+GR;,#2CJAZ@@<NYK9A7AP]=H19CG8ZE
MTLZ0GX39.=XIJ][RE!&+.B+9_:3SB!/KIV*=Z4_%-A?KQUM0!!OXV/@T*1G/
MV0A%=M%!8\(2I3")R<G8^*N/1GZX%O7(UI3%K<F%C[ O/-?,I;&-%@$Z.!+D
MCY_F$\OT!PW$[+(EPCMAYXT9=.]KSKI;2G]"'\-,[$OHH*-?2@891N=P6KKE
MO;^?4]+.>/0CB]6_F@.]X.D'89KQ"-T9(P;:+S#JIY@"_T.31 Z,22^^1' ]
M8HI^\CU$Y<]PT).PKI,GDS(-MQMU0&+I3S]3S0G#4>6P$T!P1W.C0/^CLOZ=
M<95U=X^+=GGL<M]N:PL]-P8=&+,L<%%XQ6E&(C-&U!<,;=Z9W3WX<)B6LL6=
MH.@.HEPQ48U7"$8M5!LK ^46?9%*=(Z!QJ/;#4G-<O&&7(9JTT.,*@S[19LX
MZDO^3W%S8=[IV<%TXH$K(IB7V.GOM--$:&M9(A?J*6"_:] A1P<YZVJX*5-8
M$(%\%+=U&" .7\\F=I-JT&TFB,< +R/4/5UR<_';)MF\IPTN[-?10<,O/M;Q
MYN[5K#^ 3N>!"4;/4!ZPJ"'(10#E#W>=2V3_BAXU\!MWP%9YV@^.@Z],,(L(
M,TUP,K\SYLK/2A*[L=3TMN:H<,4LC&"J"6NVEEV3(ZK-M3OP#\%9;6W&1>;2
M:XYWNX=$CRD  :NP$PB&V0Q+HTUBOQ='PPGW26G4C_X<P4+RI^%?)]PB0]0Q
MTD&L,B]].OS/,S,]%V?>S 3U$/'1T.DO:(*ET2G7QK/? 6?QEXW"6HC2_2+X
M=35WV,Z8ZSQHZLZG#"E'9HVK\Q6@D$2*P%S.JA<2UZ@RZ&D6B?:>.YJ "_!R
MTK>D_(&RQ&Z1BGEIG!?+!^B@"B0O[#7^$1E2<%ZS?G*H8WL<AD3V8,LVP[%.
M^+ T<!.4^8-H6=\Z47&BZVAJ(+N^OH)CG:JX4"3+3=O<];]D80!%&@0X_ F5
M!R1)#NNA&7B]>H$^GX-KP*?$=,'WDU9)SW<YPAX8L\ )SA:$Q5<09@!F#;@3
M/\HL-@?XN&0:'GEE4/KL!F<X,S-+SC6W[<2YQ#;&.$M<HTX;&,U6M>)/VRPW
M"O4_AI7;7UU2>#\X?SKWYWEGU2<F/U1PBK\H M0\U/0G%.%NG3F@3$R?5IQJ
MF!YWBSZ>5A5[J46 YR=9C/)T^7M&U;NN5I[IRW>4(.JT"?#AE'%_TQX8A#R!
M[++@@8 ''K]:21YO4>Q/3I8L)M?P2#PTZ.*Z("Q75P$*92#5T59@E"A+BJ F
M4#2)]V<77Z$J%+M7UV^I%^!+VSAW$S;N_/:(-M/AOC'M.]40/IO:(LO"Z&BA
MA8AK1%J*$"FQV/*G:RC\TJXY^)D1H31#_OM?RR.JW MH@A%\=+@=6EJUECN#
M"Q>&#+AO^+OQU%0W>FA^^!*_^'%AJ^6:0.7FF"%(5-#;?O@&^&5MU%H\T?<>
MM42 =A++TAI(P]427_H<WQZQ5J-F=%85\7@OQ)HB[6NZ&"Q"ZI_>;$X\AN
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M#A>2_LKJ0;D9C=Z?J5J/)3PA3P^W+F7K/YNWB8<:5T ;O]<9-ZOV:YQ1/O6
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M.#Y@UJ2![8#ARDRLO*-.KF3&NYO_]UGT!Q#,^.P?4$L#!!0    ( .6*A%:
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M:3%@78/MOZ>W+:-LS:PABLOGI;Z&*)?LC+E19I!L)U4U(<J91HS@^7P5N8C
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MUY:/]3R=..C1IXX 9R&"X#9=O_1-R7V20$^&?5_X\?4JL$56F8^[Z*?I])C
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MQ'U>V@%]X>Y*.>=HLR13D!P6,4Q[IS-4QSX)"U$^1"8<V/)X+<^V"$B^#KO
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MH+'LJ4'TIT_]+P3%.XE/JZHSI&<L\ .FVD9@'KI9@J9F?SI]I<.='=W7'3,
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MH+2@]&ZA/T 0I"J$*DA54*1W$())! 04E5X4A-![52!4 2E!$:DA]%X,G4"
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M-!\O_Z?AV-]?5:$O1IRAZ(O%@50U1P#M2]1CZK4*U_]*$?@S2BR'PV\>.,,
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MCEND#CZ\N>KQ*Q[B=T,DDQ"\MRD<^B?D1:PDT5Q^/ ZA\YJM-HPVB#'ITD^
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M)+4^3N_[38_F@4M)MC%F=]YH%D^>Z\N&7J:K_UR=1#8U-*RFI8W5O77/?5;
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M;]/C+]:D4Z+$2""D)?!Y9N:X 9"FS-DWSY=7Z/(I ["3C $EN/Q IC3>U9<
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M;)E.NI%1B/+27.4K@R8_!\X"DY*7L'%IL-#?T%*R8J&+HK)J9$?_K]I:Z4M
M\RHNX^!:K".MRB3RYEDM%MIL^?V0 'UQ((Z_.OG8. +_[BBHC0 Z/)HM ,,)
MSS&78R*7 &VK]#BG:<NXHZ%?M96P[BV995$HM=3R'ET?]2(,W%N]62Y:9T%6
M5S9Z 6L-%A@XN@18786])&1TB8 \:^GK6Y9VM,;.U$H5D]!T6Y80$J\NT=D-
M/[R,Z7TFPO5PGB'"PB2;-"3[@\;N+ZJC%O2>$4'F#%,"J'X0A-W2+P P'Y[S
M![IK1*<@\LZNVM<?)4YCK9VQV2"+>ES5?$#)>LOP9N"%( R$"/[K$=TD]S1[
M$;%Q)'*X<'*,F>[T:XCS(#QLPY.G*S7MHA>;#.I(1'"PGE5I[%Y1-?H2H* "
M.+A!$1I,UK01%K*&!(BR*M-?DT:M3[\3W7APQA%(/05P@X6*_O:U_XZ'R;''
M5R'$50A7,!H&'T/^^'&WJ0#,)IS=NJ]G1W9MEH$#A=]\*/=+*<8E,*7\>NE
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MEWI1A-.>)\9:_+-KWD&O!FC5(O]-87-9'%DA3R- XX'YVGTF$%H'()C7.]!
M6V,J@AL6OTFSV:^HXFF0$?VW=IM]2 &S(PR,4X$SZNU]K?SF$4D4O4&0>7!7
M3WKQK:7\2C0%B9W=1U6>?B::/V_>C*_4./N8#4X+=QK\IRKE$/UE^>63EQEV
M[PHA!DF<I7BY)BQ(^2A3(@(@^KEW1W6->$BV+;?,.= KY@%MKX-#IT$NP[N
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MW#6F@9LGY'6YJ4F+'[2-<J[.+M,> S&I!.2P>D;B9_\+C^DC^OT2VM'@N5B
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M.:WT:T44$>&)=IPIX^BW"_:[M@S_L20S 'FH@PK^U$$'/(.1.X3"C-)/+[Z
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ML+(YR$47I)Z-D;5LMC[#C\V6KVV1>?: JRP6S!BV'^UK5-":OO\)>:9',@5
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MF!(@Q^=Y8IRG$4Z'@N9:3I!96E_NER^#7J5%E??H.FAAC*)Q^J+![DU]\CU
MZ!]'7AHCQ_O8S']71^F<@$?KTE81>9(!M57V7'V*XN<D*&NG=L*$HT'=X-=
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M8>E_OWFG77FF<XID2HC\KZBQ$>J7IO\/&79^SQJ+W()O&&/ '!D6*,D3/P8
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M9HYAXK<>,@6MYXH/L@))3!1_B[\*D94EE+1D(Q6:RX'1PO];9*G_-R(;092
M@0$26/3*V4FNLT-[9//F\I_GOX@1": )%[M_S._\)4^D9N5PC3A^61<FR$S_
MM@L\OM2S530EF@KW1A6R<8'_HV4;*3\LZOX#("U(L_=#Y\T*Q;!'>: K0?2M
MMZH6< KF$@DU(I4/&&'=Z"RWJ)K(P*SX ?KHU2:XH(+6T?]IQ!01'&E?^?H'
MP&K\8\)1C]P%Z=6 M,T =!)%O._FP&:HMGX0.DI_2U$/P$N]0Y@8])@#GJ;
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M_,K_/$'*[YGR,2GV\K3U0EV-\.$V J!N.C*A]OFA,?=H3?8FV[W ;&,V!L'
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M>X RSL]$T=;$GYXTVL4."(SN7M[>G_N$EK$+> 78S:>JX+EE%"B&_XIKQJU
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MRHJ& [_KF ?=?+EN&K>O7TBK4MXL_S23F/\VL5Z5H\H*6Y*,P\-#,6]7]RO
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M<0JTTB\4Q0.OOO55#5#8L3G&:Q;FWFD);*H@K<TVB,WDQT0VT53!W;HPU2<
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M:[D3P"@.8VTR N/%)JMA[-ZY_;79E\KKX0YAX)171\[OB1%E2O8:4L.;;X!
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M"J]!\#NSW5K9LQ%(>)IF971V[G ;;(;PH,K'4.&K#R-B"R'>F4-'M8G0,)8
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M"'VLP!6KISV65/I5]Z]EA*HD0T;"8; ULD('X$6%V>ZUVR=;6T1T0FMY?#;
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M1BRO#TT<.$:A,1>.8_,BK\SDM*A2Y4WDR=_L?-1.WX@F$&]FG .#;ZK<3W:
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M\"F*3J7$F(2008&_-?<Z":;CPSR4I9SDS(77MG'DTF1\8G> DH:(%W'1K ,
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ME18WT!.#?P=X_>DJ[W9@06..T)_[Y?R(699:BO!^))21'82/CG.P.E[>B#6
M!BQ@J!L0OL5RSU1?;(NLJ42L=R5)6'DM;[0L8B*+]&RC:7>+0#UDG&0.5_#M
M6>;;JZ7%V].5&\6-EM G,])%=>ZIJ(<*%N8S&UO]"EB)"FXZ<\9A)>O<(7D&
MG9GW^B,/HP MF%"7^5G^R>16<;WVWJ!+2*^7)Z1+:B%?_]Y@Q=//_2F4X@''
M.Y?:=P 9BJ3$.>O>X5DF!1''"7KY-)6*"0;TZ]V;O(@;Z%K=F\PTX=8=%ED
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MW6> )!0,;TG8LV/G?\@4!\<ZO[&8LBK\MSI-+98@OV=:47\V]\^0*((]%S=
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MB;"ATS.Q]5]W@+[P+GKO0WGU5BF&^Z\\+Y^1DPTV1'?FW6XOUT/E9D_AT;?
MV+X[P'L:&77B#4/*-UA88 [N\2PT.V#0:^K/D<8J.1\$CNO:XS_T0QNA:3>6
M(,5B,O!K<@5<^$KKBMF70.C>B1?L7'&W7U2*6>$.,!<(_^?(*$S/^8G4+N\
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M2!<JVEG1_)[>BCMS#$BBS&&G38>__X?ZGKFJ^!0XPY'OKD-??QJ,':)UF^[
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M*D.L9<5K/G]&<DZ<4R?\K]UVN5J_6MLY+@(]XIX#4IN/U^'Y](RI*Q?RZ/I
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MX55U<QD&_?)5J)GY1FOJT)<+9HM*(DH^KVX)*MY.SW]P2^T*LT!Z5.+I1JW
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MXGS=V82LB3XX(49E(4ZUH]Z*X*'*P!$W&%B<&,;&RTS343T&?,-AP^R\*I4
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MXUX>MKJ(S9;PFDG-]H^ZE?'FSZ*W\4T5QQ!"-=AF:LI"Y8TNX!?4=\9INUZ
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M37%[1*@' $M!D/Z>@6"G:.3R$"+TQW-N[@6+@;,^/26[_4 YI/IHWP;X/5@
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M):@FR+Q)K%![;/?<>'$Z1-V=-'>GW-7UNB$@V Q*(>?Z+5C'O;BH>R'#+-G
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MI=D:'0E+?!@8_*0 GB?PT Y[!:U50%X!1\%LI)0.\C5>=*W<C$<X?.08($
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MH)I<]W'H/EBVJL=A[$9#<X.%9GK]J2B)0;%8_K&]@?J$(@H*O[N^Q_;[X.&
MTZ'_)]SMZ@7=8T Q7+99IU/;YF'UW:+KEUPG,X9EU76LOI2[G+=<#\D]932P
MO1[A!A1VR(;^CO)FDPAM[M&M+'S+H5I;$MGT)=N!]U&RH(#S\T*9Q? 2U8-V
M$>+\H^N?+9;',JXC**(HRZ4$L+JSX\#5"UDFL<D5C(@Z:[A:MW*"O8[-A0VZ
MP+E3X/&5GX;MC$9IZSC+Y\E>C1<.__HM2GTMM;KQW"4&.Z-E:MRG=ANNC1>3
MIZD=?=4_QZ&RGS!] TD.LPOIZ7EP9>G##0;I->O!'S(F4G)2$DFGL(KH(Z\@
ME]'N3H:4[.K+0>*6+I>V?S^2X!9PL<_-V7'ADKEEEOQA<'CGRO4B8S1I'\L)
M L%"5E_@(%KCX$Y<N89TN8E889)QMZ#I$$X@Y\654AOU8?)C):(3#3;+$R]4
MO6"$M$\VE0J?M?,-9KH!/&?]]OT#874[1V=+._KJ:8U8#WV&:B B,/'A 4K_
M-H^"(7B5;J=U^Z+E@-NM<O<G#2Y_@N>SC-;K[SP\*,$[M!M+RZPUZSGW/LFK
M@)FW"_@/6_#_D[ACRJN\5[RO0%[$YT4^2NF5\+'O.W<K:CO/(;D!M+[0Q=6[
M3C!"B /4%?J+C$V2/[,4G#?1WY0:^7\8^])X**/W[Y%*99E*I;)51%F3-=M0
M"8FQ[XP2LLT@8S>C5(HRV64;$F,?^\XH>VAD9^P[8V<&LWGT>_$\O__SZO]N
M7MR?<Y^YK^M<Y_N]KG.^E_+EN(?^-Z6TK[>1'+K[6I2SNO6>/2]LQ_DYM]5@
M3;=_S&#XE4E327_>OW1X(I=#SPF-H.ORA(@:RA1D=AB.X52),]D![O-18]4J
M3_AN6=2?2'S:\CO6J^O$X\X6H_[OQ>9+L:]%D6YOD.T-RY\]"@/@0O$5+DB)
MFK-GS*[_T'\8=OUDWY^QV':I_)3@5IX,=8!&EF[/YJ;&Q12I_D*ER^WGD7;$
MO/#B/JGMWP+W?][ZM=NI5/!U2U#V?EB.A.60?-5!X-"[&;V4R.U>.\]55F/&
M>%2M?[PS;9#50"SFD8%0=([ME]&<$/!RS@.>*8*3KBZ7BL&B_VD/5<@JB1@^
M!%[<_?&%-2Q<0V:=3.0IOJOUS,#H3&98^\&9/*8E0H"Q]Q+J;J%5@;O)E2]
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MNK9G7Z<T]=Q!?7I[C),;YYT_(T^U F>;.;JMA-TR%.B-K#4A+:WL+L!LY0]
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M)Y+*W8M^C-4$0&:. !.J93_9K]X?"8R LH_"9OWK" R6SS!:>F!'H];"IXN
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M"5V3DPRSAD-P78F^8Q50>\,--^JKJ6\XZ-*VD>+P93^>\WBOOL;LPLF8\?I
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M5+A<E>LSV)U+^NK^G3@)4!O> "JP5^C0CAA\\5D>==NZRVV<X5F+I/'RYS>
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M6H=B$(]"C>'I4(DU"TNMS'S@QI5*TNFNYVO_%Q7YP4$>\"9LD,>)Q"(;,9H
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M-ZIF43C<WO)$DX)2%JRV4U#2T_.XB$+FWHJQ>ENZLOVH87I;D'YP+Z7._@U
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M/R(P1Z_^63ZF'?)T6#*X =3>$KP']::A[H+F+77B?(1&NWN" B2FZ7;0;S)
M;VX 97BQC2L-W2%7?!_J81J0LA6Z1X*&F%25%0&52F7)&K +$(%'[>>.MM8E
M=M[0+ARV.4F*?=M[!!JZA^H )40ID$=AKH[G'$JD.#,I DYEI%E"05W< ?:M
M1]X*R_BA]R"3_-LQG>%.7OL8JH9#SMT X"?;XKU#[QMN";J"T<##/W9G*/Y
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MVV;EL;Y/LFOP$.10,FTZ6\8^H>>6ZAAMCLY&#RBIC"3IT_"I9)?51YJ-B?J
M02.<"GBUE?WLX*6KEL9FDKOZ^/2J3>';TIY))]+\#,5:XY2 !V]-7\/$56LO
MC/++PK#:P08^&CR\H#W,V1!&2,Y1Z4LZZY9)Y_V536+$4QKM[?IUQ>7QP!X
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M2HG'@NSE=-Z+1%C8<?6MO7C>$>P4D%\9;=3!?6<N4F7#Y-R7(Z-B0;ILLUG
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M@_L8=]!\USK(*R@$O=NO7E/J&TL4F@^5 .#S+@C9;P!T.!+@GN@5;';Z:Z9
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M*;*+*WG?O;QV\-AV_VFBSNZ[&U'9WP NL3QWJX$JBA7@N#/ />1Y'N2T.;G
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MW^*Y!.-1@>TRHMI V:.+&+3[L:!(6#X(XO46:3QW@IVSYK(^)SXR:%.T)9N
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M)K55$>WS1O;2T8QY84A<K:RFWEM0MDN%E']9M[H )D0P51BYJ*@6_\4X9V)
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M^RG94=>K/Q< A':<1 1J&Q/_+$LZ+O ]9Y*165(EH+6ZYYLLGJY[7)<UY30
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M'0FDCI I*S2AOX%B5J3L"+GFT>WOG5*)9XXFHRK)F!7[+7Q6-](WR[K7C':
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M!<I[IJ)""4U ->].MY;[%OR?BD]],L&HK1,&B'FE*^ L98'%91AU@O",;_%
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M46]3S3L><Y$FLAQGU5<.WY:[9E:M:"AL<2?-.Y6'V']+MZ#H>A+TR4ZXEOE
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M5+6M2/4"/?Q!?<AA,<%-7M:#A\3#),=KT"4IU?U/5>"$F9_-3!UPAB8;P*?
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M2HWHZ[O 6GH?IB"K?&,0YM*2*)SO@SC"XOG7GCD)75L[2:]D>-0R4/U>;
M4@F57S]!_&R^N,\KMPA1-ZLI9-!.PT _NZH[^E(Y!W!/ [<2$+$LF:+*7\R.
M1YF$%L-=(-Q"[AE>0'GJ=%M4\82]):R+CR@(!-]F():#HOSC$A==4KX-(BN"
MN!DZA!RXN^@;E'YW7)FLK@PLBR=#GHL-B*-[@?Z&$[]VW8_+;<3^!NDP=?(N
MQV5\S\N(O 111#QWN\<&'$)?9 />$4<'FO<I%SS2DWY<<&3Q+S%B1E@E&6Q
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M.(:)0P8E_*PGC:);99.(BHK!HC(?)*6#V5DLF9'%P03GUWIK).DHZ(IZQ#[
M#AY9B\V0@"=5K2B\E9."FD+E87@*]><S%\G#UF284=GNC(",*E42X38I-B"N
M?Y3^? ]M_9L".PD^N"##NS./3)5.]>?0I@Q+@>.6A5Y,#__FYU&FYI <;L</
M?N6SYCQ"9>U&J*^30F@R&+0R(\C]O&RW])!<;#\+@G"X["8-!MM:L[6KA>\
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MK]RL6L/!B?(_.*;;JK?7DH]&<U><[6/N$Z7D^1=?JS4I]W];(->8]RYHO.5
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M^F%O5J5+?OE7^TV!%G>[ZYM.<550\#*7FK!2[U=+M2R)N3_7:PI=ISV^";B
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MGE%.VU+YX-BW#[$T4=9$S?^9H+Y]?'H-8#X_H\8^<>/X/VG(;>G7 *:HV6M
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MUAIXQA=%E@8;WM0NJ,YO'C7%I7>&/_K,!<IKNS!@[1";R?S[V!7V<:W"FL;
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M H.A;G@42.K,_ < \ GFH.SYJ/]84'X.U'\-H)YE?5+)0B:DIB@D!+OP@ZP
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ML>4]B?2A2YUNZK$%/S?CQ37?._?J70J[:)M):9LYM@JO:;'^XLRTL-3F7-<
M,7.VDV[*[MZ+A95!@>F+<X\RU.?_JIHE#@D!X87:^F<*'JI]+7F>J5_X=/FD
M?;_#R&Z'YY_,RCD#IWZ43_*]DA:0"-G8 2=)T!:WD^/LYWRR?AK5UI3Y9;F?
MPG5/.0S\(W<B7B+3'M9ZM:\@,W+DU RBY_W2V/AY1.Y ++5T,# )]A(#QCH8
MT=+0#. !@.:'F90/\!!2[)X_UTG!)QCP1C<DG.A]G.L6BF :'!AYL3AI,EB[
MMJ="'B/S JZ+[/.L$^=\7G9)-!-@6=/ #E1C]1" 8XE\5UPG,!7N"C#M.@VM
M=]J5<6H'!\[" WGMT8H%BGO_'>/\WL";^FF-\)O/L7Q8UU2H'&)C+ :5F;P#
MCD'.7&:=$K"S],FUGU!+<67]JUZ<B]Z+13^=.F#1$NCH1T\^"1VBV^:9/CB,
M^C &Q[VH]>.I6Z@4N)<;<0%=E;(!R5@KB'D^-KPSZ:^ ^/7A3[X%3MJ$V,3K
M4+%BU[<VQPN#F@T(FJ4$,I.J;U<0R(^%2IO5DPM%2=5E2UP2=2;], ]\"7T+
M/,JV&TJK^47Q;QZ<VX?J)2<8/4!D2-F!_(/.+B,G)O(QHF/&"0D $7_69R&[
M;]; <BI'L'?GST?3O.S]-Y =C.;+]9(PFVM 85M. ^?YW[[^+N4,Q[2DX546
M_TQ)GM"$6EHF=)>\?A]'8:HF'4&0F1WA9UK199'F:K'R\ZEH)O.WV\$=KP($
M)_2J*C*02*(RE>C#_DK!G5T)$>3:FED/H6D>(NRG6'^XB)^M=I\9L&,JGYUE
M$+/5^.=%O-:]M5/4KV;2X:4 =K3BYN9>#V9YT?\YT)U2ZY3]ZKO:W_Y[B.G>
M$6--D+0V3@?7O-CZ1*FM2X2IB:;2PV(#D4.4VZRZM@R^!KQ<CM9. SLY+6*G
M&&>FW#-^5;U,@TG&)L&MUN$*2PL7N%@QM]9&NOJEQB$&\?)0R7=56G;%29E%
MFA>GK_HJV5IJ^<F2#6@#OC3"9@-DLE0LJR,I]3PG[]-04M#^"PA<YH\R52V5
MYM/PF/'T+UG&BM5#QIK]OPZ>)FN<.LV@'TCP]7E)Z*WSG*NO#7O>GU?CYR!2
MYX3TV\J$MTW+@YG']0L2?-;&$^^6]&;!&0UX_\77$[TCT&4R&7160)P'L\$;
M4*6]S/KP0C_58KOS;WBQ8X'*9P&.CZR.2O+[MC -JHRIL-_[C$V)L-S@>W:K
MV;">_M62B2<9IJ*CS1$/]TS6$^]7\HP_1%I&<M'K<]!@;_2$11X'+J$#O=5!
M(_!1^/S>A)N;4Q ZB67"R3WK/,UHN:F]0T4(1:#8 7-"FEAHBJ\!1-> <%@V
MK!%>HO5_9BE4]WY#FB65D(1/Y>07P(MZ61=%EBCLK'C156LS+.6_JGDJ4-_=
M_Q$CQN*N%S)O^<G7XAP[KZ .F"&IYF6-HD+-_ O<UDZ^+8E:^7)%!,>5X?2Y
M?,,'];U R-9N++?X?\.<\EKK 4#$/#H16GR0RBNB_C3SYFV\[$J3^;U\-UZM
M:$-<D8"RIK!_D-^]3S$R;TBJP*(<O.@T62?'I()84E9:LL1ND3,S?AG;;7"=
MP3)]\#3+:8_]GW12;N7B$JF7-G;$/%,<:YZ>JW,?K+T\$<@I^BAO#ZKU'B\R
M(YXLPC;$QQ-L^/&$0R;TCZ=-Y[*3$]F?19:[IFX6=@%W;\D<N1$8<7)4EP;[
M6=ZIIJ:Q26^_,;B,KDFS!_*9_3HMDAN>[/*PI1!]3W?Q+TCC/BN#/0* @-XR
MK>RJ/'<DNP;,(CD"->2T5&5;,+'S"[T)E977@(]N*<YK@86B'V?$ZM&$LP/I
M!OO&PGIBT?VB'!@5DT7QBWU*35EQV&5KV?'9CBUKJF5SIBRWC%CUBW6*=7TR
M@8M-PM!3<2G%>!)/D"ONBK^AP?"K-Z0'=R7GR8_(V5-KPR_UUXL7228[;*"X
M45S4S/I[,1M!R\P);R8L0JFJJ*G^JVHMFC28>HCUOW"523:%MS9_F\XT$\C*
M!CW+PJCY/;92^!>^WHZCM4OX*>+CVVQ<7>GP<6A+Z%M9#.*CB#6?!<Z(O'-U
MV;"BHJE3SM!_V-M%A AZI(%K?BP[+/2;FROD^/+21BI09P?!=D0>^(N;N0?W
M"VW,SYZ;[,[GQ)[FZG0-F,I\/1$Z!&%PZI%,(Q;-7!P>71/PRZKJJ*ON4P=L
MP_]HO/F?RK_]H_7P9DGWCYA*/WM=KVN 720NR_SS>0S[=O?DR@T-3=(LK)%*
M2D$@#>=V2.=K0&CUG6 9Q'SW%Y6X#B<9ZQO[O(5KGHMY4W#C8E TKIF\Q6RU
M';T'BFH2K0#V9UX6]^E\L.#Q'%N@; /AI*%N_VIYLKH@=!_&]X8)A$=\U#*F
MTDD8^DUUW;K%U[ZK\]SW[U,,6B6PF%?R_+YRN3RMM=LL&R[[Q=R8XDFJ<^&J
M/VL589L@,V5Z8[VUS2&NC@.1.#:O<RAVKD%9,HJZN=RK[?;R!X>YWR$-)UC_
MAT8\T=< E\LHB)'?>I'0E[#+@06$N\57;X44XE?R%N!5+UC/&V76V[Y[UO#V
MK3V_:P"?48\P_O+X!Q[[_/@[))QE8\RX DF?VPZN@P(U;KZ>NRY"#7&FPPPK
MAL#<]GZ)F10NO9G^P@4Y'39EBM'ZT_9>,"9^M$;)GI"D\E]-<>"'T=I:W\QD
MIT'HL+-.:0&VM$:0IEE"M&_?9"J!O>O9M\Y=#I#S><@I)H"L:Y]$. @;Y5S^
M>;R@ J]4P3@YN2,N0O///@7QJVUJ[E*ISFH+0P+LO ;<=[O ^^.JY4)J14TU
M:X5D,V[BU%'MQ/@CZ;$Y]T0$JVC2J^5]9Z'4O^07'9[$NQU2;AA@%V1W+6[7
MND;J%PD+&DS1ZGKS8QBV^M?75B%E@_&9&&R(F(Q3=:L%[2GAGLR*Z^'AC0%M
M.60Q2I3FV5N$K0YK!,7U/^82H;>]^Y6]1[$LGK"\ '6FK)L97PC[RX6XL"6
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M23"YUP!C7XJE:P!:YD@&A3W/,CS&77UB#D)L)?#9ISV["A_3W<)_NCPWA9V
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M*C(9?G?/X:9>F).+8:J52\5II!QU,#+C!\GGD9@Y ^/-J4)#Q_@V.(<Q_^2
MMJ6;_K<WX]['==7]K#97VB$N:8;434UZ=KTF9:BW4A$%G&ZFH =\\.WL8(H'
M'B^^OKQ7 9FP'AG,5Y?<Z##8\B6W]0\\: \=QF3R6'EF[J-QN@=(?(68\;YA
MQDB;T-3K^ZY!I:*QFT5%71%63Z;?_5'F,?&PC\4\X*C[XB]O)PC03+QS&TPF
M(I(M@B@"DYF'KWR$+,E[DXDX$16G)6^T=^T1AO=(T0M IAVWQ@!$[6&+ &R[
M@=S24N*D2L+"T3$=<MC*SV'E7&Y)IA[["U4<GU!IX.HLP/;S6+%N[+<M?SK=
M?X?S7_J<1CJNO]]Y7[P6J:W;T8.(]6\VM(:D2&'# ZR+%MHDP8U70BZGGHL7
M1YD[Y?M7Y0/[I/W5#2N1QNH0%\\8=<;=LA8B4N/<W*SG.) %_U=A7M"%@=(V
MD=BN*RPQ< 2<Y.LJ)B'T6#WR4/@$=P&%#YW>U_8ZUW#,F!N])(N_0,6@0$WC
MDKV,:T8?,A=9_#S!-KH])G<=A"6+?,?^-=13,E*^>O/\^T=$<(0/KY/:)R3K
MY,/45)]'Y"D4/1#I1-7&L+??@[H:-[.D1B<VP%GOQ:$)(HW.B5- +D[1FDX=
MG3GZ-!_=/8$UH6L Z="G<W_-,>N&?3-N6US]2]6(TLQ849O([)3^_,0'NJW$
MPC;#LA,J.#S$!D:60-H9I&48.?WK^+@3EB%^#9 .G5_.I$V%);6<KR?J&7ZR
M%X5]_%?:0.R67W8\KA9C6E2!B+94^-.]'VE'IW\45R%^E]LP3+,RI\[5V7+<
ML*6WI+CZ=J(4>&@-EV%P_HREA?/!_8J[-M)OJ#@P62/96VS+BVHU1VU^)+T"
ML?KMO_YZ+%N-82Q%#Q>1 ^J]2TV&5P8E,61,?(CHSKW$/^ARLM?L^;'?)B8#
M9C/R$]YT8S\PUI:&?B&[R\FU 3Z<O ;TN.?M!N7H'I_<)#"L3!9,3@0RW!Y;
M4'%YMZDAO/L7!FZ.BYY%AEL>@+JH78=-ZE]2TL=R;@SN\R77<LQU>'Q/%C)C
M*MDIZ-?^IOL1Y@SN"*!_G-V4+?/KDL%Z2\6CHTR#P>)%UG.,%R2LC4H@RF2#
M',&_@? L;S& UP/FD2WVFPWU3-Z.O&%R]"W5WQ7C8T'#HD(N<K'Z78T&++F\
M#N),2T9ZG/, \@WC2'P&2U,+7C^(HZO0=L>,]TBZ8S"'A_S8N9"Z=+=9K(H@
MO4]Z,DX3VUNRYU38W35_Y!AP-CW'_<_V)$4B TO<.S#A9$SV)>F/]]]7B3<I
M7:>2-*9,N\VM\.>P]+S'=B62JWA"QQZ\[F;H7S;ZX5BQK:Q=T7D>-,.^ +5P
M5.N(0&*U/CO0/2JSW/'D'T6F%/28"U)<*MMRFG&HGXZ%)>D&"THM53P(:*.@
MX#9,!TF;2,V\I_PJ,C*"PT&<%32A6QWA(HJ-=E=A286Y6:LV%SU:LDSHDB,=
MNUYI"<:%\I0<9BP)#_=H19)Y W^'F5] -:N6 C.J0E[<)Y9!JBTP0$>,A=;P
MQC2EK@'./028^E=\Q[&S6*TO.:S9VAD]X.^TMDLX[?5:DO29FAF)BRUB"^V9
MU-#0TOXGO<1>D*_2'#$8^FN.Y*R^K;WA.YG2R:6'8IOMX&-UQ8T/EZ<WW3-H
MFK'LP9C7YCG2XZ\^NN^TB/BT[46%_8NAM#J9QW[IH!<!62ILH/CBE8.0(I(<
M'/$57UO+V-\V/GE^8S9L5*_NTZ9,V7^]*\."NM0JD*S<[/JC@= A 5[Q3$RZ
M-Q5>XF=^9H3&7#[\<)24!$F<#6P-MQ_S%)&QBY1N+UOP1K<BA1AGST#F+>H.
MT?1C+VN)%5[7:6E1E1DT>OVVS-9Z5_2W SX1RT4@2Y3U'C?(</ FY]7L8"&
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M'CNVMKX(?EZE#V[IUX"W"+>L<>DFR 6L\0?ASI):F'S2L!]A[AJPA1KY]=_
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M1:??:?&"AGI[_=OE>HZ@K65:VW.9 ><LX'/,-6!1)W77M/BB8,JD::*%PS8
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MLLN\KRVIGP&XLI),;\+3MJ5$#U,S&QD 4^C&FC!Y>%P+3(%4+Z=D3HR DAF
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M;'ASSATQX*U$Y62)&Z/--F)9?#B/&FC +AR" 8@XSAF88MK[Q.Q/5[K46<@
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M'$Q9_:H2I/'CCI4^'/$S6U!L"DN1DZJ7+*E3^K(QX+#D=W"DCKNVZ'A'WY"
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M_VUFQJ]U^UH]=2AYJBXI'A$CGJ+FT)RPOSUKZRX"K\N=J(F\L*BB'/R3T,P
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MF.T[]$DOH;TKKE2A:G+82[:CX-_$XN%/3J\1>M_%05V#6M?1FR]#0W+06-7
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MJ@_@GK# P[LG;MW)?/&BAN&0D"B%*YZS#EUQLBD&GVP6#SVB0G3_0A'<QQQ
M+Y>RW\2XSF^\R^OZV2P^HTL2!/6N6[J/D)*'XP/8*VO<K7_1[_N=U5A\O)+?
M4H4BVVCLP;77M\3E>F7L9V*0+GSM:9<5I,#G8P#7N.QNI#.9XQ?9M\8[& #+
M*,7TQ/2Q)=S^7AM1RYP!&*3RZ<,3&R@)CEYLK4[E/RC^/)@+B++@6'[!IEK5
M#6%'J-"@DZHR/S0PD.2'N/46#T<)]:BM?VORK3!4/BP<^';.44U,$K9Q%)/(
MK:K4<SJ2\LMO^2 K)K)4E"8=<7<&^JPO(+A:PV(ADMQ.<J+_)I'NHYB:FK=B
MY$%Q=/+FI=29D+XNZY?[+W:^ .?@NQ#(KS3+^7 &H"GL6LUO,KQKR_>^!&J%
M[@*=D".&)N:=@.[I['W/1G91;5;AU0?O6"@[NR5Y;<"+=T68LUE 5&_Z3J"F
M**IT](1:[5FG%$C/%-1;\X/]HFLXOVKX ?$DNLJ1!VB$ 9C?-*;$W)Q_CY/Z
M%OF^FWC$S+*_3[C5A0@?&SW_PN2[!?='(=7!#WL'# !0_RJ;<,=1$(N]^4_J
M3.!%O,:%6W$:+U*EZ@WP,WQ]+QN\!:Y>\T80578U,/!#F$?7H$"5S-JY>2,Q
M-YT<.&<_RQ(%PJ+'^9-"?)?U*^5RXUZ"%D[BW#X#8/Z$B?*OSKT#-C.I>7:A
MRTGD.U8#O,DL9L^9TC..YW1ZJ;L;I:<Y@Q*>WW*-^^)QL_I#\NW1P:Y.E!*1
MI225(%[W*UG,;6BW:V?WMS:2'[=\*2,//O>1I@O[8NH-2C'3\AZ"A+\):H@$
M^WO;XA!W+KS^G?9SJDTIR)">(T_%P4*0?9BR9Z*Y5%VFT6SQ(4@]<?TNY$L\
M!.&?FLEF__N=9)_^W5BK5]Q'M7KT2]/\Y>[%=T=-ZWOY*@J+'=F4R*>KQU[/
M=Y6#E]NG4GAS+O;_A>T=G&XJ_#>S]=;H@TWDB:V9:Z*T/]MA"?^77;J_=VZO
MN&[U[M/G%)5YZ5]*0=1W@U23F3B>]7N9F;Y5)M\;DS]CPR(+8HVY$O7$HVG:
M!;0Z; 1YYZ[-KO N-&-J-/>!O$ATT:\W5]S.'%6\ZFZZB06O0L>%IA@ E?]J
MC,.WD-:Y^VIKO<]E4?G7^X_439E>^>AWS3$ E5K;T=3FH3F(%/JB.JKAM5E:
M%(#O%DQLD7.'7C #;!\["LP:"_=A/0/@7-%G )[2/+=F++C764X '94?<@J%
MWGDT2C]ANQ\F+(IM4P_F?" /(\OAQ!_WC(&\"&1@58;MCM:#5;G?2.0)7UK0
M/Z;#K2,A%'35-6+G>%/CM0]G8'JCW#8, &B0>"9UN[TJHGDC%0+\_))YBSLA
M0^:@6C.F#0^/I(0=VBU:PW?.GT=\C_:T$/L'Q8#73^3&LUY5^*&&3Z7FNBZ?
MJ!GL5N/)_-M5D)C*!RDR]OXOH0+)/CI :WCD@/HA(&SAVI_>UW(=HRG>D=S@
ME!#JI6VSO6*[=>2CJ$4F(M P!$%"Z2V>F#$JLB+LD*.93Y/<V$@%KYUB2@(8
M1[;2)FK:*^_W^L%AE:VF-+F#Z]'"&]XG?P$V-9%859B68$V@<0I<!I YP_\K
MQ;[^09,7&6.#VW=/IGD!^1B 5]NVWE40F>XYUSD_#YU%>B5HO(T&H51 D"')
MT![R::C^\9E$[]? !> D!6>WGG&@67V^RR 'I+E+;F( A(]PR,"MQJF*(WQ2
M&Z&FB1?=UJ1IR0^FH5"A/NLS04^(_&]TKL>)S4'=_DR0<SC1.!AFHO7WA T_
M U"&4JD&9EDR]8 )[M;[VS-AQ7OK=42F) _MGW,IG"JB1L)&T KD]OXZ[N5Z
MDL$Y>B[M4330R#TU'*)VN!:8'X;WB?S!7-5?57(A*]F[*(L!J#G<0N0T XW/
MS?E(A]R830*6UNX.4KI0@=N]E?<5./)#I6BLO#?!B<P5VZ-:8:VVOG9\B5[
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M\4\6!;76QP!8X;'R=>C@ :HNTKIC*;?P#FXN,H8ZF"65FIK\/Q5L704>$1D
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M5N5&:W2$^"B(EE6<=1MH $)!VU)[J9JO*#<9@)\#]5J',Z7@"T"W$_ %M&4
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M&C8KK;KP&;.4K33=8C9F'M88V3C[-^=_GL:N:%;<KHH;EH)CZ]\RX'$:7[B
M6!R3P'-:G]/_7_AN]=2U$KT:@YYUI6+!4H#;0[>'G EXM1G&PGD&T862*QSL
MA[?TPU_,/NHV_Z"1-DAO'M1_I)P5H_YI7P 'PX1[/:I+F,K1&VKI6MO1D:U[
M?P$0$OJ49^OC0P%+\,]<0"MIS<?)^^;-?5&AB!(A1=]<D(Q5Q"-CZ&HMXRA;
MY[UEJN;%OY)T>?:^/KV%V#)XIBN+P'F]DLT%7/2+F7>AB2JWA@M&NVN 7$JG
M!UQ#6#(@W6Z1">GA2[%N'!Z+L6?@*6X^/+H,'"/L )V$%TYL^K/]!UU%'IE=
M#)<D>AW;U.8H<[9)%8PAM!ME&SP#9O 7PJVK<-,<GI0^I9=C 13OP6YXNAH5
M1/PYZ5.(74&>M84W\+!"9L_-H7V,.% ?3P3%$QDH+/_&+MD3ZO[/Y+XCIH.)
M2.R&![\(+QKA]'U!!)@.F8%OX (ZP:PGH&4A%-MN7!#$\[!H3;8 WHUN\(JW
MN=(NJ+$/@9J?4(2$Q7!;UZDHHCL/(BJ -GEKE:%%H+AY;X?S)$ \"2#MF4O,
M+)8F>D4[E0LX[%4PSWDI(,7S&CSWQ0Q\D4SA< $\!HSE O0@Y-6_8P*[1KL8
MGES4UEM:DRAF0OJ&[ YJ(WD)V5HQ#=R5@^(I.![3A</;W/:&HO*&XBU<"&-/
M1)7V#!/#BH_*DC5Q;3GI#:OF8T:F HE8W7%.I1\O")W&,:S^N]!3WPRVK L/
MER_KU@ 7CFZ&5V(B^L,=WEV'QJF88@A-]FV$@14R?+AG#C3'SU[@+0.:MPQ7
M&(;(E51.))&PT4L0)YG\[BO0]KC^^O2$\II/LY?R&@7#8/'F5Q'"!7Q&TCKA
MO=)01GF5_PD@-9<W+&.!"Q 4W'SE'Q"(?%#&.3G-!:!>I''RIC E-WFXV C[
MWR='H'CY )<-,5[PWC H1T)D=NUM63"5"W 0E&<&A#4)Z$YHSS4>X52SW$$,
M_A*X=5"#\%$.+[+L !UMZ+=8KK+?I4$@\Y'$%1;\J;^,,J>6BB&F4UNP6 8O
M6"T+586X>0.7[9@NG,@5-.@SLNV![:4"_\%U@*;J^XMPZ]1Q&EUN J:S2OR>
M,Y%RQSSLLVY4C_A GM(N-+9*CZG6!FK7S&=YASGLLJ+T+RQR#(%'-+.1(7;E
M9I)G*R\Y*/_*[5SK?MM*4G_XD@](2@\IXZ0W4=_731K?>_D0/I;7A2_P>T*5
M_ZYQ<4CEPN8IN.&)Q:EX36F#78C+#=R"Q>9=UU>C(T 9Z--K8U_3471A?(@$
M)[F@B.0T^UJE@WCZFUD?T1N_H=,LVK9"[)X\:"F\(Y91*EX#2"*+2VZ@/]Z]
MLC'V*Q_1KNS%@Q)%:ZNNNM.^CJ,=*=];Q'K%O)[7=229\M_-O!-[1+A)\8/Y
ME>8S57$-G/OP(UK]1>()HVD/H[/S?^/GKNY 0HZ R3(65X//_+4Y1FBM>/*U
M6'\.L:F+._^K)GW4^FF195^P-5H?BM'Q3>6,#>/"9GYN_C@WVTD@E[-D\8@N
M#?B[5LOI "Z@Y:+NK]TCG29\\X S?NYGJ_L)B6O&;_4&M;F (6*O\^JNW<CK
MBT:C6S,1@Q23-UJ=[&:^:5B<P3/ 9= HD!C!H7B[BB#&^VU_>"A8#A"J&);_
M\_U/Z/^ :O_+#P*_3#F79-4#YF,Q7\5JE]AM]PB#<)>\)3:B7DAQ.$IL[_%D
MLY/CG4WPVYA>VQ5QC-:W3@$-+N#][G([G9)S,.8[/))MB)PF?@?09[3C<^**
MCCZ73#MGF Z_,(_$U0'?H:\ _V@%[A+NA I?J[[A@3DKIRGV3TN;VL@X(Q'>
MBB:+\I>$ *NSZ;*?&B;BH8D/_7+6GCOL8?D0JAD*?SF;+WL<#!HPD;C=2EMD
M[1VUCC"[4&X(IZ.13<H\*JWDAUU:U<588GD>7BKTDM/"MD@^X]*3MJ=;23<1
MD'1XW<@1\*S=)5&?\_"/X6K3B2P_7YW8&T_'F24=37'I9[:;MMPL",BJ+!9Z
MO^;?P.J?HF=7@;[7X7J,C>42GMOXYOPGX0>]M&C2BL8%]#Q0F6W!SQ?#J@:"
M:FIY+.$L'$+*F6NSNU#$:N*GFSI'[LJL.$1^;M5]BN>(]M%7S6:)4TN_X<"1
M^G>I5PXH.TB,@2M/,U@G_ H7+P_O#P>58%HF;-"D6(_-B\"'^2P02+4B\UT'
M.J:S%\\"Q3#4MGA_5_-6:T>])-M7Z7:70P*>)8RBZ+9[Y[_AX;\=>/!=90].
M,:1S5VYJ[I-@5.^$0V(KZ1 7 ,S#^!,)LGC#:>&F1TK>^'-PF]FI1-Q! EF&
MLH"OVY0JUYCG9 B(LVSA);[[]A($D(X3"P^E[N#.E5E]%'<7T_A9FGNA7?DA
M3(<9Y0Q4J4'</?#0W1IS8?ZRN':8B@]'S@$)VR'^@?35@M*55+W",\(E9B+$
M@40NH(&Y43"#;W0* IUU85R#90:A2: "WEI-89U!N.+I"I=^JY&2GE8:PPXS
MZVN$9E!<<-)N#U[V1Q>36OO5/WJJ&._?;VZBBNW'+S&8>&L!A+-M=I#MD-V\
M6[9AYC=3&\H^B0)W5R-MY]DI"K[LRA+^Y)'R6VI)&A3;RXK0 N#]L=I_""XH
M3"B%C+2#'-TH-B[3* <B2F+#YU]P:..%G&"=X*/I-^2."J]XO6-L-E/7M;4(
M0MI:T[)R(R,)MYODI(T^&9T]BN#9GW!H)G%(VJU<X+5@!"/1CY0O=?PZD >V
MG!Q01[=A$GB!?H@8@._03HPPBL$%K*'Q-919L9;54V$^%+G(SGA>C$0C*&AR
M25A><=V0MU(PR,)O=U=#HQJ4"F^ 4HSL,WO MDU#D/TGWSB>W(?&'1-@L& W
MJ#/ITM[?9&I_;ET7$Y.)W$&OPR)3^;&S/&H+XTV'V%G<NB-[74_FUFN&>+A=
M>ZW5TBI<&XH?Q<=J30O6HF.3&;97JA*R^4RQ0.(X2X>LXR6EM?H;7WN@!J3_
M'%^V2'#)&]@D6V&[BD(H(X PM=0PDYT2^E&(VPM7\-RR,IGPU)Z>_K/0V+S]
M4Z?LL<*MX/7H/Y('G^>(4VQ=-MEA9-TT*$O'C95PFR8NQH^@.!9.>&HC=K69
M>&<BJDBC*%S%2*-FO[0&(%6X  "E\#CT?/Z6UH\BX_6I3QGUQ^WG_RFL'=2M
M9C )2!Q*"C+40S+]XJ\/N'Q)K,EET/0MIHTU/E5#6:^38P/F[8>K%Q<0\BS0
M,)7LC-XF_E2&8/(/[$Q(:\HY7BR3C^A@A(4Q\2A^^U#(NN!:]E%0-H_\NZ#X
M_GB"R"Y$*.69(K[B=UKPR,%_"'TZUF):ALE ?5<0'H/F.$&CD$[^ B?"AP>\
M5D /I!SM\9PJAC"L?8LXA$(Z*>-DK.=6 TLP8H,FY9S(;;\-!G'O"EIH8]7B
M_(ACK&ZZ859/!V,3#FO5HJ9IS;GE;PPO15EPE 2T2NCE#";%"VQ6S9%!^PJ2
M#O1@!>)T-#5DD92H'0PF@.CT\@E_G 07<&N*M_(,((Y!<(%AG7%YSN6#5JGI
M?M#CD./#/AI^!7OWRPBZZ 7\6X1X&;JQ""=>=KX4UA"PEXQ1"LKX:;W9$=RA
M+5R0S 6D(O)H8;Q%>MA2F"Z; _\O/+WO_^;IUO ;1'A+ .O-XJYO'C!RA^R;
M6\,0 @\PMBF[?EV!FLG9'QYBYE"]T*]%S$;X+S@VL41<8CZ&[S ZEJ2;L=T5
MRH,JDLPO'>PKZ1D>\$IU*:WFRYI'C!D.\7#2..5$3SL7<)1'%'?7+]7NU4 5
M?4MHLN1A#0W8%.BIT]'7\(SR\FE_(QJ?'F9ND]PR^.UIT4O_O08O-BG"%?C=
M%R!SR $MTW;-:B">MYM0;)W:VK?]7BW;],!%@FA%S?K6'GT90FP%NFG:1VZ*
M_ #+:78 /Q<*](:&SLVT**!INV?>(2U57F3"?[,/N?\,;WI=,SAE%'LJ=.X'
M-MLV7(]QU"75@07G<7K@HYLUK:T*+1Q%TG($JG)U6Y[$\[+.7SQF.Z^[L8T9
MH<687G@C@YF3D_O:]B,/T+,8C25Z_GOMC1#8H1 'QQ/P/ WM"4EX;+'1+R[@
M2C^HC Y/9+NLMB>H^RL_A/>4T#6JI_D?\O3M5F+^(13>&CB)RW=@P5*&_,'B
M_"L4ZJRB2W4.4EW&I:IR!K$E5/L"F^T8OS-HXJHONPH7V+@^Q])A=B-5BLV^
M'7F,I, 32]_/)8#%0-.G)8\K=_ C<!CAL\8YH05RKVTE[G_!,0H&_>&@6[#O
M8=9S"?HU<^RHNJ4EY]*KU^[Q9N7<H(A_2[HA7JM,.PLW5U+RAJ/02)=M2$Y3
M!XZ!&=WKCAE[?AWTQZ7_QC2;']A>/4!HJ.O_(!6_"R]BQV41PD- >F+#]WV@
M4TTG*#(#.[M>C@,LG>"QN6T8/%,*CN*T$(J&V]LM_C @IT=B3OH>!MY%YA]D
M'=<#0 E(JU9!0_C0%D_'2WB%ZTM$J,,&N!]+A(JP?<BM#75EIP!X^G_:X$VA
MFQGA<)1,:LR&R9(-'KE)S5S QQ[2Q73A]G($;L42QK65G"AB3[3&O.U1)A77
M5=@?^<[(%@[,I4HAFXX)#*1.."!"5RD=J!-$/!Q,+&QK&81CB>V8'08"EN=,
MM]$Q3"%RI!P0?^.]-J&VS-%V@1S IV<!>]PXJEB3<E))_?F->>"N+,N''<9H
M1$/!$".[QN_;'+%RUG-A?'H8L]=2QZNST2G4<J<:@"RASSN.(YNUH:,S6\0N
M@Z8CE'=<P)Q7VJU=_G!8=IR1[*37RM"*)1:TE^!@5 P2(@.:S8-GVW8Q9X&[
M0 ,R+.V9!+_%H,'.=+K>_G&F!IH.8,,)#H1&)P5U@?QI2=N( 'A)^%D^)1^H
M1RTGDE W>F/]-+'(81N[^_8M#P&E O-HS*<+>/0A8A84N+%((+)A#2Z,O9N<
MI>H4HO,7XC&\E&V<X-MB*P4!A'66&]EPKPV&^8K1B?1:R8T;8L !MLGBM+^W
M+G*.;+NSFO'XVURI=CG(7+^FC,$Q.4A(Q,T14.7^&3SM\!<I#/D.2H%P0X7P
M\\?!VWJT-N,!IE,+S _+V+>&RHG6V.$"RI9&7:[.]G+@,\X?:RTU8:^,:)*H
M#')-2\'3_WFD8DKJ\\FJ;"WAL$F:'"+/P^6AD:H5)<);.]G4TNK_/;3Z?_*!
MC4LW)L=3D_ROS6[R8+C!.$%LBX;[E&;@0GTJA:AA3,#%.WT<*UX?;EY?JZ;6
M5(MKVA-C'#ZUL;W[>XXMP^TN=<*:LO$@Y/A@T9HN(_6IFK/^\P_CD+'H;,>$
MIM:KJ'WV+[]Q ;??;RT3=ZB/?#CS1)^W$Y*N]X)P'J22+$S0<G%NE0'-S.](
M;;'#Y=I>SIG/G$^FY)W:W;-QCVLKXM1+"T-9Q$6!/)1%SN3G>E\J]%C3@P_"
M26HVG8U&6UO+IC]"LDU?W$@Z#O_U1P4", R76 @'#C"85J)\?8:A1@[,%PZ1
MB%W,/"J?>,"SY=.G8A F/V#U<N2*Q2/;/ 82-P\M_'8_2N?&Z7&5 _*B?KN$
M^;P\N^GD@Y\;O-7RM:**^6R1'18KU7-$3O6OF6XS4RU?$;\;?5)6?O:)K/*^
M4++P9R2P4=/5@RH0%+3XEWCGV+M";0-?[:)< _6SL3S_OO_/@1LDXEGH2EO1
M9<YWQU '6B:@*T\>C_C[N9W>G^YTM*KT[J+RRJA&>]KKCX/_E!B)*N%,X7UR
M$NZ?E^5IX]O4.9O.L-$:#;"E;_>"^^KO-5;0]BO=A5'H@/O\<R90J]_MBF27
M>^EBDT_(M7K[D$\7VR^4'=W75'XH<^I1VJ\";.8I]A<NX"E]9Y':7IUZ]7"Z
MNN*J</NQU_-Q:J?VVXBV+V\$VRW$/TI>'N-75$ ?9Y3OC[F\SWB>'?;]S[+Y
M]1UV0^C!'L4)6#2MH>?:?)BNBRX273GT_W$>*-DVY^'[%[[0_%5V^R%+Q??0
MTJH?A[!WJ=] +OR:<_UGT>>GCW.0)@.N.7YL<1O@P"9E-T^ 1.R*P.K<:!/?
M/21K7 2[+O4ES7K5K]UO<S_4S"B%T<!XJ+! '$#6!69ED*_ZQ9=H\#6# /NR
M+VHR$ ]0G#8.ZQ6C=PN%NF<S.\OZ9*#.!51Z\5D/RR7XP//JXH<8LP^4.@6T
M3RH%:RYMN_K"IW3R/@()/73X4&/E^5%H$C_;EJFUCV.T^VH2/"!)#;,PX"QL
MCD285''6/^]C@=55-Y04Q,K+_W.EW1;Y*-UL86'R1H.AQRVK3<[I+\C6K;Q_
MOQ-JPY1_?GI^"70M-]W)Z^W/@!$?+F TN(HP7O;P8K59J&?)>&TA\>3%E1_%
MQJN7"I<*5=X?4T%E.+ZM0Q+)ZBI.NZ9Q\-Q(J^B/#XQ\]9O.\ +"!Z+HD_>^
MU.@W)2-W/L0[GD@$(].O;:^V:MBTH:*=\"K;HVAP;?6?T;6BUPEUID-GBY$>
M\^=RW<"G!D6S)>Q6&J<]ZA) >37WG4,6'12_+#1>//?2(D?.M:L0J25A(UMP
M2==AK'0:\OZNJ.'97UZ&>0L6EDDHY+]Y&?5W%7O#)F^GGQ%1$8O4M*RD>OLC
M+\T'3:IU/Z](UNHRF8-H+FV2/!K^A,1\[OZY>.>#R#<)K.'<'YL,#L$4^86E
M)F$=M>!H?&C&,:XJ% /XU! 3:ES!9XP!WD7L7N "2$) 1[O]$T[88W"L$:[X
MFZ:A*5IO6I$+D)EIR>UNO!K6'-OA>G$[I/O85VWOG;D7:P7PJ/5[:G%R8*JD
MQ87/<'[UH:::,MW)+=TT'8D^<;Y?VTRM M^(->?697 ,2(&CYU>*6X=_HL,*
M2'$]V+6UVC$'S'I6T;B3A\K!W'??M*+W]S6?-S6<O?1GHJX$<<0O:YMH U"0
MN'T A.M[2Q1.2NNQ&W/R*[M)SN Q^/MKZVOCHF>FTB:A3U])+]/M1\KC%YZ,
MUR..$*JC2^+>94+.N5JT XX>U]9NEI:/RT88?!?I\Z8?V*K&0-WFEE[ZJ131
M*,=I<W=-5$;_[*H8E D*/')_.HY^&SYN-['([]I\Z;;EFRA% [4K#Q0$.L"7
M/'=^,MU- C%'/H0R6)B19=SO(6EURU[+6(%-> )&%V'C\E+/N9\(0F ]330W
MG2/&G5)EUCKF[8^,Y14\"^AY4YAASM'<YM/^.Q9S-$R07232=QWF)# ?$1D+
M^G/-<F6E)2,N;TDHKF@RE9-:5+C-+$R9%UM>%BH9J?GXINM!_4M?X0 KURNC
M]_YL%;)S)\''2]KO0EL/[# -*Z*^7)Q+CYM'M)1YTD4+.(ZOBEB,%T %IFIA
ME8";'S!Y\K"P%<;^X2;=4=<!5:WM,/[(M_ >);37<FWUWH)5A\S-*W9)7RTB
MTT[$)"L^"L/0 [L!_!]LU)DZ1L8J273"IRGIK"I&2U40%W#71ZNT_^OE,(C+
MH/1,%?3#CU0%($)1;(Q \W:VKJIX9G,WSG4S0B*KYC/<U>7Q8#]:_?E% >0X
M A=.9^P(OWI-MYB:K.T+(]?5)<XM*/MAC[QR7QXK#W(E%%37.\C:5%]3HS7D
M@D7*9_,?%+1A'<\\+)1GC8 ,!::B3\T,Q!D?GIP'J<0!@\E2%SIIZO4O2S='
MR:/!QU2M?"ZANRH4B0M_=.'K/VTE@C=%GG@X6ED^F5:_<B7)P?*T(-UM[=IP
MU-[+K8QR? G6/Y,)0C(J>KUJ&RVI5M))X30NH!<DO9O.F>"?>S>ZKE57,H=Q
M\9@I@WJ&: Q?C7P*MC4KV/H<2&\U7E1^>4*C]+#ND-V?QQ\,W3Y9"7?;%/K>
M*^\!_"MA=_K[=P\UM3S4-O$=B8Y+:7EE]9O*N98K]Y>\4J\*'$Q-S%M]X;4_
M6'DNOD-#]^<QYV>T=JS%W[HW'X[:X_G'0O0_#L[;X(M:+BN:#[(P+?W,8EVC
MW1X7K_7&SW3^/IIS/4DBK""9%!NA7ZZ9Z+>JTCY^,ZC.^]7GHI07*&#M7-*Y
M]PKS,^>_B)<=T<G?+$1('OD&6?AT9M;4X$' QZ>[@2=)X'3) =E)29LBYC54
MJ-^!*%+W_+C-4Y3CR^$)DN#VZ\E*,\NC[]=D&K!//+TTIN3E%>SM.VX9[5*$
MV58('\.VC",V**<<[1[=3O@G>$HN+)FNNN5P8MQ%_:?+/QJ+S>-.Y_M#NI^$
M77 1&1$(LEZ[$\P@>CU6J'(GC)]?<)%9S$J[JJ[>':B?4/I-1\_HR7UMM# #
M,[*BIJX^:.)':\ST%EX$:7B%K8D2)&_F^DM;C'TE71@F*K5UD]%%C3=#HV[4
MBMGN$H. SH^V*A_4>-KYS10'OMM@]POIID\DO!$IBNI:6EC5"BO2,^;IF4>*
M5 UC%I&N?J75M,E1!RRJ6EIC\._TBD)FP>3BL[=F4V.0,X?.3=#3RN_:_N-1
M+76Z0RY1QFWHJM;H/HW=)*#E$4L2B[&KV"*ZG//J ?U,]*CH)RLR,!X=.<;S
MAS=+G2IB:3F-4/<8^?IZ6:C?V]<E+SG%0Z?4DQ1_799=LVFQ?I207)K[^,FQ
MMV&EGJ=[#^RKL!>FA 8.OA&[(\4C99"'.N.8BC!(V?/Q(@^?4)^YS[G?7G](
M/)$RH7;SYK.Y@D*GED5JT%QG%UA(W,O2K/%.Y]<CT6YG$P1^H=*EM.Q.._V3
MS06D<%1_1 P"NX5B GT:EU'KTJCR?$U-(^]W)-,A@SYV5N3Z9%KMKE>S7*#:
MB#3N76E1+B+HXX?H\SDA2@_:?F1#35I?SR9MK<BMJC_^!OL;,4F?A%^ \D-8
MIBC2WX\_5M?14TXSU5=3A6_^I'(!FQ,Y[HJRU3)UR:EE0?7=>8=^]N%.)'Q)
MOC56(X7T/7WXW&W_5PBS\0$P1!<&,\J,F4?TE&*7T=3T#&11:+S6MN>@1>YL
M2M!+SAB1,S41_"X^K_TI@UQZ:2O YFE!LNP\-N_M1]3^SFKQR@:1!63WSOPJ
M7U%(/V85>R>NE>XS5BD=7ZF5-T<U>0B]^X*LFX1]:2UPKKZZ8X1F'#1E?_&"
MVLW^?Y7W0[;Z!W.C&I-3V;F<OMZ<G?A-/F2WS>[.F,1XFPE@B6ZSG:>'#V55
MT?<ETF*G;N85[XI)HG2- Y-#HSQ?'ISH]J5D.]>6%K?/+/[H7#LV;X^)<ZN6
MN5IU\6%2*V<8_ \G\\57]4.)IR]IUR I_BN76/?V38>]:G1&JWC6(\)Z=XT,
MC>HX.J0);#L+WQ;+!=0'@%KJ):H:/\0H?/CCMA4H*2EI7OR+#B0GW3OL6:"N
MYG<^F2J7.)Z@(F=_/V;UU<HVBV%Y/?N2UX<=>8M7]6V+52_;G.8J@KX]+N+<
M?>(1H/BZ:^G2(],\,=WO5K['.'>"9Z\]:(WLW<@ON]^QJKE;PV+X@J+B])9_
M+L"_\5DN+$W92G\=2,)(/],\E?I"W2Z1C"[Y2%Y\Y;Q3.&HGE2R;[]Z5XQ,F
M?6'F2;[YI\3S2L^O[,]0)%FG*9RE>1L=S^N2XNUSW=BGW7]_CSE8SE!]@M[!
MW6Z/,T^F/KI;LS@2I:!Q4' I)OFZ_"GZJX_W$N<\'YHDWWFNU)K<,GG!<Y)D
M?/B8.^@IO\$RK.4#!?T58K!)#V@-Y@+R \\$@3O_;K52E?WT63 :N^JFY8W7
M*TZH<7+:Y.3G<9#H!8'GCXD9[:[R$<;"7W+M[WM8)9:"+,085_AJJQ</#AZZ
MVW_Q%4U&UTH;T(PU4?DB67)JIH@%PF4+J2XM^3T)\FU9S]K4\C;"?D^>S2 Z
ML9-Q9/4\4FQJPQ8T'>$5UB/37H=%CM:@FYW B@\NGY0P!?OK[_Z<=3EHJG3[
MF0YHB&/V6:<FV3XB/ O/X@<N+!N0R$EIE+M3Z,Q>))!S8PTVG%JB17ZT"WL9
MY*O2GOIXYN=U:;+>4.7@Z3N@\63M#S\*F\(YZS]L;1TFCZ?D7$=N[1#W23VD
MF*>#XK6#&8&()A9U36EX@AA'*J)U'!RAX1JV QV$ZI_C_=H+;ZIZ^(;\O+]V
MB9$W5BXBZCL6"=)75_A^X'GTZ2V?M7L6IPF6QRS9!CJG[EZM*H_3K465"'31
M=P*N..%4C!J8H-R"H+J!1W6X8HU=:L84!-)H_")2V?I1JB_\L-/] 8GCZDJ[
MC14=E>B4R:J?5I?WPPN1%3F]#ZRD!I;,=,32QK=3;\;0F/@T7!7#'AFX!!6N
M=5U]Y=X4Y=^H>]$9HSURJN>KDT&%R3E!MR;AM6C/23IJ?$!DM]>#A<!Q5//2
M$K?((3XD5,":\&?V[>@5],R #E3>MVP$6DYU/ZI9ON1: 3_247/%\NF/HF2U
MSV(G\I6Q V/AT/#K9W=H+N=STU_K1+*P%W!DY=B#S''I&^^(OA,E&;\I52]0
M-^>\_82Z6A\L*(@K?H2UCHQ,E#BYGTS_\=I.MFCSMYU<O-78W-CG3/EN2-W]
M*!87L+C:E_GDT.^^@P=)GU?^L?RWSB3Z_GNUVO=S2RR3)20L(4G@;YJ'QQV;
MXNGC60G@LXXQ"3IR_H)< )@II#/054+IE;/E.[4J_JBN6*!7Q/<V9GANJHZB
M1>4G-OTSVP10$FQ6$BRA\]PX.(=-1D&&PL59)P^9J[K1!7'\<7Y^&RPF?FF8
MQ;#S ?<YAG !6I'L\*L'- #\^<)[I7;,LIDAX1.[@:C_VN2N_[^^R-@/GZGA
MW(IT-: H5 ]N3TV:#Y=KQW !U5R \%.IRI@N[TU!CL#RS>[LL&.<< 1M"_*C
M'".5+\LZ9;\+BG0]!'1Y<5A63R9,;XN_&,]V6056%(CQQ\&JJA*$AUG.U.HY
M9%XU3B(D+BU'8>4_EV9&B>E98>+A1R(I]3*"B-XRJ7@_"IOQ'3ZTP"FDD&8\
MD" *O&AK]2_G#!>@*$.E0]]CR9T?NE]:0)3-#R:&K'^\WO&XXL,ABC?Z\Q^5
MD#L(6AUPF@N8(9VK]9T/HC.$S\7I_ (B@9>^[9P;NW%K9EYZ,&]TF3" LMZL
M \67]G;NE ZN.KK UX_Y6KKM"C\F=RKC+?&V'^-TZQ7'KI>6_.YX>QU$/F%Z
M1.OWZV'E%Y]\K^__I+*9T^5V-JRF@ .\E$B7B0K8LB(?*9B^]*I@A057W8#<
M<KD,.T3%M&@W'-\5TU#ZV]$S7"DS18HME:EWM['+_OCP]_6A<)S7QY4VVX-\
M<S%0T35H9HV<I^@.&W-NI??"W*,-L1Q8"W: 883737\5>O[=6+&2"@@OL&4;
M*[<!:SC*/-[Q,M- 2$>@%/3O0!=',=][S 2#'X#!7H^5'G[DLZ99L*+KJ?.*
M"QAR&1T$U>:RK"S?[1>Z$"WY^GJYCP$["BWS_43YD4L7C5"CG$PN0'PP>O2T
MIU%L+Q=0X-H%'7F>EPK$LA $C,KGB.PCE0<$4IA $COMQ5&UBF8P&&QI9V-Y
MM<74R,!4W<GIWH*S_C&U3<5V\MS[:+%9/ LZ*IJ)>U!R25" !AIA@D!*F_%9
M%S(OY ?8>I@&^B=>[;YD7QPV+\JCDF\RWWTM&$T2+/7;H68B51J,YN%^C(;M
MP><F9[]D&?G<-S[>E7O85ZUY7Y";TH&P?SN(@SX[U+K0 .)@Q_ZG+,PF?-,I
M.-SJ:&J$7TF3?-J]O9O#8!B_?%&5D11O)ZI20B@?DX#X=$#YPYZ:?[@ Q++.
M\C[]X?==Q\*0\TSXD,L]:_[4^.?!?+O5<_$4A@.#F77I8Q*VJR22K4J!MW(!
MY=AB?=G8NS=>6A3_2E)5=Q -138D'?Z:FS2;7#38KH*"'C>2&9L9^(;QF%D9
MOB']X]ET^NL[1T:(5@\LW16>GQ(M,-+66LGVM#OVW.C8ZMATJHG0[6@^ZG"
MF30O&"5&\Z B#:22M:(0W'*3UO%1NTOBWJK$3&Z<LH7<&W^^A P K)KJ5RWM
M-7A$A(.B"&]#VB^R;>;CC#4U&/RM)&6.+F6H(6)F^S_WW73+][^Y6H(W!XS<
M4&DQ7\2[RR)1>\E7EHY7Q%\!)V. P<J^<'F+Q1[LTLH.!@/)M+BSJ6.D=YIC
M3\A^+B"F45;&@E)'A]C&Q.K7%QAYM"UC#"WU.*B%!<9 UOS^:-*T6L[9COUI
MRXQ^,,@2:2\;M";Y-4DQ"6FA?6Y$\!*>W__Z61E]+L E%9BYQ%$D$QZN#/I8
MG<+96H4'5LLA\UTV*A$KU9K4TK0"]1WBE=L@"[9RQ^*$X_AV*V^K:Y5ZABY'
M- &GE4S$I)Y?ER7"8>I;1%<\+K?P;6^K\8'P@[MH#F;-(#(7BPC=7KG36^*%
MU]L[LUH./LN&HW8$$+LR5(Y0 V!6P+8'Y1]2OK1"JUY*%Z!!W1L4\ 5$?,V0
M&V<_,*>6;YXGM<9FI$'S726?ZW[30V. D5B>V;>QJY&Z2!30N0&,WQ)8G"_?
M[Q]FM WEV<!>;7B-3-45;&DJ)4%/G,7_T!\3[]K3!9TD,S]5<@'6 O;VDFYZ
MH,'02I?YN"K.4XR$RH\%Z+NV^;!0X2IEF&F'_ JI^BN"AES@/%CN2@)--+ P
M39-AA]BMDW>=_J]\:[_7,P(S[Q<7H#E.NYL.!OYVU:RIGH>%T?R)1ETYJAA(
MX__>ZQG_!Q]D< &01U=2(R6=JG_^"K">I5X *7Y$99^[!_FRNG-8+FAZM"\:
M!";2=P?CS[=FW0S@9RDC%OI331;*I[R?Q/XJ5\8.W<]M@+7L4BSA'4NUXC<W
MMT-9 =TV85,[-)NQU.JYMCL_LU6*DT=':R<6)1^Y*^>86(;_?N F,$@XA-\]
MO4#,#5FLA*_)/A(F^6T#1P<[UGE[M_EA-Q-"*1]R"Q&K:9_U.&7TUG2?4+9[
MI7)?+9F01A!KO&R.$WA.->L?KYV3E#"-O7U_-/T/JO[H1T-<DQPSV:&@YE+R
M+%Y@]'/]%Z!(+RL?3,K(&P'K^<1\HA=]<3SA_4IVL3LZVSS^UFF1^#_\V[(_
M.GYQO%BE]'T?F>08PN&7SC<]<>IA8II5,#NR-MAPVO&'O=*P8DGY:<&Y,8>8
M \HU5Q]M+)106,R-B<>!@^=(*!'6)EAUH3>."_@4\O+1UW.3U//B9]W5K.4D
M^/;]8SB0?\+4"I7R]<AUCA)K8&T!OW5T269^+/C5!WBM;CTM!W]3M6#SU_H'
M(U8W>N.F2P7%^<I?5<5W"\4"E=X2%C8IN'!>7.8"!.XY;H/DQI)-$1[_W+8_
M?&9!*SK'\]#VWV=7@X6ON)5R <G4EO7"O[?15R:E(Z?"(LP6*Z'RE2_.I$^0
M*IP%!R[6SY5Y:;HO7A450%Y"; #!WH+E=I'F_-OM>ZV[ @T"<(Z]J[VC3L\^
M#BAF:K_C%U6ZYKC*!<C?GEM:)& #IZ 9G%=K=QR#0.I]J4Q?TOI(.[MBP-H7
M&2N=^MTTHK'\C(?T?8]9HA*'\F/R>N2YPQ^N,WX+Y$\B)W/E-T\_Z/VP(7HP
M#W]J6AN[T)N2J!G1G6P#=1.9Z<S^,-C73#\@?S_3@_]XL5%1F<: Z8-CX4.)
M'-^OM\=FQPX[3,09"&\ B4RUV#=Z.5 ]X!+/0E 6KY+'-"^ *?Y<P)45RS6C
M>__K$XT+FGDW#8(B8$'#T U=S.]" ,\]K;=T%=*1E%#(C4ZBA/Z%SL-E@GF]
M4[ERE4T,MD[]-W-*)?_LP?^T/_]$O.IY+8F/L*"))@7FNWD=.*\O\,D'!L*.
MZYF?#'T(#@/E#"#K=K(RJ#?;[/W,&Z.+#S%@8V'!Y=4R["5\ T;WB[[\SJH4
M/P-!FV*EOMB1)?I!5O] 6@:FAZ#)$C[/32L!H#_/0_;>K[[7D_5%\1[\FTJE
MWS/[&:\6=N3V<MJKS3$*$S7G3,O+KORWYE_LNFJ5P. (2\8#]''#=Y;YP@8X
MLVZZ6^T?IQN(L!:)6NPS%DCYJK-/I_MM5L6G@O7]L.89/.N[5J9,SLB7]<ZI
MZ['Q*9/F:Z'W6KUMYQ+3^A*>Z5\X;!UR1MSIWZC4>&Q#[B*T0FA<+;_80_*;
MD/S\0= H4:KD2R/YI!A 3,]D6OA8/]I9P-P[;G#4X44(!/&BSUL+EM+B36U;
M4^8"*L__:%TJDK6/E/-(>F9](SO%2$-N$H-J>%H;7$H]O5[%!1PGJ+TNKZN\
M;O[M?GC$TF)HNM*Q3W:'?&^%:65F*=PW*3'R5S^+=.8OO)@[YE4/_2?K":FS
M^N_=+U-;:Q-6"0,I'IGM#WZ=:-\"#IZ1O1^&"VI6JC4==AZ\<Z7THD"4RX9,
M5LSRQXFV!/D_G7N%)DO2/F_UC]XV.7#J(,''=/=7]5E@)Q<0U5=;S8/"/F2A
M:J\TS;_@DUZLJ'8&)8$)*4AHOL(I,5K40J06=P^X/1<]_?V)T N=6.Q=B\HR
M"-VZY;[OD=^G/\(,9"WT'42E3M0[6'D%4"@PNYEO.R1(OP*K(8J!F:TK,$5N
M,A?BX+.@SJDW!+0+'OT"?5/SQ:[A I'23%6E(H%)!20)+5E]?<=R[WOG\D)-
M-B[6[7L8$GZ^,6\T-[1D.+E]/S[K;9V6)?2IIDN+=XFTX?YIAM:_^20%1469
MW,*LEHB\UBYP^-U;Z[DY9R!7H_Q##DY1OPLEZ$?EI>F$7K0#(;@ C: E S^_
MZ'J@&T6#1+Q#JEKL\(XCX8(.. ^49+6M.W?"?M]\5(1:N:S>9_VXG *AE'U
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M6F]^9N8O*ROW(_?><^[>]]R]3XG#VW*6!6/(X;\W:C(+6H&-!K]2[A-AS>[
M!6&7N!"S[<A79_61GR<VMFZDR24:W ::YT#$06=&:,/JT'%3KXM*0X71X$!U
MP=J;1LNGDCO"](6!+T\]JO_KW?7H?]'31H 3&+JDG8@]51&J(7C;P$*.@93[
M"VAG],Y" LGY6@'MOV9"C]R!N!^N?TZO ,BL;3GW#]*KCR]"\?1*BT)#6RN7
M8/?'K62R8W=9.]T)91B7[='Y2>#,[74\J131W_+K=&T^,[7KSWZ-P"8WCM$6
MICX3V6E,5X"$':Q^%M\!//L0RB2I?0)_O_Y#X8!TH0&\T*&DBL2=EOM\WKOH
M_Q6%;EYHU4-M281XJ[0XT=4.N2RAI=L&LQYJPWAG_YR!RS'')TCCYK.(Q9WY
M-#3M=P1U#1T]>EX,1/5P889&X./]7YE9>3[YZ*5<J=G1$8>D_EH6,?/M/>;(
M\V.=D1 2 G?!+/0VUXN8B +&:M "MM)?IG"*#C4_ES,!6OBPG]JM(&<Z:E G
MN>*RF-YUSHRSSHT(M;+)C;!HY+/[:#E8Y5C?*3+]16U1.!E[89%* I=H5=15
M2KB91MXAX:9^M#0^L3_?.(/@)@A8U02?_X514L$%R>L72[+ =2A?Y7-*?Y;=
M-@>MWC\HFF!I)J][NLJS,XL)L_4S3OM.K_F3_2MA5P B]*;E17^<DYLLI"IH
M% ^M"C$'SB'A#EZE8!?'S\6O$GAJW+#B;S[0!.&U;[;_N@+\%#>'N%V87G_(
MRP6OS$DG".HTN7[Y!%S)H@7WGGKT,?N8VM_]%N=:-6J57E"$1!K+Z7*2@9>P
MP@SX2PKY;W3JM]3A1= $]4V3H8 FHXUW9_0<8'][K.,4"+I2UD$^U\1=?>KH
M;;[^VD_,Z3).0MXKTT\CB?I&$:6?/DYFD%E9L1TA! "1JM+M3_0]V3*_;_C"
MON/.TJD'4\AF?VJ%H-Y%CS:.QP@"-+J(0J;S%8O*EZV9D<$D%;T>*$V8@B>T
M-7;?#XR<3XY,S<:OS8(*-D<,7%,42O-_"#*I:\I+KALE6+VHN($G<U;B/.C(
M'E!!=^9VYR6)@R63* ][V>CO%58Q? &03/&I'YU\DI3P?_\K*] 4S[!C6@>=
MI8$7@*!\?V*(M:=3E+R\K@#MUA6)["O1J)1)RSZ;K/3N817AQ^?3*S&JW;1D
MUFBPR_X2K.TVQZHJR?1PIJ/F$'PT&/"$_78 '^3 0\\^4&)G)K5B=H$9A*J"
MA^AC.$V':VLH>_.F4*RD30TDWGM>7:J26ADUZV:YOVCH;C%9\?$[N]Q9005?
M;/H_B5[@E<(/OE>!2]$HA?TR;U-?TP"WC%0Y7I_ZQ2P[6(K#LX*:#4_="8Q0
MU^Y7TRD)NUE+^U':A8/W7&9Z4!=-I]TB_H663?=G?R(D?685.,A_=7+_/;,$
M">M+<CRY]8F,(;(,-1J/^LQI.7D/S3H0_$<.;..C7SRE'@RE] XQ\S:WWV6(
M3SD*2#CL]1A=Q''C>L?/?TMN1T<;\GK$\GY^8$UJK0;T3NV.RO#,%1B\K[#"
M_OD.<T=S+7ORUX(38>)>?50;'1]S>'TO;[&#7*=/C,DH[>V[*T$C'*P':J9K
M=9)\D(BFK,B=- 166B$AX7$=?'TT<VJ:@( ZKK)DS''4NPA/%Q:HRM_\J_"-
M*J8OQVS2 51I9F)WJ9\5P<\$Z;H"A.3IC4S41S_J7M,0"+1D2%#NGSX0L[6N
M\?:Q%I4-.%-;63"G/X#AH)Z+N%^YJ*(:&]R,@1*:9SJ@91R5=G?]<U_L<WUK
M9=]XP<)@3TN"LWJ]4@"7\GD3#*"QWNQ)'[OM[J@Y2)W]6,M^$N"RU!DTN=&6
MG8L_;QF2D!X-($71M"$:E&.J0"C[\-'*TX<]V[2W_4)(HG('P _R(!+&YL9W
M,K,C*ED,V1D5HJ1JM7=CO-WUB,*)GK/^%%?$B1;[U[V\.]\1[BK]39@X@F1M
M*&,*<6_;S;1MUI=^!<L [?$TE\$ C?;5^O8DNL,A',U%1V*(AP[_'N70>&6L
MY,X^EM/4Y)(0':MD,Z"*I)S?QU1^(?DYGE=V43$2NU9GK#@B WU!DC>MOC;,
MND]?AIY+J!'=!Y_DN>N<[HW-DQMFEZ!2JFZIE(.TG:W0/;YVQS@PE80>RS,J
M(P'^9KW+2D<GA2K30G<V!DUY^X-2#K196'95!$?2X@&!,M?.O'H1')3%#&P=
MB)\. $\DF6UB[T^#[ON<ENGH>*4!W1WW4K/FK@ ,7DU/QB8U+0[$RLKM"HWJ
M@[C,)84[A/."%7XD"D1D[31X-<:SA<GT, )<1&[GD:.5C8SKPS53/=,[[ZR@
M"6;0<@G70U8"#2302UZ=:TH7A+LU:_#@TSS(LO0@Z6*K.-5K<@$FW 2O.<+:
MUUX?'<,#/A\I<S-SW_&-JI/S%$ZC9GZ^L79^^-60'V:OZD)"IFW& %5Q/,5Y
MJZ3J+9:'__Q[ F0\/8G<!X8BZ$6I'$_6Z)?WYT=FF_KG+D$P')63YREQL=?%
M[F\6;C=U.CH!R94Y/OV[;+-CB+UG*US4$:27\4BP2,/K@1E/(N4K +#\1$7@
MI^FO3W\>KRCVZ]'Z;Y:@HA'.JCKFMP_'&03=%LBH8)4+K>6)XKM6J1$I6E_T
MU+4A4^7.'1UAMUT+;LE0RY4R <.[\:CI',PH<[[/%HT2D"\2V#(R^B%VS:\S
MO3\?./#EL-,=?_%A:N&9: C5< -HE;7;['@NU;2ZX7XE;P-9ON!ZV]1Y^%I]
ME4Z#]TOFV\>SJ-+HYLJ(9P<&/9ZWGS/:>L9]!5"P3OO-O_<7?:^8Z^9*&$2-
M'AE*TT87&8?=?J'Q8/1(@EH]X@I V\RT6(5X6[-@Z27A[;SL92YOZ^W4-M\@
M9/$1?NNVF,-$Z=NE,QL>AT+T%EN#[%/.-:OTR'NN!:4+LOLCIK.:_B)J)3*P
MD^.MS('9K4E ;HRR']:7]G SR&G^Q]^/DDQ+!,W=DF/HK$=#$)S/U! N&*_]
M>=B"M:S-\C1BL:\C;5;D5E0P@XLZ\PTEID<QY'( >5$(+#XA-JI1K]#N>"#
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M*"5^L6X@:J_GR_3S4WY$)H9\4-$\Y+ 7_;VSLS=WUGCN^4JHAH- .OK\E:&
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MK;R_Z>9=(%I&JF$\QA6,6#QAH2H+@8>#6)TPZ@/J$0T(#SWPPY;4N5B4@(!
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M4W5N'JX)F46WTQ13"3]*GQJ&BW%)D8L%W<,>_KT"J'1FG?KO/(O6R_8XFPF
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MO?]=^P^H]M_P-9U,4]CO^1* ,A2F+GD*X6DT2?$:@MV6V$&0>\#]4,1$5FJ
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MC2:[(-^=X%W5]?S4HOI!87WE=&GH9=K]]0"WX-JF:T%"3TZQ/0[)XS^FYK1
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MAJ[OHZ-A57QL!%30F13545M;,:@\IC_O@1ME!A\*&T=R[WK;'22LC(]+?IQ
M)5BC(C/?,R,^I7*W>#=.)P15N?>][NNT&'DXZI-25$4O)VH'1]:>)Q5O6]>]
M5=U8"/GY-3%'+H32I'G0/]6=X.RR'/"2@H2P*B=53 (ORQ<L5/4FQ*[]Z=[
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M154]FY5 )V@+.T 2JI01&&3%"+#D[#0?,^JLK<G6/H4:>EP5FNU50X;:=IX
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MCR/%E6UW%@E/O(G "5I+%+QL+I5(O'L*O-/=MNC>?TFOX=^*XV(-$3JRRR<
MPL4=[T,.F4;*": 5V7RTC=(F_X*L>>_7QP ?2QZ>::,J$93M*S D8B=R /:\
M:9R#WYNJ"M15"=-8F8P =9P^SZP3+0'M>BL8> +HUB C1VT^@I>K#WW_RM2?
M "92CHR9XZ.5W+;_K*QU X>[QS5<!6?@XZ V+-\6/>6I9#WR-PQ_+"\N .OE
M +Q]A$LX=?8:('VGA=R0IKL/Y?*J^JDV-@B-ETR<MTX &XE#5U[7<"SR*1'"
M'Z[]X6<5P0'QQ11;<\E2=JW]")_R-PQ;^[1,1 6<-\X@\P3PB5B6>4,*O4:K
M2K=QX="I?Q+^3F?AA<AO=,SEY( U>QTE.RO6BLW0XDP=Z33U>WF>;UQH-HA\
MPL(.M^KU/$+5S>A>XY1N^;$?OQ2]10VIX]6WGI9FHKA45"[(X:9L#<XIQ>:&
M1)LX@S79D_?V:-;JJOKZ@M7M@:8O!D8]'SQK=;E]"IE:R\KWT8*:A5O!MZ;6
M-HOV 6K5HD=HDL^B#(;Y]D4E%QI+T^ZW9]LC*.:KHX6B@:/VY<7=3ZHSGIF,
MGH4]:+\5CD-B$ET4-:5=S4> M4J2]_I4S>R@RDUWOW_@_^B*YA[4,=Q[U_=4
M,,?EQZ<R20:9GZ\?OZ)$ :A*I9R'0UL3JVYH4?O"^HXZJ$'WTK%\^T.?T3=B
MMPLJOK;9W%W*U-;^4#)0,\A3RBO RIW_N(^-QD =PJIKWW"AUO$^>G46Y4.[
M::<32$9_=RU_5'I%,HWIRTBLB_V3P/FGM^_.Y&F6N);,+.F34Y307?#=>#>2
MS\P*^\ ;@]>O'\O1[W6;YYCC;UR/^'WS_@D@>:A?H,/K<]F/%BW!?IJ1P@/&
M.D<\9F55:7WZ-TZG1-2&"5,XYJ<[1[B@J&^K3,_KF#S4^_#S#1'?@%=])O0D
MM&!1VD#_M8F*B\QT&UY;.M)-2::WF9;0URP'SM--YF0_=0J]\LW( /\AQ("M
M1%301R,K0$O4>+EM/"YU8[3%9,[9;0^_;=%\I?2#W/Z?@/W*TG&%BJ!UDK:1
MO6L3K?@1A[ -[^![[LIG5$&(&;O'TX&$W,TOJ_FQG$^2%]CZ1869O39 'R +
M#ZYC'E7(Y:2T^-L(Q@JY2_'YT).,* A!H9+XI2"+]Y_QI?M*QJ7W'UT;Z?I\
MD:7LEG[RK63?\#_-LS!P80?P=]U:9X2W]C5M*L(^$/I*>%%*59^G55- E"#F
M%!%(?4#W_.RL^T58Z5U0<<.F1,7(;8'GG='IZ=JF8R]%N$KH3@!,YLNE=([9
MCK'G,_-=-PS+?Z<V&WVY^4#+K$@)P,U(#I;)P3/5OOKVO'2-M_Y[O">]D\#9
M6)\6+%5MG.K4T/"4A UV#%'&;'Q4>HHG?*5\3G[6'.>N0M!(J:2FO1**OGE7
M'=(F0^*N"39M$OS]Y=72[BK&I\'9@W!N:$11:FV%5JG$%%,3@WM.][P"4CH?
M]25; ]\W2]A;[XU("Z+3WC>OG#2LU.(W4WICHL(&8/QL_#PLW&P5:9E,8UH-
M766Y3O!]5'[#-\'8=&2 [GX,+CFFT2&&D" +5I+Z$0$:.ZAV#M9EM9#VFJ$#
MC 2N4,T),3=,VH854P*_ :,S)R_%'S4:0(B(M:Z":='12)GXV\?0-"@*8PK$
MFU'M.UO3X<K[ #X5W^>Q++F-^$<\R?N+4?!]) ^L6WD#/:E.MX<_^Y:+^]CT
M!'#Q5(;D K,2W?F$BN5CM.92Q(R3D#::/T?;<#-EC.<)876\;\Y><PL]3XZ+
MFGN;>X5:E<='Z,I Z7V$EE/5JKCWW&9(2/JW@!IY]9\U)X#8XQDOS(^"RACR
M# 4 N@V5?SO">A%2K$P=:]7XSD$N(;N<^J(CD.H;,>@,E=!?'H)@?4%+)#)V
M+::VG?4^XF?'84_!^&,5N:7)%;3^X=<)( X_"DJY!]]3/>P\/*.\4/\62>E1
MGE"\]DMF>67"7]9L+2H,.J^7</3$<"X<#UJAM;X+6_A3:/-?,94UJ;I'DY8:
M<5!D\/E7OCAJAUHW?RKM=S<UBGKH2=#H+P0A?5O_MV(V_WW#J0SP!WYGY3EH
M5!\79_&[#:JVV4LM,UJAL63^+'U_@PP_U#"&4TCA0 91+1FXL[N.Q>S.K#Y@
M^B(K"01["?0,IP[:KK$>[OI^!OEDRB*"=4$1T/_4ET.%@4F!_.-X16ZKB&*J
M6Y@2[DXF<1Q9QG>Z:F;]E90H[>JF']FN9A'OK!/2Z,REWY[2S6;&+\+C[3,/
M8,20)MR#@)*0C;X!H2N2#+PZXUVXSZ\] \]Z@R&;;_O^&#?;Y80^=$J9=6AH
M,@'T\;P$G&-A&S&$?99/MF4@V!4Y8-X Q.A?O(K1NKZX70/+Q6FM4)3PLE]*
MO06,0U 5\E+3&QS,DRBP9O++)"4S[:$UE;8KNX\(5\.ONT8WG<&OESQV?>UW
MUQW D-JC*9!< @,/+ZE\JV@?.0'D(-AC))X+9QCGTM\P_'(L/U<Z%R&WG"#%
MHULF8ZQ_U;R\5'/TL8 H=QP="HV]H2$8[Z%?M]\S+2Y^SK0A\7D>DR;7;B$;
M%2DI1DP1!J3$?["4J&E3KM#\W74"0)-IJ@?^[/5)UQ9![7^CHN8Y@QWSG9_!
MYD 20'R5Z2M*QJD^SS#KZI1%8OTF9&60E)?*HXW5U;<A^[(G@,"#6\&>(&SR
MPQ. Z8>@3@@B% >JY<$KA25!)XC%_14[0IEW%^Z;Z)+:U[X)]'P[ Y!];L[]
MDP)%!&=#_!&1KZ(J)02'F*IB0MIVF2FVJ$JE+)VL]T-5MCU06/Y24ZL><09C
MKY]09HVVW1=^Z]N3J=][^W%3U3$]#8F;D=SKGA6=JC1IE$D)^X8D7J[[#3Q2
M@^!X@I(;W2:I_0$FJ1>O*SM<?3.+SIW'-"4B2X+UI2RC$L$.-<!V%V;M,=U;
M8[C!7_.*S@4&P+B+<3E*)23++0WX<4& A^GLLT^#%V'""6YNG)]L?K;A(M(S
M'[&Y)WWXF-FIT:FZUOXS$;2H_]3YC/V/BU?P;E1N@R9R!0T)).QL"<.EDPMV
M!!9.J9A?;I_APUG!4A2* MH)E0NV1EO_WWCILOZ!FE\<=$ Z!\ZT$UMR2EHI
M^K@9%$OYBCXQT*?XH++BOY.GF )1ATVC],'.[Q)T>W?H7[J+M81*@!9"MU 5
M1D#8,QG_"$I:#5#_3U( >0]*L*=U8T.:6D4Q-\'2?!* &D-P"[UGQPL561!F
MYI0+JU?PYS@H[/7IU/AUAJW@?^?J>:\\F?A2!V/CKAQ6U_>>,EW#P1;,AM#Z
MZ))R9&H8F&GH\]PXK JTPT?%M(;ZS*I(6]U=Y$Y1DKW L/XP;@\LN=5=Q6J#
M@)IT7U#_R;_C59+BX<?O#>GFHQ[Y;L$KGY*)LP?G (V+:\\%C$=_#9>_ D.+
M#X,+-+COB5\76E_K3#-F,#2]$!*N1-\LBYM5)?[9GL9&5\N;??=[2IE)1>AM
MS@3;.]E)*:2^&>D5,])1MA?5U:LW>:,E_?"-E*!U$K ;_C%AVCQ9+PN0<'TM
M KG@W_FQR-M_\RNLFR^M!ZS7=FR/]!ZU#GX+$VKA2S'.R8;S&AFF]_2>_?N!
M#OK\)>OA<9X)Y(/J<=#.R+0%XL)A1?(/ST=?6W&_-I@;HZ85HKEBVL&7EF6O
M:&FD#;Z2(2K6!4,Y4RO"K[JVA'&D^,>F"=V^&9]A;+[WVN^)5 '[QZ]OO8[E
M?-"J%V7@'W3(0S[=.6N;W[ *'+7E![+FZ]:_QAH%Q!IYPS]/F3<-YIGN]:$'
M!0\?O3SFR'1-L:I^OMYUL()51;?S6IL\-P#0+V&"@TO(Q<[KC/C0BK%F;C Q
MO*"D"VXS[S<C$^W8GUC&X+JZ]$OM7'[*A2CE0@?9@]PR'DVV@$@4"J1<1>/+
M\@,^\8DV\9BF_26PP @)R,G@'ZYE\>B&AO>CG?.>4^^U%W<P,JZQ*0S%/50\
MM^;M$2XHWZ9U(H=BT)BNB/=05$S[PCVVA^8?640BF3]T#JLE=..\C*N'GC\?
M0D._%!1\"[]Z5_@F[;=(%/"M$B8Q37XFB!GNK^(#LM_ZRN2TM9E%T%V;L#06
M.K /V\S.BQT #YSIY ]X+_G C.VS\23P<ZT7).A"JXIO@4VM'^ST30/1"R[!
ML!(RH7[-4[K4-B*N6J;HP9LBCD;!:^)Z]QSX4S?N[#Z];CZ>Q-I,WUWU'/=H
MK=_7E]4(,N X^6O+YL=X5C-K[7V?P$%8+&KC(]B(M][[X970>D8CR+"Q49W<
M0-3M1W=3GM"+9+$HC7ZV&AVY-CJZJ/)84T719<1@&"OG+X''%I?+T(,W]MY:
MER(.N#T^&BT=A$V<JR.\G7Y!SY0E'J-YR_BR3NF9<*K2ND'8%;T2=5=SLTI>
MD[_4!W]_QF(1PUB#:OD"II3O5E%A0E6D5EGW(3,SD</.U]8RRH)[ \GQ-S.7
MU$\ 5?!+">H7,X$PD^'\=W2)2:L&<,5IL@=*,;(\T@Z^@%M5@H]2Y==/ (_%
M/+IEYDY-0]9;R7TXCLP:QNM66<G\<P[J.G?E2"#RJ!Y9K'R *0G"8^;.Z$::
M3P-)H+>:H(B @ZW^*K-*N\6L(%^ NPJ2GJ9ZAQ &_9>VM(2QFEV%T.Y,7V4C
M:Y*]]T]EXMH:YJH[\]L1W74)AC:.YYQ9_]KM'%=Y$=+'IE/.,X5[0=HX&#LU
MX8?0EG_6HCMKLL.[^]9D6(%6#0\T*@JQ567&Z\>TC]A4+OHE[D93?CM+T2?/
MVK*TA WX=HT)1OA"#<U6U2O%[8.A-4CT++(=D\B:_N("L%0D[/^P]N;14,;O
MW_B@4H1245E&$4722MF&REI,"&6;0EKL^S(82RAB+*&((?LZUL8V1EF&A*R#
ML>]F[(PQ^S-]SN\\S^<YY_G]]_WW/F?N^\S[OMZOZ_6Z[NMUO1&65G'7CM)A
M33' X![EOVIN4I[?]]&]66>GM]3S>UYN3KK"\3@-@-X"0;&:-^;$[5%(6)L[
MA0408(ME'[Z>SD<<Q3//DD@+'GX@")060$Y1)NJ>UZR3\OAW0D.,U1:WXCSS
MRJ:U*]SF)?2,D/2(>IF9DJ4GU-.1-FUQ=I>8DG4D*W6/$:1ZBJ+$5N!D!!ML
M_9+<?QX9D5YJ)?!:A>ZY<--<@^D-Y&7<0P8'E2-W^P!#0BWO=F(PW@1W(EH1
M(\$[X:&)&A+TIW*P 0]L@[:I0\H,!3U(=_,3$II?P5(A[)M.67OTO_QY")Y%
M#3*HIV9JL@!VFT/$81(QNSVJ$!)_GP6(Z$'VM( &5]D$:9=8*]='11846HRG
M3$RQ ''WEAFP8.PRKIKBC0WM4I+BUZVKP]!.N#INMY"1-N@DG.\AX)8PR%CW
ML"ZW&:*%"ES=G&;#=RS]_JS+-4TA*0@"VP\&KH&0Z"VDS7Q<,EXC1"ZDLC'G
M5!^U"$!EZW(B;70F>.K_54OH_S^U!!/8O4V:+Z@3,^P6D!HS>D*EKQC,37=>
MPZ? )AIO,!%,Y<DC]2D(+4\F[M\Q9%]?Z$G&"8?Y-<I.B-]5HI_<L)?P>Q&$
MF24(WG&0?SR_-MO*@,CZD[JW7;@E\#NW$VP5NJ18@,IE/"3U\5;YFX!H;(@F
M1SGHXDR2+8<$$ DB @,*"FP*N]F,&M*;X5<A0Y!_Z?AV.>:9Q5*+!7,:3.8K
M! V7%(@P?G-B"(-,Y,[>*U]S1@)6*YB;=@MS)>(C,+/FX*V'/+.5L3D*<T#B
M]/8%MD#WQ>89/^' CYA?&4(WJ ]@$+ $5Q&F1D"IDAF^NK;RQ*PIX-+&;<D_
M)A\HL&+$MK6?P'[YX:XE=FP)Z"HMPTD_R031 &\G ?690!9@E+2W2SC\N%FA
M]H.!Z,T%V94K5\1U<Y/--V5[KM7?OPE\9!6G,SB^ ABH^U=.*;H]K/'/!>I2
MAOB!FP.UK8\-,030P:HO&^T7E%&.FS:DM8E(.U\EN[]@M#OI3-TRP5.S;MO2
MY*2TJ*KR7$G'0M,/T(,U@3K#><\&SOMGK&;<[HIC%@KN.UZ>AUX6B++6OVFH
M>6BKH$R5N+\7DL2[/3^/Q;HT;/S!&LQ \6Z^?6\WWX_=;9XIF3KI;/!UN!%\
MYYI0G')"-<IAJ$BD];+$-?N4YQ?#- D1H0!_<;W/Q8U'2, U'%U4^6G\][JK
MT4/BP:]!F:#AN%@(A&Y^,(2F?)W\RI\G$I7O._W+>FS'SHD4-S=!J5"<6L*:
MEU]3/>TO:FVF<N'YIYS?\Z^O]RU\C+WZ^ZC/8?3(SG.AX2_BB_%<V ',TBH>
M:BH8(1>&D:4&!$3O'>NK5[]<T/JFV5+FUT9-SO2!^%@PPJ8JQGW?6@?\VE+F
M=/VKB7I9\ZDHS^[D[V$@P<]=[<*?8\HBT",3W?*2([]*K$U[^:X\,,I,1[1^
M. BY)I[VMLVXMER IG;L+"(&(E8-^<,]MS\:_G)@T O;:?C)!C^!=AI;6ZB;
MK(^_F_;Y]Q.[8A;@HVBY^N'?L_;Z[I<>CP"-L0BOQN0Y,\ 0_$>SM<O C0M\
M!7V+K2!)IDVH*+_<_/1OYX\[.#MG1&RZ7!ZJ3W]=#(L7L\0HLP!R:%F/,W?%
MDNHE\5\S,..G+5-]7J=+D(:&2V[?LIL^F]-AKGGMJ,L]A^\)TF?-HNB(3$\;
M1'6<0'&&EU&*ON -&U58RY7'>XV4<Y4!W*]Q=.6#[1&8J')#JB_](X%9]=ME
M8[9W"7I+OOZZ*73$MP"N\B$K=]K/2?I.WNG--X0+)6]ZD+""QJO5G&WH?^9C
M.M6@4>?<9<Y8KRY2C_OB8VIPT+U9'UQ;(+G[&Z;EC?J==?B,^X(2T,"YF6+=
MBI;8/*:BQ%4K.3$,K;ZVLYPW!OPIA8QY>+L[0C^JP$,HZXR#,W>JD>N)H6B3
M[H^=NT<0((2VV4?@P,![@./N;_AC=XI7DHI)5K!BX*V5S,YIH'##='WCHP R
M\@4I;F$2CU<:?7I *&NLK?::TNYXXLS8CCZQP65PX^1MYK-:?CO)T&K)5&2,
M/D>H!=.>$@Q!Z.7%'CGN;=O&^98>PI;^B;J=6:(!8IYBC[8:@;O 8UM8L6VH
M*U_VA.4UM79A6WN4^C:BRN?:^H3(S:#9CZDNBZO5-?B =*?YYSD1JP3WVEO5
M<LS-@:&W!8![@<CX761WK 9EF[#?)2;@<J/CBZ3TY],]JEB>(+3@F17UN-P#
MH\I&%>^7E]TML^B]8J9H6G1D8*,+@;_FO;U9<V+Y6>+;MT4K63D%.SI&LKUW
MKEQ]SW?))_\21YD7;K'-G[H<]13J)J[-M3W8385<.[OR._#[BEAH#*&W]X^W
M;^M&Q:2:5AQV_?-J7\*T6"/T7L::A7MB6EPX;6R<9B>7\-MV9VC)-WYD<*#?
M3EQ8-G#D0E!.HHZVPS9_8%/4&+-/7S+VJ"D/![!/W!O;QY4MBYD'=UR+GPRZ
M-RP66M-\S@6-2B1.?DW9B/N]X1J?OODJ,"R_?*J&)]D_(Z)F?\U4Q)7K051B
M@TQ^Y ^XG+R>CB5#/]EZLE/UIG6%HZ8%<-F":I(7CR\IS0@KP'53C#-KSZX4
MFWO#.S9CQ83Q:H-?QD1T%L,V#$F]WDH/NYIOJ7Q5QI^KW7KG 4_\;;3NM#'2
MZV"?%C%PN_".5T*V<MH1\?C URF6$H<BM/C>8M?Z=G_2&ZZAHN\T_(XFB'\6
M=6PQ7\L&JC<P[<8F,QJ4$3.&BV.6ZC'(_<!)CJ^/@WL[7E=]_61S;%I-5]9V
M?.^Y;V:N;;OOY6KPC<&7A8R@ZMJO!MUFB!.S$#"*0D*OZ,P$%L*&][W-Y$MH
M]DW?WGF$R03?<_CHDI .S*)"3\^\V#LYKPTP*7W<!B0<70Y3<-TR.0!N!I/2
M_GK;&:K#""R T0[QHVT+)S?P@?O!?$S2"S4BKFQ0E5]Y!=['5N?P02J$"B=N
M3FFC_:+_1IN71TGN,DE[F $RN<E$!AG8$+EL6!+DHC-(/[8 >\)-8I.ZZ3J.
M0<(=CD&[RK?'YI9PPB@)@1479Q(U"(2L6;?665]=S$\ ;Y%:X@3^6N P_66K
M*&5G5W)Y$+%LR)X%**%X#TTDD!P%U21#N^@6XYAI8+!D=XE;P1_OO[/'Z@!6
M6T\G)BSC--632,N335$VN\0D#P,6(*L.O=XY'^[>0H8H4[RSV^(:!WLVN/DH
MBC,BGG9[+,"_067SF>B='6:0NY1_U-]TCF# HOKW-@Z2$IF=]SQT\$S#M!A%
M%H! ^I?%:F$+D0)T985V?$!LXP +$'9_3\:)X03#P\"OFN:9<PLL0'%1/PL@
M ZN_>Y8%N ZK1F8+U#46/?K?92"#M3E0@XI-QSP-';D ,XHKP"Q3:>2"L9$H
M?7 P,>A_PB3X?UW@S[0<\Q)3HL8D]%9[=C^KC?KW\AI5]=5[O\;==S<,7]_$
M60I4;2V[N#)R:I6F.(MSA_M"IZ"^)^LJI=%> $.@,EQL[9BH(*@-Z'T]6A06
MM<\"%.[9'5[5C,PQ_A88E<K%Y ]-V*J>.P?<-U#C/ :0IX:_2&JY4(YI\79W
M?8/QD?CYX=2^P"[3^ER<R\0!PP2&AE7B[&9?MUW8.^C_J[UPB@4X&_Y"X.>A
MT1EP@6D]&3/YD4EE/F#+\C42DNBRS )<<6;N!10BOHAUT_-]Q(<VFQ.*QM14
MJE66SU21\Z?:UML.!M/Q];)\1$:_68O>ASY8]O:/8R?30+//19J<3C]+@$;<
M2_4*MXTTNO)$/UY%DRE^VJS/+7M^1 L*[A3?W95>?MFX\ZN3=K^S5#=S&/KV
MXM#'UV;NI@%E/!7MY_3C:H5#HNLB+D3$WK<R/"9*=+9W?Q/QUY)AQ]!I<I]0
M@'@V;'_N!U-"]L3MRC%.QLRM<3N\F->&;0-F:@S+H]"B"L=_\WXW_1O[H_FL
MMR$+L.Z$Z5'F@TN/=,XJELE 8,'*>*4QNX.0SM?:;B\[N%PVOEYOM7SB]I1S
M*LL/4SDMN?&M /5X:2'4[=?7YWJ%0]J7-=95_3+/J=Y0VKS7K;[HZ5Q6^BV*
M-UTKU<38TF];]^G3/X0_=TI\XKCU[G(V&I*X#>E'*1RX+X:#!/7P58/N"E\I
MC;EJ4XCXC70-7,>S[%>_-M&AM2C962%#C<O>P"Q%Q<SO/\90?JU8P1KO>1W@
MDKK596ZK7Y.^_*\7+:-JINSC70 \L7I/CAYZTF'MF!=I %,6C^ABGJ5K?<^+
M\V?>]I*, L2J&52<=#FG%?)8,!*]B26A2/N9\QZUXV7GY[]<&S[A_WEXB?N0
MR9)Y-QU]476P.3?MJG1B\@P0W->WNW+D&UUC=8TD#BT*D,EG 3 '?<UW/S%[
MB3T(U,V[MG4_/]JF_W$F?;T0+W;U1I7@_='\])165T_U@ZEQC\?KSB\O9\Z(
M]KO$O[*3C$T*>[,P?_9<45MXQ0Y[__:^?]1P0Y>AIR-3]^UPPM%?;XND/IF$
MJ'&D=U>K<%=*G;"ONC5B-/3T\-D_%FFRPJ: Y]LOT[0=X46JS.!,"J+/AN8Y
MW2@8)/2]V$_^A42:-FSZQ"#MU"IDP4/NW4)L./Z7JZ1$'S@:_H1/F[\>-)UI
M$RYZ6=*;!>CH66UX;_JU4WOT)[_-]^SDJER"!*SNM8S!^#XSBA&;!W=07Z+U
M@1XJ4,+I-DJ[:TX"Y_RPT',LP(,'H<L[=X[LNC;M?[ 1,9I3WN*L/Q 0B@SO
M^TAHV1?ZA1?SCT6(H-P=3R"&C>^9/%]-?E9]ZX0+\H7./)6IW+\>5=-HCO()
MDY,N[6DC\QCE21YYSDV]P *8'[><(J>@-VQO4WC.4QQJ]L1XB(4Y-3C1XDI9
MKF?!2;]V/6!YH>1+NB($O4^F'&PH>_A$^'O2-DD)SW#\3_5<H6E-,7ACX11C
MO$_P#NRQ@<[(B&0,#$7&7!AIZJ.BE9]"_[_61]+ZYN2;-"\1!P6Z8?&Z>S&Q
M3Q)N'#-J,<]P#58-^*?!OAY0WPD) TZ E2I$N1P%"H!$&,2;,.E!37]6%CHS
M_FLJ/914!WS0P\QDX*+P.!&\+@O "09J: +':W_A=UF BV0;$O'[:8$6%YT%
M-XL)2/)AG:5YQ#:FX1C]AA%;<ETKH0UL.+U%TOHHF&%V0@,0E([+4RFH 6P(
M6^53!<$_TGWZERU@)7])[G=:W<%+H&$B[B;J<.F#DYT _"/>;5(]@*E;BRXD
MFC(R_ 0%#BD("W$GV/K3/3U)H'_'6"_B7I4Y,NYPPH:#7#28S4D4% A>\,]6
MI<JO)O4LQLVU4T*)'<=K_DIUY$UU]#YI[(5?_2M;K0^-GB0EH4LN(';292_5
M"I<#.N+#8=V+OPW6.E@  R4Z4[V9O$N<EB41"VMK3Y&J\'J5BG66 NP%@$PU
M[ =LM$UJ2+  92^>KG)1DPB2]+ODC::WN >9>G-+Y+J9= * MU!H?I6$PA&;
MT3A8<7O]S X'Q&#-Z=KAL' &3)A*&U8F'P3TM,=&S? &WSL$",:,3$-\Q)Y2
MS$NY,@' !$>NO?._5P'B1^?I!AAUXC <:7,";UJ/(M7-ZT*^ASKRJVUD!*!?
M*RW BV9@CNG4^^DAH%%8$W3:E.;G_9[#P\E%HV[A'20;HW2^'(1G 9";UA"X
M5?T%'5"(WZ#CR1+=6N1J'3"&!0 '%%@00ZF9+AS49_$<Z)]<5 %2.QP3' 15
M\[BJ(05H@=6,X@DM6WXO[BW#R:'5<6A]4MO4 N\JZ,FU L1^)L<"#;<X0MW4
ME;UG*52A"!RC3XW,P"KIT&D+>L,V]41;)- X-QD S^%XI23)O/-RTW2'.)7A
M[=DW-,$O3ZKD(CB!_P;S;01M[A"]B-DD+O,%@4+J=(C3+[*2<&T]N;S6II$O
M-^SI":&%(/44ZF2]: PLE J=[D,"54EX]V"PHBT7X-Y5_A(WC@HJ>[\SB$CO
MOXN/ "ZW$UI%8,6J.YHR".3@=%,#&2&.=AWVT)S7/1^QH3LW(NP 8 $,_<D$
M=^)TBO):D&'6B'%.LO3O<^4<JAX@T1@H29D\AOMXR(:=<$72P[+K7O1X^+,
MT5 R'E?GW:^D'GSLD9A&O)I$)&]+_=PT[M]3JK%(V,/,)DV-8_1*9BJO(Z<>
M#YL# 6C3-L0*P-Q,C* .CB;=$L/I- -K%B<9HG'FDNGI8TZZ<Q-G.-<I*!DJ
ME)Q G S [MK]!,1J8PE>Z0Q=2<;\='.0*S(H2'4"4?936'4BP/\2J,U]<ZR
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MPS,\<<,)#[]T;IWNUKM04MY:PZ>0J VI2\PCQ7&H3%RUF!OZ*1)"_=G7#1=
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MLN#9)TZ,SBSE>B(NYK9SJ7.H*8:9!<,Q<]DI=ZO\"G&7"/PJ,+",0#).';
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M[7".3CQWJQ"_BBH/2KV%CKW\WO+R@[/!QSAKGEI.+5OG^^7&,USM[_7Z6(!
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MTS/:.XPV7YJ>A4+W \@VE4#K%[L'P$+^JTZ:,U9Q8(SW9E^>R\ 14BFLF(N
M_BC_\U!0$'#;$I$7Q34,;E/O3<G\;_7,&OKO*>[* )V=.<I1)\#P4)OE-@MP
M;KXHA 7@VD/ML3%I#9\2ZRI?PE#8 FENV 'G3@7_9TZ2)=>!)"-T;H;!!7#&
M#G'TT=JP^MJWXK+>?K@IZ@\+X:^8:IG*T$9V*3$+J.[_&M+PT'>902HGSQ>U
M@OI*3X0(X#)=?21.7'.Z>E<B?#/8E"OGT#S!D5D<A$BU44[6J)Q)G[BN*(H/
MNRL1%-0013?"#!\T:% C6K#4(HJ7/?D)"_!->07> I)F6C'D7X#Z,:WN+YS
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M:VM?#7[\WPWJ(0PI:#W7L(X24FB)3M<:8EN\!@P@X.A*I[J'Y2:,MUG+62L
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MK&6H7A,,UJ>;YP"A;>"RNJN>M0Z#=[5G"[FC38%0\XE>_:2A Y39_%*/I:'
M6\\P(Q+Q3M:(M_7?2O6,:P)O0H]LU%I? *(Y+% I3Y!TUWXL4R8WB 7VY!SL
M@CZRDOTA@%%E(<RH23T2&J+O\(_9BEYD52;\A8 HS[KUA=7L5<6;V-ZTJLT>
M5Q_0 C7_U^W4F:TT\G7YRQ/B.RXMIA^!+4W) LCMFX&TG=6;%MCY;_D!L^RM
M?Z'0=1HF'#+996T50]< J5THOV5"25E9>5UY=!I?9??OM$J^GS8;/DFEU/HT
MDCT %M#@\JH$[)66G$$&7@0K5WZ'%YF^+/M#3(\T%:AT4B%^$PV[OOM])?__
M]H!^7Y=!QSN'*42M2V,LX#Y&?0)IVM$RW/GLX@WWW8C5*!\/XOD1P1]X86^,
MI"3PW 5BU<7_Y1]*%?[_[*_"4WG;C'*2/>=VB<=<4L/7@ ?*-V@+O$#&OS;F
MH-YM?QJ1*TET ^A]DX0^B!]JR2](LEURBHHH(F?K[Z)UHMEB01U\>=QDEY1U
MWP]=X$R"MP*CL"&J 7=&?IP+C2_F\GOI"UJQ^]KYM(7TM%X#7.M;/MW1>P=F
MN@;$-]7D!#R>4'WN*EI0D%\8U@W>W(&$??C%JZ2T?7Y;WBVX^]PZ-,QH$?/U
MI9%'<NX=?4Y][:3%4+NFRQ=W]GY,&':)9XDB$D-F'2HJ2PRS950=RF-TC)(>
MJ':UMW1OYGNI68AJ2NMH=+WKIX]6J^*YE?! 35R\O)>VW_2\VV[>H\QYW4_A
MC5+A%'^2:WGMW7*:'86!L.4#@4 -#\KBFKJE8/G!KS75\?BG#I(Q,UN\NX[W
MF T,,!(DY\61643J9PTL(\+M['8QOLV+RU+K<1S0N(;S# L1XO:A'<M6W_"#
MK]H42WT-0A2:CQ2@Y.14_\XX<>R7Q?DKY@B/@-J#LNIX._?VHK&UTF%]\>G<
M.M&1.R([W-XA7U^CB4I<5%%.5]Y@VQO1(]WC8=G!W-C;.U%H0_NMDN%/'7E$
M1'XX@T^/H%7WIF_;4@V#NFE;7"_R9QP& VZ8/EU)?'!W"]D&3_Y(&DTJYXV^
M2,RHR+?;V+@&?,E[RUD5)#*1I^[MGTF8?:#*-* D\$ <6,,SX%*B4)@O 'H:
M>L)WZ:8;&?).6\YZ[CEB!/XJ@U7#S:C]V.3C2?UDR?A86I_][ND<66QHC=*&
MS^SEKRU*Y6]?TPO-YR<JIS@;M-$A9Y,,P> FC/^NRRZ*/9_O2XC&!]3#F:+L
MLK@OKH]: /A^R5F#B2^.L75V#%RW3GW1Y_,#T:6*=08S \VK2&^E6P\$.6@,
M:)J=B\2+BHN*HY-M6[X4[!="S;1AGB.7A)Z,@ZJ/)<G%K^2A(WEZC2UB$&!'
MNE3>+7<*6;XA!"-#D)F&6[7:J/HS33WAE%NLL)+8QU>A_R F4WUXZ^-P/DOV
M->:IO40]7?',ED=ZNMKZ2N6ZQH;V#=/M?&I]'W_H(J=UQXS?)/*0?Z.GM1'P
MM'OB\E;54%_1&NU4V1A]]X0=;P5WX&/^E<P$M".K+LMGE?.NQP_9YA6YK$*_
MYG94W;8'>U91'[-TO1<43T(SF/$]*4T(26!RMV@>Q"57-K2A!@<KIMX2F- &
MZ0CE+<>N+\S^#P3M0[NBZ-_Z.QVM>;]IEQ>2[TU:JU^C<]?2Q+$R3"7SNCL6
MCJMKG/7X7#2I/9"V$CYK_<HC3D*SIPAXZ59@U9&?GE+R*F-=Q-"OP5"5;7QJ
MO1[M>H,A'44E,=PTT;R"5Z_(.L)G\H-V>7SHA8FF$A*"*HO80CBRT]6YX,SA
M\C1GRJZ1E>G2SARG^F,,'R/)](:AB:&3-H_H,_KP2M#-5P_$*BG\:?8JG7EW
MEC^-Z^GJ-XNJN*R7E!07Q3X0??BZ2EM;F\; W8VV_K%CSU2!.]T+&O'=\E2R
M=-F*@LTI$E4MCC^3TW_64:CR^R4OI,G]F7)SF#G-J5].B1KIC!J,ZXVLI@?-
M\CR&K2^CX8K<\5=5X^\-#NQ_7B$K/F16D#^<U+&KX(W\HL;+<SQ[Z>*27YU=
M'B)\6XKF9 QLD99Z8O)H&<?APQ/R]H_L\?H@/K^),ZWH/@W1-P?G)X51^?(/
M-<GZ-GDWTPL&99,?B7V;"MI>&/^;*J5?J?^1^Q3UM*RT-*E%0HSBS:V$AD&*
MQXSTMRTU8U-"-"<G?XH*LH<PD3R3()EO>99:3%W"@,G/,N^E*7V?H$Y"BK?>
M1.FMO(Y:K2PWRB+/0GO]-*ML-*3\T._8I:46/_$]//@\>G7D414FQ._G$+N
M_N@YFDGOC[) BXCN'U5S/?:4)DX68 )3J<]WXY\^3QB"V"NJ_?YTEWF\$T:T
MVM]&@%G@U"))$#0XI]9[4E=9O$DUI5_EM+FQ*\WVV.!$_O65TDQSYIGWT'2L
MZJ.FQZQ[*_-5685>((2%W[3)G_S&G823-.U;P@+WM<7Z;M8FZWEI<P+TH>22
ME[2HJP (.+& ZF?$6Z^B^G72RL%5.&8OB +'AXK8)/6'-,U]!Z\X?][Y>(N+
M3[OUUGN1<AZ*V/B61FI#K,R<#L7MD/X7@LSFKT1IZ']]@MH+2H_:EXLZYBLH
MNO".N<L=D73%Z]/R!^B ^Q:LA87@VB!@B:I_ZDBO0[GS>Y7:2IY*OE=N_O>8
M$(SB9 \_L,@S>7O(7\&=RZ&FSWSO3MY]Q6G&&4HJ4I)#_D"*!W9GX.^BMV?$
MG:\RQX 9.)<DUUSA[P.*[:;5E )/.UC W)*Y,;MA[ ^=R7[Y-TYT@G2+"$K@
M%VI='FA5FDZ]7#LH/?P(61,,L<J F\]<6E7-AHJ]7><L'0/^_C&^MG.AY<@0
MG0,2\(IB4^%+?UP%5;MW'%7=H&CG/@B/?,_D! 7T,\9C9*RUM37UU[$= N%F
M^F/;I7&=S,EU<;%'H7]JW#DU]<SQA1 HEM6/7\$OI;7A%84V*\BJ\5>%5-!V
MBLPG1TB?_NW7#Z;TC!7 2X93&8,O7AC81Y-0J>MZ%EXX$TW]A+ C:S6J;:F'
MXRUVIY\FY.>GI$3?W5T5G\ILGKV2"9$JFID(FDB1\2N* _$*^B<]6%Q9H"Y@
M)U3[.XM5PE74GMC3:E)RF6PE&ZD,XJMJ:,4]UZ/KC51*M[\0ORF?^X"CO=@1
MM,F@[$&47!##^^)"?O.ZF')]W-U!V59 S5S+';\5B_O_([;&%47VGOO<^X1R
M&PSH 4Y-QSN_(_>WOD=$ 94ZW7NOTZM%[M><JJBD_,9T]W@69?8N0H8K]7E
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M]O5+EYAP^4)VAXCB&O&MI2#0\I[MR Y:=0BS]6K/PN,_F6_:HW<D $,I8[.
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M4,N<>W![9&+>%R9?RK>.O$>&D+6W(&,7>R&=!M07S/B<1* <A89=]T'6O!5
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M%L"5ER!WK:%"%[NX5_24Y.0;1-HHS5YTUD86K@0__EC,S-BNAI!U$&@O??H
M.K""G@#K*%GHZ0CYLY747BOR5A9,'!")*<S]$R'.:1SB8_[[8]&[PD"O>P 2
MH$K:9F-K@)G6CWF?J(J1!QN1 .X&[FZP?4I<F$VO*D=C[1?YF1V3[0//-;ZW
M:[,7"2E\]:MY2@DYI=:NH8B>R=)Q@RI?%8.K(2VJCX5T%$^R&U)0FSIZ.H=
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MV LJCDH5RYCZ NHFW".R14-]&A4K_X?UK]U)@+/CQ@ D46YG_@QX5)RYY<)
M MB.=+*QOO62XR-<_'>#A.+46[*TLNJU?$%%9@5ILG:X.P2^L3 "'*J@!<)>
MAP)&O8X?(LW UZ]>4?[0CX=8^<'3#8_E_$6VSJD? Y)5KYR>B_=-G,/0>Y99
M'E/M(=@'MVXT\Q#+DKN"JE:3(#DKE_9$45H*=FN<R18W9)H'N[K3$&$( OC?
MOUKH<5<I22"FOWYW,,?B$Q!Y?LFOEI$!U1L$:V]]JQ2"^W7*+6+W8LOB$/RV
M1]%5)\ZT]NG]H$[@ 2<:$H*V>-C*RVWV$5W9^V>57YE'_7;U*4W84P=&ZJ2(
M""<.[G+WDH><MX?[SHG=C-P5>2_12GU$L6 3.Y#:>WU]Y(F?9J:M3VC>+ G
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MAPZ*>WW:YCEGT9>^UW:H$G$ &>%ZD#E-#%Q[8$6 ^$KE'FU-BIOBZ(ZP2S>
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M(#TSCN+K23)F0J*'5Z\KDN*IK3W7'0&:X[WM>?*9.O3BQ!'6,6+1@J07L*]
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M]>BQ"**83H%+",5!GN ^4.$9T:B4#)=;7VC-Q>GTL?V)OT^VUI5SQY63/./
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M$&[?&,7O+)7'0B3?[RP,6I[^QULXU&\W?QE E@$$KUB!I]Q9L']G>S%.Z.Y
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MT>1+>1&VGG(\&OV.>.&.G\@;#G8=F^_M@_N+H"<71 ;C'B@ >_V@54QXP!^
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ML21<1-CAUSFERZI)0]&KJ\8@!,F6FDS([-)?.#YMO, Q/6"#B^Y>O7YOC<9
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MD\U3R[*F[03P;L!,,1LX*B^,'4Z#L4YD/T:@$'TRY;B\[%I-F 1#.Z_3)J>
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MG,-<8]S=4/)(4N*/G]3JXOP>M63Y].6X[#&_@;:2TVMKC:&.GC,:B#-!:N6
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M,^&\ML)P!<^KQ6=JMY /<2W8"1#Q^? Z?& 1+(RA2== <X>WL+:C!"4_%_:
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M:<IL6C6(+VK2[;EQE-Q$R^PQ_D]7UVN5\4B5X"ONM)#%Z:B!*6LE2EW-IMD
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M\;84]0T?XL PQYK85I!.RN#'5U,.CIDMPYDCS<>\]+>M]L]<7/ZA\#HJ<!<
MS!/KAF=OK,)GYH=\#(\@O-<-Q,-]1QI>TG2<#;JC5+ZGU-]I#RCWF(N[B5@K
MWW;L-#S:S'R/]\/SHMS R(7<BS".,+&A!0_J?F:+:Q(]RW&??M!6E+ND:CN/
M=,A<O\#$M?\VA>,H2K<\VTT_&T9SRGV>U?ZPT.'J9[A'5LZ&+S;1X'1)6&>G
M2_SC?[,8W=YKU3FCO]6ZD(D75-;RIJ]XL_=CB/E/SR/I1\+TC<K934(V&END
M^_K@N1&*J"SZ:4;D"-Z]ZN0FS9WYIN3#".Q":QZ"?RW>)L?*[>*0I55TG$[0
MUO2L/J16[)_%3%K1;_L2I-K4PY +F^NY/LSJTG94HZPF=3\M^_B,Z_33\T^0
M7.W#7_K1UYOE]C^Z!QP+.^ZSN0L0R^9/6OW]WH 0<'<]VOGKF-_1P)6!ONV<
M'8>V &9I'4(*)0 R"UC?\@0HS%\51;,^R!)P^?+84^W7PTNW E-7FQS. :>4
M+/@L9J"P)A81:F+CXSTFM7<!V>N^XE8'P0<O_65_>#VGLG#J4@6G?SD)!!E)
M$/:='\,3"_ 2#W(-]Z<.^6M=_I#M?OW8R[Y'C;#['D^9ED4T"$@S\D#F+N"N
MB&7%1[CL M7FG0)/7()[D]K@*+=1S['6\^0-NX ,RP_#V;<\2Y+M&GY=8X S
MX;Q27IQRX5GM^3/JQ,U/\)D(,I*AEB^!\=@%_,+2"70X2W%+7!;Y;,MU%QCO
MH0<N*5_W,O#B!&#NCA ^7U;?%FL[BIDV;X/@4QYG"MZA(R!8D& XPJ(-I1G&
MK-$)Q=@?J5-TI5^'7_-5SYVXV"J FAJ&5V]N6%&4B?9XK($>]6HO?#HT*\_@
M8U-C//WD:B3UEF/(K81/V\^2A?/./"@0J./^A,LPY$+= *W(\)E9DEZO.HQA
M1_F5[7?[[<(F3V?Y&FTDH2H-'Z%]ZYM0LCM?I3Z3GOS*T97J2J.#HI$4O^Z9
MT@[8DY3(*J>?531M:]VEN:),1R?YM$LC*HJRIJA]ET5VA%T0M9SK292L3AA;
MJY8[57A!(/Z?VGU_G8!ZJQ3W3DK?O9HOE]JN9HN\UX@7)#-3G['UL#[)JE.6
M'[<IHLR8KPQ.D\[RVUB._?.<-% /?C//^Z*X]FEY<X)]]JFH63[VW VE<$X)
M0MU2"=7=<F]1]C 7.K$T_N_<U2Y5XB67Z=71NX_&^QX>SOAXFC?=\-8P[N((
MLQ@ELR P[4A[#/K1C</$.W9"8@N&43OB"85C_K?K&RX\TW"^:"8>=#?\1?4P
M(Z)WPQ;]%2/,$*#$LWBT%N R#),I>.W?"B3;LYRU]='!NI;Y<L;>!CUR]U3V
MY6_L)V%!E:PGA@)^,WHI:*$P+YL1Y>I;53>\A;G?O:X[W&\GM1*#BHJ)NCP:
M&/.YD6[J=X.K:>]=>R>]#NFD; .X8ENN/U^67>R+RM"+[Q1Y?V_G/?#0)3QK
MN&<A-^5,U6/Q2--UYD'Q:Z,0#KW9['*98#[+;/9,\RJ<*QHV2+0[<"?!3$_P
ME="WG]RD; J.YD@]6$H'("J*H3Y\*>/G4)VSUO\AJ&'TQSO^[F9\_\4H![55
M-KE-=J6H<XT+BL_S7E(J.L^$O$ILH+%@-:G[;SP2X^"!'Z= <F- &C.]9CHN
MEU;TH9%:4C'[.27.@:XS);>SQ3B&9X/[V[ QCE,4\]NQ,Q[S8?!N6>%ZK'4>
M[Z!NN'QSHN+TX;(1U9AG]@.1D\KWQ1PD!L!'9%?,["9I.)8EPU =#7C'@H$(
M)VO';EF%YIJP@N;GG -(B7O2BI)9G'RHT5GCWJ8H&7H$&.]&P6^P4;RZ\@Y3
MBIN7"KTBPM7>83GF7><^R\X*QLW,6OYKW[F6I\=LW06\^=EMQUKYP^GRU[VE
MEA.R-PST3E:3[@A:W@\I?Z7-52E:?.EM\!!14RMGDHG#+/XRY(#$E._:+F#F
MZO@:_0VQ;Y9,:/?;/+ABX7A][+JOH4SNX0K%[S<7[G/U_#OQZM6^]N:R@@/H
M7AB Q'C!HT/FN2<W'<@.+:T9MI-2DGIFC4+[W9[<T[]F,9ZW+I'*);H(8VM3
M1QVE9FW8457)C5WJ":S#8_X+LPN;O+.K,\PZ8[\+\H//A<PXBEZ,Q!P4>"FW
MG#/9P(347@/F%K\KJ7+F42/5,]_S@=7G2:/TWG)]0855GM3R#C)PTS^X[YMU
M<'ZM^7H")0F22OL86J4H8_#\PH;5]0QKUY0KRTY?Y3*)UL<T7V07&Q-:"#_(
MS$2 !*%D_@TURE:L0015F(;\BK)T?[N2<^/]3F/LY@EDY@^EFF?EIX3D13JP
MM8L'L0K9BX<CXC>.[0)*R^1=@"X4C&#*9[8JT^(I^8\Q=Q S)@NX7CP[B+3Y
MBH*'W]\12*CZ.^ODKV;GT>><;6?FZO=Y,6_RLSXNA%D"7_S.B-P%;E^N@'3K
M_:^<HKL QP8$LZ<I&&87_.]"D#E#Q(IU:;D'M@5E*V.Q]1 <$K:U\CEW@>\F
MN\!E<9U^3+NEH2Y#:]20$XPAQA61$.K=4B6Y*1-Q6;33LX-/$&;=K9_R7*A\
MK\0X?ZQ\_LSI1N9-2D* RAOCDY50WK-PM:S_'[!"A'W-::)S.<],H_MN\"8.
M&CF,_4BK9BY]>/X2H@VE<@AP!=&']I8F6V6H4::>O+2E<SY6T\X7,FX(NN#_
MI2'N:,'G1 E&.M_;6[_IR=M9ZRMTHQ5,]:\,^'HOW:;;\/&.S/CFPF#X@^V2
M^O$-A6=]32XZMR]OW>:2 -;]WST^)& -17Y,KPB^>A=(SG3_O1UBC@N,##!?
M2_P-FRE?6OW#XBXB1KSL\4RK?'#NRYPK4_KM3N)7YFOT.2?TM$LD#K*B:1Y8
M95XY/]M'PAYJR#T1DA-<?)_;T/WH6\Z'JEZ 3*%XD.&!*88(IG,&^1CCGJ3.
MXTU=KQW343LS.N%:WGOX;B)<3F4?##OIB*^)[V7":.\I$\]2%O(%)?[BGSB$
M;,_$OI=OF6%;COK.EHD-./\B)Z,W:_)A*4-D;*&AI-3-_-S'WBC/=.Z%>WU'
M-7TY--/:(5E])G&'O?<&!V6Y"\I^5F4!JG_Z=Y^9^B37[SW]W)*'SRP>/M,@
MZ5I>\_;P(\0AUI +O O!@288"H.FU*-K&\*@EA5^M&Z@JEAR'3T<;*#>=WJ_
MY[8YY=T$2PJ@_WS% R+)-EWJ,JN[0)U  MX;\:VV,R=VYN>9$SG(%)T?T:?O
M(CULQ1^H?/\R4MXS?3UFL<+_V)?\>]][QES[>"Z.9%XI'"M?_K"%>PKW@,\(
M+V2M5Q CK6@89F& %Z7QB;:;;RBRSJ>V3V;]_LW*LA&SZ</W+-BR;ETYKP]4
M4Y9)YIWJTV-$=O1XFTA+*YA!0DKYV3K[2<65A*@%I P<0-9L\*IGU :@JEM"
M^TU$?E/_-G;82("XWC:V&JI-"DOV>YCCU28?TY[XX.#E<VW3SM>ROF5_+X?]
M2C[0>\Z/N O(K.P<;**F;D$1MCY,6>N2*NV$\Z\YG)E*/!+K,M]/VN&6S-T@
MW9.^W4-_X:^DH?#X"?D.KK5-#'6%XMB#X)AF&%$.OFO,B20Q2HLZR)NF1W<!
MWK=$;)?'(0M.T_^/IH;W^8O4V1FQ29[6=D^V,P641B:?!7:+V )FX6]:?8X_
M2PM5/2GI=,_T3"(P\!7%3\3S?+<.7<!RK3R\.P5;^_%^C!Q;O S7,)5<GJP'
M@*5$%:" #VJ&PS.J /JS__R:$?#@=2+ -:@9$7:R(,+UA8/%XI4:\Z-Q#E=.
MG><LZS9,!+Y0H#ACP!:.' 6O=N0$9"K='63FNQ\VO/7O+#!,=HG8.]'SP(@I
M(')(P$6E8%^B2@&/K"P%%X=2]-S!Q*+.NK^9[=/(M'A OQ K:PR<- 9X#P'#
M-SA+$)#A0G@L2B,8UTD:R#_XK:_<M>-VX_ABK4F@B%?HYQK!)L>E +;>+Y'6
M>S_M;Z3H15>NX^IF;;A6 EU74X??NO:6]E3/U4:2C\=V/=Z:>[55D6.84AP6
M89UD]E6[PD]:7_S0S/2GZEZ)H7OE!6Q]RH_F*T>,#OD^]'Q9Y?/'YTQ//O]$
M5=>=DVKO;@F9'\TK[_\4?>Y)>6^'H:BAS"[P^'RK3FFN<O]O?,U@3N2K7N:P
MNG0(W5VTT!2XO\/9#HN1%9EPGVI5IV [S_C_5=:XX;/#WZI9V*,I<TAP>Y)6
M]?KG#BM7%XOS<9B:#.5-J$+*.;L_]=*_<_/\(OOG#8>R@H..+!&O=OB.?!N$
MX1WHV5W@216"/TR\W9#W#W[A( 6=5<PL1<[ :[5!XI^0Y8"-1#WWP)Z''CN3
M52)LYEV&DI3EI >0JV-%P]"]5^KG8>O-L>76L@M?-^Z9F5?=@MI,!I5W@0NA
M'7C09A9#%9VP,Y)@28.11#BGM6+O8P/AXA7-2X6>D7K6B>Q'8YY*O$[&5MV5
M#8.N-=![4>5U%/N@B)T1(%',PS:H)@($%Y1I0PWLY'=NLJT]K%G;&8ZN>]GR
MD_IC?LZGVE*3_$;FV?O>R8:]J@4 W_\IJP3SZB!'DUC6AHZ<>2K P6=[WESD
M/>3].HI'8^_(%_$5D(&L 1J0)P$']/_+C0"^PR/_[>&ZO<(1I>F]+Z]Q88Z]
M:Y+S(E4IP:O,I3; SV_-(T<S0J:2J]3GS$EL@5-OR4\7^_KGE9C5C4JB$]GF
M=1G@F+D+=(:A^^!_7>["*0>7]T85W"ACY.'VX60SBS9)QH4Q'9]"XS\NL\,)
M:6SLX0GO%^X;S25[D+79IARL\Z-:!4K7D"17@0,KMKY7A#S&CXR1G&?/!<FY
M]<)=E@V56*/Y["Q^OZ>@'\FK2]I?:8<T$7"K,8?;J<XTV^3.(6QK\IGEQ$8*
MCMS;89.R-]X;ZTQVC72G:_730]/XDA:W7]*\'KX+JM[Q*@&"Q]D2%]''40]!
M..7BI#0^\<:YZE'T",2G%,MFRQ*9Z=O)6C6IZ^+ UE(U2PH]B:\M[6;ZH_3V
MQO]R4Y8*R%NZ09UJE;6A1\0>F!QA5^9-!Y1+@(<:D@5\#NI8UM$P]05D[!(U
M'UO_\^_<R;DTS]9,W3O&ZZ)F(L(#A\XXO'E9-KVZ@Y)ZEZN?.;\JFLDM<OC,
MJ<\&.S%&PJ(<BR/7:=54UP7:(S)3;R$$1W(JG/KW1,I?S]K[>QVU[+[3H1:S
M?? K9QQA)(%9*]I-RKN/D0O80ZCK-?5M8TB%^H^-$:[1MW-T57Y:)"?'<=P+
M[ 8>)D@6S;=B6=)X&B0_7H]!/AL5"F<$M$C;I"*XU0VEE'M4&!&EO0O9HE\>
M=G?%2;ST2)%D#^-H^'N'-[E: EBTY71,_JI/:L5<9+;!/=S<KV$MZL!ASUI+
M.5._*L-5KAJ;<(4$._.FF^?6IM0"-I!5[A^KFU*]/5-N2+Z^U[]J9K)/7RXU
M_B-PA2KPV. 8Z:?05'>>Y-@_BR+_D=XR9W/-PG]L[>T5(;IB+G>*0Z2"7X50
MC%MNQ4ETO%8O8(\Z[JL"S&CE0*XK[%VR CFI*,=2--L&].&F[0%]*(HTA@*O
M_<,)_+RA^-Y?O<M%[4VA[Z)80UNCLSO<_J;I]==1QW\V'TQ8:-D_VGJN:.:;
M2R_KW<S0W.T4=&(!F\.382@*V"56C&P/[H7*(%4@IE61]),<WXT6'ZN_$-MH
MG!/[+(AK=IR3DW/%Y9HM1PBM8?*>8E4QKTA@F1,YQ;A<10)@^[2OF'TON'C^
M?U&*3\:D=T2))2X1>K*LJ'#6H8]/F1ETSHTVS\D_!L/P@9Z@E ^TH8C)!7PR
M]KE+5-/MQ#+DFV$>_%9?L5Y&&I2:]OK\K@X25RE7^K6X"PS8,$)W@2KSF7<M
M?;M ZB[P[^WOI!<?36W_+&\<8;PU'?PL(80AXYF^ITV@;^WH]L.,?U 3F)WQ
MU[_(+1ARW?UXC9#$-^JEOZ!4&Y63AIR"G8%U9*G*C-Q.C$7Z#SOT+EPY4?V^
M_^.1U-<0L;Y.;)]@7"US0IE]9<CSG7KI;V6-_Y!G=G5)U6BR?=\K(ONR[GV!
M\\E!3_E7_Y<7H1)V&"RRI4STQ/ _MGT_H?.S,L#@A_)=_\/)%XG)NK;!G]>Z
M :3=_P4;_Z=RG="M+KZ*YJ9LY.%*3#C2KX=E6(S-!8@\%YSSU:6-"D8;WDRO
MOM$>]5E>[N]_?X;YJL<NX$#X-?:V!E.!W/)F7\2#2OD=B%A#76;>R>!\*90F
MA84+:U-L2@FHMQ;C3=C'57@D](QPE"59?W$,[P/)D# MXN:&-<4& 9Y;\(>?
M'Z^W.70NL^1@PNVG:MUO<^:D48%1^/L^C^YZQ$PM2OS8!6ZJ3T^PCJ-XFJA'
M4:%@TD*#VT/2_O<47$);GV_@8?,O&MM>)T-OOOHM\M!A>?TT,?+X+"V&&H>E
M3EV;T,$GS OE#XS5\R/M,A<NYYD1SK =4<M8.O"]BY'16\?79G1.F,6C1L1S
M^L)J!1(-_# +YW3]/8?F>U3/N?A)S*QR#3+D7E\T^X'(!3D$LC]:!Q-J>F-1
M D3<-*&C37&D5:MD)0@!ZEUJFE2_N^X>^RO;7S0YO49%\Y#SD*ORB?DWU1AB
M8?YOKSR-72"D=Q>PVE@K!(\5PY_ /;#</P6M?M1O=0Y(!S_=!;@C1*ZSZM@6
M$>^A-.I!/K9Q_BBSBG7BYU/?G,DJG.6!^(.%4H-BV7YBH]&'.MD>G65WOR>X
M>+@E8Q56AUC/AX"=%C5*;CHF&T^R<BWS'&/8E\X\"F4SY]S_[&U@W>$[;0Z=
M!\T-;!C"G->BUVB>K*Z9*V1+ZOX?]8MJ6VE]SJ=E/@2",<Z8^JP.+/8&[U<#
M-^I4YRY0/_FQU(?F/16"EFZL]4B5NUC>41/.N/]P??6A[8%=@"%R>=1/X-NL
M4VTS/G/5PG,LW>IM].:+I">/0F;V+?[3!SPHG!=IL%C"[TN,L]!]/&O#%'K^
M![=A4KDZ+P]UT\L'+3<5S!VPB:L[QQ,Q\'8V:%"^CF^HMTDAW7?K$22=\_ "
MP;C]/W>^[ )2+$7CK8=NK8.B^(2C3E_K?+NO1;Y:, N3-+!E;]/EVP7:+='"
MBY@O^'"((7"JLSJP* )[<(HQV7&"Q1=V>75UU3-G=97<V3!JJ9U\?^B+;>9M
M2X6,=&M4(^>G*EZB.D-$?"$_O@XF#L8[I?ZQ:FT*;S4M4^LJFS>=V;A2]@*1
MI=^^F$,WCC*$0R=^"Z4"NI)Q43EM.#(FKOE =3 L^>21U#7[$>*'-'>QAF(Y
M'Y&G!;6''_09OJG'W-T40!E2LKH1,3<.4SWCO4H8>C$NS7HTW8:W!_-EVKVG
M#<8!LT.U&G>317VP6^4$AI 7RWIX;Q!T!DI"+-;7?N9+@](0; FVGM-[W!J\
M,'#.\?*'7<#9*YPK6.'!K>^GUCLY0HY&:>ILQA(.&*J&'5#G\945_/K/^H"5
M6X/@[&S/[5@>H@%?_NIGSCACKG7?K0Y\7-YA*'?8!2Z!R 7Y!S/HYVR)<[B3
M?#4-3M4G>B=>O )$O   D)4F$[YQMJ.Y1X+5I=%#LF>HRM$Z V=U<X;.RGB:
MUV5_#9A5N>]Q)&HV%Y3L<VB_^A-?O=6]$4K&KF\5H(RH=BGUENG>.MQ'DVX/
M*%QI17MR C7EU0 @^01@2P3^SOQO(X@B;<#.S/L_&N-_;SF&.VJFN9$(!(NZ
M6%%?&6=OE2EF^J"W?MCWG[R]F*5AINEJV%$8::(LV&O?8]1#F$S%M.P"6+O^
MD[=^7Q]6=KS%VA3IL#I<[6X.GX,HI6R9C@?_V2G+*(F3&7(8\9C%'>J#?+(;
M]O*CBI0F18RWZBE,4OL4K.0[G.R6N8ED/(P2H*]BZ:O/]EW6S1]ZII RJEL
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M>V$A AF_)5:%*5IAR37_J7^9),?-]_5=(=^7]:+[KUWC_#N][YW7;MT/V1L
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M]Q-EEAR'@$(82&I?4JG\J.W<F\B%NK7428[1=0H@_(LWS$''/>!BCA>:%B1
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MB(B1CZD-K4)^T27 ]0C"+%!; ! M]Z+I;O\&G1/9? ,#Z!GUEYXY1I*ER&X
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M?B,S/NW1AXS/ >=F.%S]>*RD+YTB7]_]5NL]]'\^D:KI)MP ?^>K07Y%&K%
MO?-2]U=.ZFC?H(0ZZ?A\WO99,:Y?"E>[.G(RB[<EY(],X":8F!\W[=46;O*!
MUJ'#VZ&E:QHC4B^S+WYIR_SK:D?!$7G]];.'KI2[-*C8MWFL^A$.P[M_2CW2
M*UGG\)P.T.&=G<O2^WWAS#LK;Z9RA*@8>($RKI?3XV@[/B!$U.Q9IC>-/A4I
MU'EZN<$^/*K2'>LR*P<,'^.=]KVY#&]9H:/L,VJBP[70;P*18D/GL&(9&&#V
MBC6MA^%KZN<HB-O_RXC\[_\8H?WW"-3O$6?"GZ;?(AFV-;UN;^:TW;&*+F,H
MO>CPH;RA%=#3<.-+V].!IK[H*PFNFWKO>VQ&V,)\5Q G*9\\8W3O!M<!2>35
M5J%@A]/=U;S_6+YZOT]OO[%B%R_OPZ_X/7JY&*LO$)+-ZHC@UF3HLD>.OTO3
M4)I)(;&ZY=O[N[?K-/1T [-!+U_?,3LTKS>RATVTO*DG4;34#9]?''*64UA6
MQ,*YU (H#,TFP51).3K/54>@9Y2PAT-(?"6*D&-PB'_/PN.>8HN!V2OF$X:0
M5R+P+(C?L0<"WZV LB=X7U8 _W(UR:,>)U)W81BN2HTB5QA0 [-^C/PP4@DK
MRWHUVMC3:G-CN^3*YX?*D973) Y#VJ+O_"2)7MQ['FGGU?UUL1\;W?S(8-P4
MD1;A$#.76:B!7D42R[;P?T(FHR$EL&8Y3COJ52""T7DY&M0IA7XU(PL!VDDN
M?C[*_;*C8BCS>_<E2X2/@<1)DMGY0)R+9<0I:ADN70,ZZ<G\"8[[JP4_1=@[
M-/+M#LZ\,+^#%<IT?Y9_?C_OJ>.Z1Q_A%1I6@(Z&)(",P0'J\UC#T@]#Z#&D
M.)>32$._(!F:%+)!LQ0VDD3$-*/_=!2ATKR],=0C8UJH,.E2BYI0VQ"I[& )
M';L$<P/>:\]"7]\..22,3O8H2G7W$R?RYY4Q X65+FSF7C8QTO,M<U"\)7DY
M;6X#^Y"1P +=>4Z[#C].+2/'TXV80-\:[# U.  I01;7]3$P$1ZY=)Q"%_0L
M4^OQSQ$@*JH2]S/"<<[@/X& =.8GSHFL02G8?1>)@&+FO:H[2SVC)>Z%%^/E
MF\]4O3RC6=HU-K%DA1$(NY/38%!!&ME1J1O3W.$_(B*:";1)M66&E(DGV6/0
MH^E^V!+(?3#U#*R1!1H6FRK"$J)<*"/?RCBXOG^_^B2;*K&D\Z*=9AHV=_QG
ME.#VM"3$_XGT?8AO4[%8,PODA/N>1 2OY!(]4$?HRB&#W2:]/>)#FI=S2V0*
MPY4?ORSE>RKDX:DC/!EK<?FV(OF->[R#A9R?GQOV:]5;A'SBZ1OQ05L]BD!;
MVBV643<4RCSTGL8S3D4QC\M F(??3@GXM6J(P99=$5UKCR_+C<(_-9.?3<]%
MNH1OKU)*&"CF140K[GA?/8QW8]Y1H^WZB'(9IEHK._/XJ8M1K_;+Q^X3 [7K
MJTJV?35KO;UD%"OGV*FTY2#U=K"#;!T 7X].44Y^O%GR>#O-1H?'$B]P1EU]
M"_D]GP*B9M+NNJLD=Y9C.(+I_!^D3GJT)G\0*IQR=F@]%__IT(=]1YH>YLE)
MU\<?3:+Y(+[ 2(#FA)(F)X$^D"Z>4NH1")0=X.7=4VH+W?[HENN,R^ZJ_MQ]
M.;SS3HXAKMATJUI(DT]2%5:@2DL"@G4A(E!$R_18PF<2=@H9K:U(O]J+X(.K
M?)ON+ZOU(ME]M]4;^VBD(!(>_C[U#2FO  _BACDL@4E&D&',U&"%!VF."*7S
M/&H,8(L4CSI B1.)C]5Q%@,]UD3YIN@>/-4F*G[\\3,=8[B%()>AM\-RG-?8
MQG5_^#$I7GY)#YVL40-8V:CM-IC'+!-KQ?B(=,*%0XHQS:_H[.3]HQ,VB\>%
M4MD</QZE>.J"'NBWM>M_>$9^EW!&7[J@8 #B#!O6( "B/B%SPO>1L#ICPAKB
M@THIKRW[K@>'[9F!^ZEZYLAWF4_>NB@8&*#=,;(N:^<XR]5(T"Y95H-IK7A5
M,'%?UVU?!XWL"%&HC!?WD7?LO ],+" %B.2$BLC;M<GCA*,\MGH\#]@?%A3(
M2G"%\@OL/PYRW";.Q6RYF15".8W-LW^B-_LC+47*^4JR+&R-_'RW##;Z[O',
M+Y4P4A$'ER9*D:U!').8$+] (_:5 #>GBIJZL>E64_[XQ._LOI'1;*;G=]^4
M4P\]B>@$\_E!_X0=OQTY[K:,\G[J;F0W85?U,YP@(3:K:[:Y7_Z=_&NY$3-*
M6M?."&5-@<);BRJ?V?+VV!ZAT*)E/YQ4'_*@:<$/DME6^,D'F"+^'C8EQ9^-
M1=9O*$QXK[7;-?9^HJ>_>UTI[*240$)/>4<CE.%7>IE\<*5O$S<'RR)0DET#
MUK(/LMZ^2>.UL'C[AL1KD#EB%IGL[?QD&O<!6IQ_AB^I>;EF/!EQKDE@M$5=
M<PN;X<QXC7.&L']1"=$6W]VC1I=Q(A@]=ITI_@87REE,9#_%!)>W\EY,.W38
M9[6WDF-D'\6>^I*FJ9R4[V&;%H?U?]1\O+3N)/E)"#9X,#4G[YVJP87#56D"
M)_8>5&T3*+@=EJG2GD9S4$(:92%C_#ZJ)BO^F$Y(I+B-#DBLK&O^F"O.Y?\Y
M]('9C?Z$C\:Y"FDYM5A6S:*FL(>H7DK(X]2FYJ&0\<:VXD:]RKV]ALW/<M)C
M;2ZWSG2_7P!J!)=Z9!A_(I.#D0;Q0A[QSVRQ8B\_R69+ZOSY*LF4^,KSIZR*
M>*\"/ _C]5/=)3Q1,DKM847YCHJW94+2UV1_80MW]YMV*X_C@A2-LS?[KG6G
M+GP9K,B@.A-&D>$WX6 R7XI$7.%)'\7\_,"94Z/VBAFB8(')BROOHM\2L/"'
M5)T"^@%J+188^$>N1V!@^GA0,F&Q^TF"F*=E^T\0\>@/BT#]B41:/CW:YF9.
M^NQ@V/#.$F:RRT'=+#=WRV.D[@0"_] #?>R^MA+=EXI[3U<A(7(?]"RHC#3+
MC\'<W4.Y##R<#ZY+Z(CO;<Z9%KG<R95[V' -.11K^S$SM/!5DHQ2H#O%0':E
M6KQF5/.^+T;/D8QEMJASA&O*%?CC*>:,][ZP<#XFN(3F6/AA=,%*T+&0%ZA!
M"U*E?^YQNW-%U\8:_08D?PG+%CE]+T&]=!'3T3< ^;SH\JK)LLG&W&ZYSQBB
MFP*=_L*=9417XO+-1884S BC [),RKB"%C<X7N(.:7*0)1K7MEK08+C"Y+#,
M/?.04<>0A;0I_:[--5&?YWVQ1Z]GG=!=I;- I\VRU'MGHK"SO70[?0*_ZB0S
M?F8!=MD-]['BSTW8GD4(M^(JD)KJY>?5C:<MJZ(_E.^$M$DD,6R/>V[=)7X4
MK<2&@?=J"_L+-?*+B)&V5G0F62!NARL]!0':,=X!)9V?&V.SK7D?I">JB3WS
MZ702-A8P;&>4(Z>]S61:>D(U>PV'J)EY:T,.52+WU?M?:G4^%E&F2A51^:<X
MGM==7!0L^S#HJ,'L50\JT*@911;;'P1_;<-_Q8OM)P_QXEWV291'9BKYS=;-
MN5#?*9WOSU02R-<XN^:FR'3+UE(WPPDN(V3AO$/:QZRIAENV X5>22U,KK*A
MY<&AQ[="'DXY!=7#B;>[Y-66'%&D?,K9'J:LO_)2JPB8D5TC *9 0_NLR ?B
MOXUO5YEK[%--.GXK7CSWN]UKGYB;TCJ"/G/>4%U?LPZR7[[Z351-68F;+\YJ
MU*R)>]4,;_N=^G+*4Z@!<:&*-/Z<F*K1G%B^)("R[K6T>!'4=B*8*Z^BW<#L
MM9I99*3@)O0 $_^@83)*CO!DA9.<>8WJG;$4<ZC4VH_=QMM/:IY#U']Y:IN>
M.1PFT*;:=%XVR_U!>%S@2F;UMI>3T8%76-,;+W"R/Q?.%);%P7.?CN,C(K<4
M-VAE*U43RY[9_DE- 9@(Y#U(](A<<WZ08/^/15N+(K0V.E]O+Q'>X:(J(^ZN
MOS^?.Q:T_YU5V-FQ#*"D0?!7?,&:;^I:OY,58S^SPD=3[(/V9/=MR]\<?!??
M,_@NX3U>!C"]Z^I66$0;LD1N]X7G$0Z5)-E,<@>3TYOS6:];E6?7,UFQ?C'V
MQ+49VA4$^8$!RNMQ5/W'(_P1U$X2C,!1+P=V *K(N(RR+ :V4S@B,6212]^&
M</\HN?P8Q_[CYL_:ZYT%-[(L>J'CMJ,[$].^YO5W%J;$PGT8/U+CC+6L].Z-
M($R&YA\NF607JI>IBJNIFS=E^3G*4K4*_>6F("^U96#NB24VU"&:WK)RL=?Z
M*9KP$OLJ8#EVORRG/3K^O*Y/#7QH+)-NF*^;)?"PTV88$A_K1N^[[M_U%)*E
MK;Z(582^+*9S%@\M:[KE=!!S-2^18:ZF-@EEH29K83:)QI4NXSQ!]*E7WY5_
M>KT OT0(((</0T= $T!/=E^N&;:\QV/V[#"BD\+I@_/J'+^W'KDZBIKJ5DK)
M/U'H75N^Q'1TEN:U&=/!N*Y7*VYL^SE8SJ7T]?WL.U\_];3P;:.^ AZ2I5ZF
M^6C2FP^N2/:;>Z[Y*+,<G;?P,__IO36Q-]_3;\G_F;MM+7)HR<97)U=W7E+7
M?%'5P*90,$!Q2+<ZVB1!,F@D3-T\=\LUL=5I2'5IYT:MJQD^@+_0X*VH+\8,
M\/K\'*X;ZCV7EO2&):XFJ6GVO2(6BJ89GU\POWQ&3;W/[<L@9OFU^KO/>%AO
MB@E "6[<T[V%8JR;6+@X7S/]B@<%].D:,"7[2"WIE?U'NCY;6T%(LB]W>A#6
M/WQ0FK'*I0Z26LJC;J"V'VT3?0M6?0SK[.CX:1;(4BJA.BW^3J:06 UU'ZGZ
M$C67X&#;U+Q3.Y.:%C<UFFKJ)BVJE]!\1OZ9VC[QBXMZIQXY<+RHXX$?H=82
M]I/DFJ G_9.[[:M>6/;IO2KUYQLA7(O$Q3L>2LUL8YL=N00BF>PIH?&R0/=8
MH$8W0O=*'.0["S0%6X1YT,[!%#J^VI5[$1\K1)+32OV%"'K+8Z27S0_H5ZC(
M+/]1T\&-C3B:\H2MAWXA'!^5.78Z0O;2$9,_U$YZ=!>JCP_Z!/^,+2OTV/ZQ
M\^,8>)^PB$B6WS$;0_N?QNL/L^N$M'IK"RJ*GWN3\$;@DI^9Y+V+@PM^U5 !
MO2QI1Y=VL0O\DF;@P >;17SZ+N7O1G_4D]MP 6H\N>#G6&_2V69O?NI5BB&9
M+1P.R7NCI-$-EO;,D40I0^1'9<GHR4<O5(Y=NM>JD-Q.?4[0<B*X+#=D4EF@
MU@J8UV I3L#XP]4\XZ^](RD6Z+M1]+MJDVDO%PWR_/)T/0W<.CWIU8^WWQ >
MJ*J_\3>,<W=/3K'/ZQYW&QO?*J^V,[*?UC[NSWZ-&DS(55SE]J^;N-8G[;N-
MW63_\L?"D8M'/EU#K_5>3>-Y] S/YM7WW18N2Y4C2S4ESW0W1 4V?UL<!_=.
M]\\6D\65:;(K3F)?OW]#QPR=FBIY]TP]MNXZ.C K4"3&'5<2VN1IN]I\WZI5
M1+['MK%;%]^9O=#[VM&-!:H66Q'B?E'Y9?%*C9[FW7=W?ZXX;S.%*)L*'=I8
MTV-*;K+ZN6J=XSM8/YG[J12C)W5AHVU,$M:"S-\$?H[FV( >[2:BN/V+L66K
MQVP7JWT+M0?U,[E>KMTSN#'-JU7EE+R6?N&B(X/\',&&YJ!K0;COD>],(!MK
M^FK0R^=6DN6D.*+&W=@>KXRIMIZ_<^9<UWF8W4I=0T)/EAF'X\.;7I+*LYYG
MGK@,B$ (\YKL#.P1\%$OI?P4J^"KR/NV+<*MGOA@Z]0&>T^\6I?_@@W6)9#'
M6+-<0=J=)C B#_+^.3<T4KT:2IR:9+S7%-06U"X=!(^.(-_XM?QI/,O(>H0Z
MES!:X:4QISVPX/@'-8N(Y6,.!H0V07F6UF#^3VX,E&FISUU-M5IN';LV:BYQ
MX0./6>7MZ&,&7[YVU>06\BX7_5QF@60Z'VQ["COH=&M;G<^1M? ?RRK\$5<V
MD4)'I9VJJ$SD3Y9R$Q##OUG\,[C[>MHPIM/MB?>%\LJR6#4A(:=8^1-S&-YE
MV%ZE,5@][ ^FM(>C8,V:M[2=H9%=2)1UMM<]XZ934?7"+Z./'9P^'%&?)DV6
MP32B^>A^=4.R<C4W>0?2$K(6A[!S1LY"L;WJ25V'H*]5++XT"*CEWCG3*263
M;/=SK*:\WWRM2AYCT)YI<C-^HJH@DTUQ>;O,.T[G;M%F$%0T;9S0"Y58/"3F
M0Y<_;[8SE$M]"100?_I."-,ODC8_5M$@$8JI$D3+,6V[H.;W=[_[K$7Z+H57
M9"PES[4BAP$7>((\OJG<OUIS]DS48$2N(WR(\] 'OT2QL^-W;V4>-A"8^]BZ
M%0F9SH<?)C*=62 .Y#S9NK]01>K^0!\M#O9V.+CC(SES1?M<]W!E>4&OG[!X
M<O5B\H2%M\[<#BY$^R35C(",H,M@OWM8\0DZP2YG%KUIZQ5?D/B>=N<[X[O
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M0U-]IIX@+/;Q<9^9H+':8P$O6W6NDTTC96/KJNNZ1I[0#S=.^[K?X7%64ZV
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M".*,?0'CT]0AO72D/B5&7:$UJ3?O>&Z.)[G<I:PJFMRD\%=9GKH@EL!VBNR
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M",RJQT^EP658^\[TQP&BK,63HHZZ\AZ_((YK&76'!H!98<,B^&8%MW+($<W
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M1YR8U=C"AWU#;,%0+^=M#<199^_M$TZ"$PFCJT#V9T<?/M"X@JU1\C2D41(
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MWN'Z>'DM6J%:H_OZ(Y_\5PE>5B8]0W;8CJ#K+E?9A"&:'HZV@37866PY.FP
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MO_9J,X?%:277OZTPM3:S$D/E'W21'7#[+4UJRH^S[OYZT:3,5W&E^/OGJ#.
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M ?E9RZ-?+IV_5#G#N?6&H"%,#++ZPZ!1]\,+G6UN[%KM0?Z6%<D6?H]*ZYS
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MK(8?'KD$C/V[HS44A%*(K.(.GU#G(9:T+5^L2DR!5:)JW1@ZI6].[RF7,&<
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M]?ZG2ZW_Q0FRT61QNHNFT!"I\E?43VL0:W\WF3T!4A0,@+B'0.QKQN#4_[R
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MV&T-_&K']Q? Z#0@ )9F(+NU!!\QV6CNA.$2&SOI"LI0II8QM#R1&(7>TE
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MM: 3E$TS"F!N[O@5+\*_A_[Q9/CB!@\3^9VD1USGIX9@< #1"+.EYA$&I=K
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M-C!H(G>1ZY/MT5=DX>;$!-_7F1N^";4"5;&G)WP.%$46O_[V]?DQWGUJ_)Z
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M\Q%"8FEBF1[>([GCG J).;>^)0T_)<\5#N1BSS/2@;$,%J1"X 7>!2KJ9]Z
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M$O@'H!D2\"9P;^.&^.,1QTL$00_TK?X/U6@IY/Y!,8,_"X[7+5\VDN04&@D
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MBM @&!1LG1S<1NGXL=4V]=MLKII5JG_=.,(;$S8B!/2SD&P^P';<\9162N$
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MJP\KEM1J$L"W8[BI^=H)[ 'B?##+81PTQU'A('\ A>V92BI:I*$)F]-RGJ
M$]0FX,]_ 38B>E+_0E@/*7"1W G&/*(*@_Q)$%PZJ9B'=D.=,!CQ]PK);[IN
M)9-SM9 =M7BCEJ<>L1ZJ5@D/RV4=Q?9!(FTM"CD-F9(6BPN+L8+4)07VUMUA
MJ;/_6;1?B.7).MQRRO0?65G>)BQO0++B;9F/8MF[@^8)5#Z0OP+"5<'69>W
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MGX:KWTTE;>S 3=SEPJB0M3\6;,*M[($$-,.%-=EG_-;0X?2_SN/"_O\.W-3
M]:!^2%3*?XD*"2KA@5,&]ES8'T1V+(%M>T_E8+ 93]'3*=1_2@$QMIV!^I=\
M;*=++6DR$O\7=&U:WU\*^,]?6/Z?=&ZJ"BW)5#>8^S\(-OTO.FL.11H6/!IH
M7";^%\'P_U5;I/\@V.:_Z,S_<3.3_.7_!5TL7$2Z+.&I9"1\8^;X%+C>CO;
M\192KZD2[[FVL(LC?J$:5Q%9?C879\V>YWSF'W(8NEQ7WO?AF ]QV/;*%BM+
M8[>;!RV-8?_].=?Q9.])&(],>@^LU+YC\[71T3Q$$4]=552,O#/0YE7H^>)+
M4REQ3SWY<73=:,ND*>OQ;5S8A)5Z>Q ?&\&%,2$V,]P9D/-L)T.-C[R]D\'.
M$V\Q(I@%'4^WH- COE_S2,1U^!U+U#X<U.F37 @;<@1!!-T<8G3)3XV-6/M]
M@L?O$S8V3[#EPMQ<-J>MGP0'VA!3LT83&;6B7%@$B&TQS6[8'!(O#TEO72\)
MA*^RQ,<1]$*L+!<V2D!R81.SB!(?+FR9%L%LO@SU3)9KXD+T*39BCJD/X4!O
M3FO_"X<5D2T\SM2_1@#L2 )0H87\30U\\"5T,+.!Y7(,RN4YK,A((!B$TUCB
M7-@/+2")"WL8"G&<D(L8 [FP(@I'$ ,1(_>;&/S\SP VZQJG"&IN.GM"FXQ#
M((Q\:YQ82-\I(9LW=&H1H&:V9Q' $>:A/N LA6H/[E[APD"+3)8VA,!H@%3N
M2UK?P']4(#[A80NW, T-C41#SD.01K\A25# Y!M@@4])C42V(&10[#13IAL"
M#"W">;GBEE?A&$L4/QY0P\QC37!CCNQ_0^(:6#A(H!MR7)@ Z1]6/RYN<HI6
M_LVI;R00C?M\CW1C*Z2&/>/_T);-!ZB9SC^\%Z*SV2+\Q7X.V-Z"ZRR'#P4A
MV:#ID(U]8R:XMYUU%+Z>#1? _>M\J))^N 1^.3L."G4VXO^AUUM_DUYO5\3R
M.OS6#Q348S0 I!N(#7F$ .)ORN@@?/# "N##D(:TQ83_#?8!_/D5-[5D-)!1
MJPBG.U$&#W)A[7H %(L?1O']IE2U?SYZV$@\Q 3BW!C*XG(_."F0_ FW4$.5
M"#;XE)DEQ$"Q$>Y,4\@8_#9GN^\X!&>G0+U8Q"S8"E^Q *5QHQF0D2;<_)O%
MP=]PB4*,VQ":&6RK/.@QU8AA'[R$6_+:9'$*;+WA#@I--:+8!P>@M;_$VL39
MK,8[IPDW+5&'(1:A='FC<T.>P(^@6T,E86LI)+!$EAPDL'\OX=S&25-#PAN?
M$W"= ,'MQV:ST;"$N$'Y3SBH*-S1P$GHW#:VV(C\3XP-G*NMN"DVLCB'&-/"
M%M[&M$0L([%093'ZKF63'SC=D0L;/)>*JZ\!(,D\3(&#YO_87=^Q)!#7R)**
M!"9PG[UQKI )0&4T51C<<PNWKI6*&"VG%.=R8<FAFU/>=V@AV*_^5F3!93B;
M"WO*E!5B3$.G#F*_-HZ#!_B>(  EJ-:=^(H86^7"BBMG1OF>P/]>*O&A0/ZY
MT1('20@@7+-$0>FN80[GBM\X8"0)!9]->A4I] WBX W<MT<,J.C?8?>?*%_!
M.=O/;FQ$KN_ C9;!B[OOTOD:^=A"ER#;<=7!??9 N!9##.P2QI/H]I#5MS[_
M6[*M<;CO9Y%$!6*<*?O0(Z838OGHYM],=OA#IY]'C)90BI?OTN&;8*[_!N-;
M38&D^/H)X<H/E#0>.-8Y7V>RF:G7P#WSI/43D'"*H59^M\YF$=!" C:'Z?S-
M8Q3'[0MN6@J!7X<[6J)D(6#"?./_Q]M[1S7UM>NB45%41%0Z"%%!0*I(DQH5
M 0$ATIL0E4X$%*1)B8J(U @(" A(KR$B35HB-0HB0B@"4D+H-:&$!2G<\/O.
MM_?9>YP]SAWCCG'_2,9(LN::;WW>YUU9:\X@81;R_#]C99ECF1:IXF<Z^C4O
M+OM?8QO^/=:-<-#%(HD,O2$+8V8NYCL*E<TR;78TCIX&I7W',.&EQ9X)29<'
M>,$D:_!(J8TA^B7-#TD]-L*TA/WUV8.P^)'*Q0Q<.HO>WB[8;)Z^9-Z2[+LW
MW-7&.+E)5:Z#L@0R&>W16@0MU1C).+E*58XZ F8!_OT=E*I^$!\CD&4]CH/K
M"@CPAM;77(PI<SJYD4^Q3&K%0433>&P.IE-G"-.I2HC?2&(VC><? :#_^.L+
M=JB">9)/3%R%B2PU2,TRP?T5AM'CB?_&4&5JX,D$J,M]3&![3L]00 *W-)CH
M_6H,PC#\=W B4/>9FMZ4IR&^[Y5&[\(8PNM4%<3O!"+R7_-82![8 >$R=V!%
M<1P8D*GZEQ7E#\I #/TQ87+OQ($5![:LNB&D'? (]I\C.YF$_9]#2P-HFE@*
MTTHY_S&Z]-\Q.M*6O<4)QM&0)1+H%!R-NY'RQ"OK)!G+8'O,Q'S)3*;<'O2/
M2-J/@PW@_Z6+R;\A9]F5G6FTNP=&2\% ,.L['LQFI!FF^!?1PN06KD$S?[-.
MD8O&UXM&$1L6NI"I,G#5+U62=QR$!'-GAI^%H<P! MW]6O6&64'$#H+(R)6^
MI,#8#OD%F2J=K.I;G.H50$QAF-4GD4F-(DO#>K.WQ(!NIO,HV;3D_W3>?\J1
M]06R*,18+$O>Z*FC<<,HS^.A5P&5SE#( OB?*1_\2S1FTEQS9<IA_\^7<O_(
M81[8^ :[('D@!M0$QK1MVS#$%;''>7 1Y=4RE&&0QQ"NIVID,:U3Q&!#078E
M4_^5K_L@U%\EI@--#ASH$[V+9 C74341OU.)4!JO+5/U Q0M9_1"ML0.-I_Z
M1_9_ISKJK\*_1WI%[Z8RA*NH&I3_-!&31V][CRPS7D\R/?J_#,'XR80/)G O
M(TXQM38/VV'H?:%9/\H2(YWZ -E0)2)#U0"$[:K4#)39'[88A!T+S+M'&I_(
M)$!X)!<8EPRI2+7./SRQ=KUGV6+"4W[FA;^,W5SN0P*2V2L49M5^K=X) ^2J
M__<8F6R#;'&#F?UYPE:'LO[AV-,UF_I,E4K">C\06PXVM&\)99:UR^8(TM;D
M"%55ZPPYE<&VRC10>K<\\P1)LE<)%1^*&9"94)D?,_V;ZS F]+;AL:YX? OC
MG]'H?9#HX ?(%+.78?'2?4ABC?N "*8J#W#0KY0R?ATXQ^5K7>3EVG]B1'=S
M74]K>_,;4X)$FJ"(R#<MYCF^V<DQ#(L0;=_#.!"_PXE@VM%_D 8V O3.."-0
MYYE%_28;LV$367 (79@O4MID=ATM>F$<X-UW&DPH?%$+HZ7JT33@A"/G.4"!
M3 ,?>LR$+V2Q(R0A<J_O'>+WK0,7"5QO]0G;5L,$0P&)]599)(G:"0'8G'L9
M1G@L@8@XCEC(/KAN=XA94V2K&+V="!&5^Q9MV*VS!PGVJ1B=C2 08<RCLH!_
M'\7TN (I=@L()LK1CE;^*ZW)V=]QC)I_0$WN8)P;FI>$6!TG03HXJP72X0*G
M^225*Q]%./7FU"7>#[4[W.QXBPR-;((65: )XUY#>T/&YZ9_/;S$N9@LGNW1
M67!R(.QZ]7-KC5ZYG]RD04<YT>U=U/!?-ROP-&Q7AL&D)Y^%F1/G_!FVH[S%
M8O>L+D]#LHG0""\K^OWGLN7E$Z^;4R )Y<;$S[EY*E?CT7L"6H.LM"TZ.TBG
MV ^*V[-@XD2SZ1+O/6<M! SF@:9\@&!I2T/MFKCY?W)9U^L34_L%JC.:MDUG
ME^>10:X/HVV;;3X[C)9WW6VFL]]G]#$1*6L28/*GDVG<YSPD.5:EY';7]T'Q
MV:1\!K[R/WY,K+#./=@FX@_';N ^" <%3(5@4"$O"+F-P76T6]'">S7NN@_S
M(Y[!E3UFZTUCUFUB'/.G/H^O^Z 8&)D^M0^BGI?9!VW=WL8+>=\5\D*0F2!Y
M<H8A,3GJX!!H@2KX>X%\_USW1D+-;853F]M<1W^-%O^=N:\RE$EOSF=FW21#
MVYM4:F4[\<%%6O9?@XN3Q*(V&=OZ7M"/16),E/)RSZR D(>8OUP:KDZ03/*;
M9 35 1:</^.Z)%^2E:/5)A S3"@]"07TMV"[=&;CY,G@YG'>O/T[EVD&PI7?
MV'EFQ;Z(!>Z%6'PZ7<<$X1/,,A0C[ZM7GZ/CBFBU81;-W8,_XKY#F6J24@.#
M&:_ NT</CKFCFO>W/[<*0I GS=-9$!M,*A,A3A,+$V!6IU3&301#+-Z&53$X
M_;VE"1G]1L_><!]T ;L/XF0F\PEL!!.#Q?=![YA4):JH6[:E1WA>G7J3.4U"
M(>(/F8"F:]I8/75X2FYK3U>N) AIX8V:-D61G0)'V^12VLYVE-G>6?TN=):/
M6-)YS/BH/YB4"9@Q7F%W#S&+4+JJ\Q]5XM_AW"\0@CJIB'X4L<&D/&1%1&L
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MWVVNH25( 0L] ;R&O[+.''I.:<^2(PXR[(:E""#W03H_['K[/X>X,QIUF-W
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M^0GE@;P&;PZ:Y5"UD33.*V'7WW*5+^KT;Y4S?#2<Z([2S"3) /$2? RW4D6
MQ231%/O6-*!^0:$*\.&4$TH#1D(SI*)DD5>_7[P]=J;X%]14OX7$9(B39VG"
M]'<(=\A;K;-!(@/E##D@44KP[8?(NL2@U4^<5X0$("J!.P:CUH&^QN_]W O\
M&R8ZV;C-$C/=%])]OH3*^"[TCJI,KPBS $K$9KL685G\<#M#B)0YE^/M)A9M
M@QJ_*)VH(2[NY4\GA"<LVT(.AXGH$;,CLLYBAVG:KI"W?I!CBPT5!?#S;ZLX
M%8_WR+UO*N459SWD^PV=%2;-Z,16U;U!/&"W,ZD%/ LP]84 ^S8,,.#YRWXK
MN,_#V=UAGNXH5?^XTSK'<BP6=!B0T6OCB )7675,,XR0T0S>FU/C/G/NE,[7
M-GK!3E\UO-Q3+)C<M#3OCTFRH,YR /X+]LE>A]NP,=Q0AA.S-CSR.-3>%;U@
M&U\4E.N^-UB^DQX4Z\'SY*^4H6=S@/B'3[,J<B(7G'RD8H#>:2R/0Z!*#W"%
MK->R9YGG.FT(-S+8:><\X?G[!&NFF[]*M_KA4BX"YC%[_ANP!*,;RZT$!H7]
MYH553[:S>RR!V4-\^VC:I39CX[=41N(N!:2,.XNLE?Z1_J 1GC!<52-W<LE6
MC\;9ULI0(0N5%M80L=%J =$U)6>C-@N;!U)NAP7O"M]ATM*"</.E,DR)Y[ =
MO4<1.MQ<(-:_*([5@8<N%H:VH(#PFZ1?&6)5TYI>>&A5I+#G^'9KAX#3E/.'
M%ZH[Z ND[,Y>?O@^J$ZYGN2E^7R"V%J+/>U9$W/\X1N%C"C9LQHM$H)I!L+'
M#'8JY#4N$B"C4 JS]\!%ALD'>DW>[V/P 0%WP]L:A$OXTK_WAO)F*^%O[>HE
M\2'G6![>[+2X,]7YDI ]XDWI!'HJ:$*D54S&Z222V/S]ROY5/%V8+?FIV!_B
MXGEGO']'ZZN>%X<ZC#0TU:^OBW,QL\8.IFOQ6,>PT_!.B5VH/3I4IF;8=Z6^
MR8(0X_E<[N3?P/A.3=/ V,_NZ,!7T[?YNZ6#_NJQOI/O@/V";\Y_<S@#6$RO
MCWA)L1M2+@-%Z,"V]@8Y2OX^Z)S>FU4OV;E!5V2/W1]O]M&>V1,V-C=&^4%_
M\ZM<5[Q'8!9 )BJL5XNS">C-'[<)S'F6'&GS9M?@9W]G)^3:#434X.W(\64-
M70%%QV?KJ(;09:N<6C"WY$:590,65C\N8YP6)D+32G@\(2>T\%.)K;#VLU2I
M#B/I6BV>"Z'RB_!5\MI-(G<XR=L4B"B>!!H9G&@A &[W!LQCKY.#(\S]W?-+
M7QV!,TDHE(VF72Q>PG*( ",90U[ 6/W $9LTZV$M(7>UU+?9G>D?4_8P)8Y"
M[4.Z;",LM\;S65JJ7^V#Q$[/20=U2H7]DB(J X944XY(\$%#&(&1",12.59<
M.4.KO@L;]U)H/5]W.LP_;TW/'V].MX+__'4].M%\_G*#UX]=V%SH";(<Y14@
M3XHT:AK4ND#3P:]8MN3:=0?^_7M?M_^J-2[A>)#QM)[.8J\Q_,T@UDU3=Y.2
M# 03F"U?8,K9J5ZN0(Y[P^+!,3=Y/Q1?"G26N13YEL7'(/-K[\_KZ/<U"PAG
M&&<83OA('\*%:G0.&M=O[S9_QU-V4F#E>7^/H/T/GZF@'"Y4&\_[7>V35B_>
M-%,ID8#S%#9ZLBZR=9(]1)=$QZ *<00AAR5[Y<4 N[_Z@NWW#"*CSB@+.CKK
MF[S3X_[2VE>X*K4J,^S< $MIUHC%U-A^:?)L4@Z=Z-GS0@W_W!,;ZV!P84B;
M0"VN0^#9J/E3C42/!(?.H:68S)].K&Y'6,6O\\TU;5*"Z64:[.0=<[)N5)&#
MNW] %I@<P8AQA O7<[>G%S0W=.JL>!S.EMGY^."J(,?/X"#T*PQ?(!L!1^/B
M;8>Q-O$3A-1P+0P90+FAHIE@_=A1(+2C?PGB-#GC^"B<[5HR2,K[T4VQ$D8K
M[#CMQ'&@KQR MJ2?3D:[[X/X:(8%@8C[D=KAO_I7VY](/[WM_ZKRXJ/;-R)F
M8GW@<@]U%6?6*$8AU QIG2#+6%.[:H8]LE OAB8V<5'KG/#!W^DU*9"KBPA/
MY.HA^<P)AP#'\_/<>3 6P*P5#&)PA%SKQYQGC,*^R$4I:CI"!V[O#7>4"2FL
M\O3X#!^=;@RU'8)6YR2,\+J#I:Z%QSJ%+A[1_2VB+38C>;)V=>S-==7U[>)V
MDSA!F\G09U5;[EC@V-?'M\O$?R8^=T<-4@M3:>!W2Q*Y];\^Y49+@/Y/KR)M
MZ:$-Z=\&?5\^EHD\B/;D.C08")\^U?>]5FW9RSC&-UZ/.L'L0'M1_A)+2T*"
M/EDWA99_2%4 ?M-71"%_5!*=2M=J7;;6L /!+I4EIXL7"LSRU)@S5JH=CI;X
M],^K"4?I!7#BWSA&K'#9O-+K/:BU)$(W<B7CY?&D;LS[(.7\DBFDUIVJ+/GT
MK:7=; ;;V4:&T ^RH'=ATCZH*%ARDHUOH+U5SJ6?9ASBK&_:,O QP,0S) ER
MBKZ\V#LRUK(/(AG86TU1$A!4 YH5D% (C$*K$9[6"\I+0PG3TS=/MWJ"RR]=
M"G/<Y%G\'=*I9@)8+7"7!%N/I>%^TSKCO!UEO2SDQ"JPBF$Q@4F4@UVC[@1"
M*3Z_(1[-KM.3'>8D[R@_5_RSC/9$GN0U[@JN\#-?_N8I5_GH:IDL2<TQ"4Q=
M*U,$(Q0OH:-F<B6"+(5KP$:-645YH4*,#J,:1H)\UI_H5".N/ST#5KGU5SCO
M#T8#T<6*84.,&#3L@_KV5D.NW<#M@VR;:.QJ27/O2_5'C6SW;-3A.0LNW"5X
MD]=7='QOR5("C,H:/4)%J(\9W[&G]D&ND!?@0PP)0-!\J$()')7%H89^*S*P
MEIO(5\C3$/+GA:B;28"]?AOO=;9>ENR/I^%;W90V>AS6+7MTDJ)*3]7[!CF,
M0R%:(:1?X%5O!<N:FHT0NKK!!G;X>T;5S(\=W[@FH@B$V<FT96"G<L%;MU:9
M*I;C(;N7LCB$]):61P?N#P?7A(YC#S\=\1)9YOACFBJ3!Q<;;D4#?XOV04<5
MZ>\8_&&=^R!NFL(4,J*AHL;/M1RX)62ZN-U8/)?@XCX7&R&/XV-[BV/A_+CI
M,$M58[1/D@SED-G':49D<6V@B*P&!6Z$*)TN(3[6/V7XF+VI_\>LE,W<#:U>
M99 H+:]"Y^$^J"7X8LH8!4E2:EJN(0)/O2J:G^C,#GF @<M,I(V%T%%?]T'I
MCR!;D^56&J66)<FM:'6H4<.$OH>?;I9PEJ\ILLI8;6%H*.8Y?-)W#CLJU8JM
M6L'R>3;)404\LL3(/!'!<&_N;,H@QML5$R#YZ+9UGDSB/0FV1&-5=/$D193^
M&O%P_83;7BJ-2W":IPX=2+2LHL)H!P\0]6S8M?X!J>M:?"@[)OPP7=2QWN3^
M15\BC*0_><P]3(498R]"-/$U,=9S=55-#0,:];S74T9_!>4\7/N2_UCSY%Q]
M-B#!&U>S#P(SQF!<?NAS]Z-<:\@H1L8)MA>U%%^E<BE Y^21)9_@80L=T\*+
M#P=&#52\RX9^P(K2.HS-W1\ZQR0KCJ5*&@67&=9Y->97A H5AN' )"AT+$]G
M((?^.NPB?.(L>3PNK;Z.I!>3+\/^U^WT#5G[+S^M9)/NG.%(O\IW%0AH%P8/
MT<31DX%6[0WWA]12TH(N%^:X/LEPJLM2D2!_UN2W/J/W2*H/\@C!#\\"T2L8
M D!&VS#R:"N A];YQWUVX"^R=D$ND.\LA'X8_HQHL0QC#TPR9>H>#V0P4^84
MC=>O=$E8M.;+@'0UC&/16ZF]ER*ZF?8HRE"=YXV-]<LL&Z2OCHJTEOB(@5%'
M6>&.Y?,RRI*.&[YC:NC2&9/$5"F3D7%[]6?/[;1G]E8PK"$G@1RJ;HA.%6!'
M0K9N>J37S/^TT+)>S64YENZZ>!Z>D*+Y_8CH"[\*A&/VZ$;7A&%W[XC=].VK
M[1&S*= CDZ6Y+Q/UKTZ!U(<BOW&,21&S5W!3"%X /+56!R] QZ((T52+^-^A
M#?CN\<BZ#P_S'E4L)V4VUHGAVJS,2PW,)RNKPAI"5I[<>G_1%F)MI(>WFD'O
M;FE5'-S:Q(*F?V#PA75EJ9%1Z,Y0QW;L&2VP>Q#YW*+*NXH,S^(SX!6&S6L,
M-]_A4QE(4TYUUF^B4U;CL$J61"8_9LFAYQ9]3<A/6$O+TGM<)5\7*9IM"Y@P
M5GVGG.W2\ST,T_LG9]*&TW4C9?C[7T6_]W9>&NX9\0J-9.94!Z0*\0+BJ@FA
MM-";FQZ66[L]'QSJ/0%HZYJFJN6R_PD@!MD<KI(PXSO._?/#DYHA.\9WR&?O
MU>XIU/--"LN0A@XA6R@0 :4^ L#M>!Y#@/="\C6-6#95G7/2/XL[M'-WHUL@
M4[4-(0Z',8 Z2?MV@#UO*^/(1C5@$_7MF/H3:,G(XX_#28@643_J*BN3KI($
M1KJZA39AH_:ZY3<2E3]_O:[UZ:HNKC2:B*PM"P^L4<Y"R:;8RPSKU(]=CLB)
MCS]LGDL,[,#6!,"K]VR:>4:%/:DR8;_2UU<UR6,Z ']A8'2O=H9I9L=03LE5
ML&NTDLQ%Z^XKZ?</\UR^4.4GF9,9EC/X3 ZXI-+&[D-D^C& .,DYWJ8P-@ZL
M_5J<>35QEY"FD1(G:J')?R'YS@*L9+>.TM\OV JKU6OO%M*0P2815XWA)MX;
MQ\/M-:+JP &'WLCCSUO5AH@R8U@V;(#9#(()O6_]P^1)]O$QTT:R>-,W-C6"
M*5F"\+>)%F)*=2U/D#L!CAI>.*6^J$Q5725)BR<QMJ*K%=3MK>N?GRWKFN7=
M>E6B.#YFA8?;.:.V)W\3$-[H/U4&]"0-?<+D&9HZN3LPZ1M&&3]*;6UHZCC5
M>?5LK-?WP]@?TL9?)(N?T"1&X?/D(4S;P4K7-!,2)BM,F-&)8?LR)#!,$'M3
MRSM:6%787#;9,]-R[HMH=/D]4?77X3-)/5U>]\HGA4_7]+W,U"<X7EE']\#T
M-BVO^QH\DR 6G52[[*FB/V(O)[J&;-"ZP 1928V+D)43.0P\EK4&<<8>*&F2
M<D3#;8UFVTW'>KTHTX;)+RTO.SN-S\G:?*G\,E5U6$M(>V,;C>< APT*9*]$
M,1M;BA:0:*NO:(B-W%%#1$L3[3OA)V2VXE98=XC.-KQ\HH5_7^ @,LRY]+'.
M]N(4?Z /'*LEP.>E!08V_BX+GVVN2G"JTPE%7VZX1C)1*=.+14I:,UPNQODX
M ^F_0FKL=S]^A.6YHY/1"\]5:]E.EU#OJM5=BD[?!W&9F>Y.]/8$)81-'"SS
MVY8]$C9/H,$X_&0<I@++6MXMC2(I-0,^CS/??D<ZN==HQD.;G^NUR?T9H]P!
MCI+ 3)2JMEJ=)89ZZ=.<O>JR^$EZD5HVLC+1K,=T89E1^I=\M%LKURVD?_[A
M8/J >31NIR6;>IDR^=,JQR/L&.![L&TF/2U, $ 0)CLS>9F>.H<17A W:B)A
M:AG63>U/=#= GS!M,Z(QHO!+Q4F.H'%YRJ##N8R/Z3'>::@ARM9P"<*\#7<5
M??));!&W\)WF#'],JI6[?0%P'OL&ZPH#Q.16"W>TV.BI(0^G89%AUZGG$]U&
M(=&B[C+>:5?7OZIWV<U83JN&2W2O/(F SR!/T2Z2T;$,63O:.5(RJK:DPGY9
M[VZ-O199K"[]WBQ;^7>#ZOL\FX>D/GO]4D6; )M,^/E-1V-=,R^M=X1) $\:
M*B(?-5;4H-DG9&9,Q#I=_&,?.<59Z+L+*.D09;ZC]9A6$ W4ODL67XWSJX!U
M-$ Y &4*!4=/R[*6B=H'87V_0P0FE!PC6P?*3GY<E)%==UW&>@KCSG_>Z'0L
M)BS?HYAY]>1/IV_$#]LN5;L:37N/S#-.I%*Y_K8=1%$.&1RM=3&0N%*)J2\
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M)S0X0\D<T[RMV!4ZV,@</M:[VLW?]/E7,5;4M^I\E<24,":Y[58!_UAZ77-
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M.F=0*?[C7-7'QF*"L4+2BQ,Y%NW4*%@P2JT.C\E[]@1#]1_M'\ZU#W9C$%\
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MGNJBP'U5&I@!9F=EGO4LDBA1 6.]4<J35.!B:?*D]\F=8RW7N1J9FW1Z*B-
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M4[C ELX1.8$3(W-8M5A*M31!,6ZU^,J%1SZE.5%!5CK#9"<Y9:^$6[DS1VI
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M.0WZ*]AU*=T^MWP83'QR.9S> =;(&H$11)&3Z,V+CCHB=KP48,1;4K\W(*D
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MORD!]OA+\!4$9OC @<)C@<)E B(9_AVGH*L03L"P?]@3'W1+V6P,<@HQ__;
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M]9YTWT6I02=+17YK.U^IHTB5J'N$R9JFS%VXY2&:'2FARR2>_>ROZP+:H1\
MY^"\/PBE$:DDU&R!)W7WOL]YJW#H' !9')=(:"+V# T4$$T#-=V^.69!TA8C
M&CK7F:S''6@CZIU_WHY\9:3))<+ZEOSVPV%I@Y0$[D3!72-I9/N9'#G;N>C
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M9"MW+3>"]41UW:A4>;O-XZ_<K5S>KZUZ9;NYVHLJI@=D%-)BNV$@8*X^'8Y
MB<)H["*)D6Q,20S_0@-%FUG&1:E*>H)?VH^IRG[0='$MT5*=5?^EK:^3>S-V
M5=$Z,D>@J,WEL,FSX(;@<72M=C@-9%\^,8MZ// 2Q@R_C@_53A.XNJ8Y',S7
M*>7F':@W>=Z\S)5PC%WSD]%E3'QE&A6!F$^@@7!FUNZ$NW08!<#(*M?R=1Z\
M9Q<'W!Q?3<B!OH!?R)&;BGMYN[YC=SP>_OQ$K*;L_LU3ZGX3/N7CF\2KS.V6
MZ C4?#CLB+LWQ<"ENQ0S7GH^V?=B[Q%E:@ZG] \:B$GK5:2*Q/.I9@,@=/DB
M?BI"<48PDD1 +36WOAH4% @XHQ"]<129B1*!L)<*@59)80^1+KC,G0]?*/T9
MTY^(B>H--/+'3(]7ZN5MC_UX(!;5)YWP7N:C6Q)A*5KU <8P/)/CNZK_(II]
M8GE*,"*_#U'BPILW?-W5UH7IC$BF!7]8K)RFO?W#P\]T%+F(0$'*2'_%ZP@E
M$[5>-(-8D1CW!X82R('XN%8T490[%%?>:ODF^2-9BYCH\('XK--C:85 V.-Y
M">E<X+NGGBVCS'&-&PX ?$:OX,Y$O][[PU#[S4F-1;,.=S#1M7L,_@"#9,GU
MT0$-'-PH2? O9@.]=K@%9CQK*T_0)G-H4)E^DLX )K_7#$'[M0')(V@GX$/$
MSSAV/X7V>U'_B[SWCFJB?==&HZ)T$&E*BU*5JA11*4$! 1&QT4M>I8D(6%""
MQ R"@(" H(+ *Y$F2A'I"DCHJ*A(AR D(0H" 28H82#)<";O;W_[V]_>^UOG
M_''..F>MLQ;#6@S/S%/N^[GNZWKF*4&E@2:_*PN3O?IMQ_FO5)HFI-6\^>O\
M[7I&)EL/K\Y%: =: /Z,Y0O;B4"O&(2QCFL;Z*E/.:S[PTDI^/ND^\N(Z4=A
M5<WZR[:?(XP@+MOK(PT8E83%YB&-*2"*O!E'&* 71S.FH+3B6>!=_7"HD<G$
MJ2Z[PN3][_3'1KTP:%,PRT/WLRW_=PQX-A72XV<,(2#1P"W!\[,/PM^:MXTD
M$Y,-]Y1YX;HZ^Q;"(K$U#L*&#Z/\G\2G?ZDSTA[;=%1#^G?P$D=)EKW[UZH<
MD-1DS9;$1PPT*\W5$_T'\#<C:&S#Z-FJB&2'%IL6YXNOM Y*<0H?N#SB$7AS
M14AKJI>C$,1&<!]*II6:!1P;VM/G,V28?&),O>[]O: 1[0O9QEO]$E@+87\Y
M/7ZR.SJ(9<"JA2RIV%2@:@/5(1Z#WO%'_H[],:9&S(JPXO&O4]OGSBQ0Q/0/
MA06_+COLXO374524J-[8*BL*,F&?Q^\$EQ8$P2W=&=[J()!8L]+T;:5TFXE&
MJIJ;F^NV%*N;N!\);4W750I*JJI2DCJ])<#BE#^[.#IT0"1P_6OFS?J%(R&E
M?HJ=38VN1Q93+)S>?"K3/[1;*9^$("OU,UIBOH'"V9'4Z>Y?4?K]^_BO#92"
M4:2#[J[I  ];L<S"KQ<?2-ZSU/YM5_-72-IXZ0[ <^\6.@72DF5TLHV@<%@P
MDFT=!*.YN4WB/G?\0)M.R;'),>C4UWW/GX25QKE)#.__U!)EN5E 1;GY#M*U
ML$  *<K;#.E*.AP]IDU*,S^$<1]<-'+<GK"BZ-%^L-[@@ZS[>R=1U;2,0Z=1
M'ZDHK?D*2&N$DY_#0EJ_2GJ*Q#7\/O*5!%Z.YSQ'M) C-Q9OMX$J[B&CV"4C
M-I 6^PC$[SP2QD6WF_.#S5FAYJ6OO3S(X[-U!RN[969?O_ 3E-N:8EJ3_$#S
M^E6MW_+=%# <RSC?;#QBBF$;$WJ(NYJU+Q%V]<P3]/X3H6MM/_5PAC_J\$&
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M#2;:Z&<-,R!VQ+N!^21)A3Q[ZT7DRZL@HK5_7[[ZLK#RYI;L-6/6E0W4DZ_
M)7&VZD'LN@\X<1T /?3BE00@WCYL1G W(([05/]>]SX]CG'!,TN[P>#AH,BB
M5+<A-8D>^<U5>WR]/K24BD0+J)Z3F*,P=XHS8O.PL\U:3(#AQ*3;@F*5-W\$
M$@Z]![GY[3=Z)ZV-Y551FSM4RT;YA6P[":_P_- 2F,3Z&S)#>E,J:1,^W&<J
M5 !7ZF"_(.PQ,-;4>-]C=W39%AOE-[ZX"2=ZF.]-9^<SW?#8!FH;1Y1M 7_
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MZC5<0=OME9=U0S5VJB(^DAUEOS[0/'PK3=,JG4^/IPWA2V$AGDSZP<T&J)E
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MR?@#@W)>"#J#7E,3;I2FY 1=T9;PH 1!K]B)L?B,[0^W[[WTU3O^S<QW^'P
M<MU8LC%?L=IVI_>G/?KS8+^MXISMR.7?YY2IK[M=T/]YH<(%3R !^%&/Q*^6
MV]UPO,_9*[P%"JA_YJ1Q-9N1ES@;B9T@8/I+?;ASO!EILN8SRP7(5=C-'D1N
M752MVT!Y-^76WGXY+DZI\*Z]_<+::N__F,18.ODE=MGFW,CL.;O=R<+UE_-_
M?/CY-:(D07_['<>?GO&=  2#1-X\[@W4KZSYU]WLH0^<\V=7X1W62U/S %?2
M[)SJ0IF*=I>S4H_S*PF^2]MO%95]^=]-UQ=#LY"(F*:"")1*>CMV_7;5ZZFW
M_V4J]_]V$Z#_.RZMG@U4L#AYGB;.4&3KX=I9==#"M9<:L1S98K6O>4I/_$-T
M7ZNF7UJ@UL?J;TIW^YFHIOLIT5=D\?ZN[I<N1DR 2FD#R/RTX0(PB9[:_DRV
MLUEFB)-7@@,ZY/#ASN&$\Z\,";YG-U?4N?9UV8@DWKYK@?ZRVDH9Q[(<D+[6
M"X\O$\@(^<609]J:MT >5#/K*<B#;<JMFKM4Z/5I[=V!-LNNJ[GX+W7VQ0YW
M+T0;)I)\PRJ@0\*P0&9>8,:Z;@(;AY/[^O7KQ.[JZMJJQI2]RM9":?GE;X5*
MGJ-0+5LV-R)Z\0:&LR, 3FL%$>DN.HETU"[>]B0\WJX.S"J@MVZ@P(E91&]<
MCC)_G&B=;91Q\'O9.V?%SB-I$LK6*4;DDOTE)D+N_VJN97%8S)_[&#;G&$$%
MH \LC&6K0>;!D1V4:CA/@-GU:-.MP+!#(0Z#!OHV\0?[FC*O>3+4[KDT?G"=
M>C*RLASG=*TV<_<*_WL4PO&T@=9.+&B'(4?2@E,[!!$-01*"^,]&6MWQ:2-*
M&%GUAX;-LG[F??[I\Z[U%VB8./G\I\T/$D?1#,&Y0F[.!BH4B)V4YJ9C?+S<
M0W?AL&T$_20LLSAU(6R,/C!P6J;>>?C6P>4/LI^_/_*V7:I1B;BV=@5Z%,K0
MZ,9 QK]A 1K;&AJ"]^!/<F/PZ@UEC<U]QG&Z2S4[9_PO?E%].)LIP[3;<]$N
M[?$[C?2@@3]+D-HJ1[+ 'E(+91N/P1V "$#;6C^T9X@_S@^\4YA1?5G"8G@V
M<F^8>F2:I"$!'UNHV2%S^+EX HG:C'ZSU$$9!V !:YH\)L9=9[I\RC&.I:3$
M?)(;6]PZ[5AR=%N66NWG Q7.-Z,7[=I>NWUY:[WUZ19$<;2:8J@T#*16O&#
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M>G$D\(:J,0ET^[+-X1P+&( 5.DC;RO$.^0=?T=B'7U36_PYY497L*UGJ_;I
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MAT&)_K2&>9!U<\L+$Y;P'"/#='.87?,NJ@S]<UVTHGZ!-BHIWP!=""[8%T,
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M+_Y@BU2[A7Z[!%@L:;7<[*A8_'P@7H=G[^&M2F-CXMX3/![8.7J-5BBX6^Y
M,$M;.$TZ.[2#L/=-AIR)H_E*.\[8%8=7>PP11/U=K?U'Z74B=5?*@TR)7.+*
M\Q,;?_>:[.O,B,Z93]1932R>3!XXBZ]C#?^N]V7;R.0+ZRC"?[12=W<7DK$P
M_W-DOU!%+_0Y]<9+Z.<7G^EMO]^\8<%_]$-_NF#!!"OSPBL Y]/]=/.9*2?7
M^+/[0ER7C_^8*W):.&W_X!015#QCF,S+IJ<R'*PSE,AGS)-;;RN'>3GTQ]-
M7:N^RS=@F0IJJ^ @O1RGG'+,%'1J,EJ<D6L8J\%\Z\N^\OF145/7?5YW.;CX
MI?T /F\O7'D<OG'1YP<K(";5A10@6>"]6N+RI4)>96O9&?ND&H?IBO,YOJV)
MOB?"R !B?WU*\ _X/0;W%#IEN#P1E8/C>ALDA.A86O:9W/829R@S7^>+YWV<
M95;Y>]#G(@-=<&SOI/9'[:=1SCUUF^6_^=24TE>6GVGI?,FM*$NL&B2DBL5%
M-.DN8LXZ*EC?Q-O7N>1OU$I_@4E5.)@NA9PSMG<#5=!%41@KB:R_RF,N42XW
MMQ4E_B)Z."J\9U[GGEM]R4H([X8OU6\,E9F8JJ/5/;+SKX?PBB5HDZ<UAYX;
M!\9%PA6+ 6?(E0V>,=1:BCQR.FOTUBI[YRUE'[_PGK_'H42O?5-CA/L 9L2'
MP -]?M)5O,Q8S?>*S-\Z.;:J+<+JQC0%%WS-[]>EN#5>D&Q9-F.KY^LABC&I
MG!BRM*\FWB/=&%23=X)4=Y4M)7)%R_>K5G@VBVS?KLLX7=H'[3]O:RVQNO@9
MG%(@J(@40+M(O854/S)&X[XW(2ZDN<,;2P^ ?Q*6UNQ^*X0O&?_SY8S;*TF-
MVYEB.7JYN=G9.X21-W;FT38K*Z4U_MND 8WLIC":;HP1I2E#0==HN!:RB.SP
M71MG?H7?\ ])KZU^\I5]WC3^WL>W#-<8KIY^#+)O'(B$7J;PDB[A/LRK $5+
M1%4N[7?OY<=FP!D_A30B3SGQO7VL3A]^CB[X49%1]#&?%='B:8SS[8(!;N%&
MS,/L[*9S/ZB@OQ;=V-TB$M:6"NM$5LY:]JQ.]Y<X54^W"@H$]\>?%B$QEP4<
M<MXTRL7>16V^3W*63]KH@6B^+L]9I((BYN>]!F$O^]Z #[SMB65D3!9V][#<
M.HE_V2OACECOE#%_7)FMZ+XXKX:>;(,J3,XH4'B?^/#)>R)XR\889ANKN6XL
M_FGG_]1*YLWC4- &45Q('DO-#[N#[HRK>)3PS6V9YW4>COCWR)4)!I6Z2#92
M0=,EB[E4T#F($Y0?+IW:B1W1Q.MNWW'O&9WQZQN$#&6+MD^%O.8\,5+4>#X2
M.PX1+N+6R(FNTYTE5P 3^(H?7!CN)D$B$\D3%0H[![<$+%C*2A-NV6XW%,9W
M/+H=./Z1_CQ&QFPYV)'^2\G^+L'G[VT*WYE.1-U:%E&2I%<+VX:<F>?=Y=K4
M[KJ[/CQ:TF'PCEZWM^F??W;N[<S9OO('D[@NG^P_ 2IQR&<CY;EUW^L 'YA$
M<X>DT;)71F]5_,^K;^_SL[@&#4-Q1AFL2_K;;/D;\Y<OUU)!G$U>ME30^?4.
MIE^F2<+ONP;<?41 V]^Y=%<+Z3DLK<0R?GKL \Z^D::^#> ]O-FQ,CI@!]TO
MN%&9)(VJ-#2-._8IINQ5'2%PXO T57%"%KG8LV*ZFL+00WP A+4^;>7ZT*2X
MA!5\B(N<F3E^H",*\VQ?=[UZ4<C;Q^B:=I?!XS-\E)<D&2"P FX&Q'TE2>&:
M7J# %[<NGW@E+WA'",?;,KL/W7^5.'G:90LQM6)+.9^&7T",'N;1@*YQTE-$
M*T<+ER,7%01N4B?JD.[5QTZT0QCAM]7R_ )OGZX]NJ1Y75#VGVJQ'RD)=AI&
M.7HK=&-AGZ3O.L^B[<W]][HP 8HR,D6?;;Z1B+UB%)U47?+/DQZTLQ3]O^4)
M(WT-*0SKYR/UP_QA[:8D?J^\35-'(73JO&(V.TSH"<_\78D?*BG?/_*MH6G@
MVY$*"O8OV#[$KW<BZ;ULQ2%A7O5EKFM?[KE$!<Y\_?SNQ_YUF9[8F2VL!*(=
M@GL<B%@.F<#2LFC6T_C.@DC)IJ?S5W5^05G[+L\#LX%99IPU[6^K;)W3WX(X
M_R[V:,2=^Z!BM@0[19F&,,)L1YL4\'3W+9Q0.J9\FC<ZQ'BX^;[16S\&_Z-Q
M*FSJRD7&U&XZT<$.#0;Y?E[E_(H;98>[WBZ?-4RC;VTJJN]I;P[K#7H;CU3K
M[-Y"M+840Q;S27;=I)^NM'R@=@RG!ZIH1B]@H,>*:&[$9"CFQ,(52M]YYDBV
M#%7S:N]QJZVZ9;+-:]!1^29X3[IL@[4GTUN$HOX=849Q5_M[Y]-; V$W,)FS
MK(G%^#5@C+^/4$&+'#B5=O^?*>Q7CGJ_DLHS/6O+XA/4>D274U&TL9W^&#0.
M_09NQ<PDC 866 YA:0VNX/M^"#X9+GJYGS<IP_-ER8]33UIJ)-9E!NT("\%\
M0[<-3,$6X[8%B::4(?^Z]S 5U3R+K:-DI0MI$NW6UMHB6L).E\>]IM:;Y\=^
MWA44/.7<O5V/&R P "E$);@.^0/$;G?:XCG^T[S$L)N\2P"8W:GZ1T/@K NC
MIF<9P52!/L.5/_&6?M*/KLT]2B78Z3#3),AE_O=L&JQV^B1SN.W7%%D_]<X*
MJC[IF")1A]%_N.<C=VFZ.9B@ 6!P^P0SH+7$-W@Y97LNGW2OCM+]?7BFW?IZ
MZ,5:'X1C2--2=:NHV<6'0K[35_QB?JZ 7P+[-"EPDA,HXO"K$Q0!7Q$*0_L"
MFF%S&O7N?7>'.=S[M N#+.OG3*O(.[[=S 69**P>RG'4(.;.1$#%?OW^Z)\7
MJ^J]7L^M&\PPN]K3F0JX;L((4(!+(?R##]NN6"!+Z:"&X4Y>Z\[F*^)R_@GK
M/2;ACZM<I9L,KO1R$*MZ!OJ<T-\NIRV[&A+&@!=..+P;NB:ERUNVOMJFM+9(
M-"![DG+*K1K&S^AV[NI2$^9'"QT^I9/UR@:&-4@ >+-E/(YR>7<663#5W:"5
M?N(/.G4C]O1;K:NG77;M&P M&BYS "Q40Y&!!4 )(1*OD<"^N-Q1V\)=]_%L
M]T@6B#1R,3<D#K0:D:0DX[G1M9]Q0)(DQ;>PRXMKRXOUCF[,6$_/_VIT^()H
M?4RZ0?/_,0B<<<E J !WX^.9#H%K.$I$H'<Y-WW?-_-[_:T44&^N>ZC&K@EB
MX3N$30J%F.[]M? ;"9XD018@3%/33DI6C:YU(6O13W;"U9[?8&;#DZ1%\N!;
M1 A<2TD?:[N B :S>35&Y=<"4?E;/#MY7M<2S&HQW2HCR@)FL=P1*@DNLU30
M0FTFWYBG_LRNY>@ATYU8?MO[(Y+;0FX)';5+I]LIT_>ODY^//RW8KGSNU.SW
M#W8K&_$.I3T_0V]=:I1>+'ZB9H^^5$\S$_ZM@>6_F8P..9[T0K6S^P/<84&G
M)(I(GUYH1M?I(JA)!:E,+=;_8_H&_GW_2$/-B1Q/!;D@(B"5D(X,_26N=C3+
MGR/_/$+<G7AW,NI,Q<JC8<'*:*%(NMV("Z;2Q^[1EZ :B%:ZFI)$HBF0UND1
M)Z4_HB8PQ_2K_L+DLD-CC=B5S+-&0FX!URK"8;OV8RCEF/O9Y-6Q]I\&D*;^
M=-;?Q1E*7C))63<\1]V:#LFWU+63;BZ\/KR.%5IW6/4ZJ55^/B:/9-OB4EJK
M*[2$.G,=Z:N.S76$:I4+>\_^[GMC]B5"*%-+_@A!NOS&U4(/4" J I EH[X$
M^+T1$JN@;S76Y[1+EDS=-TVGW#/'(06QRVL]]$D_51)L_FXKLM</0>#T*T+-
M?; ]1'<SN4S1C\<8EJ KE4QOCL3H--V5OBF_?&:$NV_QVBC-LS1>Y"<M.4[!
M7L(+$@J!UF*X Y 5E.#,$WSF_3CF.A.OUT *C#'!.SMX4^O&EPA[F\>HR,ZN
MI\"+P(#:,KN5AF^?K%GI[SX'-BWT>I3GCENB JPRYQ1('&\&%AVVH[(I_>@J
M_?8PW)VB0B<J"/^:9%YW:M>+J;2J\KW!OJA7.^RN8_OG9<:+RG\W&1DU44'M
MDI1>15J^;(H^4<^;Z. D4$$D3@^*K@_!@ JJ^O?;X0P>3W?/>N,=W:.@K4TC
M%?57&F?1RM,R6J\2UJQ8PQFZS<5;R)];;OF"%\*ZL. E6$?<AU1$;(VKHILZ
M)N30*+S5]V5=@I#$6N=U>.S6U5Z!I[;GS@2J+T.!F[O;3DO0LYOS?$-_"QQ;
MTX](R;/(+DU//'LOH1R8&\<KUMOHB7N3&WKEZHH7OTLQROE@\P:CFT[S,&FJ
M4R-4($_AYIA!8.D<9=5V'3,51Q@%BHBBOH;= I<!JWPG%Y'8&N2W^:U+MWX%
MOJA53%9TS=7BT.BUMU^U$+JY[-B=3E(>:8*5D.X-'J!#V_!-6EZE%II?R>^?
M)9)1>0:LR5.\T#[QT)^MZ_(9N4Y*Y?5%,X[^ FGN?@%^KS^:34VW#>NHE+<:
ML3VW^UP) LEJ5: I5^ RP-^SXL,!!R?B@Z#!Y/&6J\!RN=/./ M.J8]'E8V/
MX[;V<YQ[DA]B/O+6Q[WG-F+/VN>Z%-()5E:-QY(56>4\&:^>:;]!W74[45<(
M5)F9\G*0IWE;_&@3)(!H!?BWZ_BNC+XBT;L(E Y].S:=LU(2]+\SSC*@;!5@
M4_ZW@+P\TVXPA1=0)'(YZHV?@#^06%G(?=Y[G)&$/\DH,ZMS]!/;^]*VO]U>
M'LKCPSK!D=:*0#\>; Q4XP4M$Y]-R/]:]D)XB> 5KACQ<W(^R"Y<-#*Z!SH%
MM?M[.E/3+@?) 8#AP[3?(>_C1=K#$54P=*A-W:4G/P+"=[Z*D/&6'W,._;_[
M/QOOA0:FD'CYJSMNZ?(9.99XW"5/(%;*WT!QCRJB!*[C-+&-^22EZOKX&B2O
MDTFM4EF:XMY<5FWRYDW&@UOYE^_YAWSI]H"J488$3@]3."F#F4J 0]9#(6\!
M,#XTK\!4J.KRBS,*SS0%M#:]Q?;GFQ,IYS%?G:<G2!P*/XY27=.T+J? BJTP
MCW/"LRD#W\-E"+(Z/&1+DR]!4SQSZ'":7QJ(Y)G++1)2 %^4#V:._R:&C^IY
M\$VP_#D=,/%(KJ_ K=+DL)%\03N38,ATD)YP4 7#J^Q);4&U:5(0TD L?%6C
M&R#MCT,.!@*@\NIDEPTH(!1'RCWW W$X8$H%C:AB/6TALYN(4&A\*!WY) 7(
M.<YQZ0R%S#PD*-0 B71^5!"[&N-D=SZ0]*1TQ)G"W4-4G<<LN3C<BM54YL[4
M./YX'F'7H3\%7=! $5VW9#XWZ1;+=X<%76R7>PAYY=MK[9QE>7$#QBOG//E2
MMEKPP@<_Z'8>G@HR)*>VR#LAV+]6$;W3DJOPPK&]/*KZ3SZ[?J^U@R75B8CQ
MKEXHU'.W8L6FX'?;(;QJHNTY<(D1C0P<L;56)QM@U=$E/NL2#'[=^@-VQ[NO
MM$]AH;C>_EFWE*UAQF#=SGS=WA8XC0KJL;!B60[/VQZ_AIZ_X>)W@.Q!K/2H
M%?P]OT(XU26.C<1?_STI-T'_K1JODY#WK]MLK[5$ZH6;C@@1 &<!B04*4D,N
M<:-8@2<MO!N9(LC?;T6F<AN<WKU[K;<*O?4BEF% ^X 5N'F.%!;$0@5-H0&7
M8WU=,KH^:@%&3L.$(0Z4BZ6K/SD-14[--ED*BB7E'EG6'D\NJUV TX]0A.$<
M0 ;>9JO#T+Q_@1^B7X^JC@7]\G9S8Q:Z?6D/2R<(6FNF 99?- P.X?E;RQRN
M1<(65VRG(I8OH!UI$?LI_SDJ2(_%&+V0CL8?XJLI_4<=R-_3Q4VK8O(C?X:A
MGM"UGK:1:)>G"1;Y&,R-8R&#OW5!')%GY/6GF5J/P.QPLR5QB3>8KE1;X$VW
MUHA-\OSF"Z4JAE6?L_+[I^E0IMC?TLYH;&!VT, TH@/*-@^7Q4]$T)((G66F
M76P O\6CR/EID/TG=,KUWCX@D5$V1WS@7.0ZPI;U6!D:BB"H.B%.C/CMX4%4
M4 )Q&4;D14F1Q9(;5-,H@[ O)'%="7165!%X>Z7>I.-PG"AU&[H$;HT"T\$O
MT@S7&6.9O 3C:RWN<;?'A5CH5UFGO>9\]\N-SOWG%?D_/)K;=;C$AP#] GA:
M9*F[BZE?2@NO-3I.U!XY.,BD:+F6D\*7:J(;0F>+=_9^&M_%?4T8OH[2C\/L
MV2.J=\E^ODB:X+#FZ!HPZ;//-I9R%(4X6.?7KRF[.Z*M:_U&=Z-JO8K$5E"5
MHV?$&X/58Y'P@:<$'%?MI!&5*'W@FLM?"ITP55(=X"N=2_T*>@E[K R^A-\S
MO\<3I,W54<D3*^STW&S?;C3^<]8NB^9B9P=(=R A'E206FH=);5\BY5P/ID"
MGF%:)&[D=81UG"];/=SKE4:TOWA%M&_F(NC6X,;"2!R]%F#Z4I><]@K?5-4;
M+XCO1\TPX;7$5S.1Z0\SE.3_U"M*:HP=F>C*(Y*1MY_(AFB/BHL6HAT3:P=,
M:[#[$RN^(F_AEY;T(]1NC\#I%LB*Y2A=ZSUEBRL<RY[1KV41(9K/NM^>$GEG
M/1: FR%<!-P#W1>@X5 NN-\2O_]8*F^_16N#5?:&]Q&C=H/4-&]?AM$[WHE3
M/WXN1#^DC6CX,@0WGOJH#N&X+SAT2+/\*P(^7PC<Z+'U&*+/\GR>(8VFVS:=
MY#N )DC PLL4(CW)6T+(AH;:(V+-\>PO5@VV=K$6[(S+?""[1> )8;B;'[^\
M\!QS5EY7ZND0W.A<.$EJ21E<"T [QKVQ?#Z#H=.;/V>[;[F^Q2=H)]R.7G"7
M?JO'FA=@THV.AE8KA*,=J"!F.#? G^<[E8];J_?PH3^*OE8]6WO$^&2HQ*)^
MZVI$Y;<+%_3<K<59H6V-KSW*GKWWNM0\/6:&"N1O&J<X2$IR9)F/3J,21YYG
MH$SV OP$-G!76 %;=.PD%93Y=]_.2)I).DD8]PK"IB8"P!;)_?L6FN4NX_[P
M%)E"^PC[+X*2IS8UMI>GFWD7%$A?,-VPD^5%)%D1]>9OX552>EC[+I&_!DF^
M%5E9<%-S2\(308P]NQ]M=^C83(-E,RO^9ZMQ2((F %EV=?D!O:(F"/PR&[TE
MKQSE)<!45;-7QBEL=U\NL1(C^:/T3]0'^YO?J[[Q8;IWWXV#SY?70"\"D$XD
M[J.O?J>QA-_BG,OVFG"\T?L>YO"@[?B$+/0\'UT2-[3F*Q44_1$(?D<%W>XJ
MH:6D"1,.^& 1P@/@5N[!=[RT &;CHX'^C&$2=WW=0([>.&!97C-B=.1FI&][
M=SSRO65J?@4B0M/*:XA,//=6[2Q<;BB(>Y+D2,YN<BG:\->K=A<*XA\D06!\
M#;&%\;53]H;7IMC%W5.V)MZ:^!0&]09=!&[ZX?.:#'&"G:G;!$(0>!1=4P/E
M-._D7V%#E7S-$ J)?I9/,!*[TY!LB$IQAZJ2*ZVAU221#\I^XCB8^DM+4E9<
MQO=WFZ]O'W"*;/-303<H$"(72I\LF/"M@@>U-YVTJE"<G&H^76(^US!_M#?X
M)WMCJ._FT%/SNUMENSDM5% 83%7/@0 #=!WP \MWXG#53\>%1A;'U(9:]JX$
MUP19-56_9@"M=,=U507Q 4P=2 X5UWR KNU.D'=6L>7YLK$(QB;VWQUT(4;,
M?:]?%^OZ2Y$NK5/T=MN@-"1*!>5RR<,(G#HPP#QU=9@*^OD \^,D-_4FM$6R
MZ=O9 4(M-X1YPDV0TSA$NS_PLWK>VNP8+0HA'J:PA!689W!01E>0V4^]25;-
M6E(J7$0N7[T=V'G?L"6'&%3@L_F'+%WU7S=J2_)+@T.G$Q32KA?]G"U@B:XX
MXY  A.&2]>G@#U$XC2]+<PK/46/74-^'#D.^F[Y(G5^@XTC8A?PA\7U[<R?6
MH^X,GF$BSQ-\H8FE OX$GY^V &:^5P5UKM,Y(V#_0-C/P>;4-:/[]E?93V>R
M>&E$XX[2BVM+=_M=_#=<+&J[9$L8"1^<<G?S*A"ZL("CV8.M./J@[A:6II0V
M-0D@:EG"UKC.EG.\;+&1]T6!IO3B^PC]+V(T/K\SG]4\8W(;7[ H2+J.ER]'
MVBV=/PP4,1Y>'*U1-;_RQ&9SW!)K4[ CW=J['LO*71YEB-/?#EE0U4:P^*8L
MF<2HW ]TN:WI'K"8<7V:U\CNKBC-RWDLK*]Q&V_>E2\CFB/:;E-!YW?;H<!#
MZ^,:-/"0:UNB6(PI&)P.[-]A;VP)X^P.JY"/S,^YB1+'?#%3%L^OT76ML_<V
MSN%^L:EPI8#7(FENUT75Z@@3D/$&"" $0*?X'K4HXA4(@O!'S!-AZF'8L]NF
M\=6_]E\+3OW&3@U<Z?2#MNV&-H [T.'^82$'9.]-"34F\:U&\2*)B?Z$N[8.
MNK_2;_YS]K7>[2Z7;/">C0P-&QA30;-.A8B7D&,Q$RA!?!-YHGTHUUS.RQ!1
MQ%T[DE3AECSAVENTO;54>+]3:-0;;9V6CFX'A_E/=(*Y'B[J7G9TW><=\ OT
MG'E177>_02L7MJC./_#LWJ9+@SYKT$\M&DR[#(0M:S9BJHF!GI_IPRS],K5@
MRC"X@[?J!L0!5+( CE2XC,!36IA>1CD>M_P>9H7@IKG4QM88?LC_,<\7O_2,
M;T?LLO;X&"J@L6"^Q[5YQ[W"(:R]S3)2S\0?\Q+KRH/U/IH>5T)$@%GEH:$"
MHC"639/75MTWFGR4@K(<9[*::S_:*^:HCL;]?"_KGKKC!?N 8 CBT\W%D'3Q
MY942+2594YC[^7^\W>6']@T]9)RN"#F6[46O?G[_&M03MAS.#A<$++S\?:!U
M83O/-&!H@A?R(AWE)V_E#"?KW\-O!45"$=L/AQ$'NG;:M8+L1??[2_;SQU"K
MW@U#TP1TW_SSPD%"@D%S/8_>B8?XS.\9>!BPONCP'K%X2C^2IAYPG<!"QXU
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MP!)<B5++X!(AJB?E]?D=(\.'*B2E:%5G.B+.E;REV\>P-3*!AA[D/?NQB+T
M59$C[X.H77OC&QH:53R.?.=_*_+-8G8GZ&!B_"J""2SW0C?/,H&=AEC**PRC
M$$RYY+B9P+.53:6(<2I$F@%KA\_;T>O34+V]S=!99 JJ51.U[83>?8.BXK1I
M?YHS 3-_)I#""N*Z[=TT3<CHKL<&4FX_6Y_JP2XL3$,VH'>PA'/8O;)>6B>4
MOI[)."?)! K40&L 4_^I/5I/1NQJ8-4N]#3J'<K#$;>Y28S=A>3 23QPNN4"
MXR&$L;/?D9N/"0REH^9O,('U(*1CGS99PYJ&C@+SXJHRC]U=BC8M=D#V7QA8
M_#?VL/+.F7_G!S+^JXI&HXDRM)>2_Y6%K7]F#YY2;DB/36("XC.RF]QKJ^,,
M))('S$"WNO^-!^@_\8?Y/B;!Z.A&)9#V"P9D$#!#H2#:CMMS^#<N(/_$X<@\
MXB3*?@[;1>FFM5"?@:@9C0Y!=?XOZ A:LH&;I3DP_@]6T6?0,5IKL?.]V,VS
MJ)V&+#A%Y9DO;8R;\9";@<=\[UQN?0K"@5)0#/#=R'\2G@PX$.X+)7:B=E'@
M](=UL<3'R/7=<@\:%DM]B54\MV0F^IG1UHU:P/V;?C^@\/AHW*8+9!>Y_Z$Z
M%(^79@*;+JA=)&KG,-*]P_C6</[#:B<:%93\0R;P/V62M=^C>Z^7-N;+@*/I
M+3 813:=A*8X<-,:L-0PK*IQ$8Q[\C.C]1L3^&^+WD<U!41Z,0$.$-HECS"!
MQW^UK9X!%U8J M^ V.CQR,*#I_OM@#"K:AA&$.-?57A+F\;OYM=!D^MEV()I
M<IN1+(U?&Y33 L,61V^#I_>AK,H@-TQ*_\.G-_@9QQ)J&0A03+(>#$(^^!@*
M/H:#CW & =-+V6,O@=R 45G![ V-^A>58GD9QWRQ# 28WLG"P$_!1R?PTS3P
M$<J8P;R8WN_X94Y_\98)]&+_1:]3^W]?*L2![ V ["4S <^_&,Z>!-^ ["?'
M@F]&FHC;^01&A>$T+9<1Q 1F^_^9;HTU.$7J-VI^'+M!9 *_K\9!\:5IU4P@
MS),)=(,0L5IRVF_/-*_&%%6PJTW;VS^5^4]^$M2*)5I,XC;=T;L@#-TYKXLF
M6AB!C[A=7]3.^< ;_+K[_9>8@'DI:G<;3&/U_MDSJ2XH/*:6 JX%>E9W%;C6
MQ>[])N/[Q%-!XIV8P!/S-D/O IXA&>$N4-LC#/U_4??:_J'22G<FD 8*O1L#
M3N *;@ O2W\S@=3#X 2@TSX9:3<<>K6,'?J>Q@A"_1OKW^"42[^U4-,W47.@
M^"8JSH%.8EJ%ZOFK_ W.YC;S=LGLW(HIHV@6N[G"!"[\:S0BLX/CC:M(3( =
M-%F96,8<J#GV6"S#V8-Q#T?O@?_11G?U"T U?D[F_/L$3$!,=HWV=P96LO9S
M< ^07 A(KC(3\#)!$S>#9B#$+.S&+*@.U]T+(ECBI0K(#5-&X2SZ'W-L!_\E
MQ5TI5.=>-0J?G8:=CT3-@?8],;3/A8XOJF>_)@T:0_7*G,5>1!G_%J@&LR?0
MOZF!"<1S__,4B2A\)A74>JCR.'3C"FI'_3:::!B$V]1&;8!P[7? KL]^4_8#
M!3PH](\"ND4GJ(Q>4!F,V]!A#I 9U&P)R,W2',C-*W?(AC83V,#O?Q:'PG^D
MAD&G#5%SH(;*S;^7;!7P@*(VW8#N;OXG.JP@XR01S1.TBP[&.RG>/:U(D>L,
M[Q&*,;F'HH/Y45GS=5 A^3[4W]_]C/146J84Z@2 >9.Y?*DU*-]L6BTI"R&@
MLIL/'2I=(IURT9\R,MK6VRK9X\E>'G.LLA?)SUP^/FE]ISJ",'5W<6;P^&/7
MML!;("I=CV3PKAS+6U2./E]0M>>8)@^YX#U31:P24IE]]O(&E7MZOTS)_5J$
MOXH$"W=7;E'N%GN$]!.#!"@+OT-^?"EW5'Q:OBZ<YZV&VZ;Q,XTI6!F-"1Q:
M>5(X%?.PR$W?'6LZMRLH=ZG4+O3F< FZ1G=P?<<E<;,#<Z[6^BI]H.:=88=I
MP5-O?,3/-*'U6'/4BXHL:%O61"PM9) )'%-:YUA:6[%G8P(=AZU)[R^*AR@Z
MC&H@E#QW4$MI)DCNE^)$GX0+&N2T [WT,BM9NR=)$OD]&2)1FN*_CJHI2GZ<
M>ZA@@G9(*+'B+ _^FB-CIGT'56],3]=UL[IM\ 1;=,#QEJ8.V1):5[Y>BK8Z
MV*HH;$65I:*R#PY?&73:_,1ZT2S9#3)=H*5@<)#Q-C?GXB97F\.+7MN+S9/7
MZO4:EVCY7K]1E\PA%T]<RFN.:/WK,J!<QJ?_?#G0V0E4[9U<[&3.W0.:)^\"
M 2;>?RP9_C3_]5<1<U%=XN/6Y]7_*FWV'6??+\*._'LA=.S?2J6YPL]'<[!6
MWHI[ P?*#36!_ZJKLM _[E=;H[8S@H<CV.T,!Q.%64+_UM_J^95 ,*Z=C411
M.4"PNF?.]T@D,78F=I?%&ES#'L8$^K\6W-_Z>*2D-P"ANE0.C*B7Z>="=1%
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M"E+4#K]Y,N\E30Y)W^RRVS\,^&Z^U.-]?L1M$14- IO>U7&JMIM/@QBEB]B
M,QN4*OI^:B<_R,M--O%]B&-5W+$\U;-*/K\?V7O^Z&V7_36#QX&AE'V<(@NF
MH2\0VQ\T?C@D]:M>2+IX]O&5MTGBEORBP6&"X??ZA$P%!G.OJ?.E3Z8.K+/A
M22<RS5+=IN+C<34^ ?Y/JU-(D<TBA^E%6,?>XW[*+2*B XI!LJUC?_:Y!%0D
MXM-'UB0ZNMZJZ8?S3&AE/0]HO_%;$@][KG&%E+P63M@_85X*B=@JV"JE.'G[
M^L\<_?WVW7S,\)T;0F"P/7I[2+I*9$?J\C7Z$ $JA/R.^P)IYN2_,2R#:Q'A
M"]O04Q>9_*.VH;5?H8JC^J"EJH:]0PSKG9C#?LFT$]BF8S,(-X+Y6O)GRI-K
MI^O\"9%Y6RJI$Y(W',5=LD=;PLP3XP1CK 9458LN;Y)5 A+*2I$K09,C. 3\
M4_HE=%6;4>B(O.V>32*Z").Q[K4"Y_$S;IZZ_,5&LJU!<&!;S_3-[<JQQ%28
MP..CG!5-IX'T@$U+*]\F=/">)NUJ3@(QL\6LRFQ#*FGGU!Y?C0YO\)MO30=8
M1$*>2&9GU#6X2/R2'WX<]6%,0YPRF0>BV])P&A^W%OUC8)!:4@,O:2>,"93]
MKL@WWE$R=SG1?'=&3.+X^)4'P$%'M9!'S_C7C*D.R-X&@'* H ^'4:JF)XWO
MUO_\C=C2OZ8W]*DFZ3?!(D6T6:MU=:*Q;,NT-_#0,HX7>2I0C=(U+1A[D 8C
M1B=59-MP3UE-=7PH>GDHDT/!_8#*TS^2U7AL[?!HBCCWJB5QI^U4PQ7B2&,W
MM,JR\V$%XI917=UK08'>1$_Y]MO+;$:F7[2.LOA<HEC%!1<\:SN?7=@_/E!E
MW.L7:*.LTN=9GA8PM51/QM6,SJ/L9']-S;<PV.A.Q#3"*?3Y]^FR_15LWI+^
M_ L1DI/+X:R9_A>4FF:56>/@%QC?^--E*'TDY6GN503APSG"L&S(E.RP(OQX
MQUR8V8;XYHSEK8>>GO/7_:AE['3M0WR-%%[R?0H_L9>05$TJ:&0<B&AI98AN
M8BN]-1N^ONF=_U:FMZ$6?<8]SC2F[5Z<*4PHN=S+JMMT=AN><"$'WK.:R9KU
M")VJ#^U!.G6BJG"1BK&C5')=V@PN#+]QGQ)'[#;J^RW#=^ORX+D0*?=,4?<1
M&[4$.HC=POO!:.41ZD:,)6L08>'SE;?79<N;/B]S2-.J7-S?_3@4D]TG+-JU
MP/.B_?(U2 R\S*,)-J9WN^1G@Z+?*6G7<?UJEU4O?_6Z-]4V1>$O^HA:<M5C
MNOEG$UE\DLC$L?'SV>5Z0IYY%GU:!_,66:<MA]NT<DZ=[!_R6$!@C[C=8KUD
MT37DH5VZ]DPU: UR!L1"/-C9B4 PEMB78_>TW<R@;I!=7=9&[!X1A-NWOF*R
M&HXB>^%'44X0+AL_/7QO"+9DB]H]X^_E0?_DZ=GP(")T!R;Z9==0Z\"AF)2N
M7+\J,HJB-X...,/?[G&2 ENS/4\<=%#0UUO;X:&GZ#S03HH_BEM7GC(>63*7
MLE&.^F!]30=J8_HJAJOPL<)B)8;_%-5Y?90R0OY$%&]"A4&(1FFH5_!R,-1)
M;W,?! $)S5,[S]6SI.(+-DSB8]=X[[>SL>+/,U8\58QM.CHX>1EL^D2GZ:*=
MV.0F"'?%^+LUR_)Z?NVAF=0@K4>!KQJLJTW%!;/&3&]T]0+T6R2]:4B+1S3R
M1%HCED]-T+[8Q4NX!^$/F0C*#NR<L,MX<^2^,/N7KJ;3&'FB-HTWG"Q%\2<\
M@POXN>$=T..%69O2UG<',;*B6NV'_,UYU1[&?$P\;W"T"8B,D7O_2<17C%#T
M<,MG_'.5>\Z3)K-H':I*4_ZU*3V3*;KB[THU8_(HQ=J-Q,I@B_VX F%OX)GT
M,X?]+"ZJNZTFT7G&6M+7LK7CJ/4+<L[[!98+>BQG\W;60Z"5N-49DO%T#)K$
MPY#Q\]#Q7XW7A^D/;G?>3X.E>:R?\TY,;##KY(RZ?/K>2\Z P;B.2P)9F@YV
M86:V1[<P;,/@-I8"_3*%+>HE',,]KRSI\937$?.Q:MLN/Q"[8Q?F'<U/3[R;
MV5\6[:IX<<.TI@RA6$S-]9VK+FLA2 PM9 S4Z.3FC"L^I*[9MZ+LL*\;3E):
M]NM3%"R)NW&GR#L+1T&=4M;4?1VO6G1N$U!;LS]M]UZ(Y\U5\XFA)IH:_5T#
M"TV<\B(O\"[%B_A[1'NX0E_CFF!7X>\+%M$U1YNUWGAL/+A[+E:0![E>W>MO
M2?@\4&2H8MMU'A-?4LD5K7ORO>, HBHWK9KHM"I.ZIZ&-F/'^<DOB9C66*&E
M/>'>5VJ>"JDFJ=G?FCBF-,D?Q6!7.N\R >R=BV>K5'Y(.C'8/Y#6IQ?:4&&I
MD-4>HEO;&51$G3G!@]?JZ*K"M<[?++>S7X8_?9"W)JIU,)Y+^4KC:8WU_7X#
M^W_AD.75)TA^>(9O*QJ<DAPZDEU\3S_?)L6AYH2.>(K@;FW11G]7'(_F_=&S
MSP$LT9Y\@9Z,=<+Q*$<V\-+.EPUL:\4^6.;G]^7W^O/KV5V$I^B[4H&7QB[W
M'S^1+"%\:?AEIGOOVYB+6U;RL_=7FF:0Q<2UCL2I=>M?E>2*8@@_$W"2AA*X
M5U_G(7OB]!?6B.^O^J1X*ID$Y8PI*/4+B0!)$J-16YV8,-!'A?R2R3\IX41Y
M,H(DD^9-1Q.+A\&MLBW]Z75MZ"_'<82@UI/39A)K]\7P"9X2C<NHZQIJC'X(
MF-$YHKG&*+DS_*]Q>F4-=53%K+A1_<</T^R"OKX6B$V$B1^::MCO@65(.84Z
MJ4DZ1FX8"=2H5(8?KS-]^O0=RUDI,S?YKC^B%MZZS#IWBA;EJ<TGB63E3SNI
MRC2L;/H:X&0[KYA\,A<V> ^!^:.\%888 8&]7_(R(C:Y[_^]:OK_JW+Z5Z4=
MQQC<BVV"_6H8P"^$8+*JAI'G8(K9K7W;D7JA)I/ C5VK6V)7GAQUGG(/8:=Y
M8<!H@J]E7$:W0BLK,.$ZDJ>"\=V2#K9M6?'^OQJR=#,9!R4)WZCO,Z*<\0^&
M-X; ? 4/^>#T[O4#^=.YY4_ATDQ $&V)'$,1=>&"R"[HH7)4; "T-9:B5QZ9
M_RG6VN+ID7*$Q)WG+:(\4I\R90)+.QR%,P$0NR7/3I!2Z7F4 >IU/UE=^D<:
M+_4,S:,J9J$1R]]PJB6G[LE!C=Y\A7AM-@XNXQ[6;HX#=A(O7MPM'")VK.XR
M 996DG[OVG9AX&%*O;MV,!+22R\B1+O;S5E/+MGO).$T?'+'3@):>$,SI!=/
MNXI4LVT[[/BV7HK&BD>]NL9,8(M4^/"Y+P5:NU9KDG",5L6N?/HP%O^.H4A$
MKQZ27>N>@;YBRZVUMK*U\-.F"M4E6-V;NN7!@?&<?QXZ;'?94# P],F-!_QS
MQ">2VZ+D.'K! +D>E+T7L@^I]G.DFSB5,*,O?IOX_E*VEQWG[U2S!T>-.(I[
M+QP]?.NST&H/\E'@>8I;<>!#2O8T+E3D#&1IZMQPT1;52?*K5G\GKS\(MF](
M!0&* R\P5MFJWQJBE3?,#'"2[ZN3!+EUBU2FMPTD;7^OP1?L%W$<H$]>0IX%
M+?U8#;UBAK2>X,D5ZU70@E]2N%FJ8\?R':/ZU3_9_;Z.S,FCHW(L0#PM,#.5
M_J2:7JP&(>(8[/[3\-'8.Y>UB>NWB4+(HT%*2W%%R$FU*SW'9]'*DL)%.<.S
M\IU'51<VQ<D?*>=15!7&SP99ROF@!3D*RBKIF*K[43E]9^0S?VN HTY6\/V!
MG0*U(Y<J++\I!A0[@_O4UJ[+3F**W>4MEW839/=L,B7>@ FH(V>6/7[E,MA8
MB1WD%")7) '&QIB<$KHZ_^FC]7) ;NA3^@G![GKQ[Z;20I^3I]O;'X>F\*<?
M92$T/*.7H)RXP[!EL.ARS+% .7K6%N1U4DU8,KD@VKAEY6A,/^Q*0I?')8)G
M+;M@$BN'RCK\#JJI ;OAM5]^+>'$;E6.-;#UF D31)2RSALM*_5W%]$PV:$1
M,7P.6[GL/F\Q1>,41%^MF]<0U%[VEQOH%,H=D\KXL-"B#Q>N%;A%%MVR5+HP
M_4B:$%7UKB]<OQ&;++#[?/+<IC%C'%[J^PKZ ,SZ?-&'*XI0U >'!]8PY?5N
MJS='X=;?WG^-_)[@^,O,N?J!3J3:P<-!O%26/U$.\%'^&<A:O0_6:42QVW,:
M=K"W(C-%^)7EA==EX?"K%A/XA\+JN\N7.M:Z19$C$*(!- 1=B7CGACGN=P,U
MS4\:' \I.T7X0VWU(V)2RN6L<13*^<4/+^/M&IQM%:T6*TNO=\-ADQ\P<K6I
M5YG !GF""9#7UMQQ4^OVTU<E>H5^WA;6#PB/>::\ZD(]'FA&+Z?9^6=2+OWN
MT/FY93&3UIHN/O0N,DCCE/B7>1WV@L0[SWV$OP?/8P+[H?@X" M2;&*"HH=G
MI9T,;_P?[;T)-)O?US":#JIHJ9J*DBIJ*EHU4^ED+DJ+&M-2-1554Q")4D--
M*8H6E;:HJJGFFA*SFFL,44.BJ#DQ1,CTQ>]]W[O>__W6]ZV[UKUKW7O7^EO.
M"L]S]MEGGSV<O9_S9&^8//')\X9)-SGG\Y[^UNG[N,8/K5'=EY.[$_R[Q)>X
M8F9K!#H5H\&5X'BT"YS=K* -AQ:<D>PL?%'3ES%TQFG[K$9NP+Z$0;J:X;&(
MJ+<LOR</4[XP (2R1*@-Q9UZ;:3Q"%\;^.:\G'!WSG3L5=LVI=X7:_ ?8H9J
MG*^>^&5;(QW5!V$%50O&+D\V74)KF-[:2%OO,4J]-U([OZ'!R@O;K:BP5[<$
MYJ:+D$=PP*1J<#22VY^MJLE/MS'4P:@3RA^G>STNI33O<=IHFHO8VS<W0290
M#J9*/^S'ST;4@*I8U[4H^I @'%>,RJ!\HW) ;T#FO+D>2^1:\*<'I\*5  -K
M=4[?/O(SI\URYE>C#'&;SC[K2\"TU?Z*K4;SNHD"1WU*%JS!58V!-</9"=2A
MU(7O*T*7CC^Q1) 5@.TB9@ZT\GDR&'B@DSB'/#5ILVP+O6QU,F$H/B;Y_D;N
M&:)>X,NTB*O4B[FK?$31GC/04O-%;TS%B.?>,W318\(,-E^W[Y/"@S+/IH!
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M,$?3M)W Q9J,>C-P*R7X@[H]#XEH*3^#&1^O'R'6T/7CJ.*_8/SDF'9K?K"
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M^?/6Z4*;!R7G;R=Z)'O8!H1 RYS[#V;$3PO>*Y"8#ZPQ71TK6O&A*I(=YAF
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MGO7CC?,?=?2^X>A:E';ZPW4U[594XAFU;E_,%!LQDG[20&=SK9#(#,A/6#
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M<2[W5I_&<9&P;)=,T_M8^=HM!B#26<K"O$?LI*>,)-_V+*'.C[1(RRJ@93,
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M9RZ('0- _%:V6RE%=]V[PJ3@VC\4W$044$\4Z]+AF@?+\+D/8(Z,@OC&VR/
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MF0\[HLS-XV@-/CC2O4,OJ_*Q^12CH%LR:2-^;D[^H-:93H#<C!W>_JHQ98[
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M$7:]^ ZC4UY%3H0K$P;P<#LOIZ@NW"<<WG1Y9O/XVJ_ +H-8MFV&(SWS2N)
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M\70NAI52C >WB_5Y_Z]UBYK^%U!+ P04    " #EBH16I&0V\JD@  #%*0
M%@   &=J>6II=C-J<FAO;# P,# P-2YJ<&?M>7=4E-N2[]<T.4A&D)PS2,Z2
M)+2(@" @6:* 3<X"C0@H2(Z201 D@Y)!<A3)N0')223GU#WMN6?FS?'<>?>\
M.[/>FK5F=J]:_<>N5;M^>U?M7]6WD5/(!8#HGC)$&0"!0( 9Z@<@9P!% !L3
M$PL3 QL+"PL'!QL7GXP 'P\/GXJ$E)",]A8]'>TM&AH&%CYV!B8>9AH:#C%.
MGML"PL+"].P2,N*"TGQ"PH(_C8!P<'#P\? I"0@H!1EI& 7_GP>R!2#&!L9
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M7)W7;+%4=T5::#!M)QI5TM.\<6C0,M'"I\<E)K78\PUL:19SZEQ?^1Y#HHL
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MU.HPT@WE[2L5(%-2%).I(9(YE_GP\#[K/2U;*?NUYD&-9!'RN.LR/U05N5:
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M7[C+"%\F^#SBXF3M*;,^]L^<-#<J'KGS^EV%KY),QVVYZH<]-<\Z@J)BS9%
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M$'KT[>@7XU'/#I7(0,CI?P%02P,$%     @ Y8J$5N)&XX1B=@  X:<  !8
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MG/VK7TCHO$/U=5; <,RMWU%WZ$X'=U$S!2FI13[UL/Z/Z28_PC'\G,Q@L)K
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MG\UN<]H)M$6Q3^ZR874#W;YKT5"1*O'#H?H#:3=#IP.A_1<W^"]+B>3JO?6
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M<$$S"6-E:1WQ7$Q0Z=U():8/:O#V,+W7+@!.-5 9%_7$_89N9*(4,.&MY%B
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MH%F(@U#F+ )I,&Y]"[B,L$.CK2B@6A02V5ZS9GN'R7$&KD5B)JJEF!DWA4/
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MONN5-<S3[18NJO,VF\GK'"JIB@JHM(&.G.;:=QYG23NSYJ$"OF]+^OU("^.
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M.&LTQ?T/]^F#N'1<WKGUX4)O?.P'):P]YT.,T3R"VOZ*W;16U)'_NI2O&Z[
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M[+RMX&C_]_7YEU#CB6IPST*:W?$#F*.3P[*+1GB%"@U=OGP^^]9&@WN,@-2
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M/[$=>'J; #BY5TL L  7Z'Z^@3*0 +C%0  LF;Y6!A#=:"SQ=Q@XL3<R4.7
M57I<SE'IMA'D9&ME>^IT37&R)/CW7%W_F:CSR]WK"0!*XFNW(^ @M*OB "ZI
M8.@K48T99K%#PLY#<.;9T53S_%*SS*#_Z!S-S\E&=#8P0!?2./8[):?CMF 0
M*U'-+T8DU!R\@R/4NRW4HHJ[RP0 JP^PW90:%7+43 !<%$KT/0()'W.B(J>Z
M&CW",_PIF&;3TPIG\W*];%FJ;Q0S2^S+\^&O$ "TD-8FXD24XNE,A/%*H&F0
M)?&3U1#>US=%:@DUJ( V.!T,613D7@ 'BA.O!*LG!N14#TT2A86UTMBWX_SL
MF;8FSFL_>OQ XII)#'P<;WV<?K60^"B&H BLS&<BL]1S^G"51QF(G^?*6;5H
MQS-!&H,;9;J>QOCUQ7PSS(&%>T:1:2?+]53%.PD)L3_DGW/P_TX5_WK,_&9+
M>%& 7%N"G_6[PV(W9C[[8E#WV7TYTHB5Z\K3@.YN^>6,UN0453U&T?:7V3.\
M_L=C^X7.;UEFFQYTHY5#6N:I.D_9I'R<,+Y:KAB:'*)T4.:V@PZD-R"8QP:P
MPJ=J/964OS4<WER[+5?9O1-(NS5ZKT\XO&HKB.0&#PK77&X>39'$/),%!.6X
M2LU1H&^F60=X>WZ5=S%0XMGK-O%"*M]Q<1\BB]0?>:ZKXLC^FP;B:FCP6T]H
M8%BD#V1A$%KHXZP^EHG62W%F7\G6IZ+RL9O08?*X=*W1K=V:-8:OV!3RUF\;
MNB5OE T\F[M:*;$E_DPGSEMC?\TP&W];$GR\I!VFS\%64];0!"T?6VYJ-+IE
M7C.\6"4W*?*$09$I+=MB_X?[-) :?&>\.B+3HD+SIC3^I<)L.+1?EN3J$F2I
M"_;E]$;XU*M"7B?KX[2J?6:=MK-S%T[A.FO"C!BC%ZC<=V"1; + ?KT6!$^$
M6.U#%I@JM+G7HKS-;?_5KIB$86\/F.-#HQB)\L3*?SC-K] ,6H7XR\.YEWZK
M@L=<63?7J2YW. F5X6!U*4]RN0CZ:!8P?X\CLQ1#]MW;E \=.2TW>UET9W!R
MEK-JZB+J 1?E<#U@+="W>RE7XK"9?GUT4.3:NNSM75B!5,?ST.N=QC6V!G#K
M/7DJ_!4%\W_12GBR,/8-M*IEG*C.Q8E_L39P#%$QL]10'.4%/M!V/YJCU0C&
MOUB:GR3QOG,>EOB=X5JF+IT,N^-I@<&C0T@2;KNU^X1"!S58[CU?+-4Y(MA4
MXYT2]]+>GHUT-D$ETM*<Q,4KYC>2GN_(C.>8@'EACA<82PX:!L6@6IK5"+[1
MD>4\[C?>L67I\_[6Z13Y/KEM"8%"J)6Y, @/>GK680YUEUJRH>X[5W2!G%Z'
M]\2 W7AKD7C<:.D*,91Z_/5C"3%4Q-X $75M/9< 6"%%8']FWJHO<N*N$2]\
M-B( HOS.T:\D_(',/F-/D6C76HD.[ZT.GH$/V_J3$[@(9P)  =R< C1>@]-O
M_PV+]+?L(0BU"6*V.^W,=2_T:4-ZR6H5NG_ML<8E78+8[HT!SF#G9,Q<Q(Y=
MT^W'_CN'^?^SVH'F?7)(1]@;)[H1[S>+>S8.(\^E+?;9;G,=2?,E;VTE8H*S
M3+8"J1N"M=^I!UR*G37J?,0Z)T7-R <C#Q1/JVJ9#IA5*1UUCVM$)<2CUMI-
MF<<\R-P=:AO>3()48%I;;CPJ;7=?J<Q_XQ Q86R']\RCVADD871&/04@^*3O
ML(B><FSG-D>7#3>Z2"=_LT4!??XU!?;&:6>\]5=3JJV>PUO@SR;T;[+!V!.^
M4C;*$;19,UH_9(=WU,-_?;<J2DOF\YN]Z[3U=^MXNN+<BBY^W]7.7-W%V!(
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MPK/3\7<$TT>=1D#]/-VF S>L*8.3ZMK![U$-TC$H1W=/U(**/QW(E/1Q3M^
M*QRDL8;"MTQ@!WO2?T3 L(DW,^$F9B*2:(YDV.)E7PS^+F:DOX&FC,=1_$FE
M6;KY-IU/"234K9_7AS9*2RU_Q!F>1L[$&=<;5X2?2!C[A6HP@2/6;S7!MJ5&
MZ8"*^.K4"-.]?F_T*+11^DM[[AIQ>VQ<+,WDYH_8JQJOJ9M93)/57N8KO1W+
M6ZH/.C#B D/ZB=-ET).EZ581[T(^O@M4ZDK K;I/#6$SQTEM<]P-Z-=PYUXU
M][EUB*;3"UX;WH*1&80H,J/0_\^D3*Q,JQB"PV][1JGU_NF5L<9ZT9Y:_4>=
M\U,VN/$6[W.F%-D+(CP[=MW($+(GK7%*@"9(>3Q8+T%1Z)?T[I2\[X$=:<WD
M4^)J519\^TI8K! CK',NS2M&-ACY@V1'-@_N"MBDB*#PKTFI39;G?=C=+88*
MAPBARKA^X:6(^!?FX:R91ZI=''_8:G.*6MBN>WRAUE"POK)S$JMB76ZFS0^A
M@[.X!;U53F)\E52!C>MH?2Z8.[(<(STCJU'D2:D<"?BGNT6[>DP:F$QK47?]
M2T\LW9WW/)\^.]G.Q/IW6FEXJ@S5MOGRFL@:'9@NXK4F]<^(JW;"V>^U>+M[
MS^K?^QNJ_9))4/S6L6^"S*=BW;<VMHWK!XH7!A1XJZ6D1.*RT_RS);945"2:
MM_34WODK<&T_Z'Y<M7K.Q>3CV/SJ8/HGQW%[B0+E9OMO(WXYEG?-GW\NF1_<
M'84[H$>Q1T%?^PMS4M*I'B\2+?_)C==?K7JASUNTV$*QU:<T^BTKW_3 @ZND
M5/S4S%HBP6]O]DAX9D6/O=O/^J(3I1^DE#BWSWFVZGCU"P[5VX&A3DMQ\TT]
M&*%*7\&H)\43P#M-BA/.OV"[J_FH)8O![=Y?.E9)@]7EFUO5!Q.>HLVFT[L?
MR0I=?<@JGR%DS>9"0-CZ'*%FNBT2XPCC] ML3.>BR'QUXX;:D=5CTDO&#.1K
M$$6CE9]5[-\P?^0 1"J"GR9=RMP^\BQ%QUMM>.#A$Z\&DR>1=1-T0'H+!IF]
M>Z&H^</2K)NF9E[>J"+18PIN0GNW2+881N_[&5*/6JZ+_VRM^53YL@,<Z(JK
M%*S"PX\.)+T&4<*;X $WV!8DG?:C:JL$^E8I9YL*Z543(<FD[T'H $*9#I!<
M#4>':9%3K\!E];6,#LPEY#F0; @EC29CNHIALT4<\U%/_9]J^3]>4W7@LHVB
M:@<K[(?UU>- D:BUY(?,K89&($JKB&[9J8:)CE!7(::>;RS/QAGE!BR4N[Z<
MNZ-:P%-3$.RCZN>++N4A>AQG>:QFYI3CDQJH76=JX8J;DFL#R4",^AI04VA"
MH]AI8A+M%.:4EM#!8SG%A?*XHZ?'-H02S2>C"D>4@W*];K2M28^*$XM(++-H
M1A)D^LN;N1E8^!R^XE-V"ISHT3?K'GC!"2[S^13EL]*B#\<D6SN6%31@_R#U
M8(C??2$9:A[IP_Z%.=\DHK_2W)BJ',FR&X6_^P@U\YUR7HX.:$*H2K;#EM+$
M4).OYIX$D^#*^L784NA*B8 ^^ZO7_N*_/UJ[DK]ZP!.[;2QP=7T6%K [&A>1
M6GA4(X9UTH_<]A,S(I_*HN7K^U=/)*EN2&'?WL(^T9&/:;@/HP2N"# 9/Z_!
MBWQ"&LOUJYIQ#C^2GSM&>L2N5ZS1(:_J9!,9)EYI9D$NSE5N4_=3(*(I9Y7G
MB"J$9##-4(0?W$? $UG^7!ORYSK_\?/JQ(1B;:6N;OAHJ]BG6XX1XJ._95)]
MD,,+[RHVW5UQ-.?E$LJ9<XM$@WY#JG8)9L>UY"'!LA7Z.HUE($F'@&F!<BP-
M1Y],\%#P<&/W/^X0"WT<P]&GN7AN>AB-:KCJ3WVW@R6SPU%+_7 9$%7=.P?!
M/>U!#>2ZTX&L8G'T2FFK4\*5CC$+.G!F*2?-?(;&VOAHN4%OJ]_"L]/\;]#^
M##H*=13IE8]Z1)*>30I3B.S.J>_,64W<.^W!?W?@J1<H=@S>"#52TW >V]2M
M/Q?6),W1E+-J+>'A76"]C'\[@ZG@:U\+.?;]0E=JJY+HP[&8/@P_[?>3E6%X
M>=N+1[V/TO3"(LOWO*LL)"Y:]>:(0!L%.6R^&8W.*1P4$5[N#)!T9\.&8'-=
M?CX[$\XT_WU(S4ZWN9OL;Z_8YW_!-86UYZN2R6JS.G+17C1O:T*D+EVRWZ#@
MR\\]FR7L2\ST^S<VQ-0:Z*[8?=32:@#U! $6B12?_G2Y8I/'+\FP[[&]HY6T
MMVK[^HR%",#]].QI/[YM^"=P]>@M8-=5G\-63'_2@=ZAW5WL^B9^K W&A7+F
MUVJ <U#4A?._&N99ZW%F/[W$9?:>2^4I*]-D@<)K-Z>XJ$_QWQ&E:*9'X@])
M4CEN5Q??V^)B?I8G)*:L_O6!X?LP9;E4;BP+:L;<&03NXI'4;)B+](N#J37R
M7#14FS0\P]O96<*V<A*'PY'>#>D)QQ6-BXD5OBX[?1TX'@\'87(3 VT$MJ,M
M#</;@4IL<X\CE8(NW84$=74.)-C\BG?!KYQ6\WEJX'4\S5Z4)6QCHO2%KJVE
M-E\)TSJWI'O-^G-_Y0WE6</\ ?/O>T?+^^.C^BS[?8H&5E!VNJS$<OSU-DH+
ME [<[(!GP2JJH&7<:-B:>2TH!@/X1_BW<#H0586'P;;/HJAG+@?'T(9%H&6L
M:#3U=A7FX,K79ZC]<WW[P8_'7J#^QK4>8.F 0=;6U?9 E)C617XWV:;J+Z'&
M/</]T*CT'%0IZ[HIGFMSQODE[<@8":\4@2G3+NT#,PE/W4TSU>_[:?"DQE?/
M:C@WZU4(;6]HO'ZWR6T:"H,:+3G+W_:KJA[H=\P77_\SP((6>GX$(P5[: '%
M#]/8 #K02:$#!_H*P:^")T2@WPUC0,_XX3K(0#[\XH>'R_U=@LQ3]?THI7ZM
M Z;7I!">Z!GKD?#6*SUW9;[[N)WMMQQ<G1S:AX(978.NABI2C+1)4-4DL#:B
M.5%N.*LEN'/U!ZMNC@ZU18\?"6?3COYE%%\M(0G70]8"9Q*9: \4(%2)%(P4
MZ"/*X'E3> .M])'5)A%:&GA?,J5FVTVF:?Y;+G^\S8'<O!_D:E&J5Z@@C]7E
M*_T>.<_K126EQI;'T;1CG&2EJC9TR&EW#;YOVVIZ,PGOMO7O]2151P+=CX&.
MRPE:H@V7>W49PDNZH/("KS".%$&"B";!-ZK6=-I=>"S/S]2HJJK^3:J$1>"]
M8L$D_O?A/+JUH/HP>&/4:#/E..G/Y!7\_ MT4[V$O]3:#89*W.(%[!%5H(O?
MC^EQJH[/^:@D3E%,@=DN7-WCH"2Y=U9#]VZY!2)T"/LNIR;W=WI'L>46[#K*
M$;.OF![V%PQ-R5] >"GAO>].UJN&EANB0V$+WH.HG6)KZFUJ8C4UF08:U$C2
M%]1A&SA97P/F4O*6R9?R!U="2]37%Z$#R"*JMWBS]+X('BI-O0C]FEYV!;LV
M@2?-T1R"P,>W9@O.)ZVSXR$Z \7R'O9SOJ\EI246_3R+/&OUW?EBVPO-XP:S
M6>Z=U&1F/-KP%10]#W9M%+\#(E)T-D@9GSE>N@TU@B+F$Q!ML/-^!4U31Z4V
MGE/U6U*B)Z(;IVP8)&1MVY>F>31Y3" 7!-R[FV;R'GEQ<EIMC=9/4+#?NI]%
M845^7RUKL)MP%HK7TQM]6A0T@,7 9G+H@#/T0!G"#.;A_RWG[4[:,<TYZ:.D
M*6+RSV$DYVR1JF6IAT OU[9^?<SLI8:[EDB'8EVO-/&3M%_02F[J*=XIRCEK
M% %'J/O[Q#*7<].1=%Q1H"S_=JYBXO)P?P\%&T'*4NZ6)<UX?=#55GDF/)"P
M;WG7H:0><^E^YZK.;E[M8>6'",%*W'(0"$5?#3C_MGHW>XHVR"0$0>\['_1'
M5KF]_AW@F=7UWVZ'JU(\Q9S!:SA%#>L&?/BQX3+)&O"O I3!YBM==,%KV9A;
MHSPUK @PJ N8C9[[EG?G4WCV88&8 9:\KH=17X'*J3_36P@T8@8S %Q6]Z[;
M__2NQ1+SCZ=;OZ[><%5K.JP9GN7>R4."LW(*/*3M'F[/F7!ON)V8Z_M7BYZ*
M"47+#0QHV*V)3KHP(N2H7Q$?(-:'I&_#<!EL51'L!V8:B/]3\,JY@+H=XI?5
M1<Q@BZK?X0ETRCRL]/S744ND[H;M;K=(,FWP?RIEJB!EV=NZ3O(,&@=J3>:4
MGB 7L/E_Y288[K!6IM:Z\Q_%:EV[W=H+IX92%Z";/?]*=!5:H*\+CO=KD_BO
MX.7_VOLK.:FG[\B#&A>Q%K3<9&PG>C9/*6999^O:L1NEL.3##6G[HINV_4@L
M<8D1<17UO'<AX$K>G8]!*X=%-_YP4$/'?WPEM]7Q_EH293_C'X5Z:[S M[4+
M 05:5\<B_E+I ZS61182$.;/%W]843/C$MZV>$4;9(L_%(M<AYOFHU;*<^OC
M:8-PORP_=>T+X*P;5XZ'D7<Y0)RCLWW]WOO?K(3SAG(QSXP1;@9_O=V."4^J
MBTYU:V&H7]G1FT:7'BU^R]X.3N"8W\T>QTQD.$PZD\T.1>&+O@W: <LCN-QX
M'X]&A<"VP39D+X]'<7XU0NG@6.2S@#XNC7*&PSUT8IXO':C0JPYR8;R_!A'^
MMX\*$K,.*OJPZO=C-Z\J_;9:P^KUTPB!]PC.4[$QY:%:52G #G:T;/HRM@W!
M.<%O8W6?NQ''DE]/<'[[I;63W3CM17KR>/37+!$5Y5\*Z\$*0\'*I+EI@:*O
MP:UT +* QS8:'-G2UV_KVTCP-K#+8@J:Z#B7T#ID8L8G^N?IV;DH$HC@&Z.H
M"6KL>*:F/CU$GM_O%J3YG-69>=<^+=H;SY&_GS/&S?YZ'G-?0H\8SBGDKE'I
M //B8+V4VS5Q-T6<860VV;SP,6>:RN6*<.)B=(-M+(0YBL^[!,IIG2OV-8'Z
M]W/:1,G*Y$3<WKX4._OY_E]W/5.))I_TVF:MA3-^;K7 _,55;B_7" 4C]Z/N
M&L[=<M"HV*4#ZW%D/A LL8(P?*8$8]_+E3/SZ8;BSZ'R^QIJO+*P(?VS#QUO
MQ"+;?V9V,"'89]._P];BYS9Q36WVVCU9[NH<K=H>@;9QP?KWL/B2O9R''(.4
MNRP^_:U&^=J#GAV(H/XU[,>6)T3'L*ZL5U'^\["7;>;RQ'>!UKCZB;MA1,'O
MU&\5L%/P3K*<KOI@PL?+NP6\R^]=D\1TU))-3$XEMP&05+Z_'&[#K89OZ !'
ML!)2II;Z!>,,AT0+WY>Z7J^!E^#@)5\,5ZX)R73W$8QE[4C[I:CQI=\;SD;J
MM*4#H4>HT=X_GO.S:Y7)DO9:N21I[]H+\R6,E-N2O03M'GB^.,W*Q$F K.43
MXNJ/4'R^#99D;\N?N.W35VMH?VDS9O5N<N7MXMQ0G(;71LAD]96!?&O3 DZG
MPKZ5(0QWR=V"A: C<JQO.K_M7#7_>NW]PCS/W>76,[8_^U==JEQ775>*GJ=L
M>ZRN6C_@PH=%JCW+5XR>QAQW.U^!:W1TOZ_8O1"K<Y2E,D,$B,/^*(XD)I-L
MN!NDT1HB)$=WF7?#!@.I9(T;_NZN0.+I($K5'?+P3U0#OQ KL:@>S X5M^F
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MI#+IS<S4\5%2?[, ZV!A>=#-O&^#4N7[@E4_QG.2'%Y[/,X3>KAUQ!WB5S(
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MB,H#CU>5,ZYNR:,"F[,J$EV!997 .::=2*)0?=4 S!'&A'VL,]A[TQDZJ>N
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M0!);HR>VC39WOX3Q8U=OL>TY%VGTVJ=LB#IZ?.T3*]UA'KP_?4P-FS2?X7+
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MX3\0?(5JV !X .*I*)EY-<Z+I5FA9LB 6I.3J0L=^CX^\H+VO>LESA\N*?F
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M/X^*:O^:':HK7<K9>V=%M*?X.&="5XY.<F:VG8;41JV,G.7,;'N-)K@9CHV
M4,&]<LHS:46F;Q.TEK;CD>Y0XM!^PL3^E3.;*P4X9]C:HY_#9J%/3)S7KI'F
ME("\A<L;M5I^3J%K6E+FTH%H2@1FO*([AV2P^<>P9BLC3R'NBO%>3&SX[B1+
M-OQ4>GV-%82O+U#G +=0-#VW,E+.OR533P\P_/G4(SP86#$OLF'6^-4]\=7!
MRGW[N?I;; Q+W^Q/7#<PE!<?WQV\'QCPO=ZP^"H8V/_SHHNS@>%81/Y>EYR\
M)A@;X(%LJ.XP96Q7HR5/,N.3H.\.8ZDJRU[R >T&@YQ)/R[.W]A H4(9THNQ
M?0D%/GJA/I3.6HO_L7U>E"4>2S^+;573A=KV<HCD'1'$7ER^-),[#\$0DV<#
MVY'I2$I8)IQS]3\GR!>S-F"KE8G-BPC*/C90CWN.I\RT]$6S[B_#6?Q";" H
MF24>0S\+_Q$P@0./(%E2^%-XHJ@%@G.M:K"%#00Z5KV<P@X;L8''" 4LL1?+
M^< %4X88C"4%]<!K/S-?LX$)T5?882(6C&-J<$RXOO(':Z#VAR^!HLO:G<[O
M]88-W)=G_<6H9@,!=IA.[,+F-@3E)IYALIL-/(!N?!PQ;F4#E)L(2(;6_X.,
MJE49;&!A\Z\U,,9V&5H:.6T"NVJ(*>(_#=D*N5V9.#3/!LJAYF$/Q@9;]0'K
MA%WF@1:H00N>0"Y5Q#K9LH'#Y.T_P]0S.<Z0=#;@7+0QM<;OD*)P*I^W5ZDI
M@Q<[)STF#-VP977B%V <4R EH+BLK6.^P4Z(0]Y8">M=J#SJ:UOY@_DI?(Z.
M'PY@Z%J+SYYC VN0C* ?D /Y:SDK1#A(&(4<B&)HBM+2H:[>&OJ>WWV.&E,\
M_U,-'H8FG ;%(-'>_^>*MA6I;Q$3HARI*V%!_!]<BEN!UAP;8(E'T,\ML)I7
M' J%19ZA*;2BAV< )!623')>@'YJ:WXRYZ*[BXXN82M@X*,2S2$LN(T-?#-M
M9 .@ISP9PO!1,@0N'NY5@ 71SV%;E3B0K60#D$ON_^F2L'^Z!(T=?H[-5V #
MS^U_?3*$\Z^X_%/8;R))/_WJ_P\A$:S=V?Q+OQ!2BJ 80V3&!KZH'?NY62#C
M VPP78@%6"MV%6;'_\,G/I!/]-C EIZ NRT_58&BQU_)?(L?K_JEOC*VZCW>
M"?>#\ANKQ__A6(-_"JG@! /."<8W+%4Y@,7K1S__<Q]_7G%*P/^#4[Q6A? @
M>N_\O77]Z1<DXE:<M H3Z?\%DU$"0Y.']HX#$PZP'O^$23EDWA\P^>L/:_I7
M7*+['WXMAIQX!=.%7>#_A1-IAB;WBEB,_R^<+ K]3YA$0[NDC/FVQ4KS)X]M
M1!![\/FG$-_^UD/_W^#ZAQZ?(#V0F"[NM-A?2R 9A'PD<\T"@B&^0H6O"?^@
M0A7BT"\JC)%F\?K2S3P[E.$,L0B65#1+'/H2_N/1! (\ F>88)+90*5J'I9S
MN8QH_F,]5)%3IEOZ"B$NA?T.B _=C VT(H[]QOKC/\):&/K/L$+%*W\),P,[
M 4_\VPQ<O@.3^_8O,][ _Y<9*VK@^[*S::X<'#S]B7,K3HCX()S?XD#TQ#]P
M_I_.+%A=@?^]PA3T&"=?O./(P9HY9%IV9S:HWQW!N<@E#C&#4  1I)V461](
MZ96\((LE]B#S49#:\@RQ;$AM X;&+"WS%]B>KJ!"YC<J4")_HV(UM\WUL,0]
MZ.:X5?]#?!P!>O20K2 J&=STBXVGS/\GOB%K'EQF==6Q;/J$5M5.@>RR9'65
M+JS(D%F1@?PM8TCIGS+2&1J$U3WB_U-M1QAC&X&6"246)*C!22SG?B>6 FK"
MSPSI7%7Z*T,>JN/\?!:'-W_M!TY +F.Z2O/^,,7A7]6 BOB?8;5E\:+HYDL<
M=(K#5KR!7_%&$\]O2_X0\2_>B&%H]-"RR>G7$: Z!&<X91K5AV?=Y[@F8 56
M^-^PNMCR3UA!N\/Y5S@TH/7<*U]'_/X:DX[]>W=HE<V"NU=)K_-7?KW(!JHR
M$4YL8)GG^NJ.@E1 <%3XM5^R.V?_%51W<#]Y @YZI).1G&SRR^AV.+@OG7S%
MF_6% U0\1XT_=^D?>OPBWRN(X6>X?&\HF:RDTU1..! 4(].^*M;].-@O7T!N
M7W6&//G=O\%;IH6QK87V'@+!JO4KIM2ETUPY,I-6HA'P.QK=_Q;0IYQ]"N^#
MBI\OFAQZ:%_-)>^PSORXWJ)?BKS]M=<1_^J1SU#ULO8#\QU4+7#H8@)*)030
M(X)LQ]DF'!\9K:@2\S\A[@C=N,CJUL[[O8*3!G+^E*JRG/H';^7_P5N(51DH
MAD8=+0?"^&\'M&*'G\'S8R "@/_DK;?(?P/8[_KK H2/#+RS9,\I*)2W5^H-
M#3PM1USY#T-P_^+3CW_XU('%:T6_!%6O$,(T5CG#Z[^=D?XOSOCXVQE(AD8Q
M+9=CR/U?Z( VJQFK>Y4];W/8\_P?[-GWBST+^9=^5D[9+'%+^B6(]O^.*XXR
MU=+7R+K/B6L,!^E=R)](C_D_6(+\KQ4I",K)EKX6,<>_1:!^BL#]'T0@*%/X
MOI955,>LIJ-+*WK)_])+93GSW](1YG=8(=+.I>61T_YVIP,9@LO14N[?[L3_
M:TA^N5,=NG&!U9W.LBGZ6XL+= M("[6_M<CY-RU<?VN!8&ADT_)_@>M73"Y@
MNE?S$P<KF'?8?^1FU3_ !:77JK=89\3R^I^F0-G]'-T"2O:PG^C,0/Q&I_<*
M.J&/$?UCQQ_ $[L0^=E0.?%SQ0GL\%-$?@'BFU B=GB24Z)8_$>IY/DS%:"J
M2L=_IE5(]8#SK&ZH2]GT4V\X90K71_@[1ME=?^95N]6<R/A=*7U&@AX&9-0O
MVN=$H!U;!;&5,W;%,DU./H(JCK\3TLN?I/$?IB"(G83\G.D_PBI/=NXW;D6L
M^C+S#PJU_46AA+\I%"IG^=.8T$]-"$"FDU=J%$A@'7,- _$S0,Z+[K]SN_.O
MW/Z''0C00XWL!MG1 G7 *]XSY2C!N3/X-[9F_P5;X-\(?P)M$F3?"+1)>'YN
M$LB_9S$]\!58>'),R?XG+-3^@,5I"!90G^3LWF/\<P44$$3?2$$,D0TPQ+-7
M@$'X!VW]FXB(Y74@%M(\9#4FK_'.N.7UWIP[SBNV0/)6C3'Z5X? 0 \ALOM_
M.42([ '=(?RZP[SR#^(Q^,_(0.[G?\7,XG3?*P;(KQ9> ;2B7X57S4IP_/XK
M.$+0II?XN=V^00LU_&B?M&^O1,)YU9Z5@TX_35PQ:!KVTQ[3?[.G 4I#/"O:
M9W.TIZY@I(,-Y!.8W%H<D.2LR!#Z+Y_ _R"?;Y-0P$U9/=B%S12HS>3O624/
M!-T::AZA?G\5[!=_/YXHR$GXYXY["2'BOV1P0&**X=R"\.[- 4G.?^-]SW\*
M>0&M.,7J,<B*_0EW4_#V+-GK3^.8UWZ'!N+'52F2_RDE?E4*=F$31Q78SP9!
MG6.._&]S+OVJ)9'_"C:HDZY*1SBW_($L3FP0SH3E]7^$1OY_AB8;O$T@W\&.
MK4!$@@,10P@V<<QLQ,3?MY#O_C?LC2%-TK#.N3W&?UJC1(=*TM7H:*V8\[^C
M$PNYQ/AW=/ZOD/\KY/\*^?^J$)Z +3M_"MGZGU1@&@'N-2<'ZF,_E&A"S-[%
MJ<^RN^^GW%-@7O\S^VO_9""CSC-ZWN,$_QUGCJ[[_]<E,#<4D\'J0.QD X[(
M0#8 TQ*E&YH0M94J"SU)S8-H!><[(G;GYD9IARO.WC)RT,XQHD:?9V;CKPVN
M[QD1S*7.$>KZ^!*2-EN,A?@0X^^NWU)?P9U<>RGWH[^PEN#:#$ /\#700R_2
M;= 68&SJ($.V'<.'_LMW'=J-M&$FM=.V@_B1V5DK8-"[2[U_S+5<)B%6P),^
M#"._7/<BVA%9N#MNU%9J@ZL6MX.8Z]=AI?6^R=JTPM96GI(SUKKTG8P[5$0=
M[I%7C+76A\("JE# 8M#M4AL7;\-K1U-."H'N']\ ([<4A-=RC6*YLS@==I_,
M6>JSU%165R[HV7.,:M<=[W)-:[>CU_/.T5.DTZ%K>-0G7[3R=)\W?\)0!=7I
M!J!Y;8'%4@3"^4")24K%F&^V+FI]O\6FEVT?LF?/'F_,#\9SO_PXX1P#3E)C
M2.-A+ T+UF=";D*^<\K4F8N;V("@=QQIW?-)SW''#8\+CMW*>OD!/4$Q'[,#
MEJ9DQI#":%YFI@Z/M^<LR;02WX>]3'49PVW]5$89#Y(U^>)%3?\R*3A^]>&]
MFT&/7._?KW5E=1/R>&HB-K :+*1K6C8>\QUF8L^6Y5HVBC9>['.VHM9;2UV"
MJJYMH7:ZMB(;;P$\;7EGK'?3[:NH'95EO)UE\@PY<%HZX$:>.-RW]D$"_,$X
M.2H(UC)^PC#BT9E[*>A/LT<E"'H^\)G85/3U,HH4CBI)PM7Q:IT1"E(6U>S7
M5ED0ED7D]IVH#M6JCYCUOO+I(-[KB$B-=_9,#/TZPZ1+1Y/ T ('LTU\DJ?C
M4FMQQ)<GG?<GA6_Z"D<X\ <G%>Y][/?RBW#UD2$3P#=,SR> _'1D5@BMP(PK
M,1G)7N/,ES[5K= 7;U03M%?A>[&_Z.C-S[?>547>66[7345;@WBZMK?:&0JJ
M]I*63+;UI(8'*S53+H"/^(G@&"LY]^)MUK@'.CS^\'H8()&DA\ZE<X%X6C@X
MFZY6TR+!\(V;-FQ?S'BI,5TE2YRV$_+.#WMFJKWF@TW:N;P#+3$]?'7'J.=(
M,;41H3@X"F&/[V4#-6= IYZCN981PMXY[ZKG_KIVIF!( +'_QA'USSF[WS>.
MOBR'ZYY!*GCW$*7)[O0C$R9422*R;M"]COJU_L/4D !U7_'ET@'U*A_93P-;
M7\R8I /#46L*V\H$N[/0>D07M6JU.-GN>)7%AVK;)GLR"IS-;F^^ZM;;^3)]
M8"?0^JI,I15_ Q]BCL^W*BATS\YE'.ID.+H1X_>/%#ZLE#J1_%=T<^_']3Z2
M\?M^G 6)WLOSU4M>JCH[.^7?C?8>4E5L$+7]_O[X,<;$FD6!$?S[]&J\&,.2
MF:#,!G8R_NJ)/]LEA2\*-TI[=*3QX,GC83EOL[G[2H/O;=R?.+X#.(.$LYJ@
MNIA<03\)(LY2R\+H9WHG*!>G.R8KNT<J5944>L5,BV\&N@4=K<OWT!WA(1^@
MJS)L*+C[B.L(X4D)>8@RP^2;PI[EVZ9EIC:]K)WH\GJ[+L)^4DC;T*IZ:Z$S
MX"NKYXT*PQQ&&[1C4<@-#,&.$H-1T.$\Y6%A81_J*Q&EZD8;0#P_]P6Y>(8B
M#(M)E]89A:B*A,UIJ<D.Q K(Z>R2CD ?HRVV,ES<;:"VZE6-4+1K^JCIX*OO
M=1G7Z%VS_<@1\R =7O2.F L4\<8ZD@GR;&$'&C':?ZAIO-AUKW[Y(QV+(]P\
M8S)URES3G>;AF&KLSA(;:@11^PMVNZL(XP)QT&G$N(=1;QL4&MS_-%A_399
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MOQ]EF"1;*<K0*O.IR5__>*UAX^E;GSM K?R)^PJC"JE\&/DH6"5TE7O1<[N
M)/RF0%2>%%A(<32G_/M56!G6KMU2QC#WTJ8\L:[J*OZOH%%72$NF?@<BPTW1
M0;ZP1BQ#;(S$2B=(PSW50>7A.'^6S(V.J389;'?6DYGZ?T^N%P]RC<O=][#[
M:'_D-%\A7Q'?_"Y$]AP]>Z]I_811;#&Q.]VT$N(*2H.,X;QA>H=LP_\^)'7>
MDGW[:M=ZP?9]B3>RKNC?N@D3-;H61!E\+VPV@YB_3J?^^02KC<<63=H\:5-P
M4\/'N_2T>S0>]'2*S_G1?KXIWB@,YX[KP,^>)4%\97.#V=;&?8/U%<YN(%G,
MN#RZJ;8$!BXP3ZZ*U>)#6K<-MEQ71 *R=5\-R (;DW@7_"V,.'JV30.T?^N+
M:<1U"AP$;;K3P&B+ND%XIZ-@'T?SO>A]Z=56%8]:^[VNZ,7$(IX%R\E.6(<+
M:33-%.;\51\0$VCSK3W;]'V=>V?B?L87&[5MY;O7,?6V6K6_-_)!467F'W/F
MGVO6G>R,G%-M,7\*\N^47$B_+(^%QP)*XE_1#U!MSPT<#H8_(\^46GG;WLM/
ML=&X7J*8L$A/8]D?7_D-:^T__D,DB/-8^YQS3WZ=V4OI'S%A)_^R'$/P9+=/
M#5&8 46&7\JX):PN)%5CJU7X+3HK$TYVJ[<TYC"EEW$N6/U/@YRQHJD7L?TY
M_L1;,4*L??FF@!'M4./W;5_EL1^PP$<[$_W'YA)[(EP'8 0L]0VC[7G)I8BP
M8OH .+8D?LR$]R?\S**!)19T0T-JY+T2;A<HG'9$JCWJN8W\-"5*"BO&DKUB
M34H9[3H8YL'^%Y5#C;P;VU^+"_L-#5.,%&@N\,V<VTJ)S'$2(J?*_,3]Y"('
M#/./T8FJ)E>(?CU+G[USOYA8P4\=FL9O%CK8/X^[ME1<Z/T_[ 2V5U2Q>ZNC
MP.8%=H'J#L(N<,'&+39P%Q##D^GM4"SJ[RT$D?"3_?U_39'^WQ;V>&;!+K!H
M,09?#Z-,L?(J*SZ\@]%B=H$T^4M0J^1.Q,[#FG>D_^T3T'!]#'$)OZVYR;$+
M3-LV[@)CP4QTD@_\-P_40]R#7>"K*3H,PO^!,PY5E:R>/-Z&D;\M24WBI. 6
M[9"O=<GB]#,,+QX!&?@9YL'1^]HM-\T9+?\9^?HSQ3IX9Q?(.$3)9SX?$&#J
MK#X+0[+X?X&<Y6$AG5>S:%7@H/3UZ6Y5<]B3*N.W'ISL3.E2'3CC<&F);_/P
MNL;"63?8I0_-:>@33BWF_KP6[9A:G?.O5 P\L$-M6Q2C6\3!(\[WS+("3F'6
M<KYR+B(8HIPLKC5*$LV,F<RPI,YV8.H$N@8?TJU:QTA)5E2E6J1.<;3?YT+%
M"3DS!<[/V\V/$,7Y>X^)GOKOXU2M$2S>@5N8<DR[)@/I_L;).DC+U^6TDS_I
MY&#*Q>^OV(8O;F"\!))<D.L_(%0I \.I\=UMAR?4JU"J%*1I:]OHWX%@OR9C
M)Y,7(S+/Q&D*MIS]ACJ[P/-7*/E=X#8J?^?F1UPAGMB<Z1A*H%C9) QX(152
M8#2#Y.JWMP6#DXX.]MYD4Z !.8PU*B=#).-33B-#](_)WNO3[92S)"'0QNIK
M7K^_S%]O?)WS4':@SW.$7G_/]K4_<F?/;W:C&T%VB/SX]R9IJV?]0MN$)NL(
MO P+RK]_*9//*\V>$DP"-G0J?G$-E>T"JII/+QM>G4H$('^-=@4SS*B.#.$6
MXE)I :$WD.,&>W5MNL6LG#42-KUD4SX@_/;O<;_YX<O/M]4IO+14YAL\,=8E
MLX2NB9Z$'T"9DFUB"#,9-\+T>N?%8[ZX>O\XV:,M="HAM";+SS%=.67&F2U-
MP2&@EX1GB&?=8+XQ4(>W8T EW/H@E=>%ROK(.^/JF]/S?-^;9!@OK<1"*=OM
MF=B1-]ZDY-C0DX5/HR!VB=;ZN4&&@<>5-_RH,1=:++5?H.S*7"I4^:QH@[ZK
MWJ\>IC1@A_$?T853 WB*)>:;E,TW:9HG@AML]O/#28?E;-$=>_0RZ4[F&D;5
M,PI1=\BQYQ?3^=(O#401'<>O 8X_AAG20;N O/C>GG'N9ED0IJS:[Z0@7L I
M 0XIE3]91YB%EZN*W5P26JU+7J!' OI:.<?#)=G/F5\$Z%C:]E0]EI?5B9<P
M,%F@K_@C*UF2:^DS<T;='G'GW75E+!9/&<1\2V1\W=M6 ST.;\S_A/E&,*7T
MKL_N+;6!E X+H5_#MV7TB.U0&EF337K\PBU*8W_,JA5DP@^IH1M1UF#DPG 2
M@I]QGH+K$=LXF4%R$UN[."%O-C.(#.0UE>.LGEGFK$<[L ;R&Q#=F^!1'C]$
M]>;&1XI-=\[P(__@B@H< )([=8\I!/7*'P@C_2E.54X8X$Y,X'C?IUI1$> 6
M)0FGV/5!6A)&L8/%[HAW;@I"(:_^3YUO/@S3Q?O69V<CKRY+Z_4+CU0+P+_%
M?L!L,692A/21S.+]&$[Z:,+BAA>NRAK4^$7>CPPRRG!IO -TA]Q\^J7XH'YD
M9ZIJ%B1/HK&L"3SEZG!R&R^(A+H]1G%,,MB_X";@AKU";>S"":^\?T%^HMHS
M.<S3^M[BI<PWHZ%A[6A-#F.E](\Q+-XURFPO1@A/S)VI;XQ"J456VA2#6)MQ
M7-4#>DC.M7JSX'2W1%Y1FU-:APSM^7K9+ $)*+LQ3P@F<$,=V:<P@3I;9NT7
MJ-Z!X7'N4SAHG\.;-5:U?!D>^SKS@GQSM>A:/L4"R?=S?F^ RY^A\'Y$+5W_
ME\%)=:69HJ6<\.(<!\,?<Q5]& ],0CXOG%@.I]@("+(^R[?+*E$&PC"?SCC&
MU:N9=.7</H$)$'L1_7M._J5F\=69RA:GPKLJ^GV]C_<&]JYBH-;;E0VE2]?W
M1K0XF7DHK_V]CP.4DSK0BI2/K_3$=DJ2OOSFKPH\H7I458LC4_?N6Z[/*=(!
MP#J<^$,$R<50 ^%4?*<COQ<)PPLR>^++C0,5&WX:CGR(2/"_>>NGX_<Q/''I
MCB,S%RU1\>X\&/4IAL 4NKA8CQ-&780Z1H'N@( Z2H-B<ITRM;Y%F;IV)K6J
M,NS-K+O?'V'IO@![B:XO U+&\BG?N]('Y/%#::FSK(-71OY%NM,B0*\#V)+K
M<]J80Y*Y_@4^/-@:R[Y/!K:<*W+VO/6.^_ 0RA$370ZF+&S.DFD#(P_<-*7]
MW. DC8;J.(E/3D?<KCK9IT2*[+?#WEI!E.ALCT$>$#JJXP]G\7#3?=Q6I=RZ
M!*^C+J=5+>:(V3_'U-?'/%= =7(\^"<"8-J_?+V N67#-?CCW3^P_G8Y/1Q8
MR<DS)S_:YEF&K))P(GZ3^>\%.L_Q\#;M;ZLBK4GJ'.##1/Q8:>0KGR\*"FC_
M%45[5\LZ>'4TV,V+)D[)?8=]<]W- B]VU[FH(;;X)GXZIV!(1%;3?/D&1'G[
M59B)__"S630@?@$9(X]E"0V*S?>Z4HKUA$]8GEL_)**[OA'5=O?*H,0)>Y,:
M,;ECVFR+:%%F,X98;LA-Z<DE#G-CV@\7C_VM.MHCK:;9,=7-YM[0F+#/7(C_
MU?'R6/;WHDMP/@;DE?L!< (Z!H.A=!\02AK$Q@TEO[DZ[0)WPFI(\]LGCS1A
MUZ=L7V:_E,O\_2-.3O<5E_RY#S\-^3'MF+_(*(S WUT@!M^XM?Z'JF4)IBVL
M.:W7^U36.0G0,KML3Q9;O26&_7B*^@)X*/QR8(O&O4%_PL,P <.S\;0/DW#?
M7*O.YL9.?)2=M^H;;T/AJ2,$)?QQ2;Y0B\/\V&:O<.4DWU.I$EH:*;F /GYF
MO_W>AH?XZ"-9<.K==S8LB[4)VM9&$"DWZ!.^)JN+( W>6+((5H,M_*J/+!WD
M/I(>5NF9KLOQX,BSVVW'P>WBU5'([WOS]^N$U;7$U6$72D;['KS7RZRBR41$
M?_MDD,KLK4(_!DL[S^BE&&B5@?"N$+_ 4M])+>=5L<%1ISO&J?&KE>9D(U@*
MAF)A,W.5M@2RT4]<]R;4PAG"D\@G.2>K2$D5:SA1<]P)V>">SZ\U_&<LN*I5
MUB82-MT<&2*.SI#O%V':3= \4(;'V6H'^=ZG"8/3S"R2?G#$.9?AZU8)HJ.2
MA1H;-_&J)WH-_MD;D*K00_@Z6#<<E,M*9-C3-=#CA ,,2Y)-[,/&)XH3#''R
M)N]T<9[/ Z?/7>_2 CP292C9@@O!MSG>'M58;PV';JLY\RV&6"*K1<&W(T!%
M3"=&,NSBJ%K(S%HW00AE7C);J7NH2.-W,<^8\7M&F_LQC"9&O?^:W/M[ E]Q
MTXTLX4W0"\F&Z9BHR9GMAE%B5S"4=-?OASP@";^>%EDHS<'H<"/^&7<<SJ>X
M0=V1J@)+=H%[<*:AD^-D2-H@?V7@]>OAH\?9%%J,-^_>_R:CA=@;.[_3)@,N
MDTH9PE=)H=%MA\-<_KA,+-6/!=P:>P!>RK"2:7OK$ZAA?[C:Z75:0W)&(R#\
MR$A&CR$$"H"AV/8V^)(1%+5_;7&<3,@8L6I>%G2G._HA:@GK0739582DH8+S
M;*\?6<VD,UE>;"U@78PSDTLI_192L;-B<_JPYL6!EL![6E!-+$0R^'B,((.;
MLD63;0!-R2EZ73>D*<:=X56^.=<U5D9U*F\:]@IEGQX>>"8+XGA'VLZLX2EF
M6/ 8K%< AA[+WV]@4@ZJD@^T!%> H=TWQ.LMLSRR,N:*+;R\T[+1H^XYFJN?
MJ17 S\]?V-HQ[>YP7_QL/KEQ_6,AZ$C+9CX.,)3X*<8Z4]]:.[4TV3:R[%:5
M2U)K&"S:7Y3N.(Q4G\=;H<\.0-*6<A$I:7,V,Y29]T\L)*#R<JRRSO8 =&_A
MS&9&,/37F?EJ%UB ,=/Q'L,P&R)\W^I7$-M]X^2D=IV#I9UBO9-\*N=S"946
M3<,IGWUO[R<=#OA',^_<G,GJQ-1O,H3827EX8OZ^,*RYH32(>!=VFS3<)>8C
MLB7NP((Y^!QUFMLRF[\?J\QW\?W,V:CSN\"!K6XA3+O. S&+B4MY2A/9GQ&M
MZ*]F-D2 H7J6=5 "%*0*D\W7CQRLIVR:OK1#<H -A!N3)S;<O3+6>?V#.&K*
MHZS"/8-#6.M^\K(BD[V,0YPVX]HX4&DK?KW>BKOJC:S\1$(BZ6@R?-3&?= 3
MT][!4J<BXO;>^<J2"HUA*;O\%%I%J]0V3FAOC5\0/[.4=\4^<VC_9Y_+M#CS
M\Y,JQ4-FYX$QB@!#_"6+NZ\<)55-[4UH._'=N[EYY9CB5LRLT<><7[Q/7\W*
M*QA>R]?KK^'D.K\_,:AQ&$,DX.-EX6TUX 3]!IC1@7WMC1 W<.<GQ*X'B"1(
M22BU95J: ]JNN N^G14FR@!@\X1AP"PQ% Q#M#<;YI=BVAM=GH\[.' U;#7>
M$(P\OW2=?4FGNR?]]V4;._E:70$7.HQV&(( /$.0666H IO&WP#=2#9Q^$.W
M&M.J&*HDJWM"P0F\K;8?>.9OFY7T&P0R"I[/Q40)#&-!!<R&'MT/I;L+Q!92
M58GBZ_9!5+\K5$RB_,ON&PJ1R,_ITH^6!G[H7LL\,=9WY/1B8WT$;J.*FL_B
MR:?[L ;11YFO4'MX\W9<^V5DQ'J5;!62)))C92G7E!@<[&"7?BG"1OY'2+E4
M2#W5D<5UCNX*22W$)(O/S_ $,Q^MY!MC6S/!T$,V6_,8_3:X)[/QWE)J0,%5
M\8'P4?.C'U2H*9L0)CIO)B(:X?'RS#PX,1/&CCZBG%S?\B3#ENI943K[2?OL
MK>.>IAI6!H%Q]!3M+TE2U9\\[QQG^T7@;E6G8C]!7FYRSOT3 8;2""X*JS !
ME4G6NI!FFEV:[43Z1_"7-XR:,R(4E'$F3@0*4@)&V=A0QVZ_K$<P)>K_ZO78
MQ./%&.?I^\'&!<<GP0^HCJGU H^;XYZ'1WKY9JY5^-;XI%\8/NSNVZ/P@M+*
M]N&@ZI\_+*[\/?*CE'Z"L86YT@Z CRAZ)'Y\DHZ-M)O13))W=>\=+\6N C:-
M=-/G/$]-!-3E=KYRWJ+?P_1W$&IQS"<TPL[5*GLL>!J?/^VX\%.>Y2NW"XQ*
MYR!FO<PG3^*)1,STLGWC:(!'?7R[[H#.J%&/-MQG,NS$ 4Z[[<1\UD&W49U(
M+YH+B/E/0O,9?RA&T^73Z"'#SL ^'@$1MATC^0O63PJ-)&S/.B[9,(34\@98
M/ -TMQ6'E!^S\$0=2:G]"U;\GLN<LK.SK!V=G< \K43&\-ZF5S]WNN,9HD6T
MVG'UNJ2RFQ^H8L4W<[PEKYQGUFKTIY\*^UO )Y"4+_(7#RI!0DBK"U^'WX 5
M$689Y\!:XL3[490]TD>!.G,JR49([)J9E\; G>JB2\TE7<AHK@-P4!7/$(FG
MW6;6[@)>TK!I7IH1E7^Y"R$5-MPU\]!E>D5*;?SVM/LSB]-Y"@3Y]URB05'.
M+\K80P7ID2@G-SB+5[U\+FR+%@:O>Q-3")K-05G@E#D^<\/@K$:JP+GE^D3)
MD6*AWK,&5WJN57VY]/TUVPS(R^+Q(<*G(^RR2+HO(1]6H(IWNMK'%DV@[(I!
MNQ.><=,OM&+4:7?EWACGIAQ]=^W!IP*!$?QT_,*;>HHK[2X800GJRG+XLRHK
M3#',*$(,>G=U*TPV!!JM/XX*R30V,]*7?W1]:F.$?G%O(>Z:QO6%*I05LT3[
M0[ -_V"CS2[P^*&5_CMIESS;D.EBS:?I8O8A1]ILGZR'776!U\ W@BA>M&^@
MGA\53PRI"C+,TNF<F7?Q%2.I5AFN[*N='7J4[6#J:+;M_"S^2N7Y VW!>\OQ
MHK\0Q/$^^&]H?BTB/DYI\I\-#]@QA6@>62?[G'RWX5[?W/CTO%2T1YIU?UM[
MW[7()O]R(WWX 8@Z7>#$(H3$7UZ,-$H<:LD,C"9W;GVMG DH+ .CG29_SXUK
MW^\:]COTX(Y<G'7_^864>Q@*!-G"8</=B$;$ABE)718T;=6K7)U9^#AEH._Y
M!UZ+@UW]Z*,V@!%,F1O37^:<;,;MAPSU[ *U/X:CH>2.RY7U!2%\LDV.W_#L
M-<J[EZ4N?4@UT/8UQS/KY;OJ4=+K/S[!5_N(()XA'$J+!XOH2IAVL]9P)-T5
M/9BG^;75CDKOV@GZ-OUMQ=>_;KI>=>N% 4XAZ8GM7*QB:+/$G+-)A0KPUP94
M\2Q57C\-160.1.<8E./7?Q'XN.8WB0\&!GTGIX:L=2G3;M.M<OLLCJ>;!S:R
M%3N\'#AH%[4G9=]!IVN/OST\HTI3I8JO+]!/,TP^4*>2#8*#2IU^[EQ^OC [
MG);)FO<?7C:%?;G@:B?\(,[,)D-2/A6JW,>PK,>R>-(HC9:3:#%K:F-G&XR"
M>1E,\;*<5$@;>G-CXTNMRZ>:&HU$J]/WJ&G:]V)O7M4I(@Z#*J$Q:, OAA0?
MBR<2YH+:]<2,S;*ZFA$QF?U^^M,7/SO<*NFQNRC&@;27>QJF%'7.A%S:F9^
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MP.H$_!QYZ_EJS;58H(/5\B%Z<V2EUF5*W^)[H6)C'_88:#?D;F^]M:A40WK
M7OD@QOC!QR!3-^E7XIK(5!E.7^N-""AUF]GG'UW(Q$&<+SY[ON5%9%@O.:BL
MC&2N(/?_V(.FPFP/=C,^57] ,4T]_- [IR\@%Q9M6]^YKJWGK/)GT13R/N33
M3/2TLDYZ5GGD8HCH4:-&$3YR5]DD^"#]%#68&(@]^J=#P%P#XJ11?J# VR=!
MJ6D&F6/G3$_D_='ZP.3JGOF)(W5B5!AA]=E&]ROFD62"L8)EQ7JA[6+/9)R
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M;EE)U2,U3<U%EM*6' 0]#3T*W;L&9 9/3$?+'PHGZ.XOS6,[L;5@B#DZ%_\
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M&#:YH["1PRL"SD.IT")Y^W,S&8Q\8HM'H4W,1-"2*7(A>SJZK2,1X?A,QX&
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MT?=FVN&V]!XC304G-2^O]<6?Z."B@>' J<=\4M=T"D\K^A?"W]CN$99/,]9
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ML-A;_/<SDG?:D_HPXGTZ DGZ[M( .[DU1)40YA/($?8F;;ZS%\FH4Z*=(U<
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M5_@X_+3-@ I!@;['7,9]'G+2>E=+OM=]3SD-FB\=K/Y&3*0JHE(Q@5Z4CUD
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M3S5OZ \;G]R9[Y\"=0-U0SJ!J'U*WSPS7!-7W$FASVY/D_]RIPZWU^%?WI2
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M21R;')VB"6<_=<6@$IWIZP16XC)>Q8)8L0QZ"V*Y;CPAV33D7ZTN61%_%?N
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M/0D),RY]6FF;2S!)S<62L6I"2V:=)&9>,H#HA'/$WD^;6VZVLV W&WY<DHJ
MUEM,N+Y)F;XXDK$RD16[O0P,N^OS-W+>NC02E^I+.?(C_A0S+8PLR%4H33K6
M%$:V\ ]1U.'N/XC]><0KO>!?CN7JS#C>U(@=+I<4RH@ TRV9,L!T/@*P)VV3
MB!,BI)Q^5&?RIWN&JR7J+>L5S[/[/W:>$ZZ%7+.Z-.^9(+<]T=T7\#)EQ@KP
MV@NB)*3KXXBK7 -/U6.[FXZ417Z;%RFF6EMTK_LFKT,EZYV]@5?=*4"(?^O&
MVJ)O3)'+";<XPJYJ7(IE:?%*QWSMT#4#B >'X>M_UCB1C@F$-"(OOJUMVB:!
MFFPHX2\0JG*F<W/1":J\!9I\N3XOW]'S]OD!,"K,QQL&R_-)'4TAX$8PKVN1
M8>A6YL'4/ 2]?S<GOO3!4X^JW 9+ RFK[>I,"<<ZX(/U^<J$K342J"VX(*0+
MS:CZ<.Y.?672]$3GG'HCZN.F;KPF]E8U"@41L>>_J6NP0,\AVI??/&WAY)L5
M8*G#&Z-285^NIJ/6__!*T,C(SI!!K,MLJ=5LH\5',4ZK&\X]/=*-23J"P0?6
M$-.=V8]UM_^GZEF'Q*#=Z7N*')F%2+/TFYB(!RXZG &B?8J5SCL;EHYZ8,UK
MU@:FFU,_ .O ]''-;"TV0830TZ_JMT*&T5?SB6_PY_:S#P-],QF MUL9\:S/
M*0X)X@'J,Y>]"R-T.Y[D%2M7'U6CCWV5G3[9YKXSUYM.\_NI8WT$=24C@[QY
M*C=<1XKM!A-WE+4Q"5-'[=GGX#=P,<O,;0DW; 87*@J#/^YKC"^@=$(F?-;D
M31]EX,[1C'P]+$FX1HP@*&6W3?P@&BUF)T@<RE>\=]F?(Z:-/[)+=YD<*'9G
M$'[)0D,;O]20^;>$FMUAH(>?_L[<SG0]NOU *,U65%.D4[);:^=:X[</IM5-
M48)>36> L#9[A.,%(D#6HFFT20UV%>%\7+QZ[-AE%6 5N-,UF[',8P;&C1 2
M<8A0M)-5PM2_"Q3C0*T38OG.V"&=6SD]2:GRT8-6DIZ&<E?,S??V5R_?M7<T
M6OZR<IB/,3 /](Q+VT1\'F3L9=?2]7#=4$W[/B'EF%:QW[2&]H<L,V^YX?2>
M1"P!6Y#A?'(3#6:N80=5^+'M_$G9S0PFU.7J9MF^"!4-Z.$%<S&IJ T*_SA9
M<XD!R;:9VN]3,&_3.+O:-Q_HDME; ?1LS^ZL6%\_<FF-=6F"6@5;H;L&;WPR
M[7APUT5+VD]71-"OWG=VO?Z8#TW2A[L0I?#SUDW$Y,7=",K-8;A)L;6&Q/ZL
MVY-!QZ)R6H>'YBD5>V4<69CX5W);3?(A \ ;9,[%?CK")YQ?[.VQ!K%OF.\N
M)T=O=Z&]UA8/=<)%7M0>LWYQY$[]V#WX7/4NSX)CIA&/!,CQ6UEI==GFU^\5
ML<;EUTOEV-;P0C=<W((J/QZ-;PRN!*'"$<[HUR%LN,&H)J9U")U<+@X<6;H=
MMHHAC$*P[ I7G]'G?-2!YW#8G(M,^<>P9B7U3D-@KWGZ0[R S4U<^J";8-87
M%)?5O8M);#H*6IX7&<[1*6Z(22N;>>!@2ZNIK2KK52XA;/ZP]E0)V>L6O4N7
M'!'E.M=LN:1Y(I4$G'R]R@.]DB<[8ZW>0AO'CM8GN@;,>SYM?%BT<;T6-^PJ
MOVKFWIMB,^'>6Z_F1;DLMXRUUEBZDXQ#Z^'(RF""7+)KX&FHTK%/G :TO\5Q
M_=;EH1?U#J^;.?AT<"K+=XIQ9ATCFQ^G)<I*\S8LX75^D;)ZJZ?C.7:2JEUZ
M=L*>13V;7:+*A0Z*ZK+XD"K\^8Z3U'BXON?/#:ZJ Y1?DNCBXR1I6\!6CN+Y
M'\W;%M$!A3D1<:K*N1+>$X=D#6"::?OOD<YA7[\&WR$)%C=HDK[EH+5XD#>?
M^.D[[P"CCC2GUL%(R_BO/%FN1"?C<0EV/:;I>S)265V*&S+:S_:SE8BE>.T.
M!&<#HH"LA?\^5$7X>E."MR'H]ENY)X6L;LFA)C1:.D*< DDZOZF1K3+_@>Q:
MO^]\>E.$.O_=TJC<K5*.SB-7:4/]Z0G?N0G?/V5;*5."YTM9KU2AIE2/KUAZ
MK#_*%T@S&OY,^V%E4S]?R!)B_V9T<83H4KGZ\DHE*/1\['YUB<M1G%T [W#\
MC:87&RICKZ84F4Z,"BR__%X=XZV4P<BZB>O7FMM?>RIT4K?JK>9Q,$((Z';6
M(1O-KV]3P&"H%RVNY/TC3C!>PJM'4NBKP7=7[0?VI+';P1MQZH>/L@.__P':
M5)%$_$D8,Q /66BQ-X'+==AE"?=0'/+T0RN_.9:^PG<VY_QY#@ZD2$4X=WH7
M=,>]H\%3MUA@*S?4U8#AJI(B#][F&/>.$(1'M:(3IF$Q<D:,<]>'5H)^XSV[
M8APDD!^P]DPUKW5$Y5?>@SWZ/996P9,],K/Y,"*?4^W[7YUZ0-U2UF,[12^Y
M(9LCWW7[G;F8PI[U><8#!)"(7 HO+)R;U1"*@!XR:8U!ISP$8E0 R/>>#826
MHQ($#5ENB&R"2\;P@1H;:^,WVQCRTQ5MQ59["5%I\O/OP31:=[75O*S]FIG<
ML9U9=XEQBZ=J'U4&V8E^AOIL<TOVL8,J.HTW:3-@-[.(Q_K.1+U%9+PZ3T@?
ME24-QC> Y#].OUV_/<Q0;?(1++F.XOT\P[[&(0 (Z'SE1C^>HJ2(<O*W")!'
MGF2E\#")/[:SN?L[0=!/R,FMH+]S-\=F$\*OTMF=HT=2(7,GM'N!^;(FIIO1
M21-\KFV$PSDC/^[J-<YEN8A2,ET]E0D[CQ%Y[7S$AP:+-7FK)A@[A_\18,E@
M9"GGR6!T /,6>V$"^7*7I*:N-RO/Q?#XL<WQI9M8NRS7)/CDZ =^N]E;[VO%
M_T7U*IA.;M*Y27!HL$4,-&VXNTR9^P67 H79Q<I/6 UO\C9LCGA)-/R\YZ1J
MQ\ND79FBB.+[F71<*X]&RGKKT4=TF.H6H224;TA5K7=FF#RL/[8JL50%=3SQ
M]VJC!MEJ')+\6+849&Q?X4:8DUR*PS%LT>\UW7OS+KPS:.+%(C)RGHTB1?E5
M)Q55ZJ.#KG;W>:39X/MR2<S9F-Q3F%Q]\TWO^?=:2U/=@YGK@3X[2 3TN\M0
M0"J[&3WCM1V&VLD%Q@R:I, LL3_8W==G %;U:T2)AENXF#;$M/+O<F?V=AO1
M:,(E<L'@G0%L4+'HP0SQ0@V!OIJ:R.5RRO6-I9P!V,X I6 %D;9E::],75?=
M#_:Y@K18J$(O1V[I4<6TZ/;QBK^A*F\Q95)=&!^?8L<TD/Z%BOO&KXXV;=E?
M^9+,#U2'K1\=T)J)D=3@VGB>,P!O";#])+,SERX*R11>"_,1L6_0>VW7'NU_
MDXV6T2/6>RD39\I.5,&W4:XQ1Q?4&2M_S)9/+[HW$'LS?@F8&",B>E'7?@W
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ME-TEZGN?.G7XI86J"U?4U,2/0]0D!;S9N?.N_/Q6 ,EF2*H/SB%4$NF+*;^
M#*4',#IB/!.PG<([(4Z^OW#Z= ,HPPU].A33ZO",IW/*WBY\&N@[WCGRFZ),
MA)"L**-K]XDN^,&6N6NXB'>5C9[CI(YAYZ;;Z4_2V]&.+T3OTSI>HO2[[Q55
M!,3: ^[03[<T\L@N%6*,DV"?_2R#3YSKU;QG]O"R:Z+)1U902>VIS8F\NJ9-
M?5]NH5CH&< I&SN"\<NZ.U9V&X>)"^'H6$)4/A.1MIIU4?E:$PY0SJY(5'DM
MH\,WMHPN1VS3XT$+:^^:1/UCEJN_TDY'1*JRS+.156Q1M +OK>D;ND8\;M'X
M5)O\XR]#$[MB5H-H^0=AA^0-&9L6"DMH8^:8_*/<&1?LYQ94 -$7+1R&E<:R
MEPO'<??Y&G)<QAK'S<L<=9]6HI_WFQ%BQ^!T=&V9=GJ_9(/YJ$'9PK$/S]U(
M^VQZ0.(K/7>A\_0DJ]9D+;_X!3>M/"[C94YTE "YUI<TEACGJEAC_*$P?Z=Z
M>6T033FW,RA(;,$M=\Q=.0VCCA88X=<D/U&Y;65-+/S""S&K&N65^IIV*G7G
M?12]$!PJ?]&3)BYPJ9$9,W_E)<@>-*VR*%^+>]?!=R<&C$=%.?XB0[YM9 G5
MC]X<XWK$F5/OX2,0YJC-C1)Y=K# 1C<&<H.]MI$BXAUP.]B6NOC/;F> 2PD=
M$D+M:0F$V.&;2<.CCP7B)1*;'-1MMXVJ#*Z8/Z4,H<\U6..#,/,,#4:+I7H&
M;^=;U.6L[4SUUK^;?:2Y?F?R;<Y%>%:LL5VC\!*_0&U60MKF!(QXH9=>V$L1
M8]+U[50B"([:@?>6P -.LT/ND1'$)) ;*(;O;M4P7&(IJ@&T"+KPQW!3>JI5
MXLJ4'#U0_[&.2@_$G= C>9^6%9N=&S()N:&J0)(@&^ 0K\G!I9NIEJ#8$F](
M1),RGK>AVT<B/%?$?-I(58>___+WMCZ'@=\:L<*#39JX'$+<:4:(%+&W,[OB
M#! *5UEFIB?N&W,U'H7[Z'M4UC<JF/HPJ+5[!<A\_]'%>D^$!G65%?"]'FY!
M[>L5<9=TCUBQB-EFPEN!4SML;H]?*?S6_]7J;CENN1U?5=K V/.SYW5'JB\-
M.G#AG-;1"/;% ;IMY["QU(U4/5*Z<[A_EZ"(#)QX>E1MVK@+"ZA7__ASI&L/
M2!0&;ODL0$(1Y?E1JM!%,!]Q3O_I.%2N"EMJU,GNY[;$YD;R/[+1%*M\W#/X
M6^SV5\:<:LW@6K^.RG>4SZ@]9 K:&1P.1!UMZ^.420OLD?#KN/DVQR4KR';"
M542KH8\'6_'*($_S=&MU[O:'!EU,OZ3'WFL9\V 3SS@!?0[5GXG/:J*ZA]YF
ME.U*HD9F42L#?1**F&M*#R1%"@ZJ"WO. &GJ/*=O$':(\V3+TRCXO65].PQ%
MOF)B]_H3*+/Q"/Q%@'L3T*$Q2YKPB#_1]HEN0%RM>85*1FRLAA\>N02,_;NC
M-12$4HBLX@Z?4.<AEK0M7ZQ*3(%5HFK=&#JE;T[O*9<P9P#R^\3>=/@! 13V
MOQ[H"'O-!JS(#U=EQ\U;I(VY)VOC;8EY&XK>+;*#T@ILN\Y\GGS:TW9BG;^,
M%SX>[ (HO387B& 2#VJK#;F9[3S,WF;VL6Z\5"9T;B2*;VF9-O.U:GP/O<J#
M@NY.MZ)2_Z*?'[+E5G.KCJQWU[W'(WAY5#,Y.J4]7+EFK>:>E09.Y1?V$3<-
MZXA#)#^B0C.70=Z>,^@*7$$AJFJ^8H"+.V:S8L7B_DU>7E:YUK6"FR?&:)S1
M ,(6P<9\$C*$/MAV>G9$9DE8G(_TSIZ::KI+W,#OR@URZS,$__3_+*@,C66P
MLXWE8$R09$NTXG3XK".P;_.59$MFPYMMTY-4-Q'T</8"%T+=QUR/%P+779/J
M_OG&\$<2Z/'0E_/1)T:1E=@%3VG/,)Z7_,$WA]$Y]8A@BO9#.^7)R\G5%?K8
M,0NINOE[O^=C*+Q$/$D!_A1/MU6+.Z^;Z V,3XWS6>3558O.8F_PO%CZNN;Y
MV_FC[KBO%^?%V<R$ZDZ3FSC\P0O([3C\^47(FVU&99N(OU?P^%;7I_AUAWVJ
M1%8"['W%=YH9*Z0Q<H>TA.J]7IY]J\[A!QW??)_HLMQ]I%8CX#$Y\7X:?IWX
M=7%PFF')#,/,!/GCJ1#5(&AGMUCO5A_U 1,$Y:E1X+95N2W9V\/^TFEU@(9-
M;/KI!\&\[*"ZB1U(^@;0B""7HS@[;2G9,[ .GU^I \J0'U!G0IIL>IJO+J^
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M#'-%W2MZ#?=?K]O/Z58'] =?["F3KWNKQA2@_5J=ELH2UK:MEF$Q:?+Y>6>
M5J'E.*X!?0VPBSW)6+D1O=,>F:Z*%ODJ;H&"26IS<"+-RYX]_"HZ\&1J<SUX
MHCOSD_EHV 7ZG<K#ZBCRK^C(F"I6X0/6(1B D59L/W@WM50]NE7[/G!* K$V
M#B(M&"4I+G,;GDO0S#=\<IZI@9'R(LS/9Q:5!KG#4J^:.VWP"&/IP_KL$J6;
M&AC5R\\ \^<R5S3"^)Z2T7ZKZP;?8EZ/QRM8E[V)R+G,=8D'@"MD^'6#^KKR
M'.BGY1E@L!)QU)S/8>MXQ=:Z]\B*5V3TR7D;Q56.)#G84:ILO3'3%X]U/4V
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M#] >P[[_!;0MF$T]_R$A88B&E#_V,:_2YT%*X(CJP:PV7 1UK  ]S9R=>)1
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MHIUM0&K.'Y>:BJ'QH'J M9U_#J23315!!*",;/S<'O;SAT79W,OK,4E/>PU
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M$6 <T7+U.N-CE< EL=+>,L."W"\4%8>M@!4TNE=*=O4 Q?90ZZE(U;P84QG
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MQ/K^V7F]@"Z*7G#UG3%W'6] V,_$O(LDI'AR>"'AG%WKC?=[1XYS<'"\=XS
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M:GP;5^T][09-='OP5K^E>.]HY/JTL[T.GQ7'M7]]L&+] T^V,CFR*,:^:!Q
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M$U^<JY_U"SU$8F]_"N7.[U;I(GB9B>2JA/A(S\ZXRYI^?D&ZFJ''YKL>1/M
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MXE)OM!,@O@$<NDU3&NV%M3;*7UTO4*G^(K]+0O.Z?SA/8@>/Q 23C'Q8*^&
M_<&%"6H,6]>5"]^SB!J[,%3EI=:Z6^1P4^7Z<83_P+%M:M(^4M5S3HRI<")V
M?R!?O?_& S1'T+HVQ2JBU>>73(+RT8[C@]N*=!:=W-FJ:A$4^B<CV< &E@^I
MA&T\IC^G(H<I;F/-3)P[K3I<>>6Y]R68>FM!ELC/<GO6!>*R,E8T2+Q4^:K1
MAW<_->^F %XX5U4O+0"4K=#"6^N;?J0G-6,B))26C41N)DMDC=6H^.W36CX3
M?J["I'A'O.(9_:#'N6-XR>ZB,=1CU"X#>>J $?PFF?F&BB\W"_)[?T;F1_VS
MKP>,!?)SK#LN^-X!7-( _7'$?L"Z :O1O=HVSONI)=RY&XF23?GV\M,SDH)^
M($_" ^>T=X'99H E_5&]$7^OD>2%,=II9I^YV^1PB+[$^Q*9+K@4DG+\TOXF
M5FZ'F4JGO7UR:J4M+;1L*,GI/0W7>$G7LO$'L\O'VF;XU\V;G(SRF&:##FV'
MTG7_FH([N+(18HXG5#7;F9]V+4EIL*OH(QM$:\T@3\#H:K"5IZ+I02M-=T@E
MG0TMP"N&RWGZ2E&^PQDU\NJ^85[^9]]J3JW']HS'D0QC;K+/ TY4@N!L,CS6
MX"1UCGA$.T;NI<.PV?7O5XZ\N1J+/^*V)T_]H>A-6P.E'/D1< ][?Q&@2$7R
M7397NN*Y1K9[(U?H!Q\^)M)_RZ/97]7B9*M,^@E8<[E2NO#V3.'W;:O+W9VY
MTZ[K1O)Z5$6[_$.Y[]X.>;PK2+7R*%U/3(_]JF81440\[Z! 3$$X*WO"[R&:
M\W]'^WR]B!$\(X^RUGZS_&3PD_'M/F9G5L41>Q2D'&/_^D>R+>1;#J3_>6%$
M6""KE.PSP]8@&WV_*Y(?EVJ-BHZVCD".O2/=>RTBC*^ZLA;#A8V/G^'"/LQO
M7@PQ;8H<>Q\,-6 ,QALN;, ?P1&6W5[B/>VJ9VL_8Y?]2]T6E;4])O>JKK.A
MIU+\SZ4ZV[:K0N#J<<[7X,W_+"?"M%)D]5)D+^[+Z72(SS3TO*^D%Y_Y.JD'
MO?*NFY"E]?!/A#@7]D6* C8XX, 7Q@Z=?<4A_WT)!!KA %M?&T<\Q<JPG3BY
MMTBNR)TAQCW5\(P!X!A4>Y-'[O^(.;T8VEH1WG5$QN30Z($;'K!C)@==<C/I
M4\Z,Q7H^LC]F4+F9<J@,?W :*TW_,[DEK"S-UQCL*4G6_=/:H90AM5[WSNWR
MX9U.54%S#I0C(3L8[F-3M)/OP%[XGNJ=H%KY1WH<G1)IH(T.W5=#/EV!N!FY
M]/.;K<S5IKBX-#-1G]3X,E"(C0!R&4CFZR3F.X!(GP+Y1<7A]86O 63#1MB$
MO7#7$;EEU]J7=30Q^2-/77:T\C8FU@U/&W<S#76#0HCMZXN !#H&Z=6?DM+Q
MDY18"*RGV[LPUJ@3N ]^_9MCLY!J,D NO'&WD9A<B=_)@L*\,K#71Z%-H#Q6
M]-L17:M[T3U=X'<$?ZT"M@5R4M&Q1?Y9LGN,@1=U&%&_P5DM_/G(IN20]?$>
M[];#KJ'E0Q/[HF6F#.\X'404(YHNX49?^[(M.9ULY4-57-CC#'V-C_BK_;5-
M3.F749CEW2JZSV 1]RU,%$E[<3=(3[%"G&I-TE.'OE02G;C"HCDV2O!_!+M,
M$E@NMN%=RG4_PD<$=_O<KU/X(AF/SB3L;?/#3*US86JM0V>2!L=5$VIJ^>+1
M(^OY^6M%VDU>)ZGVC5S8T!IXL //&&IR%J3/LJ7QMK5E]&&JR7(;)UOF\ADI
MO?HIQ5>V 8GFK^\WOP'<&?DM7-C6ZC.,MK&D6#8J)[ ?"3B.L4*#&S;"*S30
MH7<PLE$_-0NZI6"->CLN[TE8%@BLCP75PHSTD4-D3$QAIAI;6H6>>->XQZA7
M OM3\R0B\=<"!2Q8&*[ W)J*G((ST0Q\5*U1B&\MPSCJ$N!.U7YT3,/KI%UX
MX%M?XX3/)W>M';(*6]*&[19S*XF>T5GZVO?+J>(3*8UVY[)UX9'E^C7?4.8O
M_Z4RVK*!LUITB2=\!VD,AX2J0*FR1U2;9,7>,7J(WO##:<87ZPXG]8++ 2^&
M6/&_VB*FXG57.H]@OQ/X03W(_+>#\)#C#&G 9)S:G&"43Q7'(&U?C)N7E9>9
MN554+!^\O[#@(A#WG+Q_OX4"8#3$3*/S?&Y#/?B.;=YP@EK3TC1UC1BU9K,<
MCRF35]*G#MY[7'MM^?.>;:5&E]V5V?H?:@*:%Q]Q82)W:US&,"VHB&35%"I2
M,$3_X>30%?IJBFEV0_ZI .^X*YJU2W9R]N;3T;=/-9O!M.(3Y2V]JLKSRU.4
M'9@4]K?<YHJ2N5+O0N4%8E4-+7B('0MO).RJMJ4G,"< OFP*^Q9#.ZJTZ@5#
MO3BB*>&,CY_[B1GS2?[;<9EZ.HI+'_1Y0^ O'PSB/MN$XZYR86*XFBPN;*:C
M+V?88_/&_V8*N67,O<G<FHFMI1,?LX]PRIAMA6B'DN"6^(7/;WBOAMN34^H5
M/KO)OGSV>FLPW]#XF"D>JPVVCB@!U^B=)DYGKO3$X =H(K,Z9].=5JN)RU^^
M9NZ*#I+6J9O:6C+%A7ED3/:]J.US7@[5&.@>K AK5) OI-U=X#26UE9-X[4Y
MKZL5&=W,B\ %!$W_+;9[1)5A4OBZS57[2:EXD!>IN.R2<R U6<=K/ ;; I;X
M%I\\("R6\.G31U 62/I,J=C_Z)USX*>-N<^X0R$"W8'^S;.A#/)L^?EBQ/.W
MX"^)W@8MGD[I_1_'TX$U'MHIE@U;#3-8/,>\6T7',7^UESHK,5S!&@\?%Q>O
M@XROBYY2">V5[E"4O8$/;_":>)_-/NCRAP0?Y]4\5C%0B2JZSW$LMN:=)RCJ
M<5#(S<R.,D\CO(J+1WW<]=/VE(;IBY /:95OR5U#^KZT*2 D3/7F<D^VW^'!
MN=#>]8K^2VSBU!T,,X"1%&VD!O[ "1D=13Q=3*EW%N^]3D^*T" 8%&R='-Q&
MZ?BQU3;UVVRNFE6J?]TXPAL3-B($]+.0;#[ =MSQE%9*X0!0/S+^:T<F8C#N
M8*+OKOVQ0CU,5YZR>US8_"MZ/.X!%U9""JL5]]2/S<)D[XWQF'BFK\F>=Z_4
M_Z"]Y5CLSB#R0?\"3#1A#_L.E4*N&NUL'-YK<KD4M8L+JS?FD(*8+WN&0O.:
MI!Y-N/&R4OF7ML5F;TO^*B0M9NWC;Z9!>.N TEXON?SC.=WSI+U74]F<#'GE
M MVTTTBLOU8=_-$U3:);$)_Z:UL.!VK;76/8._'.?GH7Y78=K1)]>["*<LCQ
M* /^ZHO;MA[$:+I(>-AHY_T1W9[%K(H/W1K$)R.2+]SK8I5O2MTVFQ>RM9^&
M$=\45NN^'IBK2)<O_D$;[_';=?3AQI+.'_&!5-7K]MX%PNT)1V:J^[\6@1V4
MTMHDEF3@W"@^G'VL/'DMUD@:M?,CV%<^Z)XY_%/Z@N^4#V_AGFHW3<[4HJ^P
M5!FSAW'PIT:DE]\L*,^Y6Y3T(3<B)P\M]_S37;M?J+Z%>88^\3"P$W=_"1SR
M >8:</02Q!B:[[!I1GFAIR9BOHPPGY_%7]WZBT-82_%)J[Y>V\MY&W+F;6 %
M4XNQ%EEM&"K>1\AEJ_>JSGMGZ%Y^DV"1^*.ER(IOW"I[/HBE1@P3KH?3WU3+
M>343F(A2[0A:[7?KML&J]D'2MQ;]Y2J#*8-^_$T*'PF-V@[6.T3,]_O0<:"
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M!;(V+_RG@)JH\AY+\(,=:+Q6#*GK;ZQR^$%]YMLZR!^]&%-_H4@E%4?03*M
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MKP4_SF5J7ZQ(44]++W/\DL#**"W;[X]%=.6[0#XLGN]X8$VIK#H[HRLT';6
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M,?JN99,?.-V1"QL\EXJKKP$@R3Q,@8/F_]A=W[$D$-?(DHH$)G"?O7&ND E
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MPWARCO>5_".7CQ"/OKA 5&TI$>E3*NS'U@[?:5#V&+,EV=6]%]14<>2GP;$
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MASJ,-#35KZ^+<S&SQ@ZF:_%8Q[#3\$Z)7:@].E2F9MAWI;[)@A#C^5SNY-_
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M8%Q^Z'/WHUQKR"A&Q@FV%[447Z5R*4#GY)$EG^!A"QW3PHL/!T8-5+S+AG[
MBM(ZC,W='SK')"N.I4H:!9<9UGDUYE>$"A6&X< D*'0L3V<@A_XZ[")\XBQY
M/"ZMOHZD%Y,OP_[7[?0-6?LO/ZUDD^Z<X4B_RG<5"&@7!@_1Q-&3@5;M#?>'
MU%+2@BX7YK@^R7"JRU*1('_6Y+<^H_=(J@_R",$/SP+1*Q@"0$;;,/)H*X"'
MUOG'?7;@+[)V02Z0[RR$?AC^C&BQ#&,/3#)EZAX/9#!3YA2-UZ]T25BTYLN
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MB(W<44-$2Q/M.^$G9+;B5EAWB,XVO'RBA7]?X" RS+GTL<[VXA1_H \<JR7
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MV0HY%2).AMT;D)[!TQ[L+!>-M:ZYO!TUJ-2?.YRC:_BJ49]8(3G9#N6BG<(
M$?D EA#0!J<*@;OKLNU(%64EBI^CAFXYU[WQTW)_^5OB;_MUZ3^=O.!;(<X
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M5WH&>QV%(])1I^YO1%3JB?..OE[\NXC7/O )S,%EW_LA5HZD"1P!LFI&.G*
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MIZH$7'+R F,(PE&EMM4JE@AVPJMI'NJ/2U\MS>*G7DG-06)A58B##FBQ^C6
M(VTPVZ<)?,K_0]V;QT/YMO_#4RIE:;*7;2IK5+)E-Y400D2VF$_)'I*=88HD
M>P@1)EMVDBWK9 _996<,E768L8QAMM\UG^W^W/?O>S_/\\?O>;V>YX_+*V?7
M>9S'=A['^W!=UWGLZ2D\N)4@^UW'^,:M1K>(CRMUON(SLM/!,XB:SG*2F]^
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MV" ADV05_P]Q[E.E>QRLK7$;W8+C@N\^^A^K;3X>W WC"5:#J^##.Z#'+">
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M67&J4_>#S[LHG:T=E5?:..'X<-OT=C&_9M25T_>FE&42T>N+Z^Z]^9<VEZ:
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MKZE/-MS_,3M%0!EU.YS,-YYU$EEMA_Y30A0>[!9& VF;T=NY.M-[?T"QZ0U
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M82"G8[IX%2C\&8#^Z6%##O&7 _$<(-M_[^PH"I3VPL'P+N/\V?)!+H""@"/
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M/4'=;#ZZ$$=O5IK81E?G)<,\Y>9A"$[GDCAX_S*]Y8@R8%)MLK+A;1HH&ZM
MY0 R7M>R1?.?$>H\8M0 V)!(R+XJX!,+1"I637TW* ?(F4?B1T00DE2>QL5F
M!$8 1H7>8R2S0VX#B::Y#(I[!R@T[Y^!FH<+NN_Q%Q<7\B]+#YI-H7'+I;+4
MJ#Y FRY_:#-[!P@*\K\09%&Z9U[X.\Y>I[['F_U+$5PL#N_SRJO!9':%V]<;
MJ#P=?U$ HLB1Q'\H G]0L/3']GJ5<NB?%+ACJT6",J'S"6F_*0'V^$OP%01F
M^,"!PF.!PF4"(AG^':>@JQ!.P+!_V!,?=$O9; QR"C'_]L#W^8YDD)VZ3)^7
MP[A<'[17^91U]L8!L_'^=MPLAUM7T.>O_5H[")Q.C'0L%!-P'T'7=W#*WQG@
M['W&#D/G/[2[R)O<L[5HB,1R#[RDGIMLB@FBVS4)$*=^YH]Y<42OLE0:2'.,
M[BK?::#%'0! H>CN=N$)F%O,6^-/G_4#?P''U$"8J*(K,#;1X>") T]]:LBX
MNEEJ,T]<^-1$)WEGZ?1>B=\$=[_+BON?1*?^(KHK#,7IBE]Z.8V(VXN/TQP$
MT4#3D4O4X5ZE]#>[ 8\/8+W?=H1:51_A\%FJ:@OO7-#YC0GZ9&L3L]G\NU^#
MV<E60^2C&'=VHE [E371?)ALR%4TJ^U>&)1L/G7BS&#Q>O )V_C8-J2UON0"
MHA5 &V2E(3@S_FYK_6B"GP.60:=Q</?THFSNL/]+I7LFOX'<HAL7:\OS$6W%
M;UG 4[PDP,1"=.< :LPU +[FO 0B=<LI^K[I-/]69OQK:6QORFIJML$Q@-,/
M$2,^$@,MSN?BX5/0(97='PN8)<UM-0QA&Q3!7,&#5"X\) (.62A5P7BE!8V'
M_JJ,'9,;9XGOMG,]YQ7*RJWQ]-#KQ)&-[4[!*#S<"2%HM?@ MY>*LD$:4?M(
M]Z1_J=0,R+J[SOILQR:MA5)/.(FOD#300 4*)*GZ"]ID]BDC( >!$4 ZDJ8[
MES974N?5NRNN>942'W0Z=YTO]+PLTK743=A+T%$13?ZZI099F!_>@? YPB8$
M'<BBK&SLE&+(HTFEE ]HI%*7Z2ZA*).7" #1XWMM2 XB TFHGY[G];A)L*FK
M%.3ZELJBVTB#S[KWZ:X 0AS1NQV]X\$;3CW>!62R7 11!-L3"W4,I)\2$P>X
M]EJJ_0RIBI"\.K;R P#^<S*-L(]$6_'R@,SA7[]@/#9.+O7-[X3ZY&&QMB9X
MQ#,R@ N/M\113S4I&%1=":J$/B9);LQF(!MF1TX_#D@KG4=&16$@,:&+)P;5
M!X_E>?M2D(12U-J+4#=*_@=J@W_7XW$ 2+65;R"6%]Q1." 43Z\ :>=(2SH;
MBO!JE&F/.?LY#52]?#!FUML[4%\S/+TA1>*)$3 ?)2@77I *0+8GZ&S^J)KH
M)AH5E8<&@YQM)!-;:C//AEOA%5\NC-\>%:UV@8JJ]=@E@]-_=+="WCSQ3(R,
M;V:;A-OACN4M@H^01;_O"-@/W*F-'>.+,; JV'67)S3S/F%ZVWFZYA:#TJY@
M*:Z8< Z7W[J6-WHI^)+?U(+6?1LKJ[4^!W>/E<]688G1/X*WFK*G^IE=S+%L
ML\F*K85I]O&O&!JD+W;-)!@&;*_9%K;F>&5,^S87_W29)-";B=K VORBM;CE
M\-U:$JJ-A3<,-JA;&675OM5S]7!EJ 0E V'?)S3_,WYL-R*G>7Q#:%J^!SP[
M?6&-WW]IM>L(Z:1D^3B8; T%(R8DC6F@P5*7XI>*/?/OU^[G1ZC#8H*YPH+7
M' /J[-9O!5Y$R-KH6R9)FCQ]UZ".9@AILR.:#V7Q:2+,@M"I0TJ+G%--/]H#
M.L6WSM% F7K[)A^\GZ8J_/'0I5K^^(.C4)\F4I $*@F\9[95=+-'^0UR8T3R
M6MN)U:A]HQ] ^:@Z0MU_GVD<C8";ANX%F+X+#/24"67WIF*M20+E9%(Y95OG
M4PZ'8)I';)05S!;(8D@ 934[J7<X /B\FP:"#_^2?-/J^?5#W9FOI330QTD@
MF'Y"H.5>MG[=K8ZC[N>\O9^OOGYU]\.&8/40PF$",9".V/N:0U( :C<D4$AN
M/C=,99Y,GWZMS16Z*,-R( 7=_N-ICDT8Y1V >=6!W((^7 >)3$X>&\_D.'6M
M\)=?S:SPE'0=/)6H/F/T3?";Q70TV/+Y -<HS-S<_[EF.ASQ20*RO@;>WXVB
M[A<;GVN[^ZY?>23KM.[R.X./7=SQ"/3A<M&8O&PL-Q!<T!7:\N&\CQ?1I5<;
MH.M!XKLC0!I!/8Q;=Y6D/A^D__]=+./Z9+M@U;C\#.+A"G2'-9Q*B3P9D2M8
M_QBZMVZ$/;H^V9K8H6V]1^".#EAY39^B3_TR!%WF I)I< ?4,6P]UY^B->LR
M!/TH9WAPU.KW1<E"!Q#*8:# W1S,PS),RO;?CXQFLP$ T/$-(!!<BT*0MBY
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MXO%& O^MR*"_[0 A1_ Z4.($>0%P\3W)EZN-.HC8$G9"$E3]7 "H?<]TYM\
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M,2"IF@9J0W#ZO6L]>"R]8OSNE>:ZJRIO=$+)W:F25T,O'CFQ,]I]N]5SB-0
M3 93JAK%@*2/H\3"[4BVQ,66^KA7<JBC'8_V+-43Y3QF[@=].)CKNR&'%&^[
M+\E/N#O7?#B4>G*!DDAV?Y#CA*@<6/?'YRRX1Y3+*7H+!&K@@I\+M"['B"*&
M<E]+.PG;*,AH/3SZ[*3Y%1L(H8*22]8G62%:THSA3_%YL]_'*OWG(>"5M*;=
MW38]>>S8NX6H2U>M"@7J'%*QO,:&2J_')V$XM\TV! .<WB9. <X:]X7*4SF"
MJ%65I%24Z+BX%>S5CK,WZ'E('DH55C2=F3S'Q@DO> ]RI4XC<9:020[J"0Q)
MRD^,$$TI/(;*6X6>DK,*W&2%*U546%1/I_B=3S:'Y_L-0X7Z-9-U!-C,P[KM
M3=T3R4""8_0/[@IPC_:RIL]]W:P EQY4O;GJA>3V"VV+UW$>Y$?D?A(.T7YU
M^,25BWTA5_+E-Y$X4R0'D#U.0Q\-3#%BXLB<LE0F*=%$5[QD*W<M-X+U1'7=
MJ%1YN\WCK]RM7-ZOK7IEN[G:BRJF!V04TF*[82!@KCX=CD")PFCL(HF1;$Q)
M#/]" T6;6<9%J4IZ@E_:CZG*?M!T<2W14IU5_Z6MKY-[,W95T3HR1Z"HS>6P
MR;/@AN!Q=*UV. UD7SXQBWH\\!+&#+^.#]5.$[BZICD<S-<IY>8=J#=YWKS,
ME7",7?.3T65,?&4:%8&83Z"!<&;6[H2[=!@%P,@JU_)U'KQG%P?<'%]-R(&^
M@%_(D9N*>WF[OF-W/![^_$2LINS^S5/J?A,^Y>.;Q*O,[9;H"-1\..R(NS?%
MP*6[%#->>C[9]V+O$65J#J?T#QJ(2>M5I(K$\ZEF R!T^2)^*D)Q1C"21$ M
M-;>^&A04"#BC$+UQ%)F)$H&PEPJ!5DEA#Y$NN,R=#U\H_1G3GXB)Z@TT\L=,
MCU?JY6V/_7@@%M4GG?!>YJ-;$F$I6O4!QC \D^.[JO\BFGUB>4HP(K\/4>+"
MFS=\W=76A>F,2*8%?UBLG*:]_</#SW04N8A 0<I(?\7K""43M5XT@UB1&/<'
MAA+(@?BX5C11E#L45]YJ^2;Y(UF+F.CP@?BLTV-IA4#8XWD)Z5S@NZ>>+:/,
M<8T;#@!\1J_@SD2_WOO#4/O-28U%LPYW,-&U>PS^ (-DR?71 0T<W"A)\"]F
M [UVN 5F/&LK3] F<VA0F7Z2S@ FO]<,0?NU <DC:"?@0\3/.'8_A?9[4?^+
MO/>.:J)]UT:CHG00:4J+4I6J%%$I00$!$;'12UZEB0A84(+$#(* @("@@L K
MD29*$>D*2.BHJ$B'("0A"@(!)BAA(,EP)N]O?_O;W][[6^?\<<XZ9ZVS%L-:
M#,_,4^[[N>[K>N8I0:6!)K\K"Y.]^FW'^:]4FB:DU;SYZ_SM>D8F6P^OSD5H
M!UH _HSE"]N)0*\8A+&.:QOHJ4\YK/O#22GX^Z3[RXCI1V%5S?K+MI\CC" N
MV^LC#1B5A,7F(8TI((J\&4<8H!=',Z:@M.)9X%W]<*B1R<2I+KO"Y/WO],=&
MO3!H4S#+0_>S+?]W#'@V%=+C9PPA(-' +<'SLP_"WYJWC203DPWWE'GANCK[
M%L(BL34.PH8/H_R?Q*=_J3/2'MMT5$/Z=_ 21TF6O?O7JAR0U&3-EL1'##0K
MS=43_0?P-R-H;,/HV:J(9(<6FQ;GBZ^T#DIQ"A^X/.(1>'-%2&NJEZ,0Q$9P
M'TJFE9H%'!O:T^<S9)A\8DR][OV]H!'M"]G&6_T26 MA?SD]?K([.HAEP*J%
M+*G85*!J ]4A'H/>\4?^COTQID;,BK#B\:]3V^?.+%#$] ^%!;\N.^SB]-=1
M5)2HWM@J*PHR89_'[P27%@3!+=T9WNH@D%BSTO1MI72;B4:JFIN;Z[84JYNX
M'PEM3==5"DJJJE*2.KTEP.*4/[LX.G1 )'#]:^;-^H4C(:5^BIU-C:Y'%E,L
MG-Y\*M,_M%LIGX0@*_4S6F*^@<+9D=3I[E]1^OW[^*\-E()1I(/NKND #UNQ
MS,*O%Q](WK/4_FU7\U=(VGCI#L!S[Q8Z!=*2972RC:!P6#"2;1T$H[FY3>(^
M=_Q FT[)L<DQZ-37?<^?A)7&N4D,[__4$F6Y64!%N?D.TK6P0  IRML,Z4HZ
M'#VF34HS/X1Q'UPT<MR>L*+HT7ZPWN"#K/M[)U'5M(Q#IU$?J2BM^0I(:X23
MG\-"6K]*>HK$-?P^\I4$7H[G/$>TD",W%F^W@2KN(:/8)2,VD!;[",3O/!+&
M1;>;\X/-6:'FI:^]/,CCLW4'*[ME9E^_\!.4VYIB6I/\0//Z5:W?\MT4,!S+
M.-]L/&**81L3>HB[FK4O$7;US!/T_A.A:VT_]7"&/^KP08#*Q*28FT ('/(]
MKP0=HVN/U]1#\4R,PS>\55^ZG)>93JC>9XOH PU!)GC6WEVV[7),O=%V6 RI
M0+0ZW Y4&]\#_-'1I&I2UP+&&FQ.W5KZD3_ZC^N/0=T,(\G)K^?.GU']?4C?
MA"KC;[8-A>+J\A:  *WN@ \)TJ2T(UBD"/? FLU>EI:7!CHF)9BB^>.7&TSL
M&GOTNU[_8C8/CVN?^G6B:E&DK.!W*2R<LX'2DB.T BR9?M(?-E8+[J& 9REC
M)CPG7@5'6"^0U]^&A#LGQ<'ZSE\ 30EZ1N-&.M0.D&I6['^^30GDE-I-)^<'
MGCO5=-W5X'N[Z@/]\=0A-.A)67,=8"%4Y$W=$\0"9!3W*7,U%2\+5K?*D3HJ
M[L-[*_M,,<\#JR_+#5>^\M0^R'*NW!/AGS8>:^VD;?=K*\$9UPB+(:%=@VG^
M3AQAF2J<$"B3!HA\H(Q[&W[#&TLYGVG3)WR3L3/M>!!E:U"F@?HAA&BZF![8
M'%?0BC#]]J6QXC9R>6<VYQR4MF,^65)<=][Q3=)7MFE4"C$HX].%:+'@^#/9
MW!/<K U4@-X]2I5-"U8(1LCUEJ9]0?D0MNV(Z2TYKR=EFCG1#YKZ_Q+];;\G
MPO?AS\)TFUMJ3],W_>"=%DR$-&?^(=+GH0L13%F6._,)W>M7OPTZH4FM@EQ>
M5Y[?=/<! 7]BL2Q%NJY'\J.\M)_H.T67#TCG*B""V- Q !:,95_$V;#.<O,Y
MPE-;:YG&,2X=F>8& V.JM0/EY*!1JV#4YRI;[P]1VQ6R3M_.ABAT[QSJTJ@L
M+(Z"/")!'T='L5ETC6S[B\PI]:S"\>,/YUQ&OI0<;7J.VI>^ZO"F(6U$9#E!
M,2$0?2N<(V-)Z[X+\\9I!Y'^PA\%J^(N]KKUA7"$"WLBBN:V)_SU=O\<^<>O
M*I7-KQOIQYSNBFP3V)UFH50<BL2*&+B+'%)=.(^1P/@XIDSN!/7NZ_+=-DXQ
M<A0CK\D*YOH+Z!Y0WKOV]-CR&Q3-E8IVXY9BJ#/BH[)4[(,:3.P&JGHUCA/(
M7.V48]T-+;=\P5'KSU@VL;?+<\O_/3'FYG?IF6='96.7F)I$G107B2];[X+H
M6'-EWM&5I$N]HE!/.^OVDWR\+%/MC\SJ\)15RN+(J=RYX:OB-HE3.XN.SU7(
MO?DA!#V"1<A0()7W":U5>R4UX8A&+&-A94D2?W+PG-?PCDVLI \+>7=UIB+,
MF2G[EZ5.+CAG.Z-V[7PHCNC$3")XU9CAP?NP 26_XFP#3R5-I6[BV/8O%+T-
MW0I-?]WKWYRBDO"E+,UV7L6:F*N^_!-EP*>9TK/"OQ# ]H)[$6;<PCV'"(5B
M6,T-\:"&4X,9RS_=[70U\&NW0*NHCZ:],76&9T=%NH7*;'X '!G'-KF 5CWH
M<"E+"^*"9#+EQ C^YIVB7[!J[M?^0^2U;?DL<<//SPVK:I_-C"6]4[7FL]W_
M$O5[ P696+*>0W>*@-;C@#]F;("543U<JQ=#D*VM8Y)2FXSS7J_5ED;4'M8I
MNK<G6SK0O/>"H6V7U5[=GWOB%BW,N"0JN($:DV0L,#=36&AH5:/]Y1+<K9'2
M'<]H_JHVD4QB_OX9@IDPV+;P8&0VE(&X*/R56!_>\D6/E<3-)*BZ0PA%+S"U
MOR%4<\/=4]VT)^B^)W^T[X=/A_B#M$0*2HU__@% G 9'HD0/I==VG^2OES1/
M\T.(2Y5+NSU5421POGC-VW',O)=;_'--R6614]YX$/^V6YJ&!0.Q"\94AW.P
MD!O[%*$7\9J0G-) @!_OYA-!QVZ&0EV]JGZQZM9K;K&^Z4<,;'WH<?E !T/U
M.D(<'V28'$>9MT 3B+.Z$#JPU0$+BLP@5@C4 S[JSFBH;^->#E;N92M/3BX[
M2F)MKN]9#O:9C-Z3W"^;U7?LQ3?[*I4[6@ALMR&0EV^/.,'>2N;KUTB1Q3M(
ML3+-$L$81C_>IA_NX;[)//9CJ9ZZ32+I&HGO[G2QZ<@,;S(YC1*-/X/D?1P>
M\S[,1,==J:AU%+&?$L1C(L(OIYL_,UQ_WZ3_1?"ODV>?NMLV=;9'W#B1-:ZR
MA97)4: QV9U -6]F9<%4^6KTS5UE*V@9G?C8SD&=Z(R1D3/=MXK)]D>O26R@
M7M=LF@84 >I\[VADZP9JUXIC-+IJJ64I@:)846.P9["6&'_$]%S@Y\JZ,6]!
MX;5'7?&IAWVVUQVU4[3U^6/,V;$$"]]E;^?M=#LU9&H&RKL/&Z+E+CEWS;B"
M_ ^NT.L&Z75BVR>L?WY4==D>_U=1P?4/;J8=J;=#./5(LYP$6KL1V+/!0.KA
MC,-4XECQ,6@3,PXCX1%X>A)_=-BP0F!6I*'YO::65^^,XG'C;*-'!X[U[[W
M=V;?EA"M+M(E(J05SO!A.R'YAV'\T>,YL""=BE'$&7=F*AD-X,V8+O".8+&V
M-K/+PU/+PD8/[Z1/WS#L=YOP&N]1+910<,Z[\8:Z93W43&MM ,'Z%QAJR9'B
MA:VT2+W1%_,L RB5=JA9D1,9^;(I8LI>)MZ!*<X*,V99N#[:N2/!NCN[3/[>
MF=:)-*Z,RQ2)HY2\@5)?86. ,6?B!LIN[Y9% %(G<J2-79"*ILY-[A^XJ3>:
M.E7<I@=9!5]YX0:K!.I<;B@FR_WE+)*_>&#M<,C;'7KEN/"%NXC)#Q*ZT-7
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MGU)P1;FN+).]N Z]78]N++"6R.&PF #D6 &/4 0V4!>7(#7Q]EX!PC=S769
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M \T\,>*$4+O+=8/F>R:U,S*PV\WU H\42H[;Z'WZD&DPRZJ3L7BUMS\V(=%
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MK7[RE7W>-/[>Q[<,UQBNGGX,LF\<B(1>IO"2+N$^S*L 14M$52[M=^_EQV;
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M%U D<CGJC9^ /Y!86<A]WGN<D80_R2@SJW/T$]O[TK:_W5X>RN/#.L&1UHI
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M6&/D^!_L_P"SU=RMZ3=\/H(]BA';8#]S_"EPF1(=%\LD5/7JPE"2+&4<BC-
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MXD&W)2CFQPA:J^,?Z7A2&Q]4O68/F.CN%:)5:SI(G;]HNS-\#Z?HT7++>:9
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MXKKMW31-R.BNQP92;C];G^K!+BQ,0S:@=["$<]B]LEY:)Y2^GLDX)\D$"M1
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M[9Y-(KH(D['NM0+G\3-NGKK\Q4:RK4%P8%O/],WMRK'$5)C XZ.<%4VG@?2
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MF'PR%S9X#X'YH[P5AA@!@;U?\C(B-KGO_[UJ^O^K<OI7I1W'&-R+;8+]:AC
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MK;6VLK7PTZ8*U258W9NZY<&!\9Q_'CIL=]E0,##TR8T'_'/$)Y+;HN0X>L$
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M>+0+G-VLH V'%IR1["Q\4=.7,73&:?NL1F[ OH1!NIKAL8BHMRR_)P]3OC
MA+)$J W%G7IMI/$(7QOXYKR<<'?.=.Q5VS:EWA=K\!]BAFJ<KY[X95LC'=4'
M8055"\8N3S9=0FN8WMI(6^\Q2KTW4CN_H<'*"]NMJ+!7MP3FIHN01W# I&IP
M-)+;GZVJR4^W,=3!J!/*'Z=[/2ZE-.]QVFB:B]C;-S=!)E .IDH_[,?/1M2
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MN>,/OY#0&N0HYC,%QKF^;C0Y1<0B.!6C-X2N>3?W+KU7G;[YH;D#T;1G9LH
MV$',Z.Q,O3R>0@ U>X62GA(&FX&OT^D<1'EBX[A_^L2Z=OL-M>"2K^]YXB$_
MK(XM[&DL=@WDE9P<2:WZO)%2DT0;Z*OY(.MA*64EEZEDY36S;@.^O?VBJ99T
MB1:K<Y$^Z:B9,F*<11%HU=38AEKC5]L[4,B3PN]O/I/K>7!>X3EK7[OTI7HN
M[%X74SG->*G*Y2,,@#,\ J9$F(WCL8\S7MWD=M!^T_U([)WV(Y4U!D#C;6O;
MPGDY:-NG [,V-,'"C'SI.2U=&3[IVHX^H2-N1X;-FM::.)O]<DH:T%H-CQQP
MEXBF:URR3KT<A'PW]WWN""3!2GRBP"B[=+K&VKBI;,_#-:H%!_L^YE'N+O=W
M.H_BB'$,"1&]37D.FP2Q56U&\S, W\O6C)TNHX3^;LM@JA>>]>.-\Q]U]+[A
MZ%J4=OK#=37M5E3B&;5N7\P4&S&2?M) 9W.MD,@,R$]8, !;XZB;Y-?!<XFW
M\5*QBG1!]R K'>$LV_K4-I)UL:UG*,^U<^(O;+9617_!GOX!OMO5?!3L+*K+
MIE#2@T51FNYN<[J;/$@SZ/ULWI1B)Z=<G#!1;SV,)!CZ[#/'/\H 8.2=&0 3
M@>IM>P>Y<0; "9Y$%SDLY.&.X(1Z$9\FA\$+_A9!%>3]YZ)=M]>\Y3'>)$M<
MOL4+?< >OM[7/.WNY7F^HGCC#8WO?HG:+AK=DS*7Z":\H*?@I ,&8&V*B-0G
MEW^:DA\-]#M7[:5T-S@D*B'R"6G@Y(686S=^7E =;VDNC2>UT#[ZHQ&S_(F#
M+W<ZAZD\N(9SS)CH;T/2U'75(]7G(@?V.9\\6WCY*#_KD<J?JZ-#5G%1:G;8
M*3N[ WI]!?_%;VWU:GL^\-6#OPBFXL[E-JXB6>%KX1"??;.[-!1Z%,H4S\I0
MPB8])L#>;-V,N-2&%*T&'G6$^.FC*L'LU&O#4#6(8L13NWCS2_L\GL WF^<&
MN,Z_=-A\!7('3A;@!UM\3E'%:17:?/,R/MJGA;%D<$?.T1\U BGN:X;\03*!
MT(KR[../?][[R"*&=;1]7J3W04:]MC<T'X5^/VV1+S16I&NHX&G35%63PPR'
M*UXR  G:M%S0&LM'!F YU-)GHHUNN->E2)$( A]8>UEUK5^EJ$)XYA#MB'"F
M7M&%(#DS71TD_JN3JS,7&VMSZ"MNWM!Q-1VKG[C7U@N)%ZTD*J^5_V3[2>]!
M"L& 4,E1J,TGJB6!5!F&8P $(19>/.9PKM\=(@L5C>4]$H@!BP0_T=]J-R:7
MSJET6SU8Z4U;E:ZJGY1F %)/CN::YI_;+N@5O+1;X=5+_34[T4LW'<25T1"V
M8'J:O@T:"/K3",'0.]>-&0"CO"]D5KQ %(P7]JM>OP-X;%DS<2:&B9/_YM?E
M=,TJ8LGO\>^_V<YJ.*I,2$A_Y+?$GOMSRM>!=5T<CY[LZM*12.T$']N9%9[R
M$*HI"0HME8K;N(P],XPB7.!?.0?HVY^Q2VS<51FM2[]J-#"@NC-^D(W:'/T=
MG#9:YKW2[1;"M<Y$=7&V>99R45.-/OH-7@U@ .)9"4Q"1C."&8#\+8P,18_Z
M@K#7F2B'FXZ.S'/$UD;212?<!/HA/#QF)]:']:L1/X-\LX$>)+-81WDRR)/
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M#VZ! Z':0RA1^C"*FWA\!/)4W.<3.:LUXTS\8/F2G+N2V9:F&*5D[ ;@R+;
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MOQ0OTZS\-X]O\M?Y5*#!.;'3Y&H&X%(+(6:Y#+[L] !8N42-8P"XT6NZ60R
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M;0@, ,F('$H8),420>MB.!//AS$6Q(#R>*NA_G;XY$+OG4Z7!#U@G[R@5\?
MJ8I'@ G1R7\E&_C?EV3<O%#Z4NJLGI>LZ%"!]-I&TUT/.=?_#1MS,Z_W_$$Z
M"\5-_F_$S&T1\?S_#YV8!J(82U497Y#U+GT493;3QO^8[ PL8:J_Z$!84I#*
M%$2@U<)]EJ@^FCMU3>'BZ_I.+K^_9G]U&AU_47GR_N:[MF0R-YWT8<Z8B4":
M6=,S*XO",.XATPR%P^=*/R?^UX^5_MW^W?[=_MW^W?Z?;HS)_P%02P,$%
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M1HIP"Q!-$=?12Z,MKU4^GH_NUUDEK+6:-A]RI7-B'X=SK;Y]QD#TZSU ^@[
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MY8A,!_E4GLQ8[[AKXM_"<L3@[00_?-?:AJFV,#_;M# @$B*!4DC>$"K\Q-M
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M"%W- =D+<:S:*%_$$V$DLY9[L2+?6/J\*K\!7T^85CUU=65G[)K/JKM5Q#Q
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MD?';$9$B[-^(-YU/>(=Z!]>3XD+9"G,CS-JG6FVYIN/S][QP%<2D*W[]*!<
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MIEF^-S$_:VQL^O-G64L)G?3[< G!<3E)@ $>9]+ KF4*DTZDX@/L\#*9(\0
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ME&RE37* F:".*HG^6:3E].4.0-9*S'6 JL'5=UOL8MP^@]6TTV'DD]9A VW
ME?8T)V%YD97H,F=JC'+KMX"=A=RTLU@^;44?-O.D/Q7C$HPL42L'7Z"T/14S
M$%JT@+.CW_JA]0R</D/*=$?R0;!D13$95<)C4+/2J08&)R;]=N@V\0[PD95B
MI2BH0I$5[;@QR7UJ<@>PF*XDO#8L*WVMWM3:*,WH )0CE+.9RXO"NJ) L0YU
M@ES_%VOO%=94^'_Y1@$!05"0CJ "@B @TFM$I(F @/02D29=>F@)14!J!*1*
M$>DUTCN1WJ27T"$)17I"#1#"X3?SS)G_S,6Y.#,7[\V^RGYVWK76YYN\:Y-[
MC\SC24(M6/BG+(HN2E<D0TQU6S4:@QY*?5#;474M=+B4'/7T]V<S.GD<^-?Z
M-F[DBP(E3&T"G91B/R/5(](=2%-:^RJNDX%P^-3>ZIAOMZA&1]GZG8[R_1M7
MT_\]<CRE[%&HJ9G>/?Y)9A6<WC/EI*<_[E+3W[8[U5*WH9#P%+1M2GNJ^=ZC
M3BZ.HE=QQ(2]K.8![( 2MQ'N F$ACD+OMK&9YT2!:/%7 -#X6]ZBNR"->FP[
M,WR4-@C"%_6DJO$5"2!J\2M7[?7MAFP1;C5=_D"LE"+N&K!YUX^W^)QH<]K3
M!=?:2/97'=IO'BP\&I;WA:= :,&C1N:J]ZMH!;_V<W8$.EYL!U4.LL2/9O@)
M .,)E6@+'7ZO]64#Z+OLZFR8_DK]62<)K,D1B7"FO;$8\ %_S\T'M69?FTU#
M7SKS-6+DQ:]X.27DZC_9^'1"#IX%1Z<A%N+HV_96: D,3!8X3D$M=[47VU>B
M9NI$ZBNY/:X R).AS[8L)C\:\2>&/UH$77Q&B8&>VE&6DS4Q-YA[]FAD[JH6
MR=TS/X[H:I:-1 4JKWUZ'65K],.Q:B.S3!%P"2X!8=]ESTX8XR71_0JB!)G@
M[(ZYJ;\P*%F#K%CI</DW\L'[C0MEGV_TP4/$@)'O!%!LPXEK<[2+#PZS'!.2
M#>'<1SM0Y=6SRV?ZS/IY>R.Y<H90=$[I$!QL,=$WU)78'AW;801MP'VFXEC]
MV(P@Z<>PM0K=\>^I,A:>1_ZMKXUVD./+"ZG><^+]*]6_:AC[KXU;\F^Y6/>@
MNUL&1*%VLV[?T;]0T])3LEM.D[TTR_C--S>\(5SW>T&N"GVUZF29>SD#I9?\
MQY-.E6S5@P#M.QEUY:XGD71Z[)5DJZZ"&4_[]D-W01*?3K/(I@0K:C)%NW@[
MPS4**QO'X%%;$C3,EM9?)5;2^OC_!*>/XVD+'27.57)M*HS>GDA6I1EL[5(]
MBR:6F:JI 61^A0;'2</?5N.]\NVS^,VM.J?//\Z8SW7;E]B[_V%^3JY@S?LK
M6\<BF<XEP7E2\UC>Z'UA>#E?CV8LGB</'-$I$]8;$:#N5J'!4])_Y\>"LXR5
MR:TSC@=YZ+=V+,?E19!G6R_ P_+R8HNJ%S)&%J1AY3%Z^4?.'1&)%%L#5"ZZ
M;MT>"I)X!$T2)E"@4X&C,7E+:MQN4E LM?OO_F- O&KXC7=!/G9UTG [G"T,
M=05@4*8W4WW![,HU*3C+\ZF"K*,D=KC/+1G@,A\\W;)@;OR^%IUNIU'LZO=K
M="RZA[<KW<F#NUJ\MJ6ZFRRS2Y"1JJ+_RQ9!S2=!/[A]=]20%VXAYB;3#,B_
MR0  >,?PG9#4W3&;\NK+4?&E^$-D/SV!4^)28JV,%JT"K#^0]%>\I;FA]$9$
M[5!$JO^-V= B.Q!&>!5)4MT_%>GJ=_WA;*'A'@0G/.;3(6]:WB>:IH+<1]=&
MT4CS,5JA;(;;SS!SZQ3"B]N/_("%AJXD'!#/=>ZTW#U0M K9#>[@6XL#PV>A
M0:!;GJ"@:W+'8+NC!8>.NLRVZAW(]RO4;H0D2*N="V^8IY:4W/5</5;08XOV
M*/H)<VEJ5/V("?(%>'(JFBW!P<6NW*$9U.D(C^>W53SFN8KA$KCA>L:DO+\:
M?,]:K ]!XEJA1<>RGT8,?@4 <;UF]?Z-J1RKD*0S/1RGGG'%*E<!)ACD1+#"
MJ7FG*SWJMP)E*(A-D8Y?0^H+/^CQ]F0G:CRI(C!.67DY]2 XSPQ<W9VN^L59
M9;,VT*7S[=<;PQ<_OL?0]C?"CVSP^M9BMA-B:N^=JVM#IMPF[OXJY)AE(%PS
M3+L4A-XBP/6R.>#>SV>"XG'!?L3G4^X*^J&:;(F\=3;S,!/B@0+K*SOD(ZN$
MX>XS#(MT-X0)+20[M\Y/&<#?VYBVF)=V/H4=X9S!9ET@\OUTMB"M L-M[!VC
MFW>327UZ74):[Z62'-Z5L<IPUP*6!SCE!VK?=OBK*])>0!_<7/G/\2L^$B>,
M0K;O4RP07N+K*^PA;*-E>E[3I:4+2L[.3+_M*08KB7<U.#H0F:"Y'T0:ZM'=
M/5XL?$<1E4I0K*F!8C/Q-1IV>=8V/G/&L?5,J7(A\UQ26\KF[#1<]WA8[SHM
MQ=+8>)P;3>WOU-P1<O8P3A:0E04OJ>^YK!I]4-;G3N,.(&,W/*N[9O$[*5V<
MD9 7^,@"A6W@73#2?'HG X8@&UH-EY3+;OG)V=-*CH'O:EXH$R?F\NH1-3ZP
MVOW[W5QNJ+%'$RU P.97SWEO(^.7Q#.K[:RD]7/EX?1X51MJ'65J-:XXYB1]
M?<.@^S?".*8NR,FP%5QD.FB1!_KE,R?/O8I'?5P]1O2TD]7=LO"8].V:Q<=:
M]Y^VG\ UJ['#266H%="3ER(-G"D*Z+HR.5$/1ZEPZS-D&&\NK</%>5+N_3V_
MI))#@2YT^1'E[:!29+W?9'2G:M" -I)PCK.8*  ;S_B6<ZA9 "IRWV*#FUH5
M'^\8C:3./G";:RA,+2IPERL?*ACV5\1> 0A<Z<_CO_LB[T6X+0;&?C[?M"//
M\NA%66RCJ>Q)F"S"U/\<[0AT'9M^G+7*;HW"Y$A*>_2=EFCJ%/SRU230=$=3
M(Z6Y><BU!$;ASF?<A@^\[KUR=]S$CBOPB@_YZMD]=9?JPSSY+63]3MO-7'R4
M^UM;(0.,(]['3>'8H%VJYXZ_Y^/$!<(/F:%CV\<N5K&%"DG3_]HXF]H:7]]+
MH/(\J4!V FF%CB46_OD^C#GL\4..2RC086&=EW?!N;WUTW/F(76D]:]O)351
MH&'[&H_D^!]R9PFD/,A$83>;$FIAWSK6\!E.<VNCZQ#. *%61/KSWREGWQET
M1GA)@.-M7['ZL&@Y'W0!7OI";-[8@<@=UN&8];"1K09ZISV^R33M!I7\P+&&
M6K2";P#?D#?G;>(-@O5ECF!8][G#\IT *MX%FQ@E=+GWK94RAV6)3-+0?;J
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M[ZD^4IFB:@Z>X%3\)U W)D=6[/#LI@IF)O32<7^(;84FVSE$9?UCR0WRXA4
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MWLZW:"GO;^-+19('M!6.9[,?-TQ<R@V](2BMJ'&QJ02%TLOL +YO<[UB>#.
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MA,F2X;.L'Q6@90TC+5V:N=)D/%&LA&6ET_K!(+RZ1)!O-(O)D<XMZL7I%GP
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M&O-MP.,/@-?-S&7?J6YW"VZ!0B]]KX@4\SUP564/<_M2O,X%H.0"@+0H*26
M,:(_LUA)=/!8DY4,S.:]H/!7R0;&&A> E _M^?F)!J0[*D(!)0/36-'N77CM
M>B[QUH_6RV(JMU>7+3XN?)60]*:6[=&PY(DW)=,TP2[UN&54C>$,%,ZIILR/
MW?CKEKL^Y.2X4]U $(WB5)])XLK1DX0\&*D:9)>!D\1009XK!+(S^2GCS0L
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M%F0UP#0ICRNHPXA25K#1ZISI2R:6@&KX=X;GGU%-1^*99UH+/UWZ]N>->3M
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M4Y?H_7 !"/Y"@\ 5!PI?SI&Z\%+U?_OQ_0+PF],L[W(,C'/_4)C?_Z0PA@L
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M4X7:]W\R3@D8SH?6]*3MJ*0R6JN5&!C0]IX=Q,DU$ILQTF%^+[8QKJC[[GV
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M36#F9-YT!//$5E B-X 0W[AGZ6*K.>VW]]>6?6A^X?&ZAO/S@]X-2)%\BA'
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MP>4CTEN411AOF32VD);0CM3'C]#7[EL\0GR]P_-,LU.[=O/+I:/O7)Y#[YI
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M;I%H+L/+Z=(^P-Y\"-OD3+B>:BV_F#YG-.)N[093[.$TC/WYEPF+02[BJMW
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M\/%#X<<"0BR" H\%Q!\_$@/T;%W=7YM96GFRR%F\-G/U,0. 2Y\(_L2%PP'
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M(>;LE]5";XV4/5#.MIQVW*/>+*6]JQY/TI<KJ/LT65U.,%@[0HY<ET/>7U6
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MELG6.44B&;3!20&99\T7<_[K!_BIM1/+O8HI_B2:FONZKFM\OG>E\M&"UH=
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MPU_&Y?@DU-X:\_3B>(D?!R3O(_B+'\"R!X<JMQ;#-QHGM\%=MF=O+EQ6?'#
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M0H^1\EB+-NX5II_E7[H4R1P^KMZGO%7 9*V03Z30S:7KL?6@U E_)Z7 3G$
MDD51D;L0&7M#IJ1DC7PJX7W_]UX& *[A .GH4*G91TV?\-/GA8V8?+XT_ C1
M@4GM0.21?T.CR1=M-NARU,XE?HD:LF\$=F5>J_HU?CZ-3)Y<])IA\ODP;*%W
M_FO.7P._HAD-86I8F.VJ14W9P'I&8P%JXY,5JP&4"*0[HIQ\VO0'A(GA@#FO
MV-4F#".U7BGEM_["5%:&.M"W,?$ M0OC]W2J*GZ1J&._=^E'GX?4[SE.O=&C
MD5<O/*O\^X/)?RQ,>?6@<NC[M"V[<GR7WG^PSB:CA\ALAT7JN*>6,X+V3&5=
MN\9A7=G.A:?$F_VTQ*].-2<".^/F^#OO9$J@&9#+W!<-IX-[ 083LTY=JR=?
MKV7[;;D Z.KWS8N]G.6&@],/C.*",#^'M<3<PG>K%KUV3GP]L7+[9"/'\_A\
MN"QZ1/K3E/,4C+3V3-U:7^I<O5@!FX(SYH2K[@WUD7H)C*%>  "1(NCCBB+C
M#L5_X1>@\3[RN";A_N=DXR" (YJQ:XWQ6E5ICN!Q6ESG?I4X0TK4E@\<JFGC
M-;./BCST&I\M/0G_=2ESQW0@<)>\^YB_2*99ILNS?[*YZDEROF391ADWW09F
M8MUJRY<^, OK<S)1CIY;9S8"JT(9RUO57JJ[#\*-U'*2S]O#0\HN]@(*G8^W
M1W+*94(17DWKAXDGHMEBL*7 RHW Q_.I2&+]E?&1?=-<?[MAP<ZB1>3R5_"[
M'.?O]R U $ :_S)OXJ6QWKV]O_\#ZO\AET9 ^D)490WQ;K< IBI&FYZCF?W/
MDJ*V\?X?T;61W:4>-*VSN4M161[)&X\11U4K,- A:'"+?.U]A?07#/.I:0W8
MP!L'; G'ZM^L_\'$>:Q(M]&UCP.^J.<L!WYG;OM8?.(V$&@"2X==-LW?&ER'
M2A ?X0 TX=>!BQX,37WYF2+DE+X]R)]CIST$T_NF@@Z)",Z:[,OB7(NBK*2$
M^C3[W5!B5-Z6]M% (M9-G2'QCP" L"AST'._M-*\%23[GW@X#GILD3EGWH(#
MHGK27_<7[OWPXJ"D2 OFD!.B4:"^R\:4N)%\I6>/T1I6U>ABX%?8;Z5]HVOM
M9$IF-(YPZV&VV^ZAD'%XT3<S";4$8:5)XHGC27?A:?UBJ]B54_\*I<JI8[J!
MQ 7O5L,U[N;E]=;2N8UB#'8X0*(3H2T*RSS3'T8+_2K./ULG'_9'P4HNZETV
M8;)GKNL'.0O.&U>3VM>7L)6!@M&7(LL@8"7$UW,4ZB6>:BX3B]EB$G>J;CBT
M6>S&K;_S01JX_#+Q2ML-4RS6]36]S/[:_7&)D8@ON0]3 \?&@'U;"=Q8]+J6
MRYS!5N_/650]>D\S1]L5DVS]=;]>+Y ?K'LR<S'J4H4<EAHD5K/+%+*]W\1+
M:$D18G&7(E@[*,%6[MZX:4R56L-)_X6-ELR/2+F_B^B-JA5H6@'_ZM-5Z:JT
MO@_W*0B??HFG4F<EM)0CU*@HGYEISHR=6VR].N^:R=S?HPUAJF$=^9AR/!CC
M5&TUM?NR:CJC]?PRX^WV7[OS*:LQH[YE5V9LRSQOP"SN&TU&BLXRO@N?-8>Y
M-,7)KF8=C&^]1@_FGXH*=DHQK,[%=$F_..8J1E>O(ARPN@YB :E:6_-QC=M5
M&1BI0*4S4<,E+YFP\T"V/5^)M%+W:9_$.0_!ZQ4.YWZ#3\P<ZDP>5M I7]6_
MOO%S(#=Y=O+[I:96U/7+86JIUK<&1/1\Z6K6. ZU.&?'1K<K) T_?:#@"(H
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M:'S+S0B40W3 :DR"*6X1!\!;^5>06U@ON'0]6K8]/B;B"MU," DN!A^#B0#
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M*!:/'O$_=63W>NJVD[;G<TT.M=#:LU(<YRN=;ZC"YMQ4=M_[3$]&- *=?%"
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M!R>3 "AO3D7F;8\(B7[>QIEWH[ADM_2%,O6TU5:U=O."A@'I>K6Z#C8<G[0
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MDM:&6#8G)_=IE1L.4<O@GD$3=$NPKDY:H_KQ.Q)#V:JI&]W,UFN'BYR;SX%
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M_ #'C0NO'.TQCQFDEX*Q@&GS>TX>;*R0T.H=9TSL@.@S-'39+W*(=HM-8=P
M *;QDM?<*COL"HU4"$*M93@0"&HG1;) 2+2,>T$G[/A3EL3;E5A1@X(4D!/0
M\VQ@]_WO?EC8TA+B!$#$IQ@U4M<UEPN0>7AE<'*,;$F@%V3%?=R58?IASN/R
M@8XA@U(&ES^0 !#U'*F;-#9AGBL"V!ZW%27C/-G7CPU4VK1LWV1'LNDVJ0)1
MT=3(++\F!6*:B\K9K7+&C_9K[))>ILD HU7IG+RD\KI-B2<O*!P),,^<M'R_
M7M.MO!=]VU7 F$);SEEY[LHK<#3)];I>EL^3 "O7ZR&3_T<4X]0,SH*XL?[5
M7()Z=B$'N2<KUPAX8+,G$Z I:258FKU%BE=:Z$'%3ODAX,J0;&^"$[UN7&S%
M3U%CD-6(:;KB4PB=#&H-HMVQ68FL_"S)62JSJB%/$4,F:<1.UYN.+N'53ZH@
M&/8E331E0EZS)/8U@S%SM!]S78EJ><E7*=_\U.UR'XH D8+(;H/\Q.9H^//M
MA%C__6CQ'*:Y[B*5NAN^Z:3,%5=:R<#Y?*G@,^!T?K,U$0>J[9QCH:W6Z7T;
MP?%4R]I'RBH)+2,G73P$_H!<'^@N\CB!TVTU3#R(0?;4*(YZ'!^.:\JN2<J*
MN_D,3:OXLA3_21KI"O('LN?/%0#ZC? 'HF$N^@@ "%3<WAVE [;/ 8")BNWZ
M]ZA/"NS !"MP^QSV=O62)WO<)@96Q/67H.2 C5TPS\F>^R6CI+G!#R!:'.$0
MO&&K26EXA,GBI3AULI3DI(2;'<XK*QL&N?%;AULLFKSWXQY%B6^'$<MIP>.#
M[PI=\:LH:A_!0#1-$?_P'4_RX7S'"Q[/,\^;UOTRK 'KL5R11=.ZDJWVA\'X
MH*G?073Y_0%TP(;4O,L%DK&G.^*:3%;TJ/+&@]F?\N8]4T+VN]%+C4:C!PY1
M8XV'6\S3K &$X%B[+F<W!<0M-YQ!P$5;RL$&[YV'N>:0K6=^JN/8ETE9-^6V
M#5R6@Z=X!A9)7A9TLP1_ ;F4BXXG/4.XC;H;00ELQA6H&PDWGZ1]"63L$'\P
M>J;AN?<7Z(&0:+RJ\S,%^8.1I8T,:8'\]"U/]<LGA1T1"LK/3&TR0**'M/S5
M&\]];?(_YZ:R>P9W;(U,ZO;OXLRH>XFL^[DUK/F?IBC+#![<'<JH,_)(.>V!
MKZMN]-Q"4]0N@R C]M=26Q$?D'1>*]1C%7NBGBE2CJ=Y(OT$W?L$4-'$IH-S
M3I6S(-Z4">JS+5G8:96Z=!;E>8#X>^%1GHAWM1WX22YDODK,C=T@M2<'.7RY
MXY18>@5,Z92]@-[6;?^MH=KB%D;H>]>7C:4"1S]-DR+'O#Z]:_M?C+T%4!Q!
M]R^ZB[.X+++X(ED@$&RQ ,$M0!8/[NX>( 0GV.(0-,&"LRSN[I;@#DFPX$G0
MD 3R-M_]ZKVZ_UNWZE5/R_SZS)G3I[>[?SU34[L##R;^^L@E6B!Q[XQ#J87F
M9]C2L> ^LP3LF]7Y4^8^#L\/!C82+M_)F\]8@1Z>M\9]X#-@<Y_\EIR"+ !N
M"0$4M0%6G!?$>@O,K[R.R!FB1UYOVI@O5[^4QP);'0*:?6/U1_JPS<3( 7R
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MEAX+F2&;G81UBB)5)RA@KIC)4N[9"G8&Z %WPNGS!5;+'T9L+U2(2D IR+^
M9.2RU]O:RT3\.ZP]H$RQ]U=^6]'"&P!0_8M"Q%M"+EX>/A,F)ZZ(65@+:R49
M<R45.^>4X\^2;GK5JQP:4<'!IGUVZF3$6 1W 074P69-/6P[4]PZOTJ["M;
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M(R2)Z<_46X,#)*7;RPA/@VQYVXD8A/\<(5U$=G(V."^PW'3MP[D4?9ETON(
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M7-0EF]6TJ#M1="W5@_8+G-<FY[@*I(V[X%"C<QQ'OS>L,:]-O$E[:V]!\+N
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M.@S7%3J%JHJ/,41]JU/AU=A,H=@)"2S'4=7X$'3(!P0H@L"6A5@S8=J$>S,
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M,9GKL2B@P>1#0J$/KB62- 83]UPS? ;.NT4ZW1L$)1R>&D(B_ TBD%Q1AK]
MOYZ6W:%T-UT3?A^=]#$HY!H0VZE+AF^(HE!>4HQ3%OBU@'!O?%SJ&4Z@?AGO
ML.@L>[KCQ(LEXAIXXSK#W(*)IZ^;@P(?[0;A4<0I4I.UNSM^K&Q.XA3WS)Y:
M\&+(6N>J58I9H(V1D0&+][4T5V]B<9+:5O=T;,0%*T*F96V3YNUYETV@")T:
MFLMH+W,#C#/NZ_ZZ!-L"RXQ.RV]X?!AM 7(#!K?)<MU..ATM5@"_F_O:&5/6
ML-SP/9]R!_+Q(^[9;\:L$I^W83/UN;FC7$ K*02=Y(,GG2 =M**6[2N;)[V)
M3Y[:Q7N7%27;*3S'U#N@31IFSA$YM>?,5MNY]XWU['PN4P4H([;E4F^Y#SLI
MO34%AP4J2E6U63416O3<W1=:=I[YID>;"WG=)7(-H)\O-L&$L?:I,O5+[?<F
M:KIE*P577P.J6B=SL-SIVN[QS1ESB2ZIG3D?G?/9 _66U7>7J1R7%7:K'G9_
MD3KMQ9):]6[CG)WWO9(^2YL/2M%Q2,+07C359W396QW;[@[1 A6U?84$.)_7
M=STAPL^=_-@>>SKTRO5YQ),SY%DRL-UF3(J77;3'>R91R#"9LE5Y:&U!GRU)
M/;C:](*.3II3.*L?C;V3&TG*/+B>)_,Q-G\8<Y<Q.#KZ(@J+# :E(QE:@3$;
MK!>)H7BODFJ_-CS;V>&W<'66GJ'4EMKD&(9(_93%)UXT%GKA5B^8-W..].]#
MU9^G.EC4O@23G.D7[(";+Q,D6M^GH^1T:OMW!F1-5IU\4JNUG[:F1$=HM<^U
MPS3NP\\,,G/D,Y8K1(=$M%VLZ@G"4<D#&^_<;=FG?$N3[=\M^@1ZHT@(P%)U
M3VU.$P8[38=V,>$#542M7@BBFD>=VJ('?N1+OAF^=L<=' OT)X=Z89B51+D8
M5.*[H<Z$.C?"V:O?ZX2VH>Z25!;M7L=X&4Z:3A+/*6Z/MG26YW)_>%;=ORSQ
M*Y[B[2^3PW#R9IMEA$GK!)@Y\4SO[-%(*TVYB(+"FBPBJ:-NR (T<(4TWTQG
MC!0H:=8V[6I=H1VI)(U+-1J2=@)89VH_#\@J:56J@<?[!Z$RT$3&8/OT0$5.
M;*5&F3XC>^JW]19;':82-.>R963,6/86PJ'.I,)L -YA_D2 MN88P73$H6\^
M.'5/>LU9I*9S"::X9D[63."0KO2IZ1K U+1G$JD&UZJ;I(A#/FK2JOWD79"_
MKCN,898S?^[(Q*0SMBMPE*AC.V^;MN@T/_?=T53[K6E ^+;N@C9&$#1AX=/!
M37$LOE?OE6(1+ZW,R()OA\L?$8Y;>TZGZ>M;>L)(D05?S8'8O/X@@U# K,-9
M7[^_:AF1GOA=O'DF'V=K_*2:L\9S<6&FHZ878Q(D@B:GE2U9<N^ZY=CPREW'
MN&EB%NNG#9ZN72S^R1KE1Q=J47WSN+)H^X*=\5.Z%3?SSEV)PD-NP=N^PTH0
MWBK_Y<#!M$NP\6Z,V+CBJF@*@Q]OXH1$353_3V[)M0P>52;TSK:5R(8=DSK9
M0!=OYH?-4$I*^O5JQB-;-LOW-S<3H\MTY.8ZQ\#EG*]^PJM\0*_D2MN"OS6P
M:=8/8>AJJWPEY[.471#L.^Q:0I=])=Z8%HF9N 8PY_10V0:*'#&=PD$3**I;
MWW?K*1*O 3%RWH>+/]V3+,N'4&3TUB(F Q^Y!'JO 1,2]DG?,!V%K&963YDE
M3507DE BR^+. ZT/7=V]/I40]>6M9&E7%S49*]]?@VF)9$[8Y5Y029]7P<>B
M'<'-G[Y88A^&@,K*CFAA7T<)'_-H1HC:3*/:2$LJC27*:YPFJHC(2>_]V;TR
M8.+0U79:'-IF_QC8X)!*>SN%@O4DYY"AE3TE>O9 [V&#ZIXNLQ!*FU&$@A^/
M\_R\U^CQDV^V9U,;@Z-?S;U^$0.(D#<9!Q=L \+Q(GG@S*T_FR7\S[%D7-,F
M$>>?F1^( 9Y,C?UIG_/Y25F<]?XB_+WB_I)TEUAG N7PJ&"@7P8XR;$_$VW$
M'L'0G##G5((JY3]*UX"U6J>]4VLQE1X>LTK=J\(,D=76U.P]'BVMK'\87T\X
M=NBOH$3I>GJ,LOF$5 BHDMC(GQ\U4%,F:RI,:JY?F=B8\Y /H6A97@\)MFEU
M>N4S()?'3LP#-5 JN#?H\XI=-DW)_0$^0Q_'642,PNAQTU)XU@]J?/3I]XV=
MYS^XW';6MAE* !5/PQ]8XB];*-:3[ N3T&0N='0K&UA2D\ 1'A'MH_QM4S?#
M3J3&#!,)L9V)0-^35P]]<=-6?C,C37TY2*#^Z*3B46-(#51Z/!>DD$-_53II
M<*E3RN.AD%.]%2!I/DWOM#)U[M3U]<\LXD@AI_#?LD0."9E%L?$MZ0)FCR7;
M'%*1.??/-ZEC %"NZ_$WC+#O%N<^2.*9S:(QPM\0UX-MLWUQ#3B"_=@:WR(G
M=NEZ8M5QL'YC3R:M<H>'R-A\4\"5T;W>YJ@OB22(=]O^TCW!6HI9OFYT1L$Y
M'@@=J@U4LS$Z5M(^I+>EM;_3#S0RUSC,X(C+<VPVZL;PT1;@Y LFGV_C_W[Y
M5?H=@=1F92,U^9?9:T!\H(*-X)O:H$$$+4J*M=ZSB[.5YBQF+FJB-<HOZO2
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M>-M1GU/-'P6OIQ%:)*N^RQ=JT>=<AZ7"L>)'% _='?0+?(/4MRP@D'<Q\=<
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MR=796D!0X,'/KBYO6_.5#O'B_<"'V?]M6+TC!$\W6CLA?>CP3"SY=\'I9=\
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M?@8#4)!OIWG/%>U!HU&P_QXU.^3O!O->%0:AWY3\,F>$&KAXE3_AK[K>XP0
M=.]HK5I1%U)+-O9L_.XTD2G_YDH:FO<#Y'6?!7)^<8L3_Z'R%_DR'F>+HGN
M>P"IY8&6>P'=;G?BP915DVH,90TNPFD:0;<!=POR//RM\0"_R:%U=!K1O-;!
M6W2B/[3U2:Z>$8?P?,H:S5+^##Z_%4%5)L_&R?890,F2^34MF),OSS(PU:2'
MDW='K^5!Z*KU74OVG_;4@GH&PE1XX272^MR_S >0D$ZS:@BTPF#?U&.*U?2)
MJ5F !^*Q!;2P&9),WXW_V!ZB"S'8+O]S"S2MR$7?Z:%+=J?:5"FPFO][4C)9
MY-5K=D4+^D[BA#U)882NGXI '^PQ&\""O(VD,UC @@$O5I_8H/NMTF@_/B D
MV'Y4TRSU>0]+=(CF;1%?7T(H$QN++BGQO6<>!&^[E;X;=$^Q,$):HH,!9Q%W
M@I4_7P.RN^UH]*7W +PD49J:Q@OE\8P<7P E+)DD>(CI*=W":X#+-<#M83GU
M%3*M_,?C+Z*?K#C]$%KA!'=)&,6F0[<XLE&Z%'.2NAQ=;^]M ? !/$3,T5I3
M;/:W8O%XMCYR="NG*;(M/E'DTK_WA8: ( X87<B^"6$P"YZ>AE0LMU4R&DR_
MWJ+']_% W)P!#]WL/X38+6@MM )B$(DT-9@"^4UOEX<[R!OXXAUN8;=(M@ 5
M9\MMH5!\"'8+0'D/T$*\R'?DTMC-MRI.6!$!_&9Z<S5#*DX];GO<]';;?/BX
M4/A&6&XKTS)]00@MWRJ2+- E\X"8>OC\-3#XI;4Y;;<%K99%&)C8G131MQAL
M'?DA#(C/@J,CMLMNM86V550Z^VY!*[Z3F1VA;XXX8E\)0K+5Z6$B9&IF:N#2
M0I'7S5_>%CE,;%RVTKX<O PAZ30+M[NRM*.\"09MVR+U@)@7W/074U&.G+;H
M_+ME(EZP_4W/'>=__VW?3@^#K>.*:=S^X]>%PN;E1],HPD,J8@/<>4498?7F
MM.G--?.=J:WJL;-@.;Y96P7T:/HF[@LB$OPSO$@HR"]BS-20- 'WZZW<KUY7
M2GI*!A.58&?((159N$JX,G_Y5%$XZ93.^028&8Q'>=!:CC2D/ZS(AMJU3(]!
M0"93;':MY1N=8Q!A1#]$6/=..=*<Q@>1B>A_,FWF@8'T!\7"^&HBB'01_4K3
MYC3^!E:0/AJ,P80K9>>8.<W-<\ @D=7J^Q%Q-%.X3F Q O?1W01PY [INR5O
M!9'?<ZDHHW%/^.O4;\Y(H9O4AX>!#("L;A.9$AGXOV"S.^V!\9U6K'?&@S )
MQ/DPD>K$L*7I3=\M^JU[T')\W81@U='>OUHUEI"2O!R/_D8L%"9C+E.[!@@U
M;B(WS0*9/%RK8_]V,EYI=U-![?#H;SJLCOVKK5?+M%:,=_QZ/&UED&3.Z.^!
MF4XRE*<PN!$0_8I$%4SM-EUJ%87VGU7"0T$_[7Z!WF?:%TX1@-Z3O:>_)(2&
M09Y4%$Y;?:=1)YCJ<C3:+:>9-ZS\\IZIC<*4!/).KTC-:+?B[U8VS]>STW\]
M;],Q)4$XJN]4. U_G#-LYT.H3W^OND,+C=BN:_3,A5C[[E0[S1\M&+7;0][9
M[0J9-M/,&[5K(-[Y_DLV:Q?DKUM?^CC0*=/#&,5JFD%-W H=J0@EC;@E"'C"
M_<2T.<24_)>^EU.4Q_>]X,3MHB7/?(@CVC/O>\F!?</>9:GGKAQT<B16A[!=
MB+_AN"<L!3I\?3,#&(^C=.V*U(3K@K]])RKR,(N8]J4U^&4*^0^Q\+]$[,G[
M'2[CPO PCXQCFTTVD<&>-PM!DFH;>#G@Y*O*<?OS>NGJK=&-K@JQ[/^7ZIZM
M0SB?_&/8@=?!0 <E^I.TZ8'FX! SPK1-D#<NBIN9[O=@I27%@_XWI5S@7_<=
M$$_4KP$LT?HS+=> HD"#: 7I3X*BIB&K:^^-BHAX:]B-;*1_BQB*IGZZ&]CY
MK-7.S^]V1OC(&7_P-C%OPK<[#_JDJ<K)FC4:V18TGCG.YEI*$J(&:&MKGBV-
M',;O]_B2,/.$36/%W!Y",*<14QXTR#;AQ7JAP3IO!+9>Z!7*N, =)8)]Y[14
MF@;NJ?%Z1;!UGSU%2S+#/N5-S3SGZ'@WW(;9FH&)QS6FHW9&"0F>?RCT4#%3
M\B3N(>];6L?&A7= WF.6M!P#U[=?(".N;[!E?<(?'B'X9V+1K;SLE DCI:X.
MS]4F [QC1IB#/SY(,2I_<-\6_O(1W\8U (XLX/AU)3W^=7I!H?1 DYT_.0&^
M:A'?SN44PTE+)]H_I:F/Y"6[5U&VY @M*CO=D/O<\8 L?/W'(\Q==5D.3*;,
MK<G^;RI$GMZH^\]_G)&KE^AP<[?7+\4D"K]+Y]+JA\M-V*%?*;B",J0&D7-O
MLC0-E=O&*^@+C)S)X?4&DXA>@;K/"UO^L4+L_?X>]&\'5:\!S!]X^F]NK.]9
M!=!4S.QL!:Z"J;?N%VZ8_RK,:N29YMWW?L31UP 48%@%N";$L')IL/'INVGI
M&-?DL5NNZ--7NHO?6\Z0GXM+'EZ5&.2NO>17;6VRSF"/MM"=M60># <\GL7=
M&?OSYS8#$WS"7-OJ"$O,=T9 XQ]+#GM*I*:DS%+\,'U" RME=,8AP!NS/G)'
M_3GM'U%&L5+L'+B920ZQD,1D+S4--$.\A-!X+P0/;KL@,YCBS)WD?*J;!>41
M"QE,%;OP)%9S)W^_ZF8%^1]2:/CG;2I$"SE!!G:SJETH^+'242M!X=[E"&X.
M,IKLKD/7F/SV!XOERI] V#<B@2\93UH!SFMEXG.-G[M"XPI3K@%Q[9X_Y0LG
M2"H^[OFR3FVTY2+T8[?<3;7YO_9[2$%+::;6_T+96ZY/0'P_B[]86:=>2I*&
MZA1_?%_LG:2\RY-F0/!!$R6S&ZG )59#>35)%,O?<OC%[<X.S>IPJV>3 E9?
MNF>18].#7_S'U?JPU=* ?#*$W5DPORTJ(7".G67A3]Y@'D$\WY$71T4KI^D0
M_9Z:^=^6;T\-XJ;>_@&TF )%??3B^ HAUZ,&?EKMZNSR#[>7J-60-3]:ZB]<
M>^G#F1\8LL21$P$LR2)8)8C_^"A,)Q-TGW2J_[7PG6=M=I)2$BE/XM.LO)/?
M)[>XH+F^YLTK@VORK8B]Z C?X<>W.F9VR^7':CQ?U]&SAQK;$HRS)%&(9",/
MU$0]4X^#/KFGB+(NIU @W@\1O1_ZN6%^\CE-'*:W!N*;)Z1GD!7-Y-F]"V[.
M<FR9K526,)3EFV>0A7-CY4K?/EYO);#QH\.ZC+$0/0J;\X89$@Y:3(K='1;T
M9&886<5^/QB*->2]L.<JCWK_?8LO2];ZH6>4:9\;N5$*_H<$X(?H3':+HFQ.
MCCAB-CGM1Y7/^:$_QBD&]#>N>G$21LKE5M*%ZE9Z9'36.:1:5G-8QYI21PZK
M@]'6K["/9X'\!/U_WIO_:GUI&+"#/G33O?>\W9XH.EJA=V "G(G"CUFG?)4^
MIBA+,>A.5(XZN[LCNV_SM#:7)?:KE,9))A6T GQWDM(J]QO*WZ:/$U,)-NZW
MX&V=N3]^=-Y"KB>CZ<0@%)TY4M2TCLM/^7;X'FMS+TO.R8"YLBZRB"A^(M4!
MV7:S9K)ECK::>\10C9\<2T663M=A?&32Y(3I,!K?/Y<>M\6''NQQK4T.6II7
MSHX!>7<VSP>XW\#Z&VM%I(EQ@@;Q9I"O!Y4?ZQG5PM:ED *^UP#VR#'ANSL'
M#M$8B<!1MW$3R<O_1:17!L35,VTO4B@.I>CB6MR*%6_Q(L6=XKXL[NY.T0*+
M%7<IL(N[:W%9W%K<W3[NY_WQ_3DYF4QF,C-7)LG)V7V_%^B;3M!&&[88IM_2
M^ITY(P/+/>$0)P^)>4AGJ+K!*14[GYNL<-7\<&RT?^M')6TF/6GVYWH5?XU3
MNI D1C.OM4O&.[9(9T+3*PUU?"H"TZS?H*7XWZ"5"/HV4K.[QQ33._V,VZH_
M"Z@_8S2%!$:<&T>?A<\%'IH6,S$(%/<%!NI($_"M'T8FW8D2O=E)&MS4>J7)
M-[_56GWJXQ7%"D6H]3"G_\4[QP'H=:CP692I8^4P,V.2G-;AEAGJKR;;<Z\0
M4[38J^ AF2,*IF<:$4C)RL\Z_\L>FS7ODS&HKJ5^2+-YYIRNUR3^8^=:P.TQ
M9G$A;\'OM-/ILK&ORT.!>*WD]\F,0Y!(GGK45SS)%#F7MN#-QHTMO3X97G:>
MJC,R$0(34\W4P2M[QN0=10B?V1)0:KT&3X =]4U5;ELD4N8. ("SJB5!]"&E
M=Q0C[!W>><4+0-N)OJBTSFPIL8CDPZ-N62/;#UDSO+$97>-S:7V$&4AF*%U<
M9L!OEVNM^0<A,;>#(]F57=,6MUXWWOY8:\P023H?1+1:*T25]UCM_CM;B8=F
M@74T&*CW?[G^DET33J00)V?+A-/7D IV>S(BT#5B/1JR9[SE<9-A0]9R%->B
M^,7IDH&&=U<((*-IZM:/S"0W<!8DB*J/&)XW7M:9UJ&7N4I)1$JO^R;I[V/(
M+-*='RN#YB<_'D20]JV[CO2.A_-7J,5'W(KN=OGQ=MGQ__^4'P^C$)1LM3 U
M8@0R]T7M5ZVT%)#U(46^H=DB9#)=(!B*F4SDT*&S-*(R.L4#8,4/WBWGT'2[
M8(N1,*\DP1!=A_^<R<L.E;*0Q/-)Y#&P5$D0JV^U;)+P^Q!.-U9-P(5^\BYD
MQDU#\'G54H2Y^R]8Z\C2YI:[!YPT@$J@<1'S- MPG.6?!B/2H\1D.8CI->Z)
MV[>CW+Z/%-K(DH5X&LA$XI%%:1@H- ]=TO^87?/UJ@U#<:L_QR*]_]R&_MZJ
MO_]=K60R7FQ0N^92&SK_Y8?Y7])MZ!_S"<MQ0VC,GDF;WG^R6Z323LH2YV:G
MC/X51U%J5:#?CQ<D@GL6S670DF91IT 5,9,(2C#0_)!.,J\$X0+57*-(#1X&
MH\^=:0N;1=F0$[SG]]+Y\T4DP9IFW[:62H8NX5APA;7(LO$NQ:B%%E\F5CB
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M1=-B,R,#3R+.5N1V.>)W[IW=HQ5MWE5)^%. [9KW_RR:'>.T!_@AZQIFS.
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MS?]$)#.>58BF)3E.JCXTQN1@A*Q@:!'OZC&!C=&W?Q]>/_J^E$!O9KQX>S]
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M,!H1(Q$CHNO-QB=*5;XS(*M[C"FUY+89Y9CFI*=Q[?O]J6TS6#!Y</DGC>C
M!*X>E-/=6RR==8C_4:6&8.,RBZ/<')FT3%7<U_3T(D#MU[CILDC@^$#.KW'K
M91??\8&\I^FWP8O<AGI\(/M_3;?]GX87L.K#]#][QTO_&WRZ/I!W</*/<;,
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MW&AK1"EG2N_O"<3N= )H8)1]\VU,&*PQJ[G8@YRO>K11BC7KSO%[S^K*)IQ
M1>H;*>FI&";\B\ZM<=G5)Y^L2D6T&C:#V^1W?ZU/LT72/Q:PL1 G*2MTQ[-S
MWY]20)F>QJP<$;D_PH?]TCA3;OZ<<6=JND"0K[H-++T>IIT_=0FM-17B<X"4
M&(**'=X6;- M*;)!GYF$W97%:&AF[DFQ87;]19ZQ);XW(TO;!K08O<VTH1B%
M;VYO&Z,TTY.3P"";4:)0>1E6"Q8 (VB4B,J1T".BY"+K+K?$]SY\/8><81Z
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M\+M_5\^<S/PX48!/BUYT]KA&@/&C!0U$M5[,>+_<09V)'DI'G<@80*6,5V_
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M3O">B"L;7<K;XK02TXO_GFBD\7PWI;&,#:GN  I.U-!H?XN\>+=[N'^TJ6'
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MKK\8U\B0RDBYT#;DNJKG4NB[THK_#+]T/M")35?5-I4H;-%T-[V?AG;VTA&
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M*-FG6-Y&G?M$]TRYLXS(R;@F9,#%TD*&Z75!V_J"@-%L+6FBK+0I?>$-I;\
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M3:E9F]Q 5^Y:_MEYSD%4=54E]"+Y<C_^D^MS\HU+/,6G4J$$(GP[;L;KL@!
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M/J9G"190"T8I112TS],,?PBVT5>TV!@='8M+@/ ]LYQP=4> @E0A-J7:[%)
MT3C;;0^_/7EL_<@WY')$V=N@QC@-8$09X[>65G ]  6-?5@M]A6-"OS>Z[T
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MFX  !H9F=QSP3\8RULJ13=9]"5J0O8D?O&D1/(%OPX/2\OU%MQJ'NX"%@\1
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M4BE;A.G\[$,?EY  V)E'ZUEZ])27<PO-WPC:6!+3@><ZJ<Z4R?5"')6\K3[
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M;IH*-$)$<UAF/5:[0!;Q'5JULP@_*A14=E>^KQA.,#2T"K]2Z0QX=UI+YQ_
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MN62];1+EB4-3&Q!]R0,\-1T"-1P\:T"VRS5T$H=^OJ$WG-ML7W0QK==&/4Z
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M/I\"XNF_%%?1 [Y4)\]<">[P2O_#.S"VKV5W/7*Q*6>29\Q]?NRQ9U/U9N/
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M?%-[YDRAZZ'##+T_J)4WF@*6GA0,VT.;F\[ <'13\C27MYS-5'+*L\O[A&$
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M%4XLX?.O1-5SZ0+]E=7U&I09UZIZ%TP0IOP8^E-8<6@B*_96D<^?TAN)\=C
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M7M11JT>B"C>Q$*8_:YKX-76+N$C5"F4ZM.56)9F0F*>%!21^PUPSU;5CD?E
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M5[SVM :(U1"!/7R5(+6:>1*=BV2&/XA.1Z0W!Q9U@\QP#QC!RR@ IGL!!'L
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MR*WO&G 2_>"Q(]IVWF-H>1#N4"&&''P/@>VA6_N"R;'0P4Z7M#@A<Y@5/>X
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MAZQSU6)E]^]57=-LF/%P(RBP<&Q5!D :=X0025S((:]>/AMF_CGQB43O@./
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MDAV=^P^ I_[97>3PXEP@RZV>LK8@$I/F0*:7#_5C_9A.U!:'Q6*A>DD><4L
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M25>=2'QM=];)U1=3\VJ/=D'"6H-1QQIO5F;4X>)@Y:L70_\ ,M)=B^JT2U]
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ML_:?H#\@CYRW#,!>V.Q3G.,U8$^^-39E*PZ!']7/#O9J*]: UQX:DQ[/CE&
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M;</K*4(5#6-R07:;[\N^3PR)2/3@*TQHFF:%&NA94+1@#-.RF?2/VV=,X7X
M5D^($2&R4_"Y1K] Q,(5'96'HT3[[)6.=XD+\&PZ%H]87+VBV=4LJWYCM:IR
M)G3^9WU*_<O2I6Y'NR[^S3==EN43,EAS\ZHQKS9WJ=(FA>X]OMN'?-EH.=O)
M2Y=HQH$OTZE6+_!OF&Z&4.-UXJ=YS*TENN.T36(O#>[G/DP7X;)9$K1;8+07
M(>V86U;Q)=!T/4)>F<BM&YEIW!L6$2=";$'L4V.5DGSK8D\##<6>4FT@G-[I
M<;]R'.^ZZ@QO].N*/BNW.HLPVV+) *2<*#/?!\+3SW[UGC-@NLJD_]-BKZ<1
M:T5P>*5K[9Q[8^GK0<Z^ON)>9Z,_S_O;SE9JID*EC(<81!EO<F//$Q9C);41
M9BY=A&6K+%'D+;9Q>T0_ZX.M?P#3WPE9,3'H\):<K%/_RY(,,T!4W\M'@8TD
M0DH6SF(1RY:T\$VFYD;W)-WI#.3J%9NE7$$6_K!WOK"B%3&TJ':/,-MZ?JY#
MVJHB!/.5]LG4*NWL^)A9^=#'-1E]IF=X V@_ %U@T/MV-^5Y4\_2,S-CM%5;
MD)_])W4"]2YN55)RS%6X-JY,EPFW_MHM2_?\UV5NW:PJB[FC%%=N>TFNK,E,
MLSJ\,J.;F:2C8;:3%:OE]7;EL"7>&G/IVW/5;,AFC@6^S#. !QYYQDX#B+Y_
MMGMWG#>IJK!&0BXGE_EBT>7''[Z:>TI9V#%Y=$2'#+'^ H\Z:;=G>9FP64I8
MNLHE>69SNF4)G_'I=XE1:PTSJDEH'ZUP-.!\?/ #]<H77YD+BK/[6: 1!;[@
MGI<M^-C.F, !0J=+!_=\PS5V:5?0^JY+B-_<Z]7[G7A\?_SSF$!/CSUM_,_E
M&T\_A+<(*-=I2/QV[N"I\CCX]?;><'FF\<;?RU:6H80\SS_2U\JRAJU*O *C
M.$;1B>H:=7)K+CM?KT4TJ&>\Z\X;\NC@B[Z*  <<I,0U[WIV??#H9@19XGE5
MPYBD!S1FXK[-+C1ZAU 2%Z<U% :O\/GJ.#]5Q)_OT1N$P\Q1/U](M-'CMD3N
ML#5W8?3'$WS:JR_11ANE)-;V<%.HH;VXL<FJ$=9=B\5*1+7<-;OZNLWL:K&8
MZ+J1![NI2 /'.\FNNMGJ%E<%C!_>4HN=S/H;&?+^*=/OVMH?(N)@D'<;,S]X
M^I/.Q.&/FM3:WR>):^O'\[GI>Q]?A;A=2,7$"*YUU?84= C4 VLCE&GMWN"[
MZE>1RKM=WD^:+$:40GA:;,](0QK'/&=(U4_;V_,LO<PVB#PK8UJB=;6SQ]/S
M):TAN[7GZB2SUE?W>)*@6_Y3#RT&F<KJB%C-C/N,9]M*@J74OV4MO[V_;!OQ
M7R2.MF.KKB]"5>HJD#B4CN2I2%6JV'VF+GHZI'_\/TLN9DQLZT?\QWYG7L]X
M(Q%%B/AC4MS3_K,<ET?B]1C1GZJ.JX_ZLEIE5=-Q*U:/84<[3@U;7->M_%J#
MW6 ,;%Z9Z]!Z^_R+\E<B@J^K!),?O6>[""N16%TMMS1M8PC^CTOOEIY(1J^>
M"'4D1>WY?R;3.K6=W&TIW]"W6&K*?:S2OK61LJ_&]%^6"W[DZBES(9_S?F=K
MXM>?=^>O_/D:E/)F_YOP_SO@4:%!Q:L%O0P/-V$?DSJGM@5WC.(2N6X!-%N/
MF[9_O)B?['WLP_=7NT%]46;='E72:T-L<TR5KO; 5)REK4EP0&Y:%7DB]9O=
MW(G/SNA>Y&!"W_CS>B[FI&%NZ5067U51.%"/[_X'R 2YG/S>^OKGU5S1V[]7
M3C8Q;EN1;%WMA8B_ MVG2OH)4F&_B*WA\/^?;E]:CH^$;'V)7*1"3]CG6KY?
M1<I&CO\O+>A_:4TK$??;[EZ],,ZLW+NTK*8LR@:!ZBOV OCD\!TC9:ITTRK7
MA6>DDZ"%*X?F#RC!:HGRSZ%7'PG082$&7[?CMT];*YV-?MKN]U[HN]_+]SU9
MJ0ON%2'[^>_-NH/N&Z=+O@P_^[DL%&8=>50:^6\*8 :!0$SJ -1):?C53S9&
M'=/^8Z3O8CE$"-FC,*BN#@@A1AAEA1BP-#@-3WO" +],]KVW34,L4YQ;[>5!
M)!OJ(&4'-('@/.SN E%\-RDY_OQ:.LAN(T#Q\FV%7:(GIJ^&."(O!O44'%+(
M/TJ8Z.W$4-US%!?31@  JMIU$1",(>['AVZG <AX0O2Q"8@3N><.OVR%G07T
MD90@E V(+20VXF4<E,A,)*Z2]T."ED"5,$:#NQ"\@ L82[WMLS+K3[V-Z\'_
M1ZHG@\2!-?4$&0"0A0]'"]V!E??Z)#LO'6).W[5>KN6-64X#H,RII4: _Y+:
MYU?]=#P;0<ATD\H' *28RB0\=KD+K=(%FO7O9P;BRX=]A=!8Y-,]S/[S=*A7
MODLP"<H@7(_UH\I@(:H!_>&FPWB"N4LXTM-LM1^BN2!73NBJP.]ZBR"9S_,Q
M$99HA<6IUB"R6QE8F JHO@(A0U4/Z)/\RF#A*$JJFQ0I@'J[M$]HM?"3+&0<
M-,PH+\3GW)[,Y"^C%=(WQ4!T_IL8H0:! ]!9^9MC0#CBQY[/'T[.Q9@+\(DB
MJ>45.OH,)\J)P9?NL$UC0".&VV9E18<A:?F,OHC5,0BH0@TL)M$.9AI1UND2
MZYO[VB<[$EZ@Y<N Z9-=_ :FN'00\3IBW)[P?F*\0C^&XJ0O2!6CHL' "@ Z
MFO8J "!8ZEYO+P3U.3\4#4Y.9 8]!,!IE".YE"#.TZTQV&OA H#E8V-K:M&3
MY 3!JRJDO,3 >&\,]3X?<2_4UJ68"/#K8"<TZ+C$A!="0F:IP\@N 1KE%S\C
M7MZ$\^A->F_1HR<,F"LY5U3S5].0)$599[5"L*HVK8F?'N.,'<[?_MH+:64:
MTP<7$LKETCC&PE68/=($U@%&M89Q#B2+WV *X]PT@^BP(HBFL;'<P+<BQ* J
M6*Z:#O2A/[2A7*'Q\B*41"99E9@<MV8U!W47$+40( !"@AD+LH([WHC3O+$2
M4V#,&P/#GV*0'SL<C4'E>X(V$N16D1XDY==^E8E.8,'R$@0@OOR) H/8+9LL
M8%!U$&.O1NQRJKN\\!">@//K9W91G%7(9((<D7[XC)DM>*O7]"I-M!$0J#D0
MK5WPE[<IE$@'Q7#(15$220I%I<G,)!TF$$B</H5T(@CV!XPHTC6@L.(&<JAR
ML$_^_OH@9G,X7,5ON.![0Z\"^3?]R;#J7Z8NL;S5=%J;'P7F?VPTM .B\_U>
MC1J#.$Z&*&.6!]/BY7[]]N9+4$FMZ5KWZO6%[P%^U*"=W652V&%@Y$I,CC>H
M(%(@:$5EEYZ36F'@50E Y*!;?+\3_^#BL?$!"^K&< &3_?7R_#^1L#!V;UAI
M/P1$'-92QHS@P7:!(7^"UW>V$,,Q*\#R^N(D)1'P'?'G7&ZX!Q9>IY&"A^7V
M?,A$IDX-JHI;D]W.8G*J C-3OL<@ CD+>(/R20$P .\/4*45!=+4(H9E^0L*
MT/R'4"!!:CM_ =#RQ0!0+_("$+PEG$X3/E%&L+'EI_+G-_/+I5%<(*UH%2?L
MZC3B\'!Y9=:/"'#2-$ ?B&0FZ')3BA8C@&O'.N= 3(!5"K @+YS""BXO'2*
M&ACNK'Y/)N7_:KC\?H:RW)[&S.SD5\E$$,[?7N$<\5\;(V!AM6[)S+,^:<-
M + IN]Y;,%>NV!N-ZF?G@V-#U2<\T=@U669G5*$L#G K).+H':QP#AACL%M%
MAT(EP S#GZ(B'UB82I#CZ/5EP*+J;ZFT*\V^)KKH/%9.T'C;_JOBXPH'U!,.
MPPN7=S4-EPC4],JK%A1']<G<!G'(L@MNT-<C9-+ZF0K^]CVA#1)1(UPGU&:%
M;^HOD.P, !P*D.3&X#15X1_,;D_(06NPN<415"'MC\U?,)+=2L?.K1%LL)^
MA@V'>4R6Y_3)"DRZ\;'#^_><<]:$AT+\\N,95<&]8(,_N/5*KV3F?X#]UPK
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MY\:OB:.W,?JENK?Q8Z!.6FT4%V6M4P&KDJ#R:KL>8HAEPK,B?@P#WXT9D"_
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MQ*P.SA< Q!/I:F2H6SLIC C(#0$*_3J8OMK(\PQ"-Y>$RQ7WW)H5*+/!)'\
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M#Z1)*7HF)<)M_4L&9UYXA%;XZ60?,F(CC425&J6P=#>Z'=)G,C,H#0'S=?^
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M%]A0Z-0,QT#V/KZ0["C2O$?;N-+G1'O1K1VV;W+<'L37CG]E7WJF]5CZ?>>
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M9G4[%[0:FJN G-37@KBZRB[Y..1X FS7$3=\4<YG!= H("-P48-Q!@:T9ML
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M)R+LJ8<X0#+1T@=/\YFGATEP5N4+^!"@U Q*X0WPKF7&MBVI;EBNR8<R@GM
M;1O/-%5;:>.4[*8IJ4[^8"<^HG*0M^00$#8+[F(G>0BL3OC#$-"@[G^ KG_
MLN G.-<HN%U>&^=)]UT/8\90.M&\2/ZS"FE/25T7X/0PU5\N/:U<PM/&4-\7
MH8OP0&BBK/6DM 1XR,0, R(XA)41GE;M*:1&4#U.QM$9HY3!36[!HCJ_83E+
MQ/K<HG9A<+B=-U('8F:.U.7@$-.H3R:ID"6BSPJH*3BM5S2H21_GR#6$F"/H
MA0".M^2[.#;)1#;)$VJFI+)C4.(DDQMR\NGS>'[TVO JIOT;?JY@8$6 <%RF
MC-P+!*#JH2+ J!*C?WDL'_1ZI@YB_!2+L@:M^1+!J3?EM()9<T%A<6Q4N2?R
MNO5\A082"&HB%H)[/5(]0M?3JH_+%B,BQ6F64C\RE&%-.I9B-VT)B&[_6:5Q
M@ 8$!=I:BQ$V7I[,<]<!I4!< K"_EWDB\#VYTF Q0GJXSD8*9:W2F*30PD#3
M+T3DA\W/K%6UMYQPQ"+FVK(+17U9%= RH0>[UZT:P=EPL?0#55 (>.28;VL&
M3RNXHP6,E5@#Q1#HW4D#LN48^K$^6X*E4ZYL]4GRZF4_A]RA-5]!]VUH2+GD
M:S\N)EU'[U+TVG2D#7A)Y;/\9Q$0_8)01K^0YIS%B%)P/T175$=8<&&9F?0Q
M'?GNX($)J?FZ66!JF,\,:L(!&X&>R!XM<.+(S%IBVYKM-_@4L*L&QQZAT+V:
M KKM8<!&4=)Z"K!=7UI2?0K<D[%QSR..G_Z=0:\@&4A:TO'0:K, 0AMC,(^D
M5% E=7P<HS63[LE/GV=$9*/,W&6%G2QP8RDD/4F]4VO9;PAOWTY4@ L*G3WE
M@4#==?_EUH)@2*]DJH["!0YOZ:![VR*#?L0&K$(CX&UEQ_+3IG5Z/ALB?7E7
ML[ R+99RS?#U=BG8G@S\ T(OT41XT/H7-__O0% PW$I9"6F<9Z'*P^)"V _4
MP!G_@-1A- V\6$A6E,5JJJ>?!?Q&F#&$(M 4'+7A84DN-=7S(">N+--"NUZK
M1U/67EC^ ]@/@FYGXL98+2,(OOEHFX@.0Y:2;KN]7J<WCJ.4ZR-O(6$C;-BI
M.BFD]@FVF0^IZ@2'BMA;2*$U+"[1*"S, NEW!I4GGT:S#*X],2'A$^X&RI7=
MZA<>FB*,SZHYN%4*(Z*H(P>2CK<'%< 94O9BJG$(]RDNL8,QX/6# /L'R.(K
ML6VY26(5O&I9<>JTUM[JN')>,TR&[1,"D[#QVSC&9>L&IYU@V 0!^"\I5$KT
M+C!BS9,!?4X[P8OU8+M4581=I&/&N1H'_H!8+IX@J"65& -4123^U%I5'^5V
M** ZF(!AAE;\.04L(I+T+"68] _HE5Q- 00ENCC>>$\-@.Z+S(!:$T&"M<,Y
MA!L]U28:$H''IYE85A=ICK5\TFU5SY^ >BU,:\$L/MVQE +]S>#W6Q<P$Z^H
M%@CRNT4I[ N]:7?P(1&W:;?TR.^[/PI;O4P^=4-  T6/W"R+L--H,'7#+DSC
M*I/4ZTZ5N@TH]4W'METPFE9:'#-M:'O/8Q>A;KN!THED5#_+C)S841_L!FL#
M&[(P7 \?O0VHI08[MW\+,S,7ON8Q\@^ .*\P>!LS7A)BD&BA_@@YV0)^5TW;
M/\ ^M.!7/174LW-8;PGNSD&'2DN%S;'UFGGG&\O&"[IJ^!LS8=7T::X[5F9C
M:1)00%87IA2OXRBAE4D08ZF.M\\\IQK.N"L@RB1Z)72I!3?#$LV $*I!IRQE
M R%,C_""F\*$+KTF&;V7/LWK: %TV=TX>QQJ:N<SPB /7$$(Y3^_6ZF@-:RT
MN!>=*^L2&:[:^LBYU.I6B[$]CK>.19!$E*Q*HX)D@Q[*,/R7I;>S[(!@]LT:
MV-3&C)K6*C@ZAEL3.E%@"1!-5 7]O*1I5-\/@37Y_=<4@'2AT$("PF96/L!.
M_'+I3T]<^SH_PO@[C_X'?!%4>;)R'C;XLF>R7*R7Y.\Q-610TY B)09D)L?Y
MQ#\ [)S:GW\J*AIP@_>@D;]1'TJZP]V5.>/*H:OKXM!A'N*!2LGO1@UIJ2EI
M-V5YOT4W!6TJ=@)48'FBK?A4-+K!%Y!;'I7]^]D-VAWY#Z"6<V!34,C).1I1
M1X]\='FB;1T,&AWAZ;G^BF,=&F1H3*"FI69FUO,&3K2-WZJ.':NSKSZ0'2TV
M[-ZD5U7OYLV';5,0)PVR86ON+E^%MIS82%M53K\ 6PNV&8+)3M0DD91B,YV$
MOA92TXOJ%=0@W]LG 9B9?&YDA$U02IFWHX)>+Y)H;2H4]_ZF]#TU9E"_C>D'
M!+WCJ)]0+Z&[4B;KYC)YYCP3!L:!BBI*!":&P(OB?A%@P?H+'$.JHRM88UY2
M F+,:\(#DMV$-.+X8&EB]MIW3BB3"SC>9G<<=JEBZ$U(!&RXZ,6#Q< H[F"-
M&5-?30-O*^J[878.4:AGZUS.\/@'%.L#2#6Y^_ )U,>K?1G!W\CZ7.+$RD=8
MW4/WOCAY?5%5P_FQ-+ V%9U'2ZBG#M]&_ ,ZI>=X*_J82#&-_&X_$H!=$T6L
M?6K!LKMF(3JZ/VX6C39'U \*H1O[V8ADN[!=KQK:WZ:R"JA2/" 9:I'71>0T
M'/3CAG0!Y?.7G3,0Y>1QA2!\R$'1NK&-K3<CS* $P5_OV0F>'A-T8F)-R44B
M_#[N^W;Z(-B8WIIO65Q'PJV)P4&KOA(NP.I&X\U9V()9F)DT#\5D1'DUVGM/
M6@A#P\XD2L[8HI.@_^;:BMC!YU*HGWO1$Z]O?A9JVZV*JO>=JUJF1;*>.L.5
M'<N8;V)I!>MJ=$N$3+UR;=-R$/1[2 OE8P!BH1=+EQ;O1.6):1/I@[;"VJU7
MCB*JFC+V"$,6'EJYS;^W6GKH"A7&HBJD:BQOY2K"(78-XCH^@%O;FI-"6FZ7
M!D%#;-YWM&@3Q_>HI[@IRCUL\'MXABNBU%'0KLH^IJ;]L."HH^;&#6]!V.0D
M]^NZS:X3_,5KE*)80((J"$.X<XG+WR1F,8+X;IMQ3L+.U1XA#O$LI92(#A.F
M]*1T<Z0620@$=KIN%O7Q14RJ'VF7:8_OQE51H5U]O6?FO9M6*.D\FR_I4WO=
M6*5*]"FETO3CK4*F;5"#@O9;M9(>M)#;*^'W\="3-A4AO9I_9P%Y/49P/V_%
M8 B_\7-2,P G9-0Y0^<I!!0M7J#@I!2D9;&VZNQII/JZC5@%5?9]6<<D9XTE
M 4PK;V (L5R1MV5<^7_ DE1'>IO0PJ1BK[7M9<D,_BT54 'JI[!VX![[&UB]
M&"V"!83V9:Q^^39YH$Z/J_M\)F<JTD>X6>4CI7K4TC8$ !T8Z1*,3![WC1#4
MD&%MT2%P!3S5XU*WM:F0)5OWLR]C$NZFB-M8."E7I)1Z<'66MT*0"/=:4RG+
MTB+A\[XAR,M]J M+C\N2D RI:3E9RGH!?4/$!0E4",V(H9,!%'.D6%+]=+<Q
M_YEA<"VT3$:(-P!$7WO0;4SND(A8HN$&^VAZ"3/20OJ]%/ ?6?-/+7K6],%
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MFCX\NY1K8['^S8%FN520"/X'B!0<MUXF#NU5RDE?<1I"V.*%:*!<.532+?!
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M*7E7*TU#(R\.S6(T>]222K1N8H=12B$/MK-[DW^:VZK:WCUVA3%QL<A2X!P
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ME][>0!G^,FS#V#WR>G,>*)M'5?,CO8I/7FQ,81!U_&%9SA%L1(967EWQ?C2
MGB:[!D<OE"]8CT-1$H=0!PWV5V.WFW'K]2V)@F.WTS/1%WDFT[=KU%)D^ULO
M;)A#W=29E6QVY(]05,B61:O#8$'/ "'F7WM](_QDV?.0$<:_$^W/&?\ ?+[W
M?[I5G]?/XGVYXU\RV]OK_C)L_/&G_7/OXT\RV]H=NFY%HQV:8&4'3]7CVO,E
MO8.>T-Q[/Z.>9,,YX#'F2WLY_P#P2+./_P!M QP/_"1WLU$-/XQ[..0#'_N4
MXP/F6WNUYXW(LX9Y:C^^G/A6+OV]F[%RBS'RI%VG<.U3D<80#3JC)685;F$/
M\;I_3-H81QC.@A^KS'@1QGO'(@..?(.7X^/DU'7E\W 9# ?+V:!R >.7;C.3
M"'//+Y..7TCZ?GX^M_E1[0^3MX^O_E1_5X*D@;5QU=1L#D_@G P>R?/3TY$.
M89XW3\GER=M&!YUB\W&VE<*X,Z;[BP,1XSN*(H'6B/Q0L8DY$<@9./"2( Y<
M]2<G!S#->/EH>1?1<HQ=%,1VQD(Q95M(LE@U$AT7!#%,'8("'IX^L//N-WY[
M/1^+@! HAGMR/HXU+U?+CO\ T+EQCEGU=@>L>_C>3SUSK1$EWLS=]LGY:FTD
MB(E>6*7%3XW;(\PE4273AG,:8<Y*/A0<FS$?VT'"[MXJL[=O%S.'+A8QE'#A
MRH81.83^T8QCF/D1[_FX# =_H[>.7'Z_W>6/E#\6=>-0'UB.1 ?0 <9 ,ZZ<
MPR ]_+G\_ 8('9^R <:?-_2ISY=V/U> U^C]?3CG^+\?5QS'_$^7T\<_H#N]
M?=QS[.X/U?3QS]'+3\>..>?D <?3IS^7CG\F@?0(@/'/T\@]?+..,9U#LTT^
M3/'/T<@[?EY_<]?WNH<^WY./7K^EGD/=QIW>CNT]6 ''&1^Z/$S<8*E6N8JU
M=-^_MIB*U*OJ_!F-@0++R[% \5%9*(" *G+G/ CG\L./9]0XYXZ?J_AGBL[@
MUI51M8*=-QEABGG@>*@TDHIZFX9'=@)13$@*IE'';G'%WW0JFV\C5&[IE&SE
MH8MI=S;F3%\HX:Q$S:)&2^!0H1#:?EG;1,06_)_$7&"'RY(F5X6-BGLH:+CW
M<K((LD5')FD:T\,7<D^52(?P(Y#Q0$ZAC 4HB "(".H@)=1P'U@[-1[?1P5,
MP](#GD!==.KL$,8^_'<S^)S=0=N 9?%OXP?XO;8-(",R!?B@VCX+\$^&9U\3
MQ>C <^-.WTAW"/:.O"K*"AI2:>-HR4F'3:*CGK]TVA8B+4EI>5528E.9.-A8
MML9TJH/21),HF-[(#PO#V&(DX&79X]ZB9N,=QTDTZ@*[*"["222<(B)1 P <
MH=0#G7.>"*]6#^UG3G^Q_P ;H'&S&W-8H9=KMK-D*2E5ZS3BV8EL4=3"HI%E
M+5*RQ:_6D5Y:5;Q+4!#W(IB*"Y.!Q]Z, 9$V1]7X!QJ;'R#^D/$@]:P4RNQB
M(<+#*O$(MVHTCH(9-I"EEGZJ91*C$FFI9JT]Y,()@JX*3(G$"C]YD/PSQ@>S
MT>@=0QZ^/UM?1H'&=>[Y?O,![(?*8,!S'LQKV\?GL#D-/"'TZ?7X^K](?J\?
M5^DOZO'U?I#]7CZOTA^KQ]7Z0_5X^K](?J\?5^D/U>/J_2'ZO'+Z0_5X^K](
M?J\?5^D/U>/J_2'ZO  )>A37 ]0&YAV@&G+@.L/%#3&#%)Z<^SKS'Z/Z.Q]8
MIU<F;98Y=P#>-@*[&/IF6?N!$<$:QT8FLY5$ R/LE$ * CRUX\/S$[^[,[&R
M_0H#BA'D)W=G=)@H0/W#+4W:>&M;:NN3E$  DQ*11L=@XX'I\W.[:P?U1?*0
MV*(\\^R;S%AC0./YY&\V?_Q-V7_Y37'\\C>;_B;LO_RF]./YY&\W;C'DW8__
M )3? ?\ #(WF]/\ P-V/=GG_ +YOOX_GD;R]N?\ @<,?D'^<WQKYR-YN0_\
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M9O::Y@GU?AHU.%]\K+';N=L% A((\O%O.F/@WBD='*@=(FI39^^\N=N9;?\
ME=W,+MOM!5"V.5MN\,.3="*D87<NX3;^A_Q.CO7 ISJ0Q#@@G(^I<L)R/C
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M5QK\U ;NOH1?;O>3:"02*?:^GR%PL)IFWPBNX-?@Y?;Z&(VDYB!?%82RL?\
MM4ONBCI-0$;Y;:NRCZ^<E74?D:6VDSMAJP7*'//4\NX%,@K%,W?;7[4Q1/$C
M2V".C??2B'3D0QQ([A-W%-IU!CZW<[E]HKI:&;"0E*]MU&'6MDC5Z#!DL.[%
MQA&"X>Z*R$;77\6P7Z@>.VQ4G1B5>L;:UVP6>N7N6VHV^ILA)S%6<RSC=/<+
M:C:_<:2J\L3PH D*8ZFXF([XBG'D%$H_MHYV;PQ5]PEZE&#7&L6:;%JUN] >
M6T]93M1J;]KB4",LBM^?TD]CZF83R<::).<0PZ$N.*O6=X(-Q 5*86N$58GE
M,NVW=DL=1ML)MK;[G$5"]1D/-69;;:WG5K!RFC+"RC9$Q".@Z0,F;H,PCJ>=
M\\3VVJN[1 ;2]86;N:)<I:%@:G)QKT9P49AU89FSL8]&.0ZY0THM[E[H"Q#$
M+-P%WH061RWV_P!S;0V+M_O5L^^8PA]MV!SV23GK/"J[BP*X4'PQ/+UWKCYC
MHZ2@=H(@?B/4W#@X>,-*OY.%!M&W6B6Y[$S\(5JK+UFWQE-L%ADZ9:FB4BF)
MHZ7)'R!0,/Y/V3=.N<^GG]R\>4&QB1>L[_L%#4,SM8WA5+S"56.<26UUIC3'
M(JFV&Q.4C5J5$I2B>*E3Y, IDX42<)'1606\!=%0,&*; %P.=<@/S\^/T_HX
MUSZ1SIK](8QQ\F/O*.1A7Y*<W!A*IN/!(NT9L(2*JA;Z\GXM<LM&JT]XK;3K
MUZ:.HQ492K$&RBFH9)TFN[>[460F*G>;7 W5Y$P=J95J<8SM8C+)%1"B5A5I
M=C0"+31LSP'C4(XH*&Z.D2&)GB9EW]1,:R3B5R+(R#2P T@4$+K>HRVE-&PI
MH4SA$(L[9PQ* OSE$BP".!((&W!9LFE]K;>V7+<"WUYA2MV)>I1C21O@(!(,
MKDQ80(C>$(!)JD1CTGBSCDY3&.4_0$I:VU>M,:]D=N:1M\@^I&X9Z79(G[!P
M%*AF\G'6@M?FS!'S2=0'W]B#,#"S<]'O6/;,[DE-OI!":=2>\D@+HMV1<1A%
M-Z*2%>LI48T::#CHBIH1>LLOO8889CU' 'O&W#YC OHIS2JA,5FT34)<',+:
M[,M)5V,J#>P1%F)%G5J<E"TFO1<?')%)())F:'.8BGO)R#5K'6JWNA?9IN[B
M4ZO6E+W<KUN=*QU4,I-+>[VZ)01G"3R1$G#L%8V.8,6!B>*1I@#@9G SM7D=
MMHB)N=0<3+^P/2.[.T?T4VXR[D-PU*KM?!MYFPR,O;Q9"^^S9EHJ-9E3-'OS
M@;JE(C;Y\2SMI<E*7>NF2S*/K$*%'>S3UM'U>)9;-;$$0BY8DT50X!7XXQ9%
M-0_4[%UU<6Y@>IVQJQM<E+S#R":;I$+4$IA>[(W:$L!:B>F&0&R-I)HV92+L
M1_?2-*9,A69C>(%O91%->Q2%JK4S66_OUH;RSB+;RV[<#NJ5<YTZE!FDED$X
M$L:/B 4%"F%7V-$^+(WM-H1J$W*OYI96(;&E'UHBF;VG5*O*'J[QWL/>88Y9
M]>%4 $FMDIBRJ >Y23YT02/2F$P8,L =(9 <= X-KR'(#VX^[IS#&>7: \@X
MJK ^TCV5*C7+/3+M(SNY(35@?4VY;2SNS,[5=NK7+T=>Q4:&5A9P\B4DD]LQ
M22;1B ?M!F5B:386?;&T@UKUF\MK.A[<-=U#-)V0B]GZGO3&NK3+;A);4K0O
MA*2UO:%DF!8Z,\0'PFCQ: 0^*IYB%]F[N\N6X>V>\FV#_=YRC:8;9*!L&]6Z
M'F!E+A58J)EJ/\$M<^6B6Y^$0+.S"E%FZNIHZ-'F =YIU")O\! [P7.!OSJ-
MVFWKEMK[A%3E:"9^%0[N^L:Y/C-4QVUFWGQ%@,8F<YO=3)NV@I>U%MI;;N<G
MK2UML';SS=AWELLTRA_@=]<[C.%MMIB7@UMWZ%<)A9Z=(\C]MY$@%=.U"L_?
M'8G(ZJMHV0G)+;\KBIV-4&VY]5@-S9_<"G2=T"(M-NOE?V1@H"U-S0.X+R+,
MU+66,@+!HS#X@'NN34G<BPU)^E+5AQN@\FOL9?)6ER,HKNQ<+M;Y,]7DR1$Z
M2NC"&NJK0J<B298R::12R+-ZB=1J,M=(>K(TJ.D&5=8(P+9Q%/G9U86"BH9:
M7EY."@*K!2E@L!XKXA*.V<3&)K23Q0P-2 .!]>GW?T^WLY_-]YG\/U./PT].
MO&['FD6;)EW$1<H[);$**&.*D-N);HU62NVX4.NDH*82^VNWB@>&82B*,I/,
M38Z@X5677\5902>(IX:9/%Z2E HB4$P*3H*4 TYX^]&KSMU:[9TF(JMBNM\W
M(?PY)N/I=1@(\YC2SJ(&9KRLL5Q.G9QI"I*D-[Z])];&NZM/AXBJ+*[/;B$V
MPN,O8-RMMMN81K;)"3G6$%'H26Y5NJJ;D+*>JO!CP+U"L*8AH8<#7[K+Q<&Y
M(KONWV.DMLD]T=M:ENK(6]M/1$%)P47%STLYF(B75EGI6/Y6+??#0_?!5$S
M>L:7LYXKBEGNN[,%MN*T@+"T2-4&:M3>JB>2]R6KD9/.J^*HBIT?#BOE"B)0
M(4Q<54-M]Z;B\J;W>AWL?=)RY[.5ZLS5?G25"U7<DO5:W7-\-PD;Q$##T]Z5
M3]\8PY%!;![7O(=,;O!M-N%-[@;?NKHIM]96MRHL7MK=ZC<30YIZ())5B%ON
MY4(M7[)"H/!BWZ<H)CJ,'9#M6XIEZMS[7+;O0-0G:A2MPK;4]O6T02UVZWGV
MVI2UVE5),I9B +3Z:I& 1D22S(*'?B<I61TVCQ1J(<O5ZONY,3&,_L@'GCN^
M3[AZ%N2J<=D-[(O^*[>1O@YB(UB:45/#7!("(K*#-;:6D6-AC1( #[Q&D*(X
M$>+YM19DB)V*@VJ;J4\D@H51/XC R2C%04U ,J!BJG*)@ HY !P.O]&J!2NI
M0(_;?RS^5NH120D,!"@XV V[NLV8H@ %-[[:+A(/Q]+P<]WW9N^Q-6B[%;QH
M%JJM)E)I*(>0]0G;=%FA).T2%:F(.?A+FFG7)5^Q^'OB BI[X!E ,4@-S4L9
MJK/(RQUW;^\;0R][V$LU=\M5F<[4SMOAMRJ?"T =M-L4*]MU8:=?6<BH>2&-
MDTYF+F74>]9= $4#=FMKQ%\=&W#N^Q%LC[5N1O!9]UKG#L]F:EN#7F<58+/:
MH4CFWR%I4OBC_K'X9%QAF70Q8$*< (MN] ;,NXZ]W;=[;_=_>]9QN7[]7K=*
MT>SC=%XC;^&/1$WNW,/8;0<[U4)"2M)DS 4I3"4@9A*QMSL_/057;$WXD[ W
ML^Z3"S3DE<=^=CI?9+XI%RT7M;5D(BKTZ%F!?1[%2/D'YU0,7X@7J$P3MT7V
MC<PV\MX>5A]>+VON$O*5<SZ$@R1,RO0-OXBH59"K?:]P0CB1+)R-D*F<O2P!
MH41S5]N[CO3*5.?2IN\D98D(#XNGN/$FN;ZPJ(4VI?$_*5NPF-(MB)&)9:-C
M=U*/%S(/WJ3YF@8ZS]]Y@=P!:1%?NUJV;VDH]%V^FW-EN<W_ !W5"I$V;2WH
MI<W&4>O0=,A*WM#.V WN4G*R$B,L\;B4STF!:4=W.;5OGF]NVU#I^WE7W&2W
M %C1VD+M]+ K3YS^*Z+IB+Q:Y0D"0L<5R>RFBS  *"P$P '%AN]:V.EXQ?=7
M<5;=;?&.<[M)O266PK53<Z!^&;6N!VP26VPKJ3C=R6?%"0^U$G^YR@_#H$RF
MSVT\"]KEGMJ.Y#ZS6TK-O=HV;KNTE,LJEVVWV9MUK"'J!IH7>X%QL,VL^KR^
M6^&H%= ?I(V-(1NT,J+YYMGOI2IJRW[<&%M>Y<^]WUJ2\"K)36X4%M5MZO/5
M^HJ*^_1C&282$L=1V\ TS^VOR=?K[+;62B)MC8)"T3%VO6X8[JW$1=0T-#)5
M6KVAQ3:Q:8ZAM21/B$96&1M$EU] C(>R/B?<J%SBEA1E*G:*_:(]P4!RV?P4
MFE*MS &! W2JW <=O&\2,_2I>K5>V[F7BU;?O7+42P4U5)Z84F81:#EA,*+E
M$C:5*41*/LC@!P(:" CIW#C/+CH[ T_#/WN>?/\ $&.0AZ>,ZXSZ/TN?'9\P
M=GZO&O/&.[Y,<^SC0=1].@<O6''X?/Q\_?\ XN.*]<:ZZ%A/5::CYZ&>% !%
M"2B7)';94 $H@/0J0N0'F'%!\SNWZ"@4[?."3>6<B1Q.S@=T(TK5.TPC<5A\
M;P$Q5*4.KJR^;.L"!2])4Q$^3^UX).D Q[7Y00,&@Y#77]!H6T55(*LY>K"R
MA$G)B JG%,1**\O-O">*F(QU?@T'#U7I'J\)L;I 1TXIOE>VL6!#9_RIU[^+
MJ';H&ZBREY3*W+;9*3/XA 4E&81Z;!43%,H61:O#9'WHP_?Z\O3GN'Y./T^_
M'<&.?WIP(/2)L>&E@PYZ0*)_:$VFFNO#*(;ME7SI54Z*;=!+QW3@RH"J0A"D
M(*@ZAC01Y=W'DTVCO,!)5BQ.F>]V[<_799D,9*,I.[W."@88LHBH43#U4BF1
MRJ8>R(%=CGG@$E"C[2G7C0-.D.D>8B B(?>[D1%2JU2?VO<7[*1CNSW2MT+<
M*%9TB&?/9:9JIMO=QJ1:JU+_ &BGR13[WM3VV1XA,2%ZAZR6AE([<1L=9]PK
M#Y=KG>K!%RT?%P\S<_+]3[_259B+J$'3*[#5Q.^1%W:F,Q8"5*,.Q.)15][_
M &I;KK*[42Y)J6\Y<MYPJG[KN;#-6-?<6&PQLS,[?V!O_%*LG:06BXTJ2,BQ
M&& B^%3,5R@5IQ4II6VW][M/3MYH7>-AL0;<>R(;?FD86\?;UNQ:Q!2KP3&1
M+*JJ],A\,%0JBQU.G)C%-2-Z-WK7N7O2RIEBLT[$56Z[K6F7-',[.RDH=Y&U
MV<MI+0,.1-)9,O65F83@T(40# "%3I/EHAMQ-C(N NDIN.[M3C=@EJW6F+DZ
MK(U)BH&X%.HFS1X6!A:_(OV*+)G'):2#LRCASX@ 3<FZ;QT_=O>G</<JJ;@T
M2=M@;[1E==.*YN'4QJ<N]>FMFS.Y<]*W B2RADY)22\,"B!3,S 01/(JUN.F
M8J!6D7YH.+F)B/L,S'Q8K+_#8Z7FHVOU5";E$TA(51Z6-CR*G QBM2%$"!]X
M3_)?CXC+0;)W>X.QOENW D\".1G[7L'MR\G3Z\C'F_%,/I'^C6S&Z[10RL7N
MSY:-C9=-7I,7IL&W]#A=CKHQ,.FJ-IVM?"'8)3!]X!O7\_5@.W@3>D,?/COX
MMT8E9(2OLG.Y.PE'>E>;?5FT2YR[B6R:B"2L1:Y-5*R5,(,6PG69Q2A?C &!
M-V)")E,.UDHA>1W9H$S=/,AL[>4KMM'&0[:(M6U.U#V<&9B(="[;BIVF#4">
M;/HMT;X=)E,S#]I ;!0/;MO]P&]DHUR\LM\WCCW-[V<J"5H=1U/W85VSLU3"
MMS-RW$A:58C3$ 96.GXR6^)D8FZ2D+[R(&WG>;+WABP+M]YPZIMC:J-+;)UF
M*I-";[E[BV.(J/V%AEKK8:_N73*@M6Q82D;(Q\"DJF8O21TT.H)=A*[3-QK!
M_&?N[8MZE;P[GMM:]6:##5[:BPVY.[66 3I-VL)R)P)*@\")C8Z.,G*IAH=B
M()LQF]Z(W?6WEV.@J5<["K85=D8E'<M:P[>WS:"E6.J#MY_'8,!T.$MY(=_'
MOOM.)% $Q%4VA@ZN(W>.M;A2=S<+1L-+SK"&I$<XJ=79S=ADZ^A"SENB=R9^
MPP%Y:+ R-(,96N1<4!G@E923S]IB_$,XT^?GI]'WNV&W;,H>\7B^U"I$$=2E
M^/3<?%=8XSH3WG(\;Z;8[_4*&\TOE$NV\UWF:U4KD8376AUI6X39H63H-E2
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MSG)=9-R]]^),UO<NI@HN )]?O$1<'Q"@ 8(1CC/;PDF4-4^L U#43AD>88#
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M!-,@-4RD^[D>_P!'W+-YGK(D_8W2UUN\;;^5U [-^U!S=5(R(@MR-V4Y1%0
M:)[6UNZD+$@(&+)S3TH%'#!X!?K#_E=="]G2 Z 7B)W$VKN5AH=QA%/&C[!7
M),8N21$0*D8A52 'OK!0FAFQ@%,Y=!#&O!H+S[UTVR6^S&.31AO-QM#3)&8)
M/GCDQ*!-V]OJ^0)JRN%TTBE!9 PF$P !3,B (FDH:IWJ%W+@6RO[W6^$B;1
MQTJUR E.$5<X.O3L>J&O64Z6 '0#&#7[A>P"]7TAZN% [3]'^5U'D'&,C]/
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M?( _FB^7_LR&G]XO _[2/D[R/_X(OE_#U9_O%#/'\B/D[]7^]%\O_P#XC=_
M?[27D[$0[_*+Y?\ Y P-&X_D1\G?(?\ XT7R_P"O9_W#:!Q_(CY._E\HOE_[
M== &BB&N./Y$?)W_ ,47R_X[^7V&X_D1\G>G_P""+Y?^[_WA> _VD?)WZO\
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M8I@*]=G^&)%!ID1*=12)ME+GI6L62!=C(PT]#OQCY>,> 4R0F82"9B'+DAQ
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M?:D0R4I/PJ:;DZQVXKS2CPH 8W4$-.AD=<\%F[-3+'#0IG8L4Y63C%FK SX
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MA# TK92PU>X^6YO4:O7ZA (715S-TN,^SL4M P<0XO%<9IVA<#$P<QI"(C"
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MET[NS]Y@QQKY:M\^6G^U;=?Q?!AXT\M.^8Z9_DLNN<?W&'&1[N QY:M]-/\
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MZ5\V7FCW'W>D@\5<]7K_ +M&UB")XQ12C8J<L2:2*#A1-$#&2-%1I2G  R;
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MP,>G8IIG%2#N$@!F5#(1(3$DDF=O%_&7*9R)>(8GBG 0)D= ^\9VRO"@NH@
ML):&?E\6!M%=D,A+U:?B\@$K SC</#62-[(EP..H"B6&M5(,J.V6Y\*%RHAG
M"A5EHI$PG3FZC(J)F,0\O4ITJD<H8!$#=)39'JXUY#J/SZ\?+\_!BB'UL<N6
MG4(CR'GG@![P'Z,!RZ>>GWXE#7TZ9'MT#L$.SBA28-T5VM&KM\M4@FX2R7PS
MU.8J$4;IY";X_:V6H\;]&D8X&KW:3;G9C:>-7S]>)L"=TW-E@$H:%$AK4T]/
M[2X#!NHPYSH(=W>.-0#Y,\8R XY_JYXIU-\03/KE=C2@E H#U1,!#"98HF
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M$,Y..(&[-U:LK!N5,+)^#+-%3.6JI:*HB4A0^ U<$BB;J.<Z<TFZD ,*:*8
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MJJ0@^T<6'NJIC94XJLFNY;/F=SKH6.+<MA'!$DYF6A)%DL*I"&"1CY:'5*8
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M LS.03JME-[,8S3.P?";[RV13I(JKW:+=&M6&)>+B83%KVY<5-PD[$-R@(
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M.*0OP4$FO3CC9E%&7B99(NX$K0RSL.O\1@)(MGA)NA_%8]04TO>890D]U@;
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M@BZ6P5@[G::3LW5K*ZV[ISZ"K)H1O:Y.(@R+0L"8Z:3X_ORY2"0'3H2F IC
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M3#=*O0KV41LT[*DE2^^#&JBJH855+Y(U;:FSOZ$\C-HFVS ;4VS8#;N(VC^
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MAC/31"6V$KOI(6>NT>-JDU3(_P"+;G5G=B.VM1M<R4)9E7*/:8V6Z'3Y-^<
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M6M<%'0\B4)1,D2<EE=C)% 61BFME4V!?M7"&T*0"$3!3A[!%0$-*R\HIN'6
MFNDI[$M4[Y/#'(OQ$ /$L@ZNKI$W :::^L/P$>*"_,B+HM6K^X-C5)IJ1&CV
M2-UT'.%I4H^OB$G;!5*W*V:!8R[&'L<O781_(5\R9CB P<XAA"O 4BN  W4
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M=(3#\0M3F/%.HT"J)22JQA21\)LD"74H$9"-3&'0B93=X_(&?9R/JT'^B8"
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M4XBU-*0$!'E2_:#D ?OO<F3%\VJWGR\KMPV <S]>?2%3W5V2D+I)0%K,1(C
M[Z,+-S]LKDE# W%/(Q82@EDS (@R*(@+2K^7S<3^.C<9[!N(JU6+=>J%H+].
MB-BF))V#=BY)6*U0>YZJ4R\9E&0C*S%6R62?8,+Z0,8.+[8MYHFO;@SKY_OW
M==\-L=H-MI2[TS?5_<1=V&!GTKBVCSV792$VT^+QCXUCEC$E4TTA,^ 3>X/3
MW&6KVY$GND0VU]DFIS9:D;;W>9MQJ\6("$F8::CX*LF+7J]E4L?+RLK\)B#
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M[!_#33MX[>['X9[N?&,:C^ ^G4/EX_#]/[GJ'Z1XU)_E@]'/[B>>:GB<L_L
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MJI  F,ARR B(:XX/4U0-7-M86+"+L+S\KE1A-N3#,3$U\%,XLG6/O'/D(_1
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M _J8^?O_ $_Z6M-->>!#]7@!T#&,=G8/U^6!''Z /Z_/T<=V?Q\_1Q8]U?\
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MN[/=R[^_@MDIRYY6HRJ[)M>Z%(.3D@+9%D."AR'*4% CIM%,QACY I?$1/\
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MGD'=YMOE^3C_ .5G>4#74 _C \[^-?\ Y+7C_P"5F^3_ +1Q_&#YW\#G(?\
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M_P"]XVO6VBKBT@=@PW8\Q<-+M+.]9H.'*4C+5'R]QJBME<I'(W.#%2R24"=
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MI=Y9],3"!7LMN]7HEX Y$=8Z*VW50   <!^4UZ?3Q_(EO$&O_P '. '3M_\
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MNZ]#=1@'4 F@ ._B/F-_O.DSVBAS>&+BJ[<C1-AZG/BF8Z@@C8[V-MW;(JJ
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M-)G%%M*QL3&.9E,4B>$!B@B)RF>-2B7J<D 4+ >HV0:Z\E A&%@^"200;V4
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M!FS0)""DBH8K,@1J?[;$.K&3 _JCA&P?%5Z/(UEJ[ X&8>/);UP6Y)CB7XH
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M<:_I<8_6_'PB7F!_$SH 9Q@0Y#IC'!PQH4"\OZX ]/'6&@B&G/'UM?V0_I<
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M3.J]%6&EPI&V,;NE"FH"8[WM(>PK[L2!-M/@Y::!E)JW35&AY6("$CR*R49
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M;0%CD39,6L3T"*TS2KZ4I1((A6IP@E5P( ,4]=EU$0S.U&RL_<Y2"<)-U2%
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MHMIDL,=)B&0%S#\ 2X$!#9)F">+M#%1-NMR/&?Q5J4*IGN@6_C.EVEMN BC
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MRY09R*4%ZU(R27$2FM&>%T"X0M)?CMC=A()S;@>RFR+!1@"8$AN;\P^<5^O
M,58"#P<5G"#V>TS9"B260+/*@#*:'$W-?H]W/ _#FZX%&$--KB"P9EYH&*X0
M"(TC_R/@(0@%\UR!KE[*7@9$O\]-+L<0_1 _ZI3J9?(162<6&G_E1U$@FFVH
MN"Z6V8&,Y_*H072=0*)"O=5HIV.W/PTNRU996<7 -##XTS94:7F62.2SBV&:
MOO0<@()^&0['4- #G4R*!C17Z,!4RM0\9%P4'0%<9#ITH-T0"AU=>O$$ ;$(
M/Z-<Z* 8-N,U@J-?BW3N_Z=(<=TQOW<:>W0(O0!:A_,596&WMXY?6BST.>-D
M*4]3TP7WMR:W=XZ]G0EVWD$H/;C;P>)>Q;#_?*HD9\)HAS<*ZE-+Q+W.+*"H
M;Y =\4;,_XD@';^#K;@3?VC/NBP>6L@M,J\3MT*07B<>[%+'SI/]%1X#\AC]
M=U-!'FOT>VXD'.9/A^-2?W>>@T+VX>$N/EO]W3]P1P9G\?(IV !2H5+ALN>&
MM<!-J^AT6N5Y&JF41^SOF^[MX.1]V(^&1Q3J*6'<<ZQ6TVGK$CT2D]TEF!$N
MN,U*7_V1D>,DEEBM:!B'@O9)%-L7&Z9KRGM:RZULNV,=9.E/I?K[.[(08XG'
M+D0-R)[S\3NKO$\KW?JXQB)QV>&T[,,V,9R"8II!O5<UW9'8[LHR4<X-YMM8
MI.\K.E9N:. QQ[Q[#%Z@)RZ'#!ZG^T3)ALH!85ZN0!]X4BAP_W6*M2D;O TM
M5[='%E<[ZUTMY.P/GY7?BMB'W=YT$KR7) '1I T$_31J_NE$:9JO[S:'H <Q
MVG1K6:"A40/RY46U6[%0<2Z.3+&2QTN\1<K@(:0E#Y<Q_8)"@_^9IB).<L0)
M-#GY!PMW4*(;"6:\,6#,'9:^JHDT+5#&D,F2^J1H'4 ]F(A@EWX/=VR(A:4#
M&3-H^*N&NC;8J&:!F='BU(!:EHXD"B>7G /W<W>B/6@H$^6^@QB"K_K/!]CX
M$RR]3L@AC_=#K:*'HXAR(1D>H#'0=,;BI=-U!C]:(BC27 &1H&EH?D$\RJP)
ME"K6Z=B"U75)436):E% R ;FI TP_>8HAQ@=A_@+86DH0&"FR])XB8M+MDM%
ML4@.ZQ,]AY!6V4=P%%MV,$**_5M":$)Q ..PW*P"GE#,W)>=\BZP^(YD/^>W
M0W>?9M%%4!%6 .X53L:C6(3J@CELB^(MW4^GF.?IX7GQ#0( Z><T0C0.4-$9
MEH4]<&VREG/'VJ0-@%:A8-YH[G+L"%HY0.>R_%R^KYBF6*7'?8;G[I,%+)%
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M<T2.RZ_[5:>'--]IC2<!X:<Q6IJ_IC+C<8"[UJ$LVY^^T_@TSQ6_>GP6=E\
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M$$Y<_45+O@Y?/: \ADU6C"4TK\?LSC8>JOQ!G7[[]XR]R?L!K0)3RBK#[!:
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M$!+=J&\#^Y8/:\D>9@W1&XR*MM%-QH_K)VTIG?WFTX%RB1N;UH2T)C-WA7U
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MS?/O1H-V,P<Q62%PQQ@ZA<UXS<3?JCH<,[HX2_U\F$$L41Q& 2:'W=HB_DR
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M$R[IFN+V=/,;57C81.AEYA"W-#]DL>6@MG'8>F%FHW"D.SLB]L-:V$Y>77"
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M53$"&$K;(K;'.N9=$&=!,!1E0^ZZ4(SHZ6P)5?N>HU#:   *90@ \.#Q:3@
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MU(<0 35ACH;%",+ZA];HSW]Y0ZI"-4%EN\ ,"ED9%M:X".FUEF2B<-B,2%0
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M0!P>\H*O%EY;TZA76_0D-\&HT!<Q#DNWTPD*JYWFD*^##&/&<12X$>0911^
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M6RVL)E4D8KSTMVMT]H,<OR(6_E;6WH1F:%53F1#7'1%[%O6>Z<SG(XMVV$Z
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MYI;)DX7Z:]:>UPJ^^Y]8[S^4_^Q3]FG5A\SC"8UJ;^R?]8;IB4D5QA[-[N5
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M*H0H?HK//BK^6([60C6=/,RLFP_Z2F$GPQ7 I3LYQJ1'_[UV.^V9"R9_SFH
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M'W60I\2;M&9-& DJ*1 SV<WX%K;Y<ML[MIE?*_"W-YVN25J7A8@;6X$_I:J
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M#%>?9(IM(0[6?"))5,14])J^#%21L'A:\*3C\LGGM=4<XBI<S@L*!JIBOC#
MOJF9%.G/0Y(LTT/Z _*EEU1 0B[QW6*0D@;#=XU_@$P0S\0M,4F#+.<Y*AS3
MYYR&AMCSA6M7DD29EL^9Q1.K]DL-X,F \,Q8TPFBQ!TF.6K_=&U&-0WM/!D
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MW\O$]WLF^Z2) J4.U^,0"OOQGR[F5AGR M ']#7E%)XXM"+5!5X)M\:?AY0
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M&:HF/T.)%Q[FT-T&.F1<Z2AR*+B4I@20ZRE(!C8**JB9,]1RY*0!$W2  )A
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M//[G1Y]_U.?&K-J/_M=+LY?L./W(U_U.E_F.,^YM<]_NZ.=<9_8>CC]QM?\
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MRK_VWNFSEVL6U-DW)85^. &4# [HRM.5L<6S3 "MHV5;D#E_3 &"@7.3"
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MBB9RB4Z9R@<ARF#!BF*8!*8HAS >/X.8?ZC;^D?^=]X\8^&L,?\ L-OV\_\
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MXS_O,/*?D/\ \'7:#U_]QWHX_F8>4_\ XNNT'_B=Q_,P\I__ !=-H/\ Q.X
M/]Y?Y3L!R_X.FS^G/E_>=ISX_F7^4[4,#_P=-G^7=_@=RX_F8>4__BZ[0?\
MB=Q_,P\I_P#Q==H/_$[C^9AY3_\ BZ[0?^)_'\S#RG_\77:#_P 3N _X%_E.
MTY?\'39_3U?WG<?S,/*?_P 77:#_ ,3N%[;M/Y>=C=L+6Z:*,'-FV\VEH-*L
M+ABMCQF:\U6X",DE6BN ZDS*B0V-0_\ F1O_V5!+ P04    " #EBH16@!@#
M#3@0!@ E/ 8 %@   &=J>6II=C-J<FAO;# P,# Q,"YJ<&>,N@=8$UO7!CJA
M*T)4%#R"! 7%AITB @$]"NA!5%20DJ"HJ)10# *1#.5X4%$BH.(Y",%*)Z!
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M77VS:/-1;I+&$4>C,*G10QB3H%<5?T*4)\FG]]'.<I_FC5Y.=A&<K 9C?6S
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M%$Q(]N#:48?Z8J:)OO'GLQ"']\J<%RFI%*][!?S*$ >TA^R5K I.B/'I^FC
MA[)>*[?DTSXP*0MZWVFSAD0W&T@#3O0A7[0U]*D3+KUJ$DRIHKGHB0[\7_50
M[*?FT%!"@LS^FU25+ZR<^619MOTZO9"D7=I4%;_]9;./WQV%.CEP0MS5$DE9
M?B9KP65!8$ 6+1])(+VH>@959_;&R$K+(7&AJJ8U(1&I "]9^H1(H)>GZ>^
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M>4&Y3==!I24%1YOU"OS'6<L=QG=*1)92/PN-L3.0.@X&POKNKK *;87W.FN
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M#00O;EFP4K 7,SZT%FRS/(KNL#PJ6-Z@,C?WB=C_SN\B=[ERN>%/BY'B=W(
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MX$1OFT5RVL"<]=&:II$NDLKKHW.\@B.GV[2'A(8\_KM>5T,'.1"NSS<X\*(
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MR90/'R^!?SZ'X#F(/!/X^HWZ5GTL6>R94?%^I3W"80<!E6F5PJ\H*H;$5W>
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MS+?]7# 46Y6D&C [ LP6,$NB[<PJH!O&:4'*<F!C-2U-+*1@LA4?!LLH)S]
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M5WUV7]<ZAEU(0&90;6XFVZL/&/Z_+M%@>LB9:7P>#UR2!J'/J,-!4#^.Z12
MJ:TESV-]-M0QHV6G@*+!]3-6"&T+PM>W5Y.NZ1&/3P% [.Y\MNK\H@!\99F:
M?PK@QLAM> UR\SDL)^.!FM#=:AZ:%? 9L1LXO\2BTI2^?W@8!Y^S]MM%7]]8
MB)9V(_\()#?O)V':=L#<9[B$=FV.S*3_OR:354PL]F*QV!:*V$I<>M[(M0 <
MH'[UPZ_,ZI'@86)'0<9J1AI_FT+A0-LW.K] 8]80GS!X[;&])NOH1X.+K1Y4
MU/3J$:;J[(?'R?.(7&IK/)YR$CBL\2 #7DZ5Z_\$Z54[7NMFHU&+:*7>)R9Z
MD/9S>Y@@C84>#O-XV"BU.OT)'( XN[M[S^=9YQ)J#THJRS"7/Z\/9^=55.@0
M#C.5BK8/N=4F$JG=P##1+_*;SBT<"D!I_-^.S(EK>I@W<F&.FP-OD/CCZD'^
ML/@TC[&;]Z#,8Q2 Y+P#HUA"Y-E;4-_)^WH!L@>Z9PBY=AU'(&)&J_Z,'4GK
M*35477$8IS]S/@#S& (VF$@XQXCH#O>1Z%9&X#J*^'X!LO7'X-:4MF-"\2?A
M-*'1LI]'Y+EE8MB>?!4(38+D+G#5@5X2H"#I4$C0[LU1+VG&D9G&6B*@\(SL
M6U+;,?/E7_$5%^0OGK?:;9/ )ZI;OS5=A&'*8PPGV+:8,5\FE-!<C1NZWJR)
MGMP#0J^3-*"^[#"5I:6E[JG>5;WQHW4#H?A"RDYC!\>FM;*TNX;C JYX:T,%
M 5Z-ZAM"V*NQ:&14>,(:SC"'A44LS4C#K>C\_V6C_B/\HJF)03V>;B#J,*$[
M JH*UP=D>X*F2?5J96=;CXC/ W"64B+C2\GM \8%-S:>G,3']ZE-CX9=J>;#
MA5*S*68758=,C/T<;4+-0?O09P?,AA,3[8 RG-PAP*$;.;(T0Y'9M?@+F2C*
MB#]O)"CG]R5]R+;:A./I(O0N=M/23D=2C*A?%>(U^$4&KM,@\.:@]4U$=L;/
M XH*,4D#29?<B01\@-X_7N[&6U9RL-  08;GU.I30':KB) E:FV!UK!$R$JT
M:\,6!YI3)^W3@/'P\M$B<?GSP_^#S9;$OJ>EG2 M%6ZU*_YZZV3F=H40(/X\
M0[N^%/S?(<W&H#T!>PI  PEBU)]GH7T_?IWJ_75('=2).1U1HS5308(*','<
MPM>\PK)]"&)S.E;K&-&0^!B*;EO('F!,CRG,\4/\T1]O$'";0E*WYN2@7RX5
M ,_?'*F2>L"8G5:5A7TB#?K+8&8RX:\"VH*BB^D^J8K4-#1GK.EHZH^/+3$#
M]P(G")[.W$F2Q N7 [_%OJMX GJ<*U];XV^;+;/]WYP;2KN$X+03$F0NMC9_
MR"S06&2<79C*EI?F]%TW%[LAR&E:T/PV3T9&VFME]&]U8>,:=9);0T+A!L<9
M_!HDS]Y*3O6Y64*;%S/0CO YD1IKJ"A,R\N[+IFDDI-ZLYCCCVB&<N87LRKU
MFPX+ <4)\*[9+E8MY?CU8;L6F07I.HT;@^P?H8AT:R:H@EH]B[K7#4'!=<$4
M=T8G%3:=F]=0;V@$JE\]>6YFJ C_-?(YF+>)V]K<1-FR,4[ \8P"=!USL!C(
M!RE,D%\_HJ.OK' VEVA,X&#MO>]E>&GEFOK<4DA'5:+CD<9<ZK2GU<AK.S=C
M,4P_DN+0YA\CQ DQ A^S/C1\4_$S+=>LH2B'S2GT;6+19P+WJ$<XW%,GQ)U#
MX&_R/&ZU6Q)W\M*J%+VBH_8#ZIOV+2,M+DTRHUE<,DH3?15M\_E*UL6;?%X>
MS&C_L[01@AY8TAIZ*W^5R8\Z:#L9[)%Y(E?0PO.%7XM<=DT9!C5DJRJUO*I@
MJD\'_6TAI?8\,J2;1QNVJ-2N6'.TPKW5_<I7>1$M*RU<[UPP])6-\11  Y23
M;8XS+=>J'->MR]D3YJ8=*!MO6OX ])C,2[:]&\]R"HC!J7/=MK][QPBL_76_
M&"A;^Q=7"$K,RR^,4ZF3=O\S8L0B_.Y7RQUZ1[(1I7A?^ // (-^Y;;/<XBO
M\]'Z$?/T^*4#CD0I77]YD[ZJ1^)BA4RT-11Z XVVUY1+1_T[[F]#*AV15.E
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M1'?L/+(4#;AB^Z%:@<-R7WKX<H;K3/>G%:Y/B>F(ZA,2YXZ5%V>^@:<K48J
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M=$EIB+%:YJ[%5KYAY?F=8C%2.]5[/D7- \G[9=O+:^HB;;"@Q1X!LTVUOT
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M4J-VVRL:-S0F.EUWO72SY)E"@##+M_M\"6,]5\2)K'YG.6[66\D^2[J5M\U
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M)T^$%@:T43T9!T*8JHV= O8[X+_NG *&?U!,_X'<-K*!?:> UKCVTS%E17(
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M35A<7#SAB9(/3L1>@//8<:?Y).$&CB=Q%BS@O@W96; @>Q?N$YD*Y6-&9OZ
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MC5ZWR/U"3.ID"F]RFWCS($SHSL$P-[B=CTNZ7)QT;G^;K$O(]51<[*"O2*V
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M-\IE)^O&&P,_<V50?KWQ\$=>_I',@Y/#Z9D^VTE42='W5 />Q>\"ZJK3R_&
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M/#;$(*D! /BP//7->2HS,RKCVJNC;9O1"+IZ+0K7OQYJ,<2&6ZQB(6,8K59
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M;#//-GIGA)DG-=T=F(R]N[+AM!L96.RNP(6E<WK2&5LD.>1)-2QF<]"PI9R
MACN+=]!&+%]L+<(N>$%F#G]?GL4S]2M^!U,33>ZGA8P:;#W,^CP9>ZGG\#S?
MGQZ>Y0?XG&&R?7K.[")R5-Q,I_)WWJN!'PFV^(-T^[O '(9A9U!'"_<0:4*5
M'UK[Q,R7Q>X3TUX?00?^8&8'^\F5%F%E@#(R$;$JU&H)Y8O\'_F.@$[FAT+A
MP=[UO]5TL;XY$8^Q]F>RA<Y(H6I[E>AK8<#_YK,G]<WQ+!>-K&(8*$->(J96
M+$Z>Z,UY$LXK;UC6A]-XCP9V[]NGWP4(_KIEJ*;0K#/'9V[,A[QQ0L!^9ZG*
M7!Z?(G<GN&SUJ* @A)Y[6 ?-*+)T.;#B0&< P<X_FX;NBS0BUD\J_R8=*T!J
M@:GF)KR20^;?VHR\;0I$+AA*]L3W27(WR9N>S/>>B=@!CWA_HBO9P/.1I 4^
M ]E;#TST,!FR>Z7+$S.^Z.?*#C+N.=8X8<Q88NFM/@ %F4L&ZM0H7_RUO&'I
M-L'>]U_DFJJ1C9*//'N>\QFD.WRB>)?URC3 ]YK$R.^N&@0D:-&7ZM//!+77
M+ICQ'@27H@]"NK4=55REJB)A1':F,CA1(#I$;C"_N@T693BLLU5;JGS6[EF^
M+Y4=4F@4%>EW=9>91>3\TL9(=_W!;'G)O=N!KJ$%JT,CO;#@,B.9 =H]&"$)
MB;##&8/LS^)SMRAO](??:R=C/[.O=_JOL;D2 <_-&XB$887G](/=)N%TRE$V
M)UCBK8/<C :JK,RW5B]F;EVL7-6:K?FDY 8L>;P\RCCU#0JEX@:AAR)F*2FJ
M%SA#?GXU6Z:4GUY##EYVSMZ8>87I%B@S#:1=-6UK8W-<57N!;JWD5U/T+U];
M%JO8?*7F@//8? 7Q^(]%2Y9[$Z.*U_6I>,CMQ.2^)4!G<-7:\J'_+3OO?$WT
MTN>$%^2@M$[70>Z$1/)DAL<F<>ZZ[Y_1E F$<$2I<!#Y?2JF:58ESSB;C^3V
M$(RIFXLS2=-G[^$#!K_-?"*>5#-N)0YZRTJ=?O2/B8I\C3PQ3B'>JE3E6.R3
MC?=]B67(+6;'_:^;#0Z1'59D_,G<<Z^J568G[,/IB<J'2(-K!R^SS4C#2.Q9
M?6CC@4DSJ8_UV%+/F2H=9*"$J4G.83\Q);S\.<>,A'IS8UG*>.-I-FN6<4C/
ML2('H]W90?E$1;J>AO=Q<I -1 >_-:67('\.0O)<XYW?JBJY5= B9/>9?9_W
M^7]K@[.P#NT>1]_I)S@6+UA\DZ4\C<D;'[VZ^5;,<SA0+!J#C*A*C'!17.C<
M/!E[9V96N_JH&MB,VU'&06?^F8W--4])VEKKWZ&_(622T'K.4_IXZ&_2(9CE
M/&N?I.#DOZ\MV[?6OC#T2$!/(%N5W[-PQZ>S^PH>+=7?8[.V1BDT>?B76$,Y
MH%TPN5?P<;%:_U;*#+>7^EC>DRTE#8Y9/O!]CS&*9=_V1/W<=@6G&K909;\6
MHO5 ^\4#$6.IC[N?EA9XY]&NC3$!!&V0*?E)V1OX+7;<01E6'_&VB4(38@+]
M"E9AHD&YVQKHV+V;^_K&=- *C=,EF\-'H /0P-_9MB^+RZYXI*VN5BY(4.EO
M6<G#:1N?MB0[6B%YHK0Q+7;]67.[9^X,VR3&LDG<*>+$_*?;K#%:1^FE$1WD
M$-CX\'EN%_4&9?,XW"6SNKT_8>^A:@W)Y^?YRKF2J]Y#PA>_YJ4VKEE@N\X3
M0^&__QAW\2I#;9*93QBPF[G7JO$'E'<H8.L$,@_WE_]RDT^^YCGX@1%/=!0F
MH'M]'QC.QLY 3J4-9$OV:"?.K,1IUYW&E\T_V$!E]P%,Z,TIW]P\+IPP=6(^
M(6$/5TK[/:4=1 ('JXP=E^_/W7IW92J+W$NM&>$$%[L=\LMP,+4O])WH^_D.
M1C K1AC]^]1'\Q897O:<%]45E#B'0'@%E <=7UX_NWJOQ7&_=7I8&:K$ MO_
M!CZ_<3(A=K=H:R[W.EPWSAF4-LVW\;Z +7)S@"B^OY5ISU1D,^R&2^L\#QQR
M,]X$T]E#FAD([%HV^T)1*=3,FR^LE[C9<4;(&O* 8O_#^8 9N4K+I^L:E[X;
MUS@NBWJXMK>OZBAWSMDY[O8E;*H-:_0(NI>HQ@$+*@/6&"\6L*:8-#OJ>R/Q
M]DB#SH.[>L]>6/;4O]"^6])%\/CGNIV4:Q_=ATYGK$'>]?;U.RH_E3DXK'YO
M,7]U$PKYMWLH"#C319/&#K ^\-#H.>/:N#K2!@_R##XSVYX2?"A[+C"*]%J(
MU)E)1YA?%S@5&2VQ6#^N!%;GJ'9YTH=*=HWOVSN2AC!#<;=TS%8A8)E4S)^Q
M9!F9-]3%^HD2E'#ST'A64F!6TN=B0TEVR>79/Y,T5:H@UKI,?LMK->7+^CZU
M7U_63PDUXW?^9A\TSBZ$&Q8*K2"8(Y6K5>4W_?+BKM>OVT7ITC_PTY)4L/H0
M%9IAP0Q7SU0Y_&P 2V6J<G9OX\SH]0&@-9PPYNG-ZNCO6+ND7KZ(Z CBHZ7E
M>*./]>:ST9'CU^WM$:5!KD?]?"RST/G>I'4VZ^'@;./4T"3_RT@K\F-2T_V!
MQH/[-KU\-)/<JG%&;_2]WDV>M\$KS!#B7TSO$'^IOCJ#0$4=\C&YVX*O%E\]
M77-W;+S.2?Y^=FG/IJ+B@EVF.FA??!A20*?+%6_OG"%AI<JB[;,>SF!$GRZ5
MCH^K<\K^.NI4RJ]\>&;$XTWF78X?W'!E")MG\M3 ^/)WI%JM6O[VX"!LQA.=
MZ;C#V6L%'9 , 5%I.31IH0RPV!<Z_0Q?A[W:9PD[ J3)LQTZ.ZJ@MI">J D5
M#>"ONT!_2]I^!-[S^@[(C>^Q0_[F5YDI92_F(M2[JG+Q!8 '0_* Y#M[?8%+
M?DD\&>&&?$?A&-/V$I>>;C@QXX+^85\:"7^.7]I/[-_OK$1[.#?8@ZOZ"L+7
M&ESDVFL=ZKO?"BZ[6*?HH,7*4>LE'#]BPZ%+(.I!OA?&"<;V[ZH,5NX45?&'
M[Y@9I^#Q?83#T*4#_.#"+3<'!%-A?:^)X.AQ Z5-OQ<I):_>Y*K'9T]-&! <
M3Z,X(<,SK^E?##SGH_(E8I$.,/-'K-APU\J>7!L9W$HP%.=.EX]]2JGA8JP^
M-KNO:6%5(?VQEDFVZ:=".=MZ-*.DK?+]$)C*$_3Y)>6-_383B'HC;8I;_AOQ
M%Q&\[:G^^:M)VG9$)]Y\)(F@PNY)<UD#N>;FEMOT6'F%.8O+"7J DX-\^P@$
MX%_15Q^8OT..O$^LIJ8RPR\].-+#'$G6'M3O,?<V/7_E96TT+N\XXMY=%SF_
MC'BD@SC9;,Y'LO"C1O+[MV'B,]7;U[,#*'K$>G5$TKW18TC=Z1\<;P89*3K(
M-S"T6GSQ52!)"\NT ^)?FJ]:S#4_SE,6=E=G595)6<Q-<WY1E@?>9/7=BI7\
M]92N#I2DAPAPSKA Z\=B+ISG _36)/@_+O<X_(CABLB$GZG/"@:W1KI3?+S3
M;&3W<ZCP$%_SZBOA@95MRWQK^PC+TMD%)PP)3^?DC0F%(3/X_:_7LI6(ZQ/3
M9?7W;CF#]/F.R=%-I86%:-[X(=+'MN!8HRD8E-WWF\B[0_/[T\[I7VF9QU)3
MU9BBCH#L5N5L\W%TL)8AKY'7&O'O.^_KJTG8]$_@)P:I58,T:ERLU?\S[8EF
MWK *$:0"PF( 33%OW]&T6NXQW@>X6O_=4RR[+NH(::I5MM$C/]8F&>Y@3+U>
MYX(TCLON'GELG&$S))A"V/X_/-!!O\C*BBP642>P@^X$2CM66=(WA;PDZ+5Y
MOZ6OO,\2XK2CP4C&C7&ELZ6'#LI/L<25/-(R\(D(_J-UMUA]DU(MW"6_OYX!
MA47?3:L7R.DO^XBM"DF@8[[G.)#"B:%;QH%#&6,WS'_')VZ9V+XSQLE3.HB:
MB+7>VANE1K+S!]*VGA@!@H(\+K^["3.,YYGQ9E:-RP+/=$S2-V[.I!Q5ES>N
MZ HB$&!CCQ9H'V2]ZYD[ G.<R5S]9,!ZR>.Q_$T^?13]QMIDK#A;+I"FM[1%
M17A:&-7A_;2@$='T1[X=S=7?ZFPG+'CG'#E#4?>&#_MLG/&2E)F@0I^R;:A3
M<%T3NOO>T[7Z6R?Q@W(>I6D26T 2I2J+>H+(DQT3*[^&E+Z="XI7L\%(W:6Q
M%F=#HUT?567[)WN4:ELEO^^8*B_[]N91-65,>;-Z(!HV;)O[K3%.5U.HQW\*
MM>3OF^6Y& 24_:R@+JWA2BY2'*"R$=4]]92RDD92*$<#GZZ\YLR4Z%]A'ISA
M?&9W=G,R_!BN;SL&LYDC@NF') M##.><QEY&?;CL[MQ^ O$S8@^. OZ)W\&Z
M$>)*FK$-IH>,Y2 6(=JYH%WR%73!\XX% ,]"UB[=M(<"]XHW>G65SNSN88UT
M&B!<#9+TK2@M<*%;%2B_M.FG(SMEDCHWLNLJ;RW^U0%JJ98+-$:*MRL"K@]\
MM!UP@ZN;HO+&YE>6H%;IDIQM]CPT?KW/^IR* XMFV_JX>N)!3M719)D/R;[W
M1(*##J)E(_G#][YY5\#\<*7_XAT(_I/#_DQP<Q+'BK2IN<P3:/9U;"X.-ZD4
M\XZ@,H*1],/.N\#N^FG9O((*]HZ7-E>]H)0)2H@!@78IF%];N#C%/[=)G^/7
M]XH?4SBS@\OIY&%5S#QR/E]3G7\\4=(_TM@[+K^_HKNIU)@(C]Q8LKKC*N(,
M.DAU#K53,AG./R_<(Z4&8?CMI'^V=+SZTMV&,^_WDP#)AN.,_A\V751V%QIL
M1_[2\LE[*YY$S+(/G!L5=B57!WE;+?+$M$F\IN C3Y#?].',+WWC$<:ZP557
M/%,K/]^4^'CFDA_=\V9ATC...B@$V'>Y?&/&]\>/R>"Z1M3#_?$]L?Y.8[^"
M"MX1UTZCB16>6)[YUII2U+20CP^&!,^14FZHT=JFQP8K4S,8QPAZ;P">QMU2
MY>]/>>EL;M[Q7N!C>94LEIQ5BOR>B\?D'N%BZASF41;P%W<;#C5UFFR$5U26
MD*C?,-$N/$&ER"NS:HR99-76/KEB>'7K$38\1KEVFK^^5YQ14Y)U."][T9*,
M [P9R5!STDA%N>5!C9^V_<33F:DUOC7LFDM7QB8>J\7H"N=F'?2_MU4MVJ"
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M6U49:SO6@[8K$J--DIBMJUN\;3"X9]1I=,!2&<:>L .R2T0XNXB5E-R@H=;
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M3IQ!V/5.Y-3&!_KS,Z?LJ^;I;R/O&BKI"L WW$)2B30U\JR).D&2',WZU-Z
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M.;/-L*3'[>11_5G1V*BAAU/YMK\HI^!WW *!0'CY!RP1+O7\(NFO+9H_Q;]
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M]D=T%I::RO=4KQJ)V-;:E^FH10K[](7^I7R<X-Z8WJVHA;OS]7LC.T;UB@2
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M$$H'@ 9YG%RM[T"]G+@B%.V"6R@8N8 V6''ZO!G/,V[*PE\/*LU4L1SIA-J
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MJ3(9IUD2G8DJ^T= =CWT$B7Q\9)?<1O=WSAOV\%T\-R?T&\-^ B!J]B#BO
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M"HEJR.VM.M7@213U'_"MT^*?-K%SF6.V>#0>TH->9O- )7I_&^O/8\]YH%J
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MV(V!*,CD'U=;#P]E+(<])"VD)@6U.S!C'!XW.<W^Z6(+J5ZBV(5Y=,^UQ$J
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M&GZ[54XH C(*Z9V;(SF)CSF@/[YKK9$,5ZN7Q6R"OX3K85CS/%!++8GD''>
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MYEG_(YLS"V@FC_[KAER-#'] 7OS)X&.#Z VN*;>.L]8'6\J&K7/NDEU#?NQ
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M@V7\?2@X;N36[@O4<#B=.<@6M=XOJ&,,P6 EI5&$43:3,4#"YHD(1VW'UH-
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MH#9(Z$"@_<K1U0T)(" A@3\H#R3H\FR6F0FQ2_C8U#\L- I@?0*+X43]I!9
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MWRZ-5S>_\J,&@O.79]U61MT0M O>:=C(F-OG$$_9**\G5P MQ4V\3ZZ@I'N
M,L[/1-'6Q)^>--K%#@B,[E[>WI_[A):Q"W@%V,VGJN"Y910HAO^*:\:M0".!
MR_NFZ78Z(Z#\<T0[H0@;%A7NX#KA N686[@DJ3NU<9;1N0_NQ>'/VSF_JE[>
M0:+Q#)?F'4%L(]/OJ.K*PX[S6)Y(V&(N$8YZSOBD'6"R(Y)5<7/W$,D,S71
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MV:X@);ZQ)7V-H8:^,L+MW\QG .$(MZUEN+-92Q39$V2,PADQ"1"]13KH!+F
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ME^1^TK<? ER[,61D7BCH*BX4OD4_%1<G[E59L>8<7Y6LQ%*8(<?T9NIF('<
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MP%>59:C7$$0OK^@T'E.;4#4HV,T76:8R$6B'GR /O69 <^BO43K6%OSX#L/
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M2DT,WRF<.8FK="&1#KJ1>GI?Z# -YUTD[M,GC5[)T%%X9:^+[=D@$Z<0*T^
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MP9;>J4,7*?JUGO]I$,47X']C &:^D((@[TW7-QU!2:*'7LC#K&?&T/N8#T^
M4LJ:=IJZB:0>4'B=5_7R,_NZG=29$I,:#XQD8.C(L\M'8?3/(V%:&+2 _FC?
M_O^:UX+_W_-:J807R#L\;X;;>\BEI>O5Z4*7NX?L$P#2E! +-B -6D&+KN*V
MESS^RM8Z@]SJU=#.SZMC8.[$+9X_.N$AC<#(VQL>0Q3Y-O 2^>PW8;1]WR/P
MR,OI'FL/./*/@!YLZFR\RN_ZG9WKTA"L*77A[,T^)PYDCDUO!QT/("-6%9!:
M?'6CZZG6Z"< UI+-0VO-+)//)YU@?%[<E>D%[I,):Q&8'HF+<"W>W4+46$TV
M* <X1G!R>WSV4-0I7^F;R>[J^G@#K&>!21K1P]P,VGBU#52SF"R9.6EX6S.+
M,PN4<C?]YG1D=.NW$28O^+.8^,XB'=13+@_,"_RVFA1Q!T>[I 5P=W-#@AWO
MX,%:%T)W+4$9H[.N-1-8UN>!MJ2!S$&O\$F)TK!AE26OMQK\.E1[L%E,^BA2
M^-D6%*6G-BKI$;&-W-S.%B>E]+H?V;5^G-> 7$1CK15%P+[W++/DVC%XA9CA
M.,7ID Q W=)<I/43(-7WR\FRR7K87]=LUY^!CE9]"GR!;,6P.M[*Z.HRB!W4
MGF^6TB93?/[E^[2T#(/E:6$L!<MA!WB.R>E+A1Z(<;)^BL;0&$WW2^:=.2-&
MECD/'AUU%L)ES_W=R\.H"XZEO/"Z$!54RF'-IM+B,;RIOEDX_OK]YNMN?!U2
M [-OVA^-&BH^4=$HSC[?> #EN(R?O<<WCG\"M$@P[ZHV&Y[@:DYATVV B.Z#
MG@#@BP\]1R6GISFTX_([S+I'N7\%YT7S8# ;SP 7T0X-W6SQ(&_S,DAQRER$
MF.X;#ZB>T?+-=979ZOR0LQ!O6A&)GVX7/N N+3'YA-*O?<^@1/:$=V0P_;]$
MX0U1R;NDG8AID1O$ RU$TAQ_!1%H*G+0E*?;\[[^PGU*3Z$C @=$#C-3F5_%
MTRM2YS&B#PAMO_[A:?4'1*3P@M%/ITJ-7L4_.)][5423/7_PG5'&?6A1<\8%
ME5VPVF) W>1W\-@L*O&.%?$$H'SH\W3Y73ON-;]843,BVURR K?:0<P:98*Q
MTTJ@3MTDFG,:')[^] XZ;^QW%>X?!'^N[SCJUWY0'_CK6?&"MK%GLCA]M]1Y
MYH+5&!HE@F%T429_W]4A]<!\1X$DV$!09]1?]' X#)D?&]Y7?A23<E%L<FCJ
M]'0<CUVQ='.MIO[R=G<',C*+R6B6TJ\7(7Y&[6*6HT\2-?PV[2X4K48_O>Q1
M+%IOWUM$1TTO^?T>T^^<OE1(Y0G 8-*=,;$C^&Y8*M5O-6$E5<_&R-H;9KPC
M^/N?TEC.WIA4Z_+THHQP/%Q^E?#:H/F_&"H'OX;KHQ\#C!9^Z8T8:9I2[R_1
M)LQ?-74)J> <'F]#2RE0([V0/VICT/-5X-A>Q_D3@'?OUA$&M;\(C 33)^51
M_SRPFQ'G=0H8(9!_Z,LN5\>6U1C4',-3:#.@HG0_VA6:FHK!RF<(.D>7#!4+
M[68IQO+Z1D(V)R?WC-_,00AW?,_7P*S*\S-!XQ51/]G.$@P2#T=SNV,;=ZCJ
M$$.:@JLJA)WE0\MJV@VM+=+XO=>?O<<]!H^.\=[HQ3" D2!H-^VR1SQ'=(]N
MC:3;.RJIN,>D#-&ZDU2TX9T$_%+/-TCX5&(I=[%=M>7[^(FXY/Y2,[\W8>Y_
M< UEK<] 55+=7 @EDT2QKCU#/ED8+OU9,#//X<IG>3FFX@SS(2I/PP#_L[^-
M!/IV-]P$.C,8E?Q:!WXOW)%7DY_71X&[>M.T9-=2+B?B-Z,12?[.*"_*\(J.
M<$Y@0P5,=Z^05PN>-:JE3&1SP0U4W_E$]_*UX-;@&MSYW:6J3ZXE]/5R-A4K
MUC<R9JF#.KG @B4JW21@O.:W6GV*G910:<<](%=I4#!:G5)(8$:8Z^PN\.)#
MWG8!M^]GV<QE8;7.Y46'>/OAXMOWJ\B5 <;BFI&YDB1\_ _59J+Y%-U9ZY>O
M8IBR9^MQ1>@7HH[V">"C#9,48^YN]/@F'T*3:!@L+[;OO)ZA'M'Z_DG11D;.
MUZV_UN-6NID[/(C)<O'[SZ []=X"/EGD!CIZL'YM$26J)L%L!!953ZACH%'S
MZ;KZ)EDR.D.*"XP0L>Q-,IPNAKP&U.W(RM=(249W@<@DU>??5Y7=PA$9#:JJ
M-$JBBX*"H('D\O3!J1_>7SZ^LBNLBFAA*P34': "A3O7-B)U%?Y@?GVF/6NY
M$\ H#F-M,@+CQ2:K8>S>N?VUV9?*Z^$.8>"45T?.[XD194KV&E+#FV^ 0#.V
M1B__9V,:Y@YSCAYM-U6E%<3I8Z^E>_&%8,RK9?4F)XO&R<IT@_;]>J';=TCG
MG/+Z7'V-;Z\"H<1GF[E$!$&5EX?6W']R+@Y__A1 &?ZM'=U775>$"14\3!S?
M4P])V"SW[C'4AL&PE W$DZ?TM%15%>BJ/-F)9=P?)0:N==\JMZ])#T1+\V@,
M-J,M*RT/BF)'150%VB2-6:^]ZTZ_> ]9@P1<4_.BI-8D5EM](DV3<.5-"L8E
MI9S-F]J/N&A'E&8[/7&)O:Z\N64P<18X/&1?"YE/-NQV$3G/Q^Z_E6"59OTC
MG'9]+B59DC\"=_N90J&ME*:)8,%#6P714P'JY"=946FB\O4^<I<305IW<8HK
M1G!;S5DNK9<I-8M&<:[;%^D\$QQM\>,/1&2.'^_\7\E^\10(I:IK=O?D/UO]
M#Z;^5WW#K 'U!)@-^(BN[N-,K[,5;-I,^Q2JMI2[=Q=TS_0/ZN[<G<$Y.5R[
M*X]1/;XG_;^]L7797]L+!A.L%' ,6K5^2NQ^EG- D5/P1D?6)23B9\GA\=>]
M\2C-Z.&:("0 Q_/ZR@AVI,PG.I4(5\)F^*$1U/7ON"PU()-49I*^E^D[^W_J
MYTXD\1B8+E8"<POVUX WYSA_OS"KO.'KTD=.;BN-I/2/),1CZ?#9$9%>Z<<]
MS*\&,R)JR16B,7+GNX+:X,>3IEV+.O0)&>%*BM IGZ0\"LQ@>R"LJ,[M"<!1
M%_$$H((-*2"? /^T1';>GI,O*:IR!=G@M INXFE?33,Q0#DPE8'9,VIZK:'7
M:*+6!HI8MMS1[%1E:BF@_0WGR=:=[DL_0(PLFR(N[/J<^ F J^RS&KO6G]6>
M?9N0C%D%(/Q=M;]_6?G7!.WM9;+T4XQVVW4 P6SJS)$X,:DC(:1DU?I3GE4Q
M>;CK?,H<6B_V,]9 3E*QX;4&IX[0"HN.@4NA@R#S<DY-V7W88 04-.P^/7](
M8?RE=8#87A,;.\2_[G=YOD4?B+X@=D4[3]GQ9GU\25#/]?3YFX\/\N\T&CY6
MY>73$6EH.2_C+V'+:;$SL@LKJO)(>0S+QEQ[@B;>*H5^@#TR%G+HGY-ML 5P
M-N[R*_N7MJ7C<%8 6@KI9^&7%W^KG4&[)K'[DWDK:B5HQ1L&([4Z]K,4GW=&
M/OF,IB]=IGR8_@SL%:61--6T*=IY6BIQNDAF*0V3OU+@!MD?W1C$?[5\UHW#
M)L>.AGJ-&RFMF$27F[U+^#3K5G'U0 C1'4$=2DIZU9EYDZX=U8Z<5HBNAWA=
M#R,$)( +<!O!$+:2Q@MV>2H=_O1F_RLTJZY5#(FA2DC.>V#EO7&5?:K\>KXE
M"2'5]]BS&D6I+'DCQ)N$'^-]2&*V>/>+;365*Y5.VLK.5.Z=/L4>*%KUFMIT
M)-QJ@R^JS,C9B2.135_N*/?M]SPOK<T\W]FM#8$7ASO59@DO7@*$+X8M5AWZ
M/H2U#^)(B+*M;!J(X.QBLYA;JKRZ_:ZWP'_YE^T N#-2'^BYI0=$11:>H@HF
M)DY?4>-8\GWNWEG17O5N/I]>(!G3UK,M*B\?T]*1_?*2.;.BM@I'72)_U;4Z
M-2Z8OD];D\!!K9#J'^,U^'5U12A0U#HX*KT@E)):%$VZ2+H31)Z:H*Q^!Z7?
M+ERP-;5_7'&A<.Y+59E>F>MTY&NQJ#(6E%/MSEK1OKI4%/?'P?=)>:1+]MO3
M.)WACT_[I-G%JQHT/ 0YVO_2U4-1Z6=+A$W>:^B/E0H:]@NXPD"9HPT#:8.#
M+$:#AN_TUG*X$O;?);TW:MU9)M/GRRNN^>!3+#"GWQ6!HRM"%Z;]@<UN'S$L
M.XS*G_C904OP'#FBM).,6Q8"LM6.,]?%,5C_HE..F6EY08(9/I[VH*:[V<(3
M*+_U!+@H.L(_/7,4B;C#FW_(>MGIL=+C=3V'[3.W9B#N8TC!F90QK#EU/$JE
M?:@37E'QD!L@6I$U>&/ULH*(NKVS._=FT$(G=( 2 !]M)\-IAGQB-U(6"\0B
M^G:@?0"=FJ)AP)0!I,3^V!LKYIQ^ HQU;OE<H;7NDM+%,CN9N7VY9A%BD<$W
MCR=CEI6"OS>*JU(5?(X>+%12G9<665_(ZO!G<% YN!ZX.@>"D TRE15Z'TK1
MWA?E..[3JA-E45.*GC(UQH3?_>^T)L=C X*['2^I&M6HB,:>74V(:VB3E7^Q
M3IX@8EZ3T<"LYE0S_C#[04T%..4@1&R4@Y(]_^DU$;)^X?4:@=V>$$2'6\MJ
M2CN6I.N+RAQZC(=M1[1+G6=S:(/6(XZ3U#?T+]&TQX\-$STG+!7\_]-@-QH)
M1SFI/P&JE)$]66UUE7'_AZJ4G#$)1E>>$=;._>?Y*'^6ZX%]?/L$B+DYY6HQ
MAD]6%B#GT":._D^ %WP/[@M/@)<4V@D0*?K&-S)[=D'85DMSDG[Q6EHZ_FRV
M7U[BO>#G:3?C"JY<CDVTV-VZ!58"ES1,<Q'6"NV^.2\%*/<-?SBJ$Q*T,J_@
M/+BZ&N1$G8FKYL0VO;E^;9"3^G<<Q."F!E_) Z/280#Y>W'P^?9A08K38*?<
MW&>-JVG;Q^*[LT-UX.[-V4*=I'%0.=KFT?:G9]ZZC7>M7B#OR0]"[3F+5C&7
MRIUUY)THA?&:0Q9UIE,F;[Z=6FILD4R:_OR+L)\S3GJI!LO-YRS,ZN0U4F]J
MGTL";>4"(SJZDH?8IJ; ]+V D-_TX@$?GP"_^1H])0PZ)$E!W/DEZ<<2E><+
M#VGUD==1$%((/4+LP=JLBI?:-V;1R!8O#OU2OJW*?=&YD#DU:4(1^[,.<! M
MO*W]+LG=.^"->KZ\QLMP34^E JRQ8PDQH@'\3H7? ES8?IH_W-%?:<%?E-VO
MKJ6V=:\/)&?1>F B4.Z0M@_7[/JTCH\3->3\<UME*\C,Z8O=IK& #NG8?WV)
M5:EZF3([P]M5EA^[=]5A%JZ8<5XXYK)WR>Y[ZJ5/ &@WL7%()SJ&(4E4,VHX
M3!IU>'%P!LIE1PD=FX"G%FFS5AYVF!"C)UT\B!7'+6;5.9O&O+T6QXO%M@(G
M2:-JNP;/[9NO1DY6^OTE?%B:]%J_4P93,[T^(#AS3CD+R*W=2A-8WK41L:SN
MV&\6,,1CA 7PP]K@;\[IM6T ^3J#^+)R!* 18RVHPCZTMOXV S6(9H'TF\1<
M\FUS&UV3:E%&'!?DW(DU@RO9;LH$M3C<O?V[""934RFH_JS'49PWI[:]9ZLV
M3Q5CN>92*"6EK>Z0"PEZOIW*AA\R[J6]D9.K0U?\36; $:SR31;W@9K2]5:=
M><"T8B5OJ/*G@KF[0%]SX&6+#\3D6E"N0M8H ;J\*$ZSL+QXVU#_2R-^V/(B
M?7'4ZUP0.KR*;!HPPZUOB4@'S1_BA?/X._^IN#@ZDZ;3FF[2VK\#CWC4-"*6
M\S]8I[R(I4A9AT(BWL'@26#YE>X0HBO;_^IVD)=J$%&/.#&NB55JU66)B$R3
M0Z.PD1V'&X*]E;9=J%)[0YXE?D)F)'WB=PZ;Z.$^G<4F'-QWGF_X*\;YJWCC
MW9F;0ZRF0G['I/)L#-[;T]O5'>. 4YBAN[<YJ-: J-VABZK!4Z[I(X+1@CSK
M&5^Y[8/:CJ&YK7-JF05R8VH7^>/2M.H*'F+BO#QFCL5613;'0S;:@8]VAN0
M,Z/.3P_\/)-=?$8#]RYX)3[#HZ^G!6@.0G=D':2IV0Q#FJ"LHHIU([J0:]LH
M)>[=JK,'6M1(3]8C-N$HS<'Q\6IC@&?C Z$%DMETVD4TUCDK#++2%DLRH-9C
M]STC9N4J>\1C6E56WD2/48#!_7DX*9(N]5YCJX_BF[(F9/SLI?'LE%M-,"Y8
MUN?XY1#_="X44YX"JW_JC8RQ;@[RKA:4VC."O[Y BQEB.9;VVPJ62+G-D=$9
M7GL^IX:R**%5-6CVU&)BPR,>/?PL"'+.D1,Q'D@BXG]>@4'3YXE@&Q+3VW@"
MB$!V@4BM$O[/IK_.M>"324?4.C?RWD^ H?7,/'I?7]OQW\EH&Q!SYXJG:_!*
MLD3<^4WQQ6KW@I@FG6;)RV^#)R^R&U,T=8]'K"Y_.(MM%R9]^BXOY&'96@K7
M-U0N_>ALP/G) T=R]'R2AJ9L@9MHW<0HZX/V# MI(1$>1<RV(96VF\AOKI4[
M&9<G0'K)-G!4,N>.M1']>?NLVSZNNNH 'WXA5--I9.U"A?Z-"/3T@D]^BQ):
M2D^6S0M_J?J]J"(@0-' ?6:G+&[N7:R<^S*]N'(5\O.+C=G8*8JS =;#NQ?(
M9@--\KFLJWBKV#?2]BD'[.KV2A9=:CJ'J#ST,V_:"=K8Q]5&,2WW:[FE@U>^
M?LK:JWSS(BHNOY;$LL19JQP95BG_Y)R+5!?<9,^/-\Y\-A$NBU18*L##TVQ9
M%:S4NI&X.AB-/1EFXV\@QE4?&0B1AU/KN1:P%EP0FQE]<BAG-=&^T\,=FRQ1
M0Z6U-BIKH 9#7KHX_09Z>D7VKWIWOG0\/NB*RZ5NCP9++5-B^4YO?A1PGY>!
M.32.Q9470'G0RC=OZ&5)\Z5I/67+RJ[G+/EY';X--I!B1K&HLBU!OSW_97JZ
M?+(\0:8'+QM9&()_=?.CB7D"]+GNYIRG@?ZQ/3B=EJ(I_:$14OV337OC!F10
MQ@1TDFW;]R65\MAD3+B1M:*4>Q5L375H6)TR,S4]7(CM_P/Q6H_!--I'=?3/
M(BZ>Z(!>9;E58<6T;K%[V4<W'GAG-5Z;282'ET:+_0 !;GY(2(^S\(DM^G[]
MM&?ANFEWII;:X>8"O+.G8-63/Z2W(];3=&[B/2OU(N!/1X#Q;UU1Z)$+J%6(
M1GC'MG>KPMVKG:/,QI-B26&^<.#K&DG)C(+S^S1#E:95XT(1TRG)(,)+AB<
M5UX7ZS-U\<A8?2([-YR@MOET%-J$-XCPCAR^PGTWAHI?H:9?O#5!3H'Y6-A\
M6S$[251S!YX !,>&%0ZPN1 ^UH3Q[0KV;6B<Q^<.BW)"HE!21=4Y?4*+84/V
M[MB3Z9W:;>(_.H8Z\>;2GM!T@';#A*)&(K4]G7ZFB&:NPL/'):!4,E;4UR?
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M=]UQH-:+CMZQ=,Y^U_3[UO?U]<1$0$/5P>RP9-_$YX?^5^Y NSR&JD*#XQ_
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M<O1X'C%&67_9S.[\]^8]=*\TISQ& J5B;STPR%:;\#11<CAP,; 8>F[)QFB
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ME3R>AHZ>20-6_#M[O(_+6\"7X*_N(+=4Y>B_O;OY+2<G57^O(,""V[YK)Z=
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M_[,\IF5.4X<!SK MQ1%4;3.GB&%WJ4 H<0;2+C2+7S5H5W'7F)^NQXXSG)A
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M6?$;08"[1K[26<&O$LD7!;90AS?V_-/7S5^? S!3BY6W#H.AI,N0,+W+8\>
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M>W<3"P!W@*H#WH<G$>M,R'(3-!CZH((N'QK2NX'IK-J+>G5[?*JS6BF5IZ'
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M51U;.H0_-"]6L<MUL%]6BV@6<_6(0K6\ C _E61.8REOBVLWZ\1BS=^ZE!C
M,%PE%6O@Z5-+]*6I2-'AD$(@/PF9OY!6-_]$L]?Z0CM(QW9\93IP:.K7NR-
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MJ5<ESM#A9I%7'Z;.(88><O'7[=_X0:CP 2T<%/!=?8[\3'$S3VW>3S]VL"/
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M>4\NK[D7CBA8HTP[94W7<BQBN,.S3(OB2T8=!T]*?2^KBWTA?CS=6.LY0=_
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M74R'?>FEP7P-#:/PO&Y[+YV?)=6P'% _BH3"V1"LM40A6T&-P<""ROOY#S5
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MJ\EX08^N5OGD4NJ--SW][,8<;U_8GH3%BSN7B8WR[;ZJ\I9W>_)4P*.@MLY
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M 08AF#C[WOX*8!:<-3UUM5R,!\%_MBR>V+\4(\A_N5HBW3[O=^BRM[>T/6]
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MYTZ*;%0R?/58FYT=6\\.NH<^N\EW\NE>0L1:NZ*CISJ)Q*0SH'",[8C$FOJ
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M&!L JKXH-:YB;\;VE[K[<07 X_NV0M+;=30T&ODV35QZ?_WX$/53W?^^1S>
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MQMY^=PH)5("[<T.MF/'%:$)YDH@ )5#[#OXQ%%Z*>AKC9^@&*=0->/*C'&L
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M'2UEP,_^J_A1F:0.TX0&W@#ZIT<X%MPGFOZWT&'@@^)\#612H4B_!VWT]VX
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M+#+. !%5/O6&</!)6UR,IM["^-'_P0'V_]5B<S^@494QZ+&+:<!8B:BD6/&
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M^FD:G0%@?N(C)0.C.W.Z*IQ(8/Q',\]XLP"VK+*86Z'MSH>YA?%.Q \3.IP
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M:"?#J:JGB=JORT95'0$@]MKY59O"QRRD%Y-Y&P<D;Q=RL7H1B\!UT1<:(8_
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MN4$5+2,F8T.O(6Q5?!47(T_CQ4-V=F0^,R70RGQ:$VT$TK7_I09?\,!$E%N
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M;O,$1(2K\;BQ_DYF^-:[QFMM;_,'GY9LW4A+48+[5AE< !4%_P,40F9S^.
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MESM-K@P*%SL[X39HE>(\S[<7H[G@GI-'*<=;3,<+/*_F>>QJ2^HO@APW9'>
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MKHM1;VZ1'\8L:)*S8;^C@@'Z;Q86&7IUU*]-$OW?/FNR 0II-.Q@:]E'"['
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M)SY*I@A0^4I]>C[:]2\2?"?O<]77U>P0(^$GEWE(,(KZ]OKSN5DFE,1!7J4
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MPZ][Y:!.6L5&3TWN9&CO@==MVW]8VWN\X6"JHR2E,8^3GQV9EJYSX$&J<5G
M$WUM,^_(2_S+)<"M=SE,Q'>WL5 /<.M(LC]JAG\9B9JAJ[U5AI<.YQD@9K,7
M%\!IYJN,^@KC6?JYFTGA7/J0-\,_CE:S7(E'7N/7?Q"1^C_NO^,8B K:M/JL
MP+-^_!A(BZ6&DL_GLZB6L[^47\X(986Z.?)\^6F9Z7VLJN*4FX<^_NBT92O*
MKME !I>E7)9$ .:R 5F'0\%7D3TGDR@U;, $LWX0<SL^ND0TGB^*U-PG5]XB
M,0C+8J'(P<?&4.\CEED&R,;NH$ @Q!<Y=9[L5,:<+/W_45W[GS5W)W_@[O+:
MQ!TBU^?#PT'8L2=MJ +LT<D5C?7^<C[I,B-1H[,>QV2ZE*D?^?4JIKR8/#MH
MPNAG(7AN[A$^CB%W%@TFLETC=O5=S\%ZYJ*-[83U:(A[_#MBP^V\8:'_?/%J
M-3< +??%1XVM_K6$Y2^]B>17[KF88,'EP -&AF66SP_%<&=\Y$T^F: C?HC_
M(F/XG+NDSSZ:,![D4[;&@>65 G(O 9$\LJJ',]S#$.482KE\@W(-;OX-C:D?
M#DH_[08!0RBL#$YLW#CIR@:$,T[:E#,_M(;*X080KP]Z'C[_9$3@"(Q[ZOQ+
M@:#5(:2%"K;?(-/#[5Y=_>5P6KPJ<'H- ^LO^R6 )4"D(^^A@=#,@_Y13HRU
M77&W]Q1L^K+,L^01P/$E9CR&\+*9Z=&-DXQR=%!1<BQB V9Q=%@P>7**G"GK
M;H\C;'O+P3)GF3$$5/FB"3DT@"1^Z-X-U8N'-^WD$9+$B/5QUQ@;N;([2*JR
MAZXT_?Y0'7"52:O&V5+("5)SI:\C#D<>P^:DSIU&3"!:ESG7L$K.[)C=?*%$
MHY4]0JU:H/ T%G-H28;PCAD(- C$#C5'*AZZ!]R$!F^1;7PS4\451$IC=B2M
M,[T1 "9B)H.21*@[02A)<X1+GM44<-UP0RC7O&&A5D+IY7:!\&9/.<]C4JWF
MDH?0:.YM%MAP?1RV1:ZR_\5(U*W;V0HK7I*,!WWQ:ME=JR&<P^?P:4H.'U+A
M>2JDT[,LQL$$C2J4\=?[&%R/11:'1)-=K_%D((C!D[;DE!;:!!MP7U$X-M)0
M4QF436%8L!363<AC*G <+>/BEOR=RJ;*%_UXG@Q>#'V1T&03U&P[Q[7\ H3*
MZG=%M@!1.$Z6:S!2J3_I;LX=?:/VQK&ZB^),'1#G'L]IQS5+S7D^5JPY"HB@
M2+72$(V<?VP/VN1^"@B%4--2)2VI]GD_"2 *H<FI;$U7>=#+?O]R=8+':(2(
MF'M[#(=_%Q*.8H$&1][.902*)[$!PK/,-[MKC4%S1U9DSY\)GM2=F9SB#@VD
M;5)VFS"M99(6W,5Q2J=4!P*YT[V6ZSB(@0D+(H_IV'Q%6)W<T*N@H=JQ%P<0
M!!H3E(ZW+1#UTV]6'R-"KK37 >\!:OXG;\?-$ZH(9[DNH@<J)<(!F#INW<-6
M-/J@VNX( 71LBC];>"Q%^K448>">+**<-D;G8 +I65UE0&R<TM')#PZP;FQY
M_W@#X0\E'*&Y@ZE7"S63]=!D6)$/ZA$>&&\ D;':[#H9B345$+<E<*Z/S*K!
MT,4P'(^(^!@[%J2I5G:$#3C,!I2<1U0J[9(H#7SUFRQ@P:&P[,@CU8D*7OB#
MP0%!9)L K^ ([R$)$N_K<$ 4$U$^&\NY%)"-'X2J6R<2U=W"&GS;#X,.C?$'
M[\.GU,F$"Q62YWS:1]P]/13L0(TH*GA=C,+9((Y]LMJL-.DX<(+"+Q9A8'1B
M%PK"$&I.?M59_J6>1$L.YU<79@,>;W+\8>(C^6W-+RF&#."XU4G+*6CX,1J+
MAW/KZ\.^Z:^-8B5(JNK"J *1T# 4,HP>M'L"/B*=\:RSBFM'/"KT86OD<0X$
MY6(U[69@]OE2TA\O6SGB$H ;DE5G8*5[X!6%=<<(>E#AP01"_']-(!S\KY?_
M@I'SA*W#8Q988R:_^FZ^20137GL-/*/QQ7N2_LG=F &="HOZT@7-3-]B Y#2
MEBJHW%+70PCI^,#%]"W5N3"-+C8@(B@RI]!/0WDR'D:A^>!G.%F$APZD@O[H
M_0V"G%X[?S &?Y!50ND_=*5.)#8LH#\_L@%13E'W6M>*5KMM<#@CU_*W7N4
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M2S^;,Q*AA!5/9P-J#]0ZZ,9!&:(6J?WZ",X2WY$!TAL0\6%;PE2B/G9H=]4
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MLSH'P9IA#_:W]L2:MG<VE1Q;I.CMI4$*=1$H/X(:G^=C%:)[)&-='MU4$("
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M8P$.\J"8#B3#LCVD2RX5A$G:2=D(#RE /GX=40$F2=A1M 5^IUK#6Z2I6YQ
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MS\RZT!U8HE)_1=D?FP><)\D$>JULACHI\GY5GR!A//_K+.;_O^FR#Z# W>W
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MJ-7H9,IA'KXHDS.,4$J])Y>49PUEY>W6KHTFC<]]U,I <';*Z]F5"K'VO,+
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M(6JIOAX,%LQ#=*F7.?'4GT$Q@9TU2[T7K<#$?H0!;[79KL%\YYY4T.3LVWW
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M4.5M$0290_Q\*[<[^H+0R8S$[JAR[&![Z%KL%68S"I?I"CWS$4/00*CI%4!
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M'Y6M6/I=\%'VI/DER, 1+C*5L 7W7!A"*AR.9"/!U+#&3W?J1TC[ ,5Z&5[
M;I=MVO8 AZT.@\=#W?:FW,#]!P6T1L$M3D8[4W)Q],0/+UC=]3AXA#3BAVSD
MQGBY^F;9Y:V5M&&H&S\^J6S8MR]RB03MP'1.HT-0UAVK"H6^U-K.@?"@N78\
MB5[)8)K+CAVRV0<4HU_ OLY$I[$]WZ7WE9$>5[;<AC;'W(#6=2TLDYD!J7.M
M</'>2W\@^I+QIT:WV#M09S"45EL_Y3'P%-#'IHAGP?* /=D(\'J62-RII3NL
M[^!<VCX@.LG\YM\,PC/JQYT<O ;>M:,YM_58@YG PSB!JV.]1327/VGG^W25
MRNZE^8SNI'W=F&.O?IGFSSU5I134#:BV_+PU.ZJY>N0"+E7OC1HWK?;%BY+H
MUGU 29+EQHA49C,3FJ<170&ZZ[@I)HV,BKX :NNTFCWWZRFOUDK^??V529<1
M*]FGV0D?M"_B#9F=J4Z3.X9F-6=%-[NG7^I?NF$H9+84\@7V=J/T,_38^R/*
MB0/^TN+Z7#1QJ@%3*,RD:J<%-\U\D@GQ6']35=]%^*2K-,FBZK]V>?NZ^]JU
M,PR;:8J2W^M :;/7WT4,SHE(WSUC,]>2J6/Y9]2NS_MDUH*OB:DN" Z=H%'K
M[#4K+1_IRD.6KK@>&Q<$\$[JA MT[;RVHL62<*KB^X#^W-+OJ,9]P(E_KS/A
M;PYVM*2>B1[OY:G])Z'M7%6S"V/^Q?B-9B/XH*=6_O:*%?8O<-+<FLIVUFKD
M53U=!.R M10?\[:>%W^ 37W=VWTV_TB5&^S(X3$4>BZ!C33^^NLUDE&_;1ZH
MVNF1A,=?@T$[T2@AQ]E\K);_@*_[\$13/L;-F<Q,V QO2\O!35R^?N."[M-=
M8J]-D%/J9H+1ML*&]8QQB/%4MNOI'S.N*P-7,4S^!;[0-61L^'6#B))U^<"G
M?BW4Z::VI[I3:NR$_H" ^4F-5#M!\<:20)/O;H7>-<K?GF<70.7CR_X1I0J%
M!">B3AP_JO"%/I8#Y:N$&3YO41FFJLR48..,WFY<>6"GI1-)EXCJ@WXML-:Y
M*^&UG0GV'+!L4EGH&#4W&QX</.ESLE.V\CWHP\Y&ICJ&@#AP5_IHZL3$=-VR
M5-_@%) /NKI:*]354D/4PH]IH<??9X1@7)ZHACT_YX7EK[_11]L6TUI*67[9
MF!^?>UV7I3/IEFG^1HF<M.GW#6M<=+9#_X$W"/X9J;/S,S,:+Z6+RQAZNI[P
M&1625'B5IGGV77G.G["$SIUI:OX4]).P&?2!W6FS[L_8\=Y?E]MO*!>^'[QO
M\,AVV>.E\*^<R%'-9?"SD,O-BI(?',T1Y^!0[) +97F/KPOY":- PS_=\!S,
MG<0*E=?QZKG,UB72>STF%4H:G#M&+0P^MFLGOK]'/9-@J\.OH03J+E\&6MAD
M.3SF6*6,W%!G?>F(EUR@H()T.D,)6P />[6>&;F)*B222W!G!0>(8>R%U:_<
MK%K#P8GR/SBFVZJWUY*/1G-7G.UC[A.EY/D77ZLU*?=_6R#7F/<N:+SE0*FJ
MQ95<*R9X8<4HOF?G3S=1H&EP*KVI NTZEK$/6$RR]_.75U.<REY+((V%ZS62
M1A&^U'SGVLJ3/8)*/D]?7C U,KUML')R9H41^EB)1WF>4N#P+2WR2XBX%WW[
M9IL@URS&E=9OM=I,<#'\NXT_>P/=T. UN![2-U'?F.$##ZK6\+Y2AW:PT;&*
M[Z+)>KC<DE'0?'_XQ;H(NLH[44OV%2DE@\"&4)VSN>9+[=N&,!<;1_,1I;Y:
MKK6AF$+F53_#M[U[29T[Y<_KB76TB;1;-41B78U/[;V)HHZ><R9:YI<JJZMU
MJ/=,BQ\5? \\?DQ8(K:+L9V&S]2J09UI-\JE]-_&VA)" @.==](M]="!\DV#
M+^I^.14C%K(DI"ZVQCD/WZ_O]5<9Z'SB:MXF_O9QX1=#&V-1K @_3B1]M1\+
M61P)F#N^_<3TP1C(.6+V[^N-M<7&2G3M7O=*6LBZIJ6<VU[0LGR+RI>XZ_:&
MO/]\.5M2%1Q_,U?L^MDPG#=[[>X_I@./$S;6E$G65[[%LA!4P2R<LJSI^VU-
MS19(NI"=8"QZ)3W#/_!YNU8*[V[WC_A58%)HL7PMKZI7S<VG:1HU12^\F17O
M'OLOO*RD^E\1K3A\TD]6 C_A,#7W?;7[(MQ0I*O'F[[]99>W^E6)&;6Y?N!X
M4CI3ZU"X]K@MHKIZ2HCL*]?@^T$",^]"7.WMA%GH?"G]]IM01S#IFR/=QV49
M+X40/:;JM]16%M]V,XM#+ELMAV/4 M-J$]2->,P3],XUL- B-N$CD\K,^1RV
M.36Q;6JW+'<*?$[E8U_>1AF+<AZ8C@M/'\,67,C(+_OEHJY^)9I7-%=!5^?L
MNQ1S(^WC3COU4+=_M!*%/H&)R'LSO\Y],A<]^O/K#;6#;@.Q^ T#9XV-!>C6
MJ;)I[$;-97P^B4'#E%ZO%]A)QUI/O;;& @,L#>H+9?+35HF%;,I'N2_O(TM_
M@=+K#63.Y3<@5Y=;\H;4#N9><@!LAFVP@5_4PMEC0"NXJ>B6D$ O3X6_]G4[
M+A"/AY;KS9ZM*U-]!I]+.TTK(I_>:DHL6!\5/IE__63JO\C:NE<B)8\PUR$0
M:HC_^J$?4M*0%'.,+T5BMDSR6U2>*4W1S^#![P^5)D:T$]GJ1*>@ ?T(AHDJ
M>&S"G2?CZ_.':S.PI0;UL%>?KTP&O936^YZ>=\4V^7TQ4OS802]XGB ]^HS)
M7D>CC522H;9NYN\PO_6WH<$5ETWN/6]WOA%Z(4!$<2\OF__T+>633V_<G!/7
M/?G@:8KVN>FA25%/0T*T\JLIEN8]%;D&6],BLW9QJUCISS:U31K'*N>3KFSK
M,:2_@>,P$I694PDG_VX+A<V&9CP/_'CEF$&Z4 U3'*G0N%R']+:X4WQ//4UY
MZX*@Z7N%O*=[%=)]Z[;5G@_!<_(6]$R9U'"CD*M8TDQ#\%'G\^*(E&S@XK+!
MJG2/,OQDB[A?.;\S3<AC@.;X:QW6.A&N59>XMBJ),G)O+C.VDGN<V'KW=ZW:
MUZ6@P?F2N! CB9>:I]93(BZ]4(=\(?<++?Z-8=NSTH^W-34*YI8P#0LO-Y:$
MM:R3RNO6[.L#6GRA5"%G[#^U*G\NOOL^1?06]I3T][NN?TBXYK<:JBY0X)Z$
MSZNA=J#2>;9#Z;?OI%^9?%(Y@[9\OO!;L);IX)A^@P:]=OGIK?R2MHWCH^JI
ML;YK4]C,G,[/U\AJ.84=^:#(NQ49>@I/;DAD3'G4Q']<F+?@^Q""OM1\TXQM
M'&V<]LM#X?5F3P7('"HU-:416ZT:R]";H)[=U> MEQS>-AJ_^BXW![M-12J>
MAUH$/SZ7B#)0_GMR'V"8]"S0@O'I?K2)</#,(0JQ*NK1_4N%#@UAS]H"\?IA
M;U:E2W[Y5_M-@19WN^N;3G%54/ REYJP4N]72[4LB;D_UVL*7:<]O@FX@,0?
M/@.=_9@0Z611V@0*?R1<(S5"[9;KZ=T6#GN*U;+ VB^2D:$>;U5W?,+B)H-9
M$^_ID4;C>MX$&JPM\:5Z<0BN3(A\Z1QV-_Z/>NW?S83$U&>IIF+U"Z%4WCNW
MI$(63N^F1B_N,3HB27MKD(ZL'KJ_-@Y=G; QA:#X5E>,"^P&ME@B^0QJKH*,
M70(40+P(5_/?WA/'GOXP4M<[(9YM8<R;K/7%4["%IU[7U'HL(J>0-Q]#_!-2
MJ%5#*:!K,FY;3^6 VQ-I4[;PPAU!%DY-8!] SJANBKM>A?+TQ/BV9:RR:E^7
M]<W[8)VJS\LF:7_^O2!RTOK\X0M)D2R C<S2_+SZ91(%3&3;>T:<#!IB);[%
MZSNV6!%>-IHL)*H^]^BK;&8*J:+^$-=98Y0='@26V7^J7NK9%/.8\7<1!Z4Y
M8><O-I>\:PI'WON_?_([*L$YLD!?F;(%7%QY:_&6&_1"[11;$(C0L62M%"OB
M5Y66P,THT#Y@[;X=X:YE3P/#,[P!0QE_8-S6[9&%<O\#JDKGTY_+*H_)N*QS
MNO8A1N3HJ<@>G,B4@LY@[JKRUDIXD8@#MU5_?Y+QX_7,"7LJA8L.#\ \!Q%Q
MX='U(7]O?K;+!P8L53SW&EZ3M+-0;O@2QGO5Z/0I7<N8D*Y/A86/M!E,SVX(
MD?_V[:0$-\+*XGUX>O&ZN?6YN\K2EV:C==JM>CF.,:U48L=M,0#H&Z#453Z#
MJ-NYHCV5\9RKH@F?J^$0JZ1317,)_.<-=KRE8EK+3<_LHNJ)"Z+.YX;]6QZE
M=HN:6A]>5O0@WE._9.0\%R"#@(P?F37M+$DW^%B>=:SPJ6N'G==P,+'UW=<[
M?\_?O1!UO>A&5;0/7X$5^H0-PZ_H$/<C]%/).$9$_;&$_GD**+\3WQ@6XC\.
M',[2[:IM>0=#[46S:5K,(62P/XF=I7B,[4&7E8A2(QR, D-*>'?$9($:W\S&
M[OH8H4E(_[E[);YY<-N/M5T-J@?=L=.,G0*'>@:PGZ@J>\*Y596!@YO05';*
MT8--KG;AQ QVI>>QZ=Z?,^%BOC\.AHFWS8*A%NX53/7'_UW_P>P/_!_E^7_A
M!^5YX(K%,&JI+7&'Z,4O(:A_AN;= UE_AA0/A$?N X;5A7QOW<-K@2"SQC5/
M+A(^:-K7SR\K9QS&)^-G>%B]LK3+Y2&1"]SW[\Q"E)2J678A2]J/CDK"D\:B
M.]8/B2/=@!Z3D.=RK,=T/USRQVQ-\!RF;>##,-J[@9E1'0"T6%-[[^GP$V?=
M5_N6V?;9SA[0EU)RPQ,,V =48.3PR$# N\<)IY^F/0C;]8.CK$G9A_,V"R:]
M.\=8>F43-)6.W9Z].IBJN<69N)?NZ%P#;N80S-+Y$R'PUYS+0&W#+5LMXT>-
M]T[D.?4<%LUS_/TJ]#4!T]#DK</0D;:#.R+3S31%-UMS9EZ;8$N2UNC;C^J$
MMM*(=CN.LW7I3_SPGOZ*@[C@2]X9$M4HSY.I4NA&Z7*+TS=U+;0 7;*WU'\T
M%(9R^>[26'73@P-C!]<A"J)!&UIUQT]\Z"<'P^OV 7PZ9[9.[]ZJ;''T8YMY
M>31[2&IA:^J^!]B6J?J+B)U]0,!U2'97;15TP1/7UOH+OV]'QL_I'K*VPWN@
M4Z<IAL_!7 _G&@9?:,^:**&VEJ/])IT0GC%D ,]H#??,R\.O+&NWRKS 5URO
MJWXY&IN%LTT$R+"/0@W.[ .<X3Y&36Y)+(CZ 39IZ8R-3I_.X\+N T1,."A=
M.5;$?<,D*>W2Q#_QB8UB%*?/LR(#\];E#9O<2&S90V/HH_*(1%UT"1MH0VT,
M&#YTWR^,MJ.SIX;+%,&$[@;$]KA[GG):ST17^^Q:8>V-'C<0K_JF7QK_3>M4
M!#TXW^PN\MG_ W!L@GMGY\AZ<25)\)[!X2R(.F/[GQBUR4OOTXP.%^R-+TM,
MV5^MY.O\C4R6D/#:8/P^RYSTK&YW5+WXMT/1:-DU@+@(?K.(<!U0N)8*W7*?
MO:-$WW&N?P>PY5LEZ;G?.*6]N A)GV +YG3_Q5X5(8^5LN]XKK6U5&XW=38%
M*MD]#_ $0__6A40?C6HW>W;%1\, Q7/V6P*%9.HU<N1ORJE#1,8_3=,=E0G^
M87<02HKE&8:Z\0M['6I))M00/U" U<^$ EV*6PGH]K;#/@ ?BO2%*B"C\(\3
MAB;5[(OT:BMLP3=C"WN5R>6"7XZ.U#D<.[M4=$I4YTJ1 Y\&:DK3P^9G_#[@
MDU#O]L;ZY& ,!M63"!Z!+ X%_-U%DP-1*-K<,OLU763R<^)*FU.UG*,EE)52
MO<QHJU,5'"HH[2+,_'AVW?ROB[>/^9=[]R'U;K_]$I6@;C:/G5Z72_&^WIY'
M0"C49]AC*I6+- [V?',=LS<;URH;_V1<,HX-EZA2=;"Z$-&^)OYV4/V=YNCU
MJI.$3*++1;&<U/P8[^^[_*%Q_*$U9Y:['O>_$ &GZP9^1,Y]RRZI?NC=?:O@
MGH;<'IIM_]"L+RW-9?7V=;7)WSB5N;Y9C= 7B[0QR-BL=DBCP,;[@H!.]^""
MP3"W1X7:*J@ZN:E<FU>%,L'OPLBDOW5CM<J-7.5N66H4RCY 3CI*X2^YI*4N
M]H5'2TZO_W9;M2IF\]A:SNN)QS;V_1&XX=OQ;@LJ-#</%]<']9+KD]&GG][R
M[Y46-J^0D0AM]'2Z:R7MZ'UZGGAYZ,;:].G4LJ#KDB8I3/A(UGN-DEE"\.H(
M]L/CO4#;,0]6=\L*@VC?7ZNAY[DA55VW$V/:?-(C82VS=;B6#\+J4OCFNGWI
MPWV\ODH%+OH09RE0B)BF%9NDA7#PB/'M9<L-8$1X[BBZHZH144[9A4WT;&1^
MK]WAG?H*%<@PK"_ZV/3":>OV\H[EC:@K+U382NZUAMHB[I$\SR0-+K>4.0PF
M#-D;'CMAVK;DBS#=8U2O,6QYFV\BK@E1U.;9GM%[@1U&K"JF4*[3:K/Q%)*X
MWK]J!QO(7@55K/:Z,"9OO]LMF8N[5?L+>E2^8JUYV.T?@\O4TE+]&;O035RM
M.;)M:Z6Z[O4/LY(M)%W(L#\%<IB97A8XUB69V#$9^A*63[3K\#2JFP96>=_^
M\W-"XW!('EO@(R[CA%R:XOBRZW@SU;_GBIE>X%S;5)K/HUDW.ZL8\$B6E+OU
M->6NOIL0JG2T5,(F8J' Q<,#W100TXM-?1((4Y5+&_\DT#F> ?6 KO7HQ,I_
MF#"*JRL^?CN\S_##B>KV%Q_[G #UH&F-9'%S.L)DDUKY- B9+@TF/V:'7ZHC
M:*\V(F*D,J<>[XFZI-74677UQ8Z(35[H6=S<5O8+#M'L9<;RI.88#,2_KYX7
MT4Q@?&4.X+K>7\PQDMW;C:29C:U)O5B;;W/I!_;TTV?,MNA^USPPBQL8C9LA
M8<D_%ZYI.,_'6.4RT*HQX/(;6B/QN)/]#FM&U]P_0OR[3>UU(KN'C'84DBVM
M__&= 4:NU@86=MTKR@7>IS,>9?M!F=^)I&^))5\12IGZ8)FKB7%*#GNWZ2<F
M;3WC?#V:SSAHHVYBL^Q+ZGPT,FIIZVW%JT9MD09RN*#U<H].4RGC3?+5>ST7
M-<-K#>M>V4,LVGQT+XDW@/[%S!QTJ>NXRYD.&G -[ /4_40\/#/7C B3 ]MU
M0FZ_0UT>E%F.::CZCG3$74Z),+C@"?J65:NCK3F@QW32D$WR.)^RRIA>YC\J
M=BR9P(* WFRLMJLNQ[\X)IBO3=ZIER.6=ZZ_H-G?S70;#OU,@SBNZW5K*V>X
M>=WL_>NA1G[XJ_II9.JG:K7S:TLRJD2:6+J?J=<YA;0OWC,\\,]BR\,>\:/L
M:X^$X:]&$9H1\.>&C28Q^',W'K]5&3$>QH8&LJ\O2=3.=V]HD6L#/*?:W<.[
M34X/6S1U^EI]L?8^JQG5E77I@O/E^+A0%;=:T5_WZ4FH;VH*M0YO6BER>WAB
MO]%MX%N,S/4I9#7#*==Q:*&)J_J%JR_VG #R\X]UH_1F;Z\!7B-"!&[;M/L5
MLGW.24=RQ"#@WU<?ZU4>*+TG].2:.2I_2>LDL$\-6;F%N:U-I[6N9?:/JRF4
M@7JG7:KY(W!3X2T54[EUE,>3E^\/SY4$7I1V'3KSX7N*<>/COODG;ORA@_B2
M=V5!0Z\U]P$_QC*@M_D2KG!R\D?$S/*1<YU&9<[9:;LHT?,KWE WC@N]Z^ 2
MW5_ZU+IB)DN;_0T_9]3 ;B&-M)Z7<O9N!8_%6</?S/AP-")XI_(!8WO.3'].
MS_1@=S-$4ABL"8\%48GJ(=%\Y2^U[N$-I:%P$IO\A+VU$>XV=KK?;GQ3CY ,
M;TOQ F5+<%S,SC<!6'@HP:RS<(-A;9>4CR0Q(@ZO'52>5[9((SE%4C9 BB&!
MGKGGRA>96Z\/688/G/$X"3XSR"<9!WR*FXIS="6Q3R_K_@:O6R,9%6PXL?]@
MY^_YH['_75F?(+ 8&GJI2J@*Q_#@?8"WL(2TGJCTGIIT<UBCV?^] 5B,IA_:
M2F?&8C"<&+6:I_U9P"M#T.@K*!>SP#+%J=07U+GKUN&82EK+"FYB5-ZH9.&!
ML8A>P6XZF6O^A,F-+;^/_$5W"O<!.7R;7^$EA $$=''K6I$L5]MJ?]%I\!4_
MDQWD'T1JQM@NMX:0TLBG> E/^8\22O65&8:!SE6(=D^+BMV;+0,>8;09^3$[
M2[G=7\Z[.O"3HJ*'->.F##Z\4>9B*[%%V#E_WS>7QKX]:&QB)X/L#V$D6JSG
M&?T$J,<,<\?7\?H(^$)(9]%-B=#@N6+[.I,=?/%0Z&K\]-F;-CI/%% W:P)O
M:]X;4DNJJ#.12')+<F;;$XYZK/4FSLN8O0;) 5OU"L3#R%G?V8Z+VU/AE;3:
M=G<+P:5+7*?8B__(!BH6'_K!)2E\A846=Z@AH3&4MD:F<QB-ZJ+GO<I&3P6'
M-U2I^"NZF*P/=.9O3S.!?)\>6AIU1EABF]3C+N6*[CJG]Q+<>/6%+\F'5^"D
M?9K\ M: V_Q &<0/-E+3)XNKY^/H^!9TD[YGL5M/IQ.^=5(RYKFG/$ ^)5)O
M"CVK7O8W3VI,QE_JG*F<</J-O1D2P34CX=J5_802[/8D1LPT.O4LZ(98Y(9<
M]2F?88R9N^[!5/;-([VK>NW:8IK:)!781@N#G\H()ME8]0)WD[7;#V</"-]3
M.Q$]$FCIE^C7[N./-#1!=3$Q<R/!DG<Z0]SOL%7#56>$"IC ((K 6DW(W2NR
MWZ_:P5K;@ZF?W?II6VH@N[!]0-NLWP7WA+?"B3$"";I&]:3BXE75+(=T%EU,
MWJ'\IK6,XE0DHRS,5 W*:/#1Z@M+684Q>S7R E5]89_*-2YO=MTT3"F9Y0.O
M4N,=YL-7 M HM]11GN^N2_C.$ULURO.DO[])Y=7"#P)HN)SNI\4W+"#!#3=J
M+6+/I_8_96-^^3I:OY3=!XP@$*2-/%S)[[4>C:<!0^*#&#(!9(S_)<2H[)O:
M^1*KNNZ#ZR"8[,XE*6OO:H'_W(U7M?;H'=L26/:(U#O:-;P7N*+X9TWQ3PEX
MW< K%%'SI,V]O*3-A=Z $ZAS_+. 9&]K)??]TT3(-/\9!7>_HL6'----Z+5T
M^!L:)R%-S\.FA%]1S$O3#$MIK!!*S1P1,EH][#7"T9F-]27GM^,UM<H%YQ.R
M@4M;H9UJN8,!2\.\!#*\NM/++;;R2W[9J PUYV*+W4E,#1UA%SW\#VJ"93_/
M=3^2K0,!?[BYF%B;LZ[PEW>^UX2'QT5'AL>Z]UE5@TW_7+#DTOWYW6EGU2_]
M(8ES@$AH_S:#F77;IL\T L #K([>8YA>&XQO8]F!H7=T[:[]! A'@>ID64<K
M,;0W') RV2UH4+D[&(5 F,;0PXC6YJROX-C%H5L^NQO@H3@?J'=AZJ&E&2 -
M-.;QX&)_^AYD8OAZ"UXSLU83Y% <#G+(O$^::C)M0%GP< NS.DB6/7IZ;N7?
M] 8)B)V,T/+5X^97P"-8-G*W)=K+X^=FL@&2[KLE_8&(A8%TWL6A;]C:M*3F
M9S5;.JOPXHI+\J[&3SD_A4O_(<"C@ _9FVL.;7V$Z\Y)]#L[[YH7 WZMO!C?
M!SB!TQ]#>NJN0MU?U!8L+K$+"".<#R_E?/_U4)O[8E;6E_>8R>OGQE2&3Y\,
MOV,-1]&D/Y1XV)#W 6##TN4Q>8DW^X#KG<;IZ([77>B^[81S-'2IYRC7RC9M
M+TS=9_4+ K*+I HV+0!WCYF35RZV>MWF8EET[EJ'#B'.37G^B94Q!VYEQ<0+
M[5F_4*(R'8)1JFX46!3[QYB=+0BQL&RZ%!+ZGYOA')J#J/BF_^=F B.HT.XV
MR@"U5W^3+PYVO7H?4,;2&O>VH^:TSS40W2.";9/U*\[,V!4^;$XVF,&3?=E3
M>,6ZVE:.6@M5LW2*;MB)^QR5V["65M1_HD1[@WX/-Y97V*6-=87XF]R P9>(
M\$8J++JYOLZF!F[Q*@L@2HZSVPJ%HV396AO]%)(#Y//*&U?T/J!0DW^RHR8N
MY,X@6([U9N=_<?:645$]X+?PJ(0_#$1%)$<%1%JD<T0DE9)N):6&[A@!!20%
MI&/H[NX!B:&[A^Z8&7H&F.#5_[IWW?M^?-\/Y\OY<-8Y9SUK/WN?YSQ[JU1
M1\L'J<Z:*" ,\63;PSWML$DB.ZIRX3G77[9=6.OUYV\#K!KWN-28B6^KF:#?
M,3.[5SVMJ9J 6*WD<$Z*&!*MZXZEO!OQM^)T<73.]X^X*]8S:J6U'#!7WR0D
MWP*ATF#_A5:?-^V^$,NP*"GHZGX(44!Y,M6EH>H\_; \G+RAH"+CH^4'^MA$
M&GFCCS']LJH:LJO%Q2E*7KI[-RA6#BZQOUL/'2"0:A7<N^"65P$*G'CE7\KD
MMW!B\+*H]>4NKS#Q@7"_]Y6C1Q'>48S <A22,@3TW.;KVJ!OXLK%T$L0XZ<+
MOY@&QTN\U$W]%#&K<=+BPL*]O&<5X]](HBL:5>VWVAU_!'96]Y2ED9ONJSBJ
M,@GL:T"3ZX'__6S_K<Z1\S9/_D9O[;FD]HJR6VGZ.$+W7OBWZ.<Z@46+_"D+
M>]2F93ES9Q.*I&#C@G-],XIG5ZG'YUA1EWM#!FP<A?'?OJZKO[/6OEMK4IM&
MX?8$%8HH>"W1W[D4:;V55>P_>N[7(O^*D$5B83\Z&6/J24/L9X&H>AKXN'S
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M712&0@>LM=&94S:V89A9*:/'Z76-S8A6''1'9:L@<Q>%G6NT(UN<!]&X0WS
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M+]6J21R<@4*?L4U;^D1Z;_L9J#[#[V8VIC,?Y5/ OJ?]E[UW755F_+[ SH*
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M=T&<GQ.*&&VH%MN(^F'<_E-J2^_.F_UW-S ;HBY+*K\1+P831?#P L65B&L
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M/P@F6W]=2/C/AC(P\T49X^>8P>$/,H_>*)16. I:OUP$6JZ^?UZBQO2KD^7
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MIX;]"N&EB:%Y[_L'B=[IL OSE=% #Z]4<;QYNL]]&('X]88N;+S972"93E-
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MOVL GU&/,/[R^ <>^_SX.R2<96/,N ))G]L.KH,"-6Z^GKLN0@UQIL,,*X;
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MY%=%8]D68#%)5D6C1$S?/Z.3 ]\=\)EUQ86]W/O_V5VUNT(%,A=89OLL:\O
M38_R>J $1E+I F7]@&=M!:I*Z#@:P_"]:\#KW9; =<S T0&7MO!$JD_JYLL
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M8<0P8?3[E"%=<N'$7?6DSP_N>,)?[-4Y73SBF<BE"UJ$FN;+:Y]&=UC&1TJ
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M;O16/F%]D=[:ZM^-9:(7Q-5@<%?A:X#;SY%]WG;))]]Z%,99A=$_!F9&*,E
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MD/-)/;75=7_076O5SOQ7>N3X%&4K^HUFUX-AAHB!Z^2&3-W3?/W#^O?!P=<
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M4$';G=(6KU_?6H<DM"I^\41%C+NKT&9']1"[H*-Z!N DTM/Q\JB]W<.$%@9
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M*IGIY8EIVPBO0AJ.0P/!P,'_2DB3.>I>?FOP)N.,>JH[V.^WKYV'AVE97V$
M+.#/'1_1;"Q/O3I OB<G]Z"$Q_^[L7QH1U'?FDM\8NRABCI MQGJHLF1G,C
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MK8WYOBG^@NK1OQ4YW;.DH>U/HO"'S]<>I&4GU -F)^LBKGO(\LYE_U%>/I\
M6V@[#5R8\78K/I2=,5;B;RO4*7X3#LJ)D,[<R:6XOHCU#%6!X/&"SH//0Z\>
M0)=!(+U1(/]HP!\..@^/O^G6T[5?-&%GSZLN7S,4WV(57M59O<7$F-7E!6".
M=%0S+P-S;]:%EWI=@Z-BX7+#0&()NA=6]0_IM9VJ4A;AT*#O*ZAZ/O)&Y+0%
M&O8\ .*_"_/8Y%C%R@<90*^#GK7XA7AOV<JN3ZMI=5AY+N4P /Y7-,4/0U]@
MBGV<RFMU/S;LD( &6A5":UZ)W3B3]/GIF*4ESESANJ(XL>V7\KN?M"2$7%=V
M+RK"ZX3B"N7L/7&?&C]NO]'NXH_*?E^AF_I]EE]SLVPCZ&A65?K":R5W]^UQ
MX-83GRN1D,HX+.2OG&?7 LN\G2@3[4+4%71[KY;K,1!ZACDG/R=Y!]]N.5BU
M]#0@J^W@L#-^IGSTK-=VMPX5!'F]?ON=A9?'C+4+MSV5ZVYOE'+3'P*=]\\A
M"ZV;QNI":6A:"R)'EW9<67W^<9<F_'407@5*U,'5YRHDR2\)2:S0BO>$$<6:
M*Y81GKN'S"Y;>IN@M*F[.%?]J>RP3(7K)LI97>>ZO-*O7/2'[_H!.Q(@'ZH/
MX)ZPP,.[)V[=R7SQHH;AD) HA2N>LPY=<;(I!I]L%@\]HD)T_T(1W,<<0"^7
MLM_$N,YOO,OK^MDL/J-+$@3UKENZCY"2A^,#V"MKW*U_T>_[G=58?+R2WU*%
M(MMH[,&UU[?$Y7IE[&=BD"Y\[6F7%:3 YV, U[CL;J0SF>,7V;?&.Q@ RRC%
M],3TL27<_EX;4<N< 1BD\NG#$QLH"8Y>;*U.Y3\H_CR8"XBRX%A^P:9:U0UA
M1ZC0H).J,C\T,)#DA[CU%@]'"?6HK7]K\JTP5#XL'/AVSE%-3!*V<123R*VJ
MU',ZDO++;_D@*R:R5)0F'7%W!OJL+R"X6L-B(9+<3G*B_R:1[J.8FIJW8N1!
M<73RYJ74F9"^+NN7^R]VO@#GX+L0R*\TR_EP!J I[%K-;S*\:\OWO@1JA>X"
MG9 CAB;FG8#NZ>Q]ST9V46U6X=4'[U@H.[LE>6W BW=%F+-90%1O^DZ@IBBJ
M=/2$6NU9IQ1(SQ346_.#_:)K.+]J^ 'Q)+K*D0=HA &8WS2FQ-R<?X^3^A;Y
MOIMXQ,RROT^XU84('QL]_\+DNP7W1R'5P0][!PP 4/\JFW#'41"+O?E/ZDS@
M1;S&A5MQ&B]2I>H-\#-\?2\;O 6N7O-&$%5V-3#P0YA'UZ! E<S:N7DC,3>=
M'#AG/\L2!<*BQ_F30GR7]2OE<N->@A9.XMP^ V#^A(GRK\Z] S8SJ7EVH<M)
MY#M6 [S)+&;/F=(SCN=T>JF[&Z6G.8,2GM]RC?OB<;/Z0_+MT<&N3I02D:4D
ME2!>]RM9S&UHMVMG][<VDA^W?"DC#S[WD:8+^V+J#4HQT_(>@H2_"6J(!/M[
MV^(0=RZ\_IWV<ZI-*<B0GB-/Q<%"D'V8LF>BN51=IM%L\2%(/7']+N1+/ 3A
MGYK)9O_[G62?_MU8JU?<1[5Z]$O3_.7NQ7='3>M[^2H*BQW9E,BGJ\=>SW>5
M@Y?;IU)X<R[V_X7M'9QN*OPWL_76Z(--Y(FMF6NBM#_;80G_EUVZOW=NK[AN
M]>[3YQ25>>E?2D'4=X-4DYDXGO5[F9F^52;?&Y,_8\,B"V*-N1+UQ*-IV@6T
M.FP$>>>NS:[P+C1C:C3W@;Q(=-&O-U?<SAQ5O.INNHD%KT+'A:88 )7_:HS#
MMY#6N?MJ:[W/95'YU_N/U$V97OGH=\TQ )5:V]'4YJ$YB!3ZHCJJX;596A2
M[Q9,;)%SAUXP VP?.PK,&@OW83T#X%S19P">TCRW9BRXUUE. !V5'W(*A=YY
M-$H_8;L?)BR*;5,/YGP@#R/+X<0?]XR!O AD8%6&[8[6@U6YWTCD"5]:T#^F
MPZTC(11TU35BYWA3X[4/9V!ZH]PV# !HD'@F=;N]*J)Y(Q4"_/R2>8L[(4/F
MH%HSI@T/CZ2$'=HM6L-WSI]'?(_VM!#[!\6 UT_DQK->5?BAAD^EYKHNGZ@9
M[%;CR?S;59"8R@<I,O;^+Z$"R3XZ0&MXY(#Z(2!LX=J?WM=R':,IWI'<X)00
MZJ5ML[UBNW7DHZA%)B+0, 1!0NDMGI@Q*K(B[)"CF4^3W-A(!:^=8DH"&$>V
MTB9JVBOO]_K!896MIC2Y@^O1PAO>)W\!-C616%68EF!-H'$*7 :0.</_*\6^
M_D&3%QEC@]MW3Z9Y ?D8@%?;MMY5$)GN.=<Y/P^=17HE:+R-!J%40) AR= >
M\FFH_O&91._7P 7@) 5GMYYQH%E]OLL@!Z2Y2VYB (2/<,C K<:IBB-\4ANA
MIHD7W=:D:<D/IJ%0H3[K,T%/B/QO=*['B<U!W?Y,D',XT3@89J+U]X0-/P-0
MAE*I!F99,O6 ">[6^]LS8<5[ZW5$IB0/[9]S*9PJHD;"1M *Y/;^.N[E>I+!
M.7HN[5$TT,@]-1RB=K@6F!^&]XG\P5S57U5R(2O9NRB+ :@YW$+D- .-S\WY
M2(?<F$T"EM;N#E*Z4(';O97W%3CR0Z5HK+PWP8G,%=NC6F&MMKYV?(E>P-Q&
M!N"RCDEDB# \;!T2<J+R>UXL^!R9-F45\F[7!*YYPG:Z<[8<$/GY!@/P2443
M;C1'@W;AFDDAZ$KDPZ13?/CH'C)F%[K+ %CC?I$/,1//_,Z-@.9;BU./YT/)
MT*IM:(;U>E65\)M0D2Q_7_]PX2K*Q(G0FL@A9V+:I L(9*\GHHFG#K<:)EI+
M2VJ9&S9 9]+%_F997J)!MGNK?+3"_EH;$;G(]VKFN [(63;"Q>C9YL.I]LIV
M3$S_)ED?=I/.,MY.@U8A)RHNV35+\Z]Z/+#6HX&C=#7Y9\<9@/CP0P%TQ<[^
M>OG:W 7.-0_FQL72QA/5@0G;N+GUF4!HX:?*R*@D#Y91NGX<GC"(#-P()2;K
MU]/4I $'M'-GE!IXSS  <4@B_F_B+^M$C^_8B_?FX/V-9X2@XPA46.!:Y$#C
M!85](J_XNA^ EW>9R@!4=)VL[Q?V15>4G)]<]XD#, #BZ]LX9^L3"[0!G:D2
M/=A_U0;<1)JOI&Y#W"LCK,>ZCE144#?=Z+E0\$DP!N.:=]=KW"U/>^F>7I0C
MU !R]!B <+[#C4"\76/Z7$)8:T4X/U?XVDGHQ&5!@+.![54!%=/WH)^S+CD!
M?-M:M#K:%K'07^'51R#,&.BO]L#GG/]SDV-,_!^''E U1\3>XO'94V?[1_%/
M%@6UUL< 6.&Q\G7HX &J+M*Z8RFW\ YN+C*&.I@EE9J:_#\5;%T%'A$9 !M^
MFBJRXS?Q%!&/_3LFS_D"FE'"^X(UT9?>!3=R/. D%;ST/A"QU>-588)5X3&=
MW\)P7TI[BN%DU!BU&F)_@+VP$[* O40X\?(&%!"_;6?V/\U>Q@P0JZ>*-_[[
MC PC;O5=F3P%+;GED>O?-2=,()+#0Q_)G/NO1>C8DJ070!5_''2BG0*I)OU6
MH0/#14Z24ZLQMN$@*6QBOHW\3I0"OJ_=VMXBPN27 O^#(J;F\>Y _U[O/LJ:
M&),?=MU+E$99VRWIJ4//Q(3#3Y:$"=>LNG9\P#_JQBYYCP(=@Q'#$%FT1TTB
M;SS;F@ 7U:1\Z;M;HQ528"(T@V83UI1K8P(Z DXR ,Z]E6&F;]Z>YLCO^7YE
M\J*.[AGVI^W3]U1-5XK-V@"F;,XD3J)%H1G8GB3TX%3L- \MKM4]*!9;^90J
M-%&)53O;YAG?^.2.@_*F=&2)Y/RK0%,1N7H9Q)^-D6MN'A,3A>5->M?RJ_XT
M[C$ AFL&.YLY&-Q12(U@S#0M&46:E:S-J1)\/V,-%TWF#N0F421_>;)O+A56
M-[0KT#B;V6MO29NR?6, ZM#% 1G7TG;6FP=F-C_&>GM[/8=Y!/'J:OR\W=KN
MNHP)<"BMXW<7&$CT/<K,L__T?3S>3C30R9JNA3F,N&=(*":C1L-*L+=> TP2
M_SOE93':S\Z>YD_UQR.<EC8JUAL1.7(/O_0/?L8V!$[],A[N;KA;^B S_6U
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M@SS\G,I?A1A>VFX"S:SA:"?IKS9308^1NZ-#PHT.M;BW_]'8IZ#U1T":<$U
MD:>!'ZU-&D37%.#HU"<H@9E 'J.-4$WA @AT+N"N/+L*,D..6Q78#?R/8 Q[
M> +XD2,Q+4S/0>N:L+5*0?6/X\ "*WN/)$8HIN 8FBQWWAR)6(+T."C[2IS"
M7FV4B>1+_UO_#C(C94[9ID(0X,W6UI*JJ)4E(MEM/:6+DA>+W/G)T[8SCZ1(
MCR.B_C-2DP9GYHN2^LTHJ=M_BR!P<]L11V?F\^EW\P&<[77DQC_/AT%M@CR+
MXP)\TAR9,PV6S'/$5A#1R.ENY?8U@VFD_\/5*#P+5<2 X>=YR ;A3G!!:5+G
MJ+<7NN$?3_X/P6#H3(/-%2Z@+9'S*] P?Q.=M+$YOD]7]?FN:EO @X3B\=2B
M)Y @W%3J>.X[/[47M0T:3P^GC1.FM'>;E,SN+5PQ8+>PA0=&# )V^6Y\*,8(
M@=?R<IIV*-@4.WV!.@OFMV+91S^_"5^];#+]*/K8OU[T4*&/G&:28.9X<%4W
M!>-+,ETQ>*(.GV0C!BATV1;1&PV7Q^$6-'X:B-G*_N9->.GKA&"WIT?QS*5_
MIU8VORC55V=UP4BY4[%0=KL<V,SA# ;S(G'AYQ-<0'WJNTX/JI#6!+Q'=570
M'6NLP2&]+1>D Y%>WK#U5[5=+^,=]=4-/=Z''6+9*+-<5K<.C$%SU@^L,X:]
M?M)XYKE!=)\10U%[N8!#<WWZ:V9]R[Z?Q^B"F4(4R9CRJTFI8A\22ZHJ+\@&
M^'FO@P6^-3NJ=(X\5N$'L8UJ8:L,W,.?M@]#(RSN7&;IT=]Q5%5I.=KUU.=4
M"3-_7Q_)B+<N'''/B;//X L7,)L(T.ZD?74;,-;I_<1D7CGGZ:N\/X(5R)%4
MN$(X#;>YE:A4JP0W6YM8_NC^,H[:!012$34O'9\5LCY:2ZC_G/R;$ZV<Z>KV
M5.VL^1$>KWT*BI\;'.V>:)94VAA7(#]:'YQU "<G39_B"UXY)>KY<R(VX2)?
MR_.V&42!M_ZTR-\T@]1(^.;NV7 /^Q.<8HK@E..9+Z+:>W1+$ZR[,L3X_R^-
M^L^+T3?_<@$3[!%E+N#R<"A>"D@5M:14\BCY5.N5X0KGO#NGC EF]M1^I4/]
M0C^PD?Y*/CC\^.]LFY)]=_BN[S5<V>4"4HH'F[S^F?T=U+]O.M]07*+V439,
ME;([V@1:W5GY\M<8A31S7NF/B^RF_+7VRSM\@O?S,N?%&8Z)6)HP;)LXY23?
M&LUP,3G+T#_+9Z+,>#NV%-_$B^Q=1?[;Q/HIZK1(L_C].HB0;L,)3C4-%L:+
M39/D1Z8HZ,1S26)0>;E,F0I<EXVO"8'\>7V Y*T29K#J+50J#-BD@) P]F'%
M' R/E[OELD(&PUNZ%I ;E!&9=&%\JJK<\VS)K4,UO._6LM3,YY$\':06!5\#
M[\*<H*\!^U?*,?SO9I=23X* 2!K"+^RAQ2=%.CRUZ*BZ7\4V%P!:(PZG1*Q(
M):CNS&_Y*BG!OKNP=$@BFO9G;YOSN-M>OQJ=YPP1:-B=+1,&X/?P_MA_H2@'
M8E&8_=Q ^[QG[<[(%$NYE@N(9Q*<M3WP)4T"Z2J=CH#K-=-" -# "D>7PE/0
M:@TF?YLN%R=8*MB*8\Z11W>(A&EB.51XY<?4#^^]#)W'//O0XIXR-\K*J_N;
M/*<);)LCP9IS#" OY ?($ME61< AF#I?7BHR8VDO^4BZ3D2>%3J$7FL_&VJ"
M;JVI_H<007Z*XK>'8._'68ULN[&-R\3+S\-_<P&;J% ZA9SB/,W)N-V!H4E*
MCD048MF\T889E/5]TV$06_YF5]6.LWO^+I,+")W4PCLO=G<>+N<"),=C^)_O
M%:KR^7$V4<[HE?2:\GYXM^-)O\XXH8P,A;+]/#MUR4,/,'2@VT3,AI)$DVV^
MW+XGY0"8Q.X22X>(@HQR =>S&-L= J]]#RGMXT\=9^DP<0CG+2(*);5U0PQ#
M4?37N=4$+Z.2==$MI;=V01C>@( PGYWYU 35#DXZE3?W+NE  <&'G,*IA$.8
M)=/H<GDB1X9"AS10)LF4,K&:@UC3*$:&<B='U8^W6A"O*3P0D2\5P:E,QFNP
M^,D3H50GM@^M7Z!_#6J/%_^GYR%;%X.$8>U9#.*RDK>2WQ,6$K5:NZ^VC+')
MD:&:H?'.2=6#+QZ9S(?Y>:7[M"+0D,9Z1?\P1W^?GM91A-P$ \S 4]<K.3(-
M?OY&TX)W,ANSC\; 77!H"MFYH5.57KUSM)G3/@^S)PQ$[AE !(7XZ8A@J5\0
MP$.,GZ57E0/:,U(77B!5J8S'2Y:@W+#Y0!.6T.E-FA@03,W<R]8Z;MR]H7T"
MMF\PX[5Q31D0C&)B,6'HX% A]$YU_^Q4ZNLCC%3PM"BG>HDC/Z&UJ[7[0W@@
MX33LL*;L:[^.<I8+#P(ZQ4@>$)./6$&'[S]^N%P.F,]B4NUY6]$.%HG(%Q-'
MM](&NR"++"B5%KJQ0WP_:-)_^R\JYRVYM953S8^ L1C4%*=/R+6(8S?X4Y$V
M3$FA Y@I-@VR7L>RM17>3?1:N7AW5;-_'Q\70 IC(IR)F0$=&ORKNF^\]B[B
M.HBP=7@[?/WP/MAW2;[KVNF^PF+R' 7RI%]I:VRIMXZV2/:*(J6LFDF@C1/J
M\#0MTCM-%XI1O+NOLM<XHEUJ/)&M0R811XAX">,:_M3(U0-ZRFS=9)==74IZ
M]7*HM<^!,A2HKU?&8?5>9,1O1!\'4R\DL+8:NRE<D9/W__20W-[_D@B$PEM>
ML-Z4,:PA5^:!>8R7JTYZ8RP@D:WS;:OG]D)UWDL:,(,+N,8%U(@@=S S"+:+
MG[VJY%$1"BO5)4XWG&VL3)]W6%E_S 48[#7X#(W(X?0.L&WW_$36R F&KQ%H
M>(XI/T1QAFLS7QV+6!G:7+K'!22R0*MS@^$&3N&LXWH@,]6.RO#] 9QJ9MCW
MCWO-KARU>GL"%A:V02!* *O\+O1H#-($PQ_[[W^J]4,PU>+LEE=T.&[2_DY,
M)9:!Z>"4ZIR1[L&U<#YJ6&;-$[I<A36Y@*^0C0EVL)@F:&#$[[':Q"+@VS*8
MT=6;&"PZ_N-Z!@^V%H>)V?FQ3:/1&&57$PF?=M[^1(:PTPXB1!9-0:"N_&KQ
M"XN\,+ /:LO[.V@^G?&_GU'V@T)>!N"*K2TB\" QGV-:^2(((^6\*\M^2UX3
M]6B)<LY5PZO])Z.)P[^M$9,BQ#_DR(<;R\; W[+) X4?3MR#%RT@*"&4/UR
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M<U=N:NZ38%3OA$-B*^D0%P#,P_@3";)XPVGAID=*WOAS<)O9J43<00)9AK*
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M@L@N1"CEF2*^XG=:\,C!?PA].M9B6H;)0'U7$!Z#YCA!HY!._@(GPH<'O%9
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M<\@!+=-VS6H@GK>;4&R=VMJW_5XMV_3 18)H1<WZUAY]&4)L!;IIVD=NBOP
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M;!6R<R?!QTO:[T);#^PP#2NBOER<2X^;1[24>=)%"SB.KXI8C!= !:9J896
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M$:#XNFOITB/3/#'=[U:^QSAW@F>O/6B-[-W(+[O?L:JY6\-B^(*BXO26?R[
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M60'=-F%3.S2;L=3JN;8[/[-5BI-'1VLG%B4?N2OGF%B&_W[@)C!(.(3?/;U
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ME-5G?ZTPS(6WPCXOU^R\;-7M'QU/+*Q:=)O!-_^M:(4<_].W"-/W<6XDDK@
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MK[2SBSB*!VFC,T8Y6I,9?8'5A_+ _LZ)6H:O.VM'X[2BKXA5=3X03VI\NX4
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M=3\8WRXRZS80?[K3B?K85REY>^&^W;LZM'R)<=(#)11Z,@5O#/#6RV%AN!L
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M1X+]2)>][5';,?K%!!1P W'HJ12PPRM,_5^<G,ZYOF7BKGO03$97'^C-%O:
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MZ28"<H:.-$PF>*61?BA=7XC.0>7">'.5UP6&O)+I+YSMQNL3SB+"^&_N'2<
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M"L]?<T&_;Y $I[8E\;*+9QX!KNVOS"3";'H)]Y#IVYH46UBI6]PD!DB@!AY
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MSBXMU;'3>_NA^'-\LL[]RB0, Y0/XX'^ AY[['P&OL?+ >&X.O-"E[DU[Y%
M."!)+C8%Y*1QK3I,;V/S]Y')*.SVJLS3M8X%^2E.-!O[\?V"F^_8I4>4GG[)
M="W,Z^DU<\YIXGDE<OY\164 Z5XZ-+[JYB?ZPL=G1-ZPF^B%!06]:PR>/":
MM99YTSL<'\0=J#P),JA\D7@!#3<YSR7PW=)_F0/71;(-\]-;A-7L'8LVDE%U
M,LJ2#J.;<CP;[L5V]0^O#XS-?ZNL:'"8%RBZ<Z?X&KO937T9V41H_)V?8N;?
MDYO"C28MPY7KCJ 2$7";851@?X/GH9I)^>-14>#OSRRQHO&.T<.12A<B5_R&
M_Q@N-OC;[3]=G>4%-LI?+"!;>F[,;O'-=$ T_2'Z+Y_R\;5//K+@B>B-^=Y?
M!UUD51 <">*;UZGO8,H4FY2S=Q1GC;KQ-1/_G$Z C8OQ,Q/C^U8O:F*UXM_Z
M'G\%[D;Q P'![XE<,7=?9,0\5HN^:USR4MC4ZKE1KD!-F K1$5IT+Y3I+]82
M$;3RZ@Z1-PKA+^2X*>:'PUH>@"Y(*V/S*JJZQS %0Z]$M)6D_#$7*@:_F)_U
MC_\SMC!B:9%GTBN88I[]D+V-C8NM. -ON<CW!.LNNS4[W>E-Y Z_DC\696!J
MXOGK2[J$\_VPRV<JF=2;V.]8O&$].^AF,3;LD^2Q)E--NO1I>$Q%O_@PJ%?T
MNK OG$PK!+TZ^D],[0JE3UGV7@.L>6.(^=,X-%=BU/)B5K9:*FUJ.GJC\03@
MY\0'V^D-ZK1%?.(/ED0QYIC"2-DN8P=#W]\EJEC2_RD,!CZG6)*3J0S4Q>OI
M'F',M@>5/W=W?F?HGZ)8.>I[F!E\O=G+LT<@.+%4L;C$BOO4 M&4QG7L61Z;
M[;T:=M%.+>)W.3536=\]1P?2Q'N1EZQ"Y>;$8QJ2P2HK5(C'-]GM"]>F:!@J
MS":3TW7A/:R6FE TF8$[?B_(HLIX(/-2"500842-H>5@S:.Z' Z1HVOHV$L5
MI0Q:__J=R/N2FLO^8Q/N^$>= )HLX7LTZCKV]!*/!O&D,($(P3MS\D-[:ZK'
MN:GYRNYTIH(YC\1];#BI\2> =FQ-6^I80EX2TPOVQW&LQ<<8P+\$N&[$-9L&
M!OFE+6M([I3T6O^8><2%#HP0.4],CLP@R[0')<U0 FC6 2$@V+,3@+6BZ\\S
M)$Z ]'I8;N@C\@F@:A-A6;D9H!A6*::"Z)UCDSE[T7)G*S0XAM Q1;DP;455
M/9N50"=H"SM $JJ4$1ADQ0BPY.PT'S/JK*W)UCZ%&GI<%9KM54.&VG:> $J5
M4WLXF*C!B3T'Z\36)CO-N2MN%WFMTAIE:\CFXQ:4X .^>E).XS2+1 !_5K8\
M9']YIO(\$@@C$&=M>E<O'ZDES5Y')?"N)8_GYXMO:&$R7LB,C \Z"?X05Y(?
MU=5:X#,NC;[DZ"!*,)1H"5\O<V&WT*YG]J*11"GE?S<^M];'QCW7"QMDHM2M
MIOG<01]>J_?K[HC?J4EWFCL.?O"VI'^=0D*7)BCWK&.7FRV%)1WLX48&X9^Q
M1^=<[/N=K;H_&0V>=52XGD1W[>GO>B"DGQT(>7+E\L5PHU1M*A)/LS:E.3;D
M%SOX8'HKZHUV@"75C;3-J=YZF1DF\%*9LA[. ?9&1\NR 8Z$_-'U-;4P-\EI
M<;CCJG)=)#Q4N:^26U<WA&SPZ*%P9F(.2/*P,G$0J+E_\(:R?U2C,X$-;0AF
M>4>4-39ZN7;@>^E14Y!,BEYOP.ZQ7XJ7H)Q5OBY/N"CNW-;5+O;O!1.%F0%9
M#DW,*E]. #>''/'S]BVB$9><*$("U*]!^S:D8 \/;#C-NEF_^8W4<M!5C_E=
M4?!K*<O)DE%?DE/P1JQ\+/C[9&BX@6E7)IQ=/\F\=>Q",[IO*:7#E6]HDO%Y
M!W OW"9AP]:8?V0,ME2L TD?!^=/6>OD3 (YX!+H207EJL5$\X7@69[#D#].
M!7Y6HVP/EQ,YE6<G[]^REPGU",H?ZWZB+@;VN(<F/GO7L 6Y,1)1U8T"SE>9
M_<E;HS2Y$VCY?<2QM2.&VQ!/BE4*5]A-DA$XX>MA0<VNI8#[YEU\7\.UX)6<
MKT68O#]V]DFW^B]0%U=_?=TUSY)[R*1CV!IJ_O)&B-K&"0"TOK]ZNH<EP57X
MC>2=]&\'CJ/CW&;@3=Z_F/'7LY:UW GO+XTY\;R^Q?4@L-:U"?W\NZ^4G>7D
M"QYAE$7OV4"6V$3K#5!<UI^J9;ZU(VN=AEU>6,,QS//OHBPC^=@9GM Q]7?(
M\ 3@>PL_4 A)?!0Y]:.CS/"9"Y^6%B-N];/F2,?.OUKY!E^>?\D^0T*34P(^
MI*H^O;6IV5G;N'ONH<A1JK7ER/ALNJ60.)*_%+\\_J6II<O_9857*I]],=:Q
MOKCJ(_3*<5+;/;1GA:A1%R*XAU62&-*M_=54NN&U[.[/3L=C*(2$O;G5.A?-
M/F'IS94\=6RJR$-]@<!USY/V@W\X50;QB/7M^^@+< ;>OH!4W1 __I1R8VZ(
M[//:_D8O\Z\_%TX \L0'H'>34^U<E,$&/<*&+AS]W"%,_25E(KO=\N%AV1WW
MD:V$_&DYLNRS.@6S0$T"M]:-F-@D[@2E9GI&P2O+ 3ZZGDV:=*7A-+6_'P^S
M#6I)_CTL;?A,EE0\7PNVCNI2*\NAXTOQ'3 H-MX4\YG016E<+YV0$S9C;8 S
M\&E?^)Q2.)_@NII![^JL1;*S^W9?JD*Q9N]?[I5)@G;2M],7E"2&A;[P'V['
MCPG2)"">EJG4T-PU,^O+8E!=U BL6V!W>IHUC&!,P,"+MQDJ@M.$W@;>68&M
M;4$A-H2JSBKB7!7F^$G47"G3?Z*&5MV"P&WX62OSO5\<<\"=@]9ZC"G@LBKE
M[7D.1*5<4RKQH!+1C:J,#U<$B)>(GP#JP.Z!1 ;X8=BI)7/"5(Z_.74K[6N'
M2.*9$\!ZZ-8&P;ZR8G#CD/,$$,3X>ZQ&!I05C+$@C+4FVT/,>*9MEBGUF^=P
M%*6MJB B 4"'''&MGL-3^4/%O5$X C2(@ T: !!#Y4X )H,Q.#+5W0-:C'2J
MLJ_BMKH:@#A<F-5YRW95KRIX#V5Q++\$*95=T40"C<+ XMZ#*(0G >ID!2%"
M2X36/ O0K\J6234'2!#,ID@88[_F(<C SXKN_*Y>U5-/:R4F(+X21W\)I$#Y
M<\3H:@")5<>08,($7VC 6ZC)1I@XI$HQQ9V./ L+(H2%!I0@1RSQ8JP+E$@R
M0F;1:POK5OFS$9&XDO (I!+H5H/D.QC;PSC0-($FH\$ \7W9A<6?)Z=,;.MD
M<>0[Q\I!@\O48TQ. )J(7TBD;TM8J']GZ[O([KD]8F-]XF*HQU:HFY(/$P<Y
MN9/6I*]HFW *AF /:!AAG-!\-7^1RBJ0( $.7)Y[ ]EZL7>Z0&VV<;2P_"6+
MZ7AM"28BK6"&0CZX@GG: :SBK %%$CE!;[46+P)/ES( 5CQR[>C6M V)<_B\
M 54?,UN.0;8/PYTC:5:Z1PXUH^W6.1NY+$HJU+!(['M5D'+9[.5C>8O_B<7(
MDZ'_IWVX/.NQ/V>/3G*_[SU0'.O^U@AEYO>B)_1?A-*$W.^Z4P -)[/N 8\C
MQ95M=Q8)3[R)P E:2Q2\;"Z52+Q["KS3W;;HWG])K^'?BN-B#1$ZLLLG ,+%
M'>]##IE&R@F@%=E\M(W2)O^"K'GOU\< 'TL>GFFC*A&4[2LP)&(G<@#VO&F<
M@]^;J@K450G36)F, '6</L^L$RT![7HK&'@"Z-8@(T=M/H*7JP]]_\K4GP F
M4HZ,F>.CE=RV_ZRL=0.'N\<U7 5GX..@-BS?%CWEJ60]\C<,?RPO+@#KY0"\
M?81+.'7V&B!]IX7<D*:[#^7RJOJI-C8(C9=,G+=. !N)0U=>UW L\BD1PA^N
M_>%G%<$!\<446W/)4G:M_0B?\C<,6_NT3$0%G#?.(/,$\(E8EGE#"KU&JTJW
M<>'0J7\2_DYGX87(;W3,Y>2 -7L=)3LKUHK-T.),'>DT]7MYGF]<:#:(?,+"
M#K?J]3Q"U<WH7N.4;OFQ'[\4O44-J>/5MYZ69J*X5%0NR.&F; W.*<7FAD2;
M.(,UV9/W]FC6ZJKZ^H+5[8&F+P9&/1\\:W6Y?0J96LO*]]&"FH5;P;>FUC:+
M]@%JU:)':)+/H@R&^?9%)1<:2]/NMV?;(RCFJZ.%HH&C]N7%W4^J,YZ9C)Z%
M/6B_%8Y#8A)=%#6E7<U'@+5*DO?Z5,WLH,I-=[]_X/_HBN8>U#'<>]?W5##'
MY<>G,DD&F9^O'[^B1 &H2J6<AT-;$ZMN:%'[POJ..JA!]]*Q?/M#G]$W8K<+
M*KZVV=Q=RM36_E R4#/(4\HKP,J=_[B/C<9 '<*J:]]PH=;Q/GIU%N5#NVFG
M$TA&?W<M?U1Z13*-Z<M(K(O]D\#YI[?OSN1IEKB6S"SIDU.4T%WPW7@WDL_,
M"OO &X/7KQ_+T>]UF^>8XV]<C_A]\_X)('FH7Z##ZW/9CQ8MP7Z:D<(#QCI'
M/&9E56E]^C=.IT34A@E3..:G.T>XH*AOJTS/ZY@\U/OP\PT1WX!7?2;T)+1@
M4=I _[6)BHO,=!M>6SK234FFMYF6T-<L!\[33>9D/W4*O?+-R #_(<2 K414
MT$<C*T!+U'BY;3PN=6.TQ63.V6T/OVW1?*7T@]S^GX#]RM)QA8J@=9*VD;UK
M$ZWX$8>P#>_@>^[*9U1!B!F[Q].!A-S-+ZOYL9Q/DA?8^D6%F;TV0!\@"P^N
M8QY5R.6DM/C;",8*N4OQ^="3C"@(0:&2^*4@B_>?\:7[2L:E]Q]=&^GZ?)&E
M[)9^\JUDW_ _S;,P<&$'\'?=6F>$M_8U;2K"/A#Z2GA12E6?IU530)0@YA01
M2'U ]_SLK/M%6.E=4''#ID3%R&V!YYW1Z>G:IF,O1;A*Z$X 3.;+I72.V8ZQ
MYS/S73<,RW^G-AM]N?E RZQ("<#-2 Z6R<$SU;[Z]KQTC;?^>[PGO9/ V5B?
M%BQ5;9SJU-#PE(0-=@Q1QFQ\5'J*)WRE?$Y^UASGKD+02*FDIKT2BKYY5QW2
M)D/BK@DV;1+\_>75TNXJQJ?!V8-P;FA$46IMA5:IQ!13$X-[3O>\ E(Z'_4E
M6P/?-TO86^^-2 NBT]XWKYPTK-3B-U-Z8Z+"!F#\;/P\+-QL%6F93&-:#5UE
MN4[P?51^PS?!V'1D@.Y^#"XYIM$AAI @"U:2^A$!&CNH=@[69;60]IJA XP$
MKE#-"3$W3-J&%5,"OP&C,R<OQ1\U&D"(B+6N@FG1T4B9^-O'T#0H"F,*Q)M1
M[3M;T^'*^P ^%=_GL2RYC?A'/,G[BU'P?20/K%MY SVI3K>'/_N6B_O8] 1P
M\52&Y *S$MWYA(KE8[3F4L2,DY VFC]'VW S98SG"6%UO&_.7G,+/4^.BYI[
MFWN%6I7'1^C*0.E]A)93U:JX]]QF2$CZMX :>?6?-2> V.,9+\R/@LH8\@P%
M +H-E7\[PGH14JQ,'6O5^,Y!+B&[G/JB(Y#J&S'H#)707QZ"8'U!2R0R=BVF
MMIWU/N)GQV%/P?AC%;FER16T_N'7"2 ./PI*N0??4SWL/#RCO%#_%DGI49Y0
MO/9+9GEEPE_6;"TJ##JOEW#TQ' N' ]:H;6^"UOX4VCS7S&5-:FZ1Y.6&G%0
M9/#Y5[XX:H=:-W\J[7<W-8IZZ$G0Z"\$(7U;_[=B-O]]PZD,\ =^9^4Y:%0?
M%V?QNPVJMME++3-:H;%D_BQ]?X,,/]0PAE-(X4 &42T9N+.[CL7LSJP^8/HB
M*PD$>PGT#*<.VJZQ'N[Z?@;Y9,HB@G5!$=#_U)=#A8%)@?SC>$5NJXABJEN8
M$NY.)G$<6<9WNFIF_964*.WJIA_9KF81[ZP3TNC,I=^>TLUFQB_"X^TS#V#$
MD";<@X"2D(V^ :$KD@R\.N-=N,^O/0//>H,AFV_[_A@WV^6$/G1*F75H:#(!
M]/&\!)QC81LQA'V63[9E(-@5.6#> ,3H7[R*T;J^N%T#R\5IK5"4\+)?2KT%
MC$-0%?)2TQL<S),HL&;RRR0E,^VA-96V*[N/"%?#K[M&-YW!KY<\=GWM=]<=
MP)#:HRF07 (##R^I?*MH'SD!Y"#88R2>"V<8Y]+?,/QR+#]7.A<AMYP@Q:-;
M)F.L?]6\O%1S]+& *'<<'0J-O:$A&.^A7[??,RTN?LZT(?%Y'I,FUVXA&Q4I
M*49,$0:DQ'^PE*AI4Z[0_-UU D"3::H'_NSU2=<60>U_HZ+F.8,=\YV?P>9
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M&11+^8H^,="G^*"RXK^3IY@"48=-H_3!SN\2='MWZ%^ZB[6$2H 60K=0%49
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M(IYV>RS OT%E\YGHG1UFD+N4?]3?=(Y@P*+Z]S8.DA*9G?<\=/!,P[0811:
M0/J7Q6IA"Y$"=&6%=GQ ;., "Q!V?T_&B>$$P\/ KYKFF7,++$!Q43\+( .K
MOWN6!;@.JT9F"]0U%CWZWV4@@[4Y4(.*3<<\#1VY #.**\ L4VGD@K&1*'UP
M,#'H?\(D^']=X,^T'/,24Z+&)/16>W8_JXWZ]_(:5?75>[_&W7<W#%_?Q%D*
M5&TMN[@R<FJ5ICB+<X?[0J>@OB?K*J717@!#H#)<;.V8J""H#>A]/5H4%K7/
M A3NV1U>U8S,,?X6&)7*Q>0/3=BJGCL'W#=0XSP&D*>&OTAJN5".:?%V=WV#
M\9'X^>'4OL NT_I<G,O$ <,$AH95XNQF7[==V#OH_ZN]<(H%.!O^0N#GH=$9
M<(%I/1DS^9%)93Y@R_(U$I+HLLP"7'%F[@44(KZ(==/S?<2'-IL3BL;45*I5
MEL]4D?.GVM;;#@;3\?6R?$1&OUF+WH<^6/;VCV,GTT"SST6:G$X_2X!&W$OU
M"K>--+KR1#]>19,I?MJLSRU[?D0+"NX4W]V57G[9N/.KDW:_LU0W<QCZ]N+0
MQ]=F[J8!93P5[>?TXVJ%0Z+K(BY$Q-ZW,CPF2G2V=W\3\=>28<?0:7*?4(!X
M-FQ_[@=30O;$[<HQ3L;,K7$[O)C7AFT#9FH,RZ/0H@K'?_-^-_T;^Z/YK+<A
M"[#NA.E1YH-+CW3.*I;)0&#!RGBE,;N#D,[7VFXO.[A<-KY>;[5\XO:4<RK+
M#U,Y+;GQK0#U>&DAU.W7U^=ZA4/:ES765?TRSZG>4-J\UZV^Z.E<5OHMBC==
M*]7$V-)O6_?ITS^$/W=*?.*X]>YR-AJ2N WI1RD<N"^&@P3U\%6#[@I?*8VY
M:E.(^(UT#5S'L^Q7OS;1H;4HV5DA0XW+WL L1<7,[S_&4'ZM6,$:[WD=X)*Z
MU65NJU^3OORO%RVC:J;LXUT /+%Z3XX>>M)A[9@7:0!3%H_H8IZE:WW/B_-G
MWO:2C +$JAE4G'0YIQ7R6# 2O8DEH4C[F?,>M>-EY^>_7!L^X?]Y>(G[D,F2
M>3<=?5%UL#DW[:IT8O(,$-S7M[MRY!M=8W6-) XM"I#)9P$P!WW-=S\Q>XD]
M"-3-N[9U/S_:IO]Q)GV]$"]V]4:5X/W1_/245E=/]8.I<8_'Z\XO+V?.B/:[
MQ+^RDXQ-"GNS,'_V7%%;>,4.>__VOG_4<$.7H:<C4_?M<,+17V^+I#Z9A*AQ
MI'=7JW!72IVPK[HU8C3T]/#9/Q9ILL*F@.?;+].T'>%%JLS@3 JBSX;F.=TH
M&"3TO=A/_H5$FC9L^L0@[=0J9,%#[MU";#C^EZND1!\X&OZ$3YN_'C2=:1,N
M>EG2FP7HZ%EM>&_ZM5-[]">_S??LY*I<@@2L[K6,P?@^,XH1FP=W4%^B]8$>
M*E#"Z39*NVM. N?\L-!S+,"#!Z'+.W>.[+HV[7^P$3&:4][BK#\0$(H,[_M(
M:-D7^H47\X]%B*#<'4\@AHWOF3Q?37Y6?>N$"_*%SCR5J=R_'E73:([R"9.3
M+NUI(_,8Y4D>><Y-O< "F!^WG"*GH#=L;U-XSE,<:O;$>(B%.34XT>)*6:YG
MP4F_=CU@>:'D2[HB!+U/IAQL*'OX1/A[TC9)"<]P_$_U7*%I33%X8^$48[Q/
M\ [LL8'.R(AD# Q%QEP8:>JCHI6?0O^_UD?2^N;DFS0O$0<%NF'QNGLQL4\2
M;APS:C'/< U6#?BGP;X>4-\)"0-.@)4J1+D<!0J 1!C$FS#I04U_5A8Z,_YK
M*CV45 =\T,/,9."B\#@1O"X+P D&:F@"QVM_X7=9@(MD&Q+Q^VF!%A>=!3>+
M"4CR89VE><0VIN$8_8816W)=*Z$-;#B]1=+Z*)AA=D(#$)2.RU,IJ %L"%OE
M4P7!/])]^I<M8"5_2>YW6MW!2Z!A(NXFZG#I@Y.= /PCWFU2/8"I6XLN))HR
M,OP$!0XI" MQ)]CZTST]2:!_QU@OXEZ5.3+N<,*&@UPTF,U)%!0(7O#/5J7*
MKR;U+,;-M5-"B1W':_Y*=>1-=?0^:>R%7_TK6ZT/C9XD):%++B!VTF4OU0J7
M SKBPV'=B[\-UCI8  ,E.E.]F;Q+G)8E$0MK:T^1JO!ZE8IUE@+L!8!,->P'
M;+1-:DBP &4OGJYR49,(DO2[Y(VFM[@'F7IS2^2ZF70"@+=0:'Z5A,(1F]$X
M6'%[_<P.!\1@S>G:X;!P!DR82AM6)A\$]+3'1LWP!M\[! C&C$Q#?,2>4LQ+
MN3(!P 1'KKWSOU<!XD?GZ088=>(P'&ES F]:CR+5S>M"OH<Z\JMM9 2@7RLM
MP(MF8([IU/OI(:!16!-TVI3FY_V>P\/)1:-NX1TD&Z-TOAR$9P&0F]80N%7]
M!1U0B-^@X\D2W5KD:ATPA@4 !Q18$$.IF2X<U&?Q'.B?7%0!4CL<$QP$5?.X
MJB$%:('5C.()+5M^+^XMP\FAU7%H?5+;U +O*NC)M0+$?B;' @VW.$+=U)6]
M9RE4H0@<HT^-S, JZ=!I"WK#-O5$6R30.#<9 ,_A>*4DR;SS<M-TASB5X>W9
M-S3!+T^JY"(X@?\&\VT$;>X0O8C9)"[S!8%"ZG2(TR^RDG!M/;F\UJ:1+S?L
MZ0FAA2#U%.IDO6@,+)0*G>Y# E5)>/=@L*(M%^#>5?X2-XX**GN_,XA([[^+
MCP NMQ-:16#%JCN:,@CDX'13 QDACG8=]M"<UST?L:$[-R+L & !#/W)!'?B
M=(KR6I!AUHAQ3K+T[W/E'*H>(-$8*$F9/(;[>,B&G7!%TL.RZU[T>/BS -%0
M,AY7Y]VOI!Y\[)&81KR:1"1O2_W<-.[?4ZJQ2-C#S"9-C6/T2F8JKR.G'@^;
M P%HTS;$"L#<3(R@#HXFW1+#Z30#:Q8G&:)QYI+IZ6-.NG,39SC7*2@9*I2<
M0)P,P.[:_03$:F,)7ND,74G&_'1SD"LR*$AU E'V4UAU(L#_$JC-?7.L@$VR
MT.P@A%,G8+5\4@0ZHIT% ,UN3@3@K,=T% ^%0BUPU!A\O)\4"_ (NJ],MC)H
MF4G?.CS$6S@":TV<@#V"_1 G3L\0&ZT(5-0(-EX>"M<#$OSK@! H<=+;EJ^.
MFAFD-#_DZNEHB<A#$\M(N)E8<ZF8(/!?$8!"1^7F)+2\!ZW!U=/>/C)1VU(A
MD9C#CAT&K;O,>^;^;UV41(A&_>)'CN8H-M[L4KPW9<75Y!1CD>8419-"AI-U
M1"RFS9W!W<C/O4XHF .^?@3Y;^[$&OBO6A +<*\1UNH=&%TW@S*&5;( GY:'
M@>#L??=N+VJ),:B >63ESI]DJDHH,_5?,>BSDPM?;.GTH^EP[TJ)[3TZ[<L'
M\1,@POR0A./<"?.^W5DFDB1>,9$>Y*]ZRM%#%Y(7BT$>0!UQ^1\<YDW^#;PJ
M)/T]#E--A+6$'K@2]^KH$+H:K4\='1#YV01!@H%(_!7QJBF-_'I H@UV]26,
MO>RM^%5PCFLW4S6 '2,3"<9^P"V8^J>1-11->O*D!V@ME_GTE*T+;/X\_4Z=
M"WB0L;TO/@:;6#[=PWT@DGUD0^X%8A5^8/*],SBUPE;>T]:/&E '&AS[>_;T
M?/\-J5/PU'^M_C8HZ@2BCU0G0_B^D*F.@ >W*V^?*=,XPTXJ!\'3RS9978)]
MQ^WZI*YEUB1(ZAWWN+]DX?OI'L=CCT0_$!%J='KU+$=* ;V6Z"2;&SVXN,I$
M+@Z'#=!7\/Y4]8H>,JA#_N-$$'HPW4.MMAJJ(-]XLT[_?/'CIZ<>U%Z:@JK'
M .7%UY(.R9[_9?&AK?C,LQ-JD2[[)24Q^)C/7P\Y#6?/ZW/T3_Z8/636_T#J
MJK461]F5M*W=LF!(JIX8:E?F5 KQ=V8VY52_RJ.F'WS7V,"Y;I ._M1K1HIP
MP$Y2BN'-$UYGD]L&%N>2WBYZ@!J&P*\PLB8(5QV4@7CB):Z1L%H6X+"RG\L3
M_ALWL%_SY):7(=6B@=2G; EP?7()W3HZ60 9:7Q9J(1]L,!4F=G7OJ4&B<,S
M/''#"0^_=&Z=[M:[4%+>6L.GD*@-J4O,(\5QJ$Q<M9@;^BD20OW9UPT70!5D
M3:[/>[_6.U90P%[KT94JC-\PID,?$0N<7)EO?[K_*:A(>NUQS\-DQZ3\[%0Q
M<;'K;/&R_RO2+W]'ETKZR"T*'<XHT< 4:GFV+@_PEHPN!V2]N YSN-6_=="S
M0W;=1'Q%G&WDJG:GB90H(O7V(G1,'Z5T.C2W\M;9_3*Q+ZG<V3C_YV/XVF+W
M\$(&+QL7+TZ--U<D+C6?NBS=Y+C$;?C<Q<@"/F3V$B+K=7@3^ 7_"%C=.._@
ME8IE( >A2<V..W7-V/7C9MM=&Q,=KDX_?-X1FHY,YI;DY6;C#XZ3M,2DUF??
MQB9%7BA;__"C/N7NB,Y]<SIHS>N[_/B47)'#UC-)-;^A3'7MS\@\<*':88B$
MNO%K&M[-JV,)[O27M _.5R;;KUDI;'VJU7ZT4?Q#ZP'NR8;>.UF)O&29HJ*O
MR:NAV\6\X3WHAJM2!6UHZ69,W"SMP6'Q&C9]*="6;J1\>&&_YH3K%(5UR"?'
M4D#U/JYDF"2^8E,U^Y<=ZI:=-H\S"_"!.!NM?Y3L-?JEA99C_NHM\.^C(V=$
MO$IR_6)RN>"W*,RIE =-EJ7J(MK4KB,YG"%/HOU'DIG69\K6=Y1N- ??]=;!
M?BK'YT2FEM*$O?8-;/:95RR?IT^>6^^_?>:,]RWCQS$&L9\?&68'O@J+\U=?
MIS6#39'49FN95,^(S&+QY#T:C,U_S4LI[:DE%+OJYJ?(YW-O=QIECOW8/BWR
MS"7P_1=Z^HRBY_J1TD[]/9NG[]IX52Z*7>H.XA9GT- KEXET:I-*S<D2;C-0
M/ W4/7 3N?C#P24D=\431PNHRHQJ+H:.*?&_EC%)"FLND#QC94JSO(4:3^&Q
M2N&S+>P_7UU4:0M6W*^PY+GD%U'P[W3[UL:6/[HZ74B.7>SNBG;Z4N\?/ U:
M]Y;J.6_(E>^+\7>B!L6@4>53:['=R;_L?JR]U1\[ZB-@8VY<#GPUO%3\]D3W
MS1YC6].:ERY!*7T_P)*)TM;B&BS >X3Z9^E=IT+SU07N4-#26:[U(P5(NV!7
MI\>E#+6F1O@<&.(+]MDKQ\.=G(-[>ER*2]65Y.%M1HHJ#BQ KO6W+X\C%%X.
MK^N^3M'-2_N>U+MVJ+A%/L9A5,&J4&]^X*PHCG(>=BU9!_.\'&U6)22K<?<T
MLKMOG_D@%P()K&NW]5%X[0UT]\K\O1&7O99!-!]#3!S($@)V+]1 CS3;RGFD
M0T ?HBY=NW72!&YGN'=,(*2L^3TG7Y)+LNU3P<)X3KDV8PRA3S=R%9#T_.,>
M;DT5!#K J*<'FP4B\RFWXE:;^(&%/M-&SB[Q8\B*'\%3K:_EE'@RT%)=3]9-
M$LKR<S.(%F]"Y0N2&&J8E_;[27Z)U^^)JD,(=*I!/03K+Z+#4R$%C%E'4BO[
M[]^\]($>K*:1[OG29R%>[>N-PZ.A80%RG!].__UK4GY\U8V7 _NW D,=.;+@
MV2=.C,XLY7HB+N:V<ZESJ"F&F07#,7/9*7>K_ IQEPC\*C"PC$ R3AVP ,Z;
MIA9T:XO85=S[WWH+L"8NTC)!@P[[06Z 7U0N/*Y9>(]PM2I[;L%JG!HELP*H
M)8D'$2VV5DE#E]\N#MJ/S&RWC[  )GN'3GJ@EAF;^,>> Q$'VC=P*MOM[?4V
MKFZ//+LXVS+OD8U&/I+.[1%C20(DU9,'"T$@X1E@']J<XEVM[]V]X_I"P1UJ
M93._ZWC2?1-V:Q%7?-D=!T120]1#+%H2Y?>4EM,9:C3Q'*2Y#(X!(5"\1^L6
MF#G%+:$O)JS@>6QXA(XHD[/_63 :HM0V0'EU,V_G<*Z=KCZ!5G"2O]<0;/2Z
MF,7FCC:;8=T&?I*8ZE"?I0K*!X>N)ZJ_SX2QV6A4U8:KE"77?\8ZW=,0*.SJ
MT3D ,AX@LQ7JJHO,_W>QYK$SI_; ./!!B>LLAPR"XOD+9QG$AZ6Y!HLJ;^^L
M@O^G6X3^7<@ZG"\322\\_VQZM44F/:GO@/: E'O2K 5(V"$ZC'^]'- K#=]J
M16Q7S$R,GG0M\=S(WQID0)8(XU?BZKCA!#%G$DEIZ @U_;G7!$/>U8<Q5X>E
M8E[;;.'4T+X+'^*YXOPYJ3%L]6(<G$.DD#>GY-AY>&SD_7W$T3O_CN\VY?UW
ML%2JPS"ENJ+$5V@TKYV-C/&6$%$=FWV%\7:-^H33?*)!_DUO)U3T?F0^?!%W
MJBLZ^5/Q_;3A4I[=X+XC+(#C3"^:<.-3=+*4T&'P++>,J.K'6RQ 53-E=[-:
M!3GP\5/ZU=IKB#G*A=>R3[^\=N,U,,D:T-1XQ%^3/PT5AI*6-O^0^E[,E/SP
M88Y_!<[2TGFM>89,Y^2DSL^]2M(->QK@7O1<S^R0YQXY3B5R4D%AHLDD\,Z9
MTWF7#P>.;KN2_'W *91J)S*W0^U4O<<37))]0F'8G:J2*PEV]WDDC<,C/=X8
M(%F JRS XL=&YF/[+;6QB>UK^ -<2)=6:D''PNILZI4)ONAD^Z@S/'KG_ (8
M>1_*+66\$R&#L3,,:F>C@MS.XA>1_+GL>9.6@Y+H^& AR3OGO\@#6EJ*VF"P
MYEW?YFD+:P^(O)%O8@C.&,A+NV*:X? CP>:[CO*C,X>X'G.-]%.F$QH%;.UP
MCDX\=ZL0OXHJ#TJ]A8Z]_-[R\H.SP<<X:YY:3BU;Y_OEQC-<[>_U^EB 0$/=
M_8U5'YK?H:KB!3/[(S$B:2.]&I>EI.*U-$ IO![+-4W#?TSB[)=2[:M3"MK4
M1>[E%_8*6D3?S-HP>J#/*=?_8'(2WMBHB%K?/2=+AT\,PQ+F*F7-Q76K4N]"
MK=%7]F2(C*!=KDRU6?*C2?^1<<=)HX2MU9K\VXIG'_!=MD6> "VOXFT78F/B
MSY3[7N901\\L)&0(7& !'D)(;H**PAW![9.G=(R^%ENC(K[RWAY8N:?57'6R
M\AKG%8?[:@\M)X;7-B<::!D)KOXIFJ<?NYT[_<V/&!FWKPCBS 1*^"6>76(!
M_'R>:<:\^O"5.QNV MS3?:-*IZJ)"!?LF]L8MYO$M$:6GHY9[GL*N.FM_>=L
M8T!,:AVZ97[5TVXSKRF*'+P ='WZZ%)^48=<^3S5#F"E"^I7ARUUK.._H28/
MWJ3-%7TROK':%@$QC.0Y:FOA.N8F]K%>EJ]\W. #=>).; \+,$*^FQQF&:1B
M-) 3=:H-M\V(8CQ=D>WO1#YO!].X!TNK-!Q@,NG&5@1&!6KO+=!88(@%J-R?
M_&/>IRR+MNM+I KT%1_H8\[F>$OT\-Q?<ZG4R9];T^23$:HB4A&.Y2Z2U:&Y
M[J%,8^YL$C'X7&S(+L&W5NW6O_*LU[<I:;R.%Y"FY&G& EC-O]-@:\B/Y$V;
MV@'X=,.T42XB2=3GYC.1H" E.L#5@P-%!R_]# K(?K=%3,GR2K#S4--_=$5)
MF,1["V 0-<_^;43(3_8VIF):APV/GEY1ZYT^R-,N01BO#KB^.GKU&*^+\]X"
M?%_TAQ_36KE) #^HB?F;M"=)\#<AU>[MDO[UMI677L$%WFD1JEW3KRW5&@T"
M[T>QLT;4 0WICRL_%*;)%2DADA2LGRXB. '%V5#\]R93>V=]%@]1#%H_8V?=
M;_\L)NQ\M<C^U/$LV>QE8>+9&TL3E@QXK="^S8TL"P0I$$L!J1>IKSKRZ9VE
M,R$*NWN"QH%1*Y_R7+=^JT\0B[^])VD,&%_;;+NQ8.TDG [/HK*57Z;,U:8/
MS^[K_IL]TH @!=N;>'I_<REYPKT,5GB:-<^TB;KN+-AW;-EHII+G+.^8;IW0
M//P _G(:H</T4K.%%$@)9$DPCMJY#I=D^M/9W'_3VK5<OV# N22^N.5$;L++
M7*8+;I[Q09S4V@>WY%D[9BKEW39QU&+D><R'LW'2ES7B=3P.E8FG#+L6+$_#
M746]UYC67GD6DK>=CFN9-D5]WI[Z28KX:Z?JN3?/@$'/B7U'O]G.)O9?_RSY
M\.&'7HT7CV.*;Z:UO*I"G'5W9Z(&X<$2GRH*;&:-=H@QNL5A.L[7]23O?]H_
MNFM5^-%B5MSTXKBKN]VF1N3=.\1ID#K:[=DOVYKB<^,7M7.?_4WQ 1='/$IJ
MCP+!H=FS!4CSV\.(7=)E2<HA"ZE3MV,%LP^IZ&>=.FNL]UIX)@BF3E[&%;[A
M_^;]22K.I7!MSA4E:YI.GC:+]A&6_#,Q)E"(7]U\OD<TM3F#??;]5>')LY9_
M7OG;17P?8#Y_T? GX:#_4]DY;N,P7:H(^U47DL0"0-,5$4WMW[!OL(F[EY6_
M-U@1#STK!$*"=X@O<&KNSTTCYNV]=ZKDHS'E-YL?[B7>D:XX.C>.WJ2+0=6#
M'#@^5AXZY4WBW0'X8*CY0O5 2U@%>>/>#M&4Z\P9HG"*'*>XHLY;\R=N7(PJ
M_TN R%=-NGEX@L8"+=OK3$DH)0ZU"%%O]#E951J;A;@.D<F+><@%SA4BU<A=
M)"P/'%5<@-9MJ-73E$GO[I*ZN'1-DZ_],=)XHN>0L1PG?[&M6N^2:FAPPZ?7
M.T?%L_>(PZ)R.)V/,K#O@]I)O1W3E2*)DHDV@$A%'B?+,([*&3P$=*WIL)8J
M=0T2?WK:N*S,P8'.NZ/5<R",1J]Q:KS<0H"NE9JB!:RX2BBWK]N)\JH<=M:2
M2'X8HQ(L*/,IDF]/8BMH)"O-O#A)?QEYJW#@4=8ICOGJV)N.ML6=$!(!$($:
M@OO(ZIP,'PD_(E:&N\-HKWFAGG(]L?F[M.G0-H"C*9P!'H(9JM'*& 7E(8J)
M^^<OO;$<4!,L3^ROH.N&$XX>XMJ<3K4I\_/^4YI&=RH5FP\(^>2\$'FC:)&3
M^DE7.$78R$47"#9!VF:X"[_RL;G?477KW05!F3VI3QW+#S^-'!H54H7B^-&K
M..,C84LO+@QV'PL"7,L*H_X:O1V3)7[O$'0D;T?-+[Z6+ZX^^7)EH_69U,ZX
MEL-^'V0L4@"'I(+S,.BA@#BTM=6M$47O3_<<'F[_DH%)%J\4U!G=#H^]?DOI
MN!\(1UVIBI,W;%*)%98I=Z1EWOZ4DJAGDV$+-NDR$N1..V29[&_J]"<G7CUG
M.CFY68A[3<TO3/T"CC=D\1J'N5_TEIC])T%"=_<1C=QXF*[)'OG=R<=V9>\L
MZ/?1_JYY]X87C\V)5B0\?Y0?=OC+W8MM(B?W,)BW+P\, K8NU)T(6+^?Z%7;
MFR/B<;8D)M+,4O"<QH((=/@H$99JHT2MD'/34*QW#''ABR@UWST@;QJBL>5?
M,H\!UQ512C+IO+71B.S_&&&]NP>Q4L\N'VG9=>^31"#9Q!<23/0G%AQIX=B3
M"CI<VA BDV3+YH/ 8*+-9^+T8(CS*[.]50#O;N>A,LR4?!^;SE5;3/]]%FX+
M!JU_H 9STQTG&W#BE:=R$QQCIO9?.O+K F(<06MJ.#'776(M]51OBDQ,3.%Q
M]8;8KG]>7J8XFQ3."2P(5P"N2(C S16%:FNFIM.A9*0-Q7L&5=N)47V6>9>>
M0(&P$SBMC$+Z#-\_;Q#%V0:+#5$$;H+6T?CBN&01_1YRN4B&/L^VR_.>%HPH
M!XRX^6_:4_]!U-C X']_*V0-_M]>*A$6H-4],!(%0)D0EI-<#@AV6/DN7FRU
MBR4+X"D/P\.PD"SR3?,5F0)1&#:I3/ 8W9)(8KX7=[9[<0Q#<]T77P+OW5@=
MXKLBKM )2R_L6 -QXJCI0G45ZN7@OYX>("S>&P GP4IP)5FV+:>(S&PF?P47
M1:FV7&#(D@89UI'<9:<>VZ #-YM/25&+M"#8,)-C*&;7PY\[!F&N&F/%!.P3
M6("Z6":R?>!(>\\[6'<K9<_>UQS(WR UNKWCN=A"#8624*TQ#$T,<'X/)=Z*
MO\("^ C"Y>68QY1/NIZM>,\"Z&&(0*TOB3UN1VO[1O8KE[?D8:^];U.\#,+\
MR+!V6 GC.?Q>;?W,J(@%74C(D06P# XB#A:'QMUE <Q468#A--*FZ<<9%L#&
MU<ZU<"8]@2F^YF<^6-#"S=W'E.LK'*'RWZM0#??<HS(T76!(T#J#VEQ0QO$K
MII4!62:BY4B*J+_;I+FV"1MV=&WOIQJ1U%Q1H6K::9TX ._42 6;4=OHS,"0
MI/FI'0^PS<XL@@2+*I6>B,>$MW^02CQ:&_%!<7FJJ<]2XH2N..3?@/P"ZT<D
M"7='@"8:CRBLF\'_6T3+Z082QYP?A32YWB7Q+%A'V-%BGRWC'+<901L%(43M
ML,BF?Q/Z#YISNJ Q@F#5>(&1Z8)M1Q':]NPNL?4/Q3O,5,F14\'NA7,/L@4(
M"1!S8@'R^KJ1)X)30/ "*:96*!HNSH 8U@2T7AC0%.:<F9K;7R;:ZM4MT2'3
M10,AW%MQ]?PPT%"0%EH#S]"381"G&[8 KX'=Y:7^=:J<KNY]![O0Z>FH,N6Q
MHMLR8K9#?L*V?&NN>\Q<VA:%9(=E/".6<+WL21NA3N&$.)#0W3WR;'1FB47(
MT3XJ9C@N)Y)9ZN0/$ (:7[VJL<!+PYD3I/+*6D]H*)W_@ )"D%)0^TI2GV%_
MX)!X7>758!30QH % &TJ4F%@GQ*S+!):U@]IY>JA*3W7 MD2 ,4(PK+(.8LV
M:JY(0:T/4L&'RUWXD-!,-J8QX&C_+>)H%D'\!\C8;R$3_%>0CP7()FL:BJES
M4OAS;]0!M0%N_O0PO^,&L7 :S$=5N3B:8E<J R\KPY*X5IDE [!6*A0W'C!Y
M-T1YY;(JGY+DKN=+NSWF]V7ZOUEP<,L9;IOY 1>78U2!;"KCKC!JD"DSM;H\
M\O%TGCL+(#P4]- JQ-D%]&N-,U,#7<9$H;WMC/3]2?$3S]@L;<;S)TJ(\Q=;
MP2$=::B"QR1@$A2>75?!'<?!C>CF^DDN1^U[O[=*AY@/C'# N%>A_" \% ^K
M?\"PL7[+O>(/*R2Q([R+0Y/Y!G*6K_9$1GN7!)=+V'H.270<.^:J!*N;3F !
M>+S\?P,WP$6%_SY21:C/3?V7M>9.C2MC<-Q'%>:[A:);P8Z%T[4H* P_=YFX
M9)["_Z"M)O_LZGP*8&A&[WIM' IN,/Y'JR;[:M9TTMX^Y-SXYM(M?HH:%)NL
M_B!D;W4L*LC\:( "0D)J[>Z^O:#WGUO?8D8N+J2*/UF 146*=N3NM(<QKODS
M,59O:+U3T%C'BOOWI#D)WN^R4:)2M?/SGXYWT=1[(ZTP=TK-C^-D10X>\%#$
MSW"KJO?AAWT:?!["WV6/JGL^Q2Q'/BL2+9P)EH?U-=\'_Z"-+!!0;$T-MF.Z
M.=(QZE6_>3,MC*BO !2Y+7H4?T7R&L!U'S]SXBB*1OL U'PA\!?V'[/4Y50[
M<G:Q034,/4K'Y T,UR\VO,IA,W/77>^NMS1>8D&@P&J'O0B<V,*.(Y+OE(<F
M%70PF<K@9B*WE.9W]J$XQB)&X5K#EL\I3R8+D.1NUV$OM#?5 M]B 5[H8,2M
MR9D%=-W75!_('M#FU Z).X %:$)1&LY0BVC-J?XSW]M;&SMNFX>G.O_Z^KDC
M^K#C*Q9@CG['4>_J:4[^K*L*FS+!F[X@O[M*7T:87'L/4:=^S!RJG\_/'5HM
M++\<V! 3U%:W(-\QT3Q$D*9)B[N';A\^ [AS [L\L+O  NQL'LSO\GJ3>JGK
MZ]]E)B=A7[)+[P4:Z'TOGX3Z'GM">4J,7?H=X:G"__S<\[D7[P7;GS'PIW"\
M8A%*Z6<A,(ON)1!>-#@=\(8S)(C;"'856M(K^L$>;I\2GQ9_]/VJRQJY8RDM
MU]8\5/WKJO-TNG!EU=D>9$W +@>?(K9C+N*,#2_/@=6KDZ_CCKKYO3(6O+ME
M::_CJL$1(KY%VX1T3RWM7N5U[KQ^"S]3RU=8=KZ_B+H6M=6MGX!($%/I%)G,
MQ'J2;GT6YJRYZB$K]DZV[+X61]ZQT_.&809%VR;^KUY%!K( >.=OT'?O*H4T
M;_H+S<?9NV6%R6/I.DUJ^\@-G;XFO _NVP'"@/\N0R53,$Z(_-O-&(1?$2F*
M\B7G#]MMS3&>P[Z[$]O:C@0H9_@/0960$A&59]-@#7GY^LJEGVI>WC3->Q!<
MQ,4A=T.YS/W%7?(@S!D=-DHYG/A([X[!@T1@7[LH7UN(29LZ9@DK1ONRA,'-
MG3A!$;@F:IB6]C>PV9HO)-+X*8'*K<AS3> 0_."*,&A@:HDV*RD3&4Z!IR(U
M_=Y:_!NK4F0S_/^S[7)_K($V!R<7PKBW1/MPS*&^KN688-@(V?5?\0AA0_/S
M6C=13-2?4/O)#1XD\8: E<UW<_';I#IW\\6XHM*3272XP"BHE>E2.=Y*M8QW
MMB.A:-.X5=(\G@[64ZTC37;SAO&58>GGI\-^30#[YJ<P/T>(M !M!_69!<)Q
MNH!^<<P.9DPV.-LKU)'!QLN<//"CP.:@6^/$ERT2XSA5-]T*D"$(NP)KG0S
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MH1P>L'XY4L- C%I2PQ#VR[%<,U5?O-+OF32^DUV_)*5BD08W>W0I_KKPU<J
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MM&+BWSS=8]=BZ'*]^CID^$JW [-Y1U/T)RM*30+^@=7:$2EV#4@:]-#>,6S
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M !;0X/*J!.R5EIQ!!EX$*U=^AQ>9OBS[0TR/-!6H=%(A?A,-N[[[?27___:
M?E^70<<[ARE$K4MC+. ^1GT":=K1,MSY[.(-]]V(U2@?#^+Y$<$?>&%OC*0D
M\-P%8M7%_^4?2A7^_^ROPE-YVXQRDCWG=HG'7%+#UX 'RC=H"[Q QK\VYJ#>
M;7\:D2M)= /H?9.$/H@?:LDO2+)=<HJ**")GZ^^B=:+98D$=?'G<9)>4==\/
M7>!,@K<"H[ AJ@%W1GZ<"XTOYO)[Z0M:L?O:^;2%]+1> USK6S[=T7L'9KH&
MQ#?5Y 0\GE!][BI:4)!?&-8-WMR!A'WXQ:NDM'U^6]XMN/O<.C3,:!'S]:61
M1W+N'7U.?>VDQ5"[ILL7=_9^3!AVB6>)(A)#9ATJ*DL,LV54'<IC=(R2'JAV
MM;=T;^9[J5F(:DKK:'2]ZZ>/5JOBN97P0$U<O+R7MM_TO-MNWJ/,>=U/X8U2
MX11_DFMY[=URFAV%@;#E X% #0_*XIJZI6#YP:\UU?'XIPZ2,3-;O+N.]Y@-
M## 2).?%D5E$ZF<-+"/"[>QV,;[-B\M2ZW$<T+B&\PP+$>+VH1W+5M_P@Z_:
M%$M]#4(4FH\4H.3D5/_..''LE\7Y*^8(CX#:@[+J>#OW]J*QM=)A??'IW#K1
MD3LB.]S>(5]?HXE*7%113E?>8-L;T2/=XV'9P=S8VSM1:$/[K9+A3QUY1$1^
M.(-/CZ!5]Z9OVU(-@[II6UPO\F<<!@-NF#Y=27QP=PO9!D_^2!I-*N>-ODC,
MJ,BWV]BX!GS)>\M9%20RD:?N[9])F'V@RC2@)/! '%C#,^!2HE"8+P!Z&GK"
M=^FF&QGR3EO.>NXY8@3^*H-5P\VH_=CDXTG]9,GX6%J?_>[I'%EL:(W2AL_L
MY:\M2N5O7],+S><G*J<X&[31(6>3#,'@)HS_KLLNBCV?[TN(Q@?4PYFB[+*X
M+ZZ/6@#X?LE9@XDOCK%U=@Q<MTY]T>?S ]&EBG4&,P/-JTAOI5L/!#EH#&B:
MG8O$BXJ+BJ.3;5N^%.P70LVT89XCEX2>C(.JCR7)Q:_DH2-Y>HTM8A!@1[I4
MWBUW"EF^(00C0Y"9AENUVJCZ,TT]X91;K+"2V,=7H?\@)E-]>.OC<#Y+]C7F
MJ;U$/5WQS)9'>KK:^DKENL:&]@W3[7QJ?1]_Z"*G=<>,WR3RD'^CI[41\+1[
MXO)6U5!?T1KM5-D8??>$'6\%=^!C_I7,!+0CJR[+9Y7SKL</V>85N:Q"O^9V
M5-VV!WM641^S=+T7%$]",YCQ/2E-"$E@<K=H'L0E5S:TH08'*Z;>$IC0!ND(
MY2W'KB_,_@\$[4.[HNC?^CL=K7F_:9<7DN]-6JM?HW/7TL2Q,DPE\[H[%HZK
M:YSU^%PTJ3V0MA(^:_W*(TY"LZ<(>.E68-61GYY2\BIC7<30K\%0E6U\:KT>
M[7J#(1U%)3'<--&\@E>OR#K"9_*#=GE\Z(6)IA(2@BJ+V$(XLM/5N>#,X?(T
M9\JND97ITLX<I_IC#!\CR?2&H8FADS:/Z#/Z\$K0S5</Q"HI_&GV*IUY=Y8_
MC>OIZC>+JKBLEY04%\4^$'WXNDI;6YO&P-V-MOZQ8\]4@3O="QKQW?)4LG39
MBH+-*1)5+8X_D]-_UE&H\OLE+Z3)_9ER<Y@YS:E?3HD:Z8P:C.N-K*8'S?(\
MAJTOH^&*W/%75>/O#0[L?UXA*SYD5I _G-2QJ^"-_*+&RW,\>^GBDE^=71XB
M?%N*YF0,;)&6>F+R:!G'X<,3\O:/[/'Z(#Z_B3.MZ#X-T3<'YR>%4?GR#S7)
M^C9Y-],+!F63'XE]FPK:7AC_FRJE7ZG_D?L4];2LM#2I14*,XLVMA(9!BL>,
M]+<M-6-30C0G)W^*"K*',)$\DR"9;WF66DQ=PH#)SS+OI2E]GZ!.0HJWWD3I
MK;R.6JTL-\HBST)[_32K;#2D_-#OV*6E%C_Q/3SX/'IUY%$5)L3OYQ"[@/[H
M.9I)[X^R0(N([A]5<SWVE"9.%F "4ZG/=^.?/D\8@M@KJOW^=)=YO!-&M-K?
M1H!9X-0B21 T.*?6>U)76;Q)-:5?Y;2YL2O-]MC@1/[UE=),<^:9]]!TK.JC
MIL>L>ROS55F%7B"$A=^TR9_\QIV$DS3M6\("][7%^F[6)NMY:7,"]*'DDI>T
MJ*L "#BQ@.IGQ%NOHOIUTLK!53AF+X@"QX>*V"3UAS3-?0>O.'_>^7B+BT^[
M]=9[D7(>BMCXED9J0ZS,G [%[9#^%X+,YJ]$:>A_?8+:"TJ/VI>+.N8K*+KP
MCKG+'9%TQ>O3\@?H@/L6K(6%X-H@8(FJ?^I(KT.Y\WN5VDJ>2KY7;O[WF!",
MXF0//[#(,WE[R%_!G<NAIL]\[T[>?<5IQAE**E*20_Y B@=V9^#OHK=GQ)VO
M,L> &3B7)-=<X>\#BNVFU90"3SM8P-R2N3&[8>P/G<E^^3=.=()TBPA*X!=J
M71YH59I.O5P[*#W\"%D3#+'*@)O/7%I5S8:*O5WG+!T#_OXQOK9SH>7($)T#
M$O"*8E/A2W]<!56[=QQ5W:!HYSX(CWS/Y 0%]#/&8V2LM;4U]=>Q'0+A9OIC
MVZ5QG<S)=7&Q1Z%_:MPY-?7,\840*);5CU_!+Z6UX16%-BO(JO%7A530=HK,
M)T=(G_[MUP^F](P5P$N&4QF#+UX8V$>34*GK>A9>.!--_82P(VLUJFVIA^,M
M=J>?)N3GIZ1$W]U=%9_*;)Z]D@F1*IJ9")I(D?$KB@/Q"OHG/5A<6: N8"=4
M^SN+5<)5U)[8TVI2<IEL)1NI#.*K:FC%/=>CZXU42K>_$+\IG_N H[W8$;3)
MH.Q!E%P0P_OB0G[SNIAR?=S=0=E60,U<RQV_%8O[_R.VQA5%]I[[W/N$<AL,
MZ %.3<<[OR/WM[Y'1 &5.MU[K].K1>[7G*JHI/S&=/=X%F7V+D*&*_5Y0$I"
M"OU3(YO!/)EVCHS+"GN-8+^_-'^#T*DQ=AWJM@[U3QF9S=Q]"54X$+3C>- <
M@]YK:(-CILL9+>8OZF]YJ4XFWHB2&]J2C$"U5&O?\E&= MP>)LD' _%[,WA2
MR[JM:X"Y!5%HJIKD-4#?VX/BB-#SYV8U&=;R_+THAD"Z^%JPP,8#$#F(Z;_>
M&"%("4Y/1\E;LRNGH:X4WN@>UC? _!OB,EI[A):X2@7S2?U-0Z]M[_YG&%H+
M/ZFSS/6Z2YKF137Q]_Z=^CM(D+GY2L>Y3\A.XC\/#^5,8H&(K_?3+J\!9LOX
MF2N3 S&L?]$V#L7H4@_?8)U8O'UA^QT/UYG4@4(UK@'_PS-PYG^>9SX"K[9%
MO$PM20WY1*EV==&CO^A[]C1"<'\A>_!R$U;#2)#!DV(^0+Y]TI_\SS80+'E>
M"V(R6UPLIV.U4KP9GK#U'/R:"@1:F!*:1EH+=0K:!6_@B5A36WM D1$%D,'6
M<\)J =H;=3&E<@!"%>Z<7P,$*""P4.'MND'WA@X;; +KD8=^,)E&5;IH**OC
M=N#,W:A!P;;Z%6MH/0$C'9DGYW(-4+@&%!0?9#^4,O2T/OWOG< T4"TL>@[,
MT &3G)-=#JJLV*6E\W"O?.OZ^=3T\_=W1D+9].I?] V!'\:[OT*\NR3BC,6?
MT**L\\?6:7GU[MX(X'R9F6)VI/Q2'&;AF!76.2K=UM#9M!%PG!NV'H"C#38H
M_>XN7LD;O=#R:5SHTY>0X%%G/J'"T(>F<\\2@ME<,V]YTS\%9Q3Z[^L+-,0E
M157][N*3ZYA'2+\?./RE\G=^H2@NYUGD(HUI$J4UG;X*.'ZC_HFRB:A4!6V!
M7G/#4XYP\')XJEJ<;&N:F](;<:"%VY\XE4?NWE4 'C5Q&E;Z$UR/I[5D_LC\
MGW>U?2M8X)/*2M[SB*LE1H_TRFK(Q5.OX.Q>@L:B]3&B7=7F4Z:EE?69I,[A
M28=E,R7H;^%>CMGPTP-@^1_P%A3=)VH=Q]_=NDYD!R"]8D5Y[J/ZT/;=W)#W
M*\<SUP!)]4PCM6O >YEKP& LV-.(&]?+<?EKA0NHSI#_%V-.:H/HX+.M7##X
M1&[I9*V:4QXG#BUYLAN(?_%21U\#2;)?31-^]X+!_?&IK# %" &YE&'RH'N>
MK*B):TK01VQ/'$F%N*TC0W#ZEQU 6300-Y\74W_540>#J=JN\8G>Z.B00Y;U
M =VIL:PYV8F4,EZ)7Z$*R.=0:&F*<U)AL&E_? /-R)^ZCVMM3W6<6#^=[G2/
M\!RF%-R1T'/3X_/>T:::#0KVNYA=<DK:74F6IH3^V'@3RCQ3,/:2.3=VE(JF
M1AXH4RG%BT+JWL\\T3>1TL4Z*/0 1R=P0[V5_GIY3R+V_WD2BR9SJY\\83\X
MDQ?H?GD [/YQ,7CZ'"/6(7%'MKD)+UVPNU3<>)Z_\\%1HM%#Z/ML\ZA^1Y-L
MQ+W"=UTF9,PM9)/ZFFROWN;%9+@QACM&*485@ H,EUK19"4\W'*J+*R@'$6/
M_KXS:SN[;LJPM&6\XK2L649;Y_V0,U+O=P?P#_GQ-6+"JHG)QY:YL("UF96'
MGP?'TI1TZG_9J-MU1-)#/.=_O\YG*9/B*IDBK  S%DV4N>8'3/YP?V@C PR.
M @N \OSQO8(Y\9?MLWGLJ0OBW%LJ]J$;H<).&Y6[*&,O'7]/\X RZ[I *T9&
M.8\PJ<5L,6+T?-B;7QFN\.1>?SQ6E>\A[_B/_!X*JDV"%61M04!EY>F_'$.J
M52SX1XA/(<HZ.;.S<XO.J6QN5S W_K(.UK%0>EY^($!YM)@G*>G@)/+Q3FCS
MQ?+R7//<KV4S__(XS]NR*KPE57Y"9-&QRBUS><3\(H(XCCM_W]S#RK WS[_+
MWITMLKD&W%8EV[!K*6=2)6=)SPVL)#!>U+F&^61#O/S?_%LVD#6'B>$O&KOE
M#BS1C3(%S4ZHL6;)-ROA54(7?6M\ 2U:+M#C[8H*]J#U:/-^-ZQ6R^+8JL8+
M6G;#%PQ;A4Y3*:QB$POE;"[%1='O$R+O#@09D\17#-:IA5<L?_)8O]3$#93O
MR*A"K[*+'W6R,9!UUWTW</_(=[Y]W'-'S-.#@=W2],X6?3+?GBEO2H#_U&;=
MP>=7!>;TE(.=OZ8*T"%^M2B>U86OEZZR8;%28=WAS[H?')([3EQVGIX&O TH
MFUL>9(Y$F:'(6;#%&>S-6[^5VL2:UD_FWKEJWC)%R9!5SG$X._ R=MYV*S_W
M#3"3=4;]9*#:XAT<+2S[4[2V%4!V]]'SF_14C@F[H@YH 0T>S,$(9&'?5O#"
M,^:N&>W8T$"<W^%8'NR?J%T'@@-MX/=IQ&JY:&'<J.["DSLR49SO%LU)BW!^
MWMOU3%X)EZ]N?#]3;XM]9;F%0["DP'+]"BN)HJ7LG_YCS98ZWGETQ!+Y,TSW
MLF]6UJT^P(JLLPOKNY&].\\<GOMK\I?H@A-49J1(*7-15K3!T61792U7,#E2
M8WSHB65S&OK<[Z2Y,ZO16+#J?++(^:_!0IGWY<L;E5P*Z0/^JIGO 5P#/M,*
M2OQ C<TIPHYE22_#N2[G^-M+AC5SJH,X%CI_?$,56L"%;D=E)\<FB4I48867
MV-S5E)Y#OT$/T+L1BP;$Y,ZN5 _-O%8+"BYEQ."@"68K+/*;#%U':]T/C^YO
MAV^^9?@8^UL"N<&'X(PG5WF#K3X+\>^.DE2=]>WYSFO'JZK+!QB^N$I4F8F7
MI-FE;U#ORR'8+NZXUJ6"-D[7QR\3V$H>9+X8-DO;CK'P.I,ZW;E]60J[4O7R
M9YF9RPO]>)G<!7QE)^L98H>%.>#*GY![;"SGAKMM#NQ35$UAOK@4_K1U'%T8
MY-02.!+];=ARN^T\G*.D_SZ=K3(3Q9T@)++HKFWU*?1]7.VBLAK)GRE]#&[P
MC:QLT&%*X:4^;JA52*GXJLH6Z<ZR.Q<*YD3*]I"PVB!MMQ'(7O)+@?SU\KHR
MB!_R(+9\\D,Y4.P67T]U(E8CP^B5W5BT% ,5@OF)-FSG(^1]R0,?9;5^[S0L
M&#$N>"G<P(\E:9?4,IG-$^G8:14V/:RYR(OI\6&,BZFXVJ-68EWH1B^+AYKE
M5\D62 V7OHJG)=:H/LR9N@VO:V\#TI-IJ<D]![-O1(0_5&806*N\6[Z>AH&(
MG)1C0X#MP)(=H9^E!"OFQ%<]3+ ::T<<9#%<?;Z]#M)I'+1/J%[N]*12;Q:=
M<C%LO,BZ0\>M_;FH<K%I4E.>C2RDG!Q4NF;7'W?XTGJM+$TAW'5Z:'T3(A3[
MX."XF>@LV? W;S+[ORD<#F%RL4FE?D%IC<D\NPIS05$VE%R.Q2V&%I<'"IO:
M\I5?;#'4.4VKZ&7X(J<V4#8(NR8-<6V6C$*1!MVCF4"!"Z.1W^H<5#!\_@?/
M(I/-9_8Z'5517Q,FNF,F<?*A1&T=Q6N(8<^H):H6@@PZX)_64L(.86"?961E
MEN\KS,Y#_F@^B#Q@'3IZ$#Y&JRSFKMC(R.:R5E*:HO9C0*YZ@\K-LX3O]]6L
MMXY<VT3S:0T?U3>HID"Q^@,J"K5U,Z<XL4UM(+ H"U4'M'1+W/0<CF912?=
M+E>(EX[*70,V]YZ(-G TO+6[MW8!Q,-&)NI94>N3@2><'<BH?K"3\I@!'UOE
M["T%NER>"4'$U8HF5N[I'?[-\3MUCU*@:PC+6<([U:D(A0FAX!ZVY8L?;8-F
MY1Q.\GX*]D,]_/9V6M7"-J0@[?/E,RISS&3M\%F>)!//%632V_9L'1)1AZBC
M9+8E1SZVO_P;?K>=#C9S#NLQT*_3R6]K0;?#QPX(/:R344?3S+IM:*9<7[=P
M(M+3[]< 8NEK *7\_C6@'80Z0Y63_G>E9A32<K01;X\;!XI8F%QB/_[GNC9
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M#O&;'5OS?E.&<P*O/BNV2'#*R]W0)8;%/05_0.^/>DF2F .*[TP\(+&)G7L
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MXW.YRG#QM_H3[[F?5Z.>EBXY-M$JR6F:.^RPNBCRXUDM=GXD)Y_8Z*_9B$!
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M#'N_]V<-(Q^W90X<&,X[I.VT63]L]8;7/L[2^+*]0_S5:U_"7I+<RM=8B[B
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M@ V=VX>;BY,8K:\P5AF1%M!,Z#9-\X(,78>DG_#!+\<:,#0*O9V0^AMA77*
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M@IBJ97@ZO0R[ZZJ:G(T?/9X.:YNKOS.L4W\06$H5F%M0&%\S??]AO*ZX 17
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MB4^8===(+(@*\5S)$VK<TL-,>':5[3Y.SDA[7ZF2+"XDZ%*22.>21J0H+ (
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M@.4:?"ZNR!9-2&ASX2A9)5KF?%R@./J)?DAG</P=EMM4>]?:)N@2JU>=?*M
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MT93'LCXV@6N6I[(^WJ %,!J4KNF?I/-/AF"#"#_$WINVV@YD:-Y(< 55#),
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M TYF@@X4>"+\>]LJUM3;=.LP$^*! 9, ]3S=NFO1>]W))1?UXX)=Y> 2U1;
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M=D<D1<:EO:%RIM^&&' B8N[_<.W1!3G'85F9B\1?(-SG6#NF6)+GQUQRS[W
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M@"]B5F.1ZGHYOZVA=@UU&!OE'>D/V5=&_?IY7($JU,:-/]7"EN7*YTR(8.G
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M%>]!6D^;0U(9K$<.7!IE)9KW$7?)LY9!+5!_FK, CAE7((2.3SZ=:YA"/+J
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MR"X<AH?'*".8S5;7L KG;YOA"[@*.'NP'4X$#M$*6T3CB8@P\X1Q?BPVMI[
MR&^&74?3[0TYC,S 7;43#([O\"$?9!QT^WU+!GR\BF(>@XE4J>#=F(IEL\H(
MEIN!@WFXFM1"%#L3J85-9!1Z7*1(>GWFU4P415[I]13NU]M$5?F"%<?=(')6
M*T+]',@T"@H<L@L'<[;%<_%[C3Z"GQD?&BPHX&;&IG<WP"@)WM<3DXFS1(L1
MV-V?V9!VN?K1S E<0G'1=O)40D!O-*/]&WDXS$'$E Y^)LZ#38P/WU(DTA?1
MAKW,L_O,>(L"<XD<J86 NV&EK\3ZLN$S+N1]S7^Y#+!T0(ZK,RJI2R=#$)J0
M-:?^3J@,,/&$E1M-DNAE%<Z2<-5+:P+X5,9MN")3\-9E_28D(4CO$$NQ@I3@
M']147C("26QC<0G\4:9D\1!FFL]M@TR&+6G^,)?;7P?<\#T8=EBO*2!)38H0
M(ZZ)JC'P3QS7N!&$EM^MR",^RT27/?/(S3T)OI"-)"BP0A'6JWWNAF6-OK.<
M E=W[$0,Y9%%J1F%/@RBYYF3]R0%<-GB=.1MM1@E^>>6VAR;CFY^(@J)-E-R
M&QPEX*TL_$C.Z$'H8!ZLM) "U@PZTOCU7?9W[2HJ\F0XSTPF_V)#ID;?O3_#
M:;.AG"]5_U .* 2OUV%_0V6 I0),/GEN2+X4J>AR^$?J1T9A4&UIG?D2E62Z
M<!U9B;U IN(<J; 'FA@W&O0/0=X7Y?O)],\()?"]@?[W^57:U50&<1Z2:"$R
M+?D(;R2I+5YJB.J9$PJX:OK.6+Y*-'\PN,Y,!!+$-&$/Z^9=#J:'<<<Z5AH.
M=88NH ;MX,[=B=:F'&14DL>I/+-1#E07*[B3&"__2D4YR&%0=3+W593 =DB6
MZ3#YV:IPDPXYWKW@R6!L![&>D8L=RTA3Q"NI4VIKY*CDJEG$\,>1.HS*$GXX
M_@B2,%U6Q/4QC-S':;L2RLERXSW6).9L2G.<Y(MF32:_KWD>.6F+)+KKSFPW
M#U"H+_X"$Q/IMO8&31F0+.W4,5?H^#&PVPELG^59'Q4XE?W_X=O/_[WP?[@@
M8_QWH?T??4"?PX 8U<2H$E3_'Q:)5<WWA 3S8_BUU8+0+_QB"A?W_]6.5?_W
MPO\#%V1=_PM02P,$%     @ Y8J$5A-LSCE;=P  Z7H  !8   !G:GEJ:78S
M:G)H;VPP,# P,3$N:G!GQ+IE4%U!L"ZZ\2"!X [!92/!W4)P=[<0=&,;=TMP
MAP#!W=W=@FQ<-N[N[@XWY]2S>N^<6_>]/Z]7]:^9FEK?6C/=WS?=[POO&X!/
MLI(RD@ 8&!B \;\'\+X,$ =\0$1$0D3X@(2$A(S\ 04-YR,:*BH:(18V!@XI
M$3D9*1$)R6=J%KK/E$Q4)"3T/ Q,7]@X.3G)Z?B$>-D%63@XV?]C$1AD9&0T
M5#2"CQ\)V"E(*-C_7]M[-P#S \PP3  <#"4 %A,&#A/FO0] #@# (,#\IP'^
M-X.!A8-'0$3Z@(R"^F]"PR< + P<'"P\' ("//R_49]_XP!X3 0L"C8Q1&P5
M$R1*, Y[0%S.!ZJO-3VXJE,7U!S?'0.14?#P"0B):&CIZ!D8.;FX>7CY^,6_
M24A*2<O(JJEK:&IIZ^B:_C SM["TLG9R=G%U<_?P_/DK*#@D-"P\/N%W8E+R
MGY34W+S\@L*BXI+2VKKZAL:FYI;6O[U]_0.0P:%AZ/3,[-S\PN+2YM;VSN[>
M_L'AT>75]<WMW?W#X]-_X((!P,'\[_9?XL+\APL6'AX.'ND_<,' NOW'!$QX
M! HV1"PQ%203,#8E>\ 'G*]Q.34]R%0<JA>XWQVG4/"H.3=I+O\#VG\B^U\#
M%OC_"=G_ >S_Q+4$0(.#^??SX# !(H#[)_I<?Y3_OQT(-+JD3=B,P&V?/>MO
M9WG&WK6PL&M&R4Z8KBZR]/T,?9$IC!*7:=.+L.U'16#4"%$6 _P\D0!83<G$
M'3'6MR:F\T=U9M'\95[]RQDGD962"&Y^190 Z.8F. PXLJGOSI;GS)[>E-!0
M7NW1)='?8;>H$4># ^Y#U$3Q+7/# 8_'1BVS6KJ7W#DPEY1"F?E_A;ZN;;Q&
M+^);"4S'.R /PC575.%:)T/)"9GPW6JS6Z":- V_RQ(=>#Z\HEK<5F[=;X;\
MLG=)<1$88:!N;DD;BR,[4F*1NE=85E+\4[84$_C"5T:JB%J,RIUKXI4OLRAS
MU1P929Y,-B,EG3_P1CO!J#<FKGCQ#@@_<3N^HSMQ4+(W*QXWW$_A;@_M]4?_
MNBT$\MM,Z1!F[0JFG;.U9;8-7%T$\7S7D2\7DY(X*FL2O!\'5M<\N&SZL"JT
MUP<.]6EY>3]2-[NYHC@B7CD"J'C'K(?R#UDK=(\AUFOBJ'H0_F'1'X*G@ILM
MA(2'"I9]=US%N>&BN+M)F>BAWLK-#?QKC<9-C>&O5#SY);'#B_!NADBX1]^"
MX.,!I#*E7ZSF/I8-E?^%,U! 6:XOW0D,EX$CY4^04H=,Y?6G]3^MOU!1]C[S
M:"*_=C0]Z[E?-;Z6$3NE;Y.S .T,Q)7;.CJGHDM<+.R+W7-!,BQY":!^K+\D
ME&S/;:&0+5 [&<'%2ZK.E :<7L7\TNA7IV:Y/?L)_=>SF><L9$NLPZ6,@M5<
MH<H<![O*;Y72["0?NQ.NLGZ;$N38OGKXQ6:^ ^93 C;_%%W<1Y^]L.&5>10?
M[BOJ3=T->2\RYZ_7V9U+DFP\:7EI^Y)?[ 5MZJFA)\ [,/<B6A%]/6<X3?HN
MYZ6YRPVCW@ "'7>PN',>OP-.GB$ *6<3K$<+(5<R#!)?+M=P4??9QHYM 7O8
MAY@^+5\&O:3J))"V"9&S3(B,AO=H= OAH_2Y+H\1MF19J1Q>@->7\(]85T<J
M7"DQ]X.E*L&WA!!!="%0J3!<M3#.K*#075N.??&*#)@ZQ>!H?'/0D"TR>F.V
MP_2O:^K8ULJ$DT-T(_8"( A<JPS'0W7^,8^TY!V0?/AFJMEZ^PZ@BH'>9N$]
M_)6VY>RP6Y=]QLNP$EH=62R? '/6A Q 134@X+76=P#B,8_GVL^](]1/78W-
M2="=WGLBZ942LSO>B6T=+:./Y?EX2J;EUDMFLPWIKDI@,UZI3&H"Y1?C+ <$
MYU2R"(O-4[)UN6I)/7>8'M>541GJ&J$AZ@2%I1/YJ=QP1E'Z?V?G?\W+#-:7
M%G[Q<'RX3V<1V_/GL\>/Z! PFO(6QTMV*]730<Y-78*R49>THTF7K40U;]=I
M"E<PWW44'-[;;W;(*4')U5B+=7(QG<#HO8U2T2)9YZ?#D9E"P!:BLS].;TGI
M+AOO@*"OG?13>KQ=XC%W>B^,><A"L=P>'<DA#7*GXN(-G?6SDN'VYTN\^1X:
MN0T,SP6_?R8.C<.17"%H3#J32M@)LOF46+6FZ8N;^=CN#9$4;!GO#V$<<.\C
M-(LD>@K-QPBRFHLVSWW^J@B@B+DIPWQH$DN!DRKY-BSI"/,.0.DRU5Q'??ZU
M9)&QY.ZX-]WKB\DS1U3>ZAQ7G[K:;FZ>4<@60.B,Y LS+GHW6$&.>IC:+DQY
M<3.?E%P&KWE_%.50/H:FP/@G7O)D6>JK$Z3![<M#C'1&>+]W9&\CQH-JUB<K
M\8JM6\BJR*;.\.%J3$$4/R-Q6K$MY35=+*4%(56'EJVID@;3O"SL+349 XW;
M#R32K0YAB8>03>)'>XLXLMOM\(4-*?PS_7@D5<C,&^ZH=IM$U>']L#I(H>)(
MQGG[U23(-+:TZ1D.<X.,W[3"]=[HDR"Z71X^?T7>A-UN'BLJ6U1-H-ARSX 4
MKJH1\8M0/"@BKF2!9N;R3WZ+GB,UH^07/3L%ZX/9IK]O&WL&BIK[ Y[!99MC
M1&MR!V9O4Y-<R%5Q*H[C<0[NS^W[X5NWN!GM-&:;\YJ?+.WM_1*FVN]#1@CO
ML!0>M0H.=.=[F3%D&^NCWP&*S?$$@L$M\=/WM2S<&7UT?"3DU@=,[1(;/F;Y
M@7,&_!NUN:W$?NW89W").^AKB8I1$E7 IJ(2?JNJVYRYZ-\:B'/.._ -PY'_
MN3-D6 I ']N=VK-:?[]$PNQ5T^=L#4"I+AI>4H]KK:S(C@,KU1/A2< 3='"D
MU^%[G>2VM8WM,RS]C8GH=:[D2M"^<,$"Y&X4=)YJXO#P(WM63J]GJ< [7COF
M982\5.8C\. @%6(=\YDW>5$U7A(WWB[Y*)E":B4!+(\#_T9<EB>^LN"U8G-R
M+^W=U<"US"QM5]V,O6E'4QVJ(!8%DQS;D-G0\L_HP(QM>VQ]D#!)Y_3;(L[=
MM+L=ZA N[#N@PBJ/</"P1U#+MMC077BO5ZU1JK$N635@,]/=6"/N)RR[(I_@
M?<%TX85&1?BRQ,?(KE;M K_:$BM_R%KW/C7<;6'[OS7> 1MP:_^BH_@8"^7U
MK1_&0N,[@+67J* C$'&<@[JOY+Y/AOSUUO!5&W/MP7%+=02A3/J*J7Q@Y4?K
M1;G[D0#9K,]MVX>9.ED'_I?"Q!M4D-/7\"KFDT_B)+5\R+3<Z61>,W1:M7"T
M^ABJA?Z\&&3]/O952A5KR_ICV=JZ$LUZUE%VFY$A3O!&G:+ 7LSI\"ZG[9&%
MI,N\QD83Q#;[0A8W)Y(T=DA6Q[4/XWB%V<:ID;J!["OIOG+9YX^4^3V*ZM)Y
M(8 K]H\F$OGNO,>IP46EUE:"T]9 ']C\RD#V'-<S_<U01@^()WC=H&LC.SGY
M-F?D'6![C'?M7J80H]S*<4R4,=819B7SY='QX[*0L*1=9F"'W&;?M+XW_V1A
M<ZI,H9<&*W6DSI_K(;H*B^Y,%!ZVE5Y*P9I5!==R@G09^MXL"%=-[MJ!KGF:
M?<$A-+&I42&N!'[#1P$5Y(FNV_:4@8";0=MD@A4_38(AP96=SQY,^F$PG\+R
M?QH.F[M"/9-JS-##0+E'1HOW^$_A>IQOLB,-LC7/Y6Q+_@*RP#%LHTO6X-NV
M<PR0;CI_PDB!@H^I;](Q=HBH8_G/W>WBM_K6Y/"&-+_ 5OM0RO;E4@7</!F1
MI/1DYX]7VR2!7BI[2 4J^AAA@G);0%:B!R^EP"EFYXBTW4"Y$#.+EF$L44/7
MXMLCI2;=+LP7I^*#>;PEUX 888%0D7H6[N!/U)&PA1@(:5G9A&?TLG=P4&#*
MI?^HYH\->G/JS!64;6^7K55#R #68D^ED66K046Y+4T?OW2KI"L=S9^8WS#1
MMUW;7E4/"5:UU,><[ RN*9[\ITA4Q[JJ(?7QTL2[%OB5H&I=L=:OW[YM4AEU
M4/P+H!OGMV7'<XS0^D]9;3@6!.2&-\GS1<H=7DW,_F L3V;E9);AL.#M[*J*
M'F,J1<9CM507XA],H5!''G)-/BY!9":%/;WQR^8=6QN_VU+ZO-[T3"F50ZV-
M*&IB4<;%_;6VHZ_(NGT&=4H*EX)3TM5'I!,C_"[DNC?$J+L=&I*?1R)WG.-
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MC*T-1M&&]83UG*?9ADA7E._&OI2>0ZI@TTU'3Q"9!ZIR>]$?G0\AQIWN0Z_
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M-GQ \3."+ESID65>@M#]L[P+X'3/7/E\:V0!CD=P"6^T$UK(""-'9#2(=W6
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MU*(#Y8\%/VXA<YY*6]VS/H>YPV>UKI8MNL@%X(7!%Y'6/&J-03D&3%H,4;[
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M.LJ>?3N-B2\QSY.5_=.#[JT#7T1ABT4IQV_6DBT_8?!/U7[LI E>X895(W=
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M#S5#]0/[O,:2DKPWY6&;#8DRS^I4I%?NKPP,CH-,:N%[P&CDA>WBLN(/I(Y
MAOC^A>3.ANVH[D:_1"%[SF?WNW> W7+ VY2@;V+9;UU4#OE8X4O(7,G*RMGK
M*)H;63D_2CEU=;/"6'G/YQ,8&S_&I \51?;,]A6!GA1V?K)I P(HHV;MQ(,2
M?!I\U.\ S,I'D=FJ22T,X:I<*ZN(*-4E$O3-=T#NO#TV4ABAHGKQYZ<9.C?P
M4N]!;KCQ_ZR@@*.5:M6%R06L(F%NOYLKVVPK.ZQ?%@A"&N48R-Y)WR@C[39V
M+7(O&B#[,GG&>DM_L\K/C#5\). 2?="UQ,IC2YQ+M0L9@TQ.ML(<<FJENK?U
MD0E.-0 UIM/$DI@E=XUKZN(9%'I__$CJ08&-C/?48,7QEKPD"]LB7I;^#/VF
MZ[<X6U%TC=!_F0#X ]@&)!Q#?_G?AN^\V).GD(:0D@Z9+@?\T^JA[1Y;Q,!7
M\W.YVFH?<C'W^$<6U,>KY"6]$<CP%P*7^PJE4#<OYQ%\M><25#;A9;'"O(GL
MK9-Q8LTYYG(3@:N:_0]E]_E<_=;X2Q6]FVDG2>?#I0[2]YRSS0GJ,V1G!FM?
M26MBQ(Y5)Y()S:FH?MU4F7X,4M:-5F5?5FCPXDZZW+4*6:$)@W2H!55M)7;V
M.]'VW_+!>^TUG$&>* <@3DU\-Z7<8[N=!EH@<#PX]48HDKF4S3;YYM5NBW!&
MIG%N_X%:J?EMH TH4.PR8KO'1CKS SD78@0VM&5/:+:U9\HLK+]1,*E_E21,
M#'/_ [R^CWV:SXCX*U&6)ZUP*YQ\R0@\-'6 1U:_?IB/>*@;P,SKR/@=H*$X
M9R:8< "<[J2SQK):^QBO_78]7+,__?D=$.3]#$)*WSN2@ \>MGB<Q\/'F&"Q
MLA&V94*UX!JG;HW+D3I^W58EI5(*Y31)7";5K1Q_]J=H\LZ'.52?(CO\30\3
M0JZO544D8R>C<]/FQT00\)4C,"H]RS,0NG4OU:)C&NM/0'J 03;0$)1_J0>L
M5G^4X1/RX QD95\([@986+TQ3?&#XZL3Z@2(!99%"*SLT8K+/",@SX:W1\D7
MH=X\A7V]K[J27?*TP'T%=IT;(7,^&-NB/65^K_#[<^PUB[^>-HO=*<I9_1R&
MM)2!A2=1ZE6F<7,-"<1,8)(07NGY<[Z[4M>EC_TGON9% E\C?;4I!/RX2VZ
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ML",<SU^ZB#@NE$;Z?'#P)K>W9<>7;*ISO<K=G)GN+\\2W9T-*UX5V,E^E_I
M#225]0AJJ1O3N5@/:6AN5WA-]C$53+4/BM^\F7?0L$M5]:XFSEE*(7'F.N%4
MLY'ZY>[9JVV/__#]R(!D28R$QXJ)>TE],L+<<AQ+1H]6/FOKP,>C0@&[Q^CR
M1X^"P G_B415D@S%U1Y[/Q4_XB!2=O>$Z.R)2TK5 1X9#31+829)LM$5;80D
M"!EB$SV3<9KM,G,5$GM,CNRMLS4F"9L :O[RS?=[:($J#?F%8-9 JTBH)L?8
M9@4M<58&E+TN[O74'_MQWD(DQ+GE9IF9K\*_MC:>CR) !@7-STDXFX3,!T@.
M@??@%KU";>XY[RY5V_$>!&O]$Q1Q@W>J,D7#.)P6]V8A\)ZS<D7FR5XDD:ZG
M!A.A+YRL^.._3 (>]5W(9GL-Q9DC<O67:VL=QOD^&HD']TN"97?4HWY=<W^#
MM=@3O%1;6F+_-BW=#3.XGYHZ/JJO.^+ZY^I[CSDUFD4'C\H,YR"S=[/^"&_/
M..\][C1CQ ]938EB5CPNIAYP$W735\:JD/HA;YDM=0%4<<+=$'D-5&)2I;YY
MH*T%').@68T_@F=!4$5,8/VO7]4\\%&C#?NF8)7 >C<63-N5&_*P)]!1)FHJ
M#J%9W ]()4Q5%M-5Z1RT6DL1-FX$Y<FKSP9;'M[?Z3.!2)1[4:0W(?558T$A
M@,3Q@/\-MS>PCUXN\42+>79<U5+SP\LNF3D!@$,VX42\11+ECB30.G>]W=%#
M"US+#KY&9]Q!7/+ A1\F[ I-1[G;5N$T5UN8)S._YQ/ZB'<'U1OKU#0C5EH5
MG#U5CZ*02C5F$F4T]7X3T1UKP._\_*?'%"T$_)A/U4"G0;\:W;?D4[ZTUF1O
M^XF6=UR)#[8SY!(W)&V3F-@QI[UYTG0>.?Q:@4.A[L(\'BH[;$_H0=?@69@'
M[NIMM6E!&I6>$+I*W/A>0W(U_<,R#T2"%'*+5?IDT -DHMMA$C8W'&C2T= ?
MW$6)=O3\7LO5 ;_:W%I'*1#Z"$]^G5IBN\539U1G/8EK8^JNG_-/3@59 ?/$
MW3OA/N5(NM_C)H.Q5M?U6E3)N&E$Q]$E^7"_S-KN$<=?37Y3X@5?Q5B[[#45
M'5X\1GE@?R% )2-IVM3MOPI-.*G^L#+T&9XD/4OI':#A-)E0"<J9%=?5@XW+
M[,MJMZJ5*W:/%F4^75J;>:F@(L^ .(BT,I[>[F:%<%;1"MHO_VRLS9 #P@JA
M]LGB?ZOYRH&/TKML!TR#TEJB+HRNMX><\?P'J-N6WP_V<HG1<+GDE:HM%JB?
M52M5)O?XDA^$8AJ<FHHE+)W%FIP4]QM,I<H( 'H'HQ9O7I(\DGXLB3FXM_5#
MK<!0;<\P1)$,B@4=2J9%VK0  IM7)V7]HSME!@S'H*[6$/!+T ]#0R7O0/8*
M>VM%:;K]WYY@:(7PAA@8?'=\WVJ42M#EAO0L]3]J>:NN.*!N6;0)27!W=T)P
M=TV"!X?&)3@T$IS&W=W='1IWU\;=70/!W>UDGW&NG;&_>Y_N0_V#.:IFU:RU
M'J)G.IS)_A=7N0[\F='J'FE6:4+,?Q!W9ZH9K_@R#W>5*Q#/KD67EYKRWSZ4
M^=^@SK++4FU5\VRO6[VQ*CPQPM<]X: K;I_%@W3GSFW46T=6]2%^J>3,('?*
MKB-OSN_F,4N0;*:F@5>0&A!WMJH22!33*^4CDE(AY]#/ ",K->NT5FP%FF-I
MJ>"KX&)2D/.NS^LXL1D@2,G"(P X5LDB!3COIU<7<DTUE&R\\*AS2XQJ.R4
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M+-KM8=J=)KGOWM5G+/DKP1/Z_'5CLCGUVG-"[=;I%X+;_4Z_ASV.BT=[T7>
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MC#Z\W;G'#.F^N:PW-8+^9F.#LR^JZKD4/?JP17PQ]ML5>KQ(XG46/NWM6F?
M@:T\CY[(^H'#(L&,.RH^.,[>FX+JOJF+ 65T@[D== WEO/-)1SM$[B$DR%89
M>UC#Q%X-SE170>E$R7ZB%0RRC;/,>CW=5^NU@=& )^"VZ)$:43&UV[,ZE@4$
M-8!=8\<1<)T%9SG:6I]2#OZDNE?]_47G::&.);7)WB<SE'@_U<5ZOWN:JIU=
M&"XE4U+XUBZ;_K/9DJDF(?O!>*2/,56NX&V)A\1R4] TP(CC9>D$CJN*<=KB
M8IBQ'\4'\P0P;J@!?4K</<)#-(I4AP^NC3ZRI)<_3\$4T,<?H,["G TPP!.-
M*#_#$IFIV8VEJ0_[(9"X^)MKUC7>8NKFJOBY3;)J] VG?U6*\<LSQTOC#*:A
MZ=L'[X!LK1',3K^H 6BZI3_Y:KR/G:+(SP_>_!FA<!M[I>=O.%J2,#Z(<(*Q
MNFSX?R\J^)CB@8M$4';$!<_VM@)Z;'2!^?TXWEQP@4&(/W6:&CZ!UDOCU:B%
M8;^-V34!AQ^V<?SC8HU8=-U 5#K<517NU<*Y4MS;#FL=?X!.]*W=J^?QBL'@
M\NZ@G/^C.I=$.JUQ@I*XJ>A_<N?*!F:\!PM)_]>1XQO,$;\ZU>YP$IT5#RM1
MYH4WC*ZG@QY+5Q94@ /Y=^>]@<=0GS,)AXPV#LDDZX)CP5RN +<-58)-@'<D
M>#]_^[A-W9OEM](+IMTCX5UX%\Z:%FT?2OX:J3.\Y.AMI;[20\Z">YQJ;6N*
MD]1IPN[EH5X28B.ER.>"N0"]BIV;57S)N/M#)Z2O([65+[%3: MENI:U:U(+
MK=8-W2&9OM1*5[%K;NK?[2YM=1)R&ZMG*=3X^E;+B;UTU-+UP]6UNV8XR_$G
M7V["EK7A%CKX5 ?TSFAU8I?&9EY0[,KT^CQ+OC;4*R(Q!L>!2N>=0$R(,P("
MK+$E5+X#TF:7W"^\X(6)LZ%;\QQ%HZ>PI99+G/E^NS7MOF*%CP%6WK6E540$
M].//Q]_S$&AR-QYJ#YDXG6*7Z%,3[;T)K[/176WZ^A<BX%5;5J^&&&8]Q*EK
M+,JF&7]N6/K1B/81WPD=ARQZ.) %6\N.-8YSH*WWUJ! 6TKYRI*#=FKMZ@2=
M;K)Q7+G_% 3AQ5$Z!\N+X:P=OI$''8BQ'SDOYCF0.C\2):!9N2TP30Y,8BI0
M/2IIP%_WFRYKDZG\),-NES>BLDE)Z0:L5%%VE'['4&;XD6V/*9WAD?Q\2S"1
M:DU+G!@E:)]S!UDGZTXKJJ'4L30[6=@ML6DP\:)U]>/>2'*3+&4P3H5XDNV2
M%M6%W$HQD>(**0,*O5%O.^DKO_8.:V(0VG4L%Y8<<9.2S(A')O6KZKAAG>N%
M5N@5>.%,%\:\ R :U9*E/Q=IREW]W@[DGIV323,%31RNM<H)SYG/*N/["#TN
M6\4Y"L1K\,E-P  ,7WT>[E4;[?0[WN=1.B[\57+;V\.T\<_O@)]?27L$&:;8
M>LB^;[0*;&+K:59.L[<W'_ZIA&O9:7EXL=U!*EUAX+AK0HE>[\,7NS6DW_IC
M6*DE9[JNPM'C@$0J];7M4=4>],5Y51:A:'WBGN+;F\>;JG2%ZUQ$9VG1RE-I
M(/X[@#[T17I7 [LZ:^023I^24_T%AGBA,;$2C_)MO*4S04>_%@P>$A56.H^Z
M_=Y/>$+HF>I'FK5^=)O=SZ2QAIUF+_/Z8.*+,>?VNN&-V%+AZJ^7UKUNX>;W
M"6IW9Y[R5@8B#)/]+;^_&7Z.+(PY;0KXTV\6_72@T\^CI-=W[2.VG1"%]D_;
M.C#?CDX%^8HG:@,S TPEV$HG5++@NP]FJBL])%ULX#65LF='Y45D$DX&B)8.
MU"J9@A/05@S)KB:^A^*M"@T(KO?CL6NO#<1V+^%[&4(&=R!N^Q+:WP_0[9J_
M^4K.[52\ \Q=&R86YDY^V>0*3U1ZQT#RE2*+#)E&>@=RZA+77A<33K2JWF+M
MR--VQ"A4KGS8"+U(QFT5RA]:-X2@VJ#<)7%"!B] F-\L-"TY_<\D+S+:.'8,
M9?4]E"YC]9-#YEP#S$?&T,Q^>P6W>P:5="F%"M!+^:C3NDN_X7BEX^@- %7]
M9)J-+&VQ5)N#JX+Q@%%)FO<\K ?KOS+#$I^\,#K ?X<*NYU,_ ?KEV\LBH=2
M^ W061]8:T$C(0D&@YLJ6,*[9+QN]W< \J@[(JCD6MO;K,[K9<@& ?!%I8<X
MBHY0LO+(B_MB(Q(,LB@YNENX7J=OESJ=F)V.SA$N*C\606]GVGZ^JYF[5?7;
M5N13(2*%'^*#Q=GS$C3/NT1M(MI8.1Q+$ZIWX?YG[FXQF@3(J4WPT9*IOO#N
MM'GC4/.ON$KV86@]8ASCQ^WQDAJN_O!-Y7$:?I0\D%\/Y?_K8;;]>"N+PBTD
MP>%2(LK,9+0B%L>.\-'N+XJ"]4XDX7D_#S\RWM!39ADX7A1FA(4X?O8A^$!/
M93?=:=:+?-T2"/Q+]&V:Z6P[TG6E9@VEVPW%-WA7D_\'85!AE27/G>5P&4@/
MO[TMFECX("-D<-%<\2N3VJLWTNH5_<KJ[$W7OMOF"Z,^O#?(V]3;=OFUW#LY
M\AW _+)K<]Z6<3>N]N#OG)3D;$],@-0<X9:!> WY/O DG+TE1"N$NMB[^ ')
M41O"H23QK)[1C*\Q9YRY3)UV[$6W7J]'/&MK+%I++Y (91V0),L$R60+/O[(
M3!,,[D_;ZP0MKTI]-[N_\I_PA*E42D#>,A+)E%^B*#!*-DJ:=%"RWD*^UO\5
MV =-$!P[H/ O)B@$KMC345F</B@[5A8[,!S)H?0GU8*G:H!O%,L=T1!G+YR%
M7;\K 3/>ZC;>'I&C##=UM$-@_9TP.  KF"*X#O8-YV#W=TT&$6>@I,.1-Y$E
MZZ$>4=*5;1L1,IK*OP4KZ^E*UT@Q[6Q[%-/A[>\-SKD(@?0[(  +MF/.>[B\
M.VC5M;N'^FKI,-OMZJJ5S>L=H +Z^PTL5QJHM+I0'K\:EB3QM@_F.YS)$7 Q
MAGA^I(R;ZI7+_8[SMSXJ=Y'1N>DB3?DW.]TH.S%JPHJ<9JC4H2#.#L^L$UFU
M3MQ"70:K$/;B5-IMK[:KUHKXGB%K]OWP@$<I XYX'%L0,=9+^:$M^L34"^=L
ML8VN06#+F4?K8\9,P"\E::;Q7=H)'.O]A5L$Z]':E4%_._I;H]?I5Y!U #!V
M$*?  MLNL@S.S:0"]N<TTVE/?]RO/>$*,"=:JC] &F< /BUQLY19UJRF;%O4
M4*U:^HA^OM<OO=HA*U%.Y;Y]S[1U)S% LD2#MA"&/7Z??)VX[SSW+7^E[@8%
M"'(_9&(!#$JS31WDXG0U_1FBK'9:U:>5%;@%?(T?CGEU\Y*HLY.S)"+MJ!JA
MN)BO*X$[LWX'=,K]=KZ++-\8BAIC,K3ZV5>>+>HI!()<.D)7N^]F2M:&J,C=
M,H-Q4@M7(T5DF_P_5NM.>&I<@<9!2H.&3E&\&,IT\Q@2 *5N'/TW+=NC=9B;
M4F-3JUUR51U?'\L=MF(7B$K7;.[<3H_ %_U;!]0R[TG+MB@WY.FWJ6/U/%A8
MN5;7@J2%4]%$!$W1OY[P54;!I#]<#^N-KJJH%O/1UY<V2Z!W5S1/I$$=]O_'
MX>)[#1:9.+;R?ZYRI%MH@?21[F=/479NFEFK4D2V-,9U*GEVB,_N6KFCBC&.
M6C. UV0:4-W@'2RR2)+ON7,Z%@MX=>),XYGU5[T.1*.8=11WU';*7)"VM4'[
MBQ^+&'XU(XJXHFX^;CZ@893S$,Y)W!>Q]JE5!2DKO8T=IU:@$64%P5(SE8VH
M"-OD3,--%]Y#='\6:]BHG#N2',\S]ZI2\F1@EFC5?0QZM_%!E95++LCV.$>X
M.%?VEQEGG#13 :8THY=JQ*6?KDBK@MWI3!P#$5V1=&Y#DS15]+"D5#=]]CI<
M[;-C%6?C0ZS;!M>L8X]GL5X?V)VFHO&N6CK\-T?]X\$?Y]T8N%TUSG,LRQ5G
M_\*!/*W#2[D2UZBC\1EQSY2-=P#/QA<^ I&9Z..GYYYW@/[BT*W("83G=-/F
M^5/QJLC![K ^Q]L3%#3Z)OA:_;=5L8D@>,);X- W3%=;<^&\G6S'MU3:TLD6
M65]2$ ]8-IV?B/@.<(R/*#41O$[KNA0*@FQW?$U ;S*?R+D;^<"0CWBJ)G)L
M( B?%[!E? _7('FO3NV@8#ZT%L%&SFMC@;K%]LIPFO,89SXB]6_RG8IW+XIV
M/Y=!42Q)4) UC9M,[(O'8:,A@@:W1Q93VN-.I=K:_4C<VQ%N\1J&^DS<RQ#>
M(T^\RYS8+5:QP2=C_>'R'HVJR:O;XZC;\VP"(W97E&J.QC_XS\A<KL0.U-,O
MY:O9$##!=[WQ]!@LWR1 5K9,.>OC18X;,#@^^N@3,%&5+/Y3W9QCE067 T$>
M;FA^!"Z5T*6\LK,//,&K1;$#,8]0)!V E!^Q'#VEBNQ)<)D$( +QQ-GI'MSV
M2FZJU38[K%>?#)NIB?I(8$:^A6JWTAEZ:0SWAM,1P=1&R:L60AR]'IOVN+;>
MI/PU$UT"Y>'UQ)M;W6! E&1PC:_(@B-300%HV-6J1#"\Q[HUUZE-=;H;MNTO
MK3%7SAKWJT8>U=Y2@9%:MOE:^NO**]]Y6&@ADS:-G4X:6:IV5F+JCL<[H)=[
M"[6.0L]]OYX2Q2==F@4J;@9B;N)9T)*.>(E#*/C2=>_-H3FW*985NM//LI4I
M) \W"6/U]&FXQ!>Y0UBO'Y@<DJ/YP@""?6GSHWLZX0HN^OFE-C*DKV29_.V0
M6#WKGIB;U@3_4(U HQ.FW.%R0!3?L2QLRMB8/0.U@;)D>/R'+.Y=J>2]Y'A:
M#GN[1.&-9UF+L.7IP9IZV;\Y([U\!S2+)+I.--F!28O(-5;,XZWR+: ;2UPG
M"X_/G)K'U=[T*I$AL3382HK_T<BH\^TRX1ZHSYX452LNKGB>J/_^:IW;V(AO
MUJC:X.BH"(=7^L(VY>0)?%9N25:2KEHG/*1H8RLH*8-+ZG'+[1X2_$>'=2;;
MNCP*BY5<[DZQM%DS ARXVW\J+.Y%\7>O(:UT2ZC<F]M9H2 7$SN4B8)/D=MM
M#2%K^[S2PW1E$MP9]P=380UP/C?AKB<8U*T#2?FTA;C&Q"-_0N&BU/<%O1KF
ME$2))4,%L1?Y@36@0@+!=:\KW$XP-4 <?X6X9/!>'?\ (K>;KD$F7].XA -C
M\DW$'V#81KC7;D=\5>C7@Q$3;-^-SLI*U_;/=FEN"]-,%?H=5AI&,X(3);WO
M NW/MM]^W;>JMXP6*#@A2$-2HL;P3;RU]AKT =*<8Q?]FM$"VTYD*1,,Z]VF
M'C5_4KDH/*.Y2$)SO0Q9P3>59=YPE@M-BM"D859[,4W$Z+UY>328A[1]Q6CC
MBZ^\CSZ[MU7ZQS?6[BG/W YU?$HUZHX%6P"&:4'8[:39*1!_VJ_A,:EUD%G?
M.P#EU/%$5^=36[.><_#'KR]_+]E!L\,D'4F9#+1;@,CD%U#/& >>UD5H.\6(
MVV(XDV''U,;*KY0]@^(KKFNOECR=!P=E\V4.J[U$#[NP)YZ!6IDT'=F/>E:1
M_"\^/G83<O9-K?262:9(JXK3L<.,[%U1H'"DL$2$1]1%2?_1K^2MK]!=?\5=
MXH,CCH4V$E W+=0Y7KZS,5%!*F*XV=VI@NY&R,B9NC;RV8$]^C6M,RN+.R'?
M@>#'L+,IXUJ22"$KCB)Q1M3HL7:LJSLP)H#[0CP+B4!Q]Y*V303E1<#'NTAW
ME&0M?!I3W,JK(8F*K5B>_T-Q:>+6)EI;UQTT)_V76$ILL+)(H7M2-:8WBO9G
M6%# +MG)8N)#\;.!-I(V RY2!" JGW0=-'.+?X[7RZ]#5])$7QV*:?'!".$:
M.>NQ*KE*2ZUHW]:X(IJ_3?,&172MOW KP>M6]!TP&-S58*ZMVU>R@K"=2CVT
M5T56;/E7/N6>S2I#J_9N[,@;XJ#NA16ARS617;K:PW/)Z2(E<I[CRN5XQ&"I
M4LW5)D#*CQR'HL;V<^9$ZJ)C7(M;F,+'A.5&.C$(29;RJTALV7D^:/8#LU,F
M-_QJ25,6ET@JURSA,&9_VSSY+"#$T!VZ@Z]2*EP\A>B5;G3'NS]GN\0UEBW
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MH# ^P6^8&AR12XY#<AT/;/RHDD5>H1UMI.:$GZ\=R7V:*@L^QCWYIU8B.Y]
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M_53J%7T'SROY&05%R0Y/B@;)BZB60XGYB=_\!X6<)[-O3<U"*I*?+BTRVSE
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M&RXM^6^+,?\_ ?9]^7\ 4$L#!!0    ( .6*A%9;0_%L5<4! ,'L 0 6
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M([;/02ZXT'\&<KC7FL]!-1%<725JCXSCE;3</==LAPW=%%4:_4)E(=_/>HR
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MF/O>C;O:AY-D04R)B2CW90:RUWE GBU'PD6)E32QZI(P)QS],FD$Q<JI[>H
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M3:3ZY,OQ^E=>^5:K9HAPAS5_\9S].L)LN\L*A7L*J7:F"97UNRKVV2>)=*@
M7N2L2\E*HH32[A0@G$\X\+GKNZ32GG+[E8P'.2;!\:PM^BS*B[?"^2Z L\&D
MR%SB&1+J&CVE0XKQW5."#(VGA9"#EL!]TF [$B8>H5&V/D>I\I:P]^?]&,:6
M'W9?X=V5WCY6*^&2C(L?_BYAR1HT*5'22"^6'8*+QY!LT?&>FLG^"'L\. G+
MNTN\+1F/U8[2A+LY=_SYI5CVSCE,A74PH^Y9++0!7,V$6I)F5"[D$$JL#I;&
M4":+]D'FW B*"4]A11ZTNS.6B77#(G]X0V#!JO*:&??]%[KD:SL6[GYZ]Y$.
M8BKHR_^D_1YC(FVD(,($,"8/0,E5\49ZI*6!!LP);6L:>PSL_>+73Z[KM>O6
M ?<F^E1]O\PM6+T19NVGRIRV-+_%0G'N4G)=Q;%W&\(7.F? [&VL1ZQ%![T"
M$,+O^JMDV(3Z731OW3IQ5H6V@,'E@#^/=/.E,2WS*AA0TMA:HEHR)@Y!HB@?
M2$HD1)0&(]BS^R\*D+MI1C*ZX^I&7N4;]Q<"KT/M@J3W.C^W-;36)H1E%!<@
M/O>-ZAWXPLUZ(CVY2>@X&OA]V_CZHA#I=Q*^PL0M!QNFD!/W?CX@LN;*4OPK
M7'UJB=?^Z^IM: J8=!4+R"IN76,":!X [4T>ZG. +^%&^H?@4QJ,TPCIR272
M;TS55\[C1,49*27JG>D/N@/*UMQ-RU_$:L^RK_[./@2Q;:&Z3';1J6BVCI,T
M-WHCT[4XD%$]&$D U@?AV^4#(X+'="2IPT&FTUL1PR8C5VKRKP7-XIHFM:G7
M[^:,VG@X!XC=4L'!CM-,QU!WL(!!V<  Y=%4<)O:>T00:= <ERX$Y!$DI4_/
M2=*-LRP?ZZCT)R^*_9ZQS]%2?,GO?@O]VILB1V$Z[=A C ]J=G,IEVDV_E 1
M6CC];8<10,43YZ!P3[XDI'93VZCVYH>78B5N1_,L7K[A[#1Z8MQY[EE&$[V$
M*?^_0@J:R &FW;G9\WK2PL9U,-P(4U*^TBCR#)SME[1*?T-#-??\^A^LK53*
M?6^8DJ YZP?E69:!8Q=,1L@CQ&SJ69HA4W 4",AG8JU3Y-R^]AB$#@[,&] A
M/UZ?ZNPYE:>A[Q4_<;FE.4]I#O+*[Y6#8D^P[]P/AM4_@S>1'4/P,:G9OY1-
M*2,O O'*4 ]#=**XNF52YZ?#+Q5CW<%IB"AVWC8L(L)0_JRY4,VIUB]X"YSU
M+XP#ZC8,T*VBZ-+3&$: )>5Y!Y!$SE\:Z,6"+N\ IU8)C4EWIK0Q/)<_D.87
M;MZ,KJEU-^4*25W."HZ.2!72$J$*,CA3F#X-1L_!X,I<P4_4&/I#A'0N. :_
M4(/F@#-C_K[N=*'<Q-:O[-+\RU'-J4MYW=8_?_DG6=QTL7I6^:F3=14&:&!I
M0OG]J,]8FF!5'TH"XPOC!Z">Y)G$M@ \-M[)1&X\0I+OA"O\IM%-GCG[LK]S
M(=_(\UBWWHSVI(RQ/$L[-/PLC6,:A7M]4%G%[,PB.8J8167.:Y>WB1J\MM=3
M#Q#^"##F>R3T^II4:7*Z]57P\ U76,]LN%[[3E5O8[EVRJ;8DMJONMC _M<H
M<P@K"A<+KK'L3O\Q0YC9NKX$.4&S!%9(FTLBI7Z500<CO43_C<638_45FF!%
MVTG$N3"5*RTW#OPY*+?S7QQEO<7.BD]G8;9>@OD\$G\Z1*4/+7$("@ G07F#
ME]KL^6AGR9!G/^!F%IG$"VXEGQM1IZ*)8FSUO><LRKEJ<B*+^(8P@/PC")D+
M3+P=@_ CC^P:^"!_,I]7<0CZD_0/8E#.P7,/0;8JFV@F[V4<'Z'J(+^C/COW
M\0&*I4\0MF2!5=Q,GYU?W\'WZD^!>>4"0)E]?K]*<.-H0&-U=X;YL4]SO6IF
M%E##/ N_VU-[[%OL5"Z$"E.)HY#?%Z7I^2:\&PRE&2-Q?.L0==/#K&\_ QND
M9?_!QC=_.$\H[>SC-'[A"]<Z"8],9O[7%LI7:8YE/'P]+1WE-E4_RI=?B%);
MFZX5KN:LZ5.*^)XSSL-KEMS)6FMG!8+KHEP<O17B^KXE)($\2\3B1N19T@,/
M%/%Z3Y9(N?&XH,31C9;DDN&%3IYY#S-S,6.+$T]Z*NV-558@\2V7&.IDXNL:
MS.O//TW*(N\,<=Q:'/E<:"DN:6K$2?U[X:KP!<XBY<>CH+,@"FLRR%7I[2/-
M^B%8_=I!-D8_9Q#'':$X>)N=8*&"1\5II=@GYMVY=^;;W#-*CV+H] Z8^_[N
M.L,2JUGU2N@C'?@)V2Z1.YA9;?^"XD%814):8_1<G=E,'W%GO@[= T/$:&NL
MNYK)\7-0DT6.&KY\;@<?Y/IB\JS,@-&-R?_)PJJ<YMN<V\(7OOK**LF\*P0=
MC!Z9#OU8MMZB4]Z85[ L\OQBO&7 '4<%2X_$*ZLF@QQ54F0F**E0Z7F[9#>:
M')C7?23UU//IG$R9P@ P*@UY_3%69T<U"\ 2/#^P'X1^5$T[)R#J9GMK(+.B
M.]A]5_^[X2A["U!*B:MM#""V:=T)M5DV_^B>08E<BEU^?;9+W["V\V FT3T0
M<Z+CY*)FPB3L:2]+".R792GWDJ25)-M=MON;X^W;71A0W2:+\&JRHH?%FG!8
M )O3Z!GQ<]_*32+!X43<SHC-/M'09B+\I<B,74UC32.T58C_Z36Z?8/U0"#H
M+[LI'8VP?!@_M2T[?D+)+P7L'R7_YW'N>3GYWR.-KI0809S?D]WBH_LG%@)%
MKWW8N;P3VIA!1<M7<<9H[57YO7UTKNX0Q+OVX#ILHBY?4G&]8W'Q_#SC@%5_
M_WO,INM-!['%FS>]T[3],G[@'84$OEGC0&P!>SBT#,U;(X%F*)+N<R:>ZJXF
MEG&%<]X2K0]?AHF+4PCO[UU-R9K5 'QV_(I?K-37(@:X<D?'WY_^E*#E>OW)
M%4=EB)*IC6=DX_6O#%6$3_O4[\IP/NZ%]LI<UCH]O<\%-3];,LL_X,C@X"CI
M!S/?[^3X1BJ\^NKK*U][;CG3WL%.07AE\%Y^6P%V93E]W;WL3->='S9P(QZE
MB:<.E&S5]HKH=\V?IO.F';*FA^=4?J9F<BJ]?;>;:BQW<W)7\L<>S^D_088O
M?^BNO?[4P1MI51QO1C-KJFKI$*)=:R0/Y_ZH:G#;G$XT DQ![A_ FV^AI:KL
MTQU'*K \03-(B>DMG7QK"<6Z @F'=ZF4O_1=/^DH]0?)T]G.5VS_NDV%[^UY
M,"R_D2&\7O=IPI?6^\53E6Q<+CLDKZZZ?M*1F [_I#/D%\4V65QKO\>;_&VL
M_GQ]@7+/C5BZXUZ=LY(!SJIH*0U'=HU8+XUQ^L: O5:X<K_T?-/WUR4<?=OB
MYDU?(=H3%AZ,E'<;&=H&\04!49(1-]]82.VO/X_I&H[^WDKR[G(=1^38E=I@
MPLKGARX?@NI>_DUH")K^4)2UE'X".=*R]SPS1( B?>7<-Z?2?2UU32M-O>MK
MI@?W/6,HZ,2.(P5R&7L>QG*&;9EW,H?2PN1 SF+2P\BGCDQ4/W"]\:$;U264
MN"P&?W]AHV>B$'5*B75EA LYNB-O"R.D\(>=W@.'5L]+!8!9-4^RWV?)[+V5
MM0DUAZ/ZYMB3W@JL'3P55?3W?7KVYHNH;W=^GS<28%,99+(9N9Z#IH!P"P^9
MI<SJ#]XAK0TW[BS-80I0@(8ST8-JC>HZ>PCRP1RGW0' IW/9DR/027-13RMU
M8BST%:L-8K[&3=UZ+!:2X_&M-9]%5.V)Q3@+_>H8-!O\&4Q\LX1^AJZ9Z8(F
M@T4JMG[3+)>@7#<#'TQ]?U'"'RK?^*A5^;.42*1WQB%HAGY^U,C^+9 W%KJ;
MLA;Z_'&'SBV%9QF95>)_XPT$GUUEH___GUSV_]VNEN\C3N7CZB&_S73J>T59
MQ(I?*EA?/+M1[NW+V<,NBR./EQ8=25;FJ*RH:.!*2935;/A"6_=.^0;[_9[B
M0=QJ-IED,1;R308IO?U?OU1ZD"8;62YP Q5X\M/)[<SQ6P_J'D8]9Y]T;G8>
M1-=%+,?M!ATY!#5?G3'4HMW*7K"<V"WB^)=$HZZ;X#Y]?N=40;"HW*\?-YIE
METJ'?NS1$B:S"=@CP0XS76>_9[S0JQ4O2.Q\GCK4) -\AW!2\OY+FTL:<ZP7
M#%")6WM-MX_P7)2=^,(.";+\>\_R_J.8Z*K:H"3R_M,*&A2_.6P\AIS.:&L0
MR/@6Q:G9= AZ*'9 >'06R0^OA @ 3M.ZD4%T-8%QDO[RY^_]GO><;[$J=@1-
MJ>Q0.V54VX!H0HYM;W9P+]'[T[RNZ0UGY5!'^\50S6;B,PGJB-UD\%Z0D@Z/
M27AS?;-YYAGO6YU/6)3#QG*+SRQ+@-K_N_-E9MPK\OEKV'UETZ,VGM9W;B4F
M&^1X=Q[I0)%G!CRT; 37%\6X/FZ(^>B]A'@G\C^6UXR9E;X"EQ-BV2H\2;Z2
MA$^Q5M][^".D6\[@HDOTQ E- >WEG-#9SJKG1O?)Z1[D@! ]2X'U/&^K+P[2
MOS;(MB&.+S2^O:FE&9^OO#)TF5S5QW/S%UN,A2_"/D)WK^:Q]7H:_]VS;&/S
MFU!'@ O'2,#K)!_\%;T^?5?Z_2LSL]#E>\]/?O&1?A4?DPJ"HQYU< 1VR*I\
M )XO!#@=+9-70S?\C+BUS.2--Q:.N+$7LKL>+%TB43+P\^>WZE+$0DZ:7T74
M_5WX%*?Z^UY?OKC1DCR.<_8_)93/@L1 O(]81CE=_ZL6X>WG^*X^1$OEB]QV
MZ![\6>QYMP/Q,)^U5']5IG?F9P0I@<CJI8!)EV_W.:D17.&DJ]]U=B!^H.IR
MV%H06I"F08U&EF(!V-8A:%ID-=3G46^+![U41YXX!?%=;;2M>(6?O&8>O;I]
M\M\L6%F8LK\1HZW[*X+05_PEVJ<:.Q+&3.2 X4\T,/TY4@EQ:WR7&@)S @)P
M3.(?-.>;B_RC4$"<CBO-+W.S?77*2[E+/EG (C7VJ+Z[\Q\MDA^#]QO]$R9
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M/7-HR^X09%)S",+R,+1CDC"KTU J'M.?'K "'((Z^;SHJ_NHKCU&#J8:0RH
M-!CQ%>S,4!*)ID6F U=HHH<@,Z=8IL$:VC,,H6G0V["_>[D, $8N_F\?^]!>
M8X !>LBW#6EE\%7MUM-3_^UR=Z%V=?PA@%;=(6BI#M4=A<,<2-2!:>)S*/(<
M[6[0U==MO+%3V2^0[Y^[%4NINB6MB<JCBX;_3T%E>J@COYGM;M+54'ZJ;3?Q
MJ381]1-[]%-_5AC+(C.4\4'L[[=6+HPC+9RT0%)J94NAPEC:8QA*IIC^)E0N
MZ,:+$WH[O[+7^1FJ9.CG@UNM$A&)F(%Y\_)3FU+ID"&H%GJ_UE$<^B;;ZIZ;
M&W97XYJYL(77_VB]Q)V]#P9VH2D#7F1!0N1'F,)T/FFGRT2)W/ FA.]@/@7"
MM=;8,O6-'S5A[543;D]YZ8R"ZC)-X(\_MIZ=GK_?ST>_H', 8MRK8%(FS*QA
M/YBCS@Z&V^Y"IT!%&/J;KI7%@9BC"'#18N"#]K3L6SMQTQJ5(6.%8NH.LK>=
M$B.^$\18#GB8EM_VK_8X\AN6Y( 1AJ/QO%EO@7PFV22RX+Y(;$(!YZ76,]KS
MAR"%TR?L9- Z,R]FG'/&I1M%$I^M[R!F/4K_J#"XE^GY)ASH'W[]Z#J/D4?:
MTF9+(HWDE+Y%WF;R^^+2><_ R$7IT;<3BSU7)GX5Z@7=^!FA<L5[;N1/ZKPM
M*P[3D-N#/8X<8<:0F2V.,-)URQI2&<VG<30"G91GF2"LJE;?;GF]GNS84720
MVM[D\JJ2,$%47S"X)>3 !BKBF\?,/V3P\M*S_M4[]>N#UI8.V"GV1CHC)4A2
M'1KI[A.R06\^84-G ]ZXS!\[[=;Z49S_2$%O(XA0C\$58$CNZ0F'H(;5!(8A
M?&8 S6X41-4%1''OT_625\C0WOR W6$M#U*F*:5IS\VZ<EQ>T];?X4:CTU=5
M(1DXC8=>WW&$&?.+F::R-O($PL=07SL++^V*E%#/(MRD&<-3U-&?%M<K:^;=
M B.)?]QGDQSEX5+"OJF2GY+I0DP]K%&_!2@PIZ"H;9PAY)\C<RRV'RUJ H;K
M05M)):D=*;\ ]PH<VK0YZ#A^1S7B>'$:6]P?H]:8LF30('F$)AU&<MWL-2 .
M;&U2E9"C$!F&(.!\M;V:+-IGSP>WO>[!UA>^[JK2.B9_S5J\C@6QMKPX.%IS
MWO>H(-6-V>B_6AX?&(.'(-+U]/@'C>F'(+]M@9^5)7@Y*1,CDG,B,2V7 .5T
M%_CBTU[SZBEF=MPF[;-GC:74H[",'0D,R18VB\+9=\$ 1<S6$@X"@HMV?\57
MB=#$F+>V.6!FG?3.$$+<^CRE/T_I--='9IXQF;O3VI(C+G#["[??"D\3>H4)
MX;_BI?DH#YDCD<.,/=A':#9"B"1>L8^/$_YIJ=]3:O0753?EO;M[GTE1 [^K
M.;4,3@S][9,Y+8MIBM;C!-']Z)]0N&6F6T!SF1C!]RD(^DN4[W8JM/X0]*Q#
M8$,P "I8B10%? ]!5\?;]&-"5"PC:GX-^[JE6'$:T,N4JTYIQCD<K_*?0N&:
M38Z2_6B"\WW@^OVG&+^JM-R#M%<$X^MX: I2Q!S/8VWDAX<(#Q4O? G]K29\
M;(#B^,;P70?G6XA:VM:S]"YGDAY-*(K!LTC_C G4F!/LQ-3&(J? U54#56*!
M)@K3>U#.3ACB?HB7SLY&D-2VW['IXM+*G"+M?A?74TV9ERTD,*400+&*> BB
MGOD7[@Y!=YBL1!3EA^5<9XCD2/+QN]!N C$/BUU^;!BPI_J2B"O?I@_J[L[/
M#WP8'*WN?ROK\;<SU/$E*[#"G%6F_^X*-8)1M0+0=:M/D?*TT_023, 9ABIC
MM 656*?F=SFE%VF0@E^)V](,&,9O4E.:0P]!U8DYY-!WU8D]H#^-JK;8@V9Z
M!P;7BCZ"N:W!#ZC@I4N[,2E@<8Q_E12@94FN3^@&L\!=J=<GPX<-G6KBB2%[
MT<38^@J:Q77)N1J5CZE)BD4T)G^/-:X+D=G'#]"$/KFU*]JUY,Q3OEA5K#35
M-A;@XL(-_XHHN;HL#$BTJ'RX[)5M?U5E>P0XDTL3IE*\Z$F0(# W0A:X3CV%
M(891(X$G_3,CHVW"1>L!A$,0;X">;D=HOGHQP;IN:'.M(F]A&Z9NY;1XVDE=
M7YDE@RKZ[QP [%$3"&-,1IR>B_*O>HP60MV!I'B:M"8/=+I"^]1D-B_73L/4
MSZJ%_*Z$Y1RK>3CC)?WF-F+@R_'H 7PZ3>HG$]79D/?VB3Q4 QH_B?TITI@F
MGT4)!PXBJDX [[MA)P![<Z#>1VKNFIW<Q>:)U?J4WJMMD>5>#2@3=KW+,HK<
MNC2FE1U[2?]P" K$S+E1JIBS<X=V@5Z,\4I">1=X#C%_CI4EC23_UFG220T:
MF!Y>PG(F3&B$%ETJ$+5*NN9T9NA$([<H?[8YW8OYSY:*X'>3&%QV;I6W'V4(
M.U=LG_9GV:U?L?GI5WP/)7JY,UK6P2U07_;(A:5D$+V;V5@@<Q3<M*'S4VTQ
MI5@$"]!(DK0'W'!$PU[7QL0.90"YWS.GLU>:'=JHYO<0F9CY]USMSW,+UHUF
M)T]C( Q]YMUCX"-&^F3!?D]N^DN(GT8:N-XI@33DTCS&D -VF%P\KIZKB@M
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MS2\3PK?QN4.&K>GF35<]\*;P]8_"M!UFS[11N#(4Z1H8."VZA6'?8@(TWL]
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M.4(BJBF*.44:(-;6*J-1=G(%]0IRX-_[YQC@)(8FS-6/:81M72>9>0!,0FF
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MQ :&Y&#_P_LB\(JLA_O=2+6E:8V;G$9(C88B[,@JW08Y%3HYI7@[@7&( >&
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M03\RVH6/,,/QY,!]ND"L$PM0I#&'FW=2F!!Z*)!<@!KP  //:W[*@H%S!+3
MXMJ##9110XSB5,B"Z=8K!T&]ZK=<+<&&:<\[%")J:&  O>1#%X PN2;)TTP.
M6C'2G>+3C9[%4NNB1B#L]SQ4IW9^Z[5>+%CW+??X:=<GLCEZS#4YMS=#.VE:
M]*=XR'D)5[-T"PH,T $SN3QIIYG=V#J+1+07=@[G^,V$W^4[L-\-X6?9II/C
MAY:/9'1"8$BTSXEBXMM@;B_5$)ES 4O90?_6AA5H<#5O4N&Q:,DJ"*'V $1^
M"&_'S5E0_<="U/E1(Y /U;F>,@>@[GBMC8H L6Y)#PSOA^6%*T9C?ZRTMYB-
M'ESV2F_&+CO+.=I=,JIC<K&3NZ@O&25H0EN>."/+Y C2FX+N'$"I Q ;<E-"
MPV<EMY;:IJ^M8J$:)G5A_G"NI)&I#05+>:G]:R?E?/Z;=/$ $0/H]#$Y*+1+
M2"3C-5,>V.@]+$"K8TW$/!=8-]&8"H2;92<8V<.UBT>3[K_-<9P-"E!M;1JM
MWW',#'KCQ$5)^85GGNX$K.X'GA)C;T\]PO>RS9<][9=/Z*D;>C_8UOQ_&S)Y
MHQB9;8K,21C9&B*[=@#BU.*J$00JB+%)](L4CXC3G>?4U+?IQD1XHU5UGZ?O
M2=_JZN3Z\CM1BC[>$J#G?B!F /,HJA-"OH9)PM?RU/1 YUJ8G/Z5Z^ F:#>8
M%X9849<8H)23QM6/;LRUJI8Y V%[2FE=5O 0I=EW7^)_Y GH/*WX>UCJH)8Y
M!Q%O,P:XJ)V,>&0PQ6.?=(_QQOMS++&I9VC^3T.5^<XEBC:SC/CY--5P_I5"
MSOIXYY,C(7<ES4]HP7(3A6":Z X#E!:ZHPDL? #R@L7XT\SI%P!5<L72?F3K
M*9]#B7$/$2"R$%KBCR>GKIVC*F]YV.OW3*S;F_]J^VY9I_*AU<\)^WUG!DJ*
MI0LI]4! $'^\.+I#H56"."\3VGD XD%Z^E8"F(Y%@<]?S3^15)6Z<C[C8U55
M:JJ%=:JH[I9FQOG/]=->]$H]Z&=?P72K Z=6Z4+RIA1,=VXHD].*Q3+$IU'R
M=%<*+"XD FH#$T(^GJ#S!!.ROA6E6UOK(349)4&/3TTH(*ZYC1ZO%1!W0G3T
M_YEF\O0!.-(!Z!F,;*<.G%7:Y"/O4R,GT?=@LX7$DN<A:&&Z*$6;^DDW;C-P
M92*POOM]\]>:'YE+HAJNZT=["B(=S^3TX+,?UWR! 0KFARI9Z4 V^Y8098C)
MI;TT;-\-;C3&=!O[V4"[(&+PWU?@8C'Y\^IIQ6O!9;H&:=^^3,5,<JN+\YM7
MR:5J1+BQ)HI,-V/DJ:,)33#RS=%X;%WVLVTZ!TVOC^S3TW86\"=*J"C5M4VT
M\A0NW*L#U_EF!'XZ&NP3',J-UH<WF$73>O+YL)!_^4XR^R!-^UM]-"^$%)/+
MC3)-FHY&WS-$)QI,8<FPCF;62N-Q(]9$[\'Y3$/"A.WG%[]CW[N.!@H.2DD)
MCED$":<N6/[\W(2V/0#QXPA)N"/V3([@)?QLSNI230\X#L^-U.:+8RJS0F\(
M-B503>TMYGK,DLOX(]Q6HG+BR]\!(LCG#1>+JKC3THUC5PY 6[L4/).GC>7)
M7M'E@0J*%"D;8W21O+L$>U;5:G$<'[\W;$R7HMA!Q-96UB>@L7;Q=Q*6NE--
MW@:6\7\W MZE:EZ[*+'!HE1S$4^HZ0"6-<P#C"JZXM*"?:^L.N#O&;H$XT$-
MN^(3S3;P&RC>C*M3;YMT>!!Y=[.@ZK//F]^F7?)R\.R]!%'&$1;X 'GLY@YK
M9)Q(V3V8>%DMH*QP \W>IC?@1=P GP1P-\=4U(6ZP@<77-K* MB.-6LTE"MV
M(%^)S CL2J,+>=/>N:TU.[XNG-,:]2^>F?M)W0J2MS$T]>4T%<AQ_%.46L"S
M'>8]8.P/"!R HA]"",6X6MBF>@C- 34,;H!U.Z,$Z-=9]/!>KO4-<F]&S8Q[
M90Z#6E)]V[?"%W3K>S97Q(_NTK4C+K8#1R9"]Y?>^>GDM.5ZEL]8K;KXZ63M
M3V4$**_,NU^M,STST<\G50$*Z\CG^M^M=2_R9YH&/P!UJ!R /'> L_"X-B%$
M-C6?[%BW)#4:+3DV;03V]21QY<I??Y*%^)&.=ZV-D?"<O*]X;V*X_DW<#]OH
M=8C9V7R^5772/EURF#4+64 7Q6Z7E%5&;NEM$\<Z?4K9=2,W11L%EP'HSOV,
MWGC)U\8:PW8\%V7D8<:G$J#Z39K\;FS4$JH[XX7)468OCF,/$H6KPSW5PL0R
MV;[^>S6A#QJEWKBNF7]>_7>5J6=*A/W-\_.2ZZOJ39%);QAB9B!4X.&>?Y0=
MLP_+@0ODDT!W7*9+$2%"+LSQ/(.QABHNC^EJI'UH"/&/"O**KX]G102VJXIS
MKL-X^//S<HXINS7Y[0OL:]Z?W]YCGAT+@?$B8FWJI[14@Z'-XPT1YYG"'VN_
M:='6/!:WQ]<YCEB=RA-#+#@_Y!/7TZZZ[9-D%)H/J'T=+;]=^BE=GZ<J1V;B
MQMHGA_9ED7BVX']">D!H?9@DFC #!N3?%2]504GX>)0T@M;ULV(]VZ"WA,!:
M-I>^U0]SV>$^OAB9^NN1?3)!5>?KP/Y6OJS;N7_&>29+R/M,#@G:2:0^H]!$
M$O45QH;B\0#X2$HL]\CG"EBWAS^.+]-RM7Q?;Q[#-1S>*2*PGE.HD*2$>RDA
M;BAHABI>;ZY),%%&Y.DM)5BMY+EG.5I"9_=HR*4O&8!(5%(=^'._R.^=K@-0
M3#@DJO)ML'!HSM#9)Z__"&LJ5)IX-?5_\3,(&MCJ :'NT5EF$J6+&L W\K'
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M!"=6L#IU"GTOV]S)XOV$BXREEY?_B_.#7:<R(X_Q6\K]"/)X?BB$PS(J*%W
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MMN@%\\W<CBCOG.YQ]<UYHOST0JT;S'4@X(FX?:PS???D _#00OHER&L8H'P
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M!& L/$$JPO>0K^'M4[#^H=Q77Q\\S/TR?F5D95C:??))?]K )8/N&C6TV=C
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MEG[!:O\8/XHO2@+XBQ[H'7NTE)4*5LKN!LSL*G;O4[BX](8\FI0>/(HVOY/
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MR=#+E=!@=&L+1DS\C^74@S\EN1:6XH.2D'(%Y1- >(#KS'<TX]7;S,=RM!_
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M1<T.-*30M/"[_4NG2)$+]:%P'BC")N[6Y!;.3HEO[>,##D5T;9#,NO2C,W?
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MMJ<_4SX<^=D?NRONV5[GZ^'UTOXY-@@S()^Q6CCP1_2%W5PF]5(X.'D9K["
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MU@WM<M@,,8<(?C+@-5G@*-]3'98*F4PJW_JV59U 5ZL494)=ZL0; 7RI=0T
ME[D 8-QF(E6LT4#\G="HCZN2M('97:T5,$VL3(\NUB8^])-;F+[-HL?[.=L^
MYA7Y+40=E.KYWP*]VI/7L! G<H+D1II6DVW'""94J;"$8DQ[37 V4BV8/V74
MD1)_O&CQ]C))"[:I<WZ#L0)I/Y,4/C<'<>C<>5I1STH:Y&UJ:DC0]*"2PUY-
M86;DOY>0D\/O5BZE*TB9ZFM@J6^<6YTQO>CYP<,]/>*>LN2)Q?-..YZ^&G50
M-V@W&[.,BR5KNR2\RX[@359U-DS^SL@*:!Z"T\5? +Z,%.'S-3"OXDBW9_RL
M(<:-B5[KYP(=5:N65M!,)@-OJH.%#T5,HH\&.>C.XWML,3YLX9VB,&V\-68&
M%T@>UAGFCRV)4_%>N0  78.KRRIAX O VQ!-C/&78OBU*E)5Z?(@>O8]MP3[
MM>\7 )TFZQJYFXU37ML^(2$AI?.<'VXU1W8!F;'\8__P44GI5%;2H")H^.*^
M3ZC<0W>P%(=R]LSSI$XHICI/R&337\FX[V.CU= 4TY9&>*1[4@!<0Y(8G(A1
MY#04R3UR+@7O4H<[Y5_9XI'"QY]+XC-F;+ CD3(?EK8MTWHX0N:7'^#HS5A*
MD'?69-]CNA.Z M1^U5*N92QC_+P&$/$V3!C3[N2Y$Q)M'_8"0.((Z)-7 D9+
MP-$2F.$*8$2[;"GQ\_2R\91DPORSA^:#',,8\5\QO.9@&-4G)F2]L[&_R ]V
M,M0!E/&\Y8I0:TB$HI$,LS:0TMD-#O&,3SZ^OJ'08K.%)2N0^=ZGUX+OS[_M
MJH/Z1@BL-[Z";JC=@G>1;1$5'78'"^K>OXZ/FFH'%2#Z'GS!VSZ=A@E^<LM"
MQ(P0^(,]$:46\P9?9C7<O;V#TCNR6 Y8Y=5[XK#@A0"<![$0CGJ=CWD:"L1=
M (@),/95("AL %P/BA6(7T5T[5_9F/_2P1,=5&6K=?8;B;N3RXSL^#"H5OQI
MZ][#S]\'NP3/4*/D+"IUWL) S&C(W4L,<P$HRS+C2S5K&=DK\I<$J1"*?(?$
M^ZH:UIPYVUPE/O'?8.F]-\+.]TE8I#95F<M;G4NR&QX3'-"'C+*YA,\M,G.S
ML/FXNDSGFB=2-R&;;?ZBP5J)V[F;<\RA=/Y1F7C'[[+W72J><=T/5>B..-QN
M/XSG<JWI#Q>Y+?10D^NR\6,6=2X X%+N__KUE8-[%L/'%5':>N+3>>48Y\1W
MTKQ2#R':B3$_:O,"SP*JLH0HT9)<,'$L]>N]X4]?5$XL+!0SEG"3\OG00T^:
MK79"(0#)EUSLOW0)O^W[98 U>R7\I#'V;?(3H]9 +?5>XJ/(D)/U)MGC7Z-]
MWC=Z5*!B3X5U^5(>\%5<O?[#AT8619+",W[:5G-:CE[T"YE(O07(%A1,?>3P
MKO=$D(?PF/J?C26^,7\\4ZCHXZ96<[; ARDJJ.;A1\I-2=)I"5=Y JM:"6=(
M3')R^^7 DYH'H8[/E8V>UKUR3*<6,V;C%6;?$FW!( 8ZW'5I/59H+(W#>1QO
M6HXJ@.30F]MYWOM_TW4;TP*8/<:FN;PJ3&8ADY?>LB?ZNP)(*;$CU-OFX[7%
MJNX*#6^J'RB6>WI)-'Q\G&;'S!3V__%@]7\]9"B/E\\D&?T-?C?( :]PQ924
MZT]'(E:<(OZ-BXB))!76 \(\O@#,I^'ZL4W]DI3XD:X+ ->Q%_,6#PCSY4W1
M5D;6=$;>[<[V]@0W4WE7\<5=IM]V</YRA5B]B+[%</!U)*I.Z4\N"H)7S,3=
MQ]K&>O)-^'$BKQ'X)SY/>N;:-;!)E5N4JPS?E]POB;VB,WB7L@INF8\Q1<0A
M&<)8R"A!!0ZUAJ^ XNOA])L6R3T>7@;C?R8E/3YEFDQZ>?2:-%H\8])+AGN+
M&G &O>KZT;\P<MF7K+0$-DH2#;00WO7L:!D >X#WP%X:0(WL"F*J'>%T^*VS
MZ8-0T:<-$:Z>E;L-[R=>=QS6G\>[VAJVA!=:_D.E]#SME(W\;AUYZ?GS8?,3
M/<M_Z:B%AMNP(6ADA)^U/@3OCQ+G(:.W+&5N&U&VQM%CT>].HE")?*IM2M7V
MMKWVTMFV;WV7PD,@!/:C;4'"#4E<<CK#4]M$DFP*P[WW<+I/1DESU,4PZ 7@
MRA=E(%X(2&"&4IQ:#O!(\3_WT8[;QPY+GW*0(N&H:%N,'CPV'Z,/FI->*=G!
M8OE6;-^2^-QYE/&1B, ZO>EVT9(M5CF.5[EE&]^++2VM^TJ!:I;%CN</=R(+
M!UD,*B)Y_K(ONI,W5(C@\)=+F30!:@#W7P!BD#=A0"RU)GY[13S &$-*1B<*
M&M4@QZN.0]T.C1/<GBX5Q/Z.$(W9G54WMAR\RISZ\RN('MZU?N_A<HU\-WN"
MJQ,D]LRG*#+,W^2]I[%G@5P0957H$[(NF6+7>Q#1Y%CIL1[E;QM+XFS'VL16
MD$:6Z]8CCX:DAN&WC;':,2JBQ>:!83A=,Y0&-/!A[1ZJ*M2._#+Z;R=SPM^6
M* C22"<-7AM31UZP&L<V#RLV/3^FN@'(#CW+^%2R.']?-_")S$\K_H)=)^7W
M3 !%JS>8$@*7+%9BX%]->._@V7 OL;:1?I X-?XIF#"F#G44G%=HQ]_)T3C9
M+EP$/5-=CT6_GG*,.E!<.;=)XDXI?+'FN4&!UR:+:Y LGK=JE\/ZEGCPON><
M5J3ASKO$?-(]5_FL_4@$P7;5]LHBOJ2+LL_$Z$$H\X,GTQZ((^52A\Q[EO%!
M%K0.48^<98U)&4C4,A+/3YT 1^7S<.)KR#%E]>\=%B(&7K^_R^Y3%[AUWG,6
MYY9E$EE"7S_%/\8_:0^]A41:&^2M0-%P\8?9QD_T/I,$R( ,CII=OD1X2DPF
M,1&LI\%>$)Y _?YE)A7NXL#U<Q :F<S3T]W)U3!3^?1LQ*"]KG$2H'_.>'L
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MUWGMO%5G61K[/NG<B"X$MV_SI#IL^,SQ-%-S2K#I!9>E89R=X$W077Z2X 4
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M=X(HS/:>O[Q)>5#S).\*<%[F,346^H6,S<LN #?5;FXI)4>%72'_J4U2P#]
MJQY^O[21NM4T9OO@BP)-8XT&5*&V09C5R*.\*&CP:HT8W!*.RES&J"/F DBT
M%:L>+JNRR7$J#MB9U9$8<59Z1.SR#8&X<^-Q_I3>3(_/.MQ_M)L5=25<7N4]
M$W,4^)!%7/KW"[_#E?7NRUCUT) >;)'2+]='.-1E_=]/4KX.[">KG( 30ZDU
M'Z'9J\W%P2P;(_HB0]X?Y:3RY"\;S4U%I<9/YUIX_IHL']B];S+EF64@,^[R
MVYJ4&UIL->A2.C\$]:5G215.>5]&3?V'#TJ@+?<_\UH!7<:[]]T+LIA.]_*?
MC)6+^4UU<GCC*N2\=R9Y"UR7'%F])@XMV^((OI'"I<OU6@L":%M'VGJ-Q)F9
ME^PU"*P7GAZ=)\_Z7 "8?(*/5NKH%!*NA83L70^,8[!&H<\G\Z':^@3#@3X6
MMQ_]AT^;X\:[Y]W;/G[@][Z?\/M##L4[&E L"\XZ>@>-#C%GJ6ZPOD^D^)ZD
MLYH@7R,R$'=\ 6# \_7PL!AD2:1[O1A@?U^0:J^E>,C%:C2 68E!?UENGS2M
M6D:3''ZJZ'XO-<J<%+:_-Y5UHEB F30:_W60OR_66MJ][S[@.]#)"..^ +SU
MZUL!,6FENNV$S\_]<S5#;^Z/NN\YNE]5*>M,+DZT\?JSU4&6+R1$"Q[GD>W@
MF^.(;=[*.1;8Z[XWGLOACB[68X/]DSS4%*3;N$#>J]+#_WB8<T_%L3I/#'L3
MMK;-5I*_]]$0?-4/AYAHQ=]8S8PN'E/Q\/9)2:^=NJW_@9\O^D/B1*FJ5%'6
M[[X[JVQC\O"\@<TP=ONR\:%[L^8R)?%=?>,='>OWR]]_1K2W./]VJOJ\]#U/
M5I/9E/;<]6]2\_2N@)GD$N_K8S[*X^(J! /4E&.IK7@SH^:C8TO[6RF [H'Q
MY(]?KXS71JN/K/UN%YN-E2A-N-TMIGV6DS>6P";M2632WD#T_/;#0*)8(9TR
M\>ISQW/6B483E:L3E1YB]J"VA@B%&QMQU(<5Z=M]%L*O=$._D9[V31ECS;*P
M>'=[46.;=!$]=XR=)K.18O=_RA08\.?%NB7X)?V9IVPFKYT3:WJ"U&\1M,'I
MH:LV@MBV+N *XEKV]LVFK2PUEV37GZGS"?6C)3X#J4HG*S4(-B7/'[L6^H8+
M).J9EUI0B.C(/X<(6<,HD1M=4SGU":IU\27"\O7&9MW[GV<>H%J%=9R<M4VT
MM40VOD9IV;";\41"J)=2VR?.A$2'U43O\EQOI4*EJI_(;AS_7F9S?(CY9*(@
M]?.)ZNQ*N)K3N+^UBYYS*,^?/W.+ZN\6"M6TN5\R*,J.YG/B3[4)4;)J][Z^
M)8);;.(Q6M.*IL_RS/C2G\4,9#/I%*".)!AHC_I"HS$#7QWZ;03K&JWE)C=Q
M/L7#GZ0M-'_3%"K>S9B]<K*CJ#C O)*3%6?J,<>%;[?FNL+1*7U#UC")(Z=\
M\GUN?5QKW+ZPLI9H9=8]-<[ D17/>-3B[6_NK>WF";_>LE:-PQ3 6^<8@P 0
MIJ[SSL,'X!C95]1@X887(()/YW&TW@1OE!#?Q$Z&@H-.X1/W*RQ\C\L!<Z,
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MT_')=]%\G'/5=!-,N.%%HID[_\NW(>D!T_<_!P>ZFT_!O%<()3%A_/@]DFI
MO^FKRG[M"?0D+":Q.N\@[593PCTQP_47C7!3UP+@3\C?OFV"2&>O&Z3ESK^M
MX!*WY-4403PJLH776+OGN>$N;RT6=47YY\'O KXIL!\&#5B<->&JB.])=&'S
M("J".89Z=?_M;KLUYJ1O&BVQ\WL^,SAT1Z/O2U6Q52UR3E;Y]MYTTZV;_3\-
M@3?/E.( )-LP'GA7"1AC*'EY>9"G;061C+Q.X/3B7@MFZQEA)6BTM&"2XD[B
M**TU2\2<V?=0SWF6C+@L01(_=GZZ'[?A)/X6U9!&0/^4[%2L(F;)5MR^=!<>
MR0-NQ[\)(*=9W=I5<.CV.U#,F6.68<NUI$]K VL]UXHJ&T5_-[W[>D_,-W],
M3XCR(.!OZ_0(1=(/9"UPQQ<;@KN%=PK"TFVC@?VYVM:3[=;>*R!&<JH::P*_
M;C8//7$PG)R>ON66LC"G?NL2JTC7AU2SK#-*$BW9ZU+ F,A#O230-1'SPRZ-
MK&3G4RULRY]M9/>1!35<.=.:,&Z@MHT4D5R,>O?6H 3 X+XG(D1Y*/T5C-%+
MGFM"SQ"8P2L@ G/;_39L#PR.ST1G[].[XP*R-K*[RNQ*-\\\/_H*9"2N78E"
M+6R:9%L-=UF;1T3LYD\H_3>/4?X/#P/<!C/\9H7>EZ>N9,'Z]A4[_IA.1UOA
MP8I5WM=I:3GDC#'^Q5$(F,E-"1YM89FH1I]VE8E52F;8D":9"VWY>Z A- 4;
MW>_03>+(FI_WDGPV95SE<9_QCU9B^,%J;<K[D19$OAH-7@8?WVN[(%]3MWFF
MDA<DUJ*['^_8?XJ>S! +QJIS=;Y>A=PDJ+;KOYRYOH#F#U4C.AYP<S^@O.X=
M\1OR9'1F.HP:CT!? -B*7HV(;)YUCG7^>$7?'BXUUM)]$"RL>%2=W:=&,ZIB
M[>IQK*_PLSS[>5LBBZ<X=L*!XALU%\B0!I'4[H5!]JI=:67#J84N923PB&LM
MO$R=C-"K7 BSG^7V3B(*4>XKB?[VB@)Q.$KU? IL=#J(B]F5=1%\Z0E(VD_N
M@CS)"S:=K-'GPA:-M@XRQW'SWR?[2L?KVH\U ;K_-QYAVQ_4!)X;%P"A[E'P
M3@M>] *@-7,,_R_^.TH];DM/A@A@3M(W),:KY"W2%1*MY!E9$3B!'M@YO])0
ML$FZT^"^2/<'=Y/?=76RRO3C;M(OI8 K[?LXY[\<)V$+%X!Z".&Z;Z\MYK'M
M9;P1.F&Y'AGE@D_T\Q.UON(.IP1'JX'<9N1F3!E=4[Z+E0E/H'7G;ZZ%1H=Q
M1V0@U/!DYR2"W +C7FQ? (KJ3#_#NZJ7&,=@<'+>+X</17DQ+M!W4/:11/!8
M=(?;5/CM4&GSF;T7DO8]EUI"@GY=C:#HZ@.$0LB?_FL@1?A\$EWZ.<\@5G^E
M4HUM/$P.#^FWV(]J]RT(-*%T*GG@X"ZC^]FMQJP]5=<MZ[W-BRAYAWKT SE:
M1/S?$QTPQ@(X'X![2FP'.RW/ZN-D,4VO"998SI7J3^A0_0%O?*%VFDV&),/V
M?/Z[Z:P7KTX8.45_3U0A]G[^% C,N+;T\.-7 GGB$;?Q\W"\P B!M0TW08R$
MA2$Q"3!%?%ZG*!82"7J2MC/OF5T0:+%OC.6)+U.OD]+D7-HX]X#U\>IE>#(W
MZ6TA42D\-SO(XY Q7Q=Y/'?00IU-<^NT&E?84-:?+\MTLISITINIE5G%Z]'U
MH4KC6HLW?D%QM=^#8DAFXQNMAT, N 8(8VZ+%Q>,1O[E>F10H4#;,@1*><5=
M !IL^]WU0\#1^==D^LVOI?_^J4LSXV\I8-K<,J'U6: Q8AK GZ5))W^)F<0/
MTR#/H80\AR%P768/*[$B3)4T< &@627FR@R* ID#"_7&":I.H%@_$(UU3'7G
MC)^'/_LQO2GK4\]#EZ87REH"U]?YT%YX"=.8"X#K+IS$P$?,?A%&CX?T+,G@
MD>A^S%XN1K_;1B$!@E9]1;K98!FO'&JX]'R,4[ZO=V!-^4O<'?YTJ[!<V$LL
MF,!]&7N"ENS-?TU2)I*7Y,*& ?\M3W,+NX:]^LI$_(]FH9N.78Y9U..X;EXJ
MS?"%2+LH0#AP(YY$NW@!N'P+[_6W8H68Z+<_GXU.?YO%@AEK<"4\0;6=?_#<
M)TBOY'),K^Z:R&LQ7*N?D1O7=S/4MT2QVLN#UNAUR!E^,1)5I*:,3\?.X(SQ
M!N>J@8(KMKM\WEA?,XSM5_?DJW@?]T1!W5$_@^!M@X[L/@O+87!]==B IZ!^
M&<?\U!UOKO'>YG2D'1RU",<+4N]:DM7U#S$=[#9"&S;)$9H1Z8NE-$JSQ<"C
MJP2A\-I=<8)LN>6696:(-L=(@-3@376D<->PM&T6&.,&[K&EP,?C#O[:'D%K
M1D6R:*M3CBP*T0YPM]JMCH:DE0M #ZYU/ZG=FK6R]44J)2Y(TKXQ2EC@$3B#
M_5G"&@"N#<=HPY.6,4; 1-NK)-XF<E! WWF-J5O1CH;IXD!7>PHVKV^,;64I
MZBP,M]0WMK0W'3Z9FW*,V[*[+?*MCST!>B[\_]&%A&N\\OJ@,O&;0ZKI!>"5
MK,1R@>SI+N*7?&+8+:N&% >>DDJ1N8K?/WJXW@2C?(+E04D EN.3/B392W7+
MHNG78[N7E@LM+"1>ZKZDBN9^R2>8<H3(#:,,]#^&L.A6ZK-Z',4,]1K=_9%=
M9E71GY<@SZ1=L#X=KC8T4>504U-?'_MJP,N+6:_ @?,QY=F?J@PZ^GMTY;3.
M@@" E*Y@.& M[2MSP]H%@/LXT;*'K!\D$?=@)I6L_DP4^,;2YG<>6'_K&]W6
MP$8'P9=\?-PT!<"U0]PZ61W>_K5)GK"YUOP=3O)6OL6S%!%>X(M1@^=$R3Z2
M(I8E06D_6L)?5=5:5M]::;'ZQ6[EYS$)EMLMS9,2GY.@/.I)?P1CE2X LX4D
MNC;R]Z9C)'<K,,FXQ^1=S2,-X%KO?,3VZU:V@U:144NLEJ'2FLUQ4MW;5I/U
MEAT.NOJ:H2EUD "JXL7,'S]8$8E(U B1\SZ6;< 6+XSL%8=#:IKQ\< ^UT])
M![M\F<838L?YC/@OV\;ZYD[7O+D"Y+,+FEV_43VL:>FAL/UEF^"0! 1N9TVR
MLC99#"<6;)NVJAS,]\@.=:QQ^/>.AF:8,Q9%YKFN4@\Z_?+.&:4^F"//EPQK
MWD1T"L'8B*5'R%EZ$NUWS"O@/#6N.(.T )EIX(S1JD&' DU;[D.B'6N:A'F1
M]4_$,C/EI0;<.;7>U8]^?(S\"KX!1S7:8EZR$6[\..^R94:B"D$U,Z_AZ/R&
MH3!E<>?MKC#NB9T&>C,]6OYZCL:T2K=WT(ER%A%_QDL9MV"+/UF:$7BY)KTQ
M$C_9/[F2G3?93UWOY(/B@J-[#>BF]TU&;4UT]B2/AB!/L,=3425!]A-[*1*:
M,8QL\4!FLZ['A:#)90+K?O<2 ]:%P%2!FZW%=J1'#J= ,9;6DP[-G5'L#-DA
M'MX.N)!SW3M&N)#F0>8DLQ_?&[74P]P N)$WX(;\[K]'XYR@^I)N^ND6C$LO
M/++SUI2X1XF?^^Z=':AIBLVF1<2=JP&O3(7YI41OWVAZ:<5!L@"C1I)/06!4
MV3+.5@Q\=+A*ATO&R[J88 TN  0FT&IN7G,3I?9X0S*K)=[JY[B,<[<UO7GJ
M^C?@03EM]QXCH2VY*A!)8,=> /C6"2S*I,'?T:0\F)TZZ!59#K9P% K(2OH!
M OEYS5KBN/'D0>GW<1U8P+A^[S]PC\" GDR.3H/J[  [UR6G(93UN,V5%*8A
MOI_[='*'IV587Q(]&8Y2LY*Z6)6 _<D+")P\/E -8.7.6K9""Q-'=R@M/)FH
M$DR5"U&4516UF(S*5D@<9[Q3S,RHM=^I.P.E_@9&106;1&.E20SLQ':5$*R(
MD"PHQN8:MJ2O DQ5_<_3K8/N@?, DPD!#S7ESWN?Q46FQ]6Q5Q>B@)QW-,!S
M+@3F_6Z>R]B1G1OG3P+A*[)Y^2%H*.D&/NO/EK@!K[MC:UV=>Z[:XQ/*%U+%
M:R]/?2KXHI19.GUHJ$'G*G]YV#JY23/+_PBL[Q9C^+N?D#BV\^YX775+TPX(
M0'NQ; 9;G4#0BR'?*![AZHH\I"X_'6U=H\PB*80QP+M&D1ACR'SJH DQ!^D"
MFFOK E]'NL<C8BSJ@^5:R$"07G7]K<P%(/H,-O[5#CFV)WD[3M5T2(-NBRW
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MM^=NR":=KN8EHDL:L_<9GR^_;*X)J306/XF7S-QANF59E(0W9PH&XJ_K$WF
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MS 2YS4766V]1(<-43>([97,&EJ2,/.269F?5:B>XU'A81-?NB;S:A/ESS,+
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M64>^M_GAR9XBA:"I/K5I+Y,'IZE4T>O/47?U>)\^%01<,KSGT0\3)UI-M,M
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M PX7?5!9B8U^Z1I\5W\7/M<_NWE$GU)@A_Z5:B F2)BY5.P&$\6.5C9QURV
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M#6P.2'6$!OO]U@%>)@.82&PI\;#^ H#XA\R!F'RBVP5 <^\"<$"$H\"O376
M'!> 7E!@/0$'/\6"\%\^@%RJ.5@9[9"% 8^>UN(O !\MD.0K#F!AHTB"YY&2
MANOA*]BC5PK3C5?/<R!QPI"XYXD^IYX!P)>OU$E<)\5DC5T UP=7R'U:,T_3
M7Z*<$>C,4Q&>:O8D: :&\@I4W=GPI<TPK1<54LBSY3^[U@)GQ0_W=O*$C57L
M/+H]>>/VU,8+(9[AQY;L@<,4.H+,S5WP&,Q+E_J.[*<[(X&KEH22<=6S&364
M*&9F=3TQ8N9^#6+Z_KO&>N\L&C6Z^0V3\^4;J?=59+ZCXU>(CM@#L\F^)FW^
ML.VF0Q8YM#>KUQ]:/'I.__M@(L7(:VU.O,?:F/!BSAR18&/X/N>3Q2.+)?1D
MN "QK^:/?.1\LBL53V^NX!1)9/<"X-+09(G*ALB?67(,-38T.WZ@1/]]VK3I
M@.NJ[H1JY%L&NA@VCOMN/5;U+'SZPHQAP@# ?.--Z*;CCVME@;H]_!:1OF4-
MB\KB3%S&4S^H1EIR@ IMCOZ+<[-%Q,^MK0#I*'S,VK=VT=4<M.Z(64>Z<D2W
M#:W?S[ HU6,PV-;"VP#PM@N0'@KXDXWW0($2<LA&2MWS;7L3OU%H^A5N*UF7
M@ V=P@K1=(2.UA:5Q&IUU'Y[P-J?[)-<&P/9RP7EPR+R8F^4C]S[CF4?<@HO
MW@)#^_EU.5_U%8C&L4O^8KID,"DE*111!@AA. )':;."Z?'6OZ\E63R9%#6J
MNJ.C_2+@TF>P:9WR(_VJ8,__X442EYW6XLRD9S[E[@HR'<65+ZR<GFMO[16J
MO1 + Y">8N')L)N[G5(MROP\2$6THH:8V\N^)7N?J%<_HBEJTS\Z"&?,P'[E
M2K:I^&OS1N5*7^%M:TUUOEOW)YS-,>Q'<]EVWE"[2S=)I@F3\7-FMV3>G3^<
MPC-WV]S <_+HVY6Q X7?M>-AZF,L4#YL2MR#@.;R\SQ/[]LJ 9XYZ:45#7)'
MZ5K2<[[@.51O4]>_R4+;G1&BMJ%R6.CK-E!&D.8%  CU\[:2F3'2NQ+&JF.M
M1^VW[TUK\L#_J_O!&D^?YU/_*MS7\#$;WA=\J/V(\@E:B:-\ECK?,6H\L/=F
M[.>)AMF(E3C(3_8'&J_%5FZ.E0V$3!=O)D!EBNY5*%>7WHVEK'PTQKAG&@8P
M>(^FJEGK%$PQQ&>L498WV[3+ DR]#T5$A!5:[MT:!(XV5<(8 L_.'L_X QV9
M&SZ4M+!SCP'E][^+^'PG2E)M>^JCP&$-Q&K<NRP.Q^N"-]680E6.@5E*&\'+
M:.["D9B[OW_PGB^B^^(M)! 9X1.=/FBK)G!]<EF_\&D?=]F'2ZL&@ITW55DB
M*,:$/'[[FH1ULD\T#<-FU).ZM/COU#A.#(M^/,M=\-$!JKG#V;5%\#6:T@'^
MPU=X4_3BUAQX1"'[,:7+)T0I7 HF<M#^6J;T_'?^);X!81P)?)SQ9('LJS4<
M"1WZ<'CC\1CSEKKR\MZ(U-#/LBY7!SW8^]$]%PG!CQM-6U1=4#4,;6^K1]'9
M8E]K.W;/R?3]E<MT,AT C<D5)C;\S#=+MVQ8%EWSQ!YZ;Y7WK\R:07=7ETP#
M\^#"1O7_&XK^=U9?_%_68(_@W>X(K[PX,.8A>)9VS0)M@LGI;:6-U_18!;('
M<MRM&8<^&/^:BB-=QU+SZZ'[2/<;HM .&<5Q9NRC^193X)J P3P.V"2HMGEO
MD: ;./9@XAC,!7V&-UF%"'F<F;_[B?2,+JV:^WNJ//V@ZU9S$CXQE<P"=JVE
MJH[1'HY!WO%\Z"HOB:=>B;]Z#J7RGIM1H<%C 43V4A+#&'88ASIO!'G*S8VM
MF81#@:L(>MB8O5C+.%'TRY:"\;72LOG;_KC\':D5V0VSRP9C8K]HCU7^XZZX
M.(_Z/9EF.%K[J=D,%<=5%I,E4]N3%V%F>C<"MR0IK:4W\L(131)[(X3[@0F#
MG>QX/FQ"#Y"]71_3^S1+#[OQ=G7XAY<74:5<]TJTD:>>,-T;K[KRQ)6\]\\[
M,__[EJU;@)SXY5X2:Z/;B<=L^O-*A_I[-&NK@YBK8?[I(4V7?/+886*S@<+=
MGQ.+1YN]WUA;1?X,R5K/==#>85H/-=B,_\NA_ZO]"58?_*DOW7;L1I72.GK@
MR,.]L@M+E I"MFG@U/(O3_2#A#2-JPQP2/;.-'=#-J5O+Q :R3S^5/['O)L+
M,Z(E@1R#G0JY1@=URZ-BHB.3LG_2N-[_62GD^A.9]PZ@!@1_@8IC*GIR&9MX
M9GXPGQ"E-T;*P(Y.O'S/>!V;G^=&A4M,-#H%OD7E12E>\]"ZICSEPL> *^,>
ML7S5_>F53UHR&2MHC2-<C._HZ4^=) 2>>LH(U74>TZ87QXK4G!!W?Q^/A74R
M3BS:/PF!Z8IRMJ59"7C)*X>?VGRK9IS15@\<,UNZ(2S$QI@B4P4/7+6H/:(5
M)Z1408C7L(A$Z&U4FX =V*R]L\[#IO!F.G>RR ^^6^G^41*:E))4.T*@'F'>
M\:%/H+L3Z/M"0XYO!(&FWYJ5?@/*5"G,?+H ++"><G?^C.2,EZ?929/*F;\C
MK*T^7L4HA.>6SEK\0+!IJ]CM1'N*]B3C_'7>Y9G^,7ZE9FX0<YL#'L@Z27'P
M+X'0U>$^?I?HEY;NUB4%OIE',FVTR?V\'W^H">D,ZFFR/)D8(RD1M6*L&[0E
M&[\UU;9/>"Y60\?>V0\4,K1\__E%-9'=\%AS)AW*7*LB+-,^#7&Z.O&@+GUG
M[?#%#6Z[/N)^7]J,V&;R4H;1&J3/SF10O7Q<L59^"V/[7D9&1&;#72%:2OPM
M1(SC5']1=#X>L*J8QX.OUH_9RY9M+D/>OO*]J>DY(0ZU_IBO)I26Z]=V)SWV
M(%DV,R#B#*+X]?S.WT_/$V\!% H=6-4_,IV<5A>0.(CB,;V8P>K "+K-Z=)$
M7IE/NH//.,+NH%]&W@*&B*P<GY[VW4WT3.*B_2QI^E>2,DQ3OQM(?0QB$;.P
MGDVPFN*,'BY73I/_6!ZOW/U=\V@0X*U:#7EJ1F%ZIVQ%*BR?18<&0+SN2I9\
MA603RF]Y[,3;&$148>J.^CN95_$_;^0_$Q]&[W#1\AU3QP/0%>G8TH2&"P"M
M:S-_QI_:N";UV?G:OU^] ']-=?Z$&=P(E=[\Y(-+;$MM#83K)UU]WOVBT\5J
M"OXF=G#(,KE0T(6RW:1/6PI+FP2I2J[P/6J[GXJ</[P:M?XJ_@Z!X\? Z^DP
MQ=68?C 7T<Q[Y'7 J_4B;YN]5L_W4&CA_I>H 8W] [ 77KH;&1#1X-I0 ; ;
MG8/(6L(.-U#_1WOO'=3D]_6+!A!#$9#>"4I5J@*"M(!*$Q$0:5*B(KT$I$M(
M$*4WA:^@($40D69$"" M]"(@TIM "#9*(!$,#Z1PX^_>F3OSWC_.><\]OS/G
MS+Q_/),,P][/VFNM9^W/)\]::_N<V(H%GP+?<2H^007[XFJ%I#_)3L,]+- _
MI?G>X<[%:\P.7S);*QZ8>/O_9I^]W=!]EIGCJT4N"Q4LKVT1E<MUX*@JF]3/
MCF&"J0!K:U]GF=WTNL\UL'65Y=Q\?O=V-%.MW3//._'L!^WG\D&'G'V&%XG[
MCP/S V^0SUV8N%N?,OW.2R:CZI&>-:0OJQPQCA_+:NEX(S;;XS#VQHCRSZC"
M:,RO$W>,1;?5&;BU"T!U+FL 20_@YLU17@&C51OB?:V\P\? 9>&=MD/XCA)B
M7A>,,RJX+S0BHP968KH+%Q!(=.>,-N?F2!QT6VI)!1UX6Q)1F6W14:IM!92R
M,_9YMNV^?#K36<MA=TO>D@4)="E:X18NO*#WUHN6>UTGY[93%0)^RRY?O!8A
M2:LO+B]+572\9SO EPZJ*RU-#ULUDHC OR[A-C,CJB5H:F:$T<0^7Y0YU49.
MUG^'^Z:7.Z@"<(/>U=D[)MC;3GX'H<Z&_[=_/75PKZWU?2!9YK[1]&3>11X5
MK1'XU>CSE'O-<F>L_TO2SXPM?9[2X4I70M%Z<N:G7NT=53E];Y^#MH:-+;TP
M=)J66V@_3$#K.0$UH>;I6UBS]XLE-G](XK<+^+@F^(?*9_82'AM2Q<#P9E/^
M0/=[6NZ<ABF\_$>TT5ILAPZ']76:+BE+ZPN"9PV6[)@1V?B]].D1**9J0^IV
M@L5%&8]P7/#-"'S'(R*TLUW!W"7V<N\]OP=Q3*,5U(]&U)..QX1N1]TVU=DP
M>0!-T_=8W6'VO:\_X6(2G/N]IJ&Y\743*]*>(_FX &_\0$XFS8<E@YC4Q</E
MPZQ7:&M:CU0?_9F^T"<],,HAP3LX^-GP&<$\1>RL:6IRR=DJ17L;!MU69UP&
M"5%F/=;IVNX79BK&T7MO \I/&HSPN;2V/)]ZR1Y9),[R,A(=):NHW MBDLV)
M WW+M@8Q#2F4@\STB8N75?IZTP34RRR5,R.J3I_Q\E(H ?&[-B:MH3FC,C<L
M#2 .36W-:;+]C^,[)?@>OG=Y9:#K.%(L;'C6U3]2VU!L7#8F\/R,8_SAJH5C
MVS-#QW1UZ,9E2)[O01(,>1GWD9W$;V;[.RAS\[NHVTJK[+>0EP^D_F$BPS+_
MA+Z*LG:9&F^T8'T9?UK'\-YS(^&58\7='3H M*0BI2WD6)-LPZWHP%LVG1]&
M++-E$.D2V3J?44RPFU3WINRU3MV-WLSM)]4$X^95ER)=G%?' UHQ)DV/A]=U
M??::3#Y]3J[^PGB+C>.^=-%]H_7-A3C#,8:B1$"WF>:XXW/_\]FE+/^0(/%M
M!O@<?G^A,WH]^[*=/%_BV#>,QB1FU>#$T,[W0BKE-8LI.O]\4XW5.0)!$QX4
M"C#U+R(,B/8%\";B<H$X8<'UDB7O3J[T3ZRD?RF#< T+VC>\Q\3)1QP$ER@5
M->LH*,Q>K.509'IU,\P>8@3^7?'?("?_IGR?J'T"YUJ&RVI>)RP#RKLGD&D%
M[X1Q4&/7)$]?C%,?JHSR[UYX4W<O^U%7QKN -9ZB"SGY9+&#>O*G(U".*>TM
M=&NE0QVUP83^ B:%4B"H+L01"/<>2[1=2>A9A6TE4#0 ;R=@\M7&82&#U-,U
M_? N<.9?"RQM/\TG\-%">J93F7<L!,OX@G2&W%[37QV!NL2PN/J5!C2!B6)'
M_=N?)YJ^@N+21"<=@1JRNH==TH8-0J]&IO+P6<'#WG^=TWK!R99QARO4-X3[
M"*0E>?-C,*F"Y0AT/-CW, Q&M,3R;ZBODX,W'%$-D*P[;5,>31EPN'33(TN*
MIK8V*#J[+[##^I0((6L$P>W_?1P._UM5LZ"N]8]EP$)%W/=BVW.(Q.W[J?I#
M@T<@IY"'8WX@F@Q#I#>H+B^Z)E6:]I;*?@0ZML7X4PSBS 1=ASY#UVVR:#,)
M??OU:CZD1RDF[UY3L://$2A4O.HN?O5=JFQ(?-7BIYKBXOTC$-&I&%!"4?EY
MR/& -0X.*/%T89-N_>R"I;70,I.1RE2]J1NQ"MUK=JV9QW*56L]_&0NYZYJ"
M>YYP-I/;B0GV4DH9L*1841V.0(\*H8%CQZ@LM+*&XOE'^(Z/JA4AN&)Q(,DL
MS9&^-&Z:5%(0RW*EX:.(MK:>'&^;Z&VB9:8%>M)ZH9K.1?I7A_&O';SCAI+T
M*894-]1X (86;DEAA#[>\56+*XVW5/KUD'E5+KEFT3$D9]C,M27]VST;\-(*
MT0D**)GUP^?6R(_^=O./4L,9=*15 RSD;E+_0W^\/\%49\$_ZT144J^4X&3
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MKR4O&:D%)%0D=<%.!(51WJ3.]-QXKH-Q_L,6]^+:)R<FC/D)8ZHK8\QOU3%
M;8?*Z^ 4EQKYI/+%\7EQ[UZF[[EWAL[\4+_Q@"7S&1E-%5*B<RQ27!'G:.\-
MV5%=6E!<D2[T<0FMC*X^X!^"(H'[R3..AV:))GOCM-S/*KI430US,C)\[*5
MXQ[[2PD;<)\A0Z_Q'U!=?E!<+E:B@Y4!G!F(*P'+KA]##%W+2]-D[%;HU Z)
M#5\#;&)BQ=N%.0LEM[EM%MO)A,%6H<D/9LKJGR1?I/8S+!N9B#!Y$]7:TP))
MU73.Z'^*ESP[X#3I[;DP,>\G1%IRT5.]/N/S^H:C EA&BQ["P$,K#V'$FUD)
M*PSG\$+_/4O+".J/!E&])OZ,I76(IYD T:O%W+X+ H=!&$E:6U/.^L1\#OEM
MX-KM=R3$*^?[P:78+U#R35GZ*(PY13:'6-\5+?LMAY;D/;5ON,>TL_<?R)R@
MPR%!.>#=CN>Q =] K>&'4S7G&A[SW!<6]/L($^\+UTX(;]Z:SH]X7^Q7(C<?
M(;E1<M_B6KH-N.=6QDPU26U X9.*9LNS11.?QZB!CJ*L>)WU[Q47-V)2#VFO
MB4W=/!RJJQ*>,I3J1Y&5[H+B==1KH@/C9M?]UU L45UM/%6N?I85<H2Y5"=>
M>3VI"0=6Y\SH8Z$?8S(-&SW2^HY  G\.],L,_O3N-A2WW556%OASI_5;VETB
M^%+4?@D75(!J3(KL%3\"U;G$EBO_R+OPP""1!OSB;#DYX6GZD^L@6&D,O24_
ML?V][J.]2_+5% ?H<R4L40(EEI,D\<1_BZ;1]<"Z&POV>S#E*_FYU;="?W>#
M[W1]-, 2V/+T-ZM*UC_43O[)BP>MJT7I14JDFDBQM.I;QK(MHUMY)_0K8!HQ
MLNE?/8HR!J2FF#8@G/03)K%PH5;\+Y$^=8N L'XYSE.BSA7;'U>?F2U#"F/
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MVCYR^(]7S*9_VOD\9& !,\N%N26CX>.P+]@Y-3H'@2+!H"?&2 $@%">50WI
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M]X8-?/#B[T$LOCOSCFM@JE 9G;V ,<596A']-'TX,G^L-^L$8]G\@?HF.'G
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M\?%$43<G0<_;YF>-CP6;W*R;#*.=E^$NN.-9T3WB5EJ'B9^0#WU9E\FV=F-
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MOP;^[SB097+WYQ]-QAZ'.IK_OP!02P,$%     @ Y8J$5OBCZ1WHS0  4OX
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M:,/&;YMO:5*"@O_CR>/92-]GA+%OKQO$X!,G"=M0O1X1G]#X<Q6?+)7"&H<
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M@%LC2#1T+OT$@,<I*N]$61+B!LBNBBLA.LT,'QW<+/Z&-O#/Y4_>A5IT*)0
M6W""#\6=KH,5&+9;?TW\I;SV^'GKI!,6[7N0U?+$VJ9U$+E82M'2[G[1DI[!
MB&6PU.+0\UHSCF60W  )R46?:R;'R5$+8E1C3B'E ._&W"H6L35D 6[!\:L2
M-DMW>P+V1/-=Z7Y0">B^G?RZ268_CCDXF?\#QK&BUAE_20!BE S6JF.C59XU
MT^,3%9N]HG<83GE1%D2MAKZODZFWH6,33ZAE%<5)<CL;T%*^N$-%W3K+J)-,
MKJ=48$'+$=L#5@,50[W>S;Y[JPEC=0+G1/RZVMOZJT_6?+5&\^WB[%#R=F=C
M'!R'3[K--.*Y'V"ET<]$\%2F.%(T8>4<29Z8$1K&+34-KA^C[ZS+)U #BG/L
MR.#]S7]#DP^MD&JMQ$^'6TL7#?ZD(K&TA]1;_U(]PL4KS>??JM,WK+FBSV$5
MZA*$15-EC@'CVPN+(U<V+R5_ORO?XMP9B3^+WV-2CDDS+?]3%[3"&J"Q1#+P
M#5\(3E[!,\;<1P"*%PAM%7<K#K0=S]F%F1PM;[?])&:<$QSSW[M/YG<S>>O-
M5H;K 9AC'9)PD#BBZ^SQK!*^CP0J9OD= E(.(:#6=USE7='>D9\V?SAFV]1I
M!&+9<MM_U/0G5H6<++;#'+X,M<QY\F3YS.0&/7_S'\'VSWJS6.I+%@TUY']6
MX.K\UW],_KNC_QO<2&JG9^0)DO)=^_M12Q"QL2G_"G_5:X_AI<56^[YT3CIO
M_ZK9,X6^]8M VA"*[.IXN5L=GJNKEZS)ZU R]]VQ#!4;^I+#AX"PY#1W!$;M
M9I!@BR56IU\G$KQD96'$POUDN(P_$X-2UL)8H*<%T^%M+_> "U>40\U/3C65
M(Z[I6?Y2?[<?QLN-Y#EO0[0LF3\&N1U!Z,57!3E8[G\AJA1Q612OYW2-$V''
MLW!2[?+BFSCUF0,VUJ--G;#I]V!VC U2\5#K[GV*G6.2>,+@-X$1/AJ<*V-[
MC6IN<9*&@GVU\/G-)$$%!0V#\BQSV@2Y-'?'P?E^K37$EY=EZ((TFQH:EV8$
M'B4<4O?GJ_L-&JH>;MM*\9:M96C#(L_E+U9IY1O:[%)XN)Z!/2]'-5-):9)R
MDSR;+TEWE5G[I)+I924S4:1BEUJ()6&?+-,=RX\6%;W_).HOC =Z49;_/$HZ
MKWV)ZLRSNJLN3+(<WWZ6@(U^3!XNP]R3@X:L\4P@9($6?#<#<1/W31M48!ZJ
MLV.S;HUF[DQ AINR\J0'LM<9?)HB2_ E9N5=C%&0E7L6%-7T/18H:67?LAK:
MP?%1H_SZHDQ"5$+4KE9_59V>W<8K6SM<;CU)084:G9HFD+A !MQ!5S'+G;RV
M'>W/Q$6=F#'ZV_&N<8/: +1G+!RR;&2\9#JPK<@+U4#E%R 1_]*GAESZ# .9
M(D1$.^D.HR9"()4=W/.;LXN<JU]TK^Y-?CU#:F2SPNJ<E-U: D'$"$$$C'W-
MR(SS0%J6(M.0:+Z\B\0\?A2RG_DZQ:B^*M)6G0K&0[7UR)ZUKE>;\VOCF(7;
MMFDXZU@[L]E1C"03 5V/MI8G>1VGH8)B,N.N.$JN^3C>HJ4?H<'9&>N_+ZJ7
MAZKQ%NF+K'WJT=GO6S?1Z7'>?,!X3 5%8'2TL(]/,X-WCBVK_/:EW7F7S8\!
MMIG&QE#R[>@+/A-KV539&'"M-;VF$%R4Z:MF?0.3I)N;QW\N;[?ZS]2\4]GX
M%L*A/8C#QY2*5TU3%^5B0FQERQ$Q&>.CKY"**87*.%[L>I(1)C5\NHCQT2S<
M,[CGOTX>$F2S(M_\)CFFQ2]R2ZV9]?84-^1#W:$*MH[(X@./5AC/\Q4])5K/
MZ//JG^BTX!F]=C*HMQ^?1ZY2@P"+AP#<IB7580Y7P$[@"8#Z<PU="@&_/9X
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MJ3KB(NT&7CY,AAI!O;>OT,:"2,9L%OTEL%79_O4CZX+]:W7#[=GLDK8YV_<
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MK'P*FS?""T\*!R*C T<F]]$[KEC"<U+U">\$>E:,JK"1K6F*E!A"+S9 5O<
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M9*\K?!<5.IR>VAZ@0FOQ0/RC"TT3V#*58.($*LJ\O<L_/<V/HOMI781_$/P
M-PPS5;R;)Z_@/%!]@G4Q4+$YT65QB=N)EO5EC+Q)#]CQ%N MT&L7R2!!G<E9
MONXH(8&?$V1G1?>58<4QKR% #0G093N7="R$U$/O\_(=G701-7M2S>IF))-[
M$^=9B^+L5!]:/.=GPXB(;;F$)^6:RX!"NYDQ^R<EU:07!56>F W.=H7R:,**
M=ZQZC!I@^!EYEET* 9KP(=+45RTL O@2:GG)3-Y$TP!/B]R]O1=F=/3]E30Y
M3+UOO_CM,9WE9.MOLF+4U[B,JLT^BA'2=?.;*P0)#;:D$2'C2<K*'GZUU)T
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M+<5&*)$[HKTOB-FKL^+QXM"[&#\R8KZN@SZ6L+RMXG:*=E7$X/NC=C$6G0J
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MBX,K%R'[4J*FAGTGFD(7=U/QFZ31A:/BYP7\H[J](DZ?XT:$1.IIL(/&RT=
M<VEGG?5AA&VO:\+\)J 4]W=BD+<>%-N]>O%UM6<'%0+%KGQ4\5J!H5/5-_EU
M5L6LXW2!CP2X)1W$FV%K;/(B$G\VV9C7#2*8!'_XY=6CKGR=2LH(FC-="' T
M"8HR1A5M9)JD.'6C(64VF:>"&30ZQNW*8N*CKIJ(&,#CM0OD:4M,Z]<TXM^[
ML#/NQS$TA(A!=&\!LF2:=.Y! NJ<*C$\6$:?BPH_)V[GUNNV9 8Q/Q_$9"X8
M.VD(GA4"\7Y$97X\Y/LX7]?QVI+,^NNT>:*'72>N!+^'D0@S^J1\7]VN1@]8
M28V.^:CC24I*RFZFE\8UMEW0=N7V-'BZ=F=GY]&.(=<:T0-C<@B.;%?%IZ#M
M=I#-@X%ZV8$M7L2\L441RJ/C90)^J,%8GKLQH)"JV\!3DN2LO6<\HJ?P_K7O
ML;S.M"+0EBKT@*/3]OKP8AR(,_/\:=3+>C'E5TZ\ F@P;J;)0)% %<:53A;F
M_*;5O=XIH=U)N:;[3,S9XQXI)'(@0;)2X2R'2/QUBANO-'][Q[=I@G5=8:V>
MRIDYC/KJ&D>>C3MX2A):G7A*.J($AW23[TZ_5KGSLZXETIE@"$8&OFW9$+^Q
M-%W)G%&;?R7)@W^2@YB:]&1ABP0I2RMEL('3,;A.^TA--.IW?=2=$Z6YNOV[
MEN7G@2V0AZ?N^:_#W.-IG33C,/.ZO1)HX54K4MQ%.ZO*JL69%UYL-7)E>=1-
M)2XF^"?.;9L\13:^L5PNS@I536/7F[P2;\64A2=ZZ.U.R$_7F_&KTA[K2>1I
MNN1)P4Z.B'(#=Z"US4:19$6R1%%%[QU4U4-+/QC(-U;7)K.4N*;@*>D7H'[W
M!:Y #M9O_%F;3RPGI]0.;7XN4/VO$O;_MY\?!SN!/Q_LA/SK^((8.<[O'L+&
M3!=U+2"&TML<J5+CT[E&1YSV6D*QGNZW;UG?7I!S$#_ F.I*CKH9T=0G/L3O
M^N#AG-?C;&5%%$2DBJ[H;9=]' D.W'84@9M["&VO>G4%5<ANCJ_GV)B6W.PS
MEP2FC.BOV@#?TQ_B5<>YD:6=B46,R=O6I@_"0KL$EFO<6@]BJD* #QV_OHGE
MLHSP\)%4)>O[*.+3G:\5V/!DN?QSV)K2D U&3]MB.&\DR ;,&QO>?53(/.:X
MJ]))<$FW;;"A[<!K110FH^9C@G6T\GI(^%)-X;Y+Y 2)'KO4"'>XX*7&G2.9
M+$*:\_>4Z^%>W@Y0 B9YTBV^$_"AZ397 1-;L46>V:A,3LZT]12YO82CP8/=
M8JBP#K>3=(0?<66^'Y+NZ7(-(3#4K@HFFU?IF[CEQF^YU40X+CO3NRB!IQZP
M*('?G#D]W9([LQ7W$,,CJ^IAO5GX(?ZC-*:Z2;]6.7R-;WDFIM.>N.,5=X*V
M*,?2%*L=&T=I(PDH&L N,C<*Q_CAKW,]/_6/ZM(U*GFN196N*A?:]$.-,JMU
M]L5?KPX->"4W.'^./:Y+DP#KF5O9\*3+O8MECL.,9#CMLNE$.-EL<_9?V#.X
M_&?*EB-%%'+(IPB:.DC32!CY\RT;)]4<)W5*NH 2;W3-L;!":A[.=G ]LV6B
M/TB]'FU)QWB37A][QF 4%Y[L(!+8!+2ZI[\$[^FT/[(#@_>JFVJ::CCR2_S@
M#YT>Q1M_]C=^$S])6GOI= ,6A<FX!Q<LQIHO/##K=Q+AV-Q^5H1:$I\78\38
MRQ'-8]VG5G^Q.:^?F'"BGIJ5[1DPQ9Q?HKR$@3V\Q3%T@5K!E$5'YV"W]/3T
M[?&9HUK:Z;189I4'?^'4#)4W#58+Q4[BJ)]$H\%#DMAJ"M/CA(HZV\IU4M-,
M1U4=A;)Y_][")0M)J%!#7\PW/JLJ+^WD#OQFNH&8\/?LQG7>W>+MLG@/<)I
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M?M]SF)YQ<6+VWE#?>+'IO]*=X!OKRY_^,'AD<0L!(L?^WW^L8$OBD_%96X\
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MJA.'IMV]-ZW=&V0:1)?^G>HO/^]?"^[>Y+I&WO"$JXI@9*[7_.'N)@U:JWT
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M"A]K$ 0KY++<@O2>U1A:.D18^"\E?$8;:+780(_TC-737X8.L1.I/O$E<LT
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MS83-D5[MW^VIMZMYP!_XJFC5GGQFHUR.$Y)D^BHA@C%?7O[TG7:Y%"#PB-[
MZ[C02S#+/0;A84%ON!]$V,@(Z5_ZK.9R7#CZA>=<545)CY9KCUNE;U4.>1I]
MX@+V.)RGUA_9T7C4SX]?$.1' &)(+%$"/&8-*)U0UC\6?#_I)SDFR.S[?RWU
M<Z"B99;H^5R]-B11+MY-2K: N.R.H%,Q(;>G[%UJ_=#F ^BT,W]\QBRPR;Z%
MZ@'E3S_2'@@-'BH;XFP)X!J4TD\J/!#_.Q0=?UP[7]Q@M 6S#V]G>$\^Q.+S
MYZ^[@0=_M!P5BK.R[4/F]P:SMO1PCE#5VVW&UU18LL1;]O]Q9 UWA'R$C&R9
M6JF%A>J"SE.?S>;F9 B'EO=OHK6AC#V/8^4)@YGU[ID3Z];&;&\5'CN6<,"X
MI)Y-J.%Y<NESU?V7+?&T<.EW-NL?.JY[Y$D+_DD*Q%.^TM]-Z6Z==4[>T61S
M8L%&7RW%-%6Y9*& -JA QQ2</B /.J#[(J;M&$=PYJ.MP=$135"3!39Z',XE
M=WM5X7O=STP(==(!2[_KMJ]YI?Z\Y[-T0P49SF3>%C(P>P^KM*#%2$X RB1-
MX[)@*%29GYA.V1'/;J5)TQ;^,^0T[FK,@[J+;]+CWTXXA*"O>DTQO:UD?R(I
M?>WQ&!B1^ST!F@X6HR15I]1[E& 8,I]M.AB.PNK+86W-F!\\4_0F"'2":V$-
ML&B=/K(4)RYQXK.(8R)HCAL1O=QR3:C\Z]F#A7JFP/BS@-/K>;6F)HZ0P]RX
MX[T4\BJR]+>YA7E]=5[(,:NJV?97$F)<G)-/GEBTE?$60\:!5<CS?JF:"!C/
MBJ'QL*;U,W8RP+65P<9#5IF($/!^%Z*G3I)'=:!P:)H!G7DSV4&9[QC(,BNF
MX>> 1_/B3(N--05&87/F1T P=XPUF$$<G=\6((3L2,M%H;"3&MT&+I6!>]FG
M6($Q&[J;Q"%%R2L&1G^X6%Z5K"K2D4]*@WMS:S31%6V0_@F\@Z4+7]&TLAVS
MU[]JFY,1DM]\/[F)-6L.Y2SF$=4EF;UNB]"=)?WLH-#3LV]:$E;9TP#-\>LF
MB1WUHU\@P[,\TQ]X9S/4<H>4.JE6&6"F;(3_;O0+(CAHX)C]6U4O=FB7.-'\
M@24FW90TBT@RCP@^Q$0-H8$:!]"Z#)2EJ:Z-"9X.#A'&V7@.57DHZJFQ*/"X
MJ3(Z?5NX?P)U[_,-GCD]97=:R;%6A&#]VLM=M0P^9C9>G!:-ES>?WIAM;&\Y
MJ=RA5=/-O\3VQ/8&)2E0/V;YN/VN_H+=[=FL 7ZI4\:7-6H9I2(UC['2I7WD
M* $-C8JSS2YM'M$64/@8P,JC""?]9I2JSO]"A;6E^]/2?"&".)+.J[A\171L
MJT; QQ#09+>4 J0PS&  A0$Q@L;?K@K:*M+)>7FA048/$3-3>J)F[J,VE);?
M=0*2O!*E[COV-FZ=]U?;&'.YDGT=0&6?*HJ+(/TSRIH2H;<N,"1Q_P5CU=).
M@E9VW[Z:T;/SU2TX@&!%_,I^,G"6%RFX\^>'MQWM_I Q<#Q,4&R(28S-=/$\
M7+O\WXMB%4/_50I5'=:;$IY.J,V*4>SF.:Y&5;)Q+@SM.#?7P\1>V*W-/2M2
MJ]?,\0B=]D_RO4NPSZ%?""$MU$\6?4YA0QJ__ # %)@^D^I]2U7@'261FJF(
M0?MLXMVJYVE!RDJ3:O8CC_Y^(@"DAU2PINIR),9=!Y^M/1;-?FF!!A<?&!>/
MFJZ^^7#.88GA_/K@WY( 3['JWKT:'] ;&>D9U.##<0_)-:XH<_22DHU+7XI?
M%FNJN_OSX6.Y/+EAK?\+9/Q85&>L1;V3NT"PV+U_+QY^0NL3!M>E8"G15V^.
M]$RSL@AL9K[_JYL4,"\ F]V8_U$$_'?4/$.'(4<M4!:)(MGNFO.%,!CLG;Z!
M%S&>/GNC)2:>Y&E"0,7<]_]2%L3\6CA0T,"])(JG.>)0>XX-.G^VA%")9V'Q
M*E-H=Q.02G9%S^6&79-G<YG.I)V8C EKS'V S9RP@P?R32UQ3D UW<60PP>
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M)I<8Z_TU6*%WB!YC2&#,;O\10%#1J(*OMW^QO]B5?K-_9LY[U1+CB!Z=Z9H
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M HGW"/B9'O MRMADZ5!U562J9_B:Z?69(SV.QU;7U$F.,M+D/F)Q[^_7O4?
ME(-^67C:8EE[[+^'YV?1-FXO%1X!.*,%5;T-,!OG.#T=\5]P@ZV@1P )Q\8&
M[+YCY1&PGV<<)@/P H;ZJEDBSL_ZTSG"\]MCKQVT?9:DJ.J'K[>3*#R(2-D&
M!6'[SA-0K=C*)]_X<Y4"W\M<!UZ8 GT2:.R(UA29^Y^1E\+=0&@3E8JZ VC0
M 6Q6\FF&AU^[V\;'"M*YPVD6M"^ WB:.#?TR^C.;NFZ:C5\^I6RM*Q[]])>"
ME;BZ$N")B$->P+94(F_]8]B6YT??A;&$A5^9O5FDF/,T33C1A%PI:?2+XZ5^
MSNYOZMX0_;1R1?%<)VTS/)Z,T!W3%/EW)I;3>$]WE6ER%XD7PAO25>Q:9$BL
M$WFZ$&ZSH"SWD4L8/QUP?D8"/9-!0L)]09 "O_RM$;C#3KI5,W3^=::710T-
MY[  S4JU"C(VR[4<Q:$_4_$(V-K='='-)QO<99:@B5,9;%U2P3AJOKU.*X/6
M]SL?*A:VILS/+TY*9#M^H'=-2A3EA.V"?"1H>*7$PTQZYA=%X>'W9GP5YHH*
M(OR4>:#TY\_0OX=C9\LJ;*UV$BP.V/MS0:W&DB]L-Y)(+TBYT2N;$P&85]MH
MQCFU_&>+[<B8WWN$AX!S$*%MLQ"LOYK8=MYP>1DE#WLUSL^9%(2ZO+>+@<<V
M@,^^*6XHVE@'X(L&VWY5N!..4#?-PY/] *#S"*CT<7@WM]9MLRS[ B:0"Z*>
MW8WJS>9"N;.W<P9C&S$<%[8LZOEND%=QH1V",Y!O0Q$!_85TM*B4#W)_&S[=
M$@9Z!_HW-*#MY;P.)"\.DJ<2D7$$;H/#D2KW/K[FCP ?E8>/G8>1 *0X(;1<
M$3GQS2WNQ?Y[GO2Y7]='#-7Q(_-ON;#KM\T^;A$=WW#RS-=+Q]5FD4GA]<<V
MTFKAZ#+A>&>ZV-I@#(C0;?E1]#X"\"P07<V43;>GV?4]B\Y!4<O<W$0+0:&X
M+:ZHRP&IHOWF=$KQYY<KRF]3U0Q7A =7-)S8T6X <2.=/64I.)K$5'B"A UH
M.P^,#2DW6Y1\32=U/G$XR_UQ,SB&0;?I@XB;?B6ZOAS<$U]15S/65;IZD]HL
MW'6'\]'VO],?)%=RCHQGE'ZW]YU0!/;8NT8"$!/XBT6I2-%&"/ZA=W?H<2,;
M'V'HT>=_,"-EM$ 88GV#.G1!2X@Y!%\$N.II0*CYY1Z)T<5P&).^-FA/(SO%
ML:":JAJ@13O?OA8W]+YC;DMVQRDNH:.=!&  3/$"58&)T-'>MM6T]05'"OTY
M$6D'R$EU]NHZ^JJA3',(1I44>L *D<: O^"DK\YF $9O_B^X W$]3MW(&\M7
M>X'1\J3FP[ [K,[L>.8JCQ(R00$J)0 TM'S3C#]61,9RDX/(CIJ\N3%-?7I"
M^:M%LVTLS:^7BJ\'@=U$8P=*CP#B:0$]1P+=>P=JU&G]WCN/O_<7[? UWLL$
M:7;*LA3C;[$R0H$B<,7ZKVJH]JU1EG_6(,[%BS)O<S:UHX/%Z0RK UFOV#0&
MO3W#W*6MFA 2F22.2?+CVJ]1C'0'QC-E4C[.A<L#12L,E4=O7HTCSS0=^ZN=
M=;MP$>4HJ_%SQ=&M$KNVD-[6S@[.;Q>D"(#:E,2^6*>0ZK,X\G]1'NQ>*32:
MD9'QWCS<FN)[:<^]MS_OSHVQT%1U%SY'"%M>UKWT]8LB7,;C4P:%X&^"I#V
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MSO B+.CCRN0TWL+! SD?@\OS T4.Q$ 'B5X?[/QID7CEQ1*]!36=G2L@*BX
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MC/ZBG8<.R8NL*1FGJBTJ%[0QZ%Z_@V(_OY!<L C>C;J!'?DOU:)"@7'7;]I
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M@MEG'(TZ6(T;P<6,,N-U!X+QN;H : -X5%FOHZLE:UBB.4 )KHWK/F3D9F#
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MQMY2[;3)>\R>8-ZX*IS.95TEH])ARTS+<4P14:=)[!_W)QOU"\Z6B@/<LWN
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MV@N<3;4-537GVKBLR7$_BDF,*U= -R>:W$ ,+SD6/QT9'=JG>2\9:' WG]$
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M5=Q$1E8B7&K!#4$7E/IL92^--+-\J$2)RB( CI#RK*2L!;@^RC5W-C<L5A6
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M[3O)[GAI[J"+5-/X#2VR(7QW9A7C,AFT%-T,UF/VSE'WBJ*2A\]S%^GES-;
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M,O::Y;3^(K_[[/>OX'GA0,&FB0:M)A:A,]G%OG'9("KXO8L:%2W/DC<M_("
MZ$&N%9.U_48EWLKH*T9( [ZV2<OPUY#CEA'*H<A7;H-="=%)!WPN0K^9N);3
M.[<*F34#3->\G@$L))>;T58#9I"\N18Q5_24<!L!H/,O^H@C%LUIO[@,VA@G
MFQT;&00 _!A<_X=63X7?#=.UPSH,(A%6YLJ$P8[?%0$[NZ\!6C]_D\,P$AQ]
M2[3$/'%&"RE VYC#R%]Z;$#LWZFBEP^X5OM7R!I_-X'O54][;5%T@;7:LC@"
M\BYY/VL"UF->2#D5QH8?GS8#MR2$T7G -'YDI!PA2W5B2?AT&.?+1[1H>+1@
M!/L!3F4A0O.: ]\%:8%"7][RGFRS6-%I^F3SGL9Y78!#TSC2E!^W>1D(V L5
M;':_TB$J9",<F22RSH\RB\1"[1O)D6JB3*)R %DY^+']?5_];W'2?^V>_7^6
M*SNL14*AVS7B0=](-3/S'[E=E9/)3'YR_9SE>,//!<VA?S<O0=<9$G5)ZB#-
MZ,5:,,CL4+BMY)<'(46JICDM-Y1PG&7B3QTK,\I;*J]P.U&KAD7,:Z^:'Q10
MTKI3UZ9)X\#O**L+OQG@Z8+%904G>TMJPQY&+0HIY\USCI)=2=JK^PVN)3>L
MXA*ZKI-]R$/D6NIGM"E4QIKJIHN2.9;8_=:YLA;(UW#&Q?17S2S0@Q*YD@_J
M"14IT'8 &I^6WZD[79IBJ5DN*WQ2F>1@('TUH*,E&7EVQLV\,Y,V_3-\T\'!
MU4Q9FH'\9S@=VO\4KOPCH\.PLX?4,5&2T D&^ ET^0;?G41F\7IY5C+6[ZY/
M?YZF>-L3,NWYJO_V'I*OJ:6SE^9<%Y3OHU=7)HM&%^_RTP_7^,P-OMS=-=B'
M[\9G1SSR)MBE;F8RU>0>E%^.&TAC18.P%NE]2+(3?DF,NLL)XIM[FAU>U!--
M^-0K$Q\)AX04UWDBC/^?B_FO'/(?B*?_2ACSZUWYT6P46-JJ:-#C\/ZS?94R
M(J; ,R#+@BN^^8.RDNY(N[CC$Q!&=0?30DS@P"_++^^60HG'8-5[32LGIT\U
M58I2O1/<*8[7=;/:_ZXRJ'(S>%@L_ D'.2YCN>S;&ZHO-"K3Q7CYE"-'3JW:
M!A$D^Q)IV^DU_+].?<.SL5,Y^T]/KA0I/[<';"GL/ /*YN&-;%;8,\P^-!\Q
M;) )L!=;^5#6A,B&SW;]E'3XS9$?Z<?U#'@K8 3;2SMKM@V!7O>"Q!1ANL'H
M]"MGWSKB2UF= 0#)>L!.TZ@GD=X[Q?3RT ;ZA97])_55,5Y5E7"GY6-/@NX3
MHFQ2<YS]J"^,+:6%#6<];:9VOQ;&D*[;9<HWK*WDZV$NP=1@<:Z8]]E$@OI_
MX!S#STFY)6$$W>42Q-XX/5>00BWIQFHIK4T0$N5]/^%:8*_R#*?F%H3Y:WNB
M]LH@*QOU *OAC[NVCZ#!2F(.16==._V[U4_+=0?G BT^7+KAF=2C5+-WT+%'
MS-RM&<;<,)/DLV5*P]@C>C_)"D<M#7V.T\M4^KM$F^Y:&0.A4 3U#S&G]Q+>
M@F]V4BOU)K"5;9=QG@9U27PX^\ICPIV> 82+;J:T BQ78>7HT*&Y>+X@- FV
MG@R83!":N.=B,M?QZBVISS0Q53:CT;GM0_34R89Z!D6L)G19CGFZ*A'.<5%@
M!V\'VQ*<G.O),.C,/NSZ/<'B?E. &<G6\JJ)N<R)E-JFCO?P<(J#S"GO;>&A
M8TQ_3B5E(TRO/YRSA*F-Q,V!E>M0L%) 1UU(7='-H(3HA4]PI@W!>!J<J8<:
M/*G/>5G=2,1]]#VRJ<KO]FT>%!NK3F.Z4SF.F&\T5V6I?)3[F1?RNU^-]H.0
M:(IL1?3?KF^GZ\(D4@HM"338M0TL/T9\MTB_#LJ@,QI?Z:0$6:TZ 0/3C!U
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M^J:.B)6D\MH^YC9*R2L90[E?7XW9"^,7_RP^X.M-]L];M@1'=A'+:@X/[%S
MSR3X(3F( _1_-@W'$)M?K1!40;8L1NMS_Y3G2[^U,'4E4E4CU3R_55N&[U$G
MH_J=O-$SA(;#@=/-84(5++Y?5I2[I8B$\W<3HF1<%H@%WT#?=)"DG1O\'8S\
M/$W=@BW'8!W-R=P_ 9<@"C\>T_O(H_\8\?0V&^>QU"QUZS&(^VB,V\C'/NMR
M5^K)V/*&H1$^F.3_M/>547%MV;H%! D02$CP0)&@00($=PD:@ENP@B#!*0A6
M."&"N[L[!0D4[L'=K?#"W:$"!3Q.=[]QSSG=]]X>_4:/^\8;[\?\L?_L]<VY
MYUKSFVO--7<X%#*$8@7C^?R<I5@\3[@9NNGF70#'W)%1X9;I3J[11N/U"^6:
MD?8*4 YOO,J:F>4]-RW]U<=CGPV0<V(5JFMY*\Z35^=<(:GIZI)!Q]-V*)Z\
MG?A10^L3^MABJ<EC\IG8(:T>P*HY\7!U^RT /_WL\=S0IDF5/2&B!??$LE?M
M<\%$W-361<JI0V3*TVU=YO/%'].3I,&8R!'4[ ,7$?(LKU&E\QT.LU9*^X6<
M,*_BY#ID)I[WP=O1?8:8D+T(5-L->G(@,*"4L%/TY?A^TJ"B^\_U7O3=[Q5P
MF$(4EO<%8T96JD[/PA=]^/&=$1E,]#C]:<]?]/QB!#>CPC:6R\Z_1,;9N@BP
MKF@!9_SF7\O(+U]<(P1OG#=C3_S]#_8K#1]*O%_NF3B8)_\<V/_L"8&WT7T4
MI\%@;@[D\]NQ#[53PAIL53(ZQM]NM"QQGC)A?W <S126%E1UMH3W]0B]K!I!
M72:N33BHY^(Z9,W.Z"Y&FQ?V<:O(F"9)A6)KN0 (VZ<B4))'R'B0X8-WTN9N
MEL(OZ.(=Y!NSA0)I:<.7@:F:/Y#O"8-@W3S.#=^6!FL9/D24IRVEI$D,J(_?
M /4A\AAM=N'W&F 1=D:$F4-O:A$6G5^2OR1;]9[+&Y:&-HI@)ABSC.4*.F8A
MSEVK4@6Y*!6:E"EWT*\ZHGX)*H5%=F$EXD9N-''> LK7 D5:RI3#;XC$2#M_
M2).-G-H889*9@UJ<Z+Q?[ZBBQ Z+ E;'*Q6(676\^RO8:<G[;,6^$5:ZLPE.
M!R5,D+*[W+<DOG:FIH[5U^01+(MCSYJ_;!XA@S-^XQ[ $CM]Y_I6=D XI1;E
M0?A>>:J!*QN2U _?/G\XEW]8@2_H44P@NV2M&U1D6%>1GUM/G?)",L6-IB2<
MNA[IA@"C!YZQ8^R4BQ1AT-4Y+]_CH')(CTF_6KV:BI4_$FH_1D91N>UGW@Q_
MFYNE_87G^R4ZQ&G;?6I2^R%T /9=X)F99&A8#2WQFN'AT,(=^<V(*[X%>'7=
MT1;M82-'9I+HCIQ%#ZNIQ,=Y-SUZDDC'0N2T+M*_R[VAVO(5Z_=WDK.J*B$A
M*V@?A=A%?Y7I_!C;/>WCWV-ERZJJ#GE/&XA>@,*D<(YQMTNV-L'CDK4E:L^M
MB\C&$$5I)AT[\!=.N8#G]>BS#&GE.NYR6I:8C()]"NFJV"SRB&?,(DK\A4P9
MA$1C6,$D\<M[[FUZ->F=I/$N/4Y0[P.Z_L%[(\(Z+=*42#CG=\>=HDFX76H&
MLKZ#=*! 9%P[WL6A!^QD8I%E*8Z3**1"(L >$A*=QC*Z,@*K<1;@X8?-\I_=
MQZ*K>_?DS<IPTRMW]_&LGP.V&]4D$3CFK&,RM)2F;!?!!%_2?NV(4Q/FPGBI
M&<9MN<\J*JKKAMGIT@:'WD6A2'!Y85^;5.:J>,^'RD3.BQU%\EL5>>48X^9U
M>SN% A'\%ADF%+TMYS])-JI!$Y.S2'-QF+2"+:'B5PW!HBY+"M^G@"4CGX<
MH+ZC\OCIW8O-QKAW(O.BR<+(GW^E,L8@HR2S9?GD)T)(=H=!:0P);M.]") )
M+#3HR]6#>+#&\75J?87;& N058U^)'#L=.S0/,QM3$))E(_9(BHJJL9/KV(;
M8+#)U69+F9'/S\28P(VA^9.-I#\7[OF+U]37UB4-;EL'8%;'V^;GEMPGD6>F
M59-@5::+3L&=*S]<]\]K +_/VIJ$/B8)S:B48I)KI<7PD\6&^_*S$RR MMVK
MPI>#NR+7#\<4&#(9Q"9M^EW:+P_4#&\P]"47=>2A%H+KJ6OP>0.K'TPUR2"W
M SM:2X[69</()X5K2IQC\";?H-Y)O,+]K*IO0L&A34Z%9(0,(U_GW%/0'=)B
MI86Y,F2%Q_+\\TK&^-U,22*_17[&P@P3>.8K(')'V[H\7U]'OHPNWJZ&PWX@
M<W8,S8Y%IWL7U.8*Y!I*5LSCB"O"/4<AD3Q4VAUISY-.U$9L2F$[?G%JAML7
M).5PV1]OY"EHX"VK54H?/PJB&>QG'FXKZK43&5I15#:<APOVFMST!]JYL/B_
M"VWY%6+TJ9,KC&NAKF_@L?PX.TU#X^ANJ1UT\'V2M9-K> JJ1$96- :-(6Z*
M/6=&9*?]0A&=/(EUUQS.1]R-33[X"GL4.B(-(-X /H91B7FG([A#LR=H$HWE
M$1_]R5CO=]EKAQ>6R99<F\A43+&13)[I=Y;?Q^IL[;[GH_XZ5BY_=SYQY$LJ
ML_.*8-&1LF;MNC?N% \[4@YJTS2^^"%-VXT6SM&O$>7N_@E4JW^>N@0%*C0'
MG<\P/):2-Q@U_8AS4SD\R?V,2694B,M&$U_13!"W%[YEZWS'"JJ$O_\3U088
M_<)ZR_,&#1)%/=;+!HP@_W>!M&'[YTXR8[T9DCA&"@SV2PP$"A[:F5N\X/S-
M25XU?9[^N/.C]K%F'=P"S/#:3NM>886LE] C//T8");RXX!VG+&!0K::3PVY
MHKHLO+A+W[IO&-Z#H-F2;*<BHFBFK%(N(_DS&/[''!EN'O[8X+<7'0"#W^/Y
M X_]8V/ -Y99U5_SDJ3"N,G-70!,%PR^0&F'NOQV U[X>]L\:8;<CUU6 =](
M11.W?0#>E:G7B2N&3_"W2:USX,!?9F3/ FX!3D_3LQ_I%1%5;F2=W )H275
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M1FI*E48BL)2Q<I&6>7.@'1+W^<+J="65UKQO"+YI75'B&%[-IO>Q-(_2Q$O
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M^AWVF;KJW,X"?]BH6=TABH&+$LOB4S?93AO%J:#I".NA/-Z&39#&2BE.!_7
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MEM:?O7W] X-#P[^FIF=FY^87%I<VM[9W_NSN[1\<7EQ>7=_<WMT_//[#"P8
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MNAY_Y>G6Y#$)&5SKWEZ)B)2Y#R9(R/'P&]4Y3,M8^J96__$2*?6'W ;<T="
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M[N,P$:3/+Q0,+2IP/MJR593VO!ZC-]>+4NGSB@7G-O"R$LM(DM8$\;(/'7H
MTLZ8.LD\S%1FLCL;IQ6&[7;E*'EQN3[5O%)!:J1%Q0>_U+AO=,#>SFXD]P?8
M-'5B 2^IP@5?]K30B>2OX;&^ +9EH]K%:;Z#\2_12.7/=AN8N!:IFYOE9M@\
M3@8<_$S:G$T<?+\+RESLEC<*6.:4M\N;MA:,IQ3+_?;\6L[Y1TZ+UN37B4D\
MQ^R<:*"/P!Q/8[@%%;T-Y0AZK/X(L/3L;N)'.3#Y+&&,WP=CL_[\9#YT($VT
M]G3GRK*)4TY21'S<W=PI^USVT!HNV)_4H_!2B64*/W[)YHB>VV#N$=SJ\KV
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M(DH801SACITH*Q$@J]"SQ+0#PCR7"H;E_MWTI!+;G0SG\1"T0UH@/S$-F9G
M5@Q-^T,%OJ&62=:30B?,[E83")+M1.([^G2Z]KV,>70,I3*GJW6.*MJ2-T&&
M$H+0*Q/9Y+D-B<Z+:3G3'2&66;>"(A/!\F9\1RO=V4-5QD0![D$"]ZW3)C=J
MTW3,XK>_^/R:VLBLB KE,^0'Q,54J*>)/7:T]R3KD4*41H8&*>0H9-;8M#=E
M:841<!08/]D.[\N7K?46RM4HLRRL(&'WXG+5*D0@$0Y^],42OM*T\%"3II*K
MDPKR=G'36,EV'B+4%$('OC"T+2RN'_(\]H_0Z;G%;8M8:E#QK<Z@P_H;W@B
M!U">E\GGYO&D?@DU^[GN.'$H7,5EK@YXS905N?'::*?JC<1\F4#O=*X/8N.8
M(! QS0?E\1_$%-IPK%'53HX<<LB[_X&/YI%%XX)$N]60=7OL .]NRGA-\MM:
MOQ?$TV]%$_%*M=>'*6MD;' \N0SPE:9E=H14,'Q+F]L5=#,VDY"D+(WZ-?([
MLXBB0^R.V^ SM1NK7 SF4)X9"<]14 7^CPTSII;NH0E4\>LQS;2'4\MF)?:?
M4@OU63L6@%+290Z.SQFP#H*[E;YY8^U0/MJUY/- 6*F6[L5Z6#%:=R:L0G;M
M>:UXYA_,5J"G<#<BQ#NZ/;A8QU@O<TS.M,H4X^1&Z0[$Q>N#/0Z#04Z!\A\_
M3J@RZ,5?!\1^[FS<$KZ;VJ]96M%?7-%3C"KM8@2)C<!V<"@[/VAQ%ED>ZM!Z
MFJ8)%AG1#=;;&[-M:E]$(P%!C#9BR395>#]OYQV%\W':M12<D!,@#!=7Z#OQ
MCK]-"VV2!6!G#]WK5:6=\/\Y>W "<;6TIZN?GP;:>@M#!"IF(AV=[9;-<09)
MY&OT2I/)T:,=T^2NU^\E\V=8RAMT3FVE(Q72E&Y.MW<I:+U&&/_@[V% D8R^
M+,\_"UML"=*=G(Y.MG.4G^OK=0X;QWEQ\)K-^&*85O5V\%AS2\^RWI"J;:LV
M/E&E\#I5I0)UAK1OBU$Y)Y3E=@/87+K"Y^^<#JO1&#&4O0W8&Y 1DSA;6S11
M3:E3$I*!E3+TQO>I7FOX<ZX6P0J=:=T]?RJ21C!V99%5)V>$OG+.0,BZYW;\
ML6R)3[=.[W1FS^QHJVV%H3IF2C6XY3S'TDO=Q>0QGS/FM,(Z284'0UV3FCHZ
M9[EM)02]G857:LJ0\U+UK!E*^8CX^:DB $VL4=Q1K$^&(UK3+G]FRH^W.[[U
M>]>NR:W^\ID@)W&KWIMQV8L8J;O/\A5)WT)29&26V/L8@9*;H.*I2X0KPR#_
MR^ZG<0T#IAA?Q?R]<^'*XGI_\1>!S)NQ_7##VRUUS@]]R]MHWU$!=GX'P^/.
MRD:A<R&V$KM[NG,LK*Q;$?R5NN:RGTGL9)3"8&.]86(^.3G!A/G1M8/P4S['
M<;65C%V[:5[J&K 'I@ZXRZ$^Q)W U*+NG&Q7Z/_NI 5/ZZP/5ZUJ+_I&>VP^
MJ;/LKOFSZZ286*!C#74'B896&+P!OCL7RH.]FK0>H_IO5OMX58JYPA+R:]!E
MAALDHMK? %C.&7-KH3DL$2P&56?VIY490O/OXV$'X0" ;(; ?<"1&)"WCZ C
M4L$?[\ KN8S+:1"]T5GWX["-"78O5^V'C%_E*+1_[!#YC@S\(V\6N?P1C [G
MF&+8OON-KFIYQQ;[#F@3EU5X8 [J=G1D-I JS#&+J[*>5!1H1._3=6,D43GV
M+,G(OLO;(H5EMO^9TDK,%DC3=)EKS >):78\%GLNAOO1,>^ZBGJ[W?O('%6P
MXZ6<\&ZGB7>>!21^%<2'Q+3,&>\XSS6FN"64?% T!M\);(J^_$520U!01DAM
MQ.YN9@VY.(/:9-?\]ENAG77EVVV<:6#F$60<(I VC[%[/B8'.5,Z)PSP'>FV
MNL6!"P\T=5W N])6=LD7]=D$#!'XYMN5" #/M0[:L'9)SX)U7>TUPX.RPO9*
M+B7SY7ZJ,?(#\B7SGR7=@Q>::4<.S*%!-R\,WD4U[:E<#[B[,E8>?^!A=Q)2
M=' \]\J<Q^R.#+&;9L^2;TEE/TVS=([;&BJBO/,9JLO,YZC>2 ABD_&:M<E"
M_UOX[\T4:ANQ]],$??,;-^0]ILWE^(>?^L,I[V7YN6!F)Z7Q :K_%] BK?H>
MH_WC)&YQ&Z,&>1Q GN$XP#?N-6^F+QN.8F!%4J!AG]K4- 2 RS[+(!N:2[S#
MHZ.NH?7*MW PCY:K10/PKW#.;,#,<YN2#^PR%L7A"P!*9>8H@?%8_ <'$ V-
M>$&#:=O>4H0H+2JRCBN786"TL_+2]TF07# ^%0M'/B2@MY+-]W%OKM$\;G5-
MS)5OXRK.3H&,7DNP,4A\B(P>6(5TT:\HG'_Y[4E-+&!H0,2QQ8L.Z)75+@PN
M3O/+*]->7A$G6\S^-D:!TJ*]D033MF-^<1"L29NL4ZEK8F=*_7Y8$YZP9_P]
M*?\V9?8@5^5T]3%;6>:\FM]Q,026[$47';M-[S0A9H98^_G&C--2XEV\4K]\
M"L;E3O0/;BZ[P,)&;35%5XU/\=AFU!T/PQ.5;,A%OB$6U=^M:'3R9#B0JU'4
MN@.ZE!-Y8)?K:^D^-XKEN721&^3OP?NU7ZGV#9"$YSKI<JLC\_4F(PF!]BIT
MHSDFY5NTV> 9( C&HD+G2+K%<4R=-L64'DOYVSC05:]S%1'H=4":W/3Q%BMO
M @ZRW"LP %/9$^YA.BEDD3H*Z7^P\I91<05=NV 32-!@@0"A(4 WP=VZH?'@
M3G"'QEV"!P\$"#30N#N$X.X)WK@'AQ :"1XDN-S,S/KN_=X[,VO-C_E1:YU3
M/VKO<U95[?WLJN=)*\7.>B).^_.7&H(4)*)/8/Y-6P=-1RLI2FCW(1Z#EW--
M0EOG-S8XU\3=3[.%I- \C2^^,F*E8V=Y-VO6&RN= <DTW!^.)[_@[O\(B-O5
M[(ARH-)$M@V%=6*;H'-^WOO5LM'+S[.:#4SG;68] OZV%MP@^M\Q;E+,S>#,
M^3^O8!SJ?2/?BX%PY5LK;-=?Z.$ F4=T/VV*U,W-NG=;JJZR9/GN3&Q9!=E%
MY!3>S%I(*;LU#_;W,K_KHAR:N!:5H:AYU<P^\BLJO=!7CVGX<_R_2)3U%Z5X
M-L(7(-K&_?*L\/D(S?=1[52HD0T5EE")Y/Y2)[YF.D5/LV9:D16)>UFR]>X,
M<#[3+@6DU^#_V6&@[10D7](<MRTA*<ZY_LS'.4#PQW2=2BV?-;6&KT6%8!K(
M:=(\*3?-*@(=#S C<O18RJM-ENG 8+S5Q'HB&S5 B::.,L$>V8/^K<B$'LN6
M7=@T-X3VR/MV@-F1$*?O@M,2_V8.MO12 [@F=%XI@J(E'5[K4Q@M.YQ*'Z5.
M%7B:@@;E#)0=T193IT1S.(NJLGE1)QZ,[C/L#+\['4#'MM#E\/7$5=KMO93"
M9^'D0(>^^4S-"?9R[_H"A;V(V4F8P9PNE]!1^EUA-EIIPZU?U*))?M8N*ARO
M5G;^M]]FCJ,_VGA5]#PC8&NRT="J><DX:FDD85Q,9\"O#&4/GO4$ODOYN%21
M:&@GF)JXK.3!,$1-[?K50'3!>,72R<CS'#IAT+;U?&TD/<$UX64DU_ T9JM;
MXJP0%I&+XK!P4DIS\Z1A8^D2L&+NXF#T2;BR(,; I,_0#N#%F(,=EV"^*[@-
ML<&BDF=WN*9R<OY4P3E&+"LK9K9,\.^"LZ#!2WBM7<6F+$+FXZH+#^E7=VZ1
M,HZ8':;<\12%M6F-AM')"$;"=5<UJFZJ]4TS(J,P+?X)$CT'ACE_9BL?I"^>
M8 ^WG#:=-Q/"%<?4OKQB;XSCL#/+^E<CM6MJ"6-LC.:;=;S6[J'74" >L**Z
M)<GYP/8S6Z."OHZ0Q3;_6_5PGCLYVFYW;*-3W(WRGR..*2/\TU*)CK&&H]H@
MCE,G"VQ--6Q6-P-QFT> ?&N;S!FYJ9]L-,TRA$J34"I8'N7XJNO$OF).P^ZY
M@QOCCZXS0 AF@Q+N2GMGG>3#"=99OY"00VCL:L25OX8/R %:$1Y3N\JO6<A6
MG>'E%MJ)C;6)%+N4-FS>X,,3&8@?4)0?W(_@- 18ALV^IZE%_,UV<[IOA!,M
M<9;4M*0(I$',GK2%!.MZCYT>K=_$;$:WEAD9V7F_?+&\;&QJ]))DA=\>[YHI
M)2GOMR_VGV-IKY_JC6MA[)7( 8'FR 8OP>E<5@'CS1*,I5&U47S@IM>-=<,=
MUXZ> V_7[V,7?Z$E^H5"8K?83S0(OAQ9#ZVJPBBIZW%U1>UT$[5,,TILRIVP
MA! $ '+LT9O YA.NHV0WK60Q^1;<\_4KFKT%N ,YWTA*TG*D2/06?1+-7*41
M3J;]W%DK3/I;BE+F9]MI;.N,56_Y,!IULZU."&SRZ0W;0/Z/QHB&F;7Y=S^*
M?[(XX'1Y,XX.$O#5FF8Z6D6M=@UUBTA6*];.5W'"Y#P*5^W<#1I<TS>21JL8
M56X]0H9OUB>?K?ZWD[[_S\WM@>[^J)39)H5?)5J/!P5# HZ/C<,MU[*AG):\
M4J^\*$4,L4Y00:I\NMC6;]RGI<X,(@O$C-(6MM1DCF3]@GB?2[]O.G;>,$Q5
MDA@9_]7H[HH]-C3N%\!C3-(Q]4,[<* ;+Y>G#0<5@!(K;/)[AWP$*"+E5Y;)
MKQ\!WF]^14 &)+%7HF>RV*WE<*+7V#2PD8.?Z&A*JWP@O^7W-?B'ZBTS]15/
MWH@2>A,6QOUV<!9U4/I!URLGV ].3E=\G3I+*U_LL/J&$\O&@=Y=$A83X#%=
M+,\.'][?E*\< "0T-4N'Q)#,_"VS,O1.$&8?CNZ]S&6F&NIZ!(@ZR&Q/9<BH
ML;=G<6O0K_AA#/CNWFB\*2Y:EN:OQO=5Q!1Y8W3JNT[J(VJ[??"2SRO35=8=
M/]@KQU?<O]1$-3#IASF6NQ0/J\N2$$'\=S75P.0Z 2?F0@5J<.2SPUTZT/7,
M"^T9)I^AV/AV<ZKQZ;Y V,7-U-CF2QYT4GZDXG#,)SNF/&WQP9-H[-'#S4$"
MR[N)W7&WAP 'IZ/S'\VZIPJ?G(58;@NO'[0)T\MM;XI8W*P1<"M&FM/\D/V8
M>^8=Z:94OCEI@JF^=4$Y>A_MPRNB/_R_J/A\OZX<KK-9J<$L_=#GE7Q!I45I
M_KYD^2+ZK1,M.Z+,F1HS@-&$YL$!;HSN2Q3,;8R")"EFE%$B4TEP$H6A9B)7
M:64OG+EHGZ(^TIK?:=WP%#2^>(IG\PUG\+RJ9FVW:?]2D($;*[6G],.I/75Z
M@W\K*6XE[(PZZAU;#_<FMUCAK*939W1LXFRN=DAFSR6WKX8(I5=X0F@9# X^
M,9+[A%P:&"ML JSRC=8<;=9@$QZ0'4*MCQ=N=?-30_=5K3/8NWJWY79 :ZVM
M0;^HA4=?4%/<.KHF*9 LX, GZ,S6W84);3_/F-.ZN?'/^3GZ-1P3M#O#P\TQ
MW0>O]W:.=J@H*4URTBNO&T55#5G>:72$RCOR"&5](?CZ$9DY?Q6U3M.AJSQ]
M%0A=>)/,MA([3T]>G^6YXX6!+JTMCQ6+ G_Y;L&^#&$-:,':N;ZLS-8."!_)
M[]'G6N;<\==MBI*7X2PTD\5J'N[W:&=JOFP1E3%JX5Y:?HOXWAZ!YJU D&'3
M#>+0JRILFA'D0*NFH>]%0\E".LHME\AL 'X8.?8BC7_NHC++7>$DOZ(\PM45
M@#;-8-J5V;8<::5W8RZ<!$U"+WI+BD?_I(U5_(IRJNAR6NEZ"H*%+)?Z37:V
MO>(<:>&7[P%'V?^NC#!;7:Z)=4-5/?6NRJ#>G>I)Z3'4=U7'Q1FB@8*!?Y[*
MSRT)^RK/88ZZU=_G\>6H!MA>1.4UE8(C=^U<G%V11#_;40!I>O@$YA8X+I.R
MRE1[ULFIT5\TZ$ S\$'^_/)6*=EV?A0:U+=)0#+ ]D/1=EGR5N1A/V\$((C^
MB=W(4CMUQ!&9,<GOWVR^TBP:9T*DYJ:HJ0-\;T/C[<&O21ZL=,I)BT&[S>JS
M1&;)1;>3]6+IB]%>O6'?\(6'DF5\PXQ1JV,5D,6$6R\D@@J-8/MN>O#92N86
MBC?*D\(Q(\ZS\Q<VW<7O4O-B\YJ[A;H@(5T>$^L)'TI2KF'2P&C]X*CRKY.)
M3$(Q0@GSC'*X@,5"JJUJIC5I)R8LIZ!"'Q7E3/N[,-*:#@?(/X30(ZV0$QT7
M!NK"&;^%OQCRO= :7<Y>I8S=1/B?RG]MRA"*J" X-;0+)1&AVA))<XY'7(O[
M/\LL6R#DNU52GM]J;+')P!_2\<'\LJ2-LR(4"M7$@!SO&N90=#0FZBF9P^J5
M,TW'\8("*8%\;C.8@!O$WSH*B92G"0UG+=GY0)IK=1\J47_/<C^!\00/6)1E
M6DLSO97*5LS;D--$)*1KG99%.(I3O=ZOT"N:N0*P]<%\(U:Z%[G(49+(N.E-
MW2M<6$,4ER FX:IW"2&?E1V=*A1VM,A+9A)1*_;-[2^7WQ34Y8/),INE=:CY
MQ:>^9J'63CJB6X_QQESJ9)A_-OY$"#YBY P5%<D 9+36/@(8V1\!"Z!'@/V\
M@M'"(P"9$G1 \@AHM,4L^K](VM$;1 UOX;Q*M*K>LLMJ.Q*D4_H_%]D> >+S
MCX K8MN'(=/KA^^/@*XPB5<"V55[-K)3G(U/0TIM7[A&J7&-<XM>%]XR!NW<
M/ (> 4^>OU[$7_OW^/ (R "4_1+UO5/X=27 XO3JQPI@2ES=E4AU<8+&I]]9
MQ_[W[Z_D+B[)$EU/W %DW_^;/4S9Z/'_95/N0O$1,/'WWXA8KP!3!7F-32^_
M:*GPMT)'JUNB!T]>Q_"[$,ADWF:-RVHN<67(WHD0>80HM#O;*2;M#4EEM%O_
M)=_!1[M0[BT&4/2PU^20*C6!O+\SRI4&F=A#.WPW[BDN,XX_/@*F4!R,[4#F
M2[J:N\'B<<3QP=?+1G3@RM3W;3]C\K!?$Q2[M,QAGN$#3-HK%Z=N#($TJ);*
M/;N?\(A*ENG$<!GKT&CF$NO_H%N.[N,+7:0S8R9C).NA:;X/M-GO"#"%-^IJ
M3E-H#-=<^Q$F35(>4LN?7CLUO_^51+X5H/;=SV.YP41UD9S1EZ<%[D"XCLAN
M]YMU2)O")&)]NV(@*Y), 4X<F@!%([$5G!2C.E9>ZB2RDD?^15U3EA-W8V?5
MR]#%\99AZ-=?WYRO(V8#4M:$(@SM+*/TK/IHP,.'0Z)=Z._FZO5*]?Z4<^0,
MD.$47NX=]QSA]_W"&F!Y["S+CQ8"'P<B^89^YDI 4(W<+VG$Z,ON&TN3,Z0P
MSA2NNS;-"#\&Q:K8E[,985 [L1-2?JA&^*"^E^XKD(H]6^_6"LY[DL=S/+3^
M'GUG1V>XS&@5+R+U1?!Y>0OP_JCC+TK938'-47!Y!:&P@0MF_0R,K*0G84!^
M+15G?@1 ;J8[(UMK(PS?QQ8H*Y%:UO%0LO9^W[1G/L@@(D65#S<=D^E4OP8.
M?KS$+EFQB;&<X>#BTE75RF;BDZ'(P&\K',VSW(Q+EH?!EP5,0ODW6ES^NKL&
M_J&_I/5%J9EN:3_/4HUU@+QAF4]([-Z?K[FXF;[._'7[P92AP03^"<8C>LJ+
MV[7'<JJ<NT027'W;QQ6^:8DQ>W,;8*>GB_]>2>_;&.UJ-*^VM]B:6C7DO.@T
MV:4YK<O:-#UD? O]Y0:=:Z]_]"'M<[I70;[%O;R1JYQ[0%FM/;ZG"]:P<;-E
M\["$^3FH\U5PZLNI51.Z5'HZ6!_0# FQH?GC@^J4,1=83) 9Q25( /6<RK:_
M#9%?;O ('U"#;5KD!H!#\MOJ ?*_!U%49I !T?JUG"?W".I<<+Y*74V*2MJ
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M/ZW= %.BKT%D3=\M4]^&1C-_A:W_%ZC_XL*I,SZ\L?LCW3RVB+53'A,6J"W
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M5.I9D'B0AW+HIJ']BR5#&78$_.QMHKQ@RCC/'F2G^"VI/NWSO@I%M'FT$1;
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M% /?OA:R]!38/=="^@;U+7(=-#K8'3;2*%)N-L8W\"AN""WI;DHDU.I3PWA
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M-.E4.X/G.V.<!#;P18;P7O"ZY_)M5,:2$YCJE1>M&7,=YU079ZZ_"XR\W\M
MI;''2(Z-FP#%>Q3SQ.^NP\_OAPJ?UM21)ZZE"L?A4169' S)214, *B9"'L@
MTG<-FI;ZDX\*4O9B:'QC6ED54!!397BNFWI2HF.92%%E;;T,F5:\JRG)!YJ
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M#L==DR?BF<H99T2*BYVM=P@@/[K[%9OA>/(QO:'^J+)TV"BAFT]5M\P._?G
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M$0+C)QD LL,%3.H#8UU$I<-!<Z%,;I\+TSBTQX_\'@BMRHIN5NZ2?YW<GVP
M+)OD(M^145.O+>^FE,'>FMN<YD)6QI9JZ*W@ MZO1/4G3UEE_>5H7A?W]@7X
M;HAC3=>3<G)H>?*@TN-QTZ\)WC[8;4XKKVRHCOB>+M._RM%ASX.XZ'<\ ]1
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MY2IX#+F +2*FX/@3Y"QOA/)CK0YAO70]8U9PW4QP[\X"EW95>[ F]Z)>UM"
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M5_?/]U%Y.;/D,???DX?H+1TS=,7EY@< .L=$S;T.P&<S'H[ZS[L">4G?B@K
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MW,9MYQ1[26!2JU42XS%R_>'[$M?' XGTE5'#NE)A3AJV<F85>W=? FU9IT:
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MCCTRYX&_?IJWC!W1#YPD9@PW&K.L96U4.YC>7DD*1'*@'.59(21KI2T[W6@
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M+!_9%:2ZI\E#C\&Q<I,J-'J NH$=V0#9I5-2%62N^$E7JR7O4M@*Q%+ 8H3
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MYYEU<%#[B"P#YW^N^ B&B4=$Z"^:QFK94&E@/]BO)?P(9)!,*39J]S\ACQ;
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MA^)A'5RG.J3A V @2H=)DFD?,*Q*P42"M03+QO^#O3>-:BKKUH5CBX 8E4Y
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MW8R'J5<&#5-)^N-4, ;9 PJ1==ZNS6B)E#I59N7IL1+6)I44CK3.7G(%EA+
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MZN./_3+A34#R*SS8ZE9?"W)ND"6V_=QE[GET-W3EU!4K/!9[FBAEKN89#X%
M('A\:T-.P=O=E77DE\K\1[QD<@P ^G%,D"W*"B=?*$$*Q-1?E4['$6HH OS
M-[[?!I@@Q;/0S;U.6#L+WX(!C1/:^+B1'1#FVQ/;84!J39"Y(3;MMH(:]NKZ
MTQ)J'$D'/OVDM10^3-">T(4Y L><W+H@I3/:R@:/X=_SY'.]Z$^?J2^\6JBP
MCS'GM;4;WY'27$J%O0#]>G7QPMP\F0E[U6GXLD@(9XEIBX=">(,.I'G0!28M
M_G'?+Y7H&U'TQJ>1<_Y^N&Y1A&@.O?==Y_\PZ=3_'Y]E_BW,)6" @*8S[K<4
MCI/@E]*_-<X),<50A5C*G!<<@MSB9ZF3"H6O%P7MZJBJ<Y^R44PZ%J9E%@;(
M2T\SVX& D*O+VE+H!10!!FO84FH GGU/ ()S_.4Y_8@/I) ^3BB#)Z0!Z33@
M-U;*M>]-Q-7,YGOP+7SR;5'3"F11 VRUJ A9J\+IV-1[T)XP+#HV]G_$Z*?#
M"3#A)NW8ESF/>8M:OS3H+1I ,$K8Z(U@\6MA!B2:8HG+K.0#RG)>(.4&N?)$
MS:10TNZR&[1H\C 4?/OLS6H\Q;1D'*CNJO>)*@T"*CC-OEN"OS-WUD-^K+ B
M<NJ6V7D!^6,UUI*ZJ##3DF)T!]8XMK[%_U+A%I,O3B^AR_B$FD@6R8%AIRQ'
M=DHI*R=&5L/GP/SFW.5L?A90$7^K$+'MGF&M&8$3O$&+%ITE(6&8) 12$/*E
M?#>98LVI4Z>"^DO$$R&V-E4E2G7A6VF/D\=CH-&-M/H#[$-YT<,1R<W!6%T7
M9N-9]_WP%'3SX,9CM$H5;F1+Y]!#Y3=&N0I71ZMGMQ<A^IM'Y7J=#*)8Z8!J
MMD%%K3P"<_Y!#LQ4-),<X/R'$W,:2>&B%&$18V]-'V(5<*X<L8)M(VT2 L1_
MUN-+AX;=)%:* %Y?Q)(,0>0Q_O9[A7'645_JZB*CK;^3>]"_U&GW1>^):+)H
M*A*3!M.-'/3WXX!@*^\95:G/&\0P0EL40T7$I7-;']WP_:'"4<&V+^0'TW"\
M@QQC,(]J%)B>DD2!(2K< WUF$-"(!3GQ'X07PDD=A27,DY(GQR O>2JD,44I
M 7X!FM+@*&A!\\B2ER UC=D*$20C<9"MXK*B2:3%6&3*QAQNE,\Q"KD_<D]9
MJ#Z@I^2<C']K0IZJ]DDS^*;PXTBQL#NF6(BV : '.7D$FZ)P0B+5<.-+90W7
M&KD MT$#W'7!QAK)3K82@IXOC 5N:%G.6;#;%;3@A^(%@Q=C+DF!]/N?'LBY
M:[E02YYI3NC#'_<+/,X]&3=.U$*9F0WR;A#!7P?$?U"?B?BL09Y4A4M$==0O
MG!$7R$3LU4Q-27D4##Q_=P.DG@'[\AQ:#LS@M1GNT/?6"8[^A% "I'L;)OP&
M4N/M@'G!<Q1DXR"/_Z;J2K]]E/,F>JFG6R6&M@6<?[;@):!1AQ>$0;NMG NJ
MR[#%GS1=!>&;"$,V0\<A8CIRE#,V]Q8N<N]"5R'F<!ED(6GNO[GU:>"*("M.
ML./,+7JR2, T@G2ZQVYJ1]$K3=Y_J@6F'&_4<:P-LV9KWO7_K^:. "VE31JJ
M<*XT>1T&T=_%_2K<CLUH:LA'"N9^\MUPB"(8L>] #1B>_4YA#^G ;NC=/6C^
MNV\2M/!AD/=?M>_N/J1G\ZOE_0ZFZT%A\E/VSU%$_>!M[4N]PQT\(G0R"B=_
M;W4RQ)4K>..BO[DR>$3YAYIW82&#',B!-Q.F#$$'/G<+W$U&=/N;"/.VU(>!
M!%EYG%1=BHYLB 1!BPGP$0-3\PZ&9]'$B*9/=O1\?K/I5KBNZ/4+Q A,:<?'
MU3M<6E83M3 E2DHQA/$*3;05T..)L:"^@JL1 N@QMZJ1Q+G>34)<! /RP_!H
M@6]@G\B0N8G9P=U,NWG-#5G+M.R>YNJ+SGR^OP*B))+L@S+GRNO D-?>^WZB
MN_&S#$DV43Z)-,;1'V687^.VWZ?%3 94W_W;"Y+?6&X[?[])([KVBL0L[871
M3YHR(_'?Q@K;,PER8H+<%SI<*IY.X>[LY8GSC5DWN&:GT$XVCE,9^BLQ#IT'
M;^_SV^Q!;,XU@!;R=.R&%ZMP?J\ZIKA:(^XA_E!V2Z3E):GR*H%_Q#EGF!._
M]T?HQRCKZEZF,^VQD,ONUD!<3!28..ST46+0 3; ]EC UF+]XT1'8[H3:SV.
M"F^(G,Q<?CL?-6S1G,!XGBV4[8P!N)+U,"%\*C(?X4EN(2_0#JR]/61XH]=D
M$1C5K,(12"2,U5:)KG,Q<8.NP,B/N]-I99V8J >< YJ.2M-T&^\;(@?JC11V
M]!1!C>@B1$RL#'5 -];:CPYP!^1MPHKW/L.^>T!:$OD\'G8@2IJ0K;60!J*'
MES=V=,NVWRH.$2TS)6C3<T?1E:%6!SMG&B[/C<5G*/3/<#/DH1;4[HNQQG#7
ME]\4IV\N^>UE_*=5/(RQ#5%0S3>@FWP" EX#QL@9B-),73;.JQ BUGAX[Q2Z
M>H*YHLM.24$-WF5)?"T$ 'C'54I; ',_?9\\B2[OINY#W]1VDMJ=OK='*PM7
M5T-#@#53#P8DP$U1!1M9;2@&=(*-&[ZDB %, E2XQ5SX4C5F_676TFY:"WT/
MZ%;J; L9"Q]V^+DZ=RZ*KC]]KNI%3<UM<>4?0SY[]^W6'NM#N9ECRE/(+64.
M<)Z-1XYA7/8/'I^25,.U[%#S6,=IP33+74(>U.8//E9OJ0*G8-M\C-&<K%"0
MX):) Z^ZZO<\&9I G6J[N*LYR65$DN9[OT$7J<Y9FI.]>&S];5_=N7<85/D#
MO_#FK( J$6K(6\S[T>CUU?8R%J&9#D%IX&@SNJG/;I@T^TM7Q$[&KH"K(24^
M;9+6%)\TZR_V!/RXW*=]-O;(AP.A%]=G#A2<VG[@C2.03YP,4UQFM@$UW_G6
MD3+"Y"W(!340\@$=^K0G'% &L]#E[,3<!0K#M!D:'O9O=LQ,4MZ";)O\EO:7
M,]L?PD)^I&CPY/TS<_M$@]1S-U&?MEV*J",7Y10JN4DX*BJK[D"B '@[0;[H
MCR\9TIJI"Y.+.X0R]LW)W6]VM#'F61AMD#T^R+F.K@<:[7GB&)X6B42?D/^"
M4;XIML+W,V$U:CQV;7N5C+I A0LP+U&F/*;'[ %KDBI3V/#!<.J QE&0F2]O
MT&W)-6[X&LY>3OV@+F 3?7]\T\7)Z:DIH&(SBI%)\=_3R]&WOS/.0_)LA3/C
M,.26CCU\E*G"Z:/+>*VLZ\R-G1'M9$GK3:8.;_++AF?0Q1M2K*%Y,)GO&%_E
M9,O0BWS1C6ZE/YFEI-J_'C%)?"\BQN^Q^@YTNU,G'CEYR<G*7$"<4<$4LA?/
ML.!-G*D3BGV,^1C1I4IU:$WDY4QMQK;N*O)R>,'N_EE1(LFR O;Q?S@^8JK,
MX6ZC1Y$VP8%.1E+KPY/(H;ZG3ZO2:,=BCK[L&$V/QO^L.,W[A0 [S!&3")KH
M<MY4@\(/GPBL=@I]A#C"OI)OCX8)\"$G?^F:L#W@)Q;&Z4/P[\6?KQ$'9SFZ
MGZ]0!TW7]53FV(BF>(&UW)M=@U^C@!91TOW1F'I-,<S0%;?[R4[TH"/A_RJ+
MR/9IN9MQYD4O<8_#D;$YC\0[PR,^S;KW#'9(,K[_><BI5':+'M/BB<Q3/IZA
M5^98E\VP8TE;3#='#P5TS2C=&KGVKTZ+K_0NC%Q9=;TVQZ!OUZ?]:2L/,)K6
M_V%I4\NY-ES9)>1,=* MY/\B*YDU0S7I1S!0M\4F*^?Q>F\SA3;SS>+M:V]V
MLJ^3\6^W+K1<6*ZY:(]\C=67^YIUWU">).L#,)]:XS"Y!J.3W:#%:^+@Q2'Y
M,HPHJ,\Q4Z>*0*+T-ZI&.,9$";HG6P^!^]@KZM= /DTD0[A=,DSSZ6'.1S9V
M8%V0+ >=1U/MTQR\NI@;!P*]'W,*3^F8>4++;]FEN7_DI5$U 7&.-VW23=)N
M(:Z9TH'R6T3@R5VB6-[":9HZ7:SN^^ CC/7/X>I!5@Q94N!DXB^=X-W,-03#
MF29P6/X@XEL+/LB7S<BSOM%]#GK8"ICV44-6P/*+0.-A)V>P#4-C\)@HA;E$
M^4>]:QER$C[*H6-C6"2<.BNEZN^;PR=R5Z'OKP!Z))M@JCY3CV[IY/(0(1FS
M;C*VVF2#/\++_/A\]O+P[#^KAD]<X)J%")>R\A&1M-U!0HC?T,6)X.A-9'KS
M8NRLR7R'ZL>#4=F!-D]_8[O7QOL'20;0[BU>AK9NHP,?JBI>%-S*2C3X/9H[
MDUO3>9HQ9RT,Q?!MB_H& 6D#.LRKS&(QYBG\Z3X"D393&XX4 \D,_SQZC7@T
MC;3:&W[T31I_2R:,NV9S3S+T>3:;G?RJP\;)$HO\NN.1%$+<TV_%8W/>Y3Q:
MM>^NH^B]?^*L)Y!&V S5<I&R80O2C4L*/^:?U3P\:2-&V0X_)TZ*RCZK<,9.
M]K)H]\;MN4O[)LM(%L'>.?'W)+SEC"W]W<U'0G(UP-ZR,H1K5M_9?X#7&RK:
M][+AMK9RE](J4"/BX]^UIXDPX1+REG%4A8NY0A;?YRU"C1!7N!DBRCA3D1).
M D$3T99.)P'+G5S_7;=<QU^QH)&T$$3SI&S]$.J L<;DZ).)6H[\9%PA502<
M_UQ[OK"4>I5PKOL"D;@Q?H0BX&"0\T*(K,1^O":_^-[,>>\F?Z!\B&Z%S9IY
M512^LZ$\'2*D52K8R]S!";E3)0_*26@5I7 UNV=5N &9Y'S-)8PTSZ/"P$$6
M_UI$.5L6?4Q95)?],TR3OO_KLK<*%R:JXL1S5]&%\A/*QPP"5"/P'HTE+:57
MR*.QY<U)X5J#@E"') 81Y/O"EZ0>Q-:1]>",Y4.XY&._'47+-W@P-\,8I@I2
MO\O[QFN7/3O0_87<WHGH*U8S%B@K&:YBVG6R 6DMO5_NWHV_:2<:^(:Q[<J)
M3]!H.G=]2!^ KU*Z[X:<TSA\RJ+ATZ?VR-J$B8[6A<.C?)[&0'E&7A#-G/.[
M>8)7'\XK!*,R5D%%Y:(-S&ZZE1RC-#$,YK;@W&U=]6L4#.9[U+R/M*KUT1EZ
M9?NCB2L.WDL@UYPO^7GM:SXU*(Q/M49M[,UE16Y;8^K37ZE8[W9E[=TRC'?G
MB6!SYVE$=V\;MO*9:]1T<$:%2_@V(=(.I\21M)4/D8B'"#Y#0A7PDHRY26>E
M2GQCKC7<*S.$O<!6U& T/2*DW5"Z['D)?._7WBL3<[RD*A?3+&S&-_F(OJEP
M2AZR1YHX:^+ASC>^DE,\)C?V2KXXHTAIZ+SWL::#L=7J*72P^%3[<]KZS/4+
MC]CN?W5RYVD/X/I<_*L2=(@ NF#DV^CT8)"# Z^*.%D56=!:1-AF5?*%:\U\
M%^:;'U?7,[A)=FO*8-V6/[8/4(GK3@:^KNBTX+G/OFA0X2@NRN/%CY(U_RMW
M%TA.2BX7CW803%6XWW@I!$UUB91D,EB([J)ST.44> ]W(Z8#0F74!"J8!IQE
MN&.,C>&!A<,L?H/M*2B=I7PNGB((C#60@S-#["G\%'6RS.5-US0G(.5'-6;2
MW4 CP!O;Q/Y11Z[&=-TN1Y2_B>.UX,&O+^:VY>_-7?G[7;<3M7!P1%'[IB9K
M2P_?_3VRP#+=T"]"DZU_@O=RZ/V"$RU-OQ<:6YZ%(@)=,FT?=/\><_#=[(8'
M-4&N%VXA5U4X_D.RF">:N4-!AME#%!4N)X< ?L;#Q._*C;HJG$. O%N%&PV@
MOC^G/X16G"=\&[7!!J1EZN='[<L4JW#'7X@P/7L?D+2N0 .@417NWX4\5#B@
MZRCYVQ4@E(Q>"0?^Y_\!G+US]']JCMR[I08%/K'A2P+@WG^K;WK TX$$Y$<;
M#[R9D)65-5O(FG6W5N'8/XK0U9<(GP!3X!_^S@UQ7(!J*U6X@_M4N/8!9:4*
M]V.@7V[D2IC8?E:%(UV>1M;F??SX41GDKSS6!HRB0=B$K';[P6YE_]-?=O[3
MV".4\4?=YMK_!0@?8&MRR::K5Z\"WJ?^K]G^K]G^RV9KKYG$Y.="L;J8$V.A
MLHRDBYQ2%JO?><&^A/D,2PPT18@%68<L*>8%32?RP-LJW$7$#LJ*K\?XG!Y-
M0%D0B"[K(S]'_)_2 :H*E]12&*ID*^\J2XM^#!:FW5F)]<GNJ-_)76M\?BHS
M[LW?KYNVH^M0W*K.A"WG=IK+M"VLVD=\!MM^8P78M!6?N[/1!>^T3^+XXNG(
M^LH)X?TCL<:>.8-I)<W%D]D9P\\>)5LE3O^?7 ?[_ZZ%60/B<L*+5HS@^Z+M
MJ"8<JE@[0:CXD@19[8.');S5(5E 97H>9.(!VN4N[F9H0A9[>LIF2M!5<)2@
M5@&78<%\)7S>?57YY*]=)@=2?*-27D[[=TO84BJ\D8/H9J!:%@H[YH#?3\H\
MX )9#VVNK;EI3QO($A 6ASO;RH/[T)U4N,3I! !Y2J;39MJ4WFU2UHV9->L8
MI-K],=*HJ(E2YXL>!X*/!6[U&:,%S\5]('=NU%LV!_A1_Z,\&_(S-F5U3 $9
M _*I(!EQ@-C"?@XDDL_Y&AZ!33#V+4-ULX%!X 3\ZO' .!FLL./$UWK% Q+=
M% DE%CGH+!I8"XJ2J;[H^]HNIZ1SH );$C2W'O\8^;MD'+).G2Q?'7J!4.+[
MJ&9JM5L*^0)9%VU#US4H\Y ]8(6 M#0!&P?7:KROUK<_OHJ06IN5^@AR O08
M^A++"V4?LUI14\I2\[MA96\V7!E\.U[QNN/]FRA%P_];JA#Y"C2:JR4!#SQ*
M&;"59T+"9N+@=#/A^?DJ< (SHY2P(+ /J(BO@81'H:=^#CU.E\!NGVX;^UU
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MSL)5$OS@/'-;\^R(XN&V<X08+O%=KM^;F=CJJU\67#2^W;9D?J^P'E&7M=1
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M*GTBZ-89R!:*TH&%R2.;5.+> 2G?TGB#;Q'-7 _ZS$D?3)29L.H^CZUBD\2
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M9G)=;F9KMGR"FR"4P](><<=M!9IQ*3L'G@L=%=J1B!K(VX*QMSPGF1<B=PS
MVEM+H/.NT\"&N/L\^]H7#'=UJ8-,92'X>+WA]'#0,_[ZOKY7KW JEMLLT]"M
M+JD#.>5],A5[9$7V)!]C4A\K:!VT@1= 6OP5\O%3N36!.5LQBT:JUFJ-U2;O
M;:6(*A8_5M67ZE*OSX+R([%%<E5UWZO'M)\Z?]YE?+MFZ *2!J.[V,!'HV]
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MH]I$:-8@,E?+],"])X8;8?08.X<Y%]^'B4<TI$/W@Z(0>5XCVQJ.IMER%:H
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MAZ_M\XZ?+M7"APQ)F8^ZCA_3K8*>_8C\8/Z4A#MW8WU-R(.:1L2*Z(31KX3
M8V D"A/O%*K7@!Y]G)$T= YG&HA4LJ5':\$C39^"2C^;"$WF0NJ ]&,AK?UV
MCY[BR6IH!'&*8\=@R5ECA@Y-\5"(X[6]F=Y$.+VG&PY-@OB(\F?7^6! 22Y*
ME!(60#%0;XJ2.A*)E>RBV2 J+^,UY(C6HIELXXCV:6%''$Y5/5/&VS;RO8!
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M8_]5?+#<6(XO-VPFI(2OL8I8S?^SP V$F*MG@@",IH1P6WV?/@P5M$*6O$U
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MQEK<G';)R7@6.BZRAIL@*):: \VXK$2TSNKY".FKX2IANF05"-D*"ZS!9D,
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M%^7& >%'?UMU<DYP:[\K.*4I@;*<J((D%B5V7X1M9QD>I(IGM\"YENH&'U*
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MO\*L@;\TA*_MB;'"0.G^.85&)T$T-9Y;?B[G,;*5M! N?#QR5_VZK(@37&<
MF2&K;WOBB@> 1G,9:X%E0!F_%HCG@I=QC2P\(K?3)'B36(3AO\ R1@]YF0UK
M(%6@GBZ2$G3I)G !Z$=9%.RG  <)@44PLQ6/J_JRTQD_?YJ0@#>I6_F)O@-N
M>L1#/Z"V_<2- DHJN@;^!G:TY.J!D\F(#KH<>D/*"9/WV(AR1*K)?3HIJ =7
MD(0'/5F?_#$%T<(<Y6[I&GHX_%L\N0CM)IN@>+.X.G7$%KX3!#'%$<G$HS7L
MZHA68(!=O^5E1 L&:O UH%E\K2(@YB;R:A(8RV"M%J_67+X20V<D5QVTJA9M
M!?: KVM8M3M_#2/&H?\.AJQB3A3^.\D/_3!DUT/<^1 V$_,GR%"T@)MVF;S8
M[]/(D'DW8@&YB%CCVP7 4CX-8W&'NFU>6[7[57=='GPQ%?W:97?ON.7T@IK;
MO_=S:XY9!BS\$T&NWO<+Q],2>R8 ISMB 2/R&:[QT9#9PFND>?3E<!94W.H0
MF&!IC8&19:,D;?B8X'U(&VE%.=B;P7GR(^KP=V[DPS.>MV=M'A66_IB-:<U?
M767[LHQ]]M>7)O1D'QYT8_$B)&4@"]$I1A<+Y6VRX: 29!?H-(Z%D(7WX6,B
M=B)[WF5"&N](G)"22%:E;WR$>0#7ND6C=2L[+Y/3V9I5QJ299MTHOV30I6'(
MM/<[I%0DYNN-#.F#KUNYX64[A>'1CSJD\OD".&Y8V*<E,^*."<S)+E27W<0@
MEK)D%T@8KX&Z,1$:U/I*-]*=817HIJ2HDV&"^(//80MHOE@2#5K=@2Q$MDU%
MET=(QLA.**8&<QS:R"7P(8:?&49HNP?"@).%Z?Z-7!.B!>C?XK7!,7).@>U*
MFL&47$UV#1 ,4S\1T"6KI8<1*]E?I"7(<EDYT1(R$_%H0Q0U3-5)>+K1QUKE
MTW7SX<LB?O)+KN1#L9#"RMW27_J^[ZK@R\'^_3HF!CVU,J_H15:,MH#5'_)"
M9 :>?\:P-UN(.(,NPAE$QT)(:0#@E9-M83Q%[$/CL#?95@G+L-?5 CLF+# )
M)US!P#E=2\QEOB2T49?05.IYN4^+Z&OAF!A#NKS;,$MPF_UXM]1AM,ZJ$_.&
M2VG=/B^?0S49#),?NOTDPSF%'2D8&5!$<:+_HP?'R#%YL)=78PU&H(OE;ODD
M7"S=*4]H\R!\BFL E+E!W#A4KYNAA+90GP6F84"8K(\QK3F%)I(^F-7 Q=&Z
M1;TUX\.8\9E!K$229@@68O/ P58)AEZ_2*I#"VE#3=YP@=+MNX5) JB%FXA9
MT;LY!1L^;.?81-;61568(C47=#%0S.@'C+!'8:O@!BY*GLD>U2VD6\%:(GPJ
M:0%L"[V2G >I<8BC="-RN+/6\<&(UWMV\QJ,*E -8*I[CU,:J@]G-Y+F]:+F
MU!_/J%IT=T)+AQZR%CZI%HGZA?Q$K\O$0(-=W59D!\;C3K)BN57*+80D:B6N
MA6Q(]P!1KBC4J8WZ%*,D?$EDG_4 ,50435;=+ABCI/W%0PY]G)[ -?;=)3#1
MM33/-HD!-86(A_SW06T)U;YXIQ>=@RY5T@O<%5@LN8::R'*(&.9>D"9+L08&
M7$0$%FJ!:%,4:#7N7<AE:&?CEJ%YT%"A^/5%40VKNB/=Z\IK0?;B:C7;QE(A
M*_TNJYF\9(2GGBDB&X\8G+[YX*A7$%FKSGSD*0_9 SF-M?S;:XR$Z<<U+**]
MLY(/9I<<YSXS0RO;FKT 1#,?=<?,8L$7#%<LDK& Z5R&<3?Y?^-T&O=@&KA!
MFOGODI@]?YN#GJB*OO08L@^V 5DB4J60.\!K.PK'@5S, #)L0HPW"VN:\QX-
M!#,LP=O7.7Q>4..8N*7E8_FS5SUK$O_QZ=A:7[,7&2FX>;%FJI_:T#'^P G9
MU#_>^69.X28=MOP,=-J [P&"S.QY6ZJ=XRKA6:?%PWJ?V1KI[\-[PB]O.)!O
M?R3?9;%;@9WKD?QC:UM#JT0/?LZ0B]$4NG8#$I(+G3-,_>6C?IE9_\T^AFY,
MO#2VP]KB<.NA!.=NB<V/&O/&=9N^7S@R8"IAHR8<Z8$YA8^Z C/4$$BB(DCQ
M/]54>"UE8N$3) #4;?7.(0M$M,)ZJFJ=);*IL^0^J)M^<]OSCR1+6K& G4)W
MN5PTX PQ?/>(CU;V,); ^XR7C/8?>UI15<&%EGDE9C_IB'SD,X+7.&>2__NQ
M/I-W_RO05LU',\HY7XFO6L-TPX]R_9/$1K^J5U_]L'&)9GY<34W]UQ<9CHL]
MOC28O=^IFYCG9S"8>R_R9KH(.'4:742SO58?32<L/&5M0>Q@EI>=+TU]U?2=
MZ'SSV_-10K;AZO;D>M%3NZC;/I\S'XG$%LZ,OS%SQ4AC,'YV/K( ^ST,4L'<
M9J:S+J+M(;D?Z;\SG[ZPZ4U*.,@7Z9S_9UX;0C7M("5RK2-P[G]Z^L9)G<JF
MLDL8,AGT$C)LX3<WYQ32!DF#*/TX]P^S'9JJ>5RK!+J- (_OD5_.*61]XA-F
M,WXAQV1'&"U\?;J[= ^CC5H1,;%8'*VF[ *QVX"!? &EE:H;E*M=W;.>OK&0
MQA8!C?PE,)]:#GZ[S7D2<K<T-R[PR5C6E=FM986E(08)=6SC6L^7C_(NW/!]
M/_6:+I\C^113W)- @SUYO(E[BB +Y#.K9]*!4HN 'RRH]Z?L**:FS?^/HVN&
M/=&=7,TYA?$KY7,*O>&")1/%_VG[;YG:61GYT)6>_W<WOU^$)'[E3'U8FLE:
M.%#,2@46U&G0#T*%#6%+\3IT(PAH#DL<4H.X*20M6D&UL;)GF":RN1]Q?3 :
M51.+;,.0!9U0E!/8V!]UY,%EO-H/VT?#$PXDMB6WK',;7NLST& MKSBLR=7M
M1' 14@6T><9/!9Q)HCN+OB@VZN(K./5%""$/YK1Z121<8NG";"<0J5,,-=L/
MX5*JV/-IIB[0FNJ (*6"LJ A-;#T=N'%RZ'"B9466V .NE@^:$(,#6,:*F9C
MKK6!/*=PDJH/][=&H4]%7#U:4PM045C/UJ 5MC#,(9W\\&(XKCEW-:3$$3B^
M]_;MG_[B]6OR4)]-^L&?8^X]TX;%J8.#=WX&WCXB#4Z9/_Z+H,GHX,^K#0"O
M\"41$-! B/>SD+''IW!+:&[=@L!DDB'-UA=V#!&&S:?DRS??C\PIJ%:[ZHPU
M'#ACHO8"G&'^))KG[WY@E2,<F=IJXKN2]\%UT]O[1&<I&5&"LAH&@0%Q*QX3
M.(TC6/CHJI"ZF$=7A<R:PI3&N,JA=$N!<U4T>P$MF"^\7?3@"VV=L6)#C8G)
M1RNB1;[3OXM6_;OH^ZGV-7']9^Y;G2>KDK3I!-A4$(H3,AM8B4/SX-U@=Y/B
M01,#.!)L:A@R 7%7:XDV.7YS"LT&SS\BJX6NCLX?K:\_&>.5%96.4H]W3Z!?
MBD<]9S/[LR,CPZV9L77+$"OY&>_B0L0")U\00]HJIFU#*^%22 M=2E"F16.<
M$,Q%W"'@TYR"T!*^*:; 3E43CJ@F&T_+ESIB,"D^M=5A>+!V=ZGL6H>4XOY"
MNM[0<72MH@C0QCZ:#5EPKXX(.277AHM9GY0E9A [G1C$"4;70:Q4Q%.Z#ED"
MZ:80CXE82X-U#>I>BRA:(;/<V$F;T&B_OFGO5Z\IGGTV+J]*=Q[LL2HCA%FM
M>7'7V;L.+!SWD!K2M$2>B>AF&"_9)[M#-X28#77X3L1,B$M!E\%J8&437[/6
M7$C%T>;SA4Y,Q$;(-0XR658)[4D0RG#"T)S")E_\GJYI;U_'_>#"4FY<2>E]
M<%PCJ'VJ=]E"_K0LTK0>M4/?L2LF)^R(&^2Y7#4"_,0BHN;E?$$#U":8:>I(
M56PT:V8/D,'K>%6<"1Q!1>L=9B3J3%FU+%-"F:",^YI-# &2R^R;]8B<M3/0
M!K9A[<4RA )W2C49;[BZC-7P_:"X9NY2U Q]SU6JC1&S-=1T]W9/J>F%U%E"
MU#B;4."(@5O<PR"O-7\3IE58Y4$&I]F/>'^.7#GRL6T:>]*.ZQRR (N%Y5<P
M@UEL)F&.NTI-J4!C@("@1%\' 8/DTY-Q$50P$].=\T0ED@G=%C)C"]K0SZ!N
M;%MC1Z)I0RZN!^T53JJPF"1% Y,<_SF%14PF%G]?1S1R,:)>'S:?5MC$L /)
MF)$PU"!.'$/C!W89^_3$$T(JYD' F12Z!6C8Q$NOX]RG:X+\).MT@XXC'U&-
M'U'5.8^*\I$MW583=,-'P5N>S3SSLM;=L'O=[#?LV15!W?%"J16R#LX74S+P
MF&,_S8\%U%!K9"]I)5F#1(!5Y')6QA1P! *20HF^HB8Q!2_/THE()1ZDNXO>
MDYJ:T97HYUX.]QFR,R"H-)@:U%.:]\+UWUEY<N<WP&V<095EN:3%])78<J6>
MU)>07Y'@W^MJM8;@J\;9K)2P*AEA;QV$X1XF@GOPP\L5HR4%9Z+6W+E<XN/E
M_/AST"PI*\"F?3!(<KUIK.J DG)*K840,(:IS;G*4%OB%$Z?1FCU4GHJI.K"
M.UN\2&P17D5>9;RBN\PZ'6ABK/IH$QW]WLSGH\W[-;\F]_=9Q[AUC;GU3(T5
MIUH,1DX4WEX#NOI+ULG2:W>#$8WLRK8D\BG.0):/C(TH<R@BCB*BVD=2I*_O
M0=5AVQ9=#SAC=+@Y=QD<$"UT1K2%7Z*^#[>2K)ZSCW99NVS=$81XB.P?/@^R
M>>]:5G?W02R1Y21CHXJT"#$N1=[N H=HPDYY= #Z?C542#6B7^A$,6^W'VX2
MDU4&M@M?>9/58(XHX':J<CI]]WTO;YICHXZ$1^*4#@5]W"ZDJC5IOW3*&TD-
MZ4#"9;?F% +XO/.TXXPNH#*LGLQ;2ELUYM00)V8U3#+9.LKQE&1R!2!<2=(S
MV0K^Y,IB+T^.&^.D(5*+<3:/_8E'&:S% ML8V8R_]C[N'3L##SKA/_6+,2H>
M(M5E]*$;.XG;[P=C^DVZ*K14ED3"]F"W*^P)=@M^7L<UE9X<:Z:J C5\S$^I
M3''3'%KCP%?-BMM[42-D<ZH(96/2W R'AEJSF1N"&%A<*41V2(=%A'$9:"A6
M3F'HPV(1OP$?3UU6&P)Z4\.T$2.(V2S7::@FA8%%Q6DU14] D[X94DZN\J4<
M 4WJ9CD)1$+1LZ?"D-<6[J$[FZ(6CKRP=2#E_!L537:#PQ(&YGV %KP6,1R\
M*<AJ)"346</=HGFBCC0& ;X(#C;4+8*<6MC+RO(YP6,B:O+=.87$2[Z;CT##
M2;I'(,\4FXTE\*/)PSU[\D6N45,^LL*C/:N?3_,P^2C"QE)SM)U;B4=6X\'W
M;+G !R91+6#< W/,[GQEA@G=#+-++JK!G0B#G0#A6NQ_*DTOE25S"A)E"?I*
MEBHKEG#'N1.EWN,D)TGZ<,[DK?_3+>78-1-2R+^%7%Z#:*=*7L*^8*HH"UE&
M/2*[#YSA#C"%Z=C7UI?NI0?)*QCD:8Y<P=^ *FI/LR1:Y-%4&AVRZ@<8!$9#
M5%C#Q,5FL@K1X2406ZL/Y0OW< 04EM]22'(3^KT7M*G+U$U E\,=S>P?6M3O
M\H/.M[)'4Y1/3%1=559%VN $VDK6RJK.$0$P0F";6 W$ ]4=]6%Z](MP-)A_
MX!6,!Q<^>/42['NA'&M]E&3E])!.[+[\VK"%M C"9Q W!X"#HIL_/.^^YZ9-
M$JG",.4X:M^S42X'-IM1QN"*"4B.9V#\M\&<'!"V$,8U-376+>MDMBD6_#"5
MY,&&TD!9_"BY"FB1>2$8DG5AO,_5 \,:J,E[)CVXM:\M!1UJ(VV-2E]A7#-P
M%@I+F!Z3<OJC$,QFKRU%HE(E][!?#J+O^$;'80*(DT0S6\>@YVU@G.0X?)Z_
MF*1$VT4+DZ3#KX5&L*%P+/CE  A#\SY24HC.&*-W9$]0=4.BT&?$ZT4J-.Y*
M0" $F$ -._%2&$]1\A8*1+1'N((<:H53/87),V-RY0D#U,K0R1:9EJACP@7J
M:#%1?M57ZR2@IL_6Q-/#P \2J@FM1N3)M"3:@WWB)DWD!)@5BZI^&N-K7F8I
MT[>PFJAZ1%?Q<:?I_MW $H:^[ E&P:F@-Y?G(: @6D ]N<:)Q17D3H!F\B9?
MJ]'!.04#\IF.JSRE?-L6 @\0<UO9 U*).\1)]FY9BFR!^L<1DC%"ZJ9,[(ZR
M!A+K5/J<XA]"ZLQB6A;&'I-(7\#!O;"M%(/72AC-;]A7MQ%H<"<+<C'UU^>>
M4<-MJX);P&S1<#(0&&9,:VIR4<]YA'CW(%H"(!'=^ PN(,>/5XVI6=3/SB1=
MXB8]TS%9!_*90X!*NRC=\"ADEE!2NUK(7QK$F ?^11[[5OB''0HT8,CPFRX>
M/!@FW4 =U)I3."8669+_ZUR(L>\X>#UNHE*J#UM(#.3JCGY -\G*R*?)BQD?
M=;E/\1.;A=[DJ[EKX!FP>#O<$B%BF3 ^D"Q?@.3$B3K]X#J+:JAD=B9M MEY
MGR)T-;'4F,9I["P[\VM$9R:Y:  #Y!1Y)C;PGS*QYW5&<=_BHSO_F]YG%K"B
M+&LQYHS\9=E_R+^VU:D!H\_!+P"0B<QCM+-_G04JF;*_"''4V3*B#;63[T3^
M8Q1.D*6>I\YF'D#IL]OF%-X4,H%Q_]0YA9XS)A//9]D?TG)?V(^PRS;_$3!V
MW$A!*\BWN0*&^MC/()OO95;B4<#A[F=VU?:W<PJ^NFAB]4+7L#D%_%*@_PQW
MRN91C5_Q;\79ZYB4CLXIO-N(04FVY 2_0A>MG&SB25OKU/]G5[CM8MG:_Z'7
MN(AN,:>P@I\,2!R/RE]JX97>_\RJE)XQV$\<@_\M>?R_?==J/AB.:Z:R^$\+
M)S+EV9"REU4X7JHD&[:7ZK=(W>GFL(7T+.S1 !@@@?G(@M1&DCY<G(?X=-D8
M1PMT8PG^D&WSUF@1KA$#T&=";44V7_T,H>]L#LU1R+I&U ]_%!05S]O-3..6
M&OQ1D?R1L>AJ4H8\B;"*,!X-J?^6FFZ#OX$2:5,4D%SWOG@4#\;!P_MK*R!*
MXYQ"$O?32[/D6L-HD0<H%OG%"0G&K,6NHE#3O?+A1X@I:?GS&.4C/:7?%5!K
M="O0$%*W&3:38(M?R\.TQ!W1@CSD4R#))S@#)+*RG&1AUHAY31M.,EZG=C.&
MS,[*GM.I 0%*7/&8L84DZGD/8P'Z$5T VEY%5D@IC(\OZVH@[S8\F#DZIX C
MADGM@@S6/!60M6"F8&*F<9)-LI8/$R.#[F$\)\D>[,:/&!^XVA/R3EU7 4-T
M :.#C ')-B 1J/)$M K%/_,OXA/C& /<"G)3AQ[-GP)7@_GBF3;.$EH=11?V
M%G_(#KQ<2K>%J_. 1B-K@@%"AA*OBXQ=FAT2V''D4$0?,_T7L-8N[%9[Z5[8
MO\=I;9*2,",XKA6H[F5-)(#=DK_F%!(,B^&@.DV:!*=$WP('QF!ZMX3I*KMO
M5@'-2)A-5!7Z-O ZNYE$?M9E"0A/YT3AU8 PVN:=7/;;*BIL0VT+$; 'LQK]
M+/\]XUO98R:K8:ACRN!;2D5LY7>E+X!5'B%;>NHTD A8%V+N@'2O(398Y*M)
MG.+BSCCTW02OS"DTHK88(@ 16["FF;J,EKT+KH2,:$VM;/7:+5V*ON3V[HL@
M6^(FS['@AK$'/"5'07(];M!,",(C8(>X9ORJU(UV4W)!]F":G(K7M\'Q7K4P
M-D!FS106&X<:TZ2BK)9T,TE2-SV,$$NWAP;K3>Q@FYA H9J_@-Q&F$^W^VB-
M3^*JT@,M)^-JS0(@W AK $#5K61<^D8,?[6_-!L?ECK03>%\Z4%T ".#[D &
MN9(3>Y9D3;\L>XH]OIL%H$"WE*5B'T7HO=5;\D3&J5N![.JJGDPR(<L>7=I;
M:N/"XIEB $VY5KF0YGWX>9;PGY?\C-KM8E_'GX14+AAHBUA2%!AOAN0E?YCO
M. $TK:<K0(3ZC@D*? KC43 F .$*62$W",<CHYJLIT 3)8@/IL6P4 ,5="E_
MG%(-,R?P8!(FT)TRSK]@QR1U$#9%U0@0OY&;0*V(B$=U@ ;7CFOH6L8;:C6_
M-6Q04=C1T@'[&^.;73#FQ&WN4$??1(4EE'C7FZR0Y4^KS>,*_4+X%5=R1.2J
MD*S<59V(%]'O4@RE2>=(E&H7+4G->KJ_FP*;M6!2.0+(BV*T YNIX+YB<^X9
MPE5V%1_!G(OD/;P:,RA3.!!DMK$U&"K!>%W20L18=I^!IV4+;2> Z+-<1<;*
M8[2A.05/.95P]1:^CL<OO?1%681K[DB<K>TCJ]:9PYYM7L^RQ3*+)H9RC^P1
M60"&\<R:^-K5[&1RI?(X)%T.<R7ZH%F;=/*:)ML$"<L%>(7BUDPA5R/D[ACB
M"9(;Y<60=0:(+VP*2D5AC4<1,D;TAE/HH=+U= IHVQ26Y,$_0UH-M:75[F\3
M#N7,.D$AJ%H6W Y))2[P32D1N8@I=B7=#RX5 \G<&IULZ1D_&K\%F#<Q*)BY
M6HT;!WCK?K>B.O!.J7408&P]J4I?UX=:(AZR1P@ ;19%I"#&XJVVC;-3L]2X
M*F]< H\XN_4[]PFLC"$<P<>P2KBRQ1G<*1F&=X-LP2"CQZ!CPARL%#+EE^\"
M2B@)+A9^!GA:A&MU&K14,:>%D_:2VT)(XRZBFPOCNZ;4_(74YE*/P_!6"'>@
M_ 44D5:GQX=3C_:4G59T(8P]D)T#@JK^/^,NR#?8L/V8I$-6" 12D_B@"PO3
M<D$6]E%Y$4)V(XLW(YII9BU!.Z-PX\<*?VQD]/$UB98",J9K%9=X^$1R(%G7
M.=^7QF_BZG)"D2#1>ZT&!Z>XVNU"*<XDA&%:#69EA"*[A='2G)64W9@ =>79
M/AB*H P D@?/9<\ 0?Z0":L!OP@(Y29C$09=1MN)+EDM3M\LI$X,2.W@D\-^
MT/<B 26>_:RCF9/JMQ+,R!13TOPV=-%-1:^!IEP\*&%Q!FBNB#9$;O1R:J%H
M#M(<W3$89!># :&%\KK@G? 8NL07<I$L@_O!&LEK<@6A!?_)5J2<4;<6L8.<
MD+66>+&@AQXFHBRE:T.4A.K;G<3=D$5]U,+'H-]KT-^M#GW?-]6A&V2RRB"O
MNF<*/EM26--KAX,QNH$LM16PQ]OQ$W$B_""Y%<!A BS@:Y%#*3SE7;('=>N"
M^4;RPHOX*%QC.]X$OH1X<,OE$Q67!-] W$#TJKC]2[2XIM4B/;#%84]EX8B%
M<%(KR$\;+(Q#3 ,*QB)(%LK=L[_0EU%3Y/F(_* ',ZEKQ73YS/$$+*A-;55I
MY>(P#WX:\Y,84S2;H(H(3+\5\#&I<UN^;7W'@#MP2M[;T(A\DL,KEIP$R4U<
MWI&F;7"V>)+E@+Z0VM+$HK )BP!P6!S13$W #/HIT4+PVK297]F&?<I\>)U5
M*JHVC-V/!S3L0#RAWQ(5>>86VN^G@>',EK $?#6A@<,S$U$:6+S 5OY2>H28
MP(MHT2$MAH )0Y$Y/02R:&6L@J]#ZOTM=Y6RQ.18OFZ=TIG<17U$4W"PQ<$O
MKH!FT?SL[K?A1.+6$R'RW 6,.8/;<9HA^.JV"2XT)F!/A MPL?@%P#G\@/)!
M67KM":DU'"%9"?MR@$8UL*Y#LIXZX"3\<%6 3[M(W]%)/R:@*L!:+5&>UTB;
MA^B;8,\'R&9P,L.IB:^$.$"[9@S"$I&M(DM#IBR9+/C<)#5">ZB@*Y='00T-
M41U;Q)$O > OX'J8@.J/H1HXV)L+OB#&2 -H8E23#>_E"FDT-KH4#SN1A:7_
MMOUX2BZO#9%QL&"*43HN;Y:*K 9.@9_PX%9OE.M6*#(;OX/%@;6,;I*B+)VA
M23>$J5);%O:>!RF#+I+764W4BIEK* %QEE4R5M)57\(;2X/9JB@.OBBR&6X!
M!ATE!7".F*M':,9EW,6UL*^1-,&L)@X+58==!"Q=FE8;:@U]:[MF0U4=-2"T
M4K\0X-5D1+<,<\3QW4 (%E_XX*%0G,1?=K5N$]I$U44,01516_HTES6D#5(:
M.$;("4ANAF>D]D1%H2&0E&O6>XF-&QM:W$4.E)U\1[/FIO-U3L )6W)$%'WX
MBGBG?$QG +<>788IW\Y:=W#&678+<0*EZ))(S@\\AN*8$+.9J\G00<[U8E;P
M?F>;U[D$(8WN+<"E<)49>C!5,)Q.#@X-$7;$T\E@MCB=V=J1IFOI'Q!12-\'
MD=OXFIRTJ<7BSA-9GC(YM(B6MRA'31C_Y&*@@^@O/4=WA3''LM"VCQO*3\.K
M8VZR:U!,'0\#.QK19>!D*UXY&(^?MKS8QHN(G6;IT8^!!\>&UCZ7Y1&/:3\<
M,OQ(-U2.KQJY[(K?<W4JYXJ+Q5+KD8$(/A84O?'8E_$ 8'LM+(R]@+(DL+Q2
M5G!C3D$=U:"?EF63 [D#T:U1G!8RK[@>>[9EF'&F&> 3>/U-?'5T Z.+/0_Q
M%'"3V*JEUK[*@JPT=/T/KX@$Q%=(4$&.=9<<!]<42?<-P-S#L"VQGZ&)"&17
MN8(G5-"="YL[I9$%66QP+Y XI_ LHHV?X!"6>AS.M)THECKYP&/NY;(BDGD9
M$QH4$R8L1)?@&*E[<)N(WRQ;A'&KHZ!N'*(")E2UX^9MR8=4#D(139,IS!;\
MPL'MV:ZR/_!O#"<6;>%(G1C]?%WR2?Q@N[P5+,B4O($C(\";(N7QWR!7XDO5
M.</S;.S0\:';0N26L,19Y32VA F&#C-K%T($D6U3"Z1>()!W90,:&"9=1+6R
M8++BU(0CJKUJEI4P?:@/DU<O;AQ3/#SHN@*,D/P*BV=7#2-:-U&MAGQ&EUA"
MG5.('Z>[NG!XK!9V=6##*B#.STR6-UCOAZ->(VV%$\10ZAUBZ)R"REI:#E=H
MU9J:_Z/.N&)!.![<PQDT$YC()PRY0T ]/Q9[?N])%A\\P!\HE*3"BI<#P#B!
M[@3S(=I/VB3+IYM)=].W'(:&7CTYANR&2Z4.L(?0E=4T0192$DD;0BI#_$P@
M3F,[1^L+G(7A#,BL"6\00E:GKQ#+*-+UG&&"1 ZH=>@1(!Y9-MP @(<X@U1T
M2:AX<I I#FRB,NM6@>18ZQ78PHX2!CB4='?RZN7)Q"O/_%W X>8P$YJ',VAR
M4]Y-%..DV&MK"2?C&'@@!#D K8"OE]!2)@^^@&ZSQ<"/KJM<"Z3Q_V333^IP
M#2:WFQ +T7&48&'RF@#M)#_E(II2R=\R3AB!L1!1@'>*?2\*(C#DQ#+1EUTG
M+@:'F_K]U.&@$EKBS(X^IS:<XAFV7K9'/VI-\VAV*,Q  G32(8>MU%9L;;6S
MM5L!D"\D)-!= 30^$TG^CR;"0 .'K4<^,Q$FJ8+")C(AZ5Y9/F8VS)=AC=ES
M"ICK46&L !I.U2F-;<'<:%5JNYK;H+ U^1&R+%LHN2ID,W_!3-<:Z$JA$*]^
M9M:36<TQ=@;$I8$4+I117#06$=N-4:N9? D%790@W8RXR.3=#VZS*P+'^=!-
M8402214Y! <))Y-N#Y'A:%%8,D84",%>@2ET)RA;1$Z[''H:9X1855:!KJUQ
M8D>V!CF]UD+X>HLK%EWK2;J0#DN TZ05MI+,P-9*T>O 7W@)*-^7 AI\Y#F=
ML/F>2NE)WQ$VN(_,PTNBX1"A[**P?YPE-6,,F:R7/4+7TTU@5V%IB,O'*986
MG=*'A0%[6%> 4X3E1:_-Q:]-#T)'7M+#8Z C38V:8SQ<XGI,/KIOP4#!9#K=
M0K8$;>!K Z<YZ=P*5B,'$QCV]9HY>#I5ED-T(YYC&&.ZG2<F\Y1%NAGT7=9A
M22@!>\!4]1=B'"_;HX_D.(8?\+/KJG7-&V&V>:5W?+*.L:5T$S=^HSFT-WW<
M/?UM'C VBY8 YGP\)KGK;/#(:T7)MSAT2;)4B='-KL U$08-)3=E?UVB7*76
MD./JUH^8V/74+3A#7G:6H4&W K6'4\D!Q86P$V36TC^TH+O6&^0W4I<B*@_H
MA[O&:[?GP97"7"8AXW)8"N:M5\%M0IVX6<P?+< \^S4Z!]'2E3<R BD2M]YJ
M\CPX7T1A.J70 R!V&Q]7BQ'.14,WQ=P4/S*TI5#DZH=&O_K;LGI2GZWT(\+/
M&):WS3&&G_2[0KADHAHXV7CQ,RVZ07+@$\VVB5^X[( I5"FOTI9JHZWH)EDB
MAC[Y5;88Z3K%'<AN ? E<PHGR;R0EB-L([HSB!>>?@5=ZV\Q62#/] \5L#2]
MD?V]1(O+XKTVDTJ#M.AM-6#94YUG+YG,^Q^G:%6IJ793[:OC1CK@U4[(@]_H
MXE<8*-.0FLPIC!$1QT?_6UME/_"[1^<45OWW94,<@8H$4[N;_K)[Y/&K= /Y
M1H[P"8HI(CQ?ED7^^FE.(1 G74Y5XD[[T(*Y^749P"\[$56J(^!.K\M#_DQ=
MG5.X3E&?4_C4AN'RQQ^W]J6LY8R9_CFS+@2 X3CT%198\TIW>GC/*;0UXZ=Y
M!)E:4&G_$Z0>?0@(;I-_I6'\STSV=\0XAAE+I*"D#N+$<?\G%WYA7F_?_U _
M^K]2!GNUE"WO?\Q=R!4,;S''E,1!5O-)-9,RT!!K_$961IJO@13//.(J<07?
M!TQ3T46 --1E4^1?K<#I@=5II\+2R2$861^YWO'/_8RM(366-Q)/Q-XJ'!<;
MG=,Y6-3>\5;;3ZTC:^)"P?OVOK[178,'LMTO!&\*MHAT=%S]C!-0-OQGQ0AP
MYM6?[ZIQD:W1R.= 1!9R8=3PN<A]6?B+5;_CUSMQ+\Y&Z(_X?#9X>*/#=/"J
M=E%FVGF!TJ[/YU^0-\[>[-C?O[MP<"BXYOS@[ABC@V[M1AI/6=^O9VAO(]YP
M<S@E+M1&:\^[7:R_]=Q0RRSN0Z619R\A^4,YO#]?):5H'Y2Y_U20R"C/0=/Y
MB?NWA&BWK@0)(M5?-S7JT!OHEJY7%KGC8-'J!3="76Y(;AVD?YA84_,T2U9V
M^^OV\TDWAL_\.?17S!ME2.;J=6-6):EGSX&*X2O+%#->UW>,>>>N@[W%E"57
M'\/LIJC7.>GUSJ'5D>,_5Y3GFB?]"G!^MWZ7R^LK$W:A3<:[(V.Z#5WB,S[?
MH.H'.%[]*G/:WL5US$HY>L_D</(_@4QAR5A"N-V3R",&A\[#7B^&#)A5C\I[
MH//Y3O(=OXO/7W:R7KBI=5_\'F31/AHP\'H=+:T2K^ICS*]I%)V@JJR[[L+;
M?:CPX#XKW9F\-86ZM>Y]7D.#[W[>'P]05N#X,(RDAZ^\/A49D.&9L;=B3]>>
M\+A!Q:FICN /=Y6>'<X];'YO(3&C=FJR>ZSMJ_>?F^UZ4NN2&^7J0KVB!1-F
MRX\?#_S5YO6S>5COWJ$-/HY_?[WCAK>1_+I;2%G+KLHQNCQR/%R[O,?\\&V3
M0\$]A:OM"8'K]DT4GLG9=R]F]FF1?7>%V[0VQ\2/]HAWT)7J-FN9LBGD1*'J
MK[>KTAC'(V;%W?H_[2?JB_LW9<<NTU_Y>?,+%\)9]3UDZKX1PR8=-:V]M[\%
M$J^Y#!?J+9A3H*#/=FV)T#MS;OD5!<'2>'Q]+-GH\OL+GB"UF61 2WN5^N/4
MGPRMY,G4]B<!]J%GW534'[=$[U]CJ^6!4W53+UNI;5XUTEVD;74I\R^G#8V'
MJ\I_%2OOZ;Q;9%=8^L)G979JVMFI*UUO_UQ,MI:DC69IO5$Z6NRR8N?5'VY#
M]_R'\EA>V1V_KSSK%92Y#<E>&',_6%1DN5QS/+WFRZW,X\?BAI^/L7\YS)1D
M?LR\[Z^#QV_IO,'_BGD&*OO[T.+PGTXI]2=H%Z4."0Z'@H=9BO$-OWL+[;QH
M7D$GP9ZQ(T$7I<Y6@:OQL6.%=TX$[[E0W'&EEW1Z*NCA0UE_&'?RTVC55K>^
MB>VO/MTOW!%[;V(BEN*.SG\UB?-U/D'F67,(X>?G5VW<:P2>/[C+_HWX1W@*
M.!:25/KHU[/,2X[.J]*TW]AW_/G^RM*V.3U@O>N"'\8^&^SV+-ENO/W-F[9P
M?A?W*:(&Q5TS4;1Z1]_Q%G8Q]+3*I%O9XE4YB]>W:_F]+-AWR"+FG/7(.^M1
ML_=[K!]F;3X73@JS>U=\)"%@)\\MYPR@]/#>X^=3!_VFNT=YOY\Q'X]Y[2G:
M^K:GNGA-E73G2?[[9T>7K]\C,-V]V[5E.SFB?\3U:2>G3) ;[:ON_2K:9LUW
MD>.N,_G;6[_'W-?H?G3Q[GCM,6C^3"NJW3TUV%%9/91#C-"@+-C0^+["_"1O
M_]Z\JYH7</K#0Z_[A;:M[/DT%V'OS-7I]^O>5@,:1PL>\@H:TP;WZMA:?3BZ
MGIYG=/V>V%[$??B\S<9/X^L='5LFLDYH)WCZXD;;:?U$14+#]\@+PKU]"?O/
MK0R7Z-$.OO_1?3#':-.% G<K/T;AU\BRF)9C?KMWU.&9P:<C[VU>=U3_FS[#
MZIS>V?G%>CUMW=GI]A]RB.LRJ8%O_QFUVO607GJRSJ2RMZ1:[>20?<F)Y>^#
M0Y%OI]Z\^;5CR\_-K=U3-C/L%D"1OC$L8<LLOX&L'N0U-9.$/RHE79]/#7K<
M5TFL*.2%YMUQ7W6TX=>KG"^1G)MXX9;7(L/B"4K]1XK8T#'2Y[U)JE8P^31Y
M3)4B<;?JVW7Y)/[^N;UC?G>D6Y#387$,NQXA%) =;&+<:[V5ZE3W,2R/_]7O
MRVZ]:U3SK/<I>U/L!+&VBAF1B&Y+AZJ=:4MMDQ4TI]!42U)6O@,^TRQ;PU'\
M]L?/IP@Z<MC*R:_N1,+%?8DGH@Z3*S.W%'4U.S^Y<8MRT&]E.'?Q>D +]L_M
M,&S69[BDM?\NTVAQRPP^]L&3E=_N:=E\'#HPVTJ]X_%HM,.JM69W:W7F-V-N
MWPRZV!<+U!@<OG8>"]2)C#?XV0XVS@+)!01%2YOF%'!6\DSZCF?KS2;$TA,Q
M>2GF)YTF-"!#??&JB?K)-HP\'&7#JZ\KHXO3L4#V;?EQ_">R9.?R*$4I"=E:
MCQ0C?W,%1;_V\$$/,KRV9+[/.5DM]RS>_N*<@J<:I(5WVQ1C 5O\T$AY!]:9
MTJZN[[!J_[V:K!Y2LE 5*)^YJ =%+.EI^)#*6=P2#7UKB78\1-,_><AO!!4W
MCUYH$-JOM@.>;7_;B@'L/%_K\?X80N$FI[:&DLMK\Z7&M?-.; L 5MJ\=?]]
MZM:"KRB0>:JMH/AS.[U8:U?L5?5>WK$+0*] _<)F#"_TO5HRN/V$<>F])ZSE
ME W,A4\;[-_Z=Y/?5:\WW/\T95?D#6>WH[@-6]RV;L[('_S-F:'B&HPVML)#
M1D4M=ZCS!9"=CQ)^RX>+=*UWOY#LQ3EM*FN_/5]?J:)*'/7W4V=)^TR>5--W
M"0;)FVE//IWI.QKU=]'NMXTY]A<_/"SZO?N=1Y9-_C^3[_K>#3LDZVUJ7[6T
M9:-H+5(U[VGNX)4,?NGIJJ"'/@4R$6'R[_+D3-\-?UJU5&OG;]C8YN5Z\D1T
MU"/>Y>2\]5>*URXPND+>^1DZZCFS>6BCKL?Z:Y]#?;1'N6L_?+XX+0OYX\*"
MF?&_O#[-'@M3$SS]PU7]#A4U1,XV?--\N]GH7<[NY'\JSPZJN6UX\E3/SOQ
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MU+'.;REJRD>0(P]$IQ_"&SOKT0,YW:877C$'6-@ 04?:@"*.OIOYW)J2'#=
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M^ KI@,(120XF!21H<T1\0].%'MO"G8X07=B?.A: 4P5U((+GB+XOX/6AWR?
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MKLP *HMT?G?C1;_: +W6*+VQ(BC0,^/&7/+!+,*+()YLQLT$J_")6DV#8>>
M246?7LVIP0^.;@NYK0RV_L=!(/W^#8(82WJKY03I^I]#9)I6GC[VL$F\:'FH
MI$'>B?K)=T^O[O;69=8IX.1=*CQ36FCTHO0+-5BE(.D+9HQLRK*.8>/HEUK_
MW4?9LLJ56MZ27RX<O"URX&#RZCI4". 2A-EAJ'#$O%)?S=D@2K(^(>*SM*W/
MDHVW>V=]QJG786=?Q4PEB7_KR5R[O6^%NXT.0>>9H8?Z'/J54)_BP8=U4'\
ME8(//5OINK6TH5$S[!!1/GRO8[E"NU?',AO[HVLGW@7(675JS1SZ!Y>M"SDV
M3GK9T^5@?!'@9G]XE!;M>W:'L 'C;Z"[Z^($\ICQ(%0B@H<LG1HG_^*G=7?#
M*EOSQ;CA0PXH"Z5*8XU^6O]5H38P!AEZ^0 UF6R<WVLE,/KDR6?7"JX_'2&?
M]/K,EW4_K]^KS"@Z 2D1YH:_3#^,W?8C\!2^5_$ID1:WRU M]N,]CBAUE*C-
MQ#]5"WA8DV#A_6J<8J&M=__!S-NMB]7\F<.!!MJ&WU/PSEA'/:PSI5RUWK,J
M-T]!S3$^7PF5U'$U031E]@(-ER^U[];>5^0T$9?[9EZEJPBB8.!W7-U<)A*L
M\5KHI,$&+ 'IUD^/'RW,..6#2;$05*T@)T-V]%<*/LQ"='J4.P_[6+4G6!O[
M=2NC4<2+P,ZP#W@ FAD@!71086GS+\.D?40RA?&MRS-W+9Y'2#$ZWYAZJV5
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MS&9'^V58Q6QUI#V]--L0RQN^X[,F=]%3VMBLZ=;S^\BLJU;7_KS%%W7_$<9
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MJ:^D3@5HSJ(4D'9M\--:CF5P!U\7C<RN+3=[K82+KPIU31VA21\6JW%[3/2
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M0@8*-&6H8S9$/=W$F!4E+6#6?[2/'CO1G:SJ\<)M*][488F8^K6?)]9D ."
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MBQ?^9BXKJ%E1%_UZ0!9<8D9?=EW8U?/R/Z^W<-3[SS!'_5N7HT=NHGVV^Z3
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MT[KZY"/Z7X_KC\RY7X[N=_]I,-$'J5&UM9<LHH]*]+I;B!BG1+NU"2T<U.2
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M5JZ?\,NH>&5=7J\YD6)M+8S\K;5\#NB?6:9$+ONC+]<HA3B@"=S<?%=MR<2
MQ?X!65.6KQFY06+U@T1%V)"82Y^M;Z5X^KK)2/C Y%-2^?*+_=R#910#N7*M
M_'I).Z]RL(2%E4!,HYQXI?1!,[B5D:6G9L $__L/I4;5SF\M-O:JN39_!GD-
MX*'M+3!> [<IA8 V(0\7N?$'X'N!=5^9CNK;=PK#R/7S(909U]'BB(?4^$P+
MK:1 "FX^BB+21N[^V6\&9.R)"A'X,G[&YM9.]RL!OHXSCG5Q+8#'(O$UFM1
MI/E%?2)0U-94Z/$#L%;,>A)UW8!11+?LHGF(9LQRP9I_WYZI24_N]8 J6LK!
M*TVD<(>O6RHA+&<';TTR3TTP ^&-MO5 J777]*_EGTR]'L:&;]=$% >4U:PV
M A8[^K%?%6G\G.83 >9#GOU=@)Y ,<ZS/(K+M#A["ZE##R43,W#P* 'D"5H*
MXODBW4*C"E> E*3'4_L[+:#-X3N6Q^@FP*WYT@R(=NS&(:!3\?Q>.!VV%KA_
M[ >8%BF9N7Z6Y"0$^%(*1YOMAV$BEFH1'% [#P =#A"F+^73Y;F.TA&?;GD
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M&/G[4FH9+CKV%!L\)JU,M9[DX#J\B?2@CW0U^2!M@/P@:3Q6<I4H:RF+H(Z
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MU#IKGTU1V>?#-]6BMJ/DASQ02Q)B/VIC5N:]_[4-T_+GLWH>>2 ];&15^'U
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MU*X7&SS[@TMBCFC&8(]C))BXY#I$6ILX*AF[IU!M^3-,6R&5#0^F&^_7P4/
MZ+5.UX4N_!X_O-AO7.F2FJM!CAY4_5KIF%.W!>)HF6V1JUA)6=.W4M6PTI&$
MVCC'I<MO[Q $+M"4?^1O5N?O?^1L>>S?4=C>U/O8WKI'8LIF.JT9ZFHVY=>)
M:F^SE"0NE&FF6> ?(P&$)GBBB&=XAO" 54_6,S!HY\9-<*U]FQIM<@:CU PB
M&:@G1(D4#]X!X@CHV2TO5U4-%O^+N3.LXXP)I@T>P1B#F+!!<6O@U0*%J_KM
M?<M-@A]W+Q"WEA0:Y=DQ([.CB.OXB 1Z_Y)JTQ;8%_382CC@*^Y#PZKPCG@$
M#AC$ :DXLN(N1' )F?#?=J>]5-XQI1,^O0L!DG%DO@;NX1]-FJPU5CV.IOJ-
MVY$RN-B6/.;2[6GXXE5UIWO)V3;HL<3<JG\+7"<?S9'M'[Y]'IJ3DYSJC^L;
MU39TD7<RT[\Z1/[3PR<;>+^*-1'_KN=<ZNO45+NRW^5FMHYXO9KFT(_RA'4Y
M0)$KG W*S)+BD0I<43::\X8=QHR\#/;029,U/87'QMMD0%7J+"[5Y!AZD!6^
M"XG;A1"$/:\WC;;X,7/),]H-S(6878@O4A*MZ/2-[3*[4Z%G_NTW:C/HI!@S
M!8WLY IO;:- 70K](A@%)9=#097Z5B]@!IEX 2\:ADKH8?F-S0/[=R$9=&#%
M'=K,_.XNB)AZ0Z6P9N"-0.QAT!(J_7URR7".$.]I+3080CAU7VESSM3/RJ3_
M75,U(<5OK--*S.@;96 BJ7F@6-?0UM[M]PC#_/DQ]Y4WC-=IUV4_EYO%JM[.
M3)>!;EHZ5B2E;%=C>M,L+M=ZN1_);16[-3*7VRICC)AC37.%<T D?.699COT
M,'?8<*"4&4"AUNJEM>FSU<!- D;UX[=:*O\OG&@+WPZ<#0/Q *F3>O 4^+%L
MT=UP"&-#P$" ^59/>B(;24,=0P=TB<_(YUI]Y,4L_Y[N-@GP63N:PA5.84IT
MXH31FM9@VBYD_U&F4QK,%"AJYPJ !D "<@SGDV)5CMN/$0 J/S)17?U T]+,
M&B.*F@0S]2@&B72'3(Q6TT=F=DX!T-#QR*P48%@#W"J:$7'/)%N+^\'W34[4
MJV_^]DP+"Z>N.XHJ'D#=Z4.-4^F5:I.]Q5*6!8:;IQ9LT_2DS[J6^7]2!>:M
M7>4'2H0;HY#0N"S%I*[A.$M)^Z*$-.?A3E/';-'G!,>R N=)7:.BK;^<4MQL
M7 AW%%>-6E'8@:%K6*499.X%3AR&OXQ]'%CH1 EAA%#@9>YQC%H3L!:#.5WL
M&H 3U$6FAF__3F/R7_O:)HI1O8F7<L;<; 9FBDI=V&8M&;29@@ &3LB/*FQ
M%<-U\+,C&*0)?AYA_4!,AZ.0$NB!<=K"JMZ_F& 0QY3IP@GHX@]WS"+C9\3
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M#.5GGP^8Y.[7?4LZK(,\A 2CPM;I4O>"CG^?T#*<=+M>'?3G[?>R$Z?8R\F
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MF\3[WTR,V!Y57Z<I,Y)@+CWGVU7!X+M-74!#W-43XLJN=_\1:GXRU9H@ZS2
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M50TL2$Z1CTZU+;U)5F./F+Q08R_C9DMQ@*D"&#:XP@$RZ6ML'1);$PXB3/3
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M*;HO![6GW^I$/+9,78@SP65I\AULL4*\LE_;?/GC787RC&/&VD(2;I:& \_
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M@[9=/Q]@MJSJNT^^ML1.T)FV "I+A3$*G73U9?1Z"-^-AQS,$'0%&GMTIE6
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M:)"C6B.Z\5,#L&*"H'XSA3J&7-> X@NM!4E(,C02TIG;H7KN)G)R%T9[P=D
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MDT11!-<*"SFD-/PF%K\$D5H_X@1I'U0LXFVD[!J&[:F(ACP>>P8L\2-2G>-
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M')1:">K?RE&$G%Z.L7EA][16R &1V8)#]304W?6Z(7UY43E@%-XU/=<6_H%
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MK494,(_8C7.EU?T&TOR)81>OJ3,:!NN+Y+(92+NOF<Y=S1*BYOQ97%:7Y<,
MM4)JC%))NKA9T'2_M?'7$CDV9E(8;(WX.2LS\3HOHNNNF70L4QTIB$Q\7=W-
M": '4H"11:[=(W@(82%H/Z6,58R.P*=P8G4?0EJH<8E>"(['W^!U*<,+)]I$
M?B<^R?3&&_/+B9EX?7]FCT1:9:89SR/G#!?YEDD*_!AX[O<8-Y/8M%=MV+RU
M,[):^-XO0@,)333*'VO=M H*4'-:OP)KO#O8??1P<,(0QQNA#CR-VD!L!J!(
M8]E<G#%Z#&=W]NM1%;OO4;=>?0>7I!]AT\C'S*^ 4(O.X+O>QKEY< Q\FLG
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MFA *7$RT7MU>$^VZMLW>_$<CO.WH\_!-DRP67T[_?VW IK[_ 5!+ P04
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M^Y 7T IWZ5[W'9=+0YB]-AO]OI0NDR64>H0JPTYH>LT.R450.R.G^)<1!_[
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M0Z0&:^JX&/^9*MF;RFW/J,O.;*'P1)G^R!QU5X;NTN*;S55JE;Z9D<DW&MX
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M7LYD!7UFC32L6J^R!!?.=7XT*ZK=[^HCVFZ.=%4C5PMB M*%!.V:WHW+O;=
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M 2C,X$_8%M7^[ +PWUHN>?2\[E-#-B!(\WB!-9U0XJ<F!FPR*V4R:2./EKH
MT&5V$BP#C[4EWS$6Z96NXY_F[L^U[R3C:?L@%L(O>Y8VF2#J)>N/?2J$2_B*
M9\-.*9&T*@,8^H2&4,GD BD< K3QG/7'_.MCB5&'-I81+S+HO1[@=KP\K*]]
M] )0[N9O=%:K+;?44-R$IN/C#NVE( OG:J;90BWZ </"/P70T@].EY+Z]B4F
M51P$\Q]90>]Q,CQ]\ 0X8B@7U^<M=%.C) 7=V/$YAHK^Y>9\-S/97Q>*\KD
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M1E$A)I#T- E4;+66]WGZ(K_O:.7D%C5#XF?HE 7LE!)F.-+&L,'Z6[.Y7D]
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M'+7TW>[N'.;%"R!"-NWH.X_%'J@FC5LUW+,U49I%(>#L>6N<UI S(E ",5)
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MF5X='?*(^!BL0SD&_ZN-Y'^O4%Y,_2]02P,$%     @ Y8J$5HYDUK3E>
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M>UQ>4DA.R(\?S@#S@"49'=@V$LM\+$I6?M3HTEY=_],U/F2#FP/R>I[JB<R
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M[N=6O5<GOUHR OPBLF6+4/8W&M\69]M@E+#^JVP_QSL7,M4.!AF,KO'>N^G
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MI4@+;!1>Y\*]5F387J4#:$P-+M.KVE_,SJAH$$(=M 5-/RGAP?H>P(-R4T=
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M0C'VJ#Q&JZZ^H36R"!/F<HL=%1S'*H^ZEB>$**1HFS%E1H#H!3Z4+MK[3);
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M 04)U<I70^/C-8^P+5Y'7&06_WT+J]=L80F=R-FNMN:&>O7V(?/"LQMVZ;+
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MH.ZU:R5I1DQ%NK?= M_[9M*O4MTVEJP2JPO0$1/=DH@EU5A/\#NZ%AW;.T[
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M>09T3I--.=X!K,':RY^2%NM-B4)#RO=. @D(RYU$,W*+%G:\-<9<;T4'B-=
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MGJK;$M^>IJ^LS63:C"& H4=N4+I90R]&ZYB\A=D18;<!_L"@DRV6SS/:+K(
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M:+OFP0YR[?PM278F0X[45O?O3?0^3[[>/2A_JE8QX8S;GD.2CR6UQUHI-S*
M9\A=8&4Z^UW(HFCDR/6D%ZUC:FH3#FM.)>M_=>X0=X#9/K3B9O8=P$07=/9!
M<__/)P?5$%3"T!MT9U7 =E'IS'\<V_O_-*@@AW-';8Z5FXZYQHR#4\/[G_8-
MRA3&++\?]6>I=4!"NZ<R2$8+)NS]+8$<K[8>:4M@G[/\>-0("O>G:,[8-:9
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M[<6R(?_7__X,)?B/_PD;<RT@#+.G:<$[6@BA"R>FSOK,-,-'VQTLTH%Y7';
MO7+>FXE;@BRY?F3QZX:>!PH7<@;#T$/8J!.U 4BUU+TUFW "5:)LXR5)I!A9
M-%)&1=/1I27SZ64$W %PY@W4SB5!4^]G4V8"M@= JYB($./=-GHCH5O7P#L
MPJ(5<W\T8(015?17<AK/-624@V[<0>N@TJYKV],[ %)6\KDLNK1WK/[6M1ZX
M8H7N1N8#%Q"J*?1G\5C  ;8SPK_V(?>OF-"PHLL0X&TC\(30A"[F=O\>1R5*
M.PIMJL>X?/P4="$E_QUAQ'WE-L:,4KC7=$.]L?]VJCX$6%WF$Z*P49]G[@!>
MMUN9=P P2A-RY.FBD'S;'XAV'KOG?D+=GNU32-[%]KWOG??CD/NWXY!L5SF2
M!EX)W0$8Z?KO 'PHT*\_QZ*" I-?+V.H+I\/N]P!NE-!JZ;("- 42F(R_"9T
M_GZ=36?YI1)>K6<F O\Z2U/'(]ZX1\E7X=69I^T__\2A)W3/S*#'1O5 Z"'D
M7$,>Q;GW^ XPC0S0AZ!GN,]-C(+^.HY_QJ3;<7ZORB> D,_[WU^U8X[T]4+P
M,2,X!70@-X[<9]XIDCR>BFUGT];H\T9TXB*USN..4-!1:NA9N:1:NYGM\I$,
M/MW\@\M\ICN 0\!%]J#V5?+B'>#AQC/XR&?](YO8S"-]Q5NRLL+NHT?]EVX-
M?3>COT"I4S"DRYN$H^T+?/1Y%7!'/?,QTKH)&: $NM@"(C6&DMNK!4Z-45_T
MZMV0=X 4%4EZ3R6U9J@NY/(;9$OK?:\_1<(A,OSM'2#(D!YM\7EE! ]XE5PS
MTCD)ZOSF2[AJ=@?@17]'ZI<K7X>K!OP,:#U!*4? 57#4SKVGTN\ AXO/T;5I
M<"B95(ZGT>7['QG#NW! &@-O&'ZRYK[+Z&;>'2#D66?F&>#'':!=NFCW#H#O
M*U1L_7Y.WWIJBD_AT?PW4^J$AW22#7UKFO*[;&4&Z>5N/OGU_9%&TXES?<]6
M[P#1]==AS=;61?/64W7.DDQI',V/"$4X(W?="*,D@<$.U=81'J6&=&1B.K%/
MKC.W\3_M&&.YSN._6]I=T_#Y96HWY,"!:9O1EWI&+?%,"?8U/RG-VK:P*(ST
M[:TC>S.M-MM%Y ?ZN;I!V=.F]H5/2L)1>FKGPL8'H @CACL A)87]KK./GZ1
M=ISP9W  8DPM:E5]@DD?0N+Y67TR'UO2Z"0.8K\%?*N==?LW2\F FZ\8GU56
MRHO3_](#F7KSN#UF^7K?8D>2?/2,'E3MV@QV!YZ,,ANCKT5 Y>")?\,FM/%V
M5?,:"PY10^\4=?_,)?8WN-5Y_\PE];?[$#,5(=2UB-O#B;LHSU031R;Y*4O&
M<E@2P>8"NYH"( 7RYX!"RE/G/F+9EY^>%O?=GI0$Z)VI_2V2TJ:D3U'Y6(]5
M9EUY$W&</:Q.1_8A$=[D*$^PEMX$[KA8S=P6 H0R!!Y7N7T';B"$0KC+$_W/
M>Z##F5 @\MP;^*^W=J2_9H!QR#T%E7A/C?90_"BL_52D^33<R^,+FD]W?DY/
M>74C<E>1,@2Q*+=KADFQ$^@R\D^RO?V+!YI[ LKI4&[W4<?D*?N;AJ<NT30)
M>G2<2' ^,G?_B!*BFL1L>B)EWY@L?+/(%^U?4(3T6"6+R348XCR+*F$OF(SU
M?/W89<+9"RHU,6"$W\-<>-EZLQUM]^6B?MN;X Q]@G9U4#OBWC*X Z#H_4GN
M]10LR.TU24 G]JK:-4#G#K"<;03B E[EWP$"H6B%G98;[G8T!C"V1044VL)_
MG9BG/O0JD8@QY*!#LK?A",OWPZ2O"KS4D'FW=YBU0)L)OMA@)[W8?U8!,4":
MK1YHOP7K*POS[T0](B>2QL5S1]F$A[:1Z'N:=0M>-]E4+8@__QF3C4.PP3XM
M>;X[FJ%+0[,F80,&%\ZKI.FGGVHNRDSU98_)DJY\-_D?<!WQ[X)*O$RD8+P<
MSA=<'HG P@]"2?"3 ?CLMY(A:CF%@[A( %R<$R$(>@K62GIG-2U(=AW];JC
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M61\!V ",N?M)5_I_<2\)NIO]7U!+ P04    " #EBH16&JG KWXY 0",B $
M%@   &=J>6II=C-J<FAO;# P,# Q.2YJ<&?LN@=44VO7+AI$0*D"TI&H](X4
MZ<2RZ1N0(DA7D1*J]%"C($5:! 24JE(B-72D1KITZ4T(";TGE!@D)(?]_?_Y
MSSG[._?Z_?>.<^\X=]PWK#7"6F_FFN69SSOG.Q9YAKP$N**GI:L%H*"@ /PX
M_P#(\X#[@ L4?XV_SA?^&A<I_SI37;Q(>9&:BIKZ'P?-Y4OG!PTU]26Z2Y=I
M_QKGW^CI:.G_^N<O(?_VTPM4E)14M#34-+3_Z4'^"F"^1&%/E4Y)<1-P@9F"
MDIF"W 4  @ 45/]0CP+P[X/B N5%*FJ:<S7HSB?473E7GY+R7&FJ<XW/[X:=
MWP=<9*9BN7'K+C6K\1.:F]Y795\F?[S$?Z^JG<UD%"L@]]0GXC(M.P<G%[>@
MD+"(J)B\PFU%)665^W]H:FGKZ.J9FCTTMWAD:>7PS-')V07LZNOG'Q ("0J.
M?!45'1/[.BXE]6U:>L:[]YF?\@L*B^"?BTNJ:VKKZAN^-#9U='9U]_1^Z^L?
M&Y^8G)J>F9U#8Y975M?6-S:W< >'1\?XGX237W_910&@I/BOXW]J%_.Y71?^
MB@'-7W917 C\:P+S1:H;MZA9[AK3//%FO2G[\M+5>\D?J]HO\\N98-F>^HS2
ML@O(HP5Q?YGV#\O^-<,B_B]9]A^&_3>[Y@#TE!3GP:-D!H  9^[+4TGJX'DJ
M'JHPBI/":-RV-E_M;D1BQ(O*1767Y:F<2N/*!^P\O>6\P>/UM+=I+W1"CO-A
M5@'M6NUW'GGQU7IO&\Z(S(C0,?R'&(HG+<&CO>6JC_,??Y!0A%DI'</=K[I?
MI?H/T9%3_^MD_R]4^_\9CP2/5@9__]]&\?\/B6:R^M]2[?^<Z.-_EJVI^OC3
MBRJI[J/\I[],ZQ4+>7C&(GIV[/5N2Q>J.@0;5[6*4#1SC"7&;QK.++YU]](#
M>/[W4U_P5(6)S+2]W4W<U.HY^D#]?^>')\OXR0=J^A^7H ,)R%^<B$\!BH6A
M^Z=N%]1T/ZZ30AW)@._= 8^ABQDC!QI>\: 53=,IT"\3-;TX$<0'$)!6Y-.+
M_]FA[KMDL1.)&4E:I&PA1!5"IO\8<W>O$ZK..C779:4OYMG[9@+0<$TRLOJ!
MRR.R'F)&HELXPI9A3 1X)^E&P_@2N*AA3*H G&.1,4-+];0T??[++4H ZXN0
M_5FC]CE@%].,5X_&%9QT8AE1V2$(4\3!/8E'B<V[/OHBV3H:),:1SENY_7T[
ME!=$ 7V*H(?D=T^A:@,2EWG*]:8$Z\?\WG]B$$A^32OUK>AM3G=5"_H!:V[=
MTF3OTWQS5Y9FDVJ8>*"5_V;CKW2:Z .K=[SRN*N-3TQ2WVXUE4BQ_*PO.DX9
M=2]'I&K(?<M7.*+9B2F$Z'E=WLJPLM\9_TR\A[.V.3'?_VS9?@9SX]@C::4[
MBU2'K?49='D\N/.CM^BLGL0(L;]/ *+SXL:(_..A7!CK1$MW!0-AS<S;#68N
M>P)<!V_Y07MO]XQ[#@HJ'_*W6;[BCS.S"0QHG5X-F1\\L0J5CBU/&9")^N/$
M87!:8M=M[@>Q)7LAR+05ENYK:U>,M<8PQF"+1I9OUQ645\1\WF*> U?KRQQ*
MO4]W^O%9]AXBY6OZ?,Y K4P?T)PT_@NV,W J[W:[6OM4P\6JOK@"+,U[VP/^
MM;[>C>.=B9<$?#%(@+;K29SV]"I%$>$$Y_P5<7K%I4T$2"W?78VC5$A/S3\I
M7MVHT?7R8UGC7WU<S2;PY %Q/1F5<6I89^0LYK=0L!LPU99)!MA[[T*+O] +
M5/GA'GUI>OMX=8!-\MID=IYX4XV5<$C=J!R&^\AK%H5WQB%V;WS>2L^].E'F
M_G'L2>)>!>)]_=Z;RC\H[@J\20I^[+'^>21[K:T'>SL2IX@/.XNK3;R/AD8J
M>.AWVXE->=0I9^C7AD37OZKNCTH7$.CYWLDM>XOW!TA=TW^YBC7?0,S#5[<
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M^3*/9]KQU,_1S08OXV<$-3Y^&O]+9N6#XZ^V5+S21VLBU^)\O-ZK-KA)^__
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M%Z,DS(HJ>\3J_3!SHZVUR/7U7]F0)+[BEVM)4F7@X4-CH_>'/IY[:2E>.JC
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MJ=E6M6F%G'H6DT+3S?E;/W6!2FOU;=="03A0MQ'W(PAE>WWR4+&KK.Q\K\0
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MJ><<GW#V445D%QE 'VJ]=-[J$*"]36>U,C.$K%UAW8?OY&&\&H_ G(QLNJD
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MU$*' 3$0CK.LOQ/YX1LJ&3%"8TY:1C<<44IY?-8,78 /ZQ?Y&,V>_MV7Y1O
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MM8QQ K%K-4G1W<;H?V1X[;]I7@(U6UM+U,IM*O6OFRHN=4G8',4P.>RXGG=
M5N+I>N8M4OGB/=Z!M9D! >"MVC](U(0&+.BK/4_H7:88/P:K:?1Y-AS1)5(?
M_NS1_[;T_JI"?_1312\[BF%F&%6;Z<7SBJH&.][QZ_@,WI6*HS-K&W]6/2J_
MBMT=SDTW5;YHIY:2J^>!MA!8IXFP_(VF^6<9F5NEUO:VNPMSI'H7-EXR8/;+
M !6'LS [YFPX;.)I0;YCDTE"2@@S =D-H@]U.!6'*';:8_/"4KO:&#QTH97/
MQIR\&L)*<$!Q)3XKJ@3VE94WVKS.U3CMW6M8A/$9O,7_,\I5,8-$A9N*9\P(
M"WM"J2W!6?N2JK]7C%I(F;GGTD;W"W<J3^W?-2.N0<]E6]>)*"FG@EVX5D7B
M4\*G//%H-J'6G*/PG]6OBDL7#4*^IR:DZ.$-+!=:81<@D7CH6:;SA 8_@0ES
ME*N DQE?J\7NEH7SY/;S*#\S*5HS55RD;>0Q2_'1#AL8(/S$<$0>(V;COX*8
MY!?L!Z?D;>^;9IC5G*K%KY35L"?LB;%5*Y_H]H::Q_P&II/:6ZZN/L6!?GN[
MH_+IK\5=24X/1;VO5AYTCG>(F'I[K\:E9<A_%!985=9P0K,%S%57ZQ3C6#':
MD?ZH62\TJC-1W/+0/X?VT"3UWYXNT<"(RUF]=]LL\B UB8"00-C]2SD]E^8N
MR5D+;_;:#SPSI'=ZV,6YE9SSIZKAK5=L&3J:FO[!L^(G.^F];T;_M?T<^!26
M#!A,,CH.5"4#\EC4HN..]W\#K6T(=.TNJ6(=>HC1;B6*D@$IMFCD*<"2#-AX
M5?YK"*L5%8@>H=KDXT.FW,[MU&^H?_])H/A9HMD;'1HNWF>T$P=GV^O.95G:
M.S-6GIPN6OIF&2NW6WCP*#( !F6 (H.('Q$AYW,&R0 75 1)E-#,#@-&(W9N
MD$; @RC/Y&E58HN#J^)/(QOS&5VMW)NRJ=5DP(N@4,VH\KB^DK%\#E$-:\%5
M 3* ?Y5;?!KYN[6G=:3\/"W? ]/)@'_;-_L7-^B _]B?8_IWO\D3F7$QZ*GD
M4T9"S1(I'R,MW665_J6!725P9DW#_:G^_>;!2PZ\?Q#9:59_<F'W.WZ_E^?&
MK2#SUB;;&:>*M 5]V^]U)&J^NY?@^F0._^"!N77!?'-S\!:^^D!U/P;)W48#
M0> -QTC4D-YEQJHEV_L&+:F[IN"FL*[X$#I]<5G%E/(V1=U8L6XHY /Z[9-2
M8A!A'RO< [T4SD>P1Z_'>C&W2%;<Y<T,*'06GF,9%G3I.E#Y\/I]!/^55WF+
M1TLON_Z5^MVG1(G--,<LI-%:WW;_.[XP 5.\1*K )A/X#9KUW_<P*)TU"Y6/
MBA\;]D^#//?CH4PDN5"[\5!3[+P]::PJLO/YW!!HUC'&?<#[^:JW6"DP;6*%
MWG<ZTM8B3D,VE(Y0>LKK<DY4^K@+'CQ=?%P-X _C''JY7O5&5"VX^\!WQ57L
M]S;T60\.&%62A'_+.6>Y-+.F$3F-U\;'R( T)"43N)NE!U,EVP$_?C6!&5^=
MA/N#A3+K,SP"_SRPUF]NIGNW7^;Y+!KRS/)&)H?8Z!=E^DLK5X(N^B'@=8@D
M^VKG78-/X$!H+62RY1;&0W;R29[YV!,G_;2+*27FRH8=LV%E[^]UB?.FA.[_
M-NI__E$)B<[*R9R%.U>L\UG$8/ZL4!#MI84;!JR]6H8TN_\T4!@M2D3,@?!O
M"2'E1)F_7JJ#OE!17_TO[+UW6%-=UC=\O"U8P8:HE*A41<"&("UZ*R @(DJ1
M&A$1 0%1.B%'17J)@) ;$*(@HB*&CDB)= $!Z9V0(!TDH80#24Z^@\X\SXS.
M?#/OT[[G_:[Y([F2G7/66GOO57YK9^]UB/ZNW6L(QH0XXZ)KGZF_1UTLGQXY
M?G(#]IH4)J%L\A_; 8GO"D]@6NT&KZ)OO1.?[ZGP;;_917*V]&N6>A&E'V84
M<M2X6321/A!'W^5\_\-(&DUOJZ7ZT-B"N 6?7KCXK$W^YSTW#QR+*R.F^\U&
M*-GZ_9/>[-7U(PPRV:=HLK762P@*(RB1=HO[#P^'E[0[.9H5YWG$YI?&BS_'
ML]2AQ?)2536$TB-C@^_+7[XKRU\N![P4[BPEW0"5PKOZU&SJGM)UG3R5:6GW
MV;XLE0G4:OB8 ^5:R9>N 8C//+Y1J_@EK'QR]LE[C=$U#Y^=U%M^U5;SS_C(
M&#JNX2S1UG4Y;1%;PCM&A6(5Z_X(#"3GAH8EMP[;O7C;/I,:?7'QLE;R5*DT
M),D8HA(#7/$AZ&TV=#!8131--D9X[E:T9>^$T2'P[LF*S\Z[!Z,[Q>:(!%'C
M3IP 5A7"#\9R$O:U%9]Y<\O#1<LWO6$SHAA._7L,8Z4RFIKV+N"!==>ZRD1]
M>OZ&<&IQK'U8ZV9Y94<'3<;-4$</VSO1/7UGO>Z0=@:5Q;0MJ6P]O6\Y)&;A
M:O^A>(=O%%V<<7X11B]*/E%HN4 Z:<M!%N%5]&BNS$V2Y,YY8_N#1?8+'E.N
MPBBF%8-G6CH->R:A)NE ?KN\W-[R6<^-K IU6<>\#;(:1B;=Q5G;&^_6/V2M
MLM23US2%X@9)Z[&_0YQD*-!TUZ(IO3B[Q9JE$N4U%_QU[;&0WSE7'U@4@CU6
M-G!?/N+_KF(UK"L\2U%\[]L^^Y\\,6!+R/%:,_JU1LQ:R#C2$J[!""PH=^?)
MZ%29RE0U5&;(5%4N=FZ>+1+*.;[[KI98E)Y8IXQ4ZU.RC^KAJ';5>-_8>+?V
M!=6WM^]M/-'9EMD9_?0K131D\1GUS3U"B9W"K9YM[MD>-P9VZ'6WL,X@\2ZD
M6(9180AA:#["Z*GXK^Y,@<Z;WZX=Z731V703?63'!Y7[2FL!FV51UD6VZGM.
M)E:4H32GWR;YA2V?\B[2C61NQ@5>V/-\2CI9XOG$YHS7K(%-_CN7Z,R[X/_[
M@H'%]@!>W3D#I_$,QV2?28=EBYSZ5%GQBNJ-$=O.QEY*R(Y)/>1=]7[N?7H)
M1NPZY6YU* W_B,Q;*LPV@GR3V;JZMSP?-NGL74N[M7B2"SC<&K&-T?Y //S,
MZ>UII\IY/DZBFI3G:@U(<XCOT8 $%.@SF,"Y2QN@=5;M.GFL\4;$L=6F[Q]Y
M/3C?'[9U?>2L2XSW/UCJ,I1[7<<K^W):>?R#=K],LVM6C**+N)"ZTN-RL>=[
MRC0'"@[W]1J/CK <)5XD9F1\&ZAABZ%R:NZ3;4DHK#3=H\HAP]F\DPODO,1?
M?O]E-#__PU;SPTGGM,\>RWX@8:H;4M7&^ZC#MI(HB#T"^;&.>DIJX&O(-@Q)
MOXQWSYWY:E\T5L\UOL>/F'R<_7+8CARE-5XV*?"/5E]#RC6T+9L+&AI\%0KD
M'#,0$ZDRQ&]M2SV$N:S-2\S)OIR-1^?J6CK.'71P[P'M5"^23#@($22Z7?:L
MKU10Z"3 &QEI@5?4VT@GH+VGDL/?/@M^>2[F3)W2L5FE7?L4@!$LN@-M2^S.
M,?P I0Y2PJ*@SLI=^??.4/O54%OZNFK6S%;7,H/CK0,,C:PR;R12@FK^*2](
MM'TX_-5PKY%6AKR6F87RK6EK/;O*EK>33>N?M@TKUKZVW)XP@LV/USWH(.(F
MK:H-2T+1@QEGF6?H3>6],@ZXHC0HF38[6S,URR>[R^2TX["[T#?+U3N:M/%5
MZ&W%PJ]QM3@!R,;VK7/G"<H."XN!JYRD,\/E--V,XG<53R-6+BS\9]S@&T]Y
M9]#N%+:?G=_V-185;-. 5:C2/I'/.CJ<0Z$M&@[TCGEMX9^D_ ,C0'\'3BKX
M_R#B3,?5<8'9<[GDY6D7+I R4+*]T/EAZ9IV6!BKG$./*'1Q%F_(C<JIM?_<
MG-AR?/,N0U6^5#<<IL23_T6JJ:Z'[62WQ9[F^ENM\3F70AQRM,S_O/DO6WGI
MQ^; 9Z>T3NX]N===JDKO*#;%_<='H;(Z!:L4J[3K8?J?A?[5^*_&?S7^;V@\
MV)4<<6U8[.-\RNH6PO>MPH=TAJ]?\]9_,*Z352+5-?"$1WK'ZI8P/FV+'S46
M3UW]0^3)->_+4\[:)Q525]55_L6M4KQ&$CRINT6>% FVA(>/G[Z;=415ZN-\
MZH_2C:MC@A^,:_"DRE;/IUA[7Q)Z>X%/^XCJ0?<?E1Q7F%ZV.1YQL%>PI?0D
M]'DVC;TK@7K8?NIYJ5!?P*5^3<);QM*#)8,Z\WSY%,V>0NF>6O)[ENA?B/;F
MV'^UX"EV*3MYI#>OB"E5M1NA\)V\AE35JKJ*[Z2/:B!W[EXAJQ]R]/3=S.\D
MP_1#5L<$?"=W/0SIY@]2.Z_?'[;ZWO_=_X#HR>@5J?[6^/PG^K:_)T5RYW3X
M..8P%RB[GIJ$ZDJX?'[8QD1^6O6&X?75I(2G*/W'?&T;XW1B9>*;4Z;3-00M
MNI8)&[TW'E&5)D(Z8HOHC<7'75RDM<224#FVD;V'*S\^BO*)'T/$TT\(O5C^
ME])M^H<S_?^)>OV+Z;^8_H\S35YAB7" ,4M5(LA+*^3HF1NX?_]R>ML2.+K3
M"QSEEY"J C2'N<!3_94W@S]2=JY"$6 73>1U&7$D:_[#-V%1K,M8"\B&W@1O
M6D4?K2Y59&2$1Q">01O/RZ?G1WMFQU[-P\B>^LTF\@^]#1LUW.L"GZ\KG:_"
MBK+TL.*0 T, WL1'IY0ER=.-B*_LO&?NWR":YL3WK2V)572SB-(I6-M];NO]
MRJ_K'[M>DC[4.6ST+:*/3RZ7<+(ON_?+(@GR7)PZPP4TMR5S <K*PDD_BLZ8
MZ?*#(T35N0!Y!;Y_*.$"O'.<$/18GXH"%[@_S06J]']MNL)9)-#D(#V8"PPB
M/P?B<96H>9>]<IQE)'<)1Q)^/A%.$'J,=@+#6D!0KV ZA3Z#[DJ!PRLJ0(B7
MPC9$_?R]=)9]%MZ!2 'M!*E#E"P>CI!&*!? K:!U5["BAGR=;UDQ7 #FK"#Z
MB46V<A-3"H',=^@4>'4!%^#7_+5EIGBEB.0C+C #KT7]U_5=GS4C5XFFHEE(
MQJ,)BZBRMH+-E;?(BQ,@K*#)5O%A[D.D"&H&9]J0C,&)!%84<X'K^&4%OBW(
M8"F##(-?6W"L>@;??\]HHL3 LDN@8],Z:.YWNB<GE@O<TJF.[YB=8SG VTJT
M1YH?9JL/>_F[.^TQKC&_AT$A^>,%N 4U?T<-Z6_YNSDN$&'<3J8;<X'NID'P
M(\CKN6MH$+G(0J%BY@T&D\&R8\3,5=JM^]@M^9+)GJ1^6!8J52BOB9.>7$KB
M5=*_2ICJS4_@ A]5[U'Y(LB.SGC,-M>91Y0-.!EH\BJ#-V,4M!W/@AH]XYT/
M"<3!=K8&NR,4G,XW]FU^NG&1#[(B0C(8SF^X R"U+I +1#M$<X&'Q[A G?;*
M/MD^:RYPH;-]?G%Z]4OH#*P,]7\#!XOAPW1L.&WZ?"U5VL'"O"99H>=%0\B2
M]\.776#[EC?ICP975=F$5!JD!3/O:'?H4:,G.KOGE8]X:LMGXGH<*7$9XKOG
M]::]Y]5X&,8UJ)ZB,A&IMF(!&BE"33&G_83O[P["VNW%%J[5@D%/:P[8V!RZ
M4Z=Q9M_00_M ]HFFZ?V(AJT> MF'9M#0L ^I'%$1]"8N8(?HFR2E2B_4V]W/
MRXT12BT(2NG(:]KJ^^&;EUN)"#7NA5>'28_J9&AATKG377EX%PE-Z_%%D'X1
M?S^#@6?>XP3GJ?+.:3$Z0U04%()@68=Z-V6+*H%(F?*K&N''S<H_5JBL?606
M\.F&<G89,U::[^*$CJ'/>+<%6<=TX-5HQ&K^RRU^S3T]I=G#.HXS/O/-.4-D
MR([8<Q:.X*E&1#,< !EU:.I+T ZQ,10RL%1C+RY0(STO.82H\(X=U)-I=$':
M:/ \%^@"KT#'7095#\R8TIU#FBJSWLD%961L]Q(+\,'DUC.OB.F_!IP.-:(]
MS]G<F,.$8#:1!Y.X0/;B%(:.&9+$DVUTFG9[5M D_6TBJ8AMME[*R?6*VFWQ
M;61;0V*]6.2A*H'8L!QMK;I4V\WN(JF%^WJ=.LQ+2"73!7$9%TC\VNPY+7&?
M4IN.WKL44,8;M0_\15D1^]ERG'4>;/X(4;C QJ(F^!3&A'V>XP=O9%M#]:QC
M4 KS!GVSDO&#TF-V66#YV>3N26./+;;W;"6)Z:M5V\+.Z+A'R1LZQV6@;M76
M8VM9=EW8'<UD>V=!R)GI02]@HOWF?>WF^R6:6+^;/:/8_K;GIHE-E(9KU(TH
M]7I43-LUZ]7>\F-&46'6&0G==K8.:.6T1:&N,%E1/H&#.CJI*=[]EI.Z;SL'
M(FJH<O[HP9=$8;8D.$1^)( 6D.>@=,,'''^O,2T]6F= C=I^ W7KL4>$S#=T
MD:77*[@9E;<N\I6YG1*Y1@YEVF_Z^4N_:1\4SSRU/U++2,/H,?^U,VNV/5;W
M13S$&@8GI_@LC1R,VH3;R+;DO$93C2!)ZC M/S0-<J_SN<K65RDXLLWZU8G-
M^V?C8OI'$UU8M07"+3,8 <2^"&:>S%[F.(27K"2M&H<%VYWD*:JY#8>L9 K]
M:6<W3^Y;_?E85;;1=?[03ZP8P;M!:9?U=HY?E'8@E?9[S+SLW6N4HJVHV)$F
ML9!34I"W[-B-\6V^0A,AL3S9!^D"_CA)B$5SCICG\%1W9)M[8I )>]1C8K1\
M8OW5!\(5QZZ=?ZIXI>DBKQS;HI4\F(Q95<Q/)0<1!50<&'SJS6P+)TDZ9[@F
M["68^SQ<?(]!8KQ$]X'$[+5.Q3;G41>Q:R&M5S#BV;40+PINH.4<(:YB>^<U
M+VS1'M@OWN;M./QQAW9"SGUBSZ?S5)?;+_ $^0DND"_/1M'U\0%<0&!E\]5Z
M^[NRK^EI0S6!\YQU:UHUZAT<(GDC)K0E1M2+'+5OJL1<[4Q\?GK8L]'TC:RT
M1EMBOK&VW*BK^^'\8\]&]RB_3^/O[RZ4BXE;6F(8FW"*2M>/)PEVJ!UDZS$&
M\#RAKJ[M6/2H9X^Q3[J"H0WAAL?FYH>[[U OWCWZ^/00^6^8(&$(-<49!'MS
MX(V%M*;?/"?+C]N+\$$'Z0-U'2C>,0\N8$NP(%Q[']+ZV4YTJ\V,>%BF*V#V
M['!1J%P\W(FF7R#RR4T1T#5Z6W"U.5A>AKL?K5Y5S7E3 V,'O%W:T;YZUL?A
MZLA< 3GF0)^Y[,[;J[;KEM7OUTG%5Y2>;]/2ZLTG]&:P;L=;W%:_G;ZU<%2]
M8#?%IW]V;$&[=Z VMS^WD"'YB]]S7^:G3,_1G!]X=T[+/&>?9PS7/& KOWY'
M?.M043W[IM<\YW3R\3WOMY_4_2ST9ANKL5@(YX^$YC6/.,1YLI =&1CA!.5-
M8RJR;ZEI9#'&L)=TS/YP#MNND+@K>C3SFMCL%R?\+;&14_P*6GZL7;BJ 0DH
M!;E[#!IB;36%&JL[EBE#"]7A7B35HEP=8?_JB,X=+WRO_C']0NK1NY%#J8^W
MEXO'63WU>A8[L9C?T+.LL*B*#0W0#;WBDM#1DD=BB+OF:8\O&EO:CHS^TC,4
MO16=&\@1X@OG O1T)(H/Q2RHI= %F0*=Y,$T6)B#MX5LW 8Q:SPMEX=T&+LR
M2)Y1(](4?DR54V/XX6B=8;.S*J]"MSZPMC.Z;OBD87O%%]P .2NM0L\/!(IU
M23I(-[XR)"L2=73:95HK!A3IQ$H/QLEH#U1<_EEOPO:W'8\_9*ZO7FLMNN_P
M>RD.RKQBKESE0ZU$_F2!!<XXJYY##&;>BX^WWY+FY-A2-)[F4"3!5%/D @%Q
MG!?HL4&L,Q?PMQCE D(I\%Y;YF,$ICQ@D&%^#R+[[OL'+2'?O@9:-XP2[DW.
M0!*!TP2Y!["*?4_!]''6[P[2SVJI>ZBYB*F&FGSXX#<=,-'VKNTZ!,K85%B_
MI"9YL4)_ D(8 "P3+]W,EH6H+$T'2WXH;S!!QN=B 5VWH>^DQYC)=IOBG#/[
MRH3\(VN:PW&(Z?V,B0SGED+B*UGY>9'?AF<VTKE R4C)0 ='&_T+:D/_#!?=
M?&#A4=9.L/F])]+C5;U<("3EEY9W*(H73M*9+<D%0#J"&W]"F&._P+#V&<B#
M.(5X*PTJE<SF<88/X7]I0$@B^K(!09CLC?]5@J8L#F""P')PD0O\AO\%7N)_
MQ;66B.A><!5JWDD$\2,?W;D [=7?:%I!\"@ZD8-\3_D%8:;\-)W&9.H F*7)
M$0Q$IHHN3(;>H']I\!V& O_><$Z.$J&#B]/AK&-L.TZ,G,H6>@&-F?!VHL7!
MZ)ZFM8/0\Q#1J(:Y?4)\WLM7?AD!4B(X^!J=K3#52?=@7BQAD"KX_#ZHA:9K
M9G2?(W1<ROZTK2_ 4FLPI#$MC^G$5#I"UE^N/.5%<BMYZQM#QZ&AW*1=H[!-
MKPAEODPZ>98+-$H3(14TK<73#*ZJ1W$DM<>/FM505;JQ%_#U7$ Q9>7M]5&-
M@U'_+2G@OV[ZUTW_@S>I:X5(K1K E(A@2I1"-F52OO\_E*B^RJKT3VV_56"_
MEXYPV[DV8 DW[X6;GY#:M.5[88GQMDN[!(=9S<.LUE?/#BM\+SN1IG_ZJC-A
M1I,P<S'Y_@JYTF-0VWL$-79A]YMS@893A5R@V;3=EV@>D4Y'44\6,!(N<)XM
M8'C4%<).^,K,3Q\W]0GV,.L]&BV5-8-DH>,:M-3,J>-^(<%5=0,OV^PU$F*6
M7Y;.NR7]2;P<P?\#67YTS7I0#I+MF::3*D#6>GMP>6T>[J[QMZ8:L-MC$#-]
MW.%E-]:)CF;VF9Z+*GU*[O$P&M YO_,4XD-C%&X<X$P-"5G'S^$A-\TI/BYP
M#O&7LN&(^XY*;RL?>JV?_%R,"Y#BRH+*#=+U:T_@;G&!,L1AW@+7PG5@7N<C
MG!KV;,N"3C_J# OLE<F]:ATUS&9M"KW1E5V[]ZE*W45S[+,A28!S9@C?4P.O
MUV>@JKUK*M%[X&K,3I);N(_!^S8WAZ;I#=9SW](B4V-U@S,.O1N]J6RP=L]'
MP 6C"5:\05\#E_=1EESMB>P83;92"I.'"R0C,9.@@3C_6D/^K-W:[:HIHQ<[
MFGOUHN=./LNZZJW6("7OPZI;[I9-_\3F<"+)#C-^Q.S.:0(-#-[K7,'1=GZ4
M)&5A>[Z8GM*3VC[*Y*_/Z36+B?<-/_"DP%A.>EBEN3#T1A4-!4EIAG;"&Q7<
M6#Z>]S195\[2M,1;YA.U=DGX2GYR.)'OZ]]Q2C>NQ\+#_S%!L CV0Z+ /Q(7
M8_*QSLE))K\0DT99C$J)")=?*Q9%.%:@N>@ZA@^"3\'=Q$Q<'IU21:0_1U\7
MSV+45%J)E>Y#$O 3"K$#@HFULJ[/ ZR*&IX&_$:Q]KJP+89? ,]Y1W; !*)1
MY)ND!ZAU;.'GD^X?TI!,G-?RJL/BWL3<@\XN8K4W=O9F:T]-PA%+ Z^\+'DO
MHL^BJ>VH3#1GJS/[@[P>K(T$8GW6:D27UW&!^A0#+O#US:7*:X.MVJ;*DR0=
M-]] ?6M[#7VG@UIB4QD=G%V+?;--70A@)^XB6^M!XK:A:A)L'_J-^!L]O,_E
M*1]9T]JT4[*QDU=RCHB:_3ZZZ;?B67.A[3>TG,R<ZV/9'VMV\[-,:&1(DC"5
M.-2@K-/,OC?H>\\TY\M41Y-Z7GNQ;T:?9EKOJXV9'[,MM^V\!OSV"@#6*;[%
M0&[H?U=28T1)7U70QO2?C+06)\YCZ+Z8=.OJ*QE!X8J:U(?919T-TV,EVV;Y
MRF:@@Y)3M>^P^^B:#T!'?+?I3(WI:+D%NA;RR+"+3XL42CZ)_Y1?Y&]Z8K9]
MG_^F(T^/7+PN_I3<B,DC34O2\#VCS/L,GIJF779;[5HGKVC(S->;F)Z?FJ:%
M7P_8UQ#^]<"6!O_-PW\<\LO%I?YC%3 8I]TQL#]5?8P\2$K/+B5XC^G>&DIO
M,1@5MW$VMK'Q<"B2X6\* P>CB71], "5>6- *0?*H^*WV\>J2>'U?-;2Y[=J
M6\7W]:WKR]'=NBK69NF!Y%<A(TWV#DEXHV R7(,185LPC@\9B.SO.$'</;Y]
MRV7A=0-[WDFTE;9$U=PIM[->L];A,>[VB&5@01^9/H'O0L%!"K#%7@2@B:^L
M_KWB/. "8W[@</,;<-;PW.0U^WN%ZBQF:?_)"8M3-W>VR^^1ZQ^@J,Z\3!N=
M^8C@+RG=F7)43R=-8'IU!OM$8&62,)0H07*FD3<,6)ZP= Q?J-#-$EOU,/M.
MRMU,*0NURV7ME-S :066<#V]A4(5F#)FR=93W> ^O&$1@Q*Z5S#CSOLRUF$Y
M5D=!L,F!?2\J]@M*;8X2X  (I#/ (0SGSY!GQ]K12X=^=5EOX)R'S!!L]OC8
M=%[[0I;0^YF;@WUN9%W#Q9R\=C;^"1NY:.TA3A!\V.$2W((1 JVL:7)A6\==
MQA>-<NQ#!H3:SOO5LLRSM-[/&![>+A&B^TQR1N? ^6+)<C(DA0I0$P'+5$K%
MX<],HZ0#+5C?(3F1+3Y:[>SC#FN3B#;;"+IVHEMV?J)C\Z-?G:=)\3??7:6,
M&_UGQ!8U U*<3$S'%_/RM6><1;7TCCQY2A+,;<W.^_:V-YOR&2H:XF/OE&/Z
M0$1& K5F6O<=W,"$)1BI^,#J.(9#!4ZB^2TY"WMZ?.OY;].4Q8CHU44C4:)Y
MNW8O76WD$'>#95K@39(_.0<31K8E=Q$&\6&NBCA1NVRSR?HAU/:\AM@0"8T(
MS[>.[-JSZR*TKC1(2$K6V_)E&?BZ_*(/J)\U9OK.7ED3$]?2>.4,N=:T/K3=
M'Y:ZB@-F10YO<G+R"9.+WW GFS'9F'^H:&Y<P.[+% +,YQ35GIM]@$LUJ\GT
M<ZN*F.\8R-2_\4$2_]0._N7$859G+)N/$X*^B>DF5Q%$%"$Y>BM+T.!#ZT U
M;9)UDSGD5J0E%)9@&]=FDWSV\?'9A;)]RZE>?[QI)IDE2;J+A+V^,OSXSZ'S
M7D+7WXBG?P<J+,R2V+L,W>'*#P^:V)]-03A,?L'F+A?8C=O,/@$M#9KA XB[
MV++QU:%NA^\VW.S<7NY136U^%'GLPV--0ZO(QW<WK+-7K]LB:JXRI)U[<UD9
M#RG%09K4*\0EPF%P/E$Z998SH:I47J^5Z:?3ZGA9T.>6D;2GM?GA6RD;G[D#
MP"'[U*RG>3'5?\8L_/\A]/)?#(;^1>Y_#;D0Y,; VR=NRTM^;[UL+"W:=:O+
M7N]/U=%N^&P1W*+UG<@7H;=XJQ2KURH_2JC%1$[]VUVG[V:K!H0'O/A3G34C
MS<SFS+8?T'15W2?FWI-[H_]4C,U$I$*CXK+7=T%Y_M>P>N=!(U7)K6)OI_,O
M5LX$+T,M\ZK'ZUANC()89^G/,0?THL1M3WFH#PK92JZ6^.",H'G$KSQ\)X&^
MIB?RE M\D>,"%_-C7)/?&(1AC"+Y3SW7K76]H =YXZ=V< %U)IHML8"&-5)@
MD136&@0K^>*YP(82).&/3&_G M:DKAFF)D-A*IQ>4)DDSHDM%9I0BGU.'SU;
MV":_:69UEZ[\YY:KOS<=CO@2ZW%3/'2[EEC4/<M(+K#Y#&L70NTY%F%? ::!
MC/C&JV^%Q(;J950ZET3"5=($+\<35-R,N[E W!P/6U63N0&!%"P4O,.;R 5$
M$6?*I\]Y"(Z5UG"!1P.(?_W4/L\%V$=YILRX@(8_G<P%ML")?]H9N(\3"HY]
M*17@ E1R*QEJD'MWC1R+\>8"![A 5A:E"57XW\$%95X&'BY=@,]PPB-@3TX3
MN^D/-'4"G:G'$4!@)#VAC0LL[2V !<"RT^@;>N$BRJWP'O9QJ#0^J?#-B8?5
ME;<\Z$NIHG:"H[%KSSS24(EL7?UTX_)J>+<?4X8+I/P.81">R-RM;'6D<X'I
M/?1T:F"Y'"3C7#:S!2L)N3R#,+KO(5#\<P\8Z.IY^UG4W0]U>TSV&UX>UM^9
MM6?_3ML'9I=>^U=J51_2>C&0X6H9*"N].K2LU5!2*L\U5R]]0>T=HR9"19H^
M=#JZ2NU$NW_,H[N'M.Y8>1WY?&?=-IV[ONG!B "5G 0DHJ4B0.P; HS:]3F%
MK?#1R4NC,&8:G+]%N@W)LU2QO[7!6SVO7&Z#>3S5:+2A"O=C?>;FGC?;O\;T
M]&\Z?A1_N#)*2R7:W#!=^^G;B"G>WV(E\"<22I;-V/C]O[) T;N(.2!GYPLD
M+;.@<(&]I&?(B">@;3'+^RPW<H%RH]8?_ZAN[F8I(2KV&]T8WIY/9#ME+_<5
M"1.[(-S,#.8K=@F9NF"6 G*!MAZ;OY\+,-Z@J5GHFUQ@^: 68B!%9%@><P91
MSI.X1O+\Z6)^1 ,RTKZOF^W)82*A.WGM((DM[HB&^E%FA&MP3<4BB&B4Z&@3
M=%NOFPR'7 8'W\T@DNC_RFB9[U<:] 9B#HFS56XM2)6V6UF=1*3E8:JABEB=
M2R@UL.(ZK@%!5)>C$3CG ;+M\3]Q,?X"_D(!&;O;G$1P[(&G-&*S9GJP@F;'
M<!<ZB\ZA#) _+<W!@CN8SH@03XB0=!&B1@:_<"GU^QLTV,=MIR81,+>I# -I
M]X",#VH%LF4<?. W> '6;"+^/#TI/[,QG$?]0@+]ZP0N%+KS36'1'HND637L
M?Z$:X#/J,T%K*HM< D;.C;)/2DXA=ZL?1-.-$;]8_>I73KX\?X,(=+.INQ,.
M$GA(IL?DKNQ?\'6R\&.A^/HYDVP\\1=-,L7Q<E[ &R N4!D[L)6.C]@UIU],
M8?JXI/5)<%XU4HY7[[0R2-*S7^3[F;#;G'$U\3=(^B.&?LEYE9W(6GH (;FG
M@:KU,JI3JW4H/_SKP5>_#5M?VF1E8/L.F'^3%OSD163B[7?A2L>BG,]1]&95
MT54XJ2_8;<_,/5.J]M[/R\KK'>WSNLWR.*)?_O"BR?U!CW?'X;WI@P(</F1*
M'O:28/G+N(X->,3S5O*H9H#S;_8N\#W K%;;,,$%UF"%T^TI/%AI-S<WJH6:
M0T("GJ]7)>I31W.L^_5'*R7'9K5(9^KY-'G?&.CV]^JXZ[U10\/\67&YF9Z:
MZU^5Z1:^5AV6ZKY;ZZY"^HFI)EO>^*/<,JH3T;T"#-N^A 7OF1E$<;9R 60"
MJ,<=_J32/A#R]1RZ#)F:"RN5OC[43/Z!&B8@&CV/SE),@7'(G'^T1=+.)"2U
MWV)(WP0'+B ZXMCY71?_FJ<E!YG:13H?' 0BFDZ/R_NQ$T65C=R:C!I$7+V$
M(X@8ISF2S?QPY<%5J#DF'EZ-AB_,HE:QKT*^C)-FK[!\-/%2!_FS=]3J#_NL
MMG5>KC0?M1L?MY"HL%1@J8Q[XZ(9B[3JF!?=9QT<'&A:U_/R"H+$[E07&._7
M-[AVZ#X ;%YEB<3S3G7/ZD0=30=)4OR%N=DP(U'A!X8.X@U>D@ZIWVIK=/*7
M/?X""62IJAG=LU2%2/0<JKE[-EL/2J#.;,F84\QQ]#%]^-F<OWHPR4%VRLE\
M2/%3D[[Y*%N^9NHY%]!$TQ%_L<F,#U;&*"+C8L*6>0YUTLA3K,&F'=V^Z;KM
M['OBL<^=1XYY9>JH/CR?\#C /'U;S+XP^AF2.Y+9H9%[$%,8&T#/3B$ 8$DV
M]TGFO%VUH> B*=M"^$.N)6I3:+6V-D&NR+%W@M1\W!K>.\2\A 0L(H38EW]&
MX/=::;^VO04A5Q[VCG0X? A)$AN0X!8UB:+)L;=WPAL*Z*U49@E#T) 31W*6
MP:)3+.R-3WH[!^>9R-I&K(\WBA!3"-FKL?'WU_NVG_XT:<*Q7LV9*03CVCF1
M<1Z!%#GXW!2:^@YMP[=\:N4_8\BT"URI#_=S"V3D'$RFJ^OX7I?C,\=]1 L,
MM4GBL2?EQ+_$JX^.&,!=?9IU?0_8DE\Z7\J5$R&Q[8B373^3Q]=%J>[09228
M%[84'W?P2:=HRC_Y,E!UL\$S[0JG1R!NC[;7HY<75Y5'3^Y&S?C6LRM8HL=F
M^$HQ[.#YQ5_G1//7)DLYEB9<C:%K8[K]+M'=$X9FNCU,BZ.K85&\>HN9)D,B
MY4#5G>'3=MB&,R?3/A\S=F&^8DNSA)%YDBK&L$R@:*9"*VC3<!>] S([C3=N
MDTMC2"0?%GM0]7J38/CI3QB.K-IF>S7CT0?1DXHBLRS"4B!3PV8 A24O[>C]
M9\9M"45+\T<//D;<&_D-E@^R8VV%%FE&1<\"X7[,*LI$9Z2)TE$346OF8%6*
M*._O3RZ[%-VQ$0EGB>'J0/IY5*]".6'@ '2%O@[NF3O_].R[6WL[@Q:N.N>.
M7J>J5)EU7'ZW+20[AW>]HHT-3\<1],!?"=A'_B<$G,/@R70]"B1&F6JBDR]!
M)0R/P?+Q90UB'DYOY\2L[KWC0F+;]A75?ZIY-@8<KC(T"23 M40$"0Z&H_/Y
MPMWX D76<OY@ZSYWR%>Z2ZEYZ4DR:<OX6IPO=O/\!=-';\H\JL]??WLVX-+'
MHU<F=_\T@N,DR '??1:. *D4>%<^:J7 X$\-I<K%"!0<].O "'R%C!4^XK?Z
M!@A;LXYAA&6S7B=N<#HYJX+ .[[CUZX9?Y[-9Q3O0,U(3S3]8BUCRXT\+ J2
MG!^!/WTNJI@A(/#V-EAACJM#S=_C KR(?\O+_%$B])>V/ 34\]Y'G*(;V%P,
M#G>G<X%9"Q1]# 5)&G,$:V"+> 3IBC<OA/$ME@[#5O]F5PB.#7C/>8(>&X41
M?:,Z6/VI8.//;0XH6'@5$CV0")+BR07J<XRYP%<DZ']!T2^2EA7P[")Y$-9)
M^67T_C/.HPETP$#B35,'Z?5,*\9BI=YJ]F86;U:RI_;RHDXQ@N82KD37)BF:
M1#*U[G[JVB=T9-_BNC?RF<>B0NYVZA*6HE5(Q])X)&N32Q$[C%0+HQ-#50X.
M-?'U0CD?!Z1:W3)D)SVZW60DEI5#O?(+-7K%;J1;Q3P9I!M$/.N(K<"HKI@?
MP6.*9W '<7DC.-XQ6QJTDM7B<UY+,1V%3O0FRLM.?/WW5*Y-X/^&7/-?K/[[
M6(4@Y)+O#UN_>BWU^G!$2%0(\-_S]B/]?XK[B$-T]#T&3KP].5:WU MO1!"5
MQ.JA&98_%QCO:,ROX +%9]MQ-PVY@)^<YA+J ER)FK4AKP>G"!#(!72_&+\R
M)OR-ME SJ&4!C&-Z@HN>WG*?I))#/G>M/)5)>JZ V<0%G@QA]W"!;'L**X'4
M?(@]P\D!AT^AUB%0)-Z>"[">DC0/PRKD"KE/C#G2HCPL!=N^Q/4A[LC9-) #
M]JP\MP"CB]V,&+CDX R+WY4+<"0B2FTY'Q"',B#/QUIOBEQ2AKGP\R695=A;
MG4@*XX$CS2N]D4HNU+NP(M3?>TE_)?<8PY?EZ"RXLIL\+ZQ1FDN*X@)VZ*7S
M3144U@X$W']QV]N"9VP+D.8,X/"S,G '>M89WK>,\!\WD)]!YW2R'\LA,+*+
M^!(</^Q&1>>EL1-F@M1BR<N&6WP*IA!,*K8)@95,R7'BLHZPMV?3XFXN$ R?
MASXGP-KQY(41]+)Y8WG(G/"](73(?%,/60/B7QN1U*.10C5J>_G>DS@M?<2K
MTSZ?4^2RG8[D#FH$W!;V73#44H)1$*@7L(Z(H), LL0?$BS;!&8)_L#2'UU%
MQX='G<Q(EM)-L2)OK1L<#Q-KBT0G#HY >]_CKZ7.W-/>8#(I5:5M.IWL4937
M=":Y>(YI!F71],+)ZUQG@I*D<[(*2HKCJ6*A>N$M^[;?/'-_JN;9GJ]SEH'Z
MEY^^:KL3.]XU7D9[-93YA'&B=$^5%D;SYCM\!&X-$?K4%(9BRNMQ@52"X93A
M$'D5^'6H] C8U>SRHZG]VW5RZ"S^*[[Q/0BKDYD</<ZI TJ'M*6?,O%A2&Q$
M\NY9Q*G?)+,.;D+N,/7U7<+\AGA8) Q\)<,-)@A:CR(O&Z=U4@P59P9;YL&X
MR1M$?F?#I;4[]2VM9E";V4C4><+ (DE\MNU*WBT_48M807VOY\0<,X3SAZ.:
M *6KQS,6L\<R+?!;GKI$C^"0VXOU(I?X\;%B/68;:_8,SI->%YNQ4.P3#,*T
M Q7LE;[2*?^)K4]5Y=65OIA5\.'15:U-J3VQD9LE?H>*"3&1FG5/[WB@4.0;
MJ !*KG-E4R":'^O\SB'V0V"%L$N>Q3KA0R.[J>__:'"4[7T@=K$Q(<-ZM\;9
MAWVSZP%(A]E,;YI>?,:^ (G*30<R=GQ4ZDB0K!)<E5(U"$EHB1(;0UVB/Q<$
M.?:VKIGK*;&EWK,/19*FCU!?S[YU\]C]H5-669]++P87D% ^P@[C*\47="$W
MEMZ$"&];L6^&@]%=3]%*ETE3[;'%K=79??LO[\(<.Z@@87!#MG5&'S)FGH.<
MJ:B>^DIBOEI"QF24)[%*:8VWQG-K^<\2Y8I;3>\W/PLZC^+PJET(4[,=BKS/
MEP ./LCR1,-[I"L%O$W+W5ZKN-R1K]UCW*B87S![!NU9DYMESBA,K5%^0_[8
M1N>0V0)ZM">6JW3<'I0*!W3&MAMH,J-.5.Q?\ARX(66^,(!1^?:N<TB!O1W4
M9 A4<JR'!*8:6-I0*Y6W@*:33ZP,IA:]ULV8/"YP??O!9Y&;SIM\.G;L-YR!
MZ0(&@2/,_9 6:\^8=Q[Y_DR>HYD)@[]<CR:WW:'S=X>B)0&7/3W\AF>U1(%5
MU\V_V2J>6#6'"!-ZB;&.2#>CEE2]"[=Y9>?"U@@PJU?5"S4+]<]/J VQ+G01
M//A4H9$LZR6LP?< )X[K)&\@.[+ !YB\ ")]L7I A>%<T:"]^+'T.'W ;R-F
M[*6BW(N0=EFU^C4!!ZZ]O[+'Z%3,^6C"%:;']'Z6(E:&\P;>2<&BH*(76BXO
M+8_5;ZEZ^U Y5-J_L3Y(Z.%V]5K@\9G-=64Q<7I)*XLQ](MZ#]$YMI6%:D?&
M81E&8)B*]@=MNWBGC*$2.[G45AE^=R\CUO4PC9/ TX>&JPQ[WE+OJXFU'(9%
MY-B"DV]T7[Q,ZHGV?'ZC_:3_G( ^W.-_1I5-R?(2[:P7S?/6#-]!HU0U]3H/
MXJ<Z:4VA24>:L6A:4_><'J'&U!+_3L=^\>Z!@08I%>$H+9EB_4\3NS1"/^/O
M;#[#W$2"1/6F"/=HS(XK9HQ<-9'HRM ,<D67VQCAM,(^:Y3MK()_C[:+Q&"8
MP1%+Z:YB=98D6YFA,&WV#.Y2Z&G,39*@SP10SF5G!="V76=..6VP/;OM,7GY
MPM-@@.HY./Q@J8;>.\C#EB1O(ML[^R4=@LJ&0O'KV;\E&"=0$6!O7+G6,<JS
M=*!6O'R*\XTR!;FGU878),88OI"QD"ADG<'>A0I9>W!UY+7R7""DIY_,EIG9
M;3E6>H0AGS@GD:H:7OKV\'8^!:A 7;'/_&CD<XO*A]32+CIA:@L=+(O$W@S5
M84@&WT )Q4]!.=,"L:-3Q%L"5G!M$ \!GZ^#/]Y0W=9XYQXB2#YIRH>*]B-F
M$AYQ =N90'+.3+C:P5NE HPUT::ZR9.3/$&N+^.]1A6.[KYMH]7JVG*N_NN@
MM$;E]M+KP+U28<@G':X%Z89R?N3LQ7(N$(8[DD#ES/B[">MB)=,]0\R"9%Z<
M5 K9N<%_G7!'UJ>@WH=:(\>F^S'/#)?26.+L+0P*8O>#+W";H'XJ.A CE$QO
M"L J> \<8&C6I'M87!R9T'&HOQ%RD/?RN=]\[KQZO^_PB[!KQ)8Z0+J6[(Q:
M.D8)(3+W3X#+%Q8FY;]2"O#L..<J/=;6!31'PKLED)$R03YA'83$3&(*&R^(
M^,M+8.T#3QZ81EQV*R8E.XPB2? B^P^>^^"W@UP@S:QN^5#);4U6)0<S@KV)
M@K;.8R*%^<7Y@U\C[SM7_5_]!OPXNW;YMK/VQLSI,\]%OI]6,T9YL<ZR=[9^
M&\XL@4*MA+Z<;VX0=*[+5!3]QI078)\@?"0O'_0&8307J.PH+2^8)1<^E3M1
M?R4G@X^]$3WB_H.HN?%?7]G,!;:(T^7@$$LDA".)&>,$Q]]Y&+S'-WTA!P8K
M5O:(+B6^^R$ _R_7@A5:6"1&)A-6=I]R ;:NR'>^@<R72)1$4U<.-+$;.W\\
MIB@$2=6B( $NH"Z'Q.8:+@#%HZDO2M=R@6:=5H08%X E\%9F2YB^"M:5PUR
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M?DA;>]BQ=>VN&_OCG(*1P/+"Z8[6'7_CKT)NAWQ.^)X4V,@XGC>]Q*GIHA2
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M7UBNAU:E>CJA^,>56BI<7"D]>X5;=1TEQONH)C%:HHHJ=\Z0#$BJ' *9BH1
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M).M\F #"5SK5;RM5ZK]\TI*W2 ;%:LN&C'@S+GIJS9UHCYH>:5YTXZ?CV8=
M2/;_(>V]PYIJOK7A*%($$5&J"A$!06E*54"B(EV,B'0Q*B =%"E!0R(HO41
M0$&)4@1ID8ZT2!=14*H$-80J)9!0PH:T;^-SSGF_Z_></][O^OZ02X9D[YE9
M:]:Z[YDU:R%8TNYM.*;(&,@)LK' -0Z$>IVPI=\7#0..UX((\"SXP#L];+3)
M,F8J!.,+ DJ<-2,#7,MAOXQ0LAP(/XXM /YJ\H(Z"_8!I$C,@ERV*(PIKL;&
M:I!!O^?+@6S"3>@^A-DI] ;[/*L69(;P)00S>=V.XDX]H4:TH]^GN;? :UDI
MDXX#F F'D%E-;^ZURY7$3U]>OS?*5HR_Z5IX4W<8\X2I"&K,;N8IH(T&;ZL?
MB6JT(#MU#AW[Y@BMC-&"55JZW]L3?T(L!=)O[A)XQ#3GC.@+>_<9Q/\R)"@5
MU*+Q#YBU4-Q>#-7:'S1W#V"5^1P(3':#L")$*8*MSF,".) I;#[&&_&C:YQ$
MR2(GRK9AQ&0'5::^59\/R_<B:C[M"O5KOS4AI'Q5Z#@U:P!Z*E'(9M>#K_]?
M)B7P7Y.R$:PW(CI."C<0IL(ZL0=1@?U!4N:63EVV6ZZZU4WMW[.0MIW'96-:
MWW =5Y+U^_DU-<'W#]KX?]6 [_][/QBZB-45V$,.Y A[;)M$%&RHL4TWA.)P
M5#@41!D']!^6(6?-@#Z:7DLR\&88+N(AS4L+^1'XR]%?V7C5DO?99JBLC<D)
MN[O7D^LJ#Y&J2&TJ%F:L='!$;K#1A98,L7O(' E]Z&VZ[;&)$</^Z0NU(79[
M%[5S'/+&]4Z%O)BP^D#2&H?];Q(@6X.V')SV/ZL&A\&_OB5Q(,_6,.X6_R@?
M="P0,SO(G@9-,=0?:==V4#Q"7^TMH-%*#!B=R[1,T'8,RG--B^![*N>AD?JH
MB%=!WS;R_Z<L_N\7"71T>YLCF4':Y*7_@FZNPSY@5DQ^#?WG/N9F\;_?[ #:
MPBS">!7B $JTB*E/(U#\J3,,D^$2^8K!10ZD<@+;&V%T8J[YK(Q#P&[)JWR+
M1L[Z7)&FW8-)B4&8*:/K$Z_,K\;EG[5V L48LIA&QA S.@A4"T34EOMB(DW6
MD$J(S; ?E*L?U%H(2A&K.)B4(ZTEZ']Z[_7V\Z/?G9*S74'ED0)G!L2<N9T
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MO*2;EA+B;>07LV;.OKNP=>[C&GZ&7=&^IJ=.J%UA78A3++,>_D_R ?/&C*?
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MR/E"TR4"8!,F/H,5.L.6A]IQ('F5%*]_2*J28>_TQ2 F>60M/'P.\945,/%
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M)'W<3 ]12H<(/I;SDX2 IFFT@,W?1+7N@I:CXQG6[.];T_C'1+AP;51U1_G
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MF&%'^]HO2@_CMNP$'ZK]JZZ%/7Z#[V]=B\T]>+9Y/6%] KH5X)[ _G9#=,!
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M2M*5+$B_X]:@\&6W4YM=O,-MA"@' K\J5L6-?NJG%^5J=GIU%46[T5#U_9F
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MA'=4T,U8D.0\'&^-T#2A!M6]1G^"3IN'[NQ(),'P&XH ]Z[@*WD-C9I\0Q
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MJ<6V#?/A^Z,?:KB1D]6V1VVO_+$7__IQ]MJ>$Z?+'22#G&>A#'DHM*UR]NM
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MUF8DQ&AM[]_"E@Q0^<24\P]9!+L_J^ SQK^Q$&[?5L/Y32^,90LL"-7/T@\
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M,S-'N%HZQ=*@3R7+*,L&)P6U$N?@_K0+F'9.92&,#DT-R=4#5_;RSNRCI4I
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MEIE3PT=K6)JEMMP%A2C$N\FZ\\>I=\-NB+96]J0[7(_P,7AV)GPDPM]%PTI
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M,9-P=,NOV,? \ OT7#P^$EBC+&\>!F"F,3"1\*7BH'?/PEB(9W2Y-N+PBTM
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MR=-QM^*3;DY!764>SH\TL?(6DAMT8L.$OZR_1;8,,F$^#MD,.O90:'J-^(V
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M\_7 =ZBU&3CP.R8I@EY3ET$P&>(J@ 6!_,T4HPRWN&^0(RSY@S0U:.,%8$X
M21TD[P+&/V@9LST'D6"XWM(5Y15+-C3C721%$,>^$JGF&.C8.V:2+N""C&V
MGJVMMR'<ZI4;(_8.D9HK ?X0";_9IB'$IR,"M&V9E2^75N.R(X5:TT=.1+?'
M$#VH6Q !PU<(=XN?^#RZ6Y.U(M%&L6$A[)KZ"MYG61H[3QH4B57_KLDMI4B9
M*!'VQBK%*!34:H6>/TM<FCJ-?R4W@J$?1-Z!%%Q1BG0)&C<%70?L]/L$[ALI
M*#J[VM!09=Q4MU[C8/8IG[L:6D60C:Q=;D:M>M,)]' ^\:4"0)>,:"0Q5O*
MN>?5!RY/V1U>2#MZU'8UIZ<M"\<3VT!1-']H\>F+>U:P5B)J.), *_6(9U O
M;B&*-PJW/ \CQV_F2.H">8 /2MA'4X8@5R3XO-AS>MK)<4VYML_.Q!)A^<"
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MS^3Q]=H/KN9K$0/@/P364>2 R9I+_JV_+_[[XK\O_B]UL8[!-T;',22K[W\
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M0UW JS"1[K14/;^PE3(:$GV(\17-5:=.E9_>O\;AC!^V,F^5JNG)?$)/T/N
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M%3SO4B0JYS%Y">:$E+DZ*M ^>WCR5=RUD0:$^SW!XA4'2:SVM2%_7->'0?0
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M9POB52X_$\Q4.)[^::H@D&5Q2A-M@-;9Q[[ "R"<"6<[3@7AF@-#4B\JLK'
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M!)_YU**@O?^QN.YP.A><#"9XHRFI7%%0TE5;!N,:('TMEG 4P2>H6>"_EV]
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M;<2+O<--ID=4)JHO88] IPN@9?*T'G E+/HZ!UC/#<9U.&%;I:&6CZT[9:O
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MI!/AE?'PF2,^!7:,H7#!Y=7^^#'?&624KXAH8"U7DDA'?!<F^$%2)G"=Z<"
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MM42 =A++TAI(P]427_H<WQZQ5J-F=%85\7@OQ)HB[6NZ&"Q"ZI_>;$X\AN
MG+(0XL"S;.G,Q,^CTA496IM*D)TX5/1H]!//M=;AQ=Q7"*:Y*D:GW+$$?D&/
MKO1F%6?S>5CYC2)[6$ARMOMU =0-M=VY(N3[N/_ZO$H*0UO"IACJKGJYLKZ>
M6M[(NJ3^.96EH]8L0_3]>"XIYAOM[(]4YG!RRV GH$PRI7Y#BB$[T7P[N#@T
M^V9E[],I^ZS<3GS-@,?Y1/FIFTL_O((+CCET<E,%GUI[HO.7^Y>ML^.4S:M,
MKELH#9\^*?).Z;R3TX5(4\X3&J=A,5B".1BXS(DABP/%<W-&3;W";HF1!Q6_
M'L<H2OF=G$B<@*+$WM/6R8]%!"-D=T;MU;CSJ-957[!FXY3$I%^E8^^#T38M
MRT63M1#:1]Q0XJ@%Z2M@0[9#7"H!&@AEYE8>&^=T\UPW6G#]Q95AI*V$GIKI
MG8=:[&%7T>L?R.)!(J1? '<>@I=8U//NB;/-1Y$'$8%Z#D'/]WV/T<3V8THS
M/,T=7GOIS@2NP<AN"%MJ-%*B8VXS2AGKTK\1HSW+Q65[!]F;9Q/YTQS<<F'Q
M\7,GO0VV*]1!:@HC..'"T970EO-(4<JEX7<&=??-_\B<L"F2]ZF1NX?^&6GV
MO%,\XQFPQN'>6)IG--.86)6W_'?T+?N?V"SSB:$R.\KP[N=]V5DP<&%O?3$G
M:!YPU.JK5\YW]5 :J=<#O[H4,W(92=8!,A[ZLPDX5JY0#_7(\Y\UHN 1V1F#
MC7 9+$_%;.(I6UWO68-'Y^_>GK)T.'>:>?N9B]"^I]7'!-!%W;XZG6M7;G0<
M*6E=""HT@SHK%?T='L"SI$P3S!J^GL7JUXT?/A-A&V?,)<+=1'&A9B"Y*<_^
M#'5WI)UP>_\FULYTX-7&0]Q#0%6(]%TR<W#*Q,(P^ZZ/:7C9EBK1TA8B'YME
MSVH2DE.<^!(BCFI2H$D%N<XW /#B42!F.+ ;+L)F\PD2%Z LM,>\;F]62.N&
ME3^)D$UY1H"U)BM359<Q7E"5<%:JUHAZ7SDKR=5YI%-2[PJ2BT 'B6Q3X!'[
MG)>RWI[\A4YVQ;3!B%#I'?QH*BER,/N4->4<\5:)"AVDU[?P$NES-7&H07RF
M@W(V9"XW=M&*XB26&%E(![V:O"<C[D#K\4Z&;N; VAL9WI[EKE+BW:O.0(VD
MMACP849#NG-IP!1CZJ]1_ 5=]):VD"@#G"9?0H@"QV-1GUSCO[D=OU;F9IT@
M#$-)A8XPS)=SAI<>QI3YG(F]YMU!2?TTSS4J&\N+IK\C_EH<QT[(1-O0A/8;
M#A>2_LKJ0;D9C=Z?J5J/)3PA3P^W+F7K/YNWB8<:5T ;O]<9-ZOV:YQ1/O6
MT-7#93N\L(8F>%JTS\QB2MO(MX$'2TAG"DH)[2/3O(A)BO] !U56',QH!S@0
M@4(I6]=NH_KI-J=J#?>!E?9U_X;$*]0$U&/92%B)<],XZB66XYU^?']HKN5@
M<=1FA4!I?I$"^^LLUB.?9FYTB(ONT$%"$!6*$O4CY/P*FA<B"<1(*^O^>2A[
M/:X%@:&<:JT1F/?=RD_X2N)3M""%4;\TGD7V@#G@D*N4Q\1[P?:I3Y7:3TPJ
M#GP]\[TY_(.HNU?61#)(%'D>B<<2C(UBP%6P5H>"U<PG*3-V\CK" H16WW?Z
M_B+'7;U;4Y0#VL\A"EYD[#PD*):Q_O(=.VBDZ1_\7NA18(=8W+R?DZI8;E>/
M3UUP1$XP?C"Z%3P>,J?=T8KAV2C[4\1L$^1\Z\QQ [7A@(!YIEH=J +6U$O%
MS!C"J)RPPV.#59V P3EUU%C!G#"CH<XE1FTR!WFVKRBQ%>#;)_3'_:Y]7_P6
M*/",=;8>33O)(,NC8T34>MW<$L5DMB D7GWF5[S?\9H"B;'A/S(":UZ!4S_B
M?\F+W$?7/P!/X%D :(LP$Z$2/8T^[A)PX)F2;:WKEKM,2EI/.&'B]2WK-^NN
M@I2_AC2XP+AO;;T/E:[AGB6;%U>T6Z^3OV>Q0CX0,8R1P*1"6O_//ZDX!G0U
M*KI>X5-0]XT& B9F)\1#Z]Z Q]C40?O6:='[K2WL<;EA)PIVC 66< S_>@5+
M.2/>ABH3V]UKQXR2[]4-083K^.!2]_VJ[,'+KZG6=^0-1><_S1S X6^PSO@Q
MV3F6-2R1?W@VL2F1U^#KBCD=)-4%<9&9W3S7AWYW&Q+UN>GHJ1.T%$_I3S4O
MBHH=K$22[OX4C*VQ,C+6]89E0 G&>.#B0NQ<#:;Q&K)#J;+6L)B\.( X*_(L
MH*K84-^Z9/^A+V[CEXC&PURMG?>"8]PB:]Z0U! H;)N,2^DI57N3NTY 5MI@
MC+;(B:[4,.AT,9@9ZT9V@S(#[2'P$T'[J8XN@?=G\28(GZ'DJBF<>)=CO6/\
MM">FF)D9UA,8R\ O>"1$II:0&$]1_^82/)3J7;K2?C#Y.7/J1DAX&-<M+N27
MQ@YJ'&JZ"@MF#/\1#\1I8NT4[)4P;U7\HTC]@OC:[#2N#4/4, @::9OY7.U%
M3,83?12*?:,.Q0@0\M\%&19-AO@4A]W',(HX5BO9CGUB-+Y(LJ$6%69!3T#$
MQ_3RWM]. 0)-+XT;AP]?*^E^'B3-YX\C^DB.GB/V!G%?&<B5L2J *BSG#>1:
M:_QV+5ZREOCRZ??_V\!QOYFT^3"RU"R4.V842S+M.V1%)<K]_O*:3/FAVKMZ
MBS [1]JS\9S'#IG*#R5$'\<-ZIS-D[$LP%YZ^B#74*/?569M]XB7O-L">CR+
MQAI*8"9=_;/0!]\]2N2-MSXUA#S=[\GR/KU6LV7K@B'E[TCHH$@2P6(]B0XZ
M-@MT$#VGYIJ@93SQRB]V5+4ZE*I\?EXN\HEZ49YWQ:W=]WM=>%AQ]>*,I)L1
M3Q"YE3@Z:K/"/U22/WDL065P0\9SP?<WI]5D])[H<$/XS\=4BDYLU7YC5,\<
M$"G7H"&#P1HEKU(] _$5%NLA1"RI#7B)/X54"$I9/R[],WM9*=^QK/^+.,16
M;GYN,EIFA,_Q1:(;0PP.-]I*(B\A1VO_8ENAX*; 3PCERG2%E7CAT0J?HLBP
M84V=F^;I;VU/R;<P+T$!<1SE5!?I62%2AC;VSMY6G[P*!G6(]^ GW8;O/U??
MES ,FFAY@QF0!NO\N2YT%7_[=WEWB(#D'7-)&W45<Y7/\3K<I\^!\EE 3,\E
MW3W=#%]J)O!NVL@:TK ?(F')0ZT/#MKE#U:=ZW;7ZK$BRC,=+8G'**($PP^$
MQ9GA*(_RCV=U*VP\H$85ME(FF.%WXGF/]![IB28;>)IH(_H]#=<.YM^8O3;1
M/A?YGQG&_QNO9USK9F0.VB]4)30J51? 3;OD-$0JV4%;><Y'&9?A]BZ#DAM(
M*H_%DW.PDE"W1.#BYKHJ@6]#PX#@P=5JQ/GE<%=Y\41QMF=6V?CC#T&;IQ]Y
M^12TH]Q=1#3X-YH75 HO)P7:9>()7,H";Z:)8[W6=D,,;XYTWCZR7 2X6;A,
M>NZ0R:K?N[2TKI]A!N2_4TY@<K'.6$ *M=Y$."-I=VEN]BA$KF_=*]R ^%+:
MCZQY[(?3>T&_[N_"+]DMUI37SY(Y:=W0"FD,Q1X5?O D*[C@545L4&_%#K(Y
MJ+(&O%8BF>D-8Z/XTT'A_O^KN/-_2OH X_B';3?4OF 68FE^"5//5*9INJ:R
M+'/YK=.<)A8TC92A(T]IZE ROZ!V4U.S<C,R6FI$B$E,-\7\DGK(W,21Y=>X
M4E$12,1/ 1]FW>UNMW^@']X_/W?//?=Z?GC?^WED5>3Z$]I44/Z*3>1HZ%:X
M*I2!V=;=&;#?,O?8$OYE1K@098M3"^YUZ(S BXKZFQ%U9X@CQ5<-NYGB ".P
MO17T,0+PK7JX>@?O)(T"8F6(S2('&+<MFS665CW6$GCJ(KWC 5E.8=!5)Y3C
M:%F&(][.T.CO0]YG&*<NU4H2 IGR($_F&;):*=N@,5W[!CSBQ(PU,/D1B5(+
M^JC>8ZB)W0395U8[>2X6[%;CX=RLN#X(V5D=J0XI5FHF2B92:]>UE$T-&M=9
M\Y3LR-,ETAK.@L1D/OL1*E0EO$>"+ GY!J\4?*#*MRS-T@CT!GJ-\JVL5\1)
M3?U>@C]9VW"770\J#_^:4P81.!CE?<?55(I3D;!S<]%Q.4Z*M8#0<LH<Z296
MJACW^/C0O>%"1.0NWC6$MAFD/SZ([K<3AQD!)R-PD1YQ+CBJO1Q._W;D;WWR
M"P1B(F"E4U9_X(G5D[-UK]_Z70W\I>0C81U9669GL19D'0V6/IA$GKXUP@X'
M;7_FG\4OYI3?UJUM"2)-Z"3A"6_J4(@N/A8!.GBX*/ZM$$38AIV]8P1:F#T;
MM,5NAR33R-J4<D?!7VNPIJ\X"[%/A^UU-G'BF9U&8/8%XAFSY_A>QN,*ANT>
M=5&/84)TJR.-E;M)60-Y<O(.D7"V@@>3G)L,UA0^?!F9R!>0=E[7 "[./BMT
M,^SL-::@XLF.\J5>PL/RSB2R@S7%/WB7O+E _^6IFG,$:O0^8@T1S"6'*4F8
MI;D,48#8,U!ADCLD@ CY"]@VE-Y2HGT&2CW:F&99M2/=.>&+46DT=].$>H;N
M:;1EI:\NZDU>=]Q0QUT.%V3'5<=(U[X0AT*+X:)TZOX([^$?:A/C2_5+FI]F
MD_76/-EE 7_,"*08@?(+CZ*^VY+! H^.BQT(*X:[U*]CWQZ9O3""T[&UE/=F
MP^!,:_M&PXJP)LO78F/,GD,<Z 8MZ_$^MQNO5R>/FMM%UH1YB<ZGOVJP?DM:
M%X+I(2YBWNI<7ZA(/*6OFE!AG;%GF2 Z1/&-+E1,YH+"8 H XF6>&*V@Q'VP
MO6Z_9(@_>*74YI(.97,I"[Y&>.]99>:)L;R\FE::C^IZE_J3RL(N-;Z%[:.9
M;K"VRD>LH\VV?JKH.]<YDP+WYLMDJVZQF*/+OV&>MFO\;!KA^>NWN1Y*S?*[
M6W+S31\2??\7\G"":H#A'V;*5Z,8RU23&Z%MWS\J=;TB+X:7"8-A7?-5X$/M
M9L-EVGF%;RF=6 $3HY-I*C#QN6G"HGH/3Q^1+B"HCF% 9^)+18;O<N\=]@$O
MAS$E"\^<BN^VN\AEN7!8I7TA)/YJLG_+]?@EUW3Z7BCDC\\V=AIZ8X3K8T?O
MJ_.&<?'$U'RG9IH(+/@<KD9*LQ(@TS6=.>@IC8!K8U3VF48@SGV>8=]!7=_B
MU3[2E8'O#[;H3R3^/C/=X^?O1OW1C_LNF(;IG393,0HY4DE/%U*2.9ATFC?0
M.#Y@UJ2![8#ARDRLO*-.KF3&NYO_]UGT!Q#,^.P?4$L#!!0    ( .6*A%9-
M6L-G#A@  %@1 0 1    ;6%I82TR,#(S,#,S,"YX<V3M/6USXS9SWSO3_\#Z
M0^<R?6S+OO-=[IK+,[)E7]W:EL;6)4\_96 2DM"C  4D?59_?;'@&_@.4K0/
M2IG))#*Q6&!?L%@L%L O?W]>N]83YAYA]//!R='HP,+49@ZAR\\'@7>(/)N0
M@[__^L__],N_'!Y:DZOK.VML^^0)3XAGN\P+.'[S</N3]8_S^QOKP5[A-;(F
MS [6F/K6H;7R_<VGX^/OW[\?.0M"/>8&OFC*.[+9^M@Z/(P17W",H,":(!];
M\I]/UNGH].WAZ)WX=WXZ^G1R\NGTY.C=:/3A[/3LWT:C3Z.1@N"WD 9+^>>3
M=78T.CHY^O#SF0(X0_8WM,36]40!'#GO%V=G]L\C?&:_P\Z'G]_:BP_H_5OT
MN'B//[Q3ZU^PS9:3Y<JWWM@_R2X*>BG%KHNWUA6AB-H$N=9#3.G?K&MJ'UEC
MU[7NH9IGW6,/\R?L'$58GSWGDQ=R3DB#>I\<3#X?1)Q[?N3ND8?MHR5[.A8%
MQZ+%TX,(4 C(WVZPET OD/=XQ/CR."[)@'O^AI<CAI(L*/>K4"=%F0IK1% "
M"W\\$N9C>R4%#5P:O7T[2K 3NZ(?Q,Y@A4+'S\)"'TY'H[/CL# &=7R>ZS$H
M75)#%!]#,: ?'8Y.#D]/%%I+J<ST!--@?5K6D=/1,7[V,?7(HXL/ 0QSJ<K>
MX>G12)'4$J%-J:"@(-,61<3VRADDBPHL(N4T"RZ]/1:#SA<ZB6-XFP74Y]MR
M]%%AI@&7T&\U^*'X$7D)_N<"_/>W$OKDX\>/Q[(TZ4K N; V57V)2K-B>+97
MY>!0$H$BW^?D,?#Q%>/K"5Z@P!42#NB? 7+)@F!'&#D7@X7* "C%/N)+[-^A
M-?8VR,;:BBV&<AGI@E$GQ_^XO0GMXX$8])8EASU9;QCWK7#TWS!;*DX-L^&O
MPUBBA_#I\.3T\.W)D4!V8-%"?^O4X7C';L2"[]2-5&LZ=R,V -#^657+Y19#
MKTVOV&C]8-?H1).UT.]9Y;B-_SB$/VJ[5#[JNW9!':[)7RTZD1WN'7L1SY#P
M0[_M=%[MJ!DELXO\V],:$:5S4T<&)&90_M)G@6(^NXU(E_-CQ&W.7"QF-]N_
M?-ZXB"*?24T<?00+<?)>UT)\S. ZQ"FR*_'W+GV42"E>"C_3Z=0Q%4$/'?%W
MZ40K6U;A2(0_]35%=4$Z-AZ[>?!#O^'4.6S9;,&I.\:N[TE'MJ[Q$E^POX9!
M@/5,SSC<$KSW3D@3I=\)U>OO*OEXH2%_M9!]ND#I2K[J:8<LB+[H,2#KJ/?:
MB1:Z$$._1#=::$-N>:ET U'*?-FV_!9_W6P(7;#HD_@(_M\GH&0NT%A$>,US
MO!8VWL<W<H$ 15_OKQL=[] 09NNV6[8D?8I[Y> %H412,()_K$,UH!$W94%;
MOQSG:^21!1YVIO17^7O#Q<*?ALQ1:D<@=35MY-J!VZ%BVK/J>M'76!@Y&<5\
MNL<+2R[>/D43<_T2[WC#V09SGP@=45:($L&*X\7G Y#H82S&/P2%1T)N,4BA
M@:SPI-!S3(DZ&6/PB0\H+E(@*3'O;Q9RDV9 AS\?>&+HN/@EE[O'/X:I0OIM
MF9I5F'*>3A*81I;^(,)=]-B6<%$%N]4TWT"QJ>0*P]*6W+PM*J=ZID"U)CZQ
M[MJVW$?/C++U-NQB;'3C_X^I<TE%Q[;78B;A:]FI SEUW OP/[3 ZXS]28FU
M3WXBZE@A.DO!U\[^=[;BW2>.W>W_KE)\$-V6H;8+1AU,1=/BA\=<XL#ZZ1RY
M$(QZ6&'L>XHPV]1JDND)R#1!:$$$/\)IJ4BM"*L5HAU$VZ=H9X@+N!7VB>!4
M-SEG430)_;23T*TWF59^&I2@E1(D;$T^>M/%=!-'."ODWE2K2=1O2T2="CA%
M:K&%E:(=1+OC^%:E=<'6@M 5A+6?\ WS]$UY/98FT;_3'.59)<BT8T%#@S+T
MJ0PK1)?8NZ8//K._K9CK8.Y=_AD(WPE6#C;QN\T&N[31I$AGW10I[(5%J*7V
MXU_1AGG_;H7=L=Y$'?IIF%Q^J-*]D)XUJM;[5U"M095V]U,ND+>Z<MGW5FY*
M6JE)#3ZT\%( JR71#H)M#A,D>6AWR!?_G2[. X]0['ECZCP$ZS7BV^GB@2PI
M$8,%47]LR_UN0I<SP7^;8%7B?6!K4H6?99 A:4C\$;8%HH];DP&'J#WXKK1H
MI4U:<9N#GK30DWL, 7Q'S,;^=LX1]9"=7Y]H #=)^6-!RA$J2^*R5&2#^%J(
M3Z@_#[!S^;R!6;1<:GF8!F&=C K"BC!8,8I!1"U$-$-;>X7M;S,.E:!/XM>2
MHW6IL*JAF\1V4A!;C,M*D5D1MD&"+20HO),GV(%X=/&=J.8)OJ)'B/*7R*\*
MMDEZIP7I*9@LB<J*< VR:R&[![DA,UYR'.>X7@7@7X2KAE(1-E1IDN3;@B1#
MA%:"T5HP;H4XH]7+(-(6(KU"A/^&W$#XH\D1@QO X1*_RH%MJM,DU'<%H0)&
M2Z($ES0]ZZ!@':3:9J 6@@KE@[,(UB2[L^* K(HB#!)K(;%+8=78%HM5@4^X
M-&PS%]%2J56 -DGN?4%R,2(KQ60!JD%PK?R9]9KX,L(B%O+"SX#E,Z:5J_\Z
M^"81?BCQ:Q)L<F&?P3?(L84<KZD PW/T7"$WM;Q)3L4X3%C;DM4'L;29R8)'
M#_\9"$(NGT#+R^>Q/%"3@(HAE!2%%>(8I/0: =*7"93J!DQ/B]&9G0.FUIOX
MU[!Y\BHJ-(=E?,\*%.%L4I]BE*@']0G;'I1GA\AMC4J40S8)NAA0RD=Q![F]
M0/2A1HYZ-9OD6@PO:40B!E'W$Y*HD6XE<)- BZ&EFB2'08P[+9-JY%>$:A)<
M,:ZD+ID&6;VJ2S5V'$D"<I4C"1/L(^+V[&C5MM2D,\6(UN[NEYC9DRZI!S(@
M)4KV:E#!5U'!!&HL/CL$KCQZP@\K)+AR^6R[@8.=*\[6RBF\Z6(2@4'B[0QS
M"?TB6MMWYYH4O1CWZT/1%6"5#BLDQ(HIL1:"%$L][B@JQ-3()&=+T!/6&D9)
MKWE#K>UP)T1-VE>,9E;G&PWV\T47MG#-DQ.XPF;E"NJ4HBV.)GTH!D\+B^%#
M*VY%6I?"6GG0A=UUH;5Q:%._00?>-J>U#9:@7^E7YK*UUH-NF)HTHE7&W* <
M_2I'1:)<:]7H@J=),5HDXPUJT:]:U"??M=:.'= U*8E&GM]5/L]OT)9^M:4A
MI)[ZC<G9-:7&!'/RA.0"-ZTB%M2_(RZ6![[RL4[#7KD+35K9*5$QY_PJY^VR
ME?T5MM(N9S# 4C[J=7;C8=#K_O6ZM1G<!5^3QA7#X'H:-QC"'V$($\!;C*!B
M=';S<OV('0<[KVP3>^]-D[(6X^_MS:-20^TV%,4='ZSDJ_B*A2W7]OYA.Q1-
MZE6,>E?OY0X6\(65(34S7\7BS?.Q<R_^RXD-Y];EAD$[S=#'UZ0FQ?!TG9JH
MMB=NV4J;CC<_!K7I6VTB2WWYC+E-/)B.NJE+%9XF-2E)^=54DWB.29H<M*.O
M&<;S@O5&;AQ]%7VZILDN(UU&+D_$?.\+_+>MUG3'WZ!-[XKQ[]JY*>V'!1V!
MQ:#2E=1CBGMC1=T9-*TO.Y3LV,,34Z :U%'<A'N\1!R>IIH&/KQB C_AFL]P
MQ$-H<AJ*KZ75ZKG5)JTLQN!K;9RR_Q_U3_K4JON4=-%2^AC>69KVTHJZ.6CK
MZ]G%B.4O91;+T3?I7S'4KVL5@SJK&*O78!1?R"C*HG/DP75E:]B^E:1&.[D=
M39X6SB:%*MD6T#-H$LR2S5MJ^_'V]*!#/9Y2;ATHZ("F25.*H?JJT\W6F_)0
MP4^#3O1] +K#_G,W7$W:40RKUQZ<'L))_:J(<AP@F1_NL#_!"\PY=D2!\ 6P
M7^M=M\71I!+%X'7FP$%F-A'M6'%#4&Z%30W:L*LVM#80NG6;I%^,+>>D/XS_
M%QK_22#O<K' \KUG\?T>^>)+ G:.J>B]/R$"A'N02G^%A<.'7+C--("W^J""
MKK7HO\4F[:J__R$77DQZ)2T+- -?TPI6U#<KZER8CQ]USTKZ%]8<]+./2R;:
M[WRU0="D/1J74_S_-E"_'.=??HN^9%^(D^_#1<\Q2Z&!7OP!;Z0C;J^$?SG!
M3]AE&R@7PTW\5PQ"[Q[;F#R%5Q+".W5"UBUJA \7R9>S/ZT9%;+@VVL?KZ'W
M!Y8GY.@37S[?_H6S8!.#$@%R8(6_-Y@3YLPEHO!-95_TA+@NM/#YP.>!P(0$
M(HYL__/! KGR#2=9]S%\=.3S@8,?2?8)SP(C<OO^VSM&PY=R_9CP.@A3"+6%
M2]9$J;",PM[Z<FLO6O\GLBTKZIDV)PA?!GD1*8X#0.$21)O4-":Y30UC.*$C
MYB^(T"FMS&Z_88A>,;X4E,%YN9@=;6OM%4O"Y,-,EF2<57.%Y1'"A ]:H,80
MKS$R)I W[$S($W$P%9-*9,UNF2./14;M2MJU0(VA74?PEXA30I?)25/O''G$
MAH$.!S>Q$U/>#!>2[?@\?)<5:)"0KT-Z[02&R7(E^CA^$I[P4L:.& VI4#:K
M*@CO6%E5 D]"_W@^7'M> )HAWSE*J/BZ@6A[F+&0;G/'Y+>K8XSJ:PS[-I2%
M95UX$M?<'WVXIA>,TG!N^YWXJW#7)$K1I,MZ)C16-D9#=(QC)QIU=$43Q?XJ
MS34LV) ["QY=8D\A'-%:=2I0&*- .YD8>%_'%6YB=U/3C,%L[5$75"7DYHKW
M4^H9(K0H-5EVJI>;:-LUC:\-#^EJ #)&CCKF7RSGA/-'+V0HPP[OR0A#7V/G
M?\3B>*V$0/1@]XK\V_'U^!:+I1U/A*M\R;O[#A.5Z L3$_Y=NYC[,LGV6?E@
M:)?G_W$]S?99_6)HIU/[)3-HHLRK.7L0N+W%-KKDX9S1H,3D:539JY'20%F\
M(ZSF%VDRI;SJ7C%'T@5D8F<2@ \WDTW+T%%XP-^3<\4#6B31UG9U_@KL""?^
MEORHJF2B]R W/S9^I.>P465S(K6];"-%!W:OQ*[<?77!/%^L=N0.B:.YVNY<
MW1@F:3C.0K@N\KRB_YAL+,U9UMML4V.?.*&L#I(39^H"<,ZN6$ =S&<!!TA_
MSFXQ7V*>W((A367)8F,W=,;PL-VLW)5J"=<?$R-T)EKG"?$\Y@;A&+HB?)VX
MS\6"O5("V+6#JR=EIDZZ/3==U&[DJ7M^76KO%8O$7,(Q@ES[\/_7-/8ZXZB;
MG'*2<: +OE=,$.*S,7:DI+54HT4%8QBA,?.H9%TPUPW)$9Y8K</6MM9><01M
MX0/D )8$I/..6<*1EK6,X8A6MH"RXLC?!#>F3K22OZ8^%I.;+_[/HHD2W/DD
MCV W),8P3$.%HE5]N( 3\TA9=*0>9I^IK0M_Z,'N$_7JCDU&J05UL5&@,"_,
MF; &Q$ZC?EUJ&L,9O3D6/Q$6>.YVAH@3DQNM9UOL'^Z.QQBVZ:=?1F-DSK["
M&N,[%WWA[=C6 Z)]XENE4S;'S_ZYJ\Q$.I#Y,+P?%_WXM5O];9MI?GB![@X5
M#6;#!">N9OI2PY0O$27_&V[$46<FU-@F@FA/&EFQLB6.+).O'6P+'.H7I\',
MNR%"YL* ;RL845UN,%%?F%R,"H/!P;QY!$["2'^C@LH6%0PF^WJ]$:#3Q7PE
MYL0GXIQ\G"%AZM?"D-/IIH$%'2L;S(X+X4DA0N^)]PW6%5]!NO#!C]__+#*A
M516#26_(VZ^@OFTM@QF@K!AC[Z=*Y!J0!A-:?>V9? ^M./5KPQM,-*1)"#O%
MT0:+MFW8%"OF450 &)I6 1DV$QXLE8%WP?B&A;B+V3C-L(82&J\IA)&90F:]
MZS*9(Y4EL0G*4.)^9_P;>!)H0WSD)NNOW->>%U,O>C*NY.Y-,)7C[X@[7E9F
M6J"&"@Z<OL"%^ST>,'\BMG+JJ:1DGU;#D"X,T1*QR(L)$(M<.,>4G'2I!3&&
M5AUM3;*H9H'P8Y 7/;F7)%&K86@]6!/W;'5Z/F?"U"0G]=K0G*^Y5PIP X>V
MQI1. GD\+V.?RLL,-4CWR E^(T(>61H*GTWM/H9NA(OJG/E\P+[OIL9'!W*O
M5##:ORE?3,E8]47V$'V+"OOD.<2SRIR%<AS/& _C:65[/><AZOR4U+*R,8JB
M,3'77G\8O9\Y9^IN8(Y'.R#8)SY5)DJ'BE'-GPX539SME>/V*AWQ9DXC&[K7
MWR<MF<UFL$,:[=]D)\WR,D-GSLMGF (#XJW"-!+EK'FTX8!<>4ETF![Q.R>^
MCX5=7(S7\()S<FQ_5S3&"%\_+T7NFT_PHY]FF A:;3S#'$*8:(EE>+LBTWHW
M''EMVH3PKS(YUX;*OK/YB@6>$+T0]QT1@L08AL(:\COY%M(,<K&S%C4,'4-9
M$N;?1>%6G^0Z>$,)5E_USBT82DH,):),"G%(OEE>><@](G)*U6=5VRJJ3NW]
M8H:^T$N #24UG^B8I:VJU%!B8'Z$+!'P%(0L<I=!S0(_N@\JS:;0A3?&Z]!P
M.6\))>M@+3KB>6H>=,XWN,?B;RZ3'-7,5^!)LJ'3 R930@,ZOKKB2_W&P$^=
ML>\84D##0)"\9TSFU/B<);LH;6N9ZI%%!DO),,KEZ65*,BM2'[;$?OR*5)6$
M7&0+1/)F$D4IXVUEZ3R7B5"SHJE2K)QRO3E3?"Z2V4C2KF&,&6RY^"H0%D87
MU.,SNM![QH)V%XGM]_5A<1^3U)%\HK%28&+_\]Z6$ANI<L@R(*9,M5JW#M2F
M^H9!0+VTX!AVKP:F.N/D(CIEDU(!I/_IIR<=O@M@A9"]'2Q26NS(!/^'\=5E
M(LN8V-;5S!R_R69UA4SK($I$NNMUI?VX%,7GM\7Z-F^(9FBKGK]L5V=OAZ[P
M%!YC\L(,Y=QZ&9:/RO40W>H:.]@KR<DM$+794%EO_U@@UG\H</WX<NIH^3?E
MROT%C>S0PF$L:W(WG\!+6%'UG%]6"O'J"\SF\%*R8YF_TZ6PI5D$V"L3%]T;
MDHT%YCX:&@(\=Y'][6'%7 A6^BOF9(FH+#:4'"6X?"FO_<94V2R'1P$K@]$-
M\(82/!9_.A@BZ9"N*U-%4I+"X'KD]B?'/PI,V V'H8PID#"EN)$3+2L92OI_
M(AK JWD4SUGT.Z3F@3P7*!0?LCSH6MML9D0DX"=,Y^P6;><KPJ5XM1G2"8.I
M3 DHKNCYG(V#9>#Y>JS9&8^I#$H'08E)F+,K_,A3I9!31QE@Y<CJ ZFAK+N%
MY-=*&D%CR@Q)@5D[HS&4/57W#;WXC4(ONA.8N3XJB=G<83_:((JO]TB6</H5
MC%D)Z%_UH=ZAGCFW45UNBK#;7K56>-\ Q%C_(DWGZGNH">D62G;CJ++8R#AM
M[J6*L0\+=V&@O^'P7M%9%'I5L_XU*Q@;Q8TC[)6;9#4 O0JQIWUNN&8WZ>R4
MWX-W,1%K/1B%OZ^(O8KIB,H$/1NBB+1S?949CJA@@#Z7T9*^LAJ?J1LOEQPO
MY>O!9;??[8;$R'&>(<G+;BI6%.X!'8616UV^%]3 L*JF)2K= TIR#_-E$H9J
M=4^GX@O,*Z_/A2;-U:S[%^%%G=YKU?Q+\*$# PSVLNJI4,\42YP!<N<XO=N\
M:^V,2Q))\,<K@91(X1SH&&A;2M#S;0H2W2<J+^5(MM'&POBMPV.!ZAYIN+;X
M CQ2DH1>J35CMUM[94!FO*7<>!%F5[9E+*ME;C?0+L8A>0SBK;7+]<9E6V&*
MQ+J:)YO"FL#J&-X$)ACQ^0J_&YW\5\FN4K' U."D,(_312';K/#93 -Z2USL
M^8SB: 2EQS+RWXV))&DF)3_"B,B3X=VB9SANHB3+-<#M%=GJG'+/MLCUMS%!
M4WJ'?6$(TGB:)K"Q%C+N["1(;WQ(Y)A_DZ 2:J_D&V4=S 09\C39'-LKRERV
MW-Z(>8UZ:0)S:;9"BWJ&&MO6E.\_R?%(_+KQV93B<X&*Y&]%K(<QG+#Q(WO"
M3915 !E*VE=*9.*U3+O%S\A[8(&_^@Y7!/(<@5J@AI)YCY>88BZ<3>&(KY$M
M+QP5QJUP)ZD&H*DD-LVBC3/GGDPM6MY R<'-]O4R859#CG5>N(BL9=!+8LL%
M3(I%9CKST5WE= G/MUT@SK<+QN45I&G__QNC]*99;7B5WB5\^O'$*G?&P;U?
MG$!Q*"+T?"$U7H<'.Z,QD#65<KTA:P)G;=4+?= SM",L,5OC1L5H1M#_<J&?
MJ.GE8@'/G#Q%'16]OA>NX3VV&;6)2R3;@=HIS5\?I=Y6L"L68Q=3MV)^VL(A
M$(K=NZU=F,&KRW_PQ/W+,=#CV2N\1K_^'U!+ P04    " #EBH164J-V%1,-
M  #^L   %0   &UA:6$M,C R,S S,S!?8V%L+GAM;.U=;7/;-A+^?C/W'WBZ
M+^W<Z<5R'">>NAW'LC.><2*-G/;Z+0.1H(4+1:@$:4OWZV]!4B(ED2( ODA0
MDFD3FP(7NP^ Q>YB%_KEM\7,,5ZPQPAUKUMGG5[+P*Y)+>(^7[<"UD;,)*3U
MVZ]__]LO_VBWC<']PV?CQO3)"QX09CJ4!1[^Z>G3S\:?'\:/QB-QOTT0P\:
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MAG-P]6J7-^QNOMO-X$>8GH\6U*6S943XR0>J?$W<4M?"+L,6_ "K@5CPW/J
M' [VTQ1CGQ7)-P9Z7Q7H;6*8ELU$CADXX=ARP3?:XX6/H0=K185+4Z?P(5LK
MQAQJ%H#!GWSE"PIYYO3&M0;X!3MTSCN#90=_@ZYB8VQB\H(FR=R)9'/XA*;>
MZJ&#)MB).I$BV=W+,X>* 5;A,K 1FX1K 93K,T)SCEB_BQV?K9YP\?JA:/&#
MKR,/SQ&Q[A9S#ATP-/2GV+MA#."Z#3P/.!(12XI<S2+=(C:5X3EJ7S-3*1P^
M4]>41S:'0,UL#["-H2=84FQ[K>]G=^O%FME4GJ_-SLRH-WG^ZF?,-+T 6X]<
MX3K$)U@)RWPB];-/ ]=G([3D2E.-]TP*^QG/V3'^@SP/N?X*B*7<@B\D43.8
MY2;!848_F'$+ T>[S2V=S3T\A0T(]E+85.D,/U+&/F-_:']!"\EI(4>Z9E''
MV$?$Q=8=\EQPHUB*/U"XQ"128R5"K>ZQLRS"+4/DC,!L>'!OT9SXR)$:HSP2
M=9L9=#:C[I-/S6]_("<0LO[RWZW?S(OV8S5^,U^OF>6PJREU+/"][_X*0 G"
M@G,"'CX848^/^(WO>V02^%QC?Z%<15+7!Y\ N'A^<'WL82:U'JKJL8&)1WSN
M,3 PL,'9\:%W[)J@<F7G8"Z9YO88Q<VE218!GMVIH<AW#JU-85(N\XUG;G0$
M;N.J$_AQPU_>#8?$+;HLF,U":FT"KO+J?=NC,QD>8S9HSGA0#QI?M\YZO;->
MI]=K&7./4 _>O&[U6T; @%$ZCQ1URWC%/%H51@5[NDJ_=P$E:/2_#S2J4IX)
M<.?Z 5?QGD4+=N $JS<_L-IG725 7?P 2L!T3O!Z^P,O.8<I@>[R!W0E/.D$
MQW?ZX9AEWV;;3>L@22+O^Y.1MS"4M18:Q-99Z.U &2V.+":BZVTN[Q<]+R"<
M2*^A>;P5QJ?;GV1(J:$MFR_EUME.(J6&5FB^E#D';HFT&IJ2V>=D:=,Y/ M-
M9-30_"N44>B,.H% 0S,N%P+I[(,$!D4K[)?N-@J/\'L]J2_KI(_U0S:TAW/L
MA?W*I[X(TCN.U)<B9I527Y!O3K'_-$4>CI>+>(Y+UKLUQVP_8A?D=6!BWU@S
MXA+F<^E?9'@7)E7[25_6(E40I(!0W6DOT01TG^,.I<+]&2_7/8' O6?<#\5L
MZ-XM>-\!85..V- >X(G4<9( L9K%N4?$"R-@-]9_ ^9'/<?^F-1(%!!2RI*X
MG2+W&5S_->VA?3>;8 MTXCU&?N")319Q6DI<\D$<NN"\@3(SOXT\KI.Y0H6?
MGCTT>Z3(O8=1 <W@8B;.L"Q9)=YO JZU'(+<HBU?F&\9DC5/[@<7>O'C3ND,
MJYSXYM.HG?FH(P6%OO-J$YF+:U4<X13W_1G+IS#NH=347I2$&Y5VH_3K2NMR
M@,$^LP;DA5A@ @[=6)%^HA:Q290%+[P@A6C5#"P,7H))U4D9"L1KSZ6A-O%E
MIT_ZK4;'XP41)\(K=2X6Q_@_($9,]=$0('UX9U@5#9H]=EJG.52 A<)Z5,J%
M:)\ 9N(:6NNLAPR%2 OV3:TS%PKD+;!RM,Y%$#0&Z1YS52FWX&BT@0H >3Z&
MUJD"XD!(.XY:'_U+XB(;"- Z34 2&Z&HCE(*@<;JI" 4IY16H#$< D%6K7,-
M\@/H5#C&KW4:@A  A:<U6N<H[(4@_["M=*9"DV>WNY7[Z7/,C6S!M.%=XAH#
M(?K'<;8KRWP# >&,_$VP4V 2N5':@;G\ CL20Z$Q ^LR_"U>-^N-:Y7MF9E;
M.D)*)?+-,?;=1O'JJ&C;'C.5:MV]9 ZOQD6DS VT"0R2UI%)27 :7NJEJ[D.
MG@;%$_ON'?I:41;4#KGCV"@+>*W[3-?T,&)X@*-_']Q! '-HC,.J!YA*LN6N
M@@1K/ZK>YF(WK[N<5%GT#B%4.D^_M$2;Q!H79].3EK]X1I1BXX(EV:DEY=D@
MI'2.G[$^X\SXH0W_ DK"UR;)T6L<]#AE>L5.9NITN=$0ZZ'NVTAFW CX7[A7
M1=$C?A,E7\G WHP$,QD9!8A]S^E_#XP%_&:^H9T.7D@LEKSW3SP9D7L#]V Z
MITX%AO;>\P.II$05\C^2<J7NM>'S%%PV'M"9<2TGG/!51.%[SWL:PQ:RC(W^
ME)&\E)TC^^DHK=Q11'!H/[A@X")G%$P<8JZV]92;*F<QR)*M?X:8&%NA EGI
MYTS.)">0*-$&Q8MWO[L%]DPB6=>PGTZ#0H1!I&$8N& K#BQ527*('6#*A2'Q
M58RL[%3;(J:V^E-T;ZGC1'OHT'X*)LST2(B9PC7"LF1+\UZ-F2%!L<')<TO=
M%PP&.R ENU_L)5.S"'>@_$S8 .X69FAV@C&,ARX/>?'_^1T>+\CA6]D8,]\C
M)NQE_ -PK#8?I%JNK_P ?V5.&7(^>C28\[-E[K_P6ZX"\$ASRB#W(W4,W-9_
M;,,YA#G!$SZM#\O?00V",Q#=W>\^A]]P(!TTDZ%Z& &3R%"5 F92;>#^<.7I
M. )3A%J[\8UXDJ8G?K08I ZX&N;L"(Z%#C,65&UBZGT"=ZQ09RHYK>]7/#S4
MQ[ 1:UWSH+#-4T&+4>O:"#5<9/T"K6LH*H)(Q./3^A['ZI98CB^O=?U%=>CD
M!&ZTKL*H#IW= )W6)1C5+ZJ<6*S65SN64=&2(7F]"S;*3:?]!RU*=1O'CLR^
M,$E1Q;F.Y1OE8,@[Z=2ZG*,<)%(%3Q+6L>8+IU0"@])]EZ< F&2%Y>F8R2+@
MY&88E;X44S] !#/!$F1.QS061$8@W6^-3O]T3&)!=%03/A/(3L@Z%E(^HKG
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M)5P].>%:DE,^"0W,/JRPR?TEB?"<BB(Y)G<>U<#<C1\ =(G5W0(B201W'M7
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MH^S):NNHA(-LAD_F]R"*D>_&!(35"H8/2^PJXE5R Q,,#IHFB'PSGL%O "T
M&BT0H.C0[PGSW=IXAJ3]PPF2+J7=C*<D[3UP R>*\JSQ9/[#0:10X):LCH D
MEF$ZAX4%DB&IQ'-ABZ)*=QRZ"4* :&>2<*$?_/#C93K(IIE"*%2YWHR^ZAL
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M\.E9UFOW8)LV.F'-@#R8L\V/["OT/;:_*4;^K1'^L^>3-B#/(#5CKU_(52/
M(V;'I1.X2;#II'.U^1KI09H9N!WWT=#$=I];;[0-B>;N#$4F\_9S6XS"U5,2
M;QC-@E\9DZ,5D5ZF?+.E 96.2'P/GT&$-3*O.V=^PVJ]*.*T-)?@9NVEI<\H
M[3RHF<UKO(SA&A2ORI%GN8*([@8FW!E+\JSRAZSJ:0U(&-4C!MVIKR]K/@'9
M,V=:V>CLX$-#*1H<>FAG9+OGVKY5K']BW1H^Z- Z9-Q##NW,GE=WP*'5Y0X[
M4H9].2/1Y095B_WVEMR30Q>6(MB/4QS2YAX4LK2M.=FA2?0=OXA5P]N?FY 1
M5]R!M><LARH"[1@;+44M&)S"$775T.6>A4MA!,!;';,X_W68K$!Z)H*$_'?"
MAA(6,R$>,9.9#*,OEJ<HVK&.@.\]H!5@4P?%ZV(,O,4FQTV&L""0JL2^[MYP
M3WE.^GL8D?5,BO@>)5O"E1+1[(B20<8AUMH)&3ZKK;YW2)$KA3HOKI:11X:J
M9@&5WTFW[^&2W&R07V@P0??^8AEG]W72LB-V:>?FTTBJ-9[B ";$WKH!OJ&$
M6[0Z74N%NWA8E3@%6NJ]21 UV<%5X!8BB6!>PY$,]K3N @?1@93R6O> &,>D
M<!_OJTE ,^CI)>/1 XCC0*R9O# IM8:&V<5HTP2Y2R?:I$2WR@UG,':"&\='
MPHW3E4EKDZ%5KA7Y)-50Y$;Z&XBRES=%D%Q**SX1*FFH<;4WH\29X3RJHWG5
MT@=SO+^ZU,^;S.=X)"37RZR2A-KB=KSD#Q_/!LD$]=YS2J/? KPCC\(0ZS*I
M3'/%P]H;/S-_0SZGR7NZ9PQWD'8M\^F^K(N?R&919:AVEA058ZI![E-J #/O
M=3\TIOXV;PVG)(5%Y*8:I5[6J\LHJJP5J+;^^Y8'5-"8)<CT-I'7-@3]RL15
M[/*PTESJ4\Y-0,@]LS27[\S^)%NU?+7V/^NITJ_Y6K=/EOIH?6JL("]PE8?,
M)+>_$X"TY&*A"P:!Z2W:$ 2[,2<&B/WGJ:0!$0D<LE.Q_=K*A/V$9K%?=DC1
M_F*+%N$13A&P8W2F[5T]^$BDC=@9N&%9$N)YP1R!C\/4)8JYWQR6'O1K4(%E
M)\.?B7MV,JPM5:4H(\?BU/Y3QBI85!3<Y**?VW<D>.2Z".]XUR]/ #/=9F&8
M F4+ZL%DN%;)6%$KXPNVR#U2DHG'H!0WPVWFW0QNN/@"PR3ZX@2D(8EP6JO!
M"$HYN-R%V'10V?@>J24U@ZEYW40@]0&4Y&&MAHJCM2&( F7=A\8*8RK=YUM"
M0'M9U!S@D;8F>*';PP\_7HZQ(?;L>XD3D ;*+IGTZ8&+DH4A5T"E87B;(+L'
M+MFSO*PEX%H;.IR1; *BJ'H*3=NTP5$ZGDV@=(*$C/@U=4:Y@IU"E!Z X'$B
MJ\P5J1MXD?G:4M#O8O0T"S5-TW>D%WR\!&@*L<<!8A_1:4.ZVX9X!P(A_B&>
M8IBS;:C0T%1&Y#9&TPS(5SP\PEM+Z(V\%;:+,8>TX]%F,Y%O7R%(4/>%QB$V
MT5/7D6!]2UCV52X+KB$T"#$ZJ*,J&5^V<*J23&>54O*[#[75LO:0#4JHVAG9
M.@M@B\G]T(@6@Z!L3".U6JU#QJWI:F?VO+IBKU:7.Q149GTK^Q)1\/6R][;D
MJTWQ^U7N)6:B0&D#L4_58#K5=QL^!#N-;W_"1">68BXHJ].SOZ))!UI-8A(,
M._O3E%W/-,$ %;N+T/Y20FL@+(UV,C1-VU$]0I,32F<X'K:0UA,VK%SZ=>XX
M-2G /MW0J6U#5LCXLKL2[2^SU(:;>LJ?P6>_%Z8-O@8E(*P*7+A"K[-:)2RX
MNP3NSRDB#\6TX!0ND+-JL6JIT1@6U"^I\:^YP_H+J;=/_&A)[[&>DZHX^=;\
M5524\L.[! L%O)M+/VC (RMK_(%7 7Y3D_E<G/=VQNFTR= ,H)7,:^$]?>@P
MUC#AS;WY3KGOF! YI24TG4YOH9.I&,G^&_R'.YT[:C<+E-/H,?,=Y).WAY9-
M(_.>ULPPL; F\TN\1OSXQG&I5RV="*X@8H#]?:-1481;P]E7,>&@T'MX)=G1
M^NE<>K:CG_G-"H53*FFON]$W$[A?.<S:S1!6VAE]2E5*ZSHABX^E?4RO9@T(
MJ!Q-ZT/^JR$0J7_&!+8_+R L<#N^-DN9V!]^E9X+52$4)KCP3M=9X*]PV/P.
M/Q9-G34Q6UH,^S48P8*@GPKWA\;5#<5C@VXX 1YCKIC/EI91AG*G@DZ0O_#Q
M=&)ZHX%L7&)& FN2_9$EB*EV(MY:S9+-Z^MI*'&5=7/(FCR(]VKF/'FX^D!F
M.M )19?]]R>2QDN'82.DGTG,#5&"NH\Q80,G(I=*X_D9\FP3F5<B0,R$<D$/
M#BE'O_XKD3Q&*T*MJ7K!8ZS\*()H395$EE@GWK**IJDDUSJOA28=@B?\I$FJ
MY41RSW(RIR\.CT266;&%U):J$$^8R%-NHNJO0.0BG]K\LKI^ZU'-R^X:.TB>
M1X(:R'^F1>F%ZI']#Y7.M*N/T7@*_0&)*IO"7P#1PG'2PVY)2D1H([(8>P)*
M\T>$K!+OWS"M5;+ZBK J+NJP5&?=8(L/>^'AXA[@W['G>@-1<?J*:OW6AM+=
M8&-%*K#_GQ/G0Q*OC1B[4P16?B*5:A<@UFD&[WOHI!SAN;]A1-V=XQ)3FH%%
M8$:AM[-*ITE\ YP8>\W"\TR<H/8#N6G82J%GR=ZC3??C;6>.;C=%_3);@IUE
MJ+)#*PS2H9&WPZBJ=;='YE ^TZ: W\C:Q'/D"G.A+M VE4X%N'%<(%\N5TZC
ME:"$9*U/V>.ZC_\O\99"<AX$C1EF4KY>II1$;UGOH-)G;V398I\2 DI3=_8+
MSI8PB9S0P[OW[!=>#NM)"+)@A^1,%J36)J>E+FL[K->2;TV6%B&7P[N%"<T[
M"U0HUH^^K/<J].EEY?0?.H-#CYSU5:O:TS/^ 33I\3M0GFQP2:6Y\Z#B99VL
M]:WLE7Z<1WMV.=VKOYI.0IFWOA5IVWSN_!#$ (0M<EQ-4G==+PP7<2/+L(Q"
M3QGO0"GO#BR[1/G/=];];-N>5N]EQJ/3I2]QJU*^7D;!2-UZC3C<'F \U%])
MS;K0%(9UZZQOA>N5VJ9"VMX6KC<3N%^%ZS6[(%0P.'I5S*XB?I6%J%"YVC.E
MIG3UK/&V)*:O77UO6O.U<R,IQZNVYJ9.;3-^)Y21"_S)GDE=M7_S0SA0?VB*
M 67Z^(+0ZC>"4Q$E^U6$UB!JU6:[&V%GH W4Q!)/B.10_&:_N65L_G"28M9<
M(:IMWRK)6[*[04VWAQ3;OZKSMU7R[F]%IQ>F[WH4VHJ:BEP4V/3>*Z(5JJL+
M8$W=1I\NNQ6/N)77S#!Y[3\QJRKO=HD3N\/7M,K2)['8L?#3#Z:=CC81J*P\
M9"*;CI.V(7(+U:0,$/M; XC/@;UB8'9=M>F]NK7W+EZTS80?KF[G5M?G@G\:
MPFJ7."7!KB$?PM[6VED8=D7W8&"1/?+$(!C2GJ]^?"W'HP?7:@A."=X1Q5S,
M'N0,%&:^X&%1AH+]$3YYZZ_VM&\N_D4?HGJ-Q2\>SLY%%^_Z;;'H/%>G[ @]
MDWQ(QI] ,X1,\/,>E P(SW;1QA:Y\*=#<NL4NY+D8)P-QNSCM)QA4@[!V>$&
M9[>:_#!YAZ38!'HNY8*;+@=JW9VOZ9V5"VXZNZ91\/J&: R%(1BQ_&A.9>N[
M' #QO%MGC1P+;N<F).$$A4LO6;8U=<RC<5AX8M]!Q8^,0F^C[ M_5.L!:8:Y
M=((9;1_9L>!JQ])<8MSX<]_=!/9VZ*]G4+S'EC1)S4<<<CA'WC^3*$[-],R&
M$1%(D)#26:J<YBX\PDA74-#>2($S.>]@Z&:WU(E#6TNJ2:NMXM)Y)'<KN^)=
MD*I(O*H&?F6=*ZC2VM)96<ASDP*2:!XG0DNQ:=%>]'42[AKXF[Z^PNS*$36Q
M%ANO0#-LRRQ204)=;3'C\ F[B;?@&03GXD=@A<AT)<(WX!"SA18OYG_\NP\0
M-KV7"N? )0F_"C$[.%*;#_UEO<\%G5FRAVQ%*79FSN'-+";&<&'%;\#W)N$]
MN8P#X6V.'.^"(<I^_>)$?D2>IV;I#)OQH?]7 B+I8[MZ^>@GB/M>MCD@;PT?
M1>X,8MC5G'PEAZ([43"\EU:C5_MVS%IR!^(A(KJ7]NP\=D?(].O@MIIEQL.&
M9SWWZ0RWB9VCQG]BI\!-ZYX>P6?3<7&[8%.(GS H[2\JZ!Q*H<A9CJ#Q8W)V
M(:A0UG-R<5"#964AU?O'!],&FEW "><_<@ _VE]^T/G,JTB!,=QZ9 $;B1AP
M<YJL+8']I:N=3SN9'+="4PS[ZD:X+EK5&0=#)22Z^.Q3-4GK&&CN ,H&S#EG
M4LN$D^LH:8ZL9[H38YG6 $M>,"E&1W<_UF;)V$,*ML>YR4-FTK*DVB$S><A,
M'C*3A\SD(3-Y2+\=TF_#BB-46LPY:#UHEV "M&H7*4>O!T?T#$\YKI_,4K["
M";?.(E;T,.(2!IC#*(VPC3S/3YD9AW.(5A0)M3"3&G$+8D.2C.NUXZ\Q$' -
MP - S[X+^(U2[TBV-XI!V@TUFL'8"8J?7\(HOH/Q?X,83WVX"$F'I2G \Y"T
MV-G\B7SO5,:J[YHST_? E76@G=#5&WVE.G0<IMS_ $238K&?\8:_ /1#TK(P
M5Q$R2'?.FF:H"R>AIPZ:H+2K(1T;LTA%D8%'B)S2>1=EX(L;4;)*W\)6CP.Y
MZXL[9,8\3L6>0.FQ:3I%F7;O%JD*=KI;)I?.DX\U9SK^/8BPRJ7MT6X24I22
M]1A07#2BQ"U7P 6K]2Z1C5=K&%SM'.!6=Y1-PP#QDW_\IU_%P6!S\X^O7Y^
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M^(:L(88]L[NJ3JS:1X:-W'N&12^JQW1!403"_A6O&B&"RM$]AHZ]6WU;Z*C
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MJ"G3#(BDR%IR_8A2J)9VTOV>GOK:=.R#DG( E(4W.2:#6D=C6O%)PXFZ<EM
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M[A"YDD)I@8>(I7BX3#&&8:Y8F,4.1Y/2+38D<'4_E0^=8?KA_I8!@]R8Y76
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MXK*?R]S Y*=SJT+FA-4GH#FF=RULTB(GAX*'9[$@35W^1!J2<L0TD2A#W D
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MA_,T(6;/>013:CG/&=Z5H^3(9K:+.-M+NT'/-W4+;[0IN:EB4G,AZ-QA/CY
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M#%*R<;I#>$40AS"3!IP.:>/B*[*LG-=9:4^X%)J'<H69TCTWN0E!3!X?\&F
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M$E!E*1HNCR8Y.&B/>R2WBZ2 0"@L?$&.UTI^X%[1F.T5KJ1*UV$X<34+&$_
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M'&A=7U]?H2"]SM!#%NSE'_2-?%GS(*J/F)-#IFM _E^">9%NLX29#X=&HX9
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MJ7( <Y[;R!L2*>O4>Z,EO?9JFHM;Z]U2OL4#&HSJ$Q$VIY,@ ",#1YNF;,N
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M11CCPP3ZN.0,!T+5DZ_6%_7WN@U"#F8[0AX0^GX<)?0K'(WJPROE)FV]SGX
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MF+&TY<:*8RK3!"B,;C3B(JS411*#?AQI 5"LV,._=_+\/3R%"?<!\DG9P7B
MSS7&UPPW0HE/OUP]C6@;M 2O,^[E1BVAU@W7"))^NYS$ZGN+"XAVTVR%1?R9
M3B)]W515#:O-NLR*'W]Q>('NFE31JOT<7J9/O'S/4K="$E?*(3.&7#@AN%7#
MB&4-)[87):L4+R(^Y8>Q"-/PNO \'0  :];R8"USUG)G"F7U?R  >]*AW/\
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M%0@@>T3%P,QL(GEBFJ_BS*,5"NCK-4 KLO/<%T3-E6MTB\/P.XKFBT?K%8(
MF+3BJ=ZCR")"U;FR I] '!;XNT0+UW9!Z\M#3?7:.8Z;BO4[RW5N_ OKV8VH
MC >L41T)Q:R3O;"F%G!R1OYN>3%7^$_]MXJ9O<NN3#%^*S]7S'(J<2 !3'5?
M:M@(;D0O/'HS4,,'.4S(M\E- =T3M6043Z%PN0G>B6TLEC4;^B]__&X%U.&6
M$=K0*R0.J)[)PT<K"7VPL5%%=FP+(7W3N. 'O^EK]3=^$!/UOQ/?#434LT]=
MIN&=M:&*DQCOE12T;Y2.F[U$137R85AZ([4@O?U",6.)=IF.!1.!+004LWVY
M50LN< B#=>]#+<LN<LYV/Q2ZXFA- RNP5^12OT0OR,//J9G$IO$ +RB\1S9R
M7W@#R,$DU2N6ST3MOGI]IB]]PE!A(PH SD5.M3YGA2N0XI;\OLXM+")U:PAH
M85N<7VV,YD:K^2*O5'*'4Q^O"/M\]'JSV I-&]>O3FZ_/3'35]*RGTO(E,Z9
MP@#G 0)4)Z?POM0T/<82# O7!6AZU" W:F!MR/00.?!^J]M9"@*^<&1YP\*G
M"9B]%XKID4O\P-2\-$T/PH%J &KC1P[K+#59?$R/C0#8SG"[@2]'ZY/98@B,
M5ITIEP%FMEB" =:,U"2N&KTQ.5"?S998]4"U^MURB+Z8+:9 >ZD(BWQA=%A'
MK-'9S6 :P_.V":;]2(8,F1-#ZW6TQ'[LVDG*$2DY/"=FBYUV>,H!1@P;LQ6A
M=FQJ \881&;+G7:(>"(#<[1.QRZ+P%&B##JSG0'MT,D*,<X155#XX[ TJ_8X
M=8:5!BUT2+D6=PF\*Q2Y-@LQEI5X44G\,+(P=EG7%C7]L"+CAO,X2KJJD.,L
M&$%=04=?Z'<Z^$T8QFRYA/C/2.AF?19'*W+Z_[LC^T4R^J9 =NX\2':ZDZBY
M=RA(V!&<2CTYK>'YG0Y&*ZD>I@(_'DU4>IB V"%IHZ1U(C*."B_%*59K2+%:
MO*O&:GF:;3V1@V/Y.#/\S+:PR,0OD^D,.[--+S*QV[G560"FV=8840"YM#P&
MHMEV&0D@-HB_T^GZX *O)/M.IWN#"[AJP:>C,+)6:U9NK,G_,9POYL\H+;T*
MKQS"26\@-JLV;H6RC1%M,XN<V0LALT3;C;6_I\ZMT+5I,+'KQ1'?BZ\+=:&D
MLLPQD]U=H2C3[814I_GO,2"4\%]+0S'SWU'$_#NS%\OU4C=%061MC>\)K) Y
M@4D+[:-+1(X66>L7UR&G=^YO@WJ^82<O5<R]E;AH:5T0R?5P!(@K-_'@A1M1
M=F!F'/:5CKSFK=2FN%#TMKDM!$T(TVV4%$_DJ^7Z(86,"'/_ZI7R$+OA*E5G
M+M$3:"X<Q!1/Y]IR@^3Q,W/^$8=1.O+VP(+V4@LA(:%TL;+\);KQ<]KSQ=7Z
M"3E$N[A&5A0'?%5*^&D)<4D7<>[?61M[A<BC,J#:35(1.,#+P%K?8LN_)JOB
MOB#>/JA"9(5XG\7T@O1<RV]+GN+F&T)2\>:^\<DHT790(B9$9'T]#>7,IP-M
M91N,Y[U/=0CW%![:Q#X=52C9NXV2ZHGL7BO0^[3R<UTL9V ),<P^%BMM845$
M2D6)S@W8K_7?JK[$B<PD,HILL9FS=OVDVPL520)GK964\DJ 54)68"(MA'1O
M8R'I44]$N;"F!SZW4(@P7TNB=WM=V^0PUPHPF[J9?>\$T&HY<LRB>38AQBEM
M&69F]J$$8%9_N[*R$69VQI4AN(HHR1=80PHE%D&IJ."R4A''TV[B>\8PR";)
M7O=F9543Y FI+RE&/EI2A])!HE1GC6!PC5Z] INA6.F)T4LP(=,CPV_TXHS?
MULQ DZ>I'KQ\:_$BL-(4TYT <2(QW$9_.?"Z$5EQ#_EWPH%J_T5W,8-'OL@_
M4'@$H@(8BI.U@CMRA%4%F:P7HC%"#,/)MM$:.\:*K4S/ [Y008;8)-<Z1(2R
M.B0:)%W/"?K%Z-Z=NAE%)WR'''TN^@,)>89RKSS->K^*B4@+O48R.@)4*ABX
MQ@$YF7Y:^M#>)-W<K<3408YA\C<O%2?Y:S1CN;(H25H_ 1SOHH^Q*0I:0>IQ
M;N>O6,>.6<A\I'N_!D7!D*+!&EX!3P*VFH4,6YG1)$^*KDSCG<@"9C24LAJ2
M]I=8S\,;OURS:EMS3G;])@FC'X;F")R;ZI:_F5@)'W%-+<:$T30_EOZ7EJH"
MMYCK-HXN/8)L#71#_@B:6M77JB,=[^;?T/H)!1 ^"Q^IQM/RT'R1+.=W:TW^
M6+C5+C$Y45QI;!!JJB<4/X6NXUK!IL#,[-6%[9-Z(KKV]R-O8\.Z+_4I]&7I
MV%&-;R(X)#6&8^*X?H&8WF>V7;YF2V.NXS::9TNKV,(P,<N ,]N%#;C <.4%
MRX RV_;.<0PKM"/VJ#+;E].@5V)9JK'*!^J@W1.MSRCM;U+#GJ%"15TNW9 ,
M%],)TL)"P9I'6ZO[4B@-,CL?\\4](GJ3:T<4!.;K>\37.";@!'=Q0'\S>L3?
M4+!$P6P9H 0=[DJ<<L?K:;;;CA3:9KL=3[![N^U989C'H>1AB7G?HT><%5;G
MG!"$I!#/!=4A$=DW:6,F*MNQ[Z<QO;^[T2H=9%N+BZ_*<#?ZHBN W.?LF4(5
M3#MPD_NEV-B5'WL.8D)\%B[,RSB@#0P0N1>==),28%Z(M$M6^\%:\#,,I"J3
M\^38R&:\AJCR5SXGBNF?(Y=L@P=$=O6V<1?D^=]MI'Z **V**AQX!^IX,R6C
MSY-S3>Z'!R)FP\6&=?1=TWA?6'$K(=HJ9K'M=7F._9B_. N(9I]GD5WQJ>7@
MIQ4XUSA8()>SJ)V,47H\@PV<\98]DC+,T/; UP!8DT5TA(&MO:QYMPV@>MI=
M.EJ4/O[#<X^]4SUK):$W%7#Q.H^H"1[5M0=KKL>JZ)7]>!7N>Y&/F F5-6NX
M+)+(WZ$W/O!%VT*EJYFA4,LB3/\K8CRHHB*3LZX\=>:F:!3Y\4S>YE:X\E 8
M7KVBP'9#Q#(JA1F&#R%Q3OOFA1N?/!8L[RY^\EQ[OB *.,2(T6D,A;/:,YI(
M62K.,?3-2NU\E%]]7/X3RNF3%>Z^">\1834DSXP'%+RX-DJULWMDXZ6?4.&V
MC>KC1;)84BB.M(BAZH&4<-_O.ZQH*LAXD_<&KZ'>X_M+U7R;B!_4NVMZ<?55
MYUUWN&B=8^FO-X HT-(G8N^HKY? (0M?B+V)9C<SX)#%3P!;(43VVR5^>><@
M-]T%Y ]L\<E?_KCR(^H>YXY@+7\CE9U;M+2\E#YO+&KE9ZH3TBI/*3Q^N9F.
M:OM*$NP#9WKW.^5EB#.O:7@=X'5!G,(9;Z>E?C*[CODXFB]FMAVO8X\&L]0E
M5 E-M=-( P4"'FG?=:2! @$-U.\VCG(0(H(U<K+Z#R+;O9J"\F=ZY6L8SG\+
M(<73*.3"PEFO^%BY7Z#8JE3@_JK\7G47LD3WIR<,^^3VA NR&@*ZW@5[PX?@
M3*%F0E.VT)0M-&4+*4I3J#YRH\D8XA)AN%72CB51J/FFJFT9/K8T(6Z8*A2D
ML20+<6/4HO^.I<4+-UYU[QT&E-F'K_WRZ_;@W;T;3XW%48KY00+JI3OVU&SE
M39+]2P+R)<EA>$\H@(AM,Q:S9BMF;U9^A7#',3"67C3<\#0[>QA<9NLX]5=W
MI2-O]R8^,PZ6)J<GKG*WLGX\9KX=:IW2N,(5KJ*7TT&!40A%8%B8*6];L2A&
M@HRE:U7'8B4?S3PV'%%-.PC)"=%BJ$HWJ#ZG<8V1%40'AFTYQ(_!]&6"23RP
MD[5XT5 DYU !;(P$9@B.I)YP)8(",>.LR8OT$VPR<%FJ &MB\F'$\.E++V'=
M3J9S+I;ME"/X?LP[MGO^6X[CV9CO[.[9D3F.'T82NB!R ;6GSC(8IWN\+F4Z
MQ^C3=&2;4]T94J._9EO*%>1(?1[]N0,UYCP=2^.7>KSXZHGD@)V.65]C<6KE
M]L*G9V/6'.1:/K-R0#FV'Z5?E:EA[\H?3!MU0>MG&2KI$NU0H1(K*Y8!^?YL
M) %OXE90'A0-=1VJW8H[=0US*#_)<\]_2:'TT9)&<AD!)E>93(:E/"?N(6()
MK[":(7?V8<QB4;RN;H[?9S.#;.0)1(Y2RQF8'\:2D24N$$%HCOYHPRK Y\ 9
M'N$L#EQ=S?\<N?=CEH: ]@XY8!]'?T:%6WGD&'Z9-AV@GTL&V\>3,5^V<OOZ
MY)B^'_W-(:TS5([IV>B/=T67L!P='>'+6CO@53=NL\+5M8=_YMAP][?C(S>0
M[G4MS(J4$LQ<^JDR]XA_T+/WD^P4LLIRRUE+&$FH6.)=@%Y<'(?>)@D)*W:*
ME#O![@-UK@&</_B^DWUUC8,[:Y.41/%OL>4_8C*2:P.*1HJ0'DT/NZTA*-W.
M!)!.S9OXB$GA4Z@]4S,1Y>7%"@_*Q,Z[)CI"M-V3R#GAF0: F!#,-987>EK"
MF>]L <M<GN1_<:&N!_<Z=!Q%=?&I^)E<D%0L6%YV+=WX"QRL4XU)I/P4+TG5
M>Y",3?\_%1DOED>OWH("2WY T-_]A\)O@O9GEX$T-=8Y##"&#4-J,;OQ[0!9
M(;I$Z?_FX1-7KW;2C/B>*'I71$& G1K=G*FN?9@,,U\4AY[[G2:93X<\GIYQ
M:'E? QP_DR_(WVF(BNL3.3I_1D$B9D";=@C<JBY?C2+*X5V :=R=<[[Y$=);
M)[>^S8BF^P+NR FAJKRB['.JWX;44)$40+FS MH&_ ET$)OIB+UGMHKWHO(1
ML6\NY7^] ,FJ[]UF(^0DI5.R9XCP\TR J,;I;=\E69@]M%E= QV-D^C<FH2#
M6 ];+L^*X-72 <0$K1F,[@7VO-2F0)XRW;J.0\EVYIV(&WN%[#_)OT7I8.1/
MR\!:4W."$-LM%#5NGL+##'I?-)(9S*4N\I 3H=[/A+=ZE&0MII*JX@F6=?C+
M&#WB@B("G!LG0>W3VMH],M->YUE5T>MC4M0R%1+!!BTZSD%,^W22 H+L%(0A
M@MD">"EJGUBAT%^W^>P0$O,%E,_GUI"<:;:P1P$W/>V@WP7D9>4Z&3M7K]1,
MCLB+.-D4,G87WPCZCU&VW[>E#43N8@A5U1U0UC1/Z+^W+AJJYR0F#2*J"/YK
M-UY#YL5!3/%TKBTW2((^6#8=K ,G)R$#VD)?),8QH@%F,YTOKM9/R"$ZTS6R
MMMD0O&X1'EI"7'ZU7)]F_E&%_)IL!O<%^2@,YPLY#QA1\HJW,64KI'RA<.Y?
MO5+!$+OA*MV%T#<-!S$=34;/]\N_@-Q0-11TMG&FA6G(4\E#Y(61UEZFH#YB
MSM>&R$6A9GSU3_$\71?T\LZ_&LR[4^)#N\\5*?3FR:.5.O8BJJ SG%"]IFGB
M;BO%RJR;'1G>X8RT9.X?OS>[HJL<Y-1(?E:CW.R@7:7W]GY]@ JUA.%LMI30
MA3.'"JNBDO@P<XU5@][I8:2B;O>(EX'K8<T*,D]2O3/BK87DCC^:G42D2Z:W
M6-@8W-,5*@-N#MML#ODGLU,/Y6CH$",^0];LMX^ NZ0143X?$*L#+T\R#U/G
M$,,7YDID:,H3O":AR>D_9C7V37^/R(:Q.JR X6GZPT(VGJ70$]:_P.SW@@(@
M2U%)#$NS7P6RL:R,6V-@FJWS=P,3$N#(6F?(5^DQX7,HB$IR_31&PS(LS5;B
M.\0A[[I^ZB.I<R@-+^75#4IHB#U#U6SQ*1E5GGP+UD!GE*:1#F>_)OF& 3H)
M4QB@+<WP3@QW[<H'M)RWQ["<KB>QT][6]\EPOSBO.BJ4^<NZ/IEN69*S/YMS
MP!F:IMN5Y* )*1*08ZO ,7W(K\\A5*A@:V/V'0==&]VE6]@ZR+\2#_F,="P]
MQ)K927^P#;E)N0YP]WL@G<AW:@^W!Q(GP-QETU@K0;.?;=#2=%A.P3T&K^$/
M#CB\N2QH+\B8HRC1EVT(BAS5.1EZ9INZ9*'7W-'GU'"GM2B*(CT&3@UW6HMB
M*5)WF6$ZW335'I>NU;ESA$WOC"&(L(0"[PQB$]H64-.'A\,X0-^35(GYXCP.
M79K&0C3'AWB]MH(-T7G<I9](33_:1DHEW7,)+H4R1HW]#"2.TV.C QFS4)O&
M/ ^6EK\-86?=&.B1\)V[ CRT"4=BC;0\UJB!38].IVD6CP3-<P]8;U _;XIS
MQCM-2"2Y7-* O8MON<#A/K=8'G-[++TA>*_70=$+5/"O0:5]&YE!"/-:)E47
M<*X>EC$F)&9!9)77J*[F143XM=/J7:YQ3Q<++I>ITF9K#=HF+T&%3,W7@Y M
M^[PI+L:TF\? K+^%@/R.XD5X"-4EE5)^<HNWY0E)F48RO0L8GDEB"6MEJIRI
MC0X&2IQ6.H.0/?5<"C9UJ*8&$B/<I!2+BRR[>RNE!21%'87>A43+U#!@$4R5
M _MNTKWZU9Q2H(7*(&1 '8\Z3Y>0GE%+8A(,Z@1#*_BF"H2'Y)3F#9RO<7 =
M4POO;D=/3KG 1VP0XJ&%51$]H9FDH%00I:RZZULRLHB0V/^R=^%0,Q4LCKVI
MLJ)0:"RW(E>T]> 4%IS4!B$MVGC55+B>,23FB&HAI*O^?F%T$0G23*=W><(U
MS:I:9]6+8JHP2<()5]@CLPO%E(U: H,0&17LJ2[DO3\@??=T?(P B$X:1W>-
M0P!V4^7#%3F]>(,(L<@-$M7KSF/-.SAE1#.10<B)&A95O_47KH^<<^23/R0#
M"IHJ&L@H-U?LCRUFLJBGTKN<X)@BYEP,4Z4$3>APTPJI,]^Y2)(9E\@7",_C
MH#0(>='$I]H3US!R1RT#2EFQ:.%B1T3:  GW+H#$@,#B"VNJF$KK-3]:KV"Q
M5/'E(,10D2_E;1;3D3H*F68ZZGM%[@\NV!RRGDSOXH)GDIAW04P5!;2*&/IG
M3(:Y>D&%QI.\5H^:SP<A%$K,*;9X[ TG9N&H)Z*Z\]K>R$)=UVII]"X-6J>'
MN1;!5#D@G$BC._W(K#0D3>E(MX0G'-S2"B_ID!LAX=1(1GDGS)\%^ *R#+%O
MIPDC*2L=Y@6GK=JZ; 4^8846Z4EZ^G286RLI]8:Q-$6>#+[LM/O:*.G2F3M,
MH9Z&6%]L5C\DRZ@58(Z;E'H[1UY$89N-D>1<=\";FZ3R0Q"X+X2+EXX'H)Z*
MT/ZY)Q<DT:!H":5+]((\_$QE'MFDY+]D%-&]!"6K//FIBIUM)DC*#"S_B8.<
M:ET=>83<\BOR46!Y-)_ 6;N^2S5:BG"6Y=)AKXF.H"MHXQM10N*M@ZKK]0\@
MJEH$IO7,]DOU=1" ? 15)V@O%N>61XMH/*P0BB[()>[2$Y-F1W1=/A'JJK<I
M#A!1^R]BHJ_X]FX.HN\D?_72ZI9=MJWX(&+:!@HBR_7OW?!/.L / GCR#Y$K
M)&G@-!4OVH^0MBP-(W=-](00LA+[7RJ7_DLJHN[1,^V3N'U,=CE!G 053^O<
M"MUPOMA[)'>9%R]%H>-PLWZV:&7<QQ6ZH 6&3[[<6;Z#UJX]]UGU6M&#(4A=
M:"9?<=)2CYZ]I%J#ZW3E'D!1B.-;EUQF1,J+;(X6 D+\7**\%0<S A6+8"1U
M+US?=I\]%":UNEA-#-$YR!UTJM$RDAHM"O:.5J.X<6M1+XL8KN\G7,&X BXA
M!O2'"6@PT(*Z"@/]TP2Z2)4M7O66 ?UE EH$:,[W48[SR70-"N&\_XYF@$[W
M'UPL@VPK#.KI!A3:NQVL<0S[Z2(4PE[$ LQ GRY%(= Y70LYSJ?3I2@F6/B]
M4PSKZ;X45/3$O)X,^.GV% *>RZG.4)[N2;@Z"(W*8&A/%Z30GFX*U\G!?3_=
MBF+:!V]D%T-ZNA,%WI <88$,X>GR$]K+]5&A#-KIQA.4P<TQPPS@Z9(3 K@U
MO#Q'^&RZZ800AB<G,,BG*T\(\L8\%X:NANON$#+ 'I-2Z+KROW9'.^SLK^U<
M%$<+VBODQ![A;T8&=UPOID^2!V3'05(M\.J5MOQ&SC4Y6U2KCK-#LR_:Q4(+
M%8P^A2J-)%1)Y28R-9%WK]&)D'!NI#$(D5O-H39!6NK>D3#054"V4IU:MW07
M4L#6+9#E,56DM)0;%A(Q()J#$#E\'&M*?RL,O'4+.G/_GEZ(M#MN$AC6+14.
M-H"NK+_O*&)6]5D8(M8RO([+'SY^"E'P0I?GQB>J ?DQ)HOGN<FF$1?<&IF:
M*F'W6@E;_0*/)8!>> E@XDAKW'RO1<J%[MXV,H.X;FN9U*7D9Y60'\@Q=FED
M&=G=9*-1/R-S/<Z\1"0FCTUZQ)?D_8L<\MQT<>J/[/@FD,Z$ZM34G/-J5I-5
MG3^G89$VD:?9NG;$27RT'@ A3Q!J\IC]M *GR"*5=.F"AF&\3O]-+CA=1A9*
MC&1,;-W'5Z\HL%W""GQB0(*JZU'1AFYAA)Q[\M_ M<F?$D03L"7L;3'Z4]<#
M>5T/Q%9@+*I<6Y\J[G,ZEB1'CC8;DB7V6+(:Q9"%*@IC25>$H"E=/=6:JMA/
MQ76A)UOM]X-XJY6YT_9(6RQHS^07QL*]%2%9)KYNXVA[661!;H2KQ#I%?1N2
M?5/ (:;R]=K+UPNOU5@45F$\1<Z^J19(X5"GF>.XZ7QO_ 4.U@F7ERBR7$];
MZ!@/#X.X3]7,4''IRI7E+\D1*<:J;NL'L7]ZB"S?(2^9\,>S0\[0S$D/P27Y
M,T1P=Q]+=1U/40;9#E** QU&,02U#%S1HQ*Z1%[>NB'HON8FV4N5UEET807!
MAG"7>*Q Z\A'4+5"21_!-V$8(^<RIFZU](FV=8'^3'X"*HO)25!]5%,28$A$
M9\8/K120O#R!84T-=%1/(L V0DY((QRSD6]\(NLM[RY^(L)_3I04"C%H1OQ$
M>Y@>+3J7)Y]UG=8>,=4G*;$0ISN?2&0;9?&GH--33Z0?09 R)%,2E"@JKP3_
M@GP@Z^P;Q<P5GFAI$1G0W5CUM89K$'K+:5AB6N((.5GD-]$9XG6<Y ?3CK2V
M"T*5AYJ07_1W'/Q)JQ-:SVY$GX"<WL_]SW0(@E+?[]0)]DPVVP7UD 4A3<&F
M+XT3L$@ T>YYLC(GIWPRWUP_,3?<^!$B(C::__0)*ROWF0A>6O#!6J)SPI-O
M8S\BCT\R]#+]%<@L.PPRA.G?65 A"R*KO%N.1[C#:6&:&76Q+E'6V3;!O/K'
MQ;IDMT2TW41H#5ITN>,*"<],+24CSE]HH1X/)TU]OZ'U$PJXA6D;&=5I9F3,
M639FZGODGP '$=4V^+LYG-W"1ZJEN95X>ZG$_6ZMR1\+&_ 2D_7W0?*<@YJ&
M]IRNXUK!IL#,[-6%Z>'U1(1.XK?9S>PRB)>%@D(7.'C&:<E?X'GD(R;$Y^-?
M;^:/*W+&GU$<N79XX]M YAHHB"Q\&$2%12=_8PM._O)'?K'P;]7*SU2RQKOW
M*CY2P%9ZZ]*P \O?\*]M[:<*6&0IL>1!X4?)6PVVODT4-#$,6?7Z[[6YQB5H
M*XEK3\QK+F_T*>5]M"GO\C81<TJ?&NWI5WC\<9MD,SV:E>M>:$ INZX83A]'
MA=/>A8\;5! &T6<C(=)W7/?4S]TS>FH<L/5J^CX>I=-X<F;D5FMZ4^'V%QZ#
MQUQAU08/W^N<U5,\-A(I/3*+PURS*\/.S 6ZU>R%868ZMD/-%'4"!E!<::!E
M0)DI]+H!U6!X9P4B#7]F@8#C<KDPZ":5M_OU(==5EZ_-![.WM1+'*A9T(C/0
MS30G# KTZE %M@1F9]&J7H+VF!B&M-D9MGTC70ZM8LB;709?%?*5P7DYJ!\G
M4+ML9YX@S!SK3_*2&+^D6/MH28<:"]IIE"[#<]([NJ!9%9;-L)T4BFYR(8O,
M9XA.BD-GQ8$C32/'^_/T%.R$=WV*#X/8;.N;:H@YDL%RJ+^8[;/H ^J:=,(,
M\A-#_8W:(&_,2<U1-MP9U].UN)_'S.">-G77%PA'-GP.M^&^ M5P<U=5R &?
M#*'=]G>7JAUL$::G3B^+D)>082MA5JE"X>)#^6_M-.E*GC@[#;HLSZ;6NR0J
M^G+[:[<XS)MT::X*I8CMPRXD)1L4Q;6&NG6%FZWI["'I"Y(&5%V"J1N79?FI
M'IG;CJG!/ZI+=B?EDT-@RA\7+<5+N"V>#<^TW?M0=5WXK XPJZ,,9[F!2"\'
MA08UP5.%VVD-^]2?;ZH)0%.-E;*A+7^P:[]1\=Q!.2-/>8.CS1N4LX'&ES,H
M]<AC30+1]+1#G9=;ZYH5+W/3\QC!*A+F4NC&DMLH MN>ZLZ2S\SVXD"@XG^?
M,?2F^ZO7^^NV(I/ <.^O=/N+O-7(+%!L*33X=#0:L>]1$A]Z9P71IN@3D-B&
MH,L0@S ."TU =?76YSRBX8<?TGU-@WR?@$5;:XDH?@[306Y\<AO%=/@LUX1V
M"TD>;PY+-H',!T)5\02%UT3O.EQX5ACFG0?GP;V[7.4-")- N_R'X?:G(:AX
MK>  ?4Q['D<A=6,":\.WT])ZEM*4E8@&([#LE01HT+H!B/998YUQ0T,5<R;9
M/0\R*78<J<>N$SIPX!U(R!UUC^C+A28%D7LU]I*8@K158OB HLCC:_?"34JL
MFNZV>2B^BP-[985;-^].D.PCCBSOVG(#[M8FPJ25S4$JUX)\TIBV.\MUKG&0
M+=Y=@%]<![ 1&FF(<57:4?S,5'RJO,)_I=I:?BUQJ8IMM%24U5RY:$&4!3MY
MO,T7"P); "M9VDA"3%)93OQWEVQMH).\])W0Z+>(J!<SWR>"&>3M;OA8XRZ$
M.XFKON[GV(3GF^)/H%Y>"%5M3EL^ICKX9D$#]+2N(M[5=EJ]V]2XIUOI$P4M
MW/A<GR('!XL)@[$X+ 7$;@VB8_,X-MRPN/'F'XMOD0.@DG:68W-JMC.Q&9M6
M%9K5(3/[C*D6_;=5Y</&<RH;GZ>XX0D]EGH\<+":C!^LX([9G>S!J/%9M!A\
MHU3)NL&W;\9D8)J=+ D&D\>.S<H#3'=%Z3';S8W!LJ;-?M1*A);;4\8R0LV.
M:Q+!%N!YS6'\:+;R+0)CNUL^1^_3)#NYT&L/V\@A-;Q D BD>X$]&52GQY/:
MTRP"F^.X<AQ/S"[S(()C0WQ?#MNI63499K8=$*WDZO49D0F'A6#OW1^(1;(*
M4A]$$"N4=\6YM^F@554_^;UP#414IW-&*Q1(F4,;)<43N:.%BY)DRH21.TRD
M+HK<(,F?I$6#?>2<(Y_\(;KSB-39\E7@%#)9&:,)A4UL ;XGIXV(7%HT:Z<[
M4QA!E@Y*474:>\K)78 7* P3D7V-NIRG6DIZ)G*.?7+_=.!_GX#J(V1MJ+&?
MEHQ)&+ \H9""1C*]JQ\\D\2M*S$6CZP86K7G;BR)C9RP0>7O6++H@+M.QF7,
MH#7;A@*$MDVI8\$%9MN6Q>1@,V+R;P[JD!K(>U5BUJ4 Y2&^4\5S+&N> HGO
MXMP*D4/S?LD8"<7M<%LKRR,N*C#GED=K17,_#3J,(/2XR9VIV^+66R]LZI]Y
MQ*FSL,N$Q <0F@^K/E\<3<9$!"A/;Y[JG,-4P!8W>*&X[.]NM+KQ'??%=8C,
MI]T_;;KIT\HR-0<#,FDEPP\)LGMDTQLOOPHWRM"I&&E(0!1%3Z$'B#(X:L<;
M$BA:D(!,OR6)+Q>P=SA(JVQ4<0(5YH+4>UC(_&P)R'<^>I.5&&0E[N&X)O=.
MUH6D[+53<GKKQE0,SE>R-@&Y=\FCSUF[ODL??#1T?'O3PNO=<A)4/*T;G[Q?
M4%Y<\I:R[)8:>'-,IX50/]. YC,VDM&6P-CQ3'3(;)0S\N2:T&YDDKV$XTM^
ME'KH,*=(&4L:)(]X;L=L;"F0?'<S!JL48\F05'^XY6FOS.=D]IZ6_L90YON3
M'GGY@H(G/(Z5X'O?,_>7V0E[*I#N8BQBN)L=I:U[AW-:'1G\9F?W#@;^6O-W
MOA+OS5:_![,2%7X9M@9FISH,9@UX/8>L",9T.XLN3%O$J/S>Q2-0,D6#'EA5
M#;-M6LHP%X^88=!/KULAZ#M$7[%2%!KBK#4&&1+0[!6R_[P+Z$=T)/*G96"M
M)88;=AIC$(&'8C-0W"[TE9;]B-UP17<]?:P^1? FO$U4A ([]@D6\NJWS<$3
MTVJ6N?L[.4-DI>:+!3_O<L;16GK_$05KF$.__/74=Z.CQS/ -D).2/OZ,,5'
MN!L'%SG%4Z)7W7QQ089SHVO+3AZ#Y>N/8S(MA(0DP=W=W2VV,DD)K$==_;'6
M(R#6NKB>AE;FH3$;55_WL'G!41<-1#3@74A-$(B=J*,P  6\<6J8"_ZQ!#^T
M;^/:\B7C"E]H$%"U"(VQ2VSK+80;[\BQQ"6 SEV+?C.6I$L^?1$#E5R&GMD"
M#(R>2+$JT]W)'4%,G\(,++/=7=Q@R3&),"_B) 9WF[ W6,D8:!I*2&BT#!?*
MBWXGGX7;6&J)=N$.(PS"*BS"_]3OL^/TV*!;3I##F"L&IH#G"*&L=:+SP%VZ
M9#LQJ=-A;I7$>K&\ MM* HB)-G#<.<W GK_M-(2XRBKI9@5V^5M<5GPY=8R&
M;(=D0R7'_L<S]1*GP[ 1TI\!]@8O0:V&XA^^M:;QKO]-7G/D9H/Z#UN)_>&Y
MQ]ZI^L12R_7#6QR&Y-#Y5>H:9%(<Q/J0F,&#1=,PKOX9 ZL^\%#K*C/)&&LW
M#'&P221?%LA"#50BXK.1G'1>"Q64.1/2P22U'FKRJ$'P6( Z&GQ'N,X+F-LX
MYHMD[Q&PJ/@KMH+8$>'\+D(XY2Y7\"4*[<!-7G+0.WCG4\4;X6K]A!R'FN8"
M]R7)6RL$G)5_*%1%1GR,SEOH[YA*XSO\$P5)+A+M@;.BD6%)0Y&(O-"$]@\/
M62'>OQ%:ZWC]-2"W25$,IV+WFFCBODT&NT?D[P&B+;F*VY?WXI(VE.J25JEV
M8$7YD)F:<!>@M1N#8F0XB!FE20GNP"(P,]_9.Z5W<72-K"@.^.4N/T'EY2I2
M0Z9 E;#2IUU5BMU'=G+=%.7+XPKM'4,1)4-@$(UZZAZCH@IJB<P4]R9S@M_H
MV21[Y))P(3ZA72H'K-NJ+TBS(F*<>JTH!V4G T]AF1H*4JQ<P+"\NL]U@OA(
MF(3'Y=62T,TZ-#*OAH#0ZC_^Q(\K'(>6[Y";^_$G.0J;N8\R Q1P,W!2D\EI
M[8M;#NNMY*7-12+D,+PE;.BJA,="?DYXOBDEY<Q^6H&3_"?9P;Y#2T>(!=BJ
M&5_UPR<?&GCZ]SX4VG_%_F# _5;UJ6*H&KK.<^!5];5&ANN[OD,7'D)5FE22
M+E.52='O1 ^*$/(E<MQ,4G4P//:742<%IXZ"9L:A^[SZ>VU5(G>U*_&:CU5T
MI@0$]0D(S2LPEAP$KOV,VP[=6!(1&D56 TIC2T1HN9.PP"TZFN0$$>B:5":M
M4:8'),D@:O*N?#LU%D.!!TD-HB6)=V;V[FMX>^*&%S&#Q^P+ 7HX]XP7N^?O
MS%B8JHT]6+4)*X?WL]F'5*D!LNEFWC>T,L#-/O8=E!D>FWH.XQ>S=<+>]FV%
M3R;#_.1L>ACO2N9*9]ONS?717+@:G95-..U?0B>&EP=L\TCC%H<YP\GPR[K+
M ;PM9^B?&%[[L"5<I#8ONAC1PK RO?J^*%J[X4L,+[-+B8NBQ5>XX.2CV16.
M^=%KC&9D<)EM9&^'2T)T*P/3[*(9_'NO%-B<0_1)0^':04,$#%YGP)E=8T3T
M5JC,4,A!^SQVZ0;(4F&@C5W_D);'E$%Z>CQ!*I#JEL-W,NET75,><RP-[\_%
MN16K4F)SB QW+PJ<5L[$9H;@9![A2V;/$?LP'4M@*0,&G>D.F\[0%:M6Y+#I
M:"$R:-BJ#"5U=4D8:M,S+/U-CNHT&6COY8?9&6(!;JA4E(-W(OV<'AQXP,I5
M#+K)'I?^IF#),@;D]'ZMKF67(R2_Z/2AGM*&VH,,K>D6;= ]=LM(YJ#)C[D^
MN"U6O$5;BHGFL)D>6R0(6GMU68;@])JO4MX::Q#GX'TPJU/C0U+L>K8,4!(L
M>(V#ZYAZJM*'DL2RW-T'&D1U[@[3Z% OEMX<>WMR%Y7V"K&5)%0GQ"9O[F3H
MS/&>R"0>WMMI".5[?X]II%Q^)2<2,A>=/\@^"1YFUU?Y^G*C#*;;N6:AZ'YH
MI"'$5?.92.\?;O;XB*DN=YF>9H'DY_TO>[\-:Z:"07"S2&6SS=HM8#4>G;'D
M.;=@!!:$##>S'Y'UN+5?=0PCLPTW+7NK297)(3K1</PT*NB%@(!MD(KE97$
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M+RS>\U:O-$RQA!P-G@Z=E8YIV;@5]LCL0OG5C86(#\*4"V1=<>%5 @7>(/2
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MR N;A7-.ISHA%V)OX$*B?AN!4\&ULS1P:.NW2V_0<K(TE*KMM<; [72N<;!
M+FUG5M?^1AW2TGD;.M@9N\.#&LC9T(%N[.?4'\H0MOJ&V%C)/'AH"Y>WQJ8.
M]8,/'*Z*/J>][+G#Z-92?[7JA*UR>-6046-0FGM]&9-7]#(=-^$S3'ZX=Q?"
M$!&@/O ]LGM;?0UPJ"?4OVGX@4,V+%DT!<Y*#9R5OSQ3322Y$%>*#%8SR.R
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MC%$BP1E PKW;<\6 P.T+.)98C98CT.8#-@\8 1^PH1$6@EY/0V,I1#WB9ON
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MF"N/G_C>'0\BT7/Y6V?S3T/#,/UE4>>M*:=EP:&M5547P[M-RQD&[RH@+ZT
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M*@0BS< M +#!XP2/'2XN^("Y9[2J-&3FMW,M(:P>TX]T8 %\,)B^3DQ?X*V
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M@<!/W@ R%*[X+:/ (I2A\O[$2I"(2G@2%\*I3HRE1UW!/+B#Q,:K?A^D]#=
M7QY?^ELF-,6\1DO#[.$DX(Z(3E@03/I^@+60LT_K:I!O (6>PZ*6D;OG@7JV
M]*9!VE='VJUGI6\3>ZO$NY_9/%$_'?="_E>,C]_!7].E^:<NIYB_VVRU#I(/
M5<3\%34Y7&8&Q;#/R+%%T-_ "=C%$] Z6.($3#VQ.E]!LHM=FWL,QM-^ _W]
MBQ]PFX71%-H_N^/H;G-/(_Z>0?SEC=R%&R8-WL5;MAE\WUL:W_=6C^_/\UE]
MA=V=G R9YW'W<F+/)"YNBH'L-H^2#^8<E8:!K-*5-@\5-W/&X<_1<F<\^T3I
M>%HYR((ZT8I%'C3WS=$N\]':+JX-?Y;DV@?UYGXUN?;;Y;N&ZVT=UWLA4K=;
M\$<A=;N2!<@J8PL@VU9[&6L885#[A76N?OX@'CX&//3CP.8A_D2_##ES:+T_
M?W#$'?P+G\96&$U<V%!\N,Y<,? ^8L03#WX:L6 @O'K/CR)_]+$YCO0OD3^F
MK_2(\'!_/S;_\5,?9E"_YV(PC#[V?->1/X3B/_SC$=Q-W_IL)-S)QUO8T]"Z
MY/?6C3]BGKH3)_+1\X,1<^78$1*,/OP OWI<WG4'[)/!"RUUX\ZG3FCUA<L=
MZUY$0RL:<NM;H]NPNMR. Q$)>!'S'.OLP1YBM(V%<H@($:$L^-,9!\*U]FH6
MPKYA_?QA_&D.5 )<V,N!DH'*+MR^\^F__M8Z:/ZT^A>O:3=N^$ U7P3H7OH-
M:W<7$/K@^ "%C;EKG(MR/3\ G-6_G/IQS^46 F[,'$=X WVEM1A EH'[2X[!
MNMY3O,&MYBIW^-OE^>W9J=6][=R>=7_N!=:'3]VSDV\WY[?G9UVK<WEJG?WW
MR6^=RU_/K).KKU_/N]WSJTMYW^\L',*F1;Y7LTX;)PTX=?M[QR^$S6Z)8//E
MZN:KU:VWMFA)[ZC^%+)$.LZM]VM Y<SBCK?S$-V<_7K>O;WIW,+9D$?IZ]GE
MK?7M\O3LQKK][<S*'JF36^OJB]4ZWMW=(KSZ&202N'X9CT":L4G*_8)2;K.Y
MMV-Y#(5,AXN/9R1X::[B19=P9<=2TLX-[T_)Q@5^YJ^=\X[U6?A1$C5?LT"M
M:)!,E,[@T\_AF'D:L%FPI%,F(O;S![RQX/8\<YU^^-W9 ^@^M#++[UM!LB*+
MA58XYC;*R(XE/$M$H07"2@#;^5Z_;+UL2HJ'/T<,N:UDP;_L- 'LW'5A/C;0
M\.2[8L3T7<U.OODCBR-?,W#;=UTV#OE'_>$G$-><: A(!I/9H;>1:!HY>A1Y
M?;?=:.[C'3]_B)RB&^#Z[F/7GQR@U3AN/SH W+"7O>&#FJF>[QUM!&R*/TY
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ME$2.W^&.L1]RQPH9<(W(M\9QSQ7VQP+*.AUVW@FMT/<]##(?!YA\:Q/G87W
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MSZ+?F6%R_9U,W ;"GW[MS]HG\9:4VXC^#.&&;U$01\-^[%K:.PT/-*R./ #
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M)-  ^0/E&"1R .*0OB"/+,S5B0,M-[90.N _I'>8?'NR,8/U!5DE#VHT@/^
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M;:5"[GXNPX%@ !>]*)<GYZ2L)L8CKD-B'" -Z)9!\ (!AG_3Y^$I)2ZC:5L
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MP0A-M[, \\<8L^3J*])!360Q!'G70?J2"S ;4A"P5#\R[ /?EX'D;LUR<39
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M#,I3=5B25#R5%DJI<9-D/DQ@Y =Z:#/>%W21I)X/FXW)@:1"5LC *L/J0@%
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MU+@@B2_ M"JC_FS!.3 <Q' 0PT'*R4%4]"]P#E?8W$/N, BX-%5I9SPEI:#
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MH_S)V;/=6YZT2W9B&9*-2-+_<)<AV8CO?GJ<GSU_D3]_=&\M>FF7[-XYWAT
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M:NHQ.;#LY@/30[NZ#*G'!,SUT_S%T]2$>-_+<.M@,-F& U-*#TSP=W49DFT
MV_#\[%G^Y-&+W5N=![9)[B:02P>$7QS(F:JHE_?67IAL]8Y-^P-30[NZ#,E6
M8P?@\V?WUOV7=LB.[Y!D'Y+T/]QE2/;ANY_.\I/3L]U;F@>_0QY,.^6.K\RK
M#F%#2_@T:[;Q14#T!_\QYZG#<C?6;%=SAPE@9F^6*@',7!-T_/11_O3L26HB
MV<7%2<V1:2V233J8I4HVZ9KPJ&"2GMZ:!2.9I#T)=-.QY6T7X7>U+A:Z^)RM
MFKK5!?8UXC_GC5IF90V1+MQA#N%LI6WJ=[S_';(;TYZ:4?9CG5(SRNYC!J:\
M]XYOHF1CDHU)ZY1LS)<LWM.S_,E)*KVY[V78H:/5AQMQOEZH:JXS Z&E,@W.
M>*>S>I;IY41/IWJ:S;1JNR91,N[ ]MB-:7_P6FHWEB&52'UQL)CVR('OD60A
MDO0_W&5(%N*[G[X_.WF4G]P^V$N;)#5$'L3\;XOS+E0#OV^STJB)*4V[WKVT
M2++B*1OU<)<A6?'O?GKQ/'_TXO'NK4W:(CNQ#,E ).E_N,N0# 2B9.=/'C_-
MSYZG4[W[7HK=@#!-O9*;?!EUE<$O8*(Z8Q?4'@GQ7U%7Y[IIS:34<'D+H\ >
MRHU/<US50YT=UNS\OUFC2]7J:08RT9K4-[I+*W07%-!?+Z&7**!W[X3N89K@
MU%V8UB)U%Q[,4J7NPNN>]>6/SL[R%X\?)7.S?Q'?EP;@*>+K+<K[=J$;03_-
MOA<ZBSRK='M?&9+D%^Q#-C%1,A_.6B9*YKO"+3AYFK\XNS<PO@1<L+N[+UFU
MW5F+9-4>PEHFJW97\?+C_-F+T_S)\WNKK$F&;?=/4A]NR>QONLW*^O9 .ZFO
MY< 2L0D$83_6*8$@7*MDZDG^[.F+_.Q98@N[[[5(7)))=243LT_KE$S,M4S,
M6?[DV?/\[/1T]U;P(9N8U']Y;\%DIMJV,9.N55A;V]9P157 3YJZ+&%F,B/$
ME0G>=2=,S:UJ3+_>$G"-Z0,R(0D.=%?683</ QZB3MJ!:4_2OQ/+D%K_(,AX
M]CA_].C6 4;:(SL58*2^OSM=E#=:+_4TFYIS Z.;8@N@ WQ9UE,S,X5"CHG4
M*K(+B[6KN:[4*K(W2Y5:1:Y;^O+D!%.3]]XHD@I?=NDX+-FCU'1]$ N7FJYW
M8+?L9"O<M.[PX.'L^.'HL:U'+^]>O7V5_6R0:6]1P6CGZSQ[6Q7'.]A+\ "7
M;5>3;C>O/>\MWH.,E_YM]Y;Q=FT$MUO*@_8VOC]]FI^=OLB?/WFV:WT$6[7F
M@]I\MPZGDCU+]BS9LV3/'IH]0WK 1_GS^P,33?9LOT\:'Z!U\T'V2C=942^7
M=979!;QU=I1-E#4%X8I.3=FU>OK]Z2ZF>!_@JNWJ.5;?D(T:J>23W)5/\BV[
M)+[>4AZX3P)3?>_Y_.2-[,EA9;)D.Z,"DR5+EBQ9LABD]?C1K?/$R9+M?ER=
M#J_O=%'^H%OI::;.=:/FNA=;VZSN6MM"9(VM@W<;:*?D_^ZX)]\J^9_<DWU>
MR^2CW-$"(RC.T_S9TWMK*DI^RN[NOV37=F<MDEU["&N9[-H=+? 3L&O/\\>/
M;IU)?EAV[=ZWG\3@?Z."9?AT:LYO]O*]=_WWJ]^&WQM?/![.%S_R?J3]_[6=
M'W88QO,G__ZR-)4^6O"33L]@E,1U6:A2=CZ\"QZY0.@,M_@I^ZAU]EO=ZNP4
MB\;KKLE4-S48D\],I:K"J!*>HUJ-G)HV4ZN5AL% 0*Y F!<ZH\;;&?S3V&S5
MU':EB[:S&;Q -NL:XFF9ZE:9DB@Z\1<PE*(KJ347?[D1UB.-R_AI^_&=+-BM
M9$2DDZOK>7__QW<GWV6%+K%EJ( 9\7^+;J"_>P/]475M_5*T ^S,4JVL_M']
MXV4F&N3D1% _KLI/23;IQ?&+Q]^F'^66\W>U-G9^Y]G>O,@U6L7DI1X?GUSG
MK2+C7&C$R;H+ZQRKG4E=3K_07-^^4[_0RPGLYD>G>1*(1\>/;PAL\I $POEG
MI"7Y)J)0?\0^QZM2^$LSG99Z7$7>KNOUD-?A4AT].I6\)>^M?WB7YVU, XS/
M(9N$AR-F9R=;^:4N$;(D/*-SP^;CB[K"#U' AOGLN[4C6],%/0-SJ!+[LRHA
M%-39QX6&V.R-:M6/U]O.5TS; ]SGMYVHDSM!Y$Z3.S:Y9\<OGNXJWOD!3G?:
M]&G3W__DGAT_3GO^6\WVR?')TZ^UYV^?M;E-#N%P3TA?*[O8@2!M9^;C-KF1
MD^LD]@YIDK95LX_/#SM:#_N<^O0D?_$$_N]L6Z%XVFQIL]W-9KOAL=-![K4G
MSQ[G9R]NE'W<:V?EGA)5.[/D?]3-9RQ/*-3*M*K,[JI08I=#WYV9_#L/?A^4
M>K_[E-;#UO[/\R>/7N2G6^DSTMY->W<79R\Y;KAUSY[FCU]L8V].V:=#VT"?
M:O36E+5Z*SMD"HQ38'QGDY0<) B/S_*3,_B_Q]NP -..2SON#G?<@W=K3D_S
M1V?/\M/K^C4'X+X\]'P4^S5%UV ];%8:-3&E:8V^II.3@M(4E.[$["5_Z;N?
M'N5G3Y_G+TZ>IKV;]NX>S5[RO'XZRT\?/\E?O+B;K;O7'MF#<KQL6Q>?%W4Y
MU8TEYKAG+S/]K\ZTZRS%O"GF35FF;Y++/WF6/WOQ*&VXM.%2DND; +R=/C_-
MSTYNM-]VVJ-)&#'WBQ'SA\ZF>@:_R2X&U57*^M06']UEI;9V+-UUC]@M=[%V
ME]QU:U\MWO7T;#6F779'2$[/Y'T6C7NAE9KKHTFCU><C-8/W^5&5%VIMO\O^
MMI<+^&6/O$77]-@@XFZ>FZ[V+9<V,]/_^.[#VX__W__Y]=7K3^\_?/SN)_PK
MD[]N-+>G6X66QH:ZP!1?*,8W$-I7U3HSU;FV+:)2P3\)N,I!16'(AU_7)5R1
MJ6P!3P$%-F^T1L"IQMC/Q]E_UUUF%W573D&9-7K6E>4:[E!9 Z$BX53A=19^
M9XO&3/0TF^BROL@S<"Z*17:A\6^CS^$ZO6JTQ7$4H$65J1@/2V=+!>*"^%E\
M)X'7FG06-*FU.7PPUP20=6':!?W"5/CJ#(T%8\&;P8-U:?4%7(??#X&V<A@&
M_$9G:WB?I?JLX7VGNC 6;P%/Y%D:FZ'C[/=2*ZMA5EL-MQ4\+QXK3EDIV-ST
M9.2Z@@OIDKJ"J8+5L?RK"WS3=38#;^LX^[5N,OV76JY*G6?8;H_OXJ= )@I^
MWE6?P3.C(78VJQM_*S$=\6*8I9])N+"K2O-9P_<XGT5!;X6KJ$H+K[M<*=/0
MN]8KW=!,VN/L[2Q3(#*R+K.ZA)5$,P;+AZ!F?!NX-UYT[4$KF'^%4D,_SP>+
M&]#3X#WXC@1R)L."A\-MNQ*>CI,W"=)2XA# 'EM\1S6;P3+K*;Q"Q5-$0\[I
M/6"O$#3ZJC$%2?;&)N"9 7E @T^/1S'A3\L:UAX>A^^]4DV+-UCC'<+&NIG-
MWJHCMG<REKJ%ESX2 +4?CTZ.SYS>^ ;]C1]H>3_H4J&8PZ*^A[?_U:_;[[4-
MR_:;1D0\F*I703Q>LQ-T]Y.TJ5GO>-IN4D^OLX4Z1]5#.Y/DQL+-0,X+^E2O
M_"3!+TUA5LKI$]C.%Z:D'0 2WVE62+C7Y":SNI$=B7M,$[C>K&N[!C3)'T'I
M!)T BF]F*!K(Z8FB>RK8%;![BP4I9+BI[2QI8G<].J'K+Q?G2Y?A=L)[IVP*
M-&,JP^V.WCR\)Y(J3$R]6BBXJ- =>?FH)%:HZ\CP*'#3EX3X&'03&)FV;M8T
MQY<L/ZH+;[%HR?QU#L01:1QFV;^=/LF?/47H\1=TSW]#&M)GS_.STU,O!&NM
M&HMXDO#K&!\L0_0@^A6BO.2H-]'VF7-0D,?9*[K_QO4YBL9"H4R"7!3=LN-=
MCG%,84C9_=OCQQ E/X,QG='0Z3U)W$"%Z@9U "SCE(P"R-&T*Q#_TDT(B]Q<
M5SAE<%6#BAE$?-;42X:YC.[BP2ZC>QUGG^IL"K^5H9YCD'5>X[V6M6V=/@]V
M!-X;/B@T>1*X7U0#C@@!9\*SRWJU),L *U!V9!?PYV"\O#3@I?X/C.1X#]&F
M;'59:C)H.#Z0@P>Q7?1?*$E!+5EP\PT(B,)X-BCZL"\&>JN"IV46)0&N(OG-
M$1<5_2I8"0B.867!F!-VSJ=_O'TO6A)<!O+["N0V01% 3ZJI.W!3_?KTUA3W
M*TR?#E^WZ"K TT!K?@9AF*-XTX9=P?*=N\6.!9D&/&VZN7-TAF, T9G)[]'A
M^$0R;%O:7_P2'/G[,8/4U)D&K1N&!7H&O(I6.[$J&G(Q;3=!(I>6W9OZ7#SL
M:=?XG4%;9N3E41Q!YBT-J"%?5[P?+JRA$<*SW#2+GT>N4#2]-=B)YK.F1?1S
M! 8"=RUH0%!G<[ ]?W;@\DU-08,BTS7I#?XX^UD7JK/:C;CJ8()K< ;95<1)
M[RH) S#K@5F1&A8 =S4IVX$B%EW07^T+UN-=1?80WPT=3+@'&4"-X^,9 +5=
M\7(NZZXBE>&F?$JR79'ZA0!CH:L<_V%FN;?*\&KN 1,-V]@I,_9-;ZC-Z#&1
M 5[B!&Q:8'*Q_,AH&.RWCTL*"B3N&-Q(/P8D7J>0."S']"-G+F^+SOL%B+R8
M*>MG4A\=8X9M,P6]-0--X[]:MUY+_?4U[K65X5 U7\OK]DK[BD3]3D_1)?;G
M?PU>^W]]T7QB.A9\KEX^]EK&#**WFM4D/_#GC=($0I6^O]?Z&[[7R-M=\_$H
M/<_/SIZ^=#?:+D4'O(-ZT[=EB4?%87P!^F_AK]%54V/$#TKX=[+49^Q(D&W
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M%UNL X&@PL6<8+.TN+H"=N-6TV)2>M(&X(++=:IJX.VXEU9 :QC":@ 9 [^
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M@'XD.TYNB /RFZ\'*6<]$SB!P2_T.J!G,?S80DWAK2.=,8:3&^IAKZ5/#CV
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M2JQB/.]<)<L'A/ZP/<[C-WI64F2UT!$Y)%@1:VMP9O&.?O"VK"^.IGC& UN
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MWC5;@%%N!4P-T0@UH9(ELRX*$D\.(_T-D"6*^P:F57#P^F*0()7N"0QF_XQ
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M0K=576*N#)V6:;UJXTTYB(J18@-]O+^,;2,OSN<)$!!:O%#'G1E@T-WZUI)
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M+54@X(8%Q06#NM0]HB5#*HN)UA4]!)<?+ L^K5.RC6%/E5K9%MV>#24+HK_
MC;FLJYI+%-:B>'&^)J82*'4LAG/H65+(@-=XO#);EP;4>;?$TCF\P4(O84W*
M>FX*T#SH\"JJFD/5793*6OB\;;1JR7F#U8;ASM?9A1(BIPM"70\07/@77<]
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ML#J]L5:NW]Y4*]?S5@E/9X7^Q:>*SDH11T.IQ5;?Y*V+I*7:/YG;D[ (1'Q
M(""X<,&H4343NV?I)#FR4+/.AK=3'H]VC"1,L\D;Z:R7^R80O.$:90(F>GXF
M<0XZ!69X/'4E>?TTJP>3,%NFWV6$T5;UNW+5\DKPF_9=<($!M_IL9TWK1U'9
M]2D14]^T,_L6[,RQ$WFR$1>;!P4_YAIU[;C2$R6-7$,/ _X*6L5$;=SQ5M2J
M@HK^N&,*=&M>$H9/:4@./E*1^JA3BW+L18?57?%4U&OC]F>8'TW%K>OD5WU%
M%A\7+R?+&CS,RHL<^\_QJO:D?/RM>O,I0).9>-8Q+12V V,^-IDUG0M;@9=8
MD62&WX!FE4DD2(,;-N[A]][3)GD^4MF)]4G<.+=%^<[0I<X.54X3BYBD$FUW
MBZ\#BYI6AI$?R@V3EY;WO-K#\Y?\5@1T7_#!9D;:$SM_/ P[&0(XL(63R$2L
MAGDLX6?S;@OV43<FKPZX8?M@@B_-<.0\2)@Q:XK<P==@7ON#I%CE\#^R3MLF
M1:%&B^9NXE.6(^\*Q/4OZVW5!T CY//-6&OS$"Y_,M*[7T BS7K_%Z^ZK@=W
M;^(HCJ]MUW1B"'KE8KR/QGG.P5+I'_9K1A_!_[<2D4VP&%%**)\[4]J7T#0O
M]#NJ?N)QV#*)>U_'73NA 1;8&$KO"R76JM-Q82,GVS@12._"PX[#V]B05;Q2
MU<5UR4&KILBUEW%_\HG$7LE58!)@][@8FS"@K$&<WZ.-? 2RC=%.NBP3U=-%
M:?GH'A'N,FP 7I4)7)3Q&:"K3JY@=4IF50HBOIXX'\L)"99#=,B5YR=E@L$^
M:O*)1YZ4HE'8+AE<AB7XHMQSA(Y?MV4GGW;=/&N+< RM W-O8R\S>LB[>*#5
MD)- Z>5I\,OQX:-'\3*UX$]'L'3?;%A:3EXCOB>[YB&NA\GZ*/DF%B>:01+5
MO;!K9I#@,1/O^7+Q'=^C"67C90SID!=YB-,)/UY!1%-J^C-\ )I=N99[#EG+
MKU$<2C17(2Q%OSC)"B=XGRFN=43#V2G 68C#T($[\O%F@Y[SJ4>UR[F3?%&P
ME* _'NF2T??EQ^'+J?FXYJ0<O ,2QP<%&!"0F(M*;5JN_=1BY1>4(']MGM)]
M03*E1"T!3IE$=)YJ#H3W);.>2;_WQ Y-W15<PA9':/GD!]'^J.<WZ&Y$K@=/
M$^((^@=K>E+9HIN7^4DP02*NBL9[$?_;DD1A14][\H)\2345C-^^.L4/BZ*3
M8R\7JQ?2"CGOP_Q[0J+2Q(/%M@"]M#VG73E+2A:;OEH7:%GI]]5)@'XYBE9T
M)N_'BO^,,Q+U.\<-47]0=]P&@Y7D&P&KR"G:LNW8;F"NCG4@=ZAO^?KNL75M
M;Z5_ZA?#IJ-_%^UF;!$)F ?[W__H\;PEDC$LMM8%.]WT"MV.UX=,&I([2TM$
M92%R&<7.%2W@]"20?B_?"4++3^.3/W=;8>+J#=28)3=5;;-HIU^U=QIN'73;
M9NYF%UKH@J55E)S.ZYHMGVMW'1Z[X;&:1A5;TWK]O0NU1HCH_+.%2.J%]*AJ
M*/H"3VG!]Y"4&H_I$SOT-QY+$X12KS$NRV!UA!1 -$--,QV:KD/07@)"XW<V
M?!(N"SEK)W,,*TT:-WLPAZ31&TBX## O<>%PAL*$QV $?6R*JM'%Z=@>(5-*
MS+S 2A9.<9M^&8M6UA!%UA8G13XB:*9?:AEC)9Q&927 _Y;WX#61< 9/5/#K
M(@".\VSE\%W2Q%H4Y8X7W4:\01ONFW=!73!_I$A2'?M.\DEW)2^&C<N>1 P+
MZ?EWAD]\"0FZ.,.8)9,ZRC$P>&QH$VEY4<N"%Q(=0#<.#FJAZ15ZCDAA<EAJ
M RHJ:=&[H[EDY][]]7;HODE0-SE+O).=_YD/"$^6%Y]>P$);#QDP8TR;7W:O
MIPZR O(,!K*4\Z*C8]-QE04'2".VP.#E__D&UW.3S5K]@P(ON.H1!"O69 R\
M Z P<DZ7W!_O0V@\T&NZIC^B)HT._(3O-E*AP:F%1=B3S.^0^Q2L*TTCZ\GD
M;*!(+#ZE&N<WY$R4R&%XOM7\Q;*6W.2A1^*A0T@BE6*LS9KJ.U8&3,\(SZO*
M'5#HEOB89?RV %H.OR(=P6E!:?%/4;W9"M*WV&PHNSUDL029R0TNE 9!HU7=
MB0PAE"$.7I6T)MWT5)!$S]F6[]5IXY2X$R:C"7*ZF8QC+OM06U+F),/!J-R6
M$]5=5Y[-_-U-93.O2MQ<47+SU48R=A(&IW'KH>Q+&<9D^)LP26(P5:Z"S\3;
M'1:5],5X3S \7JW7#;P8]5-$\B9Q.QDG.Y?ZF:K1E3BG53.+?6LYSFFL/?T*
M1_D\LG+,^)Q#%=9,D":X3-I\#$[1UW2F&F U>Z6G-7^C1 9J>9X4P, 9*@YB
MA_(&^JB7T,##+RABS"M/>[ # /N8%GJ7^T=BVG.5:S,T_]16G0K="DQS,0AZ
MG**QAD<H^P]\LA@>L#S%I;OP?8"C828+U_3 88C94E7V6*PU]Q>LD_L@A075
MI4B'UC3Q)[F@G./93 2JC0LQN<NKNQR:,"YYM+4/(CT;:D';SA9>(B-1YE3<
MT5")*ZGR10+$&]+JF(*W8T9[3&\KEZ\:](1DN;JIJ+1@H;9W9BJ0",#ZN;0A
M8W8A&\3=")TE2K38>1#@RCQ]3@XM5D5+FZ2Y1H'""JV48NA*,RK62;,!/V&-
M^;.N7##?V%,83I8ET%(%&+YCJ%A:[:,6\PLJL&55U3;7-!V?O=7)5: LHQ\_
ME5&)>BX*'#,D6:I+"TS6.N/[9-21NW4WZO5/M''\#%IA!%!L$U'][?3JC]O,
M>(W/[R;<>YI0+-6*R7D'_1\509I'YLQ'U>\3A(D7#FI?XFDB/43[2X +8B[<
M<344^U6C]STKK@?5*[Z"!Z#)=;]?L;+9+B02D&4+V1OBF5N$XMC,N+ _7R/K
M]36#S[BP,\+>-=^@YP.Q!YO/4@!P!2/E3>P>[Y(?RH:-2[0D<W1&PGM.T 37
M)]%G@3X+].N]/\]'GD>T J8(08O6&(C)8EVSS+[F,S?+[%EFSS+[%F2V%")V
MR#Y'BUI ?32/==;L]D$4CGX9%Y)5.\T&^FT<UEG8S\)^%O:W(.R'N"PH['0A
M=:D70FJT<(R6]U;N-,OQ:SZ'LQR?Y?@LQV]!CHO1GLKD >%9=%/U\G/T?!;J
MSW*%9J$^"_5G<'^>EU#GRA7ZG<7/47[(=<$1>F%Q: Y]"LQPO1P7RZ4V:&G8
M\C!#&;#041&=]>.S[+_FLSO+_EGVS[+_5F2_(9>GVD?K3MNP.5^N>DA][=B?
M)?<UG[Q9<L^2>Y;<MR*Y,[ _F.VI_/X)""BS*+_FHSB+\EF4SZ+\5D0YHU,S
M9H\&U<&PI%)=2EPV.?\Z?VH6W<_DZ,W4DC.UY(>]V"S KX=:4B![!4U#8(;J
M<Y"%Q^8NH&5=T,($IRCA4W^LU)-_# +_\!#!$Z1 _ZE]M1[9H^M7#,!X%&@/
M^H^-$GM\#16.452Z$ 2Y&2#)@IBP51C[BW"3 )H>=P(+=0*# ^*[*V;!XIR)
MH!D)[HJ'P10**X?L(D!@]=V-HPN\WAK.3%]'GL,(.(?=7UX*-JZ+@_BUG%H*
MI<"E"V8:@TP)TY&C&4T(&XXR= CVYH@:\.V$\L9S&&/&WSB&P/>,[8&U4?PR
M)K;;M@5M0P]RP$0\--PO1D'VVQ4)I02,X2!4NW3KZK4!H49T;L' YG8=!<HW
MJ!>K!L^8-:6'IXR,7O+M.L,RP1Z']^L0TD O1CU!FP;?;UXNWD8R"<$>>1Q9
M?X#N/@6W,(0""$I7U9<D%'@@742_;FY)EXKPPGRS2[>&2X>#PM2+8)45^ 1_
M18"^^6Z*:S<GT>6<;&@!<"P960,S'2#;R+0+.@%K 'Y/3'[07C4X.HFP8W2O
MEI,X0@KE*U-@O$::5=U-X^TIPBV?+-\+(+3"ADYE6.O_LS@H_=R7?=L<@B(N
M"UJ>PXH0_% ;O>S>\:/OFRJR[>2,KRJ)/DR4^=D.:F)IFT#'(O"11@<GD)F@
MG&3D.[HS="P3NS&3_MR7&_J9AG8J,F)WB)ZM0K$!2ND \(CDA*+(-Y,M<Y$B
MF2XVLQ&%H/<KWO SO7;QXLOQC7>Q.NDQ9T#2P!#SAQT?9F:;*SM^G)VUP8#'
M4.Q?+E[5IZ2]6V71T\/DR2-5LS- 4,M:=[A)$P?9O5-VL=:.K\^+@*J@5]SE
MK'[%!HO$N[4G(7^TQ1I3 @FIA<'4?@7$U8)9,'%1\J_IHR*3$ ME?6HP!FS@
MC59B^V@$X<8P%']_4QB*S]LPN"+0Q&13)EF1W5^F5%"Z2)88AC#4K-<D(+:J
MUP4@$$K;#'RT'H1]P<I,X.#[VD"G2I''?=N*P=%-W7)3)ZQNRHAQ*.CYJM1S
M]./(RE:Q'22HU<IIHUH!$'N13#S:%.>$]D<";/B5("LE'IVRWI4KY0]SI,9/
M0G5V/H9HZB DJ6PLS%A-OQ32S#7&5Y\W6M,<8'T& =8KN$<_3X15-*%SAM2L
M78J'HOZ>>$;FNPBT7J?,]>)>7-:'6NXP)\NN+<S_RPOS69;/LOS:;]'/(\H%
MDMK5I(E(CD+8<Z2LA4&L\4TC[)$=STKZ<]TEOI7<E4?,HO[:#NDLZF=1/XOZ
MZQ#U?:T9]EHY !#JCUF4KFO6)9)^R)XP*K\F2#AM 9#LE*'(37:?W/M8:R92
M=I:+'=;E 5SBQ7VII+^T\J3UUB'"JH_+':3UOFK6R/4T*94[7.XGEF%PTESX
MEA,%##(>14YCRH/I##2YZI'1,0[G(Y<6;7..'S(3G+AILLRO3_7?AP@1UNW*
M@T+'<+(OS[1)%L6^UK0L&3[][1^Z!2 *PEVYE@11 *GGHHCOKTGAW?2WSW&R
M^XPR60?*U:49GN^5K6(CG&!MUX?!*V6)VT0;&AE#1CLVD58%%<*9#1*K:-<\
M!'# I-AR(9P>IZ:/]$!#;L(49$>:6;=DL$3#ET M $]/!Z'#W#5+>4;B2D:@
M?>B_(XG5(4_OZ:UU=@E?/T]M@W'L;!IVJ8%^K1&2U!G3(V2@_?U!:[LL;LP&
MK/ T9W4E6K+08A5YJ<8,M/B:#6,KFD[,K1>73!4 I5J(F#G7A"78?.Z:(_@A
MBPNW/9:D3*95Y4YHT<\JR."X<Y+ Q9V,4-]G,K,AEGPHGQ'NX+HYQ(HQ+5[+
MCENL9P&9!4VA#O)DY:,1'P7:<5,>07##56:]I)X'\TBCX7V1]K5[:>.:$Y5J
MRTC\<=V7Y:0].65DQ3PR]SBX*:2F#;\+[5ZN*_-Y5A7$521IQ W-)?,%R16G
MRT/5BU"T5<DLU8RHSO=":SD>RBZDA%>Y"<HYE;9.R^@V$@VLRII^) '4\@'%
MTI7'R!.#T0K0=["6X]>A4[<M[ILVO;14#\@.\VZLD;^KU\H_IB50EL-7F60:
MRNK\:)4.7&-1@G&-"8<ZHQ(#U_K'P#MSH:XONNP?6A7SHRK\Y%H\I<3O,2I7
MUHU3_##?)YVHV'0T&&:C#)V1#1.TW#A83"(NVBWRFLH)KZH7?.W#9K \*E7D
M?'&Q\.)[>D+3'\5BUE(6+H196%F><JB#WS>MR\E7>4T]PU7GI N7]E->,>3F
M3<&L0-U1;P]SGJ=]-\X^7H(;KVM]Q:RJ99#0EA2)#1V=)"%TTT0\H[B0!=Z>
M/MIJ]7(L&"I4W#A9<_.BI%[\SYY>_;-//OL4!]&?IX*46,-+1+* ?GS5L]'.
M]5FH_RXW9=&>EHNO7[U^M?ACV: HDOGD3NF3BV]HD_YRE.KQ=5/CTO,L&E*
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M7H#+T_)2TIEAG4D6O,D.?R2DYYBV82,'/!=O+%! )B)?Q/[T%6\53CZS2SA
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MQ68I/&%R?(S=4(Q#EA!EW8>S!RR=H_6?OOYF<8<RSD&<QF)AW>"8+/[1<XH
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M,.$7%+LLA3[YS1^R./ 9A"=MG1QLI1I/J4I"\I.Q4?))#1H1ME],)&S(\.#
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M:Z;6<TU>UMP7;3RQ4<A/03HF*%-!B9)B4L'3!0@T%HS.?*C70F?OYK?TL,Z
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M(XS:E28:A>NJK]XM#GV[WF$/7@IBMM#:;1+2D2TG7BFFH_0F KVV;#<OV+0
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M^FAX=N:!/60_+9'!TU^O]=\(TZV+;B>?I?$Y="=0%TIGV8:'HC4@(_J)C!#
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M8QNKW<#(8$M'C27A8(:RGWJJS'@IO\SL7)E#_%8:DX>Z;THN_0O&*PZ>Z'7
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M,R#OOJ5]BY@VAS9PX9:<($V>'G=]IP=N72A^63Q]8;OE/7GY@<F7&\.=^&-
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M/X[79'0%_DW@:>6"] ?^YF>?+.@857S86-G!')*__/N_VO$[-AS9>&C::O/
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M4S=0?'URXMAC&Q1YCO3$+/^O]Q3/\G^6_[/\?X;R'[ 05A;^U 2@1-V1!'!
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MZAF55M*+1!Y+:%K E,ZT'@FDYO?I'9%SJ2I [$RU+C&3:76*+:X26I[<R@M
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M5^*^]U)<'7LWL\]S/( !VQR.V6.^S:P,KO08S\I@5@:S,K@.93#JN(>X6_&
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M*U4NRDIA^L>A[ E@-DWT+*AHS&T)J)B=OTC;GSE(H<9%G50ZO.MDD^ M78&
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MY1RGX%G;64\ID5/.N0#96:-+5!=A6Z^IW*3&VF8)N(SE**4V"%A;HLJQGHO
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MCL0I!C"4*S. D1=O@)K)Z*7"UT!MT055^;,TP=^-ZA) 7)9:"O'K" !1@%/
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M$EWA%JL1YB< PJ;#G\1?!M*K+@I:<YG"YS4:2"Q&P&SK(!.D3DG[Z"EYJ'E
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M6TL39*@K$ EI&57DSW!405&*@=V2[9PB!-/!3:^K5''TF,W\64[>X4QA_LY
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M)0<6?S]H+MC#L9&6:7LY_6[S<R/O!J!KI*(?'+DK@R-[SCN//#E2RI$YH!Z
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M<8^U"#)63RKXL[S"XM+&N!U,Q.,,8"D'II]-#F:UMY!S"A^;2[B&35=I41L
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MCB[#HV&=955>0R\8<S535</'$M)T;6Z8' 3_FU^I2SV.I/T-I]R5SL)#NW@
M54YMJ:41YU1K#U_#QB<CE6U/]9@:7 UCM7=(X>_>R38)6G@E9V7P,7/B^2T[
M3%1,LQ\%J++049_?)9QPQ3=CC;(F7CHQR=>_"<*BNMUN'J'LLJ7$Z3%NF527
M5A^8]O7AT%!-<R\8@Y5JH;6J:/ ,3:B5^U(W8(,0L::8XD0K,9DM;HM+4WE<
MXQZVUE!@ED2D80;!ES7IFE01MR/S2A4\@[3;2TN$4TTVU@TF.+Y 5B_@$W1C
M PW>O&$9BL$VCESEKF<9V5OIY:K<OX&HY;]7TR6FN;8LG36>+#0=3W-Y;OL1
M=F5PY%H>WS9B?:/"U6%DH>OI1E7+0G<[;'!:-Z]H97]ADN <;F/:4SUZ=JFR
M1,E>U8@#BI,$=3WM@25W\A;F?M<:J;QPO0 [^-,I3">)A?!".@VYO)ZF0+8*
M[&DE#>H89"$SU\[=4\HXH<6KHAMI= =RK;TYR;;QM%5[B+6)S:^:-BE:KPN^
M,UAO$:_+D9NZO(ASKQ8\+,$(@<1I*<!-(2*+FRV$SBB0%CU>130B0L];!PYM
MS)+5C.],[V\,'EF#15$IL"QPETA*2_%*LBTM!,S*W6]=\[!<;L4P:XK'R'P*
M] #U=6!)2^KZMXQ-&8";ER4-ZF),LEP3?Y:HF:O^C<OL')#CV8 O.\6<9GJ8
MV^(:Q0\3\] KQ>,7]6-ONOP-ENX:KV=!989 7'&G.'>;NRW9O"&X+/,Q>_J$
M?GB?]()P^]=8]U]WT.6#+P9V^*V]%WC'IH,=][\"=POC;/V8#O8'SRA'+8^K
M#9&1]6R\<H8BJI!U&-)QB^:>'D%* ZIXL-]L+KNX=0 /]5J:EW71#.(VN9!4
MG DWL(("!4,3%46W+;5J(7=M_4 P7H(U'+TP%F_#+8C5A-S:6Z""O5YLE"[$
MW&&?L[GJP,9*."Y0O1A%XZ]*YF$4O.765%&^P$[>V(X&7W!8"KQ:L\Q/OR58
M>4+1PU'UP_X6R_>\G6;S>5'?BN83H]O).X^<&?W?"!6R3$J:I'E$ 1O;1O;-
M\/@@@).F$DLU =NRLNW3<422&Z,?,["C:6,%C6 G=TJA.2W;+_Y31T6E:)O\
M#/U="D_,<(K:/%WHF<)VRH>MC;S*BS2^PO2._9V-/>";I7<.M0'<_X7\*-W/
M,B%GBI/61POZ@!E;4>H(C,P;JIP@5_/KN ^<;HY+VD,=HHGLWB]J"4C85XE*
MU'OT3'?R$3_*S!B#OX/9/\?J(KMI;NG->OZAKPO:RNJ&S>L_K_Z\^MM&SGED
M[?>!A3#EJ'1U?D+>("B@I-0SARCH1/Z-G7S:':YO>%G-5=ZHHUHZ8'I[Y1OQ
M8F])R1T=<#).5(_=^8T;JU(S3TNMN,ZZ:KA3^5)HEV^W2JW2QH7E]\ORK1;L
MVQ!==>1FSX1[#([)<\!S]:6UML?)L3,*]2VO3*"\$CW4:]ZMEA]>\WK-ZS7O
M=FA>CBWBJ$_2BUG&NSXO5<;#K!R]"$+/Z,6X+K3&NL'YI.V-MH@AJN.D<A(O
M1D/P/%DSUKI33S>W4+)9,(_ #P1I,0V>'WY'55+#[\Q 2PJY<EZ']RE$9M7E
M?U614VF O>"IO>#@20J!-Q.F/KM-"%JVG?+678KXQXVEAJ+^X8E8-8(E4@3M
MMX#\NC1[A,]H:S?N;54VFU=31>%?"X<&6/%?*5-6FF= 4T=$1&1PV>@'D&B:
MSV75K]E.R0_0WYXH;#DU7^:B%;@ F&R1:?OAK"'G%C54@,I4K$&P(NG12L'3
MACHUU0G\J6$NYX,(L!L GZC2@/Z^.96.M,SR8#]D3=FP1#N1'WX96D\28)D&
MO<+9A AQV1>HTR=N HPM61SQ%SLH:NX)MNEOK#KJ?"B:U<@I!GV-0;P=6'3S
M8=N;"!/HWP+D(JJM&_%_]6P.<J&H>'2Z9OMS_%4]E\H[(-W_^_3S.?[ RVHQ
M5)A3>;+4H /::B45"W"<5>?0%0K8(\C=*I4$%SD+RITIF G%R^9UN8HH#*LW
MJ8.EB^@R2QH-P;"2@AJ3A?5Q)"_;43E#&A9A :8(2E;\<..,<"M=F_?RP*R6
M.8^*400P?O'IKU0M&+Z: QP)Z Z M8MH[!SFL:L%9$1S X#,6<WCF%HW=&9'
MB6P0B2^3,B\6&&.FJ<W7O,39%&L&,@<R-?\"?YV1G3">XAAJV8K#.4X<68L(
M!37#7U0Q;3:0322SB"M95A .V"!5DK)G&Q5IPNXQ&B(F7B]A>HX.6(OH>?2=
M4\W+?YW@7.<L2[!H);*UP<Z4;A0A'W[[% ;/1]_9:E^].Z?**RJ5)!L.#EJ6
MKB4'I)8J/-$WAX/AT7$P$E,.3:9Q\VE<AZW+M9!UX"X%3ED=@\.,!3%DWZ68
M4Y"B-Q5Q^=6-TU!7Q2WTHD;7"G-R'[2X:")&0X(Q'H4U.TLI#J0&M !M9*8-
M)9D[/N,H"1FV@P,##0 #'HRJ!X&_D7]Q([9K\/+[<>V->D&XQ+V$>;S5$KNQ
MB\G&V[1T#:_1;]AKQ].#HQB7/L)G,C@GS2 '#D;5.Q[C\AJ>G X( J%1"N?P
M@@FX'/>1Y;@4TGS$5&OK32+FI<2B=A_NLMCFBG!914P@8"^ 4<45H;<[;1LD
M4IRQ0C T)M<;=T0737,?2J<3I.WJD=S65'6VM 9)_@5+_89>6=CMR<0 6V])
M 'V)H,:B/QJCK(TDEM)4UGBC<3629=JBZ0O<'L5M.*5RE!053I;YS-DFM.8+
M(G=5 7>M2"=C))\5*Z^(8FY8-:G'I6<W-J!+A%0>1G+KDK;(I<O;BK:\)O%D
M#VL2UX?T7<&Z3DWBXY_B'SRK(_B<E%^#][*Q_D&K_C:R.8<R3U0WW:DXR#KE
M]C06$F4MDB8TR1#^U)]U?,$Z --"9M ]2JI(&C4XN/:7^R;=]LY>)M<]@V3#
M%4>4SM%>BMA.MZMXWNK.Y3,+)*GWP(X!.S$&;=EY93W.9JL< X4A'[E/RC/X
M]UC7O9J]9^R+7-0)F$+HJDJI/XI@T%R5>$Q7RAHU44#)O4*O-FD,,(@HV)2J
M2V<?JZU;Y[KXTCT8JA%T?5^DO'D3RT!ET959.$G:Y,6(%IB[+E0HL1(A+CHW
MKF-0=Z'<UH*GP&$0UK7<N<&IVZ1H@8@Z=^PWR.SBY.B*]^?%=:^7T)>S" A#
MU+)-AEH1&DN"1*WJD0&U#L_Q:DMLSQFSYZ.9"%B%0H] $%L<+,,(RR1*TIK;
M1-#GI6IO:TB:7N+&+B\+!RMG1 X6L0U*K!5L>+@.CO :@;;-\NQ3D[(3=.[+
M.08X:=DH$J@>N*)+\C0F.9RBP$FN;H%+W-"[-MK1^*5.IU+/$F&5I4/Q.'TQ
MYPXSY.2"R,,&D#@J9-LTL36IXS4Z- OR ETCW8#:Z4EU4.+O@_-!EP:(.E7%
M<PE>_N/L[#<)5'XW #41<U.T*'@#=-M4^AO[8[J-UE%$GY"::3$G;__2K_CM
MS=FGG_4[S"W=NI80BU!H,Y+"09>X4G%MY-!.RI(W:E%<A/!#S8Z:-;@81#_)
M]+;S?@.'ZG*]R#E3J:DF81*E9C-.+(I8%,0F&)<5BIB [A093L3!^Z)H930N
MM<*MV0X*T3BAZ  @"]16(DN<"5H$I;4Z+EQY<@6.!.\:+1L #;EEU"XDHA5F
M\E>)P:X/<='0K?D%+@]P]Y^H&FX -&=T8<!!3 KHY:(KL9N\B][=7DL!K.)Z
M68:M).Z (PKZ*>P [S;+1TDZZ"QEV+E+_8: -S9)UD5&,ZL$G2UKG/1+]XXF
MJR^)PO2:P[795!<A3Y*BK!K!XI$"F+,41Q^X^3)3@";!83'@>%P'?9U(D+[)
MBV@E0R D0^L],\7BFI,&NBG\GA>B'9,Z> W??*=C9?_@6)D6D$C$LO5ZI,;Y
MC"7]<K"9^YA61*(I<".QZSK343,>D\(L=KO#8[A.7Y^XB,2GR8&WMU5KV,0*
M-Z"SWX:%<)1[E "=:ZZ#64ZKS,U)P;HL2#"AU0N:.N5>]7P.ZMM,5+D_4D(G
MKD4-^AARQ1DUH*1IR3K?*\)!RM%8;\WEF@[WA>U'"PM(4,O4]"U%ML9ZT9]8
M=JB&Z4+(L?@RRMOQ9[!=W9WM M)2<D^M/?3H6HGNY;<HK05,]'\YQ(:)>T10
MS"<_?_?&SCR1GG+,/NG5S(EJY=.%%-Q^9@N4YE91:FFNB['2:Y2?P-1](-]]
M$_[(%\J= 8[0E&C%MO_""+[*+'4Y4*Y4-!/@6NJ22$AKV;,;/F?;LS.="^\@
MF[$UA>#:KG.DZ&M1N=5:%O6'V;5+-Z<1'U;(+6.J":WNY=LN/GAL@C/: =FP
M@18=_^"$$3PQ+]GZ7M;ILL[6N$KXQL26+<N+$?'T[NO&3L@B2:,";%:\TU(]
MT^.*FG:DMD Y=J')W$GDWXZH[D33R\X%8PC[?A6Z<)A]=B,!E'9MXI>5MM:Z
M9L1$E*1L1:4TS)\QY!0-A,NGEB(-LLB)VUIO<G?]_JER</SBA4U7LP>!%4PR
M"Q)?2$5,6 Y5Z#R.%(JYRVAW+7ERNH?)$U<9-:M='T<UW7:\PU.<"5/A""8V
M&)=<766&NMS"2!1+C*:V\+,7KJ&SXB76(K9#ACCKR@O-M73 >;M.>)7\ Z>N
MB->7R\2C3K>XPPRU?],R2;\-!5^,1294#M1U=+0FZ2MV%I?^LC/$V FH.=[7
MS;!L"3PVK2NR?#'0PTI#G,VV:<V6W35&\X/-S;@SI3ZT'/L=O4;K![:T0:A]
M/*.&.S0?V/(83#L\_;&4=(/)T^ SS_7Z]*.#(>'@AJB U ]Q11@;_:[5F<MT
MJ$7+_F=7PBE.UGPHQ4I" *;FGMPH/1*9@J;H!/-?&[X$4TJVVAL4FBRO">V>
MI:":<8)G!SC%L%$F$S.+8K5*B#A#G&-K"MDKDC5$6',#5.[K3'$L!S[DQNBY
MEZ6[_'OYS2N=]U6A'UNN)VT)N@!OZ?4"9?><(^KOTU.JA,YD"IYS6KZFQ%.T
MF>E64$Y6RB%'C"^GLNX@Q.WR]\AIQ7."(;>)5N"0,ZF=PVER$I>XC@QO<52A
M^/BNAUM%6P\;SR+JN2.I6(<"^<58WV"+HF+34X:!HL)672CFH(M&LVEGA::I
MM5Z*C.DB:XJ>R8=6E7/JSU+P<+DJN^DT2+S2/5.64Q::AC"OKK;N*/<V9=Q_
M*$?=K2Z\Q6!I/>>I=I?,S@_@6/=&"39M.M>#7"D'N,')]CP(83R$/:A=K;\H
M7B95N6_!4Z2&X*/#,!@>#(>@5#H2+4E'HB7J:ZI%E&>9I[28.^ZT+[LS+8U$
M2T<X8'=H\XLS(CA.8H*$,8RC+MM899=)D6<$Y>OGS<L(3VK4H\$ 93UATI"2
M5X,JDX8TD[(I=9)1#(7L*D=%2-:1Q3'5^<\+\@ABA3--\7E?L_P*)/8%C3XW
M04:RT M)H>O8.+=V:-J]6U*9OH69Y>\&["%K/YFL^2]4*3.1(CD"8S*J&^-Z
MM8JXWBO;+9&(3IF8J)3"=NJO;G#/G&:5/9Y8=]+KYN?-CPVX$WQNT^+NQP9L
MZ=B ?G/.(X\-*)+RZ_*8YE+QI!IMPM55HB>WH"SVLUM,^'R9LFY#2H*&G13#
M#PJA71/$&[A6OT3Q=O+/(PMC^4RW3&XU!& G:X&!IT(/F, "?P*";. ;/,B
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M7E7:A>-6T^N4 *K(9A@+*T!2MPSA"NPZT/',%6CK77,R7!6'0SPT<=>EW:;
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MYU%!8VK?-C99RNKJ.77#,M0PB<9JS1HT3JBW.?BP.?14IZM3=4EY.IQ-SB.
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MS,HKFMLA[]:513WVE^]<)77[AJH>QISN7MRT;]??MD:P)[<Y]ERW[=18A=[
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M#ESIL7E?6=)GU<&J@U5'F54'ZHEWI"?^-['#F (^K08IDX'RR-B?A,&-0M4
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MLT/AP$Z4#W#0?544[FU:V!F\-G_KFS=WKQT!]+T:KEV\=**+C6&AK.O9U\%
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MULH??JL<'+N0':@62H_4]1C$!6QDYD:J%SC7-3>X]3%A.5*>+(+-E!8C;G[
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M3!\[R5_ KY2?2#T=Z7V N(?/'!GZ56XCOM@,U<RTP]$>]HVM/%)+CAV-  J
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MJ15,WH<R4A%V\,.&/[-=(O$UV))T6<O-CM4]U4U9@\$@@A_VIW *OT;;<D8
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M/Z.*N??.^6QSHU?S]"=R>8&U[]Z8WCR%+I;50LS*+!7E-M0=9@>-4,'_\]$
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MK8G$?56C&./,FQ:YP%1-_^XK!-5E/&.IX 67K/]2$'JZ+"_S_+0@@B5<PXU
M/;K&"[=I\ A$^4[VP1P-IZ9-UZV^TT4(R.5!0O?<,L=)XRN#%_*Y<55%#G.L
MAO,#*NJSL@LM$RQ$(ZMTIE8<?U2+[!O86BZ.2%#0'D,)>/.MK,20K@11]6NZ
M _"HO"3"#11C$M10U827QWWP9//X,B$BHQS]4@+*[.LS,_-U\9I''IFV8YO,
M>S5&(-!N4%(;6DWY37,7PI]H&4%]@H]-/%L+22FOJ:#>03<T),;01&![*=\N
M)X9TL\1.J9LV6<&=&N=OT;U6@Q2(UO*W&EO>#> EZ((,@4;P]W)^G[K*5="E
M7;PVD36(P%4,'-Z].=?>GZMO7UKI8=Z!&(4M_B\LCBP.>P?0M*TB;'2KE1B5
M]0JAA7<!4JK737GC9!S,D'X&Q!F!CMW9Y'\2F=U=/P=^KFD6#;,_/C6W=(-Q
M5_;:)S1 OID(WD5F3539?B-<'IW60*D'-?<]HLO\T3)7GVNN#'Y,@6K](%*^
M/-9R/+69:@6;:8A<8Z["D\,GEB:>L%1<:T=)=V--(HH>,)QU95;'RS"@((9Y
M=:_T_SL=R_3U0,46TO>4-(OOVJ2D/1$&GDPY(TK ;3;L;T0Y:8Q4_*L0%8#2
MP2<*J9G+_)DY6C=B Y4*'M0<1E_M!/$K,2)80]!I_>HI<ZTO$R6S,C&3*GG-
M.75' 0L2]:><!D8QX9Y<.W1KP:#FZ'+[(="#KZ_?FQ9,R_1WM=M@@GQK-9H]
M;?1G]=:QM,>ZY>$-R1P"'B%&Q]3QH]20UQ'+5&29@'J83+3(U"H4!9UI_*)\
M_;PFC_S6H_)]DI?4B<">4)V+,4E@6Y- E\5C!T6LZ2=WP0N&2/"P*"57&IC7
M<.F?S5=:FNJP%\G5>#I);QY0H\/$-\OBBU!BK[;0TKL2H^D$_29L]X!F-FBR
MV)AEK@3["HUFT\,CFOJH5>%8^"U98&2OC0.\$$KW!5-*GY'MV&\ XXNH<@.P
M(X.T*6%F8.J6B'JSM<7-9K+!RF*C=.6MH"'L3$.0BZ6;<&58,4Z7 1KP ')*
M9G^ 991^8895@NE":17BH2;:!_):WWWH8PS-W%%]API3AA8M$/Q )X_ZIDKB
ML]G>)_2"V@!]B7$:N<;;%\ " U2.:&SI5I5X-S4:Y4]B^,VC"%T2ZQZ4>$^U
MIG5]\3I!Y"BZD@+X^1/HWD<K9R:Y-)^'HK@TBAJLE-5RC7P%DQ=2N5/6F#6Z
MZ-HBAG\R;E*ZF2D>1PL]\MFU\6%3OQIC3[O2F+1 %,8:2DTJ_&2573'KRMUM
M5,T+KL6LG.EK?V^)-IN=VZ%\^TIB+7-9-8\.BUUPR6;SR:GSTFYXOO@X%^W
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M--;-.D*?:#;USTG(SA!L?5EQU8JE[HHGWF.9//1XCX>*EL0,OVMEE+4,S+(
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MS(M%C.A':C<J[98=%L8GZ80IX9PB@ZC77E YIG:B,[>YXHF_2X=:.-=J;_0
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M (=Q1BK2KL9B8<2\?Q"QU5U-BF)9S+*897$)9?$G*E@9ZB!5*(>)9U/9298
M /O9=JAZ3J!0C'49G*Z^<_'ZS,".J$8MB2/E2O%[_;*NRX[)ZDY3)7D A^WI
MBE(BRW"6X2S#2RC#+Z67WFH45.:D*Z2-"%>.(#G7-RM'.BD\&=EP-D<F,05:
M,*K>5T$LG9%OZA/Q H>OZ':)'>O"%Y-$*&0"LN@)6^;5I$V6ZBS56:J74*J_
M_3&A0JIB\ACD.LA $/:)3B!/9(CE1T$8#P)/!6O*X$I6LOUA+G4,0.: )@AC
M&TN=1C: PQ_JFS,*K_U@F A!A7#K)Q$V*XAR;R8+\5O"'@?X,U1@D:5OW8!>
MT\H.+Z0HT*/+T@^WMDX@Y[5QH'8G21@ETLV3T?33*'$<>/T@\?)R-E2G(=V#
MR9(<Y@(4Z> XN+5#-YK-^B>1M-([,71^?6$&-;2,=:$:W<>G6RV8"/& L+$"
M#*^ @B6@J]BHE%3^F*C\X@M6AIFK3*A["_Z?_ & BM0-K"Z77(:I>-U\=U_J
MYE<RZ2ZJ9E<JRB?=!1'[9RK=$%\G*!MUD29RU^_^&#[]+%WBNR]2NMOJ^+%#
M:OX<1'$:9R&361=MZF@ZELWJ:E8PWX^NWGZ_^I_C8L51M_T<)03:R"@0L"X(
M[YJ:VY7Z[A&(P8FDD^K[E;KB*)Y.I)4%=G1[&I 'V)X&]E>\ 44N CD: OXK
M*R7.ZIEL)PQ 2(_Q'*;D*'\%")\_\JM]N40ME!T7<@>D!^B4V>91:.;-3%9M
M$C>C;WNNV.XN+P0:O;VI@Z2W]9(,D@<X2W-MN?H+%D_SS4FK<_9J^_VZVKUZ
M[_DK<_(4X!%8/*[0CXK<;-JX5Q4JK14-O);<-GS7?7?VKE? 6^]191JQPQ6P
MPWHMTYX0-TWJI79_W#Q>%\"=8^L^[06?$%,;L= >HPG5Q-'_')<.3\WU\/1D
M[0MWCJB2\A-+OJI@JGU2[YX\N@%19L2P 5$E;)64C=B 8 .BDHA:?_KE3Y'V
M]O7;B[>O']W'10@O1=I.G.!5[6S70MH6(UW+&PE3X.N(KIEMS(N/AM99[;8K
MM"YGSK*@]6'J[M%0]SCL^"CZL"R8[)X]+QT:FUM"XU.HR[+@L:0<R<*TLJB;
M<\'9OEG:B@IL&;SJHAQCUI0.C<R!E>5 -F?NC<E>A\V9?<#C%OU_,S&%_?]=
MX#&?%"2.+KYO[NT_&A)9/3ZV>GPTU+%ZO#<FSUJUL][&&O+QF) UY+XP)<O3
MRJ*.'?XU<+<JF?&@7 9S(W,C6S</QB160I<.CVS;</;_4)7EW&S@; "P./IP
MP9G_/6'-4J".M>7],_^]VMDI1\OW 94E94J6IY5%'<<"UAG58\8K<^:?V8_-
MF1UCLM=D6V8?\,B9__U0CJ]#:4?Q W4C!\9+Q8FE0!WKQONG_3<O\N>X>(GP
M6%*.9&%:6=25Q,]OMNO=4J/ON\0>ZI3V+V0QOC\@B\'<R-S(ILW#39LVFS;[
M@$=.^>^'V_\M#'!NJ^2@^#[Q8BE0Q]KQ_D'QS0OB."A>(CR6E"-9F%86=>SX
MKX>^]YX*^IX=Q>CP?\;I]OB(%$?O7W_F"D9F2+9N=EC!R)?]]P*/G/+?#]__
MM0?0DR'G_/>)%4N!.E:.]W?]6QP8WP<\EI0C69A6%G7L^J_9NU@F8>;[EPZ+
MS("594"V9NYOS9RP-;,/>.0T_WZX^B-IN^(OO[3/7L%+G&MQ^9_$'@=)M% B
M]^'+)5_UWQ=>+07J6'O>&Y/_'U_TWP]$EI0E69I6%G4<#%@/?9^FX\F(+)H1
MK"F&H>U*-FN8$=FLV1TF']+OC\V:$B&2"P#V(RKPWH[B\,&C<#AD7BI6+ 7J
M6#O>_V;<YM5Q'#(O$1Y+RI$L3"N+.O;YUQQ>- H#'\R9SU/I!7#T3S*YEF-E
MBZ.+SY_XXC]S))LWN\-D=_-^?VS>E B/7!&P'[[_9^G9_@,*Y3@F7BHF+ 7J
M6"W>W^MO<U?_/4%E29F2Y6EE4<>.__T<?YWT=Z8Q_CMW_C]M[OPS5S)7LI7S
M\(+&3I=MG'U )&?^]\/[OY#AC7*P12ZG_O>'%TN!.E:/3UH8Q\'Q$B&RI"S)
MTK2RJ.,0P'KH.W>26"[)_)]SYI_YD:V;G6;^N>7_H^"QN7..-+[_B]CN>Q(^
M==7-_0X_<];GQ;.A^UQ\Y9:6;3PQS"Z#)'1D]%*<B\LDO)%3$0S$%2BIL0SM
M2(IS)U8W*IX*Y8L/R3@;3BO^\LM9J]E\)?[QA[@<V5-+7(K7MN.,9!RK[,NW
M21A,)#ST#W@-#KR!Q?7SEFBWK8[5/>O6NKVF)9J]7K>^\&*9O_83_!6**Q5%
MB8S^\DNG]TI\$%?VR YM2\A8V)[^T&SONXRD'3HCT>E8HM5MG]3@OT[Q-1WS
M,(#0FXH7]G 8RBC"=WV6L8VS!K!"SQ0?Z/8#O_M(/R(.Q&=;^3'\?[I3"9K<
M'\8CO>87\2_E2 <@+6>VA&M\EY,@C"/1:C2[^F/;=\4[&?I_^:75ZKP"8OAO
M[3-L&1865P!.\S% ]+^U;_ S&^V'<TM\LR,GL<5'2[R1XA\)8L02'[!]PC\L
M<16$<)K:>U@'GF]W7]GBO/8/ Z"Z.(*WGQZ+"T_Y%%SY+CUY@P K8%V*2X!!
M$M'^5E#"!7*\=.(L/E,7WSX%E^+KE[>BV3QJ'=?OQ1+-<O'$UR2$0ZI8P?%<
M>0,@F(QA5V(2!L/0'HM;!?@<! [ */#%E\"O7<*#9IK3I\0?ID1X].7RXM/%
ML;4(+W%T\1V_^" G=AP SKW$L\.9/A<7%\>$@E5KT]*(#!L'8R("'0](7B3^
M&+#M2^GBXR^"T/S@5L4C.,Y .0H/H\;CQ _B$2!W,A5R,(#MT6]@16D#X\3)
M&)Z-IQ-9%V]G/Z!]X:KX5OV^ %\,RBA]=R1".0%2Q%=%H$L5O!>@#'LTI(=+
M.,$8B,M!. <39(\$H#ZMBS^DZ$M/ >A%/+)C<?7AXU=XU4"&0)5PADB%Q)"
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M6C^4]G7-'L!Y7MK>K3V-GHD7#Q>L=YU* Z!YARQ?">I[2D$#OW[@N?>&_::
MOC#$]BDC-F"$BYS6/F:T]BZCM0>>?ZM(,.K:",<@!);^^[/&,^%(ST.3!E@[
M^]L80?3W#+6\M),X>*6?1HO+LR>1?)G^XY4PIE*C8?RW."/*D499LUO7REZ;
M=6%P"^\&NZ[U;'T3K_GFI-4YV]S$TYMLG=4[8&@;4!"\H\!3KM"_$JD)EOZ
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MZ3;QX\(RU^!_U$;!+:T/U.=* (83RMB@RP$*1*#AJ>T0J',HQWK-NS%@]\/
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M[JHPHZ=X3-HW.F+20&A.S;B\X@)HZ_C%NL.L)[ &<#&..;6$5ED',T>+7KW
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M T@PUT(3^-/!!)H$OD733?0$J%RP6JLH+DG,J[BP,$8L_FP,CW8U*SB"1^L
ME,B[O-[H*U.Z$/(6UW/*K,NX#(XO2<#.X#BFS3(F>\? $\EG!CUHI]\8>D0S
M3'DCL,$T%H>$/^: 8/N=EI-/LPH:C^"M364NBL%P2''3]OQ()C,8CK*'@-2H
M7$[92\F2 DLD]/%K3C6]^_<8=R+XI!=IEABHNH^HQ@A^UZ.1=3=\JZ-YFW*G
M;%*;3B>T4=%2#4D-N@7E%W5+1IGJWJ0#B];+EVA%A;6)G'4-8YT;1ZK=2',B
M;NY2+3T]_5@FLS!@.Y;"SH]?6/*RE3<&+@XSB%P!-_*91[&D$1?UJ%ABJ"T$
MUG(*G\56PITEY;Q4,2=&T.RO DZ)"#24TAF7/SF],54SW6:@W5Z0&2'PB)3
M[]VB;^ 46Z %_NQ%#5:LMGM-'OO99/^#-3CSS$4V"UZK/_15\3FV@6)QH%CP
MP8]Y-M9%(=X  X9QYN<O!YTF%AJI=Z&:9#M;;FP_[1\>;0@?:5GMGV&U6VER
MW\.RML'HWO@;]'.X]H=46_!0@(S.:12-"DY4L0F']BM,;+(K+*_9/(F+:0V?
M1999$K6<^L\Z=QX?HV[Y=,NGM_?^_!PVC5(W<0'&$\7QM)21T^=3N%*&XM7D
MG_>"DA:8, =_IQ.5TK2##KN^:) RKR)%5_[I_J_=X,.<^'%F?]-EV&\U[:VC
MOY9_M_R[Y=^;SK\_HA1[[@KEC,9]GH6Q+A<<KFHZ0FH'2>?\[.*DY<M;1U<M
M7V[Y<LN7-YTOG[N27]-C;)*K&9?*(D+L]34ZGND\#FD\GV>?V-SM#[: MG-\
M?O)AQV+6U-\Z+@KZGG(MP0QS_V33TCK'QR>?6BZ_=53:<OF6R[=<?BNX?(&$
M,=241H!=6\N%P;;_GE7<V>X&G;QET]M&9BV;;METRZ8WG4U_2"7U[_A%5SIM
M<H%,P M,+!:-J^3@CI2)K061AL1K*S^WG%UO4&K$(^+7;:+>?2QJV";J_81$
MO2J"[AM7B59I=8M4O=J[T4S/8Q09),US^KQ!(.@&)TGU1^^]FF>AZLI*8]6Z
M-K:/&A\D$VZUYH>C-6_\#?I9B==SI'8$'^:D^V9I\)9A%H/./SZ\W4$6R(UC
MO#\_>7MB!I(V#9].ZB;D+=?>-DOM_IEVR[-;GKV]]^>>TOF(X\ZRG&$.T^!H
MU^7RU7E]P]JW(0E^/M;O#'6\ILF(=5<+'D?+P;>- EL.WG+PEH-O.@?WZF9&
MZ#/%D 1<#N,!^M4,O@@Z:CYGX$AF]0R[,-8Y< L=ZL1[Z^-&4\M<3W7*[;!,
ME/*]+J^R_'/0>7]R\GXGF%1QI!/ %;:^E:VCT9;'MSR^Y?&;SN,_^OG:QI&=
M!J]TI.N.@H8Y2U9@K%M]>^MHJ>7%+2]N>?&F\^*7==8>5&6;I0<.O)J$_?>3
M#SO=FF-K:?/9LN9M(ZV6-;>LN67-F\Z:5]+V@!58NT'JMLMU7-$V1_";(=C4
M$XY(=A&'[ :O%6 TPV[PYH1^XPY%\(B_U^'G;O!;SOV$0N7E .+3MXO9?$H;
MLNVZ^ 8E5#PBCM\F_MW'HO;:Q+\?SZC_KO-\$9Q/U>+Z=#\PT'\"&/5DJF):
M6VJ]W*<:\*RVD\X).NF\B->F!5[H+ZH(SK.JG%[I FBQK8=Z^TCR07+B5OE^
M.,KWQM^@GQZ(O,KR)+)=EFU0L2BKB-GR=4#<+6_>-K/N_EESRYE;SKR]]^<G
M%9W7O0;"K#?.I&V 8=6NBK&HYJ;'!SM1V'5B84C0D\JTG^2V"Q.T,S&M&="X
MP(,L:9GXMA%AR\1;)MXR\4UGXF]H[0ERM<=)97H/CN+,]K>W7-RV,.)R];W=
M("Z*"FV*%/H5BKY=9W<?[.X&<W0]RO5EK*]<.R/IZO1(FMH/VJ;VK<QL968K
M,UN9>5\R\UN._>:3_2:)>L,S]RB0.%J10%#7S21/3'M%9'J>Q@5LM$I2_#DV
M @?;:TT#(4+=Q!!3_O-^<*4,OA8JZ:(M'ZQ!=&6,+TUGOG7?^J11X.5ZSWVH
MRJ)4TN;N LWI\,/Q%3KF633*=W&:QCHX+_6E3H./\9R4D%<X:UEC/4_^VL-H
M=-Q*R59*ME*RE9(;9UDRCS7L_665(N3^#YVF.D*$/@>[#]Z?O0F.DR1&<A.Q
M:^[,9%@ZR9[A[N!IRYRWC;A:YMPRYY8Y;SIS]E-:3_,^YTQ);JMI,>UWDC8!
M]VD\#TS/= [<A%D/%<!I:;*JE,3GK_#ME:;9+EJ/84-]4[R^;LW7K^=6.(1C
MC+*<NT7KZ&^YJ-B@_*)')"O:9-C[6-1^FPS[XUG\J2(^'AP7TT0O;H&!^5Y7
M>=:K2\Q.J\^^6Z;-<-T^.GN0[+75Q1^.+K[Q-^@GXEM^> N]=ZXCXV]GC3JJ
MDC)(F3-GAC.W?'C;++K[9\,M%VZY\/;>GY^$OU"[*=:WXP!#?H#=-UJ&W#+D
MEB&W#'F#&3+C_M8:L,L@,4Q81PW>G"R"$JDF$7V>1GE<HCX!U;R7*D0S#W$W
M<],[.[(@"NN*'MUV3(66G;?LO&7G+3O?.';^,8_3,)XOP0;#\ZR"M)J-I'0L
MGJ%8C%87I%8!![=&<5CN_H**WU@77>*UY=3#X0&4?*Y[]@\M)]\V2FPY><O)
M6TZ^Z9S\%4V6N/5IG.O0L/#R*@MFZ@_T)Q6X8"G9(A9],=4TVP6RS:=Q$N4Z
M=0G=;[)B'I?TR3N=C !W*7WVCDEIIR6^S6ID^!,:+=<N;OE"Y5=9"K2TI)RV
M7'[;J+3E\BV7;[G\IG/Y%=!+511Q<9.#G#YYD2OZKW#MHNU7_7 "X??/L]M,
MO?M8U$&;J??C6>WK*DTK*-2?B3M^+55/E<$;NE"TKGFC;/*=@6QXI<(J*1?=
M)3Q+^_&+. NG>D:</*=G5!%<:>;MG$8=^2H]_;[V15.CMCL]7I,U,-%IN @2
M-<(N9/FB'VPYDV_S!1\(DV\U\X>CF6_\#?HY\N)%GJDHH.5,N(Z&"VQB,'KC
M!'<ZMWS"]3;<E"_1)!M43E)E[]FO$A0=&8CCQO=&#2'AU'TNVC?*/OU 8H9T
M_#R;!2-ZQ12 ;2,=H:$4C\:?J%!%-)#"AV[X6DS@SS.I((*\26EK A(E7ONI
M&;TECN(BC.?T=45?<5.8Y]D?)*Z*8+0P54N884JGX\5S S6GSQ0MQ]@CXE'R
M*HY0K$2K0[PXII$+76Q[*5'K4VI]2JWDVBC)M>GWYZ?G6**MK!$]7RD%Q:-E
MKI4S94QM:,NDMXW(6B;=,NF626\ZD_Z-89R1'1DJS+1<P#UTKL-<EZ1_]UZS
M?IY8']%%E7\&")AU+$'!EV:Q9#ID^40)"@#V(JN*VR7XA%F5%T88A%DZ(<'0
MJN7;2+$MQV\Y?LOQ-YWCWQ#JG>>ZD5^Y/O3;7=/N<-NY]09YMQ\1NVZCO/>Q
MJ,,VROL3\! C-0O^+YO/)<)K0[O'14':LBKU4H_"T_@R+N $/YG&>@QM^[S*
M)\T^X'CN!&_3(7S_>$!S6!<QXCQ+Z--^<![/9EE*&W!R1@LHZ,S8V7V2S8BY
M3W5:Q,U$2RTPOA<-U%X7/S9/D&@X5<1=MY[-MW'>!\+F6[7\X:CE&W^#?H[$
M (NFF:*^-1@3+\RN&(.1>&]A14'F1$%)+)J4;^"ZGR>92GO_X#4B)-ID[N,L
MK INQY4&U1P0Z:_/6)),]5S1[M/#\+9GHSB)$6^=\:DIY/?@J3^R.*49+<L'
MQNO=/6K%P=;9F/<O#5IAT J#[;T_/PG-<2DU\RT#J%^PO^6C::?(:OOY[\RF
MN31V&A?7X->POYU8=Q&H7(M((*:>2;0UT@E&7TBP-><H+(F&F'M]<1^P>1[/
M(!OXN38@NZVDV[+^EO6WK'_36?^[*ISV/$#USYHX\YP8.;%K@68'@VY9\5:3
M4LN*6U;<LN)-9\7714I9*385KMR?#OTQQB:KO9&\^"UL^G8]87D#>&D;T?GV
M@^Q/0*:'6 GTTB#,9G.=%AQX&"V"*[6P=@P9+K(Q19F%GTFN<9-@9!Q%F@AB
MQLXF^@IW_:!15,KI2)S5/\\Y;D+"STA'6S3 C4;F.N3N)>@<$H>T9@16Z"@*
M5S-1QH444"@RCV8:&$1]TQMW*[?^=\W6G$J*+"BJ.1*M9/-4@,*&C+<R0W<M
M6K2M]2N(DJ<9;81L0 %P/=H]X@K8/1P.@V_,<PT<:K@7B\]$^05W:3$',JKB
MA(LO)&%+NDJ262F=)O'WNLZ0[A^I+'P(T!%H#H@_^2UF4CO+NGQ%R@FO85[;
MV!YZN/GMH?_D%3"[-<J2Z)MW^GNW]5H%X:?. AS0N&0*3R3_B"WE&:(8-PY_
M2+; +W^[L$52%S1!S35@9FW;2R;U4BY<W<%EK.QOJ#MX2_RH0'6:BYT0]SHE
M.3[]IF7?Z84T6L'W6F@RK>>L"=VIM7:XUW]JGK[]KIA?H7CR[\UMPA_ND3W7
M9*&X/'#".@E)+)*#1#@LL=(J3'16<JLT_:\*4@I%]*H4&6RS.B+1#5D;H1V$
M_4Z:2ZEC*#DE:RHZC0I1#5.M2#><YMDL*V@"))IY0):^!11(%80,:$M2&%X
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M.;=99C(X+''",BBJD-2K8ERA"J&,>T;"1GDU*2Q#I%5\)@6HS"*U0 F"Z07
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M:A&M$W!"R&4$^U=2IU67>$45^[EMIA2=9?:%EL'I-'RL.!01KK4:R/(B49,
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MS(UNX$LUX]E .'ZD90=H#15-+6G&5^EC5LTM*"3V7$Q!![E'0H9HDA.M=-Y
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M+/H=I"_9;*10[(YVMML1P1M?0[+)[DI:2^1JJ3RCI(Y,BP-G70^>1NA![=P
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M3GMQ]N+3"N:8H;;&J&12Y_6@M)?.6+V^Z]^U25QJ";M.@@4FY-)8F^U'@5$
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MK#5E0EZ\[6)^ WKZ:J#& 6-_K1OQ29VI8FPCMBO7Y44W0EJW"64Q;*V#VO/
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M3J[#\0!BP<*[9#7"(& UFM1(++ WV!W4&P@+4MZWQ-!EX^ NT48+6=)/C+)
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M%Z'%M23]O0BT2)\DN%3S!>/H-(/_,["RO!7@/2!S>M9(A4Q=$+56C9/D2W\
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MG+3W2J6.FT>U.MITM$(/-P<3C#N^AT:7;']Q?<^TSILY6\S/WSSAEC58,&X
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M:[HSG-/LS&\KRP'<\TV#BT/W8O8N7S+XU+0( Z(4E*(I#C:I2;A(-Q [.+N
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MK4OU$H2(5<(5D^8(-3+NDS6&<,E5+*5QHNF'[%^0P[;R<?7G>"^^^ 87NRP
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M%JB/,BKB#(1S@!%[-XQ>ZZ7>Z+&>ZZ#O#03Z#>*\M75%U7=1W6>SM]\ 2:Q
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M9[]UTCB]_0R**)]R7S5<3HX2!6-K@B*W4#IKH4 ?PHC-NBA139YPXJ!Y'B;
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MQCTQ,V.(T!;R;5MSSYWB@9<:<<_N,<=7@UQFW7?WV?HNR9+IN6$X'BAK88O
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M4[*+%D67!*/[#5] 4C6(\;)TT?""TDY>(;AN6^:38-$>]54IKKJFG'RV#4Y
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MX_''P#81[>^.<HN*Q]GV)LNJ1AD&#9VS)?B^5O5#/DUB].9.6)=#@-XRF^
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M5W+5$Z#/)=TDQ]P$I8O:XR2H,HM>> *+=I6OA=.D]*D:.58AJYB4R/ SO;F
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M;GC9LQA<59+E0"NQJOM6ZN) 5,@,1X:NXP);Y0&L&]L"CL]TPL&PN]9C88T
MS\L]=HZ[ C49-S)<Y>5"@C?)?+>GMD=Q(9."S,:":+ZTS9>>3)T>/EKR):K
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MJ">M3 ROG+*RZI>45PN*F[?@11,P^&=NQ:6B(=!S'*8H=_-$&5SWJ_$R].X
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MIDTH40VGN$F$A^I41#-4_*E:W ]0\!VIH0ETT0<]K@7F.I;0T@(["T[?DT5
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M]R.Z"YB<F9QMA_<:.=O:)\M$SY4.G0![YX10_UAUN&YI)3(/M+[:AYU^&]#
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M,.B_(3& ,):+X\NF2'GR$04=WY,)*=@S$)TIC- <U_+S;A9CC!Q>+ WNTK.
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MBP$QH'#E7X-0!GRDA7512W;XA9$VJ%#A6&1W:*1N%AOZ4WV$>\/H4H"FL#K
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MM'Y>5<^F.BX4<'W8O2AO]#(LJ-*UO*6G8"Y]$WNA-!!-\WAU<ZHH1.:UJ!J
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M_)^@*;< V7R#_Q"J=0:SA,L%PL67M3@F6:/5),$#9UXWXUHIPA\7[ZF1XV6
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M#S#>J@"9UE7FJN&NC_9%GXS_6G5O5@=E1MDD+D@],VD]$>C!,VNQN<O2GL;
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M]C*L-67(F8(ZPTXC):+K+)=5*2T3G<6XI8IU[L3)^B;5N!_#I*<$KC9U]#5
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MDK,H^-,<K2+X9?-KO<*KPGRVT%,*E793W(2] _0CHOE$3CCL5/?VOSF@W3C
MGS4N, V]:,/Y9&V$&O#=LQF&6W%(A)SYC>=,XR23R!(\%Z"!$\$^G"'ICUZ(
M;EENV4>\DH)2GO._9JO'.9SGW M2."?SN>;OB+=Y*(9N"KAH;1"X\F\<[0H
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M]+3&24<8-AY3!IJP/OANO?;[.?3%7WY4H)U0DWMX-4IG422QU9G%3'E]_DD
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M6U-QF&:MS% 88C-9"FBXHV *M+#NLJPCU2Z@ 9;D#E$T*F@AU1GU5*$VG]6
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M7*%IP'ETA4/%*6A[YUS#+DEI I,IR0C?@98 IV_H:3A'GM$A1C@.G8X)ME=
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M:A&13B)!HKP#NKCV? [9R:>.* =V?4#*;,O*^B_!;2Q!0BD",R=;'8J@3&&
M"_!"$0=QGJ6</(A)AE1H>($QV!4B%2L>+LA9.B@&KQVI?#>^2:M@UVE20JT2
M>3'RO%J7C=G5762AE:/:DAKW'W@TU3KL+9GLLC4.1<&J.A9%9:R<,<1.\<46
MLDK:]5.<2^G/+L&)R#BIOTOHA?E K0TF?>U34G@JY!<TJ3VR$59R,"'#3OVS
M#C6TQ#COFB">7LL\D@KX3*T\*R.C(!GE$[#GJ*ZGR+@H.AQ8/:O-SKPI?"2)
MKDVEF4;,VRMO.)\DM8P2X6^O\;K@SE(Q[JM@A(45RV#BP#HE#A$;-S$!S>\&
M'QAR?(.^CH?(G;0A9!$TM3\GA2ANR.*I>>-UA5"Q'8F'6?OS8\61)?2-9T&&
M"3RH(-IU!QSO C0*1H$VR,:EIX;Y7;5FX('T$.@0'&&&>7=]Y0 S.4+O=IR'
M*\.[!SDFR0!^K@YCKN*9Q"\]LF[#F+R2?@Q4BV*<J?CPVINBM;S[7K-7 Y?(
M.93T(Z(#LC=*V4%AC#TZ"MJV?GE1MBI.C/J3PDNU]L%YWYH6B TG&9,JYHBJ
M6B*52>A$2GBJ0VU0W32Y>9 UKP7K%@NMBQQMB=4@33$6RB_$6+CP*^96$_3?
MP"-,0:;HLY;!(-4TUL$><1[YC9U>J+ZJ"5>=8GL_B@BALU*DQM[F_D)W3[,K
M&@Y>R:F$-YO7,%"(<1++U@G"O ^X6, <%!2AAU,E$/3D-6*]DT<"F+M0BBTQ
M;!U#:BAB#5J1F.(F*9*8R9_Q<#:RWJC2&PMNR9[5O-LMO=1XO:QL8OT=_()9
MHVQ]L9VCKR%$B[;(U"[L][D@IHS,5%<&FV(R0A:37HEH4@*RI7Z7\G=",[-#
MGT=^VNN7J^[08C55Q)6?-.+[RHT@VUFI &$[!6XI6MB2/1T".7@K%S.[K,A-
MG3QNQ&2C EJRM^H,Q36%2\!6@11TSS^R=H#OCI)@RF:"&(6?5#P-BTJQ<V7>
M[Q#8K8&7KL[R0$,L+71H+P&.Z$VO7>=73!WY)_[G IUN8 P-?$Q8X43G&ZPP
MO:+%/WHC+Y__$$F72R^X]:+UFJ4WVYR;4X),QST_1-[),\"PMLOCEE9:Z,6%
MU6Q^"L]+/2YVF617HH_&"P@V)Y"KH8)J*S=:BG57A2T<Y4D\50"5(UVO-@"N
M2VC3?_>S"J^"?.(ZOX HI<J*#SDH,V"X)6Q_G1)*AO#/%7*PW$N_QJT"J@MG
M/DED@<L8.%L!E0?Q^8_+:B875Y#>9C=^I&&JHBE:&LM[PE8DG_[FYM;?]GI_
M.SITU@1O/Q6JH'E.MV3%AGY.@)$#W#0[%3YRY)P]19K)-*, \ =O!*3O%9U@
M0W6#>[5?4BQF2G'%3.#46.J&A=VB*.I@%STT0F>% NX#RU? .=>:_5K(4#+H
M$"-8][:X('^([@.G\0*T5\C&)#(^^&Z+WHR6%5(@5Q/^-* -873C\C_*A?G!
MC;XRUD-QY#=/"^<.VT/*B/S'F\TWS@@4:QPJ#KLR?\L8<OI;WL._P-G:H3=-
MU8_Z'^\</3P>KIM72"I3TP$YS&OXX:V-_9VF@>8SY\S3_N_'OH6P1G#2R[-X
M<0P*%9@NR5L!U(^+"0&#Z?>,E6\Q@.:0[%\KA_[K-T%SCDH\G_Y]-1*[D1>L
M#X*G@[S4H1KF(3QD><0<X.F[[RR]? 8&K2SME( WXWH;4:$9_&69].8GHZ=B
MKE-1O4 ><VYW]P?KO>*99P\ZR.A$N@X09S>=)3B2CN$+BL53K^=XUIM<\=^;
MVD8[ (,]$U@O9GU7_%0BK4JC7S16P'\2_ \R>?A?D .=.&@C2G?BH!,'G3AH
MJSA '[(E$B3CF5K9W,9VGP)R=8,Q<,,5_1B)R>"7'O#J_LYFT29$IZ:A;SG$
M;\=!.H+78PME,_)WW4PL&7HA#S>^5HK2U8K&RW#]6[O;[[9IYB5-7%I#-_QU
M?$NE]68!+XIRFKF#3JTX#'Q/HMJEOPNI94KCTW4KWH!GXQ=APX L3R+*T&[:
MT<[F\^VH$W5+3*Z=J.M$72?JVBKJQNI6.^*!CQD_/;!E%H#:8;]F>>P+][Q5
MA\7!5*H&45XD&6H#[-H#3+>_UEM?4^O:#=;DYUJW.T3'0[M2A9MI5IIH'F*9
M:W37U'I%9UH6G>!8QL9))T.6DPXZ&=+)D$Z&M%*&2"HEBX=R&NS8XYHBG:,C
MPF!KK3]7$KBZDD JC:/8XN25B WW!2VR;+U2O*MHL(/!'C,6KB0^QN50F!VX
M,1N>M]N-Q63*TD>FCQ.\U-4)"%Z68LB!#OS);%J3!RXZ#99#PKL%7>JI^);9
M6B#G&CQ!3F3]"TR'##)L)"C/@W*UCDLP<.]1HCYL;/=Z;WL:&8^Q^]VU\Q'.
MF/%$(]\Y-MLXC&&Q-?KO)([^\J?^UM8[T*DP_S$K5F=;7Q9(G3Z]7V%9V7\W
M]#J_J$BA2FB5X)5W,  . B?F-;#F%5W@HVO^VSZJB9,//AZ7)Y668K!2=D-!
MV&K6"6[7=,%_2)%!.>QK0+Y"$>XR0E.[L3G5$^5$_MDWX%9!3I-<))%3?@O7
MR3HW-4BD]!R-T90 ZMDIQ58PO5)O,<+L47JI]<5KOM$+(_6P(X"G"T3*?3N+
M(:C<49(R7:C#C22U%)<!$$.'99/YML;_#-)4@0#4CP@)KU.5$,Y$9WF*#:YN
M(]V_E!);?#6F1K$!;Z.AFM<P&69C_;<G)V_[W(]7^!ILC_^YY<(_G+WM[;<]
M_-?>#OQ#GMS;W7X0!]1D8#(H\!A%A8UNR27>5UWJ @<I6H?A</)&D(U4@FR9
M?@1R(W-\2>\KP?*[ &^;X/0= +9"U/6I0=-# ;AUO^ #AN=:F&"QNT3GJFGE
MM<);1U[4P/S6FGG<>H7'B>I:+&R-O9+ZPWL0!]!#,(C_T1<\^;"QV^^]W<?U
MY)\%&.Y'FI5+@-]M?0+\*E@4)ZB#1/[J<)3'9IH75B6G B+_/4F"]!IKI%(K
M7\2T_JDGP!J->1R$N@S-J&1<!%F\5EX7VP,==6M;^P"E%YOLV@5-HG);'[GL
M&28._LE;LTSLM:9<VW6+':?X^8ZSAK^N9^!:SSW.V*BIOOH!EVT1G#"HPH [
M&<Y.A]<G+PH%:N"R!V_/TM#*>H(ED_IK89,[Y;R",J3B+.KMQZYJ*,OPW V;
M69FRUY,T\=3#QD>UG@,M5@%=QGR[M3TH)C;7(-(D, 6E<22&;Q#YG5P,UFFL
M$/R#*_II@7J1O8JD)3]MS)3Q(9W0(D*B/&[A,=T$:F8AO]?EQF!9S1]8<0#R
M^G *P_Q C\<V6%R^"(:8MG*),<-K5)2J&;T'[/KXHJ% $=;2BW)XBJ&68GDL
M<F74O7G< Y75@_(5A*FN!N89OD'DZIF_2C=EP2D"/,[ECI,KN TNMT8A48(R
M!OMZP=FG051N9T;$GC554+)K3*YAPQEP9X#2W2UZ*0]K79':@<%R=Y'(%&KJ
M$U.ZOA3&6JW2F!,WM6#0J&UMAH3NJ@[)/LF\\&ZU&-Z<EBBB:=C5=@2 RF"/
M(C=7,[RLL7+?M!NSRO;7BG\KY]3[@PK4J+H;9*IS$8\"H%Q' 58Y/X/H](@(
M#\].+\Y^!HYIAQOLA6UT1'99N"LJ[K0H?IASK^CP9[NX&2CD0*IP[#D5@.9W
M%'<IU4O.=V3W-GIK&>DL'_390%:\5R,LL3Z--YP=JL'O;SO':ICD:'3V#@[V
MC?NX]&11\E1D*'1E,&T-1G:!_"Z0WP7R6QG(!UFAI4^CNUN8[_^:[T[T=Z42
M5\M(-?P>3$W@Y\*V(V;PI1%>=K!]^VW&CG<6DK:IBS_M]0[VR*'=VW8^>B09
M#FAA;X*:K6\VVO"[4.^4%6YR/G4)8<M("YT<Z>1()T=:*4>P;6Q#,IBIJ>3*
M=ZM! 74^!"Y=LB":\K#*<D0,!31:FEC]0_.RZH XIO];X*K;:AP/*+^->GSI
MWC3BL&YR\+#KK]2[T=,O*&(-<TQ+8P\6K6R* >JI[C?JU!4(W5XQ+;HN&NP@
M[UNR;C5),'UP4MU5G_T]G='75H;3">M.6'?"NI7"FC+$S+!A3IH.DDGJ4BMV
M$@I%:BM-CIXH/X S*KNA(X^D]_-1)ATB,6I;$0H-R2DSO'];^SMDWSD7:IIQ
M<QLP\K9L(\\M*P%N@ZV(W_1V>P>D,O0/G+-1%N.K^IN;>VXE/=+JPXS._\XZ
M7'*BZ01.)W Z@=-*@=,0AN4*'NEF5@^ N4[F?95Q/!)^P]2C) [3^6S\V2MS
M6F7H8==1]=^<TLQJ+?B;[30=*-=IXDWQ\9)13E/GBM"\76K%5KPIW&)SK6ZI
M<S2V+*3)H6O+=FD8[462%F5&%G+C;!F5@)>-L]*.O2#$[N"DA, ![GCSI(CP
MHSP!1I>($31D$$0]/X7J?W!V8D))X(":N.V;./!U;C;^WDJQ8/#J/B&2CI"8
MV<'%NW55LN]-O"LL7<OMI >U@ME5_^,!^:U6KL',W,%JJJ"5Y,2TH)U8VV[A
MP7"*S'RC9)]$0+PYNTQ*.0<?O%M\FH#JK.%?2#U]UI4/MO?7RU$0*RGR^.3H
M@XY\S.YQ:G4,O9(FP<64 =E/P6#QUUB8?T,]R[27IY+W"0_9WAZ[@^])$5AZ
M2 6$T[?!5^2HPPD-?[&398$A3?+P2J=1)8HN8[TRYJ A1^*A:6>P9;X9K/*(
M*<E#5Y\.503'0]BXQ !6+5M^K_79\MT\Z2?;%<C1P!=*%X0O&H/<2^R<-WC?
M8YQ^/"+&DS81)HZH %:+TXL<:=<E(RD,&5*XP8Q\N6]%<0C@DC(B6_+E24&0
M=U=RVE/R>03RIGPJ3:>!H8XL!SI/L=#=EVE7G)?X9,.I6R+L/\5)EE]Y*Y5,
M_205XO/*PW',HC/]RY_Z.YOO*"492\3!S(PI^SE&'1.^[.^\2X*8*\4UF-W[
M<NPV#TQ1 /TDQXG"5CZC%(C#Z[>WWOG!50Q'39U_R=H?JVN_6)VV/K ,#GN1
M N=F",KPX$HN*/P3[_/@'0+4^:B2D0?_"[">"=I:[;0^\G>MGBX0RV+H,X?;
M82#71[[FZ_D\G#-$9405_+?ZF\_$Q UGH6+G6EE1 :I$QLTR#*J%++7!$D$E
M>:FJAL[?+I##&2:5DW@H<J3L4:-9#5LS/8T4(59<$N;[BZ9HUUXA/_'T;H),
MRSF^'#[>RAB*%[<*=K2JDL/.-6_@-I:EV%2U1Y9A&D3I5'U!Q !F2[8=P@P+
MY@K+\2*?XDA9G+%;E.?431U[:Y7)!L7@,GLJ9Z4,Q/!RNWB';_"QO$.,S*9:
MR.:CVD;R9>)1J@%.>UOK'1ST?CS8WUQWUBYN-YS0N[(_ P,7=N:KT)GH5J-I
M )JD1^-E^(7KK*/.KF3DH]($NR?F-_>>KV,[3\QV@NP/GI>S2KQGEB^#A7)X
M9PB8D-F H*:SA<B6S#"=BY/_PZ?3M/!(Z4Q;^,JXEW"2C-T1##!T]*7PW)>[
MZ MFC[T1.U/+&ZIJ?/4Y/WI&)+S22XRV9DV,1+[CPU?L?<5<(O(H%5Q&F9KK
M)-MP=G?Z'O%?_*/7V]G5*C0?G%1F^.0,X'BE)_0F\]=$(%(BU(PE^WO.>&QZ
M+2&0/\@OSCDO+A&',W\HR7+CIX+PJ0J$8]N0CNX9O7Q_?9'!M8J66G2LD(%+
M\EAI8J:]P]4AS"<'=='Y!UTF,L=J?OD_XW%3^?\&R!STK(+U"-\E547!Y@O%
M$J[QN3;UYK-_DXIN0EMQ+9HJ9)Z84XU:C+-V?'+Z<;"^0NA0\RZP</5"?=,@
MT8-I0*ZV2(KS$)C(5*ZD,PTI5Z%I-O&D=-,2&?U;1"K6(/&&SM$DP!$I*S3;
M;C9/F$GKFJ3=4J$^5I=[:<KB6EIR8K<)W>T27HL(\[,7?=&RI@FR3HD;76&S
M_PBWA :VH4715IM^KTO_TU*/3=%-?5-H*Y7WNGR>))2./GVOK2*9\:@><DJ)
M/[DZ@7K."ZKJ2?,<^]+T./+0%$U)>="//<B>G#0W,F@>I#../09FB*;3;$'@
M2E, '7,F<$_9$\D!.],%Y&^RMA>&,6?[D;K@ZQB@"8E3_P572W/3,^ >D%2:
MJZX0MSZ-FVZ(YE+SM%>4BX1'=H  $X:8-DVJI$#O?3[T A"Y(.4C3T((5E,M
MI('5:ZNUW_I X0I)S'\"._#CR0J1H)&5]W39*JO4,RM7F)Z-45FT<BJYX^5A
MR\NF&?)@AI01P(O"9GNTUII#-JDTC>&TYQFKX=L^RF0Y]'3UX38:RUZ/+SX.
MM#6^;MG,W'N&584@I5QN^AT<4-MK]'6 .1^TXWKJ6%7DX7NX.P[:_-R*!O$F
MH!E&-'RW8:9SW15V#UQVU_:H6P0>;;T9VH4ELG#OBH8K _&%ZQ<SM_5).7$#
M(S$DV'"#G&?I-.*:Z>>%274E!^CM=0#BU8\EC,UNSWM:$I52=BR@]-8)(M5+
M2:_C//0;HD1N&0D2);. ?<I>N;V.N40L8#NP\ !C819%-]$;.32^#K8JC962
M-KD*F^&\0GH!NHHM?8"#;/G(!/Q5=(6#P="76E182'G$W7V(W^\56&]TZ,9&
M4U(GYVB/?#WI$QF!M 56E.DYR2-I+U4*'@Y5^4OC%-0]A1?_:3.-U4B"<"_@
M/$PY-J*VG+Q0JU&7O=/\6&N8Z+5HX@99E4_5X_9T($S5HHRS5"*E>&3 ?3/V
M)E@GGS[97T O8T617IP,]Q6>":A[08##HI$;E+7TXL9GCD+H':SMK.OFR[15
M>XUT_8$"P5DK'OP$!E5,BO^Z<X;5)-(L48N)3V=%VP;J#8C'Q&W:2CY>Y%6<
M<(LN Q3JVY#PI5N'V3Y8ZZ^O>=2U=LV'8UT#F='@N-LX 31EYDD&"^!(9$:>
M L33-(9-TVZ!=V:CC>+DG\X<;M <T(MAEQ.,2R!C*IR)0\KX'N<A7&D)!]>R
M^$H10Y)SFT1S.4RY-:1]9;08XF49E^B&$?Z)%2XK(Y-78@IN83F4<H& JX^
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M\+)J1)1>K+&HD "E\#%U\-UP$-!A&AL2 2ZA?XB8"%@%WWA#]E5L %?<<,Y
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M2X>LC)),3<R5_5?,J\Z&XS^X5I4]5'+0UUN#-M;%8N:VCEB%/O$[6+4R'_$
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M]JE3F>OX^KOH]4(-+.G@5;XAT#M)V!%;@#^;KNE91#.CE2:[O;<"G7GL_]'
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M)!TJ(QHF>Y .=>A 347)0#JJ0(?*FEH\2NB5&B4<[MMWZY%1Q;$7IRF$<:"
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M>EE7%SN)\ZC0).R@V"68EQA:^B<)"6'1TSB.XH#P#.O4G%/FOE(X'%&O8TK
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M=0<;1IYF:]9:ZU("3/L@A+9M!RY(+[&'+JZ$$B?3Q2%U[Z]<UX_8#IE9OLP
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M\ >'K=BIPS9GP:=HE'?GN?G6R;$[E8/O,$'/#"+'<F:FR%/!LTP7'A/+S+,
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MCK:@?R'H  -TG%T8=M.%DP!\<6G(3%*G\W'V8="_@=C-#$2C1SC..] #_8\
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MFK 0P(L[8?I93ABA(&7VE D]?H7%='LG8GH):JPGIO^!6XY<DU1%N^7Y+'8
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MN;U#N^NL";(*C>V1$M_^H1K6.\FT71>SU)-Y[8LY[1L;9=5AG)J7MFQ,H"2
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M=>'6])]W],OI?S"0!X.,+6](_)VMB'_IRC<E_J<8K1N$7DC^+ELPA77=P+O
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M4!L4%E=3T9BI-<'ZK??3X\A_(3I_L4UX+W&##6#9VUWIY3(4_5>XR.- LY6
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MV(]Q)9"4 =#81BPL(29&"BC&1(,6JDH&2I\8V@0P$[O^F4P%AL_^]E63]$P
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M(=5S=&^'P,GLQG;$5WC=LI;&.V-/L9- W])[D!<H)Y# FMW%_KU<A(3U8UE
M:[65%"O2)DSW378W7@M\P["]U]UX$4 (.O<)(/()KOFQHN7SPDZ9JZDS5$0=
M8%=G4MKVR/N!4;5M'O_**GH7S6!->(<D6LKR\C7W?55J1E=T>O7>BD*LYI:_
M+WV^TJHWMGW!JDJT50L8='=1BC8U=-UDI;1^2D/'2RWR?0'PG,L_C@+0,P=?
M&-'KOJEP<PO@YK7B/1ORWWV\;G<P..'RP;( HXR(4R+PG ^C.H(4*%,1:\FP
ML?S;/G?N75**+ N8SUEG*S7@SQS,69F$NP=Y;B5CF432\4]H26N32Q)U>Z7^
MC5"QXLL5PRCC"2UIQ'))#&-CW;@J7_KX!_5]Y>T^57UJ6(;K84_.E[PV*Q50
M]ZW15@ \5&E/P4X;YP3AC2> 5VU,]C4M)9&CE!K:)%(WF)Z=V8%%)9:[1J[8
M+74:#UO,?Q'Y(/$D%R$3AI8^3$@$\8YU\O&6YR$I<KO9E'N#K E-EU?-5PF&
M2C"4!\*58"BW8$B-SBJC8,A/+UXE&'J]@:STLR9D79A@... 3VFH[X&YC.8<
MH?6KLQ=FVC/$_?.-190&]%70Y_BQM6/VQSX^@RT)("KU)J'>I*;U'5"]"<0!
MZ#>?(V&P,ZNW/^C*W69_9ZK-B3#!D@8"*]%;.E98*HRK9$)I9$)J:&?Y9,*F
M!N^@W9)[C4HFE"C6NP 9W?:Q9JY9WR%DE)*3*)75\D+&6KH <N_NZP.<0,D/
MX$!Q@@K098DG+#N)*N90R@.HE+2XDM9I[%Q)V\+4;LHM92"WF^E&%P?#M(/S
MU#(&HBL!4PF8,IQ")6#*=B+%!4RJ]\TN!,RF=GM3[C6;<G_0J@3,UOT,8TV0
MMFZ.0TOHI%:P\ZZ)F>]9*T^>^AXU9UG4G/NB@U/G30T;5!VK6='$"=XY4Y]9
M;>0P]4=-'0,0WZOFJSIWWTB_;5N4D+78XX=KOPYOA](GP_:8-K%@!<]S6;JU
MM#HE*#SZ(]?0#;B)N6NCVZE!X!OLG7K.7=D6R5%JM75C6*JE&:HIA<[:\P7!
MC>U08[&\7B;)GJ+'(]-#OS*W+5XCU4OP,QL;%M,_,0O^\.Y-U=I%8SM)R!"F
M#[WHW7]IEO>70M(61%H $XZ(*$U%)[0-.Z^MZK:F-!J+O=:R!C'PB]OU7O^7
M#Z\3PV,U?#=BYZNCS@JJ"BDZ.11E+&^?>ZA5#.K+9X @W'<"T(W6MR9Q-8BX
M<@$:@9QO]?KK_9>[/Z^OI8?KI]N'ZZ_7WYZD^R_#;R$(2+W;D7*7U1;RR*9*
M7'M,<)Z ^N]\1V)P_@:2>="\UI4FZ@M0/6,6=DB=&I[H&PDJNF=HQ@P[31N6
M9,/-[8;R]L<[N!:@8&%;Z3O-LY'C"X9?E^[#FV@1%@D)<1NVFY0,;%4]9@Z\
M8RQDR(AS0&S,BB\)%R;#_9KI([>A'Y!]ZA+[R30?$WKQ.8;&'+CN=8+]7Z<J
MO$_<K0/K\2:2#S^B$,(+T.)RQW-@8HY'5Q(D:!@:W/RW;SA<9M>E?S,);"IM
M$G7\1= ZQLCGK;5]%Y>DXL*U">#$#P07H('O>LX<L ?>B(U?Z])3K%7MJV&:
M\-@?#&YTU3$#L#O ./F;\'GQ=TBP'E DX+%+;%#J!3WS'98P05,]M86<N8H]
M'H6-Z,7J?!7O3_S.'%1/[L;TXQ)IY#K> S:4IF@T?/BJ_C2F_E3$G,/PM"=@
M2T(NZ%8+QZ4"@  Y_A>_7Z^#M@2R#FFSUGSS$<1*RK+]!;$HZLNLFBJ<B,X
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M,6,OG[BO7VH61&N_U ,T_ +;8$)$#N4*&%;J>10K+8P6-YE>9&2L.:1LX/7
MGC=04J0I?:U6N]VNNG;MR+*J[*A>KU:/6*/J'AV[[K'M.K63$UY[TR5%-N6\
MEZ,8J&7M3S70JYN+VR^7QL/Y_YE=%V2J@-;'"B3>HZ^;>&"Z?J+R;=P%83V/
M(DY5@:X%HR*1@D</^/Q5R.[.EAE]*+C,N#'L*I)AN2A,A .B(5TB$649M&U
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M YC7PSG'718;/38P6MQ@_;XG@(U8APD_BHUV$B<A1V>8VKL+&F_%P%;VDK&
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MV[^\Z\9Q_\/[]T]/3Q5PD2N=X/']>>ATP5&*WG.WP\+W+HO9>ZO9:-:LVGL
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MQ?@=8[$Q^R[\3I2&6DLQPGP!C5T%I0?0+Q3LQO,7@!MA3H?QD(/:2Q3Y81B
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M -?+6:2GRJ.1#76Z$A]@YC+=7TRG,(T.AE=E5@DN"688S.:I468V\PQ&%\H
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M,# P,# Q+FIP9U!+ 0(4 Q0    ( .6*A%: & ,-.! & "4\!@ 6
M      "  5F(  !G:GEJ:78S:G)H;VPP,# P,#(N:G!G4$L! A0#%     @
MY8J$5HD :R;;7@, SZD# !8              ( !Q9@& &=J>6II=C-J<FAO
M;# P,# P,RYJ<&=02P$"% ,4    " #EBH168!;%_V\A  !5*@  %@
M        @ '4]PD 9VIY:FEV,VIR:&]L,# P,# T+FIP9U!+ 0(4 Q0    (
M .6*A%:D9#;RJ2   ,4I   6              "  7<9"@!G:GEJ:78S:G)H
M;VPP,# P,#4N:G!G4$L! A0#%     @ Y8J$5N)&XX1B=@  X:<  !8
M         ( !5#H* &=J>6II=C-J<FAO;# P,# P-BYJ<&=02P$"% ,4
M" #EBH16B0!K)MM> P#/J0, %@              @ 'JL H 9VIY:FEV,VIR
M:&]L,# P,# W+FIP9U!+ 0(4 Q0    ( .6*A%;SH#-@L?P  % $ 0 6
M          "  ?D/#@!G:GEJ:78S:G)H;VPP,# P,#@N:G!G4$L! A0#%
M  @ Y8J$5EBX=,8:. 4 ]TL% !8              ( !W@P/ &=J>6II=C-J
M<FAO;# P,# P.2YJ<&=02P$"% ,4    " #EBH16@!@##3@0!@ E/ 8 %@
M            @ $L110 9VIY:FEV,VIR:&]L,# P,#$P+FIP9U!+ 0(4 Q0
M   ( .6*A%83;,XY6W<  .EZ   6              "  9A5&@!G:GEJ:78S
M:G)H;VPP,# P,3$N:G!G4$L! A0#%     @ Y8J$5EM#\6Q5Q0$ P>P! !8
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M=C-J<FAO;# P,# Q-2YJ<&=02P$"% ,4    " #EBH16'866':5E @ AHP(
M%@              @ %W\QX 9VIY:FEV,VIR:&]L,# P,#$V+FIP9U!+ 0(4
M Q0    ( .6*A%;[8XQUNFP  %"2   6              "  5!9(0!G:GEJ
M:78S:G)H;VPP,# P,3<N:G!G4$L! A0#%     @ Y8J$5HYDUK3E>   2)L
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M:6$M,C R,S S,S N>'-D4$L! A0#%     @ Y8J$5E*C=A43#0  _K   !4
M             ( !GQDD &UA:6$M,C R,S S,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( .6*A%8MMV!D]3(  "QW P 5              "  >4F) !M86EA+3(P
M,C,P,S,P7V1E9BYX;6Q02P$"% ,4    " #EBH16DN); Y1^  #6P0< %0
M            @ $-6B0 ;6%I82TR,#(S,#,S,%]L86(N>&UL4$L! A0#%
M  @ Y8J$5JN/.KI930  )]T% !4              ( !U-@D &UA:6$M,C R
M,S S,S!?<')E+GAM;%!+ 0(4 Q0    ( .6*A%8[16$*&@,    ,   0
M          "  6 F)0!M86EA+65X,C,R7S<N:'1M4$L! A0#%     @ Y8J$
M5M@G$$?O @  *Q   !(              ( !J"DE &UA:6$M97@R,S-?,S,R
M+FAT;5!+ 0(4 Q0    ( .6*A%8!<L\YTR(% #&<00 ,              "
G <<L)0!M86EA+7,Q82YH=&U02P4&     !P ' !3!P  Q$\J

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
